<SEC-DOCUMENT>0001193125-22-074118.txt : 20220314
<SEC-HEADER>0001193125-22-074118.hdr.sgml : 20220314
<ACCEPTANCE-DATETIME>20220314082242
ACCESSION NUMBER:		0001193125-22-074118
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		18
FILED AS OF DATE:		20220314
DATE AS OF CHANGE:		20220314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Coronado Topco, Inc.
		CENTRAL INDEX KEY:			0001906324
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-262434
		FILM NUMBER:		22735149

	BUSINESS ADDRESS:	
		STREET 1:		1001 ROUTE 202
		CITY:			RARITAN
		STATE:			NJ
		ZIP:			08869
		BUSINESS PHONE:		(908) 218-8000

	MAIL ADDRESS:	
		STREET 1:		1001 ROUTE 202
		CITY:			RARITAN
		STATE:			NJ
		ZIP:			08869
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>d273090ds4a.htm
<DESCRIPTION>S-4/A
<TEXT>
<HTML><HEAD>
<TITLE>S-4/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on March&nbsp;14, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-262434 </B></P>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT
NO. 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-4</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CORONADO TOPCO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2835</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>87-4496285</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial </B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1001 Route 202 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Raritan, NJ 08869 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">908-218-8000</FONT></FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone
number, including area code, of registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Joseph Busky
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Chief Financial Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1001 Route 202 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Raritan,
NJ 08869 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">908-218-8000</FONT></FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Ryan A. Murr</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Michelle A. Hodges</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>David I. Brown</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Stephen I. Glover</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Phillip S. Askim</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Bradley C. Faris</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Branden C. Berns</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Quidel Corporation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Richard Butterwick</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Gibson, Dunn &amp; Crutcher LLP</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>9975 Summers Ridge Road</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Latham &amp; Watkins LLP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>555 Mission Street, Suite 3000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>San Diego, CA 92121</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>555 Eleventh Street NW, Suite 1000</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>San Francisco, CA 94105-0921</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(858) 552-1100</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Washington, D.C. 20004</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>(415) 393-8373</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(202) 637-2200</B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale of the securities to the public: </B>As soon as practicable after the effectiveness of this registration
statement and completion of the Combinations described herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the securities being registered on this Form are being offered in connection with the
formation of a holding company and there is compliance with General Instruction G, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Form is filed to
register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT>
filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If applicable, place an X in the box to
designate the appropriate rule provision relied upon in conducting this transaction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exchange Act Rule <FONT STYLE="white-space:nowrap">13e-4(i)</FONT>
(Cross-Border Issuer Tender Offer) &#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exchange Act Rule <FONT STYLE="white-space:nowrap">14d-1(d)</FONT> (Cross-Border Third-Party Tender Offer)
&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration
statement shall become effective on such date as the Securities and Exchange Commission acting pursuant to said Section&nbsp;8(a) may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#eb0029"><B>Information contained in this joint proxy statement/prospectus is subject to
completion or amendment. A registration statement relating to the securities being offered by this joint proxy statement/prospectus has been filed with the U.S. Securities and Exchange Commission. These securities may not be sold nor may offers to
buy these securities be accepted prior to the time the registration statement becomes effective. This document shall not constitute an offer to sell or the solicitation of any offer to buy nor shall there be any sale of such securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. </B></FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#eb0029"><B>PRELIMINARY&#151;SUBJECT TO COMPLETION,
DATED MARCH&nbsp;14, 2022 </B></FONT></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g273090g04h96.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g273090g15s55.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS COMBINATIONS PROPOSED&#151;YOUR VOTE IS VERY IMPORTANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#9679;], 2022 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2021, Quidel
Corporation (&#147;Quidel&#148;) and Ortho Clinical Diagnostics Holdings plc (&#147;Ortho&#148;) entered into a Business Combination Agreement (the &#147;BCA&#148;) by and among Quidel, Ortho, Coronado Topco, Inc. (&#147;Topco&#148;), Orca Holdco,
Inc. (&#147;U.S. Holdco Sub&#148;) and Laguna Merger Sub, Inc. (&#147;U.S. Merger Sub&#148;), each wholly owned subsidiaries of Topco, and Orca Holdco 2, Inc., a wholly owned subsidiary of U.S. Holdco Sub (&#147;U.S. Holdco Sub 2&#148;), which
provides for the acquisition of Ortho and Quidel by Topco. The combined company will unite world-class technologies and platforms to benefit customers with expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology,
donor screening and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-care</FONT></FONT> diagnostics offerings. We are extremely pleased about this transaction and look forward to the opportunities it presents. We are
sending you this joint proxy statement/prospectus to ask you to vote in favor of these transactions and other related matters. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the BCA,
the &#147;Combinations&#148; are expected to be implemented by means of (i)&nbsp;a scheme of arrangement to be undertaken by Ortho under Part 26 of the UK Companies Act (the &#147;Ortho Scheme&#148;), pursuant to which the Scheme Shares (as defined
in the Scheme of Arrangement (hereinafter mentioned)) will be acquired by a nominee of Topco (or, if such nominee holds the Ortho Shares today, transferred within the nominee), such that Ortho will become a wholly owned subsidiary of Topco and
(ii)&nbsp;a merger (the &#147;Quidel Merger&#148;) of U.S. Merger Sub with and into Quidel immediately following consummation of the Ortho Scheme, with Quidel surviving the merger as a wholly owned subsidiary of Topco. At the effective time of the
Ortho Scheme, each Ortho Share, other than Ortho Shares held by Ortho in treasury, will be acquired by a nominee (or, if such nominee holds the Ortho Shares today, transferred within the nominee) on behalf and for the benefit of Topco in exchange
for 0.1055 shares of common stock of Topco (the &#147;Topco Shares&#148;) and $7.14 in cash. At the effective time of the Quidel Merger, each share of common stock of Quidel (each, a &#147;Quidel Share&#148;), other than Quidel Shares held by
Quidel, Ortho or U.S. Merger Sub, will be converted into the right to receive one Topco Share. The number of Topco Shares that Quidel stockholders will receive in the Quidel Merger and that Ortho shareholders will receive in the Ortho Scheme is
based on a fixed exchange ratio that will not be adjusted to reflect changes in the market value of Quidel Shares or Ortho Shares. The parties intend to list the Topco Shares to be issued in the Combinations on the Nasdaq Global Select Market
(&#147;Nasdaq&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the BCA, which was unanimously approved by the board of directors of each of Quidel and Ortho, Quidel and Ortho
are entering into a business combination under Topco, a new holding company, in which Ortho will be acquired for the <FONT STYLE="white-space:nowrap">per-share</FONT> consideration described above, including $1.75&nbsp;billion of cash in the
aggregate, funded through cash on the Quidel balance sheet and expected incremental borrowings. Following the closing of the Combinations, Ortho&#146;s current net debt of $2.0&nbsp;billion is expected to continue to be outstanding. If the
Combinations are completed, Ortho shareholders are expected to own approximately 38% of Topco and Quidel stockholders are expected to own approximately 62% of Topco on a fully diluted basis, based on the respective capitalizations of Ortho and
Quidel as of the date the parties entered into the BCA. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document, which forms part of a registration statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> filed with the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) by Topco, is a joint proxy statement/prospectus for Quidel and Ortho to solicit proxies for (i)&nbsp;the Quidel stockholders&#146;
meeting to approve and adopt the BCA and the Quidel Merger and (ii)&nbsp;the Ortho shareholder meetings to approve the Ortho Scheme, amend the articles of association of Ortho and authorize the directors of Ortho to take all such action as they may
consider necessary or appropriate for carrying the Ortho Scheme into effect. The registration statement includes the scheme circular with respect to the Ortho Scheme (as required by the UK Companies Act) and registers the Topco Shares to be issued
in the Combinations.</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your vote is very important. </B>We cannot complete these transactions unless the Quidel stockholders
vote to approve the BCA, the Quidel Merger and certain matters related thereto, and the Ortho shareholders vote to approve the Ortho Scheme and certain matters related thereto. The Ortho Scheme also requires the sanction of the High Court of Justice
of England and Wales (the &#147;Court&#148;). IT IS IMPORTANT THAT AS MANY ORTHO SHAREHOLDERS AS POSSIBLE VOTE AND/OR PROVIDE VOTING INSTRUCTIONS ON THE ORTHO SCHEME SO THAT THE COURT MAY BE SATISFIED THAT THERE IS A FAIR AND REASONABLE
REPRESENTATION OF THE OPINION OF HOLDERS OF INTERESTS IN ORTHO SHARES. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Please carefully read this entire document, including the section entitled
&#147;<A HREF="#cov273090_1">Risk Factors</A>&#148; for a discussion of the risks relating to the Combinations and Topco following the Combinations. None of the SEC, any state securities regulatory authority or the UK Financial Conduct Authority
(the &#147;FCA&#148;) has approved or disapproved of the Combinations or the securities to be issued in the Combinations or has passed upon the adequacy or accuracy of the disclosure in this joint proxy statement/prospectus. Any representation to
the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For the avoidance of doubt, this joint proxy statement/prospectus is not intended to be, and is not, a
prospectus for the purposes of the Prospectus Rules made under Part 6 of the UK Financial Services and Markets Act 2000 (as set out in the FCA&#146;s Handbook). </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The accompanying joint proxy statement/prospectus is dated [</B>&#9679;<B></B><B>], 2022, and is first being mailed to Quidel stockholders and Ortho
shareholders on or about [</B>&#9679;<B></B><B>], 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g273090g15s55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ortho Clinical Diagnostics Holdings plc </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(Incorporated and registered in England and </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Wales with registered number 13084624) </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF COURT MEETING </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON [</B>&#9679;<B></B><B>], 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>IN THE HIGH COURT OF JUSTICE&nbsp;&nbsp;&nbsp;&nbsp; </B></P></TD>
<TD ALIGN="right"><FONT STYLE="white-space:nowrap">CR-2022-000340</FONT> </TD></TR></TABLE>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BUSINESS AND PROPERTY COURTS OF ENGLAND AND WALES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COMPANIES COURT (ChD) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IN THE MATTER OF
ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#150; and &#150; </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IN THE MATTER OF THE UK COMPANIES ACT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTICE</B><B> </B><B>IS</B><B> </B><B>HEREBY</B><B> </B><B>GIVEN</B><B> </B>that, by an order dated [&#9679;], 2022, made in the above matters, the High
Court of Justice of England and Wales (the &#147;Court&#148;) has given permission for a meeting (the &#147;Ortho Court Meeting&#148;) to be convened of the holders of Scheme Shares (as defined in the Scheme of Arrangement hereinafter mentioned) as
at the Voting Record Time (each such term having the meaning given to it in the Scheme, as defined below) for the purpose of considering and, if thought fit, approving (with or without modification) a scheme of arrangement proposed to be made
pursuant to Part 26 of the UK Companies Act (the &#147;UK Companies Act&#148;) between Ortho Clinical Diagnostics Holdings plc (&#147;Ortho&#148;) and the holders of the Scheme Shares (the &#147;Scheme&#148; or the &#147;Scheme of Arrangement&#148;)
and that the Ortho Court Meeting will be held at [&#9679;], United States on [&#9679;], 2022, at [&#9679;] [a.m./ p.m.] (Eastern Standard Time) and [&#9679;] [a.m./ p.m.] (London time) at which place and time all Scheme Shareholders (as defined in
the Scheme of Arrangement) are requested to attend by following the step by step procedures (see the below section entitled &#147;Instructions for Accessing the Virtual Meeting Platform&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the Scheme and a copy of the explanatory statement required to be published pursuant to Section&nbsp;897 of the UK Companies Act are incorporated in
the accompanying joint proxy statement/prospectus of which this notice forms part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, any capitalized term used but
not defined in this notice shall have the meaning given to such term in the accompanying joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voting on the resolution to
approve the Scheme will be by poll, which shall be conducted as the Chair of the Ortho Court Meeting may determine. The poll shall remain open for a period of thirty minutes following the discussion of the matters to be determined at the Ortho Court
Meeting to enable Scheme Shareholders to amend their vote, if they so wish. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Right to Appoint a Proxy; Procedure for Appointment </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scheme Shareholders are strongly encouraged to submit proxy appointments and instructions for the Ortho Court Meeting as soon as possible, using any of the
methods (by hand, post or online) set out in the below Notes to this notice. Scheme Shareholders are also strongly encouraged to appoint the Chair of the Ortho Court Meeting as their proxy. If any other person is appointed as proxy, he or she will
not be permitted to attend the Ortho Court Meeting in person, but will be able to attend, submit written questions and vote at the Ortho Court Meeting remotely via the Virtual Meeting Platform (as defined below). Instructions for accessing the
Virtual Meeting Platform and information on how to appoint a proxy are set out in the below Notes to this notice. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Record Time </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Entitlement to attend (remotely, via the Virtual Meeting Platform) and vote (remotely, via the Virtual Meeting Platform, or by proxy) at the Ortho Court
Meeting or any adjournment thereof and the number of votes which may be cast at the Ortho Court Meeting will be determined by reference to the register of members of Ortho at the &#147;Voting Record Time,&#148; which is [&#9679;] [a.m./ p.m.]
(Eastern Standard Time) and [6:00] p.m. (London time) on [&#9679;], 2022 the date that is two Business Days (as defined herein) prior to the Ortho Court Meeting, or, if the Ortho Court Meeting is adjourned, [&#9679;] [a.m./ p.m.] (Eastern Standard
Time) and [6:00] p.m. (London time) on the date which is two Business Days before the date fixed for the adjourned meeting. Changes to the register of members of Ortho after the relevant time shall be disregarded in determining the rights of any
person to attend (remotely, via the Virtual Meeting Platform) and vote (remotely, via the Virtual Meeting Platform, or by proxy) at the Ortho Court Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Joint Holders </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of joint holders of Scheme
Shares, the vote or appointment by (as applicable) the most senior who tenders a vote, whether remotely, via the Virtual Meeting Platform, or by proxy, will be accepted to the exclusion of the vote(s) or purported appointment(s) (as applicable) of
the other joint holder(s). For this purpose, seniority will be determined by the order in which the names stand in the register of members of Ortho in respect of the joint holding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Representatives </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an alternative to
appointing a proxy, any holder of Scheme Shares which is a corporation may appoint one or more corporate representatives who may exercise on its behalf all its powers as a member, provided that if two or more corporate representatives purport to
vote in respect of the same shares, if they purport to exercise the power in the same way as each other, the power is treated as exercised in that way, and in other cases the power is treated as not exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By the said order, the Court has appointed Christopher Smith, or failing him, any other Ortho director to act as Chair of the Ortho Court Meeting and has
directed the Chair to report the result thereof to the Court. The Scheme of Arrangement will be subject to the subsequent sanction of the Court. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOUR VOTE IS IMPORTANT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your vote at
the Ortho Court Meeting is very important. You are strongly encouraged to submit proxy appointments and instructions for the Ortho Court Meeting as soon as possible. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Dated [&#9679;], 2022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Latham&nbsp;&amp; Watkins (London) LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">99 Bishopsgate </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">London EC2M 3XF </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Solicitors for the Company </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notes: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following notes explain your general rights as a Scheme Shareholder and your right to remotely attend and vote at the Ortho Court Meeting or to appoint a
proxy to vote on your behalf. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">COVID-19</FONT> RESTRICTIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the time of publication of this Notice, the UK Government has removed restrictions on large public gatherings. However, in light of the ongoing restrictions
in the United States and the uncertainty surrounding <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the possible reintroduction by the UK Government of measures restricting large public gatherings, and in order to protect the health and safety
of the Ortho shareholders and Ortho directors, officers and employees, Ortho shareholders will not be permitted to attend the Ortho Court Meeting in person, except for the Chair of the Ortho Court Meeting and anyone else nominated by the Chair of
the Ortho Court Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> situation is constantly evolving, and the UK and U.S. Governments may
change current restrictions or implement further measures relating to the holding of shareholder meetings during the affected period. Any changes to the arrangements for the Ortho Court Meeting will be publicly communicated to Scheme Shareholders
before the Ortho Court Meeting, including through Ortho&#146;s investor relations website https://ir.orthoclinicaldiagnostics.com. The information contained on Ortho&#146;s website is not incorporated into, and does not form a part of, the
accompanying joint proxy statement/prospectus or any other report or document on file with or furnished to the U.S. Securities and Exchange Commission (the &#147;SEC&#148;). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INSTRUCTIONS FOR ACCESSING THE VIRTUAL MEETING PLATFORM </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scheme Shareholders will be given the opportunity to remotely attend, speak, submit written questions and vote at the Ortho Court Meeting via a virtual meeting
platform provided by Lumi AGM UK Limited (the &#147;Virtual Meeting Platform&#148;). Holders of the beneficial interests in Ortho ordinary shares will be able to submit written questions by email to IR@orthoclinicaldiagnostics.com (emails must be
received no less than 48 hours before the start of the Ortho Court Meeting) and via the Virtual Meeting Platform from 7 days prior to the start of the Ortho Court Meeting and observe the Ortho Court Meeting remotely via the Virtual Meeting Platform.
Access to the Virtual Meeting Platform will be in line with the steps set out below for Scheme Shareholders, provided such beneficiaries shall not be entitled to vote through such Virtual Meeting Platform. Please see the section entitled
&#147;Scheme Proposal and the Ortho Shareholder Meetings&#151;Explanatory Statement&#151;Beneficial Holders&#148; of this joint proxy statement/prospectus for further information in respect of such holdings and interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scheme Shareholders can access the Virtual Meeting Platform using a web browser, on a PC or smartphone device. The web browser must be compatible with the
latest browser versions of Chrome, Firefox, Edge and Safari. To remotely attend, speak, submit written questions and/or vote using this method, please go to https://web.lumiagm.com. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(a)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>How to access and vote at the Ortho Court Meeting remotely if you are a Scheme Shareholder
</I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Log in at https://web.lumiagm.com/ at least 15 minutes before the Ortho Court Meeting starts.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enter the meeting ID: [&#9679;]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Click on &#147;I have a login.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enter your control number (which can be found on the Form of Proxy). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enter the password: [&#9679;] (case sensitive). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are unable to access your control number, please call [Computershare], Ortho&#146;s registrar, between [9:00] a.m. and [5:30]&nbsp;p.m. Monday to
Friday [(except English and Welsh public holidays)] at [&#9679;]. Calls from outside the UK will be charged at the applicable international rate. Calls are charged at the standard geographic rate and will vary by provider. Different charges may
apply to calls from mobile telephones. Please note that calls may be monitored or recorded and [Computershare], Ortho&#146;s registrar, cannot provide advice on the merits of the Combinations or the Scheme or give any financial, legal or tax advice.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Access to the Ortho Court Meeting will be available from [&#9679;] [a.m./ p.m.] (Eastern Standard Time) and [a.m./ p.m.] (London time) on [&#9679;],
2022, although the voting functionality will not be enabled until the Chair of the Ortho Court Meeting declares the poll open. Scheme Shareholders will be permitted to speak and submit written questions (via the Virtual Meeting Platform) to the
Ortho directors during the course of the Ortho Court Meeting. Scheme Shareholders may also submit written </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
questions in advance of the Ortho Court Meeting by email to IR@orthoclinicaldiagnostics.com and via the Virtual Meeting Platform from 7 days prior to the start of the Ortho Court Meeting. Emails
must be received no less than 48 hours before the start of the Ortho Court Meeting. The Chair of the Ortho Court Meeting will ensure that relevant matters relating to the formal business of the Ortho Court Meeting are addressed in the Ortho Court
Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the Ortho Court Meeting, you must ensure you are connected to the Internet at all times in order to submit written questions and vote
when the Chair commences polling. Therefore, it is your responsibility to ensure connectivity for the duration of the Ortho Court Meeting via your wireless or other Internet connection. The Virtual Meeting Guide, which is available on Ortho&#146;s
investor relations website at https://ir.orthoclinicaldiagnostics.com, contains further information on accessing and participating in the Ortho Court Meeting remotely via the Virtual Meeting Platform. The information contained on Ortho&#146;s
website is not incorporated into, and does not form a part of, the accompanying joint proxy statement/prospectus or any other report or document on file with or furnished to the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you wish to appoint a proxy and for them to attend the Ortho Court Meeting on the Virtual Meeting Platform on your behalf, please contact [Computershare],
Ortho&#146;s registrar, at [&#9679;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your ordinary shares are held through a broker, bank, trust company or other nominee and you wish to access the
Virtual Meeting Platform, you will need to contact your broker, bank, trust company or other nominee immediately. Your broker, bank, trust company or other nominee will need to have completed a [letter of representation] and presented this to
[Computershare], Ortho&#146;s registrar, no later than 72 hours before the start of the meeting in order to obtain your unique login code and PIN number to access the Virtual Meeting Platform. If you are in any doubt about your shareholding, please
contact [Computershare], Ortho&#146;s registrar, at [&#9679;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lines are open from [</B>&#9679;<B></B><B>] [a.m./ p.m.] (Eastern Standard Time) and
9:00 a.m. to 5:30 p.m. (London time) Monday to Friday; calls are charged at the standard geographic rate and will vary by provider. Calls outside the UK will be charged at the applicable international rate. </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RIGHT TO APPOINT A PROXY; PROCEDURE FOR APPOINTMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scheme Shareholders are strongly encouraged to submit proxy appointments and instructions for the Ortho Court Meeting as soon as possible, using any of the
methods (by hand, post or online) set out below. Scheme Shareholders are also strongly encouraged to appoint the Chair of the Ortho Court Meeting as their proxy. If any other person is appointed as proxy, he or she will not be permitted to attend
the Ortho Court Meeting in person, but will be able to attend, submit written questions and vote at the Ortho Court Meeting remotely via the Virtual Meeting Platform as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The completion and return of the blue form of proxy by post (or appointment of a proxy online) will not prevent you from remotely attending, submitting
questions and voting at the Ortho Court Meeting, in each case via the Virtual Meeting Platform, if you are entitled to and wish to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scheme
Shareholders are entitled to attend and vote at the Ortho Court Meeting and may appoint one or more proxies to exercise all or any of such Scheme Shareholder&#146;s rights to attend, submit written questions and, on a poll, to vote (in each case,
remotely, via the Virtual Meeting Platform), on their behalf. A proxy need not be a Scheme Shareholder but must attend the meeting for the Scheme Shareholder&#146;s vote to be counted. If a Scheme Shareholder appoints more than one proxy to attend
the meeting, each proxy must be appointed to exercise the rights attached to a different share or shares held by the Scheme Shareholder. If a Scheme Shareholder wishes to appoint more than one proxy, they should contact [Computershare], Ortho&#146;s
registrar, for further blue forms of proxy or photocopy the blue form of proxy as required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scheme Shareholders who do not appoint a proxy will still be
entitled to remotely attend, submit written questions and vote at the Ortho Court Meeting via the Virtual Meeting Platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Chair shall seek the
consent of the Court to be at liberty to accept forms of proxy (and to accept as having voted the number of Scheme Shares in respect of which the relevant Scheme Shareholder seeks to vote) notwithstanding that the form of proxy has not been
completed in accordance with the instructions contained in the forms of proxy, provided the Chair considers that the information contained in the forms of proxy is sufficient to establish the entitlement of the Scheme Shareholder to vote and
provided further that the Chair is satisfied as to the authority of the persons signing it to do so. In addition, the Chair shall seek the consent of the Court to be at liberty to accept any other forms of proxy or form of voting instructions that
are customarily provided in relation to companies that are listed on Nasdaq. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(a)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Sending blue form of proxy by post </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A blue form of proxy, for use at the Ortho Court Meeting, has been provided with this notice. Instructions for its use are set out on the form. It is requested
that the blue form of proxy (together with any power of attorney or other authority, if any, under which it is signed, or a duly certified copy thereof) be returned in the <FONT STYLE="white-space:nowrap">pre-paid</FONT> envelope provided by
[Computershare], Ortho&#146;s registrar, to [&#9679;], so as to be received as soon as possible and in any event not later than [&#9679;][a.m./ p.m.] (Eastern Standard Time) and [&#9679;] [a.m./ p.m.] (London time) on [&#9679;], 2022 (or, in the
case of an adjournment of the Ortho Court Meeting, 48 hours (excluding any part of such <FONT STYLE="white-space:nowrap">48-hour</FONT> period falling on a <FONT STYLE="white-space:nowrap">non-working</FONT> day) before the time appointed for the
adjourned meeting). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the blue form of proxy for the Ortho Court Meeting is not received by [Computershare], Ortho&#146;s registrar, by the relevant
time, it may be emailed to [&#9679;] or handed to the Chair at any time prior to the commencement of the Ortho Court Meeting otherwise it will be invalid. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(b)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Online appointment of proxies </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an alternative to completing and returning the printed blue form of proxy, proxies may be appointed electronically by logging on to the following website:
[&#9679;] and following the instructions therein. Full details of the procedure to be followed to appoint a proxy electronically are given on the website. For an electronic proxy appointment to be valid, the appointment must be received by
[Computershare], Ortho&#146;s registrar, not later than 48 hours (excluding any part of such <FONT STYLE="white-space:nowrap">48-hour</FONT> period falling on a <FONT STYLE="white-space:nowrap">non-working</FONT> day) before the time fixed for the
Ortho Court Meeting or any adjournment thereof. If the electronic proxy appointment is not received by this time, the blue form of proxy may be emailed to [&#9679;] or handed to the Chair any time prior to the commencement of the Ortho Court Meeting
or any adjournment thereof. Full details of the procedure to be followed to appoint a proxy electronically are given on the website referred to above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(c)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Appointment of a proxy by joint holders </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of joint holders, where more than one of the joint holders purports to appoint one or more proxies, only the purported appointment submitted by the
most senior holder will be accepted. For this purpose, seniority shall be determined by the order in which the names of the joint holders stand in the register of members of Ortho in respect of the joint holding. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>VOTES TO BE TAKEN BY A POLL AND RESULTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Ortho Court Meeting, voting will be by poll rather than a show of hands. This is a more transparent method of voting as member votes are to be counted
according to the number of ordinary shares held. The poll shall remain open for a period of thirty minutes following the discussion of the matters to be determined at the Ortho Court Meeting to enable Scheme Shareholders to amend their vote, if they
so wish. The results of the poll will be announced by the filing of a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> with the SEC and published on Ortho&#146;s Internet website as soon as reasonably practicable following the
conclusion of the Ortho Court Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scheme Shareholders can either vote &#147;<B>FOR</B>&#148; or &#147;<B>AGAINST</B>&#148; the resolution approving
the Scheme. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WEBSITE PROVIDING INFORMATION REGARDING THE ORTHO COURT MEETING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding the Ortho Court Meeting and a copy of this Notice may be found on Ortho&#146;s investor relations website at
https://ir.orthoclinicaldiagnostics.com. The information contained on Ortho&#146;s website is not incorporated into, and does not form a part of, this joint proxy statement/prospectus or any other report or document on file with or furnished to the
SEC. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ISSUED SHARE CAPITAL AND TOTAL VOTING RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at [&#9679;], 2022 (being the latest practicable date prior to the publication of this Notice), Ortho&#146;s issued share capital consisted of [&#9679;]
ordinary shares carrying one vote each. Therefore, the total voting rights in Ortho as at [&#9679;], 2022 were [&#9679;] votes. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g273090g15s55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ortho Clinical Diagnostics Holdings plc </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(Incorporated and registered in England and </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Wales with registered number 13084624) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF GENERAL MEETING OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON [</B>&#9679;<B></B><B>], 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTICE</B><B> </B>is hereby given that a General Meeting (the &#147;Ortho General Meeting&#148; and, together with the &#147;Ortho Court Meeting,&#148; the
&#147;Ortho Shareholder Meetings&#148;) of Ortho Clinical Diagnostics Holdings plc, a public limited company incorporated under the laws of England and Wales (&#147;Ortho&#148;), will be held on [&#9679;], 2022, at [&#9679;][a.m./ p.m.] (Eastern
Standard Time) and [&#9679;] [a.m./ p.m.] (London time) (or as soon thereafter as the meeting permitted by the High Court of Justice of England and Wales (the &#147;Court&#148;) (the &#147;Ortho Court Meeting&#148;) is concluded or adjourned), at
[&#9679;], United States for the purpose of considering and, if thought fit, passing the following resolutions, one of which is a special resolution and one of which is an ordinary resolution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, any capitalized term used but not defined in this notice shall have the meaning given to such term in the accompanying
joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special resolution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General Authorization to Carry Scheme into Effect and Amendment of the Articles of Association </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>THAT</B>, for the purpose of giving effect to the scheme of arrangement dated [&#9679;], 2022 between Ortho
and the holders of Scheme Shares (as defined in such scheme of arrangement), a print of which has been produced to this meeting and, for the purposes of identification, signed by the Chair of this meeting, in its original form or with or subject to
any modification, addition, or condition as may be agreed from time to time (including, for the avoidance of doubt, after the date of this resolution) between Ortho, Quidel Corporation, a Delaware corporation (&#147;Quidel&#148;), Coronado Topco,
Inc. a Delaware corporation and wholly owned subsidiary of Ortho (&#147;Topco&#148;), Laguna Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Topco (&#147;U.S. Merger Sub&#148;), Orca Holdco, Inc., a Delaware corporation and a
wholly owned subsidiary of Topco (&#147;U.S. Holdco Sub&#148;), Orca Holdco 2, Inc., a Delaware corporation and wholly owned subsidiary of U.S. Holdco Sub (&#147;U.S. Holdco Sub 2&#148;) and which (if required) is approved by the High Court of
Justice of England and Wales (the &#147;Court&#148;), or which is otherwise imposed by the Court and is mutually acceptable to Ortho, Quidel and Topco, each acting reasonably and in good faith (the &#147;Scheme&#148;): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the directors of Ortho (or a duly authorized committee of the directors) be and are hereby authorized to take
all such action as they may consider necessary or appropriate for carrying the Scheme into effect; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with effect from the passing of this special resolution, the draft articles of association of Ortho attached to
this joint proxy statement/prospectus as <U>Annex </U><U>F</U> and incorporated herein by reference be adopted as the articles of association of Ortho in substitution for, and to the exclusion of, Ortho&#146;s existing articles of association.
</P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ordinary resolution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Proposal to Approve Certain Compensation Arrangements </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>THAT</B>, the compensation that may be paid or become payable to Ortho&#146;s named executive officers in
connection with the Combinations, as disclosed in the table entitled &#147;Interests of Certain Persons in the Combinations (Ortho)&#151;Golden Parachute Compensation&#148; of the accompanying joint proxy statement/prospectus, including the
associated narrative discussion, and the agreements or understandings pursuant to which such compensation may be paid or become payable, are hereby approved. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOUR VOTE IS IMPORTANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your vote at the Ortho General Meeting is very important. You are strongly encouraged to submit proxy appointments and instructions for the Ortho General
Meeting as soon as possible. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>By Order of the Board</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Michael A. Schlesinger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Company Secretary</I></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registered Office: </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Felindre Meadows, Pencoed, Bridgend Mid Glamorgan, Wales, CF35 5PZ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ortho Clinical Diagnostics Holdings plc </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registered in
England and Wales No.&nbsp;13084624 </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notes: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following notes explain your general rights as an Ortho shareholder and your right to remotely attend and vote at the Ortho General Meeting or to appoint
someone else to vote on your behalf. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COVID-19 RESTRICTIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the time of publication of this Notice, the UK Government has removed restrictions on large public gatherings. However, in light of the ongoing restrictions
in the United States and the uncertainty surrounding <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the possible reintroduction by the UK Government of measures restricting large public gatherings, and in order to protect the health and safety
of the Ortho shareholders and Ortho directors, officers and employees, Ortho shareholders will not be permitted to attend the Ortho General Meeting in person, except for the Chair of the Ortho Court Meeting and anyone else nominated by the Chair of
the Ortho General Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> situation is constantly evolving, and the UK and U.S. Governments may
change current restrictions or implement further measures relating to the holding of shareholder meetings during the affected period. Any changes to the arrangements for the Ortho General Meeting will be publicly communicated to Ortho&#146;s
shareholders before the Ortho General Meeting, including through Ortho&#146;s investor relations website https://ir.orthoclinicaldiagnostics.com. The information contained on Ortho&#146;s website is not incorporated into, and does not form a part
of, the accompanying joint proxy statement/prospectus or any other report or document on file with or furnished to the U.S. Securities and Exchange Commission (the &#147;SEC&#148;). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INSTRUCTIONS FOR ACCESSING THE VIRTUAL MEETING PLATFORM </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho shareholders will be given the opportunity to remotely attend, speak, submit written questions and vote at the Ortho General Meeting via a virtual
meeting platform provided by Lumi AGM UK Limited (the &#147;Virtual Meeting Platform&#148;). Holders of the beneficial interests in Ortho ordinary shares will be able to submit written questions by email to IR@orthoclinicaldiagnostics.com (emails
must be received no less than 48 hours before the start of the Ortho General Meeting) and via the Virtual Meeting Platform from 7 days prior to the start of the Ortho General Meeting and observe the Ortho General Meeting remotely via the Virtual
Meeting Platform. Access to the Virtual Meeting Platform will be in line with the steps set out below for Ortho shareholders, provided such beneficiaries shall not be entitled to vote through such Virtual Meeting Platform. Please see the section
entitled &#147;Scheme Proposal and the Ortho Shareholder Meetings&#151;Explanatory Statement&#151;Beneficial Holders&#148; of this joint proxy statement/prospectus for further information in respect of such holdings and interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho shareholders can access the Virtual Meeting Platform using a web browser on a PC or smartphone device. The web browser must be compatible with the
latest browser versions of Chrome, Firefox, Edge and Safari. To remotely attend, submit written questions and/or vote using this method, please go to https://web.lumiagm.com. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(a)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>How to access and vote at the Ortho General Meeting remotely if you are an Ortho shareholder
</I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Log in at https://web.lumiagm.com/ at least 15 minutes before the Ortho General Meeting starts.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enter the meeting ID: [&#9679;]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Click on &#147;I have a login.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enter your control number (which can be found on the Form of Proxy). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enter the password: [&#9679;] (case sensitive). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are unable to access your control number, please call [Computershare], Ortho&#146;s registrar, between 9:00 a.m. and 5:30 p.m. Monday to Friday (except
English and Welsh public holidays) at [&#9679;]. Calls from outside the UK will be charged at the applicable international rate. Different charges may apply to calls from mobile telephones. Please note that calls may be monitored or recorded and
[Computershare], Ortho&#146;s registrar, cannot provide advice on the merits of the Combinations or the Scheme or give any financial, legal or tax advice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Access to the Ortho General Meeting will be available from [&#9679;] [a.m./ p.m.] (Eastern Standard Time) and [a.m./ p.m.] (London time) on [&#9679;], 2022,
although the voting functionality will not be enabled until the Chair of the Ortho General Meeting declares the poll open. Ortho shareholders will be permitted to speak and submit written questions (via the Virtual Meeting Platform) to the Ortho
directors during the course of the Ortho General Meeting. Ortho shareholders may also submit written questions in advance of the Ortho General Meeting by email to IR@orthoclinicaldiagnostics.com and via the Virtual Meeting Platform from
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
7 days prior to the start of the Ortho General Meeting. Emails must be received no less than 48 hours before the start of the Ortho General Meeting. The Chair of the Ortho General Meeting will
ensure that relevant matters relating to the formal business of the Ortho General Meeting are addressed in the Ortho General Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the Ortho
General Meeting, you must ensure you are connected to the Internet at all times in order to submit written questions and vote when the Chair of the Ortho General Meeting commences polling. Therefore, it is your responsibility to ensure connectivity
for the duration of the Ortho General Meeting via your wireless or other Internet connection. The Virtual Meeting Guide, which is available on Ortho&#146;s investor relations website at https://ir.orthoclinicaldiagnostics.com, contains further
information on accessing and participating in the Ortho General Meeting remotely via the Virtual Meeting Platform. The information contained on Ortho&#146;s website is not incorporated into, and does not form a part of, the accompanying joint proxy
statement/prospectus or any other report or document on file with or furnished to the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you wish to appoint a proxy and for them to attend the
Ortho General Meeting on the Virtual Meeting Platform on your behalf, please contact [Computershare], Ortho&#146;s registrar, at +44 (0)371 277 1020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
your shares are held through a broker, bank, trust company or other nominee and you wish to access the Virtual Meeting Platform, you will need to contact your broker, bank, trust company or other nominee immediately. Your broker, bank, trust company
or other nominee will need to have completed a letter of representation and presented this [Computershare], Ortho&#146;s registrar, no later than 72 hours before the start of the meeting in order to obtain your unique login code and PIN number to
access the Virtual Meeting Platform. If you are in any doubt about your shareholding, please contact [Computershare], Ortho&#146;s registrar, at [&#9679;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lines are open from [&#9679;] [a.m./ p.m.] (Eastern Standard Time) and 9:00 a.m. to 5:30 p.m. Monday to Friday (London time); calls are charged at the
standard geographic rate and will vary by provider. Calls outside the UK will be charged at the applicable international rate. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ENTITLEMENT TO ATTEND AND VOTE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho has specified that only those shareholders registered on the register of members of Ortho at [&#9679;] [a.m./ p.m.] (Eastern Standard Time) and [6:00]
p.m. (London time) on [&#9679;], 2022 (or, if the meeting is adjourned to a time more than 48 hours (excluding any part of a day that is a working day) after such time, at [&#9679;] [a.m./ p.m.] (Eastern Standard Time) and [6:00] p.m. (London time)
on the day which is two days prior to the date of the adjourned meeting) (the &#147;Voting Record Time&#148;) shall be entitled to attend (remotely, via the Virtual Meeting Platform) and vote (remotely, via the Virtual Meeting Platform, or by proxy)
at the Ortho General Meeting in respect of the number of ordinary shares registered in their name at that time. If the meeting is adjourned to a time not more than 48 hours after the Voting Record Time, that time will also apply for the purpose of
determining the entitlement of members to attend and vote (and for the purposes of determining the number of votes they may cast) at the adjourned meeting. Changes to the register of members after the relevant deadline shall be disregarded in
determining the rights of any person to attend and vote at the meeting. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RIGHT TO APPOINT A PROXY; PROCEDURE FOR APPOINTMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho shareholders are strongly encouraged to submit proxy appointments and instructions for the Ortho General Meeting as soon as possible, using any of the
methods (by hand, post or online) set out below. Ortho shareholders are also strongly encouraged to appoint the Chair of the Ortho General Meeting as their proxy. An Ortho shareholder entitled to attend and vote at the Ortho General Meeting may
appoint one or more proxies to exercise all or any of such Ortho shareholder&#146;s rights to attend, submit written questions and, on a poll, to vote (in each case, remotely, via the Virtual Meeting Platform), on their behalf. If any other person
is appointed as proxy, he or she will not be permitted to attend the Ortho General Meeting in person, but will be able to attend, submit written questions and vote at the Ortho General Meeting remotely via the Virtual Meeting Platform as described
above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The completion and return of the white form of proxy by post (or appointment of a proxy online) will not prevent you from remotely attending,
submitting questions and voting at the Ortho General Meeting, in each case via the Virtual Meeting Platform, if you are entitled to and wish to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An
Ortho shareholder entitled to attend and vote at the Ortho General Meeting may appoint one or more proxies to exercise all or any of such Ortho shareholder&#146;s rights to attend, submit written questions and, on a poll, to vote (in each case,
remotely, via the Virtual Meeting Platform), on their behalf. A proxy need not be an Ortho shareholder but must remotely attend the Ortho General Meeting for the Ortho shareholder&#146;s vote to be counted. If an Ortho shareholder appoints more than
one proxy to attend the meeting, each proxy must be appointed to exercise the rights attached to a different share or shares </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
held by the Ortho shareholder. If an Ortho shareholder wishes to appoint more than one proxy, the shareholder should contact [Computershare], Ortho&#146;s registrar, for further white forms of
proxy or photocopy the white form of proxy as required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho shareholders who do not appoint a proxy will still be entitled to remotely attend, submit
written questions and vote at the Ortho General Meeting via the Virtual Meeting Platform. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(a)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Sending white form of proxy by post </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A white form of proxy, for use at the Ortho General Meeting, has been provided with this notice. Instructions for its use are set out on the form. It is
requested that the white form of proxy (together with any power of attorney or other authority, if any, under which it is signed, or a duly certified copy thereof) be returned in the <FONT STYLE="white-space:nowrap">pre-paid</FONT> envelope provided
by [Computershare], Ortho&#146;s registrar, to [&#9679;], United Kingdom, so as to be received as soon as possible and in any event not later than [&#9679;] [a.m./ p.m.] (Eastern Standard Time) and [a.m./ p.m.] (London time) on [&#9679;], 2022 (or,
in the case of an adjournment of the Ortho General Meeting, 48 hours (excluding any part of such <FONT STYLE="white-space:nowrap">48-hour</FONT> period falling on a <FONT STYLE="white-space:nowrap">non-working</FONT> day) before the time appointed
for the adjourned meeting). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the white form of proxy for the Ortho General Meeting is not received by [Computershare], Ortho&#146;s registrar, by the
relevant time, it may be emailed to [&#9679;] or handed to the Chair at any time prior to the commencement of the Ortho General Meeting otherwise it will be invalid. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(b)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Online appointment of proxies </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an alternative to completing and returning the printed white form of proxy, proxies may be appointed electronically by logging on to the following website:
[&#9679;] and following the instructions therein. Full details of the procedure to be followed to appoint a proxy electronically are given on the website referred to above. For an electronic proxy appointment to be valid, the appointment must be
received by [Computershare], Ortho&#146;s registrar, not later than 48 hours (excluding any part of such <FONT STYLE="white-space:nowrap">48-hour</FONT> period falling on a <FONT STYLE="white-space:nowrap">non-working</FONT> day) before the time
fixed for the Ortho General Meeting or any adjournment thereof. If the electronic proxy appointment is not received by this time, the white form of proxy may be emailed to [&#9679;] or handed to the Chair any time prior to the commencement of the
Ortho General Meeting or any adjournment thereof. Full details of the procedure to be followed to appoint a proxy electronically are given on the website referred to above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>APPOINTMENT OF A PROXY BY JOINT HOLDERS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of joint holders, where more than one of the joint holders purports to appoint one or more proxies, only the purported appointment submitted by the
most senior holder will be accepted. For this purpose, seniority shall be determined by the order in which the names of the joint holders stand in the register of members of Ortho in respect of the joint holding. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CORPORATE REPRESENTATIVES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an alternative to appointing a proxy, any Ortho shareholder which is a corporation may appoint one or more corporate representatives who may exercise on its
behalf all of its powers, provided that if two or more representatives purport to vote in respect of the same shares: if they purport to exercise the power in the same way as each other, the power is treated as exercised in that way; and in other
cases, the power is treated as not exercised. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>VOTES TO BE TAKEN BY A POLL AND RESULTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Ortho General Meeting, voting on the resolutions will be by poll rather than a show of hands. This is a more transparent method of voting as member
votes are to be counted according to the number of ordinary shares held. The poll shall remain open for a period of thirty minutes following the discussion of the matters to be determined at the Ortho General Meeting to enable Ortho shareholders to
amend their vote, if they so wish. The results of the poll will be announced by the filing of a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> with the SEC and published on Ortho&#146;s Internet website as soon as reasonably
practicable following the conclusion of the Ortho General Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;<B>WITHHELD</B>&#148; option on the form of proxy is provided to enable
Ortho shareholders to abstain from voting on the resolutions. However, a vote withheld is not a vote in law and will not be counted in the calculation of proportion of votes &#147;<B>FOR</B>&#148; and &#147;<B>AGAINST</B>&#148; the resolutions. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WEBSITE PROVIDING INFORMATION REGARDING THE ORTHO GENERAL MEETING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding the Ortho General Meeting and a copy of this Notice may be found on Ortho&#146;s investor relations website at
https://ir.orthoclinicaldiagnostics.com. The information contained on Ortho&#146;s website is not incorporated into, and does not form a part of, this joint proxy statement/prospectus or any other report or document on file with or furnished to the
SEC. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ISSUED SHARE CAPITAL AND TOTAL VOTING RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at [&#9679;], 2022 (being the latest practicable date prior to the publication of this Notice), Ortho&#146;s issued share capital consisted of [&#9679;]
ordinary shares carrying one vote each. Therefore, the total voting rights in Ortho as at [&#9679;], 2022 were [&#9679;] votes. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FURTHER QUESTIONS AND COMMUNICATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As set out in paragraph 1 above, Ortho shareholders will be permitted to submit written questions (via the Virtual Meeting Platform) to the Ortho directors
during the course of the Ortho General Meeting. The Chair of the Ortho General Meeting will ensure that relevant matters relating to the formal business of the Ortho General Meeting are addressed in the Ortho General Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho shareholders who have any queries about the Ortho General Meeting should contact the Shareholder Helpline operated by [Computershare], Ortho&#146;s
registrar, between 9:00 a.m. and 5:30 p.m. Monday to Friday (except English and Welsh public holidays) at [&#9679;]. Calls from outside the UK will be charged at the applicable international rate. Calls are charged at the standard geographic rate
and will vary by provider. Different charges may apply to calls from mobile telephones. Please note that calls may be monitored or recorded and [Computershare], Ortho&#146;s registrar, cannot provide advice on the merits of the Combinations or the
Scheme or give any financial, legal or tax advice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho shareholders may not use any electronic address or fax number provided in this Notice or in any
related documents to communicate with Ortho for any purpose other than those expressly stated. Any electronic communications, including the lodgment of any electronic proxy appointment, received by Ortho or its agents that is found to contain any
virus will not be accepted. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g273090g04h96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUIDEL CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>9975 Summers Ridge Road </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92121 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">552-1100</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF SPECIAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To Be Held On [</B>&#9679;<B></B><B>], 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders of Quidel Corporation (&#147;Quidel&#148;): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The special meeting of stockholders of Quidel (together with any adjournments or postponements thereof, the &#147;Quidel Stockholders&#146; Meeting&#148;)
will be held on [&#9679;], 2022, at [&#9679;] a.m., Pacific Time. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PLACE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Quidel Stockholders&#146; Meeting will be held virtually and can be accessed online at&nbsp;www.virtualshareholdermeeting.com/QDEL2022SM.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ITEMS OF BUSINESS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1.&#8195;&#8201;Proposal to approve and adopt the Business Combination Agreement (the
&#147;BCA&#148;), dated December&nbsp;22, 2021, by and among Quidel, Ortho Clinical Diagnostics Holdings plc (&#147;Ortho&#148;), Coronado Topco, Inc. (&#147;Topco&#148;), Orca Holdco, Inc. (&#147;U.S. Holdco Sub&#148;) and Laguna Merger Sub, Inc.
(&#147;U.S. Merger Sub&#148;), each wholly owned subsidiaries of Topco, and Orca Holdco 2, Inc., a wholly owned subsidiary of U.S. Holdco Sub, including the Quidel Merger (as defined in this joint proxy statement/prospectus) and the transactions
contemplated thereby (the &#147;Merger Proposal&#148;)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">2.&#8195;&#8201;Proposal to approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, certain
compensation arrangements for Quidel&#146;s named executive officers in connection with the BCA (the &#147;Advisory Merger Compensation Proposal&#148;)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">3.&#8195;&#8201;Proposal to approve any motion to adjourn the Quidel Stockholders&#146; Meeting to another time or
place, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Quidel Stockholders&#146; Meeting to approve the Merger Proposal (the &#147;Adjournment Proposal&#148;)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">4.&#8195;&#8201;Proposal to elect the eight
directors designated herein to serve on the Quidel board of directors to hold office until the 2023 annual meeting of stockholders and until their successors are elected and qualified (the &#147;Election of Directors Proposal&#148;)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">5.&#8195;&#8201;Proposal to approve, on an
advisory basis, the compensation of Quidel&#146;s named executive officers (the &#147;Advisory Executive Compensation Proposal&#148;)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">6.&#8195;&#8201;Proposal to ratify the selection of Ernst &amp; Young LLP as Quidel&#146;s independent registered
public accounting firm for the fiscal year ending December 31, 2022 (the &#147;Independent Registered Public Accounting Firm Proposal&#148;)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">7.&#8195;&#8201;Proposal to approve an amendment and restatement of Quidel&#146;s 2018 Equity Incentive Plan (the
&#147;2018 Plan&#148;) to increase the number of Quidel Shares available under the 2018 Plan from 3,205,635 shares to 4,705,635 shares (the &#147;Equity Incentive Plan Proposal&#148;)</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">8.&#8195;&#8201;Proposal to
approve an amendment and restatement of Quidel&#146;s 1983 Employee Stock Purchase Plan (the &#147;1983 ESPP&#148;) to increase the number of Quidel Shares available under the 1983 ESPP from 30,197 shares to 780,197 shares (the &#147;ESPP
Proposal&#148;)</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>RECORD DATE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">March 14, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PROXY&nbsp;VOTING</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">It is important that your shares be represented and voted at the Quidel Stockholders&#146; Meeting. You can submit a proxy to vote your shares electronically via the Internet, by telephone or by completing and returning the proxy
card or voting instruction card. Voting instructions are printed on your proxy card and are included in this joint proxy statement/prospectus. If your shares are held in the name of a bank, broker or other nominee, follow the instructions you
receive from your nominee on how to vote your shares. You can revoke a proxy at any time prior to its exercise at the Quidel Stockholders&#146; Meeting by following the instructions in the joint proxy statement/prospectus or by voting your shares
virtually at the Quidel Stockholders&#146; Meeting. Virtual attendance by stockholders of record at the Quidel Stockholders&#146; Meeting will constitute presence in person for the purpose of determining the presence of a quorum for the transaction
of business at the Quidel Stockholders&#146; Meeting.</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This joint proxy statement/prospectus describes the proposals listed above in more detail. Please refer to the
attached document, including the BCA and all other annexes and any documents incorporated by reference herein, for further information with respect to the business to be transacted at the Quidel Stockholders&#146; Meeting. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your proxy is being solicited by the Quidel board of directors. The Quidel board of directors has determined that the transactions to be implemented pursuant
to the BCA (the &#147;Combinations&#148;), including the Quidel Merger and the other transactions contemplated by the BCA, are consistent with and will further the business strategies and goals of Quidel, and are in the best interests of Quidel and
its stockholders, and (a)&nbsp;has unanimously approved and declared advisable the BCA and Combinations, including the Quidel Merger and the transactions contemplated by the BCA, and (b)&nbsp;has determined, subject to its duties under applicable
law, to recommend that the Quidel stockholders adopt the BCA and the transactions contemplated by the BCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accordingly, the Quidel board of directors
recommends that Quidel stockholders vote: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Merger Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Advisory Merger Compensation Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Adjournment Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Election of Directors Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Advisory Executive Compensation Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Independent Registered Public Accounting Firm Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Equity Incentive Plan Proposal; and </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the ESPP Proposal. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors has fixed the close of business on March 14, 2022, as the record date for determining the Quidel stockholders entitled to
receive notice of, and to vote at, the Quidel Stockholders&#146; Meeting. Only holders of record of shares of common stock of Quidel (each, a &#147;Quidel Share&#148;) at the close of business on the record date are entitled to receive notice of,
and to vote at, the Quidel Stockholders&#146; Meeting. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your vote is very important. Whether or not you plan to attend the Quidel
Stockholders&#146; Meeting, we urge you to submit a proxy to vote by Internet or telephone to ensure that your shares are represented at the Quidel Stockholders&#146; Meeting. We cannot complete the Combinations unless you approve and adopt the BCA,
the Quidel Merger and the Combinations. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A failure to submit a proxy or attend the Quidel Stockholders&#146; Meeting, a broker non-vote (if any)
or an abstention will have the same effect as a vote &#147;AGAINST&#148; the Merger Proposal. A failure to submit a proxy or attend the Quidel Stockholders&#146; Meeting or a broker non-vote (if any) as to the Advisory Merger Compensation Proposal,
the Adjournment Proposal, the Election of Directors Proposal, the Advisory Executive Compensation Proposal, the Independent Registered Public Accounting Firm Proposal, the Equity Incentive Plan Proposal or the ESPP Proposal will have no effect on
these proposals. An abstention will have the same effect as a vote &#147;AGAINST&#148; the Advisory Merger Compensation Proposal, the Adjournment Proposal, the Election of Directors Proposal, the Advisory Executive Compensation Proposal, the
Independent Registered Public Accounting Firm Proposal, the Equity Incentive Plan Proposal and the ESPP Proposal. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By order of the Board of Directors,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REFERENCES TO ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus incorporates important business and financial information about Quidel and Ortho from other documents that each company
has filed with the SEC. For a listing of documents incorporated by reference into this joint proxy statement/prospectus, please see the section entitled &#147;Where You Can Find More Information&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can obtain the documents incorporated by reference into this joint proxy statement/prospectus free of charge by visiting the SEC&#146;s website at
http://www.sec.gov, from Quidel by visiting www.quidel.com, from Ortho by visiting www.orthoclinicaldiagnostics.com or by requesting them in writing or by telephone from the appropriate company at the following addresses and telephone numbers. The
information contained on Quidel&#146;s and Ortho&#146;s websites is not incorporated into, and does not form a part of, the accompanying joint proxy statement/prospectus or any other report or document on file with or furnished to the SEC. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Quidel&nbsp;Corporation</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Ortho Clinical Diagnostics Holdings plc</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">9975 Summers Ridge Road</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1001 Route 202</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">San Diego, California 92121</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Raritan, New Jersey 08869</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Attention:&nbsp;Phillip&nbsp;S.&nbsp;Askim,<BR>VP,&nbsp;Associate&nbsp;General&nbsp;Counsel&nbsp;&amp;&nbsp;Secretary</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Attention:&nbsp;Michael&nbsp;A.&nbsp;Schlesinger,<BR>Executive&nbsp;Vice President, General Counsel and Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">(858) <FONT STYLE="white-space:nowrap">552-1100</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(908) 218-8000</TD></TR>
</TABLE>    <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a Quidel stockholder, you may also request copies of this joint proxy statement/prospectus and any of
the documents incorporated by reference into this joint proxy statement/prospectus or other information concerning Quidel, without charge, by written or telephonic request directed to Innisfree M&amp;A Incorporated, Quidel&#146;s proxy solicitor, by
calling (877) <FONT STYLE="white-space:nowrap">750-0537.</FONT> If you would like to request any documents, please do so by [&#9679;], 2022 in order to receive them before the Quidel Stockholders&#146; Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are an Ortho shareholder, you may also request copies of this joint proxy statement/prospectus and any of the documents incorporated by reference into
this joint proxy statement/prospectus or other information concerning Ortho, without charge, by written or telephonic request directed to MacKenzie Partners, Inc., Ortho&#146;s proxy solicitor, by calling toll-free at 1-800-322-2885. If you would
like to request any documents, please do so by [&#9679;], 2022 in order to receive them before the Ortho Shareholder Meetings. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_1"></A>ABOUT THIS JOINT PROXY STATEMENT/PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document, which forms part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> filed with the SEC by Topco (File
No.&nbsp;333-262434), constitutes a prospectus of Topco under the U.S. Securities Act of 1933, as amended (the &#147;Securities Act&#148;), with respect to the Topco Shares to be issued pursuant to the BCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document also constitutes a proxy statement of each of Quidel and Ortho under Section&nbsp;14(a) of the U.S. Securities Exchange Act of 1934, as amended
(the &#147;Exchange Act&#148;), with respect to the Quidel Stockholders&#146; Meeting and the Ortho Shareholder Meetings, respectively. It also constitutes a notice of meeting with respect to the Ortho Court Meeting and the Ortho General Meeting and
contains an explanatory statement in respect of the Ortho Scheme as required by Section&nbsp;897 of the UK Companies Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the
information contained in or incorporated by reference into this joint proxy statement/prospectus. No person has been authorized to provide you with information that is different from what is contained in, or incorporated by reference into, this
joint proxy statement/prospectus, and, if given or made by any person, such information must not be relied upon as having been authorized. You should not assume that the information contained in this joint proxy statement/prospectus is accurate as
of any date other than its date as specified on the cover unless otherwise specifically provided herein. Further, you should not assume that the information contained in or incorporated by reference into this joint proxy statement/prospectus is
accurate as of any date other than the date of the incorporated document. Neither the mailing of this joint proxy statement/prospectus to Quidel stockholders and Ortho shareholders nor the issuance by Topco of Topco Shares pursuant to the BCA will
create any implication to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the SEC, the FCA, nor any securities commission of any jurisdiction has approved or disapproved any of
the transactions described in this joint proxy statement/prospectus or the securities to be issued under this joint proxy statement/prospectus or passed upon the adequacy or accuracy of this joint proxy statement/prospectus. Any representation to
the contrary is a criminal offense. This joint proxy statement/prospectus does not constitute an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities, or a solicitation of a proxy, in any jurisdiction to or from any
person to whom it is unlawful to make any such offer or solicitation in such jurisdiction. The distribution or possession of this joint proxy statement/prospectus in or from certain jurisdictions may be restricted by law. For the avoidance of doubt,
this joint proxy statement/prospectus does not constitute an offer to buy or sell securities or a solicitation of an offer to buy or sell any securities in the United Kingdom or any state in the European Economic Area or a solicitation of a proxy
under the laws of England and Wales, and it is not intended to be, and is not, a prospectus or an offer document for the purposes of the FCA&#146;s Prospectus Rules. You should inform yourself about and observe any such restrictions, and none of
Quidel, Ortho or Topco accepts any liability in relation to any such restrictions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information concerning Quidel contained or incorporated by
reference in this joint proxy statement/prospectus has been provided by Quidel, and the information concerning Ortho, Topco, U.S. Holdco Sub, U.S. Merger Sub and U.S. Holdco Sub 2 contained or incorporated by reference in this joint proxy
statement/prospectus has been provided by Ortho. As used in this joint proxy statement/prospectus, except where otherwise stated or indicated by the context, all references to Quidel are to Quidel Corporation and its consolidated subsidiaries, and
all references to Ortho are to Ortho Clinical Diagnostics Holdings plc and its consolidated subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPECTED TIMETABLE OF PRINCIPAL EVENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All dates and times relating to the Ortho Scheme are based on Ortho&#146;s and Quidel&#146;s current expectations and are subject to change. If any of the
dates or times in this expected timetable change materially, the revised dates and/or times will be published by public announcement in the United States and by making such announcement available on Ortho&#146;s website at [&#9679;]. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Expected Time and/or
Date<SUP STYLE="font-size:85%; vertical-align:top">i</SUP></B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Directions hearing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">February&nbsp;15, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-registered</FONT> shareholder record time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;] [a.m./ p.m.] (London time) on [&#9679;], 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Publication of the Ortho Scheme as contained in this joint proxy statement/ prospectus</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;], 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Latest time for receipt by Ortho&#146;s registrar of forms of proxy for the Ortho Court Meeting (blue form)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;] [a.m./ p.m.] (London time) on [&#9679;], 2022<SUP STYLE="font-size:85%; vertical-align:top">ii</SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Latest time for receipt by Ortho&#146;s registrar of forms of proxy for the Ortho General Meeting (white form)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;] [a.m./ p.m.] (London time) on [&#9679;], 2022<SUP STYLE="font-size:85%; vertical-align:top">iii</SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Voting Record Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[6:00] [p.m.] (London time) on , 2022<SUP STYLE="font-size:85%; vertical-align:top">iv</SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ortho Court Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;] [a.m./ p.m.] (London time) on [&#9679;], 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ortho General Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[<I></I>&#9679;<I></I><I></I>] [a.m./ p.m.] (London time) on [&#9679;], 2022<SUP STYLE="font-size:85%; vertical-align:top">v</SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">The following dates and times associated with the Ortho Scheme are presented for illustrative purposes only, are subject to change and will depend on, among other things, the date on which the conditions to the Ortho
Scheme are satisfied or, if capable of waiver, waived, the date on which the Court sanctions the Ortho Scheme and the date on which the Court Order is delivered to the Registrar of Companies in England and Wales (the &#147;Registrar&#148;). Ortho
will give adequate notice of all of these dates and times, when known, by public announcement in the United States and by making the announcement available of Ortho&#146;s website at [&#9679;]. Further updates and changes to these times will be
notified in the same way.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Court Sanction Hearing (as defined herein)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">D&nbsp;-[&#9679;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Last day of dealings in, and for registration of transfers of, Ortho Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">D - [&#9679;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Scheme Record Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[6:00] [p.m.] (London time) on <FONT STYLE="white-space:nowrap">D-1</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Effective Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">D&nbsp;(&#147;<B>D</B>&#148;)<SUP STYLE="font-size:85%; vertical-align:top">vi</SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date for dispatch of cheques/settlement for cash consideration (including any cash entitlement in respect of fractional shares) due under the Ortho Scheme</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]<SUP STYLE="font-size:85%; vertical-align:top">vii</SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cancellation of listing of Ortho Shares on Nasdaq</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[Listing of, and commencement of dealings in, Topco Shares on Nasdaq]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New Topco Shares credited by the Exchange Agent (as defined herein) to Cede&nbsp;&amp; Co., as nominee for DTC (in respect of Ortho Shares held in book-entry form through DTC)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]<SUP STYLE="font-size:85%; vertical-align:top">viii</SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New Topco Shares credited by the Exchange Agent in book-entry form on its books (in respect of Ortho Shares held in certificated or book-entry form on books of the Exchange Agent)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]<SUP STYLE="font-size:85%; vertical-align:top">viii</SUP></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">i</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The dates and times given are indicative only and are based on current expectations and are subject to change.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">ii</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is requested that the blue form of proxy for the Ortho Court Meeting be received by [&#9679;] [a.m./ p.m.]
(London time) on [&#9679;], 2022, or, if the Ortho Court Meeting is adjourned, 48 hours prior to the time fixed for the adjourned Ortho Court Meeting (excluding any part of such 48-hour period falling on a non-working day). If the blue form of proxy
is not lodged by this time, it may be emailed to [&#9679;] or handed to the Chair at any time prior to the commencement of the Ortho Court Meeting. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">iii</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In order to be valid, the white form of proxy for the Ortho General Meeting must be received by [&#9679;]
[a.m./ p.m.] (London time) on [&#9679;], 2022 or, if the Ortho General Meeting is adjourned, 48-hours prior to the time fixed for the adjourned Ortho General Meeting (excluding any part of such 48 hour period falling on a non-working day).
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">iv</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If either the Ortho Court Meeting or the Ortho General Meeting is adjourned, the Voting Record Time for the
relevant adjourned meeting will be [6:00] [p.m.] (London time) on the day which is two Business Days prior to the date of the adjourned meeting. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">v</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To commence at [&#9679;] [a.m./ p.m.] (London time) on [&#9679;], 2022 or as soon thereafter as the Ortho Court
Meeting concludes or is adjourned. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">vi</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Ortho Scheme will become effective pursuant to its terms upon the Court Order being delivered to the
Registrar. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">vii</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Cash Consideration under the Ortho Scheme shall be settled in accordance with the terms of the Ortho Scheme
on or as soon as reasonably practicable following the Effective Date (and in any event no later than 2 Business Days following the Effective Date). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">viii</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Share Consideration under the Ortho Scheme shall be settled in accordance with the terms of the Ortho
Scheme as soon as reasonably practicable following the Effective Date (and in any event no later than 2 Business Days following the Effective Date). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_1">ABOUT THIS JOINT PROXY STATEMENT/PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_2">QUESTIONS AND ANSWERS ABOUT THE COMBINATIONS, THE QUIDEL STOCKHOLDERS&#146;
 MEETING AND THE ORTHO SHAREHOLDER MEETINGS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_3">NOTE ON PRESENTATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_4">Ortho Financial Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_5">Quidel Financial Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_6">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_7">Information about the Parties to the Combinations </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_8">The Combinations and the Business Combination Agreement </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_9">Structure and Effective Times </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_10">Merger Consideration </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_11">Treatment of Ortho Equity Awards </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_12">Treatment of Quidel Equity Awards </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_13">Ortho Reasons for the Combinations and Recommendation of the Ortho Board of
 Directors </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_14">Quidel Reasons for the Combinations and Recommendation of the Quidel Board
 of Directors </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_15">Opinion of J.P. Morgan Securities LLC as Financial Advisor to Ortho
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_16">Opinion of Perella Weinberg Partners LP as Financial Advisor to Quidel
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_17">Material U.S. Federal Income Tax Considerations </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_18">Material UK Tax Considerations </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_19">Delisting and Deregistration of Ortho Shares and Quidel Shares
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_19a">Litigation Relating to the Combinations </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_20">Interests of Quidel Officers and Directors in the Combinations
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_21">Interests of Ortho Officers and Directors in the Combinations
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_22">Indemnification and Insurance </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_23">Board of Directors and Management of Topco Following Completion of the Combinations
 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_24">Acquisition Proposals </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_25">Conditions to the Combinations </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_26">Termination </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_27">Expenses and Termination Fees </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_28">Regulatory Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_29">Security Ownership of Quidel Directors and Executive Officers
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_30">Security Ownership of Ortho Directors and Executive Officers
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_31">No Appraisal Rights for Quidel Stockholders </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_32">No Delaware Appraisal Rights for Ortho Shareholders </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_33">Listing of Topco Shares on Stock Exchanges </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_34">Accounting Treatment </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_35">Comparison of Rights of Stockholders of Quidel, Ortho and Topco
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_36">Please Read the Risk Factors </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_37">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_38">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_39">Risks Relating to the Combinations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_40">Risks Relating to Topco Following Completion of the
Combinations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_41">Risks Relating to Quidel&#146;s Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_42">Risks Relating to Ortho&#146;s Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_43">UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_44">SCHEME PROPOSAL AND THE ORTHO SHAREHOLDER MEETINGS&#151;EXPLANATORY STATEMENT
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_45">Introduction</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_46">The Ortho Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_47">Conditions to Complete the Combinations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_48">Shareholder Meetings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_49">The Ortho Directors and the Effect of the Ortho Scheme on their Interests
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_50">Sanction of the Ortho Scheme by the Court</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_51">Solicitation of Proxies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_52">Listings, Dealings, Delisting and Settlement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_53">Overseas Ortho Shareholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_54">Action to be Taken</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_55">Forms of Proxy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_56">Further information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_57">THE ORTHO GENERAL MEETING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_58">Ortho Proposal No. 1&#151;Scheme Implementation Proposal</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_59">Ortho Proposal No. 2&#151;Non-Binding Advisory Proposal to Approve Certain
 Compensation Arrangements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_60">THE ORTHO SCHEME</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_61">The Scheme</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_62">Transfer of the Scheme Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_63">Consideration for the Transfer of the Scheme Shares&#151;Transaction Deliverables
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_64">Share Certificates and Register of Members</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_65">Appointment of Exchange Agent</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_66">Settlement of Transaction Deliverables</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_67">Cessation of Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_68">Mandates and Dividends</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_69">Effective Time</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_70">Modification</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_71">Governing Law</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_72">THE QUIDEL STOCKHOLDERS&#146; MEETING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_73">General</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_74">Recommendation of the Quidel Board of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_75">Record Date; Stockholders Entitled to Vote</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_76">Voting by Quidel&#146;s Directors and Executive Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_77">Quorum</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_78">Required Vote</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_79">Failure to Either Submit a Proxy or Attend the Quidel Stockholders&#146; Meeting,
 Broker <FONT STYLE="white-space:nowrap">Non-Votes</FONT> and Abstentions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_80">How to Vote Your Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_81">Voting in Person</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_82">Voting of Proxies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_83">Revocation of Proxies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_84">Solicitation of Proxies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_85">Quidel Proposal No. 1&#151;The Merger Proposal</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_86">Quidel Proposal No. 2&#151;The Advisory Merger Compensation
Proposal</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_86a">Quidel Proposal No. 3&#151;The Adjournment Proposal</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_86b">Quidel Proposal No. 4&#151;The Election of Directors Proposal
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_86c">Quidel Proposal No. 5&#151;The Advisory Executive Compensation Proposal
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_86d">Quidel Proposal No. 6&#151;The Independent Registered Public Accounting Firm
 Proposal </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_86e">Quidel Proposal No. 7&#151;The Equity Incentive Plan Proposal
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_86f">Quidel Proposal No. 8&#151;The ESPP Proposal </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_86g">OTHER MATTERS RELATING TO THE QUIDEL STOCKHOLDERS&#146; MEETING
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_86h">Committees and Meetings of the Quidel Board of Directors and Related Matters
 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_86i">Director Compensation </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_86j">Executive Compensation </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_87">INFORMATION ABOUT THE PARTIES TO THE COMBINATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_88">Quidel Corporation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_89">Ortho Clinical Diagnostics Holdings plc</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_90">Coronado Topco, Inc.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_91">Laguna Merger Sub, Inc.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_92">Orca Holdco, Inc</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_93">Orca Holdco 2, Inc</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_115">BUSINESS OF QUIDEL AND CERTAIN INFORMATION ABOUT QUIDEL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_116">Products</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_117">Digital and Telehealth Solutions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_118">Connectivity and Data Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_119">Marketing and Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_120">Manufacturing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_94">BUSINESS OF ORTHO</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_95">Business of Ortho</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_96">Overview of Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_98">Ortho&#146;s Competitive Strengths</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_99">Ortho&#146;s Growth Strategy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_100">Ortho&#146;s Industry</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_101">Ortho&#146;s Products, Pipeline and Services</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_102">Key Products&#151;Clinical Laboratories</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_103">Key Products&#151;Transfusion Medicine</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_104">Sales, Marketing and Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_105">Research and Development</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_106">Suppliers and Raw Materials</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_107">Manufacturing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_108">Competition</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_109">Intellectual Property</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_110">Collaboration Arrangements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_111">Human Capital Resources</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_112">Health, Safety and Environmental</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_113">Government Regulation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_114">Available Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_121">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS OF QUIDEL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_122">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS OF ORTHO</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_123">Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_124">Key Components of Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_125">Impact of the Initial Public Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_125a">Underwritten Secondary Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_126">Impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> Pandemic
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_127">Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_128">Use of <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measures
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_129">Segment Results</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_130">Liquidity and Capital Resources</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_132">Critical Accounting Estimates and Summary of Significant Accounting Policies
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_134">THE COMBINATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_135">The Combinations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_136">Background of the Combinations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_137">Ortho Scheme Consideration to Ortho Shareholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_139">Quidel Reasons for the Combinations and Recommendation of the Quidel Board
 of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_138">Ortho Reasons for the Combinations and Recommendation of the Ortho Board
 of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_141">Opinion of Perella Weinberg Partners LP as Financial Advisor to
Quidel</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_140">Opinion of J.P. Morgan Securities LLC as Financial Advisor to
Ortho</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_142">Unaudited Forward-Looking Financial Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_143">Closing Date and Effective Times</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_144">Board of Directors and Management of Topco Following Completion of the Combinations
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_145">Accounting Treatment</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_146">Regulatory Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_147">The Parties&#146; Intentions Regarding Ortho and Quidel</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_148">U.S. Federal Securities Law Consequences</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_149">Listing of Topco Shares on Stock Exchange</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_150">Delisting and Deregistration of Ortho Shares and Quidel
Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_150a">Litigation Relating to the Combinations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_151">DESCRIPTION OF TOPCO CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_152">THE BUSINESS COMBINATION AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_153">Explanatory Note Regarding the Business Combination
Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_154">Execution of the Business Combination Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_155">Structure and Effective Times</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_156">Merger Consideration</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_157">Adjustments to Prevent Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_158">Exchange of Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_159">Lost, Stolen or Destroyed Certificates</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_160">No Transfers Following the Quidel Effective Time</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_161">Termination of Exchange Fund</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_162">Withholding Taxes</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_163">Treatment of Ortho Equity Awards</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_164">Treatment of Quidel Equity Awards</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_165">Representations and Warranties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_166">Conduct of Business Prior to the Effective Times</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_167">Certain Permitted Disclosure</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_168">Stockholder Meetings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_169">Efforts to Complete the Combinations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_170">Indemnification and Insurance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_171">Employee Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_172">Corporate Governance Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_173">Other Covenants and Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_175">Conditions to the Combinations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_176">Termination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_177">Expenses and Termination Fees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_178">Specific Performance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_179">STOCKHOLDERS AGREEMENT / DEED OF IRREVOCABLE UNDERTAKING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_180">Stockholders Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_180a">Current Ortho Stockholders Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_181">Irrevocable Undertaking</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_182">INTERESTS OF CERTAIN PERSONS IN THE COMBINATIONS (QUIDEL)</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_184">Treatment of Quidel Equity Awards</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_185">Post-Combinations Compensation and Benefit Arrangements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_186">Executive Severance Arrangements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_188">Golden Parachute Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_187">Topco Positions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_189">Insurance and Indemnification of Directors and Executive
Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_190">INTERESTS OF CERTAIN PERSONS IN THE COMBINATIONS (ORTHO)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_191">Compensation Actions in Connection with the Combinations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_192">Treatment of Ortho Equity Awards</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_193">Executive Severance Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_194">Continuing Employees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_195">Retention Bonuses</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_196">Transaction Bonuses</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_197">Golden Parachute Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_198">Topco Positions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_199">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_200">MATERIAL UK TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_201">COMPARISON OF RIGHTS OF STOCKHOLDERS OF QUIDEL, ORTHO AND
TOPCO</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_202">SECURITY OWNERSHIP OF CERTAIN QUIDEL BENEFICIAL OWNERS AND
MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_203">SECURITY OWNERSHIP OF CERTAIN ORTHO BENEFICIAL OWNERS AND
MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_204">HOUSEHOLDING OF PROXY MATERIALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_205">FUTURE STOCKHOLDER PROPOSALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_206">Topco</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_207">Quidel</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_208">Ortho</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_209">NO APPRAISAL RIGHTS FOR QUIDEL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_210">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_211">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_500">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_212">ANNEX A&#151;BUSINESS COMBINATION AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_213">ANNEX B&#151;PRINCIPAL STOCKHOLDERS AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">B-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_214">ANNEX C&#151;FORM OF IRREVOCABLE UNDERTAKING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">C-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_215">ANNEX D&#151;OPINION OF PERELLA WEINBERG PARTNERS LP</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">D-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_216">ANNEX E&#151;OPINION OF J.P. MORGAN SECURITIES LLC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">E-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_217">ANNEX F&#151;ARTICLES OF ASSOCIATION OF ORTHO</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_217a">ANNEX G&#151;2018 PLAN</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273090_217b">ANNEX H&#151;1983 ESPP</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">H-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">viii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_2"></A>QUESTIONS AND ANSWERS ABOUT THE COMBINATIONS, THE QUIDEL
STOCKHOLDERS&#146; MEETING AND THE ORTHO SHAREHOLDER MEETINGS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is this document? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This document, which we refer to as the &#147;joint proxy statement/prospectus,&#148; (i) serves as the proxy
statement through which Quidel and Ortho will solicit proxies to seek to obtain the necessary Quidel stockholder and Ortho shareholder approvals for the Combinations, (ii)&nbsp;informs holders of Quidel Shares of the upcoming Quidel
Stockholders&#146; Meeting at which Quidel stockholders will vote on the adoption of the BCA and the Quidel Merger and provides details of the BCA and the consideration Quidel stockholders will receive upon completion of the Combinations,
(iii)&nbsp;informs holders of Ortho Shares of the upcoming Ortho Shareholder Meetings at which Ortho shareholders will vote on the Ortho Scheme, authorize the directors of Ortho (or a duly authorized committee of the directors) to take all such
action as they may consider necessary or appropriate for carrying the Ortho Scheme into effect, amend the articles of association of Ortho and approve (on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis) certain compensation
that may be paid or become payable to Ortho&#146;s named executive officers in connection with the Combinations, as disclosed in the table entitled &#147;Interests of Certain Persons in the Combinations (Ortho)&#151;Golden Parachute
Compensation,&#148; (iv) provides details of the BCA and the consideration Ortho shareholders will receive upon completion of the Combinations, (v)&nbsp;serves as the prospectus by which Topco will issue Topco Shares to Quidel stockholders and Ortho
shareholders in connection with the Combinations and (vi)&nbsp;provides Quidel stockholders and Ortho shareholders with important details about Topco and their rights as potential holders of Topco Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the proposed transaction I am being asked to vote on, and how will it be implemented?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On December&nbsp;22, 2021, Quidel entered into the BCA with Ortho, Topco, U.S. Holdco Sub, U.S. Merger Sub and
U.S. Holdco Sub 2, which provides for the acquisition of Ortho and Quidel by Topco. Pursuant to the BCA, the Combinations are expected to be implemented by way of: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i) a scheme of arrangement to be undertaken by Ortho under Part 26 of the UK Companies Act (the &#147;Ortho Scheme&#148;), pursuant to which
the Scheme Shares will be acquired by a nominee of Topco (or, if such nominee holds the Ortho Shares today, transferred within the nominee), such that Ortho will become a wholly owned subsidiary of Topco; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii) a merger (the &#147;Quidel Merger&#148;) of U.S. Merger Sub with and into Quidel immediately following consummation of the Ortho Scheme,
with Quidel surviving the merger as a wholly owned subsidiary of Topco (the transactions in (i)&nbsp;and (ii) together, the &#147;Combinations&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For more information about the Ortho Scheme, see the sections entitled &#147;Scheme Proposal and the Ortho Shareholder
Meetings&#151;Explanatory Statement&#148; and &#147;The Ortho Scheme&#148; of this joint proxy statement/prospectus. For more information about the Quidel Merger, see the section entitled &#147;The Quidel Stockholders&#146; Meeting&#151;Proposal No.
1&#151;The Merger&#148; of this joint proxy statement/prospectus. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why are Quidel and Ortho proposing this transaction? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The board of directors of each of Quidel and Ortho believes that the transaction will benefit Quidel
stockholders and Ortho shareholders by creating a combined company that will bring together innovative and highly complementary diagnostic portfolios with world-class technologies and platforms that enhance the health and well-being of patients
across the globe. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For more details on the reasons for the transaction, see the sections entitled &#147;The
Combinations&#151;Quidel Reasons for the Combinations and Recommendation of the Quidel Board of Directors&#148; and &#147;The Combinations&#151;Ortho Reasons for the Combinations and Recommendation of the Ortho Board of Directors&#148; of this joint
proxy statement/prospectus. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why did I receive this joint proxy statement/prospectus and proxy card? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You are receiving this joint proxy statement/prospectus because you were a stockholder of record of Quidel on
the record date for the Quidel Stockholders&#146; Meeting and/or a shareholder of record of Ortho on the record date for the Ortho Court Meeting and Ortho General Meeting, and are accordingly entitled to vote at the Quidel Stockholders&#146;
Meeting, the Ortho Court Meeting or the Ortho General Meeting (as applicable). This document serves (i)&nbsp;as a proxy </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
statement of Quidel used to solicit proxies to obtain the necessary stockholder approval for the Merger Proposal, the Adjournment Proposal, the Election of Directors Proposal, the Independent
Registered Public Accounting Firm Proposal, the Equity Incentive Plan Proposal and the ESPP Proposal and the approval (on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis) for the Advisory Merger Compensation Proposal and the
Advisory Executive Compensation Proposal at the Quidel Stockholders&#146; Meeting, (ii)&nbsp;as a proxy statement of Ortho used to solicit proxies to obtain the necessary shareholder approval for the Ortho Scheme at the Ortho Court Meeting and for
the general authorization of the directors of Ortho (or a duly authorized committee of the directors) to take all such action as they may consider necessary or appropriate for carrying the Ortho Scheme into effect, the adoption of new Ortho articles
of association and the approval (on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis) of certain compensation arrangements at the Ortho Shareholder Meetings, and (iii)&nbsp;as a prospectus of Topco used to offer Topco Shares in
exchange for Quidel Shares and Ortho Shares pursuant to the terms of the BCA. The enclosed voting materials allow both Quidel stockholders and Ortho shareholders to vote their shares by proxy without attending their respective meeting virtually.
</TD></TR></TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will Quidel stockholders and Ortho shareholders receive in the Combinations? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Combinations are approved, at the effective time of the Ortho Scheme (the &#147;Ortho Effective
Time&#148;), each Ortho Share, other than Ortho Shares held by Ortho in treasury, if any, will be acquired by a nominee (or, if such nominee holds the Ortho Shares today, transferred within the nominee) on behalf and for the benefit of Topco in
exchange for 0.1055 Topco Shares and $7.14 in cash. At the effective time of the Quidel Merger (the &#147;Quidel Effective Time&#148; and together with the Ortho Effective Time, the &#147;Effective Times&#148;), each share of common stock of Quidel
(each, a &#147;Quidel Share&#148;), other than Quidel Shares held by Quidel, Ortho or U.S. Merger Sub, will be converted into the right to receive one Topco Share. The parties intend to list the Topco Shares to be issued in the Combinations on the
Nasdaq Global Select Market (&#147;Nasdaq&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What percentage will former Quidel stockholders and Ortho shareholders hold in Topco following completion of
the Combinations? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is anticipated that, immediately following completion of the Combinations, former Quidel stockholders will
own approximately 62% of Topco on a fully diluted basis and former Ortho shareholders will own approximately 38% of Topco on a fully diluted basis, based on the respective capitalizations of Quidel and Ortho as of the date the parties entered into
the BCA. The exact equity stakes that former Quidel stockholders and former Ortho shareholders will hold in Topco immediately following the Combinations will depend on the number of Quidel Shares and Ortho Shares issued and outstanding immediately
prior to the Effective Times. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>If the Combinations are completed, will Topco Shares be listed for trading? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. The Topco Shares you will receive in the Combinations are expected to be listed on Nasdaq as of the
completion of the Combinations, which will occur on the date of the Effective Times. Completion of the Combinations is subject to the Topco Shares being approved for listing on Nasdaq, subject to official notice of issuance. Topco Shares received in
the Combinations are expected to be freely transferable under applicable securities laws (subject to any applicable minimum holding period in respect of Topco Shares received in exchange for Quidel Shares or Ortho Shares delivered upon vesting of
certain equity awards), except for any Topco Shares held by Topco&#146;s affiliates. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How will fractional entitlements to Topco Shares be dealt with? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fractions of Topco Shares that Scheme Shareholders would otherwise be entitled to will not be allotted to
Scheme Shareholders. Instead, Scheme Shareholders will receive, in lieu of such fractional entitlements, cash in an amount in U.S. dollars (rounded down to the nearest cent) equal to such fractional amount multiplied by the aggregate net proceeds
from the sale of all such fractional entitlements. The Exchange Agent will orchestrate the sale of the fractional entitlements on Nasdaq in the ten Business Days following the Scheme Effective Date (as defined herein). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>When do you expect the Combinations to be completed? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Combinations are expected to close before the end of the first half of 2022, subject to the approvals of
Quidel stockholders and Ortho shareholders, receipt of regulatory approvals and consents and satisfaction of other closing conditions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if the Combinations are not completed? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Quidel stockholders do not approve the Merger Proposal, if the Ortho shareholders do not approve the Ortho
Scheme or if the Combinations are not completed for any other reason, Quidel and Ortho will remain independent companies. In the event of a termination, Quidel Shares and Ortho Shares will continue to be listed and traded individually on Nasdaq and
both Quidel and Ortho will continue to be registered under the Exchange Act and file periodic reports with the SEC. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Quidel or Ortho may each terminate the BCA under certain circumstances, including, among others, where the other party breaches its
representations, warranties or covenants contained in the BCA (subject to customary materiality thresholds and cure periods). In connection with the termination of the BCA under specified circumstances, Quidel or Ortho may be required to pay the
other party a termination fee of approximately $207.8&nbsp;million, in the case of payment by Quidel, or approximately $46.9&nbsp;million, in the case of payment by Ortho, or may be required to reimburse the other party for its <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the BCA. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What regulatory approvals are needed to complete the Combinations? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Quidel and Ortho have agreed to use their reasonable best efforts to obtain all regulatory approvals required
to complete the transactions contemplated by the BCA. These approvals include clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &#147;HSR Act&#148;), and other merger control and foreign investment laws
and regulations. Quidel and Ortho have completed, or will complete, the filing of applications and notifications to obtain the required regulatory approvals. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For further details on regulatory approvals, see the section entitled &#147;The Combinations&#151;Antitrust and Merger Control&#148; of this
joint proxy statement/prospectus. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What other conditions must be satisfied to complete the Combinations? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition to Quidel stockholder and Ortho shareholder approvals and clearance from antitrust, competition and
foreign investment authorities in certain areas where Quidel and Ortho operate, closing of the Combinations is subject to certain additional conditions, including (i)&nbsp;the absence of any law or order prohibiting the Combinations,
(ii)&nbsp;effectiveness of a registration statement for the Topco Shares to be issued in the Combinations, (iii)&nbsp;Nasdaq listing approval for Topco Shares and (iv)&nbsp;sanction of the Ortho Scheme by the High Court of Justice of England and
Wales (the &#147;Court&#148;) and the delivery of the order of the Court sanctioning the Ortho Scheme to the Registrar. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What are the U.S. federal income tax considerations to Quidel stockholders and Ortho shareholders of the
Combinations? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The exchange of Quidel Shares for Topco Shares pursuant to the Quidel Merger, taken together with the Ortho
Scheme, will qualify as a transaction described in Section&nbsp;351 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;). As a result, subject to the limitations and qualifications described in the section entitled &#147;Material
U.S. Federal Income Tax Considerations&#148; of this joint proxy statement/prospectus no gain or loss is expected to be recognized by the U.S. Holders of Quidel Shares as a result of the Quidel Merger. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The exchange of Ortho Shares for Topco Shares and cash pursuant to the Ortho Scheme, taken together with the Quidel Merger, will qualify as a
transaction described in Section&nbsp;351 of the Code. As a result, subject to the limitations and qualifications described in the section entitled &#147;Material U.S. Federal Income Tax Considerations&#148; of this joint proxy statement/prospectus,
gain (but not loss) is expected to be recognized on the exchange of Ortho Shares for a combination of cash and Topco Shares pursuant to the Ortho Scheme in an amount equal to the lesser of: (a)&nbsp;the excess of (i)&nbsp;the sum of the fair market
value of the Topco Shares and the amount of cash received by such U.S. Holder over (ii)&nbsp;such U.S. Holder&#146;s tax basis in its Ortho Shares, and (b)&nbsp;the amount of cash received by such U.S. Holder pursuant to the Ortho Scheme. The
treatment of the cash received in lieu of fractional Topco Shares is discussed separately in the section entitled &#147;Material U.S. Federal Income Tax Considerations&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Please carefully review the information set forth in the section entitled &#147;Material U.S. Federal Income Tax Considerations&#148; of this
joint proxy statement/prospectus for a general discussion of material U.S. federal income tax considerations relating to the Quidel Merger and the Ortho Scheme. You are strongly urged to consult your tax advisors as to the specific tax consequences
to you. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What are the UK tax considerations to shareholders of the Combinations? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See the section entitled &#147;Material UK Tax Considerations&#148; of this joint proxy statement/prospectus.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>As Ortho is a UK public limited company, do the UK rules on takeovers apply to the proposed Combinations?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The UK Panel on Takeovers and Mergers has confirmed that the City Code on Takeovers and Mergers (the
&#147;City Code&#148;) will not apply to any transaction involving Ortho (including the Combinations) because the place of central management and control of Ortho for purposes of the City Code is outside of the UK, the Isle of Man and the Channel
Islands. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Are either Quidel stockholders or Ortho shareholders entitled to exercise dissenters&#146;, appraisal, cash
exit, or similar rights? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. Neither Quidel stockholders nor Ortho shareholders are entitled to appraisal or dissenters&#146; rights in
connection with the transaction. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What impact will the Ortho Scheme have on Ortho mandates relating to the payment of dividends?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any mandates relating to the payment of dividends on any Scheme Shares and other instructions (including
communications preferences) given to Ortho by Scheme Shareholders in force at the Scheme Record Time relating to Scheme Shares will, as from the Scheme Effective Date, cease to be valid. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>As an Ortho shareholder, why did I receive two forms of proxy? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ortho shareholders are entitled to vote at two meetings, the Ortho Court Meeting and the Ortho General Meeting.
Each Ortho shareholder received a blue form of proxy for use in respect of the Ortho Court Meeting and a white form of proxy for use in respect of the Ortho General Meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Whose proxies are being solicited and who is entitled to vote at the Quidel Stockholders&#146; Meeting and
the Ortho Shareholder Meetings? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Only Quidel stockholders are entitled to vote at the Quidel Stockholders&#146; Meeting and only Ortho
shareholders are entitled to vote at the Ortho Court Meeting and Ortho General Meeting. The record date for the Quidel Stockholders&#146; Meeting is March 14, 2022. Only holders of record of Quidel Shares as of the close of business on the record
date are entitled to notice of, and to vote at, the Quidel Stockholders&#146; Meeting. Each holder of Quidel Shares is entitled to cast one vote on each matter properly brought before the Quidel Stockholders&#146; Meeting for each Quidel Share that
such holder owned of record as of the close of business on the record date. </P></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Voting Record Time for the Ortho
Shareholder Meetings is [&#9679;] [a.m./ p.m.] (Eastern Standard Time) and [6:00] p.m. (London time) on [&#9679;], 2022. Only those shareholders registered on the register of members of Ortho as of such time are entitled to vote at the Ortho
Shareholder Meetings. Each holder of Ortho Shares is entitled to cast one vote on each matter properly brought before the Ortho Court Meeting and one vote on each matter properly brought before the Ortho General Meeting for each Ortho Share that
such holder owned of record as of the Voting Record Time. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What do I need to do now? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Carefully read through this joint proxy statement/prospectus. Consider all the consequences that would occur
should you vote &#147;<B>FOR</B>&#148; or &#147;<B>AGAINST</B>&#148; or &#147;<B>ABSTAIN</B>&#148; / <B>&#147;</B><B>WITHHELD</B><B>&#148;</B> on the proposals at the Quidel Stockholders&#146; Meeting if you are a Quidel stockholder, or at the Ortho
Court Meeting or the Ortho General Meeting (as applicable) if you are an Ortho shareholder, and the consequences that would occur if you fail to submit a proxy. Confer with any advisors you think necessary to make the best decision. Fill out your
proxy card(s) and send it back to Quidel or Ortho, as applicable, as soon as possible in accordance with the instructions contained herein. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Even if you plan to attend the Quidel Stockholders&#146; Meeting, the Ortho Court Meeting or the Ortho General Meeting (as applicable), after
carefully reading and considering the information contained in this joint proxy statement/prospectus, please submit your proxy promptly to ensure that your shares are represented at the respective meeting(s). If you decide to attend the meeting(s)
and vote virtually, your vote by ballot will revoke any proxy previously submitted. Your attendance at a meeting will not automatically revoke your proxy. Both the Quidel Stockholders&#146; Meeting and the Ortho Shareholder Meetings will be entirely
virtual. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner (i.e., hold Quidel Shares or Ortho Shares in &#147;street
name&#148;), please refer to the instructions provided by your bank, brokerage firm or other nominee to see which of the above choices are available to you. Please note that if you are a beneficial owner and wish to vote virtually at your respective
meeting(s), you must obtain a legal proxy from your bank, brokerage firm or other nominee. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Do I need to do anything with my Quidel Shares or my Ortho Shares other than voting for the proposals at the
Quidel Stockholders&#146; Meeting, the Ortho Court Meeting or the Ortho General Meeting? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. You do not need to take any action at this time with respect to your shares. Please do not send your stock
certificates, if any, with your proxy card. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if I sell my Quidel Shares before the Quidel Stockholders&#146; Meeting, or sell my Ortho
Shares before the Ortho Court Meeting and Ortho General Meeting? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The record date for the Quidel Stockholders&#146; Meeting and the Voting Record Time for the Ortho Shareholder
Meetings is earlier than the date of each such meeting and the date that the Combinations are expected to be completed. If you transfer your shares after the record date or Voting Record Time, as applicable, but before the Quidel Stockholders&#146;
Meeting, the Ortho Court Meeting or the Ortho General Meeting, as applicable, you will, unless the transferee receives a proxy from you, retain your right to vote at the respective meeting(s), but you will have transferred the right to receive the
consideration in connection with the Combinations. In order to receive the consideration, you must hold your Quidel Shares or Ortho Shares through the Quidel Effective Time or the Ortho Effective Time, as applicable. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the recommendation of the board of directors of Quidel as to each proposal that may be voted on at
the Quidel Stockholders&#146; Meeting? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Quidel board of directors has determined that the Combinations, including the Quidel Merger and the other
transactions contemplated by the BCA, are consistent with and will further the business strategies and goals of Quidel, and are in the best interests of Quidel and its stockholders, and (a)&nbsp;has unanimously approved and declared advisable the
BCA and Combinations, including the Quidel Merger and the transactions contemplated by the BCA, and (b)&nbsp;has determined, subject to its duties under applicable law, to recommend that the Quidel stockholders adopt the BCA and the transactions
contemplated by the BCA. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the Quidel board of directors recommends that Quidel stockholders vote: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Merger Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Advisory Merger Compensation Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Adjournment Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Election of Directors Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Advisory Executive Compensation Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Independent Registered Public Accounting Firm Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Equity Incentive Plan Proposal; and </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the ESPP Proposal. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See the sections entitled &#147;Other Matters Relating to the Quidel Stockholders&#146; Meeting&#148; and &#147;The Combinations&#151;Quidel
Reasons for the Combinations and Recommendation of the Quidel Board of Directors&#148; of this joint proxy statement/prospectus. </P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the recommendation of the board of directors of Ortho as to each proposal that may be voted on at
the Ortho Court Meeting and Ortho General Meeting? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Ortho board of directors considers the terms of the Ortho Scheme to be in the best interests of Ortho and
its shareholders taken as a whole. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the Ortho board of directors recommends that Ortho shareholders vote: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the approval of the Scheme of Arrangement at the Ortho Court Meeting; and
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the approval of each of the resolutions at the Ortho General Meeting.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See the section entitled &#147;The Combinations&#151;Ortho Reasons for the Combinations and Recommendation of the
Ortho Board of Directors&#148; of this joint proxy statement/prospectus. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What votes of the Quidel stockholders and the Ortho shareholders are required to approve the proposals
presented at the Quidel Stockholders&#146; Meeting, the Ortho Court Meeting and the Ortho General Meeting? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the Quidel Stockholders&#146; Meeting, approval of the Merger Proposal requires the affirmative vote of the
holders of a majority of the outstanding Quidel Shares entitled to vote on such matter in person (virtual attendance by stockholders of record at the Quidel Stockholders&#146; Meeting will constitute presence in person for the purpose of determining
the number of votes cast) or represented by proxy at the Quidel Stockholders&#146; Meeting, voting as a single class. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At
the Ortho Court Meeting, approval of the Ortho Scheme requires the affirmative vote by a majority in number representing 75% in value of the holders of Ortho Shares who vote in person (virtual attendance by shareholders of record at the Ortho Court
Meeting will constitute presence in person for the purpose of determining the number of votes cast) or by proxy at the Ortho Court Meeting. At the Ortho General Meeting, approval of each proposal to be considered at the Ortho General Meeting and
passed as an ordinary resolution requires the affirmative vote of a majority of the voting rights represented at the Ortho General Meeting in person or by proxy and entitled to vote on such proposal, and approval of each proposal to be considered at
the Ortho General Meeting and passed as a special resolution requires the affirmative vote of not less than 75% of the votes cast by Ortho shareholders present (in person or by proxy) at the meeting and entitled to vote on such proposal. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Will the Scheme Shareholders vote as one class at the Ortho Court Meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At a directions hearing on February&nbsp;15, 2022 the Court confirmed that the Scheme Shareholders (as defined
in the Scheme of Arrangement) should be treated by Ortho as a single class of shareholders for the purpose of voting at the Ortho Court Meeting to approve the Ortho Scheme. In accordance with section 899 of the Companies Act 2006 (the
&#147;Act&#148;) the Ortho Scheme must be approved by a majority of shareholders in number (the &#147;majority in number test&#148;) representing three-quarters or more in value of the shareholders who vote in person or by proxy (the &#147;value
test&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Majority in Number Test </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At a directions hearing on February&nbsp;15, 2022 the Court confirmed that for the purpose of the majority in number test, Ortho shall treat a
holder of Scheme Shares that casts votes both &#145;for&#146; and &#145;against&#146; the Ortho Scheme as voting in favour of the Ortho Scheme if such holder casts more votes &#145;for&#146; the Ortho Scheme than &#145;against&#146; the Ortho Scheme
and otherwise, against. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If Ortho&#146;s register of members remains unchanged, it is anticipated that at the Ortho Court Meeting Ortho
shall have two registered shareholders, and the holders of the Scheme Shares shall be Cede&nbsp;&amp; Co., as depositary nomine of The Depositary Trust Company (&#147;DTC&#148;) and GTU Ops, Inc., as nominee of Computershare
(&#147;Computershare&#148;). Accordingly, provided that a majority of the votes cast in respect of the Scheme Shares held by Computershare are voted &#145;for&#146; the Ortho Scheme, Computershare shall be considered to have voted in favour of the
Ortho Scheme. Similarly, if a majority of the votes cast in respect of the Scheme Shares held by DTC are voted &#145;for&#146; the Ortho Scheme, DTC shall be considered to have voted in favour of the Ortho Scheme. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As at March&nbsp;4, 2022 Carlyle Partners VI Cayman Holdings, L.P. (&#147;Carlyle&#148;) held 118,106,000 ordinary shares in the share capital
of Ortho via Computershare and Computershare held a total of 120,252,074 ordinary shares in the share capital of Ortho. Therefore, if Carlyle votes in favour of the Ortho Scheme 98.2% of the ordinary shares held by Computershare will be voted in
favour of the Scheme and, as this constitutes a majority, Computershare will be deemed to have voted &#145;for&#146; the Ortho Scheme. As at March&nbsp;4, 2022 DTC held 117,297,848 ordinary shares in the share capital of Ortho. Assuming that each
ordinary share held by DTC is voted at the Ortho Court Meeting, 58,648,925 of such ordinary shares in the share capital of Ortho would need to vote in favour of the Ortho Scheme in order for DTC to be considered to have voted in favour of the Ortho
Scheme. It is possible that not all of the shares held via DTC will be voted at the Ortho Court Meeting; however, provided a majority of the shares that actually vote are voted in favour of the Ortho Scheme DTC shall be considered to have voted in
favour of the Ortho Scheme. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">It is only possible for existing beneficial holders of Ortho Shares to attend and vote
directly (i.e., in their own name) at the Ortho Court Meeting (or Ortho General Meeting) in respect of all or part of their holding, if they become a registered holder of Ortho Shares. In the event that Ortho has additional registered shareholders
on its register of members as at the Voting Record Time, then it is expected that the Court will continue to require that a majority in number of all such voting holders (irrespective of the size of their shareholding) vote &#145;for&#146; the Ortho
Scheme than &#145;against&#146; the Ortho Scheme. Beneficial holders of shares of Ortho Shares may arrange to become a registered holder of Ortho Shares upon completion of a stock transfer form by the applicable registered holder nominee (DTC or
Computershare) in respect of the Ortho Shares that they wish to be transferred into their name (and pay any related UK stamp duty, if applicable) and send the completed stock transfer form and related documentation (as applicable) to Ortho&#146;s
transfer agent, Computershare Investor Services at Investor Services at 462 South 4th Street, Suite 1600, Louisville, KY, 40202, United States, to permit processing to be completed by Computershare prior to the Voting Record Time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Value Test </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As at
March 4, 2022 Ortho had 237,549,922 ordinary shares in issue. Assuming that each of such ordinary shares is voted at the Ortho Court Meeting, and if Carlyle votes in favour of the Ortho Scheme in respect of the 118,106,000 ordinary shares it holds
via Computershare, Carlyle will account for 49.7% for the purpose of the value test. Assuming that each of the remaining 119,443,922 ordinary shares vote at the Ortho Court Meeting, at least 60,056,442 of such ordinary shares (representing 50.3% of
the ordinary shares not held by Carlyle and 25.3% of the total ordinary shares) would need to vote in favour of the Ortho Scheme in order for the value test to be passed. As stated above, it is possible that not all of the ordinary shares held by
shareholders other than Carlyle will vote at the Ortho Court Meeting and, as a result, Carlyle&#146;s vote would represent a larger proportion of the three-quarters in value required to pass the value test. As a result, until the number of votes
cast at the Ortho Court Meeting are known it is not possible to state how many ordinary shares held other than by Carlyle would need to vote in favour of the Ortho Scheme in order to pass the value test (unless every ordinary share not held by
Carlyle votes at the Ortho Court Meeting&#151;as described in the calculation above). </P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What are the effects of abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> at the
Quidel Stockholders&#146; Meeting, the Ortho Court Meeting and the Ortho General Meeting? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with the Quidel Stockholders&#146; Meeting, abstentions and broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> (if any) will be considered in determining the presence of a quorum. An abstention occurs when a stockholder abstains from voting (either in person or by proxy) on one or more of the proposals.
Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> occur when a broker, bank, trust or other nominee returns a proxy but does not have authority to vote on a particular proposal. You should therefore provide your broker, bank, trust or other
nominee with instructions as to how to vote your Quidel Shares or Ortho Shares (as applicable). </P></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A failure to submit
a proxy or attend the Quidel Stockholders&#146; Meeting, a broker non-vote (if any) or an abstention will have the same effect as a vote &#147;AGAINST&#148; the Merger Proposal. A failure to submit a proxy or attend the Quidel Stockholders&#146;
Meeting or a broker non-vote (if any) as to the Advisory Merger Compensation Proposal, the Adjournment Proposal, the Election of Directors Proposal, the Advisory Executive Compensation Proposal, the Independent Registered Public Accounting Firm
Proposal, the Equity Incentive Plan Proposal or the ESPP Proposal will have no effect on these proposals. An abstention will have the same effect as a vote &#147;AGAINST&#148; the Advisory Merger Compensation Proposal, the Adjournment Proposal, the
Election of Directors Proposal, the Advisory Executive Compensation Proposal, the Independent Registered Public Accounting Firm Proposal, the Equity Incentive Plan Proposal and the ESPP Proposal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the Ortho Shareholder Meetings, abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be considered
in determining the presence of a quorum. However, abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are not considered votes cast under the UK Companies Act. An abstention occurs when an Ortho shareholder abstains from voting
(either in person or by proxy) on one or more of the proposals. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> occur when a broker, bank, trust or other nominee returns a proxy but does not have authority to vote on a particular proposal.
As a result, for purposes of determining whether each of the resolutions set out in the Notice of Ortho Court Meeting and Notice of Ortho General Meeting has been approved in accordance with the UK Companies Act, abstentions and broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will not have any effect on the outcome of the vote. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>If I am a stockholder of record for either Quidel Shares or Ortho Shares, how do I vote?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you are the stockholder of record with respect to your Quidel Shares or Ortho Shares, you may vote virtually
at the Quidel Stockholders&#146; Meeting, the Ortho Court Meeting or the Ortho General Meeting (as applicable) or by proxy. Virtual </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
attendance by stockholders of record at the Quidel Stockholders&#146; Meeting will constitute presence in person for the purpose of determining the presence of a quorum for the transaction of
business at the Quidel Stockholders&#146; Meeting. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you do not wish to vote virtually or if you will not be attending your
respective meeting(s), you may submit a proxy. You can vote by proxy over the Internet by going to www.proxyvote.com, by mail by returning the proxy card or by telephone by calling the number listed on your proxy card for your respective meeting(s)
and, in each case, following the instructions provided. Even if you plan to attend the Quidel Stockholders&#146; Meeting, the Ortho Court Meeting and/or the Ortho General Meeting and vote virtually (as applicable), we recommend you submit a proxy so
your vote will be counted even if your plans change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Both Quidel and Ortho provide Internet proxy voting to allow you to submit a proxy to
vote your Quidel Shares or Ortho Shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>If I am a beneficial owner of either Quidel Shares or Ortho Shares held in street name, how do I vote?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, on the Quidel record date, your shares were held in an account at a brokerage firm, bank, broker-dealer or
other similar organization, then you are the beneficial owner of shares held in &#147;street name,&#148; and the organization holding your account is considered the stockholder of record for purposes of voting at the Quidel Stockholders&#146;
Meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of Quidel Shares registered in the name of your broker, bank, dealer or other
similar organization and you wish to vote in person at the Quidel Stockholders&#146; Meeting, you must obtain a valid proxy from the organization that holds your Quidel Shares. If you do not wish to vote in person or you will not be attending the
Quidel Stockholders&#146; Meeting, you should have received a proxy card and voting instructions with this joint proxy statement/prospectus from that organization. Please follow the voting instructions provided by your broker, bank, dealer or other
similar organization to ensure that your vote is counted. Virtual attendance by stockholders of record at the Quidel Stockholders&#146; Meeting will constitute presence in person for the purpose of determining the presence of a quorum for the
transaction of business at the Quidel Stockholders&#146; Meeting. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If your Ortho Shares are held through a broker, bank, trust company
or other nominee and you wish to access the Virtual Meeting Platform, you will need to contact your broker, bank, trust company or other nominee immediately. Your broker, bank, trust company or other nominee will need to have completed a [letter of
representation] and presented this to [Computershare], Ortho&#146;s registrar, no later than 72 hours before the start of the meeting in order to obtain your unique login code and PIN number to access the Virtual Meeting Platform. Holders of the
beneficial interests in Ortho Shares will be able to submit written questions by email to IR@orthoclinicaldiagnostics.com (emails must be received no less than 48 hours before the start of the Ortho Shareholder Meetings) and observe the Ortho
Shareholder Meetings remotely via the Virtual Meeting Platform. Please see the section entitled &#147;Scheme Proposal and the Ortho Shareholder Meetings&#151;Explanatory Statement&#151;Beneficial Holders&#148; of this joint proxy
statement/prospectus for further information in respect of such holdings and interests. If you are in any doubt about your shareholding, please contact [Computershare], Ortho&#146;s registrar, at [&#9679;]. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if I am an Ortho shareholder located outside of the United States? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The availability of the Ortho Scheme and the transaction deliverables to overseas Ortho shareholders (i.e.,
those outside the United States) may be affected by the laws of the relevant jurisdictions. Overseas Ortho shareholders should inform themselves about, and should observe, any applicable legal requirements. It is the responsibility of all overseas
Ortho shareholders to satisfy themselves as to their full compliance with the laws of the relevant jurisdiction, including obtaining any governmental, exchange control or other consents which may be required and their compliance with any other
necessary formalities which are required to be observed and the payment of any issue, transfer or other taxes due in such jurisdiction. If you are in any doubt regarding such matters, you should consult an independent professional adviser in the
relevant jurisdiction without delay. Overseas Ortho shareholders should consult their own legal and tax advisers with respect to the legal and tax consequences of the Combinations in their particular circumstances. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if I hold both Quidel Shares and Ortho Shares? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You will receive separate proxy or voting instruction cards for each of the Quidel Stockholders&#146; Meeting,
the Ortho Court Meeting and the Ortho General Meeting (as applicable), and are advised to complete, sign and date each proxy or voting instruction card and return each proxy or voting instruction card in the appropriate postage-paid envelope or, if
available, submit a proxy or voting instruction by telephone or through the Internet for each company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How do I appoint a proxyholder? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Your proxyholder is the person you appoint to cast your votes on your behalf at the Quidel Stockholders&#146;
Meeting, the Ortho Court Meeting or the Ortho General Meeting (as applicable), if you do not attend and vote virtually. You can choose anyone you want to be your proxyholder; it does not have to be the persons Quidel or Ortho has designated. To
designate a different person to be your proxyholder, if you are a holder of Quidel Shares, write in the name of the person you would like to appoint in the blank space provided in the proxy card and, if you are a holder of Ortho Shares, contact
[Computershare], Ortho&#146;s registrar, at [&#9679;]. An Ortho shareholder entitled to attend and vote at the Ortho Court Meeting and Ortho General Meeting may appoint one or more proxies to exercise all or any of such Ortho shareholder&#146;s
rights to attend, submit written questions and, on a poll, to vote (in each case, remotely, via the Virtual Meeting Platform), on their behalf. Please ensure that the person you have appointed will be attending the Quidel Stockholders&#146; Meeting,
the Ortho Court Meeting or the Ortho General Meeting (as applicable) and is aware that he or she will be voting your shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you sign the proxy card without naming your own proxyholder and you are a holder of Quidel Shares, you thereby appoint [&#9679;] as your
proxyholders, who will be authorized to vote and otherwise act for you at the Quidel Stockholders&#146; Meeting in accordance with the instructions on the proxy card. If you sign the proxy card without naming your own proxyholder and you are a
holder of Ortho Shares, you thereby appoint the Chair of Ortho as your proxyholder, who will be authorized to vote and otherwise act for you at the Ortho General Meeting, but not the Ortho Court Meeting, in accordance with the instructions on the
proxy card. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How many proxies can I appoint? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Ortho shareholder of record may appoint one or more proxies to exercise all or any of such Ortho
shareholder&#146;s rights to attend, submit written questions and, on a poll, to vote (in each case, remotely, via the Virtual Meeting Platform), on their behalf. If an Ortho shareholder of record appoints more than one proxy to attend the meeting,
each proxy must be appointed to exercise the rights attached to a different share or shares held by such shareholder. If an Ortho shareholder of record wishes to appoint more than one proxy, they should contact [Computershare], Ortho&#146;s
registrar, for additional blue/white forms of proxy or photocopy the blue/white form of proxy as required. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How will my shares be voted at the Ortho Court Meeting and the Ortho General Meeting if I submit my proxy?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On the proxy card, you can indicate how you want your proxyholder to vote your shares. If you have specified on
the proxy card how you want to vote on a particular proposal (by marking as applicable &#147;<B>FOR</B>&#148; or &#147;<B>AGAINST</B>&#148;), then your proxyholder must vote your shares accordingly. With respect to the Ortho General Meeting, but not
the Ortho Court Meeting, you can let your proxyholder decide for you by signing and returning the proxy card without indicating a voting preference for one or all proposals. With respect to the Ortho Court Meeting, if you sign your proxy card
without giving instructions, you will have granted authority to your proxy to vote &#147;<B>FOR</B>&#148; each of the Scheme Implementation Proposal and the <FONT STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Proposal to Approve Certain
Compensation Arrangements but not the Scheme Proposal. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>When should I submit my proxy? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You should submit your proxy as soon as possible so that your shares will be voted at the Quidel
Stockholders&#146; Meeting, the Ortho Court Meeting or the Ortho General Meeting (as applicable). If you are either a Quidel stockholder of record or an Ortho shareholder of record, your proxy must be received by Internet or telephone (in the case
of Quidel only) before the Quidel Stockholders&#146; Meeting, or by hand, email or post (in the case of Ortho only) before the Ortho Court Meeting or the Ortho General Meeting (as applicable) in order for your shares to be voted at the applicable
meeting(s). If you are either a Quidel stockholder of record or an Ortho shareholder of record and you received a printed set of proxy materials, you also have the option of completing and returning the proxy card enclosed with the proxy materials
so that it is received by Quidel or Ortho, respectively, before the respective meeting(s) in order for your shares to be voted at the meeting. If you hold your shares in street name through a broker, bank or other nominee, please comply with the
deadlines included in the voting instructions provided by the broker, bank or other nominee that holds your shares. For a proxy appointment to be valid in respect of the Ortho Court Meeting and the Ortho General Meeting, the appointment must be
received by [Computershare], Ortho&#146;s registrar, not later than 48 hours (excluding any part of such <FONT STYLE="white-space:nowrap">48-hour</FONT> period falling on a <FONT STYLE="white-space:nowrap">non-working</FONT> day) before the time
fixed for the Ortho Court Meeting and the Ortho General Meeting or any adjournment thereof. If the appointment is not received by [Computershare], Ortho&#146;s registrar, by the relevant time, it may be emailed to [&#149;] or handed to the Chair at
any time prior to the commencement of the Ortho Court Meeting and Ortho General Meeting, as applicable, otherwise it will be invalid. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Can I change my vote or revoke my proxy after I have returned a proxy or voting instruction card?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. You may revoke your proxy and change your vote at any time before the final vote at the Quidel
Stockholders&#146; Meeting, the Ortho Court Meeting or the Ortho General Meeting (as applicable). The most recent proxy card or telephone (in the case of Quidel only) or Internet proxy received by the inspector of elections (for Quidel) or registrar
(for Ortho) for each meeting is the one that is counted. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Quidel Stockholder of Record</U></I><I>:</I> If you are a
Quidel stockholder of record, you may revoke your proxy or change your vote in any one of the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you may send a written notice that you are revoking your proxy to Quidel&#146;s Secretary at Quidel Corporation,
Attention: Phillip S. Askim, 9975 Summers Ridge Road, San Diego, California 92121, United States of America; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you may send a subsequent properly completed proxy card in accordance with the instructions in this joint proxy
statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you may grant a subsequent proxy by telephone or through the Internet in accordance with the instructions in this
joint proxy statement/prospectus; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you may attend the Quidel Stockholders&#146; Meeting and either vote or revoke your proxy in writing. Your
attendance at the Quidel Stockholders&#146; Meeting will not automatically revoke your proxy unless you vote again at the Quidel Stockholders&#146; Meeting or specifically request in writing that your prior proxy be revoked. Virtual attendance by
stockholders of record at the Quidel Stockholders&#146; Meeting will constitute presence in person for the purpose of determining the presence of a quorum for the transaction of business at the Quidel Stockholders&#146; Meeting.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Ortho </U></I><I><U>Shareholder of Record</U></I><I>:</I> If you are an Ortho shareholder of record, you may
revoke your proxy or change your vote for either meeting in any one of the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you may send a subsequent properly completed proxy card in accordance with the instructions in this joint proxy
statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you may grant a subsequent proxy through the Internet in accordance with the instructions in this joint proxy
statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you may send a written notice that you are revoking your proxy to Ortho Clinical Diagnostics Proxy, Attention:
[&#9679;]; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you may attend the Ortho Court Meeting and/or the Ortho General Meeting and vote via the Virtual Meeting
Platform. Your attendance at either meeting will not automatically revoke your proxy. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What should I do if I receive more than one set of voting materials for a particular meeting?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You may receive more than one set of voting materials for the same meeting, including multiple copies of this
joint proxy statement/prospectus and multiple proxy cards or voting instruction cards. For example, a holder of Quidel Shares or Ortho Shares who holds shares in more than one brokerage account would receive a separate voting instruction card for
each brokerage account in which such holder holds shares. Additionally, a holder of record of shares whose shares are registered in more than one name would receive more than one proxy card. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In order to ensure that all of your shares are voted at the Quidel Stockholders&#146; Meeting, the Ortho Court Meeting or the Ortho General
Meeting (as applicable), please complete, sign, date and return each proxy card and voting instruction card that you receive. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Are there risks associated with the Combinations that I should consider in deciding how to vote?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. You should carefully read the detailed description of the risks associated with the Combinations and
Topco&#146;s operations following the Combinations described in the section entitled &#147;Risk Factors&#148; of this joint proxy statement/prospectus. You also should read and carefully consider the risk factors associated with the businesses of
both Quidel and Ortho that are included in, or contained in the documents that are incorporated by reference into, this joint proxy statement/prospectus because these risks will relate to the business of Topco following the completion of the
Combinations. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who will count the votes at each meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the Quidel Stockholders&#146; Meeting, American Election Services LLC will serve as inspector of elections
and will count the votes. At the Ortho Shareholder Meetings, [&#9679;] will serve as registrar and will count the votes. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Where can I find the voting results of the Quidel Stockholders&#146; Meeting, the Ortho Court Meeting and
the Ortho General Meeting? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Regarding the Quidel Stockholders&#146; Meeting and the Ortho Shareholder Meetings, the preliminary voting
results will be announced at each meeting. In addition, within four Business Days following certification of the final voting results, each of Quidel and Ortho intends to file the final voting results with the SEC on a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is &#147;householding&#148;? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The SEC has adopted rules that permit companies and intermediaries (such as brokers or banks) to satisfy the
delivery requirements for proxy statements with respect to two or more security holders sharing the same address by delivering a single notice or proxy statement addressed to those security holders. This process, which is commonly referred to as
&#147;householding,&#148; potentially provides extra convenience for security holders and cost savings for companies. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Several brokers and banks with accountholders who are Quidel stockholders or Ortho shareholders will be &#147;householding&#148; Quidel&#146;s
or Ortho&#146;s proxy materials. As indicated in the notices provided by these brokers to Quidel stockholders and Ortho shareholders, a single proxy statement will be delivered to multiple stockholders sharing an address unless contrary instructions
have been received from an affected stockholder. Once you have received notice from your broker that it will be &#147;householding&#148; communications to your address, &#147;householding&#148; will continue until you are notified otherwise or until
you revoke your consent. If at any time you no longer wish to participate in &#147;householding&#148; and you prefer to receive a separate proxy statement, if you are a Quidel stockholder, please notify your broker or contact Quidel&#146;s proxy
solicitor, Innisfree M&amp;A Incorporated, at (877) <FONT STYLE="white-space:nowrap">750-0537,</FONT> or if you are an Ortho shareholder, please notify your broker or Ortho&#146;s proxy solicitor, MacKenzie Partners, Inc., toll-free at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-322-2885.</FONT></FONT></FONT> Quidel stockholders or Ortho shareholders who currently receive multiple copies of this joint proxy
statement/prospectus at their address and would like to request &#147;householding&#148; of their communications should contact their broker or nominee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See the section entitled &#147;Householding of Proxy Materials&#148; of this joint proxy statement/prospectus for additional information. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who can answer my questions? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information provided above in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">question-and-answer</FONT></FONT> format is for your convenience only and is merely a summary of some of the information contained in this joint proxy statement/prospectus. You should
read carefully the entire joint proxy statement/prospectus, including the information in the annexes. See the section entitled &#147;Where You Can Find More Information&#148; of this joint proxy statement/prospectus. If you would like additional
copies of this joint proxy statement/prospectus or the enclosed proxy card, without charge, or if you have questions about the Combinations, including the procedures for voting your shares, you should contact: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">If you are a Quidel stockholder: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">Quidel Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">9975
Summers Ridge Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">San Diego, California 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">Attention: Phillip S. Askim, Vice President, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">Associate General Counsel &amp; Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">(858) <FONT STYLE="white-space:nowrap">552-1100</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">Innisfree M&amp;A
Incorporated </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">501 Madison Avenue, 20th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">Stockholders may call toll free: (877) <FONT STYLE="white-space:nowrap">750-0537</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">Banks and brokers may call collect: (212) <FONT STYLE="white-space:nowrap">750-5833</FONT>
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are an Ortho shareholder: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho Clinical Diagnostics Holdings plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1001 Route 202 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Raritan, New Jersey 08869 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Michael A. Schlesinger,
Executive Vice President, General Counsel and Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(908) <FONT STYLE="white-space:nowrap">218-8000</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MacKenzie Partners, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1407 Broadway, 27<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Bob Marese, President </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(800) <FONT STYLE="white-space:nowrap">322-2885</FONT>
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">No other methods of
communication from stockholders will be accepted. You may not use any electronic address provided in this joint proxy statement/prospectus or any related documents to communicate with Quidel or Ortho for any purposes other than those expressly
stated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_3"></A>NOTE ON PRESENTATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_4"></A>Ortho Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historical financial information of Ortho included in this joint proxy statement/prospectus has been derived from (i)&nbsp;the audited consolidated financial
statements of Ortho as of January&nbsp;2, 2022 and January&nbsp;3, 2021 and for each of the fiscal years ended January&nbsp;2, 2022, January&nbsp;3, 2021 and December&nbsp;29, 2019 included in &#147;Item&nbsp;8. Financial Statements and
Supplementary Data&#148; of Ortho&#146;s Annual Report on Form&nbsp;10-K for the year ended January&nbsp;2, 2022 filed with the SEC on March&nbsp;8, 2022, and incorporated by reference into this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Ortho are reported pursuant to U.S. generally accepted accounting principles (&#147;U.S. GAAP&#148;) and are
presented in U.S. dollars. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_5"></A>Quidel Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial information of Quidel included in this joint proxy statement/prospectus has been derived from (i)&nbsp;the audited consolidated financial statements
of Quidel as of December&nbsp;31, 2021 and 2020 and for each of the three years in the period ended December&nbsp;31, 2021 included in &#147;Item 8. Financial Statements and Supplementary Data&#148; of Quidel&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021 filed with the SEC on February 18, 2022, and incorporated by reference into this joint proxy statement/prospectus. Each of Quidel&#146;s fiscal quarters ends on the
Sunday closest to the end of the calendar quarter. For ease of reference, the calendar&nbsp;quarter end dates are used herein. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated
financial statements of Quidel are reported pursuant to U.S. GAAP and are presented in U.S. dollars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain totals in the tables included in this joint
proxy statement/prospectus may not add up due to rounding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_6"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information from this joint proxy statement/prospectus and might not contain all of the information that is important to
you. You should read carefully this entire joint proxy statement/prospectus, including the annexes, for a more complete understanding of the Combinations. In addition, Quidel and Ortho incorporate by reference into this joint proxy
statement/prospectus important business and financial information about Quidel and Ortho, as applicable. See the section entitled &#147;Where You Can Find More Information&#148; of this joint proxy statement/prospectus for more information. </I></P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_7"></A>Information about the Parties to the Combinations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quidel Corporation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel commenced operations in
1979 and was originally incorporated as Monoclonal Antibodies, Inc. in California. In 1987, Quidel <FONT STYLE="white-space:nowrap">re-incorporated</FONT> as Quidel Corporation in the State of Delaware. Quidel has a leadership position in the
development, manufacturing and marketing of rapid diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular diagnostic solutions and
specialized diagnostic solutions. Quidel sells products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, leading
universities, retail clinics, pharmacies and wellness screening centers, as well as for individual, <FONT STYLE="white-space:nowrap">non-professional,</FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> (&#147;OTC&#148;) use. Quidel markets its products through a network of distributors and a direct sales force. Quidel operates in one business segment
that develops, manufactures and markets its products globally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel Shares are listed on Nasdaq under the symbol &#147;QDEL.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal executive offices of Quidel are located at 9975 Summers Ridge Road, San Diego, California 92121, United States of America, and its telephone
number is (858) <FONT STYLE="white-space:nowrap">552-1100.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho Clinical Diagnostics Holdings plc </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is a leading global provider of <FONT STYLE="white-space:nowrap">in-vitro</FONT> diagnostics (&#147;IVD&#148;) solutions to the clinical laboratory and
transfusion medicine communities. Ortho maintains a direct or indirect commercial presence in more than 130 countries and territories, with a direct presence in 36 countries. Ortho&#146;s instruments, assays, reagents and other consumables are used
in hospitals, laboratories, clinics, blood banks and donor centers worldwide. Ortho is globally operated with manufacturing facilities in the United States and the United Kingdom and with sales centers, administrative offices and warehouses located
throughout the world. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is a public limited company organized under the laws of England and Wales. On February 1, 2021, Ortho closed the initial
public offering of its ordinary shares, and Ortho Shares began trading on Nasdaq under the symbol &#147;OCDX&#148; on January 28, 2021. Prior to September 2021, Ortho was a &#147;controlled company&#148; within the meaning of the corporate
governance standards of Nasdaq. Under these rules, Ortho was not subject to a number of corporate governance rules relating to the composition of its board of directors and certain committees. Following the sale of Ortho Shares by the Carlyle
Stockholder in September 2021, Ortho no longer qualifies as a &#147;controlled company.&#148; As of March&nbsp;4, 2022, the Carlyle Stockholder beneficially owned approximately 49.7% of the outstanding Ortho Shares and had the ability to nominate up
to eight directors to the Ortho Board pursuant to the terms of Ortho&#146;s articles of association. Following the closing of the Combinations, we expect that the Carlyle Stockholder will beneficially own approximately 18.7% of the outstanding Topco
Shares. Pursuant to the Principal Stockholders Agreement, the Carlyle Stockholder will have the right to appoint two directors to the Topco Board while it holds at least 12% of the outstanding Topco Shares, one director while it holds at least 5%
but less than 12% of the outstanding Topco shares and no directors once it holds less than 5% of the outstanding Topco Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with
execution of the BCA, the Carlyle Stockholder delivered to Ortho and Quidel a deed of irrevocable undertaking to vote or procure votes in favor of the Ortho Scheme at the Ortho Court Meeting and the resolutions to be
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proposed at the Ortho General Meeting in respect of the 118,106,000 Ortho Shares beneficially owned by the Carlyle Stockholder, which represents approximately 49.79% of the Ortho Shares. Approval
of the Ortho Scheme requires, assuming all of the Ortho Shares continue to be held directly by Cede &amp; Co., as depositary nominee of The Depositary Trust Company, and GTU Ops, Inc., as nominee of Computershare, a vote in favor of the Ortho Scheme
by the majority of votes cast through each of these nominees. For more information, see &#147;Stockholders Agreement / Deed of Irrevocable Undertaking.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal executive offices of Ortho are located at 1001 Route 202, Raritan, New Jersey 08869, United States of America, and its telephone number at that
address is (908) <FONT STYLE="white-space:nowrap">218-8000.</FONT> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January 2, 2022, Ortho had total indebtedness of approximately $2.0 billion,
which is expected to remain outstanding following the closing of the Combinations. For more information, see &#147;Risk Factors&#151;Risks Relating to Ortho&#146;s Business&#151;Risks Relating to Ortho&#146;s Indebtedness.&#148; In addition, Ortho
has assumed certain underfunded and unfunded net pension liabilities of approximately $40.0 million in relation to defined benefit pension plans, which will need to be satisfied as they mature. Ortho also has a history of net losses and for the
fiscal years ended January 2, 2022, January 3, 2021 and December 29, 2019, Ortho recorded net losses of approximately $54.3&nbsp;million, $211.9 million and $156.9 million, respectively. For more information, see &#147;Risk Factors&#151;Risks
Relating to Ortho&#146;s Business&#151;General Risks Relating to Ortho.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coronado Topco, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Coronado Topco, Inc., a Delaware corporation (&#147;Topco&#148;), is a wholly owned subsidiary of Ortho. Ortho formed Topco on December&nbsp;17, 2021, for the
purpose of entering into the BCA. Pursuant to the BCA, after the Quidel Effective Time on the date on which the Ortho Scheme Order is duly filed with the Registrar (the &#147;Scheme Effective Date&#148;), Topco will become the parent company for the
combined businesses of Quidel and Ortho. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal executive offices of Topco are located at c/o Ortho Clinical Diagnostics Holdings plc, 1001 Route
202, Raritan, New Jersey 08869, United States of America, and its telephone number at that address is <FONT STYLE="white-space:nowrap">(908)&nbsp;218-8000.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Laguna Merger Sub, Inc. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laguna Merger Sub, Inc.,
a Delaware corporation (&#147;U.S. Merger Sub&#148;), is a wholly owned subsidiary of Topco formed solely for the purpose of effecting the Combinations. U.S. Merger Sub will not conduct any business operations other than those incidental to its
formation and in connection with the transactions contemplated by the BCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal executive offices of U.S. Merger Sub are located at c/o Ortho
Clinical Diagnostics Holdings plc, 1001 Route 202, Raritan, New Jersey 08869, United States of America, and its telephone number at that address is <FONT STYLE="white-space:nowrap">(908)&nbsp;218-8000.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orca Holdco, Inc. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orca Holdco, Inc., a Delaware
corporation (&#147;U.S. Holdco Sub&#148;), is a wholly owned subsidiary of Topco formed solely for the purpose of effecting the Combinations. U.S. Holdco Sub will not conduct any business operations prior to closing of the Combinations other than
those incidental to its formation and in connection with the transactions contemplated by the BCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal executive offices of U.S. Holdco Sub are
located at c/o Ortho Clinical Diagnostics Holdings plc, 1001 Route 202, Raritan, New Jersey 08869, United States of America, and its telephone number at that address is <FONT STYLE="white-space:nowrap">(908)&nbsp;218-8000.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orca Holdco 2, Inc. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orca Holdco 2, Inc., a
Delaware corporation (&#147;U.S. Holdco Sub 2&#148;), is a wholly owned subsidiary of U.S. Holdco Sub. U.S. Holdco Sub 2 will not conduct any business operations prior to closing of the Combinations other than those incidental to its formation and
in connection with the transactions contemplated by the BCA. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal executive offices of U.S. Holdco Sub 2 are located at c/o Ortho Clinical Diagnostics Holdings
plc, 1001 Route 202, Raritan, New Jersey, 08869, United States of America, and its telephone number at that address is <FONT STYLE="white-space:nowrap">+1&nbsp;908&nbsp;218-8000.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_8"></A>The Combinations and the Business Combination Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms and conditions of the Combinations are contained in the BCA, a copy of which is attached as Annex A to this joint proxy statement/prospectus. Quidel
and Ortho encourage you to read the entire BCA carefully because it is the principal document governing the Combinations. For more information on the Combinations, see the section entitled &#147;The Combinations&#148; of this joint proxy
statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_9"></A>Structure and Effective Times </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Combinations will be implemented in two main steps. First, pursuant to the Ortho Scheme, each Ortho Share will be acquired by a nominee of Topco (or, if
such nominee holds the Ortho Shares today, transferred within the nominee), such that Ortho will become a wholly owned subsidiary of Topco. Second, immediately following the consummation of the Ortho Scheme, U.S. Merger Sub will merge with and into
Quidel with Quidel surviving the merger as a wholly owned subsidiary of Topco. The Combinations will become effective sequentially (i)&nbsp;with the Ortho Scheme Order becoming effective on the Scheme Effective Date and at the time the Ortho Scheme
Order is duly delivered to the Registrar, such time being the &#147;Ortho Effective Time,&#148; and (ii)&nbsp;with the certificate of merger relating to the Quidel Merger (the &#147;Quidel Certificate of Merger&#148;) becoming effective on the
Scheme Effective Date immediately following the Ortho Effective Time (or such subsequent time as Ortho and Quidel shall agree and as shall be specified in the Quidel Certificate of Merger, and in no event prior to the Ortho Effective Time), such
time being the &#147;Quidel Effective Time.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the Combinations, Ortho and Quidel will each become wholly owned subsidiaries of Topco,
and Ortho shareholders and Quidel stockholders will become Topco stockholders. If the Combinations are completed, Ortho shareholders are expected to own approximately 38% of Topco and Quidel stockholders are expected to own approximately 62% of
Topco, on a fully diluted basis, based on the respective capitalizations of Ortho and Quidel as of the date the parties entered into the BCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing
of the Combinations will take place on the Scheme Effective Date (the &#147;Closing Date&#148;). Subject to the terms and conditions set forth in the BCA, on the Closing Date, and as soon as practicable after the Ortho Scheme Order is duly filed
with the Registrar, Quidel will file the Quidel Certificate of Merger with the Secretary of State of the State of Delaware in accordance with the relevant provisions of the Delaware General Corporation Law (the &#147;DGCL&#148;) and shall make all
other filings or recordings required under the DGCL. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_10"></A>Merger Consideration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho Shares Consideration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA provides that,
at the Ortho Effective Time, each Ortho Share, other than Ortho Shares held by Ortho in treasury, will be acquired by a nominee (or, if such nominee holds the Ortho Shares today, transferred within the nominee) on behalf and for the benefit of Topco
in exchange for 0.1055 Topco Shares and $7.14 in cash.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quidel Shares Consideration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA provides that, at the Quidel Effective Time, each Quidel Share, other than Quidel Shares held by Quidel, Ortho or U.S. Merger Sub, will be converted
into the right to receive one Topco Share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_11"></A>Treatment of Ortho Equity Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Ortho Effective Time, each
Ortho Stock Option, whether vested or unvested, that is outstanding immediately prior to the Ortho Effective Time will cease to represent an option to acquire Ortho Shares and will be converted into </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(a)&nbsp;an option to purchase Topco Shares (each, a &#147;Topco Stock Option&#148;) on the same terms and conditions as were applicable to such Ortho Stock Option immediately prior to the Ortho
Effective Time, except as adjusted by the BCA, (b)&nbsp;with respect to the portion of such Ortho Stock Option that is vested as of the Ortho Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect
of the Ortho Shares subject to the vested portion of such Ortho Stock Option and (c)&nbsp;with respect to the portion of such Ortho Stock Option that is not vested as of the Ortho Effective Time, the right to receive payment, in cash, equal to the
cash consideration payable in respect of the Ortho Shares subject to the unvested portion of such Ortho Stock Option when it vests in accordance with its terms. See the section of this joint proxy statement/prospectus entitled &#147;The Business
Combination Agreement&#151;Treatment of Ortho Equity Awards&#148; for further details on the treatment of Ortho Stock Options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock
Units </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Ortho Effective Time, each Ortho Equity Right that is outstanding immediately prior to the Ortho Effective Time will cease to relate
to or represent a right to receive Ortho Shares and will be converted into a Topco Equity Right of the same type and on the same terms and conditions as were applicable to the corresponding Ortho Equity Right immediately prior to the Ortho Effective
Time. Upon the subsequent vesting of any portion of such Ortho Equity Right, such portion of the Ortho Equity Right shall also be entitled to a right to receive payment, in cash, equal to the cash consideration in respect of the Ortho Shares subject
to the unvested portion of the Ortho Equity Right when it vests in accordance with its terms. See the section of this joint proxy statement/prospectus entitled &#147;The Business Combination Agreement&#151;Treatment of Ortho Equity Awards&#148; for
further details on the treatment of Ortho Equity Rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_12"></A>Treatment of Quidel Equity Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Quidel Effective Time, each
outstanding option to purchase Quidel Shares (a &#147;Quidel Stock Option&#148;) granted under the Quidel employee and director stock plans (each, a &#147;Quidel Stock Plan&#148; and together, the &#147;Quidel Stock Plans&#148;), whether vested or
unvested, will cease to represent an option to acquire Quidel Shares and will automatically, without any action on the part of the holder thereof, be converted into a Topco Stock Option on the same terms and conditions (including applicable vesting
conditions) applicable to such Quidel Stock Option under the applicable Quidel Stock Plan and award agreement in effect immediately prior to the Quidel Effective Time, except as adjusted by the BCA. See the section of this joint proxy
statement/prospectus entitled &#147;The Business Combination Agreement&#151;Treatment of Quidel Equity Awards&#148; for further details on the treatment of Quidel Stock Options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Units </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Quidel Effective
Time, each outstanding Quidel restricted stock unit (a &#147;Quidel RSU&#148;) granted under the Quidel Stock Plans will automatically, without any action on the part of the holder thereof, be converted into a restricted stock unit of Topco (a
&#147;Topco RSU&#148;) on the same terms and conditions (including applicable vesting conditions) applicable to such Quidel RSU under the applicable Quidel Stock Plan and award agreement in effect immediately prior to the Quidel Effective Time. See
the section of this joint proxy statement/prospectus entitled &#147;The Business Combination Agreement&#151;Treatment of Quidel Equity Awards&#148; for further details on the treatment of Quidel RSUs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance Restricted Stock Units </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Quidel
Effective Time, each outstanding Quidel performance restricted stock unit (a &#147;Quidel PSU&#148;) granted under a Quidel Stock Plan will automatically, without any action on the part of the holder thereof, be converted into a performance
restricted stock unit of Topco (a &#147;Topco PSU&#148;) on the same terms and conditions (including applicable vesting conditions) applicable to such Quidel PSU under the applicable Quidel Stock Plan and award agreement in effect immediately prior
to the Quidel Effective Time. See the section of this joint proxy statement/prospectus entitled &#147;The Business Combination Agreement&#151;Treatment of Quidel Equity Awards&#148; for further details on the treatment of Quidel PSUs. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_13"></A>Ortho Reasons for the Combinations and Recommendation of the Ortho Board of
Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho board of directors has determined, having been so advised by J.P. Morgan Securities LLC (&#147;J.P. Morgan&#148;), financial
advisor to Ortho in connection with the financial terms of the Combinations, that the transactions contemplated by the BCA, including the Ortho Scheme, are fair to, and in the best interests of Ortho and its shareholders. At its meeting on
December&nbsp;22, 2021, the Ortho board of directors, among other things, (a)&nbsp;determined that the Ortho Scheme and the transactions contemplated by the BCA as a whole are in the best interests of Ortho, would further the business goals and
strategies of Ortho and would promote the success of Ortho for the benefit of its shareholders as a whole, (b)&nbsp;approved the terms of the BCA, including but not limited to the Ortho Scheme, (c)&nbsp;directed that the Ortho Scheme be recommended
to Ortho&#146;s shareholders and, subject to receiving the vote of Ortho&#146;s shareholders, approved and (d)&nbsp;approved the execution and delivery of the BCA by any director of Ortho. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In arriving at its conclusion, the Ortho board of directors consulted with Ortho&#146;s management, legal, financial and other advisors, reviewed a
significant amount of information and considered a number of factors in its deliberations. For a more detailed discussion of these factors, see the section entitled &#147;The Combinations&#151;Ortho Reasons for the Combinations and Recommendation of
the Ortho Board of Directors&#148; of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_14"></A>Quidel Reasons for the Combinations and
Recommendation of the Quidel Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors has determined that the Combinations, including the Quidel Merger and
the other transactions contemplated by the BCA, are consistent with and will further the business strategies and goals of Quidel, and are in the best interests of Quidel and its stockholders. At its meeting on December&nbsp;22, 2021, the Quidel
board of directors (a)&nbsp;unanimously approved and declared advisable the BCA and the Combinations, including the Quidel Merger and the transactions contemplated by the BCA, and (b)&nbsp;determined, subject to its duties under applicable law, to
recommend that the Quidel stockholders adopt the BCA and the transactions contemplated by the BCA, including the Quidel Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In arriving at its
conclusion, the Quidel board of directors consulted with Quidel&#146;s management and its legal, financial and other advisors, reviewed a significant amount of information and considered a number of factors in its deliberations. For a more detailed
discussion of these factors, see the section entitled &#147;The Combinations&#151;Quidel Reasons for the Combinations and Recommendation of the Quidel Board of Directors&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_15"></A>Opinion of J.P. Morgan Securities LLC as Financial Advisor to Ortho </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to an engagement letter, Ortho retained J.P. Morgan as its financial advisor in connection with the Combinations. At the meeting of the Ortho board of
directors on December&nbsp;22, 2021, J.P.&nbsp;Morgan rendered its oral opinion to the Ortho board of directors that, as of such date and based upon and subject to the assumptions made, procedures followed, matters considered and limitations on the
review undertaken by J.P.&nbsp;Morgan in preparing its opinion, the Ortho Scheme Consideration to be paid to the holders of Ortho Shares was fair, from a financial point of view, to such holders. J.P.&nbsp;Morgan confirmed its December&nbsp;22, 2021
oral opinion by delivering its written opinion, dated as of December&nbsp;23, 2021, to the Ortho board of directors that, as of such date, the Ortho Scheme Consideration was fair, from a financial point of view, to the holders of Ortho Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The full text of the written opinion of J.P.&nbsp;Morgan, dated December&nbsp;23, 2021, which sets forth, among other things, the assumptions made,
procedures followed, matters considered and limitations on the review undertaken by J.P.&nbsp;Morgan in preparing its opinion, is attached as Annex E to this joint proxy statement/prospectus and is incorporated herein by reference. The summary of
the opinion of J.P.&nbsp;Morgan set forth in this joint proxy statement/prospectus is qualified in its entirety by reference to the full text of such opinion. Holders of Ortho Shares are urged to read the opinion in its entirety.
J.P.&nbsp;Morgan&#146;s opinion was addressed to the Ortho board of directors (in its capacity as such) in connection with and for the purposes of its evaluation of the Combinations, was directed only to the Ortho Scheme Consideration to be paid in
the Combinations and did not address any other aspect of the Combinations. J.P.&nbsp;Morgan expressed no opinion as to the fairness of the Ortho Scheme Consideration to the holders of any other class of securities, creditors or other constituencies
of Ortho </B></P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
or as to the underlying decision by Ortho to engage in the Combinations. The issuance of J.P.&nbsp;Morgan&#146;s opinion was approved by a fairness committee of J.P.&nbsp;Morgan. The opinion does
not constitute a recommendation to any shareholder of Ortho as to how such shareholder should vote with respect to the Combinations or any other matter. For a description of the opinion that the Ortho board of directors received from
J.P.&nbsp;
Morgan, see the section entitled &#147;The Combinations&#151;Opinion of J.P. Morgan Securities LLC as Financial Advisor to Ortho.&#148; </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_16">
</A>Opinion of Perella Weinberg Partners LP as Financial Advisor to Quidel </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel retained Perella Weinberg Partners LP (&#147;Perella Weinberg&#148;)
to act as its financial advisor in connection with the Combinations. Quidel selected Perella Weinberg based on its qualifications, expertise and reputation and its knowledge of the business and affairs of Quidel and the industry in which Quidel
conducts its businesses. On December&nbsp;22, 2021, Perella Weinberg rendered its oral opinion, subsequently confirmed in writing, to the Quidel board of directors that, as of such date and based upon and subject to the various assumptions made,
procedures followed, matters considered, and qualifications and limitations set forth therein, the consideration of 0.1055 Topco Shares and $7.14 in cash per Ortho Share (collectively, the &#147;Consideration&#148;) to be paid by Quidel pursuant to
the BCA was fair, from a financial point of view, to Quidel, taking into account the one Topco Share per Quidel Share to be received by the Quidel stockholders in the Combinations (the &#147;Quidel Exchange Ratio&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The full text of Perella Weinberg&#146;s written opinion, dated December&nbsp;22, 2021, which sets forth, among other things, the assumptions made,
procedures followed, matters considered, and qualifications and limitations on the review undertaken by Perella Weinberg in preparing its opinion, is attached hereto as Annex D and is incorporated herein by reference. Holders of Quidel Shares should
read the opinion carefully and in its entirety. Perella Weinberg&#146;s opinion does not address Quidel&#146;s underlying business decision to enter into the BCA or the relative merits of the Combinations as compared with any other strategic
alternative that may be available to Quidel. Perella Weinberg was not authorized to solicit, and did not solicit, indications of interest in a transaction with Quidel from any party. Perella Weinberg&#146;s opinion was not intended to be and does
not constitute a recommendation to any holder of Quidel Shares or Ortho Shares, or any other person, as to how such person should vote or otherwise act with respect to the Combinations or any other matter. Perella Weinberg&#146;s opinion does not in
any manner address the prices at which the Quidel Shares, the Ortho Shares or the Topco Shares will trade at any time. In addition, Perella Weinberg expressed no opinion as to the fairness of the Combinations to, or any consideration received in
connection with the Combinations by, the holders of any other class of securities, creditors or other constituencies of Quidel. Perella Weinberg provided its opinion for the information and assistance of the Quidel board of directors in connection
with, and for the purposes of its evaluation of, the Combinations. The summary of the written opinion of Perella Weinberg is qualified in its entirety by reference to the full text of the written opinion attached as Annex D to this joint proxy
statement/prospectus. For a description of the opinion that the Quidel board of directors received from Perella Weinberg, see the section entitled &#147;The Combinations&#151;Opinion of Perella Weinberg Partners LP as Financial Advisor to
Quidel.&#148; </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_17"></A>Material U.S. Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Material U.S. Federal Income Tax Considerations to U.S. Holders of Ortho Shares of the Ortho Scheme </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exchange of Ortho Shares for Topco Shares and cash pursuant to the Ortho Scheme, taken together with the Quidel Merger, will qualify as a transaction
described in Section&nbsp;351 of the Code. As a result, subject to the limitations and qualifications described in the section entitled &#147;Material U.S. Federal Income Tax Considerations&#148; of this joint proxy statement/prospectus, gain (but
not loss) will be recognized on the exchange of Ortho Shares for a combination of cash and Topco Shares pursuant to the Ortho Scheme in an amount equal to the lesser of: (a)&nbsp;the excess of (i)&nbsp;the sum of the fair market value of the Topco
Shares and the amount of cash received by such U.S. Holder over (ii)&nbsp;such U.S. Holder&#146;s tax basis in its Ortho Shares, and (b)&nbsp;the amount of cash received by such U.S. Holder pursuant to the Ortho Scheme. The treatment of the cash
received in lieu of fractional Topco Shares is discussed separately in the section entitled &#147;Material U.S. Federal Income Tax Considerations&#148; of this joint proxy statement/prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Material U.S. Federal Income Tax Considerations to U.S. Holders of Quidel Shares of the Quidel Merger
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exchange of Quidel Shares for Topco Shares pursuant to the Quidel Merger, taken together with the Ortho Scheme, will qualify as a transaction
described in Section&nbsp;351 of the Code. As a result, subject to the limitations and qualifications described in the section entitled &#147;Material U.S. Federal Income Tax Considerations&#148; of this joint proxy statement/prospectus, no gain or
loss is expected to be recognized by the U.S. Holders of Quidel Shares as a result of the Quidel Merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Material U.S. Federal Income Tax
Considerations to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Owning and Disposing of Topco Shares Received in the Combinations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Distributions to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders with respect to Topco Shares will generally be subject to U.S. federal withholding
tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) to the extent such distributions are dividends for U.S. federal income tax purposes and are not effectively connected with the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. Dividends that are effectively with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or
business within the United States will generally be subject to U.S. federal income tax on a net income basis at the regular graduated U.S. federal income tax rates and, for <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that are
corporations, may be subject to an additional branch profits tax at a rate of 30% (or a lower rate specified by an applicable income tax treaty). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject
to the exceptions and qualifications described in &#147;Material U.S. Federal Income Tax Considerations,&#148; a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income tax on any gain realized
upon the sale or other disposition of Topco Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please carefully review the information set forth in the section entitled &#147;Material U.S. Federal
Income Tax Considerations&#148; of this joint proxy statement/prospectus for a discussion of certain U.S. federal income tax considerations relating to the Combinations. Please consult your tax advisors as to the specific tax consequences to you of
the Combinations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_18"></A>Material UK Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the comments below in relation to Section&nbsp;137 of the UK Taxation of Chargeable Gains Act 1992 (the &#147;TCGA&#148;), the receipt of Topco
Shares by an Ortho shareholder in respect of, and in proportion to, such shareholder&#146;s Ortho Shares pursuant to the Combinations may potentially be treated as a scheme of reconstruction for the purposes of UK capital gains tax or corporation
tax on chargeable gain (collectively, &#147;CGT&#148;). On that basis, an Ortho shareholder would not be treated as making a disposal of their Ortho Shares and, therefore, no liability to CGT would arise in respect of the receipt of Topco Shares by
an Ortho shareholder pursuant to the Combinations. For the purposes of CGT, the Topco Shares received by an Ortho shareholder would be treated as the same asset, acquired at the same time and for the same amount, as the Ortho Shares in respect of
which they are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the &#147;rollover&#148; treatment described above is not available (and no assurance is or can be given that such treatment
will be available), an Ortho shareholder would be treated as having made a full disposal of their Ortho Shares and may, depending on such shareholder&#146;s personal circumstances, be liable to pay CGT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;137 of the TCGA, any Ortho shareholder who holds (when his, her or its relevant holding is aggregated with that of persons connected with
him, her or it) more than 5% of, or of any class of, shares in or debentures of Ortho will not in any event receive the possible &#147;rollover&#148; treatment described above if the relevant transaction has not been effected for bona fide
commercial reasons or if it forms part of a scheme or arrangement of which the main purpose, or one of the main purposes, is the avoidance of liability to CGT or UK corporation tax. It is possible to apply for statutory clearance from HM
Revenue&nbsp;&amp; Customs (&#147;HMRC&#148;) under Section&nbsp;138 of the TCGA confirming that this anti-avoidance provision does not apply. No application for clearance has been made to HMRC under Section&nbsp;138 of the TCGA in respect of the
receipt of Topco Shares pursuant to the Combinations. For the avoidance of doubt, please note that any Ortho shareholder who holds (when their relevant holding is aggregated with that of persons connected with them) 5% or less of, or of any class
of, shares in or debentures of Ortho would not have to satisfy this anti-avoidance provision. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a further discussion of the material UK tax considerations relating to the Combinations, see the section
entitled &#147;Material UK Tax Considerations&#148; of this joint proxy statement/prospectus. Please consult your tax advisors as to the specific tax consequences to you of the Combinations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_19"></A>Delisting and Deregistration of Ortho Shares and Quidel Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Promptly after the Ortho Effective Time, the Ortho Shares will be delisted from Nasdaq and deregistered under the Exchange Act, and promptly after the Quidel
Effective Time, the Quidel Shares will be delisted from Nasdaq and deregistered under the Exchange Act. Topco will be the successor to Quidel for purposes of Topco&#146;s Nasdaq listing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_19a"></A>Litigation Relating to the Combinations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the announcement of the Combinations, one putative complaint has been filed by and purportedly on behalf of an alleged Ortho shareholder: Rydberg&nbsp;v.
Ortho Clinical Diagnostics Holdings plc, et&nbsp;al., No.&nbsp;1:22-cv-01334 filed March&nbsp;10, 2022 in the United States District Court for the Eastern District of New York (the &#147;Action&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Action names as defendants Ortho and the members of Ortho&#146;s Board of Directors. The Action alleges, among other things, that the joint proxy
statement/prospectus omits certain information regarding projections of Ortho, Quidel and Topco, the analysis performed by the financial advisor of Ortho, and potential conflicts of interest involving a financial advisor and Ortho&#146;s officers
and directors. The Action seeks, among other things, injunctive relief to prevent the Combinations from closing, damages if the Combinations close, and attorneys&#146; fees. Ortho believes these claims are entirely without merit and that the joint
proxy statement/prospectus does not omit any material information about the Combinations. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_20"></A>Interests of Quidel Officers
and Directors in the Combinations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s executive officers and directors have interests in the Combinations that are different from, or in
addition to, the interests of Quidel stockholders generally. These interests may include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the treatment in the Combinations of equity awards held by Quidel directors and executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued engagement and/or employment, as applicable, of certain executive officers of Quidel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued positions of certain directors of Quidel as directors on the board of directors of Topco; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severance payments payable under existing employment and severance arrangements or arrangements that may be
entered into in connection with the Combinations. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors was aware of these potentially differing interests
and considered them, among other matters, in reaching its decision to adopt the BCA, approve the Combinations and to recommend that you vote in favor of the Merger Proposal, the Adjournment Proposal, the Election of Directors Proposal, the
Independent Registered Public Accounting Firm Proposal, the Equity Incentive Plan Proposal and the ESPP Proposal and the approval (on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis) for the Advisory Merger Compensation
Proposal and the Advisory Executive Compensation Proposal. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For further information with respect to arrangements between Quidel and its executive
officers and directors, as well as arrangements for Topco director nominees, see the section entitled &#147;Interests of Certain Persons in the Combinations (Quidel)&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the sections entitled &#147;The Combinations&#151;Background of the Combinations&#148; and &#147;The Combinations&#151;Quidel Reasons for the Combinations
and Recommendation of the Quidel Board of Directors&#148; of this joint proxy statement/prospectus. Quidel stockholders should take these interests into account in deciding whether to vote &#147;<B>FOR</B>&#148; the Merger Proposal. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_21"></A>Interests of Ortho Officers and Directors in the Combinations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s executive officers and directors have interests in the Ortho Scheme that are different from, or in addition to, the interests of Ortho
shareholders generally. These interests may include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued engagement and/or employment, as applicable, of certain board members and executive officers of
Ortho; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued positions of certain directors of Ortho as directors on the board of directors of Topco;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the treatment in the Combinations of equity awards and stock options held by Ortho directors and executive
officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention bonus awards, 40% of which will be payable at the closing of the Combinations and the remaining 60% of
which will be payable on the first anniversary of the closing of the Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transaction bonuses payable upon the closing of the Combinations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severance payments payable under existing employment and severance arrangements or arrangements that may be
entered into in connection with the Combinations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho board of directors was aware of these potentially differing interests and
considered them, among other matters, in reaching its decision to adopt the BCA, approve the Combinations and to recommend that you vote in favor of all proposals to be approved at the Ortho Shareholder Meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For further information with respect to arrangements between Ortho and its executive officers and directors, as well as arrangements for Topco director
nominees, see the section entitled &#147;Interests of Certain Persons in the Combinations (Ortho)&#148; of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the
sections entitled &#147;The Combinations&#151;Background of the Combinations&#148; and &#147;The Combinations&#151;Ortho Reasons for the Combinations and Recommendation of the Ortho Board of Directors&#148; of this joint proxy statement/prospectus.
Ortho shareholders should take these interests into account in deciding whether to vote &#147;<B>FOR</B>&#148; the proposals to be approved at the Ortho Shareholder Meetings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_22"></A>Indemnification and Insurance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the BCA, Ortho&#146;s, Quidel&#146;s and any of their subsidiaries&#146; directors, officers and employees will be entitled to certain
ongoing indemnification and insurance coverage from Topco. For additional information, see the section entitled &#147;The Business Combination Agreement&#151;Indemnification and Insurance&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_23"></A>Board of Directors and Management of Topco Following Completion of the Combinations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of the Ortho Effective Time, the Topco board of directors will consist of 12 members, comprised of: (i)&nbsp;eight directors designated by Quidel
prior to closing, one of whom will be the Chief Executive Officer of Quidel immediately prior to the Quidel Effective Time, and at least four of whom will qualify as an &#147;independent director&#148; under applicable rules of Nasdaq, and
(ii)&nbsp;four directors designated by Ortho prior to closing, at least two of whom will qualify as an &#147;independent director&#148; under the applicable rules of Nasdaq. Each of the members of the Topco board of directors designated by Ortho
shall be reasonably acceptable to the nominating and corporate governance committee of the current Quidel board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Ortho Effective
Time, the Topco board of directors will form the following board committees: the audit committee (the &#147;Audit Committee&#148;), the compensation committee (the &#147;Compensation Committee&#148;) and the nominating and corporate governance
committee (the &#147;Nominating and Governance Committee&#148;). The Audit Committee, the Compensation Committee and the Nominating and Governance Committee will each be chaired by a member of the Topco board of directors designated by Quidel. The
Audit Committee, the Compensation Committee and the Nominating and Governance Committee will each consist of one member of the Topco board of directors designated by Ortho and not less than two additional members of the Topco board of directors
designated by Quidel, in </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each case, subject to applicable legal and regulatory requirements, and, in the case of the Ortho designees, such designees must be reasonably acceptable to the Topco board of directors. The
charters for the Audit Committee, the Compensation Committee and the Nominating and Governance Committee will each be substantially similar to the charters for the respective committees of the Quidel board of directors that were in effect as of the
date of the BCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the BCA, at the Ortho Effective Time, Douglas Bryant, current President and Chief Executive Officer of Quidel,
will serve as Chair and Chief Executive Officer of Topco. Joseph M. Busky, current Chief Financial Officer of Ortho, will serve as Chief Financial Officer of Topco. Robert J. Bujarski, current Chief Operating Officer of Quidel, will serve as
President and Chief Operating Officer of Topco. Michael S. Iskra, current Executive Vice President of Commercial Excellence&nbsp;&amp; Strategy at Ortho, will serve as Chief Commercial Officer of Topco. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_24"></A>Acquisition Proposals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the BCA, each of Quidel and Ortho agrees that it will not, and agrees to cause its subsidiaries and its and their respective officers,
directors and employees not to (and use reasonable best efforts to cause its and its subsidiaries&#146; other representatives not to), directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate, solicit or knowingly facilitate or encourage (including by way of furnishing information) any
inquiries, discussions or the making, submission or announcement of any proposal, request or offer that constitutes, or could reasonably be expected to lead to or result in, an Acquisition Proposal (as defined in the section entitled &#147;The
Business Combination Agreement&#151;Acquisition Proposals&#148; of this joint proxy statement/prospectus); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have any discussion with any person relating to an Acquisition Proposal (other than, solely with respect to an
Acquisition Proposal that does not result from a material breach of this provision, to clarify the terms of an Acquisition Proposal submitted to such party after the date of the BCA for the sole purpose of enabling the Quidel board of directors or
Ortho board of directors, as applicable, to evaluate such Acquisition Proposal for the purposes of this provision), engage in, continue or otherwise participate in any negotiations concerning an Acquisition Proposal, or knowingly facilitate any
effort or attempt to make or implement an Acquisition Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide any <FONT STYLE="white-space:nowrap">non-public</FONT> or confidential information or data or afford
access to its books or records or directors, officers, employees or advisors, to any person in relation to an Acquisition Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">terminate, amend, release, modify or fail to enforce any provision of, or grant any permission, waiver or request
under, any standstill, confidentiality or similar agreement entered into by it or any of its subsidiaries (other than to the extent the Quidel board of directors or Ortho board of directors, as applicable, determines in good faith, after
consultation with its financial and outside legal advisors, that failure to take any such actions under this provision would reasonably be expected to be inconsistent with the directors&#146; fiduciary duties under applicable law);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve or recommend, or propose publicly to approve or recommend, any Acquisition Proposal;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve or recommend, propose publicly to approve or recommend, or execute or enter into, any letter of intent,
agreement in principle, merger agreement, acquisition agreement, business combination agreement, option agreement or other similar agreement relating to any Acquisition Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">take any action to make the provisions of any takeover law inapplicable to any transactions contemplated by any
Acquisition Proposal; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">propose publicly or agree to do any of the foregoing related to any Acquisition Proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, see the section entitled &#147;The Business Combination Agreement&#151;Acquisition Proposals&#148; of this joint proxy
statement/prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_25"></A>Conditions to the Combinations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of the parties to consummate the Combinations are subject to the satisfaction or waiver by the parties of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Quidel Requisite Vote (as defined in the section entitled &#147;The Business Combination
Agreement&#151;Acquisition Proposals&#148; of this joint proxy statement/prospectus) shall have been obtained at the Quidel Stockholders&#146; Meeting and the Ortho Requisite Vote (as defined in the section entitled &#147;The Business Combination
Agreement&#151;Acquisition Proposals&#148; of this joint proxy statement/prospectus) shall have been obtained at the Ortho Shareholder Meetings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Topco Shares issuable in the Combinations shall have been authorized for listing on Nasdaq, subject to
official notice of issuance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no governmental entity of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any
order or law which is in effect and prohibits, restrains, prevents or makes illegal consummation of the transactions contemplated by the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Registration Statement shall have been declared effective by the SEC under the Securities Act, and shall not
be the subject of any stop order which is in effect suspending the effectiveness of the Registration Statement or any proceedings for that purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain antitrust, competition and foreign investment approvals designated by the parties shall have been
obtained or any waiting periods thereunder shall have expired or been terminated; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Ortho Scheme Order shall have been sanctioned by the Court and the Ortho Scheme Order shall have been
delivered to the Registrar with due confirmatory receipt thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of Ortho and Topco to consummate the Combinations are
subject to the satisfaction or waiver by Ortho of each of the following additional conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain representations and warranties of Quidel set forth in the BCA relating to the authorized capital stock of
Quidel are true and correct (except for <I>de minimis</I> inaccuracies) as of the Closing Date as though made on and as of such date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which
case such representation and warranty shall be so true and correct as of such earlier date); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain representations and warranties of Quidel set forth in the BCA regarding the authorization of and other
matters relating to the capitalization of Quidel and the corporate authority of Quidel are true and correct in all material respects as of the Closing Date as though made on and as of such date (except to the extent that any such representation and
warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be so true and correct as of such earlier date); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of the other representations and warranties of Quidel set forth in the BCA are true and correct
(disregarding all qualifications or limitations as to &#147;material,&#148; &#147;Material Adverse Effect&#148; and words of similar import set forth therein) as of the date of the BCA and as of the Closing Date as though made on and as of such date
(except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct as of such earlier date), except where the failure of such
representations and warranties to be so true and correct has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on Quidel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel shall, in all material respects, have performed and complied with all obligations required to be performed
or complied with by it under the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at any time after the date of the BCA there shall not have occurred and be continuing any effect that,
individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect on Quidel; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho shall have received a certificate dated as of the Closing Date executed by a duly authorized officer of
Quidel as to the satisfaction of the conditions set forth above. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of Quidel to consummate the Combinations are subject to the satisfaction or waiver by Quidel
of the following additional conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain representations and warranties of Ortho set forth in the BCA relating to the authorized capital stock of
Ortho and Topco are true and correct (except for <I>de minimis</I> inaccuracies) as of the Closing Date as though made on and as of such date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in
which case such representation and warranty shall be so true and correct as of such earlier date); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain representations and warranties of Ortho set forth in the BCA regarding the authorization of and other
matters relating to the capitalization of Ortho and the corporate authority of Ortho are true and correct in all material respects as of the Closing Date as though made on and as of such date (except to the extent that any such representation and
warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be so true and correct as of such earlier date); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of the other representations and warranties of Ortho (and, as applicable, Topco, U.S. Merger Sub, U.S.
Holdco Sub and U.S. Holdco Sub 2) set forth in the BCA are true and correct (disregarding all qualifications or limitations as to &#147;material,&#148; &#147;Material Adverse Effect&#148; and words of similar import set forth therein) as of the date
of the BCA and as of the Closing Date as though made on and as of such date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and
correct as of such earlier date), except where the failure of such representations and warranties to be so true and correct has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on
Ortho; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho shall, in all material respects, have performed and complied with all obligations required to be performed
or complied with by it under the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at any time after the date of the BCA, there shall not have occurred and be continuing any effect that,
individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect on Ortho; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel shall have received a certificate dated as of the Closing Date executed by a duly authorized officer of
Ortho as to the satisfaction of the conditions set forth above. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_26"></A>Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA may be terminated at any time prior to the Ortho Effective Time, whether before or after receipt of the Quidel Requisite Vote or Ortho Requisite Vote,
as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by the mutual written consent of Quidel and Ortho; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Quidel or Ortho, if the Ortho Effective Time has not occurred by September&nbsp;22, 2022 (the
&#147;Termination Date&#148;); provided, however, that such date shall automatically be extended to January&nbsp;22, 2023, if the only conditions that have not been satisfied (other than those conditions that Quidel and Ortho have mutually agreed to
waive, if and to the extent that such waiver is permitted by applicable law, and other than those conditions that by their nature can only be satisfied at or immediately prior to the Scheme Effective Date) are one or more of the conditions set forth
in (a)&nbsp;clause (iii) under &#147;Conditions to the Combinations&#148; above to the extent relating to an approval required by clause (v)&nbsp;under &#147;Conditions to the Combinations&#148; above or (b)&nbsp;clause (v) under &#147;Conditions to
the Combinations&#148; above; provided, further, that the right to terminate the BCA pursuant to this provision may not be exercised by any party whose failure to perform any material covenant or obligation under the BCA has been the primary cause
of, or primarily resulted in, the failure of any such closing condition to be satisfied on or before the Termination Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Quidel or Ortho, if (a)&nbsp;the Quidel Requisite Vote has not been obtained at the Quidel
Stockholders&#146; Meeting (or at any adjournment or postponement thereof) or (b)&nbsp;the Ortho Requisite Vote has not been obtained at the Ortho Shareholder Meetings (or at any adjournment or postponement thereof) or the Ortho Scheme is not
sanctioned and the Ortho Scheme Order is not issued by the Court; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Quidel or Ortho, if any governmental entity that must grant a required regulatory approval has denied
such grant in writing and such denial has become final, binding and <FONT STYLE="white-space:nowrap">non-appealable,</FONT> or any order permanently restraining, enjoining or otherwise prohibiting consummation of the Combinations has become final
and <FONT STYLE="white-space:nowrap">non-appealable;</FONT> </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Quidel, at any time prior to the receipt of the Ortho Requisite Vote, if the Ortho board of directors has
effected an Ortho Change in Recommendation (whether or not in compliance with the applicable provisions of the BCA); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Quidel, at any time prior to the Ortho Effective Time, if Ortho breaches or fails to perform any of its
covenants or agreements contained in the BCA, or if any of the representations or warranties of Ortho contained therein fails to be true and correct, which breach or failure (a)&nbsp;would give rise to the failure of the conditions to Quidel&#146;s
obligation to close and (b)&nbsp;is not reasonably capable of being cured by Ortho by the Termination Date or is not cured by Ortho within 45 days after receiving written notice from Quidel, unless Quidel&#146;s failure to perform any material
covenant or obligation under the BCA has been the primary cause of, or primarily resulted in, the failure of any such closing condition to be satisfied on or before the Termination Date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Quidel, at any time prior to the receipt of the Quidel Requisite Vote, if the Quidel board of directors has
effected a Quidel Change in Recommendation in compliance with the BCA in response to a Quidel All Cash Superior Proposal and in order for Quidel to enter into a merger agreement, acquisition agreement or other similar agreement that the Quidel board
of directors has authorized and directed Quidel to execute with respect to such Quidel All Cash Superior Proposal; provided, however, that the BCA may not be so terminated unless (a)&nbsp;prior to or simultaneously with such termination the Quidel
Termination Payment (as defined below) has been made in full to Ortho, and (b)&nbsp;simultaneously or promptly following such termination Quidel enters into such agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Ortho, at any time prior to the receipt of the Quidel Requisite Vote, if the Quidel board of directors has
effected a Quidel Change in Recommendation (whether or not in compliance with the applicable provisions of the BCA); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Ortho, at any time prior to the Ortho Effective Time, if Quidel breaches or fails to perform any of its
covenants or agreements contained in the BCA, or if any of the representations or warranties of Quidel contained therein fails to be true and correct, which breach or failure (a)&nbsp;would give rise to the failure of the conditions to Ortho&#146;s
obligation to close and (b)&nbsp;is not reasonably capable of being cured by Quidel by the Termination Date or is not cured by Quidel within 45 days after receiving written notice from Ortho, unless Ortho&#146;s failure to perform any material
covenant or obligation under the BCA has been the primary cause of, or primarily resulted in, the failure of any such closing condition to be satisfied on or before the Termination Date; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Ortho, at any time prior to the receipt of the Ortho Requisite Vote, if the Ortho board of directors has
effected an Ortho Change in Recommendation in compliance with the BCA in response to an Ortho All Cash Superior Proposal and in order for Ortho to enter into a merger agreement, acquisition agreement or other similar agreement that the Ortho board
of directors has authorized and directed Ortho to execute with respect to such Ortho All Cash Superior Proposal; provided, however, that the BCA may not be so terminated unless (a)&nbsp;prior to or simultaneously with such termination, the Ortho
Termination Payment (as defined below) has been made in full to Quidel, and (b)&nbsp;simultaneously or promptly following such termination, Ortho enters into such agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, see the section entitled &#147;The Business Combination Agreement&#151;Termination&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_27"></A>Expenses and Termination Fees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All costs and expenses incurred in connection with the BCA and the Combinations and the other transactions contemplated by the BCA generally are to be paid by
the party incurring such costs and expenses, but Quidel and Ortho will share equally all expenses associated with antitrust filings, the Nasdaq listing application and the filing, printing and mailing of this joint proxy statement/prospectus, the
Registration Statement and other disclosure documents required in connection with the Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel must pay Ortho a termination fee of
approximately $207.8 million (the &#147;Quidel Termination Payment&#148;) if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BCA is terminated by Ortho, as a result of a Quidel Change in Recommendation; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BCA is terminated by either Quidel or Ortho if (i)&nbsp;the Combinations are not consummated by the
Termination Date or (ii)&nbsp;the Quidel Requisite Vote has not been obtained at the Quidel Stockholders&#146; Meeting and, at the time of such termination, Ortho had a right to terminate as a result of a Quidel Change in Recommendation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) an Acquisition Proposal for Quidel shall have been publicly announced or made publicly known or otherwise
communicated or made known to Quidel management or the Quidel board of directors (or any third party shall have publicly announced, communicated or made known a bona fide intention, whether or not conditional, to make a proposal with respect to an
Acquisition Proposal) and not withdrawn prior to termination or such vote to adopt the BCA, as applicable, at any time after the date of the BCA and (b)&nbsp;the BCA is subsequently terminated by Ortho as a result of Quidel&#146;s breach of the BCA
or is terminated by either Quidel or Ortho because (i)&nbsp;the Combinations are not consummated by the Termination Date or (ii)&nbsp;the Quidel Requisite Vote has not been obtained at the Quidel Stockholders&#146; Meeting and, at the time of such
termination, Ortho had a right to terminate the BCA as a result of a failure by Quidel to perform any of its covenants or agreements contained in the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BCA is terminated by Quidel in connection with a Quidel All Cash Superior Proposal, subject to certain
additional conditions; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) an Acquisition Proposal for Quidel has been publicly announced or made publicly known or otherwise
communicated or made known to Quidel management or the Quidel board of directors (or any third party shall have publicly announced, communicated or made known a bona fide intention, whether or not conditional, to make a proposal with respect to an
Acquisition Proposal) and not withdrawn prior to termination or such vote to adopt the BCA, as applicable, at any time after the date of the BCA, (b)&nbsp;the BCA is subsequently terminated by Quidel or Ortho because (i)&nbsp;the Combinations are
not consummated by the Termination Date or (ii)&nbsp;the Quidel Requisite Vote has not been obtained at the Quidel Stockholders&#146; Meeting, and (c)&nbsp;within nine months of such termination, Quidel or any of its subsidiaries executes an
acquisition agreement with respect to, or consummates, or approves or recommends to the Quidel stockholders to accept, any Acquisition Proposal (provided that, for purposes of this clause (c), the term &#147;Acquisition Proposal&#148; is defined as
in the section entitled &#147;The Business Combination Agreement&#151;Acquisition Proposals&#148; of this joint proxy statement/prospectus, except that each reference to &#147;15% or more&#148; in the definition of &#147;Acquisition Proposal&#148;
and &#147;Major Subsidiary&#148; shall be deemed to be a reference to &#147;50% or more&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the BCA is terminated
because the Quidel Requisite Vote has not been obtained at the Quidel Stockholders&#146; Meeting, and the Quidel Termination Payment is not otherwise payable, then Quidel shall pay, or cause to be paid, to Ortho by way of reimbursement its
reasonable documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs, fees and expenses incurred in connection with its investigation, consideration, documentation, diligence and negotiations of
the BCA and the transactions contemplated thereby, including all reasonable fees and expenses of Ortho&#146;s and its subsidiaries&#146; respective representatives and financing sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event the Quidel Termination Payment is payable by Quidel to Ortho after the time Quidel pays any expense reimbursement to Ortho in accordance with the
terms of the BCA, the amount of the Quidel Termination Payment payable by Quidel to Ortho will be reduced by the amount of such expense reimbursement actually paid to Ortho. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho must pay Quidel a termination fee of approximately $46.9 million (the &#147;Ortho Termination Payment&#148;) if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BCA is terminated by Quidel, as a result of an Ortho Change in Recommendation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BCA is terminated by either Quidel or Ortho if (i)&nbsp;the Combinations are not consummated by the
Termination Date or (ii)&nbsp;the Ortho Requisite Vote has not been obtained at the Ortho Shareholder Meetings or the Ortho Scheme is not sanctioned and the Ortho Scheme Order is not issued by the English Court and, at the time of such termination,
Quidel had a right to terminate as a result of an Ortho Change in Recommendation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) an Acquisition Proposal for Ortho shall have been publicly announced or made publicly known or otherwise
communicated or made known to Ortho management or the Ortho board of directors (or any third party shall have publicly announced, communicated or made known a bona fide intention, whether or not
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
conditional, to make a proposal with respect to an Acquisition Proposal) and not withdrawn prior to termination or such vote to adopt the BCA, as applicable, at any time after the date of the BCA
and (b)&nbsp;the BCA is subsequently terminated by Quidel as a result of Ortho&#146;s breach of the BCA or is terminated by either Quidel or Ortho because (i)&nbsp;the Combinations are not consummated by the Termination Date or (ii)&nbsp;the Ortho
Requisite Vote has not been obtained at the Ortho Shareholder Meetings or the Ortho Scheme is not sanctioned and the Ortho Scheme Order is not issued by the English Court and, at the time of such termination, Quidel had a right to terminate the BCA
as a result of a failure by Ortho to perform any of its covenants or agreements contained in the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BCA is terminated by Ortho in connection with an Ortho All Cash Superior Proposal, subject to certain
additional conditions; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) an Acquisition Proposal for Ortho has been publicly announced or made publicly known or otherwise
communicated or made known to Ortho management or the Ortho board of directors (or any third party shall have publicly announced, communicated or made known a bona fide intention, whether or not conditional, to make a proposal with respect to an
Acquisition Proposal) and not withdrawn prior to termination or such vote to adopt the BCA, as applicable, at any time after the date of the BCA, (b)&nbsp;the BCA is subsequently terminated by Quidel or Ortho because (i)&nbsp;the Combinations are
not consummated by the Termination Date or (ii)&nbsp;the Ortho Requisite Vote has not been obtained at the Ortho Shareholder Meetings or the Ortho Scheme is not sanctioned and the Ortho Scheme Order is not issued by the English Court, and
(c)&nbsp;within nine months of such termination, Ortho or any of its subsidiaries executes an acquisition agreement with respect to, or consummates, or approves or recommends to the Ortho shareholders to accept, any Acquisition Proposal (provided
that, for purposes of this clause (c), the term &#147;Acquisition Proposal&#148; is defined as in the section entitled &#147;The Business Combination Agreement&#151;Acquisition Proposals&#148; of this joint proxy statement/prospectus, except that
each reference to &#147;15% or more&#148; in the definition of &#147;Acquisition Proposal&#148; and &#147;Major Subsidiary&#148; shall be deemed to be a reference to &#147;50% or more&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the BCA is terminated because the Ortho Requisite Vote has not been obtained at the Ortho Shareholder Meetings or the Ortho Scheme is not
sanctioned and the Ortho Scheme Order is not issued by the English Court, and the Ortho Termination Payment is not otherwise payable, then Ortho shall pay, or cause to be paid, to Quidel by way of reimbursement its reasonable documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs, fees and expenses incurred in connection with its investigation, consideration, documentation, diligence and negotiations of the BCA and the transactions
contemplated thereby, including all reasonable fees and expenses of Quidel&#146;s and its subsidiaries&#146; respective representatives and financing sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event the Ortho Termination Payment is payable by Ortho to Quidel after the time Ortho pays any expense reimbursement to Quidel in accordance with the
terms of the BCA, the amount of the Ortho Termination Payment payable by Ortho to Quidel will be reduced by the amount of such expense reimbursement actually paid to Quidel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_28"></A>Regulatory Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho and
Quidel have agreed to use their reasonable best efforts to obtain all regulatory approvals required to complete the transactions contemplated by the BCA. These approvals include clearance under the HSR Act, and other merger control and foreign
investment laws and regulations. Ortho and Quidel have completed, or will complete, the filing of applications and notifications to obtain the required regulatory approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, see the section entitled &#147;The Combinations&#151;Regulatory Matters&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_29"></A>Security Ownership of Quidel Directors and Executive Officers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of close of business on March 4, 2022, directors and executive officers of Quidel and their affiliates were entitled to vote 1,154,623 Quidel Shares, or
approximately 2.7% of the Quidel Shares outstanding and entitled to vote on that date. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, see the section entitled &#147;Security
Ownership of Certain Quidel Beneficial Owners and Management&#148; of this joint proxy statement/prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_30"></A>Security Ownership of Ortho Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of close of business on March&nbsp;4, 2022, directors and executive officers of Ortho and their affiliates were entitled to vote 3,187,125 Ortho Shares, or
approximately 1.3% of the Ortho Shares outstanding and entitled to vote on that date. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, see the section entitled &#147;Security
Ownership of Certain Ortho Beneficial Owners and Management&#148; of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_31"></A>No Appraisal
Rights for Quidel Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Appraisal rights are statutory rights under the DGCL that enable stockholders who object to certain extraordinary
transactions to demand that the corporation pay such stockholders the fair value of their shares instead of receiving the consideration offered to stockholders in connection with the extraordinary transaction. However, appraisal rights are not
available in all circumstances. Appraisal rights are not available to Quidel stockholders in connection with the Combinations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_32"></A>No Delaware Appraisal Rights for Ortho Shareholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As shareholders in a UK public limited company, Ortho shareholders do not have appraisal rights similar to the statutory rights under the DGCL that enable
shareholders who object to certain extraordinary transactions to demand that the corporation pay such shareholders the fair value of their shares instead of receiving the consideration offered to shareholders in connection with the extraordinary
transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_33"></A>Listing of Topco Shares on Stock Exchanges </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco Shares currently are not traded or quoted on a stock exchange or quotation system. The parties expect that, following completion of the Combinations,
Topco Shares will be listed for trading on Nasdaq, and it is a condition to the parties&#146; obligations to effect the Combinations that the Topco Shares be authorized for listing on Nasdaq, subject to official notice of issuance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_34"></A>Accounting Treatment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco
will account for the Combinations using the acquisition method of accounting in accordance with ASC Topic 805. For further information, see the section entitled &#147;Unaudited Pro Forma Combined Financial Information&#148; of this joint proxy
statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_35"></A>Comparison of Rights of Stockholders of Quidel, Ortho and Topco </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel and Topco are organized under the laws of the State of Delaware. Ortho is organized under the laws of England and Wales. If the Combinations are
consummated, the Quidel stockholders and Ortho shareholders will become stockholders of Topco. After giving effect to the Combinations, the rights of stockholders of Topco and the relative powers of the Topco board of directors will be governed by
Delaware law and by the Topco Charter and Topco Bylaws. Each Topco Share will be issued pursuant to, and will carry with it the rights and obligations set forth in, the Topco Charter. As a result of differences between the respective organizational
documents of Quidel, Ortho and Topco, and applicable governing law, there will be material differences between the rights of Quidel stockholders and Ortho shareholders before consummation of the Combinations and the rights of Topco stockholders
after consummation of the Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a full description of these differences, see the section entitled &#147;Comparison of Rights of Stockholders
of Quidel, Ortho and Topco&#148; of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_36"></A>Please Read the Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should carefully read the detailed description of the risks associated with the Combinations and Topco&#146;s operations following the Combinations
described in the section entitled &#147;Risk Factors&#148; of this joint proxy statement/prospectus. You also should read and carefully consider the risk factors associated with the businesses of both Quidel and Ortho that are included in, or
contained in the documents that are incorporated by reference into, this joint proxy statement/prospectus, because these risks will relate to the business of Topco following the completion of the Combinations. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_37"></A>CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
</B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus contains forward-looking statements within the meaning of federal securities laws concerning Quidel, Ortho,
Topco, the Combinations and other matters that involve material risks, assumptions and uncertainties. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition,
or other matters, based on the current beliefs of the management of Quidel and Ortho as well as assumptions made by, and information currently available to, the management of both companies. Forward-looking statements may be accompanied by words
such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;plan,&#148; &#147;could,&#148; &#147;would,&#148; &#147;should,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;forecast,&#148; &#147;future,&#148;
&#147;guidance,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;will,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project&#148; or similar words, phrases or expressions, although some forward-looking statements are
expressed differently. These statements are subject to various risks and uncertainties, many of which are outside the parties&#146; control. Factors that could cause actual results to differ materially from those discussed in these forward-looking
statements include, but are not limited to, risks and uncertainties detailed in the section entitled &#147;Risk Factors&#148; of this joint proxy statement/prospectus, in Quidel&#146;s periodic public filings with the SEC, including those discussed
in the section entitled &#147;Risk Factors&#148; of Quidel&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2021 filed with the SEC on February&nbsp;18, 2022, and in Ortho&#146;s
periodic public filings with the SEC, including those discussed in the section entitled &#147;Risk Factors&#148; of Ortho&#146;s Annual Report on Form&nbsp;10-K for the fiscal year ended January&nbsp;2, 2022 filed with the SEC on March&nbsp;8, 2022,
factors contained or incorporated by reference into such documents and in subsequent filings by Quidel and Ortho with the SEC, and the following factors: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">global economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the occurrence of any change, effect, event, occurrence, development, matter, state of facts, series of events or
circumstances that could give rise to the termination of the BCA, including a termination of the BCA under circumstances that could require Quidel to pay a termination fee or expense reimbursement to Ortho or require Ortho to pay a termination fee
or expense reimbursement to Quidel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to obtain applicable regulatory or stockholder and shareholder approvals in a timely manner or otherwise,
or being required to accept conditions that could reduce the anticipated benefits of the Combinations as a condition to obtaining regulatory approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to satisfy other closing conditions to the Combinations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with tax liabilities, or changes in U.S., UK or other tax laws or interpretations to which the
companies are subject; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks that the newly combined businesses will not be integrated successfully or that the cost, time and effort
required to integrate the newly combined businesses may be greater than anticipated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to effectively manage the newly combined businesses, or that Topco will not realize any or all of the
estimated cost savings, value of certain tax assets, synergies and growth or that such benefits may take longer to realize than expected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to close the proposed transaction, the inability to achieve any or all of the anticipated benefits
and synergies of Topco&#146;s operations following the Combinations or the effects of the Combinations on Topco&#146;s financial condition or operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of Quidel and Ortho to meet expectations regarding the timing, completion, accounting and tax
treatments with respect to the Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reductions in customer or government spending, a slowdown in payments and changes in customer or government
demand for products and services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated changes relating to competitive factors in the industries in which the companies operate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to hire and retain personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of the attention of Quidel&#146;s and Ortho&#146;s management from ongoing business concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations placed on the ability of Quidel and Ortho to operate their respective businesses by the BCA pending
consummation of the Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating costs, customer loss or business disruption (including, without limitation, difficulties in maintaining
relationships with employees, customers, distributors or suppliers) being greater than expected in anticipation of, or, if consummated, following, the Combinations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of any legal proceedings that may be instituted against Quidel, Ortho and/or others relating to the
Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential impact of the announcement or consummation of the Combinations on relationships with third parties,
including customers, employees and competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to attract new customers and retain existing customers in the manner anticipated;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of acquisitions that the companies have made or may make; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on and integration of information technology (&#147;IT&#148;) systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in legislation or governmental regulations affecting the companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">international, national or local economic, social or political conditions that could adversely affect Ortho,
Quidel or their respective customers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market price for Topco Shares potentially being affected following the Combinations by factors that
historically have not affected the market price for Quidel Shares or Ortho Shares when Quidel and Ortho were standalone companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions in the capital and credit markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with assumptions the parties make in connection with critical accounting estimates and legal
proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the parties&#146; international operations, which are subject, among other factors, to the risks of currency
fluctuations and foreign exchange controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that Topco could fail to realize the anticipated benefits and synergies expected from the
Combinations, which could adversely affect its business, financial condition and operating results; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the unaudited prospective financial information for Quidel and Ortho included in this joint proxy
statement/prospectus reflects management estimates and may not prove to be reflective of actual future financial results. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
foregoing list of factors is not exhaustive and speaks only as of the date hereof. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the parties&#146; businesses, including those described in this
joint proxy statement/prospectus, and information contained in or incorporated by reference into this joint proxy statement/prospectus. See the section entitled &#147;Where You Can Find More Information&#148; of this joint proxy statement/prospectus
for more information. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing in this joint proxy statement/prospectus is intended, or is to be construed, as a profit projection or to be
interpreted to mean that earnings per Ortho Share or Quidel Share for the current or any future financial years or those of Topco will necessarily match or exceed the historical published earnings per Ortho Share or Quidel Share, as applicable. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise required by applicable securities laws, Quidel, Ortho and Topco are under no obligation, and each expressly disclaims any obligation,
to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_38"></A><A NAME="cov273090_1"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in Topco Shares involves risks, some of which are related to the Combinations. You should carefully consider the risks described below, as well as
the other information included in or incorporated by reference into this joint proxy statement/prospectus, including the risk factors described in Quidel&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2021, filed with the SEC on February&nbsp;18, 2022, and the risk factors described in Ortho&#146;s Annual Report on Form&nbsp;10-K for the year ended January&nbsp;2, 2022, filed with the SEC on March&nbsp;8, 2022. In particular,
you should carefully consider the risks associated with each of the businesses of Ortho and Quidel because these risks will relate to the business of Topco following the completion of the Combinations. The business of Topco, as well as the
respective businesses of Ortho and Quidel, as well as their respective financial condition or results of operations, could be materially adversely affected by any of these risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For information on where you can find the documents Quidel and Ortho have filed with the SEC and which are incorporated into this joint proxy
statement/prospectus by reference, please see the section entitled &#147;Where You Can Find More Information&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_39"></A>Risks Relating to the Combinations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Completion of the Combinations is subject to certain conditions, some of which are outside of the parties&#146; control, and if these conditions are not
satisfied or waived, the Combinations will not be completed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing of the Combinations is subject to certain conditions, including
(i)&nbsp;Quidel stockholder approval of the Merger Proposal and related matters, (ii)&nbsp;Ortho shareholder approval of the Ortho Scheme, amendments to the articles of association of Ortho and certain related matters, (iii)&nbsp;receipt of
clearance from competition and foreign investment authorities in certain areas where the companies operate, including the expiration or termination of the waiting period under the HSR Act, (iv)&nbsp;the absence of any law, injunction, order or other
judgment prohibiting the Combinations, (v)&nbsp;the effectiveness of the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> for the Topco Shares, (vi)&nbsp;receipt of Nasdaq listing approval for the Topco Shares,
(vii)&nbsp;subject to certain materiality exceptions, the accuracy of each of Ortho&#146;s and Quidel&#146;s representations and warranties in the BCA and performance by each of Ortho and Quidel of its obligations under the BCA and (viii)&nbsp;the
sanctioning of the Ortho Scheme by the Court and the delivery of the order of the Court of sanctioning the Ortho Scheme to the Registrar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The requirement
to satisfy each of the foregoing conditions could delay completion of the Combinations for a significant period of time or prevent them from occurring at all. Any delay in completing the Combinations could cause Topco not to realize some or all of
the benefits that the parties expect Topco to achieve if the Combinations are successfully completed within the expected timeframe. Further, as a condition to approving the Combinations, governmental authorities may impose conditions, terms,
obligations or restrictions on the conduct of the parties&#146; business after the completion of the Combinations. Under the terms of the BCA, the parties are not required to proffer or negotiate, or agree or consent to, any action (including any
contractual, behavioral or conduct restriction, agreement, commitment or remedy) that would, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect (as defined in the section entitled &#147;The Business
Combination Agreement&#151;Representations and Warranties&#148; of this joint proxy statement/prospectus) on Topco. Notwithstanding the provisions of the BCA, if the parties were to become subject to any conditions, terms, obligations or
restrictions (whether because such conditions, terms, obligations and restrictions do not rise to the specified level of materiality or because the parties consent to their imposition), it is possible that such conditions, terms, obligations or
restrictions will delay completion of the Combinations or otherwise adversely affect the parties&#146; business, financial condition, or operations. Furthermore, governmental authorities may require that the parties divest assets or businesses as a
condition to the closing of the Combinations. If the parties are required to divest assets or businesses, there can be no assurance that Quidel and Ortho will be able to negotiate such divestitures expeditiously or on favorable terms or that the
governmental authorities will approve the terms of such divestitures. There can be no assurance that the conditions to the closing of the Combinations will be satisfied or, where applicable, waived or that the Combinations will be completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if the Ortho Effective Time shall not have occurred by September&nbsp;22, 2022 (subject to certain extension rights), either Ortho or Quidel may
choose not to proceed with the Combinations. Quidel and Ortho may also terminate the BCA under certain specified circumstances, including, among others, in order to enter into an agreement with respect to an
<FONT STYLE="white-space:nowrap">all-cash</FONT> proposal (A)&nbsp;that is determined by the Quidel board of directors, in the case of a proposal to Quidel, or (B)&nbsp;that is determined by the Ortho board of directors, in the case of a proposal to
Ortho, to be superior to the BCA, subject to the terms and conditions of the BCA (including a requirement that the terminating party pay a termination fee to the other party in accordance with the BCA). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some of the conditions to the Combinations and termination rights may be waived by Ortho or Quidel
without resoliciting Ortho shareholder or Quidel stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the conditions and termination rights set forth in the BCA may be
waived by Ortho or Quidel, subject to certain limitations. If any conditions or termination rights are waived, Quidel and Ortho will evaluate whether amendment of this joint proxy statement/prospectus and resolicitation of proxies would be
warranted. Subject to applicable law, if Quidel and Ortho determine that resolicitation of Quidel stockholders or Ortho shareholders is not warranted, the parties will have the discretion to complete the Combinations without seeking such additional
Ortho shareholder approval or Quidel stockholder approval, as applicable. No action by the Quidel board of directors or Ortho board of directors with respect to the BCA may adversely affect the stockholders of Quidel or shareholders of Ortho,
respectively, or affect the consideration to be received by the stockholders of Quidel or the shareholders of Ortho in the Combinations, unless their stockholders or shareholders, as applicable, approve such action. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to complete the Combinations could negatively impact the stock price and the future business and financial results of Quidel and Ortho.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Combinations are not completed for any reason, including as a result of Quidel stockholders failing to adopt the BCA or Ortho shareholders
failing to approve the Ortho Scheme, the ongoing businesses of Quidel and Ortho may be adversely affected and, without realizing any of the benefits of having completed the Combinations, Quidel and Ortho would be subject to a number of risks,
including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel may be required, under certain circumstances, to pay Ortho a termination fee of approximately
$208&nbsp;million or reimburse Ortho for certain fees and expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho may be required, under certain circumstances, to pay Quidel a termination fee of approximately
$47&nbsp;million or reimburse Quidel for certain fees and expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel and Ortho are subject to certain restrictions on the conduct of their businesses prior to completing the
Combinations, which may adversely affect their respective abilities to execute certain of their respective business strategies going forward if the Combinations are not completed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho and Quidel have incurred and will continue to incur significant costs and fees associated with the proposed
Combinations, such as legal, accounting, financial advisor and printing fees, regardless of whether the Combinations are completed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho and Quidel may experience negative reactions from the financial markets, including negative impacts on
their stock prices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho and Quidel may experience negative reactions from their customers, regulators and employees; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">matters relating to the Combinations (including integration planning) will require substantial commitments of
time and resources by Ortho&#146;s and Quidel&#146;s management, which would otherwise have been devoted to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations and other opportunities that may have
been beneficial to Ortho and Quidel as independent companies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Ortho and Quidel could be subject to litigation related to
any failure to complete the Combinations or related to any enforcement proceeding commenced against Ortho, Quidel or Topco to perform its obligations under the BCA. If the Combinations are not completed, these risks may materialize and may adversely
affect Ortho&#146;s or Quidel&#146;s respective businesses, financial conditions, financial results and stock price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The number of Topco Shares
that Quidel stockholders will receive in the Quidel Merger and that Ortho shareholders will receive in the Ortho Scheme is based on a fixed exchange ratio that will not be adjusted to reflect changes in the market value of Quidel Shares or Ortho
Shares. Further, when Ortho shareholders and Quidel stockholders vote on the transactions contemplated in the BCA, they will not know the exact value of the Topco Shares that will be issued in connection with the Combinations. The value of the Topco
Shares that Quidel stockholders and Ortho shareholders receive upon completion of the Combinations could vary based on changes in the market value of Quidel Shares and Ortho Shares from the time that the Quidel stockholders and Ortho shareholders
vote to adopt the BCA or approve the Ortho Scheme, as applicable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Combinations, Quidel stockholders will be entitled to
receive 1.00 Topco Share for each Quidel Share that they own and Ortho shareholders will be entitled to receive 0.1055 Topco Shares for each Ortho Share that they own. Immediately following consummation of the Combinations, it is expected that
former Ortho shareholders will own </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximately 38% of Topco and former Quidel stockholders will own approximately 62% of Topco, on a fully diluted basis, based on the respective capitalizations of Ortho and Quidel as of the date
the parties entered into the BCA. The market value of the Topco Shares that Quidel stockholders will be entitled to receive when the Quidel Merger is completed and that Ortho shareholders will be entitled to receive when the Ortho Scheme is
completed could vary significantly due to a change in the market value of Quidel Shares or Ortho Shares from the date the BCA was entered into, the date of this joint proxy statement/prospectus or the date of the Quidel Stockholders&#146; Meeting or
the Ortho General Meeting. Because the applicable exchange ratios will not be adjusted to reflect any changes in the market value of Quidel Shares or Ortho Shares, such market price fluctuations may affect the relative value that Quidel stockholders
will receive at the Quidel Effective Time and that Ortho shareholders will receive at the Ortho Effective Time. Share price changes may result from a variety of factors, including changes in the business, operations or prospects of Quidel or Ortho,
market assessments of the likelihood that the Combinations will be completed, market assessments of the value of Topco, the timing of the Combinations, regulatory considerations, governmental actions, general market and economic conditions, legal
proceedings and other factors, each of which may be beyond the control of Topco, Quidel or Ortho. Prior to making any investment decision, stockholders are urged to obtain updated market quotations for Quidel Shares and Ortho Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The trading of Topco Shares after completion of the Combinations may cause the market price of Topco Shares to fall. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following completion of the Combinations, Topco Shares are expected to be publicly traded on Nasdaq, enabling former Quidel stockholders and former Ortho
shareholders to sell the Topco Shares that they receive in the Combinations. Such sales of Topco Shares may take place promptly following the Combinations and could have the effect of decreasing the market price for Topco Shares owned by former
Quidel stockholders and Ortho shareholders below the market price of the Quidel Shares or Ortho Shares owned by such Quidel stockholders and Ortho shareholders, respectively, prior to completion of the Combinations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Combinations may be completed even though material adverse changes subsequent to the announcement of the Combinations, such as industry-wide changes
or other events, may occur. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, either Quidel or Ortho can, on the terms and conditions set forth in the BCA, refuse to complete the
Combinations if there is a material adverse change affecting the other party. However, some types of changes do not permit either Quidel or Ortho to refuse to complete the Combinations, even if such changes would have a material adverse effect on
either of the parties. For example, a worsening of Quidel&#146;s or Ortho&#146;s financial condition or results of operations due to a decrease in commodity prices or general economic conditions, except to the extent affecting Quidel or Ortho, as
applicable, in a disproportionate manner relative to other businesses operating in the industries in which they operate, or a drop in Quidel&#146;s or Ortho&#146;s stock price, would not give the other party the right to refuse to complete the
Combinations. If adverse changes occur that affect either party, but the parties are still required to complete the Combinations, the share price of Topco Shares and the business and financial results of Topco may suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The BCA contains provisions that restrict Ortho&#146;s and Quidel&#146;s ability to pursue alternatives to the Combinations and, in specified
circumstances, would require Ortho or Quidel to pay the other party a termination fee. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCA, each of Ortho, Quidel and Topco is
restricted, subject to certain exceptions, from soliciting, initiating, knowingly encouraging or facilitating, discussing or negotiating, or furnishing <FONT STYLE="white-space:nowrap">non-public</FONT> information with regard to, any inquiry,
proposal or offer for a competing acquisition proposal from any person or entity. If any party receives a competing acquisition proposal and such party&#146;s board of directors determines (after consultation with such party&#146;s financial
advisors and outside legal counsel) that such proposal constitutes a Quidel All Cash Superior Proposal or an Ortho All Cash Superior Proposal, as the case may be, and the board of directors makes a change in recommendation in response to such
proposal to the stockholders or shareholders of such company, Quidel, on the one hand, or Ortho, on the other hand, would be entitled, upon complying with certain requirements, to terminate the BCA, subject to the terms of the BCA. Under such
circumstances, Quidel may be required to pay Ortho a termination fee of approximately $208&nbsp;million, Ortho may be required to pay Quidel approximately $47&nbsp;million, or either party may be required to reimburse the other party for its <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the BCA. These provisions could discourage a third party that may have an interest in acquiring all or a significant part of
either company from considering or proposing such an acquisition, even if such third party was prepared to enter into a transaction that would be more favorable to one of the companies and its respective stockholders or shareholders than the
Combinations. See the sections entitled &#147;The Business Combination Agreement&#151;Acquisition Proposals,&#148; &#147;The Business Combination Agreement&#151;Termination&#148; and &#147;The Business Combination Agreement&#151;Expenses and
Termination Fees&#148; of this joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quidel and Ortho will incur significant transaction and merger-related costs in connection with the
Combinations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho and Quidel have incurred and expect to incur a number of <FONT STYLE="white-space:nowrap">non-recurring</FONT> direct and
indirect costs associated with the Combinations. These costs and expenses include fees paid to financial, legal and accounting advisors, severance and other potential employment-related costs, including payments that may be made to certain Ortho and
Quidel executives, filing fees, printing expenses and other related charges. Some of these costs are payable by Ortho and Quidel regardless of whether the Combinations are completed. There are also processes, policies, procedures, operations,
technologies and systems that must be integrated in connection with the Combinations and the integration of the two companies&#146; businesses. While both Ortho and Quidel have assumed that a certain level of expenses would be incurred in connection
with the Combinations and the other transactions contemplated by the BCA and continue to assess the magnitude of these costs, there are many factors beyond their control that could affect the total amount or the timing of the integration and
implementation expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may also be additional unanticipated significant costs in connection with the Combinations that Ortho and Quidel may not
recoup. These costs and expenses could reduce the realization of efficiencies and strategic benefits Ortho and Quidel expect Topco to achieve from the Combinations. Although Ortho and Quidel expect that these benefits will offset the transaction
expenses and implementation costs over time, this net benefit may not be achieved in the near term or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In connection with the Combinations,
Quidel, Ortho and/or Topco may be required to take write-downs or write-offs, restructuring and impairment or other charges that could negatively affect the business, assets, liabilities, prospects, outlook, financial condition and results of
operations of Quidel, Ortho and/or Topco. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Quidel and Ortho have conducted extensive due diligence in connection with the Combinations and
related transactions, they cannot assure you that this diligence revealed all material issues that may be present, that it would be possible to uncover all material issues through a customary amount of due diligence or that factors outside of
Quidel&#146;s and Ortho&#146;s control will not later arise. Even if Quidel&#146;s and Ortho&#146;s due diligence successfully identifies certain risks, unexpected risks may arise and previously known risks may materialize in a manner not consistent
with Quidel&#146;s and Ortho&#146;s preliminary risk analysis. Further, as a result of the Combinations, purchase accounting and the proposed operation of Topco going forward, Quidel, Ortho and/or Topco may be required to take write-offs or
write-downs, restructuring and impairment or other charges. As a result, Quidel, Ortho and/or Topco may be forced to write-down or <FONT STYLE="white-space:nowrap">write-off</FONT> assets, restructure its operations or incur impairment or other
charges that could negatively affect the business, assets, liabilities, prospects, outlook, financial condition and results of operations of Quidel, Ortho and/or Topco. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>After the Combinations, Quidel stockholders and Ortho shareholders will have a reduced ownership and voting interest in Topco than they currently have
in Quidel and Ortho respectively, and will exercise less influence over Topco&#146;s management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately following consummation of the
Combinations, it is expected that former Ortho shareholders will own approximately 38% of Topco and former Quidel stockholders will own approximately 62% of Topco, on a fully diluted basis, based on the respective capitalizations of Ortho and Quidel
as of the date the parties entered into the BCA. Consequently, former Quidel stockholders will have a reduced ownership of Topco than they currently have of Quidel and will exercise less influence over the management and policies of Topco than they
currently have over the management and policies of Quidel. Former Ortho shareholders will have a reduced ownership of Topco than they currently have of Ortho and will exercise less influence over the management and policies of Topco than they
currently have over the management and policies of Ortho. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, pursuant to the terms of the BCA, following the closing of the Combinations,
the Topco board of directors will initially be comprised of 12 directors, consisting of eight individuals designated by Quidel, expected to consist of Messrs.&nbsp;Bryant, Buechler, Michael, Strobeck, Widder and Wilkins and Mses.&nbsp;Polan and
Rhoads, each of whom, other than Mr.&nbsp;Bryant, qualifies as an &#147;independent director&#148; under the applicable rules of Nasdaq, and four individuals designated by Ortho prior to closing, at least two of whom will qualify as an
&#147;independent director&#148; under the applicable rules of Nasdaq. Following the closing of the Combinations, (i)&nbsp;Douglas Bryant, the current President and Chief Executive Officer of Quidel, will serve as Chair and Chief Executive Officer
of Topco, (ii)&nbsp;Robert Bujarski will serve as President and Chief Operating Officer of Topco, (iii)&nbsp;Joseph Busky will serve as Chief Financial Officer of Topco, (iv)&nbsp;Michael Iskra will serve as Chief Commercial Officer of Topco and
(v)&nbsp;each of the committees of the Topco board of directors will consist of one director designated by Ortho (who is reasonably acceptable to the Topco board of directors) and not less than two additional directors designated by Quidel. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho and Quidel may have difficulty attracting, motivating and retaining executives and other key
employees due to uncertainty associated with the Combinations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco&#146;s success after completion of the Combinations will depend in part upon
the ability of Topco to retain key employees of Ortho and Quidel. Competition for qualified personnel can be intense. Current and prospective employees of Ortho or Quidel may experience uncertainty about the effect of the Combinations, which may
impair Ortho&#146;s and Quidel&#146;s ability to attract, retain and motivate key management, sales, marketing, manufacturing, technical and other personnel prior to and following the Combinations. Employee retention may be particularly challenging
during the pendency of the Combinations, as employees of Ortho and Quidel may experience uncertainty about their future roles with Topco. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition,
pursuant to change in control and/or severance provisions in Ortho&#146;s severance schemes and executive employment agreements, as well as severance provisions in Quidel&#146;s executive employment agreements, certain key employees of Quidel and
Ortho are entitled to receive severance payments upon certain qualifying terminations of their employment. Certain key Quidel and Ortho employees potentially could terminate their employment following specified circumstances set forth in the
applicable executive severance scheme or employment agreement, including certain changes in such key employees&#146; title, status, authority, duties, responsibilities or compensation, and be entitled to receive severance. Such circumstances could
occur in connection with the Combinations as a result of changes in roles and responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While Quidel and Ortho may employ the use of certain
retention programs, there can be no guarantee that they will prove to be successful. If key employees of Ortho or Quidel depart, the integration of the companies may be more difficult and Topco&#146;s business following the Combinations may be
harmed. Furthermore, Topco may be required to incur significant costs in identifying, hiring, training and retaining replacements for departing employees and may lose significant expertise and talent relating to the businesses of Ortho or Quidel,
which may adversely affect Topco&#146;s ability to realize the anticipated benefits of the Combinations. In addition, there could be disruptions to or distractions for the workforce and management associated with activities of labor unions or works
councils or integrating employees into Topco. Accordingly, no assurance can be given that Topco will be able to attract or retain key employees of Ortho and Quidel to the same extent that those companies have been able to attract or retain their own
employees in the past. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho&#146;s and Quidel&#146;s business relationships may be subject to disruption due to uncertainty associated with the
Combinations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Companies with which Ortho or Quidel do business may experience uncertainty associated with the Combinations, including with respect
to current or future business relationships with Ortho, Quidel or Topco. Ortho&#146;s and Quidel&#146;s business relationships may be subject to disruption as customers, distributors, suppliers, vendors and others may attempt to negotiate changes in
existing business relationships or consider entering into business relationships with parties other than Ortho, Quidel or Topco. These disruptions could have an adverse effect on the businesses, financial condition, results of operations or
prospects of Topco, including an adverse effect on Topco&#146;s ability to realize the anticipated benefits of the Combinations. The risk and adverse effect of such disruptions could be exacerbated by a delay in completion of the Combinations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may adversely affect Quidel&#146;s and Ortho&#146;s ability to timely consummate the
Combinations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">COVID-19</FONT> and the various precautionary measures attempting to limit its spread taken by many
governmental authorities worldwide have had a severe effect on global markets and the global economy. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts Quidel&#146;s and Ortho&#146;s respective business
operations will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, new information that may emerge concerning the severity of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the nature
and extent of governmental actions taken to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or treat its impact, the availability of effective treatments and vaccines, the ultimate duration of the pandemic and how quickly and to what extent
normal economic and operating conditions can resume. <FONT STYLE="white-space:nowrap">COVID-19</FONT> and official actions in response to it have made it more challenging for Quidel, Ortho and relevant third parties to adequately staff their
respective businesses and operations, and may cause delay in the companies&#146; ability to obtain the relevant approvals for the consummation of the Combinations. The spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> has caused Quidel and
Ortho to modify their business practices (including employee travel, employee work locations and physical participation in meetings, events and conferences), and each of Quidel and Ortho may take further actions as may be required by government
authorities or that Quidel or Ortho determines are in the best interests of their employees, customers, partners, and suppliers. Such measures may not mitigate fully the risks posed by the virus, impairing Quidel&#146;s and Ortho&#146;s ability to
perform critical functions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In response to increased <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing demand, Quidel is
continuing to rapidly and significantly expand its manufacturing capacity, including expanding and scaling its infrastructure to support existing and anticipated <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing demand and commercial
activities. This rapid expansion has placed and may continue to place significant strain on Quidel&#146;s management, personnel, operations, systems and financial resources. Failure to successfully manage this expansion, including due to
inefficiencies in implementing such expansion or higher costs for materials, technology, equipment and human capital during the intensity of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, could negatively affect Quidel&#146;s or
Topco&#146;s operating results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The respective opinions of Ortho&#146;s and Quidel&#146;s financial advisors will not reflect changes in
circumstances between the signing of the BCA and the completion of the Combinations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho board of directors and the Quidel board of
directors received opinions from their respective financial advisors in connection with their determinations to approve the BCA, the Combinations and all other transactions contemplated by the BCA. However, Ortho and Quidel do not expect to receive
updated opinions from their respective financial advisors prior to completion of the Combinations, and thus, the opinions do not speak as of the time of the Ortho Shareholder Meetings, the Quidel Stockholders&#146; Meeting or completion of the
Combinations or as of any date other than the date of such opinions. Changes in the operations and prospects of Ortho or Quidel, general market and economic conditions and other factors that may be beyond the control of Ortho or Quidel and on which
the financial advisors&#146; opinions were based may significantly affect the relative value of Ortho and Quidel and the prices of Ortho Shares or Quidel Shares by the time the Combinations are completed. As a result, the opinions will not address
the fairness, from a financial point of view, of the Ortho Scheme Consideration to be received by Ortho shareholders or to be paid by Quidel, as applicable, at the times of such meetings or the time the Combinations are completed. For a description
of the opinions that Ortho and Quidel received from their respective financial advisors, see the sections entitled &#147;The Combinations&#151;Opinion of J.P. Morgan Securities LLC as Financial Advisor to Ortho&#148; and &#147;The
Combinations&#151;Opinion of Perella Weinberg Partners LP as Financial Advisor to Quidel&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quidel&#146;s and Ortho&#146;s executive officers and directors have interests in the Combinations that may be different from the interests of Quidel
stockholders or Ortho shareholders, respectively, generally. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When considering the recommendation of the Quidel board of directors that Quidel
stockholders approve the Merger Proposal, Quidel stockholders should be aware that directors and executive officers of Quidel have certain interests in the Combinations that may be different from or in addition to the interests of Quidel
stockholders generally. These interests include, but are not limited to, the treatment of Quidel equity awards in the Quidel Merger, severance protection provided for in compensation arrangements of certain executives, and potential changes to their
roles and responsibilities with Topco following the completion of the Combinations. The Quidel board of directors was aware of these interests and considered them, among other things, in evaluating and negotiating the BCA and the Combinations and in
recommending that the Quidel stockholders approve the Merger Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When considering the recommendation of the Ortho board of directors that Ortho
shareholders approve the Ortho Scheme, Ortho shareholders should be aware that directors and executive officers of Ortho have certain interests in the Combinations that may be different from or in addition to the interests of Ortho shareholders
generally. These interests include, but are not limited to, the treatment of Ortho equity compensation awards in the Ortho Scheme. The Ortho board of directors was aware of these interests and considered them, among other things, in evaluating and
negotiating the BCA and the Combinations and in recommending that the Ortho shareholders approve the Ortho Scheme. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the sections entitled &#147;The
Combinations&#151;Background of the Combinations,&#148; &#147;Interests of Certain Persons in the Combinations&#148; and &#147;The Business Combination Agreement&#151;Indemnification and Insurance&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Completion of the Combinations may trigger <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control</FONT></FONT> or other
provisions in certain agreements that Quidel or Ortho is party to. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The completion of the Combinations may trigger
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control</FONT></FONT> or other provisions in certain agreements that Quidel or Ortho is party to. If Quidel or Ortho, as applicable, is unable to negotiate waivers of those
provisions, the respective counterparties may exercise their rights and remedies under the applicable agreements, including in some instances potentially terminating the agreements or seeking monetary damages. Even if Quidel or Ortho, as applicable,
is able to negotiate waivers, the respective counterparties may require a fee for such waivers or seek to renegotiate the agreements on terms less favorable to the combined business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the Quidel Merger does not qualify as part of an exchange described under Section&nbsp;351 of the
Code or a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code, U.S. stockholders of Quidel may be required to pay substantial U.S. federal income taxes. Likewise, if the Ortho Scheme does not qualify as part of an
exchange described under Section&nbsp;351 of the Code, U.S. shareholders of Ortho may be required to pay substantial U.S. federal income taxes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For U.S. federal income tax purposes, the Combinations, taken together as a single integrated transaction, are intended to qualify as an exchange described
under Section&nbsp;351 of the Code and the payment of cash pursuant to the Combinations is intended to be treated as a payment pursuant to Section&nbsp;351(b) of the Code (the &#147;Intended Tax Treatment&#148;). The Quidel Merger is also intended
to qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code. All parties intend to report the Combinations consistent with the Intended Tax Treatment. However, neither Quidel nor Ortho intends to obtain a ruling
from the IRS with respect to the tax consequences of the Combinations. If the IRS or a court determines that the Quidel Merger does not qualify as part of an exchange under Section&nbsp;351 of the Code and does not qualify as a
&#147;reorganization&#148; under Section&nbsp;368(a) of the Code, a U.S. stockholder of Quidel would generally recognize taxable gain or loss upon the exchange of Quidel Shares for Topco Shares pursuant to the Combinations. If the IRS or a court
determines that the Ortho Scheme does not qualify as part of an exchange under Section&nbsp;351 of the Code, a U.S. shareholder of Ortho would generally recognize taxable gain or loss upon the exchange of its Ortho Shares for Topco Shares and cash
pursuant to the Combinations (whereas if the Ortho Scheme qualifies as part of an exchange under Section&nbsp;351 of the Code, the U.S. shareholder of Ortho would only recognize taxable gain on the exchange with respect to the cash portion of the
consideration). See the section entitled &#147;Material U.S. Federal Income Tax Considerations.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_40"></A>Risks Relating to
Topco Following Completion of the Combinations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the risks described below, you should carefully consider the risks discussed under
&#147;&#151;Risks Relating to Quidel&#146;s Business&#148; and &#147;&#151;Risks Relating to Ortho&#146;s Business,&#148; as these risks will be applicable to the business of Topco following the completion of the Combinations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The failure to integrate successfully the businesses of Quidel and Ortho in the expected timeframe would adversely affect Topco&#146;s future business
and financial performance following the Combinations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combination of two independent companies is a complex, costly and time-consuming
process. As a result, the combined company will be required to devote significant management attention and resources to integrate the business practices and operations of Ortho and Quidel. The integration process may disrupt the business of either
or both of the companies and, if implemented ineffectively, could preclude realization of the full benefits expected by Ortho and Quidel from the Combinations. The failure of Topco to meet the challenges involved in successfully integrating the
operations of Ortho and Quidel or otherwise to realize the anticipated benefits of the Combinations could cause an interruption of the activities of Topco and could seriously harm its results of operations. In addition, the overall integration of
the two companies may result in material unanticipated problems, expenses, liabilities, competitive responses, loss of customer relationships and diversion of management&#146;s attention, and may cause Topco&#146;s stock price to decline. The
difficulties of combining the operations of Quidel and Ortho include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing a significantly larger company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating geographically separate organizations, including extensive international operations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential diversion of management&#146;s focus and resources from other strategic opportunities and from
operational matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance shortfalls at one or both of the companies as a result of the diversion of management&#146;s
attention caused by completing the Combinations and integrating the companies&#146; operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aligning and executing the strategy of Topco; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retaining existing customers and attracting new customers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining employee morale and retaining key management and other employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the disruption of, or the loss of momentum in, each company&#146;s ongoing business or inconsistencies in
standards, controls, systems, procedures and policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">integrating two unique business cultures, which may prove to be incompatible; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility of faulty assumptions underlying expectations regarding the integration process;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consolidating corporate and administrative infrastructures and eliminating duplicative operations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating distribution and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">integrating IT, communications and other systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in applicable laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing tax costs or inefficiencies associated with integrating the operations of Quidel and Ortho;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen expenses or delays associated with the Combinations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">taking actions that may be required in connection with obtaining regulatory approvals. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of these factors will be outside of Topco&#146;s control and any one of them could result in increased costs, decreased revenues and diversion of
management&#146;s time and energy, which could materially impact the combined company&#146;s business, financial condition and results of operations. In addition, even if the operations of Ortho and Quidel are integrated successfully, Topco may not
realize the full benefits of the Combinations, including the synergies, cost savings or sales or growth opportunities that Ortho and Quidel expect. These benefits may not be achieved within the anticipated timeframe, or at all. As a result, Ortho
and Quidel cannot assure their respective shareholders and stockholders that the combination of Ortho and Quidel will result in the realization of the full benefits anticipated from the Combinations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The synergies attributable to the Combinations may vary from expectations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco may fail to realize the anticipated benefits and synergies expected from the Combinations, which could adversely affect its business, financial condition
and operating results. The success of the Combinations will depend, in significant part, on Topco&#146;s ability to successfully integrate the businesses of Quidel and Ortho and realize the anticipated strategic benefits and synergies from the
Combinations. Quidel and Ortho believe that the combination of the two businesses will complement each party&#146;s strategy by providing a balanced and diversified product portfolio, operational efficiencies, supply chain optimization,
complementary geographic footprints, product development synergies and cash flow and margin enhancement opportunities. However, achieving these goals requires, among other things, realization of the targeted cost synergies expected from the
Combinations. The anticipated benefits of the Combinations and actual operating, technological, strategic and revenue opportunities may not be realized fully or at all, or may take longer to realize than expected. If Topco is not able to achieve
these objectives and realize the anticipated benefits and synergies expected from the Combinations within the anticipated timeframe or at all, Topco&#146;s business, financial condition and operating results may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The future results of Topco will suffer if Topco does not effectively manage its expanded operations following the Combinations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Combinations, the size of the business of Topco will increase significantly beyond the current size of either Quidel&#146;s or Ortho&#146;s
business. Topco&#146;s future results depends, in part, upon its ability to manage this expanded business, which will pose substantial challenges for management, including challenges related to the management and monitoring of new operations and
associated increased costs and complexity. There can be no assurance that Topco will be successful or that it will realize the expected operating efficiencies, cost savings, revenue enhancements and other benefits currently anticipated from the
Combinations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business issues currently faced by Quidel or Ortho may be imputed to the operations of the other. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent either Quidel or Ortho currently has, or is perceived by customers to have, operational challenges, such as service performance, safety issues or
workforce issues, those challenges may raise concerns by existing customers of the other company following the Combinations, which may limit or impede Topco&#146;s future ability to obtain additional business from those customers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Topco will be subject to certain risks relating to Ortho&#146;s indebtedness. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the consummation of the Combinations, Ortho&#146;s current net debt of $2.0&nbsp;billion is expected to continue to be outstanding, and as a
result, Topco will be subject to certain risks related to this indebtedness. For a discussion of the risks relating to this indebtedness and the related debt instruments, including the requirement to comply with certain covenants that may restrict
Topco from realizing the anticipated benefits and synergies expected from the Combinations, see &#147;&#151;Risks Relating to Ortho&#146;s Business&#151;Risks Relating to Ortho&#146;s Indebtedness.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No trading market currently exists for Topco Shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Combinations, no trading market exists for Topco Shares. Upon the closing of the Combinations, the Topco Shares are expected to be listed for
trading on Nasdaq. However, there can be no assurance that an active trading market for Topco Shares will develop after the closing of the Combinations, or if it develops, that such market will be sustained. In the absence of an active trading
market for the Topco Shares, investors may not be able to sell their Topco Shares at the time that they would like to sell. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of
Topco Shares may be volatile. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of Topco Shares may be volatile. Broad general economic, political, market and industry factors may
adversely affect the market price of Topco Shares, regardless of Topco&#146;s actual operating performance and the success of the integration of Quidel and Ortho. Factors that could cause fluctuations in the price of Topco Shares include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated variations in quarterly operating results and the results of competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial projections by Topco, if any, or by any securities analysts that may cover Topco Shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions or trends in the industry, including regulatory changes or changes in the securities marketplace;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by Topco or its competitors of significant acquisitions, strategic partnerships or divestitures;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of investigations or regulatory scrutiny of Topco&#146;s operations or lawsuits filed against it;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of key personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuances or sales of Topco Shares, including sales of shares by Topco&#146;s directors and officers or its key
investors. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of Topco Shares by Topco or its stockholders in the public market, or the perception that such sales may
occur, could reduce the price of Topco Shares, and any additional capital raised by Topco through the sale of equity or convertible securities may dilute ownership in Topco. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale of Topco Shares in the public market, or the perception that such sales could occur, could harm the prevailing market price of Topco Shares. These
sales, or the possibility that these sales may occur, also might make it more difficult for Topco to sell equity securities in the future at a time and at a price that Topco deems appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the completion of the Combinations, Topco is expected to have approximately 66.7 million outstanding Topco Shares. Following the completion of the
Combinations, it is expected that former Ortho shareholders will own approximately 38% of Topco and former Quidel stockholders will own approximately 62% of Topco, on a fully diluted basis, based on the respective capitalizations of Ortho and Quidel
as of the date the parties entered into the BCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All Topco Shares that will be issued in connection with the Combinations are expected to be freely
tradable without restriction or further registration under the Securities Act, except for any Topco Shares held by Topco&#146;s affiliates, as that term is defined under Rule 144 of the Securities Act (&#147;Rule 144&#148;), including certain of
Topco&#146;s directors, executive officers and other affiliates, which shares may be sold in the public market only if they are registered under the Securities Act or are sold pursuant to an exemption from registration such as Rule 144. Following
the completion of the Combinations, Topco Shares covered by registration rights are expected to represent approximately 19% of Topco&#146;s outstanding Topco Shares. Registration of any of these outstanding Topco Shares would result in such shares
becoming freely tradable without compliance with Rule 144 upon effectiveness of the registration statement. As restrictions on resale end or if these stockholders exercise their registration rights, the market price of Topco Shares could drop
significantly if the holders of these Topco Shares sell them or are perceived by the market as intending to sell them. These factors could also make it more difficult for Topco to raise additional funds through future offerings of Topco Shares or
other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Topco intends to file a registration statement with the SEC on Form <FONT STYLE="white-space:nowrap">S-8</FONT> providing
for the registration of [&#9679;] Topco Shares issued or reserved for issuance under the Quidel 2018 Equity Plan, as proposed to be amended and assumed by Topco. Subject to the satisfaction of vesting conditions, shares registered under the
registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> may be made available for resale immediately in the public market without restriction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the future, Topco may also issue its securities in connection with investments or acquisitions, or otherwise. Topco cannot predict the size of future
issuances of Topco Shares or securities convertible into Topco Shares or the effect, if any, that future issuances and sales of Topco Shares will have on the market price of Topco Shares. Sales of substantial amounts of Topco Shares (including
shares issued in connection with an acquisition), or the perception that such sales could occur, may adversely affect prevailing market prices of Topco Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or reports about Topco, the trading price
of Topco Shares could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for Topco Shares will be influenced by any research and reports that industry or securities
analysts publish about Topco or its business. If one or more of these analysts cease coverage of Topco or fail to publish reports on Topco regularly, Topco could lose visibility in the financial markets, which in turn could cause Topco&#146;s stock
price or trading volume to decline. Moreover, if one or more of the analysts who cover Topco downgrade the Topco Shares or if Topco&#146;s operating results do not meet their expectations, the trading price of Topco Shares could decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Topco Shares to be received by Ortho shareholders and Quidel stockholders as a result of the Combinations will have rights different from the Ortho
Shares and Quidel Shares that they hold prior to the Effective Times of the Combinations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Combinations, the rights of
former Ortho shareholders and Quidel stockholders who become stockholders of Topco will be governed by the certificate of incorporation of Topco (the &#147;Topco Charter&#148;) and the bylaws of Topco (the &#147;Topco Bylaws&#148;) and by the DGCL.
The rights associated with Ortho Shares and Quidel Shares are different from the rights associated with Topco Shares. See the section entitled &#147;Comparison of Rights of Stockholders of Quidel, Ortho and Topco&#148; of this joint proxy
statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Topco Bylaws will designate the Court of Chancery of the State of Delaware (the &#147;Court of Chancery&#148;) as the
sole and exclusive forum for certain types of actions and proceedings that may be initiated by Topco&#146;s stockholders, which could limit Topco&#146;s stockholders&#146; ability to obtain a favorable judicial forum for disputes with Topco or its
directors, officers, employees or agents. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Topco Bylaws after the Combinations will provide that, unless Topco consents in writing to the
selection of an alternative forum, (i)&nbsp;the Court of Chancery (or, if the Court of Chancery does not have, or declines to accept, jurisdiction, another state court or a federal court located within the State of Delaware) will, to the fullest
extent permitted by applicable law, be the sole and exclusive forum for any claims (other than any cause of action arising under the Securities Act), including claims in the right of Topco that are based upon a violation of duty by a current or
former director, officer, employee or stockholder in such capacity, or as to which the DGCL confers jurisdiction upon the Court of Chancery, and (ii)&nbsp;the federal district courts of the United States of America will, to the fullest extent
permitted by applicable law, be the sole and exclusive forum for any cause of action arising under the Securities Act but that the forum selection provision will not apply to claims brought to enforce a duty or liability created by the Exchange Act.
Any person or entity purchasing or otherwise acquiring any interest in shares of Topco&#146;s capital stock will be deemed to have notice of, and to have consented to, the provisions of the Topco Bylaws described in the preceding sentence. This
forum selection provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with Topco or its directors, officers, employees or agents, which may discourage such lawsuits against Topco
and such persons and result in increased costs for a stockholder to bring a claim. There is uncertainty as to whether a court would enforce such provisions. If a court were to find these provisions of the Topco Bylaws inapplicable to, or
unenforceable in respect of, one or more of the specified types of actions or proceedings, Topco may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect Topco&#146;s business, financial
condition or results of operations. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Topco fails to develop or maintain an effective system of internal controls, it may not be able to
accurately report its financial results or prevent fraud. As a result, stockholders could lose confidence in Topco&#146;s financial reporting, which would harm its business and the trading price of Topco Shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective internal controls are necessary for Topco to provide reliable financial reports, prevent fraud and operate successfully as a public company. If Topco
cannot provide reliable financial reports or prevent fraud, its reputation and operating results would be harmed. Topco cannot be certain that its efforts to develop and maintain an effective system of internal controls will be successful, that it
will be able to maintain adequate controls over its financial processes and reporting in the future, or that it will be able to comply with its obligations under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002. Any failure to develop or maintain
effective internal controls, or difficulties encountered in implementing or improving internal controls, could harm Topco&#146;s operating results or cause Topco to fail to meet its reporting obligations. Ineffective internal controls could also
cause investors to lose confidence in Topco&#146;s reported financial information, which would likely have a negative effect on the trading price of the Topco Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Topco&#146;s IT systems may be vulnerable to hacker intrusion, malicious viruses and other cybercrime
attacks, which may harm its business and expose it to liability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco&#146;s operations will depend to a great extent on the reliability and
security of its IT systems, software and network, which are subject to damage and interruption caused by human error, problems relating to telecommunications networks, software failure, natural disasters, sabotage, viruses and similar events. Any
interruption in Topco&#146;s IT systems could have a negative effect on the quality of products and services offered and, as a result, on customer demand and volume of sales. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Topco will be exposed to significant risks in relation to compliance with anti-corruption laws and regulations and economic sanctions programs.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Doing business on a worldwide basis will require the combined company to comply with the laws and regulations of various jurisdictions, and
Topco&#146;s failure to successfully comply with these rules and regulations may expose it to liabilities. These laws and regulations apply to companies, individual directors, officers, employees and agents, and may restrict the combined
company&#146;s operations, trade practices, investment decisions and partnering activities. In particular, Topco&#146;s international operations are subject to anti-corruption and anti-bribery laws and regulations, such as the U.S. Foreign Corrupt
Practices Act of 1977 (the &#147;FCPA&#148;), the UK Bribery Act of 2010 (the &#147;Bribery Act&#148;) and the Brazilian Anti-Bribery Act (also known as the Brazilian Clean Company Act), among others, and economic and trade sanctions, including
those administered by the United Nations, the European Union, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;OFAC&#148;) and the U.S. Department of State. The FCPA prohibits providing anything of value to foreign
officials for the purposes of obtaining or retaining business or securing any improper business advantage. Topco may deal with state-owned business enterprises, the employees and representatives of which may be considered foreign officials for
purposes of the FCPA. Topco is subject to the jurisdiction of various governments and regulatory agencies outside of the United States, which may bring Topco&#146;s personnel into contact with foreign officials responsible for issuing or renewing
permits, licenses or approvals or for enforcing other governmental regulations. The provisions of the Bribery Act extend beyond bribery of foreign public officials and are more onerous than the FCPA in a number of other respects, including
jurisdiction, non-exemption of facilitation payments and penalties. Economic and trade sanctions restrict Topco&#146;s transactions or dealings with certain sanctioned countries, territories and designated persons, absent authorizations or
exemptions under applicable law, such as OFAC&#146;s licenses permitting certain humanitarian trade. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of doing business in foreign countries,
including through partners, distributors, agents and other third parties acting on Topco&#146;s behalf, Topco will be exposed to a risk of violating anti-corruption and anti-bribery laws and sanctions regulations. Some of the international locations
in which Topco will operate have developing legal systems and may have higher levels of corruption than more developed nations. Topco&#146;s continued expansion and worldwide operations, including in developing countries, its development of
joint-venture relationships worldwide and the employment of local agents in the countries in which Topco will operate increase the risk of violations of anti-corruption and anti-bribery laws and economic and trade sanctions. Though these
distributors, manufacturers and other third parties acting on Topco&#146;s behalf are not Topco&#146;s affiliated legal entities, such violations could expose Topco to FCPA liability or liabilities under similar laws of the various jurisdictions in
which Topco operates and/or Topco&#146;s reputation may potentially be harmed by the third parties. Violations of anti-corruption and anti-bribery laws and economic and trade sanctions are punishable by civil penalties, including fines, denial of
export privileges, injunctions, asset seizures, debarment from government contracts (and termination of existing contracts) and revocations or restrictions of licenses, as well as criminal fines and imprisonment. In addition, any major violations
could have a significant impact on Topco&#146;s reputation and consequently on its ability to win future business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While Ortho and Quidel believe that
Topco will have a strong culture of compliance and an adequate system of internal controls, including procedures to minimize and detect fraud in a timely manner, as well as processes for complying with OFAC authorizations or exemptions, Ortho and
Quidel will seek to continuously improve Topco&#146;s system of internal controls and to remedy any weaknesses identified. There can be no assurance, however, that Topco&#146;s policies and procedures will be followed at all times or will
effectively detect and prevent violations of the applicable laws by one or more of its employees, consultants, agents or partners and, as a result, Topco could be subject to penalties and material adverse consequences on its business, financial
condition or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Topco&#146;s ability to utilize the U.S. net operating loss carryforwards may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of Topco and its affiliates, including Quidel and Ortho, to utilize any U.S. federal net operating loss carryforwards (&#147;NOLs&#148;) and other
tax attributes existing at the time of the Combinations to reduce future taxable income </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
following the consummation of the Combinations is subject to limitations under U.S. federal income tax laws and depends on many factors, including its future income, which cannot be assured. In
addition, Section&nbsp;382 of the Code (&#147;Section&nbsp;382&#148;) generally imposes an annual limitation on the amount of NOLs that may be used to offset taxable income when a corporation has undergone an &#147;ownership change&#148; (as
determined under Section&nbsp;382), as is expected to be the case for Ortho following the Combinations. An ownership change generally occurs if one or more stockholders (or groups of stockholders) who are each deemed to own at least 5% of such
corporation&#146;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Section&nbsp;382 may apply as a result of the Combinations and limit the use of any NOLs
prior to their expiration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Topco and its subsidiaries will be subject to U.S. and foreign tax laws, and changes to such tax laws or differing
interpretation of those laws by the relevant governmental authorities could adversely affect Topco. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. Congress, the Organisation for
Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development and other government agencies in jurisdictions where Topco and its affiliates do business have had an extended focus on issues related to the taxation of multinational
corporations. One example is in the area of &#147;base erosion and profit shifting,&#148; where payments are made between affiliates from a jurisdiction with high tax rates to a jurisdiction with lower tax rates. Additionally, changes proposed by
the current U.S. administration, including significant tax reform, could significantly change the U.S. federal income tax rules and regulations applicable to Topco and its affiliates, although the prospect of tax reform, and the nature of any such
reform, remains highly uncertain. Thus, the tax laws in the United States, the United Kingdom and other countries in which Topco and its affiliates do business could change on a prospective or retroactive basis, and any such changes could adversely
affect Topco. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the tax laws and regulations in the United States, the United Kingdom and the numerous other jurisdictions in which Topco and
its subsidiaries operate are inherently complex, and Topco and its subsidiaries will be obligated to make judgments and interpretations about the application of these laws and regulations to Topco and its subsidiaries and their operations and
businesses. The interpretation and application of these laws and regulations could be challenged by the relevant governmental authorities, which could result in material administrative or judicial procedures, actions or sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The unaudited prospective financial information for Quidel and Ortho included in this joint proxy statement/prospectus reflects management estimates and
may not prove to be reflective of actual future financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Combinations, Quidel and Ortho prepared and considered,
among other things, certain internal, unaudited prospective financial information for Quidel and Ortho. This unaudited prospective financial information included assumptions regarding future market conditions, operating cash flows, expenditures and
growth of Quidel and Ortho, as applicable. This internal, unaudited prospective financial information speaks only as of the date made and, except as required by applicable securities laws, will not be updated. This unaudited prospective financial
information is subject to significant economic, competitive, industry and other uncertainties, which may cause the unaudited prospective financial information or the underlying assumptions to be inaccurate. As a result of these contingencies, there
can be no assurance that the unaudited prospective financial information of Quidel and Ortho will be achieved in full, at all or within projected timeframes. In light of these uncertainties, the inclusion of the unaudited prospective financial
information of Quidel and Ortho in this joint proxy statement/prospectus should not be regarded as an indication that the Quidel board of directors, the Ortho board of directors, Quidel, Ortho, Perella Weinberg or J.P. Morgan or any other recipient
of this information considered, or now considers, it to be an assurance of the achievement of future financial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited prospective
financial information was prepared for internal use and to assist Quidel and Ortho with their due diligence investigations and their respective financial advisors with their respective financial analyses. The unaudited prospective financial
information was not prepared with a view toward public disclosure or toward compliance with published guidelines of the SEC or the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of
prospective financial information. The prospective financial information included in this joint proxy statement/prospectus has been prepared by, and is the responsibility of, Quidel&#146;s and Ortho&#146;s management. Ernst&nbsp;&amp; Young LLP
(Quidel&#146;s independent registered public accounting firm) and PricewaterhouseCoopers LLP (Ortho&#146;s independent registered public accounting firm) have not audited, reviewed, examined, compiled nor applied agreed-upon procedures with respect
to the accompanying prospective financial information and, accordingly, Ernst&nbsp;&amp; Young LLP and PricewaterhouseCoopers LLP have not expressed an opinion or any other form of assurance with respect thereto. The Ernst&nbsp;&amp; Young LLP
report incorporated by reference into this joint proxy statement/prospectus relates to Quidel&#146;s previously issued financial statements and the PricewaterhouseCoopers LLP report included in this joint proxy statement/prospectus
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relates to Ortho&#146;s previously issued financial statements. The reports do not extend to the prospective financial information and should not be read to do so. For additional information
regarding the unaudited prospective financial information, see the section entitled &#147;The Combinations&#151;Unaudited Forward-Looking Financial Information&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Topco&#146;s actual financial position and results of operations may differ materially from the unaudited pro forma financial information included in
this joint proxy statement/prospectus. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco has been recently incorporated and has no operating history and no revenues. While the unaudited pro
forma financial information contained in this joint proxy statement/prospectus represents the best estimates of Quidel&#146;s and Ortho&#146;s management, it is presented for illustrative purposes only and may not be an accurate indication of
Topco&#146;s financial position or results of operations if the Combinations and associated financing transactions are completed on the dates indicated. The unaudited pro forma financial information has been derived from the audited and unaudited
historical financial statements of Ortho and Quidel and certain adjustments and assumptions have been made regarding Topco after giving effect to the Combinations. The unaudited pro forma financial information does not include any fair value
adjustments associated with the assets and liabilities of Ortho with the exception of the fair value of long-term borrowings and intangible assets, as Quidel and Ortho&#146;s management have preliminarily concluded that these historical carrying
values approximate their fair values as of September&nbsp;30, 2021. The process for estimating the fair value of acquired assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates. These
estimates may be revised as additional information becomes available and as additional analyses are performed. Differences between preliminary estimates in the unaudited pro forma financial information and the final acquisition accounting will occur
and could have a material impact on the unaudited pro forma financial information and Topco&#146;s financial position and future results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the assumptions used in preparing the unaudited pro forma financial information may not prove to be accurate, and other factors may affect
Topco&#146;s financial condition or results of operations following the closing of the Combinations. Any potential decline in Topco&#146;s financial condition or results of operations may cause significant fluctuations in the price of Topco Shares.
See the section entitled &#147;Unaudited Pro Forma Combined Financial Information&#148; of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Topco will be
exposed to foreign currency exchange risk. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Combinations, Topco will transact business in numerous countries around the
world and expects that a significant portion of its business will continue to take place in international markets. Topco will conduct its business and prepare its consolidated financial statements in its functional currency, while the financial
statements of each of its subsidiaries will be prepared in the functional currency of that entity and the business of that entity will be conducted in the functional currency of that entity. Accordingly, fluctuations in the exchange rate of the
functional currencies of Topco&#146;s foreign currency entities against the functional currency of Topco will impact its results of operations and financial condition. Accordingly, it is expected that Topco&#146;s revenues and earnings will be
exposed to the risks that may arise from fluctuations in foreign currency exchange rates, which could have a material adverse effect on Topco&#146;s business, results of operations or financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A downgrade in Topco&#146;s or its subsidiaries&#146; credit ratings following the Combinations could impact Topco&#146;s access to capital and cost of
doing business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Combinations, rating agencies may <FONT STYLE="white-space:nowrap">re-evaluate</FONT> Topco&#146;s and its
subsidiaries&#146; credit ratings, and any additional actual or anticipated downgrades in such credit ratings could limit Topco&#146;s ability to access credit and capital markets, or to restructure or refinance its indebtedness. As a result of any
such downgrades, future financings or refinancings may result in higher borrowing costs and require more restrictive terms and covenants, including obligations to post collateral with third parties, which may further restrict operations and
negatively impact liquidity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Credit rating agencies perform independent analyses when assigning credit ratings. Each analysis includes a number of
criteria, including, but not limited to, business composition, market and operational risks, and various financial tests. Credit rating agencies continue to review the criteria for industry sectors and various debt ratings and may make changes to
those criteria from time to time. Credit ratings are not recommendations to buy, sell or hold investments in the rated entity. Ratings are subject to revision or withdrawal at any time by the rating agencies, which could have a material adverse
effect on Topco&#146;s business, results of operations or financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_41"></A>Risks Relating to Quidel&#146;s Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the foregoing risks, Quidel is, and will continue to be, and the combined company will be, subject to the risks described in Quidel&#146;s
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2021, as such risks may be updated or supplemented in Quidel&#146;s subsequently filed Annual Reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> to the extent incorporated by reference into this joint proxy
statement/prospectus, other than to the extent inconsistent with the risks described in the section entitled &#147;&#151;Risks Relating to Topco Following Completion of the Combinations.&#148; See the section entitled &#147;Where You Can Find More
Information&#148; of this joint proxy statement/prospectus. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_42"></A>Risks Relating to Ortho&#146;s Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the foregoing risks, Ortho is, and will continue to be, and the combined company will be, subject to the risks described below, as such risks
may be updated or supplemented in Ortho&#146;s subsequently filed Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q or Current Reports on Form 8-K, to the extent incorporated by reference into this joint proxy statement/prospectus, other
than to the extent inconsistent with the risks described in the section entitled &#147;&#151;Risks Relating to Topco Following Completion of the Combinations.&#148; See the section entitled &#147;Where You Can Find More Information&#148; of this
joint proxy statement/prospectus. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho has significant international sales and operations and faces risks related to health epidemics,
including the ongoing global pandemic related to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> Ortho&#146;s business, consolidated results of operations, financial position and cash flows have been and may continue to be negatively affected by
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any significant outbreak of contagious diseases and other adverse public health
developments in countries where Ortho operates could have a material and adverse effect on Ortho&#146;s business, financial condition and results of operations. Since the World Health Organization characterized
<FONT STYLE="white-space:nowrap">COVID-19</FONT> as a pandemic in March 2020, <FONT STYLE="white-space:nowrap">COVID-19</FONT> has continued to spread throughout the United States and globally and it remains unclear when the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic will abate. Although the U.S. Food and Drug Administration (the &#147;FDA&#148;) has approved certain therapeutics and authorized three <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines for
emergency use, there has been some public resistance in the implementation of a national vaccine program, new strains of <FONT STYLE="white-space:nowrap">COVID-19</FONT> have been and may continue to be discovered, and the efficacy of the existing
vaccines with respect to any such newly discovered strain of <FONT STYLE="white-space:nowrap">COVID-19</FONT> remains uncertain. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has resulted, and future significant outbreaks of
contagious diseases in the human population could result, in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for Ortho&#146;s
products and services and, as a result, likely impact Ortho&#146;s operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many countries, including the United States, have and may continue
to restrict travel and/or temporarily close businesses, schools and other public gathering spaces. Further, significant governmental measures, both in the United States and globally, have been and may continue to be implemented to control the spread
of the virus, including restrictions on manufacturing, shipping and the movement of employees. As a result of such restrictions, Ortho has and may continue to experience some restrictions on its ability to efficiently distribute its products in the
regions affected. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has also resulted in global supply chain challenges and during the
quarter ended October&nbsp;3, 2021, Ortho began to experience some supply chain disruptions. For instance, supply chain shortages of certain key components of Ortho&#146;s instruments and assays are affecting Ortho&#146;s ability to fulfill customer
orders on a timely basis and have had, and are expected to continue to have, a negative impact on Ortho&#146;s business and results of operations, which could be material. Although Ortho and its contract manufacturer partners, suppliers of raw
materials and other third-party vendors are pursuing additional sources for certain of these components, Ortho may be unable to identify additional suppliers and expects that these shortages and other supply chain challenges will continue to impact
its business. Ortho has and may continue to encounter increases in idle facility costs and freight and distribution costs, which in some instances have affected the pricing of Ortho&#146;s products. Any prolonged and significant supply chain
disruptions or inability to provide products in countries adversely impacted by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic would continue to impact Ortho&#146;s revenues, increase Ortho&#146;s costs and negatively affect
Ortho&#146;s business relationships and reputation, as well as Ortho&#146;s operating results. It is also possible that Ortho will experience an adverse impact on collections and timing of cash receipts from its customers as a result of the impact
of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which could result in significant fluctuations in Ortho&#146;s cash flows from period to period during the pandemic and in the periods that follow the end of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho maintains a direct or indirect commercial presence in more than 130 countries and
territories, with a direct presence in 36 countries, including in countries that have been severely impacted by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Government imposed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
travel restrictions and local statutory quarantines, as well as the potential impact to personnel, to the extent Ortho&#146;s employees become ill, may result in direct operational and
administrative disruptions. Ortho&#146;s business may also be impacted by the imposition of government orders relating to <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccination status or regular testing of Ortho&#146;s employees, which could
result in the loss of employees and may impact Ortho&#146;s ability to manufacture or ship its products. Ortho may also face increased risks of disputes with Ortho&#146;s business partners, litigation and governmental and regulatory scrutiny as a
result of the effects of <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Health regulatory agencies globally may also experience disruptions in their
operations as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The FDA and comparable foreign regulatory agencies may have slower response times or be under-resourced and, as a result, review and approval of product
registrations may be materially delayed. For example, as health authorities have redeployed resources to focus on the management of the pandemic, there is a reduction in available capacity for the review and approval of other less-critical product
submissions. As a result, manufacturers may incur a delay in obtaining product registrations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho cannot reasonably estimate the length or severity of
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, in particular, impacts Ortho&#146;s business or results will depend on future developments, which are
highly uncertain and cannot be predicted, including new information which may emerge concerning the severity and duration of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the actions to contain it or treat its impact, among
others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects Ortho&#146;s business and financial results or
those of Ortho&#146;s customers, it may also have the effect of heightening many of the other risks described in this &#147;Risk Factors&#148; section. The ultimate impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak on
Ortho&#146;s business, financial condition and results of operations depends on many factors, including those discussed above, that are not within Ortho&#146;s control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho faces significant competition, and Ortho&#146;s failure to compete effectively could adversely affect Ortho&#146;s sales and results of
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The markets in which Ortho and Ortho&#146;s competitors operate are rapidly evolving, and developments are expected to continue at a
rapid pace. Competition in these markets is intense and expected to increase as new products, services and technologies become available and as new competitors enter the market. Ortho faces competition from diagnostics divisions of large
multinational healthcare companies and conglomerates. Some of Ortho&#146;s existing or potential competitors have substantially greater research and development capabilities, clinical, manufacturing, regulatory and marketing experience and financial
and managerial resources than Ortho does. Some of these competitors are divisions or subsidiaries of corporations with substantial resources. Ortho&#146;s sales and results of operations may be adversely affected by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">customers&#146; perceptions of the comparative quality of Ortho&#146;s competitors&#146; products or services;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho&#146;s ability to manufacture, in a cost-effective way, sufficient quantities of Ortho&#146;s products to
meet customer demand; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of Ortho&#146;s competitors to develop products, services and technologies that are more effective
than Ortho&#146;s or that render Ortho&#146;s obsolete; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho&#146;s competitors&#146; ability to obtain patent protection or other intellectual property rights that
would prevent Ortho from offering competing products or services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of Ortho&#146;s competitors to obtain regulatory approval for the commercialization of products or
services more rapidly or effectively than Ortho does; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitive pricing by Ortho&#146;s competitors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho expects competition to intensify in the future as more companies enter Ortho&#146;s markets. Increased competition and potential new entrants in these
industries may result in lower prices and volumes, higher costs for resources and lower profitability for Ortho. Moreover, competitive and regulatory conditions in many markets in which Ortho and Ortho&#146;s competitors operate restrict
Ortho&#146;s ability to fully recover through price increases, higher costs of acquired goods and services resulting from inflation, and other drivers of cost increases. Ortho may not be able to supply customers with products and services that they
deem superior and at competitive prices, and Ortho may lose business to Ortho&#146;s competitors. Ortho also faces risks related to customers finding alternative methods for testing, which could result in lower demand for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Ortho&#146;s products. If Ortho is unable to compete successfully in these highly competitive industries, it could have a material effect on Ortho&#146;s business, financial condition and results
of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho may experience difficulties that delay or prevent Ortho&#146;s development, introduction or marketing of new or enhanced
products or services. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s success depends on Ortho&#146;s ability to effectively introduce new and competitive products and services. The
development of new or enhanced products or services is a complex, costly and uncertain process and is becoming increasingly complex and uncertain in the United States. Furthermore, developing and manufacturing new products and services requires
Ortho to anticipate customers&#146; and patients&#146; needs and emerging technology trends accurately. Ortho may experience research and development, manufacturing, regulatory,&nbsp;marketing and other difficulties that could delay or prevent
Ortho&#146;s introduction of new or enhanced products and services, including the timelines for the introduction of new products as described in this joint proxy statement/prospectus. The research and development process in the healthcare industry
generally takes a significant amount of time from design stage to product launch. This process is conducted in various stages, and each stage presents the risk that Ortho will not achieve its goals. In addition, innovations may not be accepted
quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursements. In the event of such failure, Ortho may have to abandon a product in which it has invested
substantial resources. Ortho cannot be certain that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of Ortho&#146;s products or services under development will prove to be safe and effective in clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho will be able to obtain, in a timely manner or at all, necessary regulatory approvals;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the products and services Ortho develops can be manufactured or provided at acceptable cost and with appropriate
quality; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">these products and services, if and when approved, can be successfully marketed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These factors, as well as manufacturing or distribution problems or other factors beyond Ortho&#146;s control, could delay the launch of new products or
services. Any delay in the development, approval, production, marketing or distribution of a new product or service could materially and adversely affect Ortho&#146;s competitive position, Ortho&#146;s branding and Ortho&#146;s results of
operations. Additionally, customers could adopt alternative technologies, instead of Ortho&#146;s technology, which could result in lower demand for Ortho&#146;s products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Global market, economic and political conditions may adversely affect Ortho&#146;s operations and performance. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The growth of Ortho&#146;s business and demand for Ortho&#146;s products are affected by changes in the health of the overall global economy and, in
particular, of the healthcare industry. Demand for Ortho&#146;s products and services could change more dramatically than in previous years based on activity, funding reimbursement constraints and support levels from governments, universities,
hospitals and the private industry, including laboratories. Ortho&#146;s global business is adversely affected by decreases in the general level of economic activity, such as decreases in business and consumer spending, increases in unemployment
rates and budgeting constraints of governmental entities. Disruptions in the United States, Europe or in other economies, or weakening of emerging markets, including China, could adversely affect Ortho&#146;s sales, profitability and/or liquidity.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho cannot assure you that there will not be a future deterioration in financial markets or confidence in major economies. These economic developments
affect businesses such as Ortho&#146;s in a number of ways. A tightening of credit in financial markets could adversely affect the ability of Ortho&#146;s customers and suppliers to obtain financing for significant purchases and operations, could
result in a decrease in or cancellation of orders for Ortho&#146;s products and services and could impact the ability of Ortho&#146;s customers to make payments. Similarly, a tightening of credit may adversely affect Ortho&#146;s supplier base and
increase the potential for one or more of Ortho&#146;s suppliers to experience financial distress or bankruptcy. Ortho&#146;s financial position, results of operations and cash flows could be materially adversely affected by difficult conditions and
volatility in the capital, credit and commodities markets. Difficult conditions in these markets or in the overall economy could affect Ortho&#146;s business in a number of ways. For example: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under such conditions, Ortho cannot assure you that borrowings under Ortho&#146;s multicurrency senior secured
revolving facility with commitments of $500.0&nbsp;million (the &#147;Revolving Credit Facility&#148;) will be available or sufficient, and in such a case, Ortho may not be able to obtain additional financing on reasonable terms or at all; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in order to respond to market conditions, Ortho may need to seek waivers of various provisions in the credit
agreement governing Ortho&#146;s senior secured credit facilities (the &#147;Senior Secured Credit Facilities&#148;), which consist of (i)&nbsp;the senior secured term loan facility, as amended on June&nbsp;8, 2018, in an original amount of
$2,325.0&nbsp;million (collectively, the &#147;Dollar Term Loan Facility&#148;), (ii) the euro-denominated senior secured term loan facility in an amount equal to &#128;337.4&nbsp;million (the &#147;Euro Term Loan Facility&#148; and, together with
the Dollar Term Loan Facility, the &#147;Term Loan Facilities&#148;), and (iii)&nbsp;the Revolving Credit Facility (as amended, the &#147;Credit Agreement&#148;), and Ortho might not be able to obtain such waivers on reasonable terms, if at all.
</P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho&#146;s ability to obtain additional capital on commercially reasonable terms may be limited or <FONT
STYLE="white-space:nowrap">non-existent.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Ortho believes its cash, cash equivalents and short-term investments, as well as future
cash generated from operations and availability under Ortho&#146;s Revolving Credit Facility, provide adequate resources to fund ongoing debt service and working capital requirements, capital expenditures and transition costs for the foreseeable
future, Ortho may need to seek additional financing to compete effectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Ortho is unable to obtain capital on commercially reasonable terms, or at
all, it could: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">result in reduced funds available to Ortho for purposes such as working capital, capital expenditures, research
and development, strategic acquisitions and other general corporate purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrict Ortho&#146;s ability to introduce new services or products or exploit business opportunities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increase Ortho&#146;s vulnerability to economic downturns and competitive pressures in the markets in which Ortho
operates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">place Ortho at a competitive disadvantage. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho may engage in acquisitions and divestitures, and may encounter difficulties integrating acquired businesses with, or disposing of divested
businesses from, Ortho&#146;s current operations; therefore, Ortho may not realize the anticipated benefits of these acquisitions and divestitures. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho may seek to grow through strategic acquisitions. Ortho&#146;s due diligence reviews of Ortho&#146;s acquisition targets may not identify all of the
material issues necessary to accurately estimate the cost or potential loss contingencies with respect to a particular transaction, including potential exposure to regulatory sanctions resulting from an acquisition target&#146;s previous activities
as well as potential vulnerability to cybersecurity risks. Ortho may incur unanticipated costs or expenses, including post-closing asset impairment charges, expenses associated with eliminating duplicate facilities, litigation and other liabilities.
Ortho also may encounter difficulties in integrating acquisitions with Ortho&#146;s operations, applying Ortho&#146;s internal controls processes to these acquisitions, retaining key technical and management personnel, complying with regulatory
requirements, or in managing strategic investments. Additionally, Ortho may not achieve the benefits Ortho anticipates when Ortho first enters into a transaction in the amount or timeframe anticipated. Any of the foregoing could adversely affect
Ortho&#146;s business and results of operations. In addition, accounting requirements relating to business combinations, including the requirement to expense certain acquisition costs as incurred, may cause Ortho to experience greater earnings
volatility and generally lower earnings during periods in which Ortho acquires new businesses. Furthermore, Ortho may make strategic divestitures from time to time. These divestitures may result in continued financial involvement in the divested
businesses, such as through guarantees, indemnity obligations or other financial arrangements, following those transactions. Under these arrangements, nonperformance by those divested businesses could result in financial obligations imposed upon
Ortho and could affect Ortho&#146;s future financial results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>It may be difficult for Ortho to implement Ortho&#146;s strategies for improving
growth. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho plans to continue expanding its commercial capabilities and the scope of its business, both domestically and internationally, while
maintaining its commercial operations and administrative activities. For example, Ortho intends to pursue the following growth strategies: (i)&nbsp;maximize Lifetime Customer Value (&#147;LCV&#148;) to produce and maintain a growing and recurring,
high margin, durable financial profile; (ii)&nbsp;provide an unparalleled customer experience to retain and attract existing and new customers; (iii)&nbsp;leverage Ortho&#146;s global footprint to deliver innovative solutions to meet Ortho&#146;s
customers&#146; needs in both developed and emerging markets; (iv)&nbsp;create meaningful product innovation through menu expansion, development of novel instruments and enhancement of automation and informatics; (v)&nbsp;continue to identify
operating efficiencies to allow for reinvestment in growth and improve margins; and (vi)&nbsp;pursue business development opportunities, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
partnerships and strategic acquisitions to enter adjacencies or expand Ortho&#146;s current business units. However, Ortho&#146;s ability to manage its business and conduct its global operations
while also pursuing the aforementioned growth strategies requires considerable management attention and resources. Furthermore, it is subject to the challenges of supporting a growing business on a global basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s failure to implement these strategies in a cost-effective and timely manner could have an adverse effect on Ortho&#146;s business, results of
operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho may need to recognize impairment charges related to goodwill, identified intangible assets and fixed
assets. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the acquisition method of accounting for business combinations, the net assets acquired are recorded at their fair value as of
the date of the acquisition, with any excess purchase price recorded as goodwill. Ortho was created pursuant to the acquisition by Ortho-Clinical Diagnostics Bermuda Co. Ltd., a Bermuda exempted limited liability company and direct wholly-owned
subsidiary of Ortho, pursuant to a stock and asset purchase agreement, dated January&nbsp;16, 2014 (the &#147;Acquisition Agreement&#148;), of (i)&nbsp;certain assets and liabilities and (ii)&nbsp;all of the equity interests and substantially all of
the assets and liabilities of certain entities which, together with their subsidiaries, comprised the Ortho Clinical Diagnostics business from Johnson&nbsp;&amp; Johnson (the &#147;Acquisition&#148;). The Acquisition resulted in significant balances
of goodwill and identified intangible assets. As of January&nbsp;2, 2022, the balance of goodwill and identified intangible assets was $573.6&nbsp;million and $879.2&nbsp;million, respectively. Ortho is required to test goodwill and any other
intangible asset with an indefinite life for possible impairment on the same date each year and on an interim basis if there are indicators of a possible impairment. Ortho is also required to evaluate amortizable intangible assets and fixed assets
for impairment if there are indicators of a possible impairment. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is significant judgment required in the analysis of a potential impairment of
goodwill, identified intangible assets and fixed assets. If, as a result of a general economic slowdown, deterioration in one or more of the markets in which Ortho operates or impairment in Ortho&#146;s financial performance and/or future outlook,
the estimated fair value of Ortho&#146;s long-lived assets decreases, Ortho may determine that one or more of Ortho&#146;s long-lived assets is impaired. An impairment charge would be determined based on the estimated fair value of the assets and
any such impairment charge could have a material adverse effect on Ortho&#146;s results of operations and financial position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho may be unable
to achieve some or all of the operational cost improvements and other benefits that Ortho expects to realize. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho has previously announced
several initiatives to strengthen its operational performance and has begun to execute certain of these initiatives. For example, Ortho has pursued a number of operational cost improvements associated with procurement, manufacturing, field service
organization, distribution and logistics, quality and regulatory and other general and administrative functions. However, Ortho cannot be certain that it will be able to successfully realize all the expected benefits of these initiatives. A variety
of risks could cause Ortho not to realize some or all of the expected benefits. These risks include, among others, higher-than-expected standalone overhead expenses, delays in the anticipated timing of activities related to such initiatives,
increased difficulty and cost in establishing Ortho as a standalone business and the incurrence of other unexpected costs associated with operating the business. Moreover, Ortho&#146;s continued implementation of these initiatives may disrupt its
operations and performance and Ortho&#146;s estimated cost savings from these initiatives are based on several assumptions that may prove to be inaccurate and, as a result, Ortho cannot assure you that it will realize these cost savings. If, for any
reason, the benefits Ortho realizes are less than its estimates or if Ortho&#146;s improvement initiatives adversely affect its operations or cost more or take longer to implement than Ortho projects, or if Ortho&#146;s assumptions prove inaccurate,
Ortho&#146;s results of operations may be materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho&#146;s collaboration arrangements may not operate according to its
business strategy if its collaboration arrangement partners fail to fulfill their obligations. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of Ortho&#146;s business, it has
entered into collaboration arrangements with other companies, including the ongoing collaboration with Grifols Diagnostics Solutions, Inc. (the &#147;Joint Business&#148;), which is structured as a license, research and supply agreement, and Ortho
may enter into additional collaboration arrangements in the future. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nature of a collaboration arrangement requires Ortho to share control over
significant decisions with unaffiliated third parties. Since Ortho may not exercise exclusive control over its current or future collaboration arrangements, Ortho may not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be able to require its collaboration arrangement partners to take actions that Ortho believes are necessary to implement Ortho&#146;s business strategy. Additionally, differences in views among
collaboration arrangement partners may result in delayed decisions or failures to agree on major issues. Disputes between Ortho and its collaboration arrangement partners could also result in litigation, which can be expensive and time-consuming. If
these differences cause Ortho&#146;s collaboration arrangements to deviate from its business strategy, Ortho&#146;s results of operations could be materially adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Ortho delivers products with defects, Ortho may be subject to product recalls or negative publicity, Ortho&#146;s credibility may be harmed, market
acceptance of Ortho&#146;s products may decrease and Ortho may be exposed to liability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacturing and marketing of professional and
consumer diagnostics involve an inherent risk of product liability claims. For example, a defect in one of Ortho&#146;s diagnostic products could lead to a false positive or false negative result, affecting the eventual diagnosis. Ortho&#146;s
product development and production are extremely complex and could expose Ortho&#146;s products to defects. Ortho&#146;s Immunohematology business in particular is subject to the risk of product liability claims, as even the slightest inaccuracies
in a specimen&#146;s analysis can lead to critical outcomes in the life of a patient, thereby leaving little to no room for error in the precision and accuracy of such testing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing and design defects could lead to recalls (either voluntary or required by the FDA or other government authorities) and could result in the
removal of a product from the market. Depending on the corrective action Ortho takes to redress a product&#146;s deficiencies, Ortho may be required to obtain new clearances or approvals before it may market or distribute the corrected device.
Defects in Ortho&#146;s products could also harm Ortho&#146;s reputation, lead to negative publicity and decrease sales of Ortho&#146;s products, and Ortho could also face additional regulatory enforcement action, including FDA warning letters,
untitled letters, product seizure, injunctions, administrative penalties, or civil or criminal fines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Ortho&#146;s marketing of monitoring
services may cause Ortho to be subjected to various product liability or other claims, including, among others, claims that inaccurate monitoring results lead to injury or death, or, in the case of Ortho&#146;s toxicology monitoring services, the
imposition of criminal sanctions. Any product liability or other claim brought against Ortho, regardless of merit, could be costly to defend and could result in an increase to Ortho&#146;s insurance premiums. If Ortho is held liable for a claim,
that claim could materially affect Ortho&#146;s business and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A decrease in the number of surgical procedures performed, and
the resulting decrease in blood demand, could negatively impact Ortho&#146;s financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s Immunohematology and Donor Screening
products are frequently used in connection with the testing of blood prior to transfusion, which is typically associated with surgical procedures. A decrease in the number of surgeries being performed in the markets in which Ortho operates could
result in decreased demand for blood for transfusions, which would in turn result in lower testing volumes and, therefore, decreased sales of Ortho&#146;s products. For example, Ortho believes the market in developed countries has, at times, seen a
decrease in the number of surgical procedures and lower demand for blood in recent years. A decrease in the number of surgical procedures performed could result from a variety of factors, such as fewer elective procedures and the improved efficacy
and popularity of <FONT STYLE="white-space:nowrap">non-surgical</FONT> treatments. In addition to lower surgical volumes, blood demand could also be negatively affected by more efficient blood utilization by hospitals. Blood is a large expense for
hospital laboratories and pressure on hospital budgets due to macroeconomic factors and healthcare reform could force changes in the ways in which blood is used. Fewer surgeries and lower blood demand could negatively impact Ortho&#146;s revenue,
profitability and cash flows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho&#146;s reagent rental model reduces Ortho&#146;s cash flows during the initial part of the applicable contract,
which causes Ortho&#146;s cash flows to fluctuate from quarter to quarter. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leases, rather than sales, of instruments under Ortho&#146;s reagent
rental model have the effect of reducing cash flows during the initial part of the applicable contract as Ortho supports those commercial transactions until Ortho is able to recover its investment over the life of the contract. The use of cash in
connection with this model causes Ortho&#146;s cash flows to fluctuate from quarter to quarter and may have a negative effect on Ortho&#146;s financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Johnson&nbsp;&amp; Johnson&#146;s historical and future actions, or failure to comply with its indemnification obligations, may materially affect
Ortho&#146;s business and operating results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Ortho is an independent company as a result of the Acquisition, Johnson&nbsp;&amp;
Johnson&#146;s historical and future actions may still have a material impact on Ortho&#146;s business and operating results. In connection with the Acquisition, Ortho entered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
into certain agreements with Johnson&nbsp;&amp; Johnson, including the Acquisition Agreement and certain other transitional services agreements. In addition, Johnson&nbsp;&amp; Johnson has,
subject to certain exceptions and exclusions, agreed to indemnify Ortho under the Acquisition Agreement for certain liabilities relating to historical litigation matters and divestiture agreements, tax liabilities existing at the date of the
Acquisition and certain employee-related liabilities. Ortho could incur material additional costs if Johnson&nbsp;&amp; Johnson fails to meet its obligations or if Ortho otherwise is unable to recover costs associated with such liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Risks Relating to Ortho&#146;s International Operations </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a global business, Ortho is subject to risks associated with Ortho&#146;s <FONT STYLE="white-space:nowrap">non-U.S.</FONT> operations where such risks
are not present in the United States. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho conducts its business on a global basis, with sales outside the United States constituting
approximately 50.3% of Ortho&#146;s total revenue for the fiscal year ended January&nbsp;2, 2022, and a significant number of employees and contractors located in foreign countries. Ortho anticipates that international sales will continue to
represent a substantial portion of Ortho&#146;s revenue and that Ortho&#146;s strategy for continued growth and profitability will entail further international expansion, particularly in emerging markets. Conducting business outside the United
States subjects Ortho to numerous risks, including: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lost revenue as a result of macroeconomic developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased liquidity resulting from longer accounts receivable collection cycles typical of foreign countries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lower productivity resulting from difficulties Ortho encounters in staffing and managing sales, support and
research and development operations across many countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties associated with enforcing agreements and collecting receivables through foreign legal systems;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes with third-party distributors of Ortho&#146;s products or from third parties claiming distribution
rights to Ortho&#146;s products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties associated with navigating foreign laws and legal systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in identifying potential third-party distributors or distribution channels; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the imposition by foreign governments of trade barriers such as tariffs, quotas, preferential bidding and import
restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">import or export licensing requirements, both by the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts of war, terrorism, theft or other lawless conduct or other economic, social or political instability in or
affecting foreign countries in which Ortho sells its products or operates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">international sanctions regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse effects resulting from changes in foreign regulations, rules, policies or other laws affecting sales of
Ortho&#146;s products or Ortho&#146;s foreign operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax liability resulting from international tax laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased financial accounting and reporting burdens and complexities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased costs to comply with changes in legislative or regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of laws to protect Ortho&#146;s intellectual property rights; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining import or export licenses, transportation difficulties and delays resulting from inadequate
local infrastructure. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The occurrence of any of these, or other factors over which Ortho does not have control, could lead to reduced
revenue and profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Currency translation risk and currency transaction risk may adversely affect Ortho&#146;s financial condition, results
of operations and cash flows. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho derives a significant portion of its revenue from outside the United States (approximately 50.3% for the
fiscal year ended January&nbsp;2, 2022), and Ortho conducts its business and incurs costs in the local currency of most countries in which it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operates. Because Ortho&#146;s financial statements are presented in U.S. dollars, Ortho must translate earnings as well as assets and liabilities into U.S. dollars at exchange rates in effect
during or at the end of each reporting period, as applicable. Therefore, increases or decreases in the value of the U.S. dollar against other currencies in countries where Ortho operates will affect Ortho&#146;s results of operations and the value
of balance sheet items denominated in foreign currencies. Furthermore, many of Ortho&#146;s local businesses generate revenues and incur costs in a currency other than their functional currency, which can impact the operating results for these
operations if Ortho is unable to mitigate the impact of foreign currency fluctuations. Additionally, in order to fund the purchase price for certain assets of Ortho and the capital stock of certain other
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities, a combination of equity contributions and intercompany loans were utilized to capitalize certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries. In many instances, the
intercompany loans are denominated in currencies other than the functional currency of the affected subsidiaries. Where intercompany loans are not a component of permanently invested capital of the affected subsidiaries, increases or decreases in
the value of the subsidiaries&#146; functional currency against other currencies will affect Ortho&#146;s results of operations. Ortho cannot accurately predict the effects of exchange rate fluctuations upon its future operating results because of
the number of currencies involved, the variability of currency exposures and the potential volatility of currency exchange rates. Accordingly, Ortho&#146;s profitability could be affected by fluctuations in foreign exchange rates. Given the
volatility of exchange rates, Ortho may not be able to effectively manage its currency transaction and/or translation risks, and any volatility in currency exchange rates may have an adverse effect on Ortho&#146;s financial condition, results of
operations and cash flows. Ortho has entered into hedging agreements to address certain of its currency risks and intends to utilize local currency funding of expansions when appropriate. Ortho does not intend to hold financial instruments for
trading or speculative purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New tariffs and other trade measures could adversely affect Ortho&#146;s business and financial results.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Governments sometimes impose additional duties, tariffs or taxes on certain imported products. The imposition of import tariffs or restrictions,
or other changes in U.S. trade policy, could trigger retaliatory actions by affected countries. For instance, the United States and China have implemented import tariffs and retaliatory tariffs on certain categories of goods, including from time to
time, some of Ortho&#146;s reagent products sold in China. These tariffs, depending upon their ultimate scope and value and how they are implemented, could negatively impact Ortho&#146;s business by increasing Ortho&#146;s costs and by making
Ortho&#146;s products less cost competitive in China. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The United Kingdom&#146;s withdrawal from the European Union may have a negative effect on
global economic conditions, financial markets and Ortho&#146;s business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is a multinational company with worldwide operations, including
significant business operations in Europe. Following a national referendum in which a majority of voters in the United Kingdom elected to withdraw from the European Union and the enactment of legislation by the government of the United Kingdom, the
United Kingdom formally withdrew from the European Union on January&nbsp;31, 2020. On December&nbsp;24, 2020, the United Kingdom and the European Commission reached an agreement on the terms of its future cooperation with the European Union (the <FONT
STYLE="white-space:nowrap">&#147;UK-EU</FONT> Trade and Cooperation Agreement&#148;). On December&nbsp;30, 2020, the UK Parliament provided its approval of the European Union (Future Relationship) Bill (now the European Union (Future Relationships)
Act 2020) which implements, inter alia, the <FONT STYLE="white-space:nowrap">UK-EU</FONT> Trade and Cooperation Agreement. However, significant political and economic uncertainty remains about whether the terms of the relationship will differ
materially in practice from the terms before withdrawal and uncertainty continues to persist as there are a number of areas not covered by the <FONT STYLE="white-space:nowrap">UK-EU</FONT> Trade and Cooperation Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These developments, or the perception that any of them could occur, have had and may continue to have a material adverse effect on global economic conditions
and the stability of global financial markets, and could significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. The medium- and long-term impact of withdrawal of the
United Kingdom from the European Union on these conditions and markets are not yet known. Asset valuations, currency exchange rates and credit ratings have been and may continue to be subject to increased market volatility. Lack of clarity about
future United Kingdom laws and regulations as the United Kingdom determines which European Union laws to replace or replicate could depress economic activity and investment into the United Kingdom and restrict Ortho&#146;s access to capital. The
full extent of the tax implications of the United Kingdom&#146;s departure from the European Union are also not certain as of the date of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there is a risk of delays in the delivery of Ortho&#146;s products from the United Kingdom to customers in the European Union and an increase in
associated delivery costs. Restrictions on the free movement of goods (including as a result of customers&#146; duties, import tariffs or other restrictions on trade) could also have a material adverse effect on Ortho&#146;s
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supply chains, production schedule and costs. In addition, Ortho may face challenges retaining or attracting EU staff in the United Kingdom, which could disrupt its business and growth in this
market. The full impact of the changes to immigration laws following the United Kingdom&#146;s departure from the European Union is not clear, but Ortho may face particular challenges attracting skilled talent (including scientists, engineers and
laboratory technicians) if the conditions for EU nationals to be eligible to work in the United Kingdom are found, or are perceived, to be more onerous or expensive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is also possible that the resulting uncertainty and/or economic instability in the UK outlined above, could have a wider effect in other countries, for
instance as a result of spreading economic market conditions or if other European Union member states are also prompted to leave. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these factors
could have a material adverse effect on Ortho&#146;s business, financial condition and results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Risks Relating to
Ortho&#146;s Employees, Customers and Suppliers </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho must deliver products and services that meet customers&#146; needs and expectations or
Ortho&#146;s business and results of operations will be adversely impacted. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s ability to retain customers, attract new customers, grow
Ortho&#146;s business and enhance its brand depends on Ortho&#146;s success in delivering products and services that meet its customers&#146; needs and expectations. If Ortho is unable to deliver reliable products in a timely manner, promptly
respond to and address quality issues, provide expected levels of customer service, develop and maintain cross-functional communication within Ortho&#146;s company and comply with applicable regulations and rules, Ortho&#146;s ability to deliver
products that meet its customers&#146; needs and expectations, its competitive position, branding and results of operations may be adversely and materially affected. Furthermore, any improvement in the perception of the quality of Ortho&#146;s
competitors&#146; products or services relative to the quality of Ortho&#146;s products and services could adversely and materially affect Ortho&#146;s ability to retain Ortho&#146;s customers and attract new customers. Additionally, the
introduction of counterfeit products into the markets Ortho serves may have the effect of eroding confidence in Ortho&#146;s products or in Ortho&#146;s industry as a whole. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The success of many of Ortho&#146;s products depends heavily on acceptance by directors of clinical laboratories, blood banks and hospitals, and
Ortho&#146;s failure to maintain a high level of confidence in its products could adversely affect its business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho maintains customer
relationships with numerous directors of clinical laboratories, blood banks and hospitals. Ortho believes that sales of its products depend significantly on its customers&#146; confidence in, and recommendations of, its products. In addition,
Ortho&#146;s success depends on technicians&#146; acceptance and confidence in the effectiveness and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ease-of-use</FONT></FONT> of Ortho&#146;s products, including its new products. In
order to achieve acceptance by healthcare professionals, Ortho seeks to educate the healthcare community as to the distinctive characteristics, perceived benefits, clinical efficacy and cost-effectiveness of Ortho&#146;s products compared to
alternative products, including the products offered by its competitors. Acceptance of Ortho&#146;s products also requires effective training of healthcare professionals in the proper use and application of Ortho&#146;s products. Failure to
effectively educate and train Ortho&#146;s technician <FONT STYLE="white-space:nowrap">end-users</FONT> and failure to continue to develop relationships with leading healthcare professionals could result in less frequent recommendations of
Ortho&#146;s products, which may adversely affect Ortho&#146;s sales and profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The healthcare industry and related industries that Ortho
serves have undergone, and are in the process of undergoing, significant changes in an effort to reduce costs, which could adversely affect Ortho&#146;s business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The healthcare industry and related industries that Ortho serves have undergone, and are in the process of undergoing, significant changes in an effort to
reduce costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of Ortho&#146;s customers, and the <FONT STYLE="white-space:nowrap">end-customers</FONT> to whom Ortho&#146;s customers supply
products, rely on government funding of and reimbursement for healthcare products and services and research activities. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act
(collectively, the &#147;PPACA&#148;), healthcare austerity measures in Europe and other potential healthcare reform changes and government austerity measures may reduce the amount of government funding or reimbursement available to customers or <FONT
STYLE="white-space:nowrap">end-customers</FONT> of Ortho&#146;s products and services and/or the volume of medical procedures using Ortho&#146;s products and services. Global economic uncertainty or deterioration can also adversely impact government
funding and reimbursement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Governmental and private healthcare providers and payors around the world are increasingly utilizing managed
care for the delivery of healthcare services, forming group purchasing organizations to improve their purchasing leverage and using competitive bid processes to procure healthcare products and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Health insurance premiums, <FONT STYLE="white-space:nowrap">co-payments</FONT> and deductibles have also generally increased in recent years. These increases
may cause individuals to forgo health insurance, as well as medical attention. This behavior may reduce the number of lives managed by Ortho&#146;s health information solutions, including Ortho&#146;s health improvement programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These changes have increased tax costs and may cause participants in the healthcare industry to purchase fewer of Ortho&#146;s products and services, reduce
the prices they are willing to pay for Ortho&#146;s products or services, reduce the amounts of reimbursement and funding available for Ortho&#146;s products or services from governmental agencies or third-party payors, reduce the volume of medical
procedures that use Ortho&#146;s products and services and increase Ortho&#146;s compliance and other costs. In addition, Ortho may be unable to enter into contracts with group purchasing organizations and integrated health networks on terms
acceptable to Ortho, and even if Ortho does enter into such contracts, they may be on terms that negatively affect its current or future profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the factors described above could adversely affect Ortho&#146;s business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reductions in government funding and reimbursement to Ortho&#146;s customers could negatively impact Ortho&#146;s sales and results of operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of Ortho&#146;s customers rely on government funding and on prompt and full reimbursement by Medicare and Medicaid and equivalent programs
outside of the United States. Global economic uncertainty can result in lower levels of government funding or reimbursement. A reduction in the amount or types of government funding or reimbursement that affect Ortho&#146;s customers could have a
negative impact on Ortho&#146;s sales. Additionally, the PPACA, which was enacted in 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States and expanded Medicaid program eligibility
and access to commercial health insurance coverage. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the PPACA. On June&nbsp;17, 2021, the U.S. Supreme Court dismissed the most recent
judicial challenge to the PPACA brought by several states without specifically ruling on the constitutionality of the PPACA. Prior to the Supreme Court&#146;s decision, President Biden issued an executive order to initiate a special enrollment
period for purposes of obtaining health insurance coverage through the PPACA marketplace, from February&nbsp;15, 2021 through August&nbsp;15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their
existing policies and rules that limit access to healthcare, including, among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access
to health insurance coverage through Medicaid or the PPACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the PPACA will impact the law or our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. The Budget Control Act of 2011, among other things, reduced
Medicare payments to providers by 2% per fiscal year, effective on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May&nbsp;1,
2020, through March&nbsp;31, 2022, unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals, and
increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The Medicare Access and CHIP Reauthorization Act of 2015 (&#147;MACRA&#148;), enacted on April&nbsp;16, 2015, repealed the
formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed annual updates and a new system of incentive payments that are based on various performance measures and physicians&#146;
participation in alternative payment models such as accountable care organizations. It is unclear what effect new quality and payment programs, such as MACRA, may have on our business, financial condition, results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2018, CMS implemented certain provisions of the Protecting Access to Medicare Act of 2014 (&#147;PAMA&#148;), which made substantial
changes to the way in which clinical laboratory services are paid under Medicare. Under PAMA, laboratories that receive the majority of their Medicare revenue from payments made under the CLFS or the Physician Fee Schedule are required to report to
CMS, beginning in 2017 and every three years thereafter (or annually for &#147;advanced diagnostics laboratory tests&#148;), private payer payment rates and volumes for their tests. Laboratories that fail to report the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required payment information may be subject to substantial civil monetary penalties. CMS uses the data to calculate a weighted median payment rate for each test, which is used to establish a
revised Medicare reimbursement rate. Under PAMA, the revised Medicare reimbursement rates were scheduled to apply to clinical diagnostic laboratory tests furnished on or after January&nbsp;1, 2018. The revised reimbursement methodology is expected
to result in relatively lower reimbursement under Medicare for clinical diagnostic lab tests than has been historically available. Any reduction to payment rates resulting from the new methodology is limited to 10% per test per year in 2018 through
2020, and to 15% per test per year in 2021 through 2023. For clinical diagnostic laboratory tests that are assigned a new or substantially revised Healthcare Common Procedure Coding System code, initial payment rates for clinical diagnostic
laboratory tests that are not advanced diagnostic laboratory tests will be assigned by the cross-walk or <FONT STYLE="white-space:nowrap">gap-fill</FONT> methodology. Initial payment rates for new advanced diagnostic laboratory tests will be based
on the actual list charge for the laboratory test. The Coronavirus Aid, Relief and Economic Security Act (the &#147;CARES Act&#148;), which was signed into law on March&nbsp;27, 2020, amended the timeline for reporting private payer payment rates,
and delayed by one year the payment reductions scheduled for 2021. On December&nbsp;10, 2021, Congress passed the Protecting Medicare and American Farmers from Sequester Cuts Act (&#147;PMAFSA&#148;), which delays the next data-reporting period by
an additional year and prevents any reduction in payment amounts from commercial payer rate implementation in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the CARES Act,
Congress has enacted other laws in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic to provide financial relief to healthcare providers and suppliers, including diagnostic laboratories, and to encourage implementation of
diagnostic testing and treatment for <FONT STYLE="white-space:nowrap">COVID-19.</FONT> For instance, the Families First Coronavirus Response Act (&#147;FFCRA&#148;), enacted on March&nbsp;18, 2020, requires certain governmental and commercial
insurance plans to provide coverage of <FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic testing services without imposing cost-sharing (e.g., copays, deductibles or coinsurance) or other utilization management requirements. The CARES Act
and the Paycheck Protection Program and Health Care Enhancement Act (&#147;PPPHCEA&#148;), enacted on April&nbsp;24, 2020, each appropriated approximately $100&nbsp;billion to provide financial relief for certain healthcare providers and to expand
treatment and diagnostic testing capacity for <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The Consolidated Appropriations Act of 2021 (&#147;CAA&#148;), which was enacted on December&nbsp;27, 2020 and included further pandemic relief measures,
temporarily increased payment rates under the Medicare Physician Fee Schedule by 3.75% beginning January&nbsp;1, 2021 through December&nbsp;31, 2021. The PMAFSA further established a temporary 3% payment rate increase under the Medicare Physician
Fee Schedule that will remain in effect beginning January&nbsp;1, 2022 through December&nbsp;31, 2022. The CARES Act, as subsequently amended by the CAA and PMAFSA, also suspended, for the period from May&nbsp;1, 2020 to March&nbsp;31, 2022, the 2%
payment reduction created under the sequestration required by the Budget Control Act of 2011 (as amended by the American Taxpayer Relief Act of 2012), and extended the sequester by one year, through 2030. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is unclear what impact new quality and payment programs, such as MACRA, or new pricing structures, such as those adopted under PAMA, the CARES Act, or
other legislative measures enacted in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, may have on Ortho&#146;s business, financial condition, results of operations or cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho relies on certain suppliers and manufacturers for raw materials and components for Ortho&#146;s products and services, and fluctuations in the
availability and price of such materials, products and services may interfere with Ortho&#146;s ability to meet Ortho&#146;s customers&#146; needs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For certain of Ortho&#146;s products, including finished products, Ortho is dependent on a small number of key suppliers and manufacturers. Ortho also depends
on key suppliers for critical raw materials and components. As a result, Ortho&#146;s ability to obtain, enter into and maintain contracts with these manufacturers and suppliers is important to Ortho&#146;s business. Ortho cannot ensure that it will
be able to obtain, enter into or maintain all such contracts in the future, and difficulty in obtaining such products or raw materials could affect Ortho&#146;s ability to achieve anticipated production levels. On occasion, Ortho has been forced to
revalidate the raw materials and components of products when a supplier of critical raw materials or components terminated its contract or no longer made the materials or components available to Ortho. Stringent requirements of the FDA and other
regulatory authorities regarding the manufacture of Ortho&#146;s products may prevent Ortho from quickly establishing additional or replacement sources for the raw materials, products, components or manufacturing services that Ortho uses, or from
doing so without excessive cost. Further, Ortho&#146;s suppliers may be subject to regulation by the FDA and other regulatory authorities that could hinder their ability to produce necessary raw materials, products and components. As a result, a
reduction or interruption in supply or an inability to secure alternative sources of raw materials, products, components or manufacturing services could have a material adverse effect on Ortho&#146;s business, result of operations, financial
condition and cash flows. If Ortho is unable to achieve anticipated production levels and meet Ortho&#146;s customers&#146; needs, Ortho&#146;s operating results could be adversely affected. For a discussion of the impact of global supply chain
challenges on Ortho, including on Ortho&#146;s ability to obtain certain key components of its instruments and fulfill customer orders on a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
timely basis, see &#147;&#151;Ortho has significant international sales and operations and faces risks related to health epidemics, including the ongoing global pandemic related to <FONT
STYLE="white-space:nowrap">COVID-19.</FONT> Ortho&#146;s business, consolidated results of operations, financial position and cash flows have been and may continue to be negatively affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic.&#148; In addition, Ortho&#146;s results of operations may be significantly impacted by unanticipated increases in the cost of labor, raw materials, freight, utilities and other items needed to develop, manufacture and maintain Ortho&#146;s
products and operate Ortho&#146;s business. For example, Ortho may be disadvantaged when negotiating contract terms with its suppliers, which could increase costs and reduce its margins. Suppliers may also deliver products, components or materials
that do not meet specifications, preventing Ortho from manufacturing or supplying products that meet Ortho&#146;s design specifications or customer needs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho may not be able to recruit and retain the experienced and skilled personnel it needs to compete. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s future success depends on its ability to attract, retain, develop and motivate highly skilled personnel. Ortho relies on qualified managers and
skilled employees, such as scientists, engineers and laboratory technicians, with technical expertise in operations, scientific knowledge, engineering and quality management experience in order to operate Ortho&#146;s business successfully. From
time to time, there may be a shortage of skilled labor, which may make it more difficult and expensive for Ortho to attract and retain qualified employees. If Ortho is unable to attract and retain sufficient numbers of qualified individuals or
Ortho&#146;s costs to do so increase significantly, Ortho&#146;s operations could be materially adversely affected. Additionally, if Ortho were to lose a sufficient number of its research and development scientists and were unable to replace them or
satisfy its needs for research and development through outsourcing, it could adversely affect Ortho&#146;s business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The loss of key members of
management and the risks inherent in succession planning could adversely affect Ortho&#146;s results of operations or financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho
must have talented personnel to succeed and competition for senior management in Ortho&#146;s industry is intense. Ortho&#146;s ability to meet its performance goals depends upon the personal efforts and abilities of the principal members of
Ortho&#146;s senior management who provide strategic direction, develop Ortho&#146;s business, manage Ortho&#146;s operations and maintain a cohesive and stable work environment and upon their ability to work effectively as a team. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of their ongoing effort to maximize Ortho&#146;s performance, Ortho&#146;s board of directors regularly evaluates Ortho&#146;s senior management
capabilities in light of, among other things, Ortho&#146;s business strategy, changes to Ortho&#146;s capital structure, developments in Ortho&#146;s industry and markets and Ortho&#146;s ongoing financial performance, and will consider, where
appropriate, supplementing, changing or otherwise enhancing Ortho&#146;s senior management team and operational and financial management capabilities in order to maximize Ortho&#146;s performance. Accordingly, Ortho&#146;s organizational structure
and senior management team may change in the future, which could result in a material business interruption, the risk of employment-related claims or proceedings, and the incurrence of material costs, including as a result of severance or other
termination payments, damages or other compensation. Further, Ortho cannot assure you that it will retain or successfully recruit senior executives, or that their services will remain available to Ortho. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Consolidation of Ortho&#146;s customer base and the formation of group purchasing organizations could materially adversely affect Ortho&#146;s sales and
results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidation among healthcare providers and the formation of buying groups and, with respect to Ortho&#146;s international
operations, government-sponsored tendering processes, have put pressure on pricing and sales of Ortho&#146;s products, and in some instances, required payment of fees to group purchasing organizations or providing lower pricing in the tendering
process. Ortho&#146;s success in these areas depends partly on Ortho&#146;s ability to enter into contracts with integrated health networks and group purchasing organizations. If Ortho is unable to enter into contracts with these group purchasing
organizations and integrated health networks on terms acceptable to Ortho or fails to have its pricing terms accepted in the tendering process, Ortho&#146;s sales and results of operations may be adversely affected. Even if Ortho is able to enter
into these contracts or have its pricing terms accepted in the tendering process, they may be on terms that negatively affect Ortho&#146;s current or future profitability. Furthermore, given the average industry contract length of five to seven
years, if Ortho is unable to enter into a contract with a new customer or renew a given contract with an existing customer, it may be several years before Ortho has an opportunity to acquire or reacquire, as applicable, such customer&#146;s
business, which may have a material adverse effect on Ortho&#146;s results of operations in the interim period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho may experience manufacturing or warehousing problems or delays due to, among other reasons,
Ortho&#146;s volume and specialized processes, and any interruption in supply from certain of its contract manufacturers, suppliers of raw materials and other third-party vendors, which could result in decreased revenue or increased costs.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global supply of Ortho&#146;s products depends on the uninterrupted efficient operation of its manufacturing facilities, and the continued
performance of Ortho&#146;s contract manufacturers, suppliers of raw materials and other third-party vendors under Ortho&#146;s contractual arrangements. Many of Ortho&#146;s manufacturing processes are complex and involve sensitive scientific
processes involving the use of unique and often proprietary antibodies and other raw materials that cannot be replicated or acquired through alternative sources without undue delay or expense. Other processes present difficult technical challenges
to obtain the manufacturing yields necessary to operate profitably. In addition, Ortho&#146;s manufacturing processes may require complex and specialized equipment, which can be expensive to repair or replace with required lead times of up to a
year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacturing of certain of Ortho&#146;s products is concentrated in one or more of Ortho&#146;s plants, with limited alternate facilities. Any
event that negatively impacts Ortho&#146;s manufacturing facilities, Ortho&#146;s manufacturing systems or equipment, or the facilities, systems or equipment of Ortho&#146;s contract manufacturers or suppliers, could delay or suspend shipments of
products or the release of new products or could result in the delivery of inferior products. Ortho&#146;s revenue from the affected products would decline and Ortho could incur losses until such time as Ortho or its contract manufacturers are able
to restore Ortho&#146;s or their production processes or Ortho is able to put in place alternative contract manufacturers or suppliers. Similarly, given the specialized storage requirements for Ortho&#146;s supplies and Ortho&#146;s products, any
disruption or other operational challenges to one of Ortho&#146;s two primary warehouse facilities in Memphis, Tennessee and Strasbourg, France could result in decreased revenue or increased costs given the challenge in finding suitable alternative
facilities. As a result of, among other factors, the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on supply chain operations as well as increased customer demand for Ortho&#146;s products, Ortho is currently encountering, and may
continue to encounter, increased customer backlogs of inventory shipments out of its warehouse facilities, particularly the Memphis, Tennessee facility.&nbsp;If these increased customer backlogs continue, they may adversely impact customer
relationships and affect Ortho&#146;s financial performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho also relies on contract manufacturers to manufacture certain of its products, such as
the instruments for Ortho&#146;s Transfusion Medicine and Clinical Laboratories businesses, as well as suppliers of raw materials and other third-party vendors. Any change in Ortho&#146;s relationship with its contract manufacturers, suppliers of
raw materials and other third-party vendors or changes to contractual terms of Ortho&#146;s agreements with any of them could adversely affect Ortho&#146;s financial condition and results of operations. Ortho&#146;s reliance on a small number of
contract manufacturers and a large number of single and sole source suppliers makes Ortho vulnerable to possible capacity constraints, reduced control over product availability, delivery schedules and costs and reduced ability to monitor compliance
with Ortho&#146;s product manufacturing specifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Ortho&#146;s current contract manufacturers, suppliers of raw materials and other third-party
vendors were unable or unwilling to manufacture or supply Ortho&#146;s products or requirements for raw materials in required volumes and at required quality levels or renew existing terms under supply agreements, Ortho may be required to replace
such manufacturers, suppliers and vendors and may be unable to do so in a timely or cost-effective manner, or at all. Any interruption of supply or any increase in price of the instruments or raw materials and other key products produced by such
contract manufacturers or raw materials supplied by such suppliers and vendors could adversely affect Ortho&#146;s profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Risks Relating to
Ortho&#146;s Business&#151;Government Regulation </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Ortho is unable to obtain required clearances or approvals for the commercialization of its
products in the United&nbsp;States, Ortho would not be able to sell those products in the United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s future performance depends
on, among other matters, the timely receipt of necessary regulatory clearances and approvals for its products. Regulatory clearance and approval can be a lengthy, expensive and uncertain process. In addition, regulatory processes are subject to
change, and new or changed regulations can result in increased costs and unanticipated delays. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, clearance or approval to
commercially distribute new medical devices is received from the FDA through clearance of a Premarket Notification under Section&nbsp;510(k) of the Federal Food, Drug, and Cosmetic Act (a &#147;510(k)&#148;), or through approval of a Premarket
Approval application (a &#147;PMA&#148;). Approval to commercially distribute biologics is received from the FDA through approval of a Biologics License Application (a &#147;BLA&#148;) and may also require state licensing for the movement of
biologics products in interstate commerce. The FDA may deny 510(k) clearance because, among other reasons, it determines that Ortho&#146;s product is not substantially equivalent to another U.S. legally marketed device. The FDA may deny
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval of a PMA or BLA because, among other reasons, it determines that Ortho&#146;s product is not sufficiently safe or effective. Failure to obtain FDA clearance or approval would preclude
commercialization in the United States, which could materially and adversely affect Ortho&#146;s future results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Modifications or
enhancements to a cleared or approved product that could significantly affect safety or effectiveness, or that constitute a major change in the intended use of the product, could require new 510(k) clearances or possibly approval of a new PMA or
BLA, or a supplement to those applications. The FDA requires every manufacturer to make the determination regarding the need for a new 510(k) submission in the first instance, but the FDA may review a manufacturer&#146;s decision not to seek a new
510(k). Ortho has made modifications to some of its products since receipt of initial 510(k) clearance. With respect to several of these modifications, Ortho filed new 510(k)s or PMAs; however, Ortho determined that submission was not necessary for
all of the modifications. The FDA may not agree with any of Ortho&#146;s determinations not to submit a new 510(k), PMA or PMA supplement, or BLA or BLA supplement for any modifications made to Ortho&#146;s products. If the FDA requires Ortho to
submit a new 510(k), PMA or PMA supplement, or BLA or BLA supplement for any product modification, Ortho may be prohibited from marketing the modified products until the new submission is cleared or approved by the FDA. In that case, Ortho may be
required to recall and stop marketing its products as modified, which could require Ortho to redesign its products and conduct clinical studies to support any modifications, and Ortho could be subject to enforcement action. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the results of clinical studies required to gain regulatory approval to sell Ortho&#146;s products are not available when expected, or do not
demonstrate the safety and effectiveness of those products, Ortho may be unable to sell those products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before Ortho can sell certain of its
products, Ortho must conduct clinical studies intended to demonstrate that those products are safe and effective and perform as expected. The results of these clinical studies (which are experiments involving human patients having the diseases or
medical conditions that the product is trying to evaluate or diagnose) are used to obtain regulatory clearance or approval from government authorities, such as the FDA. Conducting clinical studies is a complex, time-consuming and expensive process.
In some cases, Ortho may spend several years completing the necessary clinical studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Ortho fails to adequately manage its clinical studies, those
clinical studies and corresponding regulatory clearances or approvals may be delayed or Ortho may fail to gain clearance or approval for its products altogether. Even if Ortho successfully manages its clinical studies, Ortho may not obtain favorable
results and may not obtain regulatory clearance or approval. If Ortho is unable to market and sell its new products or is unable to obtain clearances or approvals in the time frame needed to execute its product strategies, Ortho&#146;s business and
results of operations would be materially and adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho is subject to the regulatory approval requirements of the foreign countries
in which it sells its products, and these requirements may prevent or delay Ortho from marketing its products in those countries. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is subject
to the regulatory approval requirements for each foreign country in which it sells its products. The process for complying with these approval requirements can be lengthy and expensive. Any changes in foreign approval requirements and processes may
cause Ortho to incur additional costs or lengthen review times of Ortho&#146;s products. Ortho may not be able to obtain foreign regulatory approvals on a timely basis, if at all, and any failure to do so may cause Ortho to incur additional costs or
prevent it from marketing its products in foreign countries, which may have a material adverse effect on Ortho&#146;s business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho&#146;s business is subject to substantial regulatory oversight, and Ortho&#146;s failure to comply with applicable regulations may result in
significant costs or, in certain circumstances, the suspension or withdrawal of previously obtained clearances or approvals. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s
businesses are extensively regulated by the FDA and other federal, state and foreign regulatory agencies. These regulations impact many aspects of Ortho&#146;s operations, including development, manufacturing, labeling, packaging, adverse event
reporting, storage, advertising, promotion, physician interaction and record-keeping. Any material failure by Ortho to comply with such applicable governmental regulations could result in product recalls, the imposition of fines, restrictions on
Ortho&#146;s ability to conduct or expand its operations or the cessation of all or a portion of its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and corresponding foreign
regulatory agencies may require post-market testing and surveillance to monitor the performance of cleared or approved products or may place conditions on any product clearances or approvals that could
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restrict the commercial applications of those products. The discovery of problems with a product may result in restrictions on the product, including withdrawal of the product from the market. In
addition, in some cases Ortho may sell products or provide services which are reliant on the use or commercial availability of products of third parties, including medical devices or equipment, and regulatory restrictions placed upon any such
third-party products could have a material adverse impact on the sales or commercial viability of Ortho&#146;s related products or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is
subject to routine inspection by the FDA and other agencies for compliance with the FDA&#146;s requirements applicable to Ortho&#146;s products, including, without limitation, the Quality System Regulation and Medical Device Reporting requirements
in the United States, and other applicable regulations worldwide. Ortho&#146;s manufacturing facilities and those of its suppliers and distributors also are, or can be, subject to periodic regulatory inspections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is also subject to laws relating to matters such as privacy, safe working conditions, manufacturing practices, environmental protection, fire hazard
control and disposal of hazardous or potentially hazardous substances. Ortho may incur significant costs to comply with these laws and regulations. If Ortho fails to comply with applicable regulatory requirements, Ortho may be subject to fines,
suspension or withdrawal of regulatory approvals, product recalls, seizure of products or injunctions against Ortho&#146;s distribution of products, termination of Ortho&#146;s service agreements by its customers, disgorgement of money, operating
restrictions and criminal prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in applicable laws, changes in the interpretation or application of such laws, or any failure to comply
with existing or future laws, regulations or standards could have a material adverse effect on Ortho&#146;s results of operations, financial condition, business and prospects. Moreover, new laws may be enacted, or regulatory agencies may impose new
or enhanced standards, that would increase Ortho&#146;s costs, as well as expose Ortho to risks associated with <FONT STYLE="white-space:nowrap">non-compliance.</FONT> Over the last several years, the FDA has proposed reforms to its 510(k) clearance
process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in November
2018, FDA officials announced steps that the FDA intended to take to modernize the premarket notification pathway under Section&nbsp;510(k) of the Federal Food, Drug, and Cosmetic Act. Among other things, the FDA announced that it planned to develop
proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to
potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than ten years old. These proposals have not yet been finalized or adopted, although the FDA may
work with Congress to implement such proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could impose additional regulatory requirements on Ortho that could delay its ability to obtain new 510(k)
clearances, increase the costs of compliance, restrict Ortho&#146;s ability to maintain its current clearances, or otherwise create competition that may negatively affect its business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More recently, in September 2019, the FDA issued revised final guidance describing an optional &#147;safety and performance based&#148; premarket review
pathway for manufacturers of &#147;certain, well-understood device types&#148; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the
FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA maintains a list of device types appropriate for the &#147;safety and
performance based&#148; pathway and continues to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as recommended testing methods, where feasible. The FDA may establish performance
criteria for classes of devices for which Ortho or its competitors seek or currently have received clearance, and it is unclear the extent to which such performance standards, if established, could impact Ortho&#146;s ability to obtain new 510(k)
clearances or otherwise create competition that may negatively affect Ortho&#146;s business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho is subject to extensive regulatory requirements
in connection with the emergency use authorizations (&#147;EUAs&#148;) that Ortho has received from the FDA for its <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody and antigen tests. If Ortho fails to comply with these requirements, or if
the FDA otherwise determines that the conditions no longer warrant such authorization, Ortho will be unable to market its products pursuant to this authorization and its business may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho has received EUAs from the FDA authorizing Ortho to market its
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-SARS-CoV-2</FONT></FONT> IgG Antibody test, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-SARS-CoV-2</FONT></FONT> IgG Quantitative Antibody test, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-SARS-CoV-2</FONT></FONT> Total <FONT STYLE="white-space:nowrap">(Anti-S)</FONT> Antibody test,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-SARS-CoV-2</FONT></FONT> Total <FONT STYLE="white-space:nowrap">(Anti-N)</FONT> Antibody test,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> Antigen test and related calibrators and controls on Ortho&#146;s VITROS analyzers. These EUAs allow Ortho to market and sell its antibody tests to
health-care professionals for the detection of certain <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
antibodies to aid in identifying individuals with an adaptive immune response to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> and, for Ortho&#146;s
Antigen test, for the detection of acute infection of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> without the need to obtain premarket clearance or approval under the FDA&#146;s standard review
pathways, for the duration of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> public health emergency. The FDA has also established certain conditions which must be met in order to maintain authorization under these EUAs. The requirements that
apply to the manufacture and sale of these products may be unclear and are subject to change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has the authority to issue an EUA during a public
health emergency if it determines that, based on the totality of the scientific evidence, it is reasonable to believe that the product may be effective, that the known and potential benefits of a product outweigh the known and potential risks, that
there is no adequate, approved and available alternative and if other regulatory criteria are met. These standards for marketing authorization are lower than if the FDA had reviewed Ortho&#146;s tests under its traditional marketing authorization
pathways, and Ortho cannot assure you that its tests would be cleared or approved under those more onerous clearance and approval standards. Moreover, the FDA&#146;s policies regarding EUAs can change unexpectedly, and the FDA may revoke an EUA
where it determines that the underlying health emergency no longer exists or warrants such authorization or if problems are identified with the authorized product. Ortho cannot predict how long its authorization will remain in place. FDA policies
regarding diagnostic tests, therapies and other products used to diagnose, treat or mitigate <FONT STYLE="white-space:nowrap">COVID-19</FONT> remain in flux as the FDA responds to new and evolving public health information and clinical evidence. For
example, in December 2021, the FDA issued a draft guidance describing a potential transition plan for the regulation and distribution of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">emergency-use-authorized</FONT></FONT> medical
devices in the event that the current EUA declaration is terminated. Changes to FDA regulations or requirements could require changes to Ortho&#146;s authorized tests, necessitate additional measures or make it impractical or impossible for Ortho to
market its test. The termination of an EUA for Ortho&#146;s products could adversely impact Ortho&#146;s business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or
deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or commercialized in a timely manner or at all, which could negatively impact Ortho&#146;s business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory,
regulatory and policy changes, the FDA&#146;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#146;s ability to perform routine functions. Average review times at the
FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions
at the FDA and other agencies may also slow the time necessary for new medical devices and biologics or modifications to approved or cleared medical devices and biologics to be reviewed and/or cleared or approved by necessary government agencies,
which would adversely affect Ortho&#146;s business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical
activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020, the FDA announced its
intention to postpone most inspections of foreign manufacturing facilities and products, and on March&nbsp;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July 2020, the
FDA resumed certain <FONT STYLE="white-space:nowrap">on-site</FONT> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and
where it was safest to conduct prioritized domestic inspections. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of
domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA continues to monitor and implement changes to its inspections and related activities to ensure the safety of its employees and
those of the firms it regulates as it adapts to the evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other
regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process Ortho&#146;s regulatory submissions, which could have a material adverse effect on Ortho&#146;s business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho may face business disruption and related risks resulting from President Biden&#146;s invocation
of the Defense Production Act, which could have a material adverse effect on Ortho&#146;s business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In response to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, President Biden invoked the Defense Production Act, codified at 50 U.S.C. &#167; 4501 et seq. (the &#147;Defense Production Act&#148;). Pursuant to the Defense Production Act, the federal
government may, among other things, require domestic industries to provide essential goods and services needed for the national defense. For example, in March 2021, President Biden invoked the Defense Production Act to expand production of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> vaccine. While Ortho has not experienced any impact on its business as a result of such actions, Ortho continues to assess the potential impact that the invocation of the Defense Production Act may have on
its ability to effectively conduct its business operations as planned, either as a result of becoming directly subject to the requirements of the Defense Production Act, Ortho&#146;s suppliers becoming so subject and diverting deliveries of raw
materials elsewhere, or otherwise. There can be no assurance that Ortho will not be impacted by any action taken by the federal government under the Defense Production Act, and any resulting disruption on Ortho&#146;s ability to conduct business
could have a material adverse effect on Ortho&#146;s financial condition and results or operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho could incur costs complying with
environmental and health and safety requirements, or as a result of liability for contamination or other potential environmental harm or liability caused by Ortho&#146;s operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s operations and facilities are subject to various foreign, federal, state and local environmental, health and safety laws, rules, regulations and
other requirements, including those governing the generation, use, manufacture, handling, transport, storage, treatment and disposal of, or exposure to, regulated materials, discharges and emissions to air and water, the cleanup of contamination and
occupational health and safety matters. Noncompliance with these laws, rules, regulations and other requirements can result in fines or penalties or limitations on Ortho&#146;s operations or liability for remediation costs, as well as claims
alleging personal injury, property, natural resource or environmental damages. Ortho believes that its operations and facilities are operated in compliance in all material respects with existing environmental, health and safety requirements,
including the operating permits required thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s research and development and manufacturing processes involve the use of regulated
materials subject to environmental, health and safety regulations. Ortho may incur liability as a result of any contamination or injury arising from a release of or exposure to such regulated materials. Under some environmental laws and regulations,
Ortho could also be held responsible for costs relating to any contamination at its past or present facilities and at third-party disposal sites where Ortho has sent wastes for treatment or disposal. Liability for contamination at contaminated sites
may be imposed without regard to whether Ortho knew of, or caused, the release or disposal of such regulated substances and, in some cases, liability may be joint or several. Any such future expenses or liability could have a negative impact on
Ortho&#146;s financial condition and results of operations. The enactment of stricter laws or regulations, the stricter interpretation of existing laws and regulations or the requirement to undertake the investigation or remediation of currently
unknown environmental contamination at Ortho&#146;s current or former facilities or at third-party sites where Ortho has sent waste for treatment or disposal may require Ortho to make additional expenditures or subject Ortho to additional liability
or claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Ortho&#146;s workers, properties and equipment may be exposed to potential operational hazards such as fires, process safety
incidents, releases of regulated materials, malfunction of equipment, accidents and natural disasters, which could result in personal injury or loss of life, damage to or destruction of property and equipment or environmental damage, and could
potentially result in a suspension of operations, harm to Ortho&#146;s reputation and the imposition of civil or criminal fines or penalties, all of which could adversely affect Ortho&#146;s business. See &#147;Business of Ortho&#151;Health, Safety
and Environmental.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho is subject to healthcare regulations that could result in liability, require Ortho to change its business practices
and restrict its operations in the future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is subject to healthcare fraud and abuse regulation and enforcement by both the federal
government and the governments of states and foreign countries in which Ortho conducts its business. In the United States, these healthcare laws and regulations include, for example: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting,
receiving, offering or providing remuneration, directly or indirectly, where one purpose is to induce either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may be made under a
federal healthcare program such as the Medicare and Medicaid programs. The U.S. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
government has interpreted this law broadly to apply to the marketing and sales activities of medical device manufacturers. In addition, a person or entity does not need to have actual knowledge
of the statute or specific intent to violate it to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims laws, including the federal False Claims Act, which prohibits, among
other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other federal healthcare programs that are false or fraudulent. Moreover, the government may assert that a
claim including items or services resulting from a violation of the federal <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring
remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#146;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;), which, in addition to
privacy protections applicable to healthcare providers and other entities, prohibits, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters. Similar to the federal
Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act which requires certain applicable manufacturers of drugs, devices,
biologics and medical supplies for which payment is available under certain federal healthcare programs, to monitor and report to the Centers for Medicare &amp; Medicaid Services, or CMS, certain payments and other transfers of value to physicians
(defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare providers, including physician assistants and nurse practitioners, and teaching hospitals, as well as ownership and investment interests
held by physicians and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical
devices, and regulates device marketing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm customers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may
apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws requiring device companies to comply with specific compliance standards, restrict payments made to healthcare providers and other potential
referral sources, and report information related to payments and other transfers of value to healthcare providers or marketing expenditures; and state laws related to insurance fraud in the case of claims involving private insurers.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These laws and regulations, among other things, constrain our business, marketing and other promotional and research activities by
limiting the kinds of financial arrangements, including sales programs, we may have with hospitals, physicians or other potential purchasers of our products. In particular, these laws and regulations may restrict or prohibit a wide range of pricing,
discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements, as well as interactions with healthcare professionals through consultant arrangements, product training, sponsorships, or other
activities. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare and other laws and regulations will involve substantial costs. Due to the breadth of these laws, the narrowness of statutory
exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject, governmental authorities may possibly conclude that our business practices may not comply with healthcare laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To enforce compliance with the healthcare regulatory laws, certain enforcement bodies have recently increased their scrutiny of interactions between
healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be <FONT STYLE="white-space:nowrap">time-and</FONT>
resource-consuming and can divert management&#146;s attention from the business. We may be subject to private qui tam actions brought by individual whistleblowers on behalf of the federal or state governments, with potential liability under the
federal False Claims Act including mandatory treble damages and significant <FONT STYLE="white-space:nowrap">per-claim</FONT> penalties. Additionally, as a result of these investigations and qui tam actions, we may have to agree to additional
compliance and reporting requirements as part of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business, financial condition and results
of operations. Even an unsuccessful challenge or investigation into our practices could cause adverse publicity, and be costly to respond to. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our
operations are found to be in violation of any of the federal and state laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to significant penalties,
including significant criminal, civil, and administrative penalties, damages, fines, exclusion from participation in government programs, such as Medicare and Medicaid, imprisonment, contractual damages, reputational harm, oversight if we become
subject to a consent decree or corporate integrity agreement, disgorgement and we could be required to curtail, restructure or cease our operations. Any of the foregoing consequences will negatively affect our business, financial condition and
results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho&#146;s failure to comply with the anti-corruption laws of the United States and various international jurisdictions
could negatively impact Ortho&#146;s reputation and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Doing business on a worldwide basis requires Ortho to comply with the
laws and regulations of the U.S. government and those of various international and <FONT STYLE="white-space:nowrap">sub-national</FONT> jurisdictions, and Ortho&#146;s failure to successfully comply with these rules and regulations may expose Ortho
to liabilities. These laws and regulations apply to companies, individual directors, officers, employees and agents, and may restrict Ortho&#146;s operations, trade practices, investment decisions and partnering activities. In particular,
Ortho&#146;s international operations are subject to U.S. and foreign anti-corruption laws and regulations, such as the FCPA, as well as anti-corruption laws of the various jurisdictions in which Ortho operates. The FCPA and other laws prohibit
Ortho, and Ortho&#146;s officers, directors, employees and agents acting on Ortho&#146;s behalf, from corruptly offering, promising, authorizing or providing anything of value to foreign officials or entities for the purposes of influencing official
decisions or obtaining or retaining business or otherwise obtaining favorable treatment. As part of Ortho&#146;s business, Ortho deals with state-owned business enterprises, the employees and representatives of which may be considered foreign
officials for purposes of the FCPA. Ortho is subject to the jurisdiction of various governments and regulatory agencies outside of the United States, which may bring Ortho&#146;s personnel into contact with foreign officials responsible for issuing
or renewing permits, licenses or approvals or for enforcing other governmental regulations. In addition, some of the international locations in which Ortho operates lack a developed legal system and have elevated levels of corruption. Ortho&#146;s
global operations expose Ortho to the risk of violating, or being accused of violating, the foregoing or other anti-corruption laws, including similar anti-corruption laws, rules and regulations of the various jurisdictions in which Ortho operates.
Such violations could be punishable by criminal fines, imprisonment, civil penalties, disgorgement of profits, injunctions and debarment from government contracts, as well as other remedial measures. Investigations of alleged violations can be very
expensive and disruptive. Additionally, Ortho faces a risk that its distributors, manufacturers and other third parties acting on Ortho&#146;s behalf may potentially violate the FCPA or similar laws, rules or regulations of the various jurisdictions
in which Ortho operates. Though these distributors, manufacturers and other third parties acting on Ortho&#146;s behalf are not Ortho&#146;s affiliated legal entities, such violations could expose Ortho to FCPA liability or liabilities under similar
laws of the various jurisdictions in which Ortho operates and/or Ortho&#146;s reputation may potentially be harmed by the distributors and manufacturers&#146; violations and resulting sanctions and fines. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho&#146;s international operations require it to comply with anti-terrorism laws and regulations and applicable trade embargoes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is subject to trade and economic sanctions laws and other restrictions on international trade. The United States and other governments and their agencies
impose sanctions and embargoes on certain countries, their governments and designated parties. In the United States, the economic and trade sanctions programs are principally administered and enforced by OFAC. Currently, OFAC maintains comprehensive
trade and economic sanctions against the following countries and territories: Cuba, Iran, Syria, North Korea and the Crimea region of Ukraine. If Ortho fails to comply with these laws, Ortho could be subject to civil or criminal penalties, other
remedial measures and legal expenses, which could adversely affect Ortho&#146;s business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho cannot
predict the nature, scope or effect of future regulatory requirements to which Ortho&#146;s international sales and manufacturing operations might be subject or the manner in which existing laws might be administered or interpreted. Future
regulations could limit the countries in which some of Ortho&#146;s products may be manufactured or sold, or could restrict Ortho&#146;s access to, or increase the cost of obtaining, products from foreign sources. The occurrence of any of the
foregoing could have a material adverse effect on Ortho&#146;s business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho&#146;s collection, use and disclosure of personal information, including health information, is
subject to federal and state privacy and security regulations, as well as data privacy and security laws outside the United States, including in the European Economic Area (the &#147;EEA&#148;) the United Kingdom and the People&#146;s Republic of
China, and Ortho&#146;s failure to comply with those laws and regulations or to adequately secure the information Ortho holds could result in significant liability or reputational harm. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho and its partners may be subject to federal, state, and foreign data protection laws and regulations. The legislative and regulatory landscape for privacy
and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues, which may affect its business and may increase its compliance costs and exposure to liability. In the United States, numerous
federal and state laws and regulations, including state security breach notification laws, federal and state health information privacy laws (including HIPAA) and federal and state consumer protection laws, govern the collection, use, disclosure,
and protection of personal information, including health-related information. Each of these laws is subject to varying interpretations by courts and government agencies, creating complex compliance issues. If Ortho fails to comply with applicable
laws and regulations it could be subject to penalties or sanctions, including criminal penalties if Ortho knowingly obtains or discloses individually identifiable health information from a covered entity in a manner that is not authorized or
permitted by HIPAA or applicable state laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, HIPAA imposes, among other things, certain standards relating to the privacy,
security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and
regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for Ortho and its future customers and strategic partners. For example, the California Consumer
Privacy Act of 2018 (&#147;CCPA&#148;) went into effect on January&nbsp;1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal
information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act (&#147;CPRA&#148;) recently
passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain
uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into
effect on January&nbsp;1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia and Colorado, and have been proposed in other states and at the federal level,
reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that Ortho is subject to or affected
by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect its financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, the Federal Trade Commission (the &#147;FTC&#148;) and many state Attorneys General continue to enforce federal and state consumer protection
laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, failing to take appropriate steps to keep consumers&#146; personal information secure
can constitute unfair acts or practices in or affecting commerce in violation of Section&nbsp;5(a) of the Federal Trade Commission Act. The FTC expects a company&#146;s data security measures to be reasonable and appropriate in light of the
sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HIPAA as well as numerous other federal and state laws and regulations, govern the collection, dissemination, use, privacy, security, confidentiality,
integrity and availability of personally identifiable information (&#147;PII&#148;), including protected health information (&#147;PHI&#148;). HIPAA applies national privacy and security standards for PHI to covered entities, including certain types
of healthcare entities and their service providers that access PHI, known as business associates. HIPAA requires covered entities and business associates to maintain policies and procedures governing PHI that is used or disclosed, and to implement
administrative, physical and technical safeguards to protect PHI, including PHI maintained, used and disclosed in electronic form. These safeguards include employee training, identifying business associates with whom covered entities need to enter
into HIPAA-compliant contractual arrangements and various other measures. While Ortho undertakes substantial efforts to secure the PHI Ortho maintains, uses and discloses in electronic form, a cyber-attack or other intrusion that bypasses
Ortho&#146;s information security systems causing an information security breach, loss of PHI, PII or other data subject to privacy laws or a material disruption of Ortho&#146;s operational systems could result in a material adverse impact on
Ortho&#146;s business, along with potentially substantial fines and penalties. Ongoing implementation and oversight of these security measures involves significant time, effort and expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HIPAA requires covered entities and their business associates to report breaches of unsecured PHI to
affected individuals without unreasonable delay and in no case later than 60 days after the discovery of the breach by the covered entity or its agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notification must also be made to the U.S. Department of Health and Human Services (&#147;HHS&#148;) and, in certain situations involving large breaches, to
the media. HIPAA rules created a presumption that all <FONT STYLE="white-space:nowrap">non-permitted</FONT> uses or disclosures of unsecured PHI are breaches unless the covered entity establishes that there is a low probability the information has
been compromised. A data breach affecting sensitive personal information, including health information, also could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on
Ortho&#146;s business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HIPAA also authorizes state attorneys general to bring civil actions seeking either an injunction or damages in response to
violations of HIPAA privacy and security regulations that threaten the privacy of state residents. While HIPAA does not create a private right of action allowing individuals to sue Ortho in civil court for violations of HIPAA&#146;s requirements,
its standards have been used as a basis for the duty of care in state civil suits, such as those for negligence or recklessness in the handling of PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of
covered entities and business associates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, many states in which Ortho operates may impose laws that are more protective of the privacy and
security of PII than HIPAA. Where these state laws are more protective than HIPAA, Ortho may have to comply with their stricter provisions. Not only may some of these state laws impose fines and penalties upon violators, but some may afford private
rights of action to individuals who believe their PII has been misused. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both state and federal laws and regulations are subject to modification or
enhancement of privacy and security protections at any time. Ortho&#146;s business will continue to remain subject to any federal and state privacy-related laws and regulations that are more restrictive than the privacy regulations issued under
HIPAA. Sweeping privacy measures in certain states such as the California Consumer Privacy Act impose European-like standards for the protection of personal data and allow for a private right of action. These statutes vary and could impose
additional requirements on Ortho and more severe penalties for disclosures of confidential health information. New health and consumer information standards could have a significant effect on the manner in which Ortho does business, and the cost of
complying with new standards could be significant. Ortho may not remain in compliance with the diverse privacy and security requirements in all of the jurisdictions in which Ortho does business. If Ortho fails to comply with such state laws, it
could incur substantial civil monetary or criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is also subject to data privacy and security laws in jurisdictions outside of the
United States. For example, in the EEA and the United Kingdom, Ortho is subject to the General Data Protection Regulation 2016/679 (the &#147;GDPR&#148;) and the United Kingdom data protection regime consisting primarily of the UK General Data
Protection Regulation and the UK Data Protection Act 2018 (collectively, the &#147;UK GDPR&#148;), which could limit Ortho&#146;s ability to collect, control, process, share, disclose and otherwise use personal data (including health and medical
information which are subject to strict requirements). Maintaining compliance with the GDPR and UK GDPR could cause Ortho&#146;s compliance costs to increase, ultimately having an adverse impact on Ortho&#146;s business. Ortho is implementing
measures to comply with these laws as part of Ortho&#146;s comprehensive compliance program with input from external advisors to address Ortho&#146;s compliance with these obligations under GDPR. Failure to comply with the GDPR and UK GDPR may
result in fines up to the greater of &#128;20&nbsp;million / &pound;17.5&nbsp;million or 4% of total annual revenue. In addition to the foregoing, a breach of the GDPR and UK GDPR could result in regulatory investigations, reputational damage,
orders to cease or change Ortho&#146;s processing of its data, enforcement notices or assessment notices (for a compulsory audit). Ortho may also face civil claims including representative actions and other class action type litigation (where
individuals have suffered harm), potentially amounting to significant compensation or damages liabilities, as well as associated costs, diversion of internal resources and reputational harm. In addition, in September 2021, the UK government launched
a consultation on its proposals for wide-ranging reform of UK data protection laws following Brexit. There is a risk that any material changes which are made to the UK data protection regime could result in the European Commission reviewing the UK
adequacy decision (enabling data transfers from EU member states to the UK without additional safeguards) and the UK losing its adequacy decision if the European Commission deems the UK to no longer provide adequate protection for personal data. The
relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to long term, and how data
transfers to and from the United Kingdom will be regulated in the long term. These changes could lead to additional costs and increase Ortho&#146;s overall risk exposure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is also subject to European Union and United Kingdom rules with respect to cross-border transfers of personal data out of the EEA and the United
Kingdom, respectively. Recent legal developments in Europe have created complexity and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
uncertainty regarding transfers of personal data from the EEA to the United States. For instance, on July&nbsp;16, 2020, the Court of Justice of the European Union (the &#147;CJEU&#148;)
invalidated the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield Framework (the &#147;Privacy Shield&#148;) under which personal data could be transferred from the EEA to U.S. entities who had self-certified under the Privacy Shield
scheme. While the CJEU did not invalidate standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear
that reliance on them alone may not necessarily be sufficient in all circumstances. Ortho currently relies on the standard contractual clauses among other data transfer mechanisms allowed pursuant to the GDPR to transfer personal data outside the
EEA or the United Kingdom, including to the United States. The European Commission has published revised standard contractual clauses for data transfers from the EEA: the revised clauses must be used for relevant new data transfers from
September&nbsp;27, 2021; existing standard contractual clauses arrangements must be migrated to the revised clauses by December&nbsp;27, 2022. Ortho will be required to implement the revised standard contractual clauses, in relation to both relevant
existing contracts and transfer arrangements and additional or new contracts and arrangements, within the relevant time frames. The revised standard contractual clauses apply only to the transfer of personal data outside of the EEA and not the
United Kingdom; the UK&#146;s Information Commissioner&#146;s Office launched a public consultation on its draft revised data transfers mechanisms in August 2021. Ortho is monitoring the outcome of this, and we may be required to implement new or
revised documentation and processes in relation to data transfers subject to the UK GDPR within the relevant time frames. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the
standard contractual clauses cannot be used, and/or start taking enforcement action, Ortho could suffer additional costs, complaints, regulatory investigations or fines, and if Ortho is otherwise unable to transfer personal data between and among
countries and regions in which Ortho operates, it could affect the manner in which Ortho provides its services and the geographical location or segregation of Ortho&#146;s relevant systems and operations, which could adversely affect Ortho&#146;s
financial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho depends on a number of third-parties in relation to the operation of its business, a number of which process personal data on
Ortho&#146;s behalf. With each such third party, Ortho attempts to mitigate the associated risks of using third parties by performing applicable security assessments and detailed due diligence, entering into contractual arrangements to require that
providers only process personal data according to Ortho&#146;s instructions, and that they have sufficient technical and organizational security measures in place. Where Ortho transfers personal data outside the EEA or the United Kingdom to such
third parties, Ortho does so in compliance with the relevant data export requirements, as described above. There is no assurance that these contractual measures and Ortho&#146;s own privacy and security-related safeguards will fully protect Ortho
from the risks associated with the third-party processing. Any violation of data or security laws by Ortho&#146;s third-party processors could have a material adverse effect on Ortho&#146;s business and result in the fines and penalties outlined
below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is also subject to evolving privacy laws on cookies and <FONT STYLE="white-space:nowrap">e-marketing.</FONT> In the European Union,
regulators are increasingly focusing on compliance with requirements in the online behavioral advertising ecosystem, and current national laws that implement the ePrivacy Directive will be replaced by an EU regulation known as the ePrivacy
Regulation which will significantly increase fines for <FONT STYLE="white-space:nowrap">non-compliance.</FONT> While the text of the ePrivacy Regulation is still under development, a recent European court decision and regulators&#146; recent
guidance are driving increased attention to cookies and tracking technologies. In the United States, the Federal Trade Commission and many state laws have increasingly focused on the collection and use of behavioral data including geolocation and
biometric information. As regulators start to enforce a strict approach (which has already started in Germany), this could lead to substantial costs, require significant systems changes, limit the effectiveness of Ortho&#146;s marketing activities,
divert the attention of Ortho&#146;s technology personnel, adversely affect Ortho&#146;s margins, increase costs and subject Ortho to additional liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recently many countries have enacted legislation to strengthen privacy laws to protect their residents&#146; personal data. Some countries&#146; laws have
been modeled on GDPR, including fines and penalties such as Brazil&#146;s enacted data protection law and similar pending legislation in Chile. Ortho is currently monitoring the evolving data protection landscape so that Ortho can comply with the
requirements in the countries in which Ortho does business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Data compliance in other countries outside EEA, the United Kingdom and the United States may
be even more complex and varied making it difficult to comply with them all. China&#146;s legislation and regulation of the healthcare industry involves multiple pieces of legislation prescribing complex regulatory requirements governing different
types of data across a continuum of care, and various supervisory authorities frequently conduct inspections and investigations. For example, under China&#146;s Cybersecurity Law, any collection, use, transfer and storage of personal information of
a Chinese citizen through a network by the network operator should be based on the three principles of legitimacy, justification and necessity and requires the consent of the data subject. The rules, purposes, methods and ranges of such collection
should also be disclosed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the data subject. China&#146;s data localization requirements are becoming increasingly common in sector-specific regulations. China&#146;s Cybersecurity Law requires operators of critical
information infrastructure (&#147;CIIOs&#148;) to store personal information and important data collected and generated from the critical information infrastructure within China. Failure to do so can result in fines of up to RMB 100,000 for the
relevant entity as well as for the personnel directly responsible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">China&#146;s Data Security Law (&#147;Data Security Law&#148;) became effective on
September&nbsp;1, 2021. The primary purpose of the Data Security Law is to regulate data activities, safeguard data security, promote data development and usage, protect individuals and entities&#146; legitimate rights and interests, and safeguard
state sovereignty, state security and development interests. The Data Security Law applies extraterritorially, and to a broad range of activities that involve &#147;data&#148; (not only personal or sensitive data). Under the Data Security Law,
entities and individuals carrying out data activities must abide by various data security obligations. For example, the Data Security Law proposes to classify and protect data based on the importance of data to the state&#146;s economic development,
as well as the degree of harm it will cause to national security, public interests, or legitimate rights and interests of individuals or organizations when such data is tampered with, destroyed, leaked, or illegally acquired or used. The appropriate
level of protective measures is required to be taken for each respective class of data. The Data Security Law also echoes the data localization requirement in the Cybersecurity Law and requires important data to be stored locally in China. Such
important data may only be transferred outside of China subject to compliance with certain data transfer restrictions, such as passing a security assessment organized by the relevant authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notably, China&#146;s Personal Information Protection Law (&#147;PIPL&#148;), similar to the GDPR, applies extraterritorially. The PIPL is intended to clarify
the scope of application, the definitions of personal information and sensitive personal information (which includes medical and health information), the legality of personal information processing and the basic requirements of notice and consent,
among other things. The PIPL also sets out data localization requirements for CIIOs and personal information processors who process personal information above a certain threshold prescribed by the relevant authorities. The PIPL also includes a list
of rules which must be complied with prior to the transfer of personal information outside of China, such as compliance with a security assessment or certification by an agency designated by the relevant authorities or entering into standard form
model contracts approved by the relevant authorities with the overseas recipient. Failure to comply with PIPL can result in fines of up to RMB 50&nbsp;million or 5% of the prior year&#146;s total annual revenue for the personal information processor
and/or a suspension of services or data processing activities. Other potential penalties include a fine of up to RMB 1&nbsp;million on the person in charge or directly responsible personnel and, in serious cases, individuals and entities may be
exposed to criminal liabilities under other local Chinese law, such as the Criminal Law of the People&#146;s Republic of China. The PIPL also prohibits responsible personnel for violations of the PIPL from holding high-level management or data
protection officer positions in relevant enterprises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to China&#146;s Cybersecurity Law, the Data Security Law and the PIPL, the relevant
government authorities of People&#146;s Republic of China promulgated several regulations or released a number of draft regulations for public comments which are designed to provide further implemental guidance in accordance with the laws mentioned
above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho cannot predict what impact the new laws and regulations, in particular the Data Security Law or PIPL, or the increased costs of compliance,
if any, will have on Ortho&#146;s operations in China due to their recent enactment and the limited guidance available, particularly on PIPL, which entities are awaiting further guidance on. It is also generally unclear how the laws will be
interpreted and enforced in practice by the relevant government authorities as often the abovementioned laws are drafted broadly and leaves great discretion to the relevant government authorities to exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with China&#146;s data laws mentioned above, the GDPR and UK GDPR and the various other global data privacy laws that Ortho is subject to has
required, and may continue to require, significant company resources and expenditures, and may require further changes in Ortho&#146;s products, services or business model that increase competition or reduce revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Ortho works to comply with applicable laws, regulations and standards, its contractual obligations and other legal obligations, these requirements
are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which Ortho must comply. Any failure or perceived failure by
Ortho or its employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and
liability to Ortho, damage its reputation, and adversely affect its business and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Risks Relating to Ortho&#146;s Information Technology and Intellectual Property </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho&#146;s data management and information technology systems are critical to maintaining and growing Ortho&#146;s business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s business is dependent on the effective use of information technology and, consequently, technology failure or obsolescence may negatively impact
Ortho&#146;s business. In addition, data acquisition, data quality control, data privacy, data security and data analysis are intense and complex processes subject to error. Untimely, incomplete or inaccurate data, flawed analysis of data or
Ortho&#146;s inability to properly integrate, implement, protect and update systems could have a material adverse impact on Ortho&#146;s business and results of operations. Ortho expects that it will need to continue to improve and further integrate
its information technology systems on an ongoing basis in order to effectively run Ortho&#146;s business. If Ortho fails to successfully manage its information technology systems, its business and operating results could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho&#146;s ability to protect its information systems and electronic transmissions of personal data and sensitive data from data corruption,
cyber-based attacks, security breaches or privacy violations is critical to the success of Ortho&#146;s business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is highly dependent on
information technology networks and systems, including its office networks, operational environment, special purpose networks, systems and software used to operate Ortho&#146;s instruments and devices and those networks and systems managed by
vendors or third parties, to securely process, transmit and store electronic information (including sensitive data such as trade secrets, confidential business information and personal data relating to employees, customers and business partners).
Like any large corporation, from time to time the information systems on which Ortho relies, including those controlled and managed by third-parties, may be subject to computer viruses, malicious software, attacks by hackers and other forms of cyber
intrusions or unauthorized access, any of which can create system disruptions, shutdowns or unauthorized disclosure of sensitive data. In addition, a security breach that leads to disclosure of information protected by privacy laws could compel
Ortho to comply with breach notification requirements under applicable laws, potentially resulting in litigation or regulatory action, or otherwise subjecting Ortho to liability under laws that protect personal data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Ortho experiences a significant technology incident, such as a serious product vulnerability, security breach or a failure of a system that is critical for
the operations of Ortho&#146;s business, it could impair Ortho&#146;s ability to operate its business, including its ability to provide maintenance and support services to Ortho&#146;s customers. If this happens, Ortho&#146;s revenues could decline
and its business could suffer, and it may need to make significant further investments to protect data and infrastructure. An actual or perceived vulnerability, failure, disruption or breach of Ortho&#146;s network or privileged account security in
Ortho&#146;s systems also could adversely affect the market perception of Ortho&#146;s products and services, as well as Ortho&#146;s perception among new and existing customers. Additionally, a significant security breach could subject Ortho to
potential liability, litigation and regulatory or other government action. If any of the foregoing were to occur, Ortho&#146;s business may suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho
attempts to mitigate the above risks by employing a number of measures, including monitoring and testing of Ortho&#146;s security controls, employee training and maintenance of protective systems and contingency plans. Further, Ortho&#146;s
contractual arrangements with service providers aim to ensure that third-party cybersecurity risks are appropriately mitigated. Ortho also maintains insurance relating to cybersecurity incidents, which Ortho cannot guarantee will be adequate. It is
impossible to eliminate all cybersecurity risk and thus Ortho&#146;s systems, products and services, as well as those of its service providers, remain potentially vulnerable to known or unknown threats. Additionally, Ortho&#146;s information
technology systems may also be vulnerable to damage or interruption from circumstances beyond Ortho&#146;s control, including fire, natural disasters, power outages and system failures. Any system outages or security breaches, whether caused
intentionally or unintentionally, can interrupt Ortho&#146;s operations, delay production and shipments, result in theft of trade secrets and intellectual property, damage Ortho&#146;s reputation, result in defective products or services, give rise
to legal proceedings, liabilities and penalties, and cause Ortho to incur increased costs for insurance premiums, security, remediation, and regulatory compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information security risks have generally increased in recent years because of the increased proliferation, sophistication and availability of complex malware
and hacking tools to carry out cyber-attacks. As a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, Ortho may also face increased cybersecurity risks due to its reliance on internet technology and the number of its employees
who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not
recognized until launched against a target, Ortho may be unable to anticipate these techniques or implement adequate preventative measures. Ortho may also experience security breaches that may remain undetected for an extended period of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time. As cyber threats continue to evolve, Ortho may be required to expend additional resources to mitigate new and emerging threats while continuing to enhance Ortho&#146;s information security
capabilities or to investigate and remediate security vulnerabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho&#146;s inability to protect and enforce its intellectual property
rights could adversely affect its financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellectual property rights both in the United States and in foreign countries, including
patents, trade secrets, proprietary information, trademarks and trade names, are important to Ortho&#146;s business and will be critical to its ability to grow and succeed in the future. Ortho makes strategic decisions on whether to apply for
intellectual property protection and what kind of protection to pursue based on a cost-benefit analysis. While Ortho endeavors to protect its intellectual property rights in certain jurisdictions in which its products are produced or used and in
jurisdictions into which Ortho&#146;s products are imported, the decision to file for intellectual property protection is made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. Because of the
differences in foreign trademark, patent and other laws concerning proprietary rights, Ortho&#146;s intellectual property rights may not receive the same degree of protection in foreign countries as they would in the United States. Additionally,
certain of Ortho&#146;s intellectual property rights are held through its license agreements and collaboration arrangements with third parties. Because of the nature of these licenses and arrangements, Ortho cannot assure you that it would be able
to retain all of these intellectual property rights upon termination of such licenses and collaboration arrangements. Ortho&#146;s failure to obtain or maintain adequate protection of its intellectual property rights for any reason could have a
material adverse effect on its business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho has applied for patent protection relating to certain
existing and proposed products, processes and services in certain jurisdictions. While Ortho generally considers applying for patents in those countries where it intends to make, has made, uses or sells patented products, Ortho may not accurately
assess all of the countries where patent protection will ultimately be desirable. If Ortho fails to timely file a patent application in any such country, Ortho may be precluded from doing so at a later date. Furthermore, Ortho cannot assure you that
its pending patent applications will not be challenged by third parties or that such applications will eventually be issued by the applicable patent offices as patents. Ortho also cannot assure you that the patents issued as a result of its foreign
patent applications will have the same scope of coverage as its U.S. patents. It is possible that only a limited number of the pending patent applications will result in issued patents, which may have a materially adverse effect on Ortho&#146;s
business and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patents Ortho owns could be challenged, invalidated or circumvented by others and may not be of sufficient scope
or strength to provide Ortho with any meaningful protection or commercial advantage. Furthermore, Ortho&#146;s existing patents are subject to challenges from third parties which may result in invalidations and will all eventually expire, after
which Ortho will not be able to prevent Ortho&#146;s competitors from using Ortho&#146;s previously patented technologies, which could materially adversely affect Ortho&#146;s competitive advantage stemming from those products and technologies.
Ortho also cannot assure you that competitors will not infringe Ortho&#146;s patents, or that Ortho will have adequate resources to enforce Ortho&#146;s patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho also licenses third parties to use Ortho&#146;s patents and <FONT STYLE="white-space:nowrap">know-how.</FONT> In an effort to preserve Ortho&#146;s
intellectual property rights, Ortho enters into license agreements with these third parties, which govern the use of Ortho&#146;s patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and other confidential, proprietary information. Although
Ortho makes efforts to police the use of its intellectual property by its licensees, Ortho cannot assure you that these efforts will be sufficient to ensure that Ortho&#146;s licensees abide by the terms of their licenses. In the event that
Ortho&#146;s licensees fail to do so, Ortho&#146;s intellectual rights could be impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho also relies on unpatented proprietary technology. It is
possible that others will independently develop the same or similar technology or otherwise obtain access to Ortho&#146;s unpatented technology. To protect Ortho&#146;s trade secrets and other proprietary information, Ortho requires certain
employees, consultants, advisors and collaborators to enter into confidentiality agreements as Ortho deems appropriate. Ortho cannot assure you that it will be able to enter into these confidentiality agreements or that these agreements will provide
meaningful protection for Ortho&#146;s trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or other proprietary information in the event of any unauthorized use, misappropriation or disclosure of such trade secrets, <FONT
STYLE="white-space:nowrap">know-how</FONT> or other proprietary information. If Ortho is unable to maintain the proprietary nature of Ortho&#146;s technologies, it could be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho relies on its trademarks, trade names and brand names to distinguish its products from the products of its competitors, and have registered or applied
to register many of these trademarks. Ortho cannot assure you that its trademark applications will be approved. Third parties may also oppose Ortho&#146;s trademark applications, or otherwise challenge Ortho&#146;s use of the trademarks. In the
event that Ortho&#146;s trademarks are successfully challenged, Ortho could be forced to rebrand its products, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which could result in loss of brand recognition, and could require Ortho to devote resources to advertising and marketing new brands. Further, Ortho cannot assure you that competitors will not
infringe Ortho&#146;s trademarks, or that Ortho will have adequate resources to enforce Ortho&#146;s trademarks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Risks Relating to Ortho&#146;s
Taxation </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legislative or taxation changes or HM Revenue&nbsp;&amp; Customs (&#147;HMRC&#148;) enforcement actions may have a material adverse
impact on Ortho&#146;s business, results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is subject to the laws of England and Wales and the taxation
rules administered by HMRC. Changes in legislation or regulations and actions by regulators, including changes in administration and enforcement policies, could from time to time require operational improvements or modifications, including in
relation to the conduct of reviews and audits, that could result in higher costs or restrict Ortho&#146;s ability to operate its business and, as a result, have a material adverse effect on its business, results of operations and financial
condition. HMRC may also take enforcement actions against Ortho which may result in fines, penalties and/or interest charges being imposed on Ortho which may have a material adverse effect on its business, results of operations and financial
condition. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in tax laws or exposures to additional tax liabilities could negatively impact Ortho&#146;s operating results. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in tax laws or regulations around the world, including in the United States and as led by the Organization for Economic Cooperation and Development,
could negatively impact Ortho&#146;s effective tax rate and results of operations. A change in statutory tax rate or certain international tax provisions in any country would result in the revaluation of Ortho&#146;s deferred tax assets and
liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to Ortho&#146;s consolidated statement of operations. Ortho closely monitors these
proposals as they arise in the countries where Ortho operates. Changes to tax laws or regulations may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho&#146;s ability to use its net operating loss carry forwards to offset future taxable income are expected to be subject to certain limitations
and Ortho could be subject to tax audits or examinations that could result in a loss of Ortho&#146;s net operating losses and/or cash tax exposures. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;2, 2022, Ortho had NOLs of approximately $889&nbsp;million in the United States and approximately $467&nbsp;million in Luxembourg due to
prior period losses. In addition, Ortho had approximately $446&nbsp;million of U.S. carryforward interest expense and approximately $214&nbsp;million of Luxembourg carryforward interest expense as of January&nbsp;2, 2022. Certain of these
carryforwards, if not utilized, will begin to expire through 2037. Realization of these carryforwards depends on future income, and there is a risk that Ortho&#146;s existing carryforwards could expire unused and be unavailable to offset future
income tax liabilities, which could adversely affect Ortho&#146;s cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, under Section&nbsp;382 of the Code, a corporation that
undergoes an &#147;ownership change&#148; is subject to limitations on its ability to utilize its tax attributes, including its NOLs to offset future taxable income. As of January&nbsp;2, 2022, the Ortho Scheme is expected to result in an ownership
change under Section&nbsp;382 of the Code. There is risk that subsequent changes in ownership could result in another Section 382 ownership change and further limit the use of Ortho&#146;s tax attributes. Ortho&#146;s NOLs may also be impaired under
state laws. There is also a risk that due to regulatory changes, or other unforeseen reasons, Ortho&#146;s existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities. Furthermore, any available NOLs would have
value only to the extent there is income in the future against which such NOLs may be offset. For these reasons, Ortho may not be able to realize a tax benefit from the use of Ortho&#146;s NOLs, whether or not Ortho attains profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Risks Relating to Ortho&#146;s Indebtedness </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho&#146;s substantial indebtedness could adversely affect Ortho&#146;s financial condition, limit Ortho&#146;s ability to raise additional capital to
fund its operations and prevent Ortho from fulfilling its obligations under its indebtedness. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho has a significant amount of indebtedness. As a
result of Ortho&#146;s substantial indebtedness, a significant amount of Ortho&#146;s cash flows are required to pay interest and principal on Ortho&#146;s outstanding indebtedness, and Ortho may not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generate sufficient cash flows from operations, or have future borrowings available under the Revolving Credit Facility, to enable Ortho to repay its indebtedness or to fund its other liquidity
needs. As of January 2, 2022, Ortho had total indebtedness of $2,276.9 and availability under its Revolving Credit Facility of $453.7 million (net of $46.3&nbsp;million of outstanding letters of credit). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the limits contained in the Credit Agreement, the indenture governing the $405.0&nbsp;million in aggregate principal amount of 7.250% Senior Notes
due 2028 issued by Ortho-Clinical Diagnostics S.A., a soci&eacute;t&eacute; anonyme organized under the laws of the Grand Duchy of Luxembourg (the &#147;Lux <FONT STYLE="white-space:nowrap">Co-Issuer&#148;)</FONT> and Ortho-Clinical Diagnostics,
Inc., a New York corporation (the &#147;U.S. <FONT STYLE="white-space:nowrap">Co-Issuer&#148;)</FONT> (the &#147;2028 Notes&#148; and such indenture, the &#147;2028 Notes Indenture&#148;), the indenture governing the $240.0&nbsp;million in aggregate
principal amount of 7.375% Senior Notes due 2025 issued by the Lux <FONT STYLE="white-space:nowrap">Co-Issuer</FONT> and the U.S. <FONT STYLE="white-space:nowrap">Co-Issuer</FONT> (the &#147;2025 Notes&#148; and such indenture, the &#147;2025 Notes
Indenture&#148;), the three-year accounts receivable program (the &#147;Financing Program&#148;) and Ortho&#146;s other debt instruments, Ortho may incur substantial additional debt from time to time to finance working capital, capital expenditures,
investments or acquisitions, or for other purposes. If Ortho does so, the risks related to Ortho&#146;s high level of debt would increase. Specifically, Ortho&#146;s high level of debt could have important consequences to you, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making it more difficult for Ortho to satisfy its obligations with respect to Ortho&#146;s debt, and if Ortho
fails to comply with these obligations, an event of default could result; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limiting Ortho&#146;s ability to obtain additional financing to fund future working capital, capital
expenditures, investments or acquisitions or other general corporate requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring a substantial portion of Ortho&#146;s cash flows to be dedicated to debt service payments instead of
other purposes, thereby reducing the amount of cash flows available for working capital, capital expenditures, investments or acquisitions and other general corporate purposes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increasing Ortho&#146;s vulnerability to general adverse economic and industry conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exposing Ortho to the risk of increased interest rates as certain of Ortho&#146;s borrowings, including
borrowings under the Senior Secured Credit Facilities, are at variable rates of interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limiting Ortho&#146;s flexibility in planning for and reacting to changes in the industry in which Ortho competes
as well as changing business and economic conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restricting Ortho from making strategic acquisitions or causing Ortho to make non-strategic divestitures;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impairing Ortho&#146;s ability to obtain additional financing in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preventing Ortho from raising the funds necessary to repurchase all of the 2025 Notes and the 2028 Notes
(collectively, the &#147;Senior Notes&#148;) tendered to Ortho upon the occurrence of certain changes of control, which failure to repurchase would constitute an event of default under the 2025 Notes Indenture or the 2028 Notes Indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">placing Ortho at a disadvantage compared to other, less leveraged competitors and affecting Ortho&#146;s ability
to compete; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increasing Ortho&#146;s cost of borrowing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The occurrence of any one of these events could have a material adverse effect on Ortho&#146;s business, financial condition, results of operations and
ability to satisfy Ortho&#146;s obligations in respect of Ortho&#146;s outstanding debt. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, borrowings under Ortho&#146;s Senior Secured
Credit Facilities are at variable rates of interest and expose Ortho to interest rate risk. Recent interest rates have been at historically low levels. If interest rates increase, Ortho&#146;s debt service obligations on the variable rate
indebtedness will increase even though the amount borrowed may remain the same, and Ortho&#146;s net income and cash flows, including cash available for servicing Ortho&#146;s indebtedness, will correspondingly decrease. As of January 2, 2022,
$1,292.8&nbsp;million in aggregate principal amount of indebtedness under Ortho&#146;s Term Loan Facilities is subject to variable interest rates subject to the London interbank offered rate (&#147;LIBOR&#148;). Assuming no prepayments of
Ortho&#146;s Term Loan Facilities and that Ortho&#146;s Revolving Credit Facility is fully drawn (and to the extent that the LIBOR is in excess of the 0.00% floor rate applicable to Ortho&#146;s Senior Secured Credit Facilities), each <FONT
STYLE="white-space:nowrap">one-eighth</FONT> percent change in interest rates, prior to the impact of derivative instruments, would result in a $2.6&nbsp;million change in annual interest expense on the indebtedness under Ortho&#146;s Senior Secured
Credit Facilities. In addition, certain of Ortho&#146;s variable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rate indebtedness uses LIBOR as a benchmark for establishing the rate. LIBOR is the subject of recent national, international and other regulatory guidance and proposals for reform. These reforms
and other pressures will cause LIBOR to disappear entirely or be deemed unrepresentative after June&nbsp;30, 2023 to perform differently than in the past. The consequences of these developments cannot be entirely predicted, but could include an
increase in the cost of Ortho&#146;s variable rate indebtedness. Ortho has entered into a series of interest rate cap and interest rate swap agreements to hedge Ortho&#146;s interest rate exposures related to Ortho&#146;s variable rate borrowings
under the Senior Secured Credit Facilities. However, it is possible that these interest rate cap and interest rate swap agreements or any future interest rate cap agreements or swaps Ortho enters into may not fully or effectively mitigate
Ortho&#146;s interest rate risk and Ortho may decide not to maintain interest rate swaps in the future. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, amounts drawn under
Ortho&#146;s Senior Secured Credit Facilities may bear interest rates in relation to LIBOR, depending on Ortho&#146;s selection of repayment options. On March&nbsp;5, 2021, the ICE Benchmark Administration, the administrator of LIBOR, and the
Financial Conduct Authority, the regulatory supervisor of the ICE Benchmark Administration, announced that the final publication or representativeness date for LIBOR for: (i)&nbsp;Sterling and Euros will be December&nbsp;31, 2021, (ii) Dollars for <FONT
STYLE="white-space:nowrap">1-week</FONT> and <FONT STYLE="white-space:nowrap">2-month</FONT> tenor settings will be December&nbsp;31, 2021 and (iii)&nbsp;Dollars for overnight, <FONT STYLE="white-space:nowrap">1-month,</FONT> <FONT
STYLE="white-space:nowrap">3-month,</FONT> <FONT STYLE="white-space:nowrap">6-month</FONT> and <FONT STYLE="white-space:nowrap">12-month</FONT> tenor settings will be June&nbsp;30, 2023.&nbsp;In the United States, the Alternative Rates Reference
Committee, a group of market participants convened in 2014 to help ensure a successful transition away from USD LIBOR,&nbsp;has identified the Secured Overnight Financing Rate (&#147;SOFR&#148;) as its preferred alternative rate. SOFR is a measure
of the cost of borrowing cash overnight, collateralized by U.S. Treasury securities, and is based on directly observable U.S. Treasury-backed repurchase transactions. On December&nbsp;24, 2021, Ortho entered into an amendment to the Senior Secured
Credit Facilities to account for the cessation of LIBOR for Sterling, Euros and Japanese Yen and the alternative replacement rates with respect to such currencies, as applicable. As all tenor settings for LIBOR will cease to exist on June&nbsp;30,
2023, Ortho will need to renegotiate certain provisions of its Senior Secured Credit Facilities and may not be able to do so with terms that are favorable to Ortho. The overall financing market may be disrupted as a result of the <FONT
STYLE="white-space:nowrap">phase-out</FONT> or replacement of LIBOR. Disruption in the financial market or the inability to renegotiate Ortho&#146;s Senior Secured Credit Facilities with favorable terms could have a material adverse effect on
Ortho&#146;s business, financial position, operating results and cash flows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho may not be able to generate sufficient cash flows from operating
activities to service all of its indebtedness, and may be forced to take other actions to satisfy its obligations under its indebtedness, which may not be successful. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s inability to generate sufficient cash flows to satisfy its debt obligations, or to refinance Ortho&#146;s indebtedness on commercially reasonable
terms or at all, would materially and adversely affect Ortho&#146;s business, financial position and results of operations and Ortho&#146;s ability to satisfy its debt obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, if Ortho cannot make scheduled payments on its debt, Ortho will be in default, and holders of the Senior Notes could declare all outstanding
principal and interest to be due and payable, the lenders under the Senior Secured Credit Facilities could terminate their commitments to loan additional money to Ortho, the lenders could foreclose against the assets securing their borrowings and
Ortho could be forced into bankruptcy or liquidation. All of these events could result in your losing all or a part of your investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s
ability to make scheduled payments on or refinance its debt obligations depends on Ortho&#146;s financial condition and operating performance, which are subject to prevailing economic and competitive conditions and to financial, business,
legislative, regulatory and other factors beyond Ortho&#146;s control. Ortho might not be able to maintain a level of cash flows from operating activities sufficient to permit Ortho to pay the principal, premium, if any, and interest on its
indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Ortho&#146;s cash flows and capital resources are insufficient to fund its debt service obligations, Ortho could face substantial
liquidity problems and could be forced to reduce or delay investments and capital expenditures or to dispose of material assets or operations, seek additional debt or equity capital or restructure or refinance its indebtedness. In addition,
Ortho&#146;s cash flows may be negatively impacted if Ortho is required to pay back borrowing under the Financing Program sooner than anticipated if there is a reduction in the borrowing base. Ortho may not be able to effect any such alternative
measures on commercially reasonable terms or at all and, even if successful, those alternative actions may not allow Ortho to meet its scheduled debt service obligations. The Credit Agreement, the 2025 Notes Indenture and the 2028 Notes Indenture
restrict Ortho&#146;s ability to dispose of assets and use the proceeds from such dispositions and may also restrict Ortho&#146;s ability to raise debt or equity capital to be used to repay other indebtedness when it becomes due. Because of these
restrictions, Ortho may not be able to consummate those dispositions or to obtain proceeds in an amount sufficient to meet any debt service obligations then due. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Ortho conducts substantially all of its operations through its subsidiaries, some of which are
not guarantors of Ortho&#146;s indebtedness. Accordingly, repayment of Ortho&#146;s indebtedness is dependent on the generation of cash flows by Ortho&#146;s subsidiaries and their ability to make such cash available to Ortho, by dividend, debt
repayment or otherwise. Unless they are guarantors of Ortho&#146;s indebtedness, Ortho&#146;s subsidiaries do not have any obligation to pay amounts due on Ortho&#146;s indebtedness or to make funds available for that purpose. Ortho&#146;s
subsidiaries may not be able to, or may not be permitted to, make distributions to enable Ortho to make payments in respect of its indebtedness. Each subsidiary is a distinct legal entity, and, under certain circumstances, legal and contractual
restrictions may limit Ortho&#146;s ability to obtain cash from its subsidiaries. While the Credit Agreement, the 2025 Notes Indenture and the 2028 Notes Indenture limit the ability of Ortho&#146;s subsidiaries to incur consensual restrictions on
their ability to pay dividends or make other intercompany payments to Ortho, these limitations are subject to qualifications and exceptions. In the event that Ortho does not receive distributions from Ortho&#146;s subsidiaries, Ortho may be unable
to make required principal and interest payments on its indebtedness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The terms of the Credit Agreement, the 2025 Notes Indenture and the 2028
Notes Indenture impose restrictions that may limit Ortho&#146;s current and future operating flexibility, particularly Ortho&#146;s ability to respond to changes in the economy or Ortho&#146;s industry or to take certain actions, which could harm
Ortho&#146;s long-term interests and may limit Ortho&#146;s ability to make payments on its indebtedness. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Credit Agreement, the 2025 Notes
Indenture and the 2028 Notes Indenture contain a number of restrictive covenants that impose significant operating and financial restrictions on Ortho and may limit Ortho&#146;s ability to engage in acts that may be in Ortho&#146;s long-term best
interest, including restrictions on Ortho&#146;s ability, and the ability of Ortho&#146;s subsidiaries, to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional indebtedness and guarantee indebtedness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay dividends or make other distributions in respect of, or repurchase or redeem, capital stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prepay, redeem or repurchase certain indebtedness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make loans and investments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell, transfer or otherwise dispose of assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur liens; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into transactions with affiliates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into new lines of business or alter the businesses Ortho conducts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designate any of Ortho&#146;s subsidiaries as unrestricted subsidiaries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into agreements restricting Ortho&#146;s subsidiaries&#146; ability to pay dividends; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consolidate, merge, transfer or sell all or substantially all of Ortho&#146;s assets or the assets of
Ortho&#146;s subsidiaries. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of all of these restrictions, Ortho may be: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limited in how Ortho conducts its business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unable to raise additional debt or equity financing to operate during general economic or business downturns; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unable to compete effectively or to take advantage of new business opportunities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These restrictions might hinder Ortho&#146;s ability to grow in accordance with its strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While Ortho believes that they have not historically had this impact, these covenants could materially and adversely affect Ortho&#146;s ability to finance
its future operations or capital needs. Furthermore, they may restrict Ortho&#146;s ability to expand, pursue Ortho&#146;s business strategies and otherwise conduct Ortho&#146;s business. Ortho&#146;s ability to comply with these covenants may be
affected by circumstances and events beyond Ortho&#146;s control, such as prevailing economic conditions and changes in regulations, and Ortho cannot assure you that it will be able to comply with such covenants. These restrictions also limit
Ortho&#146;s ability to obtain future financings to withstand a future downturn in Ortho&#146;s business or the economy in general. In addition, complying with these covenants may also cause Ortho to take actions that are not favorable to holders of
its ordinary shares and may make it more difficult for Ortho to successfully execute its business strategy and compete against companies that are not subject to such restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the financial covenant in the Credit Agreement requires the maintenance of a maximum first
lien leverage ratio, which ratio will be tested when it yields more than 30% at the end of any quarter when borrowings under the Revolving Credit Facility (including swingline loans and any unreimbursed drawings under any letters of credit to the
extent not cash-collateralized but excluding any guarantees and performance or similar bonds issued under Ortho&#146;s Revolving Credit Facility) exceed $105&nbsp;million at such date. As of January 2, 2022, Ortho had no borrowings outstanding under
the Revolving Credit Facility and was therefore not subject to the financial covenant. Due to the current economic and business uncertainty resulting from the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, Ortho anticipates that
Ortho will maintain increased cash on hand in order to preserve financial flexibility and that, as a result, Ortho may continue to borrow from Ortho&#146;s Revolving Credit Facility, if needed. Ortho&#146;s ability to meet the financial covenant
could be affected by events beyond Ortho&#146;s control. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A breach of the covenants under the Credit Agreement, the 2025 Notes Indenture or the 2028
Notes Indenture could result in an event of default under the applicable indebtedness. Such a default, if not cured or waived, may allow the creditors to accelerate the related debt and may result in the acceleration of any other debt that is
subject to an applicable cross-acceleration or cross-default provision. In addition, an event of default under the Credit Agreement would permit the lenders under Ortho&#146;s Senior Secured Credit Facilities to terminate all commitments to extend
further credit under the facilities. Furthermore, if Ortho were unable to repay the amounts due and payable under Ortho&#146;s Senior Secured Credit Facilities, those lenders could proceed against the collateral securing such indebtedness. In the
event Ortho&#146;s lenders or holders of the Senior Notes accelerate the repayment of Ortho&#146;s borrowings, Ortho and its subsidiaries may not have sufficient assets to repay that indebtedness. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Despite Ortho&#146;s level of indebtedness, Ortho and its subsidiaries may still incur substantially more debt. This could further exacerbate the risks
to Ortho&#146;s financial condition described above and impair Ortho&#146;s ability to operate its business. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho and its subsidiaries may
incur significant additional indebtedness in the future. Although the Credit Agreement, the 2025 Notes Indenture and the 2028 Notes Indenture contain restrictions on the incurrence of additional indebtedness, these restrictions are subject to a
number of qualifications and exceptions, including with respect to Ortho&#146;s ability to incur additional senior secured debt. The additional indebtedness Ortho may incur in compliance with these restrictions could be substantial. These
restrictions also will not prevent Ortho from incurring obligations that do not constitute indebtedness. In addition, as of January 2, 2022, our Revolving Credit Facility provides for unused commitments of $453.7&nbsp;million (net of
$46.3&nbsp;million of outstanding letters of credit). On February&nbsp;5, 2021, we entered into a Fifth Amendment of our Senior Secured Credit Facilities (the &#147;Fifth Amendment&#148;), which increased our Revolving Credit Facility contained in
the Credit Agreement by $150.0&nbsp;million to an aggregate principal amount of $500.0&nbsp;million and extended the maturity date to February&nbsp;5, 2026, provided that such date may be accelerated subject to certain circumstances as set forth in
the Fifth Amendment. To the extent that the aggregate principal amount of the Dollar Term Loan Facility and Euro Term Loan Facility (and any Refinancing Indebtedness with respect thereto that matures on or prior to June&nbsp;30, 2025) outstanding as
of March&nbsp;31, 2025 exceeds $500.0&nbsp;million then the maturity date with respect to the Revolving Credit Facility shall be March&nbsp;31, 2025. All other terms of the Senior Secured Credit Facilities will remain substantially the same except
as otherwise amended by the Fifth Amendment. Ortho&#146;s Senior Secured Credit Facilities may be increased by an amount equal to (x)&nbsp;a dollar amount of $375.0&nbsp;million (which amount was utilized in connection with Ortho&#146;s incurrence
of the Euro Term Loan Facility), plus (y)&nbsp;an unlimited amount so long as on a pro forma basis Ortho&#146;s First Lien Net Leverage Ratio (as set forth in the Credit Agreement) does not exceed 4.00 to 1.00 plus (z)&nbsp;an amount equal to all
voluntary prepayments of term loans borrowed under the Credit Agreement and revolving loans under the Credit Agreement to the extent accompanied by a permanent reduction in the commitments therefor, subject to certain conditions. If new debt is
added to Ortho&#146;s current debt levels, the related risks that Ortho now faces would increase. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>General Risks Relating to Ortho</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The insurance Ortho maintains may not fully cover all potential exposures. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s product liability, property, business interruption, cybersecurity, casualty and other insurance may not cover all risks associated with the
operation of Ortho&#146;s business and may not be sufficient to offset the costs of any losses, lost sales or increased costs experienced during business interruptions. For some risks, Ortho may not obtain insurance if Ortho believes the cost of
available insurance is excessive related to the risks presented. As a result of market conditions, premiums and deductibles for certain insurance policies can increase substantially and, in some instances, certain insurance policies may become
unavailable or available only for reduced amounts of coverage. As a result, Ortho may not be able to renew Ortho&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
insurance policies or procure other desirable insurance on commercially reasonable terms, if at all. Losses and liabilities from uninsured or underinsured events and delay in the payment of
insurance proceeds could have a material adverse effect on Ortho&#146;s financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Terrorist acts, conflicts,
wars and natural disasters may materially adversely affect Ortho&#146;s business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a
multinational company with a large international footprint, Ortho is subject to increased risk of damage or disruption to it, its employees, facilities, partners, suppliers, distributors, resellers or customers due to terrorist acts, conflicts,
wars, adverse weather conditions, natural disasters, power outages, pandemics or other public health crises and environmental incidents, wherever located around the world. The potential for future terrorist attacks and natural disasters, the
national and international responses to such attacks and natural disasters or perceived threats to national security and other actual or potential conflicts or wars may create economic and political uncertainties. In addition, as a multinational
company with headquarters and significant operations located in the United States, actions against or by the United States could result in a decrease in demand for Ortho&#146;s products, make it difficult or impossible to deliver products to
Ortho&#146;s customers or to receive components from Ortho&#146;s suppliers, create delays and inefficiencies in Ortho&#146;s supply chain and pose risks to Ortho&#146;s employees, resulting in the need to impose travel restrictions. Any
interruption in production capability could require Ortho to make substantial capital expenditures to remedy the situation, which could negatively affect Ortho&#146;s profitability and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho is subject to work stoppages, union negotiations, labor disputes and other matters associated with its labor force, which may adversely impact
Ortho&#146;s operations and cause Ortho to incur incremental costs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho has more than 4,800 employees located around the world consisting of
commercial, supply chain, quality, regulatory and compliance, research and development and general administrative personnel. Approximately 20% of Ortho&#146;s associates globally participate in a union or works council. Historically, Ortho has not
experienced work stoppages; however, in the future, Ortho may be subject to potential union campaigns, work stoppages, union negotiations and other potential labor disputes. Additionally, future negotiations with unions or works councils in
connection with existing labor agreements may (i)&nbsp;result in significant increases in Ortho&#146;s cost of labor, (ii)&nbsp;divert management&#146;s attention away from operating Ortho&#146;s business or (iii)&nbsp;break down and result in the
disruption of Ortho&#146;s operations. The occurrence of any of the preceding outcomes could impair Ortho&#146;s ability to manufacture Ortho&#146;s products and result in increased costs and/or decreased operating results. Further, Ortho may be
subject to work stoppages at Ortho&#146;s suppliers or customers that are beyond Ortho&#146;s control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Ortho is required to make unexpected
payments to any pension plans applicable to Ortho&#146;s employees, Ortho&#146;s financial condition may be adversely affected. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of
Ortho&#146;s current and former employees participate or participated in defined benefit pension plans and Ortho assumed certain underfunded and unfunded net pension liabilities of approximately $40.0 million in relation to these plans. Several of
these plans are unfunded and, while Ortho does not believe the liabilities in relation to these plans are significant, they will need to be satisfied as they mature from Ortho&#146;s cash provided by operating activities. In jurisdictions where the
defined benefit pension plans are intended to be funded with assets in a trust or other funding vehicle, Ortho expects that, while not significant, the liabilities will exceed the corresponding assets in each of the plans. Various factors, such as
changes in actuarial estimates and assumptions (including in relation to life expectancy, discount rates and rate of return on assets), as well as actual return on assets, can increase the expenses and liabilities of the defined benefit pension
plans. The assets and liabilities of the plans must be valued from time to time under applicable funding rules and as a result Ortho may be required to increase the cash payments it makes in relation to these defined benefit pension plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho could also be required in some jurisdictions to make accelerated payments up to the full <FONT STYLE="white-space:nowrap">buy-out</FONT> deficit in
Ortho&#146;s defined benefit pension plans, which would likely be far higher than the normal ongoing funding cost of the plans. Ortho&#146;s operations and financial condition may be adversely affected to the extent that Ortho is required to
(i)&nbsp;make any additional payments to any relevant defined benefit pension plans in excess of the amounts assumed in Ortho&#146;s current projections and assumptions or (ii)&nbsp;report higher pension plan expenses under relevant accounting
rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Ortho is sued for infringing intellectual property rights of third parties, it will be costly and
time-consuming, and an unfavorable outcome in any litigation would harm Ortho&#146;s business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho cannot assure you that its activities will
not, unintentionally or otherwise, infringe on the patents or other intellectual property rights owned by others. Significant litigation regarding patent rights exists in Ortho&#146;s industry. Ortho&#146;s competitors in both the United States and
foreign countries, many of which have substantially greater resources and have made substantial investments in competing technologies, may have applied for or obtained, or may in the future apply for and obtain, patents that will prevent, limit or
otherwise interfere with Ortho&#146;s ability to make and sell its products. Ortho may spend significant time and effort and incur significant litigation costs if it is required to defend itself against intellectual property rights claims brought
against it, regardless of whether the claims have merit. If Ortho is found to have infringed on the patents or other intellectual property rights of others, Ortho may be subject to substantial claims for damages, which could materially impact its
cash flow, business, financial condition and results of operations. Ortho may also be required to cease development, use or sale of the relevant products or processes, or Ortho may be required to obtain a license on the disputed rights, which may
not be available on commercially reasonable terms, if at all, or may require Ortho to <FONT STYLE="white-space:nowrap">re-design</FONT> Ortho&#146;s products or processes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho will incur increased costs as a result of operating as a publicly traded company, and Ortho&#146;s management will be required to devote
substantial time to new compliance initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a publicly traded company, Ortho incurs additional legal, accounting and other expenses that it
did not previously incur, which may be material in amount. In addition, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act and the rules of the SEC, and the stock exchange on which Ortho&#146;s ordinary shares are
listed, have imposed various requirements on public companies. Ortho&#146;s management and other personnel will need to devote a substantial amount of time to these compliance initiatives as well as investor relations. Moreover, these rules and
regulations will increase Ortho&#146;s legal and financial compliance costs and will make some activities more time-consuming and costly. For example, Ortho expects these rules and regulations to make it more difficult and more expensive for Ortho
to obtain director and officer liability insurance, and Ortho may be required to incur additional costs to maintain the same or similar coverage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_43"></A>UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2021, Quidel Corporation (&#147;Quidel&#148;) entered into a Business Combination Agreement (the &#147;BCA&#148;) by and among Quidel,
Ortho Clinical Diagnostics Holdings plc (&#147;Ortho&#148;), Coronado Topco, Inc. (&#147;Topco&#148;), Orca Holdco, Inc. (&#147;U.S. Holdco Sub&#148;) and Laguna Merger Sub, Inc. (&#147;U.S. Merger Sub&#148;), each wholly owned subsidiaries of
Topco, and Orca Holdco 2, Inc., a wholly owned subsidiary of U.S. Holdco Sub, which provides for the acquisition of Ortho and Quidel by Topco. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following unaudited pro forma combined financial information, which is referred to in this joint proxy statement/prospectus as the unaudited pro forma financial information, is presented to illustrate the estimated effects of the transactions to be
implemented pursuant to the BCA (the &#147;Combinations&#148;) based on the historical financial statements and accounting records of Quidel and Ortho after giving effect to the Combinations, and the Combinations-related pro forma adjustments as
described in the accompanying notes to the unaudited pro forma financial information. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fiscal year of each of Quidel and Ortho ends on the Sunday
nearest December&nbsp;31 of the specified period. For ease of reference, the calendar year end dates are used herein. The following unaudited pro forma combined balance sheet was prepared based on the following historical dates: (i)&nbsp;the audited
historical consolidated balance sheet of Quidel as of December&nbsp;31, 2021 and (ii)&nbsp;the audited historical consolidated balance sheet of Ortho as of December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma combined statement of income for the fiscal year ended December&nbsp;31, 2021 was prepared based on the following historical
periods: (i)&nbsp;the audited historical consolidated statement of income of Quidel for the year ended December&nbsp;31, 2021 and (ii)&nbsp;the audited historical consolidated statement of operations of Ortho for the year ended December&nbsp;31,
2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma combined financial information has been prepared to reflect the Combinations and is provided for illustrative
purposes only. The unaudited pro forma combined statements of income assume that the Combinations occurred on January&nbsp;1, 2021, the beginning of the earliest period presented, but do not necessarily reflect what Topco&#146;s results of
operations would have been had the Combinations been completed on January&nbsp;1, 2021, or for any future or historical period. The unaudited pro forma combined balance sheet assumes that the Combinations occurred on December&nbsp;31, 2021, but does
not necessarily reflect what Topco&#146;s financial position would have been had the Combinations been completed on December&nbsp;31, 2021, or for any future or historical period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma financial information was prepared using the acquisition method of accounting with Quidel treated as the accounting acquirer and,
therefore, the historical basis of Quidel&#146;s assets and liabilities was not affected by the Combinations. The pro forma financial statements should be read in conjunction with the information contained in the sections entitled &#147;The
Combinations,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations of Ortho&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations of Quidel&#148;
of this joint proxy statement/prospectus and the historical consolidated financial statements and related notes appearing elsewhere in, or incorporated in, this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this joint proxy statement/prospectus, Quidel has not completed the detailed valuation studies necessary to arrive at the final estimates of
the fair market value of the Ortho assets to be acquired and the liabilities to be assumed and the related allocations of purchase price, nor has it identified any adjustments necessary to conform Ortho to Quidel&#146;s accounting policies except
for the ones described in the accompanying notes. The acquisition method of accounting is dependent upon certain valuations that are provisional and subject to change. Accordingly, the pro forma adjustments in the unaudited pro forma combined
financial information are preliminary based upon available information and made solely for the purpose of providing these unaudited pro forma combined financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma financial information has not been adjusted to give effect to certain expected financial benefits of the Combinations, such as revenue
synergies, tax savings and cost synergies, or the anticipated costs to achieve these benefits, including the cost of integration activities. The unaudited pro forma financial information does not purport to represent what the actual consolidated
results of operations or the consolidated financial position of Topco would have been had the Combinations occurred on the dates indicated, nor is it necessarily indicative of Topco&#146;s future consolidated results of operations or consolidated
financial position. The actual financial position and results of operations will differ, potentially significantly, from the pro forma amounts reflected herein due to a variety of factors, including access to additional information, changes in value
not currently identified and changes in operating results following the date of the unaudited pro forma financial information. Accordingly, actual adjustments to Topco&#146;s financial statements following the acquisition could
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
differ, perhaps materially, from those reflected in the unaudited pro forma condensed combined financial information because the purchase price is subject to changes in the Quidel Share price on
the acquisition date, and assets and liabilities acquired and share-based compensation awards will be recorded at their respective fair values on the date the acquisition is consummated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA COMBINED BALANCE SHEET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS OF DECEMBER&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical<BR>Quidel</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical<BR>Ortho after<BR>reclassification<BR>adjustments<BR>(Note 4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>accounting<BR>adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other<BR>transaction<BR>accounting<BR>adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Combined</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 802,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 309,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,742,946</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5a</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">735,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5a</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 104,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">377,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">635,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5b</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,440,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,674,046</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">735,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,512,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Property, plant and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">791,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5c</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,140,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Marketable securities, non-current</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,700,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5d</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,611,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">879,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5e</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,578,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5f</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,658</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5g</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,430,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,363,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,649,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">735,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,178,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="28"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:9.5pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 101,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 181,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 282,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accrued payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5h</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Deferred consideration</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Current portion of borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5h</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">578,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,009,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating lease <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Deferred <FONT STYLE="white-space:nowrap">consideration&#151;non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Contingent consideration&#151;non-current</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Long-term borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,186,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">735,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,989,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Employee-related obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">453,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5f</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">525,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5j</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5j</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,425,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5k</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,817,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5l</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Retained earnings (accumulated deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,649,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,971,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,863,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5m</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,541,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,929,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,019,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,359,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,430,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,363,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,649,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">735,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,178,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying &#147;Notes to Unaudited Pro Forma Combined Financial Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA COMBINED STATEMENT OF INCOME </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEAR ENDED DECEMBER&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical<BR>Quidel after<BR>reclassification<BR>adjustments<BR>(Note 4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical<BR>Ortho after<BR>reclassification<BR>adjustments<BR>(Note 4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>accounting<BR>adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other<BR>transaction<BR>accounting<BR>adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Combined</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,698,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,042,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,741,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,006,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6a</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,495,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">414,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6b</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition and integration costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6c</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">906,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(264,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">815,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(146,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6d</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6d</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(173,658</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax indemnification expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,706</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(199,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227,456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249,408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">588,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6e</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6e</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 704,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(54,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(168,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 452,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic earnings per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted earnings per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in basic per share calculation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6f</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in diluted per share calculation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6f</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying &#147;Notes to Unaudited Pro Forma Combined Financial Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
   <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Description of the proposed Combinations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;22, 2021, Quidel entered into the BCA by and among Quidel, Ortho, Topco, U.S. Holdco Sub and U.S. Merger Sub, each wholly owned subsidiaries of Topco, and Orca Holdco 2, Inc., a wholly owned subsidiary of U.S. Holdco Sub, which
provides for the acquisition of Ortho and Quidel by Topco. The Combinations are expected to be implemented by way of (i)&nbsp;a scheme of arrangement to be undertaken by Ortho under Part 26 of the UK Companies Act 2006 (the &#147;Ortho
Scheme&#148;), pursuant to which each issued and outstanding share of Ortho (the &#147;Ortho Shares&#148;) will be acquired by a nominee of Topco (or, if such nominee holds the Ortho Shares today, transferred within the nominee), such that Ortho
will become a wholly owned subsidiary of Topco, and (ii)&nbsp;a merger (the &#147;Quidel Merger&#148;) of U.S. Merger Sub with and into Quidel immediately following consummation of the Ortho Scheme, with Quidel surviving the merger as a wholly owned
subsidiary of Topco. At the effective time of the Ortho Scheme (the &#147;Ortho Effective Time&#148;), each Ortho Share, other than Ortho Shares held by Ortho in treasury, will be acquired by a nominee (or, if such nominee holds the Ortho Shares
today, transferred within the nominee) on behalf and for the benefit of Topco in exchange for 0.1055 shares (the &#147;Ortho Exchange Ratio&#148;) of common stock of Topco (&#147;Topco Shares&#148;) and $7.14 in cash (collectively, the &#147;Ortho
Scheme Consideration&#148;). At the effective time of the Quidel Merger (the &#147;Quidel Effective Time&#148; and together with the Ortho Effective Time, the &#147;Effective Times&#148;), each share of common stock of Quidel (each, a &#147;Quidel
Share&#148;), other than Quidel Shares held by Quidel, Ortho or U.S. Merger Sub, will be converted into the right to receive one Topco Share (the &#147;Quidel Exchange Ratio&#148;) (the &#147;Quidel Merger Consideration&#148; and together with the
Ortho Scheme Consideration, the &#147;Combination Consideration&#148;). Topco will apply to list the Topco Shares to be issued in the Combinations on the Nasdaq Global Select Market (&#147;Nasdaq&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Ortho Effective Time, each option to subscribe for Ortho Shares (each, an &#147;Ortho Stock Option&#148;), whether vested or unvested, that is
outstanding immediately prior the Ortho Effective Time will cease to represent an option to acquire Ortho Shares and will be converted into (a)&nbsp;an option to purchase Topco Shares (each, a &#147;Topco Stock Option&#148;) on the same terms and
conditions as were applicable to such Ortho Stock Option immediately prior to the Ortho Effective Time, except as adjusted by the BCA, (b)&nbsp;with respect to the portion of such Ortho Stock Option that is vested as of the Ortho Effective Time, the
right to receive payment, in cash, equal to the cash consideration payable in respect of the Ortho Shares subject to the vested portion of such Ortho Stock Option and (c)&nbsp;with respect to the portion of such Ortho Stock Option that is not vested
as of the Ortho Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Ortho Shares subject to the unvested portion of such Ortho Stock Option when it vests in accordance with its terms. The
number of Topco Shares subject to each such Topco Stock Option will be equal to the product (rounded down to the nearest whole number) obtained by multiplying (i)&nbsp;the number of Ortho Shares subject to such Ortho Stock Option immediately prior
to the Ortho Effective Time by (ii)&nbsp;the Ortho Exchange Ratio, and each such Topco Stock Option will have an exercise price per share (rounded up to the nearest whole cent) equal to (x)&nbsp;the exercise price per Ortho Share of such Ortho Stock
Option immediately prior to the Ortho Effective Time divided by (y)&nbsp;the Ortho Exchange Ratio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Ortho Effective Time, each award of restricted
stock, restricted stock units or other similar rights or awards granted under an Ortho stock plan and relating to Ortho Shares (any such award, an &#147;Ortho Equity Right&#148; and such awards together with the Ortho Stock Options, the &#147;Ortho
Stock Awards&#148;) that is outstanding immediately prior to the Ortho Effective Time will cease to relate to or represent a right to receive Ortho Shares and will be converted into an award of restricted stock, restricted stock units or other
similar rights or awards, as applicable, relating to Topco Shares (a &#147;Topco Equity Right&#148;) of the same type and on the same terms and conditions as were applicable to the corresponding Ortho Equity Right immediately prior to the Ortho
Effective Time. Upon the subsequent vesting of any portion of such Ortho Equity Right, such portion of the Ortho Equity Right shall also be entitled to a right to receive payment, in cash, equal to the cash consideration in respect of the Ortho
Shares subject to the unvested portion of the Ortho Equity Right when it vests in accordance with its terms. The number of Topco Shares covered by each such Topco Equity Right will be equal to the product (rounded to the nearest whole number)
obtained by multiplying (i)&nbsp;the number of Ortho Shares subject to such Ortho Equity Right immediately prior to the Ortho Effective Time by (ii)&nbsp;the Ortho Exchange Ratio. See estimated preliminary purchase price discussed further in Note 3.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, all of Quidel&#146;s outstanding share-based compensation will be replaced with similar Topco awards as described in the section entitled
&#147;<I>The Business Combination Agreement&#151;Treatment of Quidel Equity Awards</I>.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the BCA, which was unanimously
approved by the board of directors of each of Quidel and Ortho, Quidel and Ortho are entering into a business combination under Topco, a new holding company, in which Ortho will be acquired for total consideration of approximately $4.3&nbsp;billion
(which is based on the March 4, 2022 closing price of $99.57 per Quidel </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Share, as described in further detail below), including $1.74&nbsp;billion of cash, funded through cash on the balance sheet and expected incremental borrowings. Such consideration was equal to
$6.0&nbsp;billion based on the December&nbsp;22, 2021 closing price of the Quidel Shares, and is subject to change based on the price of a Quidel Share. Topco is also expected to be subject to Ortho&#146;s existing debt of $2.2&nbsp;billion. If the
Combinations are completed, Ortho shareholders are expected to own approximately 38% of Topco on a fully diluted basis and Quidel stockholders are expected to own approximately 62% of Topco on a fully diluted basis, based on the respective
capitalizations of Quidel and Ortho as of the date the parties entered into the BCA. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Basis of pro forma presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited pro forma combined financial information was prepared in accordance with Article&nbsp;11 of the SEC&#146;s <FONT
STYLE="white-space:nowrap">Regulation&nbsp;S-X.</FONT> The historical financial statements were prepared in accordance with U.S. GAAP and presented in thousands of U.S. dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Combinations will be accounted for as a business combination using the acquisition method of accounting under the provisions of ASC Topic 805,
&#147;Business Combinations&#148; (&#147;ASC 805&#148;), and using the fair value concepts defined in ASC&nbsp;Topic&nbsp;820, &#147;Fair Value Measurements&#148; (&#147;ASC 820&#148;). ASC 820 defines the term &#147;fair value&#148; and sets forth
the valuation requirements for any asset or liability measured at fair value, expands related disclosure requirements and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop fair value measures. Fair value
is defined in ASC 820 as &#147;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#148; This is an exit price concept for the valuation of
the asset or liability. In addition, market participants are assumed to be buyers and sellers in the principal (or the most advantageous) market for the asset or liability. Many of these fair value measurements can be highly subjective, and it is
possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. Under ASC&nbsp;805, all assets acquired and liabilities assumed are recorded at
their acquisition date fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value estimates were determined based on preliminary discussions between Quidel&#146;s and Ortho&#146;s
management, due diligence efforts, and information available in public filings. The allocation of the aggregate Combination Consideration used in the preliminary unaudited pro forma combined financial information is based on preliminary estimates.
The estimates and assumptions are subject to change as of the Effective Times. The final determination of the allocation of the aggregate Combination Consideration will be based on the actual tangible assets, intangible assets, deferred tax assets,
deferred tax liabilities and liabilities of Ortho at the Effective Times. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For pro forma purposes, the valuation of consideration transferred is based
on, among other things, the closing price of Quidel Shares on March 4, 2022 of $99.57 per share. This is used for pro forma purposes only. The consideration transferred will ultimately be based on the price of Quidel Shares at the Effective Times of
the Combinations and could materially change. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant accounting policies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined financial information has been compiled in a manner consistent with the accounting policies adopted by Quidel. Based on the
procedures performed to date, the accounting policies of Ortho appear to be similar in all material respects to Quidel&#146;s accounting policies. Upon completion of the Combinations, Quidel will perform a detailed review of Ortho&#146;s accounting
policies. As a result of that review, Quidel may identify additional differences between the accounting policies of the two companies that, when conformed, could have a material impact on the consolidated financial statements of Topco. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Preliminary Purchase Price </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho shareholders will
receive 0.1055 Topco Shares and $7.14 in cash per Ortho Share as purchase consideration in connection with the Combinations as discussed above; however, because Quidel is the accounting acquirer and Ortho is the acquiree for accounting purposes, the
unaudited pro forma financial information reflects the estimated fair value of the equity to be issued, as represented by the market price of Quidel Shares, to Ortho shareholders. The total purchase consideration to be received by Ortho shareholders
will be based on the fair value of the equity deemed to be issued at the Effective Times of the Combinations. The preliminary purchase consideration below reflects the estimated fair value of equity issued, which is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
based on the March 4, 2022 closing price of Quidel Shares of $99.57 per share. The amount of total purchase consideration below is not necessarily indicative of the actual consideration that will
be transferred at the Effective Times of the Combinations to Ortho shareholders as a result of potential changes to the price per Quidel Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
preliminary estimated purchase consideration and estimated fair value of Ortho&#146;s net assets acquired as if the Combinations closed on December 31, 2021 is presented as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands, except value per share data and Ortho Exchange Ratio)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Ortho Shares subject to exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ortho Exchange Ratio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Topco Shares to be issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value per Quidel Share as of March 4, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">99.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated value of stock consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,487,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of replacement stock awards (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash consideration (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,742,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated purchase consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,280,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents estimated fair value of replacement stock options, restricted stock units and restricted stock
outstanding as of December&nbsp;31, 2021 that is attributable to <FONT STYLE="white-space:nowrap">pre-combination</FONT> service. Management is in the process of evaluating the expected impact of replacement stock awards subsequent to the
Combinations. The portion of the fair value of the replacement stock awards attributable to post-combination service will be recognized as compensation expense based on the vesting terms of the replacement stock awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents cash consideration to be paid to outstanding Ortho shareholders and to vested Ortho Stock Option
holders at the Ortho Effective Time. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash&nbsp;Per&nbsp;share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Ortho Shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,690,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested Ortho Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,742,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimate of consideration expected to be transferred reflected in these unaudited pro forma combined financial
statements does not purport to represent what the actual consideration transferred will be when the Combinations are consummated. For purposes of these unaudited pro forma combined financial statements, the market price of Quidel Shares on March 4,
2022 and outstanding Ortho Shares as of December&nbsp;31, 2021 was used to calculate the estimate of consideration expected to be transferred. However, the fair value of equity securities issued as the consideration transferred will be measured
using the market price of Quidel Shares and outstanding Ortho Shares on the closing date of the Combinations. An increase/decrease of 10% in the price of Quidel Shares would increase/decrease the total consideration by $248.8&nbsp;million, which
would be reflected in these unaudited pro forma combined financial statements as an increase or decrease to goodwill. The estimated fair value of replacement equity awards is subject to change until the Effective Times of the Combinations due to
equity awards vesting, grants or forfeitures. The estimated cash consideration was calculated using outstanding Ortho Shares and vested Ortho Stock Options as of December&nbsp;31, 2021. The cash consideration at the closing of the Combinations will
fluctuate due to changes in outstanding shares and vesting, grants or forfeitures of Ortho Stock Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the acquisition method of accounting, the
Ortho assets and liabilities will be recorded at fair value at the date of the completion of the Combinations and combined with the historical carrying amount of the assets and liabilities of Quidel. The pro forma adjustments are preliminary and
based on estimates of the fair value and useful lives of the assets as of December&nbsp;31, 2021 and have been prepared by Quidel management and Ortho management to illustrate the estimated effect of the Combinations. The unaudited pro forma
financial information does not include any fair value adjustments associated with the assets and liabilities of Ortho with the exception of the fair value of long-term borrowings, inventories, and intangible assets, as Quidel and Ortho management
have based the preliminary purchase accounting on the assumption that these historical carrying values approximate their fair values as of December 31, 2021. The purchase accounting is dependent upon certain valuation and other analyses that have
not yet been completed. Accordingly, the preliminary purchase accounting is subject to further adjustments as additional information becomes available and as additional analyses and final valuations are conducted at and following the completion of
the Combinations. The final </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
valuations could differ materially from the preliminary valuations presented below and, accordingly, no assurances can be provided regarding the preliminary purchase accounting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the preliminary purchase accounting consideration to the identifiable assets acquired and liabilities assumed of Ortho, with
the excess of the purchase consideration issued over the fair value of Ortho&#146;s net assets recorded as goodwill (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 309,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">791,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,274,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,480,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,756,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(181,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123,867</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(189,538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,257</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,254,702</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee related obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(525,891</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,475,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated purchase consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,280,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Reclassifications </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel identified certain reclassification adjustments that were necessary to conform Ortho&#146;s financial statement presentation to Quidel&#146;s financial
statement presentation. For purposes of the pro forma financial statements, Ortho&#146;s historical balance sheet and statements of operations have been adjusted to reflect these reclassifications (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Ortho Reclassifications</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>As of
December&nbsp;31, 2021</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical<BR>Ortho</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Reclassification<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical<BR>Ortho after<BR>Reclassification<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">309,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">309,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">257,200<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4a</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4a</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">791,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">791,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4b</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">879,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">879,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4c</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4c</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4b, 4d</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4d</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,363,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,363,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">181,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">181,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(299,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4e,4f,4g,4i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4e</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4f</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4g</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4h</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4h,4i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">578,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">578,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4j</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,186,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4k</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,186,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee-related obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4l</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4l</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4j,4m</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4k,4m</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,425,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,425,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,971,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,971,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,363,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,363,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Ortho Reclassifications</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>For the year
ended December&nbsp;31, 2021</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B><br><B>Ortho</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Reclassification</B><br><B>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B><br><B>Ortho after</B><br><B>Reclassification</B><br><B>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,042,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,042,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,006,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,006,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, marketing and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">555,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(555,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4n,4o</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4n,4q</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4o</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition and integration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4p</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4p,4q</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(146,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(146,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax indemnification expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4r</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4r</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(199,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(199,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(54,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(54,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following items represent certain reclassifications to conform the presentation of the historical financial
statement line items of Ortho to the expected financial statement line items of Quidel (in thousands): </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho Balance Sheet items: </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4a</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other current assets of $139,400 have been reclassified to Prepaid expenses and other current assets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4b</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other assets of $30,355 have been reclassified to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4c</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Deferred income taxes of $9,700 have been reclassified to Deferred tax asset; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4d</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other assets of $67,845 have been reclassified to Other <FONT STYLE="white-space:nowrap">non-current</FONT>
assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4e</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payroll and compensation-related accruals of $123,867 have been reclassified from Accrued liabilities to
Accrued payroll and related expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4f</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Income tax accruals of $7,252 have been reclassified from Accrued liabilities to Income tax payable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4g</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Operating lease liabilities of $13,443 have been reclassified from Accrued liabilities to Operating lease
liabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4h</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Deferred revenue of $34,500 has been reclassified to Other current liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4i</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other miscellaneous liabilities of $155,038 have been reclassified from Accrued liabilities to Other current
liabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4j</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Non-current</FONT> operating lease liabilities of $17,257 have been
reclassified from Other liabilities to Operating lease <FONT STYLE="white-space:nowrap">liabilities&#151;non-current;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4k</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Financing lease liabilities of $700 have been reclassified from Long-term borrowings to Other <FONT
STYLE="white-space:nowrap">non-current</FONT> liabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4l</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Deferred income taxes of $72,100 have been reclassified to Deferred tax liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4m</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other liabilities of $61,643 have been reclassified to Other
<FONT STYLE="white-space:nowrap">non-current</FONT> liabilities; </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho Statements of Operations items: </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4n</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the year ended December&nbsp;31, 2021, Selling, marketing and administrative expenses of $258,600 related
to sales and marketing was reclassified to Sales and marketing; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the year ended December&nbsp;31, 2021, Selling, marketing and administrative expenses of $296,400 related
to general and administrative was reclassified to General and administrative; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4p</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the year ended December 31, 2021, Other operating expenses, net of $6,978 related to costs incurred related
to the pending Combinations have been reclassified to Acquisition and integration costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4q</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the year ended December&nbsp;31, 2021, Provision for credit losses, referred to as bad debt expense by
Quidel, of $720 was reclassified from Other operating expense, net to Sales and marketing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4r</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the year ended December&nbsp;31, 2021, Loss on extinguishment of debt of $50,300 was reclassified from
Other expense, net to Loss on extinguishment of debt. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following items represent certain reclassifications and conforming
adjustments to conform to the expected financial statement line items of Quidel following the Combinations (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Quidel Reclassifications</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>For the
year ended December&nbsp;31, 2021</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B><br><B>Quidel</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Reclassification</B><br><B>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B><br><B>Quidel after</B><br><B>Reclassification</B><br><B>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,698,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,698,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4s</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4t</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4s,&nbsp;4t</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition and integration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">906,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">906,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,706</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4u,&nbsp;4v</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4u</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4v</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,706</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,706</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 704,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 704,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quidel Statements of Income items: </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4s</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the year ended December&nbsp;31, 2021, Amortization expense related to cost of sales of $7,372 was
reclassified to Amortization of intangible assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4t</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the year ended December&nbsp;31, 2021, Amortization expense related to sales and marketing of $20,067 was
reclassified to Amortization of intangible assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4u</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the year ended December&nbsp;31, 2021, Interest expense, net of $5,808 was reclassified from Interest and
other expense, net to Interest expense, net; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4v</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the year ended December&nbsp;31, 2021, Other income, net of $102 was reclassified from Interest and other
expense, net to Other expense, net. </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Transaction Accounting Adjustments for Pro Forma Combined Balance Sheet </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following represents an explanation of the various adjustments to the unaudited pro forma combined balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>(a)<B> Cash and cash equivalents </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Represents a
net decrease in cash of $1.0 billion due to $1.7&nbsp;billion of aggregate cash consideration paid to Ortho shareholders under the BCA and $15.0&nbsp;million of estimated financing costs associated with expected borrowings offset by
$750.0&nbsp;million from proceeds to be received from Quidel&#146;s presumed borrowings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>(b)<B> Inventories </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Represents an adjustment of $68.9 million to Inventories to reflect the estimated step-up in fair value of Ortho&#146;s inventory acquired, valued using a
comparative sales method. The calculated value is preliminary and subject to change and could vary materially from the final purchase price allocation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>(c)<B> Property, plant and equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel has not yet determined the fair value of property, plant and equipment to be acquired; therefore, the historical carrying value has been used in the
preliminary purchase price allocation reflected in the unaudited pro forma combined balance sheet. The fair value could be materially different from the historical carrying value. This assertion remains contingent upon receiving additional
information and performing procedures to calculate the fair value of property, plant and equipment. No adjustment was made to the unaudited pro forma combined statements of income, but any difference between the fair value and the historical
carrying value would have a direct impact on future earnings via depreciation expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>(d)<B> Goodwill </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reflects adjustments to remove $573.6&nbsp;million of historical Ortho goodwill and recognize preliminary estimated goodwill of $2.3&nbsp;billion. Goodwill
represents the excess of the purchase price over the preliminary fair value of Ortho&#146;s underlying net tangible and identifiable intangible assets net of liabilities. The goodwill created in the Combinations is not expected to be deductible for
tax purposes and is subject to material revision as the purchase price allocation is completed. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>(e)<B> Intangible Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Represents adjustments to record the preliminary estimated fair value of Ortho&#146;s intangible assets of approximately $3.5&nbsp;billion, which is an
increase of $2.6&nbsp;billion over Ortho&#146;s book value of intangible assets prior to the Combinations. The acquired identifiable intangible assets are expected to be comprised of definite-lived customer relationships, developed technology, and
trade names related to various Ortho products. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of intangible assets and related amortization are preliminary and are based on
management&#146;s assessment of comparable industry transactions. As discussed above, the amount that will ultimately be allocated to identifiable intangible assets and the related amount of amortization may differ materially from this preliminary
allocation. In addition, the periods the amortization impacts will ultimately be based upon the periods in which the associated economic benefits or detriments are expected to be derived, or where appropriate, based on the use of a straight-line
method. Therefore, the amount of amortization following the Combinations may differ significantly between periods based upon the final value assigned and amortization methodology used for each identifiable intangible asset. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>(f)<B> Deferred tax asset and liability </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Represents the removal of $9.7&nbsp;million of Ortho deferred tax asset and the removal of $72.1&nbsp;million of Ortho deferred tax liability previously
recorded. After giving effect to the estimated impact of the Combinations and the release of Ortho&#146;s U.S. valuation allowance of $381.1 million, $34.9&nbsp;million of deferred tax assets, $268.3&nbsp;million of U.S. net deferred tax liabilities
and $257.6&nbsp;million of foreign deferred tax liabilities were recorded. This estimate of deferred tax assets and liabilities is preliminary and is subject to change based upon the final determination of fair value of assets acquired and
liabilities assumed, which could be materially different. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>(g)<B> Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Represents the adjustment to remove $2.7&nbsp;million of capitalized financing costs related to Ortho&#146;s revolving line of credit in connection with
the fair value adjustment for purchase accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>(h)<B> Accrued payroll and related expenses and Other current liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Represents the pro forma adjustments to Accrued payroll and related expenses and Other current liabilities of $15.1&nbsp;million and $92.7&nbsp;million,
respectively. Refer to the tables below which reflect the components of Accrued payroll and related expenses and Other current liabilities impacted by pro forma adjustments, which reflect retention and transaction costs expected to be incurred and
not previously recognized in the historical balance sheets (in thousands): </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quidel retention costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ortho retention costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase to accrued payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quidel transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;45,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ortho transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase to other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 92,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>(i)<B> Current and Long-term borrowings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Represents the net pro forma increase to long-term borrowings of $803.7&nbsp;million. Refer to the table below which reflects the components of debt impacted
by pro forma adjustments (in thousands): </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ortho debt fair value adjustment <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 42,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Removal of Ortho original issue discount and deferred financing fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Quidel borrowings <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing fees related to new Quidel borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in Long-term borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">803,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the estimated fair value adjustment increase of $42.0&nbsp;million related to Ortho&#146;s
historical long-term borrowings. The fair value of Ortho&#146;s debt was determined based on trades as reported by a third-party bond pricing service. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents presumed issuance of new Quidel debt for the purposes of financing a portion of the cash
consideration discussed in Note 5a. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>(j)<B> Preferred and Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preferred redeemable shares are redeemable for no consideration under the BCA and have been removed as part of the Combinations adjustments. The par value
of Ortho historical common stock was immaterial. The net adjustment to common stock reflects the par value for the issuance of Topco Shares in exchange for Ortho Shares calculated by multiplying the number of shares to be exchanged (see Note&nbsp;3)
by the $0.001 par value of Topco Shares (in thousands, except Ortho Exchange Ratio and per share data): </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Ortho Shares outstanding at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ortho Exchange Ratio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Topco Shares issued in connection with the Combinations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Par value per Topco Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net adjustment for par value of Topco Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>(k)<B> Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Represents the elimination of Ortho historical additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, as well as reflecting the excess of fair
value over par value for the issuance of common stock and the fair value of acquired stock awards (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Combinations stock consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,487,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Ortho Stock Awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: par value of Topco Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of historical Ortho additional <FONT STYLE="white-space:nowrap">paid-in</FONT>
capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,425,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net adjustment to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 111,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>(l)<B> Accumulated other comprehensive loss </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Represents the elimination of $43.7&nbsp;million of historical accumulated other comprehensive loss of Ortho. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>(m)<B> Retained earnings (accumulated deficit) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Represents the pro forma adjustment to retained earnings of $1.9&nbsp;billion. Refer to the table below which reflects the components of retained earnings
(accumulated deficit) impacted by pro forma adjustments (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of Ortho&#146;s historical accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,971,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quidel transaction costs (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ortho transaction costs (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quidel retention costs (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ortho retention costs (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net adjustment to retained earnings (accumulated deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,863,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects an estimate of Quidel&#146;s and Ortho&#146;s <FONT STYLE="white-space:nowrap">non-recurring</FONT>
transaction-related costs. Transaction costs related to the Combinations include advisory, banking, and legal fees. These amounts will be expensed as incurred and are also reflected in the unaudited pro forma combined statement of income for the
year ended December&nbsp;31, 2021 (See Note 6(c)). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects an estimate of Quidel&#146;s and Ortho&#146;s non-recurring retention-related costs. Retention costs
related to the Combinations include employee compensation charges. These amounts will be expensed as incurred and are also reflected in the unaudited pro forma combined statement of income for the year ended December&nbsp;31, 2021 (See Note 6(c)).
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Transaction Accounting Adjustments for Pro Forma Combined Statement of Income </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following outlines the various adjustments to the unaudited pro forma combined statement of income. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <B>Cost of revenue</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reflects an adjustment to record an
estimate of $68.9&nbsp;million in the year ended December&nbsp;31, 2021 resulting from the unwinding of the estimated step-up in fair value of inventory acquired. This adjustment will not affect the combined statement of income beyond twelve months
after the acquisition date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <B>Amortization of intangible assets</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reflects the adjustments to record new amortization expense based on the fair value of the preliminary estimate of acquired intangible assets, which represents
the portion of the purchase price allocated to Ortho&#146;s definite-lived developed technology, customer relationships and trade names. The preliminary estimated useful lives is 15&nbsp;years for developed technology and trade names and 20 years
for customer relationships. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2021, represents a net increase of $62.8&nbsp;million from the elimination of historical
Ortho intangible asset amortization of $133.4&nbsp;million and the recognition of pro forma amortization expense of $196.2&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization expense has been calculated on a preliminary basis, using the straight-line method over the
estimated useful lives. The effect of a 10% increase or decrease in preliminary estimated fair value would result in an increase or decrease of amortization expense of $19.6&nbsp;million for the year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) <B>Acquisition and integration costs</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reflects
adjustments to record estimates of $92.7&nbsp;million, $27.1&nbsp;million and&nbsp;$12.8 million in the year ended December 31, 2021 for nonrecurring transaction-related costs, retention-related costs and an estimate of post-combination expense
related to the acceleration of employee unvested stock awards, respectively, not already incurred in the historical statements of operations for the year ended December&nbsp;31, 2021 for Quidel and Ortho in connection with the Combinations. The
transaction-related costs will include advisory, banking, and legal fees and the retention-related costs will include employee compensation charges. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
<B>Interest expense </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Represents the assumed net increase in interest expense related to Quidel&#146;s new borrowings of $750.0&nbsp;million, the
elimination of the amortization of Ortho deferred financing fees and debt discounts, and the amortization of the premium associated with the fair value adjustment to debt as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended</B><br><B>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of the amortization of deferred financing fees and discounts (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of premium associated with the fair value adjustment to debt (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense related to the issuance of new Quidel debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of financing fees associated with new Quidel debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an adjustment to eliminate the historical amortization of Ortho deferred financing fees and
discounts recognized through interest expense. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the annual incremental amortization of the premium related to the fair value adjustment increase of
$42.0&nbsp;million related to Ortho&#146;s historical long-term debt. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) <B>Income tax expense</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Represents the income tax effect of unaudited pro forma combined statement of income adjustments related to the Combinations using a federal and state combined
statutory tax rate of 23% estimated based upon the federal and state combined statutory tax rates. Because the adjustments contained in this unaudited pro forma combined financial information are based on estimates, the effective tax rate will
likely vary from the effective rate in periods subsequent to the Combinations. Adjustments to established deferred tax assets and liabilities as well as the recognition of additional deferred tax assets and liabilities upon detailed analysis of the
acquired assets and assumed liabilities may occur in conjunction with the finalization of the purchase accounting, and these items could be material. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) <B>Earnings per share </B> </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma
condensed combined basic and diluted earnings per share calculations are based on the combined basic and diluted weighted average shares, after giving effect to the Ortho Exchange Ratio and the Quidel Exchange Ratio. The historical basic and diluted
weighted average shares of Ortho are assumed to be replaced by the shares expected to be issued by Topco to effect the Combinations, as follows (in thousands, except share and per share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>For&nbsp;the&nbsp;year&nbsp;ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">452,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical Quidel basic weighted-average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Topco Shares to Ortho shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma basic weighted-average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma basic earnings per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>For&nbsp;the&nbsp;year&nbsp;ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">452,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical Quidel diluted weighted-average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Topco Shares to Ortho shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilutive impact of Ortho Stock Awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma diluted weighted-average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma diluted earnings per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPARATIVE HISTORICAL UNAUDITED PRO FORMA COMBINED PER SHARE INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below are earnings and book value per share data for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel on a historical basis for the year ended December&nbsp;31, 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho on a historical basis for the year ended December&nbsp;31, 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pro forma per share information as of and for the year ended December&nbsp;31, 2021. The pro forma per share
information shows the effect of the Combinations from the perspective of a holder of Topco Shares. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma per
share information below is presented for illustrative purposes only. It does not purport to represent the historical results or what Topco&#146;s financial position would have been if the Combinations occurred on the date assumed and it is not
necessarily indicative of Topco&#146;s future results or financial position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quidel Per Share Information </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>For&nbsp;the&nbsp;year&nbsp;ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic earnings per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted earnings per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho Per Share Information </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>For&nbsp;the&nbsp;year&nbsp;ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Topco Pro Forma Per Share Information </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>For&nbsp;the&nbsp;year&nbsp;ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic earnings per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted earnings per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value per share <SUP STYLE="font-size:85%; vertical-align:top">(a)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pro forma book value per share = Pro forma total equity / pro forma shares outstanding </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPARATIVE MARKET PRICE AND DIVIDEND INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the closing market price per share of Quidel Shares and Ortho Shares as reported on Nasdaq. In each case, the prices are given:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as of December&nbsp;22, 2021 (the last trading day prior to the public announcement of the execution of the BCA);
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as of [&#9679;], 2022 (the latest practicable trading date prior to the date of this joint proxy
statement/prospectus). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are urged to obtain
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> market prices for Quidel Shares and Ortho Shares before making your decision with respect to the approval of the BCA. Quidel Shares are listed on Nasdaq under
the symbol &#147;QDEL.&#148; Ortho shares are listed on Nasdaq under the symbol &#147;OCDX.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price per share of Quidel Shares and Ortho
Shares could change significantly and may not be indicative of the value of Topco Shares once they start trading on or after the date of completion of the Combinations. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quidel</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ortho</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;22, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#9679;], 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#9679;]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#9679;]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above table shows only historical comparisons. These comparisons may not provide meaningful information to Ortho
shareholders in determining whether to approve the Ortho Scheme or the Quidel stockholders in determining whether to approve the Quidel Merger. You are urged to review carefully the other information contained in this joint proxy
statement/prospectus or incorporated by reference into this joint proxy statement/prospectus in considering whether to approve the Ortho Scheme or Quidel Merger, as applicable. Although the exchange ratios are fixed, the market price of Quidel
Shares and Ortho Shares will fluctuate between the date of this joint proxy statement/prospectus and the Effective Times of the Combinations. No assurance can be given concerning the market price of Quidel Shares and Ortho Shares before or on the
date of completion of the Combinations, or the market price of Topco Shares on or after the date of completion of the Combinations. See the section entitled &#147;Where You Can Find More Information&#148; of this joint proxy statement/prospectus.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither Quidel nor Ortho have
historically paid any dividends to their respective shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_44"></A>SCHEME PROPOSAL AND THE ORTHO SHAREHOLDER MEETINGS&#151;
EXPLANATORY STATEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In compliance with Section&nbsp;897 of the UK Companies Act 2006) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#9679;], 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>To the holders of Ortho
Shares and, for information only, to the holders of options or awards under any Ortho Clinical Diagnostics Holdings plc employee benefit plan providing for equity or equity-based compensation. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RECOMMENDED ACQUISITION OF ORTHO AND QUIDEL BY TOPCO </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_45">
</A>Introduction </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The following section of this joint proxy statement/prospectus explains, among other things, the effect of the Ortho Scheme
and, together with the further information contained elsewhere in this joint proxy statement/prospectus, constitutes the explanatory statement in respect of the Ortho Scheme as required by section 897 of the UK Companies Act. Accordingly, in
addition to the information contained in the following section of this joint proxy statement/prospectus, your attention is drawn to the further information contained elsewhere in this joint proxy statement/prospectus and you are advised to read this
joint proxy statement/prospectus in full. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2021, it was announced that Ortho entered into the BCA with Quidel, Topco, U.S.
Merger Sub, U.S. Holdco Sub and U.S. Holdco Sub 2, pursuant to which, among other things, the entire issued and to be issued share capital of Ortho will be transferred to GTU Ops Inc. (a Computershare entity) or another company mutually acceptable
to Quidel and Ortho and falling within Section&nbsp;67(6) of the Finance Act 1986 (the &#147;DR Nominee&#148;) (or, if the DR Nominee holds the Ortho Shares today, transferred within the DR Nominee) on behalf of Topco in exchange for the aggregate
transaction deliverables (the &#147;Ortho Combination&#148;) by means of a court-sanctioned scheme of arrangement under Part 26 of the UK Companies Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your attention is drawn to the section entitled &#147;The Combinations&#148; of this joint proxy statement/prospectus, which contains, among other things,
(i)&nbsp;information on the reasons for and expected benefits of the Combinations and (ii)&nbsp;the unanimous recommendation by the Ortho board of directors to Ortho shareholders to vote in favor of the resolutions to be proposed at the Ortho Court
Meeting and the Ortho General Meeting. The Ortho Scheme is set out in full in the section entitled &#147;The Ortho Scheme&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_46"></A>The Ortho Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Ortho Combination is to be effected by means of the Ortho Scheme, a UK court-sanctioned scheme of arrangement between Ortho and the holders of Ortho Shares (i)&nbsp;in issue at the date of this document, (ii)&nbsp;issued after the date of this joint
proxy statement/prospectus and prior to the Voting Record Time (if any), and (iii)&nbsp;issued at or after the Voting Record Time and prior to the Scheme Record Time (if any), either on terms that the original or any subsequent holders thereof shall
be bound by or in respect of which the holders thereof shall have agreed in writing to be bound, by in each case, remaining in issue at the Scheme Record Time but excluding any Excluded Ortho Shares (as defined herein) and whose names appear in the
register of members of Ortho at the Scheme Record Time (&#147;Scheme Shares&#148; and the holders thereof, &#147;Scheme Shareholders&#148;), under Part 26 of the UK Companies Act. Implementation of the Ortho Combination requires (i)&nbsp;the
approval of the Ortho Scheme by the Ortho shareholders at the Ortho Court Meeting (the &#147;Scheme Proposal&#148;) and (ii)&nbsp;the approval of the proposal to (a)&nbsp;authorize the Ortho board of directors to take all action necessary or
appropriate for carrying the Ortho Scheme into effect and (b)&nbsp;adopt the Ortho Articles in substitution for, and to the exclusion of, Ortho&#146;s existing articles of association in order to facilitate the Combinations by the Ortho shareholders
at the Ortho General Meeting (the &#147;Scheme Implementation Proposal&#148;). The Ortho Scheme also requires the sanction of the Court. The Ortho Scheme is set out in full in the section entitled &#147;The Ortho Scheme&#148; of this joint proxy
statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Ortho Scheme is to enable the DR Nominee, on Topco&#146;s behalf, to acquire (or transfer within, as the case
may be) the entire issued and to be issued share capital of Ortho. This is to be achieved by the DR Nominee, on Topco&#146;s behalf, acquiring (or transferring within itself) the Ortho Shares held by the Scheme Shareholders at [&#9679;] [a.m./ p.m.]
(Eastern Standard Time) and [6:00] p.m. (London time) on the Business Day immediately prior to the Ortho Effective Date (&#147;Scheme Record Time&#148;), in return for which the Scheme Shareholders will receive the cash consideration and the share
deliverable for their Scheme Shares on the basis set out in the Ortho Scheme. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Ortho Combination is completed: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all Ortho Shares will be acquired by (or held within, as the case may be) the DR Nominee, on Topco&#146;s behalf;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders of Ortho Shares as of the Scheme Record Time will, on the terms set out in the Ortho Scheme, have the
right to receive for each Ortho Share held by them at such time the scheme deliverables, consisting of an amount equal to $7.14 in cash plus 0.1055 shares of common stock, par value $0.001 per share, of Topco. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco Shares shall be admitted to trading on Nasdaq under the trading symbol &#147;[&#9679;]&#148; no later than the time at which the Ortho Scheme shall be
delivered to the Registrar and become effective. The Ortho Scheme consideration of 0.1055 Topco Shares and $7.14 in cash per Ortho Share had an implied value of $24.75 per Ortho Share based upon the closing price of Quidel Shares on
December&nbsp;21, 2021. Please refer to the opinions of Perella Weinberg and J. P. Morgan in the sections entitled &#147;The Combinations&#151;Opinion of Perella Weinberg Partners LP as Financial Advisor to Quidel&#148; and &#147;The
Combinations&#151;Opinion of J.P. Morgan Securities LLC as Financial Advisor to Ortho,&#148; for further details of how such implied value was calculated and analysed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No fractional Topco Shares will be issued pursuant to the Ortho Scheme to any holder of Ortho Shares. Each holder of Ortho Shares whom would otherwise have
been entitled to receive a fraction of a Topco Share shall receive from the Exchange Agent, in lieu thereof, cash (without interest) in an amount representing such holder&#146;s proportionate interest in the net proceeds from the sale (after
deduction of the expenses of the sale, including commissions, taxes and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> transaction costs of the Exchange Agent) by the Exchange Agent on behalf of all
such holders of Topco Shares which would otherwise be issued (the &#147;Excess Topco Shares&#148;). The sale of the Excess Topco Shares by the Exchange Agent shall be executed on Nasdaq, and shall be executed in round lots to the extent practicable.
Until the net proceeds of such sale or sales have been distributed to such former holders of Ortho Shares, the Exchange Agent shall hold such proceeds in trust for such holders (the &#147;Fractional Interests Trust&#148;). Topco shall pay all
commissions, transfer taxes and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> transaction costs incurred in connection with such sale of the Excess Topco Shares. The Exchange Agent shall
determine the portion of the Fractional Interests Trust to which each holder of Ortho Shares shall be entitled, if any, by multiplying the amount of the aggregate net proceeds comprising the Fractional Interests Trust by a fraction, the numerator of
which is the amount of fractional Topco Shares to which such former holder of Ortho Shares is entitled and the denominator of which is the aggregate amount of fractional Topco Shares to which all holders of Ortho Shares are entitled. As soon as
practicable after the determination of the amount of cash, if any, to be paid to holders of Ortho Shares in lieu of fractional Topco Shares, the Exchange Agent shall make available such amounts to such former holders of Ortho Shares, without
interest and subject to any required tax withholding. Any such sale shall be made within ten Business Days or such shorter period as may be required by applicable law as soon as reasonably practicable after the Ortho Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Ortho Court Meeting, Quidel will irrevocably commit to Topco and, as may be required, the Court (on terms satisfactory to each of them) to make
available to Topco the cash consideration due pursuant to the Ortho Scheme, such that Quidel shall deposit, or cause to be deposited, in each case on behalf of Topco, with the Exchange Agent, for the benefit of Scheme Shareholders, for exchange
through the Exchange Agent, sufficient cash to make delivery of the cash consideration pursuant to the Ortho Scheme (the &#147;Cash Portion&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_47">
</A>Conditions to Complete the Combinations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The respective obligations of Ortho, Quidel, Topco, U.S. Merger Sub, U.S. Holdco Sub and U.S. Holdco Sub 2
to complete the Combinations are subject to the satisfaction (or, to the extent permitted by applicable law, waiver by such parties) of the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the receipt of the required Quidel stockholder approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the receipt of the required Ortho shareholder approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sanction of the Ortho Scheme by the Court and delivery to the Registrar of the Ortho Scheme Order with due
confirmatory receipt; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the absence of any judgments, orders, decisions, writs, injunctions, decrees, stipulations, legal or
arbitration awards, rulings or other findings or agency requirements promulgated, issued or entered by or with (or settlement or consent agreement subject to) any court or other governmental authority of any competent jurisdiction that remains in
effect and prohibits, restrains, prevents or makes illegal the completion of the Combinations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the absence of any applicable law enacted, entered, promulgated, adopted, enacted, issued or entered into by or
with or enforced by any governmental authority or any United States or <FONT STYLE="white-space:nowrap">non-United</FONT> States commission, board, agency or body that is not a governmental authority but is charged with the supervision or regulation
of brokers, dealers, securities underwriting or trading, stock exchanges, commodities exchanges, electronic communication networks, insurance companies or agents, investment companies or investment advisers, including Nasdaq, that remains in effect
and prohibits, restrains, prevents or makes illegal completion of the Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Statement of which this joint proxy statement/prospectus forms a part shall have been declared
effective by the SEC under the Securities Act, and shall not be the subject of any stop order which is in effect suspending the effectiveness of the Registration Statement or any proceedings for that purpose; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Topco Shares to be delivered to Ortho shareholders and Quidel stockholders in connection with the Combinations
being authorized for listing on Nasdaq, subject to official notice of issuance; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any waiting period (and any extensions thereof) applicable to the Combinations and any agreement (including any
timing agreement) with any governmental entity not to consummate the Combinations shall have, in each case, expired, been terminated, or been obtained, as applicable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligation of Ortho and Topco to complete the Combinations is subject to the satisfaction (or, to the extent permitted by applicable law, waiver by Ortho)
of the following additional conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Quidel having performed, in all material respects, all obligations required to be performed by Quidel at or
prior to the closing of the Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the representations and warranties of Quidel being true and correct to the extent specified in the BCA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no material adverse effect with respect to Quidel shall have occurred since December&nbsp;22, 2021; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the receipt of a certificate from an officer of Quidel confirming, on behalf of Quidel, the satisfaction of the
conditions set forth in the immediately preceding three clauses. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligation of Quidel to complete the Combinations is subject to
the satisfaction (or, to the extent permitted by applicable law, waiver by Quidel) of the following additional conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ortho having performed, in all material respects, all of its obligations required to be performed by it at or
prior to the closing of the Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the representations and warranties of Ortho being true and correct to the extent specified in the BCA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no material adverse effect with respect to Ortho shall have occurred since December&nbsp;22, 2021; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the receipt of a certificate from an officer of Ortho confirming the satisfaction of the conditions set forth
in the immediately preceding three clauses. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho Scheme can only become effective if all conditions to the Combinations, including
the required Ortho shareholder approvals and the sanction of the Court, have been satisfied or (to the extent permitted by law) waived. The Ortho Scheme will become effective upon a copy of the Ortho Scheme Order being delivered to the Registrar.
Subject to the satisfaction or waiver of the conditions to the Combinations, including the sanction of the Ortho Scheme by the Court, the Ortho Effective Time is expected to occur in the first half of 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_48"></A>Shareholder Meetings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before
the Court&#146;s sanction can be sought, the Ortho Scheme requires, among other things, approval of the Ortho Scheme terms and the Ortho Scheme by Scheme Shareholders at the Ortho Court Meeting. The Scheme Proposal must be approved by a simple
majority in number of Ortho ordinary shareholders present and voting (and entitled to vote), either remotely (via the Virtual Meeting Platform) or by proxy, representing at least 75% in value of the Ortho Shares in respect of which a vote has been
cast. Approval of the Scheme Proposal is required to consummate the Combinations. Ortho shareholders are also being asked to consider and approve the Scheme Implementation Proposal and the <FONT STYLE="white-space:nowrap">Non-Binding</FONT> Advisory
Proposal to Approve Certain Compensation Arrangements (as defined below) at the Ortho General Meeting. If approved, the Scheme Implementation Proposal will (i)&nbsp;authorize the Ortho board of directors to take all action necessary or appropriate
for carrying the Ortho Scheme into effect and (ii)&nbsp;adopt the Ortho Articles in substitution for, and to the exclusion of, Ortho&#146;s existing articles of association in order to facilitate the Combinations. The Scheme Implementation Proposal
will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proposed as a special resolution at the Ortho General Meeting, which means that the Scheme Implementation Proposal must be approved by at least 75% of the votes cast by Ortho ordinary
shareholders present and voting (and entitled to vote), either remotely (via the Virtual Meeting Platform) or by proxy at the Ortho General Meeting. Approval of the Scheme Implementation Proposal is required to consummate the Combinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Dodd-Frank Act and Rule <FONT STYLE="white-space:nowrap">14a-21(c)</FONT> under the Exchange Act require that Ortho seek a
<FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory vote from Ortho shareholders to approve the compensation that may be paid or become payable to Ortho&#146;s named executive officers in connection with the Combinations and the agreements
or understandings pursuant to which such compensation may be paid or become payable, as disclosed in the table entitled &#147;Interests of Certain Persons in the Combinations (Ortho)&#151;Golden Parachute Compensation&#148; of this joint proxy
statement/prospectus, including the associated narrative discussion (the <FONT STYLE="white-space:nowrap">&#147;Non-Binding</FONT> Advisory Proposal to Approve Certain Compensation Arrangements&#148;). The
<FONT STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Proposal to Approve Certain Compensation Arrangements will be proposed as an ordinary resolution at the Ortho General Meeting, which means that the
<FONT STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Proposal to Approve Certain Compensation Arrangements must be approved by a simple majority of the votes cast by Ortho ordinary shareholders present and voting (and entitled to vote),
either remotely (via the Virtual Meeting Platform) or by proxy at the Ortho General Meeting. Unlike the Scheme Proposal and Scheme Implementation Proposal, the approval of the <FONT STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Proposal to
Approve Certain Compensation Arrangements is not required to consummate the Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notices of both the Ortho Court Meeting and the Ortho General
Meeting are set out at the beginning of this joint proxy statement/prospectus. Entitlement to attend and vote at these meetings and the number of votes which may be cast will be determined by reference to the register of members of Ortho at the
Voting Record Time. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IF THE SCHEME OF ARRANGEMENT BECOMES EFFECTIVE, IT WILL BE BINDING ON ALL SCHEME SHAREHOLDERS, IRRESPECTIVE OF
WHETHER OR NOT THEY ATTENDED OR VOTED AT THE ORTHO COURT MEETING OR THE GENERAL MEETING. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Date, Time, Place and Purpose of the Ortho Court
Meeting </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho Court Meeting will be held at [&#9679;], United States at [&#9679;] [a.m./ p.m.] (Eastern Standard Time) and [&#9679;]
[a.m./ p.m.] (London time) on [&#9679;], 2022 for Scheme Shareholders on the register of members as at the Voting Record Time to consider and, if thought fit, approve the Ortho Scheme. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Ortho Court Meeting, voting will be by poll and each Scheme Shareholder present remotely (via the Virtual Meeting Platform) or by proxy will be
entitled to one vote for each Ortho Share held as at the Voting Record Time. The approval required at the Ortho Court Meeting is a simple majority in number of the Ortho ordinary shareholders present and voting (and entitled to vote) remotely (via
the Virtual Meeting Platform) or by proxy, representing at least 75% in value of the Ortho Shares in respect of which a vote has been cast. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOU ARE STRONGLY URGED TO SIGN AND RETURN YOUR BLUE FORM OF PROXY FOR THE ORTHO COURT MEETING AS SOON AS POSSIBLE. THE COMPLETION AND RETURN
OF THE FORMS OF PROXY WILL NOT PREVENT YOU FROM REMOTELY ATTENDING, SUBMITTING QUESTIONS AND VOTING AT EITHER THE ORTHO COURT MEETING OR THE ORTHO GENERAL MEETING, OR ANY ADJOURNMENT THEREOF, IN EACH CASE VIA THE VIRTUAL MEETING PLATFORM, IF YOU ARE
ENTITLED TO AND WISH TO DO SO. HOLDERS OF THE BENEFICIAL INTERESTS IN ORTHO SHARES WILL BE ABLE TO SUBMIT WRITTEN QUESTIONS AND OBSERVE THE ORTHO COURT MEETING REMOTELY VIA THE VIRTUAL MEETING PLATFORM. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Date, Time, Place and Purpose of the Ortho General Meeting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho General Meeting will be held at [&#9679;], United States at [&#9679;] [a.m./ p.m.] (Eastern Standard Time) and [&#9679;] [a.m./ p.m.] (London time)
on [&#9679;], 2022 for Ortho shareholders on the register of members as at the Voting Record Time to consider and, if thought fit, approve the Scheme Implementation Proposal as a special resolution and the
<FONT STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Proposal to Approve Certain Compensation Arrangements as an ordinary resolution. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the
Ortho General Meeting, voting on each of the Scheme Implementation Proposal and the <FONT STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Proposal to Approve Certain Compensation Arrangements will be by poll and each Ortho shareholder present
remotely (via </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Virtual Meeting Platform) or by proxy will be entitled to one vote for each Ortho ordinary share held as at the Voting Record Time. The approval required for the Scheme Implementation
Proposal to be passed is at least 75% of the votes validly cast on such resolution remotely (via the Virtual Meeting Platform) or by proxy. The approval required for the <FONT STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Proposal to
Approve Certain Compensation Arrangements to be passed is a simple majority of the votes validly cast on such resolution remotely (via the Virtual Meeting Platform) or by proxy. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOU ARE STRONGLY URGED TO SIGN AND RETURN YOUR WHITE FORM OF PROXY FOR THE GENERAL MEETING AS SOON AS POSSIBLE. THE COMPLETION AND RETURN OF
THE FORMS OF PROXY WILL NOT PREVENT YOU FROM REMOTELY ATTENDING, SUBMITTING QUESTIONS AND VOTING AT EITHER THE ORTHO COURT MEETING OR THE GENERAL MEETING, OR ANY ADJOURNMENT THEREOF, IN EACH CASE VIA THE VIRTUAL MEETING PLATFORM, IF YOU ARE ENTITLED
TO AND WISH TO DO SO. HOLDERS OF THE BENEFICIAL INTERESTS IN ORTHO ORDINARY SHARES WILL BE ABLE TO SUBMIT WRITTEN QUESTIONS AND OBSERVE THE ORTHO COURT MEETING REMOTELY VIA THE VIRTUAL MEETING PLATFORM. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adoption of the Ortho Articles </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho Shares
issued after the Scheme Record Time will not be subject to the Ortho Scheme. In order to ensure that the DR Nominee, on Topco&#146;s behalf, acquires the entire issued and to be issued share capital of Ortho, it is therefore proposed that, pursuant
to the Scheme Implementation Proposal, the Ortho Articles be adopted in substitution for, and to the exclusion of, Ortho&#146;s existing articles of association and pursuant to the Ortho Articles, Ortho Shares issued after the Scheme Record Time (if
any), other than to Topco or its nominees, will be automatically acquired by the DR Nominee, on behalf of Topco, subject to the same terms as under the Ortho Scheme. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is also proposed that, pursuant to the Scheme Implementation Proposal, the Ortho Articles be adopted to ensure that any Ortho Shares issued at or after the
Voting Record Time but prior to the Scheme Record Time will also be acquired as if they were Scheme Shares subject to the Ortho Scheme. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Promptly after
the time at which the Ortho Scheme shall be delivered to the Registrar and become effective the Ortho Shares shall be <FONT STYLE="white-space:nowrap">de-listed</FONT> from Nasdaq and the DR Nominee, on Topco&#146;s behalf, shall be the sole
shareholder in Ortho. The adoption of Ortho Articles shall reflect Ortho&#146;s status as a sole shareholder company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advisory Approval of the <FONT
STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Proposal to Approve Certain Compensation Arrangements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is proposed that, as an ordinary
resolution to be proposed at the Ortho General Meeting, the Ortho shareholders vote on the approval (on a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory basis) of the compensation that may be paid or become payable to Ortho&#146;s
named executive officers in connection with the Combinations and the agreements or understandings pursuant to which such compensation may be paid or become payable, as disclosed in the table entitled &#147;Interests of Certain Persons in the
Combinations (Ortho)&#151;Golden Parachute Compensation&#148; of this joint proxy statement/prospectus, including the associated narrative discussion. Failure to obtain this <FONT STYLE="white-space:nowrap">non-binding</FONT> approval will not
prevent the consummation of the Combinations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recommendation of the Ortho Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho board of directors has unanimously approved the BCA and the actions required and contemplated therein, including the Combinations, and determined
that such actions are advisable and in the best interests of Ortho and its shareholders. The Ortho board of directors unanimously recommends that Ortho shareholders vote &#147;<B>FOR</B>&#148; the Scheme Proposal at the Ortho Court Meeting,
&#147;<B>FOR</B>&#148; the Scheme Implementation Proposal at the Ortho General Meeting and &#147;<B>FOR</B>&#148; the <FONT STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Proposal to Approve Certain Compensation Arrangements at the Ortho
General Meeting. See the section entitled &#147;The Combinations&#151;Ortho Reasons for the Combinations and Recommendation of the Ortho Board of Directors&#148; of this joint proxy statement/prospectus for a more detailed discussion of the Ortho
board of directors&#146; recommendation with respect to the Scheme Proposal, the Scheme Implementation Proposal and the <FONT STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Proposal to Approve Certain Compensation Arrangements, including
with respect to the opinion provided to Ortho by J. P. Morgan as more fully described below in the section &#147;The Combinations&#151;Opinion of J.P. Morgan Securities LLC as Financial Advisor to Ortho.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Entitlement to Vote at the Ortho Shareholder Meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold Ortho Shares registered in your own name as of the Voting Record Time, you are entitled to attend the Ortho Court Meeting and the Ortho General
Meeting to vote either remotely or to appoint another person or persons as your proxy or proxies to attend and vote on your behalf, in accordance with the procedures further outlined in this joint proxy statement/prospectus. You are strongly
encouraged to appoint the Chair of the Ortho Shareholder Meetings as your proxy. Only directors of Ortho will be permitted to attend in person. If any other person is appointed as proxy, he or she will not be permitted to attend the Ortho
Shareholder Meetings in person, but will be able to attend, submit questions and vote at the Ortho Shareholder Meetings remotely via the Virtual Meeting Platform. Holders of the beneficial interests in Ortho Shares will be able to submit written
questions and observe the Ortho Shareholder Meetings remotely via the Virtual Meeting Platform. Please see the section entitled &#147;Explanatory Statement&#151;Beneficial Holders&#148; of this joint proxy statement/prospectus for further
information in respect of such holdings and interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Ortho Shares who hold their Ortho Shares indirectly through a broker, bank, trust
company or other nominee must rely on the procedures of such broker, bank, trust company or other nominee in order to assert the rights of a holder of Ortho Shares to vote at the Ortho Shareholder Meetings. If this applies to you, we encourage you
to consult your broker, bank, trust company or other nominee as soon as possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a beneficial holder but not the legal holder of Ortho Shares
then, as a matter of English law, your name is not entered in Ortho&#146;s register of members. Accordingly, if you wish to attend and vote directly (<I>i.e.</I>, in your own name) at the Ortho Court Meeting or Ortho General Meeting in respect of
all or part of your holding, you must become a registered holder of Ortho Shares by arranging for the completion of a stock transfer form by the applicable registered holder in respect of the Ortho Shares that you wish to be transferred into your
name, pay any related UK stamp duty, if applicable, and send the completed stock transfer form and related documentation (as applicable) to Ortho&#146;s transfer agent, Computershare Investor Services at Investor Services at 462 South 4th Street,
Suite 1600, Louisville, KY, 40202, United States, prior to the Voting Record Time. Beneficial holders who wish to attend and vote directly at the Ortho Court Meeting or Ortho General Meeting should send such stock transfer form in respect of their
Ortho Shares to permit processing to be completed by Computershare prior to the Voting Record Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If either Ortho Shareholder Meeting is adjourned,
only those Ortho shareholders on the register of members at [&#9679;] [a.m./ p.m.] (Eastern Standard Time) and [6:00] [a.m./ p.m.] (London time) on the date which is two Business Days before the adjourned meeting will be entitled to attend and vote.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quorum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The presence at the Ortho General
Meeting of two qualifying persons entitled to vote on the business to be transacted at the Ortho General Meeting, present remotely (via the Virtual Meeting Platform) or by proxy, shall be a quorum. A &#147;qualifying person&#148; means (a)&nbsp;an
individual who is a shareholder of Ortho, (b)&nbsp;a person authorized to act as the representative of a corporation in relation to the Ortho General Meeting or (c)&nbsp;a person appointed as a proxy of a shareholder in relation to the meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_49"></A>The Ortho Directors and the Effect of the Ortho Scheme on their Interests </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of the interests of Ortho directors in the share capital of Ortho and awards in respect of such share capital, are set out in the section entitled
&#147;Interests of Certain Persons in the Combinations (Ortho)&#148; of this joint proxy statement/prospectus. Scheme Shares held by the Ortho directors at the Scheme Record Time will be subject to the Ortho Scheme. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In common with the other participants who hold Ortho Equity Rights, the Ortho directors who hold Ortho Equity Rights will be able to receive Ortho Shares to
the extent that such awards vest and are exercised prior to the effective time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is proposed that, as an ordinary resolution to be proposed at the
Ortho General Meeting, the Ortho shareholders vote on the approval (on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis) of the compensation that may be paid or become payable to its named executive officers in connection with
the Combinations and the agreements and understandings pursuant to which such compensation may be paid or become payable, as disclosed in the table entitled &#147;Interests of Certain Persons in the Combinations (Ortho)&#151;Golden Parachute
Compensation&#148; of this joint proxy statement/prospectus, including the associated narrative discussion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as set out in the section entitled &#147;Interests of Certain Persons in the Combinations
(Ortho)&#148; of this joint proxy statement/prospectus and the provisions of the BCA applicable to directors as described in the section entitled &#147;The Business Combination Agreement&#148; of this joint proxy statement/prospectus, the effect of
the Ortho Scheme on the interests of Ortho directors does not differ from its effect on the interests of any other Ortho shareholder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_50">
</A>Sanction of the Ortho Scheme by the Court </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the UK Companies Act, the Ortho Scheme also requires the sanction of the Court. The Court Sanction
Hearing is currently expected to be held in the first half of 2022. Scheme Shareholders are entitled to remotely attend the Court Sanction Hearing, should they wish to do so, in person or through counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following sanction of the Ortho Scheme by the Court, the Ortho Scheme will become effective in accordance with its terms upon a copy of the Court Order being
delivered to the Registrar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the Ortho Scheme becoming effective, it will be binding on all Scheme Shareholders holding Scheme Shares at the Scheme
Record Time, irrespective of whether or not they attended or voted in favor of, or against, the Ortho Scheme at the Ortho Court Meeting or in favor of, or against, or withheld their vote on the Scheme Implementation Proposal at the Ortho General
Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Ortho Scheme does not become effective by September&nbsp;22, 2022 (or, if extended, January&nbsp;22, 2023, as further described in the
section entitled &#147;The Business Combination Agreement&#151;Termination&#148; of this joint proxy statement/prospectus), the BCA may be terminated by either Quidel or Ortho, and the Ortho Scheme may not become effective. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_51"></A>Solicitation of Proxies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho
will bear its own costs and expenses incurred in connection with the filing, printing and mailing of this joint proxy statement/prospectus to Ortho shareholders and the retention of any information agent or other service provider in connection with
the Combinations. This proxy solicitation is being made by Ortho on behalf of the Ortho board of directors. Ortho has hired MacKenzie Partners, Inc. to assist in the solicitation of proxies at an estimated total cost to Ortho of approximately in the
range of $75,000 to $125,000, <I>plus </I>reimbursement of reasonable additional costs and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses. In addition to this mailing, proxies may be solicited
by directors, officers or employees of Ortho or its affiliates in person or by telephone or electronic transmission. None of the directors, officers or employees will be directly compensated for such services. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_52"></A>Listings, Dealings, Delisting and Settlement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delisting of Ortho Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date,
entitlements to Scheme Shares will be cancelled, and share certificates in respect of Scheme Shares held in certificated form will cease to be valid documents of title and should be destroyed or, at the request of Topco, delivered up to the DR
Nominee, or to any person appointed by Topco to receive the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the consummation of the Combinations, Ortho will become a wholly owned
subsidiary of Topco following Topco&#146;s contribution of the depositary receipts in the Ortho Shares and deferred shares to U.S. Holdco Sub (and, at least two days following such contribution, further transfer such depositary interests and
deferred shares to U.S. Holdco Sub 2) and it is intended that Ortho will be <FONT STYLE="white-space:nowrap">re-registered</FONT> as a private limited company under the applicable provisions of the UK Companies Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is intended that the last day for dealings in Ortho Shares on Nasdaq will be the last Business Day before the effective time or the day of the Ortho
Effective Time. It is intended that, prior to the Ortho Effective Time, applications be made to delist the Ortho Shares from Nasdaq and terminate the registration of the Ortho Shares under the Exchange Act to take effect promptly following the Ortho
Effective Time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Listing and Dealings in Topco Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Topco Shares to be delivered pursuant to the Ortho Scheme will be delivered credited as fully paid and
<FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Topco Shares will rank pari passu in all respects with the Topco Shares in issue on the Effective Date, including the right to receive and retain dividends or other distributions on the
common stock of Topco declared, made or paid after the closing date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Closing Date, the Topco Shares will be listed on Nasdaq, and are not expected to be listed on any
other securities exchange. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Settlement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the Ortho Scheme becoming effective, settlement of the scheme deliverables to which any Ortho shareholder is entitled under the Ortho Scheme will be
effected in accordance with paragraph 5 of the Ortho Scheme which is set out in full in the section entitled &#147;The Ortho Scheme&#148; of this joint proxy statement/prospectus, as summarized below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Settlement of Cash Consideration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Settlement of
the cash consideration due pursuant to the Ortho Scheme (as well as any cash entitlement in respect of fractional shares) will be effected by cheque. All cheques will be in U.S. dollars. Payments made by cheque will be payable to the Scheme
Shareholder(s) concerned. Cheques will be despatched by mail (or by international post or airmail, if outside the United States) to the address appearing on Ortho&#146;s share register at the Scheme Record Time (or, in the case of joint holders, to
the address of that joint holder whose name stands first in the said register in respect of such joint holding). <B>If Ortho shareholders would like to receive payments in cash (by way of wire transfer), please contact the Exchange Agent at
[</B>&#9679;<B>] and complete and submit the form which will be provided in accordance with the instructions thereon on or before the date falling [5] Business Days prior to the Court Sanction Hearing. Please note there will be a $[100] fee which
will be deducted at the Ortho shareholder&#146;s expense for each wire transfer.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All cheques shall be despatched and, in respect of Ortho
shareholders who have requested that the cash consideration to which they are entitled is paid in cash, all wire transfers shall be instructed for settlement, on or as soon as reasonably practicable following the Ortho Scheme becoming effective.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Settlement of Share Consideration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco
shall issue to each Scheme Shareholder the number of Topco Shares to which such Scheme Shareholder is entitled under the Ortho Scheme, and shall credit, or cause to be credited through the facilities of the Exchange Agent, such Topco Shares in
book-entry form to the respective account of such Scheme Shareholder on the Exchange Agent&#146;s records or the participants in DTC&#146;s electronic book-entry clearing and settlement system, as soon as reasonably practicable following the
Effective Date (and in any event no later than two Business Days following the Effective Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fractions of Topco Shares will not be allotted to Scheme
Shareholders. Instead, Scheme Shareholders shall receive, in lieu of such fractional entitlements, cash in an amount in U.S. dollars (rounded down to the nearest cent) equal to such fractional amount multiplied by the aggregate net proceeds from the
sale of such fractional entitlements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of Topco Shares to which each Scheme Shareholder is entitled under the Scheme shall be subject to
adjustment for any share split, consolidation or other action impacting the number of Topco Shares to be received under the Ortho Scheme. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All documents and remittances sent to, from or on behalf of Ortho shareholders will be sent entirely at their own risk. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Beneficial Holders </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at the date of this joint
proxy statement/prospectus, Ortho has two registered holders of Ortho Shares, being GTU Ops Inc., in respect of Computershare, and Cede&nbsp;&amp; Co., in respect of The Depository Trust Company, (together the &#147;Registered Holders&#148;) who
hold the relevant Ortho Shares in their names ultimately on behalf of the beneficial holders of such Ortho Shares (the &#147;Beneficial Holders&#148;). The information set forth in this section is of importance to Beneficial Holders, as the Scheme
Shares (in respect of the Ortho Court Meeting) and Ortho Shares (in respect of the Ortho General Meeting) are held by the Registered Holders on behalf of the Beneficial Holders. As at the date of this joint proxy statement/prospectus, the Scheme
Shareholders (in respect of the Ortho Court Meeting) and Ortho Shareholders (in respect of the Ortho General Meeting) are GTU Ops Inc. and Cede&nbsp;&amp; Co. although this position might change at the time of the relevant Ortho Shareholder Meetings
if a Beneficial Holder takes their Ortho Shares out of depositary arrangements and into their own name as described further in this joint proxy statement/prospectus and below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial Holders (being holders of a book entry, beneficial or otherwise controlling voting and economic
interest in an Ortho Share, the legal ownership of which is held on their behalf by a Registered Holder, and whose names do not therefore appear in the register of members of Ortho) will not be entitled to attend, speak at, vote at or otherwise
participate in either the Ortho Court Meeting or the Ortho General Meeting (whether in person or remotely via the Virtual Meeting Platform, save in respect of an ability to submit questions and observe via the Virtual Meeting Platform as described
in this joint proxy statement/prospectus and in the Virtual Meeting Guide prepared by Lumi). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial Holders as of [&#9679;] [a.m./ p.m.] (Eastern
Standard Time) and [&#149;] p.m. (London time) on [&#149;] 2022 (the &#147;Beneficial Holder Record Time&#148;) will be entitled to instruct their brokers, investment firms, clearing houses and similar entities that own securities on behalf of the
Beneficial Holders (the &#147;Intermediaries&#148;) how to vote the Scheme Shares and Ortho Shares in which they have a beneficial interest by completing and signing the materials provided to them in accordance with the instructions provided to them
by their Intermediary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial Holders should note that only proxies deposited by Scheme Shareholders and Ortho Shareholders (that is, individuals or
entities whose names appear on the register of members of Ortho maintained by Computershare, acting as Ortho&#146;s registrar, as registered holders of Scheme Shares and Ortho Shares) will be recognised and acted upon at the Ortho Court Meeting and
the Ortho General Meeting. If Scheme Shares or Ortho Shares are listed in an account statement provided to a Beneficial Holder by an Intermediary, those Scheme Shares or Ortho Shares will, in all likelihood, be registered in the name of the
Intermediary (or its agent). As at the date of this joint proxy statement/prospectus all such Scheme Shares and Ortho Shares are registered under the name of the Registered Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notice of the Ortho Court Meeting and Ortho General Meeting, the blue and white forms of proxy, the Virtual Meeting Guide and any other instructions as to
voting from the Intermediaries (collectively, the &#147;Meeting Materials&#148;) will be sent to each Beneficial Holder by or on behalf of the Intermediary that holds Scheme Shares or Ortho Shares on their behalf. Intermediaries will typically use a
service company to forward the Meeting Materials. The majority of Intermediaries now delegate responsibility for obtaining shareholder instructions from clients to [&#9679;]. [&#9679;] typically mails a Voting Instruction Form in lieu of the Form of
Proxy. <B>BENEFICIAL HOLDERS ARE REQUESTED TO VOTE IN ACCORDANCE WITH THE INSTRUCTIONS SET FORTH IN THE VOTING INSTRUCTION FORMS PROVIDED TO THEM BY THEIR INTERMEDIARIES.</B> [&#9679;] will provide aggregate Scheme Shareholder and Ortho Shareholder
voting instructions to the relevant Intermediary (or its tabulation agent), which will tabulate the results for the Ortho Court Meeting and the Ortho General Meeting and provide appropriate instructions with respect to the voting of the Scheme
Shares and Ortho Shares to be represented at the Ortho Court Meeting and the Ortho General Meeting or the reconvening of any adjournment or postponement thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applicable securities regulatory policy requires Intermediaries, on receipt of materials that seek voting instructions from Beneficial Holders indirectly, to
seek voting instructions from Beneficial Holders in advance of meetings of security holders. Every Intermediary has its own mailing procedures and provides its own return instructions, which should be carefully followed by Beneficial Holders in
order to ensure that their wishes are expressed at the Ortho Court Meeting and the Ortho General Meeting or the reconvening or any adjournment or postponement thereof. Often, the form of proxy supplied to a Beneficial Holder by its broker is
identical to the form of proxy provided to Scheme Shareholders and Ortho Shareholders; however, its purpose is limited to instructing the relevant Scheme Shareholder and Ortho Shareholder that is an Intermediary on how to vote on behalf of the
Beneficial Holder. In the ordinary course, Beneficial Holders&#146; securities can only be voted by their Intermediaries in accordance with the Beneficial Holders&#146; instructions. Beneficial Holders should carefully follow the instructions
provided by their Intermediaries in order to ensure that their wishes in respect of the Scheme Shares and Ortho Shares that they control are reflected at the Ortho Court Meeting and Ortho General Meeting or the reconvening of or any adjournment or
postponement thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial Holders will not be entitled to attend, speak at, vote at or otherwise participate in either the Ortho Court Meeting or
the Ortho General Meeting (whether in person or remotely via the Virtual Meeting Platform). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial Holders as of the Beneficial Holder Record Time
will however be entitled to instruct their broker or other Intermediary how to vote the Scheme Shares and Ortho Shares in which they have a beneficial interest by completing and signing the materials provided to them in accordance with the
instructions provided to them by their broker or other Intermediary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial Holders will also be able to submit questions ahead of and observe (but
not participate in) the Ortho Court Meeting and the Ortho General Meeting remotely via the Virtual Meeting Platform, as described in this joint proxy statement/prospectus and the Virtual Meeting Guide prepared by Lumi. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial Holders are entitled to switch from being a Beneficial Holder to a Scheme Shareholder and/or
Ortho Shareholder (so that the Scheme Shares and/or Ortho Shares previously held by the relevant Intermediary will be held directly by them). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_53">
</A>Overseas Ortho Shareholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The availability of the Ortho Scheme and the transaction deliverables to Ortho shareholders in a jurisdiction outside
the United States may be affected by the laws of the relevant jurisdictions. Such overseas Ortho shareholders should inform themselves about, and should observe, any applicable legal requirements. It is the responsibility of all overseas Ortho
shareholders to satisfy themselves as to their full compliance with the laws of the relevant jurisdiction, including obtaining any governmental, exchange control or other consents which may be required and their compliance with any other necessary
formalities which are required to be observed and the payment of any issue, transfer or other taxes due in such jurisdiction. If you are in any doubt regarding such matters, you should consult an independent professional adviser in the relevant
jurisdiction without delay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overseas Ortho shareholders should consult their own legal and tax advisers with respect to the legal and tax consequences of
the Combinations in their particular circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_54"></A>Action to be Taken </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval required for the Scheme Proposal at the Ortho Court Meeting is a simple majority in number of the Ortho ordinary shareholders present and voting
(and entitled to vote) remotely (via the Virtual Meeting Platform) or by proxy, representing at least 75% in value of the Ortho Shares in respect of which a vote has been cast. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval required for the Scheme Implementation Proposal at the Ortho General Meeting is approval by at least 75% of the votes cast by Ortho ordinary
shareholders present and voting (and entitled to vote), either remotely (via the Virtual Meeting Platform) or by proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval required for the <FONT
STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Proposal to Approve Certain Compensation Arrangements at the Ortho General Meeting is approval by a simple majority of the votes cast by Ortho ordinary shareholders present and voting (and
entitled to vote), either remotely (via the Virtual Meeting Platform) or by proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IF THE SCHEME OF ARRANGEMENT BECOMES EFFECTIVE IT
WILL BE BINDING ON ALL HOLDERS OF SCHEME SHARES IRRESPECTIVE OF WHETHER OR NOT THEY ATTENDED OR VOTED AT THE ORTHO COURT MEETING OR THE ORTHO GENERAL MEETING. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_55"></A>Forms of Proxy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each copy of
this joint proxy statement/prospectus mailed to holders of Ortho Shares is accompanied by two forms of proxy with instructions for voting. The blue form of proxy corresponds to the Ortho Court Meeting and the white form of proxy corresponds to the
Ortho General Meeting. If you hold Ortho Shares in your name as a shareholder of record, you should complete and return both proxy cards accompanying this joint proxy statement/prospectus to ensure that your vote is counted at both of the Ortho
Shareholder Meetings, or at any adjournment or postponement of the Ortho Shareholder Meetings, regardless of whether you plan to attend the Ortho Shareholder Meetings, so as to arrive as soon as possible but in any event at least 48 hours before the
relevant meeting (excluding any part of such <FONT STYLE="white-space:nowrap">48-hour</FONT> period falling on a weekend or public holiday in the UK). You may also authorize a proxy to vote your shares online or electronically as set out in full on
the proxy cards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the blue form of proxy relating to the Ortho Court Meeting is not lodged by the relevant time, it may be emailed to [&#9679;] or
handed to the Chair at any time up to the Ortho Court Meeting, otherwise it will be invalid. In the case of the Ortho General Meeting, if the white form of proxy is not lodged so as to be received by the time mentioned above, it may be emailed to
[&#9679;] or handed to the Chair at any time up to the Ortho General Meeting, otherwise it will be invalid. The completion and return of either form of proxy will not preclude you from attending the Ortho Court Meeting or the Ortho General Meeting
and voting remotely (via the Virtual Meeting Platform), if you so wish. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold your Ortho Shares in &#147;street name&#148; through a broker, bank,
trust company or other nominee, you must direct your broker, bank, trust company or other nominee to vote in accordance with the instructions you have received from your broker, bank, trust company or other nominee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho board of directors is not currently aware of any business to be acted upon at the Ortho
Shareholder Meetings other than the matters described in this joint proxy statement/prospectus. If, however, other matters are properly brought before the Ortho Shareholder Meetings, the persons appointed as proxies will have discretion to vote or
act on those matters as in their judgment is in the best interest of Ortho and its shareholders, except that Ortho will comply with any limitations on the exercise of such discretion under applicable law and stock exchange listing rules. The latest
date by which Ortho is required to hold its annual general meeting is June&nbsp;16, 2022 and such meeting shall not take place if the proposed Combinations have closed prior to this date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The latest time for [Computershare] to receive your [Form of Proxy] will be [&#9679;] [a.m./ p.m.] (Eastern Standard Time) and
[a.m./ p.m.] (London time) on [<B><I></I></B>&#9679;<B><I></I></B><B><I></I></B><B>], 2022 (or, in the case of an adjournment of the Ortho Court Meeting, 48 hours (excluding any part of such 48 hour period falling on a non-working day) before the
time appointed for the adjourned meeting), being the latest time for receipt by Ortho&#146;s Registrar of the blue form of proxy for the Ortho Court Meeting. You should allow sufficient time for posting for your [Form of Proxy] to be received. If
the appointment is not received by [Computershare], Ortho&#146;s registrar, by the relevant time, it may be emailed to [</B>&#9679;<B></B><B>] or handed to the Chair at any time prior to the commencement of the Ortho Court Meeting otherwise it will
be invalid.</B> </P></div> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further details on how to submit your Form of Proxy are set forth in the section entitled &#147;[&#149;]&#148; of this joint proxy
statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOU ARE STRONGLY URGED TO COMPLETE AND RETURN YOUR FORMS OF PROXY AS SOON AS POSSIBLE, WHETHER OR NOT YOU INTEND
TO ATTEND THE SHAREHOLDER MEETINGS VIA THE VIRTUAL MEETING PLATFORM. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_56"></A>Further information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the Ortho Scheme are set out in full in the section entitled &#147;Scheme Proposal and the Ortho Shareholder Meetings&#151;Explanatory
Statement&#148; of this joint proxy statement/prospectus. A summary of material tax considerations are set out in the sections entitled &#147;Material U.S. Federal Income Tax Considerations&#148; and &#147;Material UK Tax Considerations&#148; of
this joint proxy statement/prospectus. Further information regarding Quidel, Ortho, Topco, U.S. Merger Sub, U.S. Holdco Sub and U.S. Holdco Sub 2 are set out in the section entitled &#147;Information about the Parties to the Combinations&#148; of
this joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_57"></A>THE ORTHO GENERAL MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_58"></A>Ortho Proposal No. 1&#151;Scheme Implementation Proposal </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the reasons described above, Ortho is requesting that the Ortho shareholders adopt the following resolution at the Ortho General Meeting, which is a
special resolution: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>THAT</I></B><I>, for the purpose of giving effect to the scheme of arrangement dated [&#149;], 2022 between Ortho
Clinical Diagnostics Holdings plc (&#147;Ortho&#148;) and the holders of Scheme Shares (as defined in such scheme of arrangement), a print of which has been produced to this meeting and for the purposes of identification signed by the Chair of this
meeting, in its original form or with or subject to any modification, addition, or condition as may be agreed from time to time (including, for the avoidance of doubt, after the date of this resolution) between Ortho, Quidel Corporation, a Delaware
corporation (&#147;Quidel&#148;), Coronado Topco, Inc. a Delaware corporation and wholly owned subsidiary of Ortho (&#147;Topco&#148;), Laguna Merger Sub, Inc. a Delaware corporation and wholly owned subsidiary of Topco, (&#147;U.S. Merger
Sub&#148;), Orca Holdco, Inc., a Delaware corporation and a wholly owned subsidiary of Topco (&#147;U.S. Holdco Sub&#148;), Orca Holdco 2, Inc., a Delaware corporation and wholly owned subsidiary of U.S. Holdco Sub (&#147;U.S. Holdco Sub 2&#148;),
and which (if required) is approved by the High Court of Justice of England and Wales (the &#147;Court&#148;), or which is otherwise imposed by the Court and is mutually acceptable to Ortho, Quidel, U.S. Merger Sub, U.S. Holdco Sub and U.S. Holdco
Sub 2 each acting reasonably and in good faith (the &#147;Scheme&#148;): </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>the directors of Ortho (or a duly authorized committee of the directors) be and are hereby authorized to
take all such action as they may consider necessary or appropriate for carrying the Scheme into effect; and</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>with effect from the passing of this resolution, the articles of association of Ortho attached as Annex F
and incorporated herein by reference be adopted as the articles of association of Ortho in substitution for, and to the exclusion of, Ortho&#146;s existing articles of association </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vote Required and Ortho board of directors Recommendation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming a quorum is present, the Scheme Implementation Proposal will be passed if at least 75% of the votes cast at the Ortho General Meeting (remotely via
the Virtual Meeting Platform, or by proxy) are cast in favor of this proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Completion of the Combinations is conditioned upon Ortho shareholder
approval of the Scheme Implementation Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE ORTHO BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#147;FOR&#148; THE SCHEME
IMPLEMENTATION </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_59"></A>Ortho Proposal No. <FONT STYLE="white-space:nowrap">2&#151;Non-Binding</FONT> Advisory Proposal to
Approve Certain Compensation Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the Dodd-Frank Act and Section&nbsp;14A of the Exchange Act, Ortho is providing Ortho
shareholders with the opportunity to cast a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on the compensation that may be paid or become payable to the Ortho&#146;s named executive officers in connection with the Combinations. As
required by those rules, Ortho is asking Ortho shareholders to vote on the approval of the following resolution, which is an ordinary resolution: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&#147;</I><B><I>THAT, </I></B><I>the compensation that may be paid or become payable to Ortho&#146;s named executive officers in connection with the
Combinations, as disclosed in the table entitled &#147;Interests of Certain Persons in the Combinations (Ortho)&#151;Golden Parachute Compensation&#148; in this joint proxy statement/prospectus, including the associated narrative discussion, and the
agreements or understandings pursuant to which such compensation may be paid or become payable, are hereby approved.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The vote on this proposal
is a vote separate and apart from the Scheme Implementation Proposal. Accordingly, you may vote in favor of the Scheme Implementation Proposal and vote not to approve this proposal and vice versa. Because this proposal is only advisory in nature, it
will not be binding on Ortho or the Ortho board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, because Ortho is contractually obligated to pay the compensation, such
compensation will be paid or become payable, subject only to the conditions applicable thereto, if the Combinations are consummated and regardless of the outcome of the advisory proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming a quorum is present, the <FONT STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Proposal to
Approve Certain Compensation Arrangements will be passed if a simple majority of the votes cast at the Ortho General Meeting (remotely via the Virtual Meeting Platform, or by proxy) are cast in favor of this resolution. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE ORTHO BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#147;FOR&#148; THE APPROVAL OF THE <FONT STYLE="white-space:nowrap">NON-BINDING</FONT>
ADVISORY PROPOSAL TO APPROVE CERTAIN COMPENSATION ARRANGEMENTS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g273090g15s55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho Clinical Diagnostics Holdings plc </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(Incorporated and registered in England and Wales with registered number 13084624) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Registered office: Felindre Meadows, Pencoed, Bridgend Mid </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Glamorgan, Wales, CF35 5PZ, United Kingdom </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSACTION PROPOSED&#151;YOUR VOTE IS VERY IMPORTANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#9679;], 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Fellow Shareholder: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously announced, on December&nbsp;22, 2021, Ortho Clinical Diagnostics Holdings plc (&#147;Ortho&#148;) entered into a transaction agreement (as it
may be amended, the &#147;Transaction Agreement&#148;) with Quidel Corporation, a Delaware corporation (&#147;Quidel&#148;), Coronado Topco, Inc. a Delaware corporation and wholly owned subsidiary of Ortho (&#147;Topco&#148;), Laguna Merger Sub,
Inc. a Delaware corporation and wholly owned subsidiary of Topco, (&#147;U.S. Merger Sub&#148;), Orca Holdco, Inc., a Delaware corporation and a wholly owned subsidiary of Topco (&#147;U.S. Holdco Sub&#148;), Orca Holdco 2, Inc., a Delaware
corporation and wholly owned subsidiary of U.S. Holdco Sub (&#147;U.S. Holdco Sub 2&#148;), pursuant to which the entire issued and to be issued share capital of Ortho will be transferred to the DR Nominee (as defined below) on behalf of Topco (the
&#147;Transaction&#148;) by means of a court-sanctioned scheme of arrangement (the &#147;Scheme of Arrangement&#148;) under Part 26 of the UK Companies Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cordially invite all holders of Ortho ordinary shares to attend two meetings of shareholders of Ortho. The first meeting (the &#147;Court Meeting&#148;)
will be held at [&#9679;], [&#9679;] on [&#9679;], 2022 at [&#9679;] [a.m./ p.m.] (Eastern Standard Time) and [&#9679;] [a.m./ p.m.] (London time). The second meeting (the &#147;General Meeting&#148; and, together with the Court Meeting, the
&#147;Shareholder Meetings&#148;) will be held at [&#9679;], United Kingdom on [&#9679;], 2022 at [&#9679;] [a.m./ p.m.] (Eastern Standard Time) and [&#9679;] [a.m./ p.m.] (London time) (or as soon thereafter as the Court Meeting shall have been
concluded or adjourned). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Court Meeting, Ortho shareholders will be asked to consider and vote on the Scheme of Arrangement. At the General
Meeting, Ortho shareholders will be asked to consider and vote on (1)&nbsp;a proposal (i)&nbsp;authorizing the Board of Directors of Ortho (the &#147;Ortho Board&#148;) to take all action necessary or appropriate for carrying the Scheme of
Arrangement into effect and (ii)&nbsp;amending the articles of association of Ortho in order to facilitate the Transaction and (2)&nbsp;a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory proposal to approve certain compensation
arrangements for the named executive officers of Ortho. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transaction Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Transaction is completed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all ordinary shares, par value $0.00001 per share, of Ortho (&#147;Ortho ordinary shares&#148;) will be
transferred to GTU Ops Inc. (a Computershare entity) or another company mutually acceptable to Ortho and Quidel falling within Section&nbsp;67(6) of the UK Finance Act 1986 that Topco appoints in order to act as transferee of the Ortho ordinary
shares pursuant to the Scheme of Arrangement (the &#147;DR Nominee&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders of Ortho ordinary shares as of the record time for the Scheme of Arrangement will, on the terms set out
in the Scheme of Arrangement, have the right to receive for each Ortho ordinary share held by them at such time an amount equal to $7.14 in cash (the &#147;cash consideration&#148;) plus an amount of Topco ordinary shares, nominal value $0.001 per
share (&#147;Topco ordinary shares&#148;), equal to 0.1055 Topco ordinary shares per Ortho ordinary share, subject to the provisions of paragraph 2.3 (&#147;the exchange ratio&#148;) (the &#147;share deliverable&#148; and, together with the cash
consideration, the &#147;scheme deliverables&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco ordinary shares shall be admitted to trading on the Nasdaq Global Select
Market under the trading symbol &#147;[&#9679;]&#148; no later than the time at which the Scheme of Arrangement shall be delivered to the Registrar of Companies in England and Wales and become effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> Restrictions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the time of mailing of this letter, the UK Government has removed restrictions on large public gatherings. However, in light of the ongoing restrictions in
the United States and the uncertainty surrounding <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the possible reintroduction by the UK Government of measures restricting large public gatherings, and in order to protect the health and safety of
the Ortho shareholders and Ortho directors, officers and employees, Ortho shareholders will not be permitted to attend the Shareholder Meetings in person, except for the Chair of the Shareholder Meetings and anyone else nominated by the Chair of the
Shareholder Meetings. However, holders of Ortho ordinary shares will be able to attend, submit written questions and vote at each Shareholder Meeting remotely via the Virtual Meeting Platform (as defined in the notices that follow), further details
of which are set out in the accompanying joint proxy statement/prospectus. We would, however, nonetheless encourage all Ortho ordinary shareholders to vote by proxy as soon as possible, by returning the accompanying forms of proxy, even if they
intend to attend the Shareholder Meetings remotely via the Virtual Meeting Platform. Holders of the beneficial interests in Ortho ordinary shares will be able to submit written questions and observe each Shareholder Meeting remotely via the Virtual
Meeting Platform. Please see the section entitled &#147;Explanatory Statement&#151;Beneficial Holders&#148; of this joint proxy statement/prospectus for further information in respect of such holdings and interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>It is important that holders of
Ortho ordinary shares vote at both of the Shareholder Meetings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Ortho ordinary shares are encouraged to submit a form of proxy (by
post, online or electronically through MacKenzie Partners, Inc.) for each of the Court Meeting and the General Meeting as soon as possible. Holders of Ortho ordinary shares who hold their Ortho ordinary shares indirectly through a broker, bank,
trust company or other nominee must rely on the procedures of such broker, bank, trust company or other nominee in order to assert the rights of a holder of Ortho ordinary shares to vote at the Shareholder Meetings. If this applies to you, we
encourage you to consult your broker, bank, trust company or other nominee as soon as possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For specific instructions on voting Ortho ordinary
shares, please refer to the accompanying joint proxy statement/prospectus and forms of proxy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recommendation of the Ortho Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Ortho Board considers, having been so advised by its financial advisor J.P. Morgan Securities LLC, financial advisor to Ortho in connection with the
Transaction, as to financial terms of the Transaction, the terms of the Transaction to be in the best interests of Ortho and its shareholders taken as a whole. Accordingly, the Ortho Board unanimously recommends that Ortho shareholders vote:
</I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>FOR</B>&#148; the approval of the Scheme of Arrangement at the Court Meeting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>FOR</B>&#148; the approval of each of the resolutions at the General Meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Ortho Board made its determination after evaluating the Transaction in consultation with Ortho&#146;s management and legal and financial advisors,
and after considering a number of factors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Ortho Board, you should be aware that directors and executive
officers of Ortho may have certain interests in the Transaction that may be different from, or in addition to, the interests of Ortho shareholders generally. See the sections entitled &#147;The Ortho General Meeting&#151;Proposal No. 2 <FONT
STYLE="white-space:nowrap">&#151;Non-Binding</FONT> Advisory Proposal to Approve Certain Compensation Arrangements&#148; and &#147;Interests of Certain Persons in the Combinations (Ortho)&#148; of the accompanying joint proxy statement/prospectus
for further information regarding these interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We urge you to read the accompanying joint proxy statement/prospectus, including any documents
incorporated by reference therein and the annexes thereto, carefully and in their entirety. In particular, we urge you to read carefully the section entitled &#147;Risk Factors&#148; in the accompanying joint proxy statement/prospectus for risks
relating to the Transaction and Topco following the Transaction. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have any questions regarding the accompanying joint proxy
statement/prospectus, including any questions on how to vote please contact Ortho&#146;s registrar, Computershare, or Ortho&#146;s proxy solicitor, MacKenzie Partners, Inc., at the contact information below. Please note that neither Computershare
(Ortho&#146;s registrar) nor MacKenzie Partners, Inc. (Ortho&#146;s proxy solicitor) can provide advice on the merits of the Combinations or the Scheme or give any financial, legal or tax advice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>[</I></B><B></B>&#9679;<B></B><B></B><B><I>]</I></B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email:[&#9679;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone (call
charges apply): [&#9679;] between [&#9679;] a.m.&#151; [&#9679;] p.m. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">([&#9679;] time) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>MacKenzie Partners, Inc. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: proxy@mackenziepartners.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone (call charges apply): <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-929-5500,</FONT></FONT> between 8:00 a.m.
- 7:00 p.m. ([&#9679;] eastern time) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Toll-free: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-800-322-2885</FONT></FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">On behalf of the Ortho board of directors, thank you for your consideration
and continued support. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yours sincerely, </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Christopher Smith </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Chairman and Chief Executive Officer</I>, Ortho Clinical Diagnostics Holdings plc </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NONE OF THE U.S. SECURITIES AND EXCHANGE COMMISSION, ANY STATE SECURITIES COMMISSION OR THE UNITED KINGDOM FINANCIAL CONDUCT AUTHORITY HAS APPROVED OR
DISAPPROVED THE TRANSACTION OR OTHER TRANSACTIONS DESCRIBED IN THE ACCOMPANYING JOINT PROXY STATEMENT/PROSPECTUS OR THE SECURITIES TO BE ISSUED IN CONNECTION WITH THE TRANSACTION, NOR HAVE THEY DETERMINED IF THE ACCOMPANYING JOINT PROXY
STATEMENT/PROSPECTUS IS ACCURATE OR ADEQUATE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>For the avoidance of doubt, the
accompanying joint proxy statement/prospectus is not intended to be, and is not, a prospectus for the purposes of the Prospectus Rules made under Part 6 of the UK Financial Services and Markets Act 2000 (as set out in the UK Financial Conduct
Authority&#146;s Handbook). </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying joint proxy statement/prospectus is dated [&#9679;], 2022 and is first being mailed or otherwise
delivered to Ortho shareholders on or about [&#9679;], 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_60"></A>THE ORTHO SCHEME </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>IN THE HIGH COURT OF JUSTICE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CR-2022-000340</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>BUSINESS AND PROPERTY COURTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>OF ENGLAND AND</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>WALES COMPANIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>COURT (ChD)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IN THE MATTER OF ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IN THE MATTER OF
THE COMPANIES ACT 2006 SCHEME OF ARRANGEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(under Part 26 of the Companies Act 2006) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>between </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORTHO CLINICAL
DIAGNOSTICS HOLDINGS PLC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE SCHEME SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(as hereinafter defined) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Scheme, unless inconsistent with the subject or context, the following expressions shall have the
following meanings: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Applicable Law&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means, with respect to any person, any federal, state, local or provincial municipal foreign, multinational or local common law, statute, treaty, ordinance, rule, regulation, Order, agency requirement, writ, franchise, variance,
exemption, approval, certificate, notice, bylaw, standard, policy guidance, license, permit or other requirements, policies or instruments of any relevant jurisdiction issued, promulgated, adopted enacted, issued or entered into by or with any
Governmental Authority that is binding on or applicable to such person, as the same may be amended from time to time;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Business Day&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means a day, other than a Saturday, Sunday or other day on which banks are open for general business in New York, New York or London, England;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Cash Consideration&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">has the meaning given to it in paragraph 2.2(A);</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;certificated&#148; or &#147;in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>certificated form&#148;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means a share or security of the Company which is not in uncertificated form;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Companies Act&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means the Companies Act 2006;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Company&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means Ortho Clinical Diagnostics Holdings plc, a public limited company incorporated in England and Wales with registered number 13084624;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Company Ordinary Shares&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means the ordinary shares of $0.00001 nominal value each in the capital of the Company;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Computershare&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means Computershare Limited;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Court&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means the High Court of Justice of England and Wales;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Court Order&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means the order of the Court sanctioning this Scheme under Section&nbsp;899 of the Companies Act;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Court Sanction Hearing&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means the hearing of the Court (and any adjournment thereof) to sanction the Scheme pursuant to 899 of the Companies Act, at which the Court Order is expected to be granted;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;DR Nominee&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means GTU Ops Inc. (a Computershare entity) or another company mutually acceptable to the Company, Quidel and Topco falling within Section&nbsp;67(6) and Section&nbsp;93(3) of the Finance Act 1986 to act as transferee of the Scheme
Shares pursuant to this Scheme appointed by Topco as nominee prior to the Effective Date in accordance with the provisions of the Transaction Agreement;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;DTC&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means the Depository Trust Company;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Effective Date&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means the date on which this Scheme becomes effective in accordance with paragraph 9.1;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Effective Time&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means the time on the Effective Date at which this Scheme becomes effective in accordance with paragraph 9.1;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Exchange Agent&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means such U.S. bank or trust company or other independent financial institution in the United States as is reasonably satisfactory to the Company, Quidel and Topco and appointed by Topco as exchange agent prior to the Effective
Date in accordance with the provisions of the Transaction Agreement;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Exchange Ratio&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means 0.1055 Topco Shares for each Scheme Share held by a Scheme Shareholder;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Exchange Shares&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means the Topco Shares to be delivered to Scheme Shareholders comprising the Share Consideration;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Excluded Ortho Shares&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means any Company Ordinary Shares held in treasury;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Governmental Authority&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means any government or governmental or regulatory authority, court or other judicial body, agency, commission, body or other governmental or regulatory entity, U.S. or <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> national or
supra-national, state, provincial, municipal or local, national, transnational, domestic or foreign federal, state or local governmental, regulatory or administrative authority, department, court, agency, commission or official, including any
political subdivision thereof, or any <FONT STYLE="white-space:nowrap">non-governmental</FONT> self-regulatory agency, commission or authority and any arbitral tribunal;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Latest Practicable Date&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means close of business on [&#9679;], 2022, being the latest practicable date prior to the date of this Scheme;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Lien&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means, with respect to any Scheme Share, any mortgage, lien, pledge, charge, option, equity, power of sale, security interest, hypothecation, right of <FONT STYLE="white-space:nowrap">pre-emption,</FONT> right of first refusal,
contract for sale or restriction of any nature retention of title arrangement or other third party right, interest or claim of any kind or another type of preferential arrangement or any agreement or commitment to create or give any of the foregoing
or any other encumbrance, whether voluntarily incurred or arising by operation of Applicable Law;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Member&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means a member of the Company on the register of members on any relevant date;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Nasdaq&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means, collectively, the Nasdaq Global Select Market and/or the Nasdaq Stock Market LLC (as applicable);</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Order&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means any order, writ, decree, judgment, award, injunction, ruling, settlement or stipulation issued, promulgated, made, rendered or entered into by or with any Governmental Authority (in each case, whether temporary, preliminary or
permanent);</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;person&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means any individual, corporation, partnership, limited liability partnership, limited liability company, association, trust or other entity or organization, including a government or political subdivision or an agency or
instrumentality of such government or political subdivision (in each case whether or not having separate legal personality);</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Quidel&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means Quidel Corporation, a Delaware corporation;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Regulations&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means the Uncertificated Securities Regulations 2001 (SI 2001 No.&nbsp;3755), as amended from time to time;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Relevant System&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means any computer-based system, and procedures, which enable title to units of a share or security to be evidenced and transferred without a written instrument, and which facilitate supplementary and incidental matters in
accordance with the Regulations;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Scheme&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means this scheme of arrangement in its present form or with or subject to any modification, addition or condition (i)&nbsp;as may be agreed between the Company, Quidel and Topco and which (if required) is approved by the Court, or
(ii)&nbsp;which is otherwise imposed by the Court and mutually acceptable to the Company, Quidel and Topco, each acting reasonably and in good faith;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Scheme Record Time&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means [6:00] p.m. (London time) on the Business Day immediately prior to the Effective Date;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Scheme Shareholders&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means the holders of Scheme Shares whose names appear in the register of Members of the Company at the Scheme Record Time;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Scheme Shares&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means the Company Ordinary Shares: (i)&nbsp;in issue at the date of this document; (ii) (if any) issued after the date of this document and prior to the Voting Record Time; and (iii) (if any) issued at or after the Voting Record
Time and prior to the Scheme Record Time, either on terms that the original or any subsequent holders thereof shall be bound by this Scheme or in respect of which the holders thereof shall have agreed in writing to be bound by this Scheme; in each
case, remaining in issue at the Scheme Record Time but excluding any Excluded Shares;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Share Consideration&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">has the meaning given to it in paragraph 2.1(B);</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Termination Date&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means (i)&nbsp;September&nbsp;22, 2022 (unless otherwise automatically extended to January&nbsp;22, 2023 or otherwise extended in accordance with the terms of the Transaction Agreement) or (ii)&nbsp;the date on which the Transaction
Agreement is terminated in accordance with its terms;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Topco&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means Coronado Topco, Inc., a Delaware corporation and a wholly owned subsidiary of the Company;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Topco Shares&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means shares of common stock, par value $0.001 per share, of Topco;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Transaction Agreement&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means the transaction agreement by and amongst others the Company, Quidel and Topco dated as of December&nbsp;22, 2021, agreeing to certain matters in connection with the Acquisition and the matters contemplated by this Scheme, as
it may be amended from time to time;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;uncertificated&#148; or &#147;in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>uncertificated form&#148;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means any share or other security of the Company in respect of which title is evidenced and transferred by means of a Relevant System;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#147;Voting Record Time&#148;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">means [6:00] p.m. (London time) on the day which is two days (excluding <FONT STYLE="white-space:nowrap">non-working</FONT> days) prior to the date of the Court Meeting and the General Meeting or, if the Court Meeting and/or the
General Meeting is adjourned, [6:00] p.m. on the day which is two days (excluding <FONT STYLE="white-space:nowrap">non-working</FONT> days) before the day of such adjourned meeting(s).</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any reference to the parties or a recital or paragraph is to the parties (and permitted assignees) or the
relevant recital or paragraph of this Scheme. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any reference to an individual includes a reference to his personal representatives, on whom this Scheme shall
be binding. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any references to time are to local time in London (England). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">E.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Paragraph headings are included for convenience only and shall not affect the interpretation of this Scheme.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">F.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Recitals form part of this Scheme and shall have effect as if set out in full in the body of this Scheme and
any reference to this Scheme includes the recitals. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">G.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As at the Latest Practicable Date, the issued share capital of the Company was divided into [&#149;] Company
Ordinary Shares, all of which are credited as fully paid up and none of which were held in treasury as Excluded Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">H.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As at the date of this Scheme, neither Quidel nor Topco own any shares in the capital of the Company and it is
not intended that Quidel will acquire any such shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">I.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Topco and Quidel have agreed, in each case subject to the terms of the Transaction Agreement, to appear by
counsel at the hearing to sanction this Scheme and to be bound by, and to undertake to the Court to be bound by, the terms of this Scheme and to execute and do, or procure to be executed and done, all such documents, acts and things as may be
necessary or desirable to be executed or done by them for the purposes of giving effect to this Scheme. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_61"></A>The Scheme </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><A NAME="rom273090_62"></A>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Transfer of the Scheme Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon and with effect from the Effective Time, the DR Nominee, on behalf and for the benefit of Topco, shall, in
accordance with paragraph 1.2, acquire all of (or, if the DR Nominee holds the Scheme Shares at the Effective Time, transferred within the DR Nominee) the Scheme Shares fully paid, with full title guarantee, free from all Liens (other than transfer
restrictions arising under applicable securities laws) and together with all rights at the Effective Time or thereafter attached or relating thereto, including voting rights and the right to receive and retain all dividends and other distributions
(if any) and any other return of capital (whether by way of reduction of share capital or share premium account or otherwise) thereon. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Scheme Shares shall be transferred to the DR Nominee (or, if the DR Nominee holds the Scheme Shares at the
Effective Time, transferred within the DR Nominee), on behalf and for the benefit of Topco, and to give effect to such transfer, any person may be appointed by Topco as attorney or agent and shall be authorized as such attorney or agent on behalf of
each of the Scheme Shareholders concerned to execute and deliver as transferor such form(s) of transfer or other instrument(s) or instruction(s) giving effect to such transfer of, or otherwise give any instruction(s) giving effect to such transfer,
the Scheme Shares and every form, instrument or instruction so executed or instruction so given shall be as effective as if it had been executed or given by the holder or holders of the Scheme Shares thereby transferred. Any such form of transfer or
other instrument or instruction shall be deemed to be the principal instrument of transfer of the relevant Scheme Shares and the equitable or beneficial interest in the Scheme Shares shall only be transferred together with the legal interest in such
Scheme Shares, pursuant to such form, instruction or instrument of transfer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From the Effective Time and pending the transfer of the Scheme Shares pursuant to paragraphs 1.1 and 1.2, each
Scheme Shareholder: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">irrevocably appoints Topco (and/or its nominee(s) and/or each of their agents and directors) as its attorney
and/or agent: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to exercise or direct the exercise of (in place of and to the exclusion of the relevant Scheme Shareholder) any
voting rights attached to the Scheme Shares and any or all other rights and privileges attaching to the Scheme Shares (including the right to requisition the convening of a general meeting of the Company or of any class of its shareholders); and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to sign on behalf of such Scheme Shareholder such documents, and to do such things, as may, in the opinion of
Topco and/or its nominee(s) and/or each of their respective agents and directors (in each case acting reasonably), be necessary or desirable in connection with the exercise of any voting rights and any or all rights and privileges attaching to such
Scheme Shares (including: (i)&nbsp;execute any consent to short notice of a general or separate class meeting; (ii)&nbsp;attend and/or execute a form of proxy or forms of proxy in respect of such Scheme Shares appointing any person nominated by
Topco and/or its nominee(s) to attend general and separate class meetings of the Company; and (iii)&nbsp;exercise or refrain from exercising the votes attaching to the Scheme Shares held by such Scheme Shareholder on such Scheme Shareholders&#146;
behalf); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">authorizes the Company and/or its agents to send to Topco and/or its nominee(s) any notice, circular, warrant
or other document or communication which may be required to be sent to them as a Member; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agrees not to exercise any votes or any other rights attaching to the relevant Scheme Shares without the
consent of Topco, and irrevocably undertakes not to appoint a proxy or representative for or to attend any general meeting or separate class meeting of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The authorities granted by each Scheme Shareholder pursuant to paragraph 1.2 and paragraph 1.3 shall be treated
for all purposes as having been granted by deed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall, subject to the UK stamping of any relevant instruments of transfer (to the extent required),
register, or procure the registration of, any transfer(s) of shares effected in accordance with paragraphs 1.1 and 1.2. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><A NAME="rom273090_63"></A>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Consideration for the Transfer of the Scheme Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On or before the Effective Time, Quidel shall deposit, or cause to be deposited, in each case on behalf of
Topco, with the Exchange Agent, for the benefit of the holders of the Scheme Shares, an amount equal to the Cash Consideration and, subject to and in exchange for the transfer of the Scheme Shares as provided in paragraphs 1.1 and 1.2, as soon as
reasonably practicable following the Effective Time, Topco shall, subject as hereinafter provided: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in accordance with paragraph 5.1(A), pay, or procure that there shall be paid, a cash amount to, or for the
account of, each Scheme Shareholder of $7.14 (seven U.S. dollars, 14 U.S. cents), without interest but subject to any adjustment in accordance with this Scheme and withholding tax required by Applicable Law, for each Scheme Share held by that Scheme
Shareholder (the &#147;Cash Consideration&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in accordance with paragraph 5.1(B), issue to or for the account of each Scheme Shareholder, such number of
Topco Shares as such Scheme Shareholder is entitled to receive pursuant to the application of the Exchange Ratio, subject to the provisions of paragraph 2.3 and any adjustment in accordance with this Scheme (the &#147;Share Consideration&#148;),
credited as fully paid, <FONT STYLE="white-space:nowrap">non-assessable</FONT> and free from all Liens (other than transfer restrictions arising under applicable securities laws), and such Topco Shares will rank pari passu in all respects with the
Topco Shares in issue on the Effective Date, including the right to receive and retain dividends and other distributions declared, made or paid by reference to a record date falling on or after the Effective Date and to participate in the assets of
Topco upon a winding up of Topco. Applications will be made for the Topco Shares to be listed on Nasdaq. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, between the date of the Transaction Agreement and the Effective Time, the outstanding Company Ordinary
Shares or Topco Shares shall have been changed to, or exchanged for, a different number or class of shares or securities by reason of any stock dividend, bonus issue, scrip dividend, subdivision, reorganization, merger, consolidation,
reclassification, redesignation, recapitalization, share split, reverse share split, combination or exchange of shares, or a stock or scrip dividend shall be declared with a record date within such period, or any similar event shall have occurred,
then the amount of the Cash Consideration and/or Exchange Ratio shall be appropriately adjusted in accordance with the provisions of the Transaction Agreement to provide to Topco and the Scheme Shareholders the same economic effect as contemplated
by the Transaction Agreement prior to such event. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fractions of Topco Shares will not be allotted to Scheme Shareholders. Instead, Scheme Shareholders shall
receive within ten Business Days or such shorter period as may be required by Applicable Law as soon as reasonably practicable after the Effective Time, in lieu of such fractional entitlements, cash in an amount in U.S. dollars (rounded down to the
nearest cent) equal to such fractional amount multiplied by the aggregate net proceeds from the sale of such fractional entitlements. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><A NAME="rom273090_64"></A>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Share Certificates and Register of Members </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect from and as of the Effective Time, all certificates representing Scheme Shares in certificated
form, if any, shall cease to have effect as documents of title to the Scheme Shares comprised therein and each Scheme Shareholder </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
shall be bound, at the request of Topco, to deliver up the same to the DR Nominee or to any person appointed by Topco to receive the same or, as Topco may direct, to destroy the same.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On or as soon as reasonably practicable after the Effective Time and subject to the completion of such
transfers, forms, instruments or instructions as may be required in accordance with paragraph 1 and the UK stamping thereof (to the extent required), the Company shall procure that appropriate entries shall be made in the register of Members of the
Company to reflect the transfer of the Scheme Shares in accordance with paragraph 1. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><A NAME="rom273090_65"></A>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Appointment of Exchange Agent </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Prior to the Effective Time, Topco shall appoint the Exchange Agent to effect the technical implementation of the settlement of the Cash
Consideration, the delivery of the Exchange Shares to all Scheme Shareholders and the sale of, and distribution of proceeds from the sale of, fractions of Topco Shares sold pursuant to paragraph 2.4. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><A NAME="rom273090_66"></A>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Settlement of the Cash Consideration and the Share Consideration </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of Scheme Shares held by Scheme Shareholders at the Scheme Record Time, settlement shall be
effected as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">settlement of the Cash Consideration to which the Scheme Shareholder is entitled (including pursuant to
paragraph 2.4) shall be effected by Topco, either directly or indirectly via the Exchange Agent: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by cheque; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[by cash (to be made by way of wire transfer), if the Scheme Shareholder has contacted the Exchange Agent at
[&#9679;] and completed and submitted the form provided in accordance with the instructions thereon on or before the date falling five Business Days prior to the Court Sanction Hearing], </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in each case, which shall be dispatched (in the case of a cheque) or for settlement (in the case of a wire transfer) on or as soon as reasonably practicable
following the Effective Date (and in any event no later than two Business Days following the Effective Date); and </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">settlement of the Share Consideration to which the Scheme Shareholder is entitled shall be effected by:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[where, immediately prior to the Scheme Record Time, a Scheme Shareholder holds their Scheme Shares in
book-entry form through a DTC participant in DTC&#146;s electronic book-entry clearing and settlement system, Topco shall procure that (1)&nbsp;the Topco Shares to which the holder of such Scheme Shares is entitled shall be issued to Cede&nbsp;&amp;
Co., which will be the registered holder of such shares, as nominee for DTC; (2)&nbsp;the interests in such Topco Shares shall be credited by DTC to the account of the DTC participant through which the Scheme Shareholder holds its Scheme Shares in
book-entry form;] or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where, immediately prior to the Scheme Record Time, a Scheme Shareholder holds their Scheme Shares in
certificated or book-entry form on the records of the Exchange Agent, Topco procuring that the relevant Topco Shares are issued by the Exchange Agent in book-entry form on the records of the Exchange Agent, registered in the same name(s) and address
as appeared on Ortho&#146;s register of members for each relevant Scheme Shareholder, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in each case, as soon as reasonably practicable
following the Effective Date (and in any event no later than [2] Business Days following the Effective Date). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All deliveries of notices, certificates and/or cheques required to be made under this Scheme shall be made by
sending the same by mail (or by international post or airmail, if outside United States), addressed to the person entitled thereto, to the address appearing in the register of members or, in the case of joint holders, to the address of the holder
whose name stands first in such register in respect of the joint holding concerned at such time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All cheques shall be in U.S. dollars and shall be made payable to the Scheme Shareholder concerned or, in the
case of joint holders, to the holder whose name stands first in the register of members in respect of the joint holding concerned at the Scheme Record Time and the encashment of any such cheque or the making of any such wire transfer as is referred
to in paragraph 5.1(A) shall be a complete discharge to Topco for the monies represented thereby. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">None of the Company, Topco or their respective agents or nominees shall be responsible for any loss or delay in
the transmission of the share certificates or cheques (as applicable) sent to Scheme Shareholders in accordance with this paragraph 5, which shall be posted at the risk of the Scheme Shareholder concerned. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Oversees Shareholders </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of paragraphs 2, 3, 4, and 5 shall be subject to any prohibition or condition imposed by
Applicable Law. Without prejudice to the generality of the foregoing, if, in respect of any Scheme Shareholder with a registered address in a jurisdiction outside the United Kingdom or the United States, Topco or the Exchange Agent is advised that
the delivery of Exchange Shares pursuant to paragraph 5 would or might infringe the laws of such jurisdiction or would require Topco, the Exchange Agent or the Company to observe any governmental or other consent or any registration, filing or other
formality with which Topco, the Exchange Agent or the Company (as the case may be) is unable to comply, or compliance with which by such person is regarded by such person or by Topco (in the case of Topco, acting reasonably) as unduly onerous, the
Exchange Agent may, in consultation with Topco, determine that the Exchange Shares shall not be delivered to such Scheme Shareholder and that (i)&nbsp;such Exchange Shares shall instead be sold by the Exchange Agent at the best price which can
reasonably be obtained in the market at the time of sale and (ii)&nbsp;the net proceeds of such sale (after the deduction of any expenses and commissions incurred in connection with such sale, including any amounts in respect of tax including any
value added tax payable thereon, without interest) shall be delivered by the Exchange Agent to the relevant Scheme Shareholder in accordance with the provisions of paragraphs 2.3, 5.1, 5.3 and 5.4 (as applicable) rounded up or down to the nearest
U.S. cent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the absence of bad faith or willful default, none of the Company, Topco, the Exchange Agent, the nominee or
any broker or agent of any of them shall have any liability for any loss or damage arising as a result of the timing or terms of any sale pursuant to paragraph 6.1 </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><A NAME="rom273090_67"></A>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cessation of Rights </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With effect from and on the Effective Time, the Scheme Shareholders shall in accordance with this Scheme cease to have any rights with respect
to the Scheme Shares, except the right to receive the Cash Considerations and the Share Consideration in exchange for the Scheme Shares as set out in paragraph 2. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><A NAME="rom273090_68"></A>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mandates and Dividends </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All mandates relating to the payment of dividends on any Scheme Shares and other instructions (including communications preferences) given to
the Company by Scheme Shareholders in force at the Scheme Record Time relating to Scheme Shares shall, as from the Effective Date, cease to be valid. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><A NAME="rom273090_69"></A>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Effective Time </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Scheme shall become effective as soon as a copy of the Court Order shall have been delivered to the
Registrar of Companies in England and Wales. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless this Scheme shall have become effective on or before the Termination Date or such later date as the
Company and Topco may agree and the Court may allow, this Scheme shall never become effective. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><A NAME="rom273090_70"></A>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Modification </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company and Topco may jointly consent on behalf of all persons concerned to any modification of or addition to this Scheme or to any
condition which the Court may think fit to approve or impose. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><A NAME="rom273090_71"></A>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Governing law </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This Scheme, any claim, dispute or matter (whether contractual or <FONT STYLE="white-space:nowrap">non-contractual)</FONT> and all rights and
obligations arising out of or in connection with it, are governed by the laws of England and Wales and are subject to the exclusive jurisdiction of the English courts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated [&#9679;], 2022 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_72"></A>THE QUIDEL STOCKHOLDERS&#146; MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_73"></A>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This joint proxy
statement/prospectus is being provided to the stockholders of Quidel as part of a solicitation of proxies by the Quidel board of directors for use at the Quidel Stockholders&#146; Meeting to be held at the time and place specified below. This joint
proxy statement/prospectus provides stockholders of Quidel with the information they need to know to be able to vote or instruct their vote to be cast at the Quidel Stockholders&#146; Meeting. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>TIME AND DATE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;], 2022, at [&#9679;] a.m., Pacific Time.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PLACE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Quidel Stockholders&#146; Meeting will be held virtually and can be accessed online at www.virtualshareholdermeeting.com/QDEL2022SM</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ITEMS OF BUSINESS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. Proposal to approve the Merger Proposal</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Proposal to approve the Advisory Merger Compensation Proposal</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Proposal to approve the Adjournment Proposal</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. Proposal to approve the Election of Directors Proposal</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. Proposal to approve the Advisory Executive Compensation Proposal</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. Proposal to approve the Independent Registered Public Accounting Firm Proposal</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. Proposal to approve the Equity Incentive Plan Proposal</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">8. Proposal to approve the ESPP Proposal</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>RECORD DATE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 14, 2022</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PROXY VOTING</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">It is important that your shares be represented and voted at the Quidel Stockholders&#146; Meeting. You can submit a proxy to vote your shares electronically via the Internet, by telephone or by completing and returning the proxy
card or voting instruction card. Voting instructions are printed on your proxy card and are included in this joint proxy statement/prospectus. If your shares are held in the name of a bank, broker or other nominee, follow the instructions you
receive from your nominee on how to vote your shares. You can revoke a proxy at any time prior to its exercise at the Quidel Stockholders&#146; Meeting by following the instructions in this joint proxy statement/prospectus or by voting your shares
in person at the Quidel Stockholders&#146; Meeting.</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>YOUR VOTE IS IMPORTANT. ACCORDINGLY, PLEASE SUBMIT YOUR PROXY PROMPTLY BY TELEPHONE, BY INTERNET OR BY MAIL, WHETHER
OR NOT YOU PLAN TO ATTEND THE QUIDEL STOCKHOLDERS&#146; MEETING IN PERSON. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_74"></A>Recommendation of the Quidel Board of
Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After careful consideration, the Quidel board of directors has determined that the Combinations, including the Quidel Merger and the other
transactions contemplated by the BCA, are consistent with and will further the business strategies and goals of Quidel, and are in the best interests of Quidel and its stockholders, and (a)&nbsp;has unanimously approved and declared advisable the
BCA and Combinations, including the Quidel Merger and the transactions contemplated by the BCA, and (b)&nbsp;has determined, subject to its duties under applicable law, to recommend that the Quidel stockholders adopt the BCA and the Combinations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accordingly, the Quidel board of directors recommends that Quidel stockholders vote: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Merger Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Advisory Merger Compensation Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Adjournment Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Election of Directors Proposal; </B></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Advisory Executive Compensation Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Independent Registered Public Accounting Firm Proposal; </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the Equity Incentive Plan Proposal; and </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FOR&#148; the ESPP Proposal. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_75"></A>Record Date; Stockholders Entitled to Vote </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors has fixed the close of business on March 14, 2022, as the record date for determining the Quidel stockholders entitled to
receive notice of, and to vote at, the Quidel Stockholders&#146; Meeting. Only holders of record of issued and outstanding Quidel Shares at the close of business on the record date are entitled to receive notice of, and to vote at, the Quidel
Stockholders&#146; Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the close of business on March 14, 2022, there were [&#9679;] Quidel Shares issued and outstanding and entitled to vote at
the Quidel Stockholders&#146; Meeting. Quidel stockholders are entitled to one vote for each Quidel Share they owned as of the close of business on the record date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_76"></A>Voting by Quidel&#146;s Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the close of business on March 4, 2022, directors and executive officers of Quidel and their affiliates were entitled to vote approximately 1,154,623 Quidel
Shares, or approximately 2.7% of the Quidel Shares outstanding on that date. We currently expect that Quidel&#146;s directors and executive officers will vote their shares in favor of each of the proposals to be considered at the Quidel
Stockholders&#146; Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="rom273090_77"></A><B>Quorum</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A majority of the Quidel Shares issued and outstanding as of the close of business on the record date and entitled to vote, present in person or represented by
proxy, at the Quidel Stockholders&#146; Meeting will constitute a quorum for the Quidel Stockholders&#146; Meeting. Abstentions and broker non-votes will be counted for purposes of establishing a quorum at the Quidel Stockholders&#146; Meeting. At
any adjourned meeting at which a quorum is present, any business may be transacted that might have been transacted at the original meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_78">
</A>Required Vote </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the Merger Proposal requires the affirmative vote of the holders of a majority of the outstanding Quidel Shares entitled
to vote on the matter at the Quidel Stockholders&#146; Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of each of (i) the Advisory Merger Compensation Proposal, (ii) the Adjournment
Proposal, (iii) the Advisory Executive Compensation Proposal, (iv) the Independent Registered Public Accounting Firm Proposal, (v) the Equity Incentive Plan Proposal and (vi) the ESPP Proposal requires the affirmative vote of a majority of the
voting power represented at the Quidel Stockholders&#146; Meeting in person or by proxy and entitled to vote on such proposals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the Election
of Directors Proposal requires the affirmative vote of a plurality of the voting power represented at the Quidel Stockholders&#146; Meeting in person or by proxy and entitled to vote on such proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="rom273090_79"></A><B>Failure to Either Submit a Proxy or Attend the Quidel Stockholders&#146; Meeting, Broker Non-Votes and Abstentions</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where a stockholder has directed how his or her proxy is to be voted, it will be voted according to the stockholder&#146;s directions. If your shares are held
in a brokerage account or by another nominee, you are considered the &#147;beneficial owner&#148; of shares held in &#147;street name,&#148; and this joint proxy statement/prospectus and the related materials are being forwarded to you by your
broker or nominee (the &#147;record holder&#148;) along with a voting instruction card. As the beneficial owner, you have the right to direct the record holder of your shares regarding how to vote your shares, and the record holder is required to
vote your shares in accordance with your instructions. If a proposal is routine, a record holder may vote on the proposal without voting instructions from the beneficial owner if the beneficial owner does not provide instructions. If a proposal is
non-routine, the record holder may vote on the proposal only if the beneficial owner has provided voting instructions. A &#147;broker non-vote&#148; occurs when the record holder is unable to vote on a proposal because the proposal is non-routine
and the beneficial owner does not provide instructions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold shares in street name and you do not give voting instructions to the record holder of your
shares prior to the Quidel Stockholders&#146; Meeting, the record holder will be entitled to vote your shares in its discretion only on the Independent Registered Public Accounting Firm Proposal and will not be able to vote your shares on the rest
of the proposals presented at the Quidel Stockholders&#146; Meeting and your shares will be treated as a &#147;broker non-vote&#148; on these proposals. If the Quidel Stockholders&#146; Meeting is adjourned, your shares may be voted by the persons
named as proxies on the new meeting date as well, unless you have revoked your proxy instructions prior to that time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to the Merger Proposal,
if you fail to submit a proxy or attend the Quidel Stockholders&#146; Meeting, fail to instruct your broker, bank, trust company or other nominee to vote (broker non-votes), or if you mark your proxy or voting instructions to abstain, it will have
the effect of a vote &#147;AGAINST&#148; the Merger Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to the Advisory Merger Compensation Proposal, the Adjournment Proposal, the
Advisory Executive Compensation Proposal, the Equity Incentive Plan Proposal and the ESPP Proposal, if you fail to submit a proxy or attend the Quidel Stockholders&#146; Meeting or fail to instruct your broker, bank, trust company or other nominee
to vote (broker non-votes), it will have no effect on these proposals; while if you mark your proxy or voting instructions to abstain, it will have the effect of a vote &#147;AGAINST&#148; these proposals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to the Election of Directors Proposal, votes may be cast in favor of a director nominee or withheld. Because directors are elected by plurality,
broker non-votes will have no effect on the outcome of this proposal. If a quorum is present at the Quidel Stockholders&#146; Meeting, the eight nominees receiving the greatest number of votes will be elected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to the Independent Registered Public Accounting Firm Proposal, if you fail to submit a proxy or attend the Quidel Stockholders&#146; Meeting, it
will have no effect on this proposal; while if you mark your proxy or voting instructions to abstain, it will have the effect of a vote &#147;AGAINST&#148; this proposal. Because the Independent Registered Public Accounting Firm Proposal is a
routine matter, no broker non-votes are expected with respect to this proposal. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_80"></A>How to Vote Your Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered Quidel stockholders may grant a proxy to vote (i)&nbsp;through the Internet by logging onto the website indicated on the enclosed proxy card and
following the prompts using the control number located on the proxy card; (ii)&nbsp;by telephone (from the United States, United States Territory and Canada) using the toll-free telephone number listed on the enclosed proxy card; or (iii)&nbsp;by
completing, signing, dating and returning the enclosed proxy card in the postage-paid envelope provided. If your shares are held in the name of a bank, broker or other nominee, follow the instructions you receive from your nominee on how to vote
your shares. Registered stockholders who attend the Quidel Stockholders&#146; Meeting may vote their shares in person even if they previously have voted their shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_81"></A>Voting in Person </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only Quidel
stockholders as of the close of business on the record date or holders of a valid proxy for the meeting are entitled to attend the virtual Quidel Stockholders&#146; Meeting. Virtual attendance by stockholders of record at the Quidel
Stockholders&#146; Meeting will constitute presence in person for the purpose of determining the presence of a quorum for the transaction of business at the Quidel Stockholders&#146; Meeting. You will be able to attend the Quidel Stockholders&#146;
Meeting, as well as vote and submit your questions during the live webcast of the meeting by visiting www.virtualshareholdermeeting.com/QDEL2022SM and entering the <FONT STYLE="white-space:nowrap">16-digit</FONT> control number included on your
proxy card. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_82"></A>Voting of Proxies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When you provide your proxy, the Quidel Shares represented by the proxy will be voted in accordance with your instructions. If you sign your proxy card without
giving instructions, you will have granted authority to [&#149;] to vote &#147;FOR&#148; each of the Merger Proposal, the Advisory Merger Compensation Proposal, the Adjournment Proposal, the Election of Directors Proposal, the Advisory Executive
Compensation Proposal, the Independent Registered Public Accounting Firm Proposal, the Equity Incentive Plan Proposal, and the ESPP Proposal. Any proxy that is marked &#147;AGAINST&#148; the Merger Proposal will not be voted &#147;FOR&#148; the
Adjournment Proposal. In all cases, the delivery of a signed proxy card shall confer authority upon the proxyholders to vote your shares in accordance with their judgment on any other matters properly presented at the Quidel Stockholders&#146;
Meeting. The Quidel board of directors currently knows of no other business that will be presented for consideration at the Quidel Stockholders&#146; Meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_83"></A>Revocation of Proxies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record, you may revoke your proxy at any time before it is exercised in any one of four ways: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by giving written notice to the Secretary of Quidel, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by submitting a subsequently dated and properly signed proxy card in accordance with the instructions in this
joint proxy statement/prospectus, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by granting a subsequent proxy by telephone or through the Internet or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by attending the virtual Quidel Stockholders&#146; Meeting and voting in person. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your attendance at the Quidel Stockholders&#146; Meeting will not automatically revoke your proxy unless you vote at the Quidel Stockholders&#146; Meeting or
specifically request in writing that your prior proxy be revoked. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The most recent proxy card or telephone or Internet proxy received by the inspector of
elections for the Quidel Stockholders&#146; Meeting is the one that is counted. Written notices of revocation and other communications with respect to the revocation of proxies should be addressed to Quidel Corporation, Attention: Phillip S. Askim,
9975 Summers Ridge Road, San Diego, California 92121, United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note that if your shares are held in the name of a broker, bank,
trust company or other nominee, you may change your voting instructions by submitting new voting instructions to your broker, bank, trust company or other nominee in accordance with its established procedures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_84"></A>Solicitation of Proxies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Directors, present and former officers and other employees of Quidel may solicit proxies by telephone, facsimile or mail, or by meetings with stockholders or
their representatives. Quidel will reimburse brokers, banks or other custodians, nominees and fiduciaries for their charges and expenses in forwarding proxy material to beneficial owners. Quidel has engaged Innisfree M&amp;A Incorporated to assist
in the solicitation of proxies and provide related advice and informational support in connection with the Quidel Stockholders&#146; Meeting, for a service fee and the reimbursement of customary disbursements that are not expected to exceed $75,000
in the aggregate. All such expenses will be borne by Quidel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adjournments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Chair of the Quidel Stockholders&#146; Meeting or the Quidel stockholders who hold a majority of the issued and outstanding Quidel Shares, present in
person or represented by proxy, at the Quidel Stockholders&#146; Meeting, whether or not a quorum is present, has the power to adjourn the Quidel Stockholders&#146; Meeting until a later date and time. If the date and time of the adjourned meeting
is given and the adjournment is for 30 days or less, no notice of the adjourned meeting need be given. At the adjourned Quidel Stockholders&#146; Meeting, if a quorum is present, Quidel may transact any business which might have been transacted at
the original Quidel Stockholders&#146; Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_85"></A>Quidel Proposal No. 1&#151;The Merger Proposal </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Item 1 on the Quidel proxy card) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This joint proxy
statement/prospectus is being furnished to you as a stockholder of Quidel as part of the solicitation of proxies by the Quidel board of directors for use at the Quidel Stockholders&#146; Meeting to consider and vote upon a proposal to adopt the BCA,
which is attached as Annex A to this joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel Merger cannot be completed without the approval of the Merger Proposal
by the affirmative vote of the holders of a majority of the outstanding Quidel Shares entitled to vote on such proposal. If you are present in person or represented by proxy at the meeting but do not vote, or if you abstain, the effect will be the
same as a vote &#147;AGAINST&#148; the Merger Proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Quidel board of directors, after due and careful discussions and consideration, has determined that
the transactions to be implemented pursuant to the BCA, including the Quidel Merger and the other transactions contemplated by the BCA, are consistent with and will further the business strategies and goals of Quidel, and are in the best interests
of Quidel and its stockholders, and (a)&nbsp;has unanimously approved and declared advisable the BCA and Combinations, including the Quidel Merger and the transactions contemplated by the BCA, and (b)&nbsp;has determined, subject to its duties under
applicable law, to recommend that the Quidel stockholders adopt the BCA and the transactions contemplated by the BCA. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE QUIDEL BOARD OF
DIRECTORS ACCORDINGLY RECOMMENDS THAT QUIDEL STOCKHOLDERS VOTE &#147;FOR&#148; THE MERGER PROPOSAL. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_86"></A>Quidel Proposal No.
2&#151;The Advisory Merger Compensation Proposal </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Item 2 on the Quidel proxy card) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Dodd-Frank Wall Street Reform and Consumer Protection Act, enacted in July 2010, requires that Quidel provide its stockholders with the opportunity to
cast a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory vote on the compensation that would be paid or become payable to Quidel&#146;s named executive officers that is based on or otherwise relates to the proposed Combinations, as
disclosed in this joint proxy statement/prospectus, including the disclosures set forth in the section entitled &#147;Interests of Certain Persons in the Combinations (Quidel)&#151;Golden Parachute Compensation&#148; of this joint proxy
statement/prospectus. This <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory vote is commonly referred to as a &#147;golden parachute say on pay&#148; vote. This <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory vote relates
only to contractual obligations of Quidel that may result in a payment to Quidel&#146;s named executive officers in connection with, or following, the consummation of the proposed Combinations and does not relate to any compensation arrangement with
Quidel&#146;s directors or executive officers who are not named executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an advisory vote, this proposal is not binding upon Quidel or the
Quidel board of directors, and approval of this proposal is not a condition to completion of the Combinations or Quidel&#146;s, Ortho&#146;s or Topco&#146;s obligations to effect the Combinations. The vote on executive compensation payable in
connection with the proposed Combinations is a vote separate and apart from the vote to approve the Merger Proposal. Accordingly, you may vote to approve the Merger Proposal, but vote not to approve the Advisory Merger Compensation Proposal. Because
the vote is advisory, it will not be binding on Quidel. Accordingly, to the extent that Quidel is contractually obligated to pay certain merger-related compensation, such compensation will be payable, subject only to the contractual conditions
applicable thereto, if the Combinations are consummated and regardless of the outcome of the advisory vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the Advisory Merger Compensation
Proposal requires the affirmative vote of a majority of the voting power represented at the Quidel Stockholders&#146; Meeting in person or by proxy and entitled to vote on such proposal. If you are present in person or represented by proxy at the
meeting but do not vote, or if you abstain, the effect will be the same as a vote &#147;AGAINST&#148; the Advisory Merger Compensation Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE
QUIDEL BOARD OF DIRECTORS RECOMMENDS THAT QUIDEL STOCKHOLDERS VOTE &#147;FOR&#148; THE ADVISORY MERGER COMPENSATION PROPOSAL. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_86a">
</A>Quidel Proposal No. 3&#151;The Adjournment Proposal </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Item 3 on the Quidel proxy card) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Quidel Stockholders&#146; Meeting, Quidel stockholders (whether voting in person or by proxy) may be asked to vote on a proposal to adjourn the Quidel
Stockholders&#146; Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Quidel Stockholders&#146; Meeting to approve the Merger Proposal. Quidel is asking that you authorize the
holder of your proxy to vote in favor of any such Adjournment Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the Adjournment Proposal requires the affirmative vote of a majority
of the voting power represented at the Quidel Stockholders&#146; Meeting in person or by proxy and entitled to vote on such proposal. If you are present in person or represented by proxy at the meeting but do not vote, or if you abstain, the effect
will be the same as a vote &#147;AGAINST&#148; the Adjournment Proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE QUIDEL BOARD OF DIRECTORS RECOMMENDS THAT QUIDEL STOCKHOLDERS VOTE &#147;FOR&#148; THE ADJOURNMENT
PROPOSAL. </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_86b"></A>Quidel Proposal No. 4&#151;The Election of Directors Proposal </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Item 4 on the Quidel proxy card) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominees for Election
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel directors are elected at each annual meeting of stockholders. The Quidel Stockholders&#146; Meeting will serve as Quidel&#146;s annual meeting
of stockholders for 2022. At the Quidel Stockholders&#146; Meeting, Quidel stockholders will vote on the election of eight directors to serve until the 2023 annual meeting of stockholders and until their successors are elected and qualified. The
eight nominees receiving the greatest number of votes at the Quidel Stockholders&#146; Meeting will be elected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors has
unanimously nominated Douglas C. Bryant, Kenneth F. Buechler, Ph.D., Edward L. Michael, Mary Lake Polan, M.D., Ph.D., M.P.H., Ann D. Rhoads, Matthew W. Strobeck, Ph.D., Kenneth J. Widder, M.D. and Joseph D. Wilkins Jr. for election to the Quidel
board of directors. Two of Quidel&#146;s current directors, Kathy P. Ordo&ntilde;ez and Charles P. Slacik, will be retiring and will not be standing for <FONT STYLE="white-space:nowrap">re-election</FONT> to the Quidel board of directors and their
terms will expire at the Quidel Stockholders&#146; Meeting. Upon the expiration of their terms, the authorized size of the Quidel board of directors will be reduced to eight members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Ortho Effective Time, the Topco board of directors will have twelve members and will initially consist of Messrs. Bryant, Buechler, Michael, Strobeck,
Widder and Wilkins and Mses. Polan and Rhoads, plus four directors designated by Ortho, each of whom will serve until his or her successor is elected and qualified, or until his or her earlier death, retirement, resignation or removal. At the Quidel
Effective Time, Messrs. Bryant, Buechler, Michael, Strobeck, Widder and Wilkins and Mses. Polan and Rhoads will resign from the Quidel board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the nominees set forth below for election as a director is an incumbent director. Each of the eight nominees has consented to serve as a director if
elected. Unless authority to vote for any director nominee is withheld in a proxy, it is intended that each proxy will be voted FOR each of the nominees. If, before the Quidel Stockholders&#146; Meeting, any of the nominees for director should
become unable to serve if elected, it is intended that shares represented by proxies will be voted for such substitute nominees, if any, as may be recommended by the existing Quidel board of directors, unless other directions are given in the
proxies. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Nominee</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Principal Occupation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Director<BR>Since</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Douglas C. Bryant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">64</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer of Quidel Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2009</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Kenneth F. Buechler, Ph.D., Chair</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">68</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Founder and former President and Chief Scientific Officer of Biosite Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2007</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Edward L. Michael</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Managing Partner and <FONT STYLE="white-space:nowrap">Co-Founder</FONT> of LionBird Ventures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mary Lake Polan, M.D., Ph.D., M.P.H.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">78</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Professor of Clinical Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1993</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ann D. Rhoads</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Former Chief Financial Officer of Forty Seven, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2020</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Matthew W. Strobeck, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">49</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Managing Partner of Birchview Capital</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Kenneth J. Widder, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">69</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer of Sydnexis Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2014</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Joseph D. Wilkins Jr.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">60</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Managing Director of JW Healthcare Insights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2021</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required and Board Recommendation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the Election of Directors<B> </B>Proposal requires the affirmative vote of a plurality of the voting power represented at the Quidel
Stockholders&#146; Meeting in person or by proxy and entitled to vote on such proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE QUIDEL BOARD OF DIRECTORS RECOMMENDS THAT QUIDEL STOCKHOLDERS VOTE &#147;FOR&#148; THE ELECTION
OF DIRECTORS PROPOSAL. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Biographical Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>DOUGLAS C. BRYANT</I>&nbsp;was appointed to the Quidel board of directors in February&nbsp;2009 and became our President and Chief Executive Officer in
March&nbsp;2009. Prior to joining us, Mr.&nbsp;Bryant served as Executive Vice President and Chief Operating Officer at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&amp;D, technical
operations, and commercial operations. From 1983 to 2007, Mr.&nbsp;Bryant held various worldwide commercial operations positions with Abbott Laboratories including, among others: Vice President of Abbott Vascular for Asia/Japan, Vice President of
Abbott Molecular Global Commercial Operations and Vice President of Abbott Diagnostics Global Commercial Operations. Earlier in his career with Abbott, Mr.&nbsp;Bryant was Vice President of Diagnostic Operations in Europe, the Middle East and
Africa, and Vice President of Diagnostic Operations in Asia Pacific. Mr.&nbsp;Bryant has nearly 40&nbsp;years of industry experience in sales and marketing, product development, manufacturing and service and support in both the diagnostics and life
sciences markets. Mr.&nbsp;Bryant holds a B.A. in Economics from the University of California at Davis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>KENNETH F.
BUECHLER,</I><I></I><I>&nbsp;Ph.D.</I>&nbsp;was appointed to the Quidel board of directors in November 2007 and has served as the Chairman of the Quidel board of directors since August 2015. Dr.&nbsp;Buechler was previously the <FONT
STYLE="white-space:nowrap">co-founder</FONT> of and held various roles at Biosite Inc. from 1988 until its acquisition by Alere Inc. in 2007, including serving as a director and as President and Chief Scientific Officer, Senior Vice President,
Research and Development, Vice President, Research and Director of Chemistry. Prior to <FONT STYLE="white-space:nowrap">co-founding</FONT> Biosite, Dr.&nbsp;Buechler was a senior research scientist for the diagnostics research and development group
at Hybritech Incorporated. Dr.&nbsp;Buechler served as chair of the board of directors of Sequenom Inc., a life sciences company, until its acquisition in September 2016, Astute Medical Inc., a company that develops biomarkers for acute medical
conditions, until its acquisition in April 2018 and Edico Genome Inc., a DNA sequencing technology company, until its acquisition in May 2018. Dr.&nbsp;Buechler received his Ph.D. in Biochemistry and his bachelor&#146;s degree in Chemistry from
Indiana University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>EDWARD L. MICHAEL</I>&nbsp;was appointed to the Quidel board of directors in December 2018. Mr.&nbsp;Michael is the Managing
Partner of LionBird Ventures, a venture capital firm he <FONT STYLE="white-space:nowrap">co-founded</FONT> in 2012, which focuses on investing in digital health and business services companies. For nearly 27 years, Mr.&nbsp;Michael held a variety of
roles at Abbott Laboratories, including most recently as Executive Vice President, Diagnostic Products and previously in legal, commercial and operational roles in various Abbott divisions. Mr.&nbsp;Michael currently serves on the board of directors
of certain LionBird portfolio companies. Mr.&nbsp;Michael received his B.A. from Indiana University and a J.D. from Indiana University School of Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MARY LAKE POLAN,</I><I></I><I>&nbsp;M.D.,</I><I></I><I>&nbsp;Ph.D., M.P.H.</I>&nbsp;was appointed to the Quidel board of directors in February 1993.
Dr.&nbsp;Polan was an Adjunct Professor in the Department of Obstetrics and Gynecology at Columbia University School of Medicine from 2007 to 2014 and then in 2015 rejoined the Department of Obstetrics and Gynecology at Yale University School of
Medicine as Professor of Clinical Obstetrics, Gynecology and Reproductive Sciences. Dr. Polan was Professor and Chair Emerita of the Department of Gynecology and Obstetrics at Stanford University School of Medicine where she served from 1990 to
2005. Dr.&nbsp;Polan received a B.A. degree from Connecticut College, a Ph.D. in Molecular Biophysics and Biochemistry and an M.D. from Yale University School of Medicine and her Master in Public Health from the University of California, Berkeley.
Dr.&nbsp;Polan remained at Yale New Haven Hospital for her residency in Obstetrics and Gynecology, followed by a Reproductive Endocrine Fellowship. Dr.&nbsp;Polan was on the faculty at Yale University until 1990, when she joined Stanford University.
Dr.&nbsp;Polan is a practicing clinical Reproductive Endocrinologist with a research interest in ovarian function and granulosa cell steroidogenesis. More recently, Dr.&nbsp;Polan&#146;s interests have been in the interaction between the immune and
endocrine systems: the role of monokines in reproductive events and gene expression in stress urinary incontinence, as well as brain activation in human sexual function. Dr.&nbsp;Polan also serves as a director at the following private companies: NX
Prenatal Inc, <FONT STYLE="white-space:nowrap">Or-Genix</FONT> Therapeutics, Inc., Residents Diagnostics, Inc., and MiraDx, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ANN D. RHOADS</I> was
appointed to the Quidel board of directors in August 2020. Ms.&nbsp;Rhoads most recently served as Chief Financial Officer of Forty Seven, Inc., a publicly traded biotechnology company, from March 2018 through June 2020. Previously, Ms.&nbsp;Rhoads
was Executive Vice President and Chief Financial Officer of Zogenix, Inc., a publicly traded pharmaceutical company, from 2010 through January 2017. From 2000 through the end of 2009, Ms.&nbsp;Rhoads served as the Chief Financial Officer of Premier,
Inc., a healthcare supply management company. From 1998 to 2000, she was Vice President, Strategic Initiatives at Premier, Inc., and from 1993 to 1998, she was an investment professional with The Sprout Group, an institutional venture capital firm.
Ms.&nbsp;Rhoads currently serves on the board of directors of the following publicly traded companies: Globus Medical Inc., a musculoskeletal solutions company, as chair of the audit committee and a member
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the nominating and governance committee; Repare Therapeutics, a precision oncology company, as chair of the audit committee; and iTeos Therapeutics, an immuno-oncology company, as chair of the
audit committee and a member of the compensation and nominating and governance committee. Ms.&nbsp;Rhoads also recently served on the board of directors of Iridex Corporation, a medical device company, from 2017 to 2018. Ms.&nbsp;Rhoads holds a B.S.
in Finance from the University of Arkansas and an M.B.A. from Harvard Graduate School of Business Administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MATTHEW W. STROBECK, Ph.D. </I>was
appointed to the Quidel board of directors in April 2018. Dr.&nbsp;Strobeck is currently the Managing Partner of Birchview Capital. Dr.&nbsp;Strobeck was a Partner and member of the management committee and advisory board of Westfield Capital
Management from 2008 until 2011, having served as a member of the investment team, specializing in healthcare and life sciences, from May 2003 to June 2008. Dr.&nbsp;Strobeck currently serves on the board of directors of Accelerate Diagnostics, a
medical diagnostics company, Biodesix, a diagnostic company, and Monteris Medical, a privately held medical device company. Dr.&nbsp;Strobeck received his B.S. from St. Lawrence University, a Ph.D. from the University of Cincinnati, an S.M. from the
Harvard University/MIT Health Sciences Technology Program, and an S.M. from the MIT Sloan School of Management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>KENNETH J. WIDDER, M.D.</I> was
appointed to the Quidel board of directors in November 2014. Dr.&nbsp;Widder has more than 30 years of experience working with biomedical companies. Dr.&nbsp;Widder has served as the Executive Chairman of OrphoMed Inc., a clinical-stage
biopharmaceutical company, since 2017, and Chairman and Chief Executive Officer of Sydnexis, Inc., an ophthalmology <FONT STYLE="white-space:nowrap">start-up</FONT> company, since 2017. Dr.&nbsp;Widder was a General Partner with LVP Life Science
Ventures, a venture capital company for biotechnology and medical device <FONT STYLE="white-space:nowrap">start-ups,</FONT> from 2007 to 2016. He is also a member of the board of directors of Evoke Pharma Inc., a pharmaceutical company.
Dr.&nbsp;Widder holds an M.D. from Northwestern University and trained in Pathology at Duke University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>JOSEPH D. WILKINS JR.</I> was appointed to the
Quidel board of directors in February 2021. Mr.&nbsp;Wilkins has served as Managing Director for JW Healthcare Insights, a healthcare consulting firm, since 2019. He is also a limited partner with Tech Council Ventures, a privately held venture
capital fund, and an advisor with Touchdown Ventures, a privately held venture capital group. Previously, from 2018 to 2019, Mr.&nbsp;Wilkins served as a Partner for TRG Healthcare, a healthcare consulting firm. From 2016 to 2018, Mr.&nbsp;Wilkins
served as Senior Vice President and Chief Transformation/Innovation Officer for Atlantic Health System, an integrated healthcare delivery system. Prior to that, Mr.&nbsp;Wilkins led commercial operations teams at Quest Diagnostics and before that
held a variety of roles at Danaher-Beckman Coulter for approximately 28 years. Mr.&nbsp;Wilkins also currently serves on the board of directors of Mazzetti, a privately held engineering and design benefit corporation. Mr.&nbsp;Wilkins earned a B.S.
and an M.B.A. degree from Argosy University and is a Board-certified Fellow of the American College of Healthcare Executives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Qualification and
Characteristics for Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Quidel board of directors should possess the highest personal and professional ethics, integrity,
judgment and values, and be committed to representing the long-term interests of Quidel&#146;s stockholders. As described in Quidel&#146;s Corporate Governance Guidelines, the Quidel board of directors is particularly interested in maintaining a mix
that includes the following attributes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">History of superior performance or accomplishments in professional undertakings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Highest personal and professional ethics and values and sound principles of corporate governance in today&#146;s
business environment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Depth of understanding of Quidel&#146;s industry, including relevant technology, leadership and objectivity and a
general understanding of marketing, finance and other disciplines relevant to the success of a publicly traded company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Diversity of background and personal experience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fit of abilities and personality with those of current and potential directors in building a board of directors
that is effective, collegial and responsive to the needs of Quidel&#146;s business; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Independence and an absence of conflicting time commitments. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel believes its board members represent a desirable mix of backgrounds, skills and experiences, and they all share the personal attributes of effective
directors, which are described above. With respect to director gender and diversity, among </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Quidel&#146;s director nominees, two directors identified themselves as female, seven directors identified themselves as white and one director identified himself as black. Below are some of the
specific experiences and skills of Quidel&#146;s director nominees: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>DOUGLAS C. BRYANT</I>. Mr. Bryant is Quidel&#146;s President and Chief Executive
Officer. Mr. Bryant has a background of strong executive experience in the diagnostics industry in the United States and internationally. Mr. Bryant brings nearly 40&nbsp;years of industry experience in sales and marketing, product development,
manufacturing and service and support in the diagnostics and life sciences markets. In addition, as Quidel&#146;s President and Chief Executive Officer, the Quidel board of directors believes it is appropriate for him to be a member of its board.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>KENNETH F. BUECHLER, Ph.D.</I> Dr. Buechler has extensive experience in the field of diagnostics as a scientist and through his founding of Biosite
Inc. Dr. Buechler also has extensive executive leadership and governance experience through his service on the boards of other companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>EDWARD L.
MICHAEL</I>. Mr. Michael has substantial experience in the diagnostics industry and technology utilized by Quidel through his executive leadership positions at Abbott Laboratories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MARY LAKE POLAN, M.D., Ph.D., M.P.H.</I> Dr. Polan is a prominent medical clinician, researcher and academician. Dr.&nbsp;Polan has extensive experience in
the area of women&#146;s health, which is an important area for Quidel. As a medical doctor, Dr.&nbsp;Polan brings an important practicing physician perspective in evaluating and overseeing Quidel&#146;s performance and strategic direction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ANN D. RHOADS</I>. Ms. Rhoads has a strong financial background as a former chief financial officer of Forty Seven, Inc., Zogenix, Inc. and Premier, Inc.
Ms.&nbsp;Rhoads is an audit committee financial expert as a result of her prior experience as a Chief Financial Officer and as a board member and chair of the audit committee of other U.S. public companies. Ms.&nbsp;Rhoads also has extensive
executive leadership and governance experience through her service on the boards of other companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MATTHEW W. STROBECK, Ph.D.</I> Dr. Strobeck has a
strong scientific background and experience investing in and working with healthcare and life sciences companies. Dr. Strobeck currently serves on the boards of various diagnostic and medical device companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>KENNETH J. WIDDER, M.D. </I>Dr. Widder has more than 30 years of experience working with biomedical companies. Dr. Widder also has a strong background
related to investments in emerging healthcare companies and serves on the boards of several other companies. As a medical doctor, trained in pathology, Dr. Widder provides valuable insight from the perspective of both an executive and that of a
physician. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>JOSEPH D. WILKINS JR.</I> Mr. Wilkins has more than 30 years of experience in the diagnostics and healthcare industry, including roles at
healthcare consulting firms and an integrated healthcare delivery system, as an investor in venture capital and as a board member of Mazzetti, an engineering and design benefit corporation. Mr. Wilkins is also a founding board director at Black
Directors Health Equity Agenda (BDHEA), a Six Sigma Certified practitioner and holds corporate governance certifications from both UCI and USC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_86c">
</A>Quidel Proposal No. 5&#151;The Advisory Executive Compensation Proposal </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Item 5 on the Quidel proxy card) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel is providing its stockholders with an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> vote on the compensation of Quidel&#146;s named
executive officers (&#147;NEOs&#148;) (commonly referred to as &#147;say on pay&#148;). Accordingly, you may vote on the following resolution at the Quidel Stockholders&#146; Meeting: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Resolved, that the compensation paid to Quidel&#146;s NEOs, as disclosed in the section entitled &#147;Other Matters Relating to the Quidel
Stockholders&#146; Meeting&#151;Compensation Discussion and Analysis,&#148; the accompanying compensation tables, and the related narrative discussion in this joint proxy statement/prospectus, is hereby approved.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The advisory approval of Quidel&#146;s executive compensation is a <FONT STYLE="white-space:nowrap">non-binding</FONT> vote on the compensation paid to
Quidel&#146;s NEOs, as described pursuant to Item&nbsp;402 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K,</FONT> including the section entitled &#147;Other Matters Relating to the Quidel Stockholders&#146; Meeting&#151;Executive
Compensation&#151;Compensation Discussion and Analysis,&#148; the accompanying compensation tables, and the related narrative discussion set forth in this joint proxy statement/prospectus. At Quidel&#146;s
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
annual meeting of stockholders in 2017, Quidel stockholders overwhelmingly indicated a preference for holding annual say on pay votes. Accordingly, Quidel is presenting this proposal for the
advisory approval of the compensation of Quidel&#146;s NEOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in detail under the section entitled &#147;Other Matters Relating to the Quidel
Stockholders&#146; Meeting&#151;Executive Compensation&#151;Compensation Discussion and Analysis,&#148; Quidel&#146;s compensation programs are designed to attract, motivate and retain highly qualified executive officers who are able to achieve
corporate objectives and create stockholder value. The compensation committee of the Quidel board of directors believes Quidel&#146;s executive compensation programs reflect a strong
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> philosophy and are well aligned with Quidel stockholders&#146; long-term interests. Quidel stockholders are encouraged to read the section entitled
&#147;Other Matters Relating to the Quidel Stockholders&#146; Meeting&#151;Executive Compensation&#151;Compensation Discussion and Analysis&#148; of this joint proxy statement/prospectus, the accompanying compensation tables, and the related
narrative discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the vote on this proposal is advisory in nature, it will not affect any compensation already paid or awarded to
Quidel&#146;s NEOs and will not be binding on the Quidel board of directors or its compensation committee. However, the compensation committee of the Quidel board of directors will consider the outcome of the vote when making future executive
compensation decisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required and Board Recommendation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the Advisory Executive Compensation Proposal<B> </B>requires the affirmative vote of a majority of the voting power represented at the Quidel
Stockholders&#146; Meeting in person or by proxy and entitled to vote on such proposal. If you are present in person or represented by proxy at the meeting but do not vote, or if you abstain, the effect will be the same as a vote &#147;AGAINST&#148;
the Advisory Executive Compensation Proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE QUIDEL BOARD OF DIRECTORS RECOMMENDS THAT QUIDEL STOCKHOLDERS VOTE &#147;FOR&#148; THE ADVISORY
EXECUTIVE COMPENSATION PROPOSAL. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_86d"></A>Quidel Proposal No. 6&#151;The Independent Registered Public Accounting Firm Proposal
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Item 6 on the Quidel proxy card) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee
of the Quidel board of directors has selected the firm of Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, to audit Quidel&#146;s consolidated financial statements for the fiscal year ending December&nbsp;31, 2022 and to
perform other appropriate accounting and tax services. Quidel is asking its stockholders to ratify the selection of Ernst&nbsp;&amp; Young LLP as Quidel&#146;s independent registered public accounting firm for 2022. Although ratification is not
required by the Quidel Bylaws or otherwise, the Quidel board of directors is submitting the selection of Ernst&nbsp;&amp; Young LLP to Quidel stockholders as a matter of good corporate practice. If Quidel stockholders do not ratify the appointment
of Ernst&nbsp;&amp; Young LLP, the selection of Quidel&#146;s independent registered public accounting firm will be reconsidered by the audit committee of the Quidel board of directors. Even if the selection is ratified, the audit committee of the
Quidel board of directors, in its discretion, may direct the appointment of a different independent registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of Quidel and its
stockholders. After consummation of the Combinations, the Topco board of directors will select an independent registered public accounting firm as its independent registered public accounting firm for fiscal year 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One or more representatives of Ernst&nbsp;&amp; Young LLP are expected to attend the Quidel Stockholders&#146; Meeting. The representatives of
Ernst&nbsp;&amp; Young LLP will have an opportunity to make a statement, if they so desire, and will be available to respond to appropriate questions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required and Board Recommendation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the
Independent Registered Public Accounting Firm Proposal requires the affirmative vote of a majority of the voting power represented at the Quidel Stockholders&#146; Meeting in person or by proxy and entitled to vote on such proposal. If you are
present in person or represented by proxy at the meeting but do not vote, or if you abstain, the effect will be the same as a vote &#147;AGAINST&#148; the Independent Registered Public Accounting Firm Proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE QUIDEL BOARD OF DIRECTORS RECOMMENDS THAT QUIDEL STOCKHOLDERS VOTE &#147;FOR&#148; THE
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM PROPOSAL. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_86e"></A>Quidel Proposal No. 7&#151;The Equity Incentive Plan Proposal
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Item 7 on the Quidel proxy card) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;4,
2022, the Quidel board of directors authorized, subject to Quidel stockholder approval, an amendment and restatement of Quidel&#146;s 2018 Equity Incentive Plan (the &#147;2018 Plan&#148;), which 2018 Plan was previously approved by Quidel
stockholders in May 2018, to increase the number of Quidel Shares available under the 2018 Plan from 3,205,635 shares to 4,705,635 shares and to make certain other ministerial changes to the 2018 Plan. The purpose of this amendment is to allow
Quidel to continue to utilize the 2018 Plan and accordingly, to provide Quidel with flexibility in attracting employees in the future. Approval of the Equity Incentive Plan Proposal will enable Quidel to continue to use equity compensation for these
purposes. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Upon consummation of the Combinations, the 2018 Plan will be assumed by Topco and a number of Topco Shares equal
to the number of Quidel Shares subject to the 2018 Plan will be issuable under the 2018 Plan following the consummation of the Combinations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the Combinations are not consummated, the Quidel board of directors has approved a reduction in the number of
Quidel Shares available for future issuance under the 2018 Plan to 4,205,635 shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March 4, 2022, there were 830,893 Quidel
Stock Options, 729,277 Quidel RSUs and 19,642 Quidel PSUs outstanding under the Quidel Stock Plans and 1,350,265 shares remained available for future issuance under the 2018 Plan. As of March 4, 2022, the weighted average exercise price of the
outstanding options was $69.84 with a weighted average remaining term of 6.54 years. Other than the foregoing, no other awards under the Quidel Stock Plans were outstanding as of March 4, 2022. The potential dilution from the 1,500,000
&#147;new&#148; shares requested to be approved by Quidel&#146;s stockholders is 3.6% of outstanding Quidel Shares as of March 4, 2022. The potential dilution from the 2,930,077&nbsp;shares currently authorized for issuance under the 2018 Plan
reflects 7.0% of outstanding Quidel Shares as of March 4, 2022. Therefore, if the Equity Incentive Plan Proposal is approved, Quidel&#146;s total potential dilution would increase from 7.0% of outstanding Quidel Shares as of March 4, 2022 to 10.6%
of outstanding Quidel Shares as of March 4, 2022. Upon consummation of the Combinations, the potential dilution would be decreased to 6.6% of outstanding Topco Shares, based on the number of outstanding Quidel Shares and Ortho Shares as of March 4,
2022. In the event the Combinations are not consummated and the number of shares available for future issuance is reduced as described above, the potential dilution would be decreased to 9.4%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel considers its long-term dilution by managing the number of shares subject to equity awards that it grants annually, commonly referred to as the burn
rate (calculated by dividing all shares subject to equity awards granted during the fiscal year by the number of outstanding shares at the end of the fiscal year). The burn rate shows how rapidly a company is depleting its shares reserved for future
issuance under its equity compensation plans. Over the past three fiscal years, Quidel&#146;s burn rate has averaged 1.3% (0.8% in fiscal year 2021, 1.5% in fiscal year 2020 and 1.8% in fiscal year 2019). Quidel believes that this burn rate is
relatively low. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When considering the increase in the number of shares under the 2018 Plan to be approved, the compensation committee of the Quidel board
of directors also reviewed, among other things, projected future share usage and projected future forfeitures, in each case assuming the Combinations are consummated. The projected future usage of shares for long-term incentive awards under the 2018
Plan was reviewed under scenarios based on a variety of assumptions, including the consummation of the Combinations. Depending on these assumptions, the&nbsp;1,500,000&nbsp;share increase to be approved under the 2018 Plan, in combination with the
remaining authorized shares and shares potentially available under the 2018 Plan from forfeitures of awards previously granted under the 2018 Plan and prior plans, is expected to satisfy Topco&#146;s equity compensation needs for approximately three
years. The compensation committee of the Quidel board of directors is committed to effectively managing the number of shares reserved for issuance under the 2018 Plan, in light of the 2018 Plan&#146;s purposes, while minimizing stockholder dilution.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted above, upon consummation of the Combinations, the 2018 Plan will be assumed by Topco. As of March&nbsp;4, 2022, on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis assuming consummation of the Combinations, there were 1,337,238 Ortho Stock Options, 36,808 unvested RSUs, 17,539 RSUs outstanding under Ortho&#146;s equity compensation plans, and 1,632,945 Ortho
Shares remained available for future issuance under Ortho&#146;s equity compensation plans. As of March&nbsp;4, 2022, the weighted average exercise price of the outstanding Ortho Stock Options was $11.51 with a weighted average remaining term of
6.76 years. Other than the foregoing, no other awards under Ortho&#146;s equity compensation plans were outstanding as of March&nbsp;4, 2022. Following the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consummation of the Combinations, if the Equity Incentive Plan Proposal is approved by the Quidel stockholders, no additional awards will be granted under Ortho&#146;s equity compensation plans.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of the 2018 Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary is a
description of the material features of the 2018 Plan, as proposed to be amended and restated, and is qualified in its entirety by reference to the full text of the 2018 Plan, as proposed to be amended and restated, a copy of which is attached
hereto as<I></I> Annex&nbsp;G. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose.</I>&nbsp;The purpose of the 2018 Plan is to promote Quidel&#146;s and its stockholders&#146; interests by
using equity interests in Quidel to attract, retain and motivate its directors, management, employees and other persons, to encourage and reward their contributions to Quidel&#146;s performance and to align their interests with the interests of
Quidel&#146;s stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration, Amendment and Termination.</I>&nbsp;The 2018 Plan is administered by the compensation committee of the
Quidel board of directors (the &#147;administrator&#148;). The administrator has the power to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">select the eligible persons to whom, and the times at which, awards will be granted, the nature of each award and
the terms and conditions of each award; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interpret the 2018 Plan and the rights of recipients of awards granted under the 2018 Plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accelerate or extend the vesting or exercise period of any award, and make such other modifications in the terms
and conditions of an award as it deems advisable; provided, however, that the administrator may not, other than in connection with a change in capitalization, reprice or otherwise reduce the exercise or base price of a Quidel Stock Option or stock
appreciation right (including by the cancellation of the Quidel Stock Option or stock appreciation right in exchange for cash, other awards, or a new Quidel Stock Option or stock appreciation right at such reduced exercise or base price or by
amendment of the Quidel Stock Option or stock appreciation right) without stockholder approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any amendment of the 2018 Plan shall,
in the discretion of the administrator, apply to and govern awards granted under the 2018 Plan prior to the date of such amendment;<I></I>&nbsp;provided, however, that the consent of an award holder is required if such amendment would alter, impair
or diminish in any material respect any rights or obligations under any award or cause the award to cease to qualify as an incentive stock option. Awards may be granted under the 2018 Plan until May&nbsp;15, 2028, unless earlier terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Securities Subject to the 2018 Plan</I>. The aggregate number of Quidel Shares issuable pursuant to the 2018 Plan, as proposed to be amended and restated,
may not exceed&nbsp;3,150,000&nbsp;shares, plus (i)&nbsp;any shares that were authorized for issuance under Quidel&#146;s 2016 Equity Incentive Plan that, as of May&nbsp;15, 2018, remained available for issuance under the 2016 Equity Incentive Plan
(not including any shares that are subject to outstanding awards under the 2016 Equity Incentive Plan or any shares that previously were issued pursuant to awards granted under the 2016 Equity Incentive Plan) and (ii)&nbsp;any shares subject to
outstanding awards under Quidel&#146;s 2001 Equity Incentive Plan, Amended and Restated 2010 Equity Incentive Plan, and 2016 Equity Incentive Plan as of May&nbsp;15, 2018, that on or after such date ceased for any reason to be subject to such awards
(other than by reason of exercise or settlement of the awards to the extent they are exercised for or settled in vested and nonforfeitable shares), subject in each case to adjustment upon a change in capitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted above, as of March&nbsp;4, 2022,&nbsp;1,350,265&nbsp;Quidel Shares remained available for issuance for future awards under the 2018 Plan.
Accordingly, if the Equity Incentive Plan Proposal is approved by Quidel&#146;s stockholders, approximately 2,850,265&nbsp;shares will be available for future awards under the 2018 Plan, consisting of&nbsp;1,500,000&nbsp;new shares and
approximately&nbsp;1,350,265&nbsp;remaining shares previously authorized and available for issuance under the 2018 Plan (as of March&nbsp;4, 2022). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
2018 Plan provides that each share issued under awards other than Quidel Stock Options or stock appreciation rights (&#147;full-value awards&#148;) will count against the number of shares available under the 2018 Plan as 1.5 shares. Shares issued
under Quidel Stock Options or stock appreciation rights count against the shares available under the 2018 Plan on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. The Quidel board of directors
believes that this formula-based limit will allow for the issuance of a sufficient number of full-value awards to satisfy projected grants thereof, while providing the flexibility to change the mix of Quidel Stock Options and full-value awards to
the extent its compensation committee determines a different mix than currently provided is in the best interests of Quidel and its stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel may issue Quidel Shares under the 2018 Plan from authorized but unissued Quidel Shares or from
previously issued Quidel Shares that it reacquired, including shares purchased on the open market. For purposes of calculating the aggregate number of shares issued under the 2018 Plan, Quidel will count only the number of shares issued upon
exercise or settlement of an award and not returned to Quidel upon expiration, termination or cancellation of any awards. However, if an award holder pays the exercise price or withholding taxes relating to a Quidel Stock Option or stock
appreciation right with Quidel Shares, or if Quidel withholds shares otherwise issuable upon exercise of a Quidel Stock Option or stock appreciation right in satisfaction of the exercise price or withholding taxes payment, then Quidel will reduce
the number of Quidel Shares available for issuance under the 2018 Plan by the gross number of shares for which the award is exercised. In addition, upon the exercise of a Quidel Stock Option or stock appreciation right, the number of Quidel Shares
available for issuance under the 2018 Plan will be reduced by the gross number of shares to which the award relates and not by the net number of shares issued to the holder in settlement thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2018 Plan provides that the administrator shall appropriately and proportionately adjust the maximum number and kind of shares subject to the 2018 Plan,
the number and kind of shares or other securities subject to then outstanding awards, the price for each share or other unit of any other securities subject to, or measurement criteria applicable to, then outstanding awards, and/or the number and
kind of shares or other securities to be issued as <FONT STYLE="white-space:nowrap">non-employee</FONT> director options if Quidel Shares are affected by any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consolidation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sale or exchange of assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recapitalization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reclassification; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock dividend; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extraordinary cash dividend; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock split; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reverse stock split; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">spin off; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">similar transaction. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted above, upon consummation of the Combinations, the 2018 Plan will be assumed by Topco and the Quidel Shares subject to the 2018 Plan will be replaced
by an equivalent number of Topco Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Awards Under the 2018 Plan</I>. Quidel may grant the following types of awards under the 2018 Plan: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel Stock Options; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance awards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restricted stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock appreciation rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock payments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dividend equivalents and dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock bonuses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock sales; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">phantom stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel RSUs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel PSUs; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other stock-based benefits. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel Stock Options granted under the 2018 Plan may be incentive stock options intended to qualify under the provisions of Section&nbsp;422 of the Code or
nonqualified stock options that do not so qualify. However, the aggregate fair market value of stock with respect to which any employee&#146;s incentive stock options first become exercisable during any calendar year (under all Quidel Stock Plans
and those of any subsidiary corporation) may not exceed $100,000 (as determined on the grant date), and may be further limited by other requirements in the Code. If this $100,000 limitation is exceeded, the excess incentive stock options will be
treated as nonqualified stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Individual Limitations on Awards</I>. No <FONT STYLE="white-space:nowrap">non-employee</FONT> director
participant in the 2018 Plan may be granted cash and awards under the 2018 Plan that exceed $750,000 in total value during a single calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. Quidel&#146;s directors, officers, employees, consultants and advisors, and those of its affiliated entities, are eligible to receive
awards under the 2018 Plan. As of March&nbsp;4, 2022, 125&nbsp;persons (not including consultants and advisors) were eligible for selection to receive awards under the 2018 Plan, consisting of: 109&nbsp;employees of Quidel other than executive
officers, 7 executive officers of Quidel and <FONT STYLE="white-space:nowrap">9&nbsp;non-employee</FONT> directors of Quidel. To date, no consultants or advisors have been granted awards under the 2018 Plan. Following consummation of the
Combinations, approximately 334&nbsp;persons (not including consultants and advisors) are expected to be eligible for selection to receive awards under the 2018 Plan, consisting of: 323 employees of Topco (including executive officers) and 11 <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors of Topco. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Terms and Conditions of <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director Options.</I><FONT STYLE="white-space:nowrap">&nbsp;Non-employee</FONT> directors of Quidel are eligible to receive grants of awards under the 2018 Plan, including nonqualified stock options, at the discretion of the administrator. Under the
2018 Plan, all grants of Quidel Stock Options to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors fully vest and become exercisable one year following the grant date if the <FONT STYLE="white-space:nowrap">non-employee</FONT> director
has remained a director for the entire period from the date of grant to the vesting date. Notwithstanding the foregoing, if the recipient has remained a director from the period of the date of grant until the next annual meeting of Quidel&#146;s
stockholders following the grant date, but ceases to be a director following the annual meeting of Quidel&#146;s stockholders (either because the director is not <FONT STYLE="white-space:nowrap">re-elected</FONT> or because the director chooses not
to run for another term), the Quidel Stock Options that were granted to the director at the annual meeting in the prior year shall continue to vest following the date that the recipient ceases to be a director and shall become exercisable one year
following the grant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Terms and Conditions of Other Awards.</I>&nbsp;The administrator will select the recipients of awards granted under the 2018
Plan from the pool of eligible persons and will set the terms of the awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Award Pricing.</I>&nbsp;The administrator will determine the exercise or
purchase price of awards granted under the 2018 Plan, which, with respect to Quidel Stock Options and stock appreciation rights, will be no less than the fair market value of the shares underlying the award as of the grant date. In addition, the
exercise price for an incentive stock option must comply with the provisions of Section&nbsp;422 of the Code. Section&nbsp;422 currently provides that the exercise price must not be less than the fair market value of the common stock on the date of
grant and not less than 110% of the fair market value as of the date of grant in the case of a grant to a person owning more than 10% of the total combined voting power of all classes of the issuer&#146;s stock or the stock of any parent or any
subsidiary corporations. On March&nbsp;4, 2022, the closing price of Quidel Shares on Nasdaq was $99.57 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Award Vesting and
Term.</I>&nbsp;The administrator will determine the date or dates on which awards granted under the 2018 Plan vest and become exercisable. In addition, the administrator may provide for accelerated vesting upon a change in control or the
recipient&#146;s death or disability. The term of each Quidel Stock Option or stock appreciation right granted will expire no later than ten (10)&nbsp;years after the date the Quidel Stock Option or stock appreciation right is granted and may be
subject to earlier termination as described below. In addition, the term for an incentive stock option must comply with the provisions of Section&nbsp;422 of the Code. Section&nbsp;422 currently provides that the incentive stock option may not be
exercisable after the expiration of 10&nbsp;years from the date of grant, or five years in the case of an incentive stock option granted to a person owning more than 10% of the total combined voting power of all classes of stock of the issuer, or of
its parent or any subsidiary corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Awards granted under the 2018 Plan may be exercised at any time after they vest and before the expiration date
determined by the administrator; provided that an award is generally exercisable following an award holder&#146;s termination of employment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
only to the extent that the award had become exercisable on or before the date of termination (other than Quidel Stock Options granted to <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors) and to the extent that the award is not forfeited under the terms of the 2018 Plan. Furthermore, in the absence of a specific agreement to the contrary, Quidel Stock Options will generally expire and become unexercisable immediately upon
termination of the recipient&#146;s employment with Quidel for just cause (as defined in the 2018 Plan); 90&nbsp;days after termination of the recipient&#146;s employment with Quidel for any reason other than just cause, death or permanent
disability; or one year after termination of the recipient&#146;s employment with Quidel due to death or permanent disability, in each case unless the term of the Quidel Stock Option provides for an earlier expiration. If the employment of a
recipient of restricted stock is terminated for any reason, any such restricted stock that remains subject to restrictions on the date of such termination will be repurchased by Quidel at the purchase price, if any, paid by the recipient, or
returned to Quidel without consideration; provided, however, that the administrator may in its discretion determine otherwise. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Award
Provisions.</I>&nbsp;The administrator will determine any applicable performance criteria, restrictions or conditions of any award. The administrator may establish performance criteria and level of achievement versus such criteria that will
determine the number of shares to be granted, retained, vested, issued or issuable under or in settlement of or the amount payable pursuant to an award, which criteria may (but need not) be based on &#147;performance criteria&#148; (as described
below) or other standards of financial performance and/or personal performance evaluations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the 2018 Plan, the term &#147;performance
criteria&#148; means any one or more of the following performance criteria, or derivations of such performance criteria, either individually, alternatively or in any combination, applied to either Quidel as a whole or to a business unit or
affiliated entity, either individually, alternatively or in any combination, and measured either annually (or over such shorter period) or cumulatively over a period of years, on an absolute basis or relative to a
<FONT STYLE="white-space:nowrap">pre-established</FONT> target, to previous years&#146; results or to a designated comparison group, in each case as specified by the administrator: (a)&nbsp;cash flow, (b)&nbsp;earnings and earnings per share
(including earnings before interest, taxes, and amortization), (c)&nbsp;return on equity, (d)&nbsp;total stockholder return, (e)&nbsp;return on capital, (f)&nbsp;return on assets or net assets, (g)&nbsp;aggregate product price or product sales,
(h)&nbsp;market share or market penetration with respect to specific designated products and/or geographic areas, (i)&nbsp;revenues, income or net income, (j)&nbsp;operating income or net operating income, (k)&nbsp;operating margin, (l)&nbsp;return
on operating revenue and (m)&nbsp;research and development milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Award Payments.</I>&nbsp;A holder of an award may pay cash or any other
consideration deemed acceptable by the administrator to pay the exercise price for the award, if any. The administrator may, in its discretion, allow an award holder to pay the exercise price for an award by delivering Quidel Shares, except in
limited circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Assignability</FONT> of Awards.</I>&nbsp;Awards are generally not transferable by the
recipient during the life of the recipient. Awards are generally exercisable during the life of a recipient only by the recipient. The administrator may, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, permit transfers for estate planning purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Award Documentation.</I>&nbsp;Each award under the 2018 Plan must be evidenced by an award document setting forth such terms and conditions applicable to
the award as the administrator may in its discretion determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rights With Respect to Stock Ownership.</I>&nbsp;No recipient of an award under the
2018 Plan or other person will have any right, title or interest in or to any Quidel Shares subject to any award or any rights as a stockholder, unless the award is duly exercised pursuant to the terms of the 2018 Plan and/or the Quidel Shares
subject to the award are issued to the recipient and/or the restrictions on the Quidel Shares subject to any award lapse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Provisions Regarding Changes
in Control.</I>&nbsp;As of the effective time and date of any change in control (as defined in the 2018 Plan), the 2018 Plan and any of the then outstanding awards (whether or not vested) will automatically terminate unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provision is made in writing in connection with such change in control transaction for the continuance of the
2018 Plan and for the assumption of such awards, or for the substitution for such awards of new awards covering the securities of a successor entity or an affiliate thereof with appropriate adjustments as to the number and kind of securities and
exercise prices or measurement criteria, in which event the 2018 Plan and such outstanding awards will continue or be replaced, as the case may be, in the manner and under the terms so provided; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Quidel board of directors otherwise provides in writing for such adjustments as it deems appropriate in the
terms and conditions of the then outstanding awards (whether or not vested), including without limitation accelerating the vesting of outstanding awards and/or providing for the cancellation of awards and their automatic conversion into the right to
receive the securities, cash or other consideration that a holder of the shares underlying such awards would have been entitled to receive upon consummation of such change in control had such shares been issued and outstanding immediately prior to
the effective date and time of the change in control (net of the appropriate option exercise prices). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, pursuant to these provisions, the 2018 Plan and the awards terminate by reason of the occurrence of
a change in control without provision for any of the actions described in the paragraph above, then any recipient holding outstanding awards will have the right, at such time immediately prior to the consummation of the change in control as the
Quidel board of directors will designate, to exercise or receive the full benefit of the recipient&#146;s awards to the full extent not theretofore exercised, including any installments that have not yet become vested. All <FONT
STYLE="white-space:nowrap">non-employee</FONT> director options granted under the 2018 Plan shall automatically vest and become exercisable immediately prior to a change in control if the optionee is a director of Quidel at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consummation of the Combinations will not be considered a change in control under the terms of the 2018 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clawback.</I>&nbsp;Every award issued under the 2018 Plan is subject to potential forfeiture or recovery to the fullest extent permitted by law, applicable
listing standards or any current or future clawback policy adopted by Quidel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2018 Plan Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of any awards under the 2018 Plan will be at the discretion of the compensation committee of the Quidel board of directors. Therefore, it is not
possible to determine the amount or form of any award that will be granted to any individual in the future. The following table sets forth the awards that were previously granted under the 2018 Plan through March&nbsp;4, 2022 to Quidel&#146;s named
executive officers (&#147;NEOs&#148;) and others. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of&nbsp;Quidel</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Stock Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of&nbsp;Quidel<BR>RSUs</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of&nbsp;Quidel<BR>PSUs</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant, President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward, Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski, Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges, SVP, General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll, Ph.D., SVP, Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers as a group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as a group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All employees as a group (excluding executive officers)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">496,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary of certain federal income tax consequences of the receipt and exercise of awards is based on the laws and regulations in effect as of the
date of this joint proxy statement/prospectus and does not purport to be a complete statement of the law in this area. Furthermore, the discussion below does not address the tax consequences of the receipt and exercise of awards under foreign, state
and local tax laws, and such tax laws may not correspond to the federal income tax treatment described herein. The exact federal income tax treatment of transactions under the 2018 Plan will vary depending upon the specific facts and circumstances
involved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Incentive Stock Options.</I>&nbsp;Except as discussed below, under federal income tax law, a recipient of an incentive stock option
generally will not realize tax on the grant or the exercise of the option if the recipient satisfies certain employment and holding period requirements.&nbsp;To satisfy the employment requirement, a recipient must exercise the option not later than
three months after the recipient ceases to be an employee of Quidel (or an employee of any parent or subsidiary corporation) (or within one year, if termination was due to a permanent and total disability), unless the recipient has died.&nbsp;To
satisfy the holding period requirement, a recipient must hold the stock acquired upon the exercise of the incentive stock option for more than two years from the date of grant of the option and more than one year after the transfer of the shares to
the recipient.&nbsp;If these requirements are met, the recipient will, on the sale of such stock, be taxed on any gain, measured by the difference between the option price and the net proceeds of sale, generally at long-term capital gains rates.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the recipient of the incentive stock option sells the shares acquired upon the exercise of the option
at any time within one year after the date Quidel issues the shares to the recipient or within two years after the date Quidel grants the incentive stock option to the recipient, then: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the recipient&#146;s sales price exceeds the purchase price the recipient paid for the shares upon exercise of
the incentive stock option, the recipient will recognize capital gain equal to the excess, if any, of the sales price over the fair market value of the shares on the date of exercise, and will recognize ordinary income equal to the excess, if any,
of the lesser of the sales price or the fair market value of the shares on the date of exercise over the purchase price paid for the shares upon exercise of the incentive stock option; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the recipient&#146;s sales price is less than the purchase price paid for the shares upon exercise of the
incentive stock option, the recipient will recognize a capital loss equal to the excess of the purchase price paid for the shares upon exercise of the incentive stock option over the sales price of the shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount by which the fair market value of shares the recipient acquires upon exercise of an incentive stock option (determined as of the date of exercise)
exceeds the purchase price paid for the shares upon exercise of the incentive stock option will be included as a positive adjustment in the calculation of the recipient&#146;s alternative minimum taxable income in the year of exercise, if the
recipient is subject to alternative minimum tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of an early disposition of shares by a recipient that results in the recognition of ordinary
income, Quidel will be entitled to a deduction equal to the amount of such ordinary income. If the recipient holds the shares for the requisite period described above and therefore solely recognizes capital gain upon the sale of such shares, Quidel
is not entitled to any deduction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nonqualified Stock Options.</I>&nbsp;The grant of a nonqualified stock option to a recipient is generally not a
taxable event for the recipient. Upon the exercise of a nonqualified stock option, the recipient will generally recognize ordinary income equal to the excess of the fair market value of the shares the recipient acquires upon exercise (determined as
of the date of exercise) over the purchase price paid for the shares upon exercise of the nonqualified stock option, subject to the deduction limitations of Section&nbsp;162(m) of the Code. Quidel generally will be entitled to deduct as a
compensation expense the amount of such ordinary income. Provided the shares are held as a capital asset, the recipient&#146;s subsequent sale of the shares generally will give rise to capital gain or loss equal to the difference between the sale
price and the sum of the purchase price paid for the shares plus the ordinary income recognized with respect to the shares, and such capital gain or loss will be taxable as long-term or short-term capital gain or loss depending upon the
recipient&#146;s holding period after exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights and Phantom Stock.</I>&nbsp;Generally, the holder of a stock appreciation
right or phantom stock award will recognize ordinary income equal to the value Quidel pays (whether in cash, stock or a combination thereof) on the date the holder receives payment. If Quidel places a limit on the amount that will be payable under a
stock appreciation right, the holder may recognize ordinary income equal to the value of the holder&#146;s right under the stock appreciation right at the time the value of such right equals such limit and the stock appreciation right is
exercisable, subject to the deduction limitations of Section&nbsp;162(m) of the Code. Quidel will generally be entitled to a deduction in an amount equal to the ordinary income recognized by the holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Purchase Rights - Restricted Stock.</I>&nbsp;Under the 2018 Plan, Quidel is authorized to grant rights to purchase its restricted common stock
subject to a right to repurchase such stock at the price paid by the participant if the participant&#146;s employment or service relationship with Quidel terminates prior to the lapse of such repurchase right. In general, there will be no tax
consequences to a participant upon the grant of a right to purchase such restricted stock or upon purchase of such restricted stock. Instead, the participant will be taxed at ordinary income rates at the time Quidel&#146;s repurchase rights expire
or are removed on an amount equal to the excess of the fair market value of the stock at that time over the amount the participant paid to acquire such stock. A participant who acquires restricted stock, however, may make an election under
Section&nbsp;83(b) of the Code with respect to such stock. If such an election is made within 30&nbsp;days after the participant&#146;s acquisition of the stock, the participant is taxed at ordinary income rates in the year in which the participant
acquires the restricted stock. The ordinary income the participant must recognize is equal to the excess of the fair market value of the stock at the time of the participant&#146;s acquisition of the stock (determined without regard to the
restrictions) over the amount that the participant paid to acquire such stock. If a participant makes a timely election under Section&nbsp;83(b) of the Code with respect to restricted stock, the participant generally will not be required to report
any additional income with respect to such restricted stock until he or she disposes of such stock, at which time he or she will generally recognize capital gain or loss (provided the shares are held as a capital asset) equal to the difference
between the sales price and the fair market value of the stock at the time of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
participant&#146;s acquisition of the stock (determined without regard to restrictions). In the event that a participant forfeits (as a result of Quidel&#146;s repurchase) restricted stock with
respect to which an election under Section&nbsp;83(b) of the Code has been made, the participant ordinarily will not be entitled to recognize any loss for federal income tax purposes (except to the extent the amount realized by the participant at
the time of such forfeiture is less than the participant&#146;s purchase price for such stock). Subject to the deduction limitations of Section&nbsp;162(m) of the Code, Quidel generally will be entitled to a deduction equal to the amount of ordinary
income (if any) recognized by a participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Awards.</I>&nbsp;In addition to the types of awards described above, the 2018 Plan authorizes
certain other awards that may include payments in cash, Quidel Shares, or a combination of cash and Quidel Shares. The tax consequences of such awards will depend upon the specific terms of such awards. Generally, however, a participant who receives
an award payable in cash will recognize ordinary income, and Quidel will, subject to the deduction limitations of Section&nbsp;162(m) of the Code, be entitled to a deduction, with respect to such award at the earliest time at which the participant
has an unrestricted right to receive the cash payment. In general, the sale or grant of stock to a participant under the 2018 Plan will be a taxable event at the time of the sale or grant if such stock at that time is not subject to a substantial
risk of forfeiture or is transferable within the meaning of Section&nbsp;83 of the Code in the hands of the participant. For such purposes, stock is ordinarily considered to be transferable if it can be transferred to another person who takes the
stock free of any substantial risk of forfeiture. In such case, the participant will recognize ordinary income, and, subject to the deduction limitations of Section&nbsp;162(m) of the Code, Quidel will be entitled to a deduction, equal to the excess
of the fair market value of such stock on the date of the sale or grant over the amount, if any, that the participant paid for such stock. Stock that, at the time of receipt by a participant, is subject to restrictions that constitute a substantial
risk of forfeiture and that is not transferable within the meaning of Section&nbsp;83 of the Code generally will be taxed under the rules applicable to restricted stock as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Withholding.</I>&nbsp;In the event that an optionee or other recipient of an award under the 2018 Plan is an employee of Quidel, Quidel ordinarily will be
required to withhold applicable federal income taxes with respect to any ordinary income recognized by such optionee or other award recipient in connection with Quidel Stock Options or other awards under the 2018 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain Additional Rules Applicable to Awards.</I>&nbsp;The terms of the awards granted under the 2018 Plan may provide for accelerated vesting in
connection with a change in control. In that event and depending upon the individual circumstances of the recipient, certain amounts with respect to such awards may constitute &#147;excess parachute payments&#148; under the &#147;golden
parachute&#148; provisions of the Code. Under these provisions, a participant will be subject to a 20% excise tax on any &#147;excess parachute payments&#148; and Quidel will be denied any deduction with respect to such excise tax payment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation in the 2018 Plan by Executive Officers, Directors and Other Employees; Interest of Certain Persons in Matters to be Acted Upon </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Quidel&#146;s current directors, executive officers and employees is eligible to receive awards under the 2018 Plan. The administrator has the
discretion to determine which eligible persons will receive awards under the 2018 Plan, though the amount and timing of such awards are not determinable at this time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required and Board Recommendation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the
Equity Incentive Plan Proposal requires the affirmative vote of a majority of the voting power represented at the Quidel Stockholders&#146; Meeting in person or by proxy and entitled to vote on such proposal. Abstentions have the same effect as a
vote &#147;AGAINST&#148; the Equity Incentive Plan Proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE QUIDEL BOARD OF DIRECTORS RECOMMENDS THAT QUIDEL STOCKHOLDERS VOTE &#147;FOR&#148;
THE EQUITY INCENTIVE PLAN PROPOSAL. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_86f"></A>Quidel Proposal No. 8&#151;The ESPP Proposal </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Item 8 on the Quidel proxy card) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;4, 2022, the
Quidel board of directors authorized, subject to Quidel stockholder approval, an amendment and restatement of Quidel&#146;s 1983 Employee Stock Purchase Plan (the &#147;1983 ESPP&#148;) to increase the number of Quidel Shares available under the
1983 ESPP from 30,197 shares to 780,197 shares. As of March&nbsp;4, 2022, 669,803 Quidel Shares have been sold under the 1983 ESPP, leaving 30,197 shares available for future issuance under the 1983 ESPP. If the ESPP Proposal is approved, a total of
780,197 Quidel Shares will be available for future issuance under the 1983 ESPP, which amount </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
represents 1.9% of the total number of Quidel Shares outstanding as of March&nbsp;4, 2022. Upon consummation of the Combinations, such would be decreased to 1.2% of outstanding Topco Shares,
based on the number of outstanding Quidel Shares and Ortho Shares as of March&nbsp;4, 2022. The purpose of this amendment is to allow Quidel to continue to utilize the 1983 ESPP and accordingly, to provide Quidel with flexibility in attracting
employees in the future and to encourage employee ownership of Quidel common stock. Approval of the ESPP Proposal will enable Quidel to continue to use equity compensation for these purposes. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Upon consummation of the Combinations, the 1983 ESPP will be assumed by Topco and a number of Topco Shares equal
to the number of Quidel Shares subject to the 1983 ESPP will be issuable under the 1983 ESPP following the consummation of the Combinations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the Combinations are not consummated, the Quidel board of directors has approved a reduction in the number of
Quidel Shares available for future issuance under the 1983 ESPP to 530,197 shares. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of the 1983 ESPP </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary is a description of the material features of the 1983 ESPP, as proposed to be amended and restated, and is qualified in its entirety by
reference to the full text of the 1983 ESPP, as proposed to be amended and restated, a copy of which is attached hereto as Annex&nbsp;H. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General</I>.&nbsp;The 1983 ESPP, which was adopted by the Quidel board of directors in March 1983 and approved by the Quidel stockholders in August 1983,
provides Quidel employees with the opportunity to purchase Quidel Shares through payroll deductions. If the ESPP Proposal is approved, a total of 780,197 Quidel Shares will be reserved for issuance under the 1983 ESPP. As noted above, upon
consummation of the Combinations, the 1983 ESPP will be assumed by Topco and the Quidel Shares subject to the 1983 ESPP will be replaced by an equivalent number of Topco Shares. Ortho does not have an employee stock purchase plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration</I>.&nbsp;The 1983 ESPP is administered by the compensation committee of the Quidel board of directors. The 1983 ESPP and the right of
participants to make purchases thereunder are intended to qualify under the provisions of Sections 421 and 423 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility and
Participation</I>.&nbsp;Any person who is customarily employed by Quidel or any of its designated subsidiaries on or before the beginning of the applicable offering period for at least 20 hours per week and more than five months per calendar year is
eligible to participate in the offering under the 1983 ESPP; provided that such person is employed by Quidel on the commencement date of the offering period, subject to certain limitations imposed by Section&nbsp;423(b) of the Code and limitations
on stock ownership as defined in the 1983 ESPP. As of March&nbsp;4, 2022, 1,300 persons (not including consultants and advisors) were eligible to participate in the 1983 ESPP, consisting of: 1,293 employees of Quidel other than executive officers
and 7 executive officers of Quidel. Following consummation of the Combinations, approximately 6,114 persons (not including consultants and advisors) are expected to be eligible to participate in the 1983 ESPP, consisting of: 6,114 employees of Topco
(including executive officers). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Offering Dates</I>.&nbsp;The 1983 ESPP is implemented by accumulating payroll deductions of participating employees
during a <FONT STYLE="white-space:nowrap">six-month</FONT> offering period, with the offering periods thereunder to commence February&nbsp;15 and August&nbsp;15 of each year. The Quidel board of directors has the power to alter the duration of the
offering periods without stockholder approval, if such change is announced at least 15 days prior to the scheduled beginning of the first offering period to be affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase Price</I>.&nbsp;The purchase price per share at which shares are sold in an offering under the 1983 ESPP is the lower of 85% of the fair market
value of a Quidel Share on the date of commencement of the <FONT STYLE="white-space:nowrap">six-month</FONT> offering period (the &#147;Entry Price&#148;), or 85% of the fair market value of a Quidel Share on the last day of the offering period (the
&#147;Exit Price&#148;). On March&nbsp;4, 2022, the closing price of Quidel Shares on Nasdaq was $99.57 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Payment of Purchase Price; Payroll
Deductions</I>.&nbsp;The purchase price of the shares is accumulated by payroll deductions over the offering period. The deductions may not exceed 10% of a participant&#146;s compensation. A participant may discontinue his or her participation in
the 1983 ESPP, and may decrease, but not increase, the rate of payroll deductions at any time during an offering period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase of
Stock</I>.&nbsp;By executing a subscription agreement to participate in the 1983 ESPP, the employee is entitled to have shares placed under option, which are exercisable on the last day of the offering period. The maximum number of shares
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
placed under option to a participant in an offering period is that number determined by dividing the amount accumulated in such participant&#146;s account during such offering period at the end
of the offering period by the lower of the Entry Price or the Exit Price, subject to a maximum of 5,000 shares. Unless the employee&#146;s participation is discontinued prior to such purchase date, his or her option for the purchase of the shares
will be exercised automatically at the end of the offering period at the applicable price. Notwithstanding the foregoing, however, no participant may receive an option (i)&nbsp;if immediately after such grant, the participant would own stock and/or
outstanding options to purchase stock possessing 5% or more of the total combined voting power of all classes of stock of Quidel or of any subsidiary of Quidel, or (ii)&nbsp;which permits the participant&#146;s rights to purchase stock to accrue at
a rate in excess of $25,000 worth of stock (determined at the fair market value of the stock at the time such option is granted) in any calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination</I>.&nbsp;The Quidel board of directors may at any time terminate or amend the 1983 ESPP. No such termination will affect options
previously granted, nor may any amendment make any change in any option previously granted which adversely affects the rights of any participant, nor may any amendment be made without prior stockholder approval if such amendment would
(i)&nbsp;increase the number of shares that may be issued under the 1983 ESPP, (ii)&nbsp;permit payroll deductions at a rate in excess of 10% of compensation, (iii)&nbsp;modify employee eligibility for participation requirements, or
(iv)&nbsp;materially increase benefits that may accrue to participants under the 1983 ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Assignability</FONT></I>.&nbsp;In general, neither payroll deductions credited to a participant&#146;s account nor any
rights with regard to the exercise of an option may be assigned, transferred, pledged or otherwise disposed of in any way by the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Adjustments upon Changes in Capitalization</I>.&nbsp;Subject to any required action by Quidel stockholders, the number of Quidel Shares covered by each
option that has not yet been exercised and the number of Quidel Shares that have been authorized for issuance under the 1983 ESPP but have not yet been placed under option, as well as the price per Quidel Share covered by each outstanding option,
shall be proportionately adjusted for any increase or decrease in the number of issued Quidel Shares resulting from a stock split or the payment of a stock dividend (but only on Quidel common stock) or any other increase or decrease in the number of
Quidel Shares effected without receipt of consideration by Quidel; provided that the conversion of convertible securities of Quidel will not be deemed to have been effected without the receipt of consideration. In the event that Quidel effects a
reorganization, recapitalization, rights offering or other increase or decrease of outstanding Quidel Shares , or in the event that Quidel is consolidated with or merged into any other corporation, the Quidel board of directors may, if it so
determines in the exercise of its discretion, make similar adjustments. As noted above, upon consummation of the Combinations, the 1983 ESPP will be assumed by Topco and the Quidel Shares subject to the 1983 ESPP shall be replaced by an equivalent
number of Topco Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Withdrawal; Termination of Employment</I>.&nbsp;A participant&#146;s interest in a given offering period may be terminated in
whole, but not in part, by signing and delivering to Quidel a notice of withdrawal from the 1983 ESPP . Such withdrawal may be elected at any time prior to the end of the applicable <FONT STYLE="white-space:nowrap">six-month</FONT> offering period.
A participant&#146;s withdrawal from one offering period does not have any effect upon such participant&#146;s eligibility to participate in subsequent offerings. Upon withdrawal from an offering period, all payroll deductions that have been
credited to the participant&#146;s account prior to the notice of withdrawal will be returned to the participant without interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Termination of a
participant&#146;s employment for any reason, including retirement or death, or the failure of the participant to remain in Quidel&#146;s continuous employ for at least 20 hours per week during the applicable offering period, cancels the
participant&#146;s participation in the 1983 ESPP. In such event, the payroll deductions credited to the participant&#146;s account will be returned to such participant or to his or her beneficiaries without interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compliance with Law</I>.&nbsp;Shares will not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such
shares pursuant thereto comply with all applicable provisions of law, including securities laws and the requirements of any stock exchange upon which the shares may then be listed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary of certain federal
income tax consequences of the grant and exercise of rights to purchase Quidel Shares under the 1983 ESPP is based on the laws and regulations in effect as of the date of this joint proxy statement/prospectus and does not purport to be a complete
statement of the law in this area. Furthermore, the discussion below does not address the tax consequences under foreign, state and local tax laws, and such tax laws may not correspond to the federal income tax treatment described herein. The exact
federal income tax treatment of transactions under the 1983 ESPP will vary depending upon the specific facts and circumstances involved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 1983 ESPP is intended to qualify as an employee stock purchase plan under Section&nbsp;423 of the
Code. If certain employment requirements are satisfied, an employee who is granted a right, or &#147;option,&#148; to purchase stock under a plan meeting the requirements of Section&nbsp;423 of the Code will not be subject to federal income tax, and
Quidel will not be entitled to any deduction, on either the grant or the exercise of such right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the employee makes no disposition of the stock
acquired pursuant to the exercise of such right within two years after the date of the grant of such stock purchase right (generally, the commencement date of the <FONT STYLE="white-space:nowrap">six-month</FONT> offering period, hereinafter
referred to as the &#147;Offering Date&#148;) or within one year after the transfer of the stock to the employee pursuant to the exercise of such right, any gain or loss on the subsequent disposition of the stock generally will be treated as capital
gain or loss, except to the extent that the employee&#146;s purchase price was less than 100% of the fair market value of the stock on the Offering Date, and no deduction will be available to Quidel at the time of such disposition. If the
employee&#146;s purchase price for the stock was less than 100% of the fair market value of the stock on the Offering Date, the employee will be required to include in his or her gross income as ordinary income for the year of the disposition (or,
if earlier, at the time of his or her death) an amount equal to the lesser of (i)&nbsp;the excess of the fair market value of the stock on the Offering Date over the purchase price that the employee would have been required to pay if the employee
had exercised such right as of the Offering Date, or (ii)&nbsp;the excess of the fair market value of the stock at the time of the disposition or death over the amount paid for the stock. No deduction will be available to Quidel with respect to any
such ordinary income recognized by the employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any sale or other disposition of stock acquired under a right granted under the 1983 ESPP at any time
within (i)&nbsp;two years after the Offering Date or (ii)&nbsp;one year after the transfer of the shares to the employee pursuant to the exercise of such right generally will be treated as a &#147;disqualifying disposition.&#148; Upon a
disqualifying disposition, the employee generally will recognize ordinary compensation income in an amount equal to the difference between the purchase price and the fair market value of the stock on the date the option was exercised. Any gain in
excess of such ordinary income amount generally will be capital gain. Quidel generally will be entitled to a deduction in an amount equal to the amount of ordinary income recognized by the employee by reason of a disqualifying disposition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation in the 1983 ESPP by Executive Officers, Directors and Other Employees; Interest of Certain Persons in Matters to be Acted Upon </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of Quidel&#146;s employees, including its employee-directors and executive officers, who satisfy the eligibility requirements described above are eligible
to participate in the 1983 ESPP. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors are not eligible to participate. Participation in the 1983 ESPP is voluntary and is dependent on each eligible employee&#146;s election to participate
and his or her determination as to the level of payroll deductions. Accordingly, future purchases by executive officers and other employees under the 1983 ESPP are not determinable. The following table sets forth the number of Quidel Shares
purchased under the 1983 ESPP through February 14, 2022 (the most recent purchase date) by Quidel&#146;s NEOs and others. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name and Position</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number&nbsp;of&nbsp;Quidel&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant, President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward, Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski, Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges, SVP, General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll, Ph.D., SVP, Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers as a group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as a group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All employees as a group (excluding executive officers)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">645,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required and Board Recommendation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the ESPP Proposal requires the affirmative vote of a majority of the voting power represented at the Quidel Stockholders&#146; Meeting in person or
by proxy and entitled to vote on such proposal. Abstentions have the same effect as a vote &#147;AGAINST&#148; the ESPP Proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE QUIDEL BOARD OF
DIRECTORS RECOMMENDS THAT QUIDEL STOCKHOLDERS VOTE &#147;FOR&#148; THE ESPP PROPOSAL. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_86g"></A>OTHER MATTERS RELATING TO THE QUIDEL STOCKHOLDERS&#146;
MEETING </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_86h"></A>Committees and Meetings of the Quidel Board of Directors and Related Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors currently has three standing committees&#151;the Audit Committee, Compensation Committee and Nominating and Corporate Governance
Committee. The Quidel board of directors held 24 meetings, excluding committee meetings, during the year ended December&nbsp;31, 2021. All current directors and nominees attended at least 75% of all meetings of the Quidel board of directors and its
committees, if any, on which the directors served during the year ended December&nbsp;31, 2021. Information about Quidel&#146;s directors and the committees of the Quidel board of directors in 2021 follows. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Director Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Committee</B></P></TD></TR>


<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Audit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nominating&nbsp;and<BR>Corporate<BR>Governance</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth F. Buechler, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B></B>&#10003;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B></B>&#10003;<B></B><B></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward L. Michael</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Chair</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathy P. Ordo&ntilde;ez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B></B>&#10003;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Lake Polan, M.D., Ph.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B></B>&#10003;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ann D. Rhoads</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B></B>&#10003;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles P. Slacik</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Chair</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew W. Strobeck, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B></B>&#10003;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth J. Widder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B></B>&#10003;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Chair</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph D. Wilkins Jr. (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B></B>&#10003;<B></B><B></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Number of Committee Meetings Held in 2021:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#10003; = Committee Member&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B> Chair </B>=
Committee Chair </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Wilkins joined the Quidel board of directors on February&nbsp;26, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Audit Committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee is responsible for
assisting the Quidel board of directors in overseeing Quidel&#146;s accounting and financial reporting processes and the audits of Quidel&#146;s consolidated financial statements. In addition, the Audit Committee assists the Quidel board of
directors in its oversight of its compliance with legal and regulatory requirements. Under the Audit Committee&#146;s written charter, the specific duties of the Audit Committee include, among others: monitoring the integrity of Quidel&#146;s
financial process and systems of internal controls regarding finance, accounting and legal compliance; selecting Quidel&#146;s independent registered public accounting firm; monitoring the independence and performance of Quidel&#146;s independent
registered public accounting firm; and providing an avenue of communication among Quidel&#146;s independent registered public accounting firm, management and the Quidel board of directors. The Audit Committee has the authority to conduct any
investigation appropriate to fulfilling its responsibilities, and it has direct access to all of Quidel&#146;s employees and to the independent registered public accounting firm. The Audit Committee also has the ability to retain, at Quidel&#146;s
expense and without further approval of the Quidel board of directors, legal, accounting or other consultants or experts that it deems necessary in the performance of its duties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has been established in accordance with applicable Nasdaq and SEC rules and regulations. The Quidel board of directors has also determined
that Ms. Rhoads and Mr.&nbsp;Slacik each qualify as an &#147;audit committee financial expert&#148; within the meaning of the SEC&#146;s rules and regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Report of the Audit Committee of the Quidel Board of Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee oversees Quidel&#146;s financial reporting process on behalf of the Quidel board of directors. Management has the responsibility for
preparing the consolidated financial statements and for the reporting process, including the Quidel&#146;s systems of internal controls. In fulfilling its oversight responsibilities, the Audit Committee reviewed and discussed the audited
consolidated financial statements in Quidel&#146;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2021 with management, including a discussion of the quality, not just the acceptability,
of accounting principles, the reasonableness of significant judgments and the clarity of disclosures in the consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has discussed and reviewed with Quidel&#146;s independent registered public
accounting firm all matters required to be discussed under the Public Company Accounting Oversight Board (&#147;PCAOB&#148;) Accounting Standard No.&nbsp;1301 (Communications with Audit Committees), as may be modified or supplemented. The Audit
Committee has met with the independent registered public accounting firm to discuss the overall scope and plans for the independent registered public accounting firm&#146;s audit, the results of its examinations, its evaluations of Quidel&#146;s
internal controls and the overall quality of Quidel&#146;s accounting and financial reporting. The Audit Committee also discussed with the independent registered public accounting firm the firm&#146;s judgments as to the substance and clarity, not
just the acceptability, of Quidel&#146;s accounting principles and financial statement disclosures. The Audit Committee has also considered whether the independent registered public accounting firm&#146;s provision of
<FONT STYLE="white-space:nowrap">non-audit</FONT> services to Quidel is compatible with the independent registered public accounting firm&#146;s independence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee also reviewed management&#146;s report on its assessment of the effectiveness of Quidel&#146;s internal control over financial reporting
and Ernst&nbsp;&amp; Young LLP&#146;s report on the effectiveness of Quidel&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has
received from the independent registered public accounting firm a formal written statement describing all relationships between the independent registered public accounting firm and Quidel that might bear on the independent registered public
accounting firm&#146;s independence consistent with PCAOB Rule&nbsp;3526 (Communication with Audit Committees Concerning Independence), has discussed with the independent registered public accounting firm any relationships that may impact its
objectivity and independence, and has satisfied itself as to the independent registered public accounting firm&#146;s independence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In reliance on the
reviews and discussions referred to above, the Audit Committee recommended to the Quidel board of directors (and the Quidel board of directors has approved) that the audited consolidated financial statements be included in Quidel&#146;s Annual
Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Audit
Committee </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Charles P. Slacik (Chair) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ann D. Rhoads </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Matthew W. Strobeck, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Kenneth J. Widder, M.D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This Audit Committee Report does not constitute soliciting material and shall not be deemed filed or incorporated by reference into any Quidel&#146;s
filing under the Securities Act or the Exchange Act, except to the extent Quidel specifically incorporates this report. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Principal Accountant Fees
and Services </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quidel&#146;s Audit Committee retained Ernst&nbsp;&amp; Young LLP (PCAOB ID: 42) (San Diego, California) to serve as
Quidel&#146;s independent registered public accounting firm for the fiscal year ended December&nbsp;31, 2021. Set forth below are the aggregate fees incurred by Quidel for audit and other professional services rendered by its independent registered
public accounting firm for the fiscal years ended December&nbsp;31, 2021 and 2020. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Years Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,009,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,654,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-related fees<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax fees<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,264,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,117,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit fees represent fees for professional services provided in connection with the audit of Quidel&#146;s
consolidated financial statements, review of quarterly consolidated financial statements, audit of compliance under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, accounting consultations, assistance with and review of documents filed with the
SEC and statutory and regulatory filings. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For fiscal years 2021 and 2020, audit-related fees consisted of
<FONT STYLE="white-space:nowrap">non-recurring</FONT> due diligence fees related to mergers and acquisitions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For fiscal years 2021 and 2020, tax fees primarily consisted of tax compliance, tax advice and tax planning
fees. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Policy on Audit Committee <FONT STYLE="white-space:nowrap">Pre-approval</FONT> of Audit and Permissible Non-audit Services
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee is responsible for appointing, compensating, retaining and overseeing the work of Quidel&#146;s independent registered public
accounting firm. The Audit Committee&#146;s policy is to <FONT STYLE="white-space:nowrap">pre-approve</FONT> all audit and permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> services provided by Quidel&#146;s independent registered public
accounting firm. <FONT STYLE="white-space:nowrap">Pre-approval</FONT> is detailed as to the particular service or category of services and is generally subject to a specific budget. The Audit Committee may also
<FONT STYLE="white-space:nowrap">pre-approve</FONT> particular services on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. In assessing requests for services to be provided by Quidel&#146;s
independent registered public accounting firm, the Audit Committee considers whether such services are consistent with the auditor&#146;s independence, whether the independent registered public accounting firm is likely to provide the most effective
and efficient services, and whether the services could enhance Quidel&#146;s ability to manage or control risk or improve audit quality. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the
audit, audit-related, tax and other fees provided by Ernst&nbsp;&amp; Young LLP in fiscal years 2021 and 2020 (and as described in the footnotes to the table above) were approved in advance by the Audit Committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Review and Approval of Related Party Transactions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Audit Committee reviews all relationships, transactions and arrangements in which Quidel and any director, nominee for director, executive officer or beneficial holder of more than 5% of Quidel&#146;s outstanding common stock or any immediate family
member of any of the foregoing are participants (&#147;Interested Transactions&#148;) to determine whether such persons have a direct or indirect material interest and whether to approve, disapprove or ratify an Interested Transaction. Quidel has
written policies and procedures for monitoring and seeking approval in connection with any Interested Transaction. Quidel&#146;s legal and finance departments assist in monitoring Interested Transactions and the Audit Committee reviews, approves (or
disapproves) or ratifies Interested Transactions. In considering whether to approve or ratify an Interested Transaction, the Audit Committee takes into account, among other factors it deems appropriate, whether the Interested Transaction is on terms
no less favorable than terms generally available to an unaffiliated third party under the same or similar terms and conditions and the extent of the related person&#146;s interest in the Interested Transaction. In addition, Quidel&#146;s written
policy provides that no director shall participate in any discussion or approval of an Interested Transaction for which he or she is a related party, except that the director shall provide all material information concerning the Interested
Transaction to the Audit Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Related Party Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No director, nominee for director, executive officer or beneficial holder of more than 5% of Quidel&#146;s outstanding common stock or any immediate family
member of any of the foregoing had any material interest, direct or indirect, in any reportable transaction with Quidel or had any reportable business relationship with Quidel during the 2021 fiscal year or since the commencement of the current
fiscal year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Compensation Committee is responsible for assisting the Quidel board of directors in discharging its responsibilities regarding the compensation of Quidel&#146;s employees and directors. Under the Compensation Committee&#146;s written charter, the
specific duties of the Compensation Committee include, among others: reviewing and approving (or recommending to the Quidel board of directors for approval) corporate goals and objectives relevant to executive compensation; evaluating Quidel&#146;s
executive officers&#146; performance in light of such goals and objectives; determining (or recommending to the Quidel board of directors for determination) the compensation levels of Quidel&#146;s executive officers based on such evaluations;
administering Quidel&#146;s incentive compensation plans, including Quidel&#146;s equity-based incentive plans; and making recommendations to the Quidel board of directors regarding Quidel&#146;s overall compensation structure, policies and programs
and human capital management matters. The Compensation Committee also has the ability to retain, at Quidel&#146;s expense and without further approval of the Quidel board of directors, compensation consultants and advisors that it deems necessary in
the performance of its duties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee Interlocks and Insider Participation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Michael, Dr.&nbsp;Buechler, Ms.&nbsp;Ordo&ntilde;ez and Dr.&nbsp;Polan are not current or former officers or employees of Quidel&#146;s, and none has
engaged in any transaction that would be required to be disclosed in this joint proxy statement/prospectus by Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> There is no relationship that requires disclosure as a compensation
committee interlock for purposes of Item 407(e)(4) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nominating and Corporate Governance
Committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee is responsible for assisting the Quidel board of directors in identifying qualified
candidates for election to the Quidel board of directors; recommending the composition of Quidel board of directors and its committees; monitoring and assessing the effectiveness of the Quidel board of directors and its committees; and performing a
leadership role in shaping and monitoring Quidel&#146;s corporate governance, environmental and sustainability policies and initiatives. Under the Nominating and Corporate Governance Committee&#146;s written charter, the specific duties of the
Nominating and Corporate Governance Committee include, among others: identifying, reviewing and recruiting candidates for election to the Quidel board of directors; reviewing the qualifications of director candidates recommended by Quidel&#146;s
stockholders; monitoring the independence of current directors and nominees; recommending to the Quidel board of directors candidates for election or <FONT STYLE="white-space:nowrap">re-election</FONT> to the Quidel board of directors at each annual
meeting of stockholders; overseeing the periodic evaluation of the Quidel board of directors, its committees and each of Quidel&#146;s incumbent directors; reviewing the Quidel board of directors succession planning; and overseeing Quidel&#146;s
Corporate Governance Guidelines, Code of Business Conduct and Ethics and sustainability strategy, initiatives and policies (including oversight of environmental management, climate risk, human rights, diversity and inclusion, stakeholder engagement
and business ethics programs). </P> <P STYLE="margin-top:17pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Meetings of Non-management Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">non-management</FONT> members of the Quidel board of directors regularly meet in executive sessions without any employee
director or other members of management in attendance. </P> <P STYLE="margin-top:17pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Nominations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee regularly assesses the appropriate size of the Quidel board of directors and whether any vacancies on the
Quidel board of directors are expected due to retirement or otherwise. The Nominating and Corporate Governance Committee utilizes a variety of methods for identifying and evaluating director candidates. Candidates may come to the attention of the
Nominating and Corporate Governance Committee through current directors, professional search firms, stockholders or other persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the Nominating
and Corporate Governance Committee has identified a prospective nominee, the Nominating and Corporate Governance Committee will evaluate the prospective nominee in the context of the then-current composition of Quidel board of directors and will
consider a variety of other factors, including the prospective nominee&#146;s business, technology, medical, scientific, industry, finance and financial reporting experience and other attributes that would be expected to contribute to an effective
board. As described in Quidel&#146;s Corporate Governance Guidelines, in evaluating the suitability of individuals to serve as board members, the Quidel board of directors and the Nominating and Corporate Governance Committee consider a number of
factors, including: experience at a policy-making level; strategic thinking; depth of understanding of Quidel&#146;s industry, including relevant technology, leadership and objectivity; and a general understanding of marketing, finance and other
disciplines relevant to the success of a publicly traded company and of sound principles of corporate governance in today&#146;s business environment. The Nominating and Corporate Governance Committee seeks to identify nominees who possess a wide
range of experience, skills, and areas of expertise, knowledge and business judgment. Nominees must have the attributes described above in the section titled &#147;The Quidel Stockholders&#146; Meeting&#151;Quidel Proposal No. 4&#151;The Election of
Directors Proposal&#151;Qualifications and Characteristics for Directors&#148; section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee will consider
stockholder recommendations for director candidates. A stockholder may propose a person for consideration by the committee by submitting the individual&#146;s name and qualifications to Quidel&#146;s Corporate Secretary, Quidel Corporation, 9975
Summers Ridge Road, San Diego, California&nbsp;92121. The Nominating and Corporate Governance Committee will consider each stockholder-recommended candidate in the same manner and under the same criteria used to evaluate all other candidates (as
described above). The Quidel board of directors and the Nominating and Corporate Governance Committee evaluate each individual in the context of the Quidel board of directors functions as a whole and in light of the then-current needs of the Quidel
board of directors, with the objective of providing independent, diversified and effective representation of the interests of Quidel&#146;s stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders who wish to nominate candidates for election to the Quidel board of directors at any annual
meeting must follow the procedures set forth in Quidel&#146;s bylaws, including providing timely written notice, in proper form, of the intent to make such a nomination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Communications with the Quidel Board of Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s stockholders may communicate with the Quidel board of directors, a committee of the the Quidel board of directors or an individual director by
sending a letter addressed to the board of directors, a committee or a director, c/o Corporate Secretary, Quidel Corporation, 9975 Summers Ridge Road, San Diego, California 92121. All communications will be compiled by Quidel&#146;s Corporate
Secretary and forwarded to the Quidel board of directors, the committee or the director accordingly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Independence </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors has determined that each of its directors, with the exception of Mr.&nbsp;Bryant, is independent within the meaning of the Nasdaq
Marketplace Rules as adopted by Nasdaq, as well as with respect to enhanced independence standards contained in Nasdaq&#146;s rules that relate specifically to audit committees and compensation committees. Mr.&nbsp;Bryant who serves as Quidel&#146;s
President and Chief Executive Officer is not considered to be independent because of his employment with Quidel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Board Leadership Structure and Risk
Oversight </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s Corporate Governance Guidelines provide its board with the flexibility to combine or separate the positions of Chairman of the
Board and Chief Executive Officer. Quidel believes this provides the Quidel board of directors with flexibility to determine the structure that is in the best interests of Quidel across a range of situations. Historically, the Quidel board of
directors has determined that the roles of Chairman and Chief Executive Officer should be separate as this structure enables Quidel&#146;s Chairman to maintain responsibility for coordinating board activities, including the scheduling of meetings
and executive sessions of the <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and managing the relevant agenda items in each case (in consultation with the Chief Executive Officer as appropriate), and Quidel&#146;s Chief Executive
Officer to focus on leading and managing Quidel. Kenneth F. Buechler, Ph.D. has served as Quidel&#146;s Chairman of the Board since 2015. If the Quidel board of directors determines that it is preferable to combine the position of Chairman and Chief
Executive Officer, the Quidel board of directors intends to designate an independent director to serve as lead independent director. The Quidel board of directors believes that its approach for overseeing risk, as described below, would be effective
under a variety of leadership frameworks. Accordingly, the Quidel board of directors&#146; risk oversight function did not significantly impact its selection of the current leadership structure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel takes a comprehensive approach to risk management. Quidel believes risk can arise in every decision and action taken, whether strategic or operational.
Quidel, therefore, seeks to include risk management principles in all of its management processes and in the responsibilities of its employees at every level. Quidel&#146;s comprehensive approach is reflected in the reporting processes by which its
management provides timely and comprehensive information to the Quidel board of directors to support the Quidel board of directors&#146; role in oversight, approval and decision-making. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors closely monitors the information it receives from the management and provides oversight and guidance to the management team
concerning the assessment and management of risk. The Quidel board of directors approves Quidel&#146;s high-level operating objectives, goals, strategies and policies to set the tone and direction for appropriate risk taking within the business. The
Quidel board of directors and its committees then emphasize this tone and direction in their oversight of management&#146;s implementation of Quidel&#146;s operating objectives, goals, strategies and policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s senior executives provide the Quidel board of directors and its committees with regular updates about Quidel&#146;s strategies and objectives
and the risks inherent within them at the Quidel board of directors and committee meetings and in regular reports. The board and committee meetings also provide a venue for directors to discuss issues with management. The Quidel board of directors
and its committees call special meetings when necessary to address specific issues or take specific actions. In addition, Quidel&#146;s directors have access to the management at all levels to discuss any matters of interest, including those related
to risk. Those members of management most knowledgeable about the issues often attend Quidel&#146;s board meetings to provide additional insight into items being discussed, including risk exposures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors has delegated oversight of matters involving certain specific areas of
risk exposure to its three standing committees. Each committee generally reports to the Quidel board of directors at regularly scheduled board meetings, and more frequently if appropriate, with respect to matters and risks for which such committee
provides oversight. The specific responsibilities of each of Quidel&#146;s board committees are more fully described above in the &#147;&#151;Audit Committee,&#148; &#147;&#151;Compensation Committee&#148; and &#147;&#151;Nominating and Corporate
Governance Committee&#148; sections. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Code of Business Conduct and Ethics </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel has adopted a Code of Business Conduct and Ethics that applies to all its officers, directors and employees. If Quidel grants any amendment or waiver,
including any implicit waiver, to its principal executive, financial or accounting officers (or&nbsp;persons performing similar functions), Quidel will disclose the nature of such amendment or waiver on Quidel&#146;s website at www.quidel.com or in
a report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> in accordance with applicable rules and regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Access to Corporate Governance
Documentation and Other Information Available on Quidel&#146;s Website </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s Code of Business Conduct and Ethics, the current charters for
each of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee and the Corporate Governance Guidelines are accessible via Quidel&#146;s website at www.quidel.com through the &#147;Investor Relations&#148; link
under the heading &#147;Governance.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Commitment to Environmental, Social and Governance (&#147;ESG&#148;) Matters </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel is committed to acting responsibly and sustainably and making a meaningful impact on the environment and on society. Quidel&#146;s goal is to ensure all
corporate actions are aligned with a long-term approach to best practices and emerging norms in the areas of environmental consciousness, social responsibility, ethics, diversity and inclusion, corporate governance, and supply chain ecosystem
responsibility, while providing value to Quidel&#146;s stockholders consistent with its business objectives. The Quidel board of directors oversees these activities, the Compensation Committee oversees human capital management and the Nominating and
Corporate Governance Committee oversees environmental and social matters. Some of Quidel&#146;s key environmental and societal priorities include: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Environmental Sustainability: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel is committed to protecting the natural environment and the community by complying with all applicable
legal and regulatory requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel engages its employees to accomplish this by conserving energy, reducing consumption of natural resources,
managing waste properly and encouraging reuse or recycling. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel has implemented a number of initiatives designed to reduce energy consumption in its manufacturing and
administrative facilities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Care for People: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Access to healthcare for all is a mission of Quidel, and Quidel is committed to democratizing access to accurate,
affordable, and where necessary, frequent testing across the United States and beyond. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As part of this commitment, Quidel has partnered with several major organizations to donate <FONT
STYLE="white-space:nowrap">COVID-19</FONT> testing products to various communities across the nation to promote increased testing within communities to help prevent the spread of <FONT STYLE="white-space:nowrap">COVID-19.</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel believes in upholding the principles of human rights and worker safety and observing fair labor practices
within its organization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel is committed to ensuring proper working conditions exist for the safety of its employees, such as
continuously improving its worker safety and health policies and systems, and providing appropriate training, reporting and controls. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel is committed to participating in and enhancing the communities it operates in, supporting diversity and
maintaining an environment of equal employment opportunities for all job applicants and members of its team. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel fulfills this commitment through a variety of measures, including internal and external posting of job
openings, hiring, training and promoting employees without regard to race, color, religion, gender identity or expression, pregnancy, national origin, ancestry, citizenship, military or veteran status, disability, medical condition, marital or
domestic partner status, sexual orientation, age, or any other considerations made unlawful by federal, state or local law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel prohibits discrimination based on a perception that anyone has any of these characteristics or is
associated with a person who has or is perceived as having any of these characteristics. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel looks at company programs, policies, procedures and activities with diversity and inclusion in mind.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In keeping with its core values, Quidel is steadfast in taking action to ensure equal employment opportunity in
accordance with all applicable federal, state and local laws. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product Quality and Safety: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel is committed to the highest product quality and safety standards. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel has adopted a comprehensive quality management system, ISO 13485, to help ensure the safety, efficacy and
customer satisfaction levels of Quidel&#146;s devices. This quality standard is the highest in the industry and more comprehensive than the more well-known ISO 9001 standards. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ethics&nbsp;&amp; Corporate Responsibility: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel is committed to ensuring ethical organizational governance, promoting business ethics and integrity, and
embracing diversity and inclusion in the board room and throughout the organization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel believes in continuing to strengthen, refine and enhance Quidel&#146;s ethics and compliance efforts with
the goal of fostering an environment where all stakeholders, including employees, customers and suppliers, can express their concerns and have them heard and considered. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel has strengthened its Code of Business Conduct and Ethics to enhance guidelines on lobbying, government
relations and political contributions, as well as human trafficking and supplier transactions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supply Chain Responsibility: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel has adopted a Conflict Minerals Compliance Program. Quidel&#146;s due diligence processes and efforts have
been designed to conform with the five-step framework recommended by the Second Edition of The Organisation for Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development Due Diligence Guidance for Responsible Supply Chains of
Minerals from Conflict-Affected and High-Risk Areas and the related Supplements for gold and for tin, tantalum and tungsten. Quidel&#146;s compliance program includes the following attributes: establishment of strong management systems; identifying
and assessing risks in the supply chain; designing and implementing a strategy to respond to identified risks; and supporting supply chain compliance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel is committed to ensuring that the standards of its suppliers are well aligned with those of Quidel. Quidel
has a documented supplier management process, including guidelines on supplier selection and supplier controls and management. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_86i">
</A>Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current compensation and benefit program for Quidel&#146;s
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors is designed to achieve the following goals: compensation should fairly pay directors for work required for a company of Quidel&#146;s size and scope; compensation should align
directors&#146; interests with the long-term interests of Quidel&#146;s other stockholders; and the structure of the compensation should be simple, transparent and easy for stockholders to understand. The table below relating to <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors&#146; compensation includes the following compensation elements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual Cash Retainers
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Chairman of the Quidel board of directors currently receives an annual cash retainer of $92,400. Each of the other <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors receives an annual cash retainer of $50,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Chair of Quidel&#146;s Audit
Committee, Compensation Committee and Nominating and Corporate Governance Committee receives an additional annual cash retainer of $20,000, $15,000 and $10,000, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> Director Deferred Compensation Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2010, the Quidel board of directors adopted a <FONT STYLE="white-space:nowrap">non-employee</FONT> director deferred compensation
program that began in 2011. Participating directors may elect on a yearly basis (for the yearly period between Quidel&#146;s annual meetings of stockholders) to receive 50% or 100% of the cash value of the director&#146;s (i)&nbsp;annual retainer
fee and (ii)&nbsp;compensation for service as a Chair of any of the Quidel board of directors&#146; standing committees (collectively, the &#147;Covered Fees&#148;) in the form of fully vested RSUs, plus an additional premium on such percentage of
the Covered Fees, in the form of additional RSUs, which are subject to a <FONT STYLE="white-space:nowrap">one-year</FONT> vesting requirement (the &#147;Director Premium RSUs&#148;). The additional premium applicable to the Director Premium RSUs
shall be determined based on the length of time of the deferral period (between the grant date and the date the shares of common stock underlying the RSUs are to be issued) selected by the participating director as follows: (i)&nbsp;if one
(1)&nbsp;year from the grant date, a premium of 10% on the amount of the Covered Fees deferred; (ii)&nbsp;if two (2)&nbsp;years from the grant date, a premium of 20% on the amount of the Covered Fees deferred; or (iii)&nbsp;if four (4)&nbsp;years
from the grant date, a premium of 30% on the amount of the Covered Fees deferred. The RSUs are currently granted under the 2018 Plan (or applicable successor plan) as of the date of the applicable annual meeting of stockholders, and the number of
shares awarded as RSUs is calculated based on the closing price of Quidel&#146;s common stock on the date of the applicable annual meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets forth the amount deferred, deferral period and amount of Covered Fees RSUs (as defined below) and Director Premium RSUs
granted to each <FONT STYLE="white-space:nowrap">non-employee</FONT> director for 2021. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B><br><B>Deferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deferral</B><br><B>Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Covered</B><br><B>Fees</B><br><B>RSUs&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director</B><br><B>Premium</B><br><B>RSUs&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth F. Buechler,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward L. Michael</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathy P. Ordo&ntilde;ez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Lake Polan,&nbsp;M.D.,&nbsp;Ph.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ann D. Rhoads</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles P. Slacik</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew W. Strobeck, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth J. Widder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph D. Wilkins Jr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Periodic Equity Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Quidel board of directors periodically assesses potential equity awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors.
On May&nbsp;18, 2021, the Quidel board of directors approved RSU grants with a total valuation of $190,000 for each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. Accordingly, a grant of 1,624 RSUs (with a fair value per RSU based on
the closing price of Quidel&#146;s common stock on the grant date) was made to each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. The RSUs vest upon the first anniversary of the grant date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Wilkins was appointed to the Quidel board of directors in February 2021. As part of Mr.&nbsp;Wilkins&#146;s appointment to the Quidel
board of directors, the Quidel board of directors approved a RSU grant with a total valuation of approximately $47,500. Accordingly, a grant was made to Mr.&nbsp;Wilkins of 289 RSUs (with a fair value per RSU based on the closing price of
Quidel&#146;s common stock on the grant date), which vested on May&nbsp;12, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Compensation Table </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or Paid in</B><br><B>Cash&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock</B><br><B>Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth F. Buechler,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward L. Michael</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathy P. Ordo&ntilde;ez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Lake Polan,&nbsp;M.D.,&nbsp;Ph.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ann D. Rhoads</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles P. Slacik</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew W. Strobeck, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth J. Widder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph D. Wilkins Jr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reports the amount of Covered Fees, including cash payments and Covered Fees deferred in exchange
for RSUs (&#147;Covered Fees RSUs&#148;). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column represents the grant date fair value with respect to the RSUs and Director Premium RSUs granted in
2021. For additional information on the valuation assumptions with respect to the 2021 grants, see the &#147;&#151;Periodic Equity Awards&#148; section above. At December&nbsp;31, 2021, the aggregate number of RSUs, including Director Premium RSUs,
held by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director was: Dr.&nbsp;Buechler 13,828 shares; Mr.&nbsp;Michael 4,285 shares; Ms.&nbsp;Ordo&ntilde;ez 2,420 shares; Dr.&nbsp;Polan 10,701 shares; Ms.&nbsp;Rhoads 2,179 shares;
Mr.&nbsp;Slacik 1,952 shares; Dr.&nbsp;Strobeck 3,273 shares; Dr.&nbsp;Widder 5,108 shares; and Mr.&nbsp;Wilkins 1,624 shares. At December&nbsp;31, 2021, the aggregate number of stock options held by the following
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors was: Dr.&nbsp;Buechler 48,820 shares; Mr.&nbsp;Slacik 12,086 shares; Dr.&nbsp;Strobeck 259 shares; and Dr.&nbsp;Widder 22,440 shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Stock Ownership Guidelines </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of
directors believes that each director should have a meaningful equity investment in Quidel. Quidel&#146;s director stock ownership guidelines were revised in November 2020 to increase the stock ownership threshold for
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors to five times their respective annual cash retainer. Directors are expected to satisfy and maintain this stock ownership threshold within five years of joining the Quidel board of
directors. All of Quidel&#146;s directors meet these stock ownership guidelines or are in compliance with the guidelines by retaining equity awards until compliance is reached. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_86j"></A>Executive Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Discussion and Analysis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Throughout this
section of this joint proxy statement/prospectus, the individuals who served as Quidel&#146;s CEO and Chief Financial Officer (&#147;CFO&#148;) during fiscal year 2021, as well as the other individuals listed in the Summary Compensation Table below,
are referred to as the &#147;Named Executive Officers&#148; or &#147;NEOs.&#148; For 2021, Quidel&#146;s NEOs are as follows: Douglas C. Bryant, President and CEO; Randall J. Steward, Chief Financial Officer; Robert J. Bujarski, Chief Operating
Officer; Michelle A. Hodges, SVP, General Counsel; and Werner Kroll, SVP, Research and Development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Summary </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel entered 2021 with considerable momentum and experienced another transformational year. Quidel opened new channels, shipped a record number of critical
products to detect <FONT STYLE="white-space:nowrap">COVID-19</FONT> infections, launched its Savanna MDx instrumented system in select <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> markets, and overcame obstacles and seized opportunities to
broaden the range of patients, partners and providers Quidel serves and established a foundation for the future, while continuing to deliver existing products to customers around the world. Among the many outstanding performance achievements during
2021 were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Total revenue for 2021 increased to $1,698.6&nbsp;million, a 2% increase from $1,661.7&nbsp;million in 2020;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Revenue for <FONT STYLE="white-space:nowrap">COVID-19</FONT> products in 2021 increased 42% to
$1,267.0&nbsp;million, from $891.0&nbsp;million in 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reported GAAP EPS of $16.43 per diluted share in 2021, compared to $18.60 per diluted share in 2020;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Entered retail and <FONT STYLE="white-space:nowrap">at-home</FONT> testing markets with QuickVue <FONT
STYLE="white-space:nowrap">At-Home</FONT> OTC <FONT STYLE="white-space:nowrap">COVID-19</FONT> test by creating partnerships with CVS, Walgreens, McKesson, and National Institutes of Health (&#147;NIH&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Secured <FONT STYLE="white-space:nowrap">12-month</FONT> agreement with U.S. government expected to be worth over
$500&nbsp;million to supply QuickVue <FONT STYLE="white-space:nowrap">At-Home</FONT> OTC <FONT STYLE="white-space:nowrap">COVID-19</FONT> tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Resolved ongoing litigation with Beckman Coulter, Inc. (&#147;Beckman&#148;); substantially completed transition
of the BNP business to Beckman in connection with which Quidel will receive cash payments of between $70.0&nbsp;million and $75.0&nbsp;million per year from 2022 through 2029; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Opened new highly automated QuickVue manufacturing facility in Carlsbad, California; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Signed definitive agreement to acquire Ortho, to be funded through a combination of cash and newly issued debt of
the combined company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel believes that the compensation to Quidel&#146;s NEOs, including certain special compensation awards
granted during 2021 in recognition of outstanding performance during the year, aligned well with both Quidel&#146;s performance in 2021 and the objectives of Quidel&#146;s executive compensation policies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview and Philosophy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the continued <FONT STYLE="white-space:nowrap">COVID-19</FONT> demands and transformational changes to Quidel in 2021, the core objectives of
Quidel&#146;s compensation program continued to be to (1)&nbsp;support Quidel&#146;s mission, values and corporate strategies by adopting a &#147;pay for performance&#148; philosophy that provides incentives to Quidel&#146;s executive officers and
employees for support of these core principles; (2)&nbsp;align the interests of management with those of Quidel&#146;s stockholders; and (3)&nbsp;attract, retain and motivate high quality executives. Towards these objectives, Quidel&#146;s
compensation program is designed with the following principles: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Provide an opportunity for Quidel to communicate to Quidel&#146;s executive officers and employees Quidel&#146;s
performance expectations and priorities directly through the selection of performance measures on which compensation is based, and calibrate payouts with achievement of those performance measures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Align pay such that management shares in value created from their efforts, and Quidel&#146;s compensation expense
is correlated to its profitability and stockholder returns; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Balance rewards appropriately between efforts and results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Offer a competitive total compensation opportunity;&nbsp;and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Have a significant portion of total compensation paid to Quidel&#146;s executive officers in equity and dependent
upon the achievement of performance goals of Quidel. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s compensation program focuses on both short and long-term results and
is composed of three key elements: (1)&nbsp;base salaries, which reflect individual positions and responsibilities; (2)&nbsp;annual cash incentive opportunities, which are a function of the short-term performance of Quidel; and (3)&nbsp;longer-term
stock-based incentive opportunities under Quidel&#146;s equity incentive plans, generally in the form of stock options or restricted stock unit (&#147;RSU&#148;) grants, which link the interests of senior management with Quidel&#146;s other
stockholders. Each of Quidel&#146;s compensation elements is designed to simultaneously fulfill one or more of Quidel&#146;s core objectives. During 2021, Quidel augmented these key compensation elements with special compensation awards made to key
employees in recognition of their outstanding leadership and performance at a transformational time for Quidel. In 2022, Quidel will continue to make special compensation awards, as appropriate, to recognize outstanding performance during a period
of unprecedented transformation, challenges, opportunities and change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When setting compensation for 2022 and in determining compensation policies, the
Compensation Committee continued its engagement of Compensia, Inc. (&#147;Compensia&#148;) to advise on Quidel&#146;s executive compensation programs and took into account the results of the stockholder advisory vote on executive compensation that
took place at the 2021 annual meeting of Quidel&#146;s stockholders. In that vote, which was advisory and not binding, Quidel&#146;s stockholders approved the compensation of Quidel&#146;s named executive officers as disclosed in the proxy statement
for the 2021 annual meeting of Quidel&#146;s stockholders with over 97.5% of votes cast in favor of the compensation of Quidel&#146;s named executive officers. The Compensation Committee considered the advice of Compensia and continued to apply the
same general compensation principles and philosophy, while making some adjustments to Quidel&#146;s compensation programs in connection with success, integration and retention matters in connection with the pending Ortho business combination. Quidel
currently holds annual advisory votes on executive compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee of the Quidel board of directors administers Quidel&#146;s executive compensation programs and approves (or recommends to the Quidel
board of directors for approval) salaries of all executive officers, including those of the NEOs named in the Summary Compensation Table. The Compensation Committee is responsible for reporting to the Quidel board of directors and administering all
other elements of executive compensation, including annual cash incentive and equity awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Plan Design and Key Elements Used to
Achieve Compensation Objectives </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cash components of salary and annual incentive bonus are targeted to be moderate, yet competitive in relation
to salaries and annual incentive bonuses paid to officers in similar positions in comparable companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s 2021 long-term equity incentive
programs for Quidel&#146;s CEO included incentive stock-based awards in the form of <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, time-based RSUs and performance-based RSUs and for other NEOs included incentive stock-based
awards in the form of <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options and/or time-based RSUs. The vesting for both the <FONT STYLE="white-space:nowrap">non-qualified</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock options and the time-based RSUs for typical annual equity awards is over a four-year period, with 25% vesting each year on the anniversary of the grant date, with certain exceptions.
Mr.&nbsp;Steward and Dr.&nbsp;Kroll received awards pursuant to the specific terms of their respective individual retirement programs, comprised entirely of time-based RSUs that vest over a three-year period, with
<FONT STYLE="white-space:nowrap">one-third</FONT> vesting each year on the anniversary of the grant date. The vesting for the performance-based RSUs for Mr.&nbsp;Bryant is over a five-year period and is tied to the achievement of net revenue growth
targets over any three consecutive fiscal year period starting with the three-year period ending in 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee engaged Compensia to
conduct a review of the competitiveness of Quidel&#146;s executive compensation programs in 2021 in connection with determining Quidel&#146;s 2022 executive compensation program, separate from the pending business combination with Ortho.
Quidel&#146;s executive compensation program design builds on the analysis and direction of Compensia, taking into account data from the annual Radford Global Life Sciences Survey (the &#147;Radford Survey&#148;) and incorporates review of
comparative groups of publicly traded companies with similar revenue and employee population profiles. The Radford Survey provides data from participating companies with respect to their compensation practices in numerous areas and with respect to
various positions, including senior management positions. Based on the assessment by Compensia and the Compensation Committee, the 2021 peer group was used for Quidel&#146;s 2022 compensation assessment and did not assume that the business
combination with Ortho was completed. For both 2021 and 2022, the following peer group companies were used for compensation comparisons: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2021 and 2022
Peer Group: </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Align Technology, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Integra LifeSciencies Holdings Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CONMED Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Masimo Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emergent BioSolutions, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Merit Medical Systems, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Envista Holdings Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NuVasive, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EXACT Sciences Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ResMed, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haemonetics Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Teleflex, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Hill-Rom</FONT> Holdings, Inc. (through acquisition in
2021)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Cooper Companies, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hologic, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Varian Medical Systems, Inc. (through acquisition in 2021)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ICU Medical, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Waters Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IDEXX Laboratories, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">West Pharmaceutical Services, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insulet Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should the business combination with Ortho be completed, Quidel&#146;s Compensation Committee, with the assistance of
Compensia, will modify this peer group, as needed, to take into account the much larger size of the combined entity and plans to adjust executive compensation if appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s Compensation Committee utilizes management and independent compensation consultants (such as Compensia in each year since 2018) to gather market
data and provide analyses of Quidel&#146;s peers&#146; compensation programs. The Compensation Committee does not have a philosophy of setting compensation based on specific formulaic benchmarking comparisons, but it does take into account the
guidance of compensation consultants and reviews peer group data and the Radford Survey data in setting moderate, yet competitive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since
2017, Quidel&#146;s Compensation Committee has continued to more evenly allocate the equity incentive awards between stock options and RSUs, with 50% of the number of shares awarded in the form of
<FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options and 50% of the number of shares awarded in the form of RSUs, with the recent exception of certain NEOs subject to individual retirement programs as the Compensation Committee deemed
appropriate. In addition, Quidel&#146;s Compensation Committee determined it would be in the interest of stockholders to eliminate performance-based RSUs for all executive officers other than the CEO in 2021 to better align with peer group
practices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Base Salary </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Base salaries are
reviewed annually and are targeted to be moderate, yet competitive in relation to salaries paid to officers in similar positions in comparable companies. With the exception of the CEO, whose performance is reviewed directly by the Quidel board of
directors, performance of all other executive officers is reviewed through regular conversations on goals and achievement with the CEO in consultation with the Compensation Committee (and/or the Quidel board of directors). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2021, in connection with the setting of the base salaries of Quidel&#146;s executive officers, the
Compensation Committee considered peer group analysis and also examined survey data for executives with similar responsibilities in comparable companies in the medical device/diagnostics and biotechnology industries, using analysis performed by
Compensia and referring to a custom report prepared by Compensia from data contained in the 2021 Radford Survey based on companies with a similar number of employees compared to Quidel. The base salaries of each of Quidel&#146;s executive officers
were set taking into account comparable data for salaries relevant for their positions, and then modified to further take into account Quidel&#146;s executive officers&#146; experience and skills. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Annual Cash Incentive Awards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s annual
cash incentive program provides the potential for receipt of competitive levels of annual incentive cash compensation and is designed to reward senior management for their contributions to Quidel&#146;s annual corporate objectives. Under
Quidel&#146;s annual cash incentive program, each participating officer is entitled to receive a cash bonus based on achievement of certain corporate goals in the particular fiscal year. Goals and payouts are calibrated to strike the appropriate
balance between being reasonably achievable, and thereby motivating executives, while targeting improved performance. The balance is intended to result in Quidel receiving an appropriate return on its annual incentive investment. The corporate
performance goals are selected to require sustained performance and results from senior management. Each eligible executive&#146;s potential annual award under the annual cash incentive program is expressed as a percentage of base salary as of the
end of the fiscal year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2021, the Compensation Committee approved the 2021 Executive Incentive Compensation Plan (the &#147;2021 Cash
Incentive Plan&#148;), subject to ongoing review throughout the year based on fluctuating demand and expectations in connection with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> impact on Quidel&#146;s business. Consistent with the 2020 Cash
Incentive Plan, the Compensation Committee determined it was appropriate to continue to use a limited set of key components. Similar to prior plans, the 2021 Cash Incentive Plan was designed to encourage improved performance in objectives and to
improve long-term performance and results for Quidel and its stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The target bonus for the 2021 Cash Incentive Plan was initially set at 100% of
annual base salary for Quidel&#146;s CEO and 75% of annual base salary for other executive officers and provided for a maximum bonus of 140% of annual base salary for Quidel&#146;s CEO and 105% of annual base salary for Quidel&#146;s other executive
officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 Cash Incentive Plan consisted of the following two components: (1)&nbsp;revenue performance; and (2)&nbsp;EBITDA targets. Each
component of the 2021 Cash Incentive Plan includes targets at minimum, plan/target and maximum payout. The minimum targets serve as the threshold level of performance upon which the incentive pool would begin to fund for that component. Achievement
of the components at plan/target will earn the target cash incentive opportunity. Payouts are calculated along a linear continuum from minimum to plan/target and from plan/target to maximum with the maximum target serving as the point at which the
management team will earn the highest possible cash incentive opportunity. The minimum target must be met in order for a portion of the bonus to be paid relative to any one of the two components and each component is measured separately. The
Compensation Committee may adjust the targets to take into account acquisitions and divestitures (so that management is not rewarded or penalized for factors outside management&#146;s control) and retains the right to exercise discretion in
modifying amounts awarded to take into account significant events that were not contemplated under the plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the time the 2021 Cash Incentive Plan was
initially reviewed and approved in early 2021, Quidel&#146;s operations and size had changed dramatically since the onset of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in March of 2020. Throughout 2020 and continuing throughout
2021, demand for <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing in general, and for Quidel&#146;s <FONT STYLE="white-space:nowrap">COVID-19</FONT> products specifically, fluctuated significantly <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">month-to-month</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> in response to vaccine rollouts, decreasing infection and death rates, and subsequent
surges resulting from variants such as Delta and Omicron. This made forecasting volume and pricing of Quidel&#146;s <FONT STYLE="white-space:nowrap">COVID-19</FONT> products difficult, which resulted in a corresponding challenge in forecasting
Quidel&#146;s revenue, EBITDA and other financial metrics. At the time the 2021 Cash Incentive Plan was initially approved, the macro environment suggested an extreme demand for <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing at higher
prices. As vaccine rollouts continued and infection and death rates declined significantly moving into the summer of 2021, the demand for <FONT STYLE="white-space:nowrap">COVID-19</FONT> tests as well as the pricing for tests declined significantly,
making it clear that the market assumptions for the 2021 Cash Incentive Plan were not likely to be realized and accordingly the metrics under the initially approved 2021 Cash Incentive Plan would not be achievable, but Quidel was performing well and
meeting significant milestone and performance targets that deserved to be rewarded and incented. In response, the Compensation Committee determined in early September 2021 that the revenue and EBITDA targets for the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2021 Cash Incentive Plan were not realistic. The Compensation Committee further determined that it needed to continue to provide incentives for its senior management team, especially considering
the extremely challenging environment Quidel was experiencing in ramping up its <FONT STYLE="white-space:nowrap">COVID-19</FONT> test production and the intense competition for qualified human resources in the economy in general. Accordingly, in
September 2021, the Compensation Committee established a modified 2021 Cash Incentive Plan that included a 2021 EBITDA target of at least $500&nbsp;million; certain Savanna launch targets by the end of the year; certain transition targets in
connection with the Beckman transition agreement; and certain <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> <FONT STYLE="white-space:nowrap">COVID-19</FONT> manufacturing milestones and Quidel home
testing app development milestones. As part of this adjustment, however, the Compensation Committee further determined to reduce the target payout percentages for senior executives by 50%, while maintaining the full percentage payout for all other
employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table represents the threshold, plan/target and maximum bonus for each of the NEOs as a percentage of such NEO&#146;s annual
base salary under the 2021 Cash Incentive Plan, as adjusted in September 2021. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Executive Officer</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Threshold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Plan/Target</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">50.0</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">62.5</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">37.5</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">46.9</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">37.5</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">46.9</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP, General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">37.5</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">46.9</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll,&nbsp;Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP, Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">37.5</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">46.9</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the 2021 Cash Incentive Plan, as modified, bonus payouts to Quidel&#146;s executive officers for 2021 were based
on achievement at 125% of target and paid out at 50% under the revised plan: 50% based on Quidel&#146;s achievement of EBITDA goals (actual results of $995&nbsp;million or 199% of $500&nbsp;million target); 20% based on achievement of Savanna launch
targets; 10% based on achievement of Beckman transition targets; 10% based on achievement of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> <FONT STYLE="white-space:nowrap">COVID-19</FONT>
manufacturing targets; and 10% based on achievement of Quidel home testing app development targets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Annual Cash Incentive Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;31, 2022, the Compensation Committee approved payouts to executive officers for achievement of all goals under the revised 2021 Cash Incentive
Plan at 62.5% of base salary for the CEO and 46.9% of base salary for the other NEOs. These payout amounts were based on achievement of (i)&nbsp;EBITDA performance at the maximum level and (ii)&nbsp;full achievement of all other milestone targets.
The bonuses earned by Mr.&nbsp;Bryant, Mr.&nbsp;Steward, Mr.&nbsp;Bujarski, Ms.&nbsp;Hodges and Dr.&nbsp;Kroll were $547,188, $234,164, $246,094, $210,938 and $257,813, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Bonus Program </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the above NEOs is
eligible to elect to participate in Quidel&#146;s Employee Deferred Bonus Compensation Program (the &#147;Employee Deferred Program&#148;) with respect to any payments received under the 2021 Cash Incentive Plan, 2022 Cash Incentive Plan (as defined
below) and future cash incentive plans. Under the Employee Deferred Program, participating officers could elect to receive 50% or 100% of the cash value of his or her annual cash incentive bonus (the &#147;Covered Bonus&#148;) (payable (if
applicable) per the terms and conditions of the 2021 and 2022 Cash Incentive Plans) in the form of fully vested RSUs (the &#147;Converted RSUs&#148;), plus an additional premium on such percentage of the Covered Bonus in the form of additional RSUs,
which are subject to a <FONT STYLE="white-space:nowrap">one-year</FONT> vesting requirement (the &#147;Premium RSUs&#148;). The additional premium applicable to the Premium RSUs will be determined based on the length of time of the deferral period
(between the grant date and the date the shares of common stock underlying the Converted RSUs are to be issued) selected by the participating officer as follows: (i)&nbsp;if one (1)&nbsp;year from the grant date, a premium of 10% on the amount
deferred of the Covered Bonus; (ii)&nbsp;if two (2)&nbsp;years from the grant date, a premium of 20% on the amount deferred of the Covered Bonus; or (iii)&nbsp;if four (4)&nbsp;years from the grant date, a premium of 30% on the amount deferred of
the Covered Bonus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elections for the Employee Deferred Program for 2021 and 2022, which are irrevocable, were made by the
following NEOs: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT STYLE="font-size:8pt"><B>2021</B></FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT STYLE="font-size:8pt"><B>2022</B></FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Executive Officer</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B><br><B>Deferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deferral</B><br><B>Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B><br><B>Deferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deferral</B><br><B>Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4&nbsp;years</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4&nbsp;years</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4 years</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP, General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll,&nbsp;Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP, Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Converted RSUs will be fully vested on the grant date. The Premium RSUs will be fully vested on the first
anniversary of the grant date. Subject to the terms and conditions in the grant award agreement, the shares of common stock underlying Converted RSUs will be issued as soon as administratively practicable after the earliest of: (1)&nbsp;the end of
the deferral period selected by the participating officer; (2)&nbsp;the participating officer&#146;s separation from Quidel; and (3)&nbsp;a change in the ownership or effective control of Quidel, or in the ownership of a substantial portion of the
assets of Quidel (a &#147;Change in Control&#148;). The shares of common stock underlying the Premium RSUs will have the same applicable issuance periods as outlined in the foregoing sentence for Converted RSUs with acceleration of the <FONT
STYLE="white-space:nowrap">one-year</FONT> vesting requirement in connection with a Change in Control; provided, however, that if a participating officer&#146;s service is terminated for any reason (outside of a Change in Control) prior to the <FONT
STYLE="white-space:nowrap">one-year</FONT> vesting requirement, the Premium RSUs shall be forfeited and canceled as of the date of such termination of service. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Longer-Term Equity Incentive Awards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Longer-term
equity-based incentive awards in the form of stock options and/or RSUs are intended to align the interests of management with those of Quidel&#146;s other stockholders and promote retention of Quidel&#146;s executives by using continued service, and
in the case of certain awards, the achievement of specified performance levels, as a requirement to receive the value of the awards. The number of stock options and/or shares of RSUs granted is related to the individual&#146;s level of
responsibility and allows executives to share in the value they help create. Generally, the Compensation Committee does not consider an executive&#146;s stock holdings or outstanding equity awards in determining the number of equity awards to be
granted; however, the Compensation Committee does take into consideration the total number of outstanding shares of Quidel&#146;s common stock, the relative dilution to stockholders, as well as Quidel&#146;s gross equity burn rate, issued equity
overhang and total equity overhang in determining the number of equity awards to be granted. The Compensation Committee believes that Quidel&#146;s executive officers should be fairly compensated each year relative to market pay levels of
Quidel&#146;s peer group. The Compensation Committee views longer-term equity incentives as a primary compensation means for retaining executives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s 2021 long-term equity incentive program for Quidel&#146;s CEO included incentive stock-based awards in the form of <FONT
STYLE="white-space:nowrap">non-qualified</FONT> stock options, time-based RSUs and performance-based RSUs and for Mr.&nbsp;Bujarski and Ms.&nbsp;Hodges included incentive stock-based awards in the form of both
<FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options and time-based RSUs. The vesting for the <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options is over a <FONT STYLE="white-space:nowrap">four-year</FONT> period, with
25% vesting each year on the anniversary of the grant date. The stock options have an exercise price equal to the closing price of Quidel&#146;s common stock on the grant date. Consistent with 2020, the Compensation Committee determined to weight
the number of shares awarded for long-term incentive awards between stock options and RSUs, which the Compensation Committee believed was in alignment with peer group practices. In 2021, for Mr.&nbsp;Bujarski and Ms.&nbsp;Hodges, 50% of the equity
incentive award shares were provided in the form of <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options and 50% of the equity award shares were provided in the form of RSUs. For the CEO, the number of RSUs were divided equally
between time-vested RSUs and performance-based RSUs. For Mr.&nbsp;Bujarski and Ms.&nbsp;Hodges, the vesting for the time-based RSUs is over a <FONT STYLE="white-space:nowrap">four-year</FONT> period, with 25% vesting each year on the anniversary of
the grant date. The vesting for the performance-based RSUs granted to the CEO is over a five-year period and is tied to the achievement of net revenue growth targets, as adjusted for the financial impact of merger, acquisition and divestiture
activities. The amounts of the awards were determined based on the executive compensation analysis and review performed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by Compensia, which takes into account data from the Radford Survey and peer group compensation practices, as discussed in the &#147;&#151;Compensation Plan Design and Key Elements Used to
Achieve Compensation Objectives&#148; section above. The awards for Mr.&nbsp;Steward and Dr.&nbsp;Kroll were comprised entirely of time-based RSUs that vest over a three-year period, with <FONT STYLE="white-space:nowrap">one-third</FONT> vesting
each year on the anniversary of the grant date, pursuant to the terms of each executive&#146;s individual retirement program. See the &#147;&#151;Employment, Change in Control and Severance Arrangements&#148; section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2021, Mr.&nbsp;Bryant,&nbsp;Mr.&nbsp;Steward, Mr.&nbsp;Bujarski, Ms.&nbsp;Hodges and Dr.&nbsp;Kroll were awarded
<FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, time-based RSUs, and performance-based RSUs, as follows: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Executive Officer</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar&nbsp;Value&nbsp;of</B><br><B>Aggregate<BR>Award</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Options/Time-</B><br><B>Based&nbsp;Restricted</B><br><B>Stock Units</B><br><B>(RSUs)/Performance-<BR>Based&nbsp;Restricted&nbsp;Stock<BR>Units
(PSUs)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,299,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4,462&nbsp;RSUs&nbsp;(1)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4,462&nbsp;PSUs&nbsp;(1)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8,924&nbsp;Options&nbsp;(1)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">749,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11,140&nbsp;Options&nbsp;(2)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,299,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5,118&nbsp;RSUs&nbsp;(1)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,299,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,516&nbsp;RSUs&nbsp;(1)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,514&nbsp;Options&nbsp;(1)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,559 RSUs (3)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">699,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,893&nbsp;RSUs&nbsp;(1)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP, General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,892&nbsp;Options&nbsp;(1)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,559 RSUs (3)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,680 RSUs (4)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,499,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11,910&nbsp;RSUs&nbsp;(5)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,937&nbsp;RSUs&nbsp;(1)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP, Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,510&nbsp;RSUs&nbsp;(6)</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Award granted in February 2021 as part of Quidel&#146;s 2021 long-term equity incentive program. Grants to
Mr.&nbsp;Steward and Dr.&nbsp;Kroll were comprised entirely of time-based RSUs pursuant to their respective individual retirement programs. See the &#147;&#151;Employment, Change in Control and Severance Arrangements&#148; section.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Award granted in July 2021 for Mr.&nbsp;Bryant&#146;s efforts and contributions to the achievement of certain
key milestones, which Mr.&nbsp;Bryant elected to receive 100% in the form of options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Award granted in October 2021 for each NEO&#146;s efforts and contributions to the resolution of the Beckman
litigation and implementation of the related transition agreements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Award granted in May 2021 for Ms.&nbsp;Hodges&#146;s extraordinary efforts and contributions related to
business development matters and for retention purposes. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Award granted in November 2021 for Ms.&nbsp;Hodges&#146;s extraordinary efforts and contributions related to
business development matters and for retention purposes. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Award granted in July 2021 for Dr.&nbsp;Kroll&#146;s efforts and contributions to the achievement of certain
key R&amp;D milestones, which Dr.&nbsp;Kroll elected to receive 100% in the form of RSUs. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2022 Compensation Actions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2022, the Compensation Committee approved Quidel&#146;s 2022 cash incentive plan for the initial <FONT STYLE="white-space:nowrap">six-month</FONT>
period of Quidel&#146;s fiscal year ending December&nbsp;31, 2022 (the &#147;2022 Cash Incentive Plan&#148;). Payout under the 2022 Cash Incentive Plan is predicated upon achievement of (i)&nbsp;revenue targets and (ii)&nbsp;EBITDA targets, with
each of the foregoing as determined by the Quidel board of directors and/or the Compensation Committee, for the initial <FONT STYLE="white-space:nowrap">six-month</FONT> period of Quidel&#146;s 2022 fiscal year, based on the assumption that the
second-half targets would be established after the anticipated closing of the Ortho business combination. The following table represents the threshold, plan/target and maximum bonus for each of the NEOs as a percentage of such NEO&#146;s annual base
salary under the 2022 Cash Incentive Plan. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Executive Officer</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Threshold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Plan/Target</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP, General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP, Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the 2022 Cash Incentive Plan, bonus payouts to Quidel&#146;s executive officers will be based 60% on achievement
of revenue performance and 40% on EBITDA goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also in January 2022, the Compensation Committee approved Quidel&#146;s 2022 long-term equity incentive
program. Under the 2022 equity incentive program, each NEO receives equity incentive awards in the form of (i)&nbsp;time-based RSUs and/or <FONT STYLE="white-space:nowrap">(ii)&nbsp;non-qualified</FONT> stock options as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Time-Based&nbsp;Restricted</FONT><BR>Stock Units</B><br><B>(#&nbsp;shares)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Qualified</FONT><BR>Stock&nbsp;Options</B><br><B>(#&nbsp;shares)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">27,043</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">27,043</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">14,512</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12,878</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12,876</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP, General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6,439</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6,438</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP, Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10,642</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The vesting periods for the <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options and time-based RSUs,
with the exception of awards to Mr.&nbsp;Steward and Dr.&nbsp;Kroll, are each over a four-year period, with 25% vesting each year on the anniversary of the grant date. The awards to Mr.&nbsp;Steward and Dr.&nbsp;Kroll in 2022 are comprised entirely
of time-based RSUs that vest over a three-year period, with <FONT STYLE="white-space:nowrap">one-third</FONT> vesting each year on the anniversary of the grant date, pursuant to the terms of such executive&#146;s individual retirement program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;31, 2022, in connection with the anticipated closing of the Ortho business combination, the Compensation Committee also approved the grant of
(i)&nbsp;success bonus awards for each of Mr.&nbsp;Bryant, Mr.&nbsp;Steward, Mr.&nbsp;Bujarski and Ms.&nbsp;Hodges in the following amounts: Mr.&nbsp;Bryant: $875,500; Mr.&nbsp;Steward: $499,550; Mr.&nbsp;Bujarski: $525,000; and Ms.&nbsp;Hodges:
$450,000; (ii) integration/retention cash bonus awards for each of Mr.&nbsp;Bryant, Mr.&nbsp;Steward, Mr.&nbsp;Bujarski, Ms.&nbsp;Hodges and Dr.&nbsp;Kroll in the following amounts: Mr.&nbsp;Bryant: $717,500; Mr.&nbsp;Steward: $349,685;
Mr.&nbsp;Bujarski: $420,000; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Ms.&nbsp;Hodges: $315,000; and Dr.&nbsp;Kroll: $385,000; and (iii)&nbsp;integration/retention equity awards for each of Mr.&nbsp;Bryant, Mr.&nbsp;Bujarski, Ms.&nbsp;Hodges and Dr.&nbsp;Kroll in
the following amounts: Mr.&nbsp;Bryant: $2,500,000; Mr.&nbsp;Bujarski: $1,400,000; Ms.&nbsp;Hodges: $750,000; and Dr.&nbsp;Kroll: $750,000. The success bonus awards will be grossed up for taxes and become payable upon the closing of the Ortho
business combination. The first 25% of the integration/retention cash bonus awards will become payable upon the closing of the Ortho business combination, and the remaining 75% upon the first anniversary thereof. The integration/retention equity
awards were granted in the form of RSUs and will vest with respect to 50% of the award on the second anniversary of the grant date and the remaining 50% in equal annual installments (25% per year) thereafter; provided, however, that (x)&nbsp;the
vesting of the RSUs is contingent upon the consummation of the Ortho business combination having occurred prior to the applicable vesting date, and (y)&nbsp;the RSUs will be automatically forfeited in the event the agreement governing the Ortho
business combination transaction is terminated in accordance with its terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Ownership Guidelines </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To further align the interests of Quidel&#146;s directors and executives with those of Quidel&#146;s other stockholders, the Quidel board of directors has
adopted stock ownership guidelines and increased ownership requirements for Quidel&#146;s CEO and directors in 2020. Under these guidelines, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director, the CEO, each Senior Vice President and
each Vice President is required to retain and hold 50% of the shares acquired under any equity incentive award granted on or after March&nbsp;19, 2004 (after subtracting shares sold to pay for option exercise costs and relevant federal and state
taxes, which are assumed to be at the highest marginal tax rates). The foregoing stock retention rule applies unless such director or officer beneficially owns shares with a value at or in excess of the following stock ownership guidelines: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CEO &#151; 6 times then-current annual base salary, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Section&nbsp;16 Officers &#151; 2 times then-current annual base salary, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Non-Section</FONT> 16 Officer Senior Vice Presidents and Vice Presidents &#151;
1 times then-current annual base salary,&nbsp;and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Non-employee</FONT> Directors &#151; 5 times then-current annual cash retainer.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The value of an individual&#146;s shares for purposes of the stock ownership guidelines is deemed to be the greater of the then-current
fair market value of the stock, or the individual&#146;s cost basis in the stock. Shares counted in calculating the stock ownership guidelines include shares beneficially owned outright, whether from open market purchases, purchases through
Quidel&#146;s ESPP, shares retained after option exercises, and shares received pursuant to RSU awards once the awards covering such shares have vested. In addition, in the case of vested, unexercised, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">in-the-money</FONT></FONT> stock options, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> value of the stock options will be included in the stock ownership guidelines
calculation. Also, the vested RSUs held pursuant to Quidel&#146;s Deferred Compensation Programs are included in the stock ownership guidelines calculation. Individuals have five years from their election, hire or promotion to satisfy the stock
ownership guidelines. All officers and directors meet these stock ownership guidelines or are in compliance with the guidelines by retaining equity awards until compliance is reached. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restrictions on Trading Securities (Including Hedging and Pledging) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel has an Insider Trading Policy that prohibits employees and directors from engaging in speculative transactions involving Quidel&#146;s securities.
Accordingly, hedging transactions involving Quidel&#146;s securities are prohibited, including, but not limited to, purchase of stock on margin, short sales, buying or selling puts or calls, and any other similar transactions or arrangements that
have an economic consequence of establishing downside price protection. Quidel&#146;s Insider Trading Policy also prohibits officers and directors from pledging Quidel stock, subject to special approval from Quidel board of directors. No special
approvals have been provided to allow any current officer or director to pledge Quidel stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pay Recoupment (Clawback) Policy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s Compensation Committee approved a clawback policy in February 2021 that covers annual and longer-term incentive compensation awarded or paid to
Quidel&#146;s Section&nbsp;16 officers. Under this policy, if Quidel is required to restate Quidel&#146;s financial statements due to fraud, misconduct or SEC or financial <FONT STYLE="white-space:nowrap">non-compliance</FONT> and the amount of
Quidel&#146;s long-term incentive compensation awarded or paid would have been lower had the achievement of the applicable financial performance been calculated based on the restated financial results, Quidel&#146;s Compensation Committee may, in
its discretion, recover the amount of excess compensation awarded or paid during the three-year period preceding the date of such restatement. Quidel believes this clawback policy enhances the accountability of Quidel&#146;s executive officers and
significantly mitigates the risks associated with Quidel&#146;s executive compensation program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment and Severance Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel has entered into change in control agreements with each of Quidel&#146;s executive officers in order to foster their objectivity in making decisions
with respect to any pending or threatened change in control transaction and to alleviate certain risks and uncertainties with regard to Quidel&#146;s executive officers&#146; financial and professional security that may be created by a pending or
threatened change in control transaction. The details of the change in control agreements and any employment, retirement or severance arrangements entered into with Quidel&#146;s executive officers are provided in the &#147;&#151;Employment, Change
in Control and Severance Arrangements&#148; section. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Deductibility of Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;162(m) of the U.S. Internal Revenue Code (the &#147;Code&#148;) precludes publicly held corporations from deducting for U.S. federal
income tax purposes in excess of $1,000,000 per year in compensation per person paid to certain executives designated as &#147;covered employees&#148; under Section&nbsp;162(m) of the Code (generally, Quidel&#146;s CEO, CFO and its three highest
paid executive officers other than its CFO). The exemption from Section&nbsp;162(m)&#146;s deduction limit for performance-based compensation has been repealed, effective for taxable years beginning after December&nbsp;31, 2017, such that
compensation paid to Quidel&#146;s covered employees in excess of $1,000,000 will not be deductible unless it qualifies for limited transition relief applicable to certain arrangements in place as of November&nbsp;2, 2017. The $1,000,000
compensation limit was also expanded to apply to executives who were covered employees in years other than the then-current taxable year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No assurance
can be given that any compensation intended to satisfy the requirements for exemption from Section&nbsp;162(m) as qualifying grandfathered arrangements in fact will or that compensation paid to Quidel&#146;s executive officers who are covered by
Section&nbsp;162(m) intended to be deductible will be deductible in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While Quidel will continue to consider the tax effect (including with
respect to the expected lack of deductibility under amended Section&nbsp;162(m)) of compensation decisions, the principal consideration behind Quidel&#146;s selection of components of executive compensation continues to be whether the component can
facilitate achievement of Quidel&#146;s executive compensation program objectives. In this regard, for 2021, we have not made any changes to the basic structure of Quidel&#146;s executive compensation program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option and RSU Grant Practices </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described
above, Quidel uses stock options as part of its overall compensation program. Stock options provide individuals with the right to purchase a specified number of shares of Quidel&#146;s stock at a specific price. Quidel sets the exercise price of the
stock options that it awards at or above the closing price of Quidel&#146;s stock on the grant date. Accordingly, the option grant will have value to the individual only if he or she continues his/her service to Quidel during the vesting period and
then generally only if and to the extent that the market price of the underlying shares of common stock appreciates over the option term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Awards of
equity-based compensation to Quidel&#146;s executive officers, such as options and RSUs, are determined and approved by the Quidel board of directors or the Compensation Committee. Equity grants are typically made at the time of hire for executives
and then annually as part of the overall executive compensation review. The specific terms of the awards are determined based on the position of the individual in the organization and as part of the applicable annual equity incentive program and
takes into account relevant Compensia and Radford Survey data and peer group compensation practices, as discussed above under the &#147;&#151;Compensation Plan Design and Key Elements Used to Achieve Compensation Objectives&#148; section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For executives, new hire grants are approved by Quidel board of directors or the Compensation Committee when the executive&#146;s hire is approved, with the
actual option grant issued on the first date of employment and the exercise price of such option set at the closing price of Quidel&#146;s common stock on that date. Annual performance grants made as part of the overall executive compensation
program are generally made as of the date of approval by Quidel board of directors or Compensation Committee. This typically occurs prior to the end of the first quarter in each calendar year, with grants effective on the date of approval by Quidel
board of directors or Compensation Committee and at a price at or above the closing price on the grant date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Compensation Committee and Quidel board of directors believe it is appropriate to
consider special compensation awards in connection with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and other special circumstances and may continue to make special compensation awards, including equity-based awards, similar to
2020 and 2021, in order to incent and reward performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Perquisites and Other Benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee believes that the NEOs should participate in the same benefit programs as Quidel&#146;s other employees and that special executive
perquisites should be minimal. Consistent with this philosophy, the NEOs participate in Quidel&#146;s employee benefit plans on the same terms as other employees. These plans include medical and dental insurance, disability coverage, life insurance,
the ESPP and the 401(k) plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of the Chief Executive Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s CEO generally participates in the same executive compensation program provided to Quidel&#146;s other executive officers and senior management as
described above, except that for 2021, Quidel&#146;s CEO received a portion of his RSUs in the form of performance-based RSUs whereas other executives only received time-based RSUs. The Compensation Committee&#146;s approach to setting compensation
for the CEO is to be competitive with comparable companies and to have a significant portion of total compensation depend upon the achievement of performance goals for Quidel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2021, the Compensation Committee approved an increase in the annual base salary for Mr.&nbsp;Bryant from $850,000 to $875,500. As described above,
under the revised 2021 Cash Incentive Plan, the Compensation Committee approved payout at 125% of target with payout reduced by 50% per the modified plan terms, effective January&nbsp;31, 2022, for combined achievement of adjusted EBITDA and other
performance goals. Accordingly, Mr.&nbsp;Bryant earned a payout of $547,188. As discussed above under the &#147;&#151;Longer-Term Equity Incentive Awards&#148; section, in 2021, Mr.&nbsp;Bryant was also awarded 4,462 shares of time-based RSUs, 4,462
shares of performance-based RSUs, and 8,924 shares of <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options under the 2021 long-term equity incentive program, as well as 11,140 shares of
<FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options for his efforts and contributions to the achievement of certain key milestones. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of the Other Named Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2021, the Compensation Committee approved an increase in the base salaries of Mr.&nbsp;Steward, Mr.&nbsp;Bujarski, Ms.&nbsp;Hodges and
Dr.&nbsp;Kroll. Ms.&nbsp;Hodges&#146;s base salary was subsequently adjusted and the base salaries were approved as follows: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Executive Officer</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Prior</B><br><B>Base&nbsp;Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B><br><B>Base&nbsp;Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">485,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">499,550</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">515,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">525,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP, General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">401,700</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">450,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP, Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">407,679</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">550,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described above, the Compensation Committee approved payout at the maximum level, effective January&nbsp;31, 2022,
under the revised 2021 Cash Incentive Plan for combined achievement of EBITDA and other performance goals for these officers, and, accordingly, Mr.&nbsp;Steward, Mr.&nbsp;Bujarski, Ms.&nbsp;Hodges and Dr.&nbsp;Kroll earned a payout of $234,164,
$246,094, $210,938 and $257,813, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed above under the &#147;&#151;Longer-Term Equity Incentive Awards&#148; section, in 2021,
Mr.&nbsp;Bujarski and Ms.&nbsp;Hodges were awarded shares of time-based RSUs and <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options and Mr.&nbsp;Steward and Dr.&nbsp;Kroll were awarded shares of time-based RSUs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Report </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee of the Quidel board of directors has reviewed the &#147;Compensation Discussion and Analysis&#148; in this joint proxy
statement/prospectus, and discussed that analysis with management. Based on its review and discussions with management, the Compensation Committee recommended to the Quidel board of directors that the &#147;Compensation Discussion and Analysis&#148;
section be included in this joint proxy statement/prospectus. This report is provided by the following independent directors, who comprise the Compensation Committee: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compensation Committee </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Edward L. Michael (Chair) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kenneth F. Buechler, Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kathy P. Ordo&ntilde;ez </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mary Lake Polan,&nbsp;M.D.,&nbsp;Ph.D., M.P.H. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This
Compensation Committee Report does not constitute soliciting material and shall not be deemed filed or incorporated by reference into any Company filing under the Securities Act or the Exchange Act, except to the extent Quidel specifically
incorporates this report. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information relating to fiscal years 2021, 2020 and 2019 compensation of Quidel&#146;s CEO, CFO and three other most highly
compensated persons serving as executive officers as of December&nbsp;31, 2021. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name and Principal Position</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock</B><br><B>Awards</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT></B><br><B>Incentive&nbsp;Plan</B><br><B>Compensation</B><br><B>($)<SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other</B><br><B>Compensation</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">856,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,348,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,783,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">547,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,546,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">777,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,342,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,857,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,190,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,177,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">633,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,213,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">885,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,168,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,323,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,056,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,499,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">509,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,513,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">771,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,580,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,129,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,307,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">793,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,244,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">652,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,391,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,401,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,241,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP, General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">490,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,499,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,258,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP, Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,649,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">428,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,509,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">480,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,232,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts shown reflect the base salary compensation earned for the executive officers during 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column represents the grant date fair value of time-based and performance-based RSUs granted during fiscal
years 2021, 2020 and 2019, as well as (i)&nbsp;for 2019, the Premium RSUs associated with the 2019 Employee Deferred Program; (ii)&nbsp;for 2020, the Premium RSUs associated with the 2020 Employee Deferred Program; and (iii)&nbsp;for 2021, the
Premium RSUs associated with the 2021 Employee Deferred Program, as described in Note (2)&nbsp;of the &#147;Nonqualified Deferred Compensation&#148; table. RSUs are valued based on the closing share price on the grant date. For additional
information with respect to the 2021 grants, refer to Note 6 of Quidel&#146;s Consolidated Financial Statements for the year ended December&nbsp;31, 2021. See the &#147;Grants of Plan-Based Awards in Fiscal Year 2021&#148; table for information on
RSUs granted in 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column represents the grant date fair value of stock options granted during fiscal years 2021, 2020 and
2019. The grant date fair value of stock options is determined using the Black-Scholes option pricing model. For additional information on the valuation assumptions with respect to the 2021 grants, refer to Note 6 of Quidel&#146;s Consolidated
Financial Statements for the year ended December&nbsp;31, 2021. See the &#147;Grants of Plan-Based Awards in Fiscal Year 2021&#148; table for information on stock options granted in 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column represents the approved awards to each executive officer under the 2021 Cash Incentive Plan, the
2020 Cash Incentive Plan and the 2019 Cash Incentive Plan. Each executive officer could also elect to participate in the 2021 Employee Deferred Program, the 2020 Employee Deferred Program and the 2019 Employee Deferred Program with respect to any
payments received under the 2021 Cash Incentive Plan, the 2020 Cash Incentive Plan and the 2019 Cash Incentive Plan, respectively. The cash bonus under the 2021 Cash Incentive Plan was paid in early 2022. The cash bonus under the 2020 Cash Incentive
Plan was paid in early 2021. The cash bonus under the 2019 Cash Incentive Plan was paid in early 2020. The amounts shown are inclusive of the cash component and deferred Covered Bonus component of the electing officer&#146;s award, but do not
include the Premium RSUs component which is included as a component of the amounts in the &#147;Stock Awards&#148; column. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the year ended December&nbsp;31, 2021, (a) we made contributions under Quidel&#146;s 401(k) plan to
Mr.&nbsp;Bryant, Mr.&nbsp;Steward, Mr.&nbsp;Bujarski, Ms.&nbsp;Hodges and Dr.&nbsp;Kroll and (b)&nbsp;we funded a group term life insurance plan providing life insurance in an amount equal to two times the executive officer&#146;s annual salary, a
benefit that is provided to all employees. Amounts related to contributions under Quidel&#146;s 401(k) plan, life insurance and other compensation for Mr.&nbsp;Bryant, Mr.&nbsp;Steward, Mr.&nbsp;Bujarski, Ms.&nbsp;Hodges and Dr.&nbsp;Kroll were as
follows: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Components of All Other Compensation </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>401(k)</B><br><B>Contributions&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Grants of Plan-Based Awards in Fiscal Year 2021 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth all plan-based awards granted to Quidel&#146;s NEOs during fiscal year 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ROWSPAN="2"><B>Name</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant</B><br><B>Date</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Future Payouts Under<BR><FONT STYLE="white-space:nowrap">Non-Equity&nbsp;Incentive&nbsp;Plan&nbsp;Awards</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;Future&nbsp;Payouts&nbsp;Under<BR>Equity&nbsp;Incentive&nbsp;Plan&nbsp;
Awards<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other</B><br><B>Stock<BR>Awards:</B><br><B>Number&nbsp;of</B><br><B>Shares of</B><br><B>Stock</B><br><B>(#)<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other</B><br><B>Option</B><br><B>Awards:</B><br><B>Number&nbsp;
of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Options:</B><br><B>(#)<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise</B><br><B>or Base</B><br><B>Price
of</B><br><B>Option</B><br><B>Awards</B><br><B>($/sh)<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date</B><br><B>Fair&nbsp;Value</B><br><B>of Stock</B><br><B>and&nbsp;Option</B><br><B>Awards</B><br><B>($)<SUP
STYLE="font-size:85%; vertical-align:top">(6)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Threshold</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Threshold</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ROWSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Douglas&nbsp;C. Bryant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,299,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">437,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">547,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/28/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">749,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Randall J. Steward</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,299,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ROWSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Robert J. Bujarski</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,299,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ROWSPAN="6"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Michelle&nbsp;A. Hodges</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">699,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/25/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/8/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,499,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Werner Kroll,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/28/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These rows show the potential value of the payout under the &#147;Estimated Future Payouts Under <FONT
STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Awards&#148; columns for each NEO under the 2021 Cash Incentive Plan, as revised, if the threshold, target, and maximum goals are satisfied for all performance measures. The business
measurements, performance goals and salary and bonus multiples for determining the payout are described in the &#147;&#151;Compensation Discussion and Analysis&#148; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
section. The performance measurements were achieved in fiscal year 2021 in the aggregate at the maximum level, as revised, for Mr.&nbsp;Bryant and the other NEOs and payouts were made as
described in the &#147;&#151;Compensation Discussion and Analysis&#151;Annual Cash Incentive Awards&#148; section and in Note (4)&nbsp;to the Summary Compensation Table. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These columns show the potential number of awards to be paid out to Mr.&nbsp;Bryant related to the
performance-based RSUs if the target is achieved. The performance-based RSUs for Mr.&nbsp;Bryant were granted on February&nbsp;1, 2021 and vest over a five-year period, the vesting of which is tied to the achievement of net revenue growth targets
over any three consecutive fiscal year period starting with the three-year period ending in 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column shows the number of time-based RSUs granted in 2021 to the NEOs. Time-based RSUs for
Mr.&nbsp;Bryant, Mr.&nbsp;Bujarski and Ms.&nbsp;Hodges vest over a <FONT STYLE="white-space:nowrap">four-year</FONT> period, with 25% vesting each year on the anniversary of the grant date. Time-based RSUs for Mr.&nbsp;Steward and Dr.&nbsp;Kroll
vest over a three-year period, with <FONT STYLE="white-space:nowrap">one-third</FONT> vesting each year on the anniversary of the grant date. This column also includes the number of RSUs granted in 2021 under the 2021 Employee Deferred Program. For
the RSUs under the 2021 Employee Deferred Program, the number is equal to (i)&nbsp;the amount of the NEO&#146;s bonus deferred under the program, divided by the market closing price of Quidel&#146;s common stock on January&nbsp;31, 2022, multiplied
by (ii)&nbsp;either 1.2 or 1.3, as a premium. For Mr.&nbsp;Bryant, Mr.&nbsp;Steward, Mr.&nbsp;Bujarski and Ms.&nbsp;Hodges $273,490, $117,004, $122,998 and $105,428 (included in the &#147;Grant Date Fair Value&#148; column), respectively, represent
compensation deferred and are included in the <FONT STYLE="white-space:nowrap">&#147;Non-Equity</FONT> Incentive Plan Compensation&#148; column of the Summary Compensation Table. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column shows the number of stock options granted in 2021 to the NEOs. These options vest and become
exercisable over a <FONT STYLE="white-space:nowrap">four-year</FONT> period, with 25% vesting each year on the anniversary of the grant date, except for the stock option granted to Mr.&nbsp;Bryant on July&nbsp;28, 2021, which vests and becomes
exercisable over a three-year period, with <FONT STYLE="white-space:nowrap">one-third</FONT> vesting and becoming exercisable each year on the anniversary of the grant date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column shows the exercise price for the stock options granted, which was the closing price of
Quidel&#146;s common stock on the grant date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column shows the full grant date fair value under ASC Topic 718 of time-based RSUs, performance-based RSUs
and stock options granted to the NEOs in 2021. For the time-based RSUs and performance-based RSUs, fair value is calculated using the closing price of Quidel&#146;s common stock on the grant date. The grant date fair value is the amount that we
would expense in Quidel&#146;s Consolidated Financial Statements over the award&#146;s vesting schedule, unless the NEO leaves Quidel. For stock options, fair value is calculated using the Black-Scholes value on the grant date and is the amount that
we would expense in Quidel&#146;s Consolidated Financial Statements over the award&#146;s vesting schedule, unless the NEO leaves Quidel. For additional information on the valuation assumptions, refer to Note 6 of Quidel&#146;s Consolidated
Financial Statements for the year ended December&nbsp;31, 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2021 Fiscal <FONT
STYLE="white-space:nowrap">Year-End</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information on the holdings of stock options, time-based RSUs and
performance-based RSUs by the NEOs as of December&nbsp;31, 2021. This table includes unexercised and unvested stock options and unvested time-based RSUs and performance-based RSUs. Each equity grant is shown separately for each NEO. The vesting
schedule for each grant is shown following this table, based on the grant date. The market value of the stock awards is based on the closing market price of Quidel&#146;s common stock as of December&nbsp;31, 2021, which was $134.99. For additional
information about the stock options and RSUs, see the &#147;&#151;Executive Compensation&#151;Longer-Term Equity Incentive Awards&#148; section. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Grant</B><br><B>Date</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="20" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options&nbsp;&#151;</B><br><B>Exercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options&nbsp;&#151;</B><br><B>Unexercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Exercise</B><br><B>Price($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock</B><br><B>Award</B><br><B>Grant</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares or</B><br><B>Units of</B><br><B>Stock&nbsp;That</B><br><B>Have&nbsp;Not</B><br><B>Vested</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market</B><br><B>Value of</B><br><B>Shares&nbsp;or</B><br><B>Units
of</B><br><B>Stock&nbsp;That</B><br><B>Have&nbsp;Not</B><br><B>Vested</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number&nbsp;of<BR>Unearned<BR>Shares,<BR>Units or<BR>Other&nbsp;Rights<BR>that
have<BR>not&nbsp;vested</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Market&nbsp;or<BR>Payout<BR>Value of<BR>Unearned<BR>Shares,<BR>Units or<BR>Other&nbsp;Rights<BR>that
have<BR>not&nbsp;vested</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Douglas&nbsp;C. Bryant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/10/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/10/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,865,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,527,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,536,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,049,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/24/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/24/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/24/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Grant</B><br><B>Date</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="20" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options&nbsp;&#151;</B><br><B>Exercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options&nbsp;&#151;</B><br><B>Unexercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Exercise</B><br><B>Price($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock</B><br><B>Award</B><br><B>Grant</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares or</B><br><B>Units of</B><br><B>Stock&nbsp;That</B><br><B>Have&nbsp;Not</B><br><B>Vested</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market</B><br><B>Value of</B><br><B>Shares&nbsp;or</B><br><B>Units
of</B><br><B>Stock&nbsp;That</B><br><B>Have&nbsp;Not</B><br><B>Vested</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number&nbsp;of<BR>Unearned<BR>Shares,<BR>Units or<BR>Other&nbsp;Rights<BR>that
have<BR>not&nbsp;vested</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Market&nbsp;or<BR>Payout<BR>Value of<BR>Unearned<BR>Shares,<BR>Units or<BR>Other&nbsp;Rights<BR>that
have<BR>not&nbsp;vested</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/28/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/28/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Randall J. Steward</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">647,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">652,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/18/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,516,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/24/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">690,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Robert J. Bujarski</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/10/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/10/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">621,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">489,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/18/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">672,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/14/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/14/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/14/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Michelle A. Hodges</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/25/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/8/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,607,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Werner Kroll, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/27/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">590,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">621,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">529,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,152,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/1/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/28/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">473,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stock options are service-based and vest over three to four years. For stock options that were not exercisable
at December&nbsp;31, 2021 and were granted on August&nbsp;24, 2020 or July&nbsp;28, 2021 presented in the table above, <FONT STYLE="white-space:nowrap">one-third</FONT> of the options vest each year on the anniversary of the grant date over a
three-year vesting period. For the remaining stock options that were not exercisable at December&nbsp;31, 2021 and were granted in 2020 or 2021 presented in the table above, 25% of the options vest each year on the anniversary of the grant date over
a four-year vesting period. For the stock options that were not exercisable at December&nbsp;31, 2021 and were granted in 2018 or 2019 presented in the table above, the first 50% of the options vest on the second anniversary of the grant date and
the remaining 50% of the options vest in equal annual installments (25% per year) thereafter through the remaining four-year vesting period. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents RSUs granted to the NEOs. For the 2018 grants, the RSUs vest on the fourth anniversary of the grant
date. For the 2019 grants, the first 50% of the RSUs vest on the second anniversary of the grant date and the remaining 50% of the RSUs vest in equal annual installments (25% per year) thereafter through the remaining four-year vesting period. For
the 2020 and 2021 grants, 25% of the RSUs vest each year on the anniversary of the grant date over a four-year vesting period. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents performance-based RSUs granted to the CEO. Performance-based RSUs granted in February 2020 and
February 2021 vest over a five-year vesting period, subject to the achievement of performance metrics tied to net revenue growth. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents RSUs granted to Mr.&nbsp;Bryant and Mr.&nbsp;Steward for their efforts and contributions to
Quidel&#146;s <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing needs. <FONT STYLE="white-space:nowrap">One-third</FONT> of the award vests each year on the anniversary of the grant date over a three-year vesting period.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the Premium RSUs component related to the 2020 and 2021 Employee Deferred Programs as detailed in
the &#147;Nonqualified Deferred Compensation&#148; table, which will vest in February 2022 and January 2023, respectively. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents RSUs granted to Mr.&nbsp;Steward and Mr.&nbsp;Bujarski for their efforts and contributions to
Quidel&#146;s integration of acquired companies. <FONT STYLE="white-space:nowrap">One-third</FONT> of the award vests each year on the anniversary of the grant date over a three-year vesting period. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents RSUs granted to Mr.&nbsp;Steward as part of his individual retirement program. <FONT
STYLE="white-space:nowrap">One-third</FONT> of the award vests each year on the anniversary of the grant date over a three-year vesting period. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents RSUs granted to Mr.&nbsp;Bujarski upon his appointment as Quidel&#146;s Chief Operating Officer. 25%
of the award vests each year on the anniversary of the grant date over a four-year vesting period. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents RSUs granted to Mr.&nbsp;Bujarski and Ms.&nbsp;Hodges for their efforts and contributions to the
resolution of the Beckman litigation and implementation of the related transition agreements. 25% of the award vests each year on the anniversary of the grant date over a four-year vesting period. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents RSUs granted to Ms.&nbsp;Hodges upon her appointment as Quidel&#146;s Senior Vice President, General
Counsel. 25% of the award vests each year on the anniversary of the grant date over a <FONT STYLE="white-space:nowrap">four-year</FONT> vesting period. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents RSUs granted to Ms.&nbsp;Hodges for her extraordinary efforts and contributions related to business
development matters and for retention purposes. 25% of the award vests each year on the anniversary of the grant date over a four-year vesting period. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents RSUs granted to Ms.&nbsp;Hodges for her extraordinary efforts and contributions related to business
development matters and for retention purposes. <FONT STYLE="white-space:nowrap">One-third</FONT> of the award vests each year on the anniversary of the grant date over a three-year vesting period. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents RSUs granted to Dr.&nbsp;Kroll upon his appointment as Quidel&#146;s Senior Vice President, Research
and Development. 25% of the award vests each year on the anniversary of the grant date over a four-year vesting period, beginning on May&nbsp;27, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents RSUs granted to Dr.&nbsp;Kroll as part of his individual retirement program. <FONT
STYLE="white-space:nowrap">One-third</FONT> of the award vests each year on the anniversary of the grant date over a three-year vesting period. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents RSUs granted to Dr.&nbsp;Kroll for his efforts and contributions to Quidel&#146;s development of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> diagnostic products. <FONT STYLE="white-space:nowrap">One-third</FONT> of the award vests each year on the anniversary of the grant date over a three-year vesting period. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents RSUs granted to Dr.&nbsp;Kroll for his efforts and contributions to the achievement of certain key
R&amp;D milestones. <FONT STYLE="white-space:nowrap">One-third</FONT> of the award vests each year on the anniversary of the grant date over a three-year vesting period. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option Exercises and RSUs Vested in Fiscal Year 2021 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table sets forth stock options that were exercised by, and RSUs that vested for, the NEOs during fiscal year 2021. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="8" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares&nbsp;Acquired</B><br><B>on Exercise&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;Realized</B><br><B>on Exercise</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares&nbsp;Acquired</B><br><B>on Vesting&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;Realized</B><br><B>on Vesting</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,616,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">898,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,836,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,731,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,330,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,023,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="8" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares&nbsp;Acquired</B><br><B>on Exercise&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;Realized</B><br><B>on Exercise</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares&nbsp;Acquired</B><br><B>on Vesting&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;Realized</B><br><B>on Vesting</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,635,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,728,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,097,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,635,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,792,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">745,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">976,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During 2021, restrictions lapsed with respect to 20,250, 7,594, 7,172 and 7,172 shares of RSUs held by
Mr.&nbsp;Bryant, Mr.&nbsp;Steward, Mr.&nbsp;Bujarski and Dr.&nbsp;Kroll, respectively. The market price for Quidel&#146;s common stock on the date of vesting was $227.97 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During 2021, restrictions lapsed with respect to 3,795, 5,616 and 1,661 shares of RSUs held by Mr.&nbsp;Bryant,
Mr.&nbsp;Steward and Mr.&nbsp;Bujarski, respectively. The market price for Quidel&#146;s common stock on the date of vesting was $236.85 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During 2021, restrictions lapsed with respect to 1,460 and 292 shares of RSUs held by Mr.&nbsp;Bryant and
Mr.&nbsp;Steward, respectively. The market price for Quidel&#146;s common stock on the date of vesting was $121.80 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During 2021, restrictions lapsed with respect to 32,538, 9,629, 8,229 and 8,531 shares of performance-based
RSUs held by Mr.&nbsp;Bryant, Mr.&nbsp;Steward, Mr.&nbsp;Bujarski and Dr.&nbsp;Kroll, respectively. The market price for Quidel&#146;s common stock on the date of vesting was $210.10 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During 2021, restrictions lapsed with respect to 1,033 and 1,033 shares of RSUs held by Mr.&nbsp;Steward and
Mr.&nbsp;Bujarski, respectively. The market price for Quidel&#146;s common stock on the date of vesting was $144.71 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During 2021, restrictions lapsed with respect to 313 shares of RSUs held by Mr.&nbsp;Bujarski. The market price
for Quidel&#146;s common stock on the date of vesting was $146.35 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During 2021, restrictions lapsed with respect to 315 and 210 shares of RSUs held by Mr.&nbsp;Bujarski and
Dr.&nbsp;Kroll, respectively. The market price for Quidel&#146;s common stock on the date of vesting was $237.25 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During 2021, restrictions lapsed with respect to 238 shares of RSUs held by Ms.&nbsp;Hodges. The market price
for Quidel&#146;s common stock on the date of vesting was $144.69 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During 2021, restrictions lapsed with respect to 4,376 shares of RSUs held by Dr.&nbsp;Kroll. The market price
for Quidel&#146;s common stock on the date of vesting was $121.50 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During 2021, restrictions lapsed with respect to 2,970 shares of RSUs held by Dr.&nbsp;Kroll. The market price
for Quidel&#146;s common stock on the date of vesting was $250.97 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During 2021, restrictions lapsed with respect to 4,268 shares of RSUs held by Dr.&nbsp;Kroll. The market price
for Quidel&#146;s common stock on the date of vesting was $228.68 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During 2021, restrictions lapsed with respect to 982 shares of RSUs held by Dr.&nbsp;Kroll. The market price
for Quidel&#146;s common stock on the date of vesting was $128.60 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The value realized on exercise equals the intrinsic value of the exercise, which is the gain realized in the
difference from the market price of the shares sold and the exercise price of the shares purchased. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The value realized on vesting equals the closing price of Quidel&#146;s common stock on the vesting date (the
date the restrictions lapsed) multiplied by the number of shares with respect to which restrictions lapsed on such date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nonqualified Deferred Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth compensation deferred by each of the NEOs during fiscal year 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Executive</B><br><B>Contributions</B><br><B>in&nbsp;Last&nbsp;FY</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Registrant</B><br><B>Contributions</B><br><B>in&nbsp;Last&nbsp;FY</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Earnings</B><br><B>in&nbsp;Last&nbsp;FY</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Withdrawals/</B><br><B>Distributions</B><br><B>in&nbsp;last&nbsp;
FY</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Balance</B><br><B>at&nbsp;Last&nbsp;FYE</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(825,878</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,650,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,620,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(545,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,032,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,051,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(417,927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(996,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">642,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the amount of incentive compensation deferred under the 2021 Employee Deferred Program by each NEO.
The amount is included as a component of <FONT STYLE="white-space:nowrap">&#147;Non-Equity</FONT> Incentive Plan Compensation&#148; for 2021 in the Summary Compensation Table. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the 10%, 20% or 30% premium above the deferred incentive compensation amount as described above.
Such amounts are included as a component of &#147;Stock Awards&#148; for 2021 in the Summary Compensation Table. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the change in value of the deferred incentive compensation for each NEO relating to the 2018
Employee Deferred Program, 2019 Employee Deferred Program, 2020 Employee Deferred Program and 2021 Employee Deferred Program (collectively, the &#147;Deferred Bonus Programs&#148;). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the market value of the stock on the date of distribution to Mr.&nbsp;Bryant, Mr.&nbsp;Bujarski and
Dr.&nbsp;Kroll in accordance with their specified distribution elections. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Aggregate deferrals include deferrals from the Deferred Bonus Programs. Each employee participating in the 2021
Employee Deferred Program is eligible for a Premium RSU equal to either 10%, 20% or 30% of the deferred 2021 cash incentive bonus, depending on the length of deferral elected by the employee, which vests on January&nbsp;31, 2023. Pursuant to this
program, Mr.&nbsp;Bryant, Mr.&nbsp;Steward, Mr.&nbsp;Bujarski and Ms.&nbsp;Hodges received the following RSUs on January&nbsp;31, 2022: 3,440 shares (including 794 shares relating to the premium component), 1,358 shares (including 226 shares
relating to the premium component), 1,547 shares (including 357 shares relating to the premium component) and 1,224 shares (including 204 shares relating to the premium component), respectively. Such prior year deferred amounts were reported as
compensation to each respective NEO for the respective prior years in the Summary Compensation Table. See Notes (1)&nbsp;and (2) above. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment, Change in Control and Severance Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the appointment of Mr.&nbsp;Bryant as Quidel&#146;s President and CEO on January&nbsp;16, 2009, Mr.&nbsp;Bryant entered into an employment
agreement with us. Mr.&nbsp;Bryant&#146;s employment agreement sets forth the terms of his employment with us and provides for, among other matters: (i)&nbsp;a minimum base salary of $450,000 per annum, subject to upward adjustment by the Quidel
board of directors or its Compensation Committee; and (ii)&nbsp;an annual cash incentive bonus based upon attainment of performance goals set by the Quidel board of directors or its Compensation Committee with a target of at least 80% of base salary
and a maximum opportunity of at least up to 120% of base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under his employment agreement, Mr.&nbsp;Bryant is an
<FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> employee of Quidel, which means that either Mr.&nbsp;Bryant or we may terminate his employment at any time for any reason. However, and except in the context of a change in control, if
Mr.&nbsp;Bryant&#146;s employment with us is terminated without &#147;cause&#148; or he terminates his employment for &#147;good reason&#148; (each as defined in his employment agreement) and thereafter delivers and does not revoke a general
release, he is entitled to a severance payment equal to eighteen (18)&nbsp;months of his then-current base salary and payment of health insurance premiums for a period of eighteen (18)&nbsp;months following termination. Amounts payable to
Mr.&nbsp;Bryant upon a change in control of Quidel are generally governed by his change in control agreement, dated as of January&nbsp;16, 2009, which is described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Steward, Mr.&nbsp;Bujarski, Ms.&nbsp;Hodges and Dr.&nbsp;Kroll are each &#147;at will&#148; employees of Quidel with compensation arrangements that
include, among other items: (i)&nbsp;a base salary for 2021 of $499,550, $525,000, $450,000 and $550,000 per annum, respectively; and (ii)&nbsp;eligibility for an annual cash bonus in accordance with Quidel&#146;s Cash Incentive Plan. In addition,
except in the context of a change in control, if we terminate Mr.&nbsp;Bujarski&#146;s employment without cause, he would be entitled to a severance payment equal to six months of his annual salary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Steward and Dr.&nbsp;Kroll each entered into individual retirement and retention programs with
us in November 2019 and February 2020, respectively. These programs were entered into and approved by the Quidel board of directors and the Compensation Committee as part of Quidel&#146;s succession planning and to incentivize Mr.&nbsp;Steward to
continue employment through at least March&nbsp;31, 2022 and Dr.&nbsp;Kroll to continue employment through at least March&nbsp;31, 2023. On February&nbsp;1, 2022, Quidel and Mr.&nbsp;Steward entered into an amendment to his individual retirement
program, which extended the term of his employment beyond March&nbsp;31, 2022 through the earlier of the consummation of the Ortho business combination or termination of the business combination agreement. For each calendar year that
Mr.&nbsp;Steward continues to be employed by Quidel as its CFO, he will receive RSUs with a value on the grant date of $1,300,000 that will vest <FONT STYLE="white-space:nowrap">one-third</FONT> each year on the anniversary of the grant date,
subject to Mr.&nbsp;Steward&#146;s continued employment with Quidel in any capacity. For each calendar year that Dr.&nbsp;Kroll continues to be employed by Quidel as its Senior Vice President, Research and Development, he will receive <FONT
STYLE="white-space:nowrap">non-qualified</FONT> stock options and/or RSUs with a value on the grant date of $1,000,000 that will vest <FONT STYLE="white-space:nowrap">one-third</FONT> each year on the anniversary of the grant date, subject to
Dr.&nbsp;Kroll&#146;s continued employment with Quidel in any capacity. The programs contemplate that the RSU and/or option grants described above will constitute the sole equity incentive compensation that Mr.&nbsp;Steward and Dr.&nbsp;Kroll will
be entitled to receive on or after January&nbsp;1, 2020, unless Quidel determines otherwise. Dr.&nbsp;Kroll&#146;s individual retirement program contemplates that if he remains employed and in good standing in his position through the target date,
then upon ceasing to serve in his current role, he will enter into a special advisor agreement, in the form provided in his program, and be engaged as a full-time employee, serving as a <FONT STYLE="white-space:nowrap">non-officer</FONT> special
advisor for a period of one year at a reduced pay rate and his equity awards will continue to vest and be governed by the applicable equity incentive plan and award agreements. Mr.&nbsp;Steward&#146;s individual retirement program contemplates that
if he remains employed and in good standing in his position through the target date, then upon ceasing to serve in his current role, he will enter into a special advisor agreement, in the form provided in his program, and be engaged as a full-time
employee, serving as a <FONT STYLE="white-space:nowrap">non-officer</FONT> special advisor for a period of one year at a pay rate of $300,000 per year and his equity awards will continue to vest and be governed by the applicable equity incentive
plan and award agreements through the <FONT STYLE="white-space:nowrap">one-year</FONT> period following the earlier of the consummation of the Ortho business combination or termination of the business combination agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Mr.&nbsp;Bryant, Mr.&nbsp;Steward, Mr.&nbsp;Bujarski, Ms.&nbsp;Hodges and Dr.&nbsp;Kroll has entered into a change in control agreement with us, which
provides for the payment of severance benefits in the event of termination of employment in connection with a change in control of Quidel. The severance benefits are payable if their respective employment with us is terminated within 30&nbsp;days
prior to or three years following a change in control, unless terminated for cause or the termination is the result of a voluntary resignation (which does not include resignations stemming from a material adverse change in responsibilities, status,
compensation, authority or location of workplace) or their death or disability. The change in control agreement for each of Quidel&#146;s NEOs includes a covenant by the NEO to not solicit, recruit or hire-away Quidel&#146;s employees or solicit,
influence or attempt to influence any person or entity to terminate such person&#146;s or entity&#146;s contractual and/or business relationship with Quidel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The severance benefits under the change in control agreements generally consist of a lump sum cash payment equal to two times the sum of (i)&nbsp;such
executive&#146;s highest annual salary rate within the three-year period ending on the date of termination, plus (ii)&nbsp;an amount equal to the annualized average of all bonuses paid to the executive during the
<FONT STYLE="white-space:nowrap">two-year</FONT> period immediately before the date of termination. In addition, the change in control agreements provide for: payment of $25,000 to help defray the legal, tax and accounting fees and other costs
associated with transitional matters; continued coverage for two years under Quidel&#146;s group medical insurance, group dental insurance and group vision insurance programs, unless and to the extent the executive obtains concurrent coverage
through another program, in which case Quidel&#146;s coverage will be terminated or reduced as applicable; and immediate vesting and exercisability of any and all unvested stock options and RSUs held by the executive (unless previously waived or
otherwise expressly agreed to by the executive). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Post-employment Payments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described above, Quidel&#146;s NEOs have employment, severance and/or change in control agreements with us. The table below illustrates the compensation
that would be payable by us to each NEO in the event of a change in control of Quidel or a termination of the NEO&#146;s employment with Quidel for various described reasons, sometimes referred to in this section as a &#147;triggering event.&#148;
In accordance with applicable SEC rules, the following illustrations assume: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the triggering event in question, the death, disability, change in control or termination occurred on
December&nbsp;31, 2021, which was the last full business day prior to the last day of Quidel&#146;s 2021 fiscal year end, which fell on Sunday, January&nbsp;2, 2022;&nbsp;and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the calculations provided below are based on the closing market price of Quidel&#146;s common stock as of
December&nbsp;31, 2021, which was $134.99. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in connection with any actual termination of employment, the Quidel board of
directors or the Compensation Committee may determine to enter into an agreement providing additional benefits or amounts, or altering the terms of benefits described below, as deemed appropriate by the Quidel board of directors or the Compensation
Committee. The illustrations exclude any vested awards deferred pursuant to Quidel&#146;s Employee Deferred Programs. The actual amounts that would be paid upon an NEO&#146;s termination of employment can only be determined at the time of such
NEO&#146;s separation from Quidel. Due to the number of factors that affect the nature and amount of any benefits provided upon the events discussed below, any actual amounts paid or distributed may be higher or lower than reported below. Factors
that could affect these amounts include Quidel&#146;s stock price at the time of termination and determinations by the Quidel board of directors. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Potential Executive Benefits</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>and&nbsp;Payments</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Voluntary</B><br><B>Termination</B><br><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Retirement</B><br><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Involuntary,</B><br><B>Not&nbsp;for&nbsp;Cause</B><br><B>or Voluntary,</B><br><B>Good Reason</B><br><B>Termination</B><br><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Involuntary,</B><br><B>for Cause</B><br><B>Termination</B><br><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change in</B><br><B>Control</B><br><B>(Qualifying</B><br><B>Termination)</B><br><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Base Salary<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,313,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,751,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="5" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term&nbsp;Incentive&nbsp;Bonus<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">808,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSU Awards-Unvested and
accelerated<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,684,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Stock&nbsp;Options-Unvested&nbsp;and&nbsp;accelerated</FONT><SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,348,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Payments<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Base Salary<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">999,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="5" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term&nbsp;Incentive&nbsp;Bonus<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSU Awards-Unvested and
accelerated<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,755,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Stock&nbsp;Options-Unvested&nbsp;and&nbsp;accelerated</FONT><SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">578,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Payments<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Base Salary<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="5" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term Incentive Bonus<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSU Awards-Unvested and
accelerated<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,837,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Stock&nbsp;Options-Unvested&nbsp;and&nbsp;accelerated</FONT><SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">766,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Payments<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Base Salary<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="5" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term Incentive Bonus<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSU Awards-Unvested and
accelerated<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,424,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Stock&nbsp;Options-Unvested&nbsp;and&nbsp;accelerated</FONT><SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Payments<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Base Salary<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="5" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term Incentive Bonus<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSU Awards-Unvested and
accelerated<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,164,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Stock&nbsp;Options-Unvested&nbsp;and&nbsp;accelerated</FONT><SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">501,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Payments<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payable in one lump sum upon termination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount represents the annualized average of all bonuses paid to the NEO in 2020 and 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This represents the value of unvested RSUs and unearned performance-based RSUs at target levels, including
Premium RSUs earned pursuant to the Employee Deferred Programs as detailed in the &#147;Nonqualified Deferred Compensation&#148; table. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This represents the intrinsic value of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> unvested stock options (based on a market price of $134.99 per share as of the last full business day prior to the end of Quidel&#146;s fiscal year 2021).
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Per the change in control agreements, for two years, coverage is continued under Quidel&#146;s group medical
insurance, group dental insurance and group vision insurance programs, unless and to the extent the NEO obtains </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
concurrent coverage through another program, in which case Quidel&#146;s coverage will be terminated or reduced as applicable. In addition, if Mr.&nbsp;Bryant&#146;s employment is terminated
without &#147;cause&#148; or he terminates his employment for &#147;good reason&#148; (each as defined in his employment agreement) and thereafter does not revoke a general release, he is entitled to receive payment of health insurance premiums for
a period of eighteen (18)&nbsp;months following termination. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each NEO&#146;s change in control agreement provides for payment of $25,000 to help defray the legal, tax and
accounting fees and other costs associated with transitional matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CEO Pay Ratio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are providing the following information regarding the relationship of the annual total compensation of Quidel&#146;s CEO and that of Quidel&#146;s
&#147;median employee,&#148; as required by Section&nbsp;953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(u) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.&nbsp;The</FONT> pay ratio information provided
below is a reasonable estimate calculated in a manner consistent with these pay ratio disclosure rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Quidel&#146;s 2021 fiscal year: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The estimated median of the annual total compensation of all of Quidel&#146;s employees, excluding the CEO, was
$79,053; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The annual total compensation of Quidel&#146;s CEO, as reported in the Summary Compensation Table, was
$5,546,216; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ratio of the annual total compensation of Quidel&#146;s CEO to the median of the annual total compensation of
all other employees was estimated to be 70 to 1. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In determining the pay ratio information provided above, we first identified
Quidel&#146;s &#147;median employee&#148; for the 2021 fiscal year by using the following methodology, as permitted by the SEC&#146;s pay ratio disclosure rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We selected December&nbsp;31, 2021 as the date upon which we would identify Quidel&#146;s employee population and
median employee and, from Quidel&#146;s tax and payroll records, we compiled a list of 1,645 total full-time, part-time, temporary and seasonal employees who were employed on that date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We used total cash compensation during the 2021 fiscal year as a consistently applied compensation measure to
identify Quidel&#146;s median employee from the employees on the list. For this purpose, we define total cash compensation as base wages. We did not include incentive cash compensation because Quidel&#146;s incentive cash compensation program does
not extend throughout the organization and would therefore not be expected to impact the determination of the median employee. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once
Quidel&#146;s median employee was identified in the manner described above, we calculated the annual total compensation of the median employee using the same methodology that we used to determine the annual total compensation of Quidel&#146;s CEO,
as reported in the Summary Compensation Table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It should be noted that the SEC&#146;s pay ratio disclosure rules provide reporting companies with
flexibility in determining the methodology used to identify the median employee and the pay ratio. Accordingly, Quidel&#146;s methodology may differ materially from the methodology used by other companies to prepare their pay ratio disclosures,
which may contribute to a lack of comparability between Quidel&#146;s pay ratio and the pay ratio reported by other companies, including those within Quidel&#146;s industry. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delinquent Section 16(a) Reports </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section 16(a) of the
Exchange Act requires Quidel&#146;s directors, executive officers and holders of more than 10% of Quidel Shares to file reports of their ownership and changes in ownership of Quidel Shares with the SEC. Specific due dates for these reports have been
established, and Quidel is required to disclose any late filings during the year ended December&nbsp;31, 2021. Based solely on Quidel&#146;s review of the reports filed during 2021 and written representations from Quidel&#146;s directors and
executive officers that no other reports were required, all Section 16(a) filing requirements were satisfied with respect to 2021, except that one Form&nbsp;4 for William&nbsp;J. Ferenczy, reporting two transactions, that was due on June&nbsp;15,
2021 and one Form&nbsp;4 for Michelle&nbsp;A. Hodges, reporting one transaction, that was due on May&nbsp;27, 2021 were filed late on June&nbsp;16, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Securities Available for Issuance under Quidel&#146;s Equity Compensation Plans</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information with respect to Quidel&#146;s equity compensation plans as of December&nbsp;31, 2021, which plans were as follows: the
1983 ESPP; the 2001 Equity Incentive Plan; the Amended and Restated 2010 Equity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Incentive Plan; the 2016 Equity Incentive Plan; and the 2018 Plan. The 2001 Equity Incentive Plan, the Amended and Restated 2010 Equity Incentive Plan, and the 2016 Equity Incentive Plan have
been terminated, expired or superseded by subsequent plans, and thus no additional awards will be made under such plans. However, any outstanding awards under such plans will continue to vest in accordance with their terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Plan Category</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Securities to<BR>be Issued upon<BR>Exercise&nbsp;of&nbsp;Outstanding<BR>Options,&nbsp;Warrants<BR>and&nbsp;Rights (a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-average<BR>Exercise&nbsp;Price of<BR>Outstanding<BR>Options,&nbsp;Warrants<BR>and Rights (b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Securities</B><br><B>Remaining&nbsp;Available&nbsp;for</B><br><B>Future Issuance
under</B><br><B>Equity&nbsp;Compensation&nbsp;Plans</B><br><B>(Excluding Securities</B><br><B>Reflected in Column (a))</B><br><B>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,309,373</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;62.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,979,251</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,309,373</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;62.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,979,251</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 587,339 RSUs, including performance-based RSUs, granted under the 2018 Plan for which there is no
exercise price reflected in column (b). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i)&nbsp;56,623 shares of Quidel common stock available for issuance under the 1983 ESPP and
(ii)&nbsp;1,922,628&nbsp;shares of Quidel common stock available for issuance, as of December&nbsp;31, 2021, under the 2018 Plan, pursuant to which incentive stock awards may be granted, including restricted stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_87"></A>INFORMATION ABOUT THE PARTIES TO THE COMBINATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_88"></A>Quidel Corporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel
commenced operations in 1979 and was originally incorporated as Monoclonal Antibodies, Inc. in California. In 1987, Quidel <FONT STYLE="white-space:nowrap">re-incorporated</FONT> as Quidel Corporation in the State of Delaware. Quidel has a
leadership position in the development, manufacturing and marketing of rapid diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular
diagnostic solutions and specialized diagnostic solutions. Quidel sells products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care
clinics, leading universities, retail clinics, pharmacies and wellness screening centers, as well as for individual, <FONT STYLE="white-space:nowrap">non-professional,</FONT> OTC use. Quidel markets its products through a network of distributors and
a direct sales force. Quidel operates in one business segment that develops, manufactures and markets its products globally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel Shares are listed on
Nasdaq under the symbol &#147;QDEL.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal executive offices of Quidel are located at 9975 Summers Ridge Road, San Diego, California 92121,
United States of America, and its telephone number is (858) <FONT STYLE="white-space:nowrap">552-1100.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_89"></A>Ortho
Clinical Diagnostics Holdings plc </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is a leading global provider of IVD solutions to the clinical laboratory and transfusion medicine communities.
Ortho maintains a direct or indirect commercial presence in more than 130 countries and territories, with a direct presence in 36 countries. Ortho&#146;s instruments, assays, reagents and other consumables are used in hospitals, laboratories,
clinics, blood banks and donor centers worldwide. Ortho is globally operated with manufacturing facilities in the United States and the United Kingdom and with sales centers, administrative offices and warehouses located throughout the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho Shares are listed on Nasdaq under the symbol &#147;OCDX.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal executive offices of Ortho are located at 1001 Route 202, Raritan, New Jersey 08869, United States of America, and its telephone number at that
address is (908) <FONT STYLE="white-space:nowrap">218-8000.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_90"></A>Coronado Topco, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Coronado Topco, Inc., a Delaware corporation (&#147;Topco&#148;), is a wholly owned subsidiary of Ortho. Ortho formed Topco on December&nbsp;17, 2021 for the
purpose of entering into the BCA. Pursuant to the BCA, after the Quidel Effective Time, Topco will become the parent company for the combined businesses of Quidel and Ortho. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal executive offices of Topco are located at c/o Ortho Clinical Diagnostics Holdings plc, 1001 Route 202, Raritan, New Jersey 08869, United States
of America, and its telephone number at that address is <FONT STYLE="white-space:nowrap">(908)&nbsp;218-8000.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_91"></A>Laguna
Merger Sub, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laguna Merger Sub, Inc., a Delaware corporation (&#147;U.S. Merger Sub&#148;), is a wholly owned subsidiary of Topco formed solely
for the purpose of effecting the Combinations. U.S. Merger Sub will not conduct any business operations other than those incidental to its formation and in connection with the transactions contemplated by the BCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal executive offices of U.S. Merger Sub are located at c/o Ortho Clinical Diagnostics Holdings plc, 1001 Route 202, Raritan, New Jersey 08869,
United States of America, and its telephone number at that address is <FONT STYLE="white-space:nowrap">(908)&nbsp;
218-8000.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_92"></A>Orca Holdco, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orca Holdco, Inc., a Delaware corporation (&#147;U.S. Holdco Sub&#148;), is a wholly owned subsidiary of Topco formed solely for the purpose of effecting the
Combinations. U.S. Holdco Sub will not conduct any business operations prior to closing of the Combinations other than those incidental to its formation and in connection with the transactions contemplated by the BCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal executive offices of U.S. Holdco Sub are located at c/o Ortho Clinical Diagnostics Holdings plc, 1001 Route 202, Raritan, New Jersey 08869,
United States of America, and its telephone number at that address is <FONT STYLE="white-space:nowrap">(908)&nbsp;218-8000.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_93"></A>Orca Holdco 2, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orca Holdco 2, Inc., a Delaware corporation (&#147;U.S. Holdco Sub 2&#148;), is a wholly owned subsidiary of U.S. Holdco Sub. U.S. Holdco Sub 2 will not
conduct any business operations prior to closing of the Combinations other than those incidental to its formation and in connection with the transactions contemplated by the BCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal executive offices of U.S. Holdco Sub 2 are located at c/o Ortho Clinical Diagnostics Holdings plc, 1001 Route 202, Raritan, New Jersey 08869,
United States of America, and its telephone number at that address is <FONT STYLE="white-space:nowrap">(908)&nbsp;218-8000.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_115"></A>BUSINESS OF QUIDEL AND CERTAIN INFORMATION ABOUT QUIDEL
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel commenced operations in 1979 and was originally incorporated as Monoclonal Antibodies, Inc. in California. In 1987, Quidel <FONT
STYLE="white-space:nowrap">re-incorporated</FONT> as Quidel Corporation in the State of Delaware. Quidel&#146;s executive offices are located at 9975 Summers Ridge Road, San Diego, California 92121, and its telephone number is (858) <FONT
STYLE="white-space:nowrap">552-1100.</FONT> Additional information about Quidel and its subsidiaries is included in documents incorporated by reference into this joint proxy statement/prospectus. See the section entitled &#147;Where You Can Find
More Information&#148; of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s primary mission is to advance diagnostics to improve human health. Quidel has a leadership position in the development, manufacturing and
marketing of rapid diagnostic testing solutions. Quidel separates these into four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular diagnostic solutions and specialized diagnostic solutions. Quidel currently sells its
products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, leading universities, retail clinics, pharmacies and wellness
screening centers, as well as for individual, <FONT STYLE="white-space:nowrap">non-professional,</FONT> OTC use. More recently, Quidel has begun to reach significant new markets as it introduced its QuickVue<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> <FONT STYLE="white-space:nowrap">At-Home</FONT> OTC COVID-19 test for reopening schools, and for health departments, employers, entertainment centers and many other locations. Quidel markets its
products through a network of distributors and a direct sales force. Quidel operates in one business segment that develops, manufactures and markets its products globally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel launched its first products, dipstick-based pregnancy tests, in 1983. Since such time, Quidel&#146;s product base and technology platforms have
expanded through internal development and acquisitions of other products, technologies and companies. Quidel&#146;s diagnostic solutions aid in the detection and diagnosis of many critical diseases and other medical conditions, including infectious
diseases, cardiovascular diseases and conditions, women&#146;s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2017, Quidel acquired the Triage<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
MeterPro<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> cardiovascular and toxicology business, and <FONT STYLE="white-space:nowrap">B-type</FONT> Natriuretic Peptide (&#147;BNP&#148;) assay business run on Beckman Coulter analyzers from
Alere Inc., which added an extensive cardiovascular and toxicology menu to its innovative medical diagnostics portfolio. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_116"></A>Products </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel provides
diagnostic testing solutions under various brand names, including, among others, the following: Quidel<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, QuickVue, QuickVue+<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, QVue<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, Sofia<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Triage, Solana<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,
Virena<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, MicroVue<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, Lyra<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, FreshCells<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, D3<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, FastPoint<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,
ReadyCells<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Super <FONT STYLE="white-space:nowrap">E-Mix</FONT><SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>,
InflammaDry<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, AdenoPlus<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, ELVIRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, ELVIS<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Thyretain<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Savanna<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The products and platforms under each product category are described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rapid Immunoassay</I></B>. The rapid immunoassay product category includes the Sofia and Sofia 2 analyzers and the QuickVue, InflammaDry and AdenoPlus
products. Sofia is the brand name for Quidel&#146;s fluorescent immunoassay systems. The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">easy-to-use</FONT></FONT> Sofia and Sofia 2 analyzers combine unique software and Sofia
fluorescent immunoassay tests to yield an automatic, objective result that is readily available on the instrument&#146;s screen, in a hard-copy printout, and in a transmissible electronic form that can network via a lab information system to
hospital and medical center databases. Quidel launched the Sofia analyzer in 2011 and Sofia 2 in 2017. These systems provide for different operational modes to accommodate both small and large laboratories, as well as other features designed to
facilitate use in a variety of healthcare settings, including hospitals, medical centers, and small clinics. Sofia 2 systems include additional benefits and features at a cost point that allows us to better address the lower-volume segment of the
diagnostic testing market. Sofia 2 analyzers also incorporate enhanced optics, which provide added performance benefits and enable positive test results to be read in as few as three minutes. In 2021, Quidel also received an emergency use
authorization to market its Sofia Q platform that offers similar features and benefits to the Sofia analyzers in a smaller and less expensive format. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">QuickVue is the brand name for Quidel&#146;s rapid, visually-read, lateral flow immunoassay products. Quidel has been a leader in the development and
production of high-quality lateral flow diagnostics since the early 1990s and offers a broad portfolio of products to diagnose a wide variety of infectious diseases and medical conditions. The QuickVue <FONT STYLE="white-space:nowrap">At-Home</FONT>
OTC <FONT STYLE="white-space:nowrap">COVID-19</FONT> test has also recently become a leading <FONT STYLE="white-space:nowrap">at-home</FONT> <FONT STYLE="white-space:nowrap">COVID-19</FONT> product for home use and is available through many retail
and online outlets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The InflammaDry and AdenoPlus products are rapid, lateral-flow based, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">point-of-care</FONT></FONT> (&#147;POC&#148;) products for the detection of infectious and inflammatory diseases and conditions of the eye. InflammaDry is a test that detects elevated levels of <FONT
STYLE="white-space:nowrap">MMP-9,</FONT> a key inflammatory marker for dry eye. AdenoPlus is a test that differentiates between a viral and bacterial infection of acute conjunctivitis (pink eye). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cardiometabolic Immunoassay</I></B>. The cardiometabolic immunoassay product category includes the Triage MeterPro, Quidel&#146;s portable testing
platform that runs a comprehensive menu of tests that enable physicians to promote improved health outcomes through the rapid diagnosis of critical diseases and health conditions, as well as the detection of certain drugs of abuse. This system aids
in the diagnosis, assessment and risk stratification of patients having critical care issues, including congestive heart failure, acute coronary syndromes, and acute myocardial infarction, and can reduce hospital admissions and improve clinical and
economic outcomes. Triage cardiovascular rapid tests include immunoassays for BNP, creatine <FONT STYLE="white-space:nowrap">kinase-MB,</FONT> <FONT STYLE="white-space:nowrap">d-dimer,</FONT> myoglobin, troponin I and
<FONT STYLE="white-space:nowrap">N-terminal</FONT> <FONT STYLE="white-space:nowrap">pro-Brain</FONT> Natriuretic Peptide <FONT STYLE="white-space:nowrap">(&#147;NT-proBNP&#148;).</FONT> Triage tests for Troponin I, high sensitivity Troponin I, PlGF
and <FONT STYLE="white-space:nowrap">NT-proBNP,</FONT> as well as certain test panels which include a combination of immunoassays, are not available for sale in the United States. Quidel has also offered a version of the Triage BNP Test for use on
Beckman Coulter Inc. lab analyzers historically but has nearly completed the transition of this business to Beckman Coulter following entry into agreements with Beckman Coulter to resolve litigation between Quidel and Beckman Coulter and provide for
the transition of the BNP business to Beckman Coulter. Quidel will continue to supply Beckman Coulter products related to this business and receive payments of between $70 and $75&nbsp;million per year through 2029 under these arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the cardiovascular menu, Quidel offers urine-specific screening tests for the detection of drug and/or the urinary metabolites for multiple
drug classes, including Quidel&#146;s new Triage TOX Drug Screen and a PlGF test for diagnosis of preterm <FONT STYLE="white-space:nowrap">pre-eclampsia</FONT> in pregnant women. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Molecular Diagnostic Solutions</I></B>. The molecular diagnostic solutions product category includes the Lyra assays and the Solana and Savanna systems.
Lyra is Quidel&#146;s open system molecular assays run on several thermocyclers currently on the market. Lyra Molecular Real-Time Polymerase Chain Reaction assays provide important benefits to the customer, including, among others, room temperature
storage, reduced process time and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-to-use</FONT></FONT> reagent configurations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Solana system was developed using Quidel&#146;s proprietary isothermal Helicase Dependent Amplification technology. Solana is an easy to run amplification
and detection system that has the ability to concurrently run up to 12 assays at a time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In late 2021, Quidel launched in Europe its <FONT
STYLE="white-space:nowrap">CE-Marked</FONT> Savanna multiplex molecular analyzer system and Savanna RVP4 assay. The Savanna system is a <FONT STYLE="white-space:nowrap">low-cost,</FONT> fully-integrated, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">sample-to-result</FONT></FONT> automated in vitro molecular diagnostic platform that enables analysis of up to 12 pathogens or targets, plus controls, from a single assay run in less than 30 minutes. The Savanna RVP4 assay
is a rapid, multiplexed nucleic acid test intended for use with the Savanna instrument for the simultaneous qualitative detection and differentiation of influenza A, influenza B, respiratory syncytial virus and
<FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT> RNA isolated from human nasal or nasopharyngeal swabs. Quidel plans to launch the Savanna system in the United States in 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Specialized Diagnostic Solutions</I></B>. The specialized diagnostic solutions product category includes a wide variety of traditional cell lines,
specimen collection devices, media and controls for use in laboratories that culture and test for many human viruses, including, among others, respiratory and herpes family viruses. Quidel provides cell-based products under the FreshCells brand in
multiple formats, including tubes, shell vials and multi-well plates. Quidel&#146;s virology product category includes the <FONT STYLE="white-space:nowrap">FDA-cleared</FONT> bioassay, Thyretain, which is used for the differential diagnosis of an
autoimmune disease called Graves&#146; Disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel also provides a variety of biomarkers for bone health and produces both clinical and research
products for the assessment of osteoporosis and the evaluation of bone resorption/formation, which, including Quidel&#146;s metabolic bone markers, are used to monitor the effectiveness of therapy in pharmaceutical and related research. In the area
of autoimmune disease, Quidel has developed enzyme linked immunosorbent assays and reagents for the detection of activation products from the three main complement pathways. Assays are developed on a microwell platform and are currently marketed to
clinicians and researchers under the Quidel and MicroVue brands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_117"></A>Digital and Telehealth Solutions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2022, Quidel introduced QVue Business, a mobile application that supports employee <FONT STYLE="white-space:nowrap">at-home</FONT> testing using QuickVue <FONT
STYLE="white-space:nowrap">At-Home</FONT> OTC <FONT STYLE="white-space:nowrap">COVID-19</FONT> tests and a reporting system for employers to help track and trend <FONT STYLE="white-space:nowrap">COVID-19</FONT> test results within
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the workplace. The QVue Business application enables employees, contractors and other visitors to provide <FONT STYLE="white-space:nowrap">COVID-19</FONT> test results in near real time to
employers. The application offers an <FONT STYLE="white-space:nowrap">at-home</FONT> testing alternative to reduce the cost and effort of <FONT STYLE="white-space:nowrap">on-site</FONT> testing and provides detailed videos to guide the user through
the testing and reporting process. QVue Business is a flexible application that can be configured to an employer&#146;s desired testing frequency to track employees&#146; symptoms or exposure risk and provide employees with a digital health passport
for safe access into the workplace. Quidel plans to further expand its digital and telehealth solutions from the <FONT STYLE="white-space:nowrap">at-home</FONT> testing, identity verification and reporting functions to the telehealth setting where
patients can use Quidel&#146;s digital testing and reporting functions to further interact with health care professionals for diagnosis, treatment and care. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_118"></A>Connectivity and Data Management </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Virena is a wireless cellular data management and surveillance system that operates as a cloud-based solution connecting Sofia and Solana instruments across a
healthcare system and automatically transmitting <FONT STYLE="white-space:nowrap">de-identified</FONT> test results to a secure database. With Virena, a health system, physician office laboratory (&#147;POL&#148;), urgent care center or retail
clinic has the ability to compile, analyze, map and generate reports of <FONT STYLE="white-space:nowrap">de-identified</FONT> test results, improving operational efficiencies, quality and patient outcome initiatives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_119"></A>Marketing and Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s current business strategy is designed to serve the continuum of healthcare delivery needs globally, starting with POC clinicians located in
doctor&#146;s office practices, to moderately complex POLs, and to highly complex hospital and clinical reference laboratories in North America and a variety of settings internationally. Within the inherent operational diversity of these various
segments, Quidel focuses on differentiating itself and enhancing its market leadership by specializing in the diagnosis and monitoring of select disease states and conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s marketing strategy includes ensuring that its key product portfolios are supported by clinical validation and health economic and outcomes
research that demonstrate that its tests deliver fast, high quality results, are cost-effective to use and improve patient outcomes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s North
America distribution strategy takes into account the highly fragmented POC market, with many small or <FONT STYLE="white-space:nowrap">medium-sized</FONT> customers. To reach customers using POC diagnostic tests, a network of national and regional
distributors is employed, as well as Quidel&#146;s own sales force. This sales force works closely with Quidel&#146;s key distributors to drive market penetration of its products in the POC market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sales, distribution and service of Quidel&#146;s cell culture tests are controlled primarily by Quidel. Quidel reaches laboratory <FONT
STYLE="white-space:nowrap">end-users</FONT> in hospitals and clinical reference laboratories using these diagnostic tests through Quidel&#146;s direct sales force and technical support services that have specialized training and understanding of
this product portfolio. Quidel sells products globally and markets and distributes products worldwide in a variety of ways, including a mix of direct and indirect distribution strategies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_120"></A>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel has
five manufacturing sites. Two are in San Diego, California, one in Carlsbad, California, one in Athens, Ohio and one in Europe. Quidel seeks to conduct its manufacturing in compliance with Quality Management System (&#147;QMS&#148;) regulatory
requirements of the United States, Australia, Brazil, Canada, Japan, Europe, South Korea and certain other countries. Quidel&#146;s manufacturing facilities have passed routine regulatory inspections confirming compliance with the QMS regulatory
requirements. Its facilities are registered with various regulatory bodies, including the FDA and the Department of Public Health of the State of California for its San Diego and Carlsbad facilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel&#146;s strategy is to target
market segments that represent significant total market opportunities, and in which Quidel can be successful by applying its expertise and <FONT STYLE="white-space:nowrap">know-how</FONT> to develop differentiated technologies and products.
Quidel&#146;s diagnostic testing solutions are designed to provide specialized results that serve a broad range of customers by addressing the market requirements of ease of use, reduced cost, increased test accuracy and reduced time to result. In
order to achieve its mission of advancing diagnostics to improve human health, Quidel&#146;s strategy is to do the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">focus on innovative products and markets and leverage core competency in new product development for the
QuickVue, Sofia and Triage immunoassay brands and next-generation products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">leverage manufacturing expertise to address increasing demand for Quidel&#146;s products, including through
expanded manufacturing capacity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">utilize Quidel&#146;s molecular assay development competencies to further develop its molecular diagnostics
franchise that includes distinct testing platforms, such as Lyra, Solana and Savanna; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strengthen Quidel&#146;s position with distribution partners and <FONT STYLE="white-space:nowrap">end-user</FONT>
customers to gain more emphasis on its products and enter new markets. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_94"></A>BUSINESS OF ORTHO </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_95"></A>Business of Ortho </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is a
leading global provider of IVD solutions to the clinical laboratory and transfusion medicine communities. Ortho maintains a direct or indirect commercial presence in more than 130 countries and territories, with a direct presence in 36 countries.
Ortho&#146;s instruments, assays, reagents and other consumables are used in hospitals, laboratories, clinics, blood banks and donor centers worldwide. Ortho is globally operated with manufacturing facilities in the United States and the United
Kingdom and with sales centers, administrative offices and warehouses located throughout the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal executive offices of Ortho are located
at 1001 Route 202, Raritan, New Jersey 08869, United States of America, and its telephone number at that address is <FONT STYLE="white-space:nowrap">(908)&nbsp;218-8000.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information about Ortho and its subsidiaries is included in documents incorporated by reference into this joint proxy statement/prospectus. See the
section entitled &#147;Where You Can Find More Information&#148; of this joint proxy statement/prospectus. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_96"></A>Overview of
Business </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is a pure-play IVD business, pioneering life-impacting advances in diagnostics for over 80 years, from our earliest work in blood
typing to our innovation in infectious diseases and our latest developments in laboratory solutions. Ortho is driven by its credo, &#147;Because Every Test is A Life.&#148; This guiding principle reflects the crucial role diagnostics play in global
health and guides its priorities as an organization. As a leader in IVD, Ortho impacts approximately 800,000 patients every day. Ortho is dedicated to improving outcomes for these patients and saving lives through providing innovative and reliable
diagnostic testing solutions to the clinical laboratory and transfusion medicine communities. Ortho&#146;s global infrastructure and commercial reach allow Ortho to serve these markets with significant scale. Ortho has an intense focus on the
customer. Ortho supports its customers with high quality diagnostic instrumentation, a broad test portfolio and market leading service. Ortho&#146;s products deliver consistently fast, accurate and reliable results that allow clinicians to make
better-informed treatment decisions. Ortho&#146;s business model generates significant recurring revenues and strong cash flow streams, primarily from the ongoing sales of high margin consumables. In fiscal 2021, these recurring revenues contributed
approximately 93% of Ortho&#146;s total and core revenue. Ortho maintains close connectivity with its customers through its global presence, with more than 4,800 employees, including approximately 2,300 commercial sales, service and marketing
teammates. This global organization allows it to support its customers across more than 130 countries and territories. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2014, Ortho was acquired
by The Carlyle Group (&#147;Carlyle&#148;) from Johnson&nbsp;&amp; Johnson and became an independent organization, solely focused on delivering high quality IVD products and service to its diagnostic customer base. At the time of the separation, its
business had global scale, a reputation for high quality products, a strong quality management system and a research and development team with extensive scientific expertise. IVD testing is a critical tool in evaluating health in many different
settings around the world. IVD is a core component of routine healthcare <FONT STYLE="white-space:nowrap">check-ups</FONT> for those who are presenting with symptoms or require procedures, and it influences up to 70% of critical healthcare clinical
decision-making. Consequently, its IVD solutions have a profound impact on the assessment of health and the delivery of care. IVD is also critical in monitoring the transmission and spread of infectious disease outbreaks, where Ortho&#146;s
longstanding excellence in infectious disease testing is particularly relevant. Ortho&#146;s solutions are central to the operations of hospitals, clinics, blood banks and donor centers around the world, where they are used to help diagnose certain
conditions, such as cancer or heart attacks, and infectious diseases, such as hepatitis, HIV, and most recently, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> where Ortho has launched four antibody tests and an antigen test, and Ortho is
actively expanding its menu of tests to address the global pandemic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho operates two lines of business, Clinical Laboratories and Transfusion
Medicine, which together generate its core revenue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Clinical Laboratories:</B> Focused on (i)&nbsp;clinical chemistry, which is the measurement of target
chemicals in bodily fluids for the evaluation of health and the clinical management of patients, (ii)&nbsp;immunoassay instruments, which test the measurement of proteins as they act as antigens in the spread of disease, antibodies in the immune
response spurred by disease, or markers of proper organ function and health, and (iii)&nbsp;testing to detect and monitor disease progression across a broad spectrum of therapeutic areas, and includes grant revenue related to development of
Ortho&#146;s <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody and antigen tests. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Transfusion Medicine:</B> Focused on (i)&nbsp;immunohematology instruments and tests used for blood typing to
ensure patient-donor compatibility in blood transfusions; and (ii)&nbsp;donor screening instruments and tests used for blood and plasma screening for infectious diseases for customers primarily in the United States. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s broad offerings allow it to support its customer base and maximize the opportunity to provide each of its customers with a comprehensive array of
products and services over time. Ortho refers to this mutually beneficial approach as focusing on LCV. Ortho&#146;s focus on LCV underpins everything it does, from the design and execution of its commercial and service model, to its instrument and
assay innovation, to the composition of its global footprint. Ortho&#146;s approach has informed its choice to focus on medium- to high-volume laboratories (Ortho&#146;s &#147;Focus Markets&#148;), which in turn has helped it become a leader in its
Focus Markets and transformed its financial profile. Ortho intends to continue to invest in and evolve its LCV framework to best support its customers and maximize its financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an example, Ortho may begin a Clinical Laboratories customer relationship by providing a standalone instrument (often a clinical chemistry analyzer) and a
set of assays that are relevant to that customer&#146;s specific testing needs. In 2021, approximately 73% of its Clinical Laboratories installed base was comprised of standalone instruments. As the customer and its testing needs grow, Ortho looks
to migrate the customer, where appropriate, to an integrated analyzer that performs both clinical chemistry and immunoassay testing. This migration helps Ortho increase its customers&#146; testing capabilities as well as the revenue it generates
from customers. Building on its differentiation in dry chemistry, Ortho grew its integrated instrument installed base at a compound annual growth rate (&#147;CAGR&#148;) of approximately 13% from 2015 to 2021, and in 2021, approximately 27% of its
Clinical Laboratories installed base was comprised of integrated instruments. For its larger customers, Ortho ultimately may expand its testing throughput by installing automation tracks that connect multiple analyzers along the automation track,
while providing the full suite of its ever-expanding assay menu. In 2021, approximately 2% of its Clinical Laboratories installed base was comprised of automated systems. As Ortho has significantly expanded its test menu offering, its integrated
analyzers are now more often where its Clinical Laboratories relationship starts. In Transfusion Medicine, the life cycle is similar, as customers graduate from manual testing processes to semi-automated capabilities to fully-automated blood and
plasma screening instrumentation as their testing volumes and technical competencies grow over time. In 2021, its installed base of Immunohematology instruments grew approximately 3%. Ortho focuses on building long-term customer relationships and
continuing to enhance both its offering and the customer&#146;s ability to care for their patients, ultimately deepening its commercial relationship and driving its financial model. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_98"></A>Ortho&#146;s Competitive Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho believes it is well positioned to drive sustained and profitable growth through its relentless focus on LCV. This customer-centric approach informs the
execution of its commercial and service model and underpins its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> strategy. Ortho&#146;s customer focus allows it to retain and grow its customers by
providing a superior customer experience driven by unparalleled quality of service, continuous innovation and access to a diverse product portfolio. Ortho is able to leverage its global footprint to gain differentiated and leading positions across
its Focus Markets. This intense focus on its customers has resulted in an attractive business model with high recurring revenues that allows it to continue to invest to reinforce its competitive strengths, which include: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intense customer focus enabled by Ortho&#146;s broad portfolio and market leading positions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s broad portfolio of Clinical Laboratories and Transfusion Medicine instruments covering the full spectrum of manual to fully automated systems
allows it to effectively target its Focus Markets. In addition to its instrument portfolio, Ortho offers a diverse menu of assays for the most commonly tested items, including infectious diseases, sepsis, cardiovascular conditions and both blood and
plasma typing and screening. Ortho&#146;s ability to respond to the full spectrum of its customers&#146; needs allows it to focus on and enhance LCV. Ortho supplements its instrument and assay offerings with its leading service, commercial, and
operational excellence, which Ortho believes improves its customer retention, sales growth and profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is a leader in its Focus Markets with
leading positions in Clinical Laboratories and Transfusion Medicine. The market opportunities for its Clinical Laboratories and Transfusion Medicine businesses are largely connected and, in both Clinical Laboratories and Transfusion Medicine, Ortho
can adapt and grow with its customers as they move from lower throughput to more automated solutions. In addition, Ortho has developed a strategy for new product introductions in order to enhance LCV. For example, in its Transfusion Medicine
business, Ortho introduced semi-automated capabilities to increase its participation in certain emerging markets, such as China, Asia Pacific and Latin America, and continue the shift of certain customers from manual to semi-automated testing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Donor Screening, Ortho is a leading player and in late 2020, it won a five-year contract with a five-year
extension option with Creative Testing Solutions, the largest U.S. blood donation testing organization, which provides testing for a majority of the U.S. blood supply and is jointly owned by three of the leading U.S. blood service providers: the
American Red Cross, OneBlood and Vitalant. Pursuant to this contract, Ortho is Creative Testing Solutions&#146; primary supplier of serology Donor Screening testing in the United States. This contract provides for collaborative research and
development on Ortho&#146;s next generation Donor Screening instrument. With renewed commitment to the Donor Screening market and joint innovation with this customer, Ortho believes this relationship has the potential to support further growth in
other international Donor Screening markets over time. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s business model and customer-centric approach results in strong customer loyalty
and a compelling financial profile with greater than 90% recurring revenue during fiscal 2021. The combination of its revenue growth and leading margin profile allows it to reinvest in innovation and commercial opportunities. In addition, Ortho
believes its broad portfolio and diversified end markets provide a resilient growth profile. For instance, its strength in acute care and infectious disease testing is durable as it requires <FONT STYLE="white-space:nowrap">on-demand</FONT> testing.
Most of these tests are conducted in <FONT STYLE="white-space:nowrap">in-patient</FONT> laboratories and demand tends to be insulated from economic downturns. In addition, Ortho believes the <FONT STYLE="white-space:nowrap">on-site</FONT> laboratory
contributes meaningfully to many of its hospital customers&#146; earnings and that its core market is relatively insulated from outsourcing to reference laboratories. Ortho believes this combination of product and end market diversification allowed
it to generally outperform the market on a core revenue growth basis during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and Ortho believes this resiliency will continue into the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Superior customer experience and brand loyalty resulting in high customer retention and win rates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho delivers industry-leading test performance in a way that is easy for laboratory directors and technical staff to manage their operations on a daily
basis, which leads to excellent customer appeal and loyalty. In 2015, Ortho launched ORTHOCARE with the goal of providing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> service and support program for
hospitals, hospital networks, blood banks and laboratories. Ortho&#146;s ORTHOCARE service program is a critical element of the superior customer experience that Ortho delivers to its customers. Since forming ORTHOCARE, Ortho was the highest
recommended manufacturer for the last six consecutive years (2016 through 2021) in a survey of clinical laboratory professionals in U.S. hospitals conducted by ServiceTrak. In the same survey in 2021, Ortho was ranked #1 in seven out of eight
categories relating to its manufacturing, system and service performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Ortho&#146;s Focus Markets, the simplicity and reliability of its
instruments and tests often reduces the need for staff <FONT STYLE="white-space:nowrap">hands-on</FONT> time, producing a lower total cost of ownership for its customers. Ortho believes that after instrument cost, the quality of service is the
largest driver of customer choice when selecting a Clinical Laboratories vendor. Ortho&#146;s superior service and customer performance contribute to its revenue retention rate of approximately 98% in 2021 and its average Clinical Laboratories and
Transfusion Medicine customer relationships of almost 13 years and 15 years, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Clinical Laboratories, beyond the simplicity of dry
chemistry slides, Ortho offers instrument <FONT STYLE="white-space:nowrap">e-connectivity,</FONT> customizable automation tracks, a suite of upgraded quality control reagents and market-leading calibration stability, producing higher efficiency and
lower total cost of ownership. In Transfusion Medicine, its ORTHO VISION platform has expanded its leadership position because it automated and simplified the test workflow for time-strained blood bank staff, increasing throughput and efficiency.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Highly compelling solutions supported by its leading and innovative research and development capabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho has a rich history of innovation spanning over eight decades and now has a portfolio of 17 instruments and over 245 assays across Clinical Laboratories
and Transfusion Medicine. Ortho&#146;s unique dry slide technology for clinical chemistry delivers accurate results, stability and reliability in challenging laboratory environments, an environmentally friendly profile and superior <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ease-of-use.</FONT></FONT> Ortho&#146;s XT Slides provide the ability to perform two tests on one slide, resulting in 40% greater VITROS throughput with 96% first-pass yield. Combined with
its robust instrument design and development capabilities, Ortho engineers laboratory testing solutions for its customers that offer industry leading cost effectiveness for medium- and high-throughput testing applications, particularly where space
is constrained. Ortho has partnered with Quotient to commercialize, when approved, the next generation product in IH that enables a high level of multiplexing and addresses the ultra-high throughput market. Since its separation from
Johnson&nbsp;&amp; Johnson, Ortho has engineered and delivered to market six new instrument platforms, and expanded its assay offering with over 120 new or improved assays, which has increased its product vitality, market share and revenue growth.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Extensive and balanced global commercial footprint with reinvigorated focus on growth </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho sells its products and services in more than 130 countries worldwide and has a direct presence in 36 countries. Ortho supports these commercial
operations with approximately 2,300 commercial sales, service and regional marketing teammates and a network of more than 300 distributors globally. Ortho also has an extensive global network of manufacturing and distribution centers that allows it
to be closer and more responsive to its customers while managing and optimizing its cost structure. Ortho&#146;s global footprint allows it to effectively launch its new product innovations, including instrument platform developments and new assays,
across the globe. Its geographic balance also provides revenue diversification, which helps it to hedge against currency fluctuations and potential regional economic downturns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho believes that opportunities in emerging markets represent a strong area of growth and profitability for its business. Ortho is using targeted commercial
activities to expand in these attractive end markets. In addition, Ortho is developing lower cost instruments and market-specific assays to compete directly with low cost local players in certain regions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disciplined approach to streamline operations and optimize its cost structure </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho has taken a rigorous approach to continuously improving its operational and administrative resources and cost structure. Ortho has an efficient network
of manufacturing, distribution and support centers to support worldwide product availability, with assay manufacturing in the United States and Wales, partner instrument manufacturing in Switzerland and Mexico, product distribution centers in
multiple locations across the globe, shared service centers in the United States and Prague and certain operations in India. This not only brings it closer to its customers, but consolidates manufacturing and several other support functions to
lower-cost geographies. Ortho has seen margin expansion over the last two years and hopes to continue capitalizing on operational efficiencies going forward. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deeply committed leadership team with broad experience in healthcare and diagnostics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s dedicated and highly respected Global Leadership Team (&#147;GLT&#148;) is comprised of 16 members with significant experience in the IVD and
healthcare industries. For instance, Ortho&#146;s Chair and Chief Executive Officer, Chief Financial Officer, Chief Innovation Officer, General Counsel, and Executive Vice President of Commercial Excellence and Strategy each have more than 25 years
of experience in their respective fields of expertise and together have more than 125 years of experience with IVD or commercial healthcare companies. These individuals are supported by their GLT colleagues with extensive industry knowledge and
long-term experience leading at Ortho or other multinational companies in the IVD industry. Under their leadership Ortho has transformed its mindset from standing up the business to executing on its growth strategies by increasing its customer focus
and its emphasis on innovation and operational efficiency. Ortho believes that the industry knowledge and dedication of its GLT members, combined with their long-term experience profitably growing multinational companies, are instrumental for the
successful execution of its growth strategy going forward. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_99"></A>Ortho&#146;s Growth Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s heritage and strength lie in its long-term customer relationships and trusted brand, which create a steady base of recurring revenue and a
foundation for future growth. By focusing on LCV, Ortho identifies ways in which it can utilize product innovation and impactful customer service and solutions to deepen these partnerships and add value over time. Ortho plans to grow its business by
broadening its existing relationships, winning new customers and targeting high-growth end markets and adjacencies. Ortho is focused on sustainable long-term growth through commercial excellence that maximizes LCV, strengthens existing relationships
through superior service and delivers innovative products for its customers and their patients. The key elements of its strategy to accelerate and sustain revenue growth and operating leverage include: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Focusing relentlessly on maximizing LCV, which is designed to produce and maintain a growing and recurring, high margin, durable financial profile and
contributes to growth </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Over its more than 80 years supporting the IVD testing needs of its customers, Ortho has developed deep and enduring
relationships with its customers. Ortho seeks to expand its relationship with both new and existing customers by offering them higher throughput integrated instrumentation, automation, and an expanding assay menu that grows with them as their needs
evolve. On average globally, when one of its Clinical Laboratories customers upgrades from a standalone instrument to an integrated instrument, Ortho typically sees an increase in annual consumable revenues of approximately 65%. After this initial
increase in utilization, Ortho typically sees that customer&#146;s recurring revenues increase by approximately 3% to 7% on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an annual basis. In Ortho&#146;s experience, by the time a customer is running sufficient volumes of tests to consider automation, annual reagent purchases have roughly doubled, and upgrading to
an automated instrument increases this average by an additional 27%. This combined effect leads to an average increase of approximately 300% in annual revenues as a customer upgrades from an initial integrated placement to automation installation.
In Transfusion Medicine, the pattern is even more striking. When customers move from manual testing to a semi-automated solution, the customers typically experience an approximately 70% increase in workflow efficiency, and Ortho sees an average 600%
increase in revenues. When they graduate to Ortho&#146;s fully automated ORTHO VISION instruments, these customers typically experience a 90% improvement in workflow efficiency and Ortho sees an additional increase of approximately 90% on average in
recurring revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Providing an unparalleled customer experience to retain and attract its existing and new customers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho continues to invest in both technology and business model innovation to expand its service advantages. For instance, improvements in instrument and assay
reliability have reduced its service intervention rate by more than 30% since <FONT STYLE="white-space:nowrap">mid-2014.</FONT> In addition to Ortho&#146;s core product innovations that continuously improve instrument reliability and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ease-of-use-for</FONT></FONT></FONT> instance, <FONT STYLE="white-space:nowrap">e-connectivity,</FONT> improved controls,
<FONT STYLE="white-space:nowrap">e-calibration</FONT> and laboratory informatics- Ortho is implementing exciting technology applications to support its award-winning service team. From smart mobile applications that enable service alerts and remote
monitoring to merged reality on mobile devices, including smart glasses that support field engineers and customers in service calls, Ortho continues to improve the efficiency and effectiveness of its service offerings. Over time, Ortho will also
seek to increase its ability to monetize its service differentiation beyond simply enhancing customer retention and contract wins. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leveraging
Ortho&#146;s global footprint to deliver innovative solutions to meet its customers&#146; needs in both developed and emerging markets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s global commercial organization is comprised of approximately 2,300 commercial sales, service and regional marketing teammates. From 2018 through
2019, Ortho invested in expanding and improving its commercial capabilities in its two most critical markets&#151;North America and China&#151;adding sales and regional marketing personnel, strengthening its distributor networks, increasing sales
analytics and targeting support though its customer relationship management system. Ortho focused its commercial teams more squarely on its Focus Markets, which increased its win rate and allowed its team to allocate resources and focus on
relationship management, menu utilization and new assay adoption, helping drive its recent revenue growth in these markets. Since the execution of its U.S. commercial excellence program, Ortho has enjoyed 12 consecutive quarters of North America
core recurring revenue growth and, up until the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, Ortho experienced similar results following implementation of its China program. Ortho is also focused on high growth emerging markets
including China, Asia Pacific, the Middle East, Africa, Eastern Europe and Latin America. Ortho is targeting increased investment in market-appropriate products and local capabilities in order to gain market share in these emerging markets and
enhance its overall growth profile. For instance, Ortho is planning the development of lower cost instruments and assays that are suitable for these emerging markets. In some countries, the government is playing a significant role in expanding
population access to healthcare and diagnostic testing, particularly in more rural populations. The Chinese government, for instance, has dramatically increased the portion of the population with access to healthcare services and is actively pushing
diagnostic volumes to tiers of smaller hospitals at the regional and provincial level, hospitals that fit well into Ortho&#146;s Focus Markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Creating meaningful product innovation through menu expansion, development of novel instruments and enhancement of automation and informatics
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its separation from Johnson&nbsp;&amp; Johnson, Ortho has focused significant investment on improving and expanding its test menu, with the
introduction of over 120 new or improved tests, which Ortho believes has contributed meaningfully to its accelerating growth. Ortho continues to focus on developing significant new assays that are critical to its Focus Market customers while
continuing to build its strength and differentiation in acute and critical care assays. In particular, recent launches in cardiac (hs Troponin, <FONT STYLE="white-space:nowrap">NT-proBNP</FONT> II), infectious disease (HIV Combo, HTLV, T. Cruzi, <FONT
STYLE="white-space:nowrap">COVID-19</FONT> antigen and multiple <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody tests), and sepsis (PCT, <FONT STYLE="white-space:nowrap">IL-6)</FONT> are generating new growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho will continue to invest in the next generation of instruments for Clinical Laboratories and Transfusion Medicine. Given the longer cycle of innovation,
it is important that Ortho remains focused on the next platforms to drive customer acquisition and retention. In addition, Ortho&#146;s team is looking into novel technologies that it can leverage across Clinical Laboratories and Transfusion
Medicine. Ortho is also evaluating using its dry technology to increase multiplexing beyond dual slides and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extending into dry immunoassay by leveraging patented microfluidics approaches. A completely dry integrated platform would likely reduce Ortho&#146;s instrument footprint, increase test
throughput and reduce user complexity with excellent test reliability and performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho continues to build on advantages in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ease-of-use</FONT></FONT> and test workflow in the laboratory, with a primary focus on the needs of its target customer. Ortho is <FONT STYLE="white-space:nowrap">co-developing</FONT>
improved automation track components and a new quality control menu with one of its partners. ORTHO CONNECT continues to evolve and develop across CL and TM as next generation middleware that enables the customer to track and control data and key
performance metrics across their laboratories. Beyond this new platform, Ortho plans to explore and seek to develop new digital solutions, such as laboratory informatics dashboards, to improve customer performance and workflow. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To support menu expansion and development of novel instruments, Ortho is pursuing &#147;Follow the Sun&#148; research and development and manufacturing
capabilities and partnerships in targeted locations across the globe that Ortho believes will increase its local market access, tailor products for local market needs, reduce the time and cost required for product launches and accelerate its cadence
of assay and instrument launches over time. As an example, Ortho has built up research and development capabilities at its Pencoed, Wales site, which has a lower cost basis and ensures proximity to manufacturing for sustaining engineering of
products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Continuing to identify operating efficiencies to allow for reinvestment in growth and improve margins </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s leadership team has taken a disciplined, continuous improvement approach to streamlining its operational resources and cost structure. Executing
on its value capture program over the last several years, its team has identified areas to improve margins and cash flows through consolidation of manufacturing to lower-cost geographies, annual Six Sigma projects in areas such as procurement, and
information technology improvements. Ortho opened a shared service center in Prague and has shifted several support functions abroad to manage costs. Ortho continues to reinvest a significant portion of these savings in commercial and research and
development projects to spur further growth. Ortho expects to leverage its fixed cost base and the expansion of its diversified product portfolio to drive incremental margin improvement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pursuing business development opportunities, partnerships and strategic acquisitions to enter adjacencies or expand Ortho&#146;s current business units
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho has a successful track record of partnering with a range of companies to accelerate research and development, add incremental competencies
and/or <FONT STYLE="white-space:nowrap">co-develop</FONT> products. Ortho believes that its partnerships with Thermo Fisher, IDEXX and Quotient will help expand its capabilities in laboratory automation, veterinary and ultra-high throughput
Immunohematology applications, respectively. In addition to these types of opportunities, Ortho plans to explore adjacencies in both Clinical Laboratories and Transfusion Medicine that will leverage its global footprint, hospital and donor center
call points and/or technology advantages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s management team is focused on mergers and acquisitions, partnerships and business development
opportunities that Ortho believes will ultimately enhance LCV and drive incremental <FONT STYLE="white-space:nowrap">top-line</FONT> growth and profitability. Ortho intends to pursue strategic opportunities that will accelerate its expansion or
entry into attractive <FONT STYLE="white-space:nowrap">end-markets</FONT> and geographies. Ortho plans to maintain a disciplined approach to mergers and acquisitions and is constantly evaluating a wide range of opportunities that are natural
adjacencies with the hospital and other call points in its Focus Markets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_100"></A>Ortho&#146;s Industry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IVD involves testing of human tissue or fluid samples outside of the body to screen and detect diseases, infections and medical conditions. IVD testing is a
core component of routine healthcare <FONT STYLE="white-space:nowrap">check-ups</FONT> for those who are presenting with symptoms or require procedures. It influences up to 70% of critical healthcare clinical decision-making and can occur in a range
of clinical settings from large reference laboratories and hospitals, to physician offices and retail clinics. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global IVD market represented
approximately $76&nbsp;billion in global revenue in 2020. IVD is divided among multiple testing disciplines, including Immunoassay, Clinical Chemistry, Molecular Diagnostics, Anatomical Pathology, Microbiology, Hematology and Coagulation, among
others. Ortho competes in the two largest testing disciplines (excluding the impact of <FONT STYLE="white-space:nowrap">COVID-19),</FONT> Immunoassay and Clinical Chemistry, which together comprise Clinical Laboratories, and represented
approximately $24&nbsp;billion of its current addressable market in 2020. Ortho is also the global leader in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Transfusion Medicine, which includes hospital-based Immunohematology and Donor Screening for blood and plasma at hospitals and other donation centers, and represents approximately $2&nbsp;billion
of its current addressable market. Today, Ortho sells diagnostic instruments and reagents in a global market worth approximately $26&nbsp;billion that is projected to grow at a CAGR of approximately 5% from 2020 to 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the approximately $26&nbsp;billion market, approximately 62% resides in the more developed regions of North America, Europe, and Japan, which are projected
to grow at a CAGR of approximately 1% to 2% from 2020 to 2024. Approximately 38% of the market is concentrated in the faster-growing regions of China, the Middle East and Africa, Asia Pacific and Latin America, which are projected to grow at a CAGR
of approximately 8% to 11% from 2020 to 2024. With approximately 31% of its core revenue coming from emerging markets, Ortho has a strong position in these growing markets. Embedded in Ortho&#146;s strategy of developing new integrated analyzers and
bringing them to market is the parallel refurbishment of used analyzers and resale of these systems, primarily in emerging markets. Ortho is focusing increased investment in market-appropriate products and local capabilities in order to gain market
share in emerging markets and enhance its overall growth. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho believes there are six key trends affecting its end markets that will drive
increasing demand for its products and solutions and offer new opportunities for business expansion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Aging population and increased need for testing of chronic conditions. Populations continue to age, particularly
in the developed economies, which is driving increased prevalence of both chronic conditions and the acute diseases of later life, such as cancer, cardiac disease, and neurodegenerative disorders. This demographic trend is leading to an increase in
surgical volumes and supports growing demand for diagnostic testing and <FONT STYLE="white-space:nowrap">pre-surgical</FONT> screening on both an acute and routine health screening basis, and accounts for a significant portion of ongoing test menu
expansion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expansion of healthcare, particularly in emerging markets. Continuing economic growth in emerging markets is
increasing the size of the middle class and available disposable income, expanding resources available for healthcare. With most health decisions informed by diagnostic testing, economic development is driving instrument purchases and higher test
volumes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Consolidation and automation. Hospitals and laboratories continue to merge into larger healthcare systems. This
trend, combined with a shortage of skilled laboratory technicians, has driven consolidation of testing volumes into medium- to high-volume centralized laboratories with fully automated instruments. These automated instruments offer higher test
throughput versus standalone specialty instruments. To enhance productivity, these platforms are also often connected by software and automation tracks to enable more seamless routing and testing of patient samples. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Digital solutions and informatics. Diagnostic tests generate information that aids in clinical practice or the
study of health and disease. This data, combined with the advancement of internet applications and software, offer new ways to create value for hospital and laboratory customers. Tying test data into laboratory information and electronic medical
record systems is only the starting point. Digital solutions can also help laboratories manage test utilization, efficiency and inventory, aid in clinical decision support and pool test data for research purposes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New diagnostic technologies and continued decentralization. Diagnostics continue to advance with new technologies
changing and improving test accuracy and operational performance. New modalities have emerged with the advent of molecular and genetic diagnostics, the expansion of proteomics supporting improved and broader immunoassay testing, and technologies
like miniaturization, sensors, and microfluidics enabling <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-care</FONT></FONT> testing. Diagnostic testing at emergency room and intensive care unit bedsides in the hospital,
physician offices, urgent care centers, pharmacy minute clinics and at the patient&#146;s home is increasing. These technologies are creating new opportunities within IVD and growth for the broader IVD market overall. As the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic has underscored, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-care</FONT></FONT> tests typically have lower test accuracy than those performed on central lab
instruments, are often more expensive on a per test basis and can struggle with throughput for mass screening. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Emergence and identification of new diseases and treatments to include plasma based therapies. The <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic is the most salient example of the continuing emergence of new infectious diseases on a global scale which highlights the importance of accurate and efficient diagnostic testing. Ortho has
witnessed the emergence of HIV, Ebola, Zika, SARS and MERS, and it is estimated that one new infectious disease is emerging every year. New diagnostic tests and test volumes are driven both by the emergence of new diseases and by the discovery of
new or improved markers for disease. Beyond infectious diseases, significant assay innovation is occurring in a range of therapy areas, including oncology, neurology and cardiovascular disease. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_101"></A>Ortho&#146;s Products, Pipeline and Services </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Throughout eight decades of innovation, Ortho has been a leader in the diagnostics field and brought multiple innovations to market such as testing for RH
phenotyping, HCV, Chagas&#146; Disease, and most recently <FONT STYLE="white-space:nowrap">COVID-19.</FONT> Since its separation from Johnson&nbsp;&amp; Johnson, Ortho has engineered and delivered six new instrument platforms to market and expanded
its assay offering with over 120 new or improved assays, which has increased its product vitality and revenue growth. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our revenue is driven by a <FONT
STYLE="white-space:nowrap">&#147;razor-razor</FONT> blade&#148; business model. Through this model, we generally sell or place instruments under long-term contracts, which support the ongoing sale of our assays, reagents and consumables. Our
instruments are closed systems, requiring customers to purchase the assays, reagents and consumables from us. These sales generate a high proportion of recurring revenues. As of January&nbsp;2, 2022, we had an installed base of approximately 21,000
instruments, which increased approximately 3% since January&nbsp;3, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Laboratories </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho has been a pioneer of important technological advances in clinical diagnostics, including its unique dry slide technology which offers customers superior
test performance with clear <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ease-of-use</FONT></FONT> advantages and lower total cost of ownership. Dry slide technology combines the spreading, masking, scavenger and reagent layers
into one <FONT STYLE="white-space:nowrap">postage-stamp-sized</FONT> slide that provides clinicians with high-quality results quickly, efficiently and economically. Ortho&#146;s slides are very stable. The current approximate <FONT
STYLE="white-space:nowrap">six-month</FONT> span between calibrations for slides is industry-leading and Ortho expects this to be significantly improved through ongoing research and development. Ortho carries a comprehensive clinical chemistry test
menu, and dry slides have long shelf life with lower laboratory shelf space required. Ortho&#146;s new XT7600 and XT3400 instruments extend these advantages with digital accuracy and XT multi-test slides, and Ortho has a pipeline opportunity to
increase multi-test capacity further over time. Ortho&#146;s dry slide chemistry is well positioned for rising environmental concerns given its <FONT STYLE="white-space:nowrap">eco-friendly</FONT> profile with no water usage and significantly
reduced clinical waste and biohazard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s flagship Clinical Laboratories platform is the VITROS family of instruments, which includes a series
of clinical chemistry, immunoassay and integrated (combined chemistry and immunoassay) systems and automation and middleware solutions. The VITROS instruments run a wide range of assays, from infectious diseases, sepsis, cardiovascular conditions
and anemia, to bone disease, diabetes, drugs of abuse / toxicology, oncology and renal disease. Ortho has six VITROS instrument analyzers that provide standardized performance, and are still sufficiently flexible to meet the needs of its customers
across the spectrum of laboratory sizes and volumes. Ortho&#146;s VITROS instruments are placed in centralized, higher-throughput testing sites (hospitals and laboratories) and decentralized, lower-throughput sites (physician offices, clinics and
specialty settings). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g273090g78n03.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho launched the next generation of VITROS instruments&#151;the XT 7600 integrated system and XT 3400
clinical chemistry analyzer &#150; in 2018 and 2019, respectively. Both instruments deploy a highly accurate, digital reflectometer that measures test results and takes advantage of new XT chemistry slides, combining two tests that are frequently
used together, and improving the economics for it and its customers. Additionally, Ortho believes that digital sensing will enable improved test accuracy through better image processing over time. Ortho believes the XT instruments offer several
important advancements over prior generations: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">40% greater test throughput when using its <FONT STYLE="white-space:nowrap">XT-slides</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">96% first-pass yield on test results </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Designed to offer high reliability with a 98% <FONT STYLE="white-space:nowrap">up-time</FONT> guarantee for U.S.
customers </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s Clinical Laboratories assay menu is quite broad, covering 24 different therapeutic areas and approximately 90%
of a typical laboratory&#146;s testing needs. Ortho is particularly known for the strength of its dry clinical chemistry tests, as well as infectious disease and acute care immunoassays, including its high-performing cardiac markers for heart attack
and congestive heart failure. In Greater China, for example, Ortho believes it is the clinical chemistry market leader in separate &#147;STAT&#148; testing laboratories that seek rapid, high-performing assays to drive rapid clinical decisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_102"></A>Key Products&#151;Clinical Laboratories </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Examples</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Standalone CC instrument(s)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">High efficiency scalable analyzers that run Ortho&#146;s broad menu of general and special chemistry tests, including its differentiated dry chemistry Microslides, with no external water supply required.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS 350 Chemistry System</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS XT3400 Chemistry System</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS 4600 Chemistry System</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Standalone IA instrument(s)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Random access, scalable throughput analyzers that run Ortho&#146;s broad immunoassay menu with no external water supply required.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS ECiQ Immunodiagnostic System</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS 3600 Immunodiagnostic System</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Integrated instruments (CC+IA)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Random access, high throughput analyzers that run Ortho&#146;s expansive chemistry and immunoassay test menu within the same unit with no external water supply required.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS 5600 Integrated System</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS XT7600 Integrated System</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Dry chemistry slides&nbsp;&amp; XT multi-slides</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Differentiated &#147;dry&#148; Microslide technology avoids the potential variability caused by water impurities and the frequent calibration
common in wet chemistry products.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">XT slides deliver higher efficiency with two tests
per slide.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS XT MicroSlide Clinical Chemistry Technology</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Acute Care-Cardiac and Sepsis markers for ED/ICU</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Critical care assays that help deliver accurate, reliable results in acute care situations.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS Immunodiagnostic Products High-sensitivity Troponin</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS Immunodiagnostic Products <FONT STYLE="white-space:nowrap">NT-proBNP</FONT> II</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS Immunodiagnostic Products B&#9679;R&#9679;A&#9679;H&#9679;M&#9679;S PCT
(Procalcitonin)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Infectious Diseases-Assays for patient management and blood donor screening</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">High performing assays to identify presence of antigen and antibodies across a wide spectrum of infectious diseases.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS HIV Combo Immunodiagnostic Assay</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS <FONT STYLE="white-space:nowrap">Anti-HCV</FONT> Immunodiagnostic
Assay</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Examples</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS Anti-SARS <FONT STYLE="white-space:nowrap">CoV-2</FONT> IgG
Immunodiagnostic Assay <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS
Anti-SARS-CoV2 Total Immunodiagnostic Assay <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS SARS <FONT STYLE="white-space:nowrap">CoV-2</FONT> Antigen Immunodiagnostic Assay <SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Other Key Assays</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Microtip assays offer a wide range of special chemistry testing using wet reagents but with no external water supply needed.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;VITROS HbA1c MicroTip Assay</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Marketed pursuant to FDA Emergency Use Authorization originally granted on April&nbsp;24, 2020, and
subsequently updated on September&nbsp;8, 2021, for use in combination with the VITROS Immunodiagnostics Products Anti- <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> IgG Quantitative Calibrator.
Ortho&#146;s VITROS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-SARS-CoV-2</FONT></FONT> IgG antibody test has an estimated 100% specificity (95% confidence interval = <FONT STYLE="white-space:nowrap">99.1-100%).</FONT>
Under the FDA&#146;s Emergency Use Authorization for the use of <FONT STYLE="white-space:nowrap">COVID-19</FONT> convalescent plasma, before a plasma donation can be released to hospitals and patients, the donation must be tested in order to confirm
the level or amounts of antibodies in such donation. Ortho&#146;s VITROS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-SARS-CoV-2</FONT></FONT> IgG antibody test is currently specified by the FDA as acceptable for use in
this manufacturing step to determine whether a donation qualifies as a high or low titer unit of <FONT STYLE="white-space:nowrap">COVID-19</FONT> convalescent plasma. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Marketed pursuant to FDA Emergency Use Authorization originally granted on April&nbsp;14, 2020 and subsequently
updated on July&nbsp;22, 2021 and subsequently revised on November&nbsp;16, 2021 for use in combination with the VITROS Immunodiagnostic Products Total N Antibody Calibrators. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Marketed throughout the European Union under CE Mark authority, designed to detect active <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> <FONT STYLE="white-space:nowrap">(COVID-19)</FONT> infection in symptomatic and asymptomatic individuals. Marketed in the United States pursuant to FDA Emergency
Use Authorization originally granted on January&nbsp;11, 2021 (product claims and indications for use vary between the European Union and U.S. markets). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfusion Medicine </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Immunohematology </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Immunohematology, Ortho is the global market leader based on the strength of its instruments and assays. Ortho&#146;s flagship IH analyzers are the ORTHO
VISION and ORTHO VISION Max systems that automate blood typing and serology disease screening for blood banks. ORTHO VISION was originally launched in 2015, followed by the ORTHO VISION Max and the Next Gen ORTHO VISION Swift, which is designed to
be faster, quieter and even more cyber-secure than previous generations of its products. ORTHO VISION has been extremely successful in driving workflow simplification and automation for the customer. In addition, Ortho sells the semi-automated Ortho
Workstation for blood bank customers that have lower volumes or need for test automation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g273090g81q04.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In fiscal 2021, Ortho launched its enhanced ORTHO VISION Swift and ORTHO VISION Max Swift Analyzer systems
that automate blood typing and serology disease screening for blood banks. Additionally, in fiscal 2021, Ortho launched the ORTHO OPTIX reader in North America. OPTIX is targeted at blood banks who desire greater precision reading their manual test
results and is designed to provide improved software and integration with laboratory information systems, improved workflow and 99.9% concordance with ORTHO VISION test results. OPTIX provides an entry point for customers that want to move from
manual to semi-automated testing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho also has a partnership with Quotient for the Immunohematology application of the MosaiQTM analyzer, which is
designed to employ a cutting-edge microarray technology to allow advanced multiplexing. MosaiQ multiplexing is expected to enable multiple tests to be run simultaneously on a single, <FONT STYLE="white-space:nowrap">low-volume</FONT> patient sample
and drive significantly higher test throughput, which would strengthen its position in the ultra-high throughput segment of the IH market. It also offers the potential for streamlined inventory management and concordant results across donor
screening and <FONT STYLE="white-space:nowrap">pre-transfusion</FONT> testing and matching. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s Immunohematology instruments operate with two
different modalities of test consumables. In the United States, its automated systems use patented <FONT STYLE="white-space:nowrap">ID-Micro</FONT> Typing System <FONT STYLE="white-space:nowrap">(&#147;IS-MTS&#148;)</FONT> gel cards and outside the
United States, Ortho sells BIOVUE cassettes that utilize column agglutination technology (&#147;CAT&#148;). Both approaches are designed to provide reliable test results and simplify test workflow. With the 2016 launch of ORTHO SERA reagents, Ortho
offers a comprehensive test Immunohematology menu that Ortho believes covers more than 99% of most tested blood antigens and all the diseases regularly required for transfusion screening globally. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Donor Screening </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s Donor Screening business is
focused on instruments and tests used for blood and plasma screening for infectious diseases for customers, which include some of the largest donor testing institutions, primarily in the United States. In Donor Screening, Ortho&#146;s core
instrument offering is the ORTHO VERSEIA Integrated Processor <FONT STYLE="white-space:nowrap">(&#147;VIP&#148;)-an</FONT> automated pipetting and processing system that brings together the ORTHO VERSEIA pipettor and ORTHO Summit Processor to enable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> pipetting and processing. For Donor Screening, its serology test menu covers the full range of blood types and a comprehensive set of infectious disease
screens, including important tests for tropical diseases like Chagas&#146; that are critical for care in emerging markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_103"></A>Key Products&#151;Transfusion Medicine </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Examples</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immunohematology</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Manual and
Semi-automated</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The only <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-in-1</FONT></FONT> blood testing system using reliable Column Agglutination Technology (CAT). The Reader delivers objective grading, results interpretation
concordant with the ORTHO VISION Analyzer.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;Manual Blood Bank Reagents</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;ORTHO Workstation</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;ORTHO OPTIX<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> Reader</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immunohematology</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Automated</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A suite of automated instrument solutions connected with an optional middleware software that bridges the gap between instruments and hospital IT networks.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;ORTHO VISION Swift Analyzer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;ORTHO VISION Max Swift Analyzer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;ORTHO CONNECT Middleware</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;ORTHO PROVUE</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;ORTHO AUTOVUE</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immunohematology</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>BIOVUE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Safe, cost-effective test format that can be used manually or with the fully automated analyzers, the ORTHO BIOVUE cassette is easy to use and ideal for both routine and specialized immunohematology testing.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;BIOVUE Cassettes</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immunohematology</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">ID-MTS</FONT> Gel Cards</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Safe, cost-effective test format that can be used manually or with the fully automated analyzers. The <FONT STYLE="white-space:nowrap">ID-MTS</FONT> Gel card is easy to use and ideal for both routine and specialized immunohematology
testing.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#149;&#8194;&#8202;ID-MTS</FONT> Gel
Cards</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Examples</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immunohematology</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Key
Screening&nbsp;&amp; Typing Assays</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BIOVUE and <FONT STYLE="white-space:nowrap">ID-MTS</FONT> product lines offer comprehensive testing solutions including: Type and screen, Donor confirmation, Antibody screening and identification, Rh phenotype, Rare antigen testing,
DAT.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#149;&#8194;&#8202;Anti-Fya,</FONT> <FONT
STYLE="white-space:nowrap">Anti-Fyb,</FONT> <FONT STYLE="white-space:nowrap">Anti-Jka,</FONT> <FONT STYLE="white-space:nowrap">Anti-Jkb,</FONT> <FONT STYLE="white-space:nowrap">Anti-S,</FONT> <FONT STYLE="white-space:nowrap">Anti-s,</FONT> <FONT
STYLE="white-space:nowrap">Anti-K,</FONT> <FONT STYLE="white-space:nowrap">Anti-D</FONT> (IAT), <FONT STYLE="white-space:nowrap">Anti-D</FONT> (DVI), <FONT STYLE="white-space:nowrap">Anti-P1,</FONT> <FONT STYLE="white-space:nowrap">Anti-Lea,</FONT> <FONT
STYLE="white-space:nowrap">Anti-Leb</FONT> and <FONT STYLE="white-space:nowrap">Anti-N</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>U.S. Donor Screening</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ultra-high throughput Donor Testing platform capable of 264 tests per hour. Designed to run a comprehensive panel of highly sensitive and specific assays for use in Donor Testing.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;ORTHO VERSEIA Integrated Processor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;ORTHO HBc ELISA</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;ORTHO <I>T. cruzi</I> ELISA</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;ORTHO HCV 3.0 ELISA</P></TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho&#146;s Services </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the products Ortho provides, ORTHOCARE services are a critical element of how Ortho delivers value to its customers. As of January&nbsp;2, 2022,
Ortho had approximately 980 service teammates globally. Ortho employs highly trained service professionals including over 360 laboratory specialists with advanced qualifications. For example, approximately 95% of its U.S. laboratory specialists have
medical technician degrees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s highly valued suite of ORTHOCARE service offerings includes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Guarantee 98% <FONT STYLE="white-space:nowrap">up-time</FONT> to Ortho&#146;s U.S. customers&#151;high instrument
reliability and a proactive maintenance program. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">E-CONNECTIVITY</FONT> Remote Monitoring Software&#151;More than 80% of
Ortho&#146;s installed base of VITROS 5600, XT 7600 and ORTHO VISION platforms are <FONT STYLE="white-space:nowrap">e-connected,</FONT> enabling remote monitoring and improved analyzer availability. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Laboratory Informatics&#151;Solutions designed to deliver incremental value to the laboratory, including
inventory planning, laboratory productivity metrics and technical documentation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ValuMetrix &#151;A highly valued consulting service proven to increase laboratory workflow, productivity and
laboratory service levels utilizing lean principles and process excellence. This service offering provides actionable insights into demand for new products, services and workflow. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Global Technical Solution Center&#151;Seven technical solution centers delivering first line support in over 15
languages, meaning Ortho can resolve service issues remotely without an <FONT STYLE="white-space:nowrap">on-site</FONT> visit approximately <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Smart Service Mobile App&#151;First in class technology enabled on iPhone and Android devices that allows
Ortho&#146;s service teams to receive <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> analyzer health checks, proactive alerts and performance monitoring to ensure the highest level of reliability is
achieved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Training and Education&#151;Flexible educational resources for the lifetime of the customer relationship,
including virtual technical training, continuing education and professional development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Smart Start&#151;Concierge implementation program led by certified project managers. Easier implementation using
collaborative software to keep up to date with real- time progress reports, customized dashboards and status updates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Merged Reality&#151;Enables product experts to provide remote &#145;side by side&#146; assistance to field
service engineers and customers through mobile devices, including smart glasses. This allows both parties to sees the same thing at the same time and provide guided instruction leading to better and faster fix rates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is globally recognized for service excellence and continues to invest in people and technology to increase value for its customers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_104"></A>Sales, Marketing and Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho uses <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT>
manufacturing and distribution capabilities to produce and deliver diagnostic instruments and assays for hospitals, laboratories and blood and plasma centers worldwide. Ortho&#146;s primary distribution center locations are centrally located in the
United States and Europe and have extended hours and efficient transportation processes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s sales team is comprised of highly skilled and
experienced professionals. In the United States, Ortho uses a generalized sales force for Immunohematology and Clinical Laboratories and a separate specialist sales force for Donor Screening. Across this global footprint, Ortho operates a
region-specific sales model. Ortho&#146;s developed markets, specifically in North America and Western Europe, are served primarily through direct sales; however, Ortho generally utilizes third-party distributors in emerging markets, such as China,
the Middle East, Africa and Eastern Europe as this model is more commercially effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s global team strives to deliver a differentiated
level of customer service and support by surrounding its customers with devoted and experienced professionals. Ortho&#146;s network of field engineers is responsible for installing its instruments and providing customer support. In addition,
Ortho&#146;s call center team and laboratory specialists are available to provide customer training and ongoing customer support. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_105">
</A>Research and Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s research and development focus is on designing and developing products while balancing its research and
development team&#146;s capacity, development timelines and overall cost. Ortho has been a pioneer of important technological advances in diagnostics, including its unique dry slide technology and its automated and semi-automated blood banking
systems. Ortho&#146;s research and development team is comprised of a balanced mix of experienced professionals with years of experience in the diagnostics industry and recently trained technologists, and together have the <FONT
STYLE="white-space:nowrap">know-how</FONT> and technical capabilities in information technology, biomedical science and engineering required to continue to innovate. Key strengths include new assay format development, new instrument systems
development and the complex integration of the two. In addition, in order to create new opportunities, manage costs and adapt to a rapidly changing industry, Ortho also enters into strategic partnerships as part of its research and development
process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s solutions are central to the operations of hospitals, clinics, blood banks and donor centers around the world, where they are used
to help diagnose certain conditions, such as cancer or heart attacks, and infectious diseases, such as hepatitis, HIV, and most recently, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> where Ortho has launched four antibody tests and an antigen
test. Ortho&#146;s primary research and development facility is located in Rochester, New York, with certain functions conducted out of Raritan, New Jersey and Pencoed, Wales. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_106"></A>Suppliers and Raw Materials </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho obtains raw materials from reputable outside suppliers and believes its business relationships with them are good. Some of its products are derived from
source biologic materials, which are available from a limited number of sources. To date, Ortho has been able to obtain sufficient quantities of required materials for use in manufacturing its products, but there can be no assurance that a
sufficient supply of required materials will always be available to it. Ortho employs a number of strategies to mitigate raw material supply risk, including managing safety stock inventories as well as developing second sources for key raw
materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Ortho has recently encountered some increasing pressures on raw material pricing. Ortho employs a number of strategies to
mitigate raw material price increases, including identifying alternative sources for raw materials and implementing operational efficiencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho
sources certain instruments from industry specific suppliers. Ortho believes that its business relationships with its instrument suppliers are good. Each instrument supplier is placed under a contract that provides terms and conditions designed to
preserve business continuity. In the event either party terminates the agreement, the &#147;out clauses&#148; provide sufficient time to effect a transition to a new supplier and maintain supply continuity. This transition would also be
characterized by the build of a strategic inventory to bridge any time period required to initiate supply from an alternate provider. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho has
experienced and continues to manage through supply chain challenges relating to key components of its instruments. For instance, Ortho has experienced supply chain shortages of certain key components of its instruments and assays, which are
impacting Ortho&#146;s ability to fulfill customer orders on a timely basis and have had, and are expected to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue to have, a negative impact on Ortho&#146;s business and results of operations, which could be material. Ortho is continuing to work closely with its primary suppliers of these
components, alongside their downstream supply chain, in order to maintain supply to its customers. In addition, Ortho is employing a number of strategies to mitigate supply chain shortages, including pursuing additional suppliers for certain of
these key components. See &#147;Risk Factors&#151;Risks Relating to Ortho&#146;s Business&#151;Ortho has significant international sales and operations and faces risks related to health epidemics, including the ongoing global pandemic related to <FONT
STYLE="white-space:nowrap">COVID-19.</FONT> Ortho&#146;s business, consolidated results of operations, financial position and cash flows have been and may continue to be negatively affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic&#148; and &#147;Risk Factors&#151;Risks Relating to Ortho&#146;s Business&#151;Ortho relies on certain suppliers and manufacturers for raw materials, components for Ortho&#146;s products and services, and fluctuations in the availability
and price of such materials, products and services may interfere with Ortho&#146;s ability to meet Ortho&#146;s customers&#146; needs.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_107">
</A>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s manufacturing operation benefits from its broad global footprint, scale and workforce capabilities. Ortho believes its
plant capacity and available space is sufficient to accommodate growth, maintain quality and ensure continuity. Ortho uses
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> manufacturing capabilities to produce the instruments and assays that Ortho sells. Ortho&#146;s manufacturing
function has extensive process excellence and high operating standards, which provide it with the capabilities to offset inflation and control costs. Ortho&#146;s primary manufacturing facilities are located in Raritan, New Jersey, Rochester, New
York and Pencoed, Wales. Each is regulated by the FDA or other international public health and regulatory agencies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_108"></A>Competition </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The IVD
market is fragmented and highly competitive in both Clinical Laboratories and Transfusion Medicine. There are several global companies with whom Ortho competes, as well as regional and local companies focused on particular markets and/or
technologies. In the Clinical Laboratories market, Ortho&#146;s principal competitors include: Abbott Laboratories, Danaher Corporation, Roche, and Siemens Healthineers. In the Transfusion Medicine market, Ortho&#146;s principal competitors include:
Abbott Laboratories, Diasorin, Roche in Donor Screening, and Bio-Rad and Immucor in Immunohematology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho believes it is well positioned to drive
sustained and profitable growth through its relentless focus on lifetime customer value. This customer-centric approach informs the execution of Ortho&#146;s commercial and service model and underpins its
<FONT STYLE="white-space:nowrap">go-to-market</FONT> strategy. Ortho&#146;s customer focus allows it to retain and grow its customers by providing a superior customer experience driven by unparalleled quality of service, continuous innovation and
access to a diverse product portfolio. Ortho is able to leverage its global footprint to gain differentiated and leading positions across medium- to high-volume laboratories. This intense focus on Ortho&#146;s customers has resulted in an attractive
business model with high recurring revenues that allows Ortho to continue to invest to reinforce its competitive strengths, which include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Intense customer focus enabled by Ortho&#146;s broad portfolio and market leading positions
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Superior customer experience and brand loyalty resulting in high customer retention and win rates
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Highly compelling solutions supported by Ortho&#146;s leading and innovative research and development
capabilities </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Extensive and balanced global commercial footprint with reinvigorated focus on growth </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Disciplined approach to streamline operations and optimize Ortho&#146;s cost structure </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Deeply committed leadership team with broad experience in healthcare and diagnostics </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_109"></A>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
course of its business, Ortho has developed and will continue to develop proprietary products, technologies, software systems, processes and other intellectual property (&#147;IP&#148;). Ortho protects its IP through filing of patents, trademarks
and domain names, as may be deemed applicable and appropriate, with appropriate regional coverage. For example, Ortho has applied for and/or obtained and maintains registrations in the United States and other countries numerous trademarks, including
ORTHO CLINICAL DIAGNOSTICS, ORTHO, VITROS and ORTHO VISION. Ortho also seeks to protect its proprietary and confidential information and trade secrets through confidentiality agreements with employees, customers, vendors and other third parties, as
well as administrative and technical safeguards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho also enters into agreements with third parties for the license and use of their intellectual
property, although no one such license is material to the business as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IP is an essential part of its business, and IP assets are, as a whole, material to the performance of its
business. No single IP asset, however, whether owned or licensed, is material to its business as a whole<B><I>. </I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;2, 2022,
Ortho owned approximately 665 patents and 1,125 trademarks and Ortho had an additional approximately 44 trademark applications and more than 80 patent applications pending. The majority of its patents and patent applications are in its Clinical
Laboratories line of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;2, 2022, Ortho was not subject to any material claim or legal action alleging infringement of
third-party owned IP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_110"></A>Collaboration Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho has various collaboration arrangements, which provide it with the rights to develop, produce and market products using certain <FONT
STYLE="white-space:nowrap">know-how,</FONT> technology and patent rights maintained by its collaborative partners. These arrangements are often entered into in order to share risks and rewards related to a specific program or product. Ortho&#146;s
collaborative arrangements include a number of ongoing relationships for test development, instrument development and automation track design and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s Joint Business is a collaboration with Grifols relating to its Hepatitis and HIV diagnostics business. The arrangement is governed by an
agreement originally entered into in 1989 with a <FONT STYLE="white-space:nowrap">50-year</FONT> term, which, among other things, provides for a profit sharing arrangement whereby, the profits Ortho generates from its production and sale of
Hepatitis and HIV diagnostics products are shared with Grifols, and the profits generated by Grifols from its sale of certain antigens and licensing of certain intellectual property rights are shared with Ortho. The agreement also gives Ortho the
right to use such intellectual property. The majority of the patents underlying these intellectual property rights have expired. Grifols also supplies Ortho with a portion of the antigens used in its production of these diagnostics products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_111"></A>Human Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;2, 2022, Ortho had approximately 4,800 employees. Approximately 51% of its employees are located outside of the United States, primarily in
Europe and Asia. Ortho employs approximately 1,025 manufacturing employees, and approximately 2,300 employees in commercial sales, service and regional marketing positions worldwide including approximately 980&nbsp;service teammates. Ortho&#146;s
highly trained service professionals include over 360&nbsp;laboratory specialists with advanced qualifications. For example, approximately 95% of its U.S. laboratory specialists have medical technician degrees, and customer excellence training has
been prepared for all teammates. Ortho supports unions, works councils and/or collective bargaining agreements in Austria, Belgium, Brazil, France, Germany, Italy, Spain, Sweden and the United Kingdom, with approximately 20% of its associates
globally participating in a union, collective bargaining agreement or works council. Ortho believes that its relations with its employees are generally good. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our teammates into
our highly collaborative culture. Ortho believes its success depends on its ability to attract, retain, develop and motivate diverse highly skilled personnel. In particular, Ortho depends upon the personal efforts and abilities of the principal
members of its senior management to partner effectively as a team, and who provide strategic direction, develop its business, manage its operations and maintain a cohesive and stable work environment. Ortho also relies on qualified managers and
skilled employees, such as scientists, engineers and laboratory technicians, with technical expertise in operations, scientific knowledge, engineering and quality management experience in order to operate its business successfully. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s compensation program is designed to retain, motivate and, as needed, attract highly qualified executives and talented teammates. Accordingly,
Ortho uses a mix of competitive base salary, cash-based annual incentive compensation, performance-based equity compensation awards and other employee benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is committed to fostering a culture that supports diversity and an environment of mutual respect, equity and collaboration that helps drive our
business. Ortho embraces diversity, equity and inclusion and celebrates the successes we achieve as &#147;One Ortho.&#148; As a global organization, Ortho&#146;s unique perspectives, diverse background and collective strengths drive creative
solutions, breakthrough innovation and highly productive teams. In April 2021, Ortho established its Diversity, Equity and Inclusion Council with a mission to foster a collaborative and innovative organization, ensuring all teammates lead with an
inclusive mindset and feel confident that their voices are being heard. Ortho plans to expand upon its foundation of diversity and inclusion and deliver a unique and globally aware Ortho identity that accelerates our growth internally and
externally. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_112"></A>Health, Safety and Environmental </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s operations and facilities are subject to various laws and regulations domestically and around the world governing the protection of the
environment and health and safety, including the discharge and emissions of pollutants to air and water and the handling, management and disposal of hazardous substances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho is committed to employee health and safety in the workplace and has an excellent safety record. In the United States, its manufacturing facilities hold
various certifications depending on the site. Our Raritan, NJ and Rochester, NY sites have both received the gold award for American Heart Association Workplace Solutions for the fourth year in a row. The Raritan and Rochester sites are also
certified as part of the OSHA Voluntary Protection Programs. Ortho&#146;s facility in Pencoed, Wales has received recognition by the Welsh government for facility safety and environmental performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho believes that all of its manufacturing and distribution facilities are operated in compliance with existing environmental requirements in all material
respects, including the operating permits required thereunder. Although Ortho does not currently expect the costs of compliance with existing environmental requirements to have a material impact on its financial position, Ortho may incur additional
costs or obligations to comply with environmental and health and safety requirements as a result of changes in law or customer demands, including those relating to its products. In addition, many of its manufacturing sites have a long history of
industrial operations, and remediation is or may be required at a number of these locations. Although Ortho does not currently expect outstanding remediation obligations to have a material impact on its financial position, the ultimate cost of
remediation is subject to a number of variables and is difficult to accurately predict. See &#147;Risk Factors&#151;Risks Relating to Ortho&#146;s Business&#151;Ortho could incur costs complying with environmental and health and safety requirements,
or as a result of liability for contamination or other potential environmental harm or liability caused by its operations.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_113">
</A>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s products and operations are subject to extensive regulation by the FDA and other federal and state authorities
in the United States, as well as comparable authorities in foreign jurisdictions. In the United States, its products are regulated as either medical devices under the Federal Food, Drug, and Cosmetic Act (&#147;FDCA&#148;) and its implementing
regulations, or as biological products under the FDCA and the Public Health Service Act (&#147;PHSA&#148;) and their implementing regulations, each as amended and enforced by the FDA. The FDA regulates the development, design, <FONT
STYLE="white-space:nowrap">non-clinical</FONT> and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, adverse event reporting, advertising,
promotion, marketing and distribution, and import and export of medical devices and biological products to ensure that such products distributed domestically are safe and effective for their intended uses and otherwise meet the applicable
requirements of the FDCA and PHSA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Regulation of Medical Devices </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The majority of Ortho&#146;s diagnostic products and analyzers are regulated by the FDA as medical devices in the United States. Unless an exemption applies,
each medical device commercially distributed in the United States requires either FDA clearance of a 510(k) premarket notification, or approval of a PMA application. Under the FDCA, medical devices are classified into one of three classes-Class I,
Class&nbsp;II or <FONT STYLE="white-space:nowrap">Class&nbsp;III-depending</FONT> on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness.
Class&nbsp;I devices are those with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA&#146;s General Controls for medical devices, which include compliance with the applicable
portions of current good manufacturing practices (&#147;cGMPs&#148;) for medical devices known as the Quality System Regulation (&#147;QSR&#148;) facility registration and product listing, reporting of adverse medical events, and truthful and <FONT
STYLE="white-space:nowrap">non-misleading</FONT> labeling, advertising, and promotional materials. Class&nbsp;II devices are subject to the FDA&#146;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and
effectiveness of the device. These special controls can include performance standards, post-market surveillance, patient registries and FDA guidance documents. Devices deemed by the FDA to pose the greatest risks, such as life sustaining, life
supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class&nbsp;III. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While most Class&nbsp;I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class&nbsp;II devices are required to
submit to the FDA a premarket notification under Section&nbsp;510(k) of the FDCA requesting permission to commercially distribute the device. The FDA&#146;s permission to commercially distribute a device subject to a 510(k)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
premarket notification is generally known as 510(k) clearance. Class&nbsp;III devices require approval of a PMA application evidencing safety and effectiveness of the device. Ortho currently
markets the majority of its diagnostic products in the United States pursuant to 510(k) clearances and PMA approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To obtain 510(k) clearance, a
manufacturer must submit a premarket notification demonstrating to the FDA&#146;s satisfaction that the proposed device is &#147;substantially equivalent&#148; to another legally marketed device that itself does not require PMA approval (a predicate
device). A predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior to May&nbsp;28, 1976 <FONT STYLE="white-space:nowrap">(pre-amendments</FONT> device) and for which a
PMA is not required, a device that has been reclassified from Class&nbsp;III to Class&nbsp;II or I, or a device that was found substantially equivalent through the 510(k) process. The FDA&#146;s 510(k) clearance process usually takes from three to
twelve months, but often takes longer. FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. In addition, the FDA collects user fees for certain medical device submissions and
annual fees for medical device establishments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA agrees that the device is substantially equivalent to a lawfully marketed predicate device, it
will grant 510(k) clearance to authorize the device for commercialization. If the FDA determines that the device is &#147;not substantially equivalent,&#148; the device is automatically designated as a Class&nbsp;III device. The device sponsor must
then fulfill more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance with the de novo classification process, which is a route to market for novel medical devices that are low to moderate
risk and are not substantially equivalent to a predicate device. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a device receives 510(k) clearance, any modification that could significantly
affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval or de novo classification. The FDA requires each
manufacturer to determine whether the proposed change requires submission of a 510(k), de novo classification request or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#146;s determination. If
the FDA disagrees with a manufacturer&#146;s determination not to seek a new 510(k) or other form of marketing authorization for the modification to the 510(k)-cleared product, the FDA can require the manufacturer to cease marketing and/or request
the recall of the modified device until 510(k) clearance or PMA approval is obtained or a de novo classification is granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PMA process is more
demanding than the 510(k) premarket notification process. In a PMA, the manufacturer must demonstrate that the device is safe and effective, and the PMA must be supported by extensive data, including data from preclinical studies and human clinical
trials. All clinical investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA&#146;s investigational device exemption (&#147;IDE&#148;) regulations which govern investigational device labeling,
prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#147;significant risk,&#148; to human health, as
defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. A significant risk device is one that presents a potential for serious risk to
the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or
otherwise presents a potential for serious risk to a subject. In addition, the study must be approved by, and conducted under the oversight of, an Institutional Review Board (&#147;IRB&#148;) for each clinical site. The IRB is responsible for the
initial and continuing review of the IDE, and may pose additional requirements for the conduct of the study. If the device presents a <FONT STYLE="white-space:nowrap">non-significant</FONT> risk to the patient, a sponsor may begin the clinical trial
after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and
labeling and record-keeping requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to clinical and preclinical data, the PMA must contain a full description of the device and its
components, a full description of the methods, facilities, and controls used for manufacturing, and proposed labeling. Following receipt of a PMA, the FDA determines whether the application is sufficiently complete to permit a substantive review. If
FDA accepts the application for review, it has 180 days under the FDCA to complete its review of a PMA, although in practice, the FDA&#146;s review often takes significantly longer, and can take up to several years. An advisory panel of experts from
outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel&#146;s recommendation. In addition, the FDA will generally
conduct a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the applicant or its third-party manufacturers&#146; or suppliers&#146; facilities to ensure compliance with the QSR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA will approve the new device for commercial distribution if it determines that the data and
information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). The FDA may approve a PMA with post-approval conditions intended to ensure the safety
and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> data from patients in the clinical study that
supported PMA approval or requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market surveillance when deemed necessary to protect the public health or to provide additional
safety and efficacy data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number of years and to make periodic reports to the FDA on the
clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval. Certain changes to an approved device, such as changes in manufacturing
facilities, methods, or quality control procedures, or changes in the design performance specifications, which affect the safety or effectiveness of the device, require submission of a PMA supplement, or in some cases a new PMA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the 510(k) clearance, PMA, and de novo classification pathways to market, the Commissioner of the FDA, under delegated authority from the
Secretary of HHS may, under certain circumstances in connection with a declared public health emergency, allow for the marketing of a product that does not otherwise comply with FDA regulations by issuing an EUA for such product. Before an EUA may
be issued by HHS, the Secretary must declare an emergency based on a determination that a public health emergency exists that effects or has the significant potential to affect, national security, and that involves a specified biological, chemical,
radiological, or nuclear agent or agents, or a specified disease or condition that may be attributable to such agent or agents. On February&nbsp;4, 2020, the HHS Secretary determined that the novel coronavirus presented a public health emergency
that has a significant potential to affect national security or the health and security of U.S. citizens living abroad and declared that circumstances existed justifying the authorization of emergency use of in vitro diagnostics for detection and/or
diagnosis of the novel coronavirus that causes <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to be the subject of an EUA, the FDA
Commissioner must conclude that, based on the totality of scientific evidence available, it is reasonable to believe that the product may be effective in diagnosing, treating, or preventing a disease attributable to the agents described above, that
the product&#146;s potential benefits outweigh its potential risks and that there is no adequate, approved alternative to the product. Products subject to an EUA must still comply with the conditions of the EUA, including labeling and marketing
requirements. Moreover, the authorization to market products under an EUA is limited to the period of time the public health emergency declaration is in effect. In the U.S., Ortho markets its VITROS <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Anti-SARS-CoV-2</FONT></FONT> IgG Antibody test and calibrators and controls and VITROS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-SARS-CoV-2</FONT></FONT> Total Antibody test and calibrators
and controls pursuant to EUAs originally granted by the FDA in April 2020, and Ortho markets its VITROS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-SARS-CoV-2</FONT></FONT> Antigen Test pursuant to an EUA originally
granted by the FDA on January&nbsp;11, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a device is cleared or approved or otherwise authorized for marketing, numerous pervasive regulatory
requirements continue to apply unless explicitly exempt. These include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment registration and device listing with the FDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design,
testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">labeling and marketing regulations, which require that promotion is truthful, not misleading, fairly balanced and
provide adequate directions for use and that all claims are substantiated, and also prohibit the promotion of products for unapproved or <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses and impose other restrictions on labeling;
FDA guidance on <FONT STYLE="white-space:nowrap">off-label</FONT> dissemination of information and responding to unsolicited requests for information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety
or effectiveness or that would constitute a major change in intended use of one of its cleared devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets
may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field
corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with requirements governing Unique Device Identifiers on devices and also requiring the submission of
certain information about each device to the FDA&#146;s Global Unique Device Identification Database; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA&#146;s recall authority, whereby the agency can order device manufacturers to recall from the market a
product that is in violation of governing laws and regulations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to
protect the public health or to provide additional safety and effectiveness data for the device. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Regulation of Biological
Products </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of Ortho&#146;s blood screening products are regulated by the FDA as biological products, also called biologics. In the United
States, biologics are subject to regulation under the FDCA, PHSA, and other federal, state, local and foreign statutes and regulations. The process required by the FDA before biologics may be marketed in the United States generally involves the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#146;s Good
Laboratory Practice requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an Investigational New Drug application (&#147;IND&#148;) which must become effective
before clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an IRB or ethics committee at each clinical site before the trial is commenced;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of
the proposed biologic product candidate for its intended purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA Advisory Committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the
manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs and to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s continued safety, purity
and potency, and of selected clinical investigation sites to assess compliance with Good Clinical Practices; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for
use in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to beginning the first clinical trial of a biologic product candidate in the United States, Ortho must
submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. An IND must become effective before human clinical trials may begin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from preclinical and clinical studies,
including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from
company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by independent investigators. The submission of a BLA requires payment of
a substantial application user fee to the FDA, unless a waiver or exemption applies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the FDA evaluates a BLA and conducts inspections of
manufacturing facilities where the investigational product and/or its drug substance will be produced and of select clinical trial sites, the FDA may issue an approval letter or a Complete Response Letter (&#147;CRL&#148;). An approval letter
authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data
supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the CRL, the FDA may recommend
actions that the applicant might take to place the BLA in condition </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional
testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If regulatory approval of a
product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. The FDA also may condition approval on, among other things, changes to proposed
labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if
problems occur after the product reaches the marketplace. The FDA may require one or more post-market studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization, and may limit further
marketing of the product based on the results of these post-marketing studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any biologics manufactured or distributed pursuant to FDA approvals are
subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion
of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products.
Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with
cGMP, which impose certain procedural and documentation requirements upon it and its third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA
approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon it and any third-party manufacturers that Ortho may decide to use. Accordingly,
manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Enforcement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may withdraw marketing
authorization if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of
unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical
studies to assess new safety risks, or imposition of distribution restrictions or other restrictions. Other potential consequences include, among other things: restrictions on the marketing or manufacturing of the product, complete withdrawal of the
product from the market, product recalls, fines, warning letters, untitled letters, clinical holds on clinical studies, refusal of the FDA to approve pending applications or supplements to approved applications, product seizures or detention,
refusal to permit the import or export of products, consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs, the issuance of corrective information, injunctions, or the imposition of civil or criminal
penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the FDA closely regulates the marketing, labeling, advertising and promotion of biologics and medical devices. A company can make
only those claims relating to safety and efficacy, purity and potency that are cleared or approved by the FDA and in accordance with the provisions of the authorized label. The FDA and other agencies actively enforce the laws and regulations
prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and
criminal penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Healthcare Laws </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
costs of healthcare have been and continue to be a subject of study, investigation and regulation by governmental agencies and legislative bodies around the world. In the United States, attention has been focused on programs that encourage doctors
to recommend, use or purchase particular medical devices. Payers have become a more potent force in the marketplace and increased attention is being paid to medical device pricing, appropriate medical device utilization and the quality and costs of
healthcare generally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The implementation of the PPACA, in the United States, for example, has changed healthcare financing and delivery by both
governmental and private insurers substantially, and affected medical device manufacturers significantly. The PPACA, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
among other things, provided incentives to programs that increase the federal government&#146;s comparative effectiveness research, and implemented payment system reforms including a national
pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Additionally, the PPACA expanded eligibility
criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. Since its enactment,
there have been judicial, executive and political challenges to certain aspects of the PPACA. On June&nbsp;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the PPACA brought by several states without specifically
ruling on the constitutionality of the PPACA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. The
Budget Control Act of 2011, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the
exception of a temporary suspension from May&nbsp;1, 2020, through March&nbsp;31, 2022, unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to
several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. MACRA, enacted on April&nbsp;16, 2015, repealed the formula by which Medicare
made annual payment adjustments to physicians and replaced the former formula with fixed annual updates and a new system of incentive payments that are based on various performance measures and physicians&#146; participation in alternative payment
models such as accountable care organizations. It is unclear what effect new quality and payment programs, such as MACRA, may have on our business, financial condition, results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2018, the Centers for Medicare and Medicaid Services (&#147;CMS&#148;) implemented certain provisions of PAMA, which made substantial
changes to the way in which clinical laboratory services are paid under Medicare. Under PAMA, laboratories that receive the majority of their Medicare revenue from payments made under the Clinical Laboratory Fee Schedule or the Physician Fee
Schedule are required to report to CMS, beginning in 2017 and every three years thereafter (or annually for &#147;advanced diagnostics laboratory tests&#148;), private payer payment rates and volumes for their tests. Laboratories that fail to report
the required payment information may be subject to substantial civil monetary penalties. CMS uses the data to calculate a weighted median payment rate for each test, which is used to establish a revised Medicare reimbursement rate. Under PAMA, the
revised Medicare reimbursement rates were scheduled to apply to clinical diagnostic laboratory tests furnished on or after January&nbsp;1, 2018. The revised reimbursement methodology is expected to generally result in relatively lower reimbursement
under Medicare for clinical diagnostic lab tests than has been historically available. Any reduction to payment rates resulting from the new methodology is limited to 10% per test per year in 2018 through 2020, and to 15% per test per year in 2021
through 2023. For clinical diagnostic laboratory tests that are assigned a new or substantially revised Healthcare Common Proceduring Coding System code, initial payment rates for clinical diagnostic laboratory tests that are not advanced diagnostic
laboratory tests will be assigned by the cross-walk or <FONT STYLE="white-space:nowrap">gap-fill</FONT> methodology. Initial payment rates for new advanced diagnostic laboratory tests will be based on the actual list charge for the laboratory test.
The CARES Act, which was signed into law on March&nbsp;27, 2020, amended the timeline for reporting private payer payment rates and delayed by one year the payment reductions scheduled for 2021. On December&nbsp;10, 2021, Congress passed the PMAFSA,
which delays the next data reporting period by an additional year and prevents any reduction in payment amounts from commercial payer rate implementation in 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the CARES Act, Congress has enacted other laws in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic to provide
financial relief to healthcare providers and suppliers, including diagnostic laboratories, and encourage implementation of diagnostic testing and treatment for <FONT STYLE="white-space:nowrap">COVID-19.</FONT> For instance, the FFCRA, enacted on
March&nbsp;18, 2020, requires certain governmental and commercial insurance plans to provide coverage of <FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic testing services without imposing cost-sharing (e.g., copays, deductibles or
coinsurance) or other utilization management requirements. The CARES Act and the PPPHCEA, enacted on April&nbsp;24, 2020, each appropriated approximately $100&nbsp;billion to provide financial relief for certain healthcare providers and to expand
treatment and diagnostic testing capacity for <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The CAA, which was enacted on December&nbsp;27, 2020 and included further pandemic relief measures, temporarily increased payment rates under the
Medicare Physician Fee Schedule by 3.75% beginning January&nbsp;1, 2021 through December&nbsp;31, 2021. The PMAFSA further established a temporary 3% payment rate increase under the Medicare Physician Fee Schedule that will remain in effect
beginning January&nbsp;1, 2022 through December&nbsp;31, 2022. The CARES Act, as subsequently amended by the CAA and PMAFSA, also suspended, for the period from May&nbsp;1, 2020 to March&nbsp;31, 2022, the 2% payment reduction created under the
sequestration required by the Budget Control Act of 2011 (as amended by the American Taxpayer Relief Act of 2012), and extended the sequester by one year, through 2030. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulatory agencies under whose purview Ortho operates have administrative powers that may subject it to actions such as product withdrawals, recalls,
seizure of products and other civil and criminal sanctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, business practices in the healthcare industry have come under increased scrutiny, particularly
in the United States, by government agencies and state attorneys general, and resulting investigations and prosecutions carry the risk of significant civil and criminal penalties under applicable laws. These laws include anti-kickback, false claims
laws, civil monetary penalties laws, data privacy and security laws, and physician payment transparency laws. See &#147;Risk Factors&#151;Risks Relating to Ortho&#146;s Business&#151;Ortho is subject to healthcare regulations that could result in
liability, require it to change its business practices and restrict its operations in the future.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_114"></A>Available
Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORTHO&#146;S WEBSITE ADDRESS IS WWW.ORTHOCLINICALDIAGNOSTICS.COM AND ITS INVESTOR RELATIONS WEBSITE IS LOCATED AT
HTTPS://IR.ORTHOCLINICALDIAGNOSTICS.COM. INFORMATION ON ITS WEBSITE IS NOT INCORPORATED BY REFERENCE HEREIN AND INCLUSION OF THE WEBSITE ADDRESS IN THIS JOINT PROXY STATEMENT/PROSPECTUS IS AN INACTIVE TEXTUAL REFERENCE ONLY. ORTHO WILL MAKE
AVAILABLE ON ITS WEBSITE, FREE OF CHARGE, ITS ANNUAL REPORT ON FORM <FONT STYLE="white-space:nowrap">10-K,</FONT> QUARTERLY REPORTS ON FORM <FONT STYLE="white-space:nowrap">10-Q,</FONT> CURRENT REPORTS ON FORM
<FONT STYLE="white-space:nowrap">8-K</FONT> AND ANY AMENDMENTS TO THOSE REPORTS FILED OR FURNISHED PURSUANT TO SECTION 13(A) OR 15(D) OF THE EXCHANGE ACT, AS SOON AS REASONABLY PRACTICABLE AFTER ORTHO ELECTRONICALLY FILES SUCH MATERIAL WITH, OR
FURNISHES IT TO, THE SEC. THE SEC MAINTAINS AN INTERNET SITE (HTTP://WWW.SEC.GOV) CONTAINING REPORTS, PROXY AND INFORMATION STATEMENTS, AND OTHER INFORMATION REGARDING ISSUERS THAT FILE ELECTRONICALLY WITH THE SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_121"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS OF QUIDEL </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; in Part II, Item 7 of Quidel&#146;s Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on February 18, 2022 (incorporated by reference herein), which can be obtained at the Internet website maintained by the
SEC at www.sec.gov. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_122"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS OF ORTHO </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis of Ortho&#146;s financial condition and results of operations
should be read in conjunction with the disclosure under &#147;Risk Factors&#148; and Ortho&#146;s consolidated financial statements and the related notes to those statements included elsewhere in this joint proxy statement/prospectus. In addition to
historical consolidated financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the convenience of
presentation. Ortho&#146;s actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under &#147;Risk Factors&#148; and &#147;Cautionary Statement
Concerning Forward-Looking Statements&#148; in this joint proxy statement/prospectus. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, references in this
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations of Ortho&#148; to &#147;we,&#148; &#147;our&#148; and &#147;us&#148; refer to the business and operations of Ortho and its consolidated subsidiaries
prior to the Combinations. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_123"></A>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a pure-play IVD business driven by the credo, &#147;Because Every Test is A Life.&#148; This guiding principle reflects the crucial role diagnostics
play in global health and guides our priorities as an organization. As a leader in IVD, we impact approximately 800,000 patients every day. We are dedicated to improving outcomes for these patients and saving lives through providing innovative and
reliable diagnostic testing solutions to the clinical laboratory and transfusion medicine communities. Our global infrastructure and commercial reach allow us to serve these markets with significant scale. We have an intense focus on the customer.
We support our customers with high quality diagnostic instrumentation, a broad test portfolio and market leading service. Our products deliver consistently fast, accurate and reliable results that allow clinicians to make better-informed treatment
decisions. Our business model generates significant recurring revenues and strong cash flow streams from ongoing sales of high margin consumables. These consumables contribute more than 90% of our total revenue. We maintain close connectivity with
customers through a global presence, with approximately 4,800 employees, including approximately 2,300 commercial sales, service and marketing teammates. This global organization allows us to support our customers across more than 130 countries and
territories. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_124"></A>Key Components of Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net revenues </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We manage our business geographically
to better align with the market dynamics of the specific geographic region with reportable segments being Americas, EMEA and Greater China. We generate revenue primarily in the following lines of business: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Core: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical Laboratories&#151;Focused on (i)&nbsp;clinical chemistry, which is the measurement of target chemicals
in bodily fluids for the evaluation of health and the clinical management of patients, (ii)&nbsp;immunoassay instruments, which test the measurement of proteins as they act as antigens in the spread of disease, antibodies in the immune response
spurred by disease, or markers of proper organ function and health and (iii)&nbsp;testing to detect and monitor disease progression across a broad spectrum of therapeutic areas, and includes grant revenue related to development of our <FONT
STYLE="white-space:nowrap">COVID-19</FONT> antibody and antigen tests. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Transfusion Medicine&#151;Focused on (i)&nbsp;immunohematology instruments and tests used for blood typing to
ensure patient-donor compatibility in blood transfusions and (ii)&nbsp;donor screening instruments and tests used for blood and plasma screening for infectious diseases for customers primarily in the United States. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-core:</FONT> </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Other Product Revenue&#151;Includes revenues primarily from contract manufacturing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Collaboration and Other Revenue&#151;Includes collaboration and license agreements pursuant to which we derive
collaboration and royalty revenues. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All <FONT STYLE="white-space:nowrap">non-core</FONT> revenue is recorded in the Americas segment for all
periods presented. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
primary components of our cost of revenue are purchased materials, the overhead costs related to our manufacturing operations and direct labor associated with the manufacture of our instruments, assays, reagents and other consumables and
depreciation of customer leased instruments. Cost of revenue excludes amortization of intangible assets. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, marketing and administrative
expenses </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary components of our selling, marketing and administrative expenses are employee-related costs in our sales, marketing and
administrative and support functions, marketing costs, distribution costs and an allocation of facility and information technology costs and other overhead costs. Employee-related costs include compensation and benefits, including stock-based
compensation expense and commissions, employee recruiting and relocation expenses, employee training costs and travel-related costs. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research
and development expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary components of our research and development expense are costs related to clinical trials and regulatory-related
spending, as well as employee-related costs in these functions, and an allocation of facility and information technology costs and other overhead costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amortization of intangible assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization of
intangible assets consists of the amortization of intangible assets primarily related to the acquisition of Ortho from Johnson&nbsp;&amp; Johnson by Carlyle. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other operating expense, net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary
components of other operating expense, net, are profit share expense related to our Joint Business and restructuring charges. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest expense, net
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary components of interest expense, net are interest charges and amortization of deferred financing charges related to our borrowings.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax indemnification expense (income), net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary components of tax indemnification expense (income), net are gains and losses related to certain federal, state and foreign tax matters that relate
to the period prior to the Acquisition and for which we have indemnification agreements. We are subject to income tax in approximately 35 jurisdictions outside the United States. Our most significant operations outside the United States are located
in China, France, Japan and the United Kingdom. For these jurisdictions for which we have significant operations, the statute of limitations varies by jurisdiction, with 2013 being the oldest tax year still open. We are currently under audit in
certain jurisdictions for tax years under the responsibility of Johnson&nbsp;&amp; Johnson. Pursuant to the Acquisition Agreement, all tax liabilities related to these tax years will be indemnified by Johnson&nbsp;&amp; Johnson. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other expense (income), net </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary
components of other expense (income), net are foreign currency related gains and losses, including unrealized gains and losses on intercompany loans denominated in currencies other than the functional currency of the affected subsidiaries, and
losses related to the early extinguishment of certain borrowings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_125"></A>Impact of the Initial Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of proceeds and impact of debt extinguishment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;1, 2021, we completed the IPO of our ordinary shares at a price of $17.00 per share. We issued and sold 76,000,000 ordinary shares in the IPO
and issued and sold an additional 11,400,000 ordinary shares on February&nbsp;4, 2021 pursuant to the full exercise of the underwriters&#146; option to purchase additional shares. The ordinary shares sold in the IPO were registered under the
Securities Act pursuant to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> which was declared effective by the SEC on January&nbsp;29, 2021. Our ordinary shares are listed on Nasdaq under the symbol &#147;OCDX.&#148;
The offering, including proceeds from the full exercise of the underwriters&#146; option to purchase additional shares, generated net proceeds of $1,426.4&nbsp;million after deducting underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We used the net proceeds from the IPO (i)&nbsp;to redeem $160.0&nbsp;million of our 2025 Notes, plus accrued interest thereon and $11.8&nbsp;million of
redemption premium, (ii)&nbsp;to redeem $270.0&nbsp;million of our 2028 Notes, plus accrued interest thereon and $19.6&nbsp;million of redemption premium, (iii)&nbsp;to repay $892.7&nbsp;million in aggregate principal amount of borrowings under our
Dollar Term Loan Facility and (iv)&nbsp;for working capital and general corporate purposes. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incremental public company expenses </I></B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a recently new public company, we have incurred significant expenses on an ongoing basis that we did not incur as a private company, including increased
director and officer liability insurance expense, as well as third-party and internal resources related to accounting, auditing, Sarbanes-Oxley Act compliance, legal and investor and public relations expenses. These costs will generally be included
in selling, marketing and administrative expenses in our audited consolidated statement of operations. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based compensation expense
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;3, 2021, the Ortho Board of Directors approved the modifications to the vesting of restricted stock and Liquidity Event option
awards held by certain current and former members of management in accordance with the 2014 Equity Incentive Plan, which governs these grants. As a result of the modification, we recorded additional stock-based compensation expense of
$6.2&nbsp;million during the fiscal year ended January&nbsp;2, 2022. Furthermore, during the fiscal quarter ended April&nbsp;4, 2021, the Ortho Board of Directors approved the share pool associated with our long-term equity incentive plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_125a"></A>Underwritten Secondary Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2021, we completed an underwritten secondary offering of 25.3&nbsp;million ordinary shares held by a selling shareholder affiliated with Carlyle,
including 3.3&nbsp;million ordinary shares pursuant to the full exercise of the underwriters&#146; option to purchase additional shares. The ordinary shares sold in the secondary offering were registered under the Securities Act pursuant to a
Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> which was declared effective by the SEC on September 9, 2021. We did not offer any ordinary shares in this transaction and did not receive any proceeds from the sale of the
ordinary shares by the selling shareholder. We incurred costs of $1.1&nbsp;million in relation to the secondary public offering for the fiscal year ended January&nbsp;2, 2022, which were recorded in Selling, marketing and administrative expenses in
our audited consolidated statement of operations. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_126"></A>Impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
Pandemic </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In response to the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we mobilized our research and development teams to
bring to market <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody and antigen tests. Our <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody tests detect whether a patient has been previously infected by
<FONT STYLE="white-space:nowrap">COVID-19</FONT> and our <FONT STYLE="white-space:nowrap">COVID-19</FONT> antigen test detects whether a patient is currently infected by <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We have received a
combination of EUA from the FDA, authority to affix a CE Mark for sale in the European Union and various other regulatory approvals globally for our <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody tests. We have also received authority to
affix a CE Mark for sale in the European Union and the FDA accepted our EUA for our <FONT STYLE="white-space:nowrap">COVID-19</FONT> antigen test. We sell these tests in various other markets globally and continue to work on gaining further
regulatory approvals in other markets. All of our <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody and antigen tests run on our existing instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2020, we began to see a decrease in the number of tests run in China. This decline spread to certain other countries in EMEA and ASPAC in early
March 2020 and resulted in a worldwide decrease in the number of tests run globally by the end of that month. In many countries, we also experienced a lag between the timing of the decrease in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of tests run and the decrease in shipments of additional products to our customers, which began to occur during the fiscal quarter ended June&nbsp;28, 2020. As a result, during the fiscal
year ended January&nbsp;3, 2021, we experienced decreased revenues and incurred idle or underutilized facilities costs, higher freight and higher distribution costs compared to the periods prior to the pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal quarter ended January&nbsp;3, 2021, we started to experience a recovery in the base business of our core revenue, which continued through
the fiscal year ended January&nbsp;2, 2022. Additionally, since the fiscal quarter ended June&nbsp;28, 2020, our results of operations were supplemented with revenue from sales of our COVID-19 antibody and antigen tests. However, starting in the
fiscal quarter ended July&nbsp;4, 2021, this supplemental revenue from sales of our COVID-19 antibody and antigen tests began to decline and continued to decline into the fourth quarter of fiscal year 2021. During the fiscal year ended
January&nbsp;2, 2022, we also continued to experience higher distribution costs due to higher shipping rates as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and beginning in the fiscal quarter ended October&nbsp;3,
2021, we experienced some supply chain disruptions. These supply chain disruptions have resulted in shortages or delays in receipts for certain key components of our instruments and assays. Additionally, we have experienced distribution challenges,
which have affected our ability to fulfill customer orders on a timely basis, including instrument placements. These supply chain and distribution challenges have impacted, and we expect will continue to impact, our results of operations and
resulted in disruption to our business operations. We are continuously evaluating our supply chain to identify potential gaps and take steps to ensure continuity, including working closely with our primary suppliers of these components and pursuing
additional suppliers for certain of these components, in order to maintain supply to our customers. We continue to monitor the potential impact of these issues on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are continually monitoring our business continuity plans. Due to the fact that our products and services are considered to be medically critical, our
manufacturing and research and development sites are generally exempt from governmental orders in the U.S. and other countries requiring businesses to cease or reduce operations. For these sites, we have implemented steps to protect our employees.
Our office-based work sites in the U.S. are subject to operating restrictions consistent with applicable health guidelines. We permit limited domestic travel for our employees, which has reduced our travel-related operating expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;9, 2021, President Biden issued the Executive Order on Ensuring Adequate COVID Safety Protocols for Federal Contractors (the &#147;Executive
Order&#148;), which directs executive departments and agencies to ensure that contracts covered by the Executive Order require relevant federal contractors and subcontractors to mandate their employees to be fully vaccinated against <FONT
STYLE="white-space:nowrap">COVID-19</FONT> by certain dates that continue to be extended by the government. The Executive Order has faced several legal challenges and on December&nbsp;7, 2021, the U.S. District Court for the Southern District of
Georgia issued a nationwide injunction blocking enforcement of the federal contractor mandate which was upheld by the Eleventh Circuit on December&nbsp;17, 2021. We continue to monitor all court developments as well as impacts of requirements as it
relates to any applicable contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic is an ongoing matter, our future assessment
of the magnitude and duration of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, as well as other factors, could result in material impacts to our consolidated financial statements in future reporting periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_127"></A>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fiscal year ended January&nbsp;2, 2022 compared with fiscal year ended January&nbsp;3, 2021 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net loss<U> </U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net loss for the fiscal year ended
January&nbsp;2, 2022 was $54.3&nbsp;million compared to net loss of $211.9&nbsp;million for the fiscal year ended January&nbsp;3, 2021, representing a decrease of $157.6&nbsp;million. The decrease in net loss was primarily due to higher net revenue,
primarily driven by growth of our base business, as well as a decrease in interest expense as a result of our debt pay down, and a decrease in other expense, primarily related to unrealized foreign currency losses in the prior year period. These
impacts were partially offset by an increase in operating expenses, primarily Selling, marketing and administrative expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net revenue for the fiscal year ended January&nbsp;2, 2022 increased by $276.6&nbsp;million, or 15.7%, compared with the fiscal year ended January&nbsp;3,
2021. Net revenue for the fiscal year ended January&nbsp;2, 2022 included operational net revenue growth of 14.2% and a positive impact of 1.5% from foreign currency fluctuations, which was primarily driven by the weakening of the U.S.&nbsp;Dollar
against a variety of currencies, primarily the Chinese Yuan, Euro and British Pound, partially offset by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
strengthening of the Japanese Yen and Brazilian Real. The increase in revenues for the fiscal year ended January&nbsp;2, 2022, excluding the impact of foreign currency exchange, was mainly driven
by our Core lines of business, as we recorded higher revenues across all geographic regions of our Clinical Laboratories and Transfusion Medicine businesses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows total net revenue by line of business: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(Dollars in millions)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical Laboratories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,350.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,154.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfusion Medicine</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">664.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Core Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,014.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,734.8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16.1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Product Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26.9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and Other Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Core</FONT> Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28.1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9.8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,042.8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,766.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Core revenue </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical Laboratories revenue for the fiscal year ended January&nbsp;2, 2022 increased by $196.2&nbsp;million, or 17.0%, compared with the fiscal year ended
January&nbsp;3, 2021, net of a decrease of $6.6&nbsp;million from our <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody and antigen tests resulting from the deceleration of <FONT STYLE="white-space:nowrap">COVID-19</FONT> related testing
year-over-year, primarily in the second half of the year. The increase included an operational net revenue growth of 15.4% and a positive impact of 1.6% from foreign currency fluctuations. The increase in Clinical Laboratories revenue was primarily
due to higher reagent revenue, driven by the recovery of testing volumes in our base business and the growth of our installed base. The growth in the base business includes increases in revenues related to our chemistry slides and our wells,
primarily our cardiac-related assays. Additionally, we recorded higher consumables and instrument sales across most regions, most notably in the Americas, and primarily related to our integrated clinical lab systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transfusion Medicine revenue for the fiscal year ended January&nbsp;2, 2022 increased by $83.7&nbsp;million, or 14.4%, compared with the fiscal year ended
January&nbsp;3, 2021. This increase included operational net revenue growth of 13.1% and a positive impact of 1.3% from foreign currency fluctuations. The increase in Transfusion Medicine revenue, excluding the impact of foreign currency exchange,
was primarily driven by strength in Donor Screening, including a new customer in our Donor Screening business in the United States, as well as an increase in Immunohematology assays. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">Non-core</FONT> revenue </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other product revenue, related to our contract manufacturing business, decreased by $2.3&nbsp;million for the fiscal year ended January&nbsp;2, 2022 compared
with the fiscal year ended January&nbsp;3, 2021, due to the timing of satisfying certain performance obligations related to a contract manufacturing arrangement in the current fiscal period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration and other revenue for the fiscal year ended January&nbsp;2, 2022 decreased by $1.0&nbsp;million compared with the fiscal year ended
January&nbsp;3, 2021. The decrease was primarily due to lower revenues related to our HCV/HIV license agreements, partially offset by an $8.5&nbsp;million award from an arbitration proceeding related to one of our collaboration agreements recorded
during the current year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cost of revenue </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(Dollars in millions)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of<BR>Net<BR>Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of<BR>Net<BR>Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,006.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">908.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase in cost of revenue was primarily driven by the increase in revenues during the current year
period. The decrease in cost of revenue as a percentage of net revenue for the fiscal year ended January&nbsp;2, 2022 compared with the fiscal year ended January&nbsp;3, 2021 was primarily due to lower manufacturing costs and lower underutilized
facility costs, as well as the impact of the previously mentioned award from an arbitration proceeding related to one of our collaboration agreements, partially offset by higher freight costs and unfavorable product mix. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating expenses </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a
summary of certain operating expenses: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(Dollars in millions)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of<BR>Net<BR>Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of<BR>Net<BR>Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, marketing and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">555.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">489.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Selling, marketing and administrative expenses </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selling, marketing and administrative expenses were $555.0&nbsp;million for the fiscal year ended January&nbsp;2, 2022, or 27.2% of net revenue, as compared
with $489.6&nbsp;million for the fiscal year ended January&nbsp;3, 2021, or 27.7% of net revenue, an increase of $65.4&nbsp;million. The increase in selling, marketing and administrative expenses was primarily due to higher employee-related costs,
including stock-based compensation, and increased distribution costs due to higher shipment volumes and higher shipping rates as a result of the ongoing global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Research and development expense </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development expense was $126.2&nbsp;million for the fiscal year ended January&nbsp;2, 2022, or 6.2% of net revenue, as compared with $112.9&nbsp;million for the fiscal year ended January&nbsp;3, 2021, or 6.4% of net revenue, an increase of
$13.3&nbsp;million. The increase was primarily due to an increased investment in costs to develop new assays, as well as an increase in employee-related costs, partially offset by the $7.5&nbsp;million
<FONT STYLE="white-space:nowrap">up-front</FONT> payment made to Quotient in the prior year period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Amortization of intangible assets </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets was $133.4&nbsp;million for the fiscal year ended January&nbsp;2, 2022 as compared with $131.9&nbsp;million for the fiscal
year ended January&nbsp;3, 2021. There were no significant changes in the composition of our intangible assets in the fiscal year ended January&nbsp;2, 2022 compared to the fiscal year ended January&nbsp;3, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Other operating expense, net </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other operating expense,
net, was $47.5&nbsp;million, or 2.3% of net revenue, for the fiscal year ended January&nbsp;2, 2022, as compared with $35.3&nbsp;million, or 2.0% of net revenue, for the fiscal year ended January&nbsp;3, 2021, an increase of $12.2&nbsp;million. The
increase was primarily due to costs incurred of $7.0&nbsp;million related to the acquisition of Ortho by Quidel and, to a lesser extent, higher profit share expense in the current year due to lower manufacturing costs related to our Joint Business.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-operating</FONT> items </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Interest expense, net </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest expense, net was
$146.0&nbsp;million for the fiscal year ended January&nbsp;2, 2022, compared with $198.2&nbsp;million for the fiscal year ended January&nbsp;3, 2021. The decrease of $52.2&nbsp;million was primarily related to lower borrowings due to the use of the
net proceeds from the IPO to (i)&nbsp;redeem $160.0&nbsp;million of our 2025 Notes, (ii)&nbsp;redeem $270.0&nbsp;million of our 2028 Notes, and (iii)&nbsp;repay $892.7&nbsp;million in aggregate principal amount of borrowings under our Dollar Term
Loan Facility. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Tax indemnification expense, net </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tax indemnification expense was $0.8&nbsp;million for the fiscal year ended January&nbsp;2, 2022, and was primarily related to the release of certain <FONT
STYLE="white-space:nowrap">pre-acquisition</FONT> U.S. state tax reserves. Tax indemnification expense was $31.2&nbsp;million for the fiscal year ended January&nbsp;3, 2021, and was primarily related to the release of certain tax reserves upon the
settlement of certain U.S. federal and state tax matters, with an offsetting benefit recorded to income tax expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Other expense, net </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expense, net was $53.1&nbsp;million for the fiscal year ended January&nbsp;2, 2022 and was comprised primarily of loss on early extinguishment of debt of
$50.3&nbsp;million, which was related to the use of proceeds from the IPO to redeem portions of our outstanding 2025 Notes, 2028 Notes and Dollar Term Loan Facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expense, net was $84.2&nbsp;million for the fiscal year ended January&nbsp;3, 2021 and primarily related to $69.5&nbsp;million of foreign currency
losses, of which $68.2&nbsp;million was unrealized, and loss on early extinguishment of the 2022 Notes of $12.6&nbsp;million. The unrealized foreign currency losses are mainly related to intercompany loans denominated in currencies other than the
functional currency of the affected subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Provision for (benefit from) income taxes </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal year ended January&nbsp;2, 2022, we incurred a loss before provision for income taxes of $26.0&nbsp;million and recognized a provision for
income taxes of $28.3&nbsp;million, resulting in a negative effective tax rate of 109.0%. The effective tax rate differs from the U.S. federal statutory rate primarily due to (i)&nbsp;a net cost of $44.7&nbsp;million for the impacts of operating
losses in certain subsidiaries not being benefited due to the establishment of valuation allowances, (ii)&nbsp;a net benefit of $23.8&nbsp;million related to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> earnings being taxed at rates that are
different than the U.S. statutory rate, and (iii)&nbsp;a net cost of $11.8&nbsp;million for the tax expense associated with the remeasurement of deferred tax assets and liabilities due to the enactment of new tax rates, primarily in the United
Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal year ended January&nbsp;3, 2021, we incurred a loss before benefit from income taxes of $225.3&nbsp;million and recognized a
benefit from income taxes of $13.4&nbsp;million resulting in an effective tax rate of 5.9%. The effective tax rate for each period differs from the U.S. federal statutory rate primarily due to (i)&nbsp;a net cost of $63.8&nbsp;million for the
impacts of operating losses in certain subsidiaries not being benefited due to the establishment of a valuation allowance, (ii)&nbsp;a net benefit of $37.3&nbsp;million related to a decrease in our
<FONT STYLE="white-space:nowrap">pre-Acquisition</FONT> reserves for uncertain tax positions due to the settlement of certain tax matters, (iii)&nbsp;partially offset by a net cost of $5.7&nbsp;million related to an increase in certain
post-Acquisition <FONT STYLE="white-space:nowrap">non-U.S.</FONT> reserves for uncertain tax positions and (iv)&nbsp;a net benefit of $23.1&nbsp;million for <FONT STYLE="white-space:nowrap">non-U.S.</FONT> earnings being taxed at rates that are
different than the U.S. statutory rate. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fiscal year ended January&nbsp;3, 2021 compared with fiscal year ended December&nbsp;29, 2019
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of results </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal year
ended January&nbsp;3, 2021, reported net loss of $211.9&nbsp;million increased by $55.0&nbsp;million compared with the fiscal year ended December&nbsp;29, 2019. Our results were materially impacted by the global
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, as net revenue for the fiscal year ended January&nbsp;3, 2021 decreased by $35.3&nbsp;million compared with the fiscal year ended December&nbsp;29, 2019. This decrease included operational
net revenue declines of 1.3% and a negative impact of 0.7% from foreign currency fluctuations. We also incurred higher idle or underutilized facilities costs, higher freight costs and higher distribution costs, which were partially offset by cost
containment measures to incur lower employee-related costs and lower travel-related costs. Our results were also affected by a research and development upfront payment of $7.5&nbsp;million, higher foreign currency losses, primarily unrealized, and
losses on early extinguishment of our 2022 Notes, partially offset by lower interest expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net revenue for the fiscal year ended January&nbsp;3, 2021 decreased by $35.3&nbsp;million, or 2.0%, compared with the fiscal year ended December&nbsp;29,
2019. Net revenue for the fiscal year ended January&nbsp;3, 2021 included operational net revenue declines of 1.3% and a negative impact of 0.7% from foreign currency fluctuations, which was primarily driven by the strengthening of the
U.S.&nbsp;dollar against a variety of currencies. The decrease in net revenue for the fiscal year ended January&nbsp;3, 2021, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
excluding the impact of foreign currency exchange, was mainly driven by lower revenues in our Clinical Laboratories business in the EMEA, Greater China and other regions due primarily to the
global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and lower local HCV revenue in the Japan region of approximately $18&nbsp;million, as well as lower revenues in our Transfusion Medicine business in all regions due primarily to the
global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. These decreases were partially offset by increases in our Clinical Laboratories business in the North America region related to sales of our
<FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody tests and other assays, instrument sales and grant revenue related to development of our <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody and antigen tests. The decrease in net
revenue was also impacted by lower Other Product Revenue due to the reduction and timing of certain performance obligations in a contract manufacturing arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows total net revenue by line of business: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>($ in millions)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;3,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;29,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical Laboratories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,154.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,142.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfusion Medicine</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">598.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Core Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,734.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,740.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Product Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and Other Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Core</FONT> Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48.7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,766.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,801.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Core revenue<B> </B> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical Laboratories revenue for the fiscal year ended January&nbsp;3, 2021 increased by $11.9&nbsp;million, or 1.0%, compared with the fiscal year ended
December&nbsp;29, 2019. This increase included operational net revenue gains of 2.3% partially offset by a negative impact of 1.2% from foreign currency fluctuations. Clinical Laboratories revenue increased in the North America region related to
sales of our <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody tests and other assays, instrument sales and grant revenue related to development of our <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody and antigen tests. These
increases were offset by lower revenues in the EMEA, Greater China and other regions due primarily to decreased shipments to customers as a result of the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and lower local HCV revenue in
the Japan region of approximately $18&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transfusion Medicine revenue for the fiscal year ended January&nbsp;3, 2021 decreased by
$17.4&nbsp;million, or 2.9%, compared with the fiscal year ended December&nbsp;29, 2019. This decrease included operational net revenue declines of 3.3% partially offset by a positive impact of 0.3% from foreign currency fluctuations. The decrease
in Transfusion Medicine revenue was primarily due to decreased shipments to customers in all regions as a result of the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">Non-core</FONT> revenue<B> </B> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other Product Revenue for the fiscal year ended January&nbsp;3, 2021 decreased by $28.8&nbsp;million, or 77.2%, compared with the fiscal year ended
December&nbsp;29, 2019. The decrease was due to the reduction and timing of certain performance obligations in a contract manufacturing arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration and Other Revenue for the fiscal year ended January&nbsp;3, 2021 decreased by $1.0&nbsp;million, or 4.2%, compared with the fiscal year ended
December&nbsp;29, 2019. The decrease was primarily due to lower revenues related to our HCV/HIV license agreements, partially offset by $7.5&nbsp;million of license revenue related to the Joint Business granting a customer a license to sell certain
products in Canada. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Cost of revenue </U></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>($ in millions)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;3,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of<BR>Net&nbsp;Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;29,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of<BR>Net&nbsp;Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">908.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">922.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase in cost of revenue, and as a percentage of net revenue for the fiscal year ended
January&nbsp;3, 2021 compared with the fiscal year ended December&nbsp;29, 2019, was primarily due to idle or underutilized facility costs of $14.8&nbsp;million and freight costs of $6.9&nbsp;million incurred as a result of the global <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. This increase was partially offset by $11.0&nbsp;million of lower restructuring costs in the fiscal year ended January&nbsp;3, 2021 compared with the fiscal year ended December&nbsp;29, 2019,
which were primarily related to depreciation related charges incurred in the fiscal year ended December&nbsp;29, 2019 related to assets no longer in use due to the transfer of certain production lines. See &#147; Restructuring Activities.&#148; </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a
summary of certain operating expenses: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>($ in millions)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;3,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of</B><br><B>Net&nbsp;Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;29,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of</B><br><B>Net&nbsp;Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, marketing and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">489.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">515.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Selling, marketing and administrative expenses<B> </B> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selling, marketing and administrative expenses were $489.6&nbsp;million for the fiscal year ended January&nbsp;3, 2021, or 27.7% of net revenue, as compared
with $515.1&nbsp;million for the fiscal year ended December&nbsp;29, 2019, or 28.6% of net revenue, a decrease of $25.5&nbsp;million. The decrease in selling, marketing and administrative expenses was primarily due to decreased employee-related
costs, including stock-based compensation and severance expense, and decreased travel-related costs, partially offset by increased distribution costs and increased third-party costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Research and development expense<B> </B> </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development expense was $112.9&nbsp;million for the fiscal year ended January&nbsp;3, 2021, or 6.4% of net revenue, as compared with research and development expense of $98.0&nbsp;million for the fiscal year ended December&nbsp;29, 2019, or 5.4% of
net revenue, an increase of $14.9&nbsp;million. The increase was primarily due to a research and development upfront payment of $7.5&nbsp;million made to Quotient upon the signing of a binding letter agreement and costs incurred to perform research
and development activities related to developing our <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody and antigen tests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Amortization of
intangible assets<B> </B> </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets was $131.9&nbsp;million for the fiscal year ended January&nbsp;3, 2021 as compared with
$131.7&nbsp;million for the fiscal year ended December&nbsp;29, 2019. There were no major changes in the composition of our intangible assets in the fiscal year ended January&nbsp;3, 2021 compared to the fiscal year ended
December&nbsp;29,&nbsp;2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Other operating expense, net<B> </B> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other operating expense, net, was $35.3&nbsp;million, or 2.0% of net revenue, for the fiscal year ended January&nbsp;3,&nbsp;2021, as compared with
$48.8&nbsp;million, or 2.7% of net revenue, for the fiscal year ended December&nbsp;29,&nbsp;2019, a decrease of $13.5&nbsp;million. The decrease was primarily due to lower profit share expense in the current year from lower revenue related to our
Joint Business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-operating</FONT> items </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Interest expense, net<B> </B> </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest expense was
$198.2&nbsp;million for the fiscal year ended January&nbsp;3, 2021, compared with $231.4&nbsp;million for the fiscal year ended December&nbsp;29, 2019. The decrease of $33.2&nbsp;million was primarily related to lower interest rates on the Dollar
Term Loan Facility. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Tax indemnification expense, net<B> </B> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tax indemnification expense was $31.2&nbsp;million for the fiscal year ended January&nbsp;3, 2021, and was primarily related to the release of certain tax
reserves upon the settlement of certain U.S. federal and state tax matters, with an offsetting benefit recorded to income tax expense. Tax indemnification expense was $29.2&nbsp;million for the fiscal year ended December&nbsp;29, 2019, and was
primarily related to the release of certain tax reserves upon the settlement of certain state tax matters, with an offsetting benefit recorded to income tax expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Other expense, net<B> </B> </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expense, net was
$84.2&nbsp;million for the fiscal year ended January&nbsp;3, 2021 and primarily related to $69.5&nbsp;million of foreign currency losses, of which $68.2&nbsp;million was unrealized and loss on early extinguishment of the 2022 Notes of
$12.6&nbsp;million. The unrealized foreign currency losses are mainly related to intercompany loans denominated in currencies other than the functional currency of the affected subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expense, net was $5.7&nbsp;million for the fiscal year ended December&nbsp;29, 2019 and primarily related to $16.0&nbsp;million of fair value losses on
interest rate caps that did not qualify for hedge accounting, partially offset by $10.5&nbsp;million of net foreign currency gains, of which $18.1&nbsp;million was unrealized. The unrealized foreign currency gains are mainly related to intercompany
loans denominated in currencies other than the functional currency of the affected subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Benefit from income taxes<B> </B> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal year ended January&nbsp;3, 2021, we incurred a loss before benefit from income taxes of $225.3&nbsp;million and recognized a benefit from
income taxes of $13.4&nbsp;million resulting in an effective tax rate of 5.9%. The effective tax rate differs from the U.S. federal statutory rate primarily due to (1)&nbsp;the impact of operating losses in certain subsidiaries not being benefited
due to the establishment of a valuation allowance (2)&nbsp;a decrease in our <FONT STYLE="white-space:nowrap">pre-Acquisition</FONT> reserves for uncertain tax positions due to the settlement of certain tax matters, (3)&nbsp;partially offset by an
increase in certain post-Acquisition <FONT STYLE="white-space:nowrap">non-U.S.</FONT> reserves for uncertain tax positions and <FONT STYLE="white-space:nowrap">(4)&nbsp;non-U.S.</FONT> earnings being taxed at rates that are different than the U.S.
statutory rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal year ended December&nbsp;29, 2019, we incurred a loss before benefit from income taxes of $180.8&nbsp;million and
recognized a benefit from income taxes of $23.9&nbsp;million resulting in an effective tax rate of 13.3%. The effective tax rate for each period differs from the U.S. federal statutory rate primarily due to (1)&nbsp;the impact of operating losses in
certain subsidiaries not being benefited due to the establishment of a valuation allowance, (2)&nbsp;a decrease in our <FONT STYLE="white-space:nowrap">pre-Acquisition</FONT> state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> reserves for
uncertain tax positions due to the settlement of certain tax matters, (3)&nbsp;an increase in our interest expense on prior year reserves for uncertain tax positions and <FONT STYLE="white-space:nowrap">(4)&nbsp;non-U.S.</FONT> earnings being taxed
at rates that are different than the U.S. statutory rate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_128"></A>Use of <FONT STYLE="white-space:nowrap">Non-GAAP</FONT>
Financial Measures </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reconciliation of Net Loss to Adjusted EBITDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our financial statements and the other financial data included in this joint proxy statement/prospectus have been prepared in a manner that
complies, in all material respects, with GAAP, and are consistent with current practice, with the exception of the inclusion of financial measures that differ from measures calculated in accordance with GAAP, including Adjusted EBITDA and Management
EBITDA. Adjusted EBITDA consists of net loss before interest expense, net provision for (benefit from) income taxes and depreciation and amortization and eliminates (i)&nbsp;certain <FONT STYLE="white-space:nowrap">non-operating</FONT> income or
expense, and (ii)&nbsp;impacts of certain noncash, unusual or other items that are included in net loss that we do not consider indicative of our ongoing operating performance. Management EBITDA consists of Adjusted EBITDA plus certain other
management adjustments. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We use these financial measures in the analysis of our financial and operating performance because they assist in the
evaluation of underlying trends in our business. Additionally, prior to fiscal year 2021, we used Management EBITDA in assessing the profitability of our geographic-based reportable segments and as a basis for calculating certain management
incentive compensation programs. Effective January&nbsp;4, 2021, we changed the basis by which we measure segment profitability to Adjusted EBITDA. In the case of Adjusted EBITDA and Management EBITDA, we believe that making such adjustments
provides management and investors meaningful information to understand our operating performance and ability to analyze financial and business trends on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis. We believe that the presentation of these financial measures enhances an investor&#146;s understanding of our financial performance. We use
certain of these financial measures for business planning purposes and measuring our performance relative to that of our competitors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other companies in our industry may calculate Adjusted EBITDA and Management EBITDA differently than we do.
As a result, these financial measures have limitations as analytical and comparative tools and you should not consider these items in isolation, or as a substitute for analysis of our results as reported under GAAP. Adjusted EBITDA and Management
EBITDA should not be considered as measures of discretionary cash available to us to invest in the growth of our business. In calculating these financial measures, we make certain adjustments that are based on assumptions and estimates that may
prove to have been inaccurate. In addition, in evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in the presentation of these metrics included in this joint proxy
statement/prospectus. Our presentation of Adjusted EBITDA and Management EBITDA should not be construed as an inference that our future results will be unaffected by unusual or <FONT STYLE="white-space:nowrap">non-recurring</FONT> items or changes
in our customer base. Additionally, our presentation of Adjusted EBITDA may differ from that included in the Credit Agreement, the 2025 Notes Indenture and the 2028 Notes Indenture for purposes of covenant calculation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA and Management EBITDA have important limitations as an analytical tool and you should not consider it in isolation or as substitutes for
analysis of our results as reported under GAAP. Some of these limitations include the fact that Adjusted EBITDA and Management EBITDA: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not reflect the significant interest expense on our debt, including the Senior Secured Credit Facilities, the
2025 Notes and the 2028 Notes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eliminate the impact of income taxes on our results of operations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not reflect any cash requirements for any future replacements of assets being depreciated and amortized,
although the assets being depreciated and amortized will often have to be replaced in the future. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We compensate for these limitations
by relying primarily on our GAAP results and using these financial measures only as a supplement to our GAAP results. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables reconcile
Net loss to Adjusted EBITDA for fiscal years ended January 2, 2022 and January 3, 2021: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(Dollars in millions)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(54.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(211.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation<SUP STYLE="font-size:85%; vertical-align:top">(a)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restructuring and severance-related
costs<SUP STYLE="font-size:85%; vertical-align:top">(b)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arbitration award<SUP STYLE="font-size:85%; vertical-align:top">(c)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quidel acquisition-related costs<SUP STYLE="font-size:85%; vertical-align:top">(d)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax indemnification expense, net<SUP STYLE="font-size:85%; vertical-align:top">(e)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs related to Ortho&#146;s initial public and secondary offerings<SUP
STYLE="font-size:85%; vertical-align:top">(f)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EU medical device regulation transition
costs<SUP STYLE="font-size:85%; vertical-align:top">(g)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized foreign currency exchange
losses<SUP STYLE="font-size:85%; vertical-align:top">(h)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other adjustments<SUP STYLE="font-size:85%; vertical-align:top">(i)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">548.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">448.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents expenses related to awards granted under our 2014 Equity Incentive Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents restructuring and severance costs related to several discrete initiatives intended to strengthen
operational performance and to support building our commercial capabilities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an award from an arbitration proceeding related to one of our collaboration agreements of $8.5
million, partially offset by related legal fees of $1.1 million. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents acquiree-related transaction costs related to the Business Combination Agreement with Quidel.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the reversal of the impact of tax indemnification income with Johnson &amp; Johnson, primarily
related to certain state tax matters, for which we recorded a tax reserve and indemnification. These state tax matters primarily include the taxability of the sale of our assets on the Acquisition date from Johnson &amp; Johnson.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents costs incurred in connection with our IPO and underwritten secondary offering.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">European Medical Device Regulation costs represent incremental consulting costs and R&amp;D manufacturing site
costs for our previously registered products under the In Vitro Diagnostic Regulation (&#147;IVDR&#148;) to align existing, on-market products, with the revised expectations under the IVDR. IVDR is a replacement of the existing European In Vitro
Diagnostics Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU IVDR beginning in May 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents noncash unrealized gains and losses resulting from the remeasurement of transactions denominated in
foreign currencies primarily related to intercompany loans. Beginning in fiscal year 2021, we initiated programs to mitigate the impact of foreign currencies related to intercompany loans in our results, and such noncash net unrealized gains were
approximately $33.0 million for the fiscal year ended January&nbsp;2, 2022. We intend for these programs to mitigate the impact of foreign currency exchange rate fluctuations related to intercompany loans in current and future periods. Therefore,
effective January 4, 2021, we no longer exclude non-cash unrealized gains and losses from Adjusted EBITDA. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents miscellaneous other adjustments related to unusual items impacting our results, including Principal
Shareholder management fees of $3.0 million in each of the fiscal years ended January 2, 2022 and January 3, 2021; noncash derivative mark-to-market losses of $0.4 million and $1.5 million during the fiscal years ended January 2, 2022 and January 3,
2021, respectively; costs related to our executive leadership reorganization, initiated in fiscal year 2019, of $1.0 million and $3.5 million during the fiscal years ended January 2, 2022 and January 3, 2021, respectively; and other individually
immaterial adjustments. </P></TD></TR></TABLE>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables reconcile Net loss to Adjusted EBITDA and Management EBITDA for fiscal years ended
January&nbsp;3, 2021 and December&nbsp;29, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>($ in millions)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;3,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;29,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(211.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(156.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized foreign currency exchanges losses
(gains)<SUP STYLE="font-size:85%; vertical-align:top">(a)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restructuring and severance-related
costs<SUP STYLE="font-size:85%; vertical-align:top">(b)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt refinancing costs and loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation<SUP STYLE="font-size:85%; vertical-align:top">(c)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax indemnification expense, net<SUP STYLE="font-size:85%; vertical-align:top">(d)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs related to Ortho&#146;s initial public
offering<SUP STYLE="font-size:85%; vertical-align:top">(e)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EU medical device regulation transition
costs<SUP STYLE="font-size:85%; vertical-align:top">(f)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other adjustments<SUP STYLE="font-size:85%; vertical-align:top">(g)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">448.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">477.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management adjustments and realized foreign exchange losses<SUP
STYLE="font-size:85%; vertical-align:top">(h)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">519.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">502.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents noncash unrealized gains and losses resulting from the remeasurement of transactions denominated in
foreign currencies primarily related to intercompany loans. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents restructuring and severance costs related to several discrete initiatives intended to strengthen
operational performance and to support building our commercial capabilities including a project announced in fiscal year ended January&nbsp;3, 2016 to outsource equipment manufacturing operations in Rochester, New York and a project announced in
fiscal year ended December&nbsp;30, 2018 to transfer certain production lines among facilities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents stock-based compensation expense including the $14.7&nbsp;million modification impact of a 2019
amendment to our stock option agreement, where performance-based options that did not previously vest based on applicable minimum earnings targets will vest over a specified future period of time. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the reversal of the impact of tax indemnification income with Johnson&nbsp;&amp; Johnson, primarily
related to certain state tax matters, for which we recorded a tax reserve and indemnification. These state tax matters primarily include the taxability of the sale of our assets on the Acquisition date from Johnson&nbsp;&amp; Johnson. Additionally,
during the second quarter ended June&nbsp;30, 2019, we recorded indemnification expense related to the release of certain tax reserves upon the settlement of certain state tax matters that were settled for an amount lower than what we had estimated.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents costs incurred in connection with our initial public offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">European Medical Device Regulation costs represent incremental consulting costs and R&amp;D manufacturing site
costs for our previously registered products under the In Vitro Diagnostic Regulation (&#147;IVDR&#148;) to align existing, on-market products, with the revised expectations under the IVDR. IVDR is a replacement of the existing European In Vitro
Diagnostics Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU IVDR beginning in May 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents miscellaneous other adjustments related to unusual items impacting our results, including Principal
Shareholder management fees of $3.0 million and $3.1 million fiscal years ended January 3, 2021 and December 29, 2019, respectively; noncash derivative mark-to-market losses of $1.5 million and $16.0 million during the fiscal years ended January 3,
2021 and December 29, 2019, respectively; costs related to our executive leadership reorganization, initiated in fiscal year 2019, of $3.5 million and $6.7 million during the fiscal years ended January 3, 2021 and December 29, 2019, respectively;
and other individually immaterial adjustments. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents realized foreign currency losses (gains), impact from adoption of accounting standards, costs in
connection with COVID-19 and other immaterial management adjustments. </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_129"></A>Segment Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Fiscal year ended January 2, 2022 compared with fiscal year ended January 3, 2021</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key indicators that we monitor are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Net revenue&#151;This measure is discussed in the section entitled &#147;Results of Operations.&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adjusted EBITDA&#151;Adjusted EBITDA by reportable segment is used by our management to measure and evaluate the
internal operating performance of our segments. It is also the basis for calculating certain management incentive compensation programs. We believe that this measurement is useful to investors as a way to analyze the underlying trends in our core
business, including at the segment level, consistently across the periods presented and also to evaluate performance under management incentive compensation programs. In fiscal year 2021, we changed the basis by which we measure segment profit or
loss from Management EBITDA to Adjusted EBITDA. The new basis has been retroactively applied to the prior year comparable period presented. </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>($ in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B><br><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Segment net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Americas<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,228.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,067.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">15.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EMEA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greater China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,042.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,766.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">15.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Americas segment revenue includes <FONT STYLE="white-space:nowrap">non-core</FONT> revenue.
</P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>($ in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B><br><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Segment Adjusted EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Americas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">516.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">463.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">11.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EMEA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greater China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(241.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(222.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Adjusted EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">548.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">448.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">22.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Americas </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net revenue was $1,228.9&nbsp;million for the fiscal year ended January&nbsp;2, 2022 compared to net revenue of $1,067.3&nbsp;million for the fiscal year ended
January&nbsp;3, 2021, including a decrease in sales of $10.0&nbsp;million from our <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody and antigen tests. The increase of $161.6&nbsp;million, or 15.1%, which included operational net revenue
growth of 14.8% and a positive impact of 0.4% from foreign currency fluctuations, was primarily due to higher reagent and instrument revenues in our Clinical Laboratories business, a new customer in our Donor Screening business in the United States,
grant revenue related to development of our <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody and antigen tests and an $8.5&nbsp;million award from an arbitration proceeding related to one of our collaboration agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA was $516.6&nbsp;million for the fiscal year ended January&nbsp;2, 2022 compared to Adjusted EBITDA of $463.1&nbsp;million for the fiscal year
ended January&nbsp;3, 2021. The increase of $53.5&nbsp;million, or 11.6%, was primarily due to higher revenues, partially offset by increased employee-related costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EMEA </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net revenue was $276.3&nbsp;million for the
fiscal year ended January&nbsp;2, 2022 compared to net revenue of $240.6&nbsp;million for the fiscal year ended January&nbsp;3, 2021, including incremental sales of $4.6&nbsp;million from our <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody
and antigen tests. The increase of $35.7&nbsp;million, or 14.8%, which included operational net revenue growth of 11.5% and a positive impact of 3.4% from foreign currency fluctuations, was primarily due to higher reagent revenue and, to a lesser
extent, instrument sales in our Clinical Laboratories business, and higher reagent revenue in our Immunohematology business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA was
$63.9&nbsp;million for the fiscal year ended January&nbsp;2, 2022 compared to Adjusted EBITDA of $41.9&nbsp;million for the fiscal year ended January&nbsp;3, 2021. The increase of $22.0&nbsp;million, or 52.4%, was primarily due to higher revenues,
partially offset by increased employee-related costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Greater China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net revenue was $274.4&nbsp;million for the fiscal year ended January&nbsp;2, 2022 compared to net revenue of $229.6&nbsp;million for the fiscal year ended
January&nbsp;3, 2021. The increase of $44.8&nbsp;million, or 19.5%, which included operational net revenue growth of 12.3% and a positive impact of 7.2% from foreign currency fluctuations, was primarily due to higher reagent revenue in both our
Clinical Laboratories and Immunohematology businesses, partially offset by lower instrument sales in our Clinical Laboratories business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA
was $129.2&nbsp;million for the fiscal year ended January&nbsp;2, 2022 compared to Adjusted EBITDA of $108.0&nbsp;million for the fiscal year ended January&nbsp;3, 2021. The increase of $21.2&nbsp;million, or 19.7%, was primarily due to higher
revenues, partially offset by increased employee-related costs and government subsidies received in the prior year period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net revenue was $263.2&nbsp;million for the fiscal year ended January&nbsp;2, 2022 compared to net revenue of $228.7&nbsp;million for the fiscal year ended
January&nbsp;3, 2021. The increase of $34.5&nbsp;million, or 15.1%, which included operational net revenue growth of 16.2% and a negative impact of 1.1% from foreign currency fluctuations, was primarily due to higher reagent revenue in our Clinical
Laboratories and Transfusion Medicine businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA was $79.9&nbsp;million for the fiscal year ended January&nbsp;2, 2022 compared to
Adjusted EBITDA of $65.9&nbsp;million for the fiscal year ended January&nbsp;3, 2021. The increase of $14.0&nbsp;million, or 21.3%, was primarily due to higher revenues, partially offset by increased employee-related and distribution costs. </P>
  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fiscal year ended January&nbsp;3, 2021 compared with fiscal year ended December 29, 2019 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key indicators that we monitored were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Net revenue&#151;This measure is discussed in the section entitled &#147;Results of Operations.&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Management EBITDA&#151;Management EBITDA by reportable segment was used by our management to measure and evaluate
the internal operating performance of our segments. It was also the basis for calculating certain </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
management incentive compensation programs. Management EBITDA was our Adjusted EBITDA further adjusted for other items including realized foreign currency gains and losses, impact from adoption
of accounting standards, costs in connection with COVID-19 and other immaterial management adjustments. We believe that this measurement was useful to investors as a way to analyze the underlying trends in our core business, including at the segment
level, consistently across the periods presented and also to evaluate performance under management incentive compensation programs. Effective January&nbsp;4, 2021, we changed our basis for which we measure segment profit or loss from Management
EBITDA to Adjusted EBITDA. However, it is impracticable for us to retroactively recast our segment results for fiscal year 2019. Accordingly, fiscal year 2020 and 2019 segment results have been presented below on our former profit or loss basis for
comparability. </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>($ in millions)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;29,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Segment net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Americas<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,067.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,042.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EMEA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greater China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13.7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,766.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,801.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Americas segment revenue includes non-core revenue. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>($ in millions)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;3,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;29,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B><br><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Segment Management EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Americas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">486.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">418.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EMEA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greater China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(199.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(177.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Management EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">519.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">502.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Americas </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net revenue was $1,067.3&nbsp;million for the fiscal year ended January&nbsp;3, 2021 compared to net revenue of $1,042.5&nbsp;million for the fiscal year ended
December&nbsp;29, 2019. The increase of $24.8&nbsp;million, or 2.4%, which included operational net revenue growth of 4.1% partially offset by a negative impact of 1.7% from foreign currency fluctuations, was primarily due to higher Clinical
Laboratories revenue in the North America region related to sales of our <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody tests and other assays, instrument sales and grant revenue related to development of our <FONT
STYLE="white-space:nowrap">COVID-19</FONT> antibody and antigen tests. These increases were partially offset by decreased shipments to customers in the North America region in the Transfusion Medicine business and in the LATAM region for both the
Clinical Laboratories and Transfusion Medicine businesses as a result of the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management EBITDA was $486.8&nbsp;million for the fiscal year ended January&nbsp;3, 2021 compared to Management EBITDA of $418.4&nbsp;million for the fiscal
year ended December&nbsp;29, 2019. The increase of $68.4&nbsp;million, or 16.3%, was primarily due to higher revenues in the North America region, lower employee-related costs and lower travel-related costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EMEA </I></B></P>   <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net revenue was $240.6&nbsp;million
for the fiscal year ended January&nbsp;3, 2021 compared to net revenue of $251.5&nbsp;million for the fiscal year ended December&nbsp;29, 2019. The decrease of $10.9&nbsp;million, or 4.3%, which included operational net revenue declines of 5.3%
partially offset by a positive impact of 1.0% from foreign currency fluctuations, was primarily due to decreased shipments to customers as a result of the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management EBITDA was $50.9&nbsp;million for the fiscal year ended January&nbsp;3, 2021 compared to
Management EBITDA of $54.9&nbsp;million for the fiscal year ended December&nbsp;29, 2019. The decrease of $4.0&nbsp;million, or 7.3%, was primarily due to decreased shipments to customers as a result of the global
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, partially offset by lower employee-related costs and lower travel-related costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Greater
China </I></B></P>   <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net revenue was $229.6&nbsp;million for the fiscal year ended January&nbsp;3, 2021 compared to net revenue of $242.5&nbsp;million
for the fiscal year ended December&nbsp;29, 2019. The decrease of $12.9&nbsp;million, or 5.3%, which included operational net revenue declines of 6.0% partially offset by a positive impact of 0.7% from foreign currency fluctuations, was primarily
due to decreased shipments to customers as a result of the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management EBITDA
was $107.3&nbsp;million for the fiscal year ended January&nbsp;3, 2021 compared to Management EBITDA of $118.4&nbsp;million for the fiscal year ended December&nbsp;29, 2019. The decrease of $11.1&nbsp;million, or 9.4%, was primarily due to decreased
shipments to customers as a result of the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, partially offset by lower travel-related costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other </I></B></P>   <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net revenue was
$228.7&nbsp;million for the fiscal year ended January&nbsp;3, 2021 compared to net revenue of $265.0&nbsp;million for the fiscal year ended December&nbsp;29, 2019. The decrease of $36.3&nbsp;million, or 13.7%, which included operational net revenue
declines of 14.0% partially offset by a positive impact of 0.3% from foreign currency fluctuations, was primarily due to decreased shipments to customers as a result of the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic as well as
the lower revenue related to a supply agreement in our HCV business in the Japan region. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management EBITDA was $73.5&nbsp;million for the fiscal
year ended January&nbsp;3, 2021 compared to Management EBITDA of $88.8&nbsp;million for the fiscal year ended December&nbsp;29, 2019. The decrease of $15.3&nbsp;million, or 17.2%, was primarily due to decreased shipments to customers as a result of
the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic as well as lower revenue related to a supply agreement in our HCV business in the Japan region, partially offset by lower employee-related costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_130"></A>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;2, 2022 and January&nbsp;3, 2021, we had $309.7&nbsp;million and $132.8&nbsp;million of Cash and cash equivalents, respectively. As of
January&nbsp;2, 2022 and January&nbsp;3, 2021, $157.5&nbsp;million and $108.8&nbsp;million, respectively, of these Cash and cash equivalents were maintained in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, primarily held in foreign
currencies. We believe our organizational structure allows us the necessary flexibility to move funds throughout our subsidiaries to meet our operational working capital needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, until the Quidel Effective Time (as defined in the Business Combination Agreement) or termination of the Business Combination
Agreement in accordance with its terms, subject to certain specified exceptions, we are subject to a variety of restrictions as specified under the Business Combination Agreement. Unless Quidel approves in writing (which approval will not be
unreasonably withheld, conditioned or delayed, subject to certain exceptions), we may not, among other things, engage in another merger, restructuring or reorganization; incur indebtedness for borrowed money or issued debt securities, except for
borrowing in amounts not to exceed $25&nbsp;million in the aggregate (including pursuant to drawdowns of credit facilities outstanding on the date of the Business Combination Agreement) (excluding with respect to financing required in order to
consummate the Combinations); or lease, license, transfer, exchange or swap, mortgage, pledge, abandon, allow to lapse or otherwise dispose of any of our assets, except for dispositions individually or in the aggregate that have a fair market value
of less than $25&nbsp;million, transactions between us and any of our subsidiaries, or in the ordinary course of business. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Historical cash
flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents a summary of our net cash inflows (outflows) for the periods shown: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>($ in millions)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,</B><br><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;3,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;29,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">286.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">143.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Fiscal year ended January&nbsp;2, 2022 </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net cash flows provided by operating activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash
provided by operating activities was $286.6 million for the fiscal year ended January&nbsp;2, 2022. Factors resulting in Cash provided by operating activities included strong collections on Accounts receivable, as well as the impact of our new
receivables purchase agreement, cash inflows from earnings before interest, taxes, depreciation and amortization expense, and increase Accounts payable and accrued expenses. These increases were partially offset by the payment of interest on
borrowings of $132.1 million and increased investments in inventories of $139.5&nbsp;million, which includes $106.3 million of instrument inventories that were transferred from Inventories to Property, plant and equipment, net, related to customer
leased instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net cash flows used in investing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities was $43.6&nbsp;million for the fiscal year ended January&nbsp;2, 2022. The primary factor resulting in Cash used in
investing activities was Purchases of property, plant and equipment during the fiscal year ended January&nbsp;2, 2022 of $58.4&nbsp;million, partially offset by proceeds of $15.2&nbsp;million related to the net settlement of our terminated cross
currency swaps. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net cash flows used in financing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in financing activities was $74.7&nbsp;million for the fiscal year ended January&nbsp;2, 2022. During the fiscal year ended January&nbsp;2, 2022,
payments on long-term borrowings of $1,423.0&nbsp;million and payments on short-term borrowings, net of $82.0&nbsp;million, including the repayment of the outstanding balance of our Financing Program, were partially offset by net proceeds from our
initial public offering of $1,426.4&nbsp;million. </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Fiscal year ended
January&nbsp;3, 2021 </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net cash flows provided by operating activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by operating activities was $46.1&nbsp;million for the fiscal year ended January&nbsp;3, 2021. Factors resulting in cash provided by
operating activities included cash inflows from earnings before interest, taxes, depreciation and amortization expense and other noncash items and lower accounts receivable of $33.3&nbsp;million, partially offset by interest paid on borrowings of
$191.8&nbsp;million, net investment in inventories of $152.0&nbsp;million, which includes $132.3&nbsp;million of instrument inventories that were transferred from &#147;Inventories&#148; to &#147;Property, plant and equipment, net&#148;. Net cash
provided by operating activities for fiscal year 2020 decreased $96.9&nbsp;million compared to fiscal year 2019 primarily due to the impact of the global pandemic. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net cash flows used in investing activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchases of
property, plant and equipment during the fiscal year ended January&nbsp;3, 2021 were $44.1&nbsp;million. As of January&nbsp;3, 2021 and December&nbsp;29, 2019, accounts payable and accrued liabilities included amounts related to purchases of
property, plant and equipment and capitalized <FONT STYLE="white-space:nowrap">internal-use</FONT> software costs, which totaled $11.4&nbsp;million and $14.1&nbsp;million, respectively. In addition to the capital expenditures of $44.1&nbsp;million,
we made noncash transfers of $132.3&nbsp;million of instrument inventories from &#147;Inventories&#148; to &#147;Property, plant and equipment, net&#148; further increasing our investment in property, plant and equipment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net cash flows provided by financing activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During
the fiscal year ended January&nbsp;3, 2021, net proceeds from the issuance of the 2025 Notes, 2028 Notes and Euro Term Loan Facility of $1,421.0&nbsp;million were offset by payments on the 2022 Notes of $1,363.5&nbsp;million. Net payments on
short-term borrowings were $3.5&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Fiscal year ended December&nbsp;29, 2019 </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net cash flows provided by operating activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash
provided by operating activities was $143.0&nbsp;million for the fiscal year ended December&nbsp;29, 2019. Factors resulting in cash provided by operating activities included cash inflows from earnings before interest, taxes, depreciation and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amortization expense and other noncash items and higher accounts payable and accrued liabilities of $83.6&nbsp;million, partially offset by interest paid on borrowings of $189.7&nbsp;million, net
investment in inventories of $108.6&nbsp;million, which includes $118.6&nbsp;million of instrument inventories that were transferred from &#147;Inventories&#148; to &#147;Property, plant and equipment, net&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net cash flows used in investing activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchases of
property, plant and equipment during the fiscal year ended December&nbsp;29, 2019 were $66.2&nbsp;million. As of December&nbsp;29, 2019 and December&nbsp;30, 2018, accounts payable and accrued liabilities included amounts related to purchases of
property, plant and equipment and capitalized <FONT STYLE="white-space:nowrap">internal-use</FONT> software costs, which totaled $14.1&nbsp;million and $17.2&nbsp;million, respectively. In addition to the capital expenditures of $66.2&nbsp;million,
we made noncash transfers of $118.6&nbsp;million of instrument inventories from &#147;Inventories&#148; to &#147;Property, plant and equipment, net&#148; further increasing our investment in property, plant and equipment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net cash flows used in financing activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash
used in financing activities was $64.4&nbsp;million for the fiscal year ended December&nbsp;29, 2019 and was primarily related to net short-term borrowings payments of $17.2&nbsp;million and payments on long-term debt of $49.7&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt capitalization </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
details our debt outstanding as of January&nbsp;2, 2022 and January&nbsp;3, 2021: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>($ in millions)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Secured Credit Facilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dollar Term Loan Facility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,292.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,185.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Euro Term Loan Facility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revolving Credit Facility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">675.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts Receivable Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale and Leaseback Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other short-term borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized deferred financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized original issue discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,250.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,718.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(160.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,186.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,558.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;2, 2022 and January&nbsp;3, 2021, there were no outstanding borrowings under the Revolving Credit
Facility. As of January&nbsp;2, 2022 and January&nbsp;3, 2021, letters of credit issued under the Revolving Credit Facility totaled $46.3&nbsp;million and $37.5&nbsp;million, respectively, which reduced the availability under the Revolving Credit
Facility. Availability under the Revolving Credit Facility was $453.7&nbsp;million and $312.5&nbsp;million as of January&nbsp;2, 2022 and January&nbsp;3, 2021, respectively. Our debt agreements contain various covenants that may restrict our ability
to borrow on available credit facilities and future financing arrangements or require us to remain below a specific credit coverage threshold. We believe that we are and will continue to be in compliance with these covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2021, we entered into a fifth amendment to the Credit Agreement, which increased the Revolving Credit Facility contained in the credit
agreement by $150&nbsp;million to an aggregate amount of $500&nbsp;million and extended the maturity date to February&nbsp;5, 2026, provided that such date may be accelerated subject to certain circumstances as set forth in the fifth amendment. To
the extent that the aggregate principal amount of the Dollar Term Loan Facility and Euro Term Loan Facility (and any Refinancing Indebtedness (as defined in the Credit Agreement) with respect thereto that matures on or prior to June&nbsp;30, 2025)
outstanding as of March&nbsp;31, 2025 exceeds $500&nbsp;million then the maturity date with respect to the Revolving Credit Facility shall be March&nbsp;31, 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;24, 2021, we entered into a sixth amendment to the Senior Secured Credit Facilities to
account for the cessation of LIBOR for Sterling, Euros and Japanese Yen and the alternative replacement rates with respect to such currencies, as applicable. All other terms of the Senior Secured Credit Facilities remain substantially the same
except as otherwise amended by the fifth and sixth amendments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2021 and February&nbsp;9, 2021, we used a portion of the proceeds from
the Ortho IPO to repay $706.6&nbsp;million and $186.1&nbsp;million, respectively, of borrowings under the Dollar Term Loan Facility. In aggregate, we repaid $892.7&nbsp;million of borrowings under the Dollar Term Loan Facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;2, 2022 and January&nbsp;3, 2021, the remaining balance of deferred financing costs related to the Dollar Term Loan Facility was
$8.1&nbsp;million and $17.3&nbsp;million, respectively. As of January&nbsp;2, 2022 and January&nbsp;3, 2021, the remaining balance of deferred financing costs related to the Euro Term Loan Facility was $3.6&nbsp;million and $4.6&nbsp;million,
respectively. As of January&nbsp;2, 2022 and January&nbsp;3, 2021, the remaining unamortized balance related to the Revolving Credit Facility was $2.7&nbsp;million and $3.4&nbsp;million, respectively. The effective interest rate of the Term Loan as
of January&nbsp;2, 2022 is 5.74%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;27, 2020, we issued $675&nbsp;million aggregate principal amount of the 2028 Notes, which bear interest
at a rate of 7.250% per annum payable semi-annually in arrears on February&nbsp;1 and August&nbsp;1 of each year. The 2028 Notes will mature on February&nbsp;1, 2028. The 2028 Notes and guarantees thereof are our senior unsecured obligations and the
2028 Notes and the guarantees rank equally in right of payment with all of the Lux <FONT STYLE="white-space:nowrap">Co-Issuer&#146;s</FONT> and U.S. <FONT STYLE="white-space:nowrap">Co-Issuer&#146;s</FONT> (together, the &#147;Issuers&#148;) and
guarantors&#146; existing and future senior debt, including the 2025 Notes. The 2028 Notes and the guarantees thereof are effectively subordinated to any of the Issuers&#146; and guarantors&#146; existing and future secured debt, including the
Senior Secured Credit Facilities, to the extent of the value of the assets securing such debt. In addition, the 2028 Notes and the guarantees thereof rank senior in right of payment to all of the Issuers&#146; and guarantors&#146; future
subordinated debt and will be structurally subordinated to the liabilities of our <FONT STYLE="white-space:nowrap">non-guarantor</FONT> subsidiaries. We incurred deferred financing costs of $12.9&nbsp;million related to the 2028 Notes, which were
capitalized as deferred financing costs and are being amortized using the effective interest method as a component of interest expense over the life of the 2028 Notes. On February&nbsp;5, 2021, we used a portion of the proceeds from the Ortho IPO to
redeem $270&nbsp;million aggregate principal amount of the 2028 Notes, plus accrued interest thereon and $19.6&nbsp;million of redemption premium. The redemption resulted in an extinguishment loss recognized of $24.3&nbsp;million during the fiscal
year ended January&nbsp;2, 2022, which consisted of $4.7&nbsp;million of unamortized deferred issuance costs and $19.6&nbsp;million of redemption premium. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the issuance of the 2028 Notes, we entered into a $350&nbsp;million U.S. dollar equivalent swap to Japanese
<FONT STYLE="white-space:nowrap">Yen-denominated</FONT> interest at a weighted average rate of 5.56%, for a five-year term. We terminated the cross currency swaps on April&nbsp;1, 2021 and received $12.8&nbsp;million of cash from net settlement in
the year ended January&nbsp;2, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;11, 2020, we issued $400&nbsp;million aggregate principal amount of the 2025 Notes, which bear interest
at a rate of 7.375% per annum, payable semi-annually in arrears on June&nbsp;1 and December&nbsp;1 of each year. The 2025 Notes will mature on June&nbsp;1, 2025. The 2025 Notes and the guarantees thereof are our unsecured obligations and the 2025
Notes and the guarantees thereof rank equally in right of payment with all of the Issuers&#146; and guarantors&#146; existing and future senior debt, including the 2028 Notes. The 2025 Notes and the guarantees thereof are effectively subordinated to
any of the Issuers&#146; and guarantors&#146; existing and future secured debt, including the Senior Secured Credit Facilities, to the extent of the value of the assets securing such debt. In addition, the 2025 Notes and the guarantees thereof rank
senior in right of payment to all of the Issuers&#146; and guarantors&#146; future subordinated debt and will be structurally subordinated to the liabilities of the Issuers&#146; <FONT STYLE="white-space:nowrap">non-guarantor</FONT> subsidiaries. We
incurred deferred financing costs of $7.5&nbsp;million related to the 2025 Notes, which were capitalized as deferred financing costs and are being amortized using the effective interest method as a component of interest expense over the life of the
2025 Notes. On February&nbsp;5, 2021, we used a portion of the proceeds from the Ortho IPO to redeem $160&nbsp;million aggregate principal amount of the 2025 Notes, plus accrued interest thereon and $11.8&nbsp;million of redemption premium. The
redemption resulted in an extinguishment loss recognized of $14.5 million for the fiscal year ended January 2, 2022, which consisted of $2.7 million of unamortized deferred issuance costs and $11.8 million of redemption premium. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2016, we entered into an accounts receivable financing program (the &#147;Financing Program&#148;) with a financial institution. The Financing
Program, which was fully paid off in June 2021 in connection with entry into the RPA (as defined below), was set to mature on January&nbsp;24, 2022 and was secured by receivables from our U.S. business that are sold or contributed to a wholly owned,
consolidated, bankruptcy remote subsidiary. The bankruptcy remote subsidiary&#146;s sole business consists of the purchase or receipt of the receivables and subsequent granting of a security interest to the financial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
institution under the program, and its assets were available first to satisfy obligations and were not available to pay creditors of our other legal entities. Under the Financing Program, we
could borrow up to the lower of $75.0&nbsp;million or 85% of the accounts receivable borrowing base. Interest on outstanding borrowings under the Financing Program was charged based on a per annum rate equal to the London Inter-bank Offered Rate
(the &#147;LIBOR Rate&#148;) (with a floor of zero percent and as defined in the agreement) plus the LIBOR Rate margin (2.25 percentage points) if the related loan was a LIBOR Rate loan. Otherwise, the per annum rate was equal to a Base Rate (as
defined in the Financing Program agreement) plus the base rate margin (1.25 percentage points). Interest was due and payable, in arrears, on the first day of each month. The Financing Program was also subject to termination under standard events of
default as defined. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;11, 2021, Ortho-Clinical Diagnostics FinanceCo I, LLC (&#147;Ortho FinanceCo I&#148;), a wholly owned receivables
financing subsidiary of us, entered into a receivables purchase agreement (the &#147;RPA&#148;) with Wells Fargo, N.A., as administrative agent (the &#147;Agent&#148;), and certain purchasers. Under the RPA, Ortho FinanceCo I may sell receivables in
amounts up to a $75.0&nbsp;million limit, subject to certain conditions, including that, at any date of determination, the aggregate capital paid to Ortho FinanceCo I does not exceed a &#147;capital coverage amount,&#148; equal to an adjusted net
receivables pool balance minus a required reserve. Ortho FinanceCo I has guaranteed the prompt payment of the sold receivables, and to secure the prompt payment and performance of such guaranteed obligations, Ortho FinanceCo I has granted a security
interest to the Agent, for the benefit of the purchasers, in all assets of Ortho FinanceCo I. We, in our capacity as master servicer under the RPA, are responsible for administering and collecting the receivables and have made customary
representations, warranties, covenants and indemnities. We have also provided a performance guarantee for the benefit of Ortho FinanceCo I to cause the due and punctual performance by us of our obligations as master servicer. The proceeds of the RPA
were used, in part, to pay off the outstanding balance of the Financing Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We or our affiliates, including investment funds affiliated with
Carlyle, at any time and from time to time, may purchase Senior Notes or our other indebtedness. Any such purchases may be made through the open market or privately negotiated transactions with third parties or pursuant to one or more tender or
exchange offers or otherwise, upon such terms and at such prices, as well as with such consideration, as we, or any of our affiliates, may determine. Such purchases could result in a change to the allocation between the Issuers of the indebtedness
represented by the Senior Notes and could have important tax consequences for holders of the Senior Notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restructuring activities </I></B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have previously undertaken several initiatives intended to strengthen operational performance and to support building our capabilities to enable us to
win in the marketplace. These activities to improve operational performance are primarily cost reduction and productivity improvement initiatives in procurement, manufacturing, supply chain and logistics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal year ended January&nbsp;3, 2016, we announced that we will outsource our equipment manufacturing operations in Rochester, New York and
refurbishment operations in Neckargemund, Germany to a third-party contract manufacturing company. These initiatives were substantially completed during the fiscal year ended December&nbsp;29, 2019, with total cumulative charges incurred of
$75.4&nbsp;million. We made cash payments of $6.5&nbsp;million during the fiscal year ended January&nbsp;3, 2021, and made cumulative cash payments of $71.1&nbsp;million to date, as of January 2, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal year ended December&nbsp;30, 2018, we announced that we will transfer certain production lines among facilities in order to achieve
operational and cost efficiencies. These initiatives were substantially completed during fiscal 2021. We have incurred net charges of $19.5&nbsp;million cumulative to date comprised of $13.3&nbsp;million in accelerated depreciation and
$6.2&nbsp;million in severance and other facility related costs. We have made cumulative cash payments of $15.4&nbsp;million related to these initiatives, including $9.4 million cumulative to date for capital expenditures through January&nbsp;2,
2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information on our restructuring activities, see Note 12, &#147;Restructuring costs,&#148; to our audited consolidated financial
statements incorporated by reference into this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outlook </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Short-term liquidity outlook </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that our cash
and cash equivalents, cash flows from operations and amounts available under the Revolving Credit Facility will be sufficient to meet debt service requirements, working capital requirements, and capital expenditures for the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
next 12 months from the date of this joint proxy statement/prospectus. Our ability to make scheduled payments of principal or interest on, or to refinance, our indebtedness or to fund working
capital requirements, capital expenditures and other current obligations will depend on our ability to generate cash from operations. Such cash generation is subject to general economic, financial, competitive, legislative, regulatory and other
factors that are beyond our control. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are focused on expanding the number of instruments placed in the field and solidifying long-term contractual
relationships with customers. In order to achieve this goal, in certain jurisdictions where it is permitted, we have leveraged a reagent rental model that has been recognized as more attractive to certain customers. In this model, we lease, rather
than sell, instruments to our customers. Over the term of the contract, the purchase price of the instrument is embedded in the price of the assays and reagents. Going forward, we intend to increase the number of reagent rental placements in
developed markets, a strategy that we believe is beneficial to our commercial goals because it lowers our customers&#146; upfront capital costs and therefore allows purchasing decisions to be made at the lab manager level. For these same reasons,
the reagent rental model also benefits our commercial strategy in emerging markets. We believe that the shift in our sales strategy will grow our installed base, thereby increasing sales of higher-margin assays, reagents and other consumables over
the life of the customer contracts and enhancing our recurring revenue and cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal year ended January 2, 2022, we transferred
$106.3 million of instrument inventories from Inventories to Property, plant and equipment, further increasing our investment in property, plant and equipment. We currently estimate that we will transfer additional instrument inventories of
approximately $135 million during fiscal year 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to make contributions of $1.9 million to our defined benefit plans in fiscal 2022. The
amount of any contributions is dependent on the future economic environment and investment returns, and we are unable to reasonably estimate pension contributions beyond fiscal 2022. See Note 14, &#147;Long-term employee benefits&#148; to our
audited consolidated financial statements incorporated by reference into this joint proxy statement/prospectus for further discussion of our defined benefit plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January 2, 2022, we had approximately $232.4 million of purchase obligations, which includes agreements to purchase goods or services that is
enforceable and legally binding, and that specifies all significant terms, including (i) fixed or minimum quantities to be purchased, (ii) fixed, minimum or variable price provisions and (iii) the approximate timing of the transaction. We expect the
majority of the payments related to these purchase obligations to be made during fiscal year 2022. We entered into a consulting services agreement with an affiliate of Carlyle, which was amended on October 15, 2020. The agreement terminates upon the
earlier of (i) the second anniversary of our IPO and (ii) the date that Carlyle collectively and beneficially owns, directly or indirectly, less than ten percent (10%) of our outstanding voting securities. For a description of the agreement and our
obligations, see Note 20, &#147;Related party transactions&#148; to our audited consolidated financial statements incorporated by reference into this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January 2, 2022, the total undiscounted future payments we expect to make in connection with our operating lease agreements was $30.7 million.
Approximately $13.7 million of these payments are expected to be made in fiscal year 2022. See Note 10, &#147;Leases&#148; to our audited consolidated financial statements incorporated by reference into this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our forecasts, we believe that cash flow from operations, available cash on hand and available borrowing capacity under our Revolving Credit Facility
will be sufficient to fund continuing operations for at least the next 12 months from the issuance date of this joint proxy statement/prospectus. Our debt agreements contain various covenants that may restrict our ability to borrow on available
credit facilities and future financing arrangements and require us to remain below a specific credit coverage threshold. Our credit agreement has a financial covenant (ratio of Net First Lien Secured Debt to Adjusted EBITDA not to exceed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">5.5-to-1,</FONT></FONT> subject to a 50 basis point step-down on September&nbsp;30, 2022) that is tested when borrowings and letters of credit issued under the Revolving Credit Facility
exceed 30% of the committed amount at any period end reporting date. As of and January&nbsp;2, 2022, we had no outstanding borrowings under our Revolving Credit Facility. Due to the current economic and business uncertainty resulting from the
ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, from time to time we may borrow from our Revolving Credit Facility, if needed, during fiscal year 2022. We believe that we will continue to comply with the financial covenant for the
next 12 months. In the event we do not comply with the financial covenant of the Revolving Credit Facility, the lenders will have the right to call on all of the borrowings under the Revolving Credit Facility. If the lenders on the Revolving Credit
Facility terminate their commitments and accelerate the loans, this would become a cross default to other material indebtedness. We believe that we will continue to be in compliance with these covenants. However, should it become necessary, we may
seek to raise additional capital within the next 12 months through borrowings on credit facilities, other financing activities and/or the private sale of equity securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Long-term liquidity outlook </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">UK Holdco is a holding company with no business operations or assets other than the capital stock of its direct and indirect subsidiaries and intercompany loan
receivables. Consequently, UK Holdco is dependent on loans, dividends, interest and other payments from its subsidiaries to make principal and interest payments on our indebtedness, meet working capital requirements and make capital expenditures. As
presently structured, its operating subsidiaries are the sole source of cash for such payments and there is no assurance that the cash for those interest payments will be available. We believe our organizational structure will allow the necessary
flexibility to move funds throughout our subsidiaries to meet our operational working capital needs. In the future, the Issuers and borrowers under our Senior Secured Credit Facilities may also need to refinance all or a portion of the borrowings
under the Senior Notes and the Senior Secured Credit Facilities on or prior to maturity. If refinancing is necessary, there can be no assurance that we will be able to secure such financing on acceptable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have milestone payment obligations to partners and suppliers which are contingent on regulatory approval. Future launch-related milestone payments of up to
$60.0&nbsp;million may be owed to Quotient for MosaiQ, however the future timing of when such payments would be made, if ever, is unclear at this time. See Note 13, &#147;Collaborations and other relationships,&#148; to our audited consolidated
financial statements incorporated by reference into this joint proxy statement/prospectus for further discussion of the Quotient relationship. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
January&nbsp;2, 2022, we had approximately $27.9&nbsp;million of uncertain tax positions, not including interest and penalties. Due to the high degree of uncertainty regarding future timing of cash flows associated with these liabilities, we are
unable to estimate the years in which settlement will occur with the respective taxing authorities. These amounts have been excluded from the above table. See Note 16, &#147;Income taxes,&#148; to our audited consolidated financial statements
incorporated by reference into this joint proxy statement/prospectus for further discussion of our tax obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to make payments on and
to refinance our indebtedness and to fund planned capital expenditures will depend on our ability to generate cash in the future. This is subject to general economic, financial, competitive, legislative, regulatory and other factors that are beyond
our control as well as the factors described in &#147;Risk Factors&#148; and &#147;Cautionary Statement Concerning Forward-Looking Statements&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding
new accounting pronouncements is included in Note 3, &#147;Summary of significant accounting policies,&#148; to our audited consolidated financial statements incorporated by reference into this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business and financial results are affected by fluctuations in world financial markets, including interest rates and currency exchange rates. We manage
these risks through normal operating and financing activities and, when deemed appropriate, through the use of derivative financial instruments. We have policies governing our use of derivative instruments, and we do not enter into financial
instruments for trading or speculative purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest rate risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to interest rate market risk in connection with our long-term debt. Our principal interest exposure will relate to outstanding amounts under our
Senior Secured Credit Facilities. Our Senior Secured Credit Facilities provide for variable rate borrowings of up to $2,325.0 million under the Dollar Term Loan Facility, &#128;337.4 million under the Euro Term Loan Facility and $500.0 million under
our Revolving Credit Facility. Assuming our Senior Secured Credit Facilities are fully drawn (and to the extent that LIBOR is in excess of the 0.00% floor rate of our Senior Secured Credit Facilities), each one-eighth percentage point increase or
decrease in the applicable interest rates would correspondingly change our interest expense on our Senior Secured Credit Facilities by approximately $2.6 million per year before considering the impact of derivative instruments. For further
discussion of the risks related to our Senior Secured Credit Facilities, see &#147;Risk Factors&#151;Risks Relating to Ortho&#146;s Business&#151;Risks Relating to Ortho&#146;s Indebtedness&#151;Ortho&#146;s substantial indebtedness could adversely
affect Ortho&#146;s financial condition, limit Ortho&#146;s ability to raise additional capital to fund its operations and prevent Ortho from fulfilling our obligations under its indebtedness.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We selectively use derivative instruments to reduce market risk associated with changes in interest
rates. The use of derivatives is intended for hedging purposes only and we do not enter into derivative instruments for speculative purposes. As of January&nbsp;2, 2022, we have an interest rate cap agreement to hedge our interest rate exposures
related to our variable rate borrowings under the Senior Secured Credit Facilities with an interest rate cap amount of 3.5%, with caplets that mature through December 31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also entered into an interest rate swap agreement, which fixed a portion of the variable interest due on our variable rate debt. Under the terms of
the agreement, we will pay a fixed rate of 1.635% and receive a variable rate of interest based on one-month LIBOR (as defined) from the counterparty which is reset every month through December&nbsp;31, 2023. As of January&nbsp;2, 2022, the notional
amount of the interest rate swap was $1,500 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notional value of these instruments is expected to be $1,000 million in fiscal 2022 and $500
million in fiscal 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign exchange rates risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to foreign currency risk by virtue of our international operations. We derived approximately 50% of our revenue for the fiscal year ended
January&nbsp;2, 2022 outside the U.S. For translation of operations in non-U.S. dollar currencies, the local currency of most entities is the functional currency. Our foreign assets and liabilities are translated into U.S. dollars at the exchange
rates existing at the respective balance sheet dates, and income and expense items are translated at the average exchange rate for each relevant period. Foreign exchange effects from the translation of our balance sheet resulted in a comprehensive
loss of $17.5 million for the fiscal year ended January&nbsp;2, 2022. Foreign exchange effects from the translation of our balance sheet resulted in a comprehensive gain of $59.4 million for the fiscal year ended January&nbsp;3, 2021. Foreign
exchange effects from the translation of our balance sheet resulted in a comprehensive loss of $0.9 million for the fiscal year ended December&nbsp;29, 2019. Adjustments resulting from the re-measurement of transactions denominated in foreign
currencies other than the functional currency of our subsidiaries are expensed as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the majority of our jurisdictions, we earn revenue and
incur costs in the currency used in such jurisdiction. We incur significant costs in foreign currencies including Brazilian Real, British Pound, Chinese Yuan/Renminbi, Euro, Indian Rupee, Japanese Yen, Mexican Peso, and the Swiss Franc. As a result,
movements in exchange rates cause our revenue and expenses to fluctuate, impacting our profitability and cash flows. Future business operations and opportunities, including the continued expansion of our business outside North America, may further
increase the risk that cash flows resulting from these activities may be adversely affected by changes in currency exchange rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Like many
multi-national companies, we have exposure to the British Pound. We are negatively impacted by a lower British Pound exchange rate from translation impact when compared to the U.S. dollar, but we also benefit from expenses denominated in British
Pound, as well as some cross-border transactions at a lower exchange rate. The magnitude of the impact is dependent on our business volumes in the U.K., forward contract hedge positions, cross currency volume and the exchange rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, in order to fund the purchase price for the assets and capital stock of certain non-U.S. entities, a combination of equity contributions and
intercompany loans were utilized to capitalize certain non-U.S. subsidiaries. In many instances, the intercompany loans are denominated in currencies other than the functional currency of the affected subsidiaries. Where intercompany loans are not a
component of permanently invested capital of the affected subsidiaries, increases or decreases in the value of the subsidiaries&#146; functional currency against other currencies will affect our results of operations. During the fiscal year ended
January&nbsp;2, 2022, we recorded foreign currency exchange losses of $2.3 million. During the fiscal year ended January&nbsp;3, 2021, we recorded net foreign currency exchange losses of $69.5 million. During the fiscal year ended December&nbsp;29,
2019, we recorded net foreign currency exchange gains of $10.5 million. The foreign currency gains/losses in each period primarily consist of unrealized gains/losses related to intercompany loans denominated in currencies other than the functional
currency of the affected subsidiaries. We may enter into derivative instruments to manage our foreign currency exposure on these intercompany loans in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign exchange risk is also managed through the use of foreign currency debt. As of January&nbsp;2, 2022, &#128;260.0 million ($296.0 million) of our senior
secured Euro Term Loan Facility has been designated as, and is effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the
Euro-denominated debt instruments are included in foreign currency translation adjustments within accumulated other comprehensive income. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into foreign-currency forward contracts to manage our foreign currency exposures on
foreign currency denominated firm commitments and forecasted foreign currency denominated intercompany and third-party transactions. We had forward contracts outstanding with total notional amount of $638.2 million as of January&nbsp;2, 2022, with
maturity dates through October 2022. Foreign-currency forward contracts that qualified and were designated for hedge accounting are recorded at their fair value as of January&nbsp;2, 2022 and the unrealized gain of $1.4 million is reported as a
component of other comprehensive income, all of which is expected to be reclassified to earnings in the next 12 months. Actual gains (losses) upon settlement will be recognized in earnings, within the line item impacted, during the estimated time in
which the transactions are incurred. Actual losses upon settlement of $2.3 million were recognized in earnings during the fiscal year ended January&nbsp;2, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_132"></A>Critical Accounting Estimates and Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of our audited consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the
reported amounts of some assets and liabilities and, in some instances, the reported amounts of revenues and expenses during the applicable reporting period. Actual results could differ from these estimates. Management believes the accounting
estimates discussed below represent those accounting estimates requiring the exercise of judgment where a different set of judgments could result in the greatest changes to our reported results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue recognition </I></B></P>   <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is
recognized when obligations under the terms of a contract with a customer are satisfied; this occurs with the transfer of control of our goods or services. We consider revenue to be earned when all of the following criteria are met: we have a
contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or consideration we expect to receive for transferring the goods or providing services, is determinable;
and we have transferred control of the promised items to the customer. A promise in a contract to transfer a distinct good or service to the customer is identified as a performance obligation. A contract&#146;s transaction price is allocated to each
performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product revenue includes sales of consumable
supplies and test kits for equipment, sales and leases of instruments, as well as services related thereto. Revenue from sales of consumable supplies and test kits is generally recognized upon shipment or delivery based on the contractual shipping
terms of the respective customer contract. Revenue from instrument sales is generally recognized upon installation and customer acceptance. Service revenue on equipment and instrument maintenance contracts is recognized over the life of the service
arrangement or as services are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A portion of our revenue relates to equipment lease transactions with our customers. We evaluate these leases
to determine proper classification, which involves specific determinations and judgment. Revenue earned from operating leases is generally recognized on a straight-line basis over the lease term, which is normally five to seven years. Revenue earned
from sales-type leases is recognized at the beginning of the lease, as well as a lease receivable and unearned interest associated with the lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the
contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. We may also enter into transactions that involve multiple performance obligations, such as the sale of products and
related services. In accounting for these transactions, we allocate the consideration to the deliverables by use of the relative standalone selling price method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A portion of our product revenue includes revenue earned under reagent rental programs which provide customers the right to use instruments at no separate
cost to the customer in consideration for a multi-year agreement to purchase reagents, assays and consumables. We allocate a portion of the revenue from the future consumable sale to the instrument based on the customers&#146; minimum volume
commitment and recognize revenue at the time of the future sale of reagents, assays and consumables. The cost of the instrument is capitalized within property and equipment, and is charged to cost of product revenue on a straight-line basis over the
term of the minimum purchase agreement. Revenue earned from operating leases is recognized over the lease term, which is normally five to seven years. Revenue earned under sales-type leases is recognized at the beginning of the lease, as well as a
lease receivable and unearned interest associated with the lease. Revenue is recognized when control has transferred for the reagents, assays and consumables. Costs related to product sales are recognized at time of delivery. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize product revenues at the net sales price, which includes estimates of variable consideration
related to rebates and volume discounts. Rights of return are generally not included in our arrangements with customers. Our estimates of rebates and discounts are determined using the expected value method and take into consideration historical
experience, contractual and statutory requirements, and other relevant information such as forecasted activity. These reserves reflect our best estimate of the amount of consideration to which it is entitled. The amount of variable consideration
included in the net sales price is limited to the amount that is probable not to result in a significant future reversal of cumulative revenue under the contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We enter into collaboration arrangements that generate collaboration revenue and royalty revenue from license agreements. Revenue from collaborations is
presented &#147;gross&#148; where we are deemed the principal in the arrangement and &#147;net&#148; where we are deemed the agent in the arrangement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inventories </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventories are stated at the lower
of cost and net realizable value on a <FONT STYLE="white-space:nowrap">first-in,</FONT> <FONT STYLE="white-space:nowrap">first-out</FONT> method. Elements of cost include raw materials, direct labor and manufacturing overhead. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We periodically review inventory for both potential obsolescence and potential declines in anticipated selling prices. In this review, we make assumptions
about the future demand for and market value of the inventory and based upon these assumptions estimate the amount of any obsolete, unmarketable, slow moving or overvalued inventory. We write down the value of our inventories by an amount equal to
the difference between the cost of the inventory and the net realizable value. Historically, such write-downs have not been significant. If actual market conditions are less favorable than those projected by management at the time of the assessment,
however, additional inventory write-downs may be required, which could reduce our gross profit and earnings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Customer leased instruments
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Determining the economic life of our leased instruments requires significant accounting estimates and judgment. These estimates are based on our
historical experience and existing contractual terms. Our estimate of the economic life of our instruments is ten years. We depreciate these assets over the lesser of the useful economic life and the length of the contract, which typically ranges
between five and eight years. We believe these lives represent the periods during which the instruments are expected to be usable, with normal repairs and maintenance, for the purposes for which they are intended. We regularly evaluate the economic
life of existing and new products for purposes of this determination. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill represents costs in excess of fair values assigned to underlying net assets of acquired companies. We evaluate goodwill for impairment on an annual
basis in our fiscal fourth quarter, unless conditions exist that would require a more frequent evaluation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When testing goodwill for impairment, an
entity has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (more than 50%) that the fair value of a reporting unit is less than its
carrying amount. Such qualitative factors may include the following: macroeconomic conditions; industry and market considerations; cost factors; overall financial performance; and other relevant entity-specific events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we elect to perform a qualitative assessment and determine that an impairment is more likely than not, we will perform a quantitative impairment test,
otherwise no further analysis is required. We may also elect not to perform the qualitative assessment and, instead, proceed directly to performing the quantitative impairment test, under which the evaluation of impairment involves comparing the
current fair value of each reporting unit to its carrying value, including goodwill. The ultimate outcome of the goodwill impairment assessment for a reporting unit should be the same whether we choose to perform the qualitative assessment or
proceed directly to the quantitative impairment test. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the carrying amount of a reporting unit, including goodwill, exceeds the estimated fair value,
then we would record an impairment charge based on the excess of a reporting unit&#146;s carrying amount over its fair value (limited to the amount of goodwill). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate the fair value of our reporting units by using forecasts of discounted future cash flows and
peer market multiples. The inputs utilized in these analyses are classified as Level&nbsp;3 inputs within the fair value hierarchy as defined in ASC 820, <I>Fair Value Measurement</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process of evaluating the potential impairment of goodwill is subjective because it requires the use of estimates and assumptions as to our future cash
flows, which includes assumed revenue growth rates, long term growth rates and discount rates. Although we base cash flow forecasts on significant assumptions, including assumed revenue growth rates, long term growth rates and discount rates, that
are consistent with plans and estimates we use to manage our Company, there is significant judgment in determining the cash flows. We also consider revenue and earnings trading multiples of the peer companies that have similar financial
characteristics to the reporting units. Due to the inherent uncertainty in forecasting cash flows and earnings, actual future results may vary significantly from the forecasts. Based on the degree of uncertainty, we cannot quantify the potential
effect of the change in estimate on our results of operations and financial position. </P>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of long-lived assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process of evaluating the potential impairment of other long-lived assets, such as our property, plant and equipment and definite-lived intangible assets,
such as technology, tradenames and customer relationships, is subjective and requires judgment. We review long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.
This impairment test may be triggered by a decrease in the market price of a long-lived asset, an adverse change in the extent or manner in which the asset is being used, or a forecast of continuing losses associated with the use of the asset. If
the fair value is less than the asset&#146;s carrying amount, we recognize a loss for the difference. The fair value methodology used is an estimate of fair market value and is based on the discounted future cash flows of the asset or quoted market
prices of similar assets. Based on these assumptions and estimates, we determine whether we need an impairment charge to reduce the value of the asset stated on our balance sheet to reflect its estimated fair value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provision for income taxes was
determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.
The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the period. Deferred taxes result from differences between the financial and tax basis of our assets and liabilities
and are adjusted for changes in tax rates and tax laws when changes are enacted. Deferred tax assets are also recognized for operating losses and tax credit carryforwards. Valuation allowances are recorded to reduce deferred tax assets when it is
more likely than not that a tax benefit will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates applicable in the years in which they are expected to be recovered or settled. The effect on deferred tax assets
and liabilities of a change in tax law is recognized in income in the period that includes the enactment date. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not intend to permanently
reinvest earnings of foreign subsidiaries at this time. As such, we provide for income taxes and foreign withholding taxes, where applicable, on undistributed earnings. Any repatriation of undistributed earnings would be done at little or no tax
cost. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The breadth of our operations and the global complexity of tax regulations require assessments of uncertainties and judgments in estimating
taxes we will ultimately pay. The final taxes paid are dependent upon many factors, including negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of disputes arising from federal, state and
international tax audits in the normal course of business. A liability for uncertain tax positions is recorded when management concludes that the likelihood of sustaining such positions upon examination by taxing authorities is less than &#147;more
likely than not.&#148; Interest and penalties accrued related to unrecognized tax benefits are included in the provision for taxes on income. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based
compensation, comprised of UK Holdco stock options and restricted shares, is measured at fair value on the grant date or date of modification, as applicable. Determining the amount of stock-based compensation expense to be recorded requires us to
develop estimates to be used in calculating the grant-date fair value of stock options. Our valuation model requires us to make estimates of the following assumptions: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair value of our ordinary shares</I>&#151;<I></I>Prior to Ortho&#146;s initial public offering in
January 2021, the valuation of our ordinary shares was determined in accordance with the guidelines outlined in the American Institute of Certified Public Accountants, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation.
</I>We considered numerous objective and subjective factors to determine our best estimate of the fair value of our ordinary shares, including but not limited to, the following factors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that we were a private company with illiquid securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">historical operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discounted future cash flows, based on projected operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial information of comparable public companies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk involved in the investment, as related to earnings stability, capital structure, competition and market
potential. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected volatility&#151;</I>We are responsible for estimating volatility and have considered a number of factors,
including third-party estimates and comparable companies, when estimating volatility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected term</I>&#151;We estimate the remaining expected life
of options as the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the expected time to vest and the maturity of the options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Risk-free
interest rate&#151;</I>The yield interpolated from U.S. Constant Maturity Treasury rates for a period commensurate with the expected term assumption is used as the risk-free interest rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_134"></A>THE COMBINATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This section of the joint proxy statement/prospectus describes material aspects of the Combinations. The description in this section and elsewhere in this
joint proxy statement/prospectus is qualified in its entirety by reference to the complete text of the BCA, a copy of which is attached to this joint proxy statement/prospectus as Annex A and is incorporated by reference into this joint proxy
statement/prospectus. This summary may not contain all of the information that is important to you. You&nbsp;should carefully read this entire document, including the full text of the BCA and the other documents referred to in this document, for a
more complete understanding of the Combinations. This section is not intended to provide you with any factual information about Ortho or Quidel. Such information can be found elsewhere in this joint proxy statement/prospectus and in the public
filings Quidel and Ortho make with the SEC, as described in the section entitled &#147;Where You Can Find More Information&#148; of this joint proxy statement/prospectus. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_135"></A>The Combinations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
discussed throughout this joint proxy statement/prospectus, Ortho is asking its shareholders to approve the Ortho Scheme and Quidel is asking its stockholders to adopt the BCA, pursuant to which Ortho and Quidel will enter into a business
combination and operate under Topco, a new holding company incorporated in Delaware. The Combinations will be implemented in two main steps, which are the Ortho Scheme and the Quidel Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Ortho Scheme: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each Ortho Share will be acquired by a nominee of Topco (or, if such nominee holds the Ortho Shares today,
transferred within the nominee), such that Ortho will become a wholly owned subsidiary of Topco; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at the effective time of the Ortho Scheme, each Ortho Share, other than Ortho Shares held by Ortho in treasury
(if any), will be acquired by a nominee (or, if such nominee holds the Ortho Shares today, transferred within the nominee) on behalf and for the benefit of Topco in exchange for 0.1055 Topco Shares and $7.14 in cash. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Quidel Merger: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. Merger Sub will merge with and into Quidel immediately following consummation of the Ortho Scheme, with
Quidel surviving the merger as a wholly owned subsidiary of Topco; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at the effective time of the Quidel Merger, each Quidel Share, other than Quidel Shares held by Quidel, Ortho or
U.S. Merger Sub, will be converted into the right to receive one Topco Share. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the Combinations, Ortho and Quidel will
each become wholly owned subsidiaries of Topco, and Ortho shareholders and Quidel stockholders will become Topco stockholders. Based on the respective capitalizations of Ortho and Quidel as of the date the parties entered into the BCA, immediately
following consummation of the Combinations, it is expected that former Ortho shareholders will receive approximately $1.7&nbsp;billion in cash in the aggregate (based on the number of Ortho Shares outstanding as of December&nbsp;31, 2021) and will
own approximately 38% of Topco and former Quidel stockholders will own approximately 62% of Topco, on a fully diluted basis, based on the respective capitalizations of Ortho and Quidel as of the date the parties entered into the BCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the number of Ortho Shares and Quidel Shares outstanding as of December&nbsp;31, 2021, Topco is expected to issue approximately 25,018,161 Topco
Shares to the Ortho shareholders upon completion of the Ortho Scheme and approximately 41,686,165 Topco Shares to the Quidel stockholders upon completion of the Quidel Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties intend to list the Topco Shares to be issued in the Combinations on Nasdaq. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_136"></A>Background of the Combinations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of their respective businesses, senior management and the boards of directors of each of Quidel and Ortho regularly review, assess and
discuss developments in their markets, their company&#146;s performance, strategy and competitive position and potential strategic initiatives and alternatives in light of economic and market conditions. From time </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to time Quidel and Ortho have also reviewed and discussed with other parties potential business combinations, joint ventures, strategic alliances and other
strategic transactions that might advance their strategic objectives and enhance stockholder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
value. As part of these ongoing reviews and discussions with respect to the Combinations, Quidel and Ortho have each considered, among other things, the significant opportunity presented by the
Combinations to enhance their respective offerings in a rapidly evolving industry and the current strategic environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to and following
completion of its initial public offering, continuing into 2021, Ortho engaged in discussions with a number of potential strategic parties regarding potential strategic transactions, among other things, acquisition transactions consistent with
Ortho&#146;s growth strategy, strategic alliances and potential business combinations. From time to time during this period, Ortho engaged in discussions with a strategic party referred to as Party A with respect to a potential business combination
transaction. Although Ortho and Party A discussed terms for a potential business combination transaction at a high level, Ortho and Party A mutually agreed in spring 2021 not to proceed further with negotiations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During early 2021, consistent with Quidel&#146;s growth strategy, Quidel engaged in discussions with several potential strategic parties regarding potential
strategic transactions or acquisitions, including to assess strategic fit, financial fit and ability to execute. The Quidel board of directors determined that each such potential transaction was not a strategic fit at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of Ortho&#146;s ongoing consideration of strategic transaction opportunities, on May&nbsp;18, 2021, Ortho held an M&amp;A strategy session in Denver,
Colorado with members of Ortho&#146;s senior management, representatives of Carlyle (attending virtually) and representatives of Goldman Sachs&nbsp;&amp; Co. LLC (&#147;Goldman Sachs&#148;), at which a range of potential strategic transaction
opportunities were discussed, including potential transformative business combination transactions with three parties. At the conclusion of the meeting, Ortho senior management asked Goldman Sachs to initiate outreach to certain potential strategic
partners, including Quidel, a strategic party referred to as &#147;Party B&#148; and a strategic party referred to as &#147;Party C,&#148; with respect to potential strategic transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the meeting, as requested by Ortho senior management, a representative of Goldman Sachs contacted Doug Bryant, Quidel&#146;s President and Chief
Executive Officer, to seek approval to provide Mr.&nbsp;Bryant&#146;s contact information to Christopher Smith, Ortho&#146;s Chairman and Chief Executive Officer. On May&nbsp;20, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith were introduced by email.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, following the May&nbsp;18 strategy session, representatives of Goldman Sachs contacted Party B and Party C to explore the possibility of
strategic discussions with Ortho. Mr.&nbsp;Smith exchanged messages with the chief executive officer of Party B, but these messages did not result in any transaction proposals or substantive discussions. Party C indicated to representatives of
Goldman Sachs that it would consider a transaction at an attractive valuation, but after further analysis, Ortho senior management concluded that a transaction with Party&nbsp;C was not an optimal strategic fit with Ortho, and that the transaction
would result in limited growth opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;25, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to discuss potential
transactions between Quidel and Ortho, including collaboration and partnership opportunities. In particular, Mr.&nbsp;Bryant and Mr.&nbsp;Smith discussed Quidel&#146;s Sofia and Savanna platforms and how such platforms could complement Ortho&#146;s
larger-scale instrumentation for clinical chemistry and high-throughput immunoassay platforms. Mr.&nbsp;Bryant and Mr.&nbsp;Smith also discussed Ortho&#146;s interests in expanding its product offerings into molecular testing products and leveraging
Ortho&#146;s global footprint and international sales force, along with the complementary nature of Quidel&#146;s and Ortho&#146;s customer bases and potential opportunities for the two companies to collaborate. In addition, Mr.&nbsp;Bryant and
Mr.&nbsp;Smith discussed Quidel&#146;s potential interest in exploring how their company might benefit from Ortho&#146;s larger global commercial footprint for the launch of Quidel&#146;s Savanna instrument. A potential combination of Quidel and
Ortho was briefly discussed; however, Mr.&nbsp;Bryant and Mr.&nbsp;Smith agreed at that point to focus solely on jointly exploring various collaboration structures and to assess how working together might benefit both companies. Following the
meeting, Mr.&nbsp;Bryant and Mr.&nbsp;Smith each agreed that they would convene a small group of executives to further explore collaboration opportunities and review publicly available investor relations materials about the other company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;8, 2021, members of Quidel&#146;s and Ortho&#146;s senior management met at Ortho&#146;s temporary office facility in Denver, Colorado to learn
about the other company&#146;s business at a high level and discuss potential collaboration frameworks. As a result of the discussions at the meeting, the parties identified complementary aspects of the businesses and determined that a collaboration
had the potential to benefit both companies by fostering the ability through greater scale and scope to compete with larger diagnostic companies. Specifically, for Quidel, a collaboration would provide access to a larger global commercial footprint,
and for Ortho, a collaboration would provide access to higher-growth IVD segments, including molecular and <FONT STYLE="white-space:nowrap">point-of</FONT> care testing platforms. Quidel and Ortho also discussed potential opportunities for joint or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complementary technology development to advance both companies&#146; R&amp;D pipelines. The parties also decided to put in place a Confidentiality Agreement to initiate the exploration of
potential collaboration frameworks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;12, 2021, Quidel sent Ortho a draft Confidentiality Agreement, that included updates to an expired
agreement entered into between the parties in August 2018. On June&nbsp;18, 2021, Quidel and Ortho entered into a Confidentiality Agreement, covering the sharing of confidential information. The Confidentiality Agreement did not include a
stand-still provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;25, 2021, at a business update meeting of the Quidel board of directors, members of Quidel&#146;s senior management
provided a summary of potential collaborations and other business development opportunities for Quidel, including potential collaboration opportunities with Ortho, as well as the potential acquisition of another target company. The Quidel board of
directors and members of Quidel&#146;s management reviewed preliminary information regarding factors relating to a potential acquisition of such target company prepared by representatives of Perella Weinberg, who Quidel management and the Quidel
board of directors regularly consulted in the ordinary course of business regarding potential merger and acquisition transactions. The Quidel board of directors approved an outreach to such target company at the board meeting, but that outreach did
not progress beyond an initial contact. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;8, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met in Orange County, California to discuss each
company&#146;s goals for a potential collaboration. Mr.&nbsp;Bryant noted a collaboration could be a good strategic fit for Quidel, and could provide Quidel with an opportunity to expand its geographic reach and to compete more effectively with
larger diagnostic players, especially in supporting the launch of Quidel&#146;s Savanna platform. Mr.&nbsp;Smith agreed and noted that a collaboration could assist Ortho in expanding its product offerings, but emphasized that the collaboration would
need to result in long-term sustainable growth for both companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on July&nbsp;8, 2021, members of Quidel senior management discussed with
representatives of Perella Weinberg preliminary financial information regarding a potential combination transaction with Ortho, assuming <FONT STYLE="white-space:nowrap">all-stock,</FONT> <FONT STYLE="white-space:nowrap">all-cash</FONT> or
50&nbsp;percent stock/50&nbsp;percent cash consideration. Quidel management had requested such information to assist them in developing preliminary thoughts on potential financial implications if the discussions with Ortho moved beyond a potential
collaboration to a potential combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;19, 2021, Mr.&nbsp;Smith met with representatives of J.P. Morgan at their offices in New York, New
York to discuss the strategic rationale for opportunities to collaborate with Quidel and engagement of J.P. Morgan for financial advice on such opportunities. A <FONT STYLE="white-space:nowrap">follow-up</FONT> discussion on such matters occurred on
July&nbsp;23, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;20, 2021, members of Quidel&#146;s and Ortho&#146;s senior management met at Quidel&#146;s offices in San Diego,
California to continue discussions regarding potential collaboration and partnership opportunities between the two companies. During the meetings, members of management of each of Ortho and Quidel provided overviews of their respective businesses
and discussed potential opportunities to collaborate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;23, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to discuss the
July&nbsp;20 meeting and agreed that each company&#146;s respective teams would continue working to assess whether and how the parties might collaborate. Mr.&nbsp;Bryant told Mr.&nbsp;Smith that he would provide the Quidel board of directors at the
board meeting later that day with a brief update on the potential opportunities being discussed with Ortho. Mr.&nbsp;Bryant also told Mr.&nbsp;Smith that Mr.&nbsp;Bryant intended to provide the Quidel board of directors with a more detailed
assessment of the potential opportunities identified by the companies at the regularly scheduled quarterly board meeting on August&nbsp;30, 2021. During that same discussion, Mr.&nbsp;Smith informed Mr.&nbsp;Bryant that Ortho had begun working with
J.P. Morgan to provide financial advice regarding the opportunities being discussed with Quidel. Mr.&nbsp;Bryant and Mr.&nbsp;Smith agreed to meet in person in New York in early September. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on July&nbsp;23, 2021, at a business update meeting of the Quidel board of directors, members of Quidel&#146;s senior management provided an update on
the potential collaboration opportunity with Ortho, and the Quidel board of directors and management discussed potential financial advisors who might be able to advise the board and management with respect to the potential opportunities, including
Perella Weinberg. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;5, 2021, as a <FONT STYLE="white-space:nowrap">follow-up</FONT> to the July&nbsp;20 meeting, Ed Russell, Quidel&#146;s
Senior Vice President, Business Development, Rhys de Callier, Quidel&#146;s Vice President, Strategy and Portfolio Management, Michael S. Iskra, Ortho&#146;s Executive Vice President of Commercial Excellence and Strategy, and Thomas Robinson,
Ortho&#146;s Vice President, Strategy and Corporate Development, met telephonically to discuss preliminary collaboration ideas and frameworks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;6, 2021, at a business update meeting of the Quidel board of directors, Quidel&#146;s senior
management provided an update on the review of the potential collaboration opportunity with Ortho, among other topics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;11, 2021,
Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to discuss the status of each company&#146;s review of the potential collaboration opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;13, 2021, at a meeting of the Ortho board of directors to discuss various matters, Mr.&nbsp;Smith provided a summary of potential business
development opportunities for Ortho, including potential collaboration opportunities with Quidel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;13, 2021, Ortho&#146;s senior management
and representatives of J.P. Morgan met telephonically to discuss the meeting of the Ortho board of directors earlier that day and certain financial information regarding Quidel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;18, 2021, Ortho provided Quidel with a proposal of potential collaboration opportunities that Ortho had identified, including: (1)&nbsp;in the
United States, some form of commercial collaboration between the companies for the launch of Quidel&#146;s Savanna platform, with the potential to expand to other Quidel products, (2)&nbsp;outside of the United States, Ortho could become a
distributor for Quidel legacy products for select countries where Ortho had an existing direct commercial model, with the addition of Quidel&#146;s Savanna platform when production capacity allowed, (3)&nbsp;a research and development collaboration
to develop a &#145;Sofia-like&#146; small benchtop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-care</FONT></FONT> analyzer for clinical chemistry, using Ortho&#146;s dry chemistry technology, and (4)&nbsp;certain
potential collaborations relating to manufacturing and operations. This proposed collaboration framework did not contemplate a business combination between Ortho and Quidel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;20, 2021, Ortho&#146;s senior management and representatives of J.P. Morgan met telephonically for an initial discussion of exploring a
potential merger of equals transaction with Quidel in parallel with the ongoing discussions of collaboration opportunities with Quidel, in light of the potential complexities of, and potentially lower synergies associated with, a strategic
partnership. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;23, 2021, Robert Bujarski, Quidel&#146;s Chief Operating Officer, Mr.&nbsp;Russell, Mr.&nbsp;Iskra, and Mr.&nbsp;Robinson met
telephonically to discuss Ortho&#146;s collaboration proposal. Following the August&nbsp;23, 2021 meeting with Quidel, representatives of Ortho directed J.P. Morgan to focus more fully on the potential merger of equals in light of the potential
complexities of a strategic partnership, Ortho&#146;s initial perceptions of which were confirmed at the August&nbsp;23, 2021 meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;26,
2021, at the direction of management of Quidel and Ortho, respectively, representatives of Perella Weinberg and J.P. Morgan held an initial telephonic meeting to discuss a potential business combination between Quidel and Ortho and considerations
regarding the process for exploring a potential transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;30, 2021, at a regularly scheduled quarterly meeting of the Quidel board of
directors, which was attended in part by certain members of Quidel&#146;s senior management, among other matters, Mr.&nbsp;Russell provided an update on the collaboration discussions between Quidel and Ortho. At the request of the Quidel board of
directors, senior management also discussed certain preliminary financial information relating to a potential combination of Quidel and Ortho prepared by Perella Weinberg that was based on information provided by Quidel senior management and
publicly available information. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;1, 2021, J.P. Morgan delivered a presentation to Ortho&#146;s senior management and representatives
of Carlyle regarding its preliminary analysis of the potential combination of Ortho and Quidel. Throughout fall 2021, representatives of Carlyle were involved in Ortho&#146;s evaluation of the potential combination both through participation from
members of the Ortho board of directors appointed by Carlyle and evaluation of the transaction from Carlyle&#146;s perspective as a significant shareholder that would continue to hold a meaningful interest in the combined company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;7, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met in person in New York, New York, and discussed the potential benefits of a collaboration
between the companies and considerations related to a potential combination of the companies as a merger of equals, including potential governance structures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;8, 2021, Mr.&nbsp;Smith let Mr.&nbsp;Bryant know that Ortho announced and commenced a secondary offering on September&nbsp;7, 2021.
Mr.&nbsp;Smith also suggested they schedule a meeting in San Diego, California later that month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;13, 2021, at the direction of
Quidel&#146;s and Ortho&#146;s management, representatives from Perella Weinberg and J.P. Morgan met telephonically to discuss a possible business combination. Representatives from J.P. Morgan discussed the potential for a merger transaction between
Quidel and Ortho. As proposed by Ortho, the combined company would have a chief executive officer from one company and a chairman from the other and the board of directors would be split based on relative ownership. Later in the call,
representatives from Perella Weinberg and J.P. Morgan discussed whether the parties would exchange long-range plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on September&nbsp;13, 2021, representatives of J.P. Morgan sent to Ortho an initial draft of a <FONT
STYLE="white-space:nowrap">non-binding</FONT> summary of proposed terms. On September&nbsp;16, 2021, representatives of J.P. Morgan shared with representatives of Carlyle a draft <FONT STYLE="white-space:nowrap">non-binding</FONT> summary of
proposed terms, draft exclusivity agreement and illustrative work plan for the proposed combination with Quidel, reflecting input from Ortho senior management, certain representatives of Carlyle, Latham&nbsp;&amp; Watkins LLP (&#147;Latham&#148;),
Ortho&#146;s outside counsel, and J.P. Morgan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;21, 2021 Mr.&nbsp;Bryant, Randy Steward, Quidel&#146;s Chief Financial Officer,
Mr.&nbsp;Bujarski, Michelle Hodges, Quidel&#146;s Senior Vice President, General Counsel, Mr.&nbsp;Smith, Joseph Busky, Ortho&#146;s Chief Financial Officer, Mr.&nbsp;Robinson and Mr.&nbsp;Iskra met at Quidel&#146;s offices in San Diego, California
to discuss matters related to a proposed merger of equals, including the drivers for a combination, the potential exchange of each of Quidel&#146;s and Ortho&#146;s long-range plans, research and development opportunities, structuring of a combined
company, and next steps, including undertaking an analysis of potential synergies from a combination and directing financial advisors for each company to prepare preliminary financial information relating to each of the companies and the proposed
transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;22, 2021, Mr.&nbsp;Smith suggested to Mr.&nbsp;Bryant that Mr.&nbsp;Steward and Mr.&nbsp;Busky share the long-range plans
discussed at the prior day&#146;s meeting. Mr.&nbsp;Smith also told Mr.&nbsp;Bryant that he would put Mr.&nbsp;Bryant in contact with representatives of Carlyle so that they could separately schedule a meeting, which he did on September&nbsp;23,
2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;22, 2021, at the direction of Quidel management, representatives of Perella Weinberg delivered a copy of the Quidel long-range
plan to J.P. Morgan, who then shared the Quidel long-range plan with members of Ortho&#146;s senior management. See the section entitled &#147;Ortho Unaudited Forward-Looking Financial Information&#151;Ortho Management Projections for Quidel.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;23, 2021, members of Ortho&#146;s senior management met telephonically with representatives of J.P. Morgan and Latham to discuss
high-level terms for a potential transaction with Quidel, including relating to structure and timing of sharing Ortho&#146;s long-range plan. Members of Ortho&#146;s senior management and representatives of Carlyle, J.P. Morgan and Latham met
telephonically on September&nbsp;24, 2021 to further discuss high-level transaction terms, including with respect to the relative ownership of the combined company, and agreed that Mr.&nbsp;Steward and Mr.&nbsp;Busky should work together to analyze
potential synergies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;27, 2021, Mr.&nbsp;Robinson sent Mr.&nbsp;Bryant, Mr.&nbsp;Steward and Mr.&nbsp;Bujarski high-level summaries of
performance data for Ortho&#146;s microslides and microwells for the proposed collaboration between Quidel and Ortho. Mr.&nbsp;Robinson also sent a request for information to prepare a mutual synergies document, which he suggested both parties use
to prepare data ahead of a contemplated synergies workshop. Mr.&nbsp;Robinson also indicated that Mr.&nbsp;Smith planned to meet with the Ortho board of directors the next day to discuss next steps for a potential combination transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;28, 2021, at a meeting of the Ortho board of directors that was attended by certain members of Ortho&#146;s senior management and
representatives of J.P. Morgan and Latham, Mr.&nbsp;Smith provided an overview of recent communications with Quidel and Mr.&nbsp;Robinson provided a summary of the strategic rationale for a combination. Representatives of J.P. Morgan provided a
preliminary overview of certain financial information with respect to Quidel and Ortho. The members of the Ortho board of directors and representatives of J.P. Morgan discussed, among other things, the strategic rationale for a potential combination
and next steps for pursuing a potential combination. The Ortho board of directors directed Ortho&#146;s senior management and J.P. Morgan to advise Quidel, including through Perella Weinberg, that Ortho was willing to move forward to enter into an
exclusivity agreement for a period of up to 60 days, subject to extension, based on a mutually acceptable <FONT STYLE="white-space:nowrap">non-binding</FONT> summary of proposed terms. The Ortho board of directors authorized Ortho&#146;s senior
management and J.P. Morgan to provide to Quidel a <FONT STYLE="white-space:nowrap">non-binding</FONT> summary of proposed terms and Ortho&#146;s long-range plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2021, upon the request of Mr.&nbsp;Smith, Mr.&nbsp;Robinson sent Mr.&nbsp;Bryant a <FONT STYLE="white-space:nowrap">non-binding</FONT>
summary of proposed terms for a business combination, which would be structured as an <FONT STYLE="white-space:nowrap">all-stock</FONT> merger of equals at a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">to-be-determined</FONT></FONT> exchange ratio. The proposed terms provided for a <FONT STYLE="white-space:nowrap">12-member</FONT> board of directors with balanced representation,
inclusive of board seats for Mr.&nbsp;Smith and Mr.&nbsp;Bryant, a headquarters of the combined company in San Diego and for further discussion regarding management and other key terms. The proposed terms also included a mutual exclusivity
agreement, which was never signed by either party. In this communication, Mr.&nbsp;Robinson noted that representatives of J.P. Morgan would discuss the proposed terms with representatives of Perella Weinberg. Proposed next steps included further due
diligence and workshops to analyze synergies and potential stockholder value opportunities. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on September&nbsp;29, 2021, at the direction of the Ortho board of directors, senior management of
Ortho provided representatives of Perella Weinberg with a copy of Ortho&#146;s long range plan. See the section entitled &#147;Ortho Unaudited Forward-Looking Financial Information&#151;Ortho Management Projections for Ortho.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;3, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to discuss the request for an exclusivity period and the potential benefits of
a combination of Ortho and Quidel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;8, 2021, at a meeting of the Quidel board of directors that was attended by certain members of
Quidel&#146;s senior management and representatives of Perella Weinberg, Mr.&nbsp;Bryant provided an overview of recent communications with Ortho&#146;s senior management, including the summary of proposed terms received from Ortho. At the meeting,
senior management of Quidel reviewed the strategic rationale for Quidel to enter into a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transaction, including, among other things, that the
business combination would create a leading diagnostics player with a global presence, would create the potential for further advancement in telehealth technology and digital health, would increase Quidel&#146;s global commercial footprint and
infrastructure and would present an opportunity to realize significant cost and cross-selling revenue synergies. Representatives of Perella Weinberg also reviewed with the Quidel board of directors certain updated preliminary financial information
relating to a potential combination of Quidel and Ortho. The members of the Quidel board of directors and representatives of Perella Weinberg discussed, among other things, the strategic rationale for a combination with Ortho, potential strategic
alternatives and merger of equals considerations. The Quidel board of directors discussed the potential benefits and risks of a potential combination with Ortho, each company&#146;s growth expectations and various strategic alternatives. The Quidel
board of directors also discussed the proposed mutual exclusivity agreement and Ortho&#146;s summary of proposed terms. Following this discussion, the Quidel board of directors determined that any agreement on exclusivity was premature, although
they might consider such an agreement for a very short period later in the process after key terms were agreed upon, in order to finalize documentation. The Quidel board of directors then authorized Quidel senior management to proceed to the next
stage of review of the potential business combination with Ortho, including to conduct business and legal diligence and to further discuss potential transaction structures with Ortho. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on October&nbsp;8, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to discuss next steps for the proposed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transactions. At Mr.&nbsp;Bryant and Mr.&nbsp;Smith&#146;s direction, Mr.&nbsp;Steward and Mr.&nbsp;Busky also met telephonically to discuss general process and to facilitate introductions of
their respective finance teams, so that the finance teams could communicate regarding continued modeling of revenue and cost synergy assumptions and considerations of how a business combination could be beneficial for both parties. Mr.&nbsp;Bryant
and Mr.&nbsp;Smith agreed to schedule a meeting between representatives of Carlyle and Mr.&nbsp;Bryant to begin discussing a potential strategic plan for the combined business and future governance, as well as potential deal terms and the cultures
of each of Quidel and Ortho. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;10, 2021, Mr.&nbsp;Bryant explained to Mr.&nbsp;Smith Quidel&#146;s position that exclusivity may be
appropriate after key terms had been agreed upon, but not at the current stage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;11, 2021, Mr.&nbsp;Steward and Mr.&nbsp;Busky met
telephonically to discuss next steps regarding analysis of synergies and commencement of discussions regarding transaction structure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;12,
2021, Mr.&nbsp;Bryant met with representatives from Carlyle. In the meeting, Mr.&nbsp;Bryant provided high-level information on Quidel and the parties discussed the rationale for a combination of Quidel and Ortho. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on October&nbsp;12, 2021, Mr.&nbsp;Robinson proposed to Mr.&nbsp;Steward that Latham prepare an initial draft of the BCA, given the complexity of
Ortho&#146;s global legal structure, and the parties agreed on drafting responsibility for the BCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;14, 2021, representatives of Latham
and Gibson, Dunn&nbsp;&amp; Crutcher LLP (&#147;Gibson Dunn&#148;) met telephonically for an initial discussion regarding, among other things, the legal due diligence process and transaction structure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;15, 2021, at a business update meeting of the Quidel board of directors that was attended by certain members of Quidel&#146;s senior
management, Mr.&nbsp;Bryant provided an overview of the recent discussions with Mr.&nbsp;Smith and his meeting with representatives from Carlyle. Ms.&nbsp;Hodges provided an overview of the directors&#146; fiduciary duties in connection with their
evaluation of the proposed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transaction, including considerations related to selection of advisors. At the same meeting, the Quidel board of directors
approved the engagement of Perella Weinberg as Quidel&#146;s financial advisor and Gibson Dunn as outside counsel. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on October&nbsp;15, 2021, Mr.&nbsp;Steward, Mr.&nbsp;Busky, Mr.&nbsp;Iskra and Mr.&nbsp;Robinson met
telephonically to continue discussions regarding synergy assumptions and related matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2021, representatives of Perella Weinberg
and J.P. Morgan met telephonically to discuss the process of negotiations going forward as well as preliminary, high-level considerations relating to the relative values of the two companies and governance structures of a post-combination company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;18, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to discuss expected synergies from the proposed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transaction, as well as diligence questions about the businesses. Mr.&nbsp;Bryant told Mr.&nbsp;Smith that as an initial matter, Quidel needed assistance in
assessing the state of Ortho&#146;s film technology and its opportunities to develop high sensitivity immunoassay products, as well as understanding the future of Ortho&#146;s blood bank business. Mr.&nbsp;Smith told Mr.&nbsp;Bryant that Ortho
needed assistance in understanding Quidel&#146;s expectation for the future of Quidel&#146;s <FONT STYLE="white-space:nowrap">COVID-19</FONT> business. Mr.&nbsp;Bryant and Mr.&nbsp;Smith committed to providing resources to assist in answering the
other&#146;s diligence questions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on October&nbsp;18, 2021, Quidel engaged Deloitte Touche Tohmatsu Limited (&#147;Deloitte&#148;) to serve as
Quidel&#146;s tax advisor for the proposed transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;19, 2021, members of Quidel&#146;s and Ortho&#146;s management met telephonically
with representatives from Deloitte, Gibson Dunn and Latham to discuss transaction structuring considerations, particularly with respect to tax consequences, and plans for further structuring discussions, as well as synergy analyses and drafting
responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;20, 2021, Mr.&nbsp;Steward, Mr.&nbsp;Bujarski, Mr.&nbsp;Busky, Mr.&nbsp;Robinson and Mr.&nbsp;Iskra met telephonically
to continue discussions regarding synergy assumptions and related matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;21, 2021, at a business update meeting of the Quidel board of
directors that was attended by certain members of Quidel&#146;s senior management and representatives from Perella Weinberg, Mr.&nbsp;Bryant provided a detailed summary of the recent communications with Mr.&nbsp;Smith and representatives of Carlyle
that were originally mentioned at the October&nbsp;15, 2021 board meeting. The Quidel board of directors then discussed these communications and certain directors&#146; diligence questions regarding Ortho. At the same meeting, representatives of
Perella Weinberg discussed with the Quidel board of directors certain updated preliminary financial information regarding Quidel and Ortho and the potential business combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the period beginning on October&nbsp;21, 2021 through the date of the execution of the BCA, representatives of Ortho and Quidel, with the assistance of
their respective advisors, conducted oral and documentary due diligence with respect to each other&#146;s business, financial, commercial, technology, legal and other matters and held discussions concerning their respective businesses, prospects,
key standalone and pro forma opportunities and risks and potential synergies that could result from a potential combination. As part of the due diligence process, Ortho and Quidel each made available to the other and its advisors an electronic data
room containing certain business, financial, commercial, technology, legal and other information of such party. A clean team agreement was executed on November&nbsp;22, 2021 to facilitate the sharing of certain information among a designated clean
team of each of Quidel and Ortho. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;26, 2021, members of Quidel management and Ortho management met to discuss their respective long range
plans. Representatives of Perella Weinberg, J.P. Morgan and Carlyle also participated in this meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;29, 2021, Ortho engaged The Boston
Consulting Group (&#147;BCG&#148;) to perform market and customer due diligence on Quidel&#146;s commercial product portfolio and to provide a qualitative and quantitative review of Quidel&#146;s long range plan and potential cross-selling revenue
synergies from a combination of Quidel and Ortho. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;5, 2021, members of Quidel&#146;s and Ortho&#146;s senior management met
telephonically with representatives from Perella Weinberg and J.P. Morgan to review preliminary financial information relating to the proposed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger-of-equals</FONT></FONT>
transaction, including with respect to estimates of synergies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;8, 2021, at a regularly scheduled quarterly meeting of the Quidel board
of directors, which was attended in part by certain members of Quidel&#146;s senior management, among other matters, Mr.&nbsp;Steward provided an update on the potential
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transaction with Ortho, including key assumptions of potential cost and revenue synergies. Mr.&nbsp;Steward also discussed with the Quidel board of
directors various options for the consideration to be paid to Ortho shareholders in the potential transaction and the Quidel board of directors provided feedback with respect to such options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;12, 2021, members of Quidel&#146;s and Ortho&#146;s senior management met telephonically
with representatives from J.P. Morgan, BCG, Perella Weinberg and Carlyle to discuss long-range plans for the two companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;15, 2021,
Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically and Mr.&nbsp;Bryant shared Quidel&#146;s position on the proposed transaction structure, including that Topco would need to be a U.S. entity so that the transaction would be <FONT
STYLE="white-space:nowrap">tax-free</FONT> to Quidel&#146;s stockholders. Mr.&nbsp;Smith committed to update the Ortho board of directors that week. Mr.&nbsp;Smith also shared that he would like the companies to work together on a joint stockholder
deck and set a goal of completing diligence and signing the BCA by <FONT STYLE="white-space:nowrap">mid-December.</FONT> Following the meeting, Mr.&nbsp;Smith informed Mr.&nbsp;Bryant that Ortho was in agreement on a U.S. Topco and that Carlyle was
aligned. He told Mr.&nbsp;Bryant that Mr.&nbsp;Steward and Mr.&nbsp;Busky should continue to work on the financial models. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;16, 2021, the
Quidel board of directors met telephonically with certain members of Quidel&#146;s senior management and representatives from Perella Weinberg to discuss the status of the proposed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transaction, including the status of transaction structure discussions and due diligence workstreams. Representatives of Perella Weinberg also discussed
with the Quidel board of directors certain updated preliminary financial information relating to the potential transaction, including preliminary revenue and cost synergy estimates being developed by management of the two companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on November&nbsp;16, 2021, members of Quidel&#146;s and Ortho&#146;s management met telephonically with representatives from Deloitte,
PricewaterhouseCoopers LLP (&#147;PwC&#148;), Ortho&#146;s tax advisor, and Latham to discuss tax structuring matters, including potential internal reorganizations and timing thereof. On November&nbsp;16, 2021, Mr.&nbsp;Busky sent an <FONT
STYLE="white-space:nowrap">e-mail</FONT> to the Ortho board of directors to provide an update on the status of transaction structure discussions and general updates from Mr.&nbsp;Bryant and Mr.&nbsp;Smith&#146;s telephonic meeting on
November&nbsp;15, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;18, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith communicated regarding Quidel&#146;s November&nbsp;16, 2021 board
meeting and upcoming conversations between Mr.&nbsp;Smith and representatives of Carlyle. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;19, 2021, Quidel entered into an engagement
letter with Perella Weinberg confirming the engagement of Perella Weinberg as its financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;22, 2021, members of Quidel&#146;s
and Ortho&#146;s senior management met telephonically with representatives from Deloitte, PWC and Perella Weinberg to discuss potential transaction structures and related tax implications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on November&nbsp;22, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to discuss the proposed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transaction. They agreed that Mr.&nbsp;Steward and Mr.&nbsp;Busky should meet in person to continue to work on the financial models and to discuss the proposed terms. Over the course of the
following month, Mr.&nbsp;Steward and Mr.&nbsp;Busky, along with other members of the Quidel and Ortho finance teams, continued to meet regularly to discuss finance-related matters and develop analyses for joint synergies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on November&nbsp;22, 2021, at the direction of Quidel&#146;s and Ortho&#146;s management, representatives of Perella Weinberg and J.P. Morgan met
telephonically and representatives of J.P. Morgan indicated that the exchange ratio should be based on trading prices over a longer time period, in light of volatility in stock prices. The parties discussed the fact that the proposed pro forma
ownership represented an implied premium to the Ortho shareholders and considered whether such premium would result in adjustments to proposed governance rights for the Ortho shareholders in exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;23, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith discussed the status of ongoing due diligence and details for an
<FONT STYLE="white-space:nowrap">in-person</FONT> meeting the following week. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;24, 2021, at a business update meeting of the Quidel board
of directors that was attended by certain members of Quidel&#146;s senior management and representatives from Perella Weinberg, Mr.&nbsp;Bryant provided a summary of his recent discussions with Mr.&nbsp;Smith and the plans for an upcoming meeting
with Mr.&nbsp;Smith and representatives from Carlyle, where the parties expected to discuss potential terms for the proposed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transaction, including
transaction structure, exchange ratio, management of the combined company, board size and relative composition, headquarters and combined company name. Following discussion, the Quidel board of directors approved proceeding with next steps for the
proposed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transaction, including the planned meeting. At the same meeting, representatives from Perella Weinberg and the members of the Quidel board of
directors discussed certain recent developments with respect to the proposed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transaction, strategic rationale considerations for the proposed transaction, cost and revenue synergy estimates developed by management of the two companies and certain updated preliminary
financial information relating to the proposed transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;29, 2021, Mr.&nbsp;Smith communicated to Mr.&nbsp;Bryant regarding timing
for delivery of the initial draft of the BCA in light of ongoing discussions regarding valuation, and Mr.&nbsp;Bryant asked that Mr.&nbsp;Smith instruct Latham to send the initial draft of the BCA even though such discussions were ongoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;30, 2021, Latham provided an initial draft of the BCA to Gibson Dunn. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In early December 2021, Quidel management discussed the potential transaction with representatives from Citigroup Global Markets Inc. (&#147;Citi&#148;), with
whom Quidel management had a longstanding relationship. Quidel management identified benefits to Citi serving as an additional financial advisor with respect to the proposed transaction, particularly with respect to any financing needs that may
arise. Over the following weeks, Citi provided advice to Quidel management regarding financing options for the proposed transaction, but did not advise the Quidel board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;1, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met in person in New York, New York to discuss each company&#146;s views on a proposed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transaction, including factors such as synergies that would affect the ultimate success of such transaction. Representatives of Carlyle then joined
Mr.&nbsp;Bryant and Mr.&nbsp;Smith to discuss the strategic rationale for the proposed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;2, 2021, at a meeting of the Ortho board of directors that was attended by certain members of Ortho&#146;s senior management and
representatives from J.P. Morgan and Latham, Mr.&nbsp;Smith provided an update on progress with respect to the proposed transaction with Quidel since the September&nbsp;28, 2021 meeting, including alignment on certain key deal terms and substantial
progress on due diligence. Mr.&nbsp;Robinson noted that the exchange ratio for the proposed transaction and division of key leadership roles were key open issues. Representatives of BCG presented their findings with respect to market and customer
diligence and answered questions from members of the Ortho board of directors. Mr.&nbsp;Busky then provided an overview of Ortho management&#146;s analysis of Quidel&#146;s long-range plan. Representatives of J.P. Morgan discussed updated
preliminary financial information regarding Quidel and Ortho and a potential combination. Representatives of Latham then provided a summary of fiduciary duties of the members of the Ortho board of directors in their capacity as directors of a UK
company. The Ortho board of directors directed Ortho and its advisors to finalize diligence and engage in negotiations regarding the proposed transaction with Quidel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on December&nbsp;2, 2021, Mr.&nbsp;Smith informed Mr.&nbsp;Bryant that he thought that good progress was made in the prior day&#146;s meeting.
Mr.&nbsp;Smith and Mr.&nbsp;Bryant discussed their mutual goal of working to complete diligence as quickly as possible in order to be in a position to execute the BCA prior to the upcoming holidays. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;5, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to discuss transaction terms and status ahead of the December&nbsp;6, 2021
meeting of the Quidel board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;6, 2021, representatives of Latham and Gibson Dunn met telephonically with representatives of
Erskine Chambers to discuss joint engagement of a Queen&#146;s Counsel from Erskine Chambers for the Ortho Scheme and certain considerations in structuring the Ortho Scheme. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;6, 2021, representatives of BCG reviewed their view of potential cross-selling synergies with Mr.&nbsp;Steward and Kristin Caltrider,
Quidel&#146;s Vice President, Finance, Mr.&nbsp;Busky, Mr.&nbsp;Iskra and Mr.&nbsp;Robinson. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on December&nbsp;6, 2021, at a business update
meeting of the Quidel board of directors that was attended by certain members of Quidel&#146;s senior management and representatives from Perella Weinberg, Mr.&nbsp;Bryant provided a summary of his recent meeting with Mr.&nbsp;Smith and
representatives of Carlyle, during which the parties discussed items including a structure for the proposed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transaction, the exchange ratio, combined
company management and Carlyle&#146;s post-closing rights in its capacity as a shareholder with a meaningful interest in the combined company. At the same meeting, representatives from Perella Weinberg discussed with the Quidel board of directors
certain updated preliminary financial information regarding Ortho, Quidel and the proposed transaction. The Quidel board of directors and representatives of Perella Weinberg also discussed the potential benefits of the proposed transaction and a
proposed negotiation strategy. Ms.&nbsp;Hodges then described the proposed deal protections under the BCA and provided an overview of the BCA structure and other transaction terms. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on December&nbsp;6, 2021, representatives of Perella Weinberg and J.P. Morgan met telephonically to
discuss the pro forma ownership of the combined company. On behalf of Ortho, representatives from J.P. Morgan proposed that the Ortho shareholders and Quidel stockholders should own 49% and 51% of the combined company on a pro forma basis,
respectively. Representatives from Perella Weinberg maintained, on behalf of Quidel and at the direction of Quidel management, that the Ortho shareholders and Quidel stockholders should own 45% and 55% of the combined company on a pro forma basis,
respectively, based on that day&#146;s closing stock prices and historical stock prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;7, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met
telephonically to discuss the status of the proposed transaction. Mr.&nbsp;Smith and Mr.&nbsp;Bryant later communicated regarding certain outstanding due diligence requests and the status of the revised summary of proposed terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on December&nbsp;7, 2021, Mr.&nbsp;Smith and representatives of J.P. Morgan communicated regarding the appropriate exchange ratio and premium for Ortho
shareholders, including in light of certain <FONT STYLE="white-space:nowrap">non-economic</FONT> terms in Quidel&#146;s favor, such as the location of the combined company&#146;s headquarters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on December&nbsp;7, 2021, Mr.&nbsp;Bryant sent Mr.&nbsp;Smith a revised <FONT STYLE="white-space:nowrap">non-binding</FONT> summary of proposed terms,
which provided for an <FONT STYLE="white-space:nowrap">all-stock</FONT> merger of equals, whereby the Ortho shareholders and Quidel stockholders would own 46% and 54% of the combined company on a pro forma basis, respectively. Under the summary of
proposed terms, Mr.&nbsp;Bryant would serve as the chief executive officer of the combined company, Mr.&nbsp;Smith would serve as chairman of the board of directors of the combined company and the Quidel management team would continue at the
combined company. The board of directors of the combined company would have 11 members, with five directors from Ortho and six directors from Quidel, and Ortho would have the right to designate one committee chair and Quidel would have the right to
designate two committee chairs. The proposal included that the certificate of incorporation and bylaws of the combined company would be the same as Quidel&#146;s current certificate of incorporation and bylaws in all material respects. With respect
to the deal protection provisions in the BCA, the summary of proposed terms provided that there would not be a &#147;force the vote&#148; provision, the parties would have five and two Business Days, respectively, to match unsolicited offers and
amendments thereto and the parties would have the same termination fee. Separately, the proposal included the right for Carlyle to appoint two board members as long as it held at least 20% of the combined company, and one board member as long as it
held between 10% and 20% of the combined company, and also included a 24 month post-closing lock up for Carlyle. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on December&nbsp;7, 2021,
Mr.&nbsp;Smith confirmed receipt of the revised summary of proposed terms and told Mr.&nbsp;Bryant that he would follow up once he discussed the proposal with the Ortho board of directors, representatives from Carlyle and J.P. Morgan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;8, 2021, Mr.&nbsp;Smith informed Mr.&nbsp;Bryant that Ortho and representatives from Carlyle were working through a few points from the
summary of proposed terms. Mr.&nbsp;Bryant responded that from Quidel&#146;s perspective, the major open point was the exchange ratio and pro forma ownership percentages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on December&nbsp;8, 2021, Mr.&nbsp;Smith sent Mr.&nbsp;Bryant a further revised <FONT STYLE="white-space:nowrap">non-binding</FONT> summary of proposed
terms, which provided for an <FONT STYLE="white-space:nowrap">all-stock</FONT> merger of equals, whereby the Ortho shareholders and Quidel stockholders would own 49% and 51% of the combined company on a pro forma basis, respectively. Under this
summary of proposed terms, Mr.&nbsp;Bryant would serve as the chief executive officer of the combined company, Mr.&nbsp;Smith would serve as chairman of the board of directors of the combined company and the management team of the combined company
would include Mr.&nbsp;Busky as chief financial officer, Mr.&nbsp;Iskra as chief commercial officer and Mr.&nbsp;Bujarski as chief operating officer with the remaining officers selected from the best of each company&#146;s management. The board of
directors of the combined company would have 12 members, with six directors from each of Quidel and Ortho, and Ortho would have the right to designate one committee chair and Quidel would have the right to designate two committee chairs. The
proposal included that the combined company would have a staggered board, which Quidel did not currently have. With respect to the deal protection provisions in the BCA, the summary of proposed terms provided that the respective boards of directors
could respond to unsolicited offers based on a fiduciary out with a superior proposal standard, the parties would have five and three Business Days to match unsolicited offers and amendments thereto, respectively, there would be a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;force-the-vote&#148;</FONT></FONT> provision, and the parties would each have a termination fee tailored to the maximum amounts typically permitted under Delaware and UK law,
respectively. Separately, the proposal included the right for Carlyle to appoint two board members as long as it held at least 15% of the combined company, and one board member as long as it held between 10% and 15% of the combined company, and did
not include a post-closing lock up for Carlyle. Furthermore, it included a right for Carlyle to sell up to 25% of its Ortho Shares after the filing of the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> subject to certain
conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on December&nbsp;8, 2021, members of Quidel&#146;s and Ortho&#146;s senior management met
telephonically with representatives from J.P. Morgan, BCG, Perella Weinberg and Carlyle to discuss long-range plans for the two companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on
December&nbsp;8, 2021, at the direction of Ortho management, representatives from J.P. Morgan discussed with representatives from Perella Weinberg the proposed pro forma ownership percentages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;9, 2021, Mr.&nbsp;Bryant met with Mr.&nbsp;Smith in person in Orange County, California to discuss the terms of the proposed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transaction, including the proposed exchange ratio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on
December&nbsp;9, 2021, Mr.&nbsp;Smith proposed to Mr.&nbsp;Bryant transfer restrictions for Carlyle&#146;s Ortho Shares, which proposal provided that (i)&nbsp;Carlyle would not sell shares prior to the filing of the Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> for the proposed transaction, (ii)&nbsp;after the filing, Carlyle could sell up to 25% of its holdings, but any sales made prior to the Ortho shareholder vote could only be to buyers who agree to be bound by
comparable voting and transfer restrictions, and (iii)&nbsp;after the Ortho shareholder vote is obtained, all transfer restrictions would fall away. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;10, 2021, at the direction of Ortho management, representatives from J.P. Morgan followed up with representatives from Perella Weinberg and Citi to provide a summary of certain preliminary exchange ratio analyses. Representatives from
J.P. Morgan reiterated Ortho&#146;s position that the Ortho shareholders and Quidel stockholders should own 49% and 51% of the combined company on a pro forma basis, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;10, 2021, at a business update meeting of the Quidel board of directors that was attended by certain members of Quidel&#146;s senior
management and representatives from Perella Weinberg, Mr.&nbsp;Bryant provided a summary of his recent meeting with Mr.&nbsp;Smith and representatives of Carlyle, including discussions regarding the exchange ratio (including Ortho&#146;s proposal of
pro forma stock ownership of the combined company of 51% Quidel stockholders and 49% Ortho shareholders) and the premium Ortho expected its shareholders to receive in the proposed transaction in light of recent stock price changes and the intended
composition of the board of directors of the combined company (including Ortho&#146;s request for a classified board of directors), as well as certain registration rights of Carlyle in the combined company. Representatives from Perella Weinberg
responded to questions from the Quidel board of directors regarding methods for establishing the exchange ratio at the market or at a premium and Quidel&#146;s and Ortho&#146;s respective positions with respect to the exchange ratio. The Quidel
board of directors also discussed with Quidel management and representatives of Perella Weinberg the potential for incremental synergies from the proposed transaction, the expected time frame for Quidel&#146;s stockholders to be able to benefit from
such synergies and how this expected timing may change depending on whether the exchange ratio is set at the market or at a premium. At the same meeting, Ms.&nbsp;Hodges reviewed the directors&#146; fiduciary duties in connection with their
evaluation of the proposed transaction and the Quidel board of directors discussed with the advisors considerations such as market checks, premiums, transaction rationale, opportunities for shareholder value creation and financial and related items.
Representatives of Perella Weinberg also discussed with the Quidel board of directors certain updated preliminary financial information relating to Quidel, Ortho and the proposed transaction and an overview of certain other strategic alternatives.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on December&nbsp;10, 2021, at the direction of the Quidel board of directors, Mr.&nbsp;Bryant reiterated to Mr.&nbsp;Smith that he thought the
combination of the two companies would create significant revenue and cost synergies, which would, in turn, create a rare opportunity for both companies&#146; stockholders. Mr.&nbsp;Bryant then explained that Quidel could not accept pro forma stock
ownership of the combined company greater than 47% ownership for the Ortho shareholders and less than 53% ownership for the Quidel stockholders. He also stated that upon further analysis, Quidel could not agree to allowing Carlyle to sell shares
between signing of the BCA and closing of the proposed transaction, but would be receptive to considering alternatives. Mr.&nbsp;Smith agreed to discuss further with Carlyle. Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to again discuss
these topics later that day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;11, 2021, Mr.&nbsp;Bryant sent Mr.&nbsp;Smith a further revised
<FONT STYLE="white-space:nowrap">non-binding</FONT> summary of proposed terms, which provided for an <FONT STYLE="white-space:nowrap">all-stock</FONT> merger of equals, whereby the Ortho shareholders and Quidel stockholders would own 47% and 53% of
the combined company on a pro forma basis, respectively. Under this summary of proposed terms, Mr.&nbsp;Bryant would serve as the chief executive officer of the combined company, Mr.&nbsp;Smith would serve as chairman of the board of directors of
the combined company and the management team of the combined company would include Mr.&nbsp;Busky as chief financial officer, Mr.&nbsp;Iskra as chief commercial officer and Mr.&nbsp;Bujarski as chief operating officer with the remaining officers
selected by the management team (with the final determination made by Mr.&nbsp;Bryant). The board of directors of the combined company would have 12 members, with six directors from each of Quidel and Ortho, and each of Quidel and Ortho would have
the right to designate two committee chairs. The certificate of incorporation and bylaws of the combined company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would be the same as Quidel&#146;s current certificate of incorporation and bylaws in all material respects, with the parties to consider any changes proposed by Ortho, to the extent consistent
with governance best practices. With respect to the deal protection provisions in the BCA, the summary of proposed terms provided that there would not be a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;force-the-vote&#148;</FONT></FONT> provision based on a fiduciary out with a superior proposal, the parties would have five and three Business Days to match unsolicited offers
and amendments thereto, respectively, and the parties would each have an equal termination fee. Separately, the proposal provided that Carlyle could not sell any shares prior to closing of the transaction, but would not be subject to a <FONT
STYLE="white-space:nowrap">lock-up</FONT> after closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on December&nbsp;11, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to
discuss the further revised <FONT STYLE="white-space:nowrap">non-binding</FONT> summary of proposed terms that Mr.&nbsp;Bryant had sent earlier that day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;12, 2021, Gibson Dunn delivered a revised draft of the BCA to Latham. Over the next two weeks, the parties and their advisors continued to
work on the various workstreams, including exchanging drafts of the transaction documents, including the BCA, Principal Stockholders Agreement and Irrevocable Undertaking, and discussing open issues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on December&nbsp;12, 2021, Mr.&nbsp;Smith contacted Mr.&nbsp;Bryant to confirm receipt of the revised <FONT STYLE="white-space:nowrap">non-binding</FONT>
summary of terms and Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to discuss the status of the transaction process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2021,
Mr.&nbsp;Smith sent Mr.&nbsp;Bryant a further revised <FONT STYLE="white-space:nowrap">non-binding</FONT> summary of proposed terms, which provided for an <FONT STYLE="white-space:nowrap">all-stock</FONT> merger of equals, whereby the Ortho
shareholders and Quidel stockholders would own 48% and 52% of the combined company on a pro forma basis, respectively. The governance terms remained unchanged, except that Ortho proposed a staggered board of directors for the combined company. With
respect to the deal protection provisions in the BCA, the summary of proposed terms provided that there would be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;force-the-vote&#148;</FONT></FONT> provision and the
termination fee payable by Quidel would equal four percent of Quidel&#146;s equity value and the termination fee payable by Ortho would equal one percent of Ortho&#146;s equity value. Separately, the proposal included the right for Carlyle to
appoint two board members as long as it held at least 10% of the combined company, and one board member as long as it held between 5% and 10% of the combined company, provided Carlyle certain board committee membership rights and gave Carlyle the
right to designate one additional board member (who is not a current or former Carlyle employee) on a <FONT STYLE="white-space:nowrap">one-time</FONT> basis at closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on December&nbsp;13, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to discuss certain matters regarding the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on December&nbsp;13, 2021, Mr.&nbsp;Bryant and representatives from Carlyle met telephonically to discuss whether Carlyle should have registration rights
and information rights with respect to the combined company substantially similar to the rights that it had with respect to Ortho. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;14,
2021, Gibson Dunn sent Latham a further revised <FONT STYLE="white-space:nowrap">non-binding</FONT> summary of proposed terms, which provided for an <FONT STYLE="white-space:nowrap">all-stock</FONT> merger of equals, whereby the Ortho shareholders
and Quidel stockholders would own 47% and 53% of the combined company on a pro forma basis, respectively. With respect to the governance terms, the summary of proposed terms removed the staggered board proposal and added that the directors appointed
by each party must be reasonably acceptable to the nominating and corporate governance committee of the other party&#146;s board of directors. With respect to the deal protection provisions in the BCA, the summary of proposed terms was revised to
provide that both parties&#146; termination fee would equal one percent of such party&#146;s equity value. Separately, the proposal included the right for Carlyle to appoint two board members as long as it held at least 15% of the combined company,
and one board member as long as it held between 8% and 15% of the combined company, and deleted the committee membership rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on
December&nbsp;14, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to discuss the revised summary of proposed terms. Mr.&nbsp;Bryant also met telephonically with representatives from Carlyle regarding the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on December&nbsp;14, 2021, Latham sent Gibson Dunn a draft of the Principal Stockholders Agreement, which provided for certain registration rights and
information rights for Carlyle, as well as certain transfer restrictions, as described in the section entitled &#147;Stockholders Agreement / Deed of Irrevocable Undertaking&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;15, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to discuss the revised summary of proposed terms and Ms.&nbsp;Hodges and
Mr.&nbsp;Schlesinger met telephonically to discuss certain legal diligence matters and the revised summary of proposed terms. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on December&nbsp;15, 2021, representatives from Carlyle proposed to Mr.&nbsp;Bryant that the
termination fee in the BCA payable by Quidel should equal four percent of the equity value for Quidel and that Carlyle&#146;s representation on the board of directors of the combined company should initially be three directors (out of the six
directors designated by Ortho), as well as one director appointed by Carlyle on each board committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on December&nbsp;15, 2021, representatives
from J.P. Morgan indicated to representatives from Citi that Latham was sending proposed language on the proposed termination fee for Quidel and the &#147;force the vote&#148; provision to Gibson Dunn. Citi responded to indicate that Quidel was not
in agreement on the proposed &#147;force the vote&#148; language. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;16, 2021, Latham sent Gibson Dunn a further revised <FONT
STYLE="white-space:nowrap">non-binding</FONT> summary of proposed terms, which provided for an <FONT STYLE="white-space:nowrap">all-stock</FONT> merger of equals, whereby the Ortho shareholders and Quidel stockholders would own 47% and 53% of the
combined company on a pro forma basis, respectively. The governance terms previously proposed by Quidel were not revised. With respect to the deal protection provisions in the BCA, the summary of proposed terms provided that there would be a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;force-the-vote&#148;</FONT></FONT> provision, except in the case of an all cash offer with no financing conditions that is determined to be a superior proposal by the recipient&#146;s
board of directors, and the termination fee payable by Quidel would equal three percent of Quidel&#146;s equity value and the termination fee payable by Ortho would equal one percent of Ortho&#146;s equity value, respectively, consistent with
variations in Delaware and UK law. Separately, the proposal included the right for Carlyle to appoint two board members as long as it held at least 12% of the combined company and one board member as long as it held between 5% and 12% and gave
Carlyle the right to designate one additional board member (who is not a current or former Carlyle employee) on a <FONT STYLE="white-space:nowrap">one-time</FONT> basis at closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on December&nbsp;16, 2021, at a meeting of the Ortho board of directors that was attended by certain members of Ortho&#146;s senior management and
representatives from J.P. Morgan and Latham, Mr.&nbsp;Robinson provided an update on certain financial metrics for Quidel that were adjusted to reflect changes in the prevalence of, and testing for, <FONT STYLE="white-space:nowrap">COVID-19</FONT>
since the last meeting and to adjust certain cost synergies. Mr.&nbsp;Robinson also provided a summary of Ortho&#146;s and its advisors&#146; due diligence, which was substantially complete. Representatives of J.P. Morgan provided an overview of
financial terms and discussed the financial aspects of the proposed transaction. Mr.&nbsp;Schlesinger then provided a summary of certain key terms of the BCA, including with respect to deal protection and interim operating covenants, and an overview
of various ancillary documents and related workstreams. Members of the Ortho board of directors agreed that Ortho and its advisors should seek to finalize transaction documents within the next few days, based on an understanding that Quidel and its
advisors were working on a similar timeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the meeting of the Ortho board of directors, Mr.&nbsp;Smith and Mr.&nbsp;Bryant agreed that,
because of the recent volatility in the stock market with respect to both companies&#146; stock prices, the parties should plan to sign the BCA before the stock markets open on December&nbsp;20, 2021. Mr.&nbsp;Bryant agreed, provided the parties
could reach an agreement on terms on that timeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;17, 2021, Gibson Dunn sent Latham a further revised
<FONT STYLE="white-space:nowrap">non-binding</FONT> summary of proposed terms; the only change was to delete the <FONT STYLE="white-space:nowrap">one-time</FONT> right of Carlyle to designate a third board designee, at the closing of the
Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;17, 2021, at a meeting of the Quidel board of directors that was attended by certain members of Quidel&#146;s senior
management and representatives from Perella Weinberg, representatives from Perella Weinberg discussed with the Quidel board of directors preliminary information relating to the proposed transaction, including an update on proposed premiums for the
transaction and exchange ratio considerations. Members of Quidel&#146;s senior management and the Quidel board of directors discussed the current price of Quidel common stock and the volatility observed in the stock prices of each of Quidel and
Ortho. At the same meeting, Ms.&nbsp;Hodges provided a summary of the terms of the BCA and an overview of the transaction structure and the proposed board of directors and governance structure for the combined company. The Quidel board of directors
discussed potential resolution of the open deal points and authorized Mr.&nbsp;Bryant to continue to negotiate these open deal points, and confirmed that the board remained fully supportive of the transaction and would continue discussion and
consideration of any changes arising from such negotiations at their meeting scheduled for December&nbsp;20, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;17, 2021,
Mr.&nbsp;Bryant and Mr.&nbsp;Smith communicated before and after the meeting of the Quidel board of directors regarding the remaining open terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;19, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically to discuss the status of the BCA draft and action items with respect to the proposed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transaction. Mr.&nbsp;Smith also inquired about Quidel&#146;s business and the current </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
events in South Africa relating to the Omicron variant of the coronavirus. They also discussed Quidel&#146;s planned strategy and messaging points for obtaining approval of the transaction by its
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;19, 2021, Gibson Dunn sent Latham a draft of the deed of irrevocable undertaking (&#147;Irrevocable Undertaking&#148;),
pursuant to which Carlyle would agree to vote or procure votes in favor of the Ortho Scheme at the Ortho Court Meeting and the resolutions to be proposed at the Ortho General Meeting the shares beneficially owned by Carlyle, as described in the
section entitled &#147;Stockholders Agreement / Deed of Irrevocable Undertaking&#148; of this joint proxy statement/prospectus. On December&nbsp;19, 2021, Gibson Dunn also sent Latham revised drafts of the BCA and the Stockholders Agreement, which
Ortho&#146;s senior management discussed with representatives of Carlyle and Latham on the afternoon of December&nbsp;19, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the request of
Quidel&#146;s management due to ongoing concerns establishing an appropriate exchange ratio for the proposed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger-of-equals</FONT></FONT> transaction, particularly in light of the
recent volatility of Quidel&#146;s stock price, in part due to the surging Omicron variant of the coronavirus, and the relative stability of Ortho&#146;s stock price, Citi provided Quidel with its analyses of the financial impact of a transaction
utilizing cash and stock consideration, and related governance terms of precedent cash and stock transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;19, 2021, Mr.&nbsp;Bryant
and Mr.&nbsp;Smith met telephonically and Mr.&nbsp;Bryant notified Mr.&nbsp;Smith that Quidel would be sending a further revised proposal and outlined the challenges he would face in obtaining the approval of Quidel stockholders for the transaction
at the previously proposed relative stock ownership of 47% for the Ortho shareholders and 53% for the Quidel stockholders, and that in light of the increase in Quidel&#146;s stock price, this now represented an implied 40% premium for Ortho
shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the morning of December&nbsp;20, 2021, Mr.&nbsp;Smith updated Mr.&nbsp;Bryant regarding the status of a revised proposal and testing
data from South Africa and reiterated Ortho&#146;s excitement about the opportunity to combine Quidel and Ortho. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shortly thereafter, Mr.&nbsp;Bryant sent
Mr.&nbsp;Smith a further revised <FONT STYLE="white-space:nowrap">non-binding</FONT> summary of proposed terms (the &#147;December 20 Proposal&#148;) that reflected significant adjustments to the structure of the transaction. The December&nbsp;20
Proposal provided for a transaction in which Ortho shareholders and Quidel stockholders would own approximately 34% and 66% of the combined company on a pro forma basis, respectively. Under the revised proposal, Ortho shareholders would receive
implied total consideration of $22 per share, consisting of $6.13 in cash and 0.0895 Topco Shares per Ortho Share (representing a total of $1.5&nbsp;billion in cash consideration). This reflected an implied 16.6% premium to Ortho shareholders based
on then current stock prices. Under this summary of proposed terms, Mr.&nbsp;Bryant would serve as the chief executive officer of the combined company, a Quidel director would serve as chairman of the board of directors of the combined company, a
Quidel officer would serve as president of the combined company and the management team of the combined company would include Mr.&nbsp;Busky as chief financial officer, Mr.&nbsp;Iskra as chief commercial officer and Mr.&nbsp;Bujarski as chief
operating officer, with the remaining officers selected by the designated management team (with the final determination to be made by Mr.&nbsp;Bryant). The board of directors of the combined company would have 10 members, with three directors from
Ortho and seven directors from Quidel, inclusive of the board seats for Mr.&nbsp;Smith and Mr.&nbsp;Bryant, and Quidel would have the right to designate all committee chairs. The deal protection terms were unchanged, as were Carlyle&#146;s rights.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s senior management participated in multiple teleconferences with representatives of J.P. Morgan and Carlyle to discuss the December&nbsp;20
Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shortly after delivery of the December&nbsp;20 Proposal, Mr.&nbsp;Bryant inquired of Mr.&nbsp;Smith how the revised proposal was received by
Ortho. Mr.&nbsp;Smith responded that Ortho had not received the proposal well, particularly given the volatility of Quidel&#146;s stock price, and Ortho would formally respond after the next day&#146;s meeting of the Ortho board of directors.
Mr.&nbsp;Smith added that, at a high level, a business combination with governance terms comparable to an acquisition could be acceptable to Ortho, but the December&nbsp;20 Proposal was inadequate and the Ortho shareholders needed to receive an
appropriate premium for such a transaction. Representatives of J.P. Morgan also informed representatives of Citi that the December&nbsp;20 Proposal was not acceptable and would need to be improved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on December&nbsp;20, 2021, at a meeting of the Quidel board of directors that was attended by certain members of Quidel&#146;s senior management and
representatives from Perella Weinberg, Mr.&nbsp;Bryant discussed with the Quidel board of directors the revised proposed transaction terms, including the addition of a cash component to the consideration. Mr.&nbsp;Bryant also described to the Quidel
board of directors the feedback that he had received on Ortho&#146;s reaction to the December&nbsp;20 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Proposal. Representatives from Perella Weinberg then discussed certain updated market information and certain preliminary financial information regarding the December&nbsp;20 Proposal, taking
into account recent increases in Quidel&#146;s share price relative to Ortho&#146;s share price. Following discussion of the financial information presented by Perella Weinberg and other information presented, the Quidel board of directors
authorized Mr.&nbsp;Bryant and the financial advisors to continue to negotiate the transaction terms (subject to the final approval of the Quidel board of directors), including authority to increase the proposed consideration, and confirmed that the
board remained fully supportive of the transaction and would continue discussion and consideration of any changes arising from such negotiations. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;21, 2021, Mr.&nbsp;Bryant communicated with Mr.&nbsp;Smith regarding the performance of the Quickvue and Sofia tests in detecting the Omicron variant of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and noted that he expected an
announcement from the FDA shortly with respect to the ability of such tests to detect the Omicron variant of the coronavirus. On December&nbsp;21, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith also communicated regarding the timing of a response from
Ortho to the December&nbsp;20 Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;21, 2021, Ortho&#146;s senior management participated in a series of teleconferences with
representatives of Carlyle, J.P. Morgan and Latham to discuss a response to the proposal made by Quidel on December&nbsp;20, 2021 in preparation for the meeting of the Ortho board of directors that afternoon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;21, 2021, at the direction of the Quidel board of directors, representatives from Perella Weinberg and Citi spoke with representatives of
J.P. Morgan by telephone to convey Quidel&#146;s revised proposal, which provided that Ortho shareholders would receive $7.14 in cash and 0.0895 Topco Shares per Ortho Share (representing a total of $1.75&nbsp;billion in cash) (the &#147;Initial
December&nbsp;21 Proposal&#148;). Such consideration would, based on Quidel&#146;s closing stock price on December&nbsp;21, 2021, represent total implied value of $24 per share, which would represent a 23% premium to Ortho&#146;s current stock
price, and result in Ortho shareholders owning approximately 37% of the combined company. Also on December&nbsp;21, 2021, Mr.&nbsp;Bryant called Mr.&nbsp;Smith and delivered Quidel&#146;s revised proposal. Representatives from Carlyle also
participated in teleconferences regarding the Initial December 21 Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on December 21, 2021, at the direction of Quidel senior management,
representatives from Perella Weinberg prepared analyses of various cash and stock consideration alternatives, which were reviewed by Quidel senior management. Quidel senior management engaged in a series of communications with Citi regarding the
availability of potential financing for the various consideration alternatives proposed by Perella Weinberg. Mr. Bryant participated in a series of teleconferences with Dr. Buechler regarding such analyses and the status of negotiations with Ortho.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on December&nbsp;21, 2021, at a meeting of the Ortho board of directors that was attended by certain members of Ortho&#146;s senior management
and representatives from J.P. Morgan and Latham, J.P. Morgan provided a summary of the updated proposals made by Quidel on December&nbsp;20, 2021 and December&nbsp;21, 2021. The members of the Ortho board of directors discussed the Initial
December&nbsp;21 Proposal with J.P. Morgan and concluded that the deal was attractive, but that Ortho should continue to seek improved terms that include at least $1.75&nbsp;billion in cash consideration and total implied value of $25 per share. The
Ortho board of directors discussed the proposed fixed exchange ratio and possible alternative structures, such as a floating exchange ratio, or a cap or collar structure that could account for changes in the Quidel stock price prior to closing of
the Combinations, potentially resulting in adjustments to the stock portion of the Ortho Scheme Consideration, but recognized that a fixed exchange ratio is the most common structure for stock merger transactions and offers certainty of relative
ownership in the combined company (and resulting participation in anticipated synergies in the combined company), whereas such alternative structure negotiated for the Combinations would have been reciprocal, could have negatively impacted the value
to be received by Ortho&#146;s shareholders in the transaction (including the participation of Ortho&#146;s shareholders in anticipated synergies in the combined company) and could have reduced certainty of closing of the Combinations if an
additional termination right were negotiated as part of an alternative structure and would not be customary for transactions of this type. In addition, the Ortho board of directors acknowledged that the inclusion of a fixed amount of cash per share
as a component of the overall consideration that Ortho shareholders would receive offered significant certainty in value to the Ortho shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on December&nbsp;21, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith met telephonically and taking into account the consideration analyses prepared by Perella
Weinberg, the financing availability evaluation provided by Citi and the discussions with members of the Quidel board of directors, and discussions with the Ortho board of directors, respectively, agreed in principle on the terms for the combination
at an implied value of $24.75 per share based on Quidel&#146;s closing stock price on December&nbsp;21, 2021, consisting of $7.14 in cash and 0.1055 Topco Shares per Ortho Share (referred to in this joint proxy statement/prospectus as the
&#147;Ortho Scheme Consideration&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;21, 2021, Ortho entered into an engagement letter with J.P. Morgan confirming the
engagement of J.P. Morgan as its financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2021, Mr.&nbsp;Bryant and Mr.&nbsp;Smith agreed in principle that the board of
directors of the combined company would have 12 members, with four directors from Ortho and eight directors from Quidel. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2021,
at a meeting of the Quidel board of directors that was attended by certain members of Quidel&#146;s senior management and representatives from Perella Weinberg, Ms.&nbsp;Hodges provided an overview of the directors&#146; fiduciary duties in
connection with their evaluation of the proposed transaction, and summarized the terms of the proposed transaction, as reflected in the BCA and the Stockholders Agreement. In the course of their deliberation, the Quidel board of directors reviewed a
variety of materials, including the forecasts prepared by Quidel management and Ortho management, including the Ortho Synergies Estimates. The Quidel board of directors did not give any particular materials more weight than any other materials in
its decision making process. Representatives of Perella Weinberg then reviewed with the Quidel board of directors Perella Weinberg&#146;s financial analysis with respect to the Consideration of 0.1055 Topco Shares and $7.14 in cash per Ortho Share
to be paid by Quidel pursuant to the BCA, taking into account the Quidel Exchange Ratio of one Topco Share per Quidel Share to be received by the Quidel stockholders in the Combinations and rendered an oral opinion, subsequently confirmed in
writing, to the Quidel board of directors that, as of such date and based upon and subject to the various assumptions made, procedures followed, matters considered, and qualifications and limitations set forth therein, the consideration of 0.1055
Topco Shares and $7.14 in cash per Ortho Share to be paid by Quidel pursuant to the BCA was fair, from a financial point of view, to Quidel, taking into account the Quidel Exchange Ratio, as described in the section entitled &#147;The
Combinations&#151;Opinion of Perella Weinberg Partners LP as Financial Advisor to Quidel&#148; of this joint proxy statement/prospectus. Ms.&nbsp;Hodges then presented a set of proposed resolutions approving the BCA and the transactions contemplated
thereby. On a motion duly made and seconded, the Quidel board of directors approved the resolutions by a unanimous vote. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on December&nbsp;22,
2021, at a meeting of the Ortho board of directors that was attended by certain members of Ortho&#146;s senior management and representatives from J.P. Morgan and Latham, representatives of J.P. Morgan summarized the current proposal of
consideration equal to $7.14 in cash and 0.1055 Topco Shares per Ortho Share, which would represent an implied premium of 25% when compared to Ortho&#146;s closing stock price on December&nbsp;22, 2021. Representatives of J.P. Morgan then reviewed
with the Ortho board of directors the strategic rationale for the transaction and their financial analysis with respect to the proposed consideration, and rendered an oral opinion, subsequently confirmed in writing that, subject to customary
qualifications and as of such date, the consideration of $7.14 in cash and 0.1055 Topco Shares per Ortho Share was fair from a financial perspective to Ortho shareholders, as described in the section entitled &#147;The Combinations&#151;Opinion of
J.P. Morgan Securities LLC as Financial Advisor to Ortho&#148; of this joint proxy statement/prospectus. Representatives of Latham then summarized key terms of the BCA, Stockholders Agreement and Irrevocable Undertaking, and summarized fiduciary
duties of the members of the Ortho board of directors as directors of a UK company. On a motion duly made and seconded, the Ortho board of directors approved the resolutions previously circulated to the directors by a unanimous vote, unanimously
agreed that Mr.&nbsp;Smith and Robert Schmidt of Carlyle were authorized to approve final changes to the BCA and transaction documents, and then adjourned the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on December&nbsp;22, 2021, Ortho and Quidel executed the BCA. Also on December&nbsp;22, 2021, Carlyle executed its Irrevocable Undertaking and Carlyle,
Ortho and Quidel executed the Stockholders Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;23, 2021, Quidel entered into an engagement letter with Citi confirming the
engagement of Citi as its financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;23, 2021, Ortho and Quidel issued a joint press release announcing the transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_137"></A>Ortho Scheme Consideration to Ortho Shareholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA provides that, at the Ortho Effective Time, each Ortho Share issued and outstanding immediately prior to the Scheme Record Time (other than Ortho
Shares that are held in treasury by Ortho, if any (each, an &#147;Excluded Ortho Share&#148;)), will be acquired by GTU Ops Inc. (a Computershare entity) or another company mutually acceptable to Quidel and Ortho and falling within
Section&nbsp;67(6) of the Finance Act 1986 (the &#147;DR Nominee&#148;) (or, if the DR Nominee holds the Ortho Shares today, transferred within the DR Nominee) on behalf and for the benefit of Topco in exchange for (a) 0.1055 Topco Shares and (b)
$7.14 in cash (collectively, the &#147;Ortho Scheme Consideration&#148;). As of the Ortho Effective Time, holders of Ortho Shares (and any holders of depositary interests in Ortho Shares) shall cease to have any rights with respect to Ortho Shares,
except their rights under the Ortho Scheme to receive the Ortho Scheme Consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_139"></A>Quidel Reasons for the Combinations and Recommendation of the Quidel Board of
Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors has determined that the Combinations, including the Quidel Merger and the other transactions contemplated by
the BCA, are consistent with and will further the business strategies and goals of Quidel, and are in the best interests of Quidel and its stockholders. At its meeting on December&nbsp;22, 2021, the Quidel board of directors (a)&nbsp;unanimously
approved and declared advisable the BCA and Combinations, including the Quidel Merger and the transactions contemplated by the BCA, and (b)&nbsp;determined, subject to its duties under applicable law, to recommend that the Quidel stockholders adopt
the BCA and the transactions contemplated by the BCA, including the Quidel Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors recommends that Quidel stockholders
vote: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>FOR</B>&#148; the Merger Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>FOR</B>&#148; the Advisory Merger Compensation Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>FOR</B>&#148; the Adjournment Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>FOR</B>&#148; the Election of Directors Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>FOR</B>&#148; the Advisory Executive Compensation Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>FOR</B>&#148; the Independent Registered Public Accounting Firm Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>FOR</B>&#148; the Equity Incentive Plan Proposal; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>FOR</B>&#148; the ESPP Proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors considered many factors in reaching its conclusion that the transactions contemplated by the BCA as a whole, including the
Combinations, are fair to, and in the best interests of Quidel and its stockholders. In arriving at its conclusion, the Quidel board of directors consulted with Quidel&#146;s management and its legal, financial and other advisors, reviewed a
significant amount of information (including information prepared by its advisors) and considered the following factors in its deliberations: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Strategic Considerations</I>. The Quidel board of directors believes that the Combinations present, and are expected to provide, a number of significant
strategic opportunities and benefits to Quidel and its stockholders, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that the combined company will meet patient testing needs at all points of the care continuum,
including reference labs, hospitals, physicians&#146; offices, urgent care centers and <FONT STYLE="white-space:nowrap">at-home</FONT> / retail locations, due to the complementary nature of the companies&#146; products and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that Ortho&#146;s commercial team will better position and support a successful launch of
Quidel&#146;s new flagship product, the Savanna molecular platform, by providing access to more customers in the United States and worldwide; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that the transaction will accelerate development of a global commercial footprint for sales of other
Quidel products by utilizing Ortho&#146;s commercial teams, customer support, regulatory teams and other infrastructure across over 130 countries and provide accelerated international commercial opportunities for products such as Sofia;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that the transaction will provide immediate potential product development opportunities, including dry
film technology expansion opportunities for Quidel&#146;s point of care customers and immunoassay expansion opportunities for Ortho&#146;s instruments, particularly given the strength of each company&#146;s research and development capabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that the combined company will unite world-class technologies and platforms to benefit customers with
multiple modalities to address increasingly diverse clinical and customer needs and expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">point-of-care</FONT></FONT> diagnostics offerings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expectation that the transaction would provide Quidel with organic and inorganic expansion opportunities into
significant new and emerging markets, including for continued diversification in telehealth technology and digital health; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that the transaction will position Quidel as a leader in the diagnostics industry, bringing together
innovative, complementary products, solutions and services that enhance the health and well-being of patients </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
across the globe, including a larger more broad-based company with greater flexibility to support our communities in their testing needs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expectation that the combined company will realize approximately $90&nbsp;million of <FONT
STYLE="white-space:nowrap">run-rate</FONT> cost-related synergies, excluding <FONT STYLE="white-space:nowrap">one-time</FONT> costs, by the end of year three, driven primarily from operational efficiencies, supply chain optimization, and shared
administrative functions, including public company costs, and has the potential to realize even greater synergies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expectation that the transaction will generate strong cross-selling revenue synergies in excess of
$100&nbsp;million by 2025 and meaningful adjusted EBITDA benefits, which are expected to be driven by the enhanced global commercial reach and expansive product portfolio of the combined company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expectation that the combined company will have improved talent attractiveness, offering more opportunities
to employees functionally and globally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cultural alignment between Quidel and Ortho, which both have talented and experienced employees who share a
commitment to customers, patients and the communities the companies serve; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expectation that the transactions will result in a more diversified combined company with more stable and
consistent revenue profile that can also continue to benefit from seasonal opportunities, and with a strong balance sheet with significant cash generation potential; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that the transaction provides an attractive use of Quidel&#146;s cash and presents significant
potential growth and value creation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Factors Considered by the Quidel Board of Directors</I>. In addition to considering the
strategic factors described above, the Quidel board of directors considered the following additional factors, all of which it viewed as supporting its decision to approve the Combinations and make its recommendations to Quidel stockholders: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that eight of the members of the <FONT STYLE="white-space:nowrap">12-member</FONT> Topco board of
directors will be designated by Quidel, and that the committees of the Topco board of directors will be comprised of one director designated by Ortho and at least two directors designated by Quidel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that Douglas Bryant, current President and Chief Executive Officer of Quidel, will serve as the Chief
Executive Officer of Topco and Chair of the Topco board of directors and that Robert Bujarski, current Chief Operating Officer of Quidel, will serve as the President and Chief Operating Officer of Topco; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that the above-described governance matters would position the combined company for a successful
integration process, future success and synergies realization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fixed exchange ratio of one Ortho Share for 0.1055 Topco Shares, which, by its nature, would not adjust to
compensate for increases or declines in the price of Ortho Shares prior to completion of the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fixed exchange ratio of one Quidel Share for one Topco Share, which, by its nature, would not adjust to
compensate for increases or declines in the price of the Quidel Shares prior to completion of the Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, based on the shares outstanding as of the date of the BCA, Quidel&#146;s former stockholders will
own approximately 62% of the combined company following completion of the Combinations and will continue to participate in potential appreciation in equity value of the combined company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, in certain circumstances, the Quidel board of directors has the right under the BCA to change its
recommendation to Quidel stockholders that they adopt the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its knowledge and understanding of the Quidel business, operations, financial condition, earnings, strategy,
risks and future prospects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information and discussions with Quidel&#146;s management regarding Ortho&#146;s business, operations, financial
condition, earnings, strategy and future prospects, and the results of Quidel&#146;s due diligence review of Ortho; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the current and prospective business environment in which Quidel and Ortho operate, including the impact of the
COVID pandemic, international, national and local economic conditions, the competitive and regulatory environment, and the likely effect of these factors on Quidel and the combined company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recommendation of Quidel&#146;s senior management in favor of the Combinations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the financial analyses presented by Perella Weinberg to the Quidel board of directors and the opinion of Perella
Weinberg delivered to the Quidel board of directors to the effect that, as of December&nbsp;22, 2021, and based upon and subject to the various assumptions made, procedures followed, matters considered and qualifications and limitations set forth in
Perella Weinberg&#146;s written opinion, the Ortho Scheme Consideration of 0.1055 Topco Shares and $7.14 in cash per Ortho Share to be paid by Quidel pursuant to the BCA was fair, from a financial point of view, to Quidel, taking into account the
Quidel Exchange Ratio of one Topco Share per Quidel Share, as more fully described in the section entitled &#147;The Combinations&#151;Opinion of Perella Weinberg Partners LP as Financial Advisor to Quidel&#148; of this joint proxy
statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood that the Combinations will be completed on a timely basis and the belief that antitrust clearance
could be obtained without the imposition of conditions that would be materially adverse to the combined company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Quidel Merger is subject to approval by the Quidel stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, subject to certain limited exceptions, Ortho is prohibited from soliciting, participating in any
discussions or negotiations with respect to, providing <FONT STYLE="white-space:nowrap">non-public</FONT> information to any third party with respect to or entering into any agreement providing for, the acquisition of Ortho; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that Ortho may be required to pay Quidel a termination fee of approximately $46.9&nbsp;million and/or
reimburse Quidel for certain reasonable costs, fees and expenses it incurs if the BCA is terminated under certain circumstances specified in the BCA; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Quidel Exchange Ratio will not be negatively affected in the event of a decrease in the share
price of the Quidel Shares prior to the Quidel Effective Time and that the terms of the BCA do not include termination rights for Ortho triggered in the event of an increase of the value of Ortho relative to the value of Quidel.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors also considered the following specific aspects of the BCA: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representations and warranties of Ortho and Quidel, as well as the interim operating covenants requiring the
parties to conduct their respective businesses in the ordinary course prior to completion of the Combinations, subject to specific limitations, which are generally reciprocal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of consummation of the Combinations and the Quidel board of directors&#146; evaluation of the
likely time period necessary to complete the Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the nature of the closing conditions included in the BCA, including the exceptions to the events that would
constitute a material adverse effect with respect to Ortho or Quidel for purposes of the BCA, as well as the likelihood of satisfaction of all conditions to consummation of the Combinations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel&#146;s right to engage in negotiations with, and provide information to, a third party that makes an
unsolicited Acquisition Proposal for Quidel (as defined in the section entitled &#147;The Business Combination Agreement&#151;Acquisition Proposals&#148; of this joint proxy statement/prospectus), if the Quidel board of directors determines in good
faith, after consultation with its outside legal and financial advisors, that such proposal constitutes or would reasonably be expected to lead to, a Superior Proposal (as defined in the section entitled &#147;The Business Combination
Agreement&#151;Acquisition Proposals&#148; of this joint proxy statement/prospectus); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Quidel board of directors&#146; ability to change its recommendation that Quidel stockholders vote in favor
of the adoption of the BCA if it determines in good faith after consultation with its outside counsel that failure to take such action would be inconsistent with its fiduciary duties under applicable law, subject to compliance by Quidel with certain
obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement for the parties to use reasonable best efforts to obtain all regulatory approvals or clearances;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the restrictions in the BCA on Ortho&#146;s ability to respond to and negotiate certain alternative transaction
proposals from third parties and the requirement that Ortho pay Quidel an approximately $46.9&nbsp;million termination fee if the BCA is terminated under certain circumstances; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain other provisions in the BCA, including the termination provisions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that the size of the termination fee that might be payable to Ortho pursuant to the BCA (i)&nbsp;was
reasonable in light of the overall terms of the BCA, (ii)&nbsp;was within the range of termination fees in other transactions of this size and nature and (iii)&nbsp;would not be likely to preclude another party from making a competing proposal for
Quidel. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors weighed these advantages and opportunities against a number of potentially
negative factors in its deliberations concerning the BCA and the Combinations, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Ortho Exchange Ratio will not be reduced in the event of an increase in the share price of Quidel Shares
prior to the Quidel Effective Time, and that the terms of the BCA do not include termination rights for Quidel triggered in the event of a decrease in the value of Ortho relative to the value of Quidel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cash consideration payble to the Ortho shareholders by Quidel under the BCA is fixed and will not be reduced
in the event of a decrease in the share price of Ortho Shares prior to the Effective Time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential that the fixed exchange ratio under the BCA could result in Quidel delivering greater value to the
Ortho shareholders than had been anticipated by Quidel should the value of the Quidel Shares increase relative to Ortho Shares after the date of execution of the BCA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the significant costs to be incurred in connection with the Combinations, including the substantial cash and
other costs required to integrate the businesses of Quidel and Ortho, as well as transaction expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that projections of future results of operations and synergies are necessarily estimates based on
assumptions, the risk of not realizing the estimates of synergies anticipated by Quidel&#146;s management to result from the Combinations and cost savings between Quidel and Ortho, or that such benefits may take longer than expected to be realized,
if at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the difficulties inherent in the combination of two companies of the size and scope of Quidel and Ortho,
including (i)&nbsp;challenges related to integrating and retaining management and employees and (ii)&nbsp;the possible diversion of management focus and resources from operational matters and other strategic opportunities for an extended period of
time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the adverse impact that business uncertainty prior to the closing of the Combinations and during the post-closing
integration period could have on the ability of both Quidel and Ortho to attract, retain and motivate key personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential adverse effect that the Combinations could have on Quidel&#146;s business and relationships with
employees, customers, suppliers, regulators and the communities in which it operates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that governmental entities may not approve the Combinations or may impose conditions on Quidel or Ortho
in order to gain approval for the Combinations that may adversely impact the ability of Topco to realize the estimates of synergies anticipated by Quidel&#146;s management to result from the Combinations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limited circumstances under which Quidel could terminate the BCA or refuse to consummate the Combinations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that Quidel, subject to customary exceptions, is prohibited during the term of the BCA from soliciting,
participating in any discussions or negotiations with respect to, and providing nonpublic information to any third party with respect to, the acquisition of Quidel and that Quidel is prohibited from terminating the BCA to enter into any agreement
providing for the acquisition of Quidel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that certain provisions of the BCA, although reciprocal, may have the effect of discouraging alternative
proposals involving Quidel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that, pursuant to the terms of the BCA, Quidel may become obligated to pay a termination fee of
approximately $207.8&nbsp;million and/or reimburse Ortho for certain reasonable costs, fees and expenses it incurs in certain circumstances; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the generally reciprocal restrictions on operations until completion of the Combinations which could have the
effect of preventing Quidel from pursuing certain other strategic transactions during the pendency of the BCA as well as taking certain other actions relating to the conduct of its business without the prior consent of Ortho; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, if the Quidel board of directors effects a Change in Laguna Recommendation (as defined in the BCA)
(a &#147;Quidel Change in Recommendation&#148;), Quidel will nonetheless be obligated to hold the Quidel Stockholders&#146; Meeting and submit the proposals described in this joint proxy statement/prospectus to its stockholders for their vote unless
Quidel terminates the BCA or except in the case of a Quidel All Cash Superior Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that failure to complete the Combinations could cause Quidel to incur significant fees and expenses and could
lead to negative perceptions among investors, potential investors, customers and employees; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for litigation relating to the Combinations and the associated costs, time, burden and
inconvenience involved in defending those proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that Ortho shareholders or Quidel stockholders, as applicable, may vote down the proposals at the Ortho
Court Meeting or Quidel Stockholders&#146; Meeting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other risks of the type and nature described under the sections entitled &#147;Risk Factors&#148; and
&#147;Cautionary Statement Concerning Forward-Looking Statements&#148; of this joint proxy statement/prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of
directors concluded that the uncertainties, risks and potentially negative factors relevant to the Combinations were outweighed by the potential benefits that it expected Quidel and the Quidel stockholders would achieve as a result of the
Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing discussion of the information and factors considered by the Quidel board of directors is not exhaustive but is intended to
reflect the material factors considered by the Quidel board of directors in its consideration of the business combination with Ortho. In view of the large number of factors considered and their complexity, the Quidel board of directors, both
individually and collectively, did not find it practicable to and did not attempt to quantify or assign any relative or specific weight to the various factors. Rather, the Quidel board of directors based its recommendation on the totality of the
information presented to and considered by it. In addition, individual members of the Quidel board of directors may have given different weights to different factors. The foregoing discussion of the information and factors considered by the Quidel
board of directors is forward-looking in nature. This information should be read in light of the factors described under the section entitled &#147;Cautionary Statement Concerning Forward-Looking Statements&#148; of this joint proxy
statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_138"></A>Ortho Reasons for the Combinations and Recommendation of the Ortho Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho board of directors has determined, having consulted with J.P. Morgan, financial advisor to Ortho in connection with the Combinations, that the
transactions contemplated by the BCA, including the Ortho Scheme, are fair to, and in the best interests of, Ortho and its shareholders. At its meeting on December&nbsp;22, 2021, the Ortho board of directors, among other things, (a)&nbsp;determined
that the Ortho Scheme and the transactions contemplated by the BCA as a whole are in the best interests of Ortho, would further the business goals and strategies of Ortho and would promote the success of Ortho for the benefit of its shareholders as
a whole, (b)&nbsp;approved the terms of the BCA, including but not limited to the Ortho Scheme, (c)&nbsp;directed that the Ortho Scheme be recommended to Ortho&#146;s shareholders and, subject to receiving the vote of Ortho shareholders, that the
Ortho Scheme be approved and (d)&nbsp;approved the execution and delivery of the BCA by any director of Ortho. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Ortho board of directors recommends
that Ortho shareholders vote &#147;FOR&#148; each of the proposals at the Ortho Court Meeting and &#147;FOR&#148; each of the proposals at the Ortho General Meeting. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho board of directors considered many factors in reaching its conclusion that the transactions contemplated by the BCA as a whole, including the
Combinations, are fair to, and in the best interests of Ortho and its shareholders. In arriving at its conclusion, the Ortho board of directors consulted with Ortho&#146;s management and its legal, financial and other advisors, reviewed a
significant amount of information and considered the following factors in its deliberations: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that the combination will result in the creation of a leader in the diagnostics industry with <FONT
STYLE="white-space:nowrap">top-tier</FONT> research and development capabilities, a more diverse product pipeline and a broader geographic footprint; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that Ortho&#146;s and Quidel&#146;s product and service offerings are highly complementary and provide
opportunities to capture significant growth globally while enhancing cross-selling opportunities across a diversified customer and channel mix, including by enhancing the ability to meet patient needs at all points of the care continuum;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that Ortho and Quidel have complementary cultures and that their respective management teams will
successfully integrate the two businesses after closing of the Combinations and provide a strong foundation for the combined management team to accelerate growth, stimulate the sharing of expertise and support faster innovation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that the combination will accelerate innovative product expansion through complementary capabilities
and product development synergies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that the combination will allow Topco to achieve estimated cost synergies of $95&nbsp;million by the
end of the third year after closing of the Combinations, driven primarily by operational efficiencies, supply chain optimization and shared administrative functions, and cross-selling revenue synergies in excess of $100&nbsp;million by 2025, as well
as opportunities for adjusted EBITDA margin expansion, supporting enhanced cash generation; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These beliefs are based in part on the
following factors that the Ortho board of directors considered: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its knowledge and understanding of Ortho&#146;s business, operations, financial condition, earnings, strategy and
future prospects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information and discussions with Ortho&#146;s management regarding Quidel&#146;s business, operations, financial
condition, earnings, strategy and future prospects, and the results of Ortho&#146;s due diligence review of Quidel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that <FONT STYLE="white-space:nowrap">one-third</FONT> of the Topco board of directors following
completion of the Combinations will be designated by Ortho; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Topco board of directors shall have an Audit Committee, a Nominating and Corporate Governance
Committee and a Compensation Committee, each of which will include one director designated by Ortho at the closing of the Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that Joseph M. Busky, the current chief financial officer of Ortho, will be the chief financial officer
of Topco and Michael Iskra, the current executive vice president of commercial excellence and strategy of Ortho, will be the chief commercial officer of Topco; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the current and prospective economic climate generally and the competitive climate in the industries in which
Ortho and Quidel operate, including the combination of certain other companies in such industries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, based on the shares outstanding as of the date of signing of the BCA, Ortho&#146;s former
shareholders will own approximately 38% of Topco following completion of the Combinations and will continue to participate in potential appreciation in the equity value of Topco; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the financial analyses presented by J.P. Morgan and the oral opinion of J.P.&nbsp;Morgan delivered to the Ortho
board of directors on December&nbsp;22, 2021, which was confirmed by delivery of a written opinion, dated as of December&nbsp;23, 2021, to the effect that, as of such date and based upon and subject to the assumptions made, procedures followed,
matters considered and limitations on the review undertaken by J.P.&nbsp;Morgan in preparing its opinion, the Ortho Scheme Consideration was fair, from a financial point of view, to the holders of Ortho Shares, as more fully described below in the
section entitled &#147;Opinion of J.P. Morgan Securities LLC as Financial Advisor to Ortho&#148;<I> </I>of this joint proxy statement/prospectus (with the full text of the written opinion of J.P.&nbsp;Morgan, dated as of December&nbsp;23, 2021,
which sets forth, among other things, the assumptions made, procedures followed, matters considered and limitations on the review undertaken by J.P.&nbsp;Morgan in preparing its opinion, attached as Annex E to this joint proxy statement/prospectus
and incorporated herein by reference); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the review by the Ortho board of directors with its legal advisor of the structure of the proposed business
combination transaction and the terms of BCA, including the conditions to their respective obligations and the termination provisions, as well as the likelihood of consummation of the Combinations and the Ortho board of directors&#146; evaluation of
the likely time period necessary to complete the Combinations: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the degree of mutuality and symmetry of representations, obligations and rights of the parties under the BCA, the
conditions to each party&#146;s obligation to close the transaction and the circumstances in which each party is permitted to terminate the BCA, and the likelihood that the Combinations will be completed on a timely basis and the belief that
antitrust clearance could be obtained without the imposition of conditions that would be materially adverse to Topco; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the nature of the closing conditions included in the BCA, including the exceptions to the events that would
constitute a material adverse effect with respect to Ortho or Quidel for purposes of the BCA, as well as the likelihood of satisfaction of all conditions to consummation of the Combinations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho&#146;s right to engage in negotiations with, and provide information to, a third party that makes an
unsolicited Acquisition Proposal for Ortho (as defined in the section entitled &#147;The Business Combination Agreement&#151;Acquisition Proposals&#148; of this joint proxy statement/prospectus), if the Ortho board of directors determines in good
faith, after consultation with its legal and financial advisors, that such proposal constitutes or would reasonably be expected to lead to a Superior Proposal (as defined in the section entitled &#147;The Business Combination
Agreement&#151;Acquisition Proposals&#148; of this joint proxy statement/prospectus); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Ortho board of directors&#146; ability to change its recommendation that Ortho shareholders vote in favor of
the adoption of the BCA if it determines in good faith after consultation with its outside counsel that failure to take such action would be inconsistent with its fiduciary duties under applicable law, subject to compliance by Ortho with certain
obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the right of Ortho to terminate the BCA if the Ortho board of directors makes a Change in Orca Recommendation (as
defined in the BCA) (an &#147;Ortho Change in Recommendation&#148;) in response to a Superior Proposal for Ortho that includes only cash consideration, is fully financed and does not include any financing condition (an &#147;Ortho All Cash Superior
Proposal&#148;), subject to certain requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain other provisions in the BCA, including the termination provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Ortho Scheme is subject to approval by the Ortho shareholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that Carlyle Partners VI Cayman Holdings, L.P. (the &#147;Carlyle Stockholder&#148;) entered into a deed
of irrevocable undertaking (as further described in the section entitled &#147;Stockholders Agreement / Deed of Irrevocable Undertaking&#148; of this joint proxy statement/prospectus), which requires the Carlyle Stockholder to vote its 118,106,000
Ortho Shares (representing approximately 49.79% of the Ortho Shares) in favor of the Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, subject to certain limited exceptions, Quidel is prohibited from soliciting, participating in any
discussions or negotiations with respect to, providing <FONT STYLE="white-space:nowrap">non-public</FONT> information to any third party with respect to or entering into any agreement providing for, the acquisition of Quidel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that Quidel may be required to pay Ortho a termination fee of approximately $208&nbsp;million and/or
reimburse Ortho for reasonable expenses it incurs if the BCA is terminated under certain circumstances specified in the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Ortho shareholders will receive $7.14 in cash for each Ortho Share, which significantly
increases certainty in the value of the Ortho Scheme Consideration to Ortho shareholders, regardless of changes in the price of the Quidel Shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Ortho Exchange Ratio of 0.1055 Topco Shares for each Ortho Share will not be reduced under the
BCA in the event of a decrease in the share price of the Ortho Shares, or any increase in the price of Quidel Shares, prior to the Ortho Effective Time and that the terms of the BCA do not include termination rights for Quidel triggered in the event
of an increase of the value of Quidel relative to the value of Ortho. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In making its determination, the Ortho board of directors also
considered Ortho&#146;s strategic alternatives to the proposed business combination with Quidel for maximizing shareholder value over the long-term, including the alternative of attempting to replicate the capabilities inherent in the proposed
business combination by continuing as a standalone company or through an alternative business combination. In considering these alternatives, the Ortho board of directors weighed the potential risks, rewards and uncertainties associated with each
and took into consideration the fact that, prior to the initial public offering of Ortho, Ortho&#146;s financial advisors had explored alternative business combination opportunities and none were identified that were expected to be as attractive to
Ortho and its shareholders as the Combinations. The Ortho board of directors concluded, based on its understanding of the business, assets, financial condition, results of operations, current business strategy, projections and prospects of Ortho,
that the business combination transaction with Quidel was the best alternative reasonably available to Ortho. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho board of directors weighed these
factors against the following uncertainties, risks and potentially negative factors relevant to the Combinations: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Ortho Exchange Ratio will not be increased under the BCA in the event of an increase in the share price of
Ortho Shares, or a decrease in the share price of the Quidel Shares prior to the Ortho Effective Time, and the terms of the BCA do not include termination rights for Ortho triggered in the event of a decrease in the value of Quidel relative to the
value of Ortho; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential that the fixed exchange ratio under the BCA could result in greater value to the Quidel
stockholders than had been anticipated by Ortho should the market value of the Ortho Shares increase relative to Quidel Shares after the date of execution of the BCA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the adverse impact that business uncertainty prior to the closing of the Combinations and during the post-closing
integration period could have on the ability of both Ortho and Quidel to attract, retain and motivate key personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the challenges inherent in the combination of two business enterprises of the size and scope of Ortho and Quidel,
including (a)&nbsp;the possible diversion of management focus and resources from operational matters and other strategic opportunities for an extended period of time and (b)&nbsp;difficulties in integrating and retaining management and employees;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that projections of future results of operations and synergies are necessarily estimates based on
assumptions, the risk of not realizing the estimates of synergies anticipated by Ortho&#146;s management to result from the Combinations and cost savings between Ortho and Quidel and the risk that other anticipated benefits might not be realized;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the substantial costs to be incurred in connection with the transaction, including the substantial cash and other
costs of integrating the businesses of Ortho and Quidel, as well as transaction expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that failure to complete the Combinations could cause Ortho to incur significant fees and expenses and could lead
to negative perceptions among investors, potential investors and customers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential effect of the transaction on Ortho&#146;s business and relationships with employees, customers,
suppliers, regulators and the communities in which it operates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that governmental entities may not approve the transaction, or may impose conditions on Ortho or Quidel
in order to gain approval for the transaction that may adversely impact the ability of Topco to realize the estimates of synergies anticipated by Ortho&#146;s management to result from the Combinations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limited circumstances under which Ortho could terminate the BCA or refuse to consummate the Combinations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that Ortho, subject to customary exceptions, is prohibited during the term of the BCA from soliciting,
participating in any discussions or negotiations with respect to, and providing <FONT STYLE="white-space:nowrap">non-public</FONT> information to any third party with respect to, the acquisition of Ortho and that, subject to limited exceptions in
response to an Ortho All Cash Superior Proposal, Ortho may not terminate the BCA to enter into any agreement providing for the acquisition of Ortho; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that, pursuant to the terms of the BCA, Ortho may become obligated to pay a termination fee of
approximately $47&nbsp;million and/or reimburse Quidel for certain reasonable costs, fees and expenses it incurs in certain circumstances; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the generally reciprocal restrictions on operations until completion of the Combinations which could have the
effect of preventing Ortho from pursuing certain other strategic transactions during the pendency of the BCA as well as taking certain other actions relating to the conduct of its business without the prior consent of Quidel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, if the Ortho board of directors effects an Ortho Change in Recommendation, subject to limited
exceptions in response to an Ortho All Cash Superior Proposal, Ortho will nonetheless be unable to terminate the BCA and will be obligated to hold the Ortho Shareholder Meetings and submit the proposals described in this joint proxy
statement/prospectus to its shareholders for their vote unless Quidel terminates the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the deed of irrevocable undertaking entered into by the Carlyle Stockholder will remain in effect
after an Ortho Change in Recommendation such that the Carlyle Stockholder would still be required to vote in favor of the Combinations, notwithstanding the Ortho Change in Recommendation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that the transaction might not be completed, or that completion might be unduly delayed, for
reasons beyond either party&#146;s control and the potential negative impact that may have on each party&#146;s business and relationships with employees, customers, suppliers, regulators and the communities in which it operates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, if the Combinations are completed, the Ortho Scheme will bind all Ortho shareholders, including
those who did not vote to approve the Scheme Proposal at the Ortho Court Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, after announcement of the Combinations, the share price of Ortho Shares is expected to be
influenced by the pendency of the Combinations and, in that context, changes in the share price of Quidel Shares, the perceived likelihood of completion of the Combinations and the anticipated performance of Topco after the Combinations could impact
the price of Ortho Shares, in addition to the performance of Ortho as a standalone company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potentially differing interests of Ortho directors and executive officers with respect to the consummation of
the Combinations, including in connection with (a)&nbsp;the continued engagement and/or employment of such directors </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and executive officers, (b)&nbsp;the continued positions of certain of such directors as directors on the Topco board of directors and (c)&nbsp;the treatment in the Combinations of equity awards
held by Ortho directors and executive officers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks of the type and nature described under the sections entitled &#147;Risk Factors&#148; and
&#147;Cautionary Statement Concerning Forward-Looking Statements&#148; of this joint proxy statement/prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho board of
directors concluded that the uncertainties, risks and potentially negative factors relevant to the Combinations were outweighed by the potential benefits that it expected Ortho and the Ortho shareholders would achieve as a result of the
Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing discussion of the information and factors considered by the Ortho board of directors is not exhaustive but is intended to
reflect the material factors considered by the Ortho board of directors in its consideration of the business combination with Quidel. In view of the large number of factors considered and their complexity, the Ortho board of directors, both
individually and collectively, did not find it practicable to and did not attempt to quantify or assign any relative or specific weight to the various factors. Rather, the Ortho board of directors based its recommendation on the totality of the
information presented to and considered by it. In addition, individual members of the Ortho board of directors may have given different weights to different factors. The foregoing discussion of the information and factors considered by the Ortho
board of directors is forward-looking in nature. This information should be read in light of the factors described under the sections entitled &#147;Cautionary Statement Concerning Forward-Looking Statements&#148; and &#147;Risk Factors&#148; of
this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_141"></A>Opinion of Perella Weinberg Partners LP as Financial Advisor to Quidel </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel retained Perella Weinberg to act as its financial advisor in connection with the Combinations. Quidel selected Perella Weinberg based on its
qualifications, expertise and reputation and its knowledge of the business and affairs of Quidel and the industry in which Quidel conducts its businesses. Perella Weinberg, as part of its investment banking business, is continually engaged in
performing financial analyses with respect to businesses and their securities in connection with mergers and acquisitions, leveraged buyouts and other transactions as well as for corporate and other purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2021, Perella Weinberg rendered its oral opinion, subsequently confirmed in writing, to the Quidel board of directors that, as of such
date and based upon and subject to the various assumptions made, procedures followed, matters considered and qualifications and limitations set forth therein, the Ortho Scheme Consideration of 0.1055 Topco Shares and $7.14 in cash per Ortho Share to
be paid by Quidel pursuant to the BCA was fair, from a financial point of view, to Quidel, taking into account the Quidel Exchange Ratio of one Topco Share per Quidel Share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The full text of Perella Weinberg&#146;s written opinion, dated December&nbsp;22, 2021, which sets forth, among other things, the assumptions made,
procedures followed, matters considered and qualifications and limitations on the review undertaken by Perella Weinberg in preparing its opinion, is attached hereto as Annex D and is incorporated herein by reference. Holders of Quidel Shares should
read the opinion carefully and in its entirety. Perella Weinberg&#146;s opinion does not address Quidel&#146;s underlying business decision to enter into the BCA or the relative merits of the Combinations as compared with any other strategic
alternative that may be available to Quidel. Perella Weinberg was not authorized to solicit, and did not solicit, indications of interest in a transaction with Quidel from any party. Perella Weinberg&#146;s opinion was not intended to be and does
not constitute a recommendation to any holder of Quidel Shares or Ortho Shares, or any other person, as to how such person should vote or otherwise act with respect to the Combinations or any other matter. Perella Weinberg&#146;s opinion does not in
any manner address the prices at which the Quidel Shares, the Ortho Shares or the Topco Shares will trade at any time. In addition, Perella Weinberg expressed no opinion as to the fairness of the Combinations to, or any consideration received in
connection with the Combinations by, the holders of any other class of securities, creditors or other constituencies of Quidel. Perella Weinberg provided its opinion for the information and assistance of the Quidel board of directors in connection
with, and for the purposes of its evaluation of, the Combinations. The summary of the written opinion of Perella Weinberg is qualified in its entirety by reference to the full text of the written opinion attached as Annex D to this joint proxy
statement/prospectus. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with rendering its opinion and performing its related financial analyses, Perella Weinberg, among other things:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed certain publicly available financial statements and other business and financial information with
respect to Quidel and Ortho, including equity research analyst reports; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed certain internal financial statements, analyses and forecasts, including sensitivities thereto (the
&#147;Quidel Management Projections for Quidel&#148;), and other financial and operating data relating to the business of Quidel, in each case, prepared by management of Quidel (as set forth in &#147;Unaudited Forward-Looking Financial
Information&#151;Quidel Unaudited Forward-Looking Financial Information&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed certain internal financial statements, analyses and forecasts (the &#147;Ortho Management Projections
for Ortho&#148;), and other financial and operating data relating to the business of Ortho, in each case, prepared by management of Ortho and approved for Perella Weinberg&#146;s use by management of Quidel (as set forth in &#147;Unaudited
Forward-Looking Financial Information&#151;Ortho Unaudited Forward-Looking Financial Information&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed certain internal financial statements, analyses and forecasts (the &#147;Quidel Management Projections
for Ortho&#148;) relating to the business of Ortho prepared by management of Quidel (as set forth in &#147;Unaudited Forward-Looking Financial Information&#151;Quidel Unaudited Forward-Looking Financial Information&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed the Quidel Synergies Estimates (as defined below); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussed the past and current business, operations, financial condition and prospects of Quidel, including the
Quidel Synergies Estimates, with the management and other representatives of Quidel, and discussed the past and current business, operations, financial condition and prospects of Ortho with the management and other representatives of Quidel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed the relative financial contributions of Quidel and Ortho to the future financial performance of Topco on
a pro forma basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compared the financial performance of Quidel and Ortho with that of certain other publicly traded companies which
Perella Weinberg believed to be generally relevant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compared the financial terms of the proposed Combinations with the publicly available financial terms of certain
transactions which Perella Weinberg believed to be generally relevant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed the historical trading prices and trading activity for the Quidel Shares and Ortho Shares, and compared
such prices and trading activity of the Quidel Shares and Ortho Shares with those of securities of certain other publicly traded companies which Perella Weinberg believed to be generally relevant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">participated in discussions among representatives of Quidel and Ortho and their respective advisors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed a draft, dated December&nbsp;22, 2021, of the BCA; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducted such other financial studies, analyses and investigations, and considered such other factors, as
Perella Weinberg deemed appropriate. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In arriving at its opinion, Perella Weinberg assumed and relied upon, without independent
verification, the accuracy and completeness of the financial and other information supplied or otherwise made available to it (including information that was available from generally recognized public sources) for purposes of its opinion and further
relied upon the assurances of the management of Quidel that, to their knowledge, the information furnished, or approved for Perella Weinberg&#146;s use, by them for purposes of Perella Weinberg&#146;s analysis did not contain any material omissions
or misstatements of material fact. With respect to the Quidel Management Projections for Quidel, Perella Weinberg was advised by the management of Quidel, and assumed, with the consent of the Quidel board of directors, that they were reasonably
prepared on bases reflecting the best currently available estimates and good faith judgments of the management of Quidel as to the future stand-alone financial performance of Quidel and the other matters covered thereby. Perella Weinberg expressed
no view as to the assumptions on which the Quidel Management Projections for Quidel were based. With respect to the Ortho Forecasts, Perella Weinberg assumed, with the consent of the Quidel board of directors, that they were reasonably prepared on
bases reflecting the best currently available estimates and good faith judgments of the management of Ortho as to the future stand-alone financial performance of Ortho and the other matters covered thereby and Perella Weinberg expressed no view as
to the assumptions on which they were based. With respect to the Quidel Management Projections for Ortho, Perella Weinberg assumed, with the consent of the Quidel board of directors, that they were reasonably prepared on bases reflecting the best
currently available estimates and good faith judgments of the management of Quidel as to the future standalone financial performance of Ortho and the other matters covered thereby and Perella Weinberg expressed no view as to the assumptions on which
they were based. Perella Weinberg assumed, with the consent of the Quidel board of directors, that the Quidel Synergies Estimates and potential strategic implications and operational benefits (including the amount, timing and achievability thereof)
anticipated by management of Quidel to result from the Combinations will be realized in the amounts </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and at the times projected by management of Quidel, and Perella Weinberg expressed no view as to the assumptions on which they were based. Perella Weinberg relied without independent verification
upon the assessment by the management of Quidel of the timing and risks associated with the integration of Quidel and Ortho. In arriving at its opinion, Perella Weinberg did not make any independent valuation or appraisal of the assets or
liabilities (including any contingent, derivative or <FONT STYLE="white-space:nowrap">off-balance-sheet</FONT> assets and liabilities) of Quidel or Ortho, nor was it furnished with any such valuations or appraisals. Perella Weinberg did not assume
any obligation to conduct, nor did it conduct, any physical inspection of the properties or facilities of Quidel or Ortho. In addition, Perella Weinberg did not evaluate the solvency of any party to the BCA (or the impact of the Combinations
thereon), including under any applicable laws relating to bankruptcy, insolvency or similar matters. Perella Weinberg assumed that the final executed BCA would not differ from the form of the BCA that it reviewed in any respect material to its
analysis, and that the Combinations would be consummated in accordance with the terms set forth in the BCA, without modification, waiver or delay in any respect material to its analysis. Perella Weinberg also assumed that the Quidel Merger and Ortho
Scheme, taken together as a single integrated transaction, would qualify as an exchange described under Section&nbsp;351 of the Code and that the Quidel Merger will also qualify as a &#147;reorganization&#148; within the meaning of
Section&nbsp;368(a) of the Code. In addition, Perella Weinberg assumed that in connection with the receipt of all the necessary approvals for the Combinations, no delays, limitations, conditions or restrictions would be imposed that could have an
adverse effect on Quidel, Ortho or the contemplated benefits expected to be derived in the Combinations, in each case, in any way meaningful to its analysis. Perella Weinberg relied upon the advice of counsel as to all legal matters relevant to
rendering its opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg&#146;s opinion addressed only the fairness from a financial point of view, as of the date thereof, of the Ortho
Scheme Consideration of 0.1055 Topco Shares and $7.14 in cash per Ortho Share provided for in the BCA to Quidel taking into account the Quidel Exchange Ratio of one Topco Share per Quidel Share. Perella Weinberg was not asked to, and it did not,
offer any opinion as to any other term of the BCA or any other document contemplated by or entered into in connection with the BCA, the form, structure or financing of the Combinations or the likely timeframe in which the Combinations would be
consummated. In addition, Perella Weinberg expressed no opinion as to the fairness of the amount or nature of any compensation to be received by any officers, directors or employees of any parties to the BCA, or any class of such persons, whether
relative to the Ortho Scheme Consideration of 0.1055 Topco Shares and $7.14 in cash per Ortho Share provided for in the BCA or otherwise. Perella Weinberg did not express any opinion as to any tax or other consequences that may result from the
transactions contemplated by the BCA or any related document, nor did its opinion address any legal, tax, regulatory or accounting matters, as to which it understood Quidel had received such advice as it deemed necessary from qualified
professionals. Perella Weinberg&#146;s opinion did not address the underlying business decision of Quidel to enter into the BCA or the relative merits of the Combinations as compared with any other strategic alternative which may have been available
to Quidel. Perella Weinberg was not authorized to solicit, and did not solicit, indications of interest in a transaction with Quidel from any party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg&#146;s opinion was necessarily based on financial, economic, market and other conditions as in effect on, and the information made available
to it as of, the date of its opinion. It should be understood that subsequent developments may affect Perella Weinberg&#146;s opinion and the assumptions used in preparing it, and Perella Weinberg does not have any obligation to update, revise, or
reaffirm its opinion. The issuance of Perella Weinberg&#146;s opinion was approved by a fairness opinion committee of Perella Weinberg. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of
Material Financial Analyses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of the material financial analyses performed by Perella Weinberg and reviewed with the
Quidel board of directors in connection with Perella Weinberg&#146;s opinion and does not purport to be a complete description of the financial analyses performed by Perella Weinberg. The order of analyses described below does not represent the
relative importance or weight given to those analyses by Perella Weinberg. <B>Some of the summaries of the financial analyses include information presented in tabular format. In order to fully understand Perella Weinberg&#146;s financial analyses,
the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses. Considering the data below without considering the full narrative description of the financial
analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of Perella Weinberg&#146;s financial analyses.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of its analyses, Perella Weinberg calculated that the Ortho Scheme Consideration of 0.1055 Topco Shares and $7.14 in cash per Ortho Share had an
implied value of $24.75 per Ortho Share based upon the closing price of Quidel Shares on December&nbsp;21, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Historical Stock Trading </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg reviewed the historical intraday market prices for each of the Quidel Shares and the Ortho Shares for the
<FONT STYLE="white-space:nowrap">52-week</FONT> period ended on December&nbsp;21, 2021 (the last trading day prior to the Quidel board of directors&#146; meeting approving the execution of the BCA). Perella Weinberg noted that the range of low and
high intraday prices of the Quidel Shares during the <FONT STYLE="white-space:nowrap">52-week</FONT> period ended on December&nbsp;21, 2021 was $103.31 to $265.00 and that the range of low and high closing prices of the Ortho Shares during the
period commencing with Ortho&#146;s initial public offering on January&nbsp;28, 2021 and ended on December&nbsp;21, 2021 was $15.14 to $22.99. Perella Weinberg also reviewed the historical intraday market prices of the Quidel Shares and the Ortho
Shares for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended December&nbsp;21, 2021, which ranged from $109.75 to $180.06 per Quidel Share and from $17.34 to $22.86 per Ortho Share. Perella Weinberg compared these ranges to the
closing price of $166.94 per Quidel Share and the closing price of $19.49 per Ortho Share on December&nbsp;21, 2021 and to the implied value of $24.75 per Ortho Share in the Combinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg then calculated the exchange ratio range implied by the <FONT STYLE="white-space:nowrap">52-week</FONT> historical stock trading review.
Perella Weinberg calculated (i)&nbsp;the ratio of the highest intraday market price of the Ortho Shares (less $7.14 per share) to the lowest intraday market price of the Quidel Shares and (ii)&nbsp;the ratio of the lowest intraday market price of
the Ortho Shares (less $7.14 per share) to the highest intraday market price of the Quidel Shares to derive a range of implied exchange ratios of 0.0302x to 0.1534x. Perella Weinberg compared this implied exchange ratio range to the exchange ratio
of 0.1055 Topco Shares per Ortho Share provided for in the BCA. Perella Weinberg noted that the exchange ratio implied by the closing prices of the Ortho Shares and the Quidel Shares on December&nbsp;21, 2021 (after deducting $7.14 per Ortho Share)
was 0.0740x and that the range of such implied exchange ratios for the <FONT STYLE="white-space:nowrap">90-day</FONT> period ended on December&nbsp;21, 2021 was 0.0690x to 0.1046x. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Research Analyst Price Target Statistics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg observed the most recent publicly available research analyst price targets for the Quidel Shares prepared and published by four selected
equity research analysts prior to December&nbsp;21, 2021. Perella Weinberg noted that the range of these recent equity analyst price targets for Quidel Shares was $74.23 to $203.21 per share, in each case as discounted to December&nbsp;31, 2021
using an 8.0% cost of equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg also observed the most recent publicly available research analyst price targets for the Ortho Shares
prepared and published by six selected equity research analysts prior to December&nbsp;21, 2021. Perella Weinberg noted that the range of these recent equity analyst price targets for the Ortho Shares was $23.20 to $29.69 per share, in each case as
discounted to December&nbsp;31, 2021 using an 8.0% cost of equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg compared these ranges to the closing price of $166.94 per Quidel
Share and the closing price of $19.49 per Ortho Share on December&nbsp;21, 2021 and to the implied value of $24.75 per Ortho Share in the Combinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg then calculated the exchange ratio range implied by the equity research analyst price target review. Perella Weinberg calculated the ratios
of (i)&nbsp;the highest most recently publicly available research analyst price target for the Ortho Shares (discounted to December&nbsp;31, 2021 using an 8.0% cost of equity less $7.14 per share) to the lowest most recently publicly available
research analyst price target for Quidel Shares (discounted to December&nbsp;31, 2021 using an 8.0% cost of equity) and (ii)&nbsp;the lowest most recently publicly available research analyst price target for the Ortho Shares (discounted to
December&nbsp;31, 2021 using an 8.0% cost of equity less $7.14 per share) to the highest most recently publicly available research analyst price target for Quidel Shares (discounted to December&nbsp;31, 2021 using an 8.0% cost of equity) to derive
an implied exchange ratio range of 0.0790x to 0.3038x. Perella Weinberg compared this implied exchange ratio range to the exchange ratio of 0.1055 Topco Shares per Ortho Share provided for in the BCA. Perella Weinberg noted that the exchange ratio
implied by the closing prices of the Ortho Shares and the Quidel Shares on December&nbsp;21, 2021 (after deducting $7.14 per Ortho Share) was 0.0740x and that the range of such implied exchange ratios for the
<FONT STYLE="white-space:nowrap">90-day</FONT> period ended on December&nbsp;21, 2021 was 0.0690x to 0.1046x. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The public market trading prices published
by equity research analysts do not necessarily reflect current market trading prices for Quidel Shares or the Ortho Shares. Further, these estimates are subject to uncertainties, including the future financial performance of Quidel and Ortho and
future market conditions, and the public market trading price targets published by these equity research analysts represent price targets to be achieved over a 12&nbsp;month period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selected Publicly Traded Companies Analysis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg reviewed and compared certain financial information for Quidel and Ortho with corresponding financial information, ratios and public market
multiples for nine publicly held companies in the diagnostics industry described below (the &#147;Selected Publicly Traded Companies&#148;). Although none of the following companies is identical to Quidel or Ortho, Perella Weinberg selected these
companies because they had publicly traded equity securities and were deemed to be similar to Quidel and Ortho in one or more respects, including operating in the diagnostics and life sciences industry, and engaged in the development, manufacture
and sale of instruments and reagents used by clinical laboratories, healthcare providers, life science researchers, and the pharmaceutical industry. Perella Weinberg selected the companies used in the analysis on the basis of its experience and
knowledge of companies in the industry and various factors, including the size of the company (companies with enterprise values greater than $5 billion), the similarity of the lines of business to Quidel and Ortho&#146;s lines of business
(development, manufacture and sale of instruments and reagents used by clinical laboratories, healthcare providers, life science researchers and the pharmaceutical industry), as well as the business models, technology, service offerings and <FONT
STYLE="white-space:nowrap">end-market</FONT> exposure of such companies. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Quidel, Ortho and each of the Selected Publicly Traded Companies,
Perella Weinberg calculated and compared financial information and various financial market multiples and ratios based on company filings for historical information and consensus third-party research estimates from FactSet. Perella Weinberg also
calculated such information, multiples and ratios for the combined company based upon both (a)&nbsp;the Ortho Forecasts and Quidel Management Projections for Quidel (using the Case 1 projections as described below under &#147;Unaudited
Forward-Looking Financial Information&#151;Quidel Unaudited Forward-Looking Financial Information&#148;) and (b)&nbsp;consensus third-party research estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to Quidel, Ortho and each of the Selected Publicly Traded Companies, Perella Weinberg reviewed enterprise value (&#147;EV&#148;) as of
December&nbsp;21, 2021 as a multiple of both estimated revenue for the calendar year 2022 (&#147;2022E Revenue&#148;) and estimated earnings before interest, taxes, depreciation and amortization (&#147;EBITDA&#148;) for (i)&nbsp;the calendar year
2022 (&#147;2022E EBITDA&#148;) and (ii)&nbsp;the calendar year 2023 (&#147;2023E EBITDA&#148;). The results of these analyses are summarized in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Selected Publicly Traded Companies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EV/2022E<BR>Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EV/2022E<BR>EBITDA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EV/2023E<BR>EBITDA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thermo Fisher Scientific Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abbott Laboratories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Danaher Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sysmex Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hologic, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">bioM&eacute;rieux SA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qiagen N.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DiaSorin S.p.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Median</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7.1x</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21.8x</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19.9x</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quidel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ortho</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Newco (Consensus)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Newco (Ortho Forecasts/Quidel Management Projections for Quidel (Case 1))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the analysis of the relevant metrics described above and on professional judgments made by Perella Weinberg, Perella
Weinberg selected and applied a range of multiples of 3.0x to 4.0x to 2022E Revenue of Ortho using both consensus third-party research estimates and the Ortho Forecasts and a range of 4.5x to 6.0x to 2022E Revenue of Quidel using consensus
third-party research estimates and the Quidel Management Projections for Quidel (using the Case 1 Estimates as described below under &#147;Unaudited Forward-Looking Financial Information&#151;Quidel Unaudited Forward-Looking Financial
Information&#148;). Further, based on the analysis of the relevant metrics described above and on professional judgments made by Perella Weinberg, Perella Weinberg applied a range of 12.0x to 16.0x to 2022E EBITDA of Ortho using consensus
third-party research estimates and the Ortho Forecasts and a range of 12.0x to 14.0x to 2022E EBITDA of Quidel using consensus third-party research estimates and the Quidel Management Projections for Quidel (using the Case 1 Estimates as described
below under &#147;Unaudited Forward-Looking Financial Information&#151;Quidel Unaudited Forward-Looking Financial Information&#148;). For purposes of this analysis utilizing the Ortho Forecasts, Perella Weinberg used 2022E EBITDA for Ortho
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of approximately $538&nbsp;million as provided by management of Ortho. From these analyses, Perella Weinberg derived ranges of implied equity values for each of Ortho and Quidel. Perella Weinberg
calculated implied values per share by dividing the implied equity values by the applicable fully diluted shares (based upon the number of issued and outstanding shares and other equity interests in each case provided by the managements of Ortho and
Quidel, as applicable, and using the treasury method for calculation of option dilution). The ranges of implied values per share derived from these calculations are summarized in the following table: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Metric</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Implied Value<BR>Range<BR>Per Share</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Ortho</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consensus Estimates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2022E&nbsp;Revenue</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$17.31&nbsp;-&nbsp;$25.63</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2022E&nbsp;EBITDA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$19.25 - $28.21</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ortho Forecasts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2022E Revenue</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$18.11 - $26.70</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2022E EBITDA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$18.16 - $26.76</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Quidel</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consensus Estimates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2022E Revenue</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$109.89&nbsp;-&nbsp;$142.46</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2022E EBITDA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$134.17&nbsp;-&nbsp;$154.50</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quidel Management Projections for Quidel (Case&nbsp;1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2022E Revenue</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$123.71&nbsp;-&nbsp;$160.88</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2022E EBITDA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$132.44&nbsp;-&nbsp;$152.48</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg compared these ranges to the closing price of $166.94 Quidel Share and the closing price of $19.49 per Ortho
Share on December&nbsp;21, 2021 and to the implied value of $24.75 per Ortho Share in the Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg then calculated the exchange
ratio ranges implied by the Selected Publicly Traded Companies analysis consensus third-party research estimates. For each of the foregoing analyses, Perella Weinberg calculated (i)&nbsp;the ratio of the highest implied value per Ortho Share (less
$7.14 per share) to the lowest implied value per Quidel Share and (ii)&nbsp;the ratio of the lowest implied value per Ortho Share (less $7.14 per share) to the highest implied value per Quidel Share, in each case as derived from the Selected
Publicly Traded Companies analysis. The following table sets forth the results of this analysis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Metric</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Implied Exchange <BR>Ratio Range</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consensus Estimates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2022E&nbsp;Revenue</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.0714x&nbsp;-&nbsp;0.1682x</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2022E&nbsp;EBITDA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.0784x - 0.1570x</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg compared these implied exchange ratio ranges to the exchange ratio of 0.1055 Topco Shares per Ortho Share
provided for in the BCA. Perella Weinberg noted that the exchange ratio implied by the closing prices of the Ortho Shares and the Quidel Shares on December&nbsp;21, 2021 (after deducting $7.14 per Ortho Share) was 0.0740x and that the range of such
implied exchange ratios for the <FONT STYLE="white-space:nowrap">90-day</FONT> period ended on December&nbsp;21, 2021 was 0.0690x to 0.1046x. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although
the Selected Publicly Traded Companies were used for comparison purposes, no business of any selected company was either identical or directly comparable to Ortho&#146;s or Quidel&#146;s business. Perella Weinberg&#146;s comparison of Selected
Publicly Traded Companies to Ortho and Quidel and analysis of the results of such comparisons were not purely mathematical, but instead necessarily involved complex considerations and judgments concerning differences in financial and operating
characteristics and other factors that could affect the relative values of the Selected Publicly Traded Companies, Ortho and Quidel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selected
Transactions Analysis </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using publicly available information, Perella Weinberg reviewed the financial terms of the selected precedent transactions
described below (the &#147;Selected Transactions&#148;) involving companies that operated in, or were exposed to, the diagnostics industry announced between May 2011 and April 2021. Perella Weinberg selected these transactions in the exercise of its
professional judgment and experience because Perella Weinberg deemed them to be most similar in size, scope and impact on the industry to Ortho or otherwise relevant to the Combinations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For each of the Selected Transactions, Perella Weinberg calculated and compared the resulting EV in the
transaction as a multiple of (i)&nbsp;revenue over the last 12 months (&#147;LTM Revenue&#148;) publicly reported prior to the announcement of the transaction (&#147;EV/LTM Revenue&#148;) and (ii)&nbsp;EBITDA over the last 12 months (&#147;LTM
EBITDA&#148;) publicly reported prior to the announcement of the transaction (&#147;EV/LTM EBITDA&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table lists the Selected
Transactions and summarizes the observed EV/LTM Revenue and EV/LTM EBITDA multiples: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EV / LTM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Announcement</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Acquiror</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Revenue</B><br><B>Multiple</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EBITDA</B><br><B>Multiple <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Luminex&nbsp;Corporation</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">DiaSorin&nbsp;S.p.A.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">GenMark Diagnostics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Roche Holding Ltd</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Not&nbsp;Meaningful</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Oxford&nbsp;Immunotec&nbsp;Global&nbsp;PLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">PerkinElmer, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Not Meaningful</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">EUROIMMUN US, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">PerkinElmer, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Cepheid</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Danaher Corporation</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Not Meaningful</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Alere Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Abbott Laboratories</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BioFire Diagnostics, LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">bioM&eacute;rieux SA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 2012</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">One Lambda, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Thermo Fisher Scientific Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April 2012</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Gen-Probe</FONT> Incorporated</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Hologic, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May 2011</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phadia AB</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Thermo&nbsp;Fisher&nbsp;Scientific&nbsp;Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Median</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mean</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EV/EBITDA multiples less than 0.0x or greater than 100.0x were deemed to be not meaningful for the analysis.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the multiples of enterprise value to LTM Revenue and LTM EBITDA described above, Perella Weinberg&#146;s analyses of the
various Selected Transactions and on professional judgments made by Perella Weinberg with respect to, among other things, the financial performance and competitive positioning of Ortho and the target companies in the Selected Transactions, Perella
Weinberg applied a range of multiples of 5.0x to 7.0x to Ortho&#146;s estimated 2021 revenue based on consensus third-party research estimates to derive a range of implied values of approximately $33.17 to $49.49 per Ortho Share and a range of
multiples of 16.0x to 20.0x to Ortho&#146;s estimated 2021 EBITDA based on consensus third-party research estimates to derive a range of implied values of approximately $27.19 to $35.90 per Ortho Share. Perella Weinberg compared these ranges to the
closing price of $19.49 per Ortho Share on December&nbsp;21, 2021 and to the implied value of $24.75 per Ortho Share in the Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the
Selected Transactions were used for comparison purposes, none of the Selected Transactions nor the companies involved in them was either identical or directly comparable to the Combinations or Ortho. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Discounted Cash Flow Analysis </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ortho </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg conducted a discounted cash flow analyses for Ortho based on the Ortho Forecasts, the Quidel Management Projections for Ortho and consensus
third-party research estimates by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">calculating the present value as of December&nbsp;31, 2021 of the estimated standalone unlevered free cash flows
that Ortho could generate for fiscal year 2022 through fiscal year 2026 using discount rates ranging from 7.0% to 8.0% based on estimates of the weighted average cost of capital of Ortho derived using the Capital Asset Pricing Model (referred to as
&#147;CAPM&#148;), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding terminal values calculated using perpetuity growth rates ranging from 2.0% to 3.0% and discounted using
rates ranging from 7.0% to 8.0%, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding the present value of the benefit of the utilization of net operating losses as provided by management of
Ortho discounted using a rate of 7.5%. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The range of perpetuity growth rates was estimated by Perella Weinberg utilizing its
professional judgment and experiences, taking into account the Ortho Forecasts and market expectations regarding long-term real growth of gross domestic product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and inflation. Perella Weinberg also cross-checked such estimates of perpetuity growth rates against the EBITDA multiples implied by such growth rates and a range of discount rates to be applied
to Ortho&#146;s future unlevered cash flow forecasts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg used a range of discount rates from 7.0% to 8.0% derived by application of the
CAPM, which takes into account certain company-specific metrics, including Ortho&#146;s target capital structure, the cost of long-term debt, forecasted tax rate and predicted (Barra) beta, as well as certain financial metrics for the United States
financial markets generally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From the range of implied enterprise values, Perella Weinberg derived ranges of implied equity values for Ortho. To
calculate the implied equity value from the implied enterprise value, Perella Weinberg added cash and cash equivalents of $289&nbsp;million and subtracted net debt of $2.283&nbsp;billion as of December&nbsp;31, 2021 as estimated by Ortho management.
Perella Weinberg calculated implied value per share by dividing the implied equity value by the fully diluted shares (using the treasury method). Perella Weinberg performed the same analyses taking into account the present value, using a discount
rate of 7.5%, of (i)&nbsp;approximately $88&nbsp;million of annual run rate cost synergies by the end of the third year following the Combinations, as estimated by management of Ortho and Quidel to result from the Combinations, with illustrative 3%
annual growth for two years thereafter and assuming costs to achieve such synergies equal to the <FONT STYLE="white-space:nowrap">run-rate</FONT> cost synergies spread over two years and (ii)&nbsp;approximately $105&nbsp;million of annual <FONT
STYLE="white-space:nowrap">run-rate</FONT> revenue synergies by the end of the fourth year following the Combinations, as estimated by management of Quidel to result from the Combinations, with illustrative 8.2% annual growth for one year thereafter
and assuming approximately 50% margin contribution from revenue synergies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These analyses resulted in the following reference ranges of implied equity
value per Ortho Share: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Range&nbsp;of&nbsp;Implied&nbsp;Present&nbsp;Value&nbsp;Per&nbsp;Share</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without Quidel<BR>Synergies<BR>Estimates</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With Quidel<BR>Synergies<BR>Estimates</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ortho Forecasts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$24.94&nbsp;&#150;&nbsp;38.42</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$31.59-48.36</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quidel Management Projections for Ortho</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$24.41-$37.68</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$31.06&nbsp;-&nbsp;$47.62</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consensus Estimates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$25.11&nbsp;-&nbsp;$38.87</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$31.76&nbsp;-&nbsp;$48.82</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg compared these ranges to the closing price of $19.49 per Ortho Share on December&nbsp;21, 2021 and to the
implied value of $24.75 per Ortho Share in the Combinations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Quidel </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg conducted discounted cash flow analyses for Quidel based on the Quidel Management Projections for Quidel (using both the Case 1 Estimates and
Case 2 Estimates as described below under &#147;Unaudited Forward-Looking Financial Information&#151;Quidel Unaudited Forward-Looking Financial Information&#148;) and consensus third-party research estimates by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">calculating the present value as of December&nbsp;31, 2021 of the estimated standalone unlevered free cash flows
that Quidel could generate for fiscal year 2022 through fiscal year 2026 using discount rates ranging from 7.0% to 8.0% based on estimates of the weighted average cost of capital of Quidel derived using the CAPM, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding terminal values calculated using perpetuity growth rates ranging from 2.0% to 3.0% and discounted using
rates ranging from 7.0% to 8.0%. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The range of perpetuity growth rates was estimated by Perella Weinberg utilizing its professional
judgment and experiences, taking into account the Quidel Management Projections for Quidel and market expectations regarding long-term real growth of gross domestic product and inflation. Perella Weinberg also cross-checked such estimates of
perpetuity growth rates against the EBITDA multiples implied by such growth rates and a range of discount rates to be applied to Quidel&#146;s future unlevered cash flow forecasts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg used a range of discount rates from 7.0% to 8.0% derived by application of the CAPM, which takes into account certain company-specific
metrics, including Quidel&#146;s target capital structure, the cost of long-term debt, forecasted tax rate and predicted (Barra) beta, as well as certain financial metrics for the United States financial markets generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From the range of implied enterprise values, Perella Weinberg derived ranges of implied equity values for Quidel. To calculate the implied equity value from
the implied enterprise value, Perella Weinberg added cash and cash equivalents of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$862&nbsp;million and subtracted debt of $1&nbsp;million and net <FONT STYLE="white-space:nowrap">non-operating</FONT> liabilities of $85&nbsp;million, as of December&nbsp;31, 2021 as estimated
by management of Quidel. Perella Weinberg calculated implied value per share by dividing the implied equity value by the fully diluted shares (using the treasury method). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These analyses resulted in the following reference ranges of implied equity value per Quidel Share: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Range&nbsp;of&nbsp;Implied&nbsp;Equity&nbsp;Values</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quidel Management Projections for Quidel (Case&nbsp;1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$200.49&nbsp;-&nbsp;$280.56</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quidel Management Projections for Quidel (Case&nbsp;2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$171.74&nbsp;-&nbsp;$238.98</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consensus Estimates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$93.33 - $122.00</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg compared these ranges to the closing price of $166.94 per Quidel Share on December&nbsp;21, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg then calculated (i)&nbsp;the ratio of the highest implied value per Ortho Share (less $7.14 per share) to the lowest implied value per Quidel
Share and (ii)&nbsp;the ratio of the lowest implied value per Ortho Share (less $7.14 per share) to the highest implied value per Quidel Share, in each case as derived from these reference ranges of implied equity value per Ortho Share and per
Quidel Share. Perella Weinberg derived ranges of implied exchange ratios as set forth in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Range&nbsp;of&nbsp;Implied&nbsp;Exchange&nbsp;Ratios</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ortho Forecasts/Quidel Management Projections for Quidel (Case&nbsp;1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.0635x&nbsp;&#150;&nbsp;0.1560x</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quidel Management Projections for Ortho/Quidel Management Projections for Quidel (Case
2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.0723x &#150; 0.1778x</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consensus Estimates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.1473x &#150; 0.3400x</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg compared these implied exchange ratio ranges to the exchange ratio of 0.1055 Topco Shares per Ortho Share
provided for in the BCA. Perella Weinberg noted that the exchange ratio implied by the closing prices of the Ortho Shares and the Quidel Shares on December&nbsp;21, 2021 (after deducting $7.14 per Ortho Share) was 0.0740x and that the range of such
implied exchange ratios for the <FONT STYLE="white-space:nowrap">90-day</FONT> period ended on December&nbsp;21, 2021 was 0.0690x to 0.1046x. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Miscellaneous </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of a fairness
opinion is a complex process and is not necessarily susceptible to partial analysis or summary description. Selecting portions of the analyses or of the summary set forth herein, without considering the analyses or the summary as a whole, could
create an incomplete view of the processes underlying Perella Weinberg&#146;s opinion. In arriving at its fairness determination, Perella Weinberg considered the results of all of its analyses and did not attribute any particular weight to any
factor or analysis considered. Rather, Perella Weinberg made its determination as to fairness on the basis of its experience and professional judgment after considering the results of all of its analyses. No company or transaction used in the
analyses described herein as a comparison is directly comparable to Quidel, Ortho or the Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg prepared the analyses described
herein for purposes of providing its opinion to the Quidel board of directors as to the fairness, from a financial point of view, as of the date of such opinion, of the Ortho Scheme Consideration of 0.1055 Topco Shares and $7.14 in cash per Ortho
Share provided for in the BCA to Quidel taking into account the Quidel Exchange Ratio of one Topco Share per Quidel Share. These analyses do not purport to be appraisals or necessarily reflect the prices at which businesses or securities actually
may be sold. Perella Weinberg&#146;s analyses were based in part upon the Quidel Management Projections for Quidel, the Ortho Forecasts, the Quidel Management Projections for Ortho and third-party research analyst estimates, which are not
necessarily indicative of actual future results, and which may be significantly more or less favorable than suggested by Perella Weinberg&#146;s analyses. Because these analyses are inherently subject to uncertainty, being based upon numerous
factors or events beyond the control of the parties to the BCA or their respective advisors, none of Quidel, Ortho, Perella Weinberg or any other person assumes responsibility if future results are materially different from those forecasted by the
Quidel or Ortho management or third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described above, the opinion of Perella Weinberg to the Quidel board of directors was one of many factors
taken into consideration by the Quidel board of directors in making its determination to approve the Combinations. Perella Weinberg </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was not asked to, and did not, recommend the specific consideration provided for in the BCA, which consideration was determined through arms-length negotiations between Quidel and Ortho. Perella
Weinberg did not recommend any specific amount of consideration to the stockholders of Quidel or the Quidel board of directors or that any specific amount of consideration constituted the only appropriate consideration for the Combinations. Also, as
discussed above, Perella Weinberg&#146;s opinion was not intended to be and does not constitute a recommendation to any holder of Quidel Shares or Ortho Shares, or any other person, as to how such person should vote or otherwise act with respect to
the proposed Combinations or any other matter and does not in any manner address the prices at which the Quidel Shares, the Ortho Shares or the Topco Shares will trade at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg has acted as financial advisor to Quidel in connection with the Combinations and, pursuant to the terms of the engagement letter between
Perella Weinberg and Quidel, dated November&nbsp;19, 2021, Quidel agreed to pay Perella Weinberg $5,000,000 upon the rendering of Perella Weinberg&#146;s opinion (which amount would have also become payable if Perella Weinberg had determined that it
was not able to deliver its opinion) and an additional fee of $25,000,000, which is contingent upon the consummation of the Combinations. In addition, Quidel agreed to reimburse Perella Weinberg for certain expenses that may arise, and to indemnify
Perella Weinberg for certain liabilities and other items that may arise, out of its engagement by Quidel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the
<FONT STYLE="white-space:nowrap">two-year</FONT> period prior to the date of its opinion, no material relationship existed between Perella Weinberg and its corporate advisory affiliates and Ortho pursuant to which compensation was received by
Perella Weinberg or its corporate advisory affiliates. In the past, Perella Weinberg and its corporate advisory affiliates have provided financial advisory services unrelated to the Combinations to The Carlyle Group, a controlling shareholder of
Ortho, or its affiliates pursuant to which Perella Weinberg has received fees of approximately $8.33&nbsp;million within the <FONT STYLE="white-space:nowrap">two-year</FONT> period prior to the date of its opinion. In the past, Perella Weinberg and
its affiliates have provided financial advisory and other financial services to Quidel and its affiliates unrelated to the Combinations, for which it has received no compensation within the <FONT STYLE="white-space:nowrap">two-year</FONT> period
prior to the date of its opinion. Perella Weinberg and its corporate advisory affiliates may in the future provide investment banking and other financial services to Quidel, Ortho, The Carlyle Group and their respective affiliates and in the future
may receive compensation for the rendering of such services. In the ordinary course of its business activities, Perella Weinberg or its affiliates may at any time hold long or short positions, and may trade or otherwise effect transactions, for its
own account or the accounts of customers or clients, in debt or equity or other securities (or related derivative securities) or financial instruments (including bank loans or other obligations) of Quidel, Ortho, The Carlyle Group or any of their
respective affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_140"></A>Opinion of J.P. Morgan Securities LLC as Financial Advisor to Ortho </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to an engagement letter, Ortho retained J.P. Morgan as its financial advisor in connection with the Combinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the meeting of the Ortho board of directors on December&nbsp;22, 2021, J.P. Morgan rendered its oral opinion to the Ortho board of directors that, as of
such date and based upon and subject to the assumptions made, procedures followed, matters considered and limitations on the review undertaken by J.P. Morgan in preparing its opinion, the Ortho Scheme Consideration was fair, from a financial point
of view, to the holders of Ortho Shares. J.P. Morgan confirmed its December&nbsp;22, 2021 oral opinion by delivering its written opinion, dated December&nbsp;23, 2021, to the Ortho board of directors that, as of such date, the Ortho Scheme
Consideration was fair, from a financial point of view, to the holders of Ortho Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The full text of the written opinion of J.P. Morgan, dated
December&nbsp;23, 2021, which sets forth, among other things, the assumptions made, procedures followed, matters considered and limitations on the review undertaken by J.P. Morgan in preparing its opinion, is attached as Annex E to this joint proxy
statement/prospectus and is incorporated herein by reference. The summary of the opinion of J.P. Morgan set forth in this joint proxy statement/prospectus is qualified in its entirety by reference to the full text of such opinion. Holders of Ortho
Shares are urged to read the opinion in its entirety. J.P. Morgan&#146;s opinion was addressed to the Ortho board of directors (in its capacity as such) in connection with and for the purposes of its evaluation of the Combinations, was directed only
to the Ortho Scheme Consideration and did not address any other aspect of the Combinations. J.P. Morgan expressed no opinion as to the fairness of the Ortho Scheme Consideration to the holders of any other class of securities, creditors or other
constituencies of Ortho or as to the underlying decision by Company to engage in the Combinations. The issuance of J.P. Morgan&#146;s opinion was approved by a fairness committee of J.P. Morgan. The opinion does not constitute a recommendation to
any shareholder of Ortho as to how such shareholder should vote with respect to the Combinations or any other matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In arriving at its opinion, J.P. Morgan, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed the Business Combination Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed certain publicly available business and financial information concerning Ortho and Quidel and the
industries in which they operate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compared the financial and operating performance of Ortho and Quidel with publicly available information
concerning certain other companies J.P. Morgan deemed relevant and reviewed the current and historical market prices of Ortho Shares and Quidel Shares and certain publicly traded securities of such other companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed certain internal financial analyses and forecasts prepared by the management of Ortho relating to its
business and Quidel&#146;s business, as well as the estimated amount and timing of cost savings and related expenses and synergies expected to result from the Combinations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performed such other financial studies and analyses and considered such other information as J.P. Morgan deemed
appropriate for the purposes of its opinion. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, J.P. Morgan held discussions with certain members of the management of Ortho
and Quidel with respect to certain aspects of the Combinations, and the past and current business operations of Ortho and Quidel, the financial condition and future prospects and operations of Ortho, Quidel and Topco, the effects of the Combinations
on the financial condition and future prospects of Ortho, Quidel and Topco, and certain other matters J.P. Morgan believed necessary or appropriate to its inquiry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In giving its opinion, J.P. Morgan relied upon and assumed the accuracy and completeness of all information that was publicly available or was furnished to or
discussed with J.P. Morgan by Ortho and Quidel or otherwise reviewed by or for J.P. Morgan. J.P. Morgan did not independently verify any such information or its accuracy or completeness, and pursuant to its engagement letter with Ortho, J.P. Morgan
did not assume any obligation to undertake any such independent verification. J.P. Morgan did not conduct and was not provided with any valuation or appraisal of any assets or liabilities, nor did J.P. Morgan evaluate the solvency of Ortho, Quidel
or Topco under any state or federal laws relating to bankruptcy, insolvency or similar matters. In relying on financial analyses and forecasts provided to J.P. Morgan or derived therefrom, including the Ortho Management Projections for Ortho, the
Ortho Management Projections for Quidel (each as defined in the section below entitled &#147;Ortho Unaudited Forward-Looking Financial Information&#148;) and the Ortho Synergies Estimates (as defined below) J.P. Morgan assumed that they were
reasonably prepared based on assumptions reflecting the best currently available estimates and judgments by management as to the expected future results of operations and financial condition of Ortho and Quidel to which such analyses or forecasts
relate. J.P. Morgan expressed no view as to such analyses or forecasts (including the Ortho Synergies Estimates) or the assumptions on which they were based. J.P. Morgan also assumed that the Combinations and the other transactions contemplated by
the Business Combination Agreement will qualify as a <FONT STYLE="white-space:nowrap">tax-free</FONT> reorganization for United States federal income tax purposes and will be consummated as described in the Business Combination Agreement and this
Joint Proxy Statement/Prospectus. J.P. Morgan also assumed that the representations and warranties made by Ortho and Quidel in the Business Combination Agreement and the related agreements were and will be true and correct in all respects material
to its analysis. J.P. Morgan is not a legal, regulatory or tax expert and relied on the assessments made by advisors to Ortho with respect to such issues. J.P. Morgan further assumed that all governmental, regulatory or other consents and approvals
necessary for the consummation of the Combinations will be obtained without any adverse effect on Ortho, Quidel or Topco or on the contemplated benefits of the Combinations, in each case, that would be material to its analysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho Management Projections for Ortho and the Ortho Management Projections for Quidel furnished to J.P. Morgan were prepared by the management of Ortho
as discussed below more fully under the section entitled &#147;Unaudited Forward-Looking Financial Information&#148;. Ortho does not publicly disclose internal management projections of the type provided to J.P. Morgan in connection with J.P.
Morgan&#146;s analysis of the Combinations, and such projections were not prepared with a view toward public disclosure. These projections were based on numerous variables and assumptions that are inherently uncertain and may be beyond the control
of Ortho&#146;s management, including, without limitation, factors related to general economic and competitive conditions and prevailing interest rates. Accordingly, actual results could vary significantly from those set forth in such projections.
For more information regarding the use of projections and other forward-looking statements, please refer to the section below entitled &#147;Ortho Unaudited Forward-Looking Financial Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan&#146;s opinion was necessarily based on economic, market and other conditions as in effect on, and the information made available to J.P. Morgan
as of, the date of such opinion. J.P. Morgan&#146;s opinion noted that subsequent developments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">258 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may affect J.P. Morgan&#146;s opinion and that J.P. Morgan does not have any obligation to update, revise, or reaffirm such opinion. J.P. Morgan&#146;s opinion is limited to the fairness, from a
financial point of view, of the Ortho Scheme Consideration, and J.P. Morgan has expressed no opinion as to the fairness of any consideration to be paid in connection with the Combinations to the holders of any other class of securities, creditors or
other constituencies of Ortho or as to the underlying decision by Ortho to engage in the Combinations. Furthermore, J.P. Morgan expressed no opinion with respect to the amount or nature of any compensation to any officers, directors, or employees of
any party to the Combinations, or any class of such persons relative to the Ortho Scheme Consideration or with respect to the fairness of any such compensation. J.P. Morgan expressed no opinion as to the price at which Ortho Shares, Quidel Shares or
shares of Topco Common Stock will trade at any future time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan was not authorized to and did not solicit any expressions of interest from any
other parties with respect to the sale of all or any part of Ortho or any other alternative transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the Business Combination Agreement
were determined through arm&#146;s length negotiations between Ortho and Quidel, and the decision to enter into the Business Combination Agreement was solely that of the Ortho board of directors and the Board of Directors of Quidel. J.P.
Morgan&#146;s opinion and financial analyses were only one of the many factors considered by the Ortho board of directors in its evaluation of the Combinations and should not be viewed as determinative of the views of the Ortho board of directors or
its management with respect to the Combinations or the Ortho Scheme Consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with customary investment banking practice, J.P. Morgan
employed generally accepted valuation methodologies in rendering its opinion to the Ortho board of directors on December&nbsp;22, 2021 and in the financial analysis presented to the Ortho board of directors on such date in connection with the
rendering of such opinion. The following is a summary of the material financial analyses utilized by J.P. Morgan in connection with rendering its opinion to the Ortho board of directors and does not purport to be a complete description of the
analyses or data presented by J.P. Morgan. Some of the summaries of the financial analyses include information presented in tabular format. The tables are not intended to stand alone, and in order to more fully understand the financial analyses used
by J.P. Morgan, the tables must be read together with the full text of each summary. Considering the data set forth below without considering the full narrative description of the financial analyses, including the methodologies and assumptions
underlying the analyses, could create a misleading or incomplete view of J.P. Morgan&#146;s analyses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Public Trading Multiples </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using publicly available information, J.P. Morgan compared selected financial data of Ortho and Quidel with similar data for selected publicly traded companies
engaged in businesses which J.P. Morgan judged to be sufficiently analogous to those engaged in by Ortho and Quidel, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The companies
selected by J.P. Morgan with respect to Ortho were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Avantor, Inc. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PerkinElmer, Inc. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories, Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hologic, Inc. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">BioMerieux SA </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Grifols SA </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Qiagen NV </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DiaSorin S.p.A. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The companies selected by J.P. Morgan with respect to Quidel were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Avantor, Inc. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PerkinElmer, Inc. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories, Inc. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">259 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hologic, Inc. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">BioMerieux SA </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Grifols SA </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Qiagen NV </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DiaSorin S.p.A. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">10X Genomics, Inc. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">NanoString Technologies Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These companies were selected by J.P. Morgan based on its experience and familiarity with Ortho&#146;s and Quidel&#146;s industry, because of similarities in
one or more of their business characteristics and, in certain cases, similarities to Ortho and Quidel, as applicable, based on certain operational characteristics and/or certain financial metrics. However, certain of these companies may have
characteristics that are materially different from those of Ortho and Quidel, as applicable. The analyses necessarily involve complex considerations and judgments concerning differences in financial and operational characteristics of the companies
involved and other factors that could affect the selected companies differently than they would affect Ortho and Quidel, as applicable. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using
publicly available information, J.P.&nbsp;Morgan calculated, for each selected company, the ratios of the company&#146;s firm value (&#147;FV&#148;) to the consensus equity research analyst estimates for the company&#146;s adjusted earnings before
interest, taxes, depreciation and amortization post-stock based compensation (&#147;Adj. EBITDA&#148;) for the year ending December&nbsp;31, 2022 (the &#147;FV/2022E Adj. EBITDA&#148;). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Selected Publicly Traded Companies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FV/2022E<BR>Adj.<BR>EBITDA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avantor, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PerkinElmer, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hologic, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BioMerieux SA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grifols SA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qiagen NV</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DiaSorin S.p.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10X Genomics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/M</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NanoString Technologies Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/M</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not meaningful </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the results of this analysis, J.P.&nbsp;Morgan selected a reference range of 12.0x &#150; 24.0x for FV/2022E Adj. EBITDA for Ortho and a reference
range of 12.0x &#150; 22.0x for FV/2022E Adj. EBITDA for Quidel. After applying such ranges to the projected Adj. EBITDA for Ortho and Quidel for the twelve month period ending December&nbsp;31, 2022, as set forth in the Ortho Management Projections
for Ortho and the Ortho Management Projections for Quidel, as applicable, the analysis indicated the following ranges of implied per share equity value (rounded to the nearest $0.25) for Ortho Shares and Quidel Shares: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Implied&nbsp;Per&nbsp;Share&nbsp;Equity&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Low&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;High&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ortho FV/2022E Adj. EBITDA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Quidel FV/2022E Adj. EBITDA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">287.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ranges of implied per share equity values for Ortho Shares and Quidel Shares were compared to the closing share prices of
Ortho Shares of $19.49 and Quidel Shares of $166.94 on December&nbsp;21, 2021, the trading day immediately preceding the date on which J.P. Morgan rendered its oral opinion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">260 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Discounted Cash Flow Analysis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan conducted a discounted cash flow analysis for the purpose of determining an implied fully diluted equity value per share for Ortho Shares and
Quidel Shares. J.P. Morgan calculated the unlevered free cash flows that Ortho and Quidel are expected to generate during fiscal years 2022E through 2026E (as set forth in the Ortho Management Projections for Ortho and the Ortho Management
Projections for Quidel, as applicable, described in the section entitled &#147;Ortho Unaudited Forward-Looking Financial Information,&#148; which were discussed with, and approved by, the Ortho board of directors for use by J.P. Morgan in connection
with its financial analyses). J.P.&nbsp;Morgan also calculated a range of terminal values for Ortho and Quidel at the end of this period by applying perpetual growth rates ranging from 2.0% to 3.0%, to estimates of the unlevered terminal free cash
flows for each of Ortho and Quidel at the end of fiscal-year 2026E, as provided in the Ortho Management Projections for Ortho and the Ortho Management Projections for Quidel, as applicable. J.P. Morgan then discounted the unlevered free cash flow
estimates and the range of terminal values to present value as of December&nbsp;31, 2021 using discount rates ranging from 6.5% to 7.5% for Ortho, and 7.5% to 8.5% for Quidel, which ranges were chosen by J.P. Morgan based upon an analysis of the
weighted average cost of capital of Ortho and Quidel, respectively. The present value of the unlevered free cash flow estimates and the range of terminal values were then adjusted by subtracting net debt for each of Ortho and Quidel as of
December&nbsp;31, 2021, and for Ortho, by adding the value of Ortho&#146;s net operating losses as provided by the management of Ortho. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the
foregoing, this analysis indicated the following ranges of implied per share equity value for Ortho Shares and Quidel Shares (rounded to the nearest $0.25): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Implied&nbsp;Per&nbsp;Share&nbsp;Equity&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Low&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;High&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ortho Discounted Cash Flow</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Quidel Discounted Cash Flow</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">240.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ranges of implied per share equity values for Ortho Shares and Quidel Shares were compared to the closing share prices of
Ortho Shares of $19.49 and Quidel Shares of $166.94 on December&nbsp;21, 2021, the trading day immediately preceding the date on which J.P. Morgan rendered its oral opinion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Relative Value Analysis </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P.&nbsp;Morgan compared
the results for Ortho to the results for Quidel with respect to the public trading multiples and discounted cash flow analyses described above. J.P.&nbsp;Morgan compared the lowest equity value per share for Ortho to the highest equity value per
share for Quidel to derive the lowest exchange ratio implied by each pair of results. J.P.&nbsp;Morgan also compared the highest equity value per share for Ortho to the lowest equity value per share for Quidel to derive the highest exchange ratio
implied by each pair of results. The ranges of implied exchange ratios resulting from this analysis (adjusted to reflect cash consideration of $7.14 per share) were: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Implied&nbsp;Exchange&nbsp;Ratios</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Low&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;High&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FV/2022E Adj. EBITDA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0463x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2491x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Discounted Cash Flow</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0697x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1875x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ranges of implied exchange ratios resulting from the foregoing analysis were compared to (i)&nbsp;the implied exchange
ratio (adjusted to reflect cash consideration of $7.14 per share) of 0.0740x on December&nbsp;21, 2021, the trading day immediately preceding the date on which J.P. Morgan rendered its opinion, and (ii)&nbsp;the stock consideration per Ortho Share
of 0.1055x, as contemplated in the Business Combination Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Value Creation Analysis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan conducted an analysis of the theoretical value creation to the existing holders of Ortho Shares that compared the estimated implied equity value of
Ortho Shares and Quidel Shares on a standalone basis, based on the midpoint value determined in J.P. Morgan&#146;s discounted cash flow analyses described above, to the estimated implied equity value of the ownership in the combined company of
former holders of Ortho Shares, pro forma for the Combinations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">261 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan calculated the pro forma implied equity value of Ortho Shares by (1)&nbsp;adding the sum of
(a)&nbsp;the implied equity value of Ortho on a stand-alone basis of approximately $7,276&nbsp;million, using the midpoint value determined in J.P. Morgan&#146;s discounted cash flow analysis of Ortho described above, (b)&nbsp;the implied equity
value of Quidel on a stand-alone basis of approximately $8,652&nbsp;million, using the midpoint value determined in J.P. Morgan&#146;s discounted cash flow analysis of Quidel described above, and (c)&nbsp;the estimated value of the Ortho Synergies
Estimates, as reflected in estimates Ortho&#146;s management provided to J.P. Morgan for use in connection with its analysis, in the aggregate amount of approximately $2,176&nbsp;million, (2)&nbsp;subtracting (a) the cash consideration to be paid to
the holders of Ortho Shares in connection with the Combinations, in the aggregate amount of approximately $1,750&nbsp;million and (b)&nbsp;estimated transaction expenses, in an aggregate amount of approximately $180&nbsp;million, as estimated by
J.P. Morgan and approved by the management of Ortho and (3)&nbsp;multiplying such result by the pro forma equity ownership of the combined company by the existing holders of Ortho Shares of approximately 37.7%. This analysis indicated that the
Combinations implied equity value of the Topco Shares received by the holders of Ortho Shares of approximately $6,095&nbsp;million, which, when combined with the cash consideration paid to the holders of Ortho Shares, represents accretion in value
of approximately $569&nbsp;million, or 7.8%, compared to the estimated standalone equity value of Ortho Shares. There can be no assurance, however, that the implied Ortho Synergies Estimates, transaction-related expenses and other impacts referred
to above will not be substantially greater or less than those estimated by Ortho&#146;s management and described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Miscellaneous </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of certain material financial analyses does not purport to be a complete description of the analyses or data presented by J.P. Morgan.
The preparation of a fairness opinion is a complex process and is not necessarily susceptible to partial analysis or summary description. J.P. Morgan believes that the foregoing summary and its analyses must be considered as a whole and that
selecting portions of the foregoing summary and these analyses, without considering all of its analyses as a whole, could create an incomplete view of the processes underlying the analyses and its opinion. As a result, the ranges of valuations
resulting from any particular analysis or combination of analyses described above were merely utilized to create points of reference for analytical purposes and should not be taken to be the view of J.P. Morgan with respect to the actual value of
Ortho or Quidel. The order of analyses described does not represent the relative importance or weight given to those analyses by J.P. Morgan. In arriving at its opinion, J.P. Morgan did not attribute any particular weight to any analyses or factors
considered by it and did not form an opinion as to whether any individual analysis or factor (positive or negative), considered in isolation, supported or failed to support its opinion. Rather, J.P. Morgan considered the totality of the factors and
analyses performed in determining its opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Analyses based upon forecasts of future results are inherently uncertain, as they are subject to numerous
factors or events beyond the control of the parties and their advisors. Accordingly, forecasts and analyses used or made by J.P. Morgan are not necessarily indicative of actual future results, which may be significantly more or less favorable than
suggested by those analyses. Moreover, J.P. Morgan&#146;s analyses are not and do not purport to be appraisals or otherwise reflective of the prices at which businesses actually could be acquired or sold. None of the selected companies reviewed as
described in the above summary is identical to Ortho or Quidel. However, the companies selected were chosen because they are publicly traded companies with operations and businesses that, for purposes of J.P. Morgan&#146;s analysis, may be
considered similar to those of Ortho and Quidel. The analyses necessarily involve complex considerations and judgments concerning differences in financial and operational characteristics of the companies involved and other factors that could affect
the companies compared to Ortho and Quidel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a part of its investment banking business, J.P. Morgan and its affiliates are continually engaged in the
valuation of businesses and their securities in connection with mergers and acquisitions, investments for passive and control purposes, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and
valuations for corporate and other purposes. J.P. Morgan was selected to advise Ortho with respect to the Combinations and deliver an opinion to Ortho&#146;s board of directors with respect to the Combinations on the basis of, among other things,
such experience and its qualifications and reputation in connection with such matters and its familiarity with Ortho and the industries in which it operates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho has agreed to pay J.P.&nbsp;Morgan a fee of up to $50&nbsp;million (but not less than $40 million), $3&nbsp;million of which became payable to J.P.
Morgan at the time J.P. Morgan delivered its opinion and the remainder of which is contingent and payable upon the consummation of the Combinations. In addition, Ortho has agreed to reimburse J.P.&nbsp;Morgan for certain of its expenses incurred in
connection with its services, including the fees and disbursements of counsel, and will indemnify J.P.&nbsp;Morgan against certain liabilities arising out of J.P.&nbsp;Morgan&#146;s engagement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">262 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the two years preceding the date of J.P.&nbsp;Morgan&#146;s opinion, J.P.&nbsp;Morgan and its
affiliates have had commercial or investment banking relationships with Ortho for which J.P.&nbsp;Morgan and such affiliates have received customary compensation. Such services during such period have included acting as joint lead bookrunner on
offerings of debt securities of Ortho subsidiaries in May 2020 and January 2020, and joint lead bookrunner on offerings of Ortho&#146;s equity securities in September 2021 and January 2021. During the two years preceding the date of J.P.
Morgan&#146;s opinion, J.P. Morgan and its affiliates have had commercial or investment banking relationships with The Carlyle Group Inc. (&#147;Carlyle&#148;), Ortho&#146;s approximately 50% shareholder, for which J.P. Morgan and such affiliates
have received customary compensation. Such services during such period have included acting as joint lead bookrunner on an offering of debt securities of a Carlyle subsidiary in May 2021. In addition, during the two years preceding the date of J.P.
Morgan&#146;s opinion, J.P. Morgan and its affiliates have had commercial or investment banking relationships with Carlyle portfolio companies for which J.P. Morgan and such affiliates have received customary compensation. Such services during such
period have included providing debt syndication, equity underwriting, debt underwriting and financial advisory services to Carlyle portfolio companies. J.P. Morgan&#146;s commercial banking affiliate is an agent bank and a lender under outstanding
credit facilities of Carlyle and Carlyle portfolio companies for which it receives customary compensation or other financial benefits. During the two years preceding the date of J.P. Morgan&#146;s opinion, neither J.P. Morgan nor its affiliates have
had any material financial advisory or other material commercial or investment banking relationships with Quidel. In addition, J.P.&nbsp;Morgan and its affiliates hold, on a proprietary basis, less than 1% of the outstanding common shares of each of
Ortho, Carlyle and Quidel. In the ordinary course of their businesses, J.P.&nbsp;Morgan and its affiliates may actively trade the debt and equity securities or financial instruments (including derivatives, bank loans or other obligations) of Ortho,
Carlyle or Quidel for their own accounts or for the accounts of customers and, accordingly, may at any time hold long or short positions in such securities or other financial instruments. During the two year period preceding the date of J.P.
Morgan&#146;s opinion, the aggregate fees recognized by J.P. Morgan from each of Ortho, Carlyle and its controlled portfolio companies, and Quidel were approximately $21&nbsp;million, $278&nbsp;million, and $0.2&nbsp;million, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_142"></A>Unaudited Forward-Looking Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quidel Unaudited Forward-Looking Financial Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel does not as a matter of course publicly disclose projections as to future sales, earnings, or other results due to the inherent unpredictability and
subjectivity of the underlying assumptions and estimates. However, in connection with the discussions regarding the Combinations, each of Quidel and Ortho supplied the other with certain unaudited business and financial information that was not
publicly available. Quidel provided its board of directors, Perella Weinberg, and Ortho with certain financial projections that were prepared by and are the responsibility of the management of Quidel, and which are referred to in this section as the
&#147;Quidel Management Projections.&#148; The Quidel Management Projections include projections for Quidel prepared by Quidel management (which Quidel refers to as the &#147;Quidel Management Projections for Quidel&#148;) and projections for Ortho
prepared by Quidel management (which Quidel refers to as the &#147;Quidel Management Projections for Ortho&#148;). The Quidel Management Projections treat each of Quidel and Ortho on a stand-alone basis, without giving effect to, and as if Quidel
and Ortho never contemplated, the Combinations, including the impact of negotiating or executing the BCA, the expenses that may be incurred in connection with consummating the Combinations, the potential synergies that may be achieved by the
combined company as a result of the Combinations, the effect of any business or strategic decision or action that has been or will be taken as a result of the BCA having been executed, or the effect of any business or strategic decisions or actions
which would likely have been taken if the BCA had not been executed but which were instead altered, accelerated, postponed or not taken in anticipation of the Combinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel Management Projections were not prepared with a view toward public disclosure and, accordingly, do not necessarily comply with published guidelines
of the SEC, the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of financial forecasts or GAAP, but, in the view of Quidel&#146;s management, were prepared on a reasonable basis,
reflected the best available estimates and judgments at the time of preparation and presented as of the time of preparation, to the best of Quidel&#146;s management&#146;s knowledge and belief, the reasonable projections of the future financial
performance of Quidel and Ortho, respectively. Neither Quidel&#146;s independent registered public accounting firm, nor any other independent accountants, have audited, reviewed, compiled or performed any procedures with respect to the Quidel
Management Projections or expressed any opinion or any form of assurance related thereto. The summary of the projections is included in this joint proxy statement/prospectus solely to give you access to certain financial projections that were made
available to the Quidel board of directors, Perella Weinberg and Ortho, and is not being included in this joint proxy statement/prospectus to influence a stockholder&#146;s decision whether to vote for the Merger Proposal or any other proposal. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">263 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel Management Projections, while presented with numerical specificity, necessarily were based on
numerous variables and assumptions (described in greater detail below) are inherently uncertain and many of which are beyond the control of Quidel&#146;s management. Because the projections cover multiple years, by their nature, they also become
subject to greater uncertainty with each successive year. The Quidel Management Projections constitute forward-looking information and are subject to risks and uncertainties that could cause actual results to differ materially from the results
forecasted, including risks and uncertainties relating to Quidel&#146;s and Ortho&#146;s businesses (including their ability to achieve strategic goals, objectives and targets over applicable periods), industry performance, the COVID-19 pandemic,
general business and economic conditions, the Combinations (including risks that the Combinations are not consummated for any reason or that the Combinations fail to generate the anticipated benefits and synergies), the business of the combined
company, and other factors described in this joint proxy statement/prospectus. Please consider carefully the sections of this joint proxy statement/prospectus entitled &#147;Cautionary&nbsp;Statement Concerning Forward-Looking Statements&#148; and
&#147;Risk Factors.&#148; Accordingly, there can be no assurance that the Quidel Management Projections will be realized. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The inclusion of the
projections in this joint proxy statement/prospectus should not be regarded as an indication that Quidel, Ortho or any of their respective affiliates, advisors (including Perella Weinberg and J.P. Morgan), officers, directors or representatives
considered or considers the Quidel Management Projections to be necessarily predictive of actual future events, and that the Quidel Management Projections should not be relied upon as such. Quidel does not intend to make publicly available any
update or other revision to the Quidel Management Projections, except as otherwise required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the projected financial information set
forth herein may be considered <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures. <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> financial measures should not be considered in isolation from, or as a substitute for, financial
information presented in compliance with GAAP, and <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures as used by Quidel may not be comparable to similarly titled amounts used by other companies. Financial measures provided to a
board of directors or financial advisor in connection with a business combination are excluded from the definition of <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures under the rules of the SEC, and therefore the Quidel Management
Projections are not subject to SEC rules regarding disclosures of <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures, which would otherwise require a reconciliation of a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial
measure to a GAAP financial measure. No reconciliation of <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures in the Quidel Management Projections to GAAP measures was created or used in connection with preparing the Quidel
Management Projections. Accordingly, no reconciliation of the financial measures included in the Quidel Management Projections is provided in this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In light of the foregoing factors and the uncertainties inherent in the Quidel Management Projections, Quidel stockholders are cautioned not to place undue
reliance on the Quidel Management Projections. </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Quidel Management Projections for Quidel </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the Quidel Management Projections for Quidel. In connection with the evaluation of the Combinations, Quidel&#146;s
management prepared projections of Quidel&#146;s financial results for calendar years 2021 through 2026. Two sets of financial projections, which are referred to in this section as the Case 1 projections (the LRP projections) and the Case 2
projections (the adjusted LRP projections), respectively, were prepared by Quidel&#146;s management in order to give the Quidel board of directors insight into possible alternative outcomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the Case 1 projections, Quidel&#146;s management utilized Quidel&#146;s long range plan projections (the &#147;Quidel LRP&#148;) initially developed in
August 2021. Some of the key assumptions Quidel management made in preparing the Quidel LRP were: continued growth in sales of Quidel&#146;s Sofia and QuickVue products after the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic ends;
continued market demand for Quidel&#146;s <FONT STYLE="white-space:nowrap">COVID-19</FONT> tests after the prevalence of the delta and omicron variants has decreased; and future success of its new product launches, specifically its Savanna
instrumented system and assays and a U.S. launch of its high-sensitive troponin assay that would run on its MeterPro instrument. Also, Quidel&#146;s management assumed that <FONT STYLE="white-space:nowrap">at-home</FONT> testing and OTC testing will
continue to grow due to the market movement toward more decentralized testing, which trend should favor both Quidel&#146;s Sofia 2 and SofiaQ platforms, as well as its QuickVue product lines. Quidel&#146;s management believes that its current
products, and its new products that are expected to be launched over the next several years, will realize revenue growth due to the following product attributes of these products: ease of use, fast turn time, and cost effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key difference between Case 1 and Case 2 is that the Case 1 projections represent Quidel management&#146;s view of Quidel&#146;s projected financial
results assuming a favorable outcome on a number of key assumptions, while the Case 2 projections were risk adjusted for years 2023 and beyond to take into account a view that the following risks could result in less favorable results than those
assumed in preparation of the Case 1 projects: the risks associated with estimating the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
duration of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and its impact, the risks associated with Quidel&#146;s development and commercialization of new technologies, products
and markets, and the difficulty of estimating the timing, nature and magnitude of future opportunities for Quidel&#146;s <FONT STYLE="white-space:nowrap">at-home</FONT> testing products and services. The Case 2 projections reflected what
Quidel&#146;s management and the Quidel board of directors believed to be a more conservative view of Quidel&#146;s projected financial results for such years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Case 1 projections were made available to Ortho in connection with its due diligence review of Quidel, but the Case 2 projections were not made available
to Ortho prior to signing of the BCA. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel board of directors instructed Perella Weinberg to use both the Case 1 and Case 2 Quidel Management
Projections for Quidel for purposes of performing its financial analyses summarized under &#147;The Combinations&#151;Opinion of Perella Weinberg Partners LP as Financial Advisor to Quidel&#148; in this joint proxy statement/prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2021E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2022E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2023E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2024E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2025E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2026E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Terminal<BR>2026E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="28"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Case 1 Projections of Quidel</I></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBITDA<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unlevered Free Cash Flow<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="29"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="28"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Case 2 Projections of Quidel</I></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBITDA<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unlevered Free Cash Flow<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBITDA is a non-GAAP financial measure which is calculated as earnings before interest expense, net provision
for (benefit from) income taxes, depreciation and amortization and should not be considered as an alternative to net income as a measure of operating performance. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unlevered Free Cash Flow is calculated as EBITDA less taxes and capital expenditures, and adjusted for changes
in net working capital. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Quidel Management Projections for Ortho </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the Quidel Management Projections for Ortho. The Quidel Management Projections for Ortho were prepared by Quidel
management, after review of the Ortho Management Projections for Ortho made available to Quidel in connection with its due diligence review of Ortho and the Combinations and reflect the results of Quidel&#146;s due diligence review and various
assumptions and estimates as to future events made by Quidel management. These projections were used by the Quidel board of directors in connection with the evaluation of the Combinations and were made available to Perella Weinberg for purposes of
performing its financial analyses summarized under &#147;The Combinations&#151;Opinion of Perella Weinberg Partners LP as Financial Advisor to Quidel&#148; in this joint proxy statement/prospectus. Some of the key assumptions Quidel management made
in preparing the Quidel Management Projections for Ortho were a differing view than that adopted by Ortho management regarding non-GAAP add-backs in calculating EBITDA. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2021E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2022E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2023E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2024E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2025E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2026E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Terminal<BR>2026E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBITDA<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unlevered Free Cash Flow<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBITDA is a non-GAAP financial measure which is calculated as earnings before interest expense, net provision
for (benefit from) income taxes, depreciation and amortization and should not be considered as an alternative to net income as a measure of operating performance. Quidel&#146;s projections do not eliminate (i)&nbsp;certain <FONT
STYLE="white-space:nowrap">non-operating</FONT> income or expense, and (ii)&nbsp;impacts of certain noncash, unusual or other items that are included in net income (loss) that Ortho does not consider indicative of its ongoing operating performance,
including but not limited to stock based compensation expense on historical equity awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unlevered Free Cash Flow is calculated as EBITDA less taxes and capital expenditures, and adjusted for changes
in net working capital. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">265 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho Unaudited Forward-Looking Financial Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho does not as a matter of course publicly disclose long-term financial projections due to, among other reasons, the uncertainty, unpredictability and
subjectivity of the underlying assumptions and estimates. As a result, Ortho does not endorse unaudited forward-looking financial information as a reliable prediction of future results. The limited unaudited forward-looking financial information set
out below is included in this joint proxy statement/prospectus solely because it was among the financial information made available to the Ortho board of directors and its financial advisors in connection with their respective evaluations of the
Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited forward-looking financial information presented below includes projections for Ortho prepared by Ortho management (the
&#147;Ortho Management Projections for Ortho&#148;) and projections for Quidel prepared by Ortho management (the &#147;Ortho Management Projections for Quidel&#148;). Ortho refers to both the Ortho Management Projections for Ortho and the Ortho
Management Projections for Quidel as the &#147;Ortho Management Projections.&#148; The Ortho Management Projections were based on estimates and assumptions made by management at the respective times of their preparation and speak only as of such
times, as applicable. Except to the extent required by applicable law, Ortho has no intention to update or revise the forward-looking financial information included in this joint proxy statement/prospectus and, except as provided below, has not done
so and does not intend to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The inclusion of this unaudited forward-looking financial information should not be regarded as an indication that any
of Ortho, Quidel, J.P. Morgan, Perella Weinberg or any of their respective affiliates, officers, directors, partners, advisors or other representatives considered, or now considers, it to be an accurate prediction of actual future results, and
readers of this joint proxy statement/prospectus are cautioned not to rely on this forward-looking information. There can be no assurance that the forward-looking results will be achieved or that actual results will not be significantly higher or
lower than estimated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the Ortho Management Projections cover multiple years, such information by its nature becomes less accurate with each
successive year. Quidel stockholders and Ortho shareholders are urged to review the risk factors described in the section entitled &#147;Risk Factors&#151;Risks Relating to Ortho&#146;s Business&#148; of this joint proxy statement/prospectus with
respect to the business of Ortho. Quidel stockholders and Ortho shareholders are also urged to review the risks and other factors described in the sections entitled &#147;Risk Factors&#148; and &#147;Cautionary Statement Concerning Forward-Looking
Statements&#148; of this joint proxy statement/prospectus with respect to the business of Quidel. The Ortho Management Projections were not prepared with a view toward public disclosure, nor were they prepared with a view toward compliance with
published guidelines of the SEC, the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of forward-looking financial information or U.S. GAAP. The Ortho Management Projections included
in this proxy statement/prospectus have been prepared by, and is the responsibility of, Ortho management. PricewaterhouseCoopers LLP and Ernst&nbsp;&amp; Young LLP have not audited, reviewed, examined, compiled nor applied agreed-upon procedures
with respect to the accompanying Ortho Management Projections and, accordingly, PricewaterhouseCoopers LLP and Ernst&nbsp;&amp; Young LLP do not express an opinion or any other form of assurance with respect thereto. The PricewaterhouseCoopers LLP
report included in this document relates to Ortho&#146;s previously issued financial statements. It does not extend to the Ortho Management Projections and should not be read to do so. The Ortho Management Projections include certain financial
measures that are not consistent with U.S. GAAP. Adjusted EBITDA and Unlevered Free Cash Flow are <FONT STYLE="white-space:nowrap">non-U.S.</FONT> GAAP financial measures that are not consistent with U.S. GAAP and should not be considered in
isolation from, or as a substitute for, financial information presented in compliance with U.S. GAAP. Financial measures that are not consistent with U.S. GAAP as used by Ortho may not be comparable to similarly titled amounts used by other
companies. The footnotes to the table below provide certain supplemental information with respect to the calculation of these financial measures that are not consistent with U.S. GAAP. Furthermore, the Ortho Management Projections do not take into
account any circumstances or events occurring after the date they were prepared and do not give effect to the Combinations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">266 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ortho Management Projections for Ortho </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the Ortho Management Projections for Ortho. The Ortho Management Projections for Ortho were prepared according to
Ortho internal management financial reporting framework. These projections were used by the Ortho board of directors in connection with the evaluation of the Combinations and were made available to J.P. Morgan for purposes of performing its
financial analyses summarized under &#147;Opinion of J.P. Morgan Securities LLC as Financial Advisor to Ortho&#148; in this joint proxy statement/prospectus. In addition, these projections were made available to Quidel in connection with its due
diligence review of Ortho and the Combinations. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ortho Management Projections for Ortho</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B><I>(In millions of dollars)</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2021E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2022E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2023E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2024E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2025E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2026E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Terminal</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Core Revenue<SUP STYLE="font-size:85%; vertical-align:top">(1) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA (excluding Ortho Synergies
Estimates)<SUP STYLE="font-size:85%; vertical-align:top">(2) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unlevered Free Cash Flow<SUP STYLE="font-size:85%; vertical-align:top">(3) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Core Revenue is defined as revenue from Ortho&#146;s Clinical Laboratories and Transfusion Medicine businesses
and does not include &#147;other product revenue&#148; (primarily revenue from contract manufacturing) or revenue from collaboration and license agreements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjusted EBITDA is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure which is calculated as
earnings before interest expense, net provision for (benefit from) income taxes, depreciation&nbsp;&amp; amortization and eliminates (i)&nbsp;certain <FONT STYLE="white-space:nowrap">non-operating</FONT> income or expense and (ii)&nbsp;impacts of
certain noncash, unusual or other items that are included in net income (loss) that we do not consider indicative of our ongoing operating performance, including but not limited to stock based compensation expense on historical equity awards granted
under Ortho&#146;s 2014 Equity Incentive Plan prior to Ortho&#146;s IPO. Ortho&#146;s projections include stock based compensation expense on equity awards granted after the Ortho IPO under Ortho&#146;s 2021 Incentive Award Plan and any future
equity incentive plans adopted by Ortho. Adjusted EBITDA should not be considered as an alternative to net income as a measure of operating performance. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unlevered Free Cash Flow was calculated by J.P. Morgan, for purposes of its discounted cash flow analysis and
based on estimates provided by Ortho management, as future cash flows generated by an asset without including in such calculation any debt servicing costs. Specifically, unlevered free cash flow for this purpose represents Adjusted EBITDA less
taxes, capital expenditures, increases in net working capital, stock-based compensation and reagent rental instruments. For purposes of its discounted cash flow analyses and based on estimates provided by Ortho management, Perella Weinberg
calculated Unlevered Free Cash Flow of Ortho for this purpose as EBITDA less taxes, plus depreciation and amortization, and less capital expenditures and increases in net working capital, resulting in Unlevered Free Cash Flow of approximately
$313&nbsp;million, $284&nbsp;million, $337&nbsp;million, $382&nbsp;million, $425&nbsp;million, $476&nbsp;million and $523&nbsp;million for 2021E, 2022E, 2023E, 2024E, 2025E, 2026E and the terminal year, respectively. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although presented with numerical specificity, the Ortho Management Projections for Ortho reflect numerous assumptions and estimates as to future events made
by Ortho management. At the time the Ortho Management Projections were prepared, Ortho management believed such assumptions and estimates were reasonable. In preparing the Ortho Management Projections, Ortho management made assumptions regarding,
among other things, IVD market growth and the impact of COVID-19 in future years, sales of our <FONT STYLE="white-space:nowrap">COVID-19</FONT> assays, successful execution on our new product portfolio and commercial excellence initiative, and
movement of foreign currency. Ortho assumes that the IVD market will revert to its historical trajectory as the COVID-19 impact dissipates in fiscal year 2022. Ortho also anticipates that sales of our <FONT STYLE="white-space:nowrap">COVID-19</FONT>
assays peaked in fiscal year 2021 and will substantially decline in fiscal year 2022 onwards. Foreign currency rates were projected based on rates at the time the projections were prepared. As of December&nbsp;31, 2021, foreign currency has become a
headwind as the U.S. dollar strengthened against Ortho&#146;s key currencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho Management Projections for Ortho do not reflect various risks to
achieving these projections. These risks include, but are not limited to, changes in market growth or other factors that could impact our expected growth; accelerated decline of Ortho&#146;s COVID-19 assays; foreign currency changes; continued
supply chain constraints and increasing costs resulting from such constraints; and the timely launch and successful execution of new Ortho products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with commercial diligence, Ortho management provided to Quidel its initial estimates of the ability to utilize Ortho&#146;s net operating losses
over the projection period, which amounts were calculated as a tax benefit equal to $49 million in 2022, $53 million in 2023, $61 million in 2024, less than $1 million in 2025, and $0 thereafter. Perella Weinberg utilized
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">267 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these initial estimates for purposes of its financial analyses. After further internal review, Ortho management updated its estimates for purposes of the Ortho Management Projections for Ortho,
calculating such tax benefit as the amount equal to, $16 million in 2022, $36 million in 2023, $50 million in 2024, $56 million in 2025 and $29 million in 2026. The updated estimates of tax benefits, which were not provided to Quidel or Perella
Weinberg, were utilized by J.P. Morgan for purposes of its financial analyses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ortho Management Projections for Quidel </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the Ortho Management Projections for Quidel. The Ortho Management Projections for Quidel were prepared by Ortho
management, after review of the Quidel Management Projections for Quidel&#151;LRP Projections (Case 1) made available to Ortho in connection with its due diligence review of Quidel and the Combinations and reflect the results of Ortho&#146;s due
diligence review and various assumptions and estimates as to future events made by Ortho management. The Quidel Management Projections for Quidel&#151;Adjusted LRP Projections (Case 2) was not made available to Ortho prior to signing of the BCA.
These projections were used by the Ortho board of directors in connection with the evaluation of the Combinations and were made available to J.P. Morgan for purposes of performing its financial analyses summarized under &#147;Opinion of J.P. Morgan
Securities LLC as Financial Advisor to Ortho&#148; in this joint proxy statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ortho Management Projections</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><B><I>(In millions of dollars)</I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2021E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2022E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2023E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2024E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2025E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2026E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Terminal</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Net Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA (post-stock based compensation and excluding synergies)<SUP
STYLE="font-size:85%; vertical-align:top">1</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unlevered Free Cash Flow<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjusted EBITDA is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure which is calculated as
earnings before interest expense, net provision for (benefit from) income taxes, depreciation&nbsp;&amp; amortization and eliminates (i)&nbsp;certain <FONT STYLE="white-space:nowrap">non-operating</FONT> income or expense and (ii)&nbsp;impacts of
certain noncash, unusual or other items that are included in net income (loss) that we do not consider indicative of our ongoing operating performance. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unlevered Free Cash Flow was calculated by J.P. Morgan, for purposes of its discounted cash flow analysis and
based on estimates provided by Ortho management, as future cash flows generated by an asset without including in such calculation any debt servicing costs. Specifically, unlevered free cash flow for this purpose represents adjusted EBITDA less
taxes, capital expenditures, increases in net working capital, stock-based compensation and reagent rental instruments. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although
presented with numerical specificity, the Ortho Management Projections for Quidel reflect various assumptions and estimates as to future events made by Ortho management. At the time the Ortho Management Projections for Quidel were prepared, Ortho
management believed such assumptions and estimates were reasonable. In preparing the Ortho Management Projections for Quidel, Ortho management made assumptions regarding, among other things, the market demand for
<FONT STYLE="white-space:nowrap">COVID-19</FONT> testing, growth in <FONT STYLE="white-space:nowrap">Non-COVID</FONT> PoC testing (Sofia and QuickVue) and successful execution on Quidel&#146;s new product portfolio (Savanna launch). Ortho
anticipates that there will be continued testing demand for <FONT STYLE="white-space:nowrap">COVID-19</FONT> as the disease transitions from a pandemic towards an endemic state, where it will be additive to other seasonal respiratory disease testing
such as, but not limited to, Flu A/B and RSV. Ortho anticipates that <FONT STYLE="white-space:nowrap">at-home</FONT> and OTC testing will remain a critical part of combating <FONT STYLE="white-space:nowrap">COVID-19</FONT> as additional variants
emerge, and will shift over time to multiplex panel-based testing where Quidel is well-positioned with both antigen and molecular respiratory panels on the Sofia2 and Savanna platforms. Based on market and customer research, Ortho believes that the
launch of the Savanna multiplex molecular platform will provide significant opportunity due to ease of use, rapid time to result, and relative cost position, and that the platform will be competitive across various molecular segments in both
hospital and clinic-based settings, and across various geographies around the world. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Ortho Management Projections for Quidel do not reflect
various risks to achieving these projections. These risks include, but are not limited to, COVID-19 testing declining more rapidly than anticipated, increased competition which erodes pricing for COVID-19 tests and multiplex panels, regulatory
timing and other regulatory issues with the Savanna platform and test panels, regulatory timing and other regulatory issues with the high-sensitivity troponin assay, supply chain constraints inhibiting procurement of key components, and the
inability of Quidel to capture market share in the white-label rapid antigen testing market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">268 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Synergy Estimates for Topco </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the discussions regarding the Combinations, Quidel and Ortho jointly prepared estimates of the cost and revenue synergies expected to be
realized by Topco following completion of the Combinations. These jointly prepared estimates included estimated cost synergies to be achieved by year 3 and revenue synergies for years 2022 through 2025 (the &#147;Joint Synergies Estimates&#148;).
Each of Ortho and Quidel separately prepared an estimate of the revenue synergies for 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While such potential cost and revenue synergies were
collaboratively developed by Quidel management and Ortho management, each of Quidel and Ortho separately established its own assumptions relating to the timing of the cost and revenue synergies, any annual inflation adjustment to baseline costs and
the expected cost to achieve these synergies. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This unaudited prospective financial information represents Ortho management&#146;s and Quidel
management&#146;s joint estimates and assumptions regarding the potential cost synergies realizable in Topco through operational efficiencies, supply chain optimization and shared administrative functions, and revenue synergies realizable through
Quidel&#146;s expansive point-of-care diagnostics portfolio with access to Ortho&#146;s broad global reach. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Quidel</I>: Using the Joint Synergies
Estimates and Quidel management&#146;s estimate of the revenue synergies for 2026, Quidel management prepared estimates of the net cost synergies on a pre-tax and post-tax basis and estimates of the revenue synergies contribution to pre-tax and
post-tax earnings (collectively, the &#147;Quidel Synergies Estimates&#148;). In preparing the Quidel Synergies Estimates, Quidel management used as the foundation for these estimates the unaudited forward-looking financial information presented to
the Quidel board of directors on December 22, 2021 (referenced above in the section entitled &#147;Quidel Unaudited Forward-Looking Financial Information&#148; of this joint proxy statement/prospectus. Quidel management reviewed the Quidel Synergies
Estimates with the Quidel board of directors on December 22, 2021. The Quidel Synergies Estimates were also provided to Perella Weinberg and, at the direction of the management of Quidel, were utilized by Perella Weinberg for purposes of its
financial analyses as described above in the section entitled &#147;Opinion of Perella Weinberg Partners LP as Financial Advisor to Quidel&#148;. The following table sets forth a summary of the Quidel Synergies Estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cost Synergies </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I></I></B>Year Ending December 31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B><I>(In millions of dollars)</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I></I></B>2022E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2023E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2024E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2025E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2026E</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cost synergies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>59</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>88</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>91</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>94</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net realized synergies contribution to EBIT<SUP STYLE="font-size:85%; vertical-align:top">(1</SUP><SUP
STYLE="font-size:85%; vertical-align:top">)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total post-tax synergies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">EBIT is a non-GAAP financial measure which is calculated as earnings before interest expense, net and provision
for (benefit from) income taxes. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue Synergies </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I></I></B>Year Ending December 31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B><I>(In millions of dollars)</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I></I></B>2022E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2023E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2024E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2025E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2026E</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue synergies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>105</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>114</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue synergies contribution to EBIT<SUP STYLE="font-size:85%; vertical-align:top">(1</SUP><SUP
STYLE="font-size:85%; vertical-align:top">)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total post-tax synergies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">EBIT is a non-GAAP financial measure which is calculated as earnings before interest expense, net and provision
for (benefit from) income taxes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ortho</I>: Using the Joint Synergies Estimates and Ortho management&#146;s estimate of the revenue
synergies for 2026, Ortho management prepared estimates of the net cost synergies on a pre-tax and post-tax basis and estimates of the revenue synergies contribution to pre-tax and post-tax earnings (collectively, the &#147;Ortho Synergies
Estimates&#148;). Ortho management reviewed the Ortho Synergies Estimates with the Ortho board of directors on December 22, 2021. The Ortho Synergies Estimates, which were not provided to Quidel or Perella Weinberg, were also provided to J.P. Morgan
and, at the direction of the management of Ortho, were utilized by J.P. Morgan for purposes of its financial analyses as described above under the section entitled &#147;Opinion of J.P. Morgan Securities LLC as Financial Advisor to Ortho&#148;. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">269 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables set forth a summary of the Ortho Synergies Estimates. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ending December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B><I>(In millions of dollars)</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2022E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2023E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2024E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2025E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2026E</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cost synergies (net of phase-in)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57</B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76</B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>93</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>95</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>97</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net realized synergies contribution to
EBIT<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unlevered free cash flow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Cost synergy amounts assume a 2.5% inflation adjustment starting from Year Ending December&nbsp;31, 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">EBIT is a non-GAAP financial measure which is calculated as earnings before interest expense, net and provision
for (benefit from) income taxes. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ending December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B><I>(In millions of dollars)</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2022E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2023E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2024E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2025E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2026E</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue synergies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>105</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>149</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue synergies contribution to
EBIT<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">post-tax</FONT> synergies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unlevered free cash flow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">EBIT is a non-GAAP financial measure which is calculated as earnings before interest expense, net and provision
for (benefit from) income taxes. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Important factors that may affect actual results and result in the Quidel Synergies Estimates or
the Ortho Synergies Estimates not being achieved include, but are not limited to: the failure to integrate successfully the businesses of Quidel and Ortho in the expected timeframe; the failure of Topco to effectively manage its expanded operations
following the Combinations; risks relating to Ortho&#146;s indebtedness; the failure to realize the targeted cost synergies expected from the Combinations; and foreign currency exchange risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No assurances can be given that the assumptions made in preparing the Ortho Management Projections, the Quidel Management Projections, the Quidel Synergies
Estimates or the Ortho Synergies Estimates will accurately reflect future conditions. The estimates and assumptions underlying the unaudited forward-looking financial information involve judgments with respect to, among other things, future
economic, competitive, regulatory and financial market conditions and future business decisions which may not be realized and that are inherently subject to significant business, economic, competitive and regulatory uncertainties and contingencies,
including, among others, risks and uncertainties described under the sections entitled &#147;Risk Factors&#148; and &#147;Cautionary Statement Concerning Forward-Looking Statements&#148; of this joint proxy statement/prospectus, all of which are
difficult to predict and many of which are beyond the control of Ortho and/or Quidel and will be beyond the control of the combined company. There can be no assurance that the underlying assumptions will prove to be accurate or that the projected
results will be realized, and actual results likely will differ, and may differ materially, from those reflected in the unaudited forward-looking financial information, whether or not the Combinations are completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither Quidel nor Ortho or any of their respective affiliates, advisors (including J.P. Morgan and Perella Weinberg), officers, directors or representatives
has made or makes any representation to any Quidel stockholder, any Ortho shareholder or any other person regarding the ultimate performance of Quidel or Ortho compared to the information contained in the foregoing unaudited forward-looking
financial information or can give any assurance that actual results will not differ materially from such unaudited forward-looking financial information, and none of them undertakes any obligation to update or otherwise revise or reconcile such
unaudited forward-looking financial information to reflect circumstances existing after the date that such unaudited forward-looking financial information was generated or to reflect the occurrence of future events even in the event that any or all
of the assumptions underlying such unaudited forward-looking financial information are shown to be in error. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited forward-looking financial
information referred to as the Ortho Management Projections above was prepared by Ortho management and was not approved by Quidel or any affiliate or employee thereof. The unaudited forward-looking financial information referred to as the Quidel
Management Projections above was prepared by Quidel management and was not approved by Ortho or any affiliate or employee thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORTHO AND QUIDEL HAVE
NOT UPDATED OR OTHERWISE REVISED AND DO NOT INTEND TO UPDATE OR OTHERWISE REVISE FOR THE PURPOSE OF THIS JOINT PROXY STATEMENT/PROSPECTUS THE ORTHO MANAGEMENT PROJECTIONS, THE QUIDEL MANAGEMENT PROJECTIONS, THE QUIDEL SYNERGIES
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">270 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ESTIMATES OR THE ORTHO SYNERGIES ESTIMATES TO REFLECT CIRCUMSTANCES EXISTING AFTER THE DATE PREPARED OR TO REFLECT THE OCCURRENCE OF FUTURE EVENTS, EVEN IN THE EVENT THAT ANY OR ALL OF THE
ASSUMPTIONS UNDERLYING SUCH FORWARD-LOOKING FINANCIAL INFORMATION ARE NO LONGER APPROPRIATE, EXCEPT AS MAY BE REQUIRED BY LAW. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_143">
</A>Closing Date and Effective Times </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the BCA, Ortho and Topco will each use their respective reasonable best efforts to
obtain an order of the High Court of Justice of England and Wales under Part 26 of the UK Companies Act sanctioning the Ortho Scheme (the &#147;Ortho Scheme Order&#148;), which shall be effective once the Ortho Scheme Order is duly filed with the
Registrar of Companies in England and Wales (the &#147;Registrar&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing of the Combinations will take place on the Closing Date the Ortho
Scheme Order is duly filed with the Registrar (the &#147;Scheme Effective Date&#148;). Subject to the terms and conditions set forth in the BCA, on the Closing Date, and as soon as practicable after the Ortho Scheme Order is duly filed with the
Registrar, Quidel will file the Quidel Certificate of Merger with the Secretary of State of the State of Delaware in accordance with the relevant provisions of the DGCL and shall make all other filings or recordings required under the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Combinations will become effective sequentially (i)&nbsp;with the Ortho Scheme Order becoming effective on the Scheme Effective Date and at the time the
Ortho Scheme Order is duly delivered to the Registrar, such time being the &#147;Ortho Effective Time&#148; and (ii)&nbsp;with the Quidel Certificate of Merger providing that the Quidel Merger shall become effective on the Scheme Effective Date
immediately following the Ortho Effective Time (or such subsequent time as Ortho and Quidel shall agree and as shall be specified in the Quidel Certificate of Merger, and in no event prior to the Ortho Effective Time), such time being the
&#147;Quidel Effective Time.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the satisfaction or waiver of the conditions to the closing described in the section entitled &#147;The
Business Combination Agreement&#151;Conditions to the Combinations&#148; of this joint proxy statement/prospectus, including the approval of the Ortho Scheme by Ortho shareholders at the Ortho Court Meeting and adoption of the BCA by the Quidel
stockholders at the Quidel Stockholders&#146; Meeting, the sanction hearing of Ortho having taken place and the filing of the Ortho Scheme Order with the Registrar, it is anticipated that the Combinations will close in the first half of 2022.
However, neither Ortho nor Quidel can predict the actual date on which the Combinations will be completed, or if the Combinations will occur at all, because completion of the Combinations is subject to conditions and factors outside the control of
both companies. It is possible that factors outside the control of both companies could result in the Combinations being completed at a different time, or not at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_144"></A>Board of Directors and Management of Topco Following Completion of the Combinations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board of Directors </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of the Ortho
Effective Time, the Topco board of directors will consist of 12 members and be composed as follows: (i)&nbsp;eight directors designated by Quidel prior to closing, expected to consist of Messrs. Bryant, Buechler, Michael, Strobeck, Widder and
Wilkins and Mses.&nbsp;Polan and Rhoads, each of whom, other than Mr.&nbsp;Bryant, qualifies as an &#147;independent director&#148; under applicable rules of Nasdaq, and (ii)&nbsp;four directors designated by Ortho prior to closing, at least two of
whom will qualify as an &#147;independent director&#148; under the applicable rules of Nasdaq. Each of the members of the Topco board of directors designated by Ortho shall be reasonably acceptable to the nominating and corporate governance
committee of the current Quidel board of directors. In connection with the BCA, Ortho and the Carlyle Stockholder executed a letter agreement pursuant to which Ortho agrees that, at the closing, the Ortho designees to the Topco board of directors
will include two Carlyle nominees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, pursuant to the terms of the BCA, Douglas Bryant, current President and Chief Executive Officer of
Quidel, will serve as the Chair of the Topco board of directors at the Ortho Effective Time. The Topco board of directors intends to appoint a lead independent director, since Mr. Bryant will serve as the Chief Executive Officer of Topco and Chair
of the Topco board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Douglas C. Bryant</I>, age 64, will serve as Chief Executive Officer of Topco and Chair of the Topco board of
directors. Mr.&nbsp;Bryant is currently President and Chief Executive Officer of Quidel and a member of the Quidel board of directors. Prior to joining Quidel in 2009, Mr.&nbsp;Bryant served as Executive Vice President and Chief Operating Officer at
Luminex </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">271 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&amp;D, technical operations and commercial operations. From 1983 to 2007, Mr.&nbsp;Bryant
held various worldwide commercial operations positions with Abbott Laboratories, including, among others: Vice President of Abbott Vascular for Asia/Japan, Vice President of Abbott Molecular Global Commercial Operations and Vice President of Abbott
Diagnostics Global Commercial Operations. Earlier in his career with Abbott, Mr.&nbsp;Bryant was Vice President of Diagnostic Operations in Europe, the Middle East and Africa and Vice President of Diagnostic Operations in Asia Pacific.
Mr.&nbsp;Bryant has over 30 years of industry experience in sales and marketing, product development, manufacturing and service and support in both the diagnostics and life sciences markets. Mr.&nbsp;Bryant holds a B.A. in Economics from the
University of California at Davis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Committees of the Topco Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Ortho Effective Time, the Topco board of directors will form the following board committees: the Audit Committee, the Compensation Committee and the
Nominating and Governance Committee. The Audit Committee, the Compensation Committee and the Nominating and Governance Committee will each be chaired by a member of the Topco board of directors designated by Quidel. The Audit Committee, the
Compensation Committee and the Nominating and Governance Committee will each consist of one member of the Topco board of directors designated by Ortho and not less than two additional members of the Topco board of directors designated by Quidel, in
each case, subject to applicable legal and regulatory requirements, and, in the case of the Ortho designees, such designees must be reasonably acceptable to the Topco board of directors. The charters for the Audit Committee, the Compensation
Committee and the Nominating and Governance Committee will each be substantially similar to the charters for the respective committees of the Quidel board of directors that were in effect as of the date of the BCA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the BCA, at
the Ortho Effective Time, Douglas Bryant, current President and Chief Executive Officer of Quidel, will serve as Chair and Chief Executive Officer of Topco. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, at the Ortho Effective Time, the following individuals will serve as officers of Topco: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Joseph M. Busky</I>, age 54, will serve as Chief Financial Officer. Mr.&nbsp;Busky is currently Chief Financial Officer of Ortho. Prior to joining Ortho in
2020, Mr.&nbsp;Busky served as chief financial officer for global medical device company, Vyaire Medical, Inc., from 2018 through 2020, as chief executive officer of Qualtek from 2017 to 2018, and as chief financial officer of FDH Velocitel from
2015 to 2017. He has also previously held leadership roles at InnerWorkings, Inc. and Siemens Medical Solutions Diagnostics/Dade Behring Holdings, Inc. Mr.&nbsp;Busky holds an MBA with a finance concentration, as well as a BBA in accounting, from
Loyola University in Baltimore. He also holds a CPA certification in Maryland from the American Institute of Certified Public Accountants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Robert J.
Bujarski</I>, age 53, will serve as President and Chief Operating Officer. Mr.&nbsp;Bujarski is currently Chief Operating Officer of Quidel, a position he has held since 2020. Previously, Mr.&nbsp;Bujarski was Quidel&#146;s Senior Vice President,
North America Commercial Operations from 2019 to 2020, Senior Vice President, General Counsel from 2007 to 2020, Senior Vice President, Business Development from 2009 to 2019 and General Counsel and Vice President from 2005 to 2007. Prior to joining
Quidel, Mr.&nbsp;Bujarski was an associate attorney with the law firm of Gibson, Dunn&nbsp;&amp; Crutcher LLP in its transactions practice group from 2001 to 2005. Mr.&nbsp;Bujarski holds a B.A. from the University of Arizona and a J.D. from the
University of Arizona. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Michael S. Iskra</I>, age 52, will serve as Chief Commercial Officer. Mr.&nbsp;Iskra is currently Executive Vice President of
Commercial Excellence&nbsp;&amp; Strategy at Ortho, a position he has held since 2020. Mr.&nbsp;Iskra was the President, North America for Ortho from 2015 through <FONT STYLE="white-space:nowrap">mid-2020.</FONT> From 2014 to 2015, he served as
Senior Vice President for business development at Healthways. Prior to that, he was Chief Operating Officer, from 2010 to 2012, and Chief Executive Officer, in 2013, for Simplex Healthcare. From 2007 to 2010, he was the Executive Vice President and
General Manager at CCS Medical and prior to 2007, he spent 14 years at Bayer/Siemens Diagnostics in various sales and marketing roles. Mr.&nbsp;Iskra holds a B.A. from the University of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No family relationships exist among any of the above-listed persons chosen to become officers, and there are no arrangements or understandings between any of
the above-listed persons chosen to become officers and any other person pursuant to which they will serve as an officer. During the past ten years, none of the above-listed persons chosen to become officers was involved in any legal proceedings as
defined in Item 401(f) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> All persons chosen to become officers will be elected by the Topco board of directors to hold office until their successors are elected and qualified. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">272 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_145"></A>Accounting Treatment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco will account for the Combinations using the acquisition method of accounting in accordance with ASC Topic 805. For further information, see the section
entitled &#147;Unaudited Pro Forma Combined Financial Information&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_146"></A>Regulatory Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho and
Quidel have agreed to use their reasonable best efforts to obtain all regulatory approvals required to complete the transactions contemplated by the BCA. These approvals include clearance under the HSR Act, and other merger control and foreign
investment laws and regulations. Ortho and Quidel have completed, or will complete, the filing of applications and notifications to obtain the required regulatory approvals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Antitrust and Merger Control </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>United
States</I>. Under the HSR Act, and the rules and regulations promulgated thereunder, the Combinations may not be completed until notification and report forms have been filed with the FTC and the Antitrust Division of the U.S. Department of Justice
(the &#147;Antitrust Division&#148;) and all applicable waiting periods have expired or been terminated. Ortho and Quidel each filed an HSR notification with the FTC and the Antitrust Division on January&nbsp;10, 2022. The waiting period under the
HSR Act with respect to the filed notifications expired at 11:59&nbsp;p.m., Eastern Time, on February&nbsp;9, 2022. Ortho and Quidel continue to expect the Combinations to close in the first half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>United Kingdom</I>. Under the Enterprise Act 2002 and the rules and regulations promulgated thereunder, the merger control regime in the UK is voluntary
and in any event the merger control thresholds are not met. The parties do not intend to make a voluntary filing unless the UK CMA opens or indicates that it intends to open an <FONT STYLE="white-space:nowrap">own-initiative</FONT> investigation
prior to closing of the Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Jurisdictions</I>. Ortho and Quidel have ensured the filing of notifications, notices or applications
pursuant to antitrust and competition laws in Russia and Turkey and foreign investment laws in France, Italy and Spain. Clearance decisions have been granted in Russia and Italy as of March 1, 2022. The parties must observe mandatory waiting periods
and/or obtain the necessary waivers, consents, clearances, approvals or authorizations pursuant to these remaining foreign antitrust, competition and foreign investment laws before completing the Combinations. The parties will also file a
notification under foreign investment laws in Canada after closing of the Combinations. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time before or after completion of the Combinations,
the Antitrust Division, the FTC, state attorneys general, or foreign antitrust, competition and foreign investment authorities could take any action under U.S. federal or state antitrust laws, or foreign laws, as they deem necessary or desirable in
the public interest, including seeking to enjoin the Combinations, or seeking the divestiture of substantial assets or other divestiture, behavioral or conduct remedies, conditions or commitments. Private parties may also bring legal actions under
U.S. federal, state or foreign antitrust, competition and foreign investment laws under certain circumstances. There can be no assurance that a challenge to the Combinations on antitrust, competition and foreign investment grounds will not be made
or, if a challenge is made, of the result of the challenge. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Commitment to Obtain Approvals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho and Quidel have agreed to cooperate with each other and use reasonable best efforts to take all actions and do all things necessary, proper or advisable
to consummate the Combinations as soon as practicable. These reasonable best efforts include an obligation to obtain as promptly as practicable all regulatory approvals and consents necessary or advisable in order to consummate the Combinations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Assurance of Approvals </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of
this joint proxy statement/prospectus, Ortho and Quidel have completed, or will complete, the filing of applications and notifications to obtain the required regulatory approvals. The parties believe that the Combinations can be completed in
compliance with all applicable regulatory laws. However, there can be no assurance that the antitrust, competition or foreign investment authorities will terminate or permit the applicable waiting periods to expire, or approve or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">273 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clear the Combinations at all, or that they will do so without restrictions, required commitments or conditions. There also can be no assurance that a challenge to completion of the Combinations
under the antitrust, competition or foreign investment laws will not be made or that, if such a challenge were made, the parties would prevail or would not be required to accept certain conditions, possibly including divestitures and behavioral and
conduct restrictions, conditions or commitments, in order to complete the Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot assure you that all of the regulatory approvals
described above will be obtained, and, if obtained, we cannot assure you as to the date of any approvals or the absence of any litigation or remedies, conditions or commitments related to such approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ortho and Quidel are not aware of any material governmental approvals or actions that are required for completion of the Combinations other than those
described above. It is presently contemplated that if any such additional governmental approvals or actions are required, those approvals or actions will be sought. There can be no assurance, however, that any additional approvals or actions will be
obtained. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_147"></A>The Parties&#146; Intentions Regarding Ortho and Quidel </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel and Ortho have commenced, and following the Closing Date, Topco will continue, a comprehensive evaluation of Topco&#146;s operations and will identify
the best way to integrate the organizations in order to further improve Topco&#146;s ability to serve its customers, as well as achieve revenue and cost synergies. Employees from both Ortho and Quidel are and will be involved in the evaluation,
formation and execution of the integration plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until these evaluations and formation of plans have been completed, Ortho and Quidel are not in a
position to comment on prospective potential impacts upon employment, specific locations or any redeployment of fixed assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_148"></A>U.S. Federal Securities Law Consequences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the effectiveness of the registration statement of which this joint proxy statement/prospectus forms a part, Topco Shares issued in the Combinations
will not be subject to any restrictions on transfer arising under the Securities Act or the Exchange Act, except for Topco Shares issued to any Ortho shareholder or Quidel stockholder who may be deemed an &#147;affiliate&#148; of Topco after
completion of the Combinations. This joint proxy statement/prospectus does not cover resales of Topco Shares received by any person upon completion of the Combinations, and no person is authorized to make any use of this joint proxy
statement/prospectus in connection with any resale of Topco Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_149"></A>Listing of Topco Shares on Stock Exchange </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco Shares currently are not traded or quoted on a stock exchange or quotation system. The parties expect that, following completion of the Combinations,
Topco Shares will be listed for trading on Nasdaq, and it is a condition to the parties&#146; obligations to effect the Combinations that the Topco Shares be authorized for listing on Nasdaq, subject to official notice of issuance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_150"></A>Delisting and Deregistration of Ortho Shares and Quidel Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Promptly after the Ortho Effective Time, the Ortho Shares will be delisted from Nasdaq and deregistered under the Exchange Act, and promptly after the Quidel
Effective Time, the Quidel Shares will be delisted from Nasdaq and deregistered under the Exchange Act. Topco will be the successor to Quidel for purposes of Topco&#146;s Nasdaq listing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_150a"></A>Litigation Relating to the Combinations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the announcement of the Combinations, one putative complaint has been filed by and purportedly on behalf of an alleged Ortho shareholder: Rydberg v.
Ortho Clinical Diagnostics Holdings plc, et&nbsp;al., No.&nbsp;1:22-cv-01334 filed March&nbsp;10, 2022 in the United States District Court for the Eastern District of New York (the&nbsp;&#147;Action&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Action names as defendants Ortho and the members of Ortho&#146;s Board of Directors. The Action alleges, among other things, that the joint proxy
statement/prospectus omits certain information regarding projections of Ortho, Quidel and Topco, the analysis performed by the financial advisor of Ortho, and potential conflicts of interest involving a financial advisor and Ortho&#146;s officers
and directors. The Action seeks, among other things, injunctive relief to prevent the Combinations from closing, damages if the Combinations close, and attorneys&#146; fees. Ortho believes these claims are entirely without merit and that the joint
proxy statement/prospectus does not omit any material information about the Combinations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">274 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_151"></A>DESCRIPTION OF TOPCO CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following information is a summary of the
material terms of the capital stock of Topco (upon effectiveness of the Combinations). You are encouraged to read the Topco Charter and the Topco Bylaws, which, following completion of the Combinations, will be substantially in the forms attached
hereto as Exhibit 3.1 and Exhibit 3.2 of this joint proxy statement/prospectus, respectively. For more information, see the comparison of relative rights described in the section entitled &#147;Comparison of Rights of Stockholders of Quidel, Ortho
and Topco&#148; of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco&#146;s authorized capital stock consists of [&#9679;] shares of common stock, par value $0.001 per share, and [&#9679;] shares of preferred stock, par
value $0.001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting.</I>&nbsp;Except as otherwise required by law (and subject to the rights of any other outstanding capital stock under
the Topco Charter), each outstanding share of common stock is entitled to vote on each matter on which Topco&#146;s stockholders are entitled to vote, and each holder thereof shall be entitled to one vote for each share of common stock held by such
holder. Holders of shares of common stock do not have cumulative voting rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends.</I><I></I>&nbsp;Holders of Topco Shares have the right to
receive dividends when, as and if declared by the Topco board of directors from funds legally available therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special Meetings and Notice
Procedures.</I>&nbsp;The Topco Bylaws provide that special meetings of stockholders may only be called by stockholders of record, as of the record date fixed as provided therein, holding in the aggregate not less than 50% of the voting power of
Topco&#146;s issued and outstanding capital stock. In addition, the Topco Bylaws establish an advance written notice procedure for stockholders seeking to nominate candidates for election to the Topco board of directors or to propose matters to be
acted upon at stockholders&#146; meetings. As a result, these provisions of the Topco Bylaws may delay stockholder actions with respect to business combinations or a change in management and may make it more difficult for third parties to acquire
control of Topco. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advanced Notice Bylaws.</I> For director nominations or other business to be properly brought before an annual meeting by a
stockholder, such stockholder must generally provide notice to Topco no later than 90 days and no more than 120&nbsp;days prior to the first anniversary of the date of the prior year&#146;s annual meeting; provided, that if the date of the annual
meeting is advanced by more than 30&nbsp;days prior to or delayed by more than 60&nbsp;days after the anniversary of the preceding year&#146;s annual meeting, such notice must be delivered no more than 120 days prior to such annual meeting nor less
than the later of (i) 90 days prior to such annual meeting and (ii)&nbsp;ten days after the day on which public disclosure of the date of such meeting is first made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusive Jurisdiction.</I> The Topco Bylaws provide that unless Topco selects or consents in writing to the selection of an alternative forum,
(i)&nbsp;the sole and exclusive forum for any complaint by any current or former stockholder asserting any internal corporate claims, to the fullest extent permitted by law, and subject to applicable jurisdictional requirements, shall be the Court
of Chancery of the State of Delaware (or, if the Court of Chancery does not have, or declines to accept, jurisdiction, another state court or a federal court located within the State of Delaware), and (ii)&nbsp;the sole and exclusive forum for any
complaint by any current or former stockholder asserting a cause of action arising under the Securities Act, to the fullest extent permitted by law, shall be the federal district courts of the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware Anti-takeover </I><I>Statute</I><I>.</I> Topco has opted out of Section&nbsp;203 of the DGCL, which is a statute that (if applicable) would have
served to make certain types of unfriendly or hostile corporate takeovers, or other <FONT STYLE="white-space:nowrap">non-board</FONT> approved transactions involving a corporation and one or more of its significant stockholders, more difficult. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Rights.</I>&nbsp;Holders of Topco Shares do not have any preemptive, subscription or conversion rights under the Topco Charter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Topco board of directors is
authorized to issue from time to time, without further vote or action by the stockholders, up to an aggregate of [&#9679;] shares of preferred stock in one or more series. The Topco board of directors is authorized, within the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">275 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitations and restrictions stated in the Topco Charter, to determine or alter the rights, preferences, privileges and restrictions granted to or imposed on any wholly unissued series of
preferred shares, and the number of shares constituting such series and the designation thereof. No preferred shares are currently outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco
currently has no plans to issue any shares of preferred stock, but Topco believes that the ability to issue shares of preferred stock without the expense and delay of a special stockholders&#146; meeting will provide Topco with increased flexibility
in structuring possible future financings and acquisitions, and in meeting other corporate needs that might arise. The Topco board of directors could issue shares of preferred stock having voting, dividend and liquidation rights superior to those of
the shares of common stock, which could adversely affect the voting power of the common stockholders, including the loss of voting control to others, and delay, defer or prevent a change in control of Topco without further action by the
stockholders. This could discourage an acquisition attempt or other transaction that stockholders might believe to be in their best interests or in which they might receive a premium for their stock over the then-market price of the stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Topco board of directors were to issue a new series of preferred stock, the issuance of such shares could: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decrease the amount of earnings and assets available for distribution to existing holders of Topco Shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make removal of Topco management more difficult; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">result in restrictions upon the payment of dividends and other distributions to the existing holders of Topco
Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay or prevent a change in control of Topco; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the price that investors are willing to pay in the future for Topco Shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Stockholders
Agreement, the Carlyle Stockholder (or its permitted transferees or affiliates) is entitled to demand and piggyback rights with respect to the registration of its Topco Shares under the Securities Act. In certain instances, the Carlyle Stockholder
may cause Topco, at Topco&#146;s expense, to file registration statements under the Securities Act covering resales of Topco Shares held by the Carlyle Stockholder (or such permitted transferees or affiliates) or to piggyback on other registration
statements in certain circumstances. For more information, see the section entitled &#147;Stockholders Agreement / Deed of Irrevocable Undertaking&#148; of this joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">276 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_152"></A>THE BUSINESS COMBINATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This section of the joint proxy statement/prospectus describes material terms and conditions of the BCA. The description in this section and elsewhere in
this joint proxy statement/prospectus is qualified in its entirety by reference to the complete text of the BCA, a copy of which is attached as</I><B><I> </I></B><I>Exhibit 2.1 and is incorporated by reference into this joint proxy
statement/prospectus. This summary may not contain all of the information that is important to you. You should carefully read this entire document, including the full text of the BCA and the other documents referred to therein, for a more complete
understanding of the Combinations before making any decisions regarding the Combinations, including approval of the Ortho Scheme or the Merger Proposal, as applicable, as it is the legal document governing the Combinations. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_153"></A>Explanatory Note Regarding the Business Combination Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA and this summary of terms are included to provide you with information regarding the terms of the BCA. Factual disclosures about Quidel, Ortho and
Topco contained in this joint proxy statement/prospectus or in the public reports of Quidel, Ortho and Topco filed with the SEC may supplement, update or modify the factual disclosures about Quidel, Ortho and Topco contained in the BCA. See the
section entitled &#147;Where You Can Find More Information&#148; of this joint proxy statement/prospectus. The representations, warranties and covenants made in the BCA by Quidel, Ortho, Topco, U.S. Merger Sub, U.S. Holdco Sub and U.S. Holdco Sub 2
were qualified and subject to important limitations agreed to by Quidel, Ortho, Topco, U.S. Merger Sub, U.S. Holdco Sub and U.S. Holdco Sub 2 in connection with negotiating the terms of the BCA. In particular, in your review of the representations
and warranties contained in the BCA and described in this summary, it is important to bear in mind that the representations and warranties were negotiated with the principal purpose of establishing circumstances in which a party to the BCA may have
the right, subject to certain materiality exceptions, not to consummate the Combinations if the representations and warranties of the other party prove to be untrue due to a change in circumstance or otherwise, and allocating risk among the parties
to the BCA, rather than establishing matters as facts. The representations and warranties also may be subject to a contractual standard of materiality different from that generally applicable to shareholders or stockholders and reports and documents
filed with the SEC, and in some cases were qualified by the matters contained in the confidential disclosures that Quidel and Ortho each delivered to the other party in connection with the BCA, which disclosures were not reflected in the BCA itself.
Moreover, information concerning the subject matter of the representations and warranties, which do not purport to be accurate as of the date of this joint proxy statement/prospectus, may have changed since the date on which they were made. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_154"></A>Execution of the Business Combination Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;
22, 2021, the parties executed the BCA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_155"></A>Structure and Effective Times </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA provides for two transactions, which will occur in immediate succession. First, when the Ortho Scheme Order becomes effective upon the delivery of the
Ortho Scheme Order to the Registrar, each issued and outstanding Ortho Share at the Ortho Effective Time (other than Excluded Ortho Shares) shall be transferred to the DR Nominee (or, if the DR Nominee holds the Ortho Shares today, transferred
within the DR Nominee) for the benefit and on behalf of Topco in exchange for the consideration described under &#147;Merger Consideration&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately following the Ortho Effective Time, U.S. Merger Sub will merge with and into Quidel in a statutory merger under Delaware law, pursuant to which,
following the Quidel Effective Time, the independent existence of U.S. Merger Sub will cease, with Quidel surviving as a wholly owned subsidiary of Topco, and pursuant to which each Quidel Share, other than any Quidel Shares held by Quidel, Ortho or
U.S. Merger Sub (the &#147;Excluded Quidel Shares&#148;), will automatically be converted into the right to receive the Quidel Merger Consideration of one Topco Share, in each case subject to the terms and conditions of the BCA and as described
under &#147;Merger Consideration&#148; below. Immediately following consummation of the Combinations, it is expected that former Quidel stockholders will own approximately 62% of Topco and former Ortho shareholders will own approximately 38% of
Topco, on a fully diluted basis, based on the respective capitalizations of Quidel and Ortho as of the date the parties entered into the BCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Quidel
Merger will be completed at the Quidel Effective Time, which will immediately follow the Ortho Effective Time. Subject to the satisfaction or waiver of certain conditions contained in the BCA, as described under &#147;Conditions to the
Combinations&#148; below, Topco and Ortho are required under the BCA to appear at the Ortho Court Meeting to seek sanctioning of the Ortho Scheme Order under Part 26 of the UK Companies Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">277 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the date on which the Ortho Scheme Order is filed with the Registrar, and as soon as practicable after
such time, and in no event prior thereto, Quidel will file the Quidel Certificate of Merger with the Secretary of State of the State of Delaware, which will provide that the Quidel Merger will become effective on such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately following the Combinations, Topco shall transfer 100% of the depositary interests in the issued and outstanding Ortho Shares held by the DR
Nominee and the deferred shares in Topco to U.S. Holdco Sub as a contribution to capital and, at least two days following such contribution, U.S. Holdco Sub will transfer such depositary interests and deferred shares to U.S. Holdco Sub 2. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_156"></A>Merger Consideration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho Shares Consideration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA provides that,
at the Ortho Effective Time, each Ortho Share issued and outstanding immediately prior to the Ortho Effective Time, other than the Excluded Ortho Shares (if any), will be exchanged for (a) 0.1055 Topco Shares and (b) $7.14 in cash (collectively, the
&#147;Ortho Scheme Consideration&#148;), and the Scheme of Arrangement further provides that such exchange shall be settled as soon as reasonably practicable following the Ortho Effective Date and in any event no later than two Business Days
thereafter. As of the Ortho Effective Time, the holders of the Ortho Shares (and any holders of depositary interests in Ortho Shares) shall cease to have any rights with respect to the Ortho Shares, except their rights under the Ortho Scheme in
accordance with the terms of the BCA. No fractional Topco Shares will be issued to any holders of Ortho Shares and such holders shall receive, in lieu of fractional Topco Shares, cash as described further in &#147;Ortho Shareholder
Meetings&#151;Scheme of Arrangement.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quidel Shares Consideration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA provides that, at the Quidel Effective Time, each Quidel Share issued and outstanding immediately prior to the Quidel Effective Time, other than
Excluded Quidel Shares, will be exchanged for one Topco Share, in accordance with the terms of the BCA. As of the Quidel Effective Time, the holders of the Quidel Shares shall cease to have any rights with respect to the Quidel Shares, except their
rights under the Quidel Merger in accordance with the terms of the BCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;262(b)(1) of the DGCL, Quidel stockholders are not
entitled to exercise dissenters&#146;, appraisal, cash exit or similar rights in connection with the Combinations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_157"></A>Adjustments to Prevent Dilution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that between the date of the BCA and the Ortho Effective Time, the outstanding Quidel Shares or Ortho Shares, or securities convertible into, or
exercisable or exchangeable for Quidel Shares or Ortho Shares, change into a different number of shares or a different class by reason of any stock dividend, stock distribution or other similar event, then the Quidel Exchange Ratio or the Ortho
Exchange Ratio, as the case may be, will be appropriately adjusted to provide to the stockholders of both Quidel and Ortho the same economic effect as contemplated by the BCA prior to such event. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_158"></A>Exchange of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ortho Scheme </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco will appoint a U.S. bank or
trust company or other independent financial institution in the United States reasonably satisfactory to Quidel and Ortho (the &#147;Exchange Agent&#148;) which will, among other things, deliver the Ortho Scheme Consideration and the Quidel Merger
Consideration to former Ortho shareholders and former Quidel stockholders, respectively. Ortho Shares will be transferred under the Ortho Scheme in accordance with the terms of the BCA, the terms of the Ortho Scheme and the rules and procedures of
any depositary or clearing agency through which such shares are held or traded and applicable law. Prior to the Court Sanction Hearing, Quidel will irrevocably commit to Topco and, as may be required, the Court to make available to Topco the Cash
Portion, which will be deposited with the Exchange Agent on or before the Ortho Effective Time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quidel Merger </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco will deposit with the Exchange Agent, for the benefit of holders of Quidel Shares, the number of Topco Shares issuable in the Quidel Merger (the
&#147;Exchange Fund&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">278 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Quidel Shares represented by certificates, as soon as practicable after the Quidel Effective Time, but
in no event later than five days thereafter, Topco will cause the Exchange Agent to mail to each holder of a Quidel Share certificate a letter of transmittal and instructions describing how such holder may exchange its Quidel Shares for the Quidel
Merger Consideration in respect of its shares under the BCA. Upon surrender of a certificate (or an affidavit of loss in lieu thereof, and, if required the posting of a bond) for cancellation to the Exchange Agent and delivery of a duly executed
letter of transmittal in proper form, the holder of such shares will be entitled to receive the Quidel Merger Consideration (after giving effect to any required tax withholdings). Holders of Quidel Shares represented by certificates will not be
entitled to receive the Quidel Merger Consideration or any other payments in respect of their shares under the BCA unless and until such holders have delivered a duly completed and executed letter of transmittal to the Exchange Agent, accompanied by
the required share certificates and such other customary documents as may be reasonably required by the Exchange Agent. Surrendered share certificates will be cancelled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Quidel Shares in book-entry form through DTC will automatically be entitled to receive, and Topco will cause the Exchange Agent to pay and deliver
as promptly as practicable after the Quidel Effective Time, the Quidel Merger Consideration in respect of such shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As soon as practicable after the
Quidel Effective Time, but in no event later than five days thereafter, Topco will cause the Exchange Agent to deliver to each holder of a Quidel Share that is held in book-entry form, but that is not held through DTC, a letter of transmittal and
instructions describing how such holder may exchange its Quidel Shares for the Quidel Merger Consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_159"></A>Lost, Stolen
or Destroyed Certificates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any certificate representing Quidel Shares has been lost, stolen or destroyed, the holder thereof will be entitled to
receive, in exchange for such lost, stolen or destroyed Quidel Share certificate, the applicable Quidel Merger Consideration as contemplated by the BCA upon the making of an affidavit to the Exchange Agent by the holder claiming such certificate to
be lost, stolen or destroyed and, if required by the Exchange Agent or Topco, the posting by such person of a bond in such sum as it may reasonably direct as indemnity against any claim with respect to such certificate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_160"></A>No Transfers Following the Quidel Effective Time </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Quidel Effective Time, the stock transfer books of Quidel will be closed, and there will be no further registration of transfers on records of
Quidel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_161"></A>Termination of Exchange Fund </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any Topco Shares that remain in the Exchange Fund as of the first anniversary of the Ortho Effective Date will be delivered to Topco by the Exchange Agent if
Topco so requires. Thereafter, holders of Quidel Shares will be entitled to look only to Topco with respect to the payment of the Quidel Merger Consideration. If, prior to six&nbsp;years after the Ortho Effective Date (or otherwise immediately prior
to such time as the applicable amount would become the property of any governmental entity under applicable law), any holder of Quidel Share certificates or Quidel Shares held in book-entry form has not complied with the procedures set forth in the
BCA to receive the Quidel Merger Consideration to which such holder would otherwise be entitled, such Quidel Merger Consideration will, to the extent permitted by applicable law, become the property of Topco, free and clear of all claims or interest
of any person previously entitled thereto. Neither Topco nor the Exchange Agent will be liable to any former holder of Quidel Shares for any amount properly delivered to a public official pursuant to any applicable abandoned property, escheat or
similar law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_162"></A>Withholding Taxes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Quidel, Ortho, Topco, the Quidel Merger surviving company, and the Exchange Agent will be entitled to deduct and withhold applicable taxes from the
consideration otherwise payable pursuant to the BCA such amounts as it is required to deduct and withhold with respect to the making of such payment. Any amount so withheld will be treated for all purposes as having been paid to such holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">279 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_163"></A>Treatment of Ortho Equity Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCA, awards outstanding under the Ortho Stock Plans will be treated as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options</I></B><B>.</B> At the Ortho Effective Time, each Ortho Stock Option, whether vested or unvested, that is outstanding immediately prior to
the Ortho Effective Time will cease to represent an option to acquire Ortho Shares and will be converted into (a)&nbsp;a Topco Stock Option on the same terms and conditions as were applicable to such Ortho Stock Option immediately prior to the Ortho
Effective Time, except as adjusted by the BCA, (b)&nbsp;with respect to the portion of such Ortho Stock Option that is vested as of the Ortho Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect
of the Ortho Shares subject to the vested portion of such Ortho Stock Option and (c)&nbsp;with respect to the portion of such Ortho Stock Option that is not vested as of the Ortho Effective Time, the right to receive payment, in cash, equal to the
cash consideration payable in respect of the Ortho Shares subject to the unvested portion of such Ortho Stock Option when it vests in accordance with its terms. The number of Topco Shares subject to each such Topco Stock Option will be equal to the
product (rounded down to the nearest whole number) obtained by multiplying (i)&nbsp;the number of Ortho Shares subject to such Ortho Stock Option immediately prior to the Ortho Effective Time by (ii)&nbsp;the Ortho Exchange Ratio, and each such
Topco Stock Option will have an exercise price per share (rounded up to the nearest whole cent) equal to (x)&nbsp;the exercise price per Ortho Share of such Ortho Stock Option immediately prior to the Ortho Effective Time divided by (y)&nbsp;the
Ortho Exchange Ratio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the Ortho Stock Options outstanding as of December&nbsp;20, 2021, and assuming no Ortho Stock Options are exercised
between December&nbsp;20, 2021 and the Ortho Effective Time, 1,375,955&nbsp;Topco Shares will be issuable pursuant to Topco Stock Options issued in exchange for such Ortho Stock Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Units and Restricted Stock.</I></B> At the Ortho Effective Time, each Ortho Equity Right that is outstanding immediately prior to the
Ortho Effective Time will cease to relate to or represent a right to receive Ortho Shares and will be converted into a Topco Equity Right of the same type and on the same terms and conditions as were applicable to the corresponding Ortho Equity
Right immediately prior to the Ortho Effective Time. Upon the subsequent vesting of any portion of such Ortho Equity Right, such portion of the Ortho Equity Right shall also be entitled to a right to receive payment, in cash, equal to the cash
consideration in respect of the Ortho Shares subject to the unvested portion of the Ortho Equity Right when it vests in accordance with its terms. The number of Topco Shares covered by each such Topco Equity Right will be equal to the product
(rounded to the nearest whole number) obtained by multiplying (i)&nbsp;the number of Ortho Shares subject to such Ortho Equity Right immediately prior to the Ortho Effective Time by (ii)&nbsp;the Ortho Exchange Ratio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the Ortho Equity Rights outstanding as of December&nbsp;20, 2021, and assuming none of such rights vest by their terms between December&nbsp;20, 2021
and the Ortho Effective Time, 58,618&nbsp;Topco Shares will be issuable pursuant to Topco Equity Rights issued in exchange for such Ortho Equity Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any Ortho Stock Award is, immediately prior to the Ortho Effective Time, subject to any performance-based vesting based on the attainment of a stock price
level or target, such hurdle shall be adjusted to reflect the Ortho Scheme Consideration, and the Ortho board of directors will take all necessary action to effect such adjustment prior to the Ortho Effective Time, conditioned upon the consummation
of the Combinations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_164"></A>Treatment of Quidel Equity Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the BCA, each award of outstanding Quidel Stock Options, Quidel RSUs and Quidel PSUs will be treated as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options. </I></B>At the Quidel Effective Time, each outstanding Quidel Stock Option, granted under a Quidel Stock Plan, whether vested or
unvested, will automatically, without any action on the part of the holder thereof, cease to represent an option to acquire Quidel Shares and be converted into a Topco Stock Option on the same terms and conditions (including applicable vesting
conditions) applicable to such Quidel Stock Option under the applicable Quidel Stock Plan and award agreement in effect immediately prior to the Quidel Effective Time, except as adjusted by the BCA. The number of Topco Shares subject to each such
Topco Stock Option will be equal to the number of Quidel Shares subject to such Quidel Stock Option immediately prior to the Quidel Effective Time, and each such Topco Stock Option will have an exercise price per share equal to the exercise price
per Quidel Share of such Quidel Stock Option immediately prior to the Quidel Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">280 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the Quidel Stock Options outstanding as of December&nbsp;22, 2021, and assuming no Quidel Stock
Options are exercised between December&nbsp;22, 2021 and the Quidel Effective Time, 722,034 Topco Shares will be issuable pursuant to Topco Stock Options issued in exchange for such Quidel Stock Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Units. </I></B>At the Quidel Effective Time, each outstanding Quidel RSU granted under a Quidel Stock Plan will automatically, without
any action on the part of the holder thereof, be converted into a Topco RSU on the same terms and conditions (including applicable vesting conditions) applicable to such Quidel RSU under the applicable Quidel Stock Plan and award agreement in effect
immediately prior to the Quidel Effective Time. The number of Topco Shares covered by each such Topco RSU will be equal to the number of Quidel Shares subject to such Quidel RSU immediately prior to the Quidel Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the Quidel RSUs outstanding as of December&nbsp;22, 2021, and assuming none of such rights vest by their terms between December&nbsp;22, 2021 and the
Quidel Effective Time, 566,770 Topco Shares will be issuable pursuant to Topco RSUs issued in exchange for such Quidel RSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance Restricted
Stock Units.</I></B> At the Quidel Effective Time, each outstanding Quidel PSU granted under a Quidel Stock Plan will automatically, without any action on the part of the holder thereof, be converted into a Topco PSU on the same terms and conditions
(including applicable vesting conditions) applicable to such Quidel PSU under the applicable Quidel Stock Plan and award agreement in effect immediately prior to the Quidel Effective Time. The number of Topco Shares covered by each such Topco PSU
will be equal to the number of Quidel Shares subject to such Quidel PSU immediately prior to the Quidel Effective Time. The Quidel board of directors, or an applicable committee thereof, may, prior to the Ortho Effective Time make such equitable
adjustments, if any, to the applicable performance goals or conditions relating to such Quidel PSU, as the Quidel board of directors may determine to be necessary or appropriate as a result of the consummation of the Combinations, which equitable
adjustments shall take effect upon and be subject to the consummation of the Combinations and, in each case, subject to and in accordance with the terms and conditions of the Quidel Stock Plans and Quidel PSU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the Quidel PSUs outstanding as of December&nbsp;22, 2021, and assuming none of such rights vest by their terms between December&nbsp;22, 2021 and the
Quidel Effective Time, 19,642 Topco Shares will be issuable pursuant to Topco PSUs issued in exchange for such Quidel PSUs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_165"></A>Representations and Warranties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA contains representations and warranties that Quidel, on the one hand, and Ortho and Topco, on the other hand, have made to each other as of specific
dates and are subject to and qualified by certain information included in certain public filings each of Quidel and Ortho has made. These representations and warranties have been made for the benefit of the other parties to the BCA and may be
intended not as statements of fact, but rather as a way of allocating risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties are qualified by information in a
confidential disclosure letter provided by Quidel to Ortho, on the one hand, and in a confidential disclosure letter provided by Ortho to Quidel, on the other hand, delivered in connection with the execution of the BCA. While the parties do not
believe that these disclosure letters contain information required to be publicly disclosed under the applicable securities laws (other than information that has already been so disclosed), the disclosure letters do contain information that
modifies, qualifies and creates exceptions to the representations and warranties set forth in the BCA. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about Quidel or Ortho
since they were made as of specific dates, may be intended merely as risk allocation mechanisms between Quidel and Ortho and are modified in important part by the confidential disclosure letters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA contains representations and warranties from Quidel to Ortho, on the one hand, and from Ortho to Quidel, on the other hand, in each case regarding the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">organization, existence, good standing (if applicable), qualification to do business and corporate or other legal
power; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">capital structure, including the number of shares of capital stock, stock options and other equity-based awards
outstanding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporate power and authority with respect to the due execution and delivery of the BCA and completion of the
Combinations, the authorization and adoption of the BCA and the Combinations by the board of directors or similar governing body and the enforceability of the BCA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">281 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">absence of breaches of, or conflicts with, organizational documents, certain contracts and applicable laws as a
result of entry into, or consummation of the transactions contemplated by, the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">required consents, approvals, authorizations or permits of, or filings or registrations with or notifications to,
governmental entities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with listing and corporate governance rules and regulations of Nasdaq and the SEC;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with U.S. GAAP; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">internal controls over financial reporting and disclosure controls and procedures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct of business in the ordinary course of business consistent with past practice since December&nbsp;31,
2020, in the case of Quidel, and January&nbsp;3, 2021, in the case of Ortho; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">absence of a Material Adverse Effect on Quidel or Ortho since December&nbsp;31, 2020 or January&nbsp;3, 2021,
respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with laws and required permits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">absence of any civil, criminal, administrative or regulatory actions, suits, claims, litigation, hearings,
investigations or proceedings pending or, to the knowledge of the parties, threatened; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">absence of any judgments, orders, decisions, writs, injunctions, decrees, stipulations, legal or arbitration
awards, rulings or other findings or agency requirements of any governmental entity outstanding against either party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">absence of undisclosed liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee benefit matters and compliance with the Employee Retirement Income Security Act of 1974, as amended, as
applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax laws and other tax matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collective bargaining agreements and other labor matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material contracts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">data protection; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real and personal property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">environmental matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant customers and suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">absence of related party transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inapplicability of takeover statutes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with the FCPA, the UK Bribery Act 2010 and other anti-corruption laws, as applicable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with economic sanctions laws and other similar laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with FDA regulations and other laws and regulations relating to healthcare matters;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accuracy of information supplied in connection with this joint proxy statement/prospectus and other public
filings; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, finders or investment bankers entitled to fees or commissions in connection with the Combinations.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the representations and warranties in the BCA are subject to knowledge qualifications, which means that those
representations and warranties would not be deemed untrue, inaccurate or incorrect as a result of matters of which certain officers of the party making the representation did not have actual knowledge. Many of the representations and warranties in
the BCA are qualified by a materiality or a Material Adverse Effect standard (that is, they will not be deemed to be untrue or incorrect unless their failure to be true or correct is material or would result in a Material Adverse Effect on the
company making such representation or warranty). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">282 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain exclusions (which are summarized below), for purposes of the BCA, a &#147;Material
Adverse Effect,&#148; when used in reference to Quidel, Ortho, or, following the consummation of the Combinations, Topco, as applicable, means any event, change, circumstance, effect, occurrence, state of facts or development (each, an
&#147;Effect&#148;) that, individually or in the aggregate with all other such Effects, has a material adverse effect on the condition (financial or otherwise), assets, liabilities, business or results of operations of Quidel and its subsidiaries,
Ortho and its subsidiaries, or, following the consummation of the Combinations, Topco and its subsidiaries, in each case taken as a whole, respectively (including for purposes of the references to Quidel, Ortho and Topco in the proviso below);
provided, however, that none of the following, and no effect resulting from the following (to the extent attributable to the following), will constitute a Material Adverse Effect or be considered in determining whether a Material Adverse Effect has
occurred or would be reasonably likely to occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any change or development in general or industry economic or regulatory, legislative or political conditions or
securities, credit, financial or other capital markets conditions, in each case in the United States or any other jurisdiction, except to the extent that such change or development affects Quidel, Ortho or Topco, respectively, in a disproportionate
manner relative to other businesses operating in the industries in which Quidel, Ortho or Topco, respectively, operates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any change or development to the extent resulting from the execution and delivery of the BCA or the public
announcement, pendency or consummation of the Combinations or any of the other transactions contemplated by the BCA (in the case of execution and delivery of the BCA, or consummation, other than for purposes of any representation or warranty the
purpose of which is to address the consequences resulting therefrom, including stockholder litigation and the impact of such changes or developments on the relationships, contractual or otherwise, of such party or any of its subsidiaries with
employees, labor unions, clients, customers, suppliers or partners); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any change or development to the extent resulting from any failure of Quidel, Ortho or Topco, respectively, to
meet any internal or published projections, forecasts, estimates or predictions in respect of revenues, earnings or other financial or operating metrics for any period (it being understood that the facts and circumstances giving rise to such failure
may be deemed to constitute, and may be taken into account in determining whether there has been, a Material Adverse Effect); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any change, in and of itself, in the market price, credit rating (with respect to such party or its securities)
or trading volume of such party&#146;s securities (it being understood that the facts and circumstances giving rise to such change may be deemed to constitute, and may be taken into account in determining whether there has been, a Material Adverse
Effect); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any change in applicable law or GAAP (or, in each case, authoritative interpretation thereof), except to the
extent that such change or development affects Quidel, Ortho or Topco, respectively, in a disproportionate manner relative to other businesses operating in the industries in which Quidel, Ortho or Topco, respectively, operates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">geopolitical conditions, the outbreak of hostilities, any acts of war, sabotage or terrorism, any pandemic,
epidemic or disease outbreak (including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and any evolutions or other mutations thereof, collectively, <FONT
STYLE="white-space:nowrap">&#147;COVID-19&#148;)</FONT> or any escalation or worsening of any such hostilities, acts of war, sabotage, terrorism, pandemic, epidemic or disease outbreak threatened or underway as of the date of the BCA, except to the
extent that such change or development affects Quidel, Ortho or Topco, respectively, in a disproportionate manner relative to other businesses operating in the industries in which Quidel, Ortho or Topco, respectively, operates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any hurricane, tornado, flood, earthquake or other natural disaster, except to the extent that such change or
development affects Quidel, Ortho or Topco, respectively, in a disproportionate manner relative to other businesses operating in the industries in which Quidel, Ortho or Topco, respectively, operates; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any change or development to the extent resulting from any action by Quidel, Ortho or Topco, respectively, that
is expressly required to be taken by the BCA (other than any actions required to be taken under the section of the BCA relating to the operations of the businesses after signing of the BCA and prior to the consummation of the Combinations).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The representations and warranties of each of the parties to the BCA do not survive the consummation of the Combinations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_166"></A>Conduct of Business Prior to the Effective Times </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the BCA, each of Quidel and Ortho has agreed that until the Quidel Effective Time or termination of the BCA in accordance with its terms, subject to certain
specified exceptions, and unless the other party approves in writing (which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">283 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval will not be unreasonably withheld, conditioned or delayed, subject to certain exceptions), it will, and will cause its respective subsidiaries to use commercially reasonable efforts to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct its business in the ordinary and usual course consistent with past practice; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preserve intact its business organization and consistent with prior practice maintain its existing relations and
goodwill with all governmental entities (including applicable regulatory authorities) and self-regulatory organizations, clients, customers, suppliers, distributors, creditors, lessors, employees, stockholders and other persons with which it or its
subsidiaries has material business relations, as applicable. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, without limiting the foregoing and subject to certain
specified exceptions, each of Quidel and Ortho has agreed that until the Quidel Effective Time or termination of the BCA in accordance with its terms, subject to certain specified exceptions, and unless the other party approves in writing (which
approval will not be unreasonably withheld, conditioned or delayed, subject to certain exceptions), it will not, and will not permit any of its subsidiaries to, do any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amend, modify or waive its organizational documents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">split, combine or reclassify its shares of capital stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">declare, set aside or pay any dividend; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">engage in another merger, restructuring or reorganization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">repurchase, redeem or acquire any shares of its capital stock, including securities that may convert into shares
of capital stock, and that it will not allow its subsidiaries to do the same, except in connection with payment of the exercise price of stock awards in existence on the date of the BCA and disclosed to the other party, for tax withholding purposes
with regard to such stock awards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, sell, pledge, dispose of, or encumber any security that has the right to vote (or which is convertible
into securities which have a right to vote) by its stockholders on any matter, except for (i)&nbsp;shares issuable pursuant to stock awards outstanding on or awarded prior to the signing date of the BCA or issued in the ordinary course of business,
(ii)&nbsp;issuances up to the limits set forth in the disclosure letter of each party or (iii)&nbsp;in connection with internal reorganizations in the ordinary course of business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur indebtedness for borrowed money or issue debt securities, except for borrowing in amounts not to exceed
$25&nbsp;million in the aggregate (including pursuant to any drawdowns of credit facilities outstanding on the date of the BCA) (excluding with respect to financing required in order to consummate the Combinations); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make, authorize or commit to make any material capital expenditures, other than in the ordinary course of
business and subject to an obligation to notify the other party of material capital expenditures not contemplated by the capital budget of the party making such material capital expenditures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">terminate, establish, adopt, enter into or materially amend any benefit plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">materially increase salaries, wages, bonuses, fringe benefits or any other compensation of any director, manager,
officer or employee of either party or enter into an arrangement to do so; other than in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into agreements providing for payment to directors, managers, officers or employees in connection with or
contingent upon the Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">take any action to accelerate the vesting, payment or funding of any equity-related award or benefit plan in
connection with the consummation of the Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish, adopt, enter into, materially amend or terminate any collective bargaining agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lease, license, transfer, exchange or swap, mortgage, pledge, abandon, allow to lapse, or otherwise dispose of,
any portion of its assets, except for (a)&nbsp;dispositions individually or in the aggregate that have a fair market value of less than $25&nbsp;million, (b)&nbsp;transactions between it and any of its subsidiaries (or between any such
subsidiaries), or (c)&nbsp;in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell, lease, license, transfer, exchange, lien, pledge, abandon, allow to lapse or otherwise dispose of any
material intellectual property, except for in the ordinary course of business; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">284 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any acquisitions, except for acquisitions (a)&nbsp;entered into on an
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> basis, (b)&nbsp;that do not exceed $25&nbsp;million (including indebtedness assumed) and (c)&nbsp;which are not reasonably likely to prevent or materially delay satisfaction of the closing
conditions set forth in the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settle any material litigation or arbitration (other than any litigation or arbitration brought by Quidel or
Ortho against the other arising out of the BCA) if such settlement involves, individually or together with all such other settlements or compromises, a payment of money by such party or its subsidiaries in excess of $25&nbsp;million over the
available insurance coverage or applicable reserves (if any), or if the settlement would involve admission of material wrongdoing or any material <FONT STYLE="white-space:nowrap">non-monetary</FONT> restriction on such party or its subsidiaries,
except in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify, renew, amend or terminate in any material respect any of its material contracts (except in the ordinary
course of business), or waive, release or assign any material rights thereunder in excess of $20&nbsp;million, individually or in the aggregate, or enter into any contract that would be a material contract if existing on the date of the BCA, except
in the ordinary course of business or as permitted by certain other provisions of this section; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except to the extent required by law or in the ordinary course of business, (a)&nbsp;make or change any material
tax election; (b)&nbsp;adopt or change any material method of tax accounting; (c)&nbsp;file any material amended tax return or enter into a closing agreement or advance pricing agreement in respect of a material amount of taxes or compromise any
material audit, assessment, notice, tax claim or proceeding relating to taxes; (d)&nbsp;surrender any material right to claim a refund or offset of any taxes; (e)&nbsp;agree to or request an extension or waiver of the statute of limitations with
respect to any material amount of taxes; (f)&nbsp;surrender any material right to claim a refund or offset of any taxes; or (g)&nbsp;change the classification of Quidel or Ortho, as applicable, or any of its subsidiaries for U.S. tax purposes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any material changes in its financial accounting policies, except to adhere to any changes required by U.S.
GAAP or SEC rules and regulations and authoritative interpretations thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into contracts that grant most favored nation status to any counterparty or any <FONT
STYLE="white-space:nowrap">non-compete</FONT> or similar contract that would materially restrict Topco following the consummation of the Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any material loans, advances or capital contributions to, or investments in any other person, except for
routine business expenses in the ordinary course and trade credit to customers made in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any material new line of business outside of its existing business segments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convene any regular or special meeting of its stockholders, except for (a)&nbsp;stockholder meetings to adopt the
BCA and approve the Combinations and (b)&nbsp;regular annual meetings in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implement or announce any material plant closing, material reductions in labor forces or other material group
layoffs other than in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to the provisions regarding Acquisition Proposals, take any action that would reasonably be expected to
prevent or materially impair or delay the consummation of the Combinations or satisfaction of the closing conditions set forth in the BCA; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize or enter into an agreement, arrangement or understanding to do any of the foregoing.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acquisition Proposals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to
the terms of the BCA, each of Quidel and Ortho agrees that it will not, and agrees to cause its subsidiaries and its and their respective officers, directors and employees not to (and use reasonable best efforts to cause its and its
subsidiaries&#146; other representatives not to), directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate, solicit or knowingly facilitate or encourage (including by way of furnishing information) any
inquiries, discussions or the making, submission or announcement of any proposal, request or offer that constitutes, or could reasonably be expected to lead to or result in, an Acquisition Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have any discussion with any person relating to an Acquisition Proposal (other than, solely with respect to an
Acquisition Proposal that does not result from a material breach of this provision, to clarify the terms of an Acquisition Proposal submitted to such party after the date of the BCA for the sole purpose of enabling the Quidel
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">285 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
board of directors or Ortho board of directors, as applicable, to evaluate such Acquisition Proposal for the purposes of this provision), engage in, continue or otherwise participate in any
negotiations concerning an Acquisition Proposal, or knowingly facilitate any effort or attempt to make or implement an Acquisition Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide any <FONT STYLE="white-space:nowrap">non-public</FONT> or confidential information or data or afford
access to its books or records or directors, officers, employees or advisors, to any person in relation to an Acquisition Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">terminate, amend, release, modify or fail to enforce any provision of, or grant any permission, waiver or request
under, any standstill, confidentiality or similar agreement entered into by it or any of its subsidiaries (other than to the extent the Quidel board of directors or Ortho board of directors, as applicable, determines in good faith, after
consultation with its financial and outside legal advisors, that failure to take any such actions under this provision would reasonably be expected to be inconsistent with the directors&#146; fiduciary duties under applicable law);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve or recommend, or propose publicly to approve or recommend, any Acquisition Proposal;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve or recommend, propose publicly to approve or recommend, or execute or enter into, any letter of intent,
agreement in principle, merger agreement, acquisition agreement, business combination agreement, option agreement or other similar agreement relating to any Acquisition Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">take any action to make the provisions of any takeover law inapplicable to any transactions contemplated by any
Acquisition Proposal; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">propose publicly or agree to do any of the foregoing related to any Acquisition Proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCA and throughout this joint proxy statement/prospectus, an &#147;Acquisition Proposal&#148; with respect to Quidel or Ortho means any offer or
proposal for, or any indication of interest in, (a)&nbsp;any direct or indirect acquisition or purchase, in a single transaction or a series of related transactions, of Quidel or Ortho, as applicable, or any of its subsidiaries that constitutes 15%
or more of the consolidated gross revenue or consolidated gross assets of Quidel or Ortho, as applicable, and its subsidiaries, taken as a whole (such subsidiary, a &#147;Major Subsidiary&#148;); (b)&nbsp;any direct or indirect acquisition or
purchase of (i)&nbsp;15% or more of any class of equity securities or voting power or 15% or more of the consolidated gross assets of Quidel or Ortho, as applicable, or (ii)&nbsp;15% or more of any class of equity securities or voting power of any
of its Major Subsidiaries; (c)&nbsp;any tender offer that, if consummated, would result in any person beneficially owning 15% or more of any class of equity securities or voting power of Quidel or Ortho, as applicable; or (d)&nbsp;any merger,
reorganization, share exchange, consolidation, business combination, recapitalization, liquidation, dissolution or similar transaction involving Quidel or Ortho, as applicable, or any Major Subsidiary of Quidel or Ortho, as applicable, in each case,
with a person other than the other party or any of its affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Existing Discussions or Negotiations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the BCA, each of Quidel and Ortho agrees that it will immediately cease and cause to be terminated any activities, discussions or
negotiations existing as of the date of the BCA with any persons conducted prior to the signing of the BCA with respect to any Acquisition Proposal (or that could reasonably be expected to lead to an Acquisition Proposal), and request that any such
person promptly return and destroy (and confirm destruction of) all <FONT STYLE="white-space:nowrap">non-public</FONT> information. Unless the BCA will have been earlier terminated, neither Quidel nor Ortho will submit to the vote of its
stockholders any Acquisition Proposal other than the Combinations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Superior Proposals and Intervening Events </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the BCA, if (a)&nbsp;in the case of Quidel, prior to the approval and adoption of the BCA by the holders of a majority of the
outstanding Quidel Shares entitled to vote thereon (the &#147;Quidel Requisite Vote&#148;) and (b)&nbsp;in the case of Ortho, prior to the approval of the Ortho shareholders to the Ortho board of director&#146;s implementation of the Ortho Scheme,
adoption of the new Ortho articles of association (subject to any further amendments as the parties may agree) and the ancillary matters contemplated by the BCA (the &#147;Ortho Requisite Vote&#148;), (i)&nbsp;Quidel or Ortho, respectively, has
received a bona fide Acquisition Proposal from a third party that was not received or obtained as a result of any violation of these provisions of the BCA, which the Quidel board of directors or the Ortho board of directors, respectively, determines
in good faith (after consultation with its outside legal counsel and financial advisors) constitutes, or would reasonably be expected to lead to, a Superior Proposal (as defined below) and (ii)&nbsp;the Quidel board of directors or the Ortho board
of directors, respectively, determines in good faith (after consultation with its outside legal counsel) that failure to take such action would be inconsistent with the directors&#146; fiduciary duties under applicable law, then Quidel or Ortho, as
applicable, may (x)&nbsp;furnish </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">286 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">non-public</FONT> information to such person that has delivered such bona fide Acquisition Proposal and (y)&nbsp;engage in discussions or negotiations with such
person with respect to the Acquisition Proposal. Under such circumstances, and prior to furnishing such information or engaging in any such discussion or negotiations, the applicable party must have received an executed confidentiality and
standstill agreement from the proposing party, and any <FONT STYLE="white-space:nowrap">non-public</FONT> information being provided to such proposing party not previously provided or made available to Quidel or Ortho, as applicable, will be made
available to such party within 24 hours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time prior to the earlier of (a)&nbsp;the receipt by Quidel of the Quidel Requisite Vote or receipt by
Ortho of the Ortho Requisite Vote, as applicable, or (b)&nbsp;the termination of the BCA in accordance with its terms, subject to compliance with the provisions set forth below, the Quidel board of directors and the Ortho board of directors,
respectively, will be entitled to make a Quidel Change in Recommendation or an Ortho Change in Recommendation, respectively, in each case (i)&nbsp;if such party receives a Superior Proposal or (ii)&nbsp;in response to an Intervening Event (as
defined below), provided that, in each case, only to the extent such board of directors determines in good faith (after consultation with its outside legal counsel) that the failure to make such a change in recommendation would be inconsistent with
its fiduciary duties under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither of the Quidel board of directors nor the Ortho board of directors will be entitled to make a Quidel
Change in Recommendation or an Ortho Change in Recommendation, respectively, unless (i)&nbsp;such party is in compliance with the relevant provisions of the BCA, (ii)&nbsp;such party provides the other with a written notice that it intends to make
such a change in recommendation, (iii)&nbsp;such party complies with a five Business Day negotiation period with the other parties to the BCA to make such adjustments in the terms and conditions of the BCA so that any Superior Proposal ceases to
constitute a Superior Proposal or, with respect to an Intervening Event, as would permit such board of directors to not change their recommendation with respect to the Combinations and (iv)&nbsp;such board of directors determines in good faith,
after consultation with its outside legal and financial advisors, that such Superior Proposal continues to constitute a Superior Proposal or, as applicable, with respect to an Intervening Event, that its fiduciary duties still require it to make a
Quidel Change in Recommendation or an Ortho Change in Recommendation, as applicable. Any amendment to the financial terms or any other material amendment of a Superior Proposal, or any material change to the facts and circumstances relating to an
Intervening Event, as applicable, will require delivery of a new written notice described in the foregoing clause (ii), with a new notice period, but the reference to a &#147;five Business Day negotiation period&#148; in the preceding clause
(iii)&nbsp;will be deemed to be a reference to a &#147;three Business Day negotiation period.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCA and throughout this joint proxy
statement/prospectus, a &#147;Superior Proposal&#148; means, with respect to Quidel or Ortho, a bona fide Acquisition Proposal that did not result from a material breach of these provisions of the BCA and as to which the party recipient of the
Acquisition Proposal complied with the applicable provisions of the BCA for or in respect of 80% or more of the outstanding Quidel Shares or Ortho Shares (as applicable) or 80% or more of the assets of Quidel and its subsidiaries, on a consolidated
basis, or Ortho and its subsidiaries, on a consolidated basis, as applicable, in each case on terms that the Quidel board of directors or the Ortho board of directors, as applicable, determines in good faith (following receipt of the advice of its
financial advisors and outside legal counsel) is reasonably likely to be consummated in accordance with its terms and, taking into account, among other things, (a)&nbsp;all legal, financial, antitrust or other regulatory, timing and other aspects of
the Acquisition Proposal and the BCA deemed relevant by such board of directors (including conditions to, expected timing and risks of consummation of, and the ability of the party making such proposal to obtain financing for such Acquisition
Proposal), (b) any improved terms that Ortho (in the case of an Acquisition Proposal for Quidel) or Quidel (in the case of an Acquisition Proposal for Ortho) may have offered pursuant to this section is more favorable from a financial point of view
to Quidel and its stockholders or Ortho and its shareholders, as the case may be, than the Combinations (after taking into account any such improved terms) and (c)&nbsp;the value of the synergies expected to be recognized as a result of the
Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCA and throughout this joint proxy statement/prospectus, an &#147;Intervening Event&#148; means any material event or
development or material change in circumstances first occurring after the date of the BCA and prior to, in the case of Quidel, receipt by Quidel of the Quidel Requisite Vote and, in the case of Ortho, receipt by Ortho of the Ortho Requisite Vote, to
the extent that such event, development or change in circumstances was not reasonably foreseeable as of or prior to the date of the BCA; provided, however, that in no event shall the following events, developments or changes in circumstances
constitute an Intervening Event: (a)&nbsp;the receipt, existence or terms of an Acquisition Proposal or any matter relating thereto or consequence thereof, or (b)&nbsp;changes in the market price or trading volume of Ortho Shares or Quidel Shares or
the fact that a party meets or exceeds internal or published projections, forecasts or revenue or earnings predictions for any period; provided, however, that the underlying causes of such change or fact shall not be excluded by this clause (b).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">287 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the BCA, from and after the date of the BCA, Quidel or Ortho, as applicable, will promptly (and in any event within 24 hours) notify
the other party orally and in writing in the event that it, one of its subsidiaries or any of its representatives receives (i)&nbsp;any Acquisition Proposal, (ii)&nbsp;any request for <FONT STYLE="white-space:nowrap">non-public</FONT> information
relating to such party or any of its subsidiaries, other than requests for information in the ordinary and usual course of business and consistent with past practice and unrelated to an Acquisition Proposal, or (iii)&nbsp;any inquiry or request for
discussions or negotiations regarding any Acquisition Proposal. Such notice must include the identity of such person and provide an unredacted copy of such Acquisition Proposal, inquiry or request (or, where no such copy is available, a reasonably
detailed description of such Acquisition Proposal, inquiry or request), including any debt financing materials related thereto, if any. Subject to applicable law, Quidel or Ortho, as applicable, will keep the other party reasonably informed on a
current basis of the status of any Acquisition Proposal, inquiry or request, and any material developments, discussions and negotiations related thereto. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_167"></A>Certain Permitted Disclosure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing in the BCA will prevent Quidel or Ortho from complying with its disclosure obligations under applicable laws with regard to a competing Acquisition
Proposal, except that Quidel and Ortho must nevertheless comply with their obligations under the BCA and any such disclosure (other than a &#147;stop, look and listen&#148; communication or similar communication contemplated by Section&nbsp;14d 9(f)
under the Exchange Act) shall be deemed to be a Quidel Change in Recommendation or an Ortho Change in Recommendation, as applicable, unless the Quidel board of directors or the Ortho board of directors, as applicable, expressly reaffirms its
recommendation to its stockholders in favor of the approval of the BCA and the Combinations in such disclosure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_168"></A>Stockholder Meetings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel
will take, in accordance with applicable law, the applicable rules and regulations of the SEC and Nasdaq and its organizational documents, all action necessary to convene the Quidel Stockholders&#146; Meeting as promptly as practicable after the
later of (a)&nbsp;the expiration of any creditor rights opposition period under English law and (b)&nbsp;the date the Registration Statement is declared effective. Quidel will, unless a Quidel Change in Recommendation has been made in accordance
with the BCA, use its reasonable best efforts to solicit from its stockholders proxies in favor of the adoption of the BCA and to take all other action reasonably necessary or advisable to secure the Quidel Requisite Vote. Any Quidel Change in
Recommendation shall not limit or modify the obligation of Quidel to present the BCA for adoption at a meeting of its stockholders, and, if the BCA is not otherwise terminated by either Quidel or Ortho in accordance with the terms thereof, the BCA
and the transactions contemplated thereby shall be submitted to the stockholders of Quidel at such meeting of the Quidel stockholders for the purpose of obtaining the Quidel Requisite Vote, except in the event of a Quidel Change in Recommendation
made in accordance with the terms of the BCA in response to a Superior Proposal for Quidel that (i)&nbsp;includes only cash consideration and (ii)&nbsp;is fully financed and does not include any financing condition (including any financing
contingency to the right of Quidel to seek specific performance) (a &#147;Quidel All Cash Superior Proposal&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho will take, in accordance with
applicable law, the applicable rules and regulations of the SEC and Nasdaq and its organizational documents, all action necessary to convene a meeting of its shareholders in accordance with Part 26 of the UK Companies Act to approve the Ortho
Scheme, such as the Ortho Court Meeting, and a general meeting of its shareholders to adopt new articles of association and to resolve and approve the Ortho board of directors implementing the Ortho Scheme, and other matters as specified in the BCA,
such as the Ortho General Meeting, as promptly as practicable after the later of (a)&nbsp;the expiration of any creditor rights opposition period under English law and (b)&nbsp;the date the Registration Statement is declared effective. Ortho will,
unless an Ortho Change in Recommendation has been made in accordance with the BCA, use its reasonable best efforts to solicit from its shareholders proxies in favor of the adoption of the terms relating to the Ortho Scheme and to take all other
action reasonably necessary or advisable to secure the Ortho Requisite Vote. Any Ortho Change in Recommendation shall not limit or modify the obligation of Ortho to present the BCA for adoption at a meeting of its shareholders, and, if the BCA is
not otherwise terminated by either Quidel or Ortho in accordance with the terms thereof, the BCA and the transactions contemplated thereby shall be submitted to the shareholders of Ortho at the Ortho Shareholder Meetings for the purpose of obtaining
the Ortho Requisite Vote, except in the event of an Ortho Change in Recommendation made in accordance with the terms of the BCA in response to an Ortho All Cash Superior Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the timetable for the Ortho Scheme and subject to any directions or requirements of the Court, Quidel and Ortho will each use their
commercially reasonable efforts to cause the Quidel Stockholders&#146; Meeting and the Ortho Shareholder Meetings to be held on the same date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">288 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_169"></A>Efforts to Complete the Combinations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to facilitate completion of the Combinations, the parties to the BCA, subject to certain exceptions, have agreed to use (and cause their respective
subsidiaries to use) their respective reasonable best efforts to take or cause to be taken all actions, and do or cause to be done all things, necessary, proper or advisable on their part under the BCA and applicable law to consummate the
Combinations and the other transactions contemplated by the BCA as soon as practicable, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing and filing all documentation to effect all necessary notices, reports and other filings as promptly as
practicable and obtaining as promptly as practicable all consents, registrations, approvals, authorizations and other permits (including approvals related to applicable competition and antitrust laws) necessary or advisable to be obtained from any
governmental entity or any self-regulatory organization in order to consummate the Combinations, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">using their reasonable best efforts to resolve any objections as may be asserted with respect to the Combinations
under any laws, including defending and contesting (through litigation on the merits and any appeals) any legal proceedings, whether judicial or administrative or otherwise, challenging the BCA or the consummation of the transactions contemplated
thereby, including seeking to have any order entered by any court or other governmental entity vacated or reversed, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">executing and delivering any additional instruments necessary to consummate the transactions contemplated by, and
to fully carry out the purposes of, the BCA pursuant to its terms and conditions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel and Ortho will each provide the other party
and/or its counsel with a reasonable advance opportunity to review and comment upon and consider in good faith the views of the other party in connection with all submissions, filings or communications, and agree not to participate independently in
any meeting with any governmental entity or self-regulatory organization in connection with the Combinations. Subject to applicable law, Quidel and Ortho will keep each other apprised of all correspondence and discussions with any governmental
entity or any self-regulatory organization in connection with the transactions contemplated by the BCA. Further, Quidel and Ortho will keep the other apprised of the status of matters relating to the completion of the transactions contemplated by
the BCA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_170"></A>Indemnification and Insurance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA provides that, to the extent permitted by applicable law, for a period of six years from and after completion of the Combinations, Topco&nbsp;will
indemnify and hold harmless and provide advancement of expenses to each past and present (as of completion of the Combinations) director, officer, and employee of Quidel, Ortho or any of their subsidiaries against all costs or expenses (including
reasonable attorneys&#146; fees and disbursements), judgments, inquiries, fines, losses, claims, damages or liabilities incurred by such individual in connection with any civil, criminal, administrative or investigative proceeding arising out of or
pertaining to any act or omission of such director, officer or employee prior to completion of the Combinations (i)&nbsp;in each case, to the same extent as such person is indemnified or has the right to advancement of expenses as of the date of the
BCA by Quidel, Ortho or their subsidiaries, as applicable, pursuant to the organizational documents and indemnification agreements thereof and (ii)&nbsp;to the fullest extent permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA further provides that, for a period of not less than six years after completion of the Combinations, the organizational documents of Topco (and any
successor thereto) will contain provisions providing for the elimination of liability of directors, indemnification of officers and directors and advancement of expenses to the fullest extent permitted by applicable law.&nbsp;Additionally, Topco
will purchase a <FONT STYLE="white-space:nowrap">six-year</FONT> &#147;tail&#148; prepaid policy on terms and conditions no less advantageous than the current directors&#146; and officers&#146; liability insurance and fiduciary liability insurance
maintained by each of Quidel and Ortho for the benefit of Quidel&#146;s and Ortho&#146;s officers and directors; provided that the amount paid for such policy shall not exceed, for each of Quidel and Ortho, 300% of the annual premiums currently paid
by Quidel or Ortho, as applicable, for such policy; provided further, that with respect to Quidel&#146;s officers and directors, Quidel may, in lieu of Topco&#146;s purchase of a &#147;tail&#148; prepaid policy, elect to continue coverage for the
insured under its current directors&#146; and officers&#146; liability insurance and fiduciary liability insurance.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_171"></A>Employee Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel and
Ortho agreed that continuing employees of each of Quidel and its subsidiaries (each, a &#147;Quidel Continuing Employee&#148;) and Ortho and its subsidiaries (each, an &#147;Ortho Continuing Employee&#148;) shall, until the first anniversary of the
Quidel Effective Time and the Ortho Effective Time, receive base salary or base wage, severance benefit protections and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">289 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pension and welfare benefits that are no less favorable, in the aggregate, than those provided to such employees immediately prior to the Quidel Effective Time or the Ortho Effective Time, as
applicable; provided, however, that the requirements of the preceding sentence shall not apply to Quidel Continuing Employees or Ortho Continuing Employees who are covered by a collective bargaining agreement, union, labor or similar contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to any benefit plan in which a Quidel Continuing Employee or Ortho Continuing Employee first becomes eligible to participate on or after the
Quidel Effective Time or Ortho Effective Time, respectively (a &#147;Relevant Benefit Plan&#148;), each party shall use reasonable best efforts to (a)&nbsp;cause any <FONT STYLE="white-space:nowrap">pre-existing</FONT> conditions or limitations and
eligibility waiting periods under any of its group health plans which is a Relevant Benefit Plan to be waived with respect to the other party&#146;s continuing employees and their eligible dependents, (b)&nbsp;give the other party&#146;s continuing
employees credit for the plan year in which the Quidel Effective Time or Ortho Effective Time, respectively, occurs (or the plan year in which any applicable continuing employee first becomes eligible to participate in the applicable Relevant
Benefit Plan, if later) towards applicable deductibles and annual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> limits for medical expenses incurred during the plan year but prior to the Quidel
Effective Time or Ortho Effective Time, respectively (or eligibility date, as applicable), for which payment has been made and (c)&nbsp;give the other party&#146;s continuing employees service credit for such continuing employees&#146; employment
with the other party for purposes of vesting, benefit accrual and eligibility to participate under each applicable Relevant Benefit Plan, as if such service had been performed with such party, except for benefit accrual under defined benefit pension
plans, for purposes of qualifying for subsidized early retirement benefits (unless otherwise required under applicable law) or to the extent it would result in a duplication of benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_172"></A>Corporate Governance Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Ortho Effective Time, the sole stockholder of Topco will adopt the [Topco Charter] and the Topco board of directors will adopt the [Topco
Bylaws], in each case to take effect as of the Ortho Effective Time (or prior to such time if mutually agreed by the parties). The [Topco Charter] and [Topco Bylaws] will remain in effect as of the Quidel Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the BCA, the parties will cause the Topco board of directors to consist, at the Ortho Effective Time, of 12 members, comprised of:
(a)&nbsp;eight members designated by Quidel, expected to consist of Messrs. Bryant, Buechler, Michael, Strobeck, Widder and Wilkins and Mses. Polan and Rhoads, each of whom, other than Mr. Bryant, qualifies as an &#147;independent director&#148;
under applicable rules of Nasdaq, and (b)&nbsp;four members designated by Ortho, at least two of whom will qualify as an &#147;independent director&#148; under applicable rules of Nasdaq. In connection with the BCA, Ortho and the Carlyle Stockholder
executed a letter agreement pursuant to which Ortho agrees that, at the closing of the Combinations, the Ortho designees to the Topco board of directors will include two Carlyle nominees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, pursuant to the terms of the BCA, at the Ortho Effective Time, the Topco board of directors shall constitute the following committees, each of
which shall consist of one member designated by Ortho and no less than two members designated by Quidel, in each case subject to applicable legal and regulatory requirements: (a)&nbsp;the Audit Committee, (b)&nbsp;the Nominating and Governance
Committee and (c)&nbsp;the Compensation Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the consummation of the Combinations, unless otherwise agreed by Quidel and Ortho, Douglas Bryant
will serve as the Chair and Chief Executive Officer, Robert Bujarski will serve as the President and Chief Operating Officer, Joseph Busky will serve as the Chief Financial Officer, and Michael Iskra will serve as the Chief Commercial Officer, in
each case of Topco. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_173"></A>Other Covenants and Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA contains certain other covenants and agreements, including covenants relating to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cooperation between the parties in the preparation and filing of the Registration Statement and this joint proxy
statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convening by Quidel of the Quidel Stockholders&#146; Meeting and the convening by Ortho of the Ortho
Shareholder Meetings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cooperation between the parties in the preparation of the scheme terms relating to the Ortho Scheme and related
formalities (including the application to the Court to convene the meeting of the Ortho shareholders and satisfaction of requirements under the Part 26 of the UK Companies Act); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">290 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the preparation and filing of the necessary documentation required to effect the Combinations with the applicable
regulatory authorities in the United States and the United Kingdom; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining the approval for listing of the Topco Shares issuable in the Combinations on Nasdaq;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delisting the Ortho Shares from Nasdaq and deregistering the Ortho Shares under the Exchange Act following the
Ortho Effective Time and delisting the Quidel Shares from Nasdaq and deregistering the Quidel Shares under the Exchange Act following the Quidel Effective Time. Topco will be the successor to Quidel for purposes of Topco&#146;s Nasdaq listing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">access to certain information about Quidel and Ortho during the period prior to the Quidel Effective Time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">press releases and public statements relating to the BCA or the Combinations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain matters relating to taxes and consummation of certain preliminary transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the obligation, subject to certain exceptions described below in the section entitled &#147;Expenses and
Termination Fees,&#148; of each party to pay the fees and expenses incurred by such party in connection with the Combinations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exemption under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> under the Exchange Act with respect to
dispositions of Quidel and Ortho securities and the acquisition of Topco Shares (including derivative securities) pursuant to the transactions contemplated by the BCA by officers or directors of Quidel or Ortho; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining all necessary waivers or consents, or refinancing, renewing or replacing, contracts relating to
indebtedness that becomes or may become due and payable as a result of the Combinations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efforts by Quidel to obtain debt financing and Ortho to cooperate with such efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_175"></A>Conditions to the Combinations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of the parties to consummate the Combinations are subject to the satisfaction or waiver by the parties of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Quidel Requisite Vote shall have been obtained at the Quidel Stockholders&#146; Meeting and the Ortho
Requisite Vote shall have been obtained at the Ortho Shareholder Meetings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Topco Shares issuable in the Combinations shall have been authorized for listing on Nasdaq, subject to
official notice of issuance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no governmental entity of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered
any order or law which is in effect and prohibits, restrains, prevents or makes illegal consummation of the transactions contemplated by the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Statement shall have been declared effective by the SEC under the Securities Act, and shall
not be the subject of any stop order which is in effect suspending the effectiveness of the Registration Statement or any proceedings for that purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">certain antitrust, competition and foreign investment approvals designated by the parties shall have been
obtained or any waiting periods thereunder shall have expired or been terminated; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Ortho Scheme Order shall have been sanctioned by the Court and the Ortho Scheme Order shall have been
delivered to the Registrar with due confirmatory receipt thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of Ortho and Topco to consummate the Combinations are
subject to the satisfaction or waiver by Ortho of each of the following additional conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain representations and warranties of Quidel set forth in the BCA relating to the authorized capital stock of
Quidel are true and correct (except for <I>de minimis</I> inaccuracies) as of the Closing Date as though made on and as of such date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which
case such representation and warranty shall be so true and correct as of such earlier date); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain representations and warranties of Quidel set forth in the BCA regarding the authorization of and other
matters relating to the capitalization of Quidel and the corporate authority of Quidel are true and correct in all material respects as of the Closing Date as though made on and as of such date (except to the extent that any such representation and
warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be so true and correct as of such earlier date); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">291 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of the other representations and warranties of Quidel set forth in the BCA are true and correct
(disregarding all qualifications or limitations as to &#147;material,&#148; &#147;Material Adverse Effect&#148; and words of similar import set forth therein) as of the date of the BCA and as of the Closing Date as though made on and as of such date
(except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct as of such earlier date), except where the failure of such
representations and warranties to be so true and correct has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on Quidel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel shall, in all material respects, have performed and complied with all obligations required to be performed
or complied with by it under the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at any time after the date of the BCA, there shall not have occurred and be continuing any effect that,
individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect on Quidel; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho shall have received a certificate dated as of the Closing Date executed by a duly authorized officer of
Quidel as to the satisfaction of the conditions set forth above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of Quidel to consummate the Combinations are subject
to the satisfaction or waiver by Quidel of the following additional conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain representations and warranties of Ortho set forth in the BCA relating to the authorized capital stock of
Ortho and Topco are true and correct (except for <I>de minimis</I> inaccuracies) as of the Closing Date as though made on and as of such date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in
which case such representation and warranty shall be so true and correct as of such earlier date); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain representations and warranties of Ortho set forth in the BCA regarding the authorization of and other
matters relating to the capitalization of Ortho and the corporate authority of Ortho are true and correct in all material respects as of the Closing Date as though made on and as of such date (except to the extent that any such representation and
warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be so true and correct as of such earlier date); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of the other representations and warranties of Ortho (and, as applicable, Topco, U.S. Merger Sub, U.S.
Holdco Sub and U.S. Holdco Sub 2) set forth in the BCA are true and correct (disregarding all qualifications or limitations as to &#147;material,&#148; &#147;Material Adverse Effect&#148; and words of similar import set forth therein) as of the date
of the BCA and as of the Closing Date as though made on and as of such date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and
correct as of such earlier date), except where the failure of such representations and warranties to be so true and correct has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on
Ortho; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho shall, in all material respects, have performed and complied with all obligations required to be performed
or complied with by it under the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at any time after the date of the BCA, there shall not have occurred and be continuing any effect that,
individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect on Ortho; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel shall have received a certificate dated as of the Closing Date executed by a duly authorized officer of
Ortho as to the satisfaction of the conditions set forth above. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_176"></A>Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA may be terminated at any time prior to the Ortho Effective Time, whether before or after receipt of the Quidel Requisite Vote or Ortho Requisite Vote,
as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by the mutual written consent of Quidel and Ortho; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Quidel or Ortho, if the Ortho Effective Time has not occurred by September&nbsp;22, 2022 (the
&#147;Termination Date&#148;); provided, however, that such date shall automatically be extended to January&nbsp;22, 2023, if the only conditions that have not been satisfied (other than those conditions that Quidel and Ortho have mutually agreed to
waive, if and to the extent that such waiver is permitted by applicable law, and other than those conditions that by their nature can only be satisfied at or immediately prior to the Scheme Effective Date) are one or more of the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">292 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
conditions set forth in (a)&nbsp;clause (iii) under &#147;Conditions to the Combinations&#148; above to the extent relating to an approval required by clause (v)&nbsp;under &#147;Conditions to
the Combinations&#148; above or (b)&nbsp;clause (v) under &#147;Conditions to the Combinations&#148; above; provided, further, that the right to terminate the BCA pursuant to this provision may not be exercised by any party whose failure to perform
any material covenant or obligation under the BCA has been the primary cause of, or primarily resulted in, the failure of any such closing condition to be satisfied on or before the Termination Date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Quidel or Ortho, if (a)&nbsp;the Quidel Requisite Vote has not been obtained at the Quidel
Stockholders&#146; Meeting (or at any adjournment or postponement thereof) or (b)&nbsp;the Ortho Requisite Vote has not been obtained at the Ortho Shareholder Meetings (or at any adjournment or postponement thereof) or the Ortho Scheme is not
sanctioned and the Ortho Scheme Order is not issued by the Court; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Quidel or Ortho, if any governmental entity that must grant a required regulatory approval has denied
such grant in writing and such denial has become final, binding and <FONT STYLE="white-space:nowrap">non-appealable,</FONT> or any order permanently restraining, enjoining or otherwise prohibiting consummation of the Combinations has become final
and <FONT STYLE="white-space:nowrap">non-appealable;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Quidel, at any time prior to the receipt of the Ortho Requisite Vote, if the Ortho board of directors has
effected an Ortho Change in Recommendation (whether or not in compliance with the applicable provisions of the BCA); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Quidel, at any time prior to the Ortho Effective Time, if Ortho breaches or fails to perform any of its
covenants or agreements contained in the BCA, or if any of the representations or warranties of Ortho contained therein fails to be true and correct, which breach or failure (a)&nbsp;would give rise to the failure of the conditions to Quidel&#146;s
obligation to close and (b)&nbsp;is not reasonably capable of being cured by Ortho by the Termination Date or is not cured by Ortho within 45 days after receiving written notice from Quidel, unless Quidel&#146;s failure to perform any material
covenant or obligation under the BCA has been the primary cause of, or primarily resulted in, the failure of any such closing condition to be satisfied on or before the Termination Date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Quidel, at any time prior to the receipt of the Quidel Requisite Vote, if the Quidel board of directors has
effected a Quidel Change in Recommendation in compliance with the BCA in response to a Quidel All Cash Superior Proposal and in order for Quidel to enter into a merger agreement, acquisition agreement or other similar agreement that the Quidel board
of directors has authorized and directed Quidel to execute with respect to such Quidel All Cash Superior Proposal; provided, however, that the BCA may not be so terminated unless (a)&nbsp;prior to or simultaneously with such termination the Quidel
Termination Payment (as defined below) has been made in full to Ortho, and (b)&nbsp;simultaneously or promptly following such termination Quidel enters into such agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Ortho, at any time prior to the receipt of the Quidel Requisite Vote, if the Quidel board of directors has
effected a Quidel Change in Recommendation (whether or not in compliance with the applicable provisions of the BCA); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Ortho, at any time prior to the Ortho Effective Time, if Quidel breaches or fails to perform any of its
covenants or agreements contained in the BCA, or if any of the representations or warranties of Quidel contained therein fails to be true and correct, which breach or failure (a)&nbsp;would give rise to the failure of the conditions to Ortho&#146;s
obligation to close and (b)&nbsp;is not reasonably capable of being cured by Quidel by the Termination Date or is not cured by Quidel within 45 days after receiving written notice from Ortho, unless Ortho&#146;s failure to perform any material
covenant or obligation under the BCA has been the primary cause of, or primarily resulted in, the failure of any such closing condition to be satisfied on or before the Termination Date; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Ortho, at any time prior to the receipt of the Ortho Requisite Vote, if the Ortho board of directors has
effected an Ortho Change in Recommendation in compliance with the BCA in response to an Ortho All Cash Superior Proposal and in order for Ortho to enter into a merger agreement, acquisition agreement or other similar agreement that the Ortho board
of directors has authorized and directed Ortho to execute with respect to such Ortho All Cash Superior Proposal; provided, however, that the BCA may not be so terminated unless (a)&nbsp;prior to or simultaneously with such termination the Ortho
Termination Payment (as defined below) has been made in full to Quidel, and (b)&nbsp;simultaneously or promptly following such termination Ortho enters into such agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event the BCA is terminated by either Quidel or Ortho, the BCA will become void and of no effect and there will be no liability or obligation on the
part of any party or any of their respective directors, officers, employees, agents, legal and financial advisors or other representatives, in each case, except with respect to certain obligations to pay certain expenses and termination fees
provided for under the BCA, as described in the section entitled &#147;Expenses and Termination Fees&#148; below. Notwithstanding the foregoing, the termination of the BCA will not relieve any party from liability for any fraud or willful
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">293 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and material breach of any of its representations, warranties, covenants or agreements set forth in the BCA. In the event of any such termination, the parties will cooperate with each other in
connection with the withdrawal of any applications to, or termination of proceedings before, any governmental entity or self-regulatory organization in connection with the transactions contemplated by the BCA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_177"></A>Expenses and Termination Fees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All costs and expenses incurred in connection with the BCA and the Combinations and the other transactions contemplated by the BCA generally are to be paid by
the party incurring such costs and expenses, but Quidel and Ortho will share equally all expenses associated with antitrust filings, the Nasdaq listing application and the filing, printing and mailing of this joint proxy statement/prospectus, the
Registration Statement and other disclosure documents required in connection with the Combinations.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel must pay Ortho a termination fee of
$207,839,918.46 (the &#147;Quidel Termination Payment&#148;) if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BCA is terminated by Ortho, as a result of a Quidel Change in Recommendation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BCA is terminated by either Quidel or Ortho if (i)&nbsp;the Combinations are not consummated by the
Termination Date or (ii)&nbsp;the Quidel Requisite Vote has not been obtained at the Quidel Stockholders&#146; Meeting and, at the time of such termination, Ortho had a right to terminate as a result of a Quidel Change in Recommendation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) an Acquisition Proposal for Quidel shall have been publicly announced or made publicly known or otherwise
communicated or made known to Quidel management or the Quidel board of directors (or any third party shall have publicly announced, communicated or made known a bona fide intention, whether or not conditional, to make a proposal with respect to an
Acquisition Proposal) and not withdrawn prior to termination or such vote to adopt the BCA, as applicable, at any time after the date of the BCA and (b)&nbsp;the BCA is subsequently terminated by Ortho as a result of Quidel&#146;s breach of the BCA
or is terminated by either Quidel or Ortho because (i)&nbsp;the Combinations are not consummated by the Termination Date or (ii)&nbsp;the Quidel Requisite Vote has not been obtained at the Quidel Stockholders&#146; Meeting and, at the time of such
termination, Ortho had a right to terminate the BCA as a result of a failure by Quidel to perform any of its covenants or agreements contained in the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BCA is terminated by Quidel in connection with a Quidel All Cash Superior Proposal, subject to certain
additional conditions; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)&nbsp;an Acquisition Proposal for Quidel has been publicly announced or made publicly known or otherwise
communicated or made known to Quidel management or the Quidel board of directors (or any third party shall have publicly announced, communicated or made known a bona fide intention, whether or not conditional, to make a proposal with respect to an
Acquisition Proposal) and not withdrawn prior to termination or such vote to adopt the BCA, as applicable, at any time after the date of the BCA, (b)&nbsp;the BCA is subsequently terminated by Quidel or Ortho because (i)&nbsp;the Combinations are
not consummated by the Termination Date or (ii)&nbsp;the Quidel Requisite Vote has not been obtained at the Quidel Stockholders&#146; Meeting, and (c)&nbsp;within nine months of such termination, Quidel or any of its subsidiaries executes an
acquisition agreement with respect to, or consummates, or approves or recommends to the Quidel stockholders to accept, any Acquisition Proposal (provided that, for purposes of this clause (c), the term &#147;Acquisition Proposal&#148; is defined as
in the section entitled &#147;The Business Combination Agreement&#151;Acquisition Proposals&#148; of this joint proxy statement/prospectus, except that each reference to &#147;15% or more&#148; in the definition of &#147;Acquisition Proposal&#148;
and &#147;Major Subsidiary&#148; shall be deemed to be a reference to &#147;50% or more&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the BCA is terminated
because the Quidel Requisite Vote has not been obtained at the Quidel Stockholders&#146; Meeting, and the Quidel Termination Payment is not otherwise payable, then Quidel shall pay, or cause to be paid, to Ortho by way of reimbursement its
reasonable documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs, fees and expenses incurred in connection with its investigation, consideration, documentation, diligence and negotiations of
the BCA and the transactions contemplated thereby, including all reasonable fees and expenses of Ortho&#146;s and its subsidiaries&#146; respective representatives and financing sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event the Quidel Termination Payment is payable by Quidel to Ortho after the time Quidel pays any expense reimbursement to Ortho in accordance with the
terms of the BCA, the amount of the Quidel Termination Payment payable by Quidel to Ortho will be reduced by the amount of such expense reimbursement actually paid to Ortho. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">294 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho must pay Quidel a termination fee of $46,880,426.11 (the &#147;Ortho Termination Payment&#148;) if:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BCA is terminated by Quidel, as a result of an Ortho Change in Recommendation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BCA is terminated by either Quidel or Ortho if (i)&nbsp;the Combinations are not consummated by the
Termination Date or (ii)&nbsp;the Ortho Requisite Vote has not been obtained at the Ortho Shareholder Meetings or the Ortho Scheme is not sanctioned and the Ortho Scheme Order is not issued by the Court and, at the time of such termination, Quidel
had a right to terminate as a result of an Ortho Change in Recommendation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) an Acquisition Proposal for Ortho shall have been publicly announced or made publicly known or otherwise
communicated or made known to Ortho management or the Ortho board of directors (or any third party shall have publicly announced, communicated or made known a bona fide intention, whether or not conditional, to make a proposal with respect to an
Acquisition Proposal) and not withdrawn prior to termination or such vote to adopt the BCA, as applicable, at any time after the date of the BCA and (b)&nbsp;the BCA is subsequently terminated by Quidel as a result of Ortho&#146;s breach of the BCA
or is terminated by either Quidel or Ortho because (i)&nbsp;the Combinations are not consummated by the Termination Date or (ii)&nbsp;the Ortho Requisite Vote has not been obtained at the Ortho Shareholder Meetings or the Ortho Scheme is not
sanctioned and the Ortho Scheme Order is not issued by the Court and, at the time of such termination, Quidel had a right to terminate the BCA as a result of a failure by Ortho to perform any of its covenants or agreements contained in the BCA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BCA is terminated by Ortho in connection with an Ortho All Cash Superior Proposal, subject to certain
additional conditions; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)&nbsp;an Acquisition Proposal for Ortho has been publicly announced or made publicly known or otherwise
communicated or made known to Ortho management or the Ortho board of directors (or any third party shall have publicly announced, communicated or made known a bona fide intention, whether or not conditional, to make a proposal with respect to an
Acquisition Proposal) and not withdrawn prior to termination or such vote to adopt the BCA, as applicable, at any time after the date of the BCA, (b)&nbsp;the BCA is subsequently terminated by Quidel or Ortho because (i)&nbsp;the Combinations are
not consummated by the Termination Date or (ii)&nbsp;the Ortho Requisite Vote has not been obtained at the Ortho Shareholder Meetings or the Ortho Scheme is not sanctioned and the Ortho Scheme Order is not issued by the Court, and (c)&nbsp;within
nine months of such termination, Ortho or any of its subsidiaries executes an acquisition agreement with respect to, or consummates, or approves or recommends to the Ortho shareholders to accept, any Acquisition Proposal (provided that, for purposes
of this clause (c),&nbsp;the term &#147;Acquisition Proposal&#148; is defined as in the section entitled &#147;The Business Combination Agreement&#151;Acquisition Proposals&#148; of this joint proxy statement/prospectus, except that each reference
to &#147;15% or more&#148; in the definition of &#147;Acquisition Proposal&#148; and &#147;Major Subsidiary&#148; shall be deemed to be a reference to &#147;50% or more&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the BCA is terminated because the Ortho Requisite Vote has not been obtained at the Ortho Shareholder Meetings or the Ortho Scheme is not
sanctioned and the Ortho Scheme Order is not issued by the Court, and the Ortho Termination Payment is not otherwise payable, then Ortho shall pay, or cause to be paid, to Quidel by way of reimbursement its reasonable documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs, fees and expenses incurred in connection with its investigation, consideration, documentation, diligence and negotiations of the BCA and the transactions
contemplated thereby, including all reasonable fees and expenses of Quidel&#146;s and its subsidiaries&#146; respective representatives and financing sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event the Ortho Termination Payment is payable by Ortho to Quidel after the time Ortho pays any expense reimbursement to Quidel in accordance with the
terms of the BCA, the amount of the Ortho Termination Payment payable by Ortho to Quidel will be reduced by the amount of such expense reimbursement actually paid to Quidel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_178"></A>Specific Performance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel
and Ortho have agreed that Quidel and Ortho will be entitled to an injunction, specific performance and other equitable relief to prevent breaches or threatened breaches of the BCA by the other parties and to enforce specifically the terms and
provisions of the BCA, in addition to any other remedy to which they are entitled. However, a party will not be entitled to both specific performance and the payment of any termination fee described above under &#147;Expenses and Termination
Fees.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">295 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_179"></A>STOCKHOLDERS AGREEMENT / DEED OF IRREVOCABLE UNDERTAKING
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_180"></A>Stockholders Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with execution of the BCA, Ortho, Quidel, Topco and the Carlyle Stockholder entered into a stockholders agreement (the &#147;Stockholders
Agreement&#148;) which will replace the stockholders agreement currently in effect between Ortho and the Carlyle Stockholder, which provides for, among other things, certain registration and information rights (the &#147;Current Ortho Stockholders
Agreement&#148;). A copy of the Stockholders Agreement is attached to this joint proxy statement/prospectus as Annex B and is incorporated by reference into this joint proxy statement/prospectus. The Stockholders Agreement provides, among other
things, that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Board Representation</I>. So long as the Carlyle Stockholder holds at least 12% of the outstanding Topco
Shares, then the Carlyle Stockholder may nominate two individuals to the Topco board of directors. If the Carlyle Stockholder holds at least 5% but less than 12% of the outstanding Topco Shares, then it may nominate one individual to the Topco board
of directors. The Carlyle Stockholder is not entitled to any nomination rights with respect to the Topco board of directors if it holds less than 5% of the outstanding Topco Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Registration Rights</I>. The Stockholders Agreement grants the Carlyle Stockholder registration rights,
including demand rights and piggyback rights, each subject to certain limitations. The Carlyle Stockholder&#146;s demand rights (excluding rights with respect to &#147;shelf&#148; registrations) expire in the event that the Carlyle Stockholder owns
less than 5% of the outstanding Topco Shares, and its other registration rights expire on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">holder-by-holder</FONT></FONT> basis when a given Carlyle Stockholder owns less than 1% of
the outstanding Topco Shares, in each case, only if such Carlyle Stockholder can sell its Topco Shares without volume or manner of sale restrictions under Rule 144 under the Securities Act. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Corporate Opportunity Waiver</I>. The Stockholders Agreement includes a customary corporate opportunity waiver
provision, duly adopted by the Topco board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Information Rights</I>. The Stockholders Agreement provides the Carlyle Stockholder with (a)&nbsp;customary
rights to financial information so long as the Carlyle Stockholder holds 5% or more of the outstanding Topco Shares, and (b)&nbsp;additional access to information and Topco management so long as the Carlyle Stockholder holds 10% or more of the
outstanding Topco Shares. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_180a"></A>Current Ortho Stockholders Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Current Ortho Stockholders Agreement provides for registration and information rights that are generally similar to those that will exist under the
Stockholders Agreement. However, there are certain changes in the Stockholders Agreement including: (i)&nbsp;an increase to the minimum transaction size for <FONT STYLE="white-space:nowrap">non-shelf</FONT> demand offerings and shelf takedowns from
$50&nbsp;million to $250&nbsp;million, (ii)&nbsp;termination of registration rights when the Carlyle Stockholder (with any affiliates or transferees) owns less than 5% of the outstanding Topco Shares or if it is able to sell Topco Shares under Rule
144 of the Securities Act, without volume or manner of sale restrictions, (iii)&nbsp;removal of the right to receive an annual budget and (iv)&nbsp;termination of access rights when the Carlyle Stockholder (with any affiliates or transferees) owns
less than 10% of the outstanding Topco Shares. The Stockholders Agreement also includes director appointment rights, which are currently addressed in the articles of association of Ortho. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_181"></A>Irrevocable Undertaking </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with its entry into the BCA, Ortho and Quidel received from the Carlyle Stockholder a deed of irrevocable undertaking (&#147;Irrevocable Undertaking&#148;) to vote or procure votes in favor of the Ortho Scheme of arrangement at the Ortho
Court Meeting and the resolution to be proposed at the Ortho General Meeting, in respect of 118,106,000 Ortho Shares beneficially owned by the Carlyle Stockholder, representing approximately 49.79% of the Ortho Shares. The Irrevocable Undertaking,
which terminates if the BCA is terminated, requires the Carlyle Stockholder to vote their Ortho Shares in favor of and accept the Combinations, and, subject to certain exceptions, prohibits the applicable shareholder from dealing in (including
transferring or encumbering) its Ortho Shares. A copy of the Irrevocable Undertaking is attached to this joint proxy statement/prospectus as Annex C and is incorporated by reference into this joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">296 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_182"></A>INTERESTS OF CERTAIN PERSONS IN THE COMBINATIONS (QUIDEL)
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="rom273090_183"></A>Quidel&#146;s executive officers and directors have interests in the Combinations that are different from, or in addition
to, the interests of Quidel stockholders generally. The Quidel board of directors was aware of these potentially differing interests and considered them, among other matters, in reaching its decision to adopt the BCA, approve the Combinations and to
recommend that you vote in favor of the Merger Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the sections entitled &#147;The Combinations&#151;Background of the Combinations&#148; and
&#147;The Combinations&#151;Quidel Reasons for the Combinations and Recommendation of the Quidel Board of Directors&#148; of this joint proxy statement/prospectus. Quidel stockholders should take these interests into account in deciding whether to
vote &#147;<B>FOR</B>&#148; the Merger Proposal. These interests are described in more detail below, and certain of them are quantified in the narrative and the table included under the section entitled &#147;<I>&#151;</I>Golden Parachute
Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These interests may include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the treatment in the Combinations of equity awards held by Quidel directors and executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">success bonus awards payable upon the consummation of the Combinations, the amounts of which are described in the
section entitled &#147;&#151;Success Bonuses;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">integration/retention cash bonus awards, 25% of which will be payable upon the consummation of the Combinations
and the remaining 75% of which will be payable on the first anniversary of the consummation of the Combinations, the amounts of which are described in the section entitled &#147;&#151;Integration/Retention Bonuses&#151;Cash&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">integration/retention equity bonus awards, which were granted in the form of Quidel RSUs and will vest with
respect to 50% of the award on the second anniversary of the grant date and the remaining 50% in equal annual installments (25% per year) thereafter, which are described in the section entitled &#147;&#151;Integration/Retention
Bonuses&#151;Equity&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued employment of certain executive officers of Quidel, as described in the section entitled
&#147;Topco Positions;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued positions of certain directors of Quidel as directors on the board of directors of Topco, as
described in the section entitled &#147;Topco Positions;&#148; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severance payments payable under existing employment and severance arrangements or arrangements that may be
entered into in connection with the Combinations. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_184"></A>Treatment of Quidel Equity Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Combinations will not constitute a change in control under the Quidel Stock Plans. Nonetheless, pursuant to the terms of the BCA, each award of outstanding
Quidel Stock Options, Quidel RSUs and Quidel PSUs will be treated as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Quidel Effective Time, each outstanding Quidel Stock Option granted under a Quidel Stock Plan, whether vested or unvested, will automatically, without
any action on the part of the holder thereof, cease to represent an option to acquire Quidel Shares and be converted into a Topco Stock Option on the same terms and conditions (including applicable vesting conditions) applicable to such Quidel Stock
Option under the applicable Quidel Stock Plan and award agreement in effect immediately prior to the Quidel Effective Time, except as adjusted by the BCA. The number of Topco Shares subject to each such Topco Stock Option will be equal to the number
of Quidel Shares subject to such Quidel Stock Option immediately prior to the Quidel Effective Time, and each such Topco Stock Option will have an exercise price per share equal to the exercise price per Quidel Share of such Quidel Stock Option
immediately prior to the Quidel Effective Time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Units </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Quidel Effective Time, each outstanding Quidel RSU granted under a Quidel Stock Plan will automatically, without any action on the part of the holder
thereof, be converted into a Topco RSU on the same terms and conditions (including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">297 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable vesting conditions) applicable to such Quidel RSU under the applicable Quidel Stock Plan and award agreement in effect immediately prior to the Quidel Effective Time. The number of
Topco Shares covered by each such Topco RSU will be equal to the number of Quidel Shares subject to such Quidel RSU immediately prior to the Quidel Effective Time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance Restricted Stock Units </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Quidel
Effective Time, each outstanding Quidel PSU granted under a Quidel Stock Plan will automatically, without any action on the part of the holder thereof, be converted into a Topco PSU on the same terms and conditions (including applicable vesting
conditions) applicable to such Quidel PSU under the applicable Quidel Stock Plan and award agreement in effect immediately prior to the Quidel Effective Time. The number of Topco Shares covered by each such Topco PSU will be equal to the number of
Quidel Shares subject to such Quidel PSU immediately prior to the Quidel Effective Time. The Quidel board of directors, or an applicable committee thereof, may, prior to the Ortho Effective Time make such equitable adjustments, if any, to the
applicable performance goals or conditions relating to such Quidel PSU, as the Quidel board of directors may determine to be necessary or appropriate as a result of the consummation of the Combinations, which equitable adjustments shall take effect
upon and be subject to the consummation of the Combinations and, in each case, subject to and in accordance with the terms and conditions of the Quidel Stock Plans and Quidel PSU. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Success Bonuses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Combinations,
Quidel approved the grant of success bonus awards to certain employees and executive officers (the &#147;Success Bonuses&#148;). The Success Bonuses are being implemented to reward key talent and will be paid out to recipients upon the consummation
of the Combinations. The Success Bonuses will be grossed up for taxes. The following executives are entitled to receive a Success Bonus in the following amounts: Douglas Bryant: $875,500; Randall Steward: $499,550; Robert Bujarski: $525,000; and
Michelle Hodges: $450,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Integration/Retention Bonuses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel has approved the grant of
integration/retention cash bonuses to certain employees and executive officers (the &#147;Cash Retention Bonuses&#148;). The Cash Retention Bonuses are being implemented to retain key talent following the consummation of the Combinations. The first
25% of the Cash Retention Bonus will become payable upon the closing of the Combinations, and the remaining 75% upon the first anniversary thereof, subject to the recipient&#146;s continued employment through such dates. If a recipient&#146;s
employment is terminated by Quidel without cause prior to the full payment of the Cash Retention Bonus, then the unpaid portion of the Cash Retention Bonus will be paid by the 60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following
such termination, subject to the recipient&#146;s execution, and <FONT STYLE="white-space:nowrap">non-revocation,</FONT> of a general release of claims in favor of Quidel. Cash Retention Bonuses have been awarded to the following executives in the
following amounts: Douglas Bryant: $717,500; Randall Steward: $349,685; Robert Bujarski: $420,000; Michelle Hodges: $315,000; and Dr.&nbsp;Werner Kroll: $385,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel has also approved the grant of
integration/retention equity bonuses to certain employees and executive officers (the &#147;Equity Retention Bonuses&#148;), which have been approved to retain key talent following the consummation of the Combinations. The Equity Retention Bonuses
were granted in the form of Quidel RSUs and will vest with respect to 50% of the award on the second anniversary of the grant date and the remaining 50% in equal annual installments (or 25% per year) thereafter; provided, however, that (x)&nbsp;the
vesting of the Quidel RSUs is contingent upon the consummation of the Combinations having occurred prior to the applicable vesting date, and (y)&nbsp;the Quidel RSUs will be automatically forfeited in the event the BCA is terminated in accordance
with its terms. If a recipient&#146;s employment is terminated by Quidel without cause prior to the full vesting of the Equity Retention Bonus, then the unvested portion of the Equity Retention Bonus will vest immediately upon such termination of
employment, subject to the recipient&#146;s execution, and <FONT STYLE="white-space:nowrap">non-revocation,</FONT> of a general release of claims in favor of Quidel. Equity Retention Bonuses have been awarded to the following executives in the
following amounts: Douglas Bryant: target value of $2,500,000; Robert Bujarski: target value of $1,400,000; Michelle&nbsp;Hodges: target value of $750,000; and Dr.&nbsp;Werner Kroll: target value of $750,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">298 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_185"></A>Post-Combinations Compensation and Benefit Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the BCA, employees of Quidel and its subsidiaries at the Quidel Effective Time who continue to remain employed with Quidel or its subsidiaries (the
&#147;Quidel Continuing Employees&#148;) shall, during the period commencing at the Quidel Effective Time and ending on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary thereof, be provided with base salary or base wage, severance
benefit protections, and pension and welfare benefits that are no less favorable, in the aggregate, than those provided to such Quidel Continuing Employees immediately prior to the Quidel Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, executive officers and directors who are retained to provide services to Quidel following the consummation of the Combinations may enter into new
individualized compensation arrangements. As of the date of this joint proxy statement/prospectus, no compensation arrangements have been established. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_186"></A>Executive Severance Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Douglas Bryant, Randall Steward and Robert Bujarski are party to agreements with Quidel which provide for severance benefits in the event of a
qualifying termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Messrs. Bryant, Steward and Bujarski, Ms.&nbsp;Hodges and Dr.&nbsp;Kroll are party to change in control agreements
with Quidel, though the Combinations do not constitute a &#147;change in control&#148; within the meaning of such agreements, and therefore no compensation or benefits are payable thereunder as a result of the Combinations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Douglas Bryant </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Mr.&nbsp;Bryant&#146;s
employment with Quidel is terminated without &#147;cause&#148; (as defined in his employment agreement) or he terminates his employment for &#147;good reason&#148; (as defined in his employment agreement) and thereafter delivers and does not revoke
a general release, he is entitled to a severance payment equal to 18 months of his then-current base salary and payment of health insurance premiums for a period of 18 months following termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Cause&#148; is generally defined in Mr.&nbsp;Bryant&#146;s employment agreement as: (i)&nbsp;fraud; (ii) personal dishonesty involving money or property
of Quidel or that results in material harm to Quidel; (iii)&nbsp;Mr.&nbsp;Bryant&#146;s willful misconduct that is materially injurious to Quidel; (iv)&nbsp;a serious breach of a fiduciary duty to Quidel involving personal profit;
(v)&nbsp;Mr.&nbsp;Bryant&#146;s conviction for a felony (including a guilty or nolo contendere plea), excluding traffic offenses; (vi)&nbsp;Mr.&nbsp;Bryant&#146;s willful and continued neglect of duties (other than any such failure resulting from
his incapacity because of physical or mental illness); or (vii)&nbsp;Mr.&nbsp;Bryant&#146;s material breach of certain provisions of his employment agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Good reason&#148; is generally defined in Mr.&nbsp;Bryant&#146;s employment agreement as: (i)&nbsp;the failure to elect and continue Mr.&nbsp;Bryant as
Chief Executive Officer of Quidel, or if the scope of Mr.&nbsp;Bryant&#146;s duties and responsibilities are in the aggregate materially reduced; (ii)&nbsp;a requirement by Quidel or the Quidel board of directors that Mr.&nbsp;Bryant, without his
prior consent, be relocated to a Quidel office more than 50 miles from the current executive offices of Quidel, or Quidel requires Mr.&nbsp;Bryant to be based anywhere other than the principal executive offices of Quidel; (iii)&nbsp;any material
reduction in Mr.&nbsp;Bryant&#146;s base salary, provided that Quidel does not pay Mr.&nbsp;Bryant an appropriate cash amount to reimburse him for the base salary reduction; or (iv)&nbsp;a material breach by Quidel of any of the terms of the
employment agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Randall Steward </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel
and Mr.&nbsp;Steward have entered into an individual retirement program, which outlines the terms of Mr.&nbsp;Steward&#146;s compensation through the date on which his employment with Quidel terminates. The program previously contemplated that
Mr.&nbsp;Steward&#146;s employment would terminate on March&nbsp;31, 2022, though in connection with the anticipated transactions contemplated by the BCA the parties determined it to be in their mutual interest to amend Mr.&nbsp;Steward&#146;s
individual retirement program to provide that he will remain employed until the earlier of (i)&nbsp;the consummation of the Combinations or (ii)&nbsp;the termination of the BCA. Upon the termination of Mr.&nbsp;Steward&#146;s employment, the parties
will enter into a &#147;special advisor transition agreement.&#148; This agreement will have an initial term of one year from the effective date thereof, which may be extended until March&nbsp;31, 2024. During the term of the &#147;special advisor
transition agreement,&#148; Mr.&nbsp;Steward shall be entitled to receive $300,000 per year in compensation, which shall be paid in equal installments in accordance with Quidel&#146;s regular payroll. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">299 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Robert Bujarski </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Bujarski is party to an employment agreement with Quidel which provides that if his employment is terminated by Quidel without cause, he is entitled
to a severance payment equal to six months of his annual then-current base salary. Cause is not defined in Mr.&nbsp;Bujarski&#146;s employment agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_188"></A>Golden Parachute Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section sets forth the information required by Item 402(t) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> regarding the compensation of each of
Quidel&#146;s five current NEOs that is based on or otherwise relates to the Combinations and that will or may become payable to the NEOs at the Quidel Effective Time or upon a qualifying termination of employment on or following the Quidel
Effective Time. This compensation is referred to as &#147;golden parachute&#148; compensation by the applicable SEC disclosure rules, and in this section we use such term to describe the Combinations-related compensation payable to Quidel&#146;s
NEOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts shown in the table below are estimates based on multiple assumptions that may or may not actually occur or be accurate on the relevant
date, including the assumptions described below and in the footnotes to the table, and do not reflect certain compensation actions that may occur before consummation of the Combinations. For purposes of calculating such amounts, the following
assumptions were used: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Quidel Effective Time is April&nbsp;30, 2022, which is the assumed date of the closing of the Quidel Merger
solely for purposes of this golden parachute compensation disclosure; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Each NEO experienced a qualifying termination (i.e., a termination without &#147;cause&#148; or for &#147;good
reason,&#148; as defined in the relevant agreements), immediately following the assumed Quidel Effective Time ; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The per share value of Quidel Shares is $103.36, which is the closing price for Quidel Shares on January&nbsp;31,
2022, the grant date of the Equity Retention Bonuses. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the foregoing assumptions, the actual amounts, if any, to be
received by a NEO may materially differ from the amounts set forth below. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cash<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Equity<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Perquisites&nbsp;/</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Benefits<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Tax<BR>Reimbursement</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Other</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total Value<BR>($)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,537,500</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,499,968</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,364</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,736,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,593,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,408,246</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">849,235</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,140,012</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,400,011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">945,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,656,577</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,283</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">765,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,203,146</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,283</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,135,283</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts shown reflect the cash severance payable to each NEO upon a qualifying termination of employment.
Mr.&nbsp;Bryant is entitled to receive severance in the event of a termination of employment without cause or for good reason, and Mr.&nbsp;Bujarski is entitled to severance upon a termination of employment without cause. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the termination of Mr.&nbsp;Steward&#146;s employment, Mr.&nbsp;Steward will enter into a special advisor
transaction agreement, which provides for base compensation of $300,000 per year for the duration of such agreement, which shall be paid in equal installments in accordance with Quidel&#146;s regular payroll. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column represent the value of unvested equity awards held by each NEO that would be
accelerated upon a qualifying termination of employment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For Mr.&nbsp;Bryant, represents the value of continued health insurance benefits pursuant to his employment
agreement, which would be payable only if Mr.&nbsp;Bryant&#146;s employment was terminated without cause or he resigned for good reason. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column reflect the tax reimbursement payable to each NEO who is entitled to a success
bonus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes the value of the Success Bonus and Cash Retention Bonus payable to each NEO. The Success Bonus is
payable upon the consummation of the Combinations, subject to continued employment through such date. Messrs. Bryant, Steward and Bujarski and Ms.&nbsp;Hodges are eligible for Success Bonuses equal to $875,500, $499,550, $525,000, and $450,000,
respectively. The Cash Retention Bonus is payable 25% upon the consummation of the Combinations, and the remaining 75% upon the first anniversary thereof; provided that the Cash Retention Bonus will become payable upon a termination without cause.
Messrs. Bryant, Steward and Bujarski, Ms.&nbsp;Hodges and Dr.&nbsp;Kroll are eligible for Cash Retention Bonuses equal to $717,500, $349,685, $420,000, $315,000 and $385,000. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">300 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_187"></A>Topco Positions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of the Ortho Effective Time, the Topco board of directors will consist of 12 members, comprised of (i)&nbsp;eight members designated by Quidel,
expected to consist of Messrs. Bryant, Buechler, Michael, Strobeck, Widder and Wilkins and Mses. Polan and Rhoads, each of whom, other than Mr.&nbsp;Bryant, qualifies as an &#147;independent director&#148; under applicable rules of Nasdaq and
(ii)&nbsp;four members designated by Ortho, at least two of whom will qualify as an &#147;independent director&#148; under applicable rules of Nasdaq. Each of the members of the Topco board of directors designated by Ortho shall be reasonably
acceptable to the nominating and corporate governance committee of the current Quidel board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Douglas Bryant, current President and Chief
Executive Officer of Quidel, will serve as the Chair of the Topco board of directors and as the Chief Executive Officer of Topco. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, Robert
Bujarski, current Chief Operating Officer of Quidel, will serve as the President and Chief Operating Officer of Topco. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_189"></A>Insurance and Indemnification of Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the BCA provide for certain post-closing covenants related to insurance and indemnification of directors and executive officers. For a description
of such covenants, see the section entitled &#147;The Business Combination Agreement&#151;Indemnification and Insurance&#148; of this joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">301 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_190"></A>INTERESTS OF CERTAIN PERSONS IN THE COMBINATIONS (ORTHO)
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s executive officers and directors have interests in the Ortho Scheme that are different from, or in addition to, the interests of Ortho
shareholders generally. The Ortho board of directors was aware of these potentially differing interests and considered them, among other matters, in reaching its decision to adopt the BCA, approve the Combinations and to recommend that you vote in
favor of all proposals to be approved at the Ortho Shareholder Meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the sections entitled &#147;The Combinations&#151;Background of the
Combinations&#148; and &#147;The Combinations&#151;Ortho Reasons for the Combinations and Recommendation of the Ortho Board of Directors&#148; of this joint proxy statement/prospectus. Ortho shareholders should take these interests into account in
deciding whether to vote &#147;<B>FOR</B>&#148; the Ortho Scheme Proposal. These interests are described in more detail below, and certain of them are quantified in the narrative and the table included under the section entitled &#147;Golden
Parachute Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These interests may include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued engagement and/or employment, as applicable, of certain board members and executive officers of
Ortho, as described in the section entitled &#147;Topco Positions&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued positions of certain directors of Ortho as directors on the board of directors of Topco, as
described below in the section entitled &#147;Topco Positions&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the treatment in the Combinations of equity awards and stock options held by Ortho directors and executive
officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention bonus awards, 40% of which will be payable at the closing of the Combinations and the remaining 60% of
which will be payable on the first anniversary of the closing of the Combinations, the amounts of which are described in the section entitled &#147;Retention Bonuses&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transaction bonuses payable upon the closing of the Combinations, the amounts of which are described in the
section entitled &#147;Transaction Bonuses&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severance payments payable under existing employment and severance arrangements or arrangements that may be
entered into in connection with the Combinations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In respect of the Ortho directors and named executive officers, the Combinations
shall impact their board service and results in equity and cash based awards as summarized below: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Payable as a Result of the
Combinations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All directors and executive officers of Ortho who are Ortho shareholders will receive Ortho Scheme Consideration in respect of their
Ortho Shares, calculated in the same manner as the Ortho Scheme Consideration is calculated for all other Ortho shareholders. As described below in the section entitled &#147;Interests of Certain Persons in the Combinations (Ortho)&#151;Executive
Severance Agreements&#148; and as summarized in the table entitled &#147;Interests of Certain Persons in the Combinations (Ortho)&#151;Golden Parachute Compensation&#148; Messrs. Smith, Iskra, Busky, Palaniappan and Schlesinger, as well as certain
other executive officers who are Ortho shareholders, are eligible for severance payments under certain circumstances. The severance arrangements are contractual and were established prior to signing of the BCA and not in anticipation of the
Combinations. As described below in the sections entitled &#147;Interests of Certain Persons in the Combinations (Ortho)&#151;Retention Bonuses&#148; and &#147;Interests of Certain Persons in the Combinations (Ortho)&#151;Transaction Bonuses&#148;
and as summarized in the table entitled &#147;Interests of Certain Persons in the Combinations (Ortho)&#151;Golden Parachute Compensation,&#148; Ortho has approved retention bonuses for Messrs. Busky, Iskra, Palaniappan and Schlesinger and
transaction bonuses for Messrs. Smith, Busky, Iskra and Schlesinger. The retention bonuses and transaction bonuses were approved by the compensation committee of the Ortho board of directors in connection with the Combinations and are consistent
with typical market practice in the United States for similarly situated executives in a transaction similar to the Combinations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation
following the Combinations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA contemplates that Mr. Busky will serve as the Chief Financial Officer of Topco, and Mr. Iskra will serve as the
Chief Commercial Officer of Topco, in each case after closing the Combinations. Compensation for Messrs. Busky and Iskra in such roles has not yet been determined. Quidel and Ortho have not yet identified which other executives of Ortho will
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">302 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
serve in senior management positions of Topco, although the BCA provides that, for 12 months following the Ortho Effective Time, each Ortho Continuing Employee will receive base salary or wages,
severance benefit protections and pension and welfare benefits that are no less favorable, in the aggregate, than those provided to such Ortho Continuing Employees immediately prior to the Ortho Effective Time. Four members of the post-closing board
of directors of Topco will be appointed by Ortho, but Ortho and Quidel have not yet determined what compensation, if any, will be paid to such individuals in consideration for serving as directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of Ortho Equity Awards </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the
section below entitled &#147;Interests of Certain Persons in the Combinations (Ortho)&#151;Treatment of Ortho Equity Awards&#148; for a description of the treatment of Ortho Equity Awards held by members of the board of directors of Ortho and
management of Ortho after closing of the Combinations. In general, directors and members of management will receive the same treatment as holders of other Ortho Equity Awards, provided that certain of Mr. Smith&#146;s Ortho Equity Awards contain
different vesting terms than apply to other holders of Ortho Equity Awards. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholding by Directors and Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the section below entitled &#147;Security Ownership of Certain Ortho Beneficial Owners and Management&#148; for a summary of the shareholding of members of
the board of directors of Ortho and the named executive officers of Ortho. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_191"></A>Compensation Actions in Connection with the
Combinations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Combinations, Ortho retained the discretion to take action to: (i)&nbsp;deem a &#147;Liquidity Event&#148; (as
defined under the Ortho equity awards) to have occurred with respect to Ortho&#146;s outstanding equity awards upon any of (A)&nbsp;the completion of the Combinations, (B)&nbsp;an involuntary (&#147;without cause&#148;) or constructive (&#147;good
reason&#148;) termination of employment upon or following the completion of the Combinations, or (C)&nbsp;the completion of a specified period of service after the closing of the Combinations, and the deemed occurrence of a Liquidity Event may
result in vesting of certain Ortho equity awards; (ii)&nbsp;modify vesting and related provisions of outstanding Ortho equity awards that, without modification, would result in forfeitures in connection with the Combinations; (iii)&nbsp;provide that
outstanding equity awards held by Ortho&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors who will not serve on the Topco board of directors following the completion of the Combinations will vest upon the closing of the
Combinations; (iv)&nbsp;provide that Ortho&#146;s outstanding equity awards will vest as a result of an involuntary (&#147;without cause&#148;) or constructive (&#147;good reason&#148;) termination of employment upon or following the completion of
the Combinations; (v)&nbsp;provide for awards containing &#147;Liquidity Event&#148; vesting provisions to vest upon the earlier of the time specified in the applicable award agreement or upon a specified date that is not less than six months
following the completion of the Combinations, (vi)&nbsp;enter into change in control severance agreements with officers and employees on terms and conditions no more favorable than those in place for comparable Quidel employees and
(vii)&nbsp;provide for certain incremental cash payment programs for succession and/or retention purposes, payable upon or after completion of the Combinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the execution of the BCA, as detailed below, Ortho has approved certain retention and transaction bonus arrangement for Ortho&#146;s executive
officers and has determined that all of Ortho&#146;s outstanding and unvested stock options, restricted stock and restricted stock units will vest on a &#147;double trigger&#148; basis in the event the holder&#146;s service is terminated without
cause in connection with the Combinations. In addition, prior to the closing of the Combinations, Ortho may make additional changes to compensation arrangements for Ortho&#146;s officers and board members, as permitted under the BCA, although no
determinations have yet been made in regard to the foregoing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_192"></A>Treatment of Ortho Equity Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;20, 2022, there
were 12,723,304 outstanding Ortho Stock Options. If at the Ortho Effective Time there are outstanding Ortho Stock Options, then each such Ortho Stock Option will be converted into (i)&nbsp;a Topco Stock Option on the same terms and conditions as
were applicable to such Ortho Stock Option immediately prior to the Ortho Effective Time, (ii)&nbsp;with respect to the portion of the Ortho Stock Option that is vested at the Ortho Effective Time, a right to receive payment, in cash, upon the
closing of the Combinations, equal to the Cash Portion in respect of the Ortho Shares that are subject to the vested portion of the Ortho Stock Option, and (iii)&nbsp;with respect to the portion of the Ortho Stock Options that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">303 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are unvested at the Ortho Effective Time, a right to receive payment, in cash, equal to the Cash Portion in respect of the Ortho Shares that are subject to the unvested portion of the Ortho Stock
Option, payable through the payroll system or payroll provider of Topco or its affiliate and subject to applicable withholding, as and when the corresponding portion of the Ortho Stock Option would have vested. The number of Topco Shares subject to
each such Topco Stock Option shall be equal to the product (rounded down to the nearest whole number) of (x)&nbsp;the number of Ortho Shares subject to such Ortho Stock Option immediately prior to the Ortho Effective Time and (y)&nbsp;the Ortho
Exchange Ratio, and such Topco Stock Option shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A)&nbsp;the exercise price per Ortho Share of such option immediately prior to the Ortho Effective Time divided by
(B)&nbsp;the Ortho Exchange Ratio; provided, however, that the exercise price and the number of Topco Shares purchasable pursuant to such Topco Stock Option will be determined in a manner consistent with the requirements of Section&nbsp;409A of the
Code, without reducing the total value of consideration provided to the holders of Ortho Stock Options hereunder; provided, further, that in the case of any Ortho Stock Option to which Section&nbsp;422 of the Code applies, the exercise price and the
number of Topco Shares purchasable pursuant to such Ortho Stock Option will be determined in accordance with the foregoing, subject to such adjustments as are necessary in order to satisfy the requirements of Section&nbsp;424(a) of the Code without
reducing the total value of consideration provided to the holders of Ortho Stock Options hereunder. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the service of a holder of
Ortho Stock Options is terminated without cause in connection with or following the closing of the Combinations, such holder&#146;s Ortho Stock Options will become fully vested. In addition, all unvested Ortho Stock options held by Mr. Smith as of
the Closing will become fully vested. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Units and Restricted Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;20, 2022, there were 166,250 Ortho restricted stock unit awards and 388,724 unvested shares of Ortho restricted stock outstanding. Each
award of restricted stock, restricted stock units or other similar rights or awards granted under an Ortho Stock Plan and relating to Ortho Shares (any such award, an &#147;Ortho Equity Right&#148; and such awards together with the Ortho Stock
Options, the &#147;Ortho Stock Awards&#148;) that is outstanding immediately prior to the Ortho Effective Time will automatically be converted, at the Ortho Effective Time, into (i)&nbsp;an award of restricted stock, restricted stock units or other
similar rights or awards, as applicable, relating to Topco Shares (a &#147;Topco Equity Right&#148; and, together with the Topco Stock Options, &#147;Topco Stock Awards&#148;) of the same type and on the same terms and conditions as were applicable
to the corresponding Ortho Equity Right, and (ii)&nbsp;a right to receive payment, in cash, equal to the Cash Portion in respect of the Ortho Shares that are subject to the Ortho Equity Right, payable through the payroll system or payroll provider
of Topco or its affiliate and subject to applicable withholding, as and when the corresponding Ortho Equity Right vests. The number of Topco Shares covered by each such Topco Equity Right will be equal to the product (rounded to the nearest whole
number) of (x)&nbsp;the number of Ortho Shares subject to the Ortho Equity Right immediately prior to the Ortho Effective Time and (y)&nbsp;the Ortho Exchange Ratio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the service of a holder of Ortho restricted stock or restricted stock units is terminated without cause in connection with or following the
closing of the Combinations, such holder&#146;s restricted stock or restricted stock units will become fully vested. In addition, a portion of the restricted stock held by Mr. Smith will vest upon the closing and a portion will vest over an expected
time period of 12 months based on continued service following the closing (with acceleration in the event of being removed from the board) pursuant to terms to be agreed between Mr. Smith and Ortho&#146;s compensation committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">304 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the number of Ortho Stock Options and Ortho Equity Rights that were awarded
to and held by Ortho executive officers and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as of January&nbsp;20, 2022 under an Ortho Stock Plan and the value of these awards in the Combinations, assuming a per share value of
Ortho&#146;s ordinary shares equal to $20.79, which is the average of the closing price of Ortho&#146;s ordinary shares over the first five trading days following the announcement of the Combinations. The foregoing equity awards will be treated in
the same manner as outstanding equity awards generally and described above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ortho<BR>Options<BR>(Vested)<BR>(#)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ortho&nbsp;Options<BR>(Vested) ($)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ortho<BR>Options<BR>(Unvested)<BR>(#)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ortho Options<BR>(Unvested) ($)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ortho<BR>Restricted<BR>Stock and<BR>Restricted<BR>Stock&nbsp;Units<BR>(Unvested)<BR>(#)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ortho<BR>Restricted<BR>Stock and<BR>Restricted<BR>Stock&nbsp;Units<BR>(Unvested)<BR>($)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">590,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,859,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,380,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,365,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,453,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph Busky</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">546,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,732,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Iskra</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,793,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,857,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,118,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chockalingam Palaniappan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">437,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,185,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Schlesinger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,086,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,748,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ortho&nbsp;Options<BR>(Vested) (#)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ortho&nbsp;Options<BR>(Vested) ($)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ortho&nbsp;Options<BR>(Unvested)<BR>(#)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ortho&nbsp;Options<BR>(Unvested)<BR>($)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ortho<BR>Restricted<BR>Stock and<BR>Restricted<BR>Stock&nbsp;Units<BR>(Unvested)<BR>(#)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ortho<BR>Restricted<BR>Stock and<BR>Restricted<BR>Stock&nbsp;Units<BR>(Unvested)<BR>($)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen Bechtel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evelyn Dilsaver</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allan Holt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Yates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,876,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Mac Mahon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald Labrum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Perez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carl Hull</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen H. Wise</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert R. Schmidt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_193"></A>Executive Severance Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Christopher Smith </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho previously entered into an
employment agreement with Mr.&nbsp;Smith, pursuant to which he is eligible for severance payments and benefits in the event of a qualifying termination of employment. Specifically, if Mr.&nbsp;Smith&#146;s employment is terminated without
&#147;cause&#148; or he resigns for &#147;good reason,&#148; subject to his execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a release in favor of Ortho, he is entitled to receive (i)&nbsp;an amount equal to one times the sum
of his then-current base salary and target annual bonus, payable in installments for 12 months following Mr.&nbsp;Smith&#146;s termination of employment, and (ii)&nbsp;payments lasting for up to 12 months equal to the amounts Mr.&nbsp;Smith would be
required to pay for continued coverage under Ortho&#146;s group medical and dental benefit plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Mr.&nbsp;Smith&#146;s employment
agreement: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;cause&#148; means, subject to notice and cure rights, Mr.&nbsp;Smith&#146;s (i)&nbsp;failure to
(A)&nbsp;substantially perform his duties with Ortho (other than any such failure resulting from disability) or (B)&nbsp;comply with, in a material respect, any of Ortho&#146;s policies, in each case that results in material damage to Ortho&#146;s
property, business or reputation, (ii)&nbsp;repeated failure in a material respect to carry out or comply with any lawful and reasonable directive of the Ortho board of directors within the scope of his duties, (iii)&nbsp;breach of a material
provision of his employment agreement that results in material damage to Ortho&#146;s property, business or reputation, (iv)&nbsp;conviction, plea of no contest, plea of nolo contendere or imposition of unadjudicated probation for any felony or
crime involving moral turpitude, (v)&nbsp;unlawful use (including being under the influence) or possession of illegal drugs on Ortho&#146;s (or any of its affiliate&#146;s) premises or while performing his duties and responsibilities under the
employment agreement or&nbsp;(vi) commission of an act of fraud, embezzlement, misappropriation, or breach of fiduciary duty against Ortho or any of its affiliates; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">305 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;good reason&#148; means, subject to notice and cure rights, Mr.&nbsp;Smith&#146;s resignation following any
of the following without his prior written approval: (i)&nbsp;a decrease in his annual base salary or target bonus, other than a reduction in annual base salary of less than 10% that is implemented in connection with a contemporaneous and
proportional reduction in annual base salaries affecting all other senior executives of Ortho, (ii)&nbsp;a material decrease in his authority or areas of responsibility as are commensurate with his title or position (other than in connection with a
corporate transaction where he continues to hold his position with respect to Ortho&#146;s business, substantially as such business exists prior to the date of consummation of such corporate transaction, but does not hold such position with respect
to the successor corporation) or (iii)&nbsp;Ortho&#146;s material breach of any material agreement with him. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Michael Iskra
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a severance letter agreement with Ortho, if Mr.&nbsp;Iskra&#146;s employment is terminated without cause, he will be entitled to
severance payments equal to six months of his annual base salary, 50% of his target bonus and subsidized health benefit coverage during the <FONT STYLE="white-space:nowrap">six-month</FONT> period following his termination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Joseph Busky </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a severance letter
agreement with Ortho, if Mr.&nbsp;Busky&#146;s employment is terminated without cause, he will be entitled to severance payments equal to six months of his annual base salary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Chockalingam Palaniappan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a severance
letter agreement with Ortho, if Dr.&nbsp;Palaniappan&#146;s employment is terminated without cause, he will be entitled to severance payments equal to 12 months of his annual base salary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Michael A. Schlesinger </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho entered into an
employment agreement with Mr.&nbsp;Schlesinger, pursuant to which he is eligible for severance payments and benefits in the event of a qualifying termination of employment. If Ortho terminates Mr.&nbsp;Schlesinger&#146;s employment without
&#147;cause&#148; or he resigns for &#147;good reason,&#148; subject to his execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a release in favor of Ortho, he is entitled to receive (i)&nbsp;an amount equal to 1.25 times the sum
of his then-current annual base salary and target annual bonus, payable in installments for 15 months following Mr.&nbsp;Schlesinger&#146;s termination of employment, and (ii)&nbsp;payments lasting for up to 15 months equal to the amounts
Mr.&nbsp;Schlesinger would be required to pay for continued coverage under Ortho&#146;s group medical and dental benefit plans. For purposes of Mr.&nbsp;Schlesinger&#146;s employment agreement, &#147;cause&#148; and &#147;good reason&#148; have
substantially the same meaning as in Mr.&nbsp;Smith&#146;s employment agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Severance Pay Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive officers are eligible for severance benefits under the Ortho Clinical Diagnostics Severance Pay Plan (the &#147;Severance Plan&#148;). Under the
Severance Plan, benefits are payable to employees upon a position elimination, reduction in force or such other reasons the Severance Plan administrator deems appropriate, subject to an employee&#146;s execution and
<FONT STYLE="white-space:nowrap">non-revocation</FONT> of a release agreement. Severance benefits for executives who are eligible for the Ortho Executive Bonus Program include a minimum of 12 weeks&#146; base salary pay plus two weeks&#146; base
salary pay for each completed year of service, up to a maximum of 26 weeks&#146; base salary pay, paid in substantially equal installments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_194">
</A>Continuing Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCA provides that from the Ortho Effective Time until 12 months following the Ortho Effective Time, each Ortho Continuing
Employee will receive base salary or wages, severance benefit protections and pension and welfare benefits that are no less favorable, in the aggregate, than those provided to such Ortho Continuing Employees immediately prior to the Ortho Effective
Time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_195"></A>Retention Bonuses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Combinations, Ortho approved the grant of retention bonuses to certain employees and executive officers (the &#147;Retention
Bonuses&#148;). The Retention Bonuses, which will be administered by the compensation committee of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">306 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Ortho board of directors, are being put in place to retain key talent during the period between the signing of the BCA and the consummation of the Combinations and the <FONT
STYLE="white-space:nowrap">12-month</FONT> period following the consummation of the Combinations. Forty percent of the Retention Bonus is expected to be paid out to recipients at the consummation of the Combinations, with the remaining 60% payable
on the first anniversary thereof, subject to earlier payment upon termination if the employee or executive officer is terminated without cause. Retention Bonuses in the following amounts for the executive officers are: Mr.&nbsp;Busky: $384,375;
Mr.&nbsp;Iskra: $375,000; Dr.&nbsp;Palianiappan: $461,250; and Mr.&nbsp;Schlesinger: $421,563. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_196"></A>Transaction Bonuses
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Combinations, Ortho approved the grant of transaction bonuses to certain employees and executive officers (the
&#147;Transaction Bonuses&#148;). The Transaction Bonuses, which will be administered by the compensation committee of the Ortho board of directors, are being put in place to reward key talent and will be payable upon the consummation of the
Combinations. Transaction Bonuses in the following amounts for the executive officers are: Mr.&nbsp;Smith: $937,500; Mr.&nbsp;Busky: $384,375; Mr.&nbsp;Iskra: $375,000; and Mr.&nbsp;Schlesinger: $421,563. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_197"></A>Golden Parachute Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section sets forth the information required by Item&nbsp;402(t) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> regarding the compensation of
each of Ortho&#146;s five current named executive officers that is based on or otherwise relates to the Combinations and that will or may become payable to the named executive officers at the Ortho Effective Time or on a qualifying termination of
employment on or following the Ortho Effective Time. This compensation is referred to as &#147;golden parachute&#148; compensation by the applicable SEC disclosure rules, and in this section we use such term to describe the Ortho Scheme-related
compensation payable to Ortho&#146;s named executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts in the following table are estimates based on multiple assumptions that may
not actually occur, including assumptions described in this joint proxy statement/prospectus, and do not include amounts that were vested as of the assumed closing date of the Combinations as described below. In addition, certain amounts will vary
depending on the actual date of closing of the Combinations, which is presently expected to be in the first half of 2022. As a result, the actual amounts, if any, to be received by a named executive officer may differ in material respects from the
amounts set forth below. In the footnotes to the table below, we refer to payments that are conditioned on the occurrence of both the Combinations and the named executive officer&#146;s qualifying termination of employment as being payable on a
&#147;double trigger&#148; basis and payment or benefits that are conditioned only upon the occurrence of the Combinations as being payable on a &#147;single trigger&#148; basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The potential payments in the table below are based on the following assumptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the closing date of the Combinations is April&nbsp;30, 2022, which is the estimated date of the completion of the
Combinations solely for purposes of this golden parachute compensation disclosure; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the per share value of Ortho&#146;s ordinary shares is $20.79, which is the average of the closing price of
Ortho&#146;s ordinary shares over the first five trading days following the announcement of the Combinations. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Cash&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Equity ($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Perquisites/<br>Benefits&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Other<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total($)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Christopher Smith</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,990,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">937,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,456,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Joseph Busky</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,732,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">768,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,757,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Michael Iskra</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,976,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,726,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, Strategy&nbsp;&amp; Commercial Excellence</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Chockalingam Palaniappan, Ph.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,748,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,687,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Innovation Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Michael A. Schlesinger</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,053,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,748,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">843,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,668,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, General Counsel&nbsp;&amp; Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash severance is payable only if the named executive officer is terminated without cause or, for Messrs. Smith
or Schlesinger, resigns for good reason. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">307 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column represent the value of unvested equity awards held by each named executive officer.
For executives other than Mr. Smith, the amounts would vest on a double trigger basis. For Mr. Smith, the amount shown includes the value of unvested stock options ($11,365,194), which will vest on a single trigger basis and unvested restricted
stock ($6,625,357), of which (i) 39,385 shares would vest on a single trigger basis pursuant to the existing terms of Mr. Smith&#146;s restricted stock agreements and (ii) the remaining shares will vest over an expected time period of 12 months
based on continued service following the closing (with acceleration in the event of being removed from the board) pursuant to terms to be agreed between Mr. Smith and Ortho&#146;s compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For Messrs. Smith, Iskra and Schlesinger, represents the value of continued health benefits pursuant to their
Severance Agreements, which would be payable only if such named executive officers are terminated without cause or, for Messrs. Smith or Schlesinger, resign for good reason. For Messrs. Busky and Palaniappan, represents the value of continued health
benefits payable to them pursuant to the Severance Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes the value of retention bonuses and transaction bonuses approved by Ortho. Retention bonuses are
payable 40% upon the closing of the Combinations and 60% upon the first anniversary, subject to continued employment through such dates; provided that the retention bonuses will become payable upon a termination without cause by Ortho. Messrs.
Busky, Iskra, Palaniappan and Schlesinger are eligible for retention bonuses equal to $384,375, $375,000, $461,250, and $421,563, respectively. Transaction bonuses are payable upon the closing of the Combinations, subject to continued employment
through such dates; provided that the transaction bonuses will become payable upon a termination without cause by Ortho. Messrs. Smith, Busky, Iskra and Schlesinger are eligible for transaction bonuses equal to $937,500, $384,375, $375,000 and
$421,563. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_198"></A>Topco Positions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The post-closing Topco board of directors will consist of 12 members, comprised of: (i)&nbsp;four members designated by Ortho, two of whom will qualify as an
&#147;independent director&#148; under applicable rules of Nasdaq, and (ii)&nbsp;eight members designated by Quidel, four of whom will qualify as an &#147;independent director&#148; under applicable rules of Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Douglas Bryant, the current President and Chief Executive Officer of Quidel, will be the Chief Executive Officer of Topco and Chair of the Topco board of
directors. Additionally, Robert Bujarski, the current Chief Operating Officer of Quidel, will serve as the President and Chief Operating Officer of Topco. The chairperson of each of the Audit Committee, the Nominating and Governance Committee and
the Compensation Committee shall be selected from among the eight directors designated by Quidel and each of the committees of the Topco board of directors will consist of one director designated by Ortho (who is reasonably acceptable to the Topco
board of directors) and not less than two additional directors designated by Quidel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joseph Busky, the current Chief Financial Officer of Ortho, will
serve as the Chief Financial Officer of Topco. Additionally, Michael Iskra, the current Executive Vice President of Commercial Excellence and Strategy at Ortho, will serve as the Chief Commercial Officer of Topco. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;15, 2022, Mr. Smith entered into a Special Advisor Agreement with Topco, pursuant to which, subject to the consummation of the Combinations,
Mr. Smith will (i) transition from the role of Chief Executive Officer of Ortho and (ii)&nbsp;be engaged as a Special Advisor to Topco for an initial term of one year, for which services he will receive an advisory fee of $52,083 per month.
Mr.&nbsp;Smith will receive severance payments in accordance with the terms of his existing employment agreement with Ortho and will vest 100% in his outstanding stock options, effective upon the consummation of the Combinations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">308 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_199"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a discussion of the material U.S. federal income tax considerations to U.S. Holders (as defined below) of Ortho Shares of the Ortho Scheme
and to U.S. Holders and <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Quidel Shares of the Quidel Merger, and the material U.S. federal income tax considerations to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of owning and
disposing of Topco Shares received in the Combinations. The discussion is based on and subject to the Code, the U.S. Treasury Regulations promulgated thereunder, administrative guidance and court decisions, in each case, as of the date hereof, all
of which are subject to change, possibly with retroactive effect, and to differing interpretations. The discussion assumes that Ortho shareholders hold their Ortho Shares, Quidel stockholders hold their Quidel Shares, and both Ortho shareholders and
Quidel stockholders will hold their Topco Shares, as &#147;capital assets&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). The discussion does not constitute tax advice and does not address all
aspects of U.S. federal income taxation that may be relevant to particular holders of Ortho Shares, Quidel Shares, or Topco Shares in light of their personal circumstances, including any tax consequences arising under the Medicare contribution tax
on net investment income, or to any holders subject to special treatment under the Code, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, thrifts, mutual funds and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts and regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities who elect to apply a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers or brokers in securities or foreign currency; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">individual retirement and other deferred accounts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. Holders whose functional currency is not the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;passive foreign investment companies&#148; or &#147;controlled foreign corporations,&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. Holders who own, or are deemed to own, 5% or more of Topco&#146;s or Ortho&#146;s voting stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold their shares as part of a straddle, hedging, conversion, constructive sale or other risk
reduction transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who purchase or sell their shares as part of a wash sale for tax purposes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other entities or arrangements classified as partnerships for U.S. federal income tax purposes,
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other pass-through entities (and investors therein); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who received their shares through the exercise of employee stock options or otherwise as compensation or
through a tax qualified retirement plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No rulings will be sought by Topco, Ortho or Quidel from the IRS with respect to the
Combinations and there can be no assurance that the IRS or a court will not take a contrary position regarding the tax consequences described herein. The discussion does not address any <FONT STYLE="white-space:nowrap">non-income</FONT> tax
considerations or any <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> state or local tax considerations. For purposes of this discussion, a &#147;U.S. Holder&#148; means a beneficial owner of Ortho Shares, Quidel Shares or, after the completion of
the Combinations, Topco Shares that for U.S. federal income tax purposes is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or
organized in the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">309 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if (i)&nbsp;a court within the United States is able to exercise primary supervision over the
administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (ii)&nbsp;the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S.
person for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; means a beneficial
owner of Ortho Shares, Quidel Shares or, after the completion of the Combinations, Topco Shares who is an individual, corporation, estate or trust, in each case, that is not a U.S. Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a partnership, including for this purpose any arrangement or entity that is treated as a partnership for U.S. federal income tax purposes, holds Ortho
Shares, Quidel Shares or, after the completion of the Combinations, Topco Shares, the tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partnership. A holder that is a
partnership for U.S. federal income tax purposes and the partners in such partnership are urged to consult their tax advisors about the U.S. federal income tax consequences of the Combinations and the ownership and disposition of the Topco Shares.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HOLDERS OF ORTHO SHARES AND QUIDEL SHARES OR, AFTER THE COMPLETION OF THE COMBINATIONS, TOPCO SHARES SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT
TO THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE COMBINATIONS AND THE OWNERSHIP AND DISPOSITION OF TOPCO SHARES TO THEM IN LIGHT OF THEIR PARTICULAR CIRCUMSTANCES, AS WELL AS ANY TAX CONSEQUENCES OF SUCH MATTERS ARISING UNDER THE U.S. FEDERAL TAX
LAWS OTHER THAN THOSE PERTAINING TO INCOME TAX, INCLUDING ESTATE OR GIFT TAX LAWS, OR UNDER ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX LAWS OR UNDER ANY APPLICABLE INCOME TAX TREATY. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Material U.S. Federal Income Tax Considerations to U.S. Holders of Ortho Shares of the Ortho Scheme </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion regarding U.S. federal income tax considerations relating to the Ortho Scheme assumes that the Combinations will be consummated as
described in the BCA and this joint proxy statement/prospectus. The opinions described below will be based on customary assumptions and representations from Ortho and Quidel, as well as certain covenants and undertakings by each of Ortho, Quidel and
other parties to the BCA. If any of the assumptions, representations, covenants or undertakings is incorrect, incomplete or inaccurate or is violated, the validity of the opinions described below may be affected and the tax consequences of the Ortho
Scheme could differ from those described in this joint proxy statement/prospectus. An opinion of counsel represents counsel&#146;s best legal judgment but is not binding on the IRS or any court, so there can be no certainty that the IRS will not
challenge the conclusions reflected in the opinions or that a court would not sustain such a challenge. Neither Topco nor Ortho (or any of their affiliates) intends to request a ruling from the IRS regarding the U.S. federal income tax treatment of
the Ortho Scheme. Consequently, no assurance can be given that the IRS will not challenge the tax treatment described below, or that a court would not sustain such challenge. The following discussion assumes that Ortho was not a passive foreign
investment company, as described below under &#147;Passive Foreign Investment Company Status.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Receipt of Topco Shares and Cash in Exchange
for Ortho Shares </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the assumptions, qualifications and limitations described herein and in the Latham &amp; Watkins LLP opinion included as
Exhibit 8.1 hereto, and the representations provided to Latham &amp; Watkins LLP by officers of Ortho and Quidel, it is the opinion of Latham &amp; Watkins LLP as counsel to Ortho that, for United States federal income tax purposes, the exchange of
Ortho Shares for Topco Shares and cash pursuant to the Ortho Scheme, taken together with the Quidel Merger, will qualify as a transaction described in Section&nbsp;351 of the Code and that, as a result, gain (but not loss) will be recognized on the
exchange of Ortho Shares for a combination of cash and Topco Shares pursuant to the Ortho Scheme in an amount equal to the lesser of: (a)&nbsp;the excess of (i)&nbsp;the sum of the fair market value of the Topco Shares and the amount of cash
received by such U.S. Holder over (ii)&nbsp;such U.S. Holder&#146;s tax basis in its Ortho Shares, and (b)&nbsp;the amount of cash received by such U.S. Holder pursuant to the Ortho Scheme.&nbsp;The aggregate adjusted tax basis of the Topco Shares
received pursuant to the Ortho Scheme will be equal to the aggregate adjusted tax basis of the Ortho Shares surrendered by the U.S. Holder, reduced by the amount of cash such U.S. Holder receives and increased by the amount of gain such U.S. Holder
of Ortho Shares recognizes. The holding period of Topco Shares received pursuant to the Ortho Scheme will include the holding period of the Ortho Shares exchanged for such Topco Shares. Lastly, if a U.S. Holder acquired different blocks of Ortho
Shares at different times and different prices, any gain will be determined separately with respect to each block of Ortho Shares, and the cash received will be allocated pro rata to each such block of shares. Any gain recognized by a U.S.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">310 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holder in connection with such receipt of cash in exchange for Topco Shares will generally constitute capital gain, and any such capital gain will constitute long-term capital gain if the U.S.
Holder&#146;s holding period is greater than one year as of the date of the Ortho Scheme. Any gain recognized by a U.S. Holder will generally be treated as U.S. source gain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The discussion above assumes that Section&nbsp;304 of the Code is not applicable to the Ortho Scheme because Ortho shareholders who, in the aggregate, owned
stock possessing at least 50% of the total combined voting power of all shares of Ortho, will not also own at least 50% of the total combined voting power of Topco following the Combinations. U.S. Holders of Ortho Shares should consult their own tax
advisors regarding the possibility and consequences of the application of Section&nbsp;304 of the Code to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Holders should consult their own tax
advisors about reporting requirements and information statements that could be applicable to the Ortho Scheme and any potential penalties associated with a failure to satisfy such requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Receipt of Cash in lieu of Fractional Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although
not entirely free from doubt, the receipt of cash in lieu of fractional Topco Shares should be treated as if a fractional share had been issued by Topco to the affected U.S. Holder as part of the Ortho Scheme, and then sold by such U.S. Holder for
cash in a taxable exchange. A U.S. Holder will generally recognize gain or loss equal to the difference between the amount of the cash received instead of the fractional shares and the U.S. Holder&#146;s adjusted tax basis in such fractional shares.
Any gain or loss recognized by a U.S. Holder in connection with receipt of cash in lieu of fractional Topco Shares will generally constitute capital gain or loss, and any such capital gain or loss will constitute long-term capital gain or loss if
the U.S. Holder&#146;s holding period is greater than one year as of the date of the Ortho Scheme. The deductibility of capital losses is subject to limits. Any gain or loss recognized by a U.S. Holder will generally be treated as U.S. source gain
or loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Passive Foreign Investment Company Status </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho believes that it was not a passive foreign investment company (generally, a foreign corporation that has a specified percentage of &#147;passive&#148;
income or assets, after the application of certain &#147;look-through&#148; rules) for U.S. federal income tax purposes for its 2021 taxable year or any prior taxable year and does not expect to be a passive foreign investment company for its 2022
taxable year. If Ortho were a passive foreign investment company for any taxable year during which a U.S. Holder held Ortho Shares, certain adverse tax consequences could apply to such U.S. Holder as a result of the Ortho Scheme. A U.S. Holder
should consult its tax advisor with respect to the U.S. federal income tax consequences of the Ortho Scheme if such U.S. Holder believes that Ortho was a passive foreign investment company for any taxable year during which it held Ortho Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Material U.S. Federal Income Tax Considerations to U.S. Holders of Quidel Shares of the Quidel Merger </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion regarding U.S. federal income tax considerations relating to the Quidel Merger assumes that the Combinations will be consummated as
described in the BCA and this joint proxy statement/prospectus. The opinions described below will be based on customary assumptions and representations from Ortho and Quidel, as well as certain covenants and undertakings by each of Ortho, Quidel,
and other parties to the BCA thereto. If any of the assumptions, representations, covenants or undertakings is incorrect, incomplete or inaccurate or is violated, the validity of the opinions described below may be affected and the tax consequences
of the Quidel Merger could differ from those described in this joint proxy statement/prospectus. An opinion of counsel represents counsel&#146;s best legal judgment but is not binding on the IRS or any court, so there can be no certainty that the
IRS will not challenge the conclusions reflected in the opinions or that a court would not sustain such a challenge. Neither Topco nor Quidel (or any of their affiliates) intends to request a ruling from the IRS regarding the U.S. federal income tax
treatment of the Quidel Merger. Consequently, no assurance can be given that the IRS will not challenge the tax treatment described below, or that a court would not sustain such challenge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the assumptions, qualifications and limitations described herein and in the Gibson, Dunn &amp; Crutcher LLP opinion included as Exhibit 8.2 hereto,
and representations provided to Gibson, Dunn &amp; Crutcher LLP by officers of Ortho and Quidel, it is the opinion of Gibson, Dunn &amp; Crutcher as counsel to Quidel that, for United States federal income tax purposes, the Quidel Merger, taken
together with the Ortho Scheme, will qualify as a transaction described in Section 351(a) of the Code and no gain or loss will be recognized on the exchange of Quidel Shares solely for Topco Shares in the Quidel Merger. The aggregate adjusted tax
basis of the Topco Shares received pursuant to the Quidel Merger will be equal to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">311 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aggregate adjusted tax basis of the Quidel Shares surrendered by the U.S. Holder. The holding period of Topco Shares received pursuant to the Quidel Merger will include the holding period of the
Quidel Shares exchanged for such Topco Shares. Lastly, if a U.S. Holder acquired different blocks of Quidel Shares at different times and different prices, any gain or loss will be determined separately with respect to each block of Quidel Shares.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Holders should consult their own tax advisors about reporting requirements and information statements that could be applicable to the Quidel
Merger and any potential penalties associated with a failure to satisfy such requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Material U.S. Federal Income Tax Considerations to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Owning and Disposing of Topco Shares Received in the Transactions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distributions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Topco makes distributions on Topco Shares, such distributions of cash or property on its shares will constitute dividends for U.S. federal income tax
purposes to the extent paid from Topco&#146;s current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of
capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its Topco Shares, but not below zero. Any excess amount will be treated as capital gain and will be treated as
described below in the section relating to the sale or disposition of Topco Shares. Because Topco may not know the extent to which any distribution is a dividend for U.S. federal income tax purposes at the time it is made, for purposes of the
withholding rules discussed below Topco or the applicable withholding agent may treat the entire distribution as a dividend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion
below on backup withholding and foreign accounts, dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of Topco Shares that are not effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s
conduct of a trade or business within the United States will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders will be entitled to a reduction in or an exemption from withholding on dividends as a result of
either (a)&nbsp;an applicable income tax treaty or (b)&nbsp;the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holding Topco Shares in connection with the conduct of a trade or business within the United States and dividends being
effectively connected with that trade or business. To claim such a reduction in or exemption from withholding, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must provide the applicable withholding agent with a properly executed
(a)&nbsp;IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable documentation) claiming an exemption from or reduction of the
withholding tax under the benefit of an income tax treaty between the United States and the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established, or (b)&nbsp;IRS Form
<FONT STYLE="white-space:nowrap">W-8ECI</FONT> stating that the dividends are not subject to withholding tax because they are effectively connected with the conduct by the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of a trade or
business within the United States, as may be applicable. These certifications must be provided to the applicable withholding agent prior to the payment of dividends and must be updated periodically. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
holders that do not timely provide the applicable withholding agent with the required certification, but that qualify for a reduced rate under an applicable income tax treaty, may obtain a refund of any excess amounts withheld by timely filing an
appropriate claim for refund with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with
the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a
permanent establishment in the United States to which such dividends are attributable), then, although exempt from U.S. federal withholding tax (provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder provides the appropriate
certification, as described above), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will generally be subject to U.S. federal income tax on such dividends on a net income basis at the regular graduated U.S. federal income tax rates. In
addition, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on its effectively connected earnings
and profits for the taxable year that are attributable to such dividends, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding their entitlement to benefits under any
applicable income tax treaty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sale or Other Disposition of Topco Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussions below on backup withholding and foreign accounts, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to
U.S. federal income tax on any gain realized upon the sale or other disposition of Topco Shares unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct
of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is
attributable); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">312 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the
United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Topco Shares constitute U.S. real property interests, or &#147;USRPIs,&#148; by reason of Topco&#146;s status as
a U.S. real property holding corporation, or &#147;USRPHC,&#148; for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gain described in the first
bullet point above will generally be subject to U.S. federal income tax on a net income basis at the regular graduated U.S. federal income tax rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a foreign corporation also may be
subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in the second bullet point above will be subject to U.S. federal income tax at a rate of
30% (or such lower rate specified by an applicable income tax treaty) on any gain derived from the disposition, which may be offset by certain U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the
individual is not considered a resident of the United States) provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the third bullet point above, Topco does not anticipate becoming a USRPHC. Because the determination of whether Topco is a USRPHC depends on
the fair market value of its USRPIs relative to the fair market value of its other business assets and its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests, however, there can be no assurance Topco will not become a USRPHC in
the future. Even if Topco were to become a USRPHC, gain arising from the sale or other taxable disposition by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of Topco Shares will not be subject to U.S. federal income tax if Topco Shares
are &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established securities market, and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of Topco Shares
throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders
are encouraged to consult their tax advisors regarding the possible consequences to them if Topco were to become a USRPHC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding potentially applicable income tax treaties that may
provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Information Reporting and Backup Withholding </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion below on foreign accounts, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to backup withholding with
respect to distributions on Topco Shares made to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, provided the applicable withholding agent does not have actual knowledge or reason to know such holder is a U.S. person and the holder
certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by providing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT
STYLE="white-space:nowrap">W-8ECI,</FONT> or other applicable certification. However, information returns generally will be filed with the IRS in connection with any distributions (including deemed distributions) made on Topco Shares to the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. Copies of these information returns may also be made available under the provisions of a specific treaty or agreement to the tax authorities of
the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information reporting and backup withholding
may apply to the proceeds of a sale or other taxable disposition of Topco Shares within the United States, and information reporting may (although backup withholding generally will not) apply to the proceeds of a sale or other taxable disposition of
Topco Shares outside the United States conducted through certain U.S.-related financial intermediaries, in each case, unless the beneficial owner certifies under penalty of perjury that it is a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
on IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> or other applicable form (and the payor does not have actual knowledge or reason to know that the
beneficial owner is a U.S. person) or such owner otherwise establishes an exemption. Proceeds of a disposition of Topco Shares conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker generally will not be subject to backup withholding or information reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding
is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the
required information or claim is timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Additional Withholding Tax on Payments Made to Foreign Accounts </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Withholding taxes may be imposed under the legislation and administrative guidance commonly known as &#147;FATCA,&#148; on certain types of payments made to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">313 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
withholding tax may be imposed on dividends (including deemed dividends) paid on Topco Shares unless (a)&nbsp;the foreign financial institution undertakes certain diligence and reporting
obligations, (b)&nbsp;the <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding
each substantial United States owner, or (c)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial
institution and is subject to the diligence and reporting requirements in (a)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain
&#147;specified United States persons&#148; or &#147;United States-owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to <FONT
STYLE="white-space:nowrap">non-compliant</FONT> foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA
may be subject to different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to
payments of dividends (including deemed dividends) paid on Topco Shares. Because Topco may not know the extent to which a distribution is a dividend for U.S. federal income tax purposes at the time it is made, for purposes of these withholding
rules, Topco or the applicable withholding agent may treat the entire distribution as a dividend. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding the potential application of these withholding
provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">314 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_200"></A>MATERIAL UK TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following paragraphs are intended as a general guide to current UK tax law and HMRC published practice applying as of the date of this joint proxy
statement/prospectus (all of which are subject to change at any time, possibly with retrospective effect) for holders of Ortho Shares who are transferring their Ortho Shares as part of the Combinations. They do not constitute legal or tax advice and
do not purport to be a complete analysis of all UK tax considerations relating to the Combinations. They relate only to persons who are absolute beneficial owners of Ortho Shares who are resident for tax purposes in (and only in) the United Kingdom
(except to the extent that the position of <FONT STYLE="white-space:nowrap">non-UK</FONT> resident persons is expressly referred to). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These paragraphs
may not relate to certain classes of holders of Ortho Shares, such as (but not limited to): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who are connected with Ortho or Topco; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">charities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collective investment schemes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pension schemes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers or dealers in securities or persons who hold Ortho Shares or Topco Shares otherwise than as an
investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who have (or are deemed to have) acquired their Ortho Shares or Topco Shares by virtue of an office or
employment or who are or have been officers or employees of Ortho, Topco or any of their affiliates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">individuals who are subject to UK taxation on a remittance basis. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These paragraphs do not describe all of the circumstances in which holders of Ortho Shares may benefit from an exemption or relief from UK taxation. It is
recommended that all holders of Ortho Shares obtain their own tax advice. In particular, <FONT STYLE="white-space:nowrap">non-UK</FONT> resident or domiciled persons are advised to consider the potential impact of any relevant double tax agreements.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material UK Tax Considerations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Chargeable
Gains </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the comments below in relation to Section&nbsp;137 of the TCGA, the receipt of Topco Shares by an Ortho shareholder in respect
of, and in proportion to, such shareholder&#146;s Ortho Shares pursuant to the Combinations may potentially be treated as a scheme of reconstruction for the purposes of UK capital gains tax or corporation tax on chargeable gain (collectively,
&#147;CGT&#148;). On that basis, an Ortho shareholder would not be treated as making a disposal of their Ortho Shares and, therefore, no liability to CGT would arise in respect of the receipt of Topco Shares by an Ortho shareholder pursuant to the
Combinations. For the purposes of CGT, the Topco Shares received by an Ortho shareholder would be treated as the same asset, acquired at the same time and for the same amount, as the Ortho Shares in respect of which they are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the &#147;rollover&#148; treatment described above is not available (and no assurance is or can be given that such treatment will be available), an Ortho
shareholder would be treated as having made a full disposal of their Ortho Shares and may, depending on such shareholder&#146;s personal circumstances, be liable to pay CGT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;137 of the TCGA, any Ortho shareholder who holds (when his, her or its relevant holding is aggregated with that of persons connected with
him, her or it) more than 5% of, or of any class of, shares in or debentures of Ortho will not in any event receive the possible &#147;rollover&#148; treatment described above if the relevant transaction has not been effected for bona fide
commercial reasons or if it forms part of a scheme or arrangement of which the main purpose, or one of the main purposes, is the avoidance of liability to CGT or UK corporation tax. It is possible to apply for statutory clearance from HMRC under
Section&nbsp;138 of the TCGA confirming that this anti-avoidance provision does not apply. No application for clearance has been made to HMRC under Section&nbsp;138 of the TCGA in respect of the receipt of Topco Shares pursuant to the Combinations.
For the avoidance of doubt, please note that any Ortho shareholder who holds (when their relevant holding is aggregated with that of persons connected with them) 5% or less of, or of any class of, shares in or debentures of Ortho would not have to
satisfy this anti-avoidance provision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>UK Stamp Duty and UK Stamp Duty Reserve Tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No liability to UK stamp duty or Stamp Duty Reserve Tax will arise to holders of Ortho Shares on the issue of the Topco Shares pursuant to the Combinations.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">315 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_201"></A>COMPARISON OF RIGHTS OF STOCKHOLDERS OF QUIDEL, ORTHO AND
TOPCO </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel and Topco are each organized under the laws of the State of Delaware. Ortho is organized under the laws of England and Wales. If the
Combinations are consummated, the Quidel stockholders and Ortho shareholders will become stockholders of Topco. After giving effect to the Combinations, the rights of stockholders of Topco and the relative powers of the Topco board of directors will
be governed by Delaware law and by the Topco Charter and Topco Bylaws. Each Topco Share will be issued pursuant to, and will carry with it the rights and obligations set forth in, the Topco Charter. This section summarizes material differences
between the rights of Quidel stockholders and Ortho shareholders before consummation of the Combinations and the rights of Topco stockholders after consummation of the Combinations. These differences in stockholder rights result from the differences
between the respective organizational documents of Quidel, Ortho and Topco and the applicable governing law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary does not include a
description of rights or obligations under the U.S. federal securities laws, English securities law or relevant Nasdaq listing requirements or standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary is not a complete statement of the rights of the Quidel stockholders, the Ortho shareholders or the Topco stockholders or a complete
description of the specific provisions referred to below. The identification of specific differences is not intended to indicate that other equally significant or more significant differences do not exist. This summary is qualified in its entirety
by reference to Quidel&#146;s, Ortho&#146;s and Topco&#146;s organizational documents, which you are urged to read carefully. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The form of the Topco
Charter, the Topco Bylaws, the Quidel Charter, the amendment to the Quidel Charter, the Quidel Bylaws and Ortho&#146;s articles of association are attached hereto as Exhibit&nbsp;3.1, Exhibit&nbsp;3.2, Exhibit&nbsp;3.3, Exhibit&nbsp;3.4,
Exhibit&nbsp;3.5 and Exhibit&nbsp;3.6, respectively, of this joint proxy statement/prospectus and are incorporated herein by reference. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Authorized Share Capital</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The authorized capital stock of Quidel consists of 97,500,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of
preferred stock, par value $0.001 per share.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The shares of common stock are
subdivided into two classes, consisting of 95,000,000 shares that are designated as &#147;common stock&#148; and 2,500,000 shares designated as &#147;Class&nbsp;A common stock.&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The authorized capital stock of Ortho consists of 1,000,000,000 ordinary shares, par value $0.00001 per share, and an unlimited number of deferred shares.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">It is currently estimated that, following the Combinations, the authorized capital stock of Topco will consist of [&#9679;] shares of common stock, par value $0.001 per share, and [&#9679;] shares of preferred stock, $0.001 per
share.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Structure of Board of
Directors</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel has a <FONT STYLE="white-space:nowrap">one-tier</FONT> board structure and currently has 10 directors.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Quidel&#146;s amended and restated bylaws (the &#147;Quidel Bylaws&#148;), the
business and affairs of Quidel are managed under the direction of the board of directors, and the board of directors may exercise all such powers as are not required to be exercised by the stockholders.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the DGCL, a corporation must have at least one director and the</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho has a staggered board structure and currently has 11 directors.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the UK Companies Act, a public limited company must have at least two directors
and the number of directors may be fixed by or in the manner provided in a company&#146;s articles of association.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under Ortho&#146;s articles of association, Ortho may not have fewer than two directors on the board of directors and not more than 15.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco has a <FONT STYLE="white-space:nowrap">one-tier</FONT> board structure and currently has one director. After the closing of the
Combinations, the Topco board of directors will have 12 directors.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Topco
Bylaws, the business and affairs of Topco are managed under the direction of the board of directors, and the board of directors may exercise all such powers as are not required to be exercised by the stockholders.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the DGCL, a corporation must have at least one director and the number of
directors shall be fixed by or in the</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">316 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">number of directors shall be fixed by or in the manner provided in the bylaws. The Quidel Bylaws provide that the board of directors shall
have no fewer than five nor more than 12 members, with the size at any time to be established exclusively by resolution of the board of directors.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Quidel Bylaws, each member of the Quidel board of directors shall hold office until the next annual meeting of stockholders, and until such
director&#146;s successor is elected and qualified or until such director&#146;s earlier death, resignation or removal.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The board of directors are also empowered by the Quidel Bylaws to appoint directors to fill a vacancy or as an addition to the existing board of directors in
accordance with the Quidel Bylaws.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">manner provided in the bylaws. The Topco Bylaws to be in effect as of the Ortho Effective Time provide that the board of directors shall have
no fewer than five nor more than 14 members, with the size at any time to be established exclusively by resolution of the board of directors.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Topco Bylaws, each member of the Topco board of directors shall hold office until the next annual meeting of stockholders, and until such
director&#146;s successor is elected and qualified or until such director&#146;s earlier death, resignation or removal.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The board of directors are also empowered by the Topco Bylaws to appoint directors to fill a vacancy or as an addition to the existing board of directors in
accordance with the Topco Bylaws.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Nomination and Appointment of
Directors</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pursuant to the Quidel Bylaws, each director shall be elected by a plurality of the voting power of Quidel&#146;s capital stock present in person or represented by proxy at a meeting of stockholders and entitled to vote on the
election of directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the provisions of Ortho&#146;s articles of association, Ortho may, by ordinary resolution of the shareholders or a decision of the
directors, elect any person to be a director, as an addition to the existing board, provided the total number of directors does not exceed the maximum number fixed, provided, further, that a vacancy caused by the departure of a Carlyle Stockholder
appointee may only be filled by the Carlyle Stockholder. However, any person that is not a director retiring from the existing board must be recommended by the board or the person must have confirmed in writing to Ortho their willingness to be
elected as a director.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s articles of association provide for a staggered
board consisting of three classes of directors. Directors of each class are chosen for three-year terms, with only one class of directors being elected at each annual meeting of shareholders. At the first annual meeting of shareholders, the terms of
the Class&nbsp;I directors (other than a Carlyle Stockholder appointee who is a Class&nbsp;I director) will expire and Class&nbsp;I directors (other than a Carlyle Stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the closing of the Combinations, directors will be identified and recommended by the Nominating and Governance Committee of the Topco
board of directors, although the Topco Bylaws also permit stockholders to nominate directors subject to certain conditions. Pursuant to the Topco Bylaws, directors shall be elected by a plurality of the voting power of Topco Shares present in person
or represented by proxy at a meeting of stockholders and entitled to vote on the election of directors.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, the Carlyle Stockholder has the right to appoint directors while it holds at least a certain percentage of Topco Shares, as described in the
section entitled &#147;Stockholders Agreement / Deed of Irrevocable Undertaking&#151; Stockholders Agreement&#148; of this joint proxy statement/prospectus.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">317 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">appointee who is a Class&nbsp;I director) will be elected for a full term of three years. At the second annual meeting of shareholders, the terms of the Class&nbsp;II directors (other than a Carlyle Stockholder appointee who is a
Class&nbsp;II director) will expire and Class&nbsp;II directors (other than a Carlyle Stockholder appointee who is a Class&nbsp;II director) will be elected for a full term of three years. At the third annual meeting of shareholders, the terms of
the Class&nbsp;III directors (other than a Carlyle Stockholder appointee who is a Class&nbsp;III director) will expire and Class&nbsp;III directors (other than a Carlyle Stockholder appointee who is a Class&nbsp;III director) will be elected for a
full term of three years. At each succeeding annual meeting, directors (other than Carlyle Stockholder appointees) will be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual general
meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Removal of Directors and
Vacancies</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the DGCL, vacancies may be filled as provided for in the bylaws of a corporation. The Quidel Bylaws provide that directors may be
removed, with or without cause, solely by the affirmative vote of the holders of a majority of the total voting power of all classes of outstanding stock of Quidel entitled to vote in the election of directors.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Quidel Bylaws provide that vacancies on the Quidel board of directors will be filled
by the affirmative vote of a majority of the directors then in office.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho may, by ordinary resolution, remove any director from office. No special notice need be given of any resolution to remove a director in
accordance with Ortho&#146;s articles of association and no director proposed to be removed in accordance with Ortho&#146;s articles of association has any special right to protest against their removal. Where a Carlyle Stockholder appointee is
removed the Carlyle Stockholder may nominate his replacement provided the conditions for such an appointment subsist. Certain other procedural requirements under the UK Companies Act must also be followed such as allowing the director to make
representations against his or her removal either at the meeting or in writing.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Subject to the provisions of Ortho&#146;s articles of association, Ortho may, by ordinary resolution of the shareholders or a decision of the directors, elect
any person to be a director to fill a casual vacancy. Under the UK Companies Act, where two or more persons are appointed as directors of a public limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the DGCL, vacancies may be filled as provided for in the bylaws of a corporation. The Topco Bylaws provide that directors may be
removed, with or without cause, solely by the affirmative vote of the holders of a majority of the total voting power of all classes of outstanding stock of Topco entitled to vote in the election of directors.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Topco Bylaws provide that vacancies on the Topco board of directors will be filled
by the affirmative vote of a majority of the directors then in office.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">318 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">company by resolution of the shareholders, resolutions appointing each director must be voted on individually.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Remuneration of Directors</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Quidel Bylaws authorize the board of directors to set director compensation, and generally do not give stockholders the right to approve director compensation.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho&#146;s articles of association state that each of the directors is entitled to remuneration as determined by the board for their
service as directors and other services undertaken for Ortho.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Each director may be
paid his expenses in connection with such director&#146;s attendance at meetings of the board or committees of the board or general meetings or separate meetings of the holders of class of shares or of debentures, or otherwise in connection with the
exercise of powers and the discharge of responsibilities in relation to Ortho.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Topco Bylaws authorize the board of directors to set director compensation, and generally do not give stockholders the right to approve director compensation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Annual Meetings of
Stockholders</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the DGCL, the annual meeting of stockholders shall be held at such place, on such date and at such time as provided in a
corporation&#146;s bylaws. The Quidel Bylaws provide that Quidel must hold an annual meeting of stockholders on such date and at such time as may be fixed by resolution of the Quidel board of directors.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Pursuant to the DGCL, any stockholder or director may petition the Court of Chancery to
order a meeting to elect directors if the annual meeting has not been held within 30 days of the date set for such meeting or 13 months following the date the previous annual meeting was held.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In accordance with the UK Companies Act, Ortho is required in each year to hold an annual general meeting in addition to any other general meetings in that year and to specify the meeting as such in the notice convening it. The
annual general meeting shall be convened whenever and wherever the board sees fit, subject to the requirements of the UK Companies Act, which state that a public limited company must hold an annual general meeting in each <FONT
STYLE="white-space:nowrap">six-month</FONT> period following the company&#146;s annual accounting reference date.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the DGCL, the annual meeting of stockholders shall be held at such place, on such date and at such time as provided in a
corporation&#146;s bylaws. The Topco Bylaws provide that Topco must hold an annual meeting of stockholders on such date and at such time as may be fixed by resolution of the Topco board of directors.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Pursuant to the DGCL, any stockholder or director may petition the Court of Chancery to
order a meeting to elect directors if the annual meeting has not been held within 30 days of the date set for such meeting or 13 months following the date the previous annual meeting was held.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>General / Special Meetings of
Stockholders</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the DGCL, special meetings of stockholders may be called by the board of directors or by such person or persons as may be authorized by a corporation&#146;s bylaws. Under the Quidel Bylaws, a special meeting of stockholders
may be called at any time by (i)&nbsp;the secretary of Quidel, following the secretary&#146;s receipt of</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the UK Companies Act, a general meeting of the shareholders of Ortho may be called by the directors.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ortho shareholders holding at least 5% of the
<FONT STYLE="white-space:nowrap">paid-up</FONT> capital of Ortho carrying voting rights at general meetings (excluding any <FONT STYLE="white-space:nowrap">paid-up</FONT> capital held as treasury shares) can require the directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the DGCL, special meetings of stockholders may be called by the board of directors or by such person or persons as may be authorized by a corporation&#146;s bylaws. Under the Topco Bylaws, a special meeting of stockholders may
be called at any time by (i)&nbsp;the secretary of Topco, following the secretary&#146;s receipt of one or more written demands to call a</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">319 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">one or more written demands to call a meeting from stockholders of record who hold no less than 50% of the voting power of Quidel&#146;s issued and outstanding capital stock, (ii)&nbsp;the Quidel board of directors, (iii)&nbsp;the
Chairman of the Quidel board of directors or (iv)&nbsp;the president of Quidel. The business to be conducted at the special meeting shall be limited to the purpose or purposes stated in the notice of such meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">to call a general meeting and, if the directors fail to do so within a certain period, may themselves convene a general meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">meeting from stockholders of record who hold no less than 50% of the voting power of Topco&#146;s issued and outstanding capital stock, (ii)&nbsp;the Topco board of directors, (iii)&nbsp;the Chair of the Topco board of directors or
(iv)&nbsp;the president of the corporation. The business to be conducted at the special meeting shall be limited to the purpose or purposes stated in the notice of such meeting.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Notice of Stockholder
Meetings</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, the DGCL requires that notice to stockholders of the place (if any), date, and hour, and means of remote communication (if any) of
each annual and special meeting of stockholders be given at least 10 days, but no more than 60 days, before the meeting date. The Quidel Bylaws provide that notice of any meeting shall be given not less than 10 nor more than 60 days before the date
of the meeting.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Pursuant to the DGCL, notice of a meeting of stockholders to vote
upon a merger or a sale of all or substantially all of the corporation&#146;s assets must be delivered at least 20 days before the meeting date. In the case of a special meeting, the notice must also state the purpose or purposes for which the
meeting is called.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the UK Companies Act, 21 clear days&#146; notice must be given for an annual general meeting and any resolutions to be proposed at the meeting. At least 14 clear days&#146; notice (but no more than 60 days&#146; notice under
Ortho&#146;s articles of association) is required for any other general meeting. In addition, certain matters, such as the removal of directors or auditors, require special notice, which is 28 clear days&#146; notice. Ortho shareholders may in all
cases consent to a shorter notice period, the proportion of shareholders&#146; consent required being 100% of those entitled to attend and vote in the case of an annual general meeting and, in the case of any other general meeting, a majority in
number of the members having a right to attend and vote at the meeting, being a majority who together hold not less than 95% in nominal value of the shares giving a right to attend and vote at the meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, the DGCL requires that notice to stockholders of the place (if any), date, and hour, and means of remote communication (if any) of
each annual and special meeting of stockholders be given at least 10 days, but no more than 60 days, before the meeting date. The Topco Bylaws provide that notice of any meeting shall be given not less than 10 nor more than 60 days before the date
of the meeting.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Pursuant to the DGCL, notice of a meeting of stockholders to vote
upon a merger or a sale of all or substantially all of the corporation&#146;s assets must be delivered at least 20 days before the meeting date. In the case of a special meeting, the notice must also state the purpose or purposes for which the
meeting is called.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Quorum at Stockholder
Meetings</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Quidel Bylaws provide that the holders of a majority of the voting power of Quidel&#146;s outstanding capital stock entitled to vote, present in person or represented by proxy, constitute a quorum at all meetings of stockholders
except as otherwise provided by law or Quidel&#146;s restated certificate of incorporation (the &#147;Quidel Charter&#148;).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Ortho&#146;s articles of association, no business shall be transacted at any general meeting unless a quorum is present. At least two Ortho shareholders present in person or by proxy and entitled to vote shall be a quorum for
all purposes.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Topco Bylaws provide that the holders of a majority of the voting power of Topco&#146;s outstanding capital stock entitled to vote, present in person or represented by proxy, constitute a quorum at all meetings of stockholders
except as otherwise provided by law or the Topco Charter.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Stockholder Voting Rights</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Quidel Bylaws, each stockholder of record entitled to vote</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Without prejudice to any special rights, privileges or restrictions as to voting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the Topco Bylaws, each stockholder of record entitled to vote at</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">320 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">at any meeting may do so in person or by proxy. Each Quidel Share entitles its holder to one vote.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Generally, under the Quidel Bylaws, when a quorum is present, the affirmative vote of
holders of a majority of the voting power of Quidel&#146;s capital stock, present in person or represented by proxy, at a meeting of stockholders and entitled to vote on a matter shall be the act of the stockholders.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">rights attached to any Ortho Shares forming part of Ortho&#146;s share capital from time to time, all votes at a general meeting shall be
taken on a poll and each holder of the shares of the class shall, on a poll, have one vote in respect of every share of the class held by them.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An ordinary resolution is passed on a poll if it is approved by holders representing a simple majority of the total voting rights of shareholders present, in
person or by proxy, who, being entitled to vote, vote on the resolution.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A special
resolution is passed on a poll if it is approved by holders representing not less than 75% of the total voting rights of shareholders present (in person or by proxy) who (being entitled to vote) vote on the resolutions.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">any meeting may do so in person or by proxy. Each Topco Share entitles its holder to one vote.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Generally, under the Topco Bylaws, when a quorum is present, the affirmative vote of a
majority of the shares present in person or represented by proxy at a meeting of stockholders and entitled to vote on a matter shall be the act of the stockholders.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Approval of Mergers and Business
Combinations</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL requires, with limited exceptions, a merger, consolidation or sale of substantially all of the assets of a corporation to be
approved by the corporation&#146;s board of directors and a majority of the issued and outstanding shares entitled to vote thereon.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, if a target corporation is listed on a national securities exchange or its shares are held of record by more than 2,000 holders immediately prior to
the execution of a merger agreement, then the target corporation may opt into Section&nbsp;251(h) of the DGCL. If the parties opt into Section&nbsp;251(h) of the DGCL and a sufficient number of shares are accepted in the tender offer that are
required to approve a merger, then the merger may be consummated without a vote of the target stockholders.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Quidel Bylaws provide that Quidel expressly elects not to be governed by Section&nbsp;203 of the DGCL, which restricts certain transactions with
stockholders who own 15% or more of a corporation&#146;s voting stock.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Neither the UK Companies Act nor Ortho&#146;s articles of association stipulate a specific approval in respect of mergers and business combinations generally. However, the manner in which a merger or business approval is structured
may require certain specific approvals. For example, as is the case for the Combinations, a business combination by way of a scheme of arrangement requires, according to the UK Companies Act, approval of the terms of the scheme of arrangement and
the scheme itself by a majority in number of shareholders representing 75% in value of share capital held by the members who vote in person or by proxy as well as the receipt of the required approval of the scheme of arrangement by the Court.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL requires, with limited exceptions, a merger, consolidation or sale of substantially all of the assets of a corporation to be
approved by the corporation&#146;s board of directors and a majority of the issued and outstanding shares entitled to vote thereon.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, if a target corporation is listed on a national securities exchange or its shares are held of record by more than 2,000 holders immediately prior to
the execution of a merger agreement, then the target corporation may opt into Section&nbsp;251(h) of the DGCL. If the parties opt into Section&nbsp;251(h) of the DGCL and a sufficient number of shares are accepted in the tender offer that are
required to approve a merger, then the merger may be consummated without a vote of the target stockholders.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Topco Charter provides that Topco expressly elects not to be governed by Section&nbsp;203 of the DGCL, which restricts certain transactions with
stockholders who own 15% or more of a corporation&#146;s voting stock.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">321 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Mandatory Tender Offer and <FONT
STYLE="white-space:nowrap">Squeeze-out</FONT> Thresholds</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pursuant to the DGCL, a corporation or other entity owning at least 90% of the outstanding shares of a subsidiary corporation may effect a merger with or into such subsidiary by resolution of the board of directors of the parent and
without any action on the part of the board of directors or the other stockholders of the subsidiary.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to Sections 979 to 991 of the UK Companies Act, where a takeover offer has been made for Ortho and the offeror has acquired or unconditionally contracted to acquire not less than 90% in value of the Ortho Shares to which
the offer relates and not less than 90% of the voting rights carried by those Ortho Shares, the offeror may give notice to the holder of any Ortho Shares to which the offer relates which the offeror has not acquired or unconditionally contracted to
acquire that he wishes to acquire, and is entitled to so acquire, those Ortho Shares on the same terms as the general offer. The offeror would do so by sending a notice to the outstanding minority Ortho shareholders telling them that it will
compulsorily acquire their Ortho Shares. Such notice must be sent within three months of the last day on which the offer can be accepted in the prescribed manner. The <FONT STYLE="white-space:nowrap">squeeze-out</FONT> of the minority Ortho
shareholders can be completed at the end of six weeks from the date the notice has been given, subject to the minority Ortho shareholders failing to successfully lodge an application to the court to prevent such
<FONT STYLE="white-space:nowrap">squeeze-out</FONT> any time prior to the end of those six weeks following which the offeror can execute a transfer of the outstanding Ortho Shares in its favor and pay the consideration to Ortho, which would hold the
consideration on trust for the outstanding minority Ortho shareholders. The consideration offered to the outstanding minority Ortho shareholders whose Ortho Shares are compulsorily acquired under the UK Companies Act must, in general, be the same as
the consideration that was available under the takeover offer.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to the DGCL, a corporation or other entity owning at least 90% of the outstanding shares of a subsidiary corporation may effect a merger with or into such subsidiary by resolution of the board of directors of the parent and
without any action on the part of the board of directors or the other stockholders of the subsidiary.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Related Party Transactions</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The DGCL provides that a corporation may lend money to, or guarantee any obligation incurred by, its officers or employees if, in the judgment of the board of directors, the loan or guarantee may reasonably</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If a situation arises in which a director of Ortho has, or can have, a direct or indirect interest that conflicts, or possibly may conflict, with Ortho&#146;s interests (other than a situation that cannot reasonably be regarded as
likely to give rise to a conflict of interest or a</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The DGCL provides that a corporation may lend money to, or guarantee any obligation incurred by, its officers or employees if, in the judgment of the board of directors, the loan or guarantee may reasonably be expected to benefit
the corporation.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">322 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">be expected to benefit the corporation.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The DGCL further provides that any other contract or transaction between the corporation and one or more of its directors or officers is neither void nor
voidable solely because the interested director or officer was present, participates or votes at the board or board committee meeting that authorizes the contract or transaction, if either: (i)&nbsp;the director&#146;s or officer&#146;s interest is
made known to the disinterested directors or the stockholders of the corporation, who thereafter approve the transaction in good faith; or (ii)&nbsp;the contract or transaction is fair to the corporation as of the time it is approved or ratified by
either the board of directors, a committee thereof, or the stockholders.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">conflict of interest arising in relation to a transaction or arrangement with Ortho), the Ortho board may authorize in accordance with the UK
Companies Act the director&#146;s interest and the continuing performance by the relevant director of his duties as a director on such terms as the Ortho board may determine.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A director of Ortho shall not be accountable to Ortho for any benefit which he derives from or in connection with a relationship involving a conflict of
interest or possible conflict of interest which has been authorized by the directors or by Ortho in a general meeting and any such transaction or arrangement shall not be liable to be avoided on the grounds of any such benefit.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Subject to the requirements under Sections 175, 177 and 182 of the UK Companies Act, a
director shall declare the nature and extent of such conflicts.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The DGCL further provides that any other contract or transaction
between the corporation and one or more of its directors or officers is neither void nor voidable solely because the interested director or officer was present, participates or votes at the board or board committee meeting that authorizes the
contract or transaction, if either: (i)&nbsp;the director&#146;s or officer&#146;s interest is made known to the disinterested directors or the stockholders of the corporation, who thereafter approve the transaction in good faith; or (ii)&nbsp;the
contract or transaction is fair to the corporation as of the time it is approved or ratified by either the board of directors, a committee thereof, or the stockholders.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Stockholder Proposals</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Quidel Bylaws, nominations of directors and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders by, subject to certain requirements, any stockholder of record who
is entitled to vote at the meeting and who complies with specific notice procedures set forth in the Quidel Bylaws.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to the UK Companies Act and Ortho&#146;s articles of association, Ortho shareholders may require Ortho to give notice of a resolution to Ortho shareholders entitled to receive notice of the next annual general meeting. The
resolution must be one which may properly be moved, and is intended to be moved at that meeting. Ortho is required to give notice of a resolution once it has received requests to do so from either Ortho shareholders representing at least 5% of the
total voting rights of all the Ortho shareholders who have a right to vote on the resolution at the annual general meeting in question, or at least 100 Ortho shareholders who have a right to vote on the resolution at the annual general meeting in
question and hold shares in Ortho on which there has been paid up an average sum, per Ortho shareholder, of at least &pound;100.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the Topco Bylaws, nominations of directors and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders by, subject to certain requirements, any stockholder of record who
is entitled to vote at the meeting and who complies with specific notice procedures set forth in the Topco Bylaws.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Stockholder Information
Rights</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The DGCL allows any stockholder of a corporation the right to inspect a complete list of the stockholders entitled to vote at a meeting of stockholders, both during the time of</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to the UK Companies Act and Ortho&#146;s articles of association, Ortho shareholders are entitled to receive a copy of the Ortho&#146;s annual accounts and reports for the relevant financial year</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The DGCL allows any stockholder of a corporation the right to inspect a complete list of the stockholders entitled to vote at a meeting of stockholders, both during the time of the meeting
and</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">323 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the meeting and during the 10 days preceding the meeting, for a purpose germane to the meeting.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The DGCL allows any stockholder in person or by attorney or other agent, upon written
demand under oath stating the purpose thereof, during the usual hours for business to inspect for any proper purpose, and to make copies and extracts from: (a)&nbsp;a corporation&#146;s stock ledger, a list of its stockholders, and its other books
and records; and (b)&nbsp;any subsidiary&#146;s books and records, to the extent that: (i)&nbsp;the corporation has actual possession and control of such records of such subsidiary; or (ii)&nbsp;the corporation could obtain such records through the
exercise of control over such subsidiary, provided that as of the date of the making of the demand: (x)&nbsp;the stockholder inspection of such books and records of the subsidiary would not constitute a breach of an agreement between the corporation
or the subsidiary and a person or persons not affiliated with the corporation; and (y)&nbsp;the subsidiary would not have the right under the law applicable to it to deny the corporation access to such books and records upon demand by the
corporation.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">which must, at least 21 clear days before the date of the meeting at which copies of those documents are to be laid, be sent to such Ortho shareholders. As set out above, each Ortho shareholder is entitled to receive notice of any
general meeting and information concerning the resolutions to be voted on at such a general meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">during the 10 days preceding the meeting, for a purpose germane to the meeting.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL allows any stockholder in person or by attorney or other agent, upon written
demand under oath stating the purpose thereof, during the usual hours for business to inspect for any proper purpose, and to make copies and extracts from: (a)&nbsp;a corporation&#146;s stock ledger, a list of its stockholders, and its other books
and records; and (b)&nbsp;any subsidiary&#146;s books and records, to the extent that: (i)&nbsp;the corporation has actual possession and control of such records of such subsidiary; or (ii)&nbsp;the corporation could obtain such records through the
exercise of control over such subsidiary, provided that as of the date of the making of the demand: (x)&nbsp;the stockholder inspection of such books and records of the subsidiary would not constitute a breach of an agreement between the corporation
or the subsidiary and a person or persons not affiliated with the corporation; and (y)&nbsp;the subsidiary would not have the right under the law applicable to it to deny the corporation access to such books and records upon demand by the
corporation.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, the Carlyle Stockholder has additional information rights
as described in the section entitled &#147;Stockholders Agreement / Deed of Irrevocable Undertaking&#151;Stockholders Agreement&#148; of this joint proxy statement/prospectus.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Amendments of Organizational
Documents</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pursuant to the DGCL, an amendment to the Quidel Charter generally requires: (a)&nbsp;recommendation of the board of directors; (b)&nbsp;the affirmative vote of a majority of the voting power of the outstanding stock entitled to
vote; and (c)&nbsp;the affirmative vote of a majority of the voting power of the outstanding stock of each class entitled to vote. The Quidel Charter does not include any additional conditions on its amendment.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ortho&#146;s articles of association may be varied or amended only by special resolution passed at a general meeting of the Ortho shareholders. Special resolutions require the affirmative vote of not less than 75% of the votes cast
by Ortho shareholders present (in person or by proxy) at the meeting. If a poll is demanded, a special resolution is passed if it is approved by Ortho shareholders representing not less than 75% of the total voting rights of Ortho shareholders
present (in person or by proxy) who</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the DGCL, an amendment to the Topco Charter generally requires: (a)&nbsp;recommendation of the board of directors; (b)&nbsp;the
affirmative vote of a majority of the voting power of the outstanding stock entitled to vote; and (c)&nbsp;the affirmative vote of a majority of the voting power of the outstanding stock of each class entitled to vote. The Topco Charter does not
include any additional conditions on its amendment.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the Topco Charter and the Topco Bylaws, the Topco Bylaws may be adopted, amended or repealed by
(a)&nbsp;a</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">324 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the Quidel Charter and the Quidel Bylaws, the Quidel Bylaws may
be adopted, amended or repealed by (a)&nbsp;a majority of the voting power of Quidel&#146;s issued and outstanding capital stock entitled to vote thereon and (b)&nbsp;the Quidel board of directors.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(being entitled to vote) vote on the resolutions.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">majority of the voting power of Topco&#146;s issued and outstanding capital stock entitled to vote thereon and (b)&nbsp;the Topco board of directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Indemnification of Directors and
Officers</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL permits a corporation to indemnify any persons who are, or are threatened to be made, parties to any threatened, pending or
completed legal action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was a director, officer, employee or
agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#146; fees), judgments, fines and
amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the
best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe that the person&#146;s conduct was unlawful.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Quidel Charter and Quidel Bylaws authorize Quidel to indemnify its directors and officers to the fullest extent permitted by the DGCL, including as it may
be amended (unless, to the extent permitted by the DGCL, such amendment would adversely affect any right of a current or former director or officer).</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Every director, officer or former director or officer of Ortho may be indemnified against all costs, charges, losses, expenses and liabilities incurred by him in connection with any negligence, default, breach of duty, or breach of
trust by him in relation to Ortho or in connection with Ortho&#146;s activities as a trustee of an occupational pension scheme, in the actual or purported exercise of his powers or duties or otherwise as an officer of Ortho, to the extent permitted
under the UK Companies Act.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL permits a corporation to indemnify any persons who are, or are threatened to be made, parties to any threatened, pending or
completed legal action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was a director, officer, employee or
agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#146; fees), judgments, fines and
amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the
best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe that the person&#146;s conduct was unlawful.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Topco Charter and Topco Bylaws authorize Topco to indemnify its directors and officers to the fullest extent permitted by the DGCL, including as it may be
amended (unless, to the extent permitted by the DGCL, such amendment would adversely affect any right of a current or former director or officer).</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">325 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Authority to Allot</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the DGCL, if the corporation&#146;s charter or certificate of incorporation so provides, the board of directors has the power to authorize the issuance of stock. It may authorize capital stock to be issued for consideration
consisting of cash, any tangible or intangible property or any benefit to the corporation or any combination thereof.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the UK Companies Act, the directors of a company must not allot shares or grant rights to subscribe for or to convert any security into
shares unless an exception applies or an ordinary resolution to the contrary has been passed by shareholders in a general meeting or the articles of association provide otherwise, in each case in accordance with the provisions of the UK Companies
Act.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Pursuant to Ortho&#146;s articles of association, Ortho&#146;s directors are
authorized to exercise all of the powers of the company to allot shares in Ortho, and to grant rights to subscribe for or to convert any security into shares in Ortho, up to a maximum aggregate nominal value of $10,000 (in addition to any authority
to allot that has not yet expired granted to the board prior to the date of the adoption of Ortho&#146;s articles of association) for a period expiring (unless previously renewed, varied or revoked by Ortho in a general meeting) on February&nbsp;1,
2026.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the DGCL, if the corporation&#146;s charter or certificate of incorporation so provides, the board of directors has the power to authorize the issuance of stock. It may authorize capital stock to be issued for consideration
consisting of cash, any tangible or intangible property or any benefit to the corporation or any combination thereof.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Preemptive Rights / Preferential Subscription
Rights</I></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pursuant to the DGCL, a stockholder is not entitled to preemptive rights to subscribe for additional issuances of stock or any security convertible into stock unless they are specifically granted in the certificate of incorporation.
The Quidel Charter does not provide for any preemptive rights.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the UK Companies Act, &#147;equity securities,&#148; being (i)&nbsp;shares in Ortho other than shares that, with respect to dividends and capital, carry a right to participate only up to a specified amount in a distribution
(&#147;ordinary shares&#148;) or (ii)&nbsp;rights to subscribe for, or to convert securities into, ordinary shares, proposed to be allotted for cash must be offered first to the existing equity shareholders in Ortho in proportion to the respective
nominal value of their holdings, unless an exception applies or a special resolution to the contrary has been passed by Ortho shareholders in a general meeting or Ortho&#146;s articles of association provide otherwise, in each case in accordance
with the provisions of the UK Companies Act. On February&nbsp;1, 2021, Ortho shareholders approved the exclusion of preemptive rights for a period of five years from the date of the approval in respect of the allotment of up to a maximum amount of
one billion Ortho Shares.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to the DGCL, a stockholder is not entitled to preemptive rights to subscribe for additional issuances of stock or any security convertible into stock unless they are specifically granted in the certificate of incorporation.
The Topco Charter does not provide for any preemptive rights.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">326 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Dividends</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The DGCL provides that, subject to any restrictions in a corporation&#146;s certificate of incorporation, dividends may be declared from the corporation&#146;s surplus, or if there is no surplus, from its net profits for the fiscal
year in which the dividend is declared and for the preceding fiscal year. Dividends may not be declared out of net profits, however, if the corporation&#146;s capital has been diminished to an amount less than the aggregate amount of all capital
represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets until the deficiency in the amount of capital represented by the issued and outstanding stock of all classes having a preference upon
the distribution of assets is repaired.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho may, by ordinary resolution of the Ortho shareholders, declare dividends out of profits available for distribution in accordance with
the respective rights of Ortho shareholders but no such dividend shall exceed the amount recommended by the directors. The Ortho board may from time to time pay Ortho shareholders such interim dividends as they appear to the board to be justified by
Ortho&#146;s financial position.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to any special rights attaching to or the
terms of issue of any share, all dividends shall be declared and paid according to the amounts paid up on the Ortho Shares and shall be apportioned and paid pro rata according to the amounts paid up on the Ortho Shares during any part or parts of
the period in respect of which the dividend is paid.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No dividend or other moneys
payable by Ortho on or in respect of any share shall bear interest against Ortho unless otherwise provided by the rights attached to the share or the provisions of another agreement between the Ortho shareholder and Ortho. Any dividend unclaimed
after a period of 12 years from the date such dividend became due for payment shall be forfeited and cease to remain owing.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends may be declared or paid in any currency and the Ortho board may decide the rate of exchange for any currency conversions that may be required, and
how any costs involved are to be met, in relation to the currency of any dividend.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any general meeting declaring a dividend may by ordinary resolution of the Ortho shareholders, upon the recommendation of the Ortho board, direct payment or
satisfaction of such dividend wholly or in part by the distribution of <FONT STYLE="white-space:nowrap">non-cash</FONT> assets of equivalent value, including shares or other securities in any company.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The directors may, if authorized by an ordinary resolution of Ortho shareholders, offer
any holders of Ortho</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The DGCL provides that, subject to any restrictions in a corporation&#146;s certificate of incorporation, dividends may be declared from the corporation&#146;s surplus, or if there is no surplus, from its net profits for the fiscal
year in which the dividend is declared and for the preceding fiscal year. Dividends may not be declared out of net profits, however, if the corporation&#146;s capital has been diminished to an amount less than the aggregate amount of all capital
represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets until the deficiency in the amount of capital represented by the issued and outstanding stock of all classes having a preference upon
the distribution of assets is repaired.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">327 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shares the right to elect to receive in lieu of a dividend, or part of a dividend, an allotment of ordinary shares credited as fully paid up.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Repurchases and Redemptions</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the DGCL, a corporation may purchase, redeem, receive, take or otherwise acquire, own and hold, sell, lend, exchange, transfer or
otherwise dispose of, pledge, use and otherwise deal in and with its own shares; provided, however, that no corporation shall: (i)&nbsp;purchase or redeem its own shares of capital stock for cash or other property when the capital of the corporation
is impaired or when such purchase or redemption would cause any impairment of the capital of the corporation, except that a corporation may purchase or redeem out of capital any of its own shares which are entitled upon any distribution of its
assets, whether by dividend or in liquidation, to a preference over another class or series of its stock, or, if no shares entitled to such a preference are outstanding, any of its own shares, if such shares will be retired upon their acquisition
and the capital of the corporation reduced; (ii)&nbsp;purchase, for more than the price at which they may then be redeemed, any of its shares which are redeemable at the option of the corporation; or (iii)&nbsp;redeem any of its shares unless their
redemption is authorized by a subsection of the DGCL and then only in accordance with such section and the certificate of incorporation.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Generally, pursuant to the DGCL, a corporation has a right to resell any of its shares theretofore purchased or redeemed and which have not been retired, for
such consideration as shall be fixed by the board of directors.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho may purchase its own fully paid Ortho Shares otherwise than on a recognized investment exchange pursuant to a purchase contract
authorized by resolution of the Ortho shareholders before the purchase takes place. Any authority will not be effective if any Ortho shareholder from whom Ortho proposed to purchase shares votes on the resolution and the resolution would not have
been passed if they had not done so. The resolution authorizing the purchase must specify a date, not being later than five years after the passing of the resolution, on which the authority to purchase is to expire.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ortho may issue shares which are to be redeemed or are to be liable to be redeemed at
the option of Ortho or the holder. The Ortho board may determine the terms, conditions and manner of redemption of shares provided that it does so before the shares are allotted. The 50,001 deferred shares of &pound;1.00 each in the capital of Ortho
can be redeemed by the Ortho board for nil value at the Ortho board&#146;s discretion.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the DGCL, a corporation may purchase, redeem, receive, take or otherwise acquire, own and hold, sell, lend, exchange, transfer or
otherwise dispose of, pledge, use and otherwise deal in and with its own shares; provided, however, that no corporation shall: (i)&nbsp;purchase or redeem its own shares of capital stock for cash or other property when the capital of the corporation
is impaired or when such purchase or redemption would cause any impairment of the capital of the corporation, except that a corporation may purchase or redeem out of capital any of its own shares which are entitled upon any distribution of its
assets, whether by dividend or in liquidation, to a preference over another class or series of its stock, or, if no shares entitled to such a preference are outstanding, any of its own shares, if such shares will be retired upon their acquisition
and the capital of the corporation reduced; (ii)&nbsp;purchase, for more than the price at which they may then be redeemed, any of its shares which are redeemable at the option of the corporation; or (iii)&nbsp;redeem any of its shares unless their
redemption is authorized by a subsection of the DGCL and then only in accordance with such section and the certificate of incorporation.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Generally, pursuant to the DGCL, a corporation has a right to resell any of its shares theretofore purchased or redeemed and which have not been retired, for
such consideration as shall be fixed by the board of directors.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Stockholder Suits</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pursuant to the DGCL, a stockholder may initiate a derivative action to enforce a right of a corporation if the</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under English law, generally, the company, rather than its shareholders, is the proper claimant in an action in</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to the DGCL, a stockholder may initiate a derivative action to enforce a right of a corporation if the</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">328 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">corporation fails to enforce the right itself. The complaint must: (i)&nbsp;state that the plaintiff was a stockholder at the time of the
transaction of which</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the plaintiff complains or that the plaintiff&#146;s shares thereafter devolved on the plaintiff by operation of law; and
(ii)&nbsp;allege with particularity (a)&nbsp;the efforts, if any, made by the plaintiff to obtain the action the plaintiff desires from the directors; or (b)&nbsp;the reasons for the plaintiff&#146;s failure to obtain the action or for not making
the effort. Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the court.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">An individual may also maintain a class action suit on behalf of himself or herself and
other similarly situated stockholders where the requirements for maintaining a class action under Delaware law have been met.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">respect of a wrong done to the company or where there is an irregularity in the company&#146;s internal management. Notwithstanding this general position, the UK Companies Act provides that (i)&nbsp;a court may allow a shareholder
to bring a derivative claim (that is, an action in respect of and on behalf of the company) in respect of a cause of action arising from a director&#146;s negligence, default, breach of duty or breach of trust and (ii)&nbsp;a shareholder may bring a
claim for a court order where the company&#146;s affairs have been or are being conducted in a manner that is unfairly prejudicial to some of its shareholders.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">corporation fails to enforce the right itself. The complaint must: (i)&nbsp;state that the plaintiff was a stockholder at the time of the
transaction of which</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the plaintiff complains or that the plaintiff&#146;s shares thereafter devolved on the plaintiff by operation of law; and
(ii)&nbsp;allege with particularity (a)&nbsp;the efforts, if any, made by the plaintiff to obtain the action the plaintiff desires from the directors; or (b)&nbsp;the reasons for the plaintiff&#146;s failure to obtain the action or for not making
the effort. Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the court.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">An individual may also maintain a class action suit on behalf of himself or herself and
other similarly situated stockholders where the requirements for maintaining a class action under Delaware law have been met.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Standard of Conduct for
Directors</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of
directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the
stockholders.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Directors of a Delaware corporation owe fiduciary duties of care and
loyalty to the corporation and to its stockholders. The duty of care generally requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must
inform himself or herself of all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he or she reasonably</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under English law, a director owes various statutory and fiduciary duties to the company, including:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to act in the way he
considers, in good faith, would be most likely to promote the success of the company for the benefit of its members as a whole;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to avoid a situation in which he has, or can have, a direct or indirect interest that conflicts,
or possibly conflicts, with the interests of the company;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to act in accordance with the company&#146;s constitution and only exercise his powers for the
purposes for which they are conferred;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to exercise independent judgment;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to exercise reasonable care,
skill, and diligence;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;not
to accept benefits from a third party conferred by reason of his</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of
directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the
stockholders.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Directors of a Delaware corporation owe fiduciary duties of care and
loyalty to the corporation and to its stockholders. The duty of care generally requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must
inform himself or herself of all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he or she reasonably believes to be in the best interests of the
corporation. He or she must not use his or her corporate position for personal</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">329 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ortho</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topco</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal gain or advantage. In general, but subject to certain exceptions, actions of a director with no conflicting
interest are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the
fiduciary duties. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">being a director or doing, or not doing, anything as a director; and</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a duty to declare any interest that he has, whether directly or indirectly, in a
proposed or existing transaction or arrangement with the company.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">gain or advantage. In general, but subject to certain exceptions, actions of a director with no conflicting interest are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken
was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware
corporation who take any action designed to defeat a threatened change in control of the corporation.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">330 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_202"></A>SECURITY OWNERSHIP OF CERTAIN QUIDEL BENEFICIAL OWNERS AND
MANAGEMENT </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth, as of March&nbsp;4, 2022, except where otherwise noted, certain information with respect to the amount
of Quidel Shares beneficially owned (as defined by the SEC&#146;s rules and regulations) by (1)&nbsp;each person known by Quidel to beneficially own more than 5% of the outstanding Quidel Shares, (2)&nbsp;each member of the Quidel board of
directors, (3)&nbsp;each of Quidel&#146;s NEOs and (4)&nbsp;all current directors and executive officers as a group. Applicable percentage ownership is based on 41,812,718 Quidel Shares outstanding as of March&nbsp;4, 2022. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Beneficial&nbsp;Ownership&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(#)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Percent&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(%)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&gt;5% Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T. Rowe Price Associates, Inc.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100&nbsp;E.&nbsp;Pratt Street</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Baltimore, Maryland 21202</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,108,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jack W. Schuler<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 N. Field Drive Suite 360</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Lake Forest, IL 60045</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,292,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Vanguard Group<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Vanguard Blvd.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Malvern, Pennsylvania 19355</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,426,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BlackRock, Inc.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">55&nbsp;E.&nbsp;52nd Street</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10055</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,301,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brown Capital Management, LLC<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1201 N. Culver Street</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baltimore, Maryland 21202</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,642,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alger Associates, Inc.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Pearl Street, 27th Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10004</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,223,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas C. Bryant<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">638,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth F. Buechler<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward L. Michael<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathy P. Ordo&ntilde;ez<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Lake Polan<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ann D. Rhoads<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles P. Slacik<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew W. Strobeck<SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth J. Widder<SUP STYLE="font-size:85%; vertical-align:top">(17)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph D. Wilkins Jr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randall J. Steward<SUP STYLE="font-size:85%; vertical-align:top">(18)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Bujarski<SUP STYLE="font-size:85%; vertical-align:top">(19)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle A. Hodges<SUP STYLE="font-size:85%; vertical-align:top">(20)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Werner Kroll<SUP STYLE="font-size:85%; vertical-align:top">(21)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group (16&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(22)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,154,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>    <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates ownership of less than 1% of the outstanding Quidel Shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Beneficial ownership is determined in accordance with the rules of the SEC. Unless otherwise noted, and subject
to applicable community property laws, each director and executive officer has sole voting and dispositive power with respect to the shares indicated. The address for Quidel&#146;s directors and executive officers is c/o Quidel Corporation, 9975
Summers Ridge Road, San&nbsp;Diego, CA 92121. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">331 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Quidel Shares subject to options or RSUs exercisable or vesting on or within 60&nbsp;days of March&nbsp;4, 2022
are deemed outstanding for computing the number of shares and the percentage ownership of the person holding such&nbsp;options or RSUs, but are not deemed outstanding for computing the percentage ownership of any other person. </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information reported in Amendment No. 24 to Schedule 13G filed with the SEC dated February 14, 2022 by
T. Rowe Price Associates, Inc., which reported beneficial ownership of 6,108,899 Quidel Shares with respect to which T. Rowe Price Associates, Inc. has sole voting power of 2,289,575 shares and sole dispositive power of 6,108,899 shares as of
December 31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information reported in Amendment No. 5 to Schedule 13D filed with the SEC dated May 21, 2019 by
Mr.&nbsp;Jack W. Schuler, Jack W. Schuler Living Trust, Renate Schuler and Schuler Family Foundation, which reported beneficial ownership of 4,292,374 Quidel Shares with respect to which Mr. Schuler has sole voting and dispositive power of 3,122,111
shares and shared voting and dispositive power of 1,105,263 shares. Mr. Schuler disclaims beneficial ownership of 1,105,263 shares held indirectly by the Schuler Family Foundation and 65,000 shares owned by the Renate Schuler Trust, except to the
extent of his pecuniary interest in such shares, if any. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information reported in Amendment No. 8 to Schedule 13G filed with the SEC dated February 10, 2022 by
The Vanguard Group, which reported beneficial ownership of 3,426,080 Quidel Shares with respect to which The Vanguard Group has shared voting power of 20,380 shares, sole dispositive power of 3,373,746 shares and shared dispositive power of 52,334
shares as of December 31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information reported in Amendment No. 3 to Schedule 13G filed with the SEC dated February 1, 2022 by
BlackRock, Inc., which reported beneficial ownership of 3,301,994 Quidel Shares with respect to which BlackRock, Inc. has sole voting power of 3,153,141 shares and sole dispositive power of 3,301,994 shares as of December 31, 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information reported in Amendment No. 12 to Schedule 13G filed with the SEC dated February 14, 2022 by
Brown Capital Management, LLC, which reported beneficial ownership of 2,642,671 Quidel Shares with respect to which Brown Capital Management, LLC has sole voting power of 1,703,207 shares and sole dispositive power of 2,642,671 shares as of December
31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information reported in Schedule 13G filed with the SEC dated February 14, 2022 by Alger Associates,
Inc., which reported beneficial ownership of 2,223,343 Quidel Shares with respect to which Alger Associates, Inc. has sole voting power of 2,223,343 shares and sole dispositive power of 2,223,343 shares as of December 31, 2021. The Schedule 13G
indicates that the shares are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC (&#147;FAM&#148;), and that FAM and Alger Group Holdings,
LLC each beneficially owns 5% or greater of the outstanding shares of our common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 120,369 Quidel Shares issuable upon exercise of options that are exercisable on or within 60 days
of March&nbsp;4, 2022 and (ii) 12,147 Quidel Shares underlying an equal number of fully vested RSUs for which Mr. Bryant has no voting or dispositive power over such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 48,820 Quidel Shares issuable upon exercise of options that are exercisable on or within 60 days
of March&nbsp;4,&nbsp;2022, (ii) 11,968 Quidel Shares underlying an equal number of fully vested RSUs for which Dr. Buechler has no voting or dispositive power over such shares, (iii) 200 Quidel Shares that are beneficially owned by Dr. Buechler as
custodian of his children&#146;s Uniform Transfers to Minors Act accounts and (iv) 200 Quidel Shares jointly owned with his children. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 2,495 Quidel Shares underlying an equal number of fully vested RSUs for which Mr. Michael has no
voting or dispositive power over such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 754 Quidel Shares underlying an equal number of fully vested RSUs for which Ms. Ordo&ntilde;ez has no
voting or dispositive power over such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 8,949 Quidel Shares underlying an equal number of fully vested RSUs for which Dr. Polan has no voting
or dispositive power over such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 427 Quidel Shares underlying an equal number of fully vested RSUs for which Ms. Rhoads has no voting
or dispositive power over such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 299 Quidel Shares underlying an equal number of fully vested RSUs for which Mr. Slacik has no voting
or dispositive power over such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 259 Quidel Shares issuable upon exercise of options that are exercisable on or within 60 days of
March&nbsp;4,&nbsp;2022, (ii) 1,564 Quidel Shares underlying an equal number of fully vested RSUs for which Dr. Strobeck has no voting or dispositive power over such shares, (iii) 38,145 Quidel Shares held by Birchview Fund, LLC (Dr. Strobeck has
sole voting and dispositive power with respect to such shares in his capacity as the Managing Partner of such entity), (iv) 3,869 Quidel Shares held directly by Dr. Strobeck and (v) 16,630 Quidel Shares beneficially owned by Dr. Strobeck as
custodian of his children&#146;s Uniform Gift to Minors Act accounts. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 22,440 Quidel Shares issuable upon exercise of options that are exercisable on or within 60 days
of March&nbsp;4, 2022 and (ii) 3,331 Quidel Shares underlying an equal number of fully vested RSUs for which Mr. Widder has no voting or dispositive power over such shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">332 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 20,639 Quidel Shares issuable upon exercise of options that are exercisable on or within 60 days
of March&nbsp;4, 2022 and (ii) 1,132 Quidel Shares underlying an equal number of fully vested RSUs for which Mr. Steward has no voting or dispositive power over such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(19)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 59,583 Quidel Shares issuable upon exercise of options that are exercisable on or within 60 days
of March&nbsp;4, 2022 and (ii) 7,886 Quidel Shares underlying an equal number of fully vested RSUs for which Mr. Bujarski has no voting or dispositive power over such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(20)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 473 Quidel Shares issuable upon exercise of options that are exercisable on or within 60 days of
March&nbsp;4,&nbsp;2022 and (ii) 1,020 Quidel Shares underlying an equal number of fully vested RSUs for which Ms. Hodges has no voting or dispositive power over such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(21)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 4,265 Quidel Shares issuable upon exercise of options that are exercisable on or within 60 days of
March&nbsp;4,&nbsp;2022 and (ii) 3,566 Quidel Shares underlying an equal number of fully vested RSUs for which Dr. Kroll has no voting or dispositive power over such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(22)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All directors and executive officers as a group, including an aggregate of (i) 311,619 Quidel Shares issuable
upon exercise of options that are exercisable on or within 60 days of March 4, 2022, (ii) 434 Quidel Shares underlying an equal number of RSUs issuable upon vesting on or within 60 days of March 4, 2022, and (iii) 55,538 Quidel Shares underlying an
equal number of fully vested RSUs for which no member of the group has voting or dispositive power over such shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">333 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_203"></A>SECURITY OWNERSHIP OF CERTAIN ORTHO BENEFICIAL OWNERS AND
MANAGEMENT </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table and accompanying footnotes set forth information with respect to the beneficial ownership of the ordinary shares
of Ortho Clinical Diagnostics Holdings plc as of March&nbsp;4, 2022 by: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person known by Ortho to own beneficially 5% or more of Ortho&#146;s outstanding ordinary shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of Ortho&#146;s directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of Ortho&#146;s named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho&#146;s directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership for the purposes of the following table is determined in accordance with the rules and regulations of the SEC. A person is a
&#147;beneficial owner&#148; of a security if that person has or shares &#147;voting power,&#148; which includes the power to vote or to direct the voting of the security, or &#147;investment power,&#148; which includes the power to dispose of or to
direct the disposition of the security or has the right to acquire such powers within 60 days. Unless otherwise noted in the footnotes to the following table, and subject to applicable community property laws, the persons named in the table have
sole voting and investment power with respect to their beneficially owned ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated in the footnotes below, the
address of each beneficial owner is c/o Ortho Clinical Diagnostics Holdings plc, 1001 Route 202, Raritan, New Jersey 08869. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applicable percentage
ownership and voting power is based on 237,549,922 Ortho Shares outstanding as of March 4, 2022. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Shareholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carlyle Stockholder<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,106,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">T. Rowe Price Associates, Inc.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,981,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher M.&nbsp;Smith<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">957,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph M. Busky<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chad Dale<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael S. Iskra<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chockalingam Palaniappan<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Schlesinger<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen H. Bechtel<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evelyn Dilsaver<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allan Holt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carl Hull<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ron Labrum<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Mac Mahon<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Perez<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert R. Schmidt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen H. Wise</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Yates<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,027,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group (16 persons)<SUP
STYLE="font-size:85%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,187,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects ordinary shares held of record by the Carlyle Stockholder. The Carlyle Group Inc., a publicly traded
company listed on Nasdaq, is the sole member of Carlyle Holdings II GP L.L.C., which is the managing member of Carlyle Holdings II L.L.C., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings
L.L.C., which is the general partner of TC Group Cayman Investment Holdings, L.P., which is the general partner of TC Group Cayman Investment Holdings Sub L.P., which is the sole member of TC Group VI Cayman, L.L.C., which is the general partner of
TC Group VI Cayman, L.P., which is the general partner of the Carlyle Investor. Voting and investment determinations with respect to the ordinary shares held of record by the Carlyle Investor are made by an investment committee of TC Group VI
Cayman, L.P. Accordingly, each of the foregoing entities may be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">334 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
deemed to share beneficial ownership of the securities held of record by the Carlyle Investor. Each of them disclaims beneficial ownership of such securities. The address for each of TC Group
Cayman Investment Holdings, L.P., TC Group Cayman Investment Holdings Sub L.P., TC Group VI Cayman, L.P. and the Carlyle Investor is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman <FONT STYLE="white-space:nowrap">KY1-9001,</FONT> Cayman
Islands. The address of each of the other entities named in this footnote is c/o The Carlyle Group, 1001 Pennsylvania Avenue, NW, Suite 220 South, Washington, D.C. 20004. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount and percentage shown and the information contained in this footnote are based on a Schedule 13G
filed by T. Rowe Price Associates, Inc. (&#147;T. Rowe Price&#148;) with the SEC on February 14 , 2022. T.Rowe Price has sole voting power with respect to 6,886,191 ordinary shares and sole dispositive power with respect to 19,981,658 ordinary
shares. The address of T. Rowe Price is 100 E. Pratt Street, Baltimore, MD 21202. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 590,473 ordinary shares issuable upon the exercise of options exercisable within 60 days following
March&nbsp;4, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 66,392 ordinary shares issuable upon the exercise of options exercisable within 60 days following
March&nbsp;4, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As disclosed in Ortho&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the
SEC on May&nbsp;3, 2021, on April&nbsp;27, 2021, Mr.&nbsp;Dale resigned as Chief Operating Officer of the Company, effective May&nbsp;7, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 301,683 ordinary shares issuable upon the exercise of options exercisable within 60 days following
March&nbsp;4, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 106,227 ordinary shares issuable upon the exercise of options exercisable within 60 days following
March&nbsp;4, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 186,303 ordinary shares issuable upon the exercise of options exercisable within 60 days following
March&nbsp;4, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 2,600 ordinary shares issuable upon the settlement of restricted stock units that will vest within 60
days following March&nbsp;4, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 2,600 ordinary shares issuable upon the settlement of restricted stock units that will vest within 60
days following March&nbsp;4, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 41,172 ordinary shares held by Mr.&nbsp;Hull in his capacity as a Trustee of the Hull Living Trust
and (ii)&nbsp;1,300 ordinary shares issuable upon the settlement of restricted stock units that will vest within 60 days following March&nbsp;4, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 1,300 ordinary shares issuable upon the settlement of restricted stock units that will vest within 60
days following March&nbsp;4, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i)&nbsp;27,584 ordinary shares held by Mr.&nbsp;Mac Mahon in his capacity as a Trustee of the Kelly M
Ewing 2012 Trust U/A DTD 7/3/2012, (ii)&nbsp;27,584 ordinary shares held by Mr.&nbsp;Mac Mahon in his capacity as a Trustee of the Lauren C. Hand 2012 Trust U/A/ DTD 7/3/2012, (iii)&nbsp;24,501 ordinary shares held by Mr.&nbsp;Mac Mahon in his
capacity as a Trustee of The Thomas&nbsp;&amp; Sarah Mac Mahon Family Charitable Foundation Trust (dated 11/24/2003) and (iv)&nbsp;1,300 ordinary shares issuable upon the settlement of restricted stock units that will vest within 60 days following
March&nbsp;4, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 1,300 ordinary shares issuable upon the settlement of restricted stock units that will vest within 60
days following March&nbsp;4, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i)&nbsp;1,025,225 ordinary shares issuable upon the exercise of options exercisable within 60 days
following March&nbsp;4, 2022, and (ii)&nbsp;1,832 ordinary shares issuable upon the settlement of restricted stock units that will vest within 60 days following March&nbsp;4, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i)&nbsp;2,276,303 ordinary shares issuable upon the exercise of options exercisable within 60 days
following March&nbsp;4, 2022, and (ii)&nbsp;12,232 ordinary shares issuable upon the settlement of restricted stock units that will vest within 60 days following March&nbsp;4, 2022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">335 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_204"></A>HOUSEHOLDING OF PROXY MATERIALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC has adopted rules that permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy statements and annual reports
with respect to two or more stockholders sharing the same address by delivering a single proxy statement or annual report, as applicable, addressed to those stockholders. As permitted by the Exchange Act, only one copy of this joint proxy
statement/prospectus is being delivered to stockholders residing at the same address, unless such stockholders have notified the company whose shares they hold of their desire to receive multiple copies of this joint proxy statement/prospectus. This
process, which is commonly referred to as &#147;householding,&#148; potentially provides extra convenience for stockholders and cost savings for companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, at any time, you no longer wish to participate in &#147;householding&#148; and would prefer to receive a separate joint proxy statement/prospectus, or if
you are receiving multiple copies of this joint proxy statement/prospectus and wish to receive only one, please contact Quidel or Ortho, as applicable, at the address identified below. Quidel and Ortho will promptly deliver, upon oral or written
request, a separate copy of this joint proxy statement/prospectus to any Quidel stockholder or Ortho shareholder residing at an address to which only one copy was mailed. Requests for additional copies should be directed to: Quidel Corporation,
Attention: Phillip S. Askim, VP, Associate General Counsel&nbsp;&amp; Secretary, 9975 Summers Ridge Road, San Diego, California 92121, United States of America, Telephone (858) <FONT STYLE="white-space:nowrap">552-1100,</FONT> or Innisfree M&amp;A
Incorporated, Quidel&#146;s proxy solicitor, by calling (877) <FONT STYLE="white-space:nowrap">750-0537.</FONT> You may also request copies of this joint proxy statement/prospectus, without charge, by written or telephonic request directed to Ortho
Clinical Diagnostics Holdings plc, Attention: Michael&nbsp;A.&nbsp;Schlesinger, Executive Vice President, General Counsel and Secretary, 1001 Route 202, Raritan, New Jersey 08869, United States of America, Telephone (908) <FONT
STYLE="white-space:nowrap">218-8000,</FONT> or MacKenzie Partners, Ortho&#146;s proxy solicitor, by calling <FONT STYLE="white-space:nowrap">toll-free</FONT> at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-800-322-2885.</FONT></FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">336 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_205"></A>FUTURE STOCKHOLDER PROPOSALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_206"></A>Topco </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming consummation
of the Combinations, Topco stockholders will be entitled to present proposals for consideration at forthcoming Topco stockholder meetings, provided that they comply with the proxy rules promulgated by the SEC and the Topco Charter. The deadline for
submission of all Topco stockholder proposals to be considered for inclusion in Topco&#146;s proxy statement for its next annual meeting will be disclosed in a subsequent filing with the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_207"></A>Quidel </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel held its
2021 Annual Meeting of Stockholders on May&nbsp;18, 2021. Quidel does not intend to hold an annual meeting of stockholders in 2022, but this joint proxy statement/prospectus includes certain matters that would have been proposals at its 2022 Annual
Meeting of Stockholders, had it been held. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom273090_208"></A>Ortho </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho does not intend to hold an annual meeting of shareholders in 2022, and will hold an annual meeting in 2022 only if the Combinations are not completed
before June&nbsp;16, 2022. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_209"></A>NO APPRAISAL RIGHTS FOR QUIDEL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Appraisal rights are statutory rights under the DGCL that enable stockholders who object to certain extraordinary transactions to demand that the corporation
pay such stockholders the fair value of their shares instead of receiving the consideration offered to stockholders in connection with the extraordinary transaction. However, appraisal rights are not available in all circumstances. Appraisal rights
are not available to Quidel stockholders in connection with the Combinations. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NO DELAWARE APPRAISAL RIGHTS FOR ORTHO SHAREHOLDERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As shareholders of a UK public limited company, Ortho shareholders do not have appraisal rights similar to the statutory rights under the DGCL that
enable shareholders who object to certain extraordinary transactions to demand that the corporation pay such shareholders the fair value of their shares instead of receiving the consideration offered to shareholders in connection with the
extraordinary transaction. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_210"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The legality of the Topco Shares issuable in the Combinations will be passed upon for Topco by Latham&nbsp;&amp; Watkins LLP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">337 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_211"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Quidel Corporation at December 31, 2021 and 2020, and for each of the three years in the period ended December 31,
2021, incorporated by reference in the joint proxy statement/prospectus and Amendment No. 1 to the Registration Statement of Coronado Topco, Inc., have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set
forth in their report incorporated by reference herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements incorporated in this joint proxy statement/prospectus by reference to the Annual Report on Form&nbsp;10-K of Ortho Clinical
Diagnostics Holdings plc for the year ended January&nbsp;2, 2022 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in
auditing and accounting. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PwC completed an independence assessment to evaluate the services and relationships with Ortho and its affiliates that may
bear on PwC&#146;s independence under the SEC and the PCAOB (United States) independence rules for an audit period commencing January&nbsp;1, 2018, PwC informed Ortho that certain of its member firms within PricewaterhouseCoopers International
Limited, each member firm of which is a separate legal entity (&#147;PwC member firm&#148;), were engaged to perform <FONT STYLE="white-space:nowrap">non-audit</FONT> services by and had relationships with entities that are under common control with
Ortho. These <FONT STYLE="white-space:nowrap">non-audit</FONT> services and relationships are not in accordance with the SEC and PCAOB auditor independence rules and are described below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From April 2019 to September 2020, a PwC member firm assisted in the preparation and submission of two
statistical reports to a <FONT STYLE="white-space:nowrap">non-tax</FONT> authority for an entity under common control with Ortho. The fees for these services were approximately $1,600. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From April 2018 to March 2019, a PwC covered person, who was not involved in the audit of Ortho, held an
impermissible financial interest in an affiliate of Ortho. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From August 2017 to January 2018, a PwC member firm had a business relationship with an entity under common
control with Ortho. The fees for these services were approximately $180,000. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From November 2018 to February 2019, a PwC member firm provided an expert service to an entity under common
control with Ortho. The fees for these services were approximately $360,000 (fees for the services were not invoiced or collected). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">During March 2019, a PwC member firm held custody of documents and provided a registered office address for an
entity under common control with Ortho. There were no fees earned for this service. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PwC provided an overview of the facts and
circumstances surrounding the services and relationships to Ortho&#146;s audit committee and management, including the entities involved, the nature of the relationships, where applicable, an approximation of the fees earned related to the services
and relationships and other relevant factors. Considering the facts presented, Ortho&#146;s audit committee and PwC have concluded that the relationships would not impair PwC&#146;s application of objective and impartial judgment on any matters
encompassed within the audit engagement performed by PwC for Ortho&#146;s consolidated financial statements for each of the three years in the period ended January&nbsp;2, 2022, and that no reasonable investor would conclude otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">338 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273090_500"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel and Ortho file annual, quarterly and current reports, proxy statements and other information with the SEC. Quidel&#146;s and Ortho&#146;s SEC filings
are available to the public over the Internet at the SEC&#146;s website at www.sec.gov. Quidel&#146;s common stock is listed on Nasdaq under the symbol &#147;QDEL&#148; and the reports and other information filed by Quidel with the SEC are also
available at Quidel&#146;s Internet website (www.quidel.com). Ortho&#146;s ordinary shares are listed on Nasdaq under the symbol &#147;OCDX&#148; and the reports and other information filed by Ortho with the SEC are also available at Ortho&#146;s
Internet website (<U>www.orthoclinicaldiagnostics.com</U>). We have included the web addresses of the SEC, Quidel and Ortho as inactive textual references only. Except as specifically incorporated by reference into this joint proxy
statement/prospectus, information on those websites is not part of this joint proxy statement/prospectus. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco has filed with the SEC a
registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> to register the Topco Shares to be issued in the Combinations. This joint proxy statement/prospectus is a part of that registration statement and constitutes a prospectus of
Topco, in addition to being a proxy statement of Quidel for the Quidel Stockholders&#146; Meeting and Ortho for the Ortho Shareholder Meetings. As allowed by SEC rules, this joint proxy statement/prospectus does not contain all of the information
you can find in the registration statement or the annexes to the registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows Quidel and Ortho to incorporate by reference
information into this joint proxy statement/prospectus. This means that Quidel and Ortho can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is
considered to be a part of this joint proxy statement/prospectus, except for any information that is superseded by information that is included directly in this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus incorporates by reference the following documents previously filed with the SEC (other than documents or information
deemed to have been furnished and not filed in accordance with SEC rules, including Items 2.02 and 7.01 and the related exhibits under Item 9.01 of Form <FONT STYLE="white-space:nowrap">8-K):</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;
31, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/353569/000035356922000026/qdel-20211231.htm">February 18, 2022</A>, as amended on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/353569/000035356922000030/qdel-20211231.htm">March&nbsp;11,
 2022</A>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel&#146;s Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/353569/000035356921000031/qdel-20210226.htm">March&nbsp;2,
 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/353569/000035356921000058/qdel-20210507.htm">May&nbsp;
12, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/353569/000035356921000064/qdel-20210518.htm">May&nbsp;
19, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/353569/000119312521223723/d182480d8k.htm">July&nbsp;
26, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/353569/000119312521365588/d270785d8k.htm">December&nbsp;
23, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/353569/000035356922000008/qdel-20220122.htm">January 27, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/353569/000035356922000011/qdel-20220131.htm">February&nbsp;4,
 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/353569/000119312522039227/d310290d8k.htm">February 14, 2022</A>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ortho&#146;s Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1828443/000095017022003035/ocdx-20220102.htm">Form
 10-K</A> for the fiscal year ended January 2, 2022, filed with the SEC on March 8, 2022. </P></TD></TR></TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Quidel and Ortho also
incorporates by reference additional documents that Quidel and Ortho file with the SEC under Sections&nbsp;13(a), 13(c), 14 and 15(d) of the Exchange Act (i)&nbsp;after the date of the initial filing and prior to the effectiveness of the
registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> of which this joint proxy statement/prospectus forms a part and (ii)&nbsp;after the date of this joint proxy statement/prospectus and prior to the date of the Quidel
Stockholders&#146; Meeting or the Ortho Shareholder Meetings, as applicable (other than information furnished pursuant to Item&nbsp;2.02 or Item 7.01 of any Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> unless expressly stated
otherwise therein). Such documents are considered to be a part of this joint proxy statement/prospectus, effective as of the date such documents are filed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can obtain any of these documents from the SEC, through the SEC&#146;s website at the address described above. You may also request copies of this joint
proxy statement/prospectus and any of the documents incorporated by reference into this joint proxy statement/prospectus or other information concerning Quidel or Ortho, without charge, by written or telephonic request directed to the appropriate
company at the following addresses and telephone numbers: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Quidel Corporation</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9975 Summers Ridge Road</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">San Diego,
California 92121</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Phillip S. Askim, VP, Associate</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Counsel &amp; Secretary</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone (858) 552-1100</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Innisfree M&amp;A Incorporated</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Quidel&#146;s proxy solicitor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: (877) 750-0537</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ortho Clinical Diagnostics Holdings plc</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1001 Route 202</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Raritan, New Jersey
08869</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Michael A. Schlesinger, Executive</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Vice President, General Counsel and Secretary</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: (908) 218-8000</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacKenzie Partners, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ortho&#146;s proxy solicitor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: 1-800-322-2885</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">339 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS JOINT PROXY STATEMENT/PROSPECTUS IS DATED AS OF THE DATE ON THE COVER HEREOF. YOU SHOULD NOT ASSUME
THAT THE INFORMATION CONTAINED IN THIS JOINT PROXY STATEMENT/PROSPECTUS IS ACCURATE AS OF ANY DATE OTHER THAN THAT DATE AND THE MAILING OF THIS JOINT PROXY STATEMENT/PROSPECTUS TO QUIDEL STOCKHOLDERS AND ORTHO SHAREHOLDERS DOES NOT CREATE ANY
IMPLICATION TO THE CONTRARY. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">340 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="exind273090_5"></A><A NAME="rom273090_212"></A>Annex A </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:125pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BUSINESS COMBINATION AGREEMENT </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and among </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">QUIDEL CORPORATION,
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CORONADO TOPCO, INC., </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ORTHO
CLINICAL DIAGNOSTICS HOLDINGS PLC, </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LAGUNA MERGER SUB, INC., </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ORCA HOLDCO, INC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ORCA HOLDCO 2, INC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of
December&nbsp;22, 2021 </P> <P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:120pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE I</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">THE COMBINATIONS</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Combinations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.4.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of the Orca Scheme on Orca Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.5.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of the Laguna Merger on Laguna Shares; Laguna Merger Exchange</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.6.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of the Combinations on Options and Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.7.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exchange of Orca Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.8.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exchange of Laguna Certificates and Laguna Book-Entry Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.9.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Contributions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.10.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Withholding</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.11.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Merger Consideration Adjustment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.12.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Orca and Topco Actions Prior to and at Closing<I></I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.13.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Assurances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE II</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">GOVERNING DOCUMENTS AND</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ADDITIONAL MATTERS CONCERNING TOPCO GROUP</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Topco Charter and Bylaws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Matters Concerning Topco and its Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE III</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">BOARD AND MANAGEMENT OF TOPCO GROUP</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Board of Directors and Board Committees of Topco; Management of the Topco Group</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Management</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE IV</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">REPRESENTATIONS AND WARRANTIES</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization, Good Standing and Qualification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Corporate Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.4.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Conflicts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.5.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governmental Approvals and Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.6.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reports; Financial Statements; Internal Control and Disclosure Control</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.7.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Certain Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.8.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.9.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Litigation and Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.10.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Employee Benefits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.11.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.12.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Labor Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.13.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Material Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.14.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.15.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Data Protection</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.16.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Properties and Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.17.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Environmental Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.18.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Customers and Suppliers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.19.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Real Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.20.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Personal Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.21.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Related Party Transactions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.22.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Takeover Statutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.23.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.24.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Anti-Corruption, Trade Sanctions, and Trade Control Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.25.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Healthcare Compliance Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.26.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Information in Public Filings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.27.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Brokers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE V</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">COVENANTS</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Interim Operations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Acquisition Proposals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preparation of Orca Scheme Terms, Registration Statement, Nasdaq Listing Application; Publications; Stockholders&#146; Meetings; Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.4.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Reasonable Best Efforts; Regulatory Filings and Other Actions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.5.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Access</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.6.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Transaction Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.7.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Publicity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.8.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Certain Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.9.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.10.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Indemnification; Directors&#146; and Officers&#146; Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.11.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;16 Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.12.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Financing Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.13.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Employment Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.14.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Obligations of Topco, U.S. Merger Sub, U.S. Holdco Sub and U.S. Holdco Sub 2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE VI</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">CONDITIONS TO THE COMBINATIONS</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Condition to Each Party&#146;s Obligation to Effect the Combinations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Conditions to Orca&#146;s and Topco&#146;s Obligations to Effect the Combinations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Conditions to Laguna&#146;s Obligations to Effect the Combinations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE VII</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">TERMINATION</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination by Mutual Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination by Either Laguna or Orca</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination by Laguna</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.4.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination by Orca</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.5.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of Termination and Abandonment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE VIII</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">MISCELLANEOUS AND GENERAL</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Survival</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Modification or Amendment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Extension; Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.4.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.5.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law; Jurisdiction, Waiver of Trial by Jury</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.6.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disclosure Letters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.7.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.8.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.9.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Third-Party Beneficiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.10.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Obligations of Laguna and Orca</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.11.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.12.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interpretation; Construction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.13.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assignment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.14.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Specific Performance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Annex&nbsp;I&nbsp;&#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Defined Terms</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;A&nbsp;&#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Orca Articles of Association</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit B &#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Laguna Post-Merger Certificate of Incorporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit C &#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Laguna Post-Merger Bylaws</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit D &#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Topco Certificate of Incorporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit E &#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Topco Bylaws</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS COMBINATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This BUSINESS COMBINATION AGREEMENT (this &#147;<U>Agreement</U>&#148;), dated as of December&nbsp;22, 2021, is by and among Quidel
Corporation, a Delaware corporation (&#147;<U>Laguna</U>&#148;), Coronado Topco, Inc., a Delaware corporation and a wholly owned subsidiary of Orca (&#147;<U>Topco</U>&#148;), Laguna Merger Sub, Inc., a Delaware corporation and a wholly owned
subsidiary of Topco (&#147;<U>U.S. Merger Sub</U>&#148;), Orca Holdco, Inc., a Delaware corporation and a wholly owned subsidiary of Topco (&#147;<U>U.S. Holdco Sub</U>&#148;), Orca Holdco 2, Inc., a Delaware corporation and a wholly owned
subsidiary of U.S. Holdco Sub (&#147;<U>U.S. Holdco Sub 2</U>&#148;), and Ortho Clinical Diagnostics Holdings plc, a public limited company incorporated under the laws of England and Wales (&#147;<U>Orca</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RECITALS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, each of
Laguna and Orca desire, upon the terms and subject to the conditions set forth in this Agreement, to effect a strategic combination of their businesses through the Combinations and other transactions contemplated hereby; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on December&nbsp;17, 2021, Orca formed Topco and each of Laguna and Orca have determined that from and after the Laguna Effective
Time on the Scheme Effective Date, Topco shall act as the parent company for their combined global businesses, incorporated under the General Corporation Law of the State of Delaware (the &#147;<U>DGCL</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, upon the terms and subject to the conditions set forth in this Agreement, the board of directors of each of Orca and Topco have
unanimously approved the terms for the scheme of arrangement (the &#147;<U>Orca Scheme</U>&#148;) (subject to passing of the Orca Requisite Vote), to be implemented in accordance with, in the case of Orca, Part 26 of the Companies Act 2006, all
other relevant provisions of the Companies Act 2006, the UK companies law and all relevant procedural rules and practice directions or similar relating to and relevant to a scheme of arrangement under Part 26 of the Companies Act 2006 (collectively,
the &#147;<U>UK Scheme Regulations</U>&#148;) and, in the case of Topco, the relevant provisions of the DGCL; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of
directors of each of Orca and Topco have, upon the terms and subject to the conditions set forth in this Agreement and in accordance with the Laws of England and Wales (&#147;<U>English Law</U>&#148;) and the DGCL, respectively, unanimously approved
this Agreement and the Combinations, including the Orca Scheme and the Contributions, pursuant to which each issued and outstanding ordinary share, par value $0.00001 per share, of Orca (the &#147;<U>Orca Shares</U>&#148;), other than any Orca
Shares held by Orca in treasury, shall be acquired by (or transferred within, as the case may be) a DR Nominee on behalf of Topco in exchange for Topco Shares pursuant to the Orca Scheme in exchange for (i) 0.1055 (the &#147;<U>Orca Exchange
Ratio</U>&#148;) shares of common stock, par value $0.001 per share, of Topco (the &#147;<U>Topco Shares</U>&#148;); and (ii)&nbsp;the Cash Portion (as defined below) to be paid pursuant to Section&nbsp;1.4 below, Topco will thereafter contribute
depositary interests in the Orca Shares held by the DR Nominee received by it in the Orca Scheme to U.S. Holdco Sub and U.S. Holdco Sub will thereafter contribute such depositary interests in the Orca Shares to U.S. Holdco Sub 2; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of directors of Laguna (the &#147;<U>Laguna Board</U>&#148;) has, upon the terms and subject to the conditions set forth in
this Agreement and in accordance with the DGCL, unanimously approved this Agreement and the Combinations, including the proposed merger of U.S. Merger Sub with and into Laguna immediately following consummation of the Orca Scheme, with Laguna
surviving the Laguna Merger as a wholly owned subsidiary of Topco (the &#147;<U>Laguna Merger</U>&#148; and, together with the Orca Scheme, the &#147;<U>Combinations</U>&#148;), pursuant to which each share of common stock, par value $0.001 per
share, of Laguna (the &#147;<U>Laguna Shares</U>&#148;), other than Laguna Shares owned by Laguna, Orca, Topco, U.S. Merger Sub or any of their respective wholly owned Subsidiaries, shall be converted into the right to receive one (the
&#147;<U>Laguna Exchange Ratio</U>&#148;) Topco Share; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of directors of Orca (the &#147;<U>Orca Board</U>&#148;) has
determined that the Combinations, including the Orca Scheme and the other transactions contemplated by this Agreement, are consistent with and will further the business strategies and goals of Orca, and are in the best interests of Orca and its
stockholders and (a)&nbsp;has approved the Combinations, including the Orca Scheme (subject to passing of the Orca Requisite Vote) and the other transactions contemplated by this Agreement, (b)&nbsp;declared it advisable to enter into this Agreement
and approved the execution, delivery and performance of this Agreement, and (c)&nbsp;has determined, subject to its duties under applicable Law, to recommend that the Orca Shareholders adopt this Agreement, approve the Orca Scheme and the
transactions contemplated by this Agreement and pass the Orca Requisite Vote (such recommendation, the &#147;<U>Orca Recommendation</U>&#148;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Laguna Board has determined that the Combinations, including the Laguna Merger
and the other transactions contemplated by this Agreement, are consistent with and will further the business strategies and goals of Laguna, and are in the best interests of Laguna and its stockholders, and (a)&nbsp;has approved and declared
advisable this Agreement and Combinations, including the Laguna Merger and the transactions contemplated by this Agreement, and (b)&nbsp;has determined, subject to its duties under applicable Law, to recommend that the Laguna stockholders adopt this
Agreement and the transactions contemplated by this Agreement (such recommendation, the &#147;<U>Laguna Recommendation</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, each of the sole stockholder of Topco and the Board of Directors of Topco, the sole stockholder and the Board of Directors of U.S.
Merger Sub, the sole stockholder and the Board of Directors of U.S. Holdco Sub, and the sole stockholder and the Board of Directors of U.S. Holdco Sub 2, has determined that the Combinations, including the Orca Scheme, the Laguna Merger and the
other transactions contemplated by this Agreement, are consistent with and will further the business strategies and goals of Topco, U.S. Merger Sub, U.S. Holdco Sub, and U.S. Holdco Sub 2, respectively, and are in the best interest of Topco, U.S.
Merger Sub, U.S. Holdco Sub, and U.S. Holdco Sub 2, respectively, and each of their respective stockholders, and has approved this Agreement and the Combinations, including the Orca Scheme (subject to receipt of the Orca Requisite Vote), the Laguna
Merger and the other transactions contemplated by this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, for United States federal income Tax purposes, it is intended
that the Combinations, taken together as a single integrated transaction, will qualify as an exchange described in Section&nbsp;351 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) and the payment of the Cash Portion shall be
treated as a payment pursuant to Section&nbsp;351(b) of the Code and that the Laguna Merger will also qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, this Agreement shall constitute an &#147;agreement of merger&#148; for purposes of Section&nbsp;251 of the DGCL and a &#147;plan of
reorganization&#148; within the meaning of Treasury Regulations Sections <FONT STYLE="white-space:nowrap">1.368-2(g)</FONT> and <FONT STYLE="white-space:nowrap">1.368-3;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of this Agreement, Carlyle Partners VI Cayman Holdings, L.P., a Cayman Islands exempted limited
partnership (&#147;<U>Carlyle</U>&#148;) and holder of approximately 49.79% of the Orca Shares (as defined below) that are issued and outstanding on the date hereof, is executing and delivering to Laguna a transaction support agreement, pursuant to
which Carlyle is agreeing to, among other things, take certain actions in support of the Combinations on the terms and conditions set forth therein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of this Agreement, Topco, Laguna, Orca and Carlyle are entering into a stockholders agreement
regarding certain rights of Carlyle as a stockholder of Topco from and after the Orca Effective Time; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, each of the parties
desires to make certain representations, warranties, covenants and agreements in connection with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in
consideration of the premises, and of the representations, warranties, covenants and agreements contained herein, the parties agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THE COMBINATIONS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.1. </B><U>The </U><U>Combinations</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with English Law (including the UK Scheme
Regulations), the Orca Scheme and the DGCL, as applicable, at the Orca Effective Time, having received the Orca Scheme Order which shall have been duly filed with the Registrar, the Orca Scheme shall occur, upon the consummation of which all Orca
Shares, other than the Excluded Orca Shares, will be transferred to Computershare Limited or another company mutually acceptable to Laguna and Orca and falling within Section&nbsp;67(6) of the Finance Act 1986 (such company, a &#147;<U>DR
Nominee</U>&#148;) on behalf of Topco in exchange for Topco Shares, such that Orca will become a wholly-owned direct subsidiary of the DR Nominee on behalf of Topco and Topco shall allot and issue the Topco Shares in accordance with
Section&nbsp;1.4. The Orca Scheme shall have the effects set forth in this Agreement and the Orca Scheme Terms. The parties shall take all actions necessary so that the articles of association of Orca shall be amended as part of the Orca Scheme, and
as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Orca Effective Time, to read in their entirety in the form attached hereto as <U>Exhibit A</U>, and such articles, as so amended, shall be the articles of Orca until thereafter changed or
amended as provided therein or by applicable Law. In this Clause 1.1(a), references to Orca Shares being transferred to the DR Nominee on behalf of Topco shall, to the extent that such Orca Shares are already held by the DR Nominee at the Orca
Effective Time, be construed as references to the DR Nominee ceasing to hold such Orca Shares on behalf of any other person and commencing holding such Orca Shares on behalf of Topco. As of the Orca Effective Time, the sole member of the board of
directors of Orca shall be an individual reasonably acceptable to Laguna, and shall hold office in accordance with the articles of association of Orca, as amended as part of the Orca Scheme. As of the Orca Effective Time, the officers of Orca shall
be individuals reasonably acceptable to Laguna, and shall hold office in accordance with the articles of association of Orca, as amended as part of the Orca Scheme. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the DGCL, at the Laguna Effective Time,
the Laguna Merger shall occur, upon the consummation of which U.S. Merger Sub shall be merged with and into Laguna, the separate existence of U.S. Merger Sub shall thereupon cease and Laguna shall continue as the surviving corporation (the
&#147;<U>Laguna Merger Surviving Corporation</U>&#148;). The Laguna Merger shall be preceded by the completion of the Orca Scheme. As a result of the Laguna Merger, Laguna shall become a wholly owned direct Subsidiary of Topco. The Laguna Merger
shall have the effects specified in the DGCL. Without limiting the generality of the foregoing, from and after the Laguna Effective Time, the Laguna Merger Surviving Corporation shall possess all the rights, powers, privileges and franchises and be
subject to all of the obligations, liabilities and duties of Laguna and U.S. Merger Sub, all as provided under the DGCL. At the Laguna Effective Time, the certificate of incorporation of Laguna shall be amended to read in its entirety in the form
attached hereto as <U>Exhibit B</U>, and as so amended, shall be the certificate of incorporation of the Laguna Merger Surviving Corporation until thereafter changed or amended as provided therein or by applicable Law. The parties shall take all
actions necessary so that the bylaws of Laguna shall be amended as of the Laguna Effective Time to read in their entirety in the form attached hereto as <U>Exhibit C</U>, and such bylaws, as so amended, shall be the bylaws of the Laguna Merger
Surviving Corporation until thereafter changed or amended as provided therein or by applicable Law. As of the Laguna Effective Time, the sole member of the board of directors of U.S. Merger Sub shall be an individual reasonably acceptable to Laguna,
and shall hold office in accordance with the certificate of incorporation and bylaws of the Laguna Merger Surviving Corporation. As of the Laguna Effective Time, the sole officer of Laguna immediately prior to the Laguna Effective Time shall be an
individual reasonably acceptable to Laguna, and shall hold office in accordance with the certificate of incorporation and bylaws of the Laguna Merger Surviving Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.2. </B><U>Closing</U>. Topco and Orca shall each use their respective reasonable best efforts to obtain the
Orca Scheme Order, including by promptly making all necessary applications under, and otherwise satisfying the requirements of, the UK Scheme Regulations, as promptly as practicable after the date hereof (but excluding any obligation to agree to any
conditions or modifications to the Orca Scheme in respect of any substantive action or agreement) and subject to the satisfaction or (to the extent permitted by applicable Law) waiver of the conditions set forth in Article VI (other than those
conditions that by their terms are to be satisfied at the Closing, but subject to the satisfaction or (to the extent permitted by applicable Law) waiver of such conditions), and will appear by counsel reasonably satisfactory to the parties (the
&#147;<U>Scheme Counsel</U>&#148;) at a hearing (an &#147;<U>Orca Sanction Hearing</U>&#148;) to seek an order of the High Court of England and Wales (the &#147;<U>English Court</U>&#148;) under the UK Scheme Regulations sanctioning the Orca Scheme
(the &#147;<U>Orca Scheme Order</U>&#148;) which shall be effective once the Orca Scheme Order is duly filed with the Registrar in accordance with Section&nbsp;1.3(a) (such date the &#147;<U>Scheme Effective Date</U>&#148;). The date on which the
Orca Scheme Order is filed with the Registrar in accordance with Section&nbsp;1.3(a) shall be the &#147;<U>Closing Date,</U>&#148; and the time at which the Registrar receives the Orca Scheme Order shall be the &#147;<U>Closing</U>.&#148; Following
the receipt of the Orca Scheme Order, the parties shall not take any action to amend, modify, rescind or terminate the Orca Scheme Order. For purposes of this Agreement, &#147;<U>Business Day</U>&#148; means a day (other than a Saturday or Sunday)
on which banks are open for general business in (i)&nbsp;London, England and (ii)&nbsp;New York, State of New York, United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.3. </B><U>Effective Time</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The parties shall make or cause to be made all filings and recordings required by English Law and the DGCL in connection with the due and
effective implementation of the Orca Scheme, including the due filing of the Orca Scheme Order with the Registrar of Companies in England and Wales (the &#147;<U>Registrar</U>&#148;), as required in accordance with the UK Scheme Regulations and
applicable Law as promptly as practicable following the grant by the English Court of the Orca Scheme Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to the terms and
conditions set forth in this Agreement, on the date on which the Orca Scheme Order is duly filed with the Registrar, and as soon as practicable after such time, and in no event prior thereto, Laguna shall file a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certificate of merger relating to the Laguna Merger (the &#147;<U>Laguna Certificate of Merger</U>&#148;) with the Secretary of State of the State of Delaware in accordance with the relevant
provisions of the DGCL and shall make all other filings or recordings required under the DGCL, which Laguna Certificate of Merger shall specify the Laguna Effective Time contemplated by Section&nbsp;1.3(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The parties agree that the Combinations shall become effective sequentially (i)&nbsp;with the Orca Scheme Order becoming effective on the
Scheme Effective Date at the time the Orca Scheme Order is duly delivered to the Registrar, such time being the &#147;<U>Orca Effective Time</U>&#148; and (ii)&nbsp;with the Laguna Certificate of Merger providing that the Laguna Merger shall become
effective on the Scheme Effective Date immediately following the Orca Effective Time (or such subsequent time as Orca and Laguna shall agree and as shall be specified in the Laguna Certificate of Merger, and in no event prior to the Orca Effective
Time), such time being the &#147;<U>Laguna Effective Time</U>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.4. </B><U>Effect of the Orca Scheme
on Orca Shares</U>. As a result of the Orca Scheme and without any action on the part of Topco (other than in respect of the allotment and issuance of Topco shares in accordance with Section&nbsp;1.7), Orca, or the holder of any capital stock of
Topco or Orca, at the Orca Effective Time: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Transfer of Orca Shares. </I>Each issued and outstanding Orca Share at the Orca
Effective Time (other than Orca Shares that are held in the treasury of Orca immediately prior to the Orca Effective Time (each, an &#147;<U>Excluded Orca Share</U>&#148;)) shall be transferred to the DR Nominee (for the benefit of Topco) in
accordance with the terms of this Agreement and the Orca Scheme such that the holders of the Orca Shares (and any holders of depositary interests in Orca Shares) shall cease to have any rights with respect to the Orca Shares, except their rights
under the Orca Scheme. At the Orca Effective Time, or as soon as reasonably practicable thereafter, the statutory register of members for Orca shall be updated in accordance with the Orca Scheme to reflect the transfer of the Orca Shares under the
Orca Scheme to Topco. In this Clause 1.4(a), references to Orca Shares being transferred to the DR Nominee (for the benefit of Topco) shall, to the extent that such Orca Shares are already held by the DR Nominee at the Orca Effective Time, be
construed as references to the DR Nominee ceasing to hold such Orca Shares for the benefit of any other person and commencing holding such Orca Shares for the benefit of Topco. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Topco Share and Cash Allotment.</I> Subject to and in consideration for the transfer of the Orca Shares pursuant to
Section&nbsp;1.4(a), Topco shall, under the Orca Scheme and subject to the terms and conditions thereof and subject to Section&nbsp;1.7, allot and issue, for each issued and outstanding Orca Share at the Orca Effective Time (other than the Excluded
Orca Shares<U>)</U>, (i) the Orca Exchange Ratio of a validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> Topco Share, having the terms set forth in the Topco Charter together with all rights at the Orca Effective
Time or thereafter attached thereto, including the right to receive and retain all dividends and other distributions (if any) (the &#147;Share Portion&#148;) and (ii)&nbsp;the right to receive from Topco $7.14 in cash (the &#147;Cash Portion&#148;
and, together with the Share Portion, the &#147;<U>Orca Scheme Consideration</U>&#148;) immediately following the Orca Effective Time, without any interest thereon and, in each case, subject to any withholding Taxes required by applicable Law in
accordance with Section&nbsp;1.10. The parties&#146; obligations in relation to the allotment and issue of the Topco Shares will be as set out more specifically in the Orca Scheme. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Exchange of Interests in Orca Shares</I>. As of the Orca Effective Time, the DR Nominee on behalf of Topco shall (to the extent that it
is not already the holder) become the holder of all such Orca Shares and each depositary receipt with depositary intermediaries participating in the centralized depositary and clearing system managed by Computershare Trust Company, N.A. (the
&#147;<U>Orca Depositary</U>&#148;) previously representing any such shares shall thereafter be represented by Topco Shares allotted for such Orca Shares in the Orca Scheme in accordance with the Orca Scheme Terms, and Section&nbsp;1.4(a),
Section&nbsp;1.4(b) and Section&nbsp;1.7 of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I>No Fractional Shares</I>. No fractional Topco Shares will be issued in
the Orca Scheme to any holder of Orca Shares. Notwithstanding any other provision of this Agreement, each holder of Orca Shares converted pursuant to Section&nbsp;1.4Section 1.5(a) whom would otherwise have been entitled to receive a fraction of a
Topco Share shall receive from the Exchange Agent, in lieu thereof, cash (without interest) in an amount representing such holder&#146;s proportionate interest in the net proceeds from the sale by the Exchange Agent on behalf of all such holders of
Topco Shares which would otherwise be issued (the &#147;<U>Excess Orca Scheme Shares</U>&#148;). The sale of the Excess Orca Scheme Shares by the Exchange Agent shall be executed on Nasdaq, and shall be executed in round lots to the extent
practicable. Until the net proceeds of such sale or sales have been distributed to such former holders of Orca Shares, the Exchange Agent shall hold such proceeds in trust for such holders (the &#147;<U>Fractional Interests Trust</U>&#148;). Topco
shall pay all commissions, transfer Taxes and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> transaction costs incurred in connection with such sale of the Excess Orca Scheme Shares. The Exchange
Agent shall determine the portion of the Fractional Interests Trust to which each holder of Orca Shares shall be entitled, if any, by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
multiplying the amount of the aggregate net proceeds comprising the Fractional Interests Trust by a fraction, the numerator of which is the amount of fractional Topco Shares to which such former
holder of Orca Shares is entitled and the denominator of which is the aggregate amount of fractional Topco Shares to which all holders of Orca Shares are entitled. As soon as practicable after the determination of the amount of cash, if any, to be
paid to holders of Orca Shares in lieu of fractional Topco Shares, the Exchange Agent shall make available such amounts to such former holders of Orca Shares. Any such sale shall be made within ten (10)&nbsp;Business Days or such shorter period as
may be required by applicable Law as soon as reasonably practicable after the Orca Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <I>Orca Shareholder
Definition</I>. As used in this Agreement, &#147;<U>Orca Shareholder</U>&#148; means a registered holder of Orca Shares as shown from time to time on Orca&#146;s register of members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Topco and Orca shall take all action necessary so that the Topco Shares owned by Orca shall be transferred to Topco, effective as of the
Orca Effective Time, for no consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.5. </B><U>Effect of the Laguna Merger on Laguna Shares; Laguna
Merger Exchange</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) As a result of the Laguna Merger and the transactions contemplated by Section&nbsp;1.2 and without any
additional action on the part of Laguna, U.S. Merger Sub or the holders of any capital stock of Laguna or U.S. Merger Sub, at the Laguna Effective Time: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <I>Laguna Merger Consideration.</I> Topco shall allot and issue for each Laguna Share (other than Excluded Laguna Shares) issued and
outstanding immediately prior to the Laguna Effective Time, and each such Laguna Share shall automatically be converted into the right to receive, the Laguna Exchange Ratio of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT>
Topco Shares, having the terms set forth in the Topco Charter (such number of Topco Shares, the &#147;<U>Laguna Merger Consideration</U>&#148; and, together with the Orca Scheme Consideration, the &#147;<U>Combination Consideration</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <I>Excluded Laguna Shares</I>. Each Laguna Share owned by Laguna, Orca or U.S. Merger Sub, and in each case not held on behalf of third
parties (each, an &#147;<U>Excluded Laguna Share</U>&#148;), issued and outstanding immediately prior to the Laguna Effective Time shall automatically be cancelled and shall cease to exist, with no consideration being paid with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <I>U.S. Merger Sub Shares</I>. Each issued and outstanding share of common stock, par value $0.01 per share, of U.S. Merger Sub issued
and outstanding immediately prior to the Laguna Effective Time shall automatically be converted into the right to receive one fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> share of common stock, par value $0.01, of the Laguna
Merger Surviving Corporation, which shares at such time shall comprise the only outstanding shares of capital stock of the Laguna Merger Surviving Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In accordance with Section&nbsp;262 of the DGCL, no appraisal rights shall be available to holders of Laguna Shares in connection with the
Laguna Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>No Fractional Shares</I>. No fractional Topco Shares will be issued in the Laguna Merger to any holder of Laguna
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I>Unclaimed Funds</I>. Any portion of the Exchange Fund and Fractional Interests Trust that remains unclaimed by the former
stockholders of Laguna for 180 days after the Laguna Effective Time shall be delivered to Topco. Any former stockholders of Laguna who have not theretofore complied with Section&nbsp;1.8 shall thereafter look only to Topco for delivery of any Topco
Shares or Fractional Interests Trust of such stockholders and payment of any dividends and other distributions in respect of Topco Shares of such stockholder payable and/or issuable pursuant to this Section&nbsp;1.5 upon delivery to the Exchange
Agent of the applicable certificates formerly representing the Laguna Shares or written instructions for the transfer and cancellation of any entry in the records of Laguna or its transfer agent formerly representing the Laguna Shares, in each case,
without any interest thereon. Notwithstanding the foregoing, none of Topco, Orca, Laguna, U.S. Merger Sub, the Exchange Agent or any other Person shall be liable to any former holder of Laguna Shares for any amount properly delivered to a public
official pursuant to applicable abandoned property, escheat or similar Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.6. </B><U>Effect of the
Combinations on Options and Awards</U>.<I><SUP STYLE="font-size:85%; vertical-align:top"> </SUP></I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Effect of the Orca Scheme on
Orca Stock Awards</I><I>.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Each option to subscribe for Orca Shares (an &#147;<U>Orca Stock Option</U>&#148;)
granted under the employee and director stock plans of Orca (the &#147;<U>Orca Stock Plans</U>&#148;), whether vested or unvested, that is outstanding immediately prior to the Orca Effective Time shall cease to represent a right to acquire Orca
Shares and shall automatically, without any action on the part of the holders thereof, be converted, at the Orca Effective Time, into (A)&nbsp;an option to purchase Topco Shares (a &#147;<U>Topco Stock Option</U>&#148;) on the same terms and
conditions as were applicable under such Orca Stock Option, except as adjusted hereby, (B)&nbsp;with respect to the portion of such Orca Stock Option that is vested as of the Orca Effective Time, a right to receive payment, in cash, equal to the
Cash Portion in respect of the Orca Shares that are subject to the vested portion of the Orca Stock Option, and payable pursuant to Section&nbsp;1.6(a)(vi) below, and (C)&nbsp;with respect to the portion of such Orca Stock Option that is not vested
as of the Orca Effective Time, a right to receive payment, in cash, equal to the Cash Portion in respect of the Orca Shares that are subject to the unvested portion of the Orca Stock Option, payable through the payroll system or payroll provider of
Topco or its affiliate and subject to applicable withholding, as and when the corresponding portion of the Orca Stock Option vests in accordance with its existing terms (and subject to the same vesting conditions as the existing Orca Stock Option).
The number of Topco Shares subject to each such Topco Stock Option shall be equal to the product (rounded down to the nearest whole number) of (x)&nbsp;the number of Orca Shares subject to such Orca Stock Option immediately prior to the Orca
Effective Time and (y)&nbsp;the Orca Exchange Ratio, and such Topco Stock Option shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A)&nbsp;the exercise price per Orca Share of such option immediately prior to
the Orca Effective Time divided by (B)&nbsp;the Orca Exchange Ratio; <U>provided</U>, <U>however</U>, that the exercise price and the number of Topco Shares purchasable pursuant to such Topco Stock Option will be determined in a manner consistent
with the requirements of Section&nbsp;409A of the Code, without reducing the total value of consideration provided to the holders of Orca Stock Options hereunder; <U>provided</U>, <U>further</U>, that in the case of any Orca Stock Option to which
Section&nbsp;422 of the Code applies, the exercise price and the number of Topco Shares purchasable pursuant to such Orca Stock Option shall be determined in accordance with the foregoing, subject to such adjustments as are necessary in order to
satisfy the requirements of Section&nbsp;424(a) of the Code without reducing the total value of consideration provided to the holders of Orca Stock Options hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Each award of restricted stock, restricted stock units or other similar rights or awards granted under an Orca Stock Plan and relating
to Orca Shares (any such award an &#147;<U>Orca Equity Right</U>&#148; and such awards together with the Orca Stock Options, the &#147;<U>Orca Stock Awards</U>&#148;) that is outstanding immediately prior to the Orca Effective Time shall
automatically, without any action on the part of the holders thereof, cease to relate to or represent a right to receive Orca Shares and shall be converted, at the Orca Effective Time, into (A)&nbsp;an award of restricted stock, restricted stock
units, or other similar rights or awards, as applicable, relating to Topco Shares (a &#147;<U>Topco Equity Right</U>&#148; and, together with the Topco Stock Options, &#147;<U>Topco Stock Awards</U>&#148;) of the same type and on the same terms and
conditions as were applicable to the corresponding Orca Equity Right, except as adjusted hereby, and (B)&nbsp;with respect to the portion of such Orca Equity Right that is not vested as of the Orca Effective Time, a right to receive payment, in
cash, equal to the Cash Portion in respect of the Orca Shares that are subject to the unvested portion of the Orca Equity Right, payable through the payroll system or payroll provider of Topco or its affiliate and subject to applicable withholding,
as and when the corresponding portion of the Orca Equity Right vests in accordance with its existing terms (and subject to the same vesting conditions as the existing Orca Equity Right). The number of Topco Shares covered by each such Topco Equity
Right shall be equal to the product (rounded to the nearest whole number) of (x)&nbsp;the number of Orca Shares subject to the Orca Equity Right immediately prior to the Orca Effective Time and (y)&nbsp;the Orca Exchange Ratio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) To the extent any Orca Stock Award is, immediately prior to the Orca Effective Time, subject to performance-based vesting based on the
attainment of a stock price level or target (a &#147;<U>Stock Price Hurdle</U>&#148;), such Stock Price Hurdle shall be adjusted to reflect the Orca Scheme Consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) As soon as practicable after the Orca Effective Time, Topco shall deliver to the holders of Orca Stock Awards appropriate notices
setting forth such holders&#146; rights pursuant to the respective Orca Stock Awards and stating that such Orca Stock Awards and the agreements relating thereto have been assumed by Topco and shall continue in effect on the same terms and conditions
(subject to the adjustments required or permitted by Section&nbsp;1.6(a) after giving effect to the Orca Scheme and the terms of the Orca Stock Plans). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Prior to the Orca Effective Time, Orca shall take all necessary actions for the adjustment of Orca Stock Awards under this
Section&nbsp;1.6(a); <U>provided</U> that such actions shall expressly be conditioned upon the consummation of the Combinations and the other transactions contemplated hereby and shall be of no effect if this Agreement is terminated. Topco shall
reserve for issuance a number of Topco Shares at least equal to the number of Topco Shares that will be issuable pursuant to Topco Stock Awards as a result of the actions contemplated by this Section&nbsp;1.6(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) All cash payments described in this Section&nbsp;1.6(a) shall be paid through the
payroll system or payroll provider of Topco or its affiliate; provided that for purposes of Section&nbsp;1.10, the withholding applicable to the Cash Portion shall be applied solely to such Cash Portion and the withholding applicable to the Share
Portion shall be applied solely to such Share Portion. Notwithstanding the foregoing, if any such payment cannot be made through such payroll system or payroll provider, then Topco or its affiliate will issue a check for such payment promptly
following the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Effect of the Laguna Merger on Laguna Stock Awards</I><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Each option to purchase Laguna Shares (a &#147;<U>Laguna Stock Option</U>&#148;) granted under the employee and director stock plans of
Laguna (the &#147;<U>Laguna Stock Plans</U>&#148;), whether vested or unvested, that is outstanding immediately prior to the Laguna Effective Time shall automatically, without any action on the part of the holders thereof, cease to represent a right
to acquire Laguna Shares and shall be converted, at the Laguna Effective Time, into a Topco Stock Option on the same terms and conditions as were applicable under such Laguna Stock Option, except as adjusted hereby. The number of Topco Shares
subject to each such Topco Stock Option shall be equal to the product (rounded down to the nearest whole number) of (x)&nbsp;the number of Laguna Shares subject to such option immediately prior to the Laguna Effective Time and (y)&nbsp;the Laguna
Exchange Ratio, and such Topco Stock Option shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A)&nbsp;the exercise price per Laguna Share of such Laguna Stock Option immediately prior to the Laguna Effective
Time divided by (B)&nbsp;the Laguna Exchange Ratio; <U>provided</U>, <U>however</U>, that the exercise price and the number of Topco Shares purchasable pursuant to such Topco Stock Option will be determined in a manner consistent with the
requirements of Section&nbsp;409A of the Code; <U>provided</U>, <U>further</U>, that in the case of any Laguna Stock Option to which Section&nbsp;422 of the Code applies, the exercise price and the number of Topco Shares purchasable pursuant to such
Laguna Stock Option shall be determined in accordance with the foregoing, subject to such adjustments as are necessary in order to satisfy the requirements of Section&nbsp;424(a) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Each award of restricted stock units, performance restricted stock units or other similar rights or awards granted under a Laguna Stock
Plan and relating to Laguna Shares (any such award a &#147;<U>Laguna Equity Right</U>&#148; and such awards together with the Laguna Stock Options, the &#147;<U>Laguna Stock Awards</U>&#148;) that is outstanding immediately prior to the Laguna
Effective Time shall automatically, without any action on the part of the holders thereof, cease to relate to or represent a right to receive Laguna Shares and shall be converted, at the Laguna Effective Time, into a Topco Equity Right of the same
type and on the same terms and conditions as were applicable to the corresponding Laguna Equity Right, except as adjusted hereby. The number of Topco Shares covered by each such Topco Equity Right shall be equal to the product (rounded to the
nearest whole number) of (x)&nbsp;the number of Laguna Shares subject to the Laguna Equity Right immediately prior to the Laguna Effective Time and (y)&nbsp;the Laguna Exchange Ratio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) To the extent any Laguna Stock Award is, immediately prior to the Laguna Effective Time, subject to any performance-based vesting or
other performance conditions, the Laguna Board, or an applicable committee thereof, may, prior to the Orca Effective Time make such equitable adjustments, if any, to the applicable performance goals or conditions relating to such Laguna Stock
Awards, as the Laguna Board may determine to be necessary or appropriate as a result of the consummation of the Combinations, which equitable adjustments shall take effect upon and be subject to the consummation of the Combinations and, in each
case, subject to and in accordance with the terms and conditions of the Laguna Stock Plans and the Laguna Stock Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) As soon as
practicable after the Laguna Effective Time, Topco shall deliver to the holders of Laguna Stock Awards appropriate notices setting forth such holders&#146; rights pursuant to the respective Laguna Stock Awards and stating that such Laguna Stock
Awards and the agreements relating thereto have been assumed by Topco and shall continue in effect on the same terms and conditions (subject to the adjustments required or permitted by Section&nbsp;1.6(b) after giving effect to the Laguna Merger and
the terms of the Laguna Stock Plans). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Prior to the Laguna Effective Time, Laguna shall take all necessary action for the adjustment
of Laguna Stock Awards under this Section&nbsp;1.6(b); <U>provided,</U> that such actions shall expressly be conditioned upon the consummation of the Combinations and the other transactions contemplated hereby and shall be of no effect if this
Agreement is terminated. Topco shall reserve for issuance a number of Topco Shares at least equal to the number of Topco Shares that will be issuable pursuant to Topco Stock Awards as a result of the actions contemplated by this Section&nbsp;1.6(b).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) Prior to the Laguna Effective Time, the Board of Directors of Laguna or the appropriate committee thereof shall take all reasonable
actions, including adopting any necessary resolutions or amendments with respect to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Laguna&#146;s Amended and Restated 1983 Employee Stock Purchase Plan (the &#147;<U>Laguna ESPP</U>&#148;) to effectuate the following: (i)&nbsp;to cause the &#147;Purchase Period&#148; (as
defined in the Laguna ESPP) commencing on August&nbsp;15, 2021 to be the final Purchase Period under the Laguna ESPP and the options under the Laguna ESPP to be exercised on the earlier of (x)&nbsp;the scheduled purchase date for such Purchase
Period and (y)&nbsp;the date that is five business days prior to the Laguna Effective Time (with any participant payroll deductions not applied to the purchase of shares returned to the participant) and (ii)&nbsp;to terminate the Laguna ESPP
effective immediately prior to the Laguna Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) Prior to the Scheme Effective Date, Topco shall adopt an employee stock
purchase plan on terms mutually agreeable between Laguna and Orca, and submit such employee stock purchase plan for approval by the stockholders of Topco in a manner compliant with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) At the Orca Effective Time and the Laguna Effective Time, as applicable, if Topco determines that it desires to do so, Topco may assume
any or all of the Orca Stock Plans or Laguna Stock Plans. If Topco elects to so assume any Orca Stock Plan or Laguna Stock Plan, then, under such Orca Stock Plan or Laguna Stock Plan, as applicable, Topco will be entitled to grant stock awards, to
the extent permissible under applicable Laws, using the share reserves of such Orca Stock Plan or Laguna Stock Plan, as applicable, as of the Orca Effective Time or Laguna Effective Time, as applicable (including any shares returned to such share
reserves as a result of the termination or forfeiture of a Topco Stock Award that is issued or granted in substitution of an Orca Stock Award or Laguna Stock Award pursuant to this Section&nbsp;1.6), except that: (i)&nbsp;shares covered by such
awards will be Topco Shares; (ii)&nbsp;all references in such Orca Stock Plan or Laguna Stock Plan to a number of shares will be deemed amended to refer instead to that number of Topco Shares (rounded down to the nearest whole share) as adjusted
pursuant to the application of the Orca Exchange Ratio or Laguna Exchange Ratio, as applicable; and (iii)&nbsp;the Board of Directors of Topco (the &#147;<U>Topco Board</U>&#148;) or a committee thereof will succeed to the authority and
responsibility of the Orca Board or Laguna Board or any committee thereof with respect to the administration of such Orca Stock Plan or Laguna Stock Plan, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) As soon as practicable following the Laguna Effective Time, Topco shall file a registration statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> (or any successor or other appropriate forms) with respect to Topco Shares subject to the Topco Stock Awards held by individuals who are employees, directors or consultants of Topco and its Subsidiaries as of
the Scheme Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.7. </B><U>Exchange of Orca </U><U>Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Exchange Agent</I>. As promptly as practicable following the date hereof, Topco shall appoint a United States bank or trust company or
other independent financial institution in the United States reasonably satisfactory to Orca and Laguna (the &#147;<U>Exchange Agent</U>&#148;) to act, among other things, as exchange agent for the Orca Scheme and the Laguna Merger and to deliver
the Orca Scheme Consideration (including all cash payable pursuant to Section&nbsp;1.6) and the Laguna Merger Consideration to former stockholders of Orca and Laguna, respectively. The parties shall enter into an Exchange Agent Agreement with the
Exchange Agent, which agreement shall set forth the duties, responsibilities and obligations of the Exchange Agent consistent with the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Orca Shares shall be transferred under the Orca Scheme in exchange for the Orca Scheme Consideration (without interest and after giving
effect to any required Tax withholdings as provided in Section&nbsp;1.10) in accordance with this Agreement, the Orca Scheme Terms, the Orca Scheme Order, the rules and procedures of any depositary or clearing agency through which such shares are
held or traded and applicable Law. Prior to the Orca Sanction Hearing, Laguna will irrevocably commit to Topco and, as may be required, the English Court (on terms satisfactory to each of them) to make available to Topco the Cash Portion of the Orca
Scheme Consideration, such that on the Closing Date and immediately following the Laguna Effective Time and in full satisfaction of any obligation to pay the Cash Portion to holders of Orca Shares, Laguna shall deposit, or cause to be deposited, in
each case on behalf of Topco, with the Exchange Agent, for the benefit of the holders of Orca Shares issued and outstanding immediately prior to the Orca Effective Time, for exchange in accordance with Section&nbsp;1.6 through the Exchange Agent,
sufficient cash to make delivery of the Cash Portion to such holders pursuant to Section&nbsp;1.4(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Excluded Orca Share shall
immediately following the Orca Effective Time be cancelled and shall cease to exist, with no consideration being paid with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.8. </B><U>Exchange of </U><U>Laguna</U><U> Certificates and Laguna Book-Entry Shares</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Exchange Fund. </I>Topco shall deposit with the Exchange Agent, for the benefit of
the holders of Laguna Shares (other than the Excluded Laguna Shares), for exchange in accordance with this ARTICLE I, a number of Topco Shares equal to the total number of Topco Shares issuable pursuant to Section&nbsp;1.5 (the &#147;<U>Exchange
Fund</U>&#148;). The Exchange Agent shall, pursuant to irrevocable instructions, deliver Topco Shares contemplated to be issued pursuant to Section&nbsp;1.5 out of the Exchange Fund. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Exchange Procedures</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <I>Certificates.</I> As soon as practicable after the Laguna Effective Time (and in no event later than five (5) days after the Laguna
Effective Time), Topco shall cause the Exchange Agent to mail to each Person that was, immediately prior to the Laguna Effective Time, a holder of record of Laguna Shares (other than the Excluded Laguna Shares) represented by a certificate (each a
&#147;<U>Laguna Certificate</U>&#148;): (A) an appropriate and customary letter of transmittal, which shall specify that delivery shall be effected, and risk of loss and title to the Laguna Certificates shall pass, only upon delivery of the Laguna
Certificates to the Exchange Agent, and shall otherwise be in such form as Topco, Laguna and the Exchange Agent shall reasonably agree; and (B) instructions for use in effecting the surrender of the Laguna Certificates (or affidavits of loss in lieu
of the Laguna Certificates as provided in Section 1.8(e)) in exchange for the Laguna Merger Consideration. Upon surrender of a Laguna Certificate (or affidavit of loss in lieu of the Laguna Certificate as provided in Section 1.8(e)) to the Exchange
Agent in accordance with the terms of such letter of transmittal, duly executed, the holder of such Laguna Certificate shall be entitled to receive in exchange therefor the Laguna Merger Consideration (after giving effect to any required Tax
withholdings as provided in Section 1.10), and the Laguna Certificate so surrendered shall forthwith be cancelled. No interest will be paid or accrued on any amount payable upon due surrender of the Laguna Certificates. In the event of a transfer of
ownership of Laguna Shares that is not registered in the transfer records of Laguna, the Laguna Merger Consideration, upon due surrender of the Laguna Certificate, may be issued to such transferee if the Laguna Certificate formerly representing such
Laguna Shares is presented to the Exchange Agent, accompanied by all documents reasonably required by Topco to evidence and effect such transfer and to evidence that any applicable stock transfer Taxes have been paid or are not applicable. Until
surrendered as contemplated hereby, each Laguna Certificate shall be deemed at any time after the Laguna Effective Time to represent only the right to receive the Laguna Merger Consideration (in each case, without interest and after giving effect to
any required Tax withholdings as provided in Section 1.10) as contemplated by this Agreement. For the purposes of this Agreement, the term &#147;Person&#148; means any individual, corporation (including not-for-profit), general or limited
partnership, limited liability company, joint venture, estate, trust, association, organization, Governmental Entity or Self-Regulatory Organization or other entity of any kind or nature. &#147;Self-Regulatory Organization&#148; means any United
States or non-United States commission, board, agency or body that is not a Governmental Entity but is charged with the supervision or regulation of brokers, dealers, securities underwriting or trading, stock exchanges, commodities exchanges,
electronic communication networks, insurance companies or agents, investment companies or investment advisers, including Nasdaq Global Select Market (&#147;<U>Nasdaq</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <I>Laguna Book-Entry Interests</I>. Notwithstanding anything to the contrary contained in this Agreement, no holder of rights to an
entry in the records of Laguna or its transfer agent representing Laguna Shares (the &#147;<U>Laguna Book-Entry Interests</U>&#148;) shall be required to deliver a Laguna Certificate or, in the case of holders of Laguna Book-Entry Interests held
through The Depositary Trust Company, an executed letter of transmittal to the Exchange Agent to receive the Laguna Merger Consideration that such holder is entitled to receive pursuant to this Section&nbsp;1.8. In lieu thereof, each holder of
record of one or more Laguna Book-Entry Interests held through The Depositary Trust Company whose Laguna Shares were converted into the right to receive the Laguna Merger Consideration shall automatically upon the Laguna Effective Time be entitled
to receive, and Topco shall cause the Exchange Agent to pay and deliver as promptly as practicable after the Laguna Effective Time, in respect of each such Laguna Book-Entry Interest the Laguna Merger Consideration, without interest and after giving
effect to any required Tax withholdings as provided in Section&nbsp;1.10), and such Laguna Book-Entry Interests of such holder shall forthwith be cancelled. As soon as practicable after the Laguna Effective Time (and in no event later than five
(5)&nbsp;days after the Laguna Effective Time), Topco shall cause the Exchange Agent to mail to each Person that was, immediately prior to the Laguna Effective Time, a holder of record of Laguna Book-Entry Interests not held through The Depositary
Trust Company: (A)&nbsp;an appropriate and customary letter of transmittal, which shall be in such form as Topco, Laguna and the Exchange Agent shall reasonably agree; and (B)&nbsp;instructions for returning such letter of transmittal in exchange
for the Laguna Merger Consideration. Upon delivery of such letter of transmittal to the Exchange Agent, in accordance with the terms of such letter of transmittal, duly executed, the holder of such Laguna Book-Entry Interests shall be entitled to
receive in exchange therefor the Laguna Merger Consideration (after giving effect to any required Tax withholdings as provided in Section&nbsp;1.10), and such Laguna Book-Entry Interests so surrendered shall forthwith be cancelled. No interest will
be paid or accrued on any amount payable upon due surrender of Laguna Book-Entry Interests. The Laguna </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Merger Consideration with respect to Laguna Book-Entry Interests shall only be made to the Person in whose name such Laguna Book-Entry Interests are registered. Until paid or surrendered as
contemplated hereby, each Laguna Book-Entry Interest shall be deemed at any time after the Laguna Effective Time to represent only the right to receive the Laguna Merger Consideration as contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Transfer Books; No Further Ownership Rights in Shares</I>. At the Laguna Effective Time, the stock transfer books of Laguna shall be
closed and thereafter there shall be no further registration of transfers of Laguna Shares on the records of Laguna. From and after the Laguna Effective Time, the holders of Laguna Certificates and Laguna Book-Entry Interests representing Laguna
Shares outstanding immediately prior to the Laguna Effective Time shall cease to have any rights with respect to such shares except as otherwise provided for herein or by applicable Law, <U>subject</U>, <U>however</U>, to the Laguna Merger Surviving
Corporation&#146;s obligation to pay any dividends or make any other distributions with a record date prior to the Laguna Effective Time that may have been declared or made by Laguna on such Laguna Shares not in violation of the terms of this
Agreement or prior to the date of this Agreement and which remain unpaid at the Laguna Effective Time. If, after the Laguna Effective Time, Laguna Certificates representing Laguna Shares are presented to Topco for any reason, they shall be cancelled
and exchanged for the Laguna Merger Consideration as provided in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I>Termination of Fund; Abandoned Property; No
Liability</I>. At any time following one (1)&nbsp;year after the Scheme Effective Date, Topco shall be entitled to require the Exchange Agent to deliver to it, or its nominee, any Topco Shares remaining in the Exchange Fund made available to the
Exchange Agent and not delivered to holders of Laguna Certificates or Laguna Book-Entry Interests, and thereafter such holders shall be entitled to look only to Topco (subject to abandoned property, escheat or other similar Laws) as general
creditors thereof with respect to the Laguna Merger Consideration payable upon due surrender of their Laguna Certificates or Laguna Book-Entry Interests and compliance with the procedures in Section&nbsp;1.8. If, prior to six (6)&nbsp;years after
the Scheme Effective Date (or otherwise immediately prior to such time on which any payment in respect hereof would escheat to or become the property of any Governmental Entity pursuant to any applicable abandoned property, escheat or similar Laws),
any holder of Laguna Certificates or Laguna Book-Entry Interests has not complied with the procedures in Section&nbsp;1.8 to receive the Laguna Merger Consideration to which such holder would otherwise be entitled, the Laguna Merger Consideration to
which such holder would otherwise be entitled in respect of such Laguna Certificates or Laguna Book-Entry Interests shall, to the extent permitted by applicable Law, become the property of Topco, free and clear of all claims or interest of any
Person previously entitled thereto. Notwithstanding the foregoing, neither Topco nor the Exchange Agent shall be liable to any holder of a Laguna Certificate or Laguna Book-Entry Interests for Laguna Merger Consideration delivered to a public
official pursuant to any applicable abandoned property, escheat or similar Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <I>Lost, Stolen or Destroyed Certificates</I>. In the
event that any Laguna Certificates shall have been lost, stolen or destroyed, the Exchange Agent shall issue in exchange for such lost, stolen or destroyed Laguna Certificates, upon the making of an affidavit of that fact by the holder thereof, the
Laguna Merger Consideration payable in respect thereof pursuant to Section&nbsp;1.5 hereof (after giving effect to any required Tax withholdings as provided in Section&nbsp;1.10); <U>provided</U>, <U>however</U>, that Topco or the Exchange Agent
may, in its reasonable discretion and as a condition precedent to the payment of the Laguna Merger Consideration, require the owners of such lost, stolen or destroyed Laguna Certificates to deliver a bond in such sum as it may reasonably direct as
indemnity against any claim that may be made against Topco or the Exchange Agent with respect to the Laguna Certificates alleged to have been lost, stolen or destroyed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <I>Distributions with Respect to Unexchanged Topco Shares</I>. No dividends or other distributions declared or made after the Laguna
Effective Time with respect to Topco Shares with a record date after the Laguna Effective Time shall be paid to the holder of any unsurrendered Laguna Certificate or Laguna Book-Entry Interest with respect to Topco Shares represented thereby, unless
and until the holder of such Laguna Certificate or Laguna Book-Entry Interest shall surrender such Laguna Certificate or Laguna Book-Entry Interest. Subject to the effect of escheat, Tax or other applicable Laws, following surrender of any such
Laguna Certificate, there shall be paid by Topco to the holder of the certificates representing Topco Shares issued in exchange therefor, without interest, (i)&nbsp;promptly, the amount of dividends or other distributions with a record date after
the Laguna Effective Time theretofore paid with respect to such Topco Shares and (ii)&nbsp;at the appropriate payment date, the amount of dividends or other distributions, with a record date after the Laguna Effective Time but prior to surrender and
a payment date occurring after surrender, payable with respect to such Topco Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.9.
</B><U>Contributions</U>. Immediately following, and as part of a plan that includes, the Combinations, Topco shall transfer (the &#147;<U>First Contribution</U>&#148;) 100% of the depositary interests in the issued and outstanding Orca Shares held
by the DR Nominee and the Deferred Shares to U.S. Holdco Sub as a contribution to capital and, at least two days following the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
First Contribution, U.S. Holdco Sub will transfer (the &#147;<U>Second Contribution</U>&#148; and, collectively with the First Contribution, the &#147;<U>Contributions</U>&#148;), 100% of the
depositary interests in the issued and outstanding Orca Shares held by U.S. Holdco Sub and the Deferred Shares to U.S. Holdco Sub 2, a newly formed Delaware corporation wholly owned by U.S. Holdco Sub. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.10. </B><U>Withholding</U>. Each of Laguna, Orca, Topco, the Laguna Merger Surviving Corporation and the
Exchange Agent shall be entitled to deduct and withhold from any consideration payable pursuant to this Agreement or the Orca Scheme such amounts, if any, as it is required to deduct and withhold with respect to the making of such payment under the
Code and the rules and regulations promulgated thereunder, or any provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law. To the extent that amounts are so withheld by Laguna, Orca, Topco, the Laguna Merger Surviving
Corporation or the Exchange Agent, as the case may be and paid over to the appropriate Tax authority, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the recipient in respect of which such deduction
and withholding was made. All parties to this Agreement shall cooperate in coordinating the deduction and withholding of any Tax required to be deducted and withheld under applicable Tax Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.11. </B><U>Merger Consideration Adjustment</U>. In the event that between the date of this Agreement and the
Laguna Effective Time, the outstanding Orca Shares or Laguna Shares or securities convertible into, or exercisable or exchangeable for Orca Shares or Laguna Shares shall have been changed into a different number of shares or a different class, by
reason of any stock dividend or distribution, subdivision, reclassification, recapitalization, split, combination, consolidation or exchange of shares, or any similar event shall have occurred, then any number or amount contained herein (including
any exchange ratio) which is based upon the number of Orca Shares or Laguna Shares, as the case may be, will be appropriately adjusted to provide to the stockholders of both Orca and Laguna the same economic effect as contemplated by this Agreement
prior to such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.12. </B><U>O</U><U>rca and Topco Actions Prior to and at Closing</U><I><U>.</U></I>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) On or prior to Closing, Orca shall procure that a meeting of the Orca Board is held at which resolutions are passed (conditional upon
the delivery of the Orca Scheme Order to the Registrar and effective as at the Orca Effective Time) approving: (i)&nbsp;the transfer to (or, as applicable, within) the DR Nominee of the Orca Shares provided to be transferred under the Orca Scheme
and the registration as a member of such person(s) in accordance with the Orca Scheme in respect of such Orca Shares, with such Orca Shares to be subsequently transferred by the DR Nominee to Topco, (ii)&nbsp;the removal or resignation of the
directors of Orca, (iii)&nbsp;the appointment of such persons as Orca shall determine (acting reasonably) as the directors of Orca and (iv)&nbsp;the (A) transfers to (a)&nbsp;Topco at the Orca Effective Time; (b)&nbsp;to U.S. Holdco Sub at the time
of the First Contribution and (c)&nbsp;to U.S. Holdco Sub 2 at the time of the Second Contribution, each for nil consideration and (B)&nbsp;subsequent repurchase by Orca (no earlier than one day after the Orca Conversion) for nil consideration, and
subsequent cancellation, of the 50,001 deferred shares of &pound;1.00 each in the share capital of Orca (the &#147;<U>Deferred Shares</U>&#148;), and directing Orca&#146;s officers to take such actions within their control to effect such transfers,
repurchase and cancellation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) On or prior to Closing, Topco shall procure that a meeting of the Topco Board is held at which
resolutions are passed (conditional upon the delivery of the Orca Scheme Order to the Registrar and effective as at the Orca Effective Time) approving (i)&nbsp;the allotment and issue, in accordance with and subject to the terms and conditions of
the Orca Scheme, to holders of the Orca Shares, subject to the Orca Scheme, of the number of Topco Shares provided for in the Orca Scheme and (ii)&nbsp;the appointment to the Topco Board of such persons as are nominated pursuant to Section&nbsp;3.1.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) On the Closing Date, Orca shall: (i)&nbsp;deliver the Orca Scheme Order to the Registrar with a copy to Topco and Laguna,
(ii)&nbsp;deliver to Topco a certified copy of the resolutions referred to in Section&nbsp;1.12(a) and (iii)&nbsp;deliver to Topco all share certificates received by Orca in respect of the Orca Shares transferred to a DR Nominee in accordance with
the Orca Scheme, <U>provided</U> that, to the extent that any such share certificates are received after the Closing Date, delivery to Topco shall be made as soon as reasonably practicable thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) On the Closing Date, Topco shall deliver to Orca and Laguna a certified copy of the resolutions referred to in Section&nbsp;1.12(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.13. </B><U>Further Assurances</U>. If at any time before or after the Orca Effective Time, the parties
reasonably believe or are advised that any further instruments, deeds, documents, conveyances, assignments or assurances are reasonably necessary or desirable to consummate the Combinations or to carry out the purposes and intent of this Agreement
at or after the Orca Effective Time, then the parties and their respective officers and directors shall execute and deliver all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such proper instruments, deeds, assignments or assurances and do all other things reasonably necessary or desirable to consummate the Combinations and to carry out the intent and purposes of this
Agreement in accordance with its terms and conditions. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE II </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GOVERNING DOCUMENTS AND </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ADDITIONAL MATTERS CONCERNING TOPCO GROUP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.1. </B><U>Topco </U><U>Charter and Bylaws</U>. Prior to the Orca Effective Time, the sole stockholder of Topco
shall adopt the Amended and Restated Certificate of Incorporation of Topco, substantially in the form attached hereto as <U>Exhibit D</U> and as otherwise set forth in this Agreement (the &#147;<U>Topco Charter</U>&#148;), to be in effect as of the
Orca Effective Time, or prior to the Orca Effective Time if mutually agreed by Laguna and Orca. Prior to the Orca Effective Time, the board of directors of Topco shall adopt the Amended and Restated Bylaws of Topco, substantially in the form
attached hereto as <U>Exhibit E</U> and as otherwise set forth in this Agreement (the &#147;<U>Topco Bylaws</U>&#148;), to be in effect as of the Orca Effective Time, or prior to the Orca Effective Time if mutually agreed by Laguna and Orca. The
Topco Charter and Topco Bylaws shall remain in effect as of the Laguna Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.2.
</B><U>Additional Matters Concerning Topco </U><U>and its Subsidiaries</U>. From and after the Laguna Effective Time, unless prohibited by applicable Law, Topco and its Subsidiaries (together, following the consummation of the Combinations, the
&#147;<U>Topco Group</U>&#148;) shall undertake the following, and have the following characteristics, as of and after the Laguna Effective Time: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Corporate Name and Headquarters</I>. As of each of the Orca Effective Time and the Laguna Effective Time, the name of Topco shall be
&#147;Quidel Holdings Co.&#148; or such other name mutually agreed by Orca and Laguna prior to the Closing, as reflected in the Topco Charter. The executive headquarters of the Topco Group shall be in San Diego, California, and other appropriate
offices shall be in various locations consistent with the business needs of the Topco Group. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Listing Matters</I>. Prior to the Orca
Effective Time, (i)&nbsp;Orca shall take all actions as may be reasonably necessary such that the <FONT STYLE="white-space:nowrap">de-listing</FONT> of the Orca Shares from Nasdaq and the deregistration of the Orca Shares under the Exchange Act
shall occur promptly after the Orca Effective Time and (ii)&nbsp;Laguna shall take all actions as may be reasonably necessary such that the <FONT STYLE="white-space:nowrap">de-listing</FONT> of the Laguna Shares from Nasdaq and the deregistration of
the Laguna Shares under the Exchange Act shall occur promptly after the Laguna Effective Time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Exchange Listing and Ticker Symbol.
</I>Prior to the Orca Effective Time, Topco, Laguna and Orca shall use their respective reasonable best efforts to cause Topco Shares to be issued in the Combinations and the other Topco Shares to be reserved for issuance upon exercise of the Topco
Stock Awards pursuant to this Agreement to be approved for listing on Nasdaq under a ticker symbol mutually agreed by Laguna and Orca, subject, in each case, to official notice of issuance, prior to the Scheme Effective Date. If at any time prior to
the Orca Effective Time any of the parties discover that an amendment or supplement to documents or other information filed with Nasdaq should be filed pursuant to applicable Law, or so that any such documents or information would not include any
misstatement of a material fact or any omission of any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, the party that makes such discovery shall promptly notify the
other parties and each party shall use reasonable best efforts to cause an appropriate amendment or supplement to be filed with Nasdaq, and, to the extent required by applicable Law, to cause such information to be made public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I><FONT STYLE="white-space:nowrap">Tax-Free</FONT> Reorganization Matters</I>. Each of the parties intends that, for United States
federal income tax purposes, (i)&nbsp;the Laguna Merger and the Orca Scheme, taken together as a single integrated transaction, will qualify as an exchange described under Section&nbsp;351 of the Code and the payment of the Cash Portion shall be
treated as a payment pursuant to Section&nbsp;351(b) of the Code (this clause (i), the &#147;<U>Intended Tax Treatment</U>&#148;) and (ii)&nbsp;the Laguna Merger will also qualify as a &#147;reorganization&#148; within the meaning of
Section&nbsp;368(a) of the Code and the Treasury Regulations promulgated thereunder, and (iii)&nbsp;this Agreement is, and is hereby adopted as, a &#147;plan of reorganization&#148; within the meaning of Treasury Regulations Sections <FONT
STYLE="white-space:nowrap">1.368-2(g)</FONT> and <FONT STYLE="white-space:nowrap">1.368-3.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <I>Successor Status</I>. The
parties agree that Laguna will be the successor issuer for purposes of Section&nbsp;12 of the Exchange Act and shall be deemed the acquirer for accounting purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE III </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BOARD AND MANAGEMENT OF TOPCO GROUP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.1. </B><U>Board of Directors and Board Committees of Topco; Management of the Topco Group</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Unless otherwise agreed by Orca and Laguna prior to the Orca Effective Time, the parties shall cause the Topco Board to consist, at the
Orca Effective Time, of twelve (12)&nbsp;members, comprised of: (i)&nbsp;eight (8) members designated by Laguna, of which one shall be the Chief Executive Officer of Laguna immediately prior to the Laguna Effective Time and at least four (4)&nbsp;of
whom shall qualify as an &#147;independent director&#148; under applicable rules of Nasdaq and (ii)&nbsp;four (4) members designated by Orca, of which at least two (2)&nbsp;of whom shall qualify as an &#147;independent director&#148; under
applicable rules of Nasdaq. Each of the members of the Topco Board designated by Orca shall be reasonably acceptable to the Nominating and Governance Committee of the Laguna Board. Unless otherwise agreed by Orca and Laguna, at the Orca Effective
Time, a member of the Laguna Board immediately prior to the Laguna Effective Time shall be chairman of the Topco Board, Douglas Bryant (&#147;<U>Bryant</U>&#148;) shall be the Chief Executive Officer of Topco and an officer of Laguna immediately
prior to the Laguna Effective Time shall be the President of Topco. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) At the Orca Effective Time, the Topco Board shall constitute the
following committees of the Topco Board, each of which shall consist of one (1)&nbsp;member of the Topco Board designated by Orca and not less than two (2)&nbsp;additional members of the Topco Board designated by Laguna, in each case, subject to
applicable legal and regulatory requirements (including listing standards of applicable Self-Regulatory Organizations) and, in the case of the of the Orca designees, shall be reasonably acceptable to the Topco Board: (i)&nbsp;the Audit Committee,
(ii)&nbsp;the Nominating and Governance Committee, and (iii)&nbsp;the Compensation Committee. As of the Orca Effective Time, the Audit Committee. the Nominating and Governance Committee, and the Compensation Committee shall each be chaired by a
member of the Topco Board designated by Laguna. The charters for the Audit Committee, the Nominating and Governance Committee and the Compensation Committee shall each be substantially similar to the charters for the respective Laguna committees
that are in effect as of the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.2. </B><U>Management</U>. Unless otherwise agreed by
Orca and Laguna, at the Orca Effective Time, Joseph Busky shall be the Chief Financial Officer of Topco, Michael Iskra shall be Chief Commercial Officer of Topco and Robert Bujarski shall be Chief Operating Officer of Topco (the three foregoing
individuals, together with Bryant, the &#147;<U>Designated Executives</U>&#148;). The other individuals to be appointed as executive officers of Topco as of the Orca Effective Time shall be selected by the Designated Executives, subject to the final
determination of Bryant. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IV </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REPRESENTATIONS AND WARRANTIES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth (1)&nbsp;in the case of any representation and warranty made by Laguna, in the disclosure letter dated as of the date
hereof, delivered to Orca by Laguna on or prior to entering into this Agreement (the &#147;<U>Laguna Disclosure Letter</U>&#148;) and except as disclosed in any report, schedule, form, statement or other document of Laguna filed with or furnished to
the United States Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) no later than the Business Day immediately preceding the date hereof and on or after December&nbsp;31, 2020 and publicly available on the date hereof on the SEC&#146;s
Electronic Data Gathering, Analysis and Retrieval System (EDGAR) (collectively, the &#147;<U>Laguna Reports</U>&#148;) (other than disclosures in the &#147;Risk Factors&#148; or &#147;Forward Looking Statements&#148; sections of any Laguna Reports
or any other disclosure in any Laguna Report to the extent that such disclosure is predictive or forward-looking in nature), and (2)&nbsp;in the case of any representation and warranty made by Orca, in the disclosure letter dated as of the date
hereof, delivered to Laguna by Orca on or prior to entering into this Agreement (the &#147;<U>Orca Disclosure Letter</U>&#148;) and except as disclosed in any report, schedule, form, statement or other document of Orca filed with or furnished to the
SEC no later than the Business Day immediately preceding the date hereof and on or after December&nbsp;31, 2020 and publicly available on the date hereof on the SEC&#146;s Electronic Data Gathering, Analysis and Retrieval System (EDGAR)
(collectively, the &#147;<U>Orca Reports</U>&#148;) (other than disclosures in the &#147;Risk Factors&#148; or &#147;Forward Looking Statements&#148; sections of any Orca Reports or any other disclosure in any Orca Report to the extent that such
disclosure is predictive or forward-looking in nature), each of Laguna and Orca hereby represents and warrants to the other as set forth in this Section&nbsp;4.1; <U>provided</U>, that any representation or warranty in this Section&nbsp;4.1 that
relates (i)&nbsp;specifically to Laguna or its Subsidiaries shall be deemed to be a representation or warranty made only by Laguna to Orca or (ii)&nbsp;specifically to Orca or its Subsidiaries, including Topco, U.S. Merger Sub, U.S. Holdco Sub, and
U.S. Holdco Sub 2, shall be deemed to be a representation or warranty made only by Orca to Laguna. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.1. </B><U>Organization, Good Standing and Qualification</U>.
Such party is an entity duly organized, validly existing and in good standing (where such concept is recognized under applicable Law) under the laws of its jurisdiction of organization. Each of such party&#146;s Subsidiaries is an entity duly
organized, validly existing and in good standing (where such concept is recognized under applicable Law) under the laws of its respective jurisdiction of organization, except where the failure to be so organized, existing and in good standing when
taken together with all other such failures, individually or in the aggregate, (a)&nbsp;has not had and is not reasonably expected to have a Material Adverse Effect on such party and (b)&nbsp;is not reasonably expected to prevent or materially
impair or delay the consummation of the Combinations or any of the other transactions contemplated by this Agreement. Each of such party and its Subsidiaries has all requisite corporate, company or similar power and authority to own and operate its
properties and assets and to carry on its business as presently conducted, except where the failure to have such power or authority when taken together with all other such failures, individually or in the aggregate, (x)&nbsp;has not had and is not
reasonably expected to have a Material Adverse Effect on such party and (y)&nbsp;is not reasonably expected to prevent or materially impair or delay the consummation of the Combinations or any of the other transactions contemplated by this
Agreement. Topco is and, as of Closing, U.S. Merger Sub shall be an entity duly organized, validly existing and in good standing (where such concept is recognized under applicable Law) under the laws of its jurisdiction of organization. Each of
Topco, U.S. Holdco Sub, U.S. Holdco Sub 2, and U.S. Merger Sub is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. None of Topco, U.S. Holdco Sub, U.S. Holdco Sub 2, or U.S. Merger Sub has
conducted any business other than activities incidental to its organization and the consummation of the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Adverse Effect</U>&#148; on Laguna, Orca, or, following the consummation of the transactions contemplated by
this agreement, Topco, as applicable, means any event, change, circumstance, effect, occurrence, state of facts or development (collectively, &#147;<U>Effect</U>&#148;) that, individually or in the aggregate with all other Effects, materially
adversely affects the condition (financial or otherwise), assets, liabilities, business or results of operations of Laguna Group, Orca Group, or, following the consummation of the transactions contemplated by this Agreement, Topco Group taken as a
whole, respectively; <U>provided</U>, <U>however</U>, that none of the following, and no Effect resulting from (but only to the extent attributable to), the following, shall constitute a Material Adverse Effect or be considered in determining
whether a Material Adverse Effect has occurred or would be reasonably likely to occur: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;any change or development in general
economic or regulatory, legislative or political conditions or securities, credit, financial or other capital markets conditions, in each case in the United States or any other jurisdiction, except to the extent that such change or development
affects the Laguna Group, the Orca Group or the Topco Group, respectively, in a disproportionate manner relative to other businesses operating in the industries in which the Laguna Group, the Orca Group or the Topco Group, respectively, operate;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;any change or development to the extent resulting from the execution and delivery of this Agreement or the public announcement,
pendency or consummation of the Combinations or any of the other transactions contemplated by this Agreement (in the case of execution and delivery of this Agreement, or consummation, other than for purposes of any representation or warranty
contained in Section&nbsp;4.4(a), including stockholder litigation and the impact of such changes or developments on the relationships, contractual or otherwise, of such party or any of its Subsidiaries with employees, labor unions, clients,
customers, suppliers or partners); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) any change or development to the extent resulting from any failure of the Laguna Group, the Orca
Group or the Topco Group, respectively, to meet any internal or published projections, forecasts, estimates or predictions in respect of revenues, earnings or other financial or operating metrics for any period (it being understood that the facts
and circumstances giving rise to such failure may be deemed to constitute, and may be taken into account in determining whether there has been, a Material Adverse Effect); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) any change, in and of itself, in the market price, credit rating (with respect to such party or its securities) or trading volume of such
party&#146;s securities (it being understood that the facts and circumstances giving rise to such change may be deemed to constitute, and may be taken into account in determining whether there has been, a Material Adverse Effect); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) any change in applicable Law or GAAP (or, in each case, authoritative interpretation thereof), except to the extent that such change or
development affects the Laguna Group, the Orca Group or the Topco Group, respectively, in a disproportionate manner relative to other businesses operating in the industries in which the Laguna Group, the Orca Group or the Topco Group, respectively,
operate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) geopolitical conditions, the outbreak of hostilities, any acts of war, sabotage or terrorism, any pandemic, epidemic or
disease outbreak (including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and any evolutions or other mutations thereof,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
collectively, &#147;<U><FONT STYLE="white-space:nowrap">COVID-19</FONT></U>&#148;) or any escalation or worsening of any such hostilities, acts of war, sabotage, terrorism, pandemic, epidemic or
disease outbreak threatened or underway as of the date of this Agreement, except to the extent that such change or development affects the Laguna Group, the Orca Group or the Topco Group, respectively, in a disproportionate manner relative to other
businesses operating in the industries in which the Laguna Group, the Orca Group or the Topco Group, respectively, operate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) any
hurricane, tornado, flood, earthquake or other natural disaster, except to the extent that such change or development affects the Laguna Group, the Orca Group or the Topco Group, respectively, in a disproportionate manner relative to other
businesses operating in the industries in which the Laguna Group, the Orca Group or the Topco Group, respectively, operate; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) any
change or development to the extent resulting from any action by any member of the Laguna Group, the Orca Group or the Topco Group, respectively, that is expressly required to be taken by this Agreement (other than any actions required to be taken
under Section&nbsp;5.1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Laguna Group</U>&#148; means Laguna and its Subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orca Group</U>&#148; means Orca and its Subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; means, with respect to any Person, any entity, whether incorporated or unincorporated, of which
at least a majority of the securities or ownership interests having by their terms voting power to elect a majority of the board of directors or other Persons performing similar functions is directly or indirectly owned or controlled by such Person
or by one or more of its respective Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.2. </B><U>Capitalization</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of Laguna consists of 97,500,000 Laguna Shares and 5,000,000 shares of preferred stock, par value $0.001 per
share (the &#147;<U>Laguna Preferred Stock</U>&#148;). At the close of business on December&nbsp;22, 2021, (i) 41,685,949 Laguna Shares were issued and outstanding (not including unvested Laguna Equity Rights), (ii) no shares of Laguna Preferred
Stock were issued and outstanding, (iii)&nbsp;no Laguna Shares were held in treasury by Laguna, (iv) 722,034 Laguna Shares were subject to outstanding Laguna Stock Options previously granted under the Laguna Stock Plans, (v) 587,485 Laguna Shares
were subject to outstanding Laguna Equity Rights previously granted under the Laguna Stock Plans (which number represents, for outstanding awards subject to performance-based vesting under a Laguna Stock Plan, the &#147;target&#148; award level, if
applicable), and (vi) 1,979,736 Laguna Shares were reserved and available for future awards that may be granted under the Laguna Stock Plans (exclusive of the outstanding Laguna Stock Options and Laguna Equity Rights reflected in the foregoing
clauses (iv)&nbsp;and (v)). From the close of business on December&nbsp;22, 2021 to the date of this Agreement, there have been no issuances by Laguna of shares of capital stock or voting securities of, or other equity interests in, Laguna, other
than upon the exercise of Laguna Stock Options or upon the vesting or settlement of Laguna Equity Rights, in each case outstanding at the close of business on December&nbsp;22, 2021 and in accordance with their terms in effect at such time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of the outstanding shares of capital stock or other equity interests in Laguna are duly authorized, validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> Except as set forth above, there are no preemptive or other outstanding rights, options, warrants, conversion rights, stock appreciation rights, redemption rights, repurchase rights, agreements,
arrangements, calls, profits interests, commitments or rights of any kind that obligate Laguna to issue or sell any shares of capital stock or other equity interests of Laguna or any securities or obligations convertible or exchangeable into or
exercisable for, or giving any Person a right to subscribe for or acquire, any shares of capital stock or other equity interests of Laguna, and no securities or obligations evidencing such rights are authorized, issued or outstanding. There are no
outstanding bonds, debentures, notes or other debt of Laguna having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matter on which stockholders of Laguna may vote or be entitled to vote.
There are no voting trusts or other agreements or understandings to which Laguna is a party with respect to the voting of capital stock of or equity interests in Laguna. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each of the outstanding shares of capital stock or other equity interests in each of Laguna&#146;s Subsidiaries is duly authorized,
validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and owned by Laguna or by a direct or indirect wholly owned Subsidiary of Laguna. Each of the Laguna Subsidiaries is wholly owned by Laguna or by a direct or
indirect wholly owned Subsidiary of Laguna. All shares of capital stock or other equity interests in each of Laguna&#146;s Subsidiaries owned by Laguna </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or by a direct or indirect wholly owned Subsidiary of Laguna are free and clear of any lien, mortgage, pledge, charge, security interest, easement, covenant, condition, restriction, option, right
of first refusal, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-way,</FONT></FONT> encroachment, occupancy right, title matter or other encumbrance of any kind, whether voluntarily incurred or arising by operation of Law
(&#147;<U>Lien</U>&#148;). There are no preemptive or other outstanding rights, options, warrants, conversion rights, stock appreciation rights, redemption rights, repurchase rights, agreements, arrangements, calls, profits interests, commitments or
rights of any kind that obligate Laguna or any of its Subsidiaries to issue or sell any shares of capital stock or other equity interests of any Laguna Subsidiary or any securities or obligations convertible or exchangeable into or exercisable for,
or giving any Person a right to subscribe for or acquire, any shares of capital stock or other equity interests of any Laguna Subsidiary, and no securities or obligations evidencing such rights are authorized, issued or outstanding. There are no
outstanding bonds, debentures, notes or other debt of Laguna&#146;s Subsidiaries having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matter on which stockholders of Laguna&#146;s
Subsidiaries may vote or be entitled to vote. Except as has not had and is not reasonably expected to have a Material Adverse Effect on Laguna Group, there are no voting trusts or other agreements or understandings to which any of Laguna&#146;s
Subsidiaries is a party with respect to the voting of capital stock of or equity interests in any of Laguna&#146;s Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The
authorized capital stock of Orca consists of 1,000,000,000 Orca Shares and an unlimited number of Deferred Shares (the &#147;<U>Orca Deferred Stock</U>&#148;). At the close of business on December&nbsp;20, 2021, (i) 237,174,462 Orca Shares were
issued and outstanding (not including unvested Orca Equity Rights), (ii) 50,001 shares of Orca Deferred Stock were issued and outstanding and each of such shares of Orca Deferred Stock are redeemable for no consideration, (iii)&nbsp;no Orca Shares
were held in treasury by Orca, (iv) 13,104,644 Orca Shares were subject to outstanding Orca Stock Options previously granted under the Orca Stock Plans, (v) 561,212 Orca Shares were subject to outstanding Orca Equity Rights previously granted under
the Orca Stock Plans, and (vi) 7,961,054 Orca Shares were reserved and available for future awards that may be granted under the Orca Stock Plans (exclusive of the outstanding Orca Stock Options and Orca Equity Rights reflected in the foregoing
clauses (iv)&nbsp;and (v)). From the close of business on December&nbsp;20, 2021 to the date of this Agreement, there have been no issuances by Orca of shares of capital stock or voting securities of, or other equity interests in, Orca, other than
upon the exercise of Orca Stock Options, upon the vesting or settlement of Orca Equity Rights, in each case outstanding at the close of business on December&nbsp;20, 2021 and in accordance with their terms in effect at such time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Each of the outstanding shares of capital stock or other equity interests in Orca are duly authorized, validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> Except as set forth above, there are no preemptive or other outstanding rights, options, warrants, conversion rights, stock appreciation rights, redemption rights, repurchase rights, agreements,
arrangements, calls, profits interests, commitments or rights of any kind that obligate Orca to issue or sell any shares of capital stock or other equity interests of Orca or any securities or obligations convertible or exchangeable into or
exercisable for, or giving any Person a right to subscribe for or acquire, any shares of capital stock or other equity interests of Orca, and no securities or obligations evidencing such rights are authorized, issued or outstanding. There are no
outstanding bonds, debentures, notes or other debt of Orca having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matter on which stockholders of Orca may vote or be entitled to vote. There
are no voting trusts or other agreements or understandings to which Orca is a party with respect to the voting of capital stock of or equity interests in Orca. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Each of the outstanding shares of capital stock or other equity interests of each of Orca&#146;s Subsidiaries is duly authorized, validly
issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and is owned by Orca or by a direct or indirect wholly owned Subsidiary of Orca. Each of the Orca Subsidiaries is wholly owned by Orca or by a direct or indirect wholly
owned Subsidiary of Orca. All shares of capital stock or other equity interests in each of Orca&#146;s Subsidiaries owned by Orca or by a direct or indirect wholly owned subsidiary of Orca are free and clear of any Lien. There are no preemptive or
other outstanding rights, options, warrants, conversion rights, stock appreciation rights, redemption rights, repurchase rights, agreements, arrangements, calls, profits interests, commitments or rights of any kind that obligate Orca or any of its
Subsidiaries to issue or sell any shares of capital stock or other equity interests of any Orca Subsidiary or any securities or obligations convertible or exchangeable into or exercisable for, or giving any Person a right to subscribe for or
acquire, any shares of capital stock or other equity interests of any Orca Subsidiary, and no securities or obligations evidencing such rights are authorized, issued or outstanding. There are no outstanding bonds, debentures, notes or other debt of
Orca&#146;s Subsidiaries having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matter on which stockholders of Orca&#146;s Subsidiaries may vote or be entitled to vote. Except as has not had
and is not reasonably expected to have a Material Adverse Effect on Orca Group, there are no voting trusts or other agreements or understandings to which any of Orca&#146;s Subsidiaries is a party with respect to the voting of capital stock of or
equity interests in any of Orca&#146;s Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) As of the date hereof, the authorized capital stock of Topco consists of 1,000 shares of
common stock, par value $0.001 per share. As of the date hereof, all of the Topco Shares in issue have been duly authorized and are validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and all of Topco Shares to be
issued in connection with the transactions contemplated by this Agreement will be, at the time of issuance, duly authorized, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> Except as contemplated by this
Agreement, there are no preemptive or other outstanding rights, options, warrants, conversion rights, stock appreciation rights, redemption rights, repurchase rights, agreements, arrangements, calls, profits interests, commitments or rights of any
kind that obligate Topco or any of its Subsidiaries to issue or sell any shares of capital stock or other equity interests of Topco or any of its Subsidiaries or any securities or obligations convertible or exchangeable into or exercisable for, or
giving any Person a right to subscribe for or acquire, any shares of capital stock or other equity interests of Topco or any of its Subsidiaries, and no securities or obligations evidencing such rights are authorized, issued or outstanding. There
are no outstanding bonds, debentures, notes or other debt of Topco or any of its Subsidiaries having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matter on which stockholders of Topco or
any of its Subsidiaries may vote or be entitled to vote. There are no voting trusts or other agreements or understandings to which Topco or any of its Subsidiaries is a party with respect to the voting of capital stock of or equity interests in
Topco or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.3. </B><U>Corporate Authority</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Laguna has all requisite corporate power and authority and has taken all corporate action necessary in order to authorize, execute,
deliver and perform its obligations under this Agreement, and to consummate the Laguna Merger and the other transactions contemplated hereby (including those steps set forth in Section&nbsp;5.4), subject only to, in the case of the Laguna Merger,
the approval and adoption of this Agreement and the Laguna Merger by the holders of a majority of the outstanding Laguna Shares entitled to vote thereon (the &#147;<U>Laguna Requisite Vote</U>&#148;). This Agreement is a valid and binding agreement
of Laguna enforceable against Laguna in accordance with its terms, subject, as to enforcement, to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting
creditors&#146; rights and to general equity principles (the &#147;<U>Bankruptcy and Equity Exception</U>&#148;). The Laguna Board, at a meeting duly called and held: (A)&nbsp;duly adopted resolutions (x)&nbsp;unanimously approving and declaring
advisable this Agreement and the transactions contemplated by this Agreement, including the Laguna Merger and (y)&nbsp;unanimously determining, subject to applicable Law, to recommend that the holders of Laguna Shares adopt this Agreement and the
transactions contemplated by this Agreement; (B)&nbsp;directing that this Agreement be submitted to the holders of the issued and outstanding Laguna Shares for their adoption as promptly as practicable; and (C)&nbsp;authorizing and approving the
execution, delivery and performance of this Agreement and the transactions contemplated by this Agreement by Laguna. The Laguna Board has received the opinion of Perella Weinberg Partners LP, to the effect that, as of the date of such opinion and
based upon and subject to the assumptions, qualifications and limitations set forth therein, the Orca Scheme Consideration was fair, from a financial point of view, to Laguna, taking into account the Laguna Exchange Ratio. Laguna shall deliver a
true and complete copy of such opinion to Orca for informational purposes only promptly following the execution and delivery of this Agreement. Such opinion is for the benefit of the Laguna Board and may not be relied on by Orca. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of Topco, U.S. Merger Sub, U.S. Holdco Sub, and U.S. Holdco Sub 2 has all requisite corporate power and authority and has taken all
corporate action necessary in order to authorize, deliver and perform its obligations under this Agreement, and to consummate the Combinations and the other transactions contemplated hereby. This Agreement is a valid and binding agreement of Topco
enforceable against it in accordance with its terms, subject, as to enforcement, to the Bankruptcy and Equity Exception. Each of the sole stockholder of Topco and the Topco Board&nbsp;has approved and authorized this Agreement, the Combinations and
the other transactions contemplated hereby (subject to the approval of the Orca Scheme Terms pursuant to Section&nbsp;5.3(a)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Orca
has all requisite company power and authority and has taken all company action necessary in order to authorize, execute, deliver and perform its obligations under this Agreement, and to consummate the Orca Scheme and the other transactions
contemplated hereby (including those steps set forth in Sections 5.3 and 5.4), subject only to, (i)&nbsp;in the case of the Orca Scheme, the filing of the Orca Scheme Terms with the English Court and the English Court consenting to the convening of
a meeting of Orca Shareholders as a single class to approve the Orca Scheme, the receipt of the required approval of the Orca Scheme by the English Court, and the approval of the Orca Scheme Terms and the Orca Scheme by a vote of the holders of more
than three-quarters of the voting rights attached to the Orca Shares present at a meeting of the stockholders of Orca representing a majority of the registered Orca Shareholders; and (ii)&nbsp;in the case of the Orca General Meeting, the receipt of
the required approval of the Orca Shareholders to the Orca Board&#146;s implementation of the Orca Scheme, adoption of the new Orca Articles of Association as set out in <U>Exhibit A</U> (subject to any further amendments as the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
parties may agree) and the ancillary matters contemplated by this Agreement (the required votes in clauses (i)&nbsp;and (ii) collectively, the &#147;<U>Orca Requisite Vote</U>&#148;). This
Agreement is a valid and binding agreement of Orca, enforceable against Orca in accordance with its terms, subject, as to enforcement, to the Bankruptcy and Equity Exception. The Orca Board, at a meeting duly called and held duly adopted resolutions
(x)&nbsp;unanimously approving and declaring advisable this Agreement and the transactions contemplated by this Agreement, including the Orca Scheme (subject to the approval by the Orca Board of the Orca Scheme Terms pursuant to
Section&nbsp;5.3(a)), (y) unanimously recommending that, subject to applicable Law, the Orca Shareholders approve the Orca Scheme Terms and the transactions contemplated thereby; and (z)&nbsp;authorizing and approving the execution, delivery and
performance of this Agreement and the transactions contemplated by this Agreement by Orca. The Orca Board has received the opinion of its financial advisor, J.P. Morgan Securities LLC, to the effect that, as of the date of such opinion and based
upon and subject to the assumptions made, procedures followed, matters considered and limitations on the review undertaken by J.P. Morgan Securities LLC in preparing its opinion, the Orca Scheme Consideration, was fair, from a financial point of
view, to the Orca Shareholders (other than holders of Excluded Orca Shares). Orca shall provide a true and complete copy of which opinion and deliver to Laguna for informational purposes only promptly following the execution and delivery of this
Agreement. Such opinion is for the benefit of the Orca Board and may not be relied on by Laguna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.4.
</B><U>No Conflicts</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Neither the execution and delivery by such party of this Agreement, the compliance by it with all of the
provisions of and the performance by it of its obligations under this Agreement, nor the consummation of the Combinations and the other transactions contemplated hereby, (i)&nbsp;will conflict with, or result in a breach or violation of, a
termination (or right of termination), modification, cancellation, loss of a benefit under, a requirement of consent or approval, constitute a change of control under or result in any acceleration of any rights or obligations or the payment of any
penalty under or the creation of a Lien on the assets of such party or any of its Subsidiaries (with or without the giving of notice or the lapse of time or both) pursuant to, or permit any other party any improvement in rights with respect to or
permit it to exercise, or otherwise constitute a default under, any provision of any Contract or Permit, or result in any change in the rights or obligations of any party under any Contract or Permit, in each case to which such party or any of its
Subsidiaries is a party or by which such party or any of its Subsidiaries or any of their respective assets is bound,&nbsp;or (ii)&nbsp;will result in any breach or violation of, or a default under, the provisions of the Organizational Documents of
such party or any of its Subsidiaries, or any Law applicable to it, except (in the case of clause (i)) for the respective rights of Creditors under English Law and such conflicts, breaches, violations, defaults, payments, accelerations, creations,
permissions or changes that, individually or in the aggregate, (A)&nbsp;have not had and are not reasonably expected to have a Material Adverse Effect on such party and (B)&nbsp;are not reasonably expected to prevent or materially impair or delay
the consummation of the Combinations or any of the other transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The execution and delivery,
compliance, performance or consummation of this Agreement shall not result in any breach or violation of, or a default under, the provisions of Topco&#146;s, U.S. Merger Sub&#146;s, U.S. Holdco Sub&#146;s, or U.S. Holdco Sub 2&#146;s Organizational
Documents as of Closing, except for such breaches, violations or defaults that, individually or in the aggregate, (A)&nbsp;have not had and are not reasonably expected to have a Material Adverse Effect on Topco and (B)&nbsp;are not reasonably
expected to prevent or materially impair or delay the consummation of the Combinations or any of the other transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Contract</U>&#148; means, with respect to any Person, any agreement, indenture, loan agreement, undertaking, note or
other debt instrument, contract, lease, mortgage, deed of trust, permit, license, understanding, arrangement, commitment or other obligation, written or oral, to which such Person or any of its Subsidiaries is a party or by which any of them may be
bound or to which any of their properties may be subject, other than any Benefit Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Organizational
Documents</U>&#148; means, with respect to any Person, the certificate of incorporation, articles of association, limited liability company agreement, bylaws or similar organizational documents of such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.5. </B><U>Governmental Approvals and Consents</U>. Other than (a)&nbsp;notifications, filings, notices,
reports and applications (collectively, &#147;<U>Filings</U>&#148;) and approvals, consents, clearances, permits, authorizations, waivers and waiting period expirations or terminations (collectively, &#147;<U>Approvals</U>&#148;) under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &#147;<U>HSR Act</U>&#148;) and the other antitrust, competition, merger control or foreign investment Laws set forth on Section&nbsp;4.5 of each of the Laguna Disclosure Letter
and the Orca Disclosure Letter (such Approvals, collectively, the &#147;<U>Antitrust Approvals</U>&#148;), (b)&nbsp;the approvals and consents to be obtained from the SEC and Nasdaq, (c)&nbsp;the receipt and filing of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Orca Scheme Order with the Registrar,<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>(d)&nbsp;the filing of the Laguna Certificate of Merger, (e)&nbsp;as required in order to comply
with other state or local securities, takeover and &#147;blue sky&#148; laws and (f)&nbsp;such other authorizations, consents, approvals, orders, permits, notices, reports, filings, registrations, qualifications and exemptions that, if not obtained,
made or given, individually or in the aggregate, (i)&nbsp;are not reasonably expected to have a Material Adverse Effect on such party and (ii)&nbsp;are not reasonably expected to prevent or materially impair or delay the consummation of the
Combinations or any of the other transactions contemplated by this Agreement, no authorizations, consents, approvals, orders, permits, notices, reports, filings, registrations, qualifications and exemptions of, with or from, or other actions are
required to be made by such party or any of its Subsidiaries with, or obtained by such party or any of its Subsidiaries from, any government or governmental or regulatory authority, court or other judicial body, agency, commission, body or other
governmental or regulatory entity, United States or <FONT STYLE="white-space:nowrap">non-United</FONT> States, national or supra-national, state, provincial, municipal or local, including the SEC and the other Regulatory Authorities
(&#147;<U>Governmental Entity</U>&#148;) or any Self-Regulatory Organization, in connection with the execution and delivery by such party of this Agreement, the performance by such party of its obligations hereunder and the consummation of the
transactions contemplated hereby. For purposes of this Agreement, the term &#147;<U>Regulatory Authority</U>&#148; means any and all relevant regulatory agencies or authorities of the United States, the United Kingdom and other regulatory agencies
or authorities, in each case only to the extent that such agency or authority has authority and jurisdiction in the particular context. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.6. </B><U>Reports; Financial Statements; Internal Control and Disclosure Control</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of the Laguna Reports and Orca Reports were (and any report filed after the date hereof and prior to the Closing of the type that
would be a Laguna Report or an Orca Report if filed prior to the date hereof will be) filed in a timely manner and in material compliance with all applicable Laws and other requirements applicable thereto. As of their respective dates (or if amended
prior to the date hereof, as of the date of such amendment), the Laguna Reports and the Orca Reports compiled (and any report filed after the date hereof and prior to the Closing of the type that would be a Laguna Report or an Orca Report if filed
prior to the date hereof will comply) in all material respects with the requirements under applicable Law regarding the accuracy and completeness of the disclosures contained therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All of the audited consolidated financial statements and unaudited consolidated interim financial statements of Laguna and its
consolidated Subsidiaries included in the Laguna Reports or any report filed after the date hereof and prior to the Closing of the type that would be a Laguna Report if filed prior to the date hereof (collectively, the &#147;<U>Laguna Financial
Statements</U>&#148;) (i)&nbsp;fairly present in all material respects the consolidated financial position and the results of operations, cash flows and changes in stockholders&#146; equity of Laguna and its consolidated Subsidiaries as of the dates
and for the periods referred to therein, (ii)&nbsp;have been or will be, as the case may be, prepared in accordance with United States generally accepted accounting principles (&#147;<U>GAAP</U>&#148;) applied on a consistent basis during the
periods involved (except as may be indicated in the notes thereto or, in the case of interim financial statements, for normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments that are not material in amount or nature) and
(iii)&nbsp;have been or will be prepared from, are in accordance with and accurately reflect (or with respect to Laguna Reports filed after the date hereof and prior to the Closing, will be prepared from, in accordance with and accurately reflect)
the books and records of Laguna and its consolidated Subsidiaries in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All of the audited consolidated financial
statements and unaudited consolidated interim financial statements of Orca and its consolidated Subsidiaries included in the Orca Reports or any report filed after the date hereof and prior to the Closing of the type that would be an Orca Report if
filed prior to the date hereof (the &#147;<U>Orca Financial Statements</U>&#148;) (i) fairly present in all material respects the consolidated financial position and the results of operations, cash flows and changes in stockholders&#146; equity of
Orca and its consolidated Subsidiaries as of the dates and for the periods referred to therein, (ii)&nbsp;have been or will be, as the case may be, prepared in accordance with GAAP applied on a consistent basis during the periods involved (except as
may be indicated in the notes thereto or, in the case of interim financial statements, for normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments that are not material in amount or nature) and (iii)&nbsp;have been or will
be prepared from, are in accordance with and accurately reflect (or with respect to Orca Reports filed after the date hereof and prior to the Closing, will be prepared from, in accordance with and accurately reflect) the books and records of Orca
and its consolidated Subsidiaries in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Each of Laguna and Orca maintains a system of accounting and internal
controls effective to provide reasonable assurances regarding the reliability of the consolidated financial reporting and the preparation of the consolidated financial statements of such party and its consolidated Subsidiaries in accordance in all
material respects with GAAP and the rules and regulations of the SEC. Based on its most recent evaluation of internal control prior to the date hereof, such party has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosed to its auditors and the audit committee of the Laguna Board or the Orca Board, as applicable, (x)&nbsp;any significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect such party&#146;s ability to record, process, summarize and report financial information and (y)&nbsp;any fraud, whether or not material, that involves
management or other employees who have a significant role in such party&#146;s internal control over financial reporting and any such disclosures have been made available to the other party. Such party is not an &#147;ineligible issuer&#148; as such
term is defined in Rule 405 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Each of Laguna and Orca is in compliance in all material respects with the
applicable listing and corporate governance rules and regulations of Nasdaq and the SEC. As of the date hereof, there are no outstanding or unresolved comments in any comment letters received from the staff of the SEC or Nasdaq (as the case may be)
with respect to the Laguna Reports or the Orca Reports. To the knowledge of each of Laguna and Orca, as of the date of this Agreement none of the Laguna Reports, in the case of Laguna, or Orca Reports, in the case of Orca is subject to ongoing
review or outstanding comment or investigation by the SEC or Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.7. </B><U>Absence of Certain
Changes</U>. Except as disclosed in the Laguna Financial Statements for the year ended December&nbsp;31, 2020 (in the case of Laguna) or the Orca Financial Statements for the year ended January&nbsp;3, 2021 (in the case of Orca), since
December&nbsp;31, 2020 (in the case of Laguna) or since January&nbsp;3, 2021 (in the case of Orca), (a) such party and its Subsidiaries have conducted their respective businesses only in, and have not engaged in any material transaction other than
according to, the ordinary and usual course of such businesses consistent with past practice, (b)&nbsp;there has not been any Effect that, individually or in the aggregate, (i)&nbsp;has had or is reasonably expected to have a Material Adverse Effect
on such party or (ii)&nbsp;is reasonably expected to prevent or materially impair or delay the consummation of the Combinations or any of the other transactions contemplated by this Agreement, and (c)&nbsp;there has not been any action taken by
Laguna or Orca or any of their respective Subsidiaries since December&nbsp;31, 2020 (in the case of Laguna) or since January&nbsp;3, 2021 (in the case of Orca) through the date of this Agreement that, if taken during the period between the date of
this Agreement through the Orca Effective Time, would constitute a breach of Section&nbsp;5.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.8.
</B><U>Compliance</U>. Neither such party nor any of its Subsidiaries is in conflict with, or in default or violation of, (a)&nbsp;any federal, state, local or provincial, municipal, foreign, multinational or common law, statute, treaty, ordinance,
rule, regulation, Order, agency requirement, writ, franchise, variance, exemption, approval, certificate, notice, bylaw, standard, policy guidance, license, permit or other requirements, policies or instruments of any relevant jurisdiction,
including in the United States, United Kingdom or elsewhere issued, promulgated, adopted, enacted, issued or entered into by or with any Governmental Entity or any Self-Regulatory Organization (each, a &#147;<U>Law</U>&#148; and collectively
&#147;<U>Laws</U>&#148;) or (b)&nbsp;any Contract to which such party or any of its Subsidiaries is a party or by which such party or any of its Subsidiaries or its or any of their respective properties is bound or affected, except in each of
clauses (a)&nbsp;and (b), for any such conflicts, defaults or violations that, individually or in the aggregate, have not had and are not reasonably expected to have a Material Adverse Effect on such party. Each of such party and its Subsidiaries
has all permits, licenses, certificates, clearances, franchises, variances, exemptions, orders, registrations and other authorizations, consents and approvals (together, &#147;<U>Permits</U>&#148;) of all Governmental Entities or other third parties
necessary to conduct its business as presently conducted, except where the failure to have such Permits, individually or in the aggregate, has not had and is not reasonably expected to have a Material Adverse Effect on such party. All Permits held
by such party and its Subsidiaries are valid and in full force and effect, except where the failure of any such Permits to be valid or in full force and effect, individually or in the aggregate, has not had and is not reasonably expected to have a
Material Adverse Effect on such party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.9. </B><U>Litigation and Liabilities</U>. There are no
(a)&nbsp;civil, criminal, administrative or regulatory actions, suits, claims, litigations, hearings, investigations or proceedings (collectively, &#147;<U>Proceedings</U>&#148;) pending or, to the knowledge of such party, threatened against such
party, any of its Subsidiaries or any of their respective directors or officers in their capacity as such, (b)&nbsp;judgments, orders, decisions, writs, injunctions, decrees, stipulations, legal or arbitration awards, rulings or other findings or
agency requirements promulgated, issued or entered by or with (or settlement or consent agreement subject to) any Governmental Entity (collectively, &#147;<U>Orders</U>&#148;) or (c)&nbsp;except as disclosed in the Laguna Financial Statements for
the year ended December&nbsp;31, 2020 (in the case of Laguna) or the Orca Financial Statements for the year ended January&nbsp;3, 2021 (in the case of Orca), obligations or liabilities, whether accrued, contingent or otherwise and whether required
to be disclosed, including those relating to, or any other facts or circumstances of which, to the knowledge of Laguna or Orca, as applicable, could result in any claims against, or obligations or liabilities of, such party, any of its Subsidiaries
or any of their respective directors or officers in their capacity as such, except, in case of clauses (a)&nbsp;through (c) (inclusive), for those that, individually or in the aggregate, (i)&nbsp;have not had and are not reasonably expected to have
a Material Adverse Effect on such party and (ii)&nbsp;are not reasonably expected to prevent or materially impair or delay the consummation of the Combinations or any of the other transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.10. </B><U>Employee Benefits</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) As used in this Agreement, the term &#147;<U>Benefit Plans</U>&#148; means all material benefit and compensation plans, contracts,
policies or arrangements covering current or former employees of such party and its Subsidiaries and current or former directors or consultants of such party and its Subsidiaries, including pension, retirement, profit-sharing, deferred compensation,
stock option, change in control, retention, equity or equity-based compensation, stock purchase, employee stock ownership, termination, end of service or severance pay (each a &#147;<U>Severance Pay</U>&#148;), vacation, holiday pay or other paid
time off, bonus or other incentive plans, medical, retiree medical, vision, dental or other health plans, life insurance plans, and other employee benefit plans or fringe benefit plans (but excludes any employment contracts or consultancy agreements
for employees or consultants outside the United States where the employee or consultant&#146;s base compensation is less than $500,000 per annum and there is no provision for severance compensation or notice of termination other than as required by
applicable Law). All <FONT STYLE="white-space:nowrap">non-government</FONT> sponsored Benefit Plans containing unfunded actuarial benefit obligations in excess of $1,000,000 (determined on the basis of the methodologies and assumptions utilized in
the Laguna Financial Statements for the year ended December&nbsp;31, 2020 or Orca Financial Statements for the year ended January&nbsp;3, 2021, as applicable) are disclosed in the Laguna Financial Statements for the year ended December&nbsp;31, 2020
or otherwise listed in Section&nbsp;4.10(a) of the Laguna Disclosure Letter (in the case of Laguna) or disclosed in the Orca Financial Statements for the year ended January&nbsp;3, 2021 or otherwise listed in Section&nbsp;4.10(a) of the Orca
Disclosure Letter (in the case of Orca). Each of Laguna and Orca had made available copies of each such Benefit Plan to the other party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as, individually or in the aggregate, has not had and is not reasonably expected to have a Material Adverse Effect on such party,
all contributions or other amounts payable by each party and its Subsidiaries with respect to all Benefit Plans in respect of current or prior plan years have been paid or accrued in accordance with GAAP. There are no pending or, to Laguna&#146;s or
Orca&#146;s knowledge, respectively, threatened, claims (other than routine claims for benefits or immaterial claims) by, on behalf of or against any of the Benefit Plans or any trusts related thereto except where such claims would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect on the relevant party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as, individually or in
the aggregate, has not had and is not reasonably expected to have a Material Adverse Effect on such part, each Benefit Plan that is intended to meet the requirements to be qualified under Section&nbsp;401(a) of the Code is the subject of a favorable
determination letter or is covered by a favorable opinion letter from the Internal Revenue Service, and neither Laguna nor Orca is aware of any facts or circumstances that would reasonably be expected to jeopardize the qualification of such Benefit
Plan. No Benefit Plan is, and neither the Laguna Group nor the Orca Group nor any of their respective ERISA Affiliates, maintains, sponsors or contributes to, or have, in the past six years, maintained, sponsored or contributed to (i)&nbsp;an
employee benefit plan subject to Title IV of ERISA or Section&nbsp;412 of the Code; (ii)&nbsp;a &#147;multiemployer plan&#148; (within the meaning of Section&nbsp;4001(a)(3) of ERISA); or (iii)&nbsp;a &#147;multiple employer plan&#148; (within the
meaning of Section&nbsp;413(c) of the Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as, individually or in the aggregate, has not had and is not reasonably expected
to have a Material Adverse Effect on such party, (i)&nbsp;each Benefit Plan has been established, operated and administered in accordance with its terms and the requirements of all applicable Laws, government taxation, social security and funding
requirements and with any agreement entered into with a union or labor organization (ii)&nbsp;to the extent required to be registered or approved by a Governmental Entity, has been registered with or approved by a Governmental Entity and to the
knowledge of each party nothing has occurred that would adversely affect such registration or approval (iii)&nbsp;all Benefit Plans intended to qualify for special tax treatment meet all requirements for such treatment, and (iv)&nbsp;all Benefit
Plans required to be funded and/or book-reserved are funded and/or book reserved, as appropriate, based upon reasonable actuarial assumptions and in accordance with any applicable Laws or requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Neither the execution of this Agreement nor the consummation of the transactions contemplated hereby (alone or in conjunction with any
other event, including any termination of employment) will (i)&nbsp;entitle any current or former directors, officers, employees or other service providers of such party and its Subsidiaries to additional compensation or to severance pay or any
increase in Severance Pay upon any termination of employment after the date hereof, (ii)&nbsp;accelerate the time of payment or vesting or result in any payment or funding (through a grantor trust or otherwise) of compensation or benefits under,
increase the amount payable or result in any other material obligation pursuant to, any of the Benefit Plans, (iii)&nbsp;accelerate the time of payment or vesting of the Laguna Stock Awards (in the case of Laguna) or the Orca Stock Awards (in the
case of Orca), (iv)&nbsp;limit or restrict the right of such party or, after the consummation of the Combinations or any other transactions contemplated hereby, Topco to merge, amend or terminate any of the Benefit Plans or (v)&nbsp;result in any
payments, including under any Benefit Plan, that reasonably could be expected to be &#147;excess parachute payments&#148; pursuant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to Section&nbsp;280G of the Code. Neither the Laguna Group nor the Orca Group is obligated to pay a Tax <FONT STYLE="white-space:nowrap">gross-up</FONT> or reimbursement payment to any employees.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except as, individually or in the aggregate, has not had and is not reasonably expected to have a Material Adverse Effect on such
party, with respect to each Benefit Plan subject to the Laws of a jurisdiction other than the United States, whether or not U.S. Law also applies (each, a &#147;<U><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Benefit Plan</U>&#148;) the fair
market value of the assets of each such funded <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Benefit Plan, the liability of each insurer for any such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Benefit Plan funded through insurance or the
book reserve established for any such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Benefit Plan, together with any accrued contributions, is sufficient to procure or provide for the benefits determined on an ongoing basis (actual or contingent)
with respect to all current or former participants under such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Benefit Plan according to the actuarial assumptions and valuation most recently used to determine employer contributions to such <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Benefit Plan, and none of the transactions contemplated by this Agreement will cause such assets, insurance obligations or book reserves to be less than such benefit obligations. Each such <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Benefit Plan required to be registered has been registered and has been maintained in all material respects in good standing with each applicable Governmental Entity. No
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Benefit Plan that is maintained, contributed to or required to be contributed to by Laguna, Orca or any of their respective Subsidiaries is a defined benefit pension plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.11. </B><U>Tax Matters</U>. Other than with respect to clause (g)&nbsp;below, except as, individually or in
the aggregate, has not had and is not reasonably expected to have a Material Adverse Effect on such party: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of Laguna and Orca
and each of their Subsidiaries (i)&nbsp;has timely filed, taking into account any extensions, all material income and other Tax Returns required to have been filed and such Tax Returns are accurate and complete in all respects and have been prepared
in compliance with applicable Tax Laws; and (ii)&nbsp;has timely paid all material Taxes required to have been paid by it other than Taxes that are not yet due or that are being contested in good faith in appropriate proceedings. No deficiency for
any Tax has been asserted or assessed by a Tax authority against Laguna or any of its Subsidiaries (in the case of Laguna) or Orca or any of its Subsidiaries (in the case of Orca) which deficiency has not been paid or is not being contested in good
faith in appropriate proceedings (for which adequate reserves have been maintained in accordance with GAAP). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) No Tax Return of Laguna
or Orca, or any of its Subsidiaries, is under audit or examination by any Tax authority, and no written (or, to the knowledge of Laguna or Orca, as applicable, oral) notice of such an audit or examination has been received by Laguna or Orca or any
of its Subsidiaries. No requests for waivers of the time to assess any Taxes are pending. There are no outstanding waivers of any limitation periods or agreements providing for an extension of time for the filing of any material Tax Return, the
assessment or collection thereof by any relevant Tax authority or the payment of any Tax by Laguna or Orca or any of its Subsidiaries. No other procedure, proceeding or contest of any refund or deficiency in respect of Taxes is pending in or on
appeal from any Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each of Laguna or Orca and each of such party&#146;s Subsidiaries has complied in all material
respects with all applicable Laws relating to the withholding, collection and remittance of Taxes and other deductions required to be withheld and paid over to the proper Tax authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Neither Laguna nor Orca, nor any of its Subsidiaries, has requested or received a ruling from any Tax authority or signed a closing or
other agreement with any Tax authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Other than for Taxes not yet due and delinquent or that are being contested in good faith in
appropriate proceedings (for which adequate reserves have been maintained in accordance with GAAP), there are no Liens with respect to Taxes against any of the assets of Laguna or Orca, or any of its Subsidiaries. No written (or, to the knowledge of
Laguna or Orca, as applicable, oral) claim has been received by Laguna or Orca, or any of its Subsidiaries from a Tax authority in a jurisdiction where such entity does not currently file a Tax Return that it is or may be subject to taxation by such
jurisdiction. Neither Laguna nor Orca, nor any of its Subsidiaries has a permanent establishment or is resident for Tax purposes outside of its jurisdiction or territory of incorporation or formation, other than as specified under
Section&nbsp;4.11(e) of the Laguna Disclosure Letter or Orca Disclosure Letter, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither Laguna nor Orca, nor any of
its Subsidiaries is a party to or is otherwise bound by any Tax sharing, allocation or indemnification agreement or arrangement (other than such an agreement or arrangement exclusively between or among such party and any of its wholly owned
Subsidiaries), or has any liability for Taxes of any Person (other than </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Laguna or Orca, as applicable, or any of its Subsidiaries) under United States&nbsp;Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any similar provision of
state, local or <FONT STYLE="white-space:nowrap">non-United</FONT> States&nbsp;Law), as a transferee or successor, by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Within the past three (3)&nbsp;years, neither Laguna nor Orca, nor any of its Subsidiaries has been a &#147;distributing corporation&#148;
or a &#147;controlled corporation&#148; (within the meaning of Section&nbsp;355(a)(1)(A)&nbsp;of the Code) in a distribution intended to qualify for <FONT STYLE="white-space:nowrap">tax-free</FONT> treatment under Section&nbsp;355 of the Code (or a
similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law). Neither Laguna nor Orca, nor any of its Subsidiaries has, within the past six (6)&nbsp;years, (i) been engaged in, or been party to, any of the transactions
set out in Chapter 5 of Part 23 of the UK Corporation Tax Act 2010, or (ii)&nbsp;made or received a chargeable payment as defined in section 1086 of that Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Neither Laguna nor Orca, nor any of its Subsidiaries has participated in or been a party to a transaction that, as of the date of this
Agreement, constitutes a &#147;listed transaction&#148; as defined in Section&nbsp;6707A(c)(2) of the Code and Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)</FONT> (or any similar provision under state, local or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Law) or any arrangements which have been or are required to be disclosed pursuant to Part 7 of the UK Finance Act 2004 (or a similar provision of state or <FONT STYLE="white-space:nowrap">non-U.K.</FONT>
Law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Neither Laguna nor Orca, nor any of their Subsidiaries beneficially owns shares or other equity interests (for any applicable
Tax purposes) in the other party.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) None of Laguna, Topco, U.S. Merger Sub, U.S.
Holdco Sub, U.S. Holdco Sub 2, or Orca, nor any of their respective Subsidiaries has taken or agreed to take any action, or has any knowledge of any fact, agreement, plan or other circumstance, that could reasonably be expected to prevent the
Combinations from qualifying for the Intended Tax Treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) As used in this Agreement, (i)&nbsp;the term &#147;<U>Tax</U>&#148;
(including the plural form &#147;<U>Taxes</U>&#148; and, with correlative meaning, the terms &#147;<U>Taxable</U>&#148; and &#147;<U>Taxation</U>&#148;) means all taxes, customs, tariffs, imposts, levies, duties, fees or other like assessments or
charges of any kind imposed by a Governmental Entity, together with all estimated payments related thereto, interest, penalties and additions imposed with respect to such amounts, including any liability for the Taxes of another Person as transferee
or successor, by Contract or otherwise, and (ii)&nbsp;the term &#147;<U>Tax </U><U>Return</U>&#148; means all Tax returns, declarations, statements, reports, claims for refund, estimates and information returns and any amended Tax return, in each
case, including any schedules or forms attached thereof, relating to Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.12. </B><U>Labor Matters</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Neither such party nor any of its Subsidiaries is a party to any collective bargaining agreement, Contract or other agreement,
understanding or obligation with or with respect to a labor union, works council or labor organization or similar employee or worker representative body (&#147;<U>Labor Agreements</U>&#148;), nor is such party or any of its Subsidiaries the subject
of any proceeding asserting that such party or any of its Subsidiaries has committed an unfair labor practice or is seeking to compel it to bargain or consult with any labor union, works council or labor organization nor is there pending or, to the
knowledge of Laguna or Orca, as applicable, contemplated, threatened, nor has there been during the past three (3)&nbsp;years, any labor strike, dispute, <FONT STYLE="white-space:nowrap">walk-out,</FONT> work stoppage, slow-down or lockout
(&#147;<U>Strikes</U>&#148;) involving such party or any of its Subsidiaries, except for any general Strikes that are not directed exclusively at such party or any of its Subsidiaries. Laguna and Orca, in each case, have made available to the other
party true and complete copies of each Labor Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Laguna and Orca and each of its Subsidiaries, in each case, have complied
with any obligations to inform and consult with trade unions, works councils, labor organizations and other representatives of employees or workers, whether pursuant to a Labor Agreement, or otherwise as required in connection with the transactions
contemplated by this Agreement, except to the extent that noncompliance would not have or be reasonably expected to have a Material Adverse Effect on such party or would not be reasonably expected to prevent or materially impair or delay the
consummation of the Combinations or any of the other transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Section&nbsp;4.12(c) of the Laguna
Disclosure Letter (in the case of Laguna) or Section&nbsp;4.12(c) of the Orca Disclosure Letter (in the case of Orca) sets forth a true and correct list of each Labor Agreement with respect to which such party or any of its Subsidiaries is subject
to any requirement or local custom to inform or consult in connection with the transactions contemplated by this Agreement. Neither party is subject to any requirement or local custom to provide employee representation on its board of directors or
similar governing body or on the Topco Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Laguna and Orca and each of its Subsidiaries, in each case, is in compliance with
(i)&nbsp;all applicable Laws relating to employment and employment practices with respect to both present and former employees and personnel (including workers, independent contractors and consultants), including payment of wages and salaries,
hours, overtime, terms and conditions of employment and engagement, mandatory accrual of statutory leave allowances, collective bargaining, unemployment insurance, worker&#146;s compensation, equal employment opportunity, classification of employees
and contractors, staff leasing, discrimination, immigration, the payment and withholding of Taxes, collective redundancy, and the termination of employment; and (ii)&nbsp;applicable Labor Agreements and individual labor contracts, except to the
extent that noncompliance would not have a Material Adverse Effect on such party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except as, individually or in the aggregate, would
not reasonably be expected to have a Material Adverse Effect on Laguna or Orca, respectively, as of the date of this Agreement, there are no complaints, charges or claims against such party pending or, to the knowledge of Laguna or Orca, as
applicable, threatened to be brought or filed with any Governmental Entity or before any court, tribunal or arbitral body, based on, arising out of, in connection with, or otherwise relating to the employment of, or termination of employment by,
such party of any person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.13. </B><U>Material Contracts</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section&nbsp;4.13 of the Laguna Disclosure Letter or Orca Disclosure Letter, as applicable, sets forth a true and complete list of each
Contract to which Laguna or Orca, as applicable, or any of its respective Subsidiaries is a party or which binds or affects their respective properties or assets, and which falls within any of the categories listed below (each Contract of the type
described in this Section&nbsp;4.13, together with this Agreement, the Contracts filed, or incorporated by reference, as exhibits to the Laguna Reports or Orca Reports, as applicable, and each Contract entered into after the date of this Agreement
that, if existing on the date hereof, would be of the type described in this Section&nbsp;4.13 is referred to herein as a &#147;<U>Material Contract</U>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) any Contract with respect to a material joint venture, partnership, strategic alliance partnership, limited liability or
other similar agreement or arrangement related to the formation, creation, operation or management; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) is a
&#147;material contract&#148; (as such term is defined in Item&nbsp;601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of the SEC) (regardless of whether or not Orca is subject to Item&nbsp;601(b)(10) of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> of the SEC); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) any Contract with a Significant Customer or Significant Supplier;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) any acquisition or divestiture Contract (1)&nbsp;with a purchase price in excess of $25,000,000 entered into since
December&nbsp;31, 2019 or (2)&nbsp;that contains continuing <FONT STYLE="white-space:nowrap">&#147;earn-out&#148;</FONT> provisions or other contingent payment obligations; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) any material hedges, derivatives or other similar instruments or Contracts related thereto; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(F) any collective bargaining, union, labor or similar Contract; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(G) any Contract that grants &#147;most favored nation&#148; status to any counterparty or any
<FONT STYLE="white-space:nowrap">&#147;non-compete&#148;</FONT> or similar Contract that, in any case, materially restricts the business of such party or its Subsidiaries with respect to engaging or competing in any line of business or in any
geographic area </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(H) any material contract with a Governmental Entity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(I) that (1) (x) has an aggregate principal amount, or provides for an aggregate obligation, in excess of $25,000,000
evidencing indebtedness for borrowed money, (y)&nbsp;guarantees any indebtedness of a third party in excess of $25,000,000 or (z)&nbsp;contains a covenant restricting the payment of dividends in excess of $25,000,000 or (2)&nbsp;has the economic
effect of any of the items set forth in the foregoing clause (1); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(J) any other agreement which would prohibit or
materially delay the consummation of the Combinations or any other transaction contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as,
individually or in the aggregate, has not had or is not reasonably expected to have a Material Adverse Effect on Laguna or Orca, as applicable, neither Laguna nor Orca, as applicable, nor any of its Subsidiaries is in breach of or default under the
terms of any Material Contract, and no event has occurred that (with or without notice or lapse of time or both) is reasonably expected to result in a breach or default under any Material Contract. To the knowledge of Laguna or Orca, as applicable,
no other party to any Material Contract is in breach of or default under the terms of any Material Contract where such breach or default has had, or is reasonably expected to have, individually or in the aggregate, a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Material Adverse Effect on Laguna or Orca, as applicable. Except as, individually or in the aggregate, has not had and is not reasonably expected to have a Material Adverse Effect on Laguna or
Orca, as applicable, each Material Contract is a valid, binding and enforceable obligation of Laguna or Orca, as applicable, or any of its Subsidiaries which is party thereto and, to the knowledge of Laguna or Orca, as applicable, each other party
thereto, and is in full force and effect, except that such enforcement may be subject to the Bankruptcy and Equity Exception. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.14. </B><U>Intellectual Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For the purposes of this Agreement, &#147;<U>Intellectual Property</U>&#148; means all inventions, discoveries, patents, patent
applications, trademarks, service marks, logos and trade names and all goodwill associated therewith and symbolized thereby, Internet domain names, copyrights (including databases and other compilations of information and including copyrights in
software), confidential information, trade secrets and <FONT STYLE="white-space:nowrap">know-how,</FONT> including processes, techniques, schematics, business methods, formulae, drawings, prototypes, models, designs, specifications, research and
development records and other information, customer and supplier lists and information, and all other intellectual property and proprietary rights and rights equivalent to any of the foregoing in any jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as, individually or in the aggregate, has not had and is not reasonably expected to have a Material Adverse Effect with respect to
such party, such party or one of its Subsidiaries exclusively owns or otherwise has a valid right to use all Intellectual Property used in the operation of the business of such party and its Subsidiaries as currently conducted. The consummation of
the transactions contemplated by this Agreement will not alter or impair in any material respect any rights of such party or any of its Subsidiaries with respect to any Intellectual Property that is material to its business (the &#147;<U>Material
Intellectual Property</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as, individually or in the aggregate, has not had and is not reasonably expected to have a
Material Adverse Effect with respect to such party, (i)&nbsp;the conduct of the business of such party and its subsidiaries is not infringing, misappropriating, diluting or otherwise violating any Intellectual Property rights of any Person, and
(ii)&nbsp;neither such party nor any of its Subsidiaries has received any written claim, demand or other notice during the past three (3)&nbsp;years (or earlier, if presently not resolved) alleging any such infringement, misappropriation, dilution
or violation (including any claim that such party or any of its Subsidiaries must license or refrain from using any Intellectual Property rights of any Person). To the knowledge of Laguna or Orca, as applicable, no Person is, infringing or
misappropriating, diluting or otherwise violating any Material Intellectual Property of such party and its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Such party
and its Subsidiaries have taken commercially reasonable steps to maintain, police and protect the Material Intellectual Property of such party and its Subsidiaries. All Material Intellectual Property of such party and its Subsidiaries that derives
independent economic value, actual or potential, from not being generally known to the public or to other Persons who can obtain economic value from its disclosure or use has been maintained in confidence in accordance with protection procedures
that are adequate for protection, and in accordance with procedures customarily used in the industry to protect rights of like importance. To the knowledge of Laguna or Orca, as applicable, there has been no unauthorized use or disclosure of any
Material Intellectual Property of such party or any of its Subsidiaries. To the knowledge of Laguna or Orca, as applicable, all former and current officers, directors, employees, personnel, consultants, advisors, agents, and independent contractors
of such party and each of its Subsidiaries (or their predecessors), who have contributed to or participated in the conception and development of Intellectual Property for such entities have entered into valid and binding agreements with such party
or one of its Subsidiaries (or their respective predecessors) assigning to, or vesting ownership in, such party or one of its Subsidiaries all right, title and interest of such Intellectual Property, or granting a license for commercial use to such
party or one of its Subsidiaries. No such Person has asserted, and to the knowledge of Laguna or Orca, as applicable, no such Person has basis to assert, an ownership interest in any Material Intellectual Property of such party and its Subsidiaries
that is not subject to a license from such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The IT Assets of such party and its Subsidiaries operate and perform in all
material respects in accordance with their documentation and functional specifications, to the extent available, or as otherwise required by such party and its Subsidiaries in connection with the business of such party and its Subsidiaries as
currently conducted, and have not materially malfunctioned or failed within the last three (3)&nbsp;years. Such party and its Subsidiaries have implemented commercially reasonable measures to protect the confidentiality and security of the IT Assets
of such party and its Subsidiaries (and all information stored or contained therein) against any unauthorized use, access, interruption, and corruption. Such party and its Subsidiaries have implemented commercially reasonable data backup, data
storage, system redundancy and disaster avoidance and recovery procedures, as well as a commercially reasonable business continuity plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>IT Assets</U>&#148; means, with respect to Orca or Laguna, computers, software,
firmware, middleware, servers, workstations, routers, hubs, networks, switches, data communications lines, and all other information technology infrastructure and equipment and elements, and all associated documentation, used in the business of Orca
or Laguna, as applicable, and its Subsidiaries as currently conducted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.15. </B><U>Data Protection</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) As used in this Agreement: (i) &#147;<U>Applicable Data Protection Laws</U>&#148; means: (A)&nbsp;the General Data Protection
Regulation 2016/679; (B) the Privacy and Electronic Communications Directive 2002/58/EC; (C)&nbsp;the UK Data Protection Act 2018 (&#147;DPA&#148;), the UK General Data Protection Regulation as defined by the DPA as amended by the Data Protection,
Privacy and Electronic Communications (Amendments etc) (EU Exit) Regulations 2019, and the Privacy and Electronic Communications Regulations 2003; (D) HIPAA, as amended; (E)&nbsp;the California Consumer Privacy Act; (F)&nbsp;the Federal Trade
Commission Act; and (G)&nbsp;relevant law, statute, declaration, decree, directive, legislative enactment, order, ordinance, regulation, rule or other binding instrument which supplements or implements any of the above or which otherwise relates to
data protection, privacy or the use of Personal Data, in each case as applicable and in force from time to time, and as amended, consolidated, <FONT STYLE="white-space:nowrap">re-enacted</FONT> or replaced from time to time and (ii)&nbsp;each of
&#147;<U>Personal Data</U>&#148; and &#147;<U>Processing</U>&#148; has the meaning given by the relevant Applicable Data Protection Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as, individually or in the aggregate, had not had and would not reasonably be expected to have a Material Adverse Effect, such
party and its Subsidiaries, and so far as such party is aware, each third party Processing Personal Data on behalf of such party or its Subsidiaries is, and has been for the last three (3)&nbsp;years prior to the date of this Agreement, in material
compliance with all: (i)&nbsp;Applicable Data Protection Laws; (ii)&nbsp;contractual obligations and other commitments; and (iii)&nbsp;such party&#146;s own policies and procedures, in each case as relating to privacy, data protection, and the
Processing of Personal Data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as, individually or in the aggregate, had not had and would not reasonably be expected to have a
Material Adverse Effect, such party and its Subsidiaries, and so far as such party is aware, each third party processing Personal Data on behalf of such party or its Subsidiaries, has established, implemented and maintains appropriate technical and
organizational measures to protect against the unauthorized or unlawful Processing of, or accidental loss or damage to, any Personal Data processed by such party and its Subsidiaries or on their behalf. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as, individually or in the aggregate, had not had and would not reasonably be expected to have a Material Adverse Effect, to the
extent any Personal Data originating in the United Kingdom or European Economic Area is transferred by such party outside of the United Kingdom or European Economic Area (as applicable), this is carried out in accordance with Applicable Data
Protection Laws and with appropriate safeguards in place for such transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except as, individually or in the aggregate, had not had
and would not reasonably be expected to have a Material Adverse Effect, neither the Combinations nor the execution or performance of this Agreement or any document delivered pursuant to this Agreement, will: (i)&nbsp;conflict with or result in a
breach of any Applicable Data Protection Laws, contractual obligations and other commitments to third parties, or such party&#146;s own policies and procedures, in each case relating to privacy, data protection, and the Processing of Personal Data;
or (ii)&nbsp;give rise to any right of termination or other restriction on the rights of such party or any of its Subsidiaries to Process any Personal Data as necessary to carry on such party or its Subsidiaries&#146; business in the same manner as
it is currently carried on. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except as, individually or in the aggregate, had not had and would not reasonably be expected to have a
Material Adverse Effect, in the last three (3)&nbsp;years: (i) such party and its Subsidiaries have not received a written complaint, claim, request, correspondence, objection, or other communication in relation to their collection, use or
Processing of Personal Data that remains unresolved; and (ii)&nbsp;the collection, use and Processing of Personal Data by such party and its Subsidiaries has not been the subject of any investigation, audit, action or proceedings (whether of a
criminal, civil or administrative nature). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Except as, individually or in the aggregate, had not had and would not reasonably be
expected to have a Material Adverse Effect, none of the Personal Data Processed by such party and its Subsidiaries, or on its behalf, has been subject to unauthorized or unlawful processing, or accidental loss or damage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.16. </B><U>Properties and Assets</U>. Such party and its Subsidiaries have, and immediately following the
Laguna Effective Time will continue to have (including through any successor entity to such party), good and valid title to their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
owned assets and properties, or in the case of assets and properties they lease, license, or have other rights in, good and valid rights by lease, license or other agreement to use, all assets
and properties (in each case, tangible and intangible) necessary and desirable to permit such party and its Subsidiaries to conduct their respective businesses as currently conducted, except, in each case, which, individually or in the aggregate,
has not had and is not reasonably expected to have a Material Adverse Effect on such party. The assets and properties (in each case, tangible or intangible) owned or used by such party and its Subsidiaries are in satisfactory condition for their
continued use as they have been used and are adequate for their current use, subject to reasonable wear and tear, except, in each case, which, individually or in the aggregate, has not had and is not reasonably expected to have a Material Adverse
Effect on such party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.17. </B><U>Environmental Matters</U>. To the knowledge of such party, except as,
individually or in the aggregate, has not had or is not reasonably expected to have a Material Adverse Effect on such party, (a)&nbsp;such party and its Subsidiaries hold, and are now and for the last five (5)&nbsp;years have been in compliance with
all permits, licenses, certificates, clearances, variances, exemptions, and other authorizations (including emission or discharge allowances and credits) required under any foreign, federal, state, local or municipal law (including common law),
statute, treaty, ordinance, rule, regulation, judgment, order or decree promulgated or issued by any Governmental Entity (including guidance notes that are implemented in jurisdictions outside of the United States) relating to contamination,
pollution or protection of human health, natural resources or the environment (the &#147;<U>Environmental Laws</U>&#148;) for such party to conduct its operations (the &#147;<U>Environmental Permits</U>&#148;), and are in compliance with all
applicable Environmental Laws and Environmental Permits and to the knowledge of such party, there is no condition (including the Combinations) that would reasonably be expected to prevent or interfere with compliance with all applicable
Environmental Laws and all applicable Environmental Permits in the future, (b)&nbsp;such party and its Subsidiaries have not received any written notice, claim, demand, action, suit, complaint, proceeding or other communication by any Person
alleging any violation of, or any actual or potential liability under, any Environmental Laws or Environmental Permit (an &#147;<U>Environmental Claim</U>&#148;), and such party has no knowledge of any pending or threatened Environmental Claim,
(c)&nbsp;no hazardous, dangerous or toxic substance, including petroleum (including crude oil or any fraction thereof), asbestos and asbestos-containing materials, polychlorinated biphenyls, radon, fungus, mold, urea-formaldehyde insulation or any
other material that is regulated pursuant to any Environmental Laws or that could result in liability under any Environmental Laws has been generated, transported, treated, stored, installed, disposed of, arranged to be disposed of, released or
threatened to be released at, on, from or under any of the properties or facilities currently or formerly owned, leased or otherwise used by such party or its Subsidiaries, in violation of, or in a manner or to a location that could give rise to
liability to such party or its Subsidiaries under Environmental Laws, (d)&nbsp;such party and its Subsidiaries have not assumed, contractually or by operation of Law, any liabilities or obligations under or relating to any Environmental Laws,
(e)&nbsp;such party and its Subsidiaries have not entered into or agreed to any order or Contract, and are not subject to any judgment, settlement or agreement relating to compliance with or liability under any Environmental Laws, and (f)&nbsp;none
of such party and its Subsidiaries are an indemnitor in connection with any potential or actual claim for any liability or responsibility under any Environmental Laws. Except for Section&nbsp;4.6 (Reports; Financial Statements; Internal Control and
Disclosure Control), Section&nbsp;4.7 (Absence of Certain Changes), Section&nbsp;4.13 (Material Contracts), Section&nbsp;4.16 (Properties and Assets), Section&nbsp;4.19 (Real Property), and Section&nbsp;4.26 (Information in Public Filings),
Section&nbsp;4.17 (Environmental Matters) shall be the exclusive representations and warranties with respect to matters relating to contamination, pollution or protection of human health, natural resources or the environment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.18. </B><U>Customers and Suppliers</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;4.18(a)</U> of the Laguna Disclosure Letter or Orca Disclosure Letter, as applicable, sets forth a list
showing the 10 largest customers of Laguna and Orca, as applicable, and its respective Subsidiaries by total sales by Laguna and Orca, as applicable, and its respective Subsidiaries, taken as a whole, during the twelve (12)&nbsp;month period ending
on September&nbsp;30, 2021 (each, a &#147;<U>Significant Customer</U>&#148;). Since September&nbsp;30, 2021, no Significant Customer has indicated in writing an intention to (x)&nbsp;stop purchasing products from Laguna and Orca, as applicable, or
its respective Subsidiaries; or (y)&nbsp;change, materially and adversely, the terms and conditions on which it purchases products from Laguna and Orca, as applicable, or its respective Subsidiaries, except as, individually or in the aggregate, had
not had and would not reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Section</U><U></U><U>&nbsp;4.18(b)</U> of the
Laguna Disclosure Letter or Orca Disclosure Letter, as applicable, sets forth a list showing the 10 largest suppliers of Laguna and Orca, as applicable, and its respective Subsidiaries by gross sales to Laguna and Orca, as applicable, and its
respective Subsidiaries, taken as a whole, during the twelve (12)&nbsp;month period ending on September&nbsp;30, 2021 (each, a &#147;<U>Significant Supplier</U>&#148;). Since September&nbsp;30, 2021, no Significant Supplier has indicated in writing
an intention to (x)&nbsp;stop supplying Laguna and Orca, as applicable, or its respective Subsidiaries; or (y)&nbsp;change, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
materially and adversely, the terms and conditions on which it is prepared to supply Laguna and Orca, as applicable, or its respective Subsidiaries except as, individually or in the aggregate,
had not had and would not reasonably be expected to have a Material Adverse Effect. Each of Laguna and Orca, as applicable, and its respective Subsidiaries has delivered or caused to be delivered to the other party true and complete copies of the
each currently effective Contract between Laguna and Orca, as applicable, or its respective Subsidiaries and a Significant Supplier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.19. </B><U>Real Property.</U><U> </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, (i)&nbsp;each of Laguna
and Orca, as applicable, and its respective Subsidiaries has good, valid and marketable title to each real property owned by such person (&#147;<U>Owned Real Property</U>&#148;), in each case free and clear of any Liens, other than Permitted Liens
and (ii)&nbsp;no Owned Real Property of Laguna or Orca, as applicable, or its respective Subsidiaries is subject to any option, obligation or right of first refusal or contractual right to purchase, lease or acquire any interest in any Owned Real
Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, each of
Laguna and Orca, as applicable, and its respective applicable Subsidiaries has good and valid leasehold interests in each real property leased by such person (&#147;<U>Leased Real Property</U>&#148; and, together with the Owned Real Property, the
&#147;<U>Real Property</U>&#148;), in each case free and clear of any Liens, other than Permitted Liens. Each Contract of Laguna and Orca, as applicable, or any of its Subsidiaries for any Leased Real Property is legal, valid, enforceable and
binding on Laguna and Orca, as applicable, or any of its Subsidiaries that is a party thereto and, to the knowledge of Laguna or Orca, each other party thereto and is in full force and effect, except that (i)&nbsp;such enforcement may be subject to
applicable bankruptcy, insolvency or other similar Laws, now or hereafter in effect, affecting creditors&#146; rights generally and (ii)&nbsp;the remedy of specific performance and injunctive and other forms of equitable relief may be subject to
equitable defenses and to the discretion of the court before which any proceeding therefor may be brought, and except for such failures to be valid and binding or to be in full force and effect that would not reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect, and neither Laguna and Orca, as applicable, nor any of its Subsidiaries is in breach of or default under, or has received written notice of any breach of or default under, and no condition
exists which (with notice or lapse of time or both) would constitute a default under, any lease of Leased Real Property where such breach or default would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) There are no pending or, to the knowledge of Laguna or Orca, as applicable, threatened condemnation or similar proceedings related
to its Real Property where such condemnation or similar proceeding would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Liens</U>&#148; means (a)&nbsp;encumbrances for current Taxes or other governmental charges not yet
delinquent and payable without penalty or the amount or validity of which is being contested in good faith by appropriate proceedings by Laguna or Orca, as applicable, or its Subsidiaries, and for which appropriate reserves have been established in
accordance with GAAP; (b)&nbsp;mechanics&#146;, carriers&#146;, workmen&#146;s, repairmen&#146;s, materialmens&#146;, contractors&#146; or other like encumbrances arising or incurred in the ordinary course of business consistent with past practice
relating to obligations that are not yet overdue by more than thirty (30)&nbsp;days and payable or that are being diligently contested in good faith by appropriate proceedings; (c)&nbsp;zoning, entitlement, building and other land use regulations
imposed by any Governmental Entity having jurisdiction over the Real Property of Laguna or Orca, as applicable, which are not, individually or in the aggregate, violated in any material respect by the current use and operation of the Real Property
of Laguna or Orca, as applicable; (d)&nbsp;purchase money liens and liens securing rental payments under capital lease arrangements; (e) other minor encumbrances of record that do not, individually or in the aggregate, materially impair the
continued use, operation, value or marketability of the specific parcel of the Real Property of Laguna or Orca, as applicable, to which they relate or the conduct of the business of Laguna or Orca, as applicable, and its Subsidiaries as presently
conducted; and (f)&nbsp;any condition or other matter, if any, that may be shown or disclosed by a current and accurate survey of such Real Property that does not, individually or in the aggregate, materially impair the continued use, operation,
value or marketability of the specific parcel of the Real Property of Laguna or Orca, as applicable, to which it relates or the conduct of the business of Laguna or Orca, as applicable, and its Subsidiaries as presently conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.20. </B><U>Personal Propert</U><U>y</U>. Except as has not resulted, and would not reasonably be expected to
result, in, individually or in the aggregate, a Material Adverse Effect, each of Laguna and Orca, as applicable, and its respective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subsidiaries has good and valid title to its respective owned assets and properties, or in the case of assets and properties it leases, licenses, or has other rights in, good and valid rights by
lease, license or other agreement to use, all assets and properties necessary and desirable to permit Laguna and Orca, as applicable, and its respective Subsidiaries to conduct their respective businesses as currently conducted, free and clear of
any Liens other than Permitted Liens, other than (x)&nbsp;personal property sold or otherwise disposed of in the ordinary course of business consistent with past practice since December&nbsp;31, 2020; and (y)&nbsp;Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.21. </B><U>Related Party Transactions</U>. There are no outstanding amounts payable to or receivable from, or
advances by Laguna and Orca, as applicable, or any of its respective Subsidiaries to, and neither Laguna and Orca, as applicable, nor any of its respective Subsidiaries is otherwise a creditor or debtor to, or party to any Contract or transaction
with, any holder of five (5)&nbsp;percent or more of the Laguna Shares or Orca Shares, as applicable, or any director, officer, employee or affiliate of Laguna and Orca, as applicable, or its respective Subsidiaries, or to any relative of any of the
foregoing, except for (a)&nbsp;employment or compensation agreements or arrangements with directors, officers and employees made in the ordinary course consistent with past practice and (b)&nbsp;in the case of Orca, any Contracts entered into in the
ordinary course of business on arms&#146; length terms between portfolio companies and other affiliates of any person owning five (5)&nbsp;percent or more of the Orca Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.22. </B><U>Takeover Statutes</U>. The Laguna Board or the Orca Board, as applicable, has taken all actions
necessary to render inapplicable to this Agreement, and the consummation of the transactions contemplated hereby or thereby, including the Combinations, the restrictions on business combinations contained in Section&nbsp;203 of the DGCL and all
takeover-related provisions set forth in the Organizational Documents of Laguna or Orca, as applicable, without any further action on the part of the respective stockholders or the Laguna Board or the Orca Board, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.23. </B><U>Insurance</U>. Except as would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect, as of the date hereof, (a)&nbsp;all current insurance policies and Contracts of each of Laguna and Orca, as applicable, and its respective Subsidiaries are in full force and effect and are valid and enforceable
and (b)&nbsp;all premiums due thereunder have been paid. Neither Laguna, Orca nor any of their respective Subsidiaries has received notice of cancellation or termination with respect to any third party insurance policies or Contracts (other than in
connection with normal renewals of any such insurance policies or Contracts) where such cancellation or termination would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.24. </B>Anti-Corruption, Trade Sanctions, and Trade Control Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as, individually or in the aggregate, has not had and is not reasonably expected to have a Material Adverse Effect on such party,
none of such party, such party&#146;s Subsidiaries, their respective officers, directors, or employees, nor, to the knowledge of such party, any of their respective Representatives, has in the past five (5)&nbsp;years, directly or indirectly,
corruptly offered, paid, given, promised, or authorized, requested, solicited, or accepted any money, financial or other advantage, or anything else of value, to or from any Person, including: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any official, officer, employee or representative of, or any person acting in an official capacity or exercising a public function for or
on behalf of, any Governmental Entity (which for purposes of this Section&nbsp;4.24, includes (1)&nbsp;any national, federal, state, county, municipal, or local government or any entity exercising executive, legislative, judicial, regulatory,
taxing, administrative, or public functions of a country or territory or pertaining to government, (2)&nbsp;any public international organization, (3)&nbsp;any agency, division, bureau, department, or other political subdivision of any government,
entity, or organization described in the foregoing clauses (1)&nbsp;or (2) of this definition, or (4)&nbsp;any company, business, enterprise, or other entity majority-owned or controlled by any government, entity, or organization described in the
foregoing clauses (1), (2), or (3)&nbsp;of this definition), and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any political party, party official or candidate for political
office (in each case a &#147;Government Official&#148;) (1) for the purpose of influencing any act or decision of a Government Official in his or her official capacity, inducing a Government Official to omit to do any act in violation of a lawful
duty, securing any improper advantage, inducing a Government Official to affect or influence any act or decision of any Governmental Entity or inducing or rewarding the improper performance of a function or activity by any Person; or (2)&nbsp;which
would otherwise constitute or have the purpose or effect of public or commercial bribery kickbacks or other unlawful or improper means of obtaining business or any improper business advantage. Such party and its Subsidiaries are and at all times in
the past five (5)&nbsp;years have been (A)&nbsp;in compliance in all material respects with and have not committed any offense under the United States Foreign Corrupt Practices Act of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
1977, as amended (the &#147;<U>FCPA</U>&#148;) the U.K. Bribery Act 2010 (the &#147;<U>Bribery Act</U>&#148;) or any other applicable Laws of regarding bribery or corruption, including all Laws
enacted to implement the OECD Convention on Combating Bribery of Foreign Officials in International Business Transactions (together with the FCPA and the Bribery Act, &#147;<U>Anti-Corruption Laws</U>&#148;), and (B)&nbsp;subject to policies and
procedures reasonably designed to ensure compliance with the Anti-Corruption Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as, individually or in the aggregate, has
not had and is not reasonably expected to have a Material Adverse Effect on such party: (i)&nbsp;there is not currently, and there has not been in the past five (5)&nbsp;years, any actual, pending, or, to such party&#146;s knowledge, threatened
investigation or litigation by any Governmental Entity with respect to compliance with any applicable Anti-Corruption Laws by such party or its Subsidiaries, (ii)&nbsp;such party and its Subsidiaries are, and for the past five (5)&nbsp;years have
been, in compliance in all material respects with all applicable Trade Sanctions Laws and Trade Control Laws, (iii)&nbsp;in the past five (5)&nbsp;years, none of such party, such party&#146;s Subsidiaries nor any of their officers, directors,
employees or Representatives has been or is designated on the list of Specially Designated Nationals and Blocked Persons maintained by the United States Department of Treasury&#146;s Office of Foreign Assets Control (&#147;<U>OFAC</U>&#148;), or
similar lists maintained by the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or any other relevant sanctions authority and (iv)&nbsp;none of such party or such party&#146;s Subsidiaries nor, to their knowledge,
any of their Representatives, has participated in the past five (5)&nbsp;years in any transaction or dealing involving a designated person or entity, or any Person or entity resident, operating in, or organized under the laws of a country or
territory that is subject to sanctions under Trade Sanctions Laws, in violation of Trade Sanctions Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As used in this Agreement,
(i) &#147;<U>Trade Sanctions Laws</U>&#148; means all applicable economic financial sanctions or trade embargoes imposed, administered or enforced from time to time by (A)&nbsp;the U.S. government, including those administered by OFAC or the U.S.
Department of State, or (B)&nbsp;the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other applicable sanctions authorities, (ii) &#147;<U>Trade Control Laws</U>&#148; means all applicable Laws and regulations
related to the regulation of imports, trade, export control, or antiboycott laws and regulations imposed, administered, or enforced by the U.S. government, the European Union, Her Majesty&#146;s Treasury, or other relevant authorities, including
(A)&nbsp;the United States International Traffic in Arms Regulations administered by the United States State Department&#146;s Directorate of Defense Trade Controls; (B)&nbsp;the Export Administration Regulations administered by the United States
Commerce Department (including the antiboycott regulations administered by the Office of Antiboycott Compliance); (C) nuclear export regulations administered by the United States Nuclear Regulatory Commission and the United States Department of
Energy; (D)&nbsp;United States customs Laws and regulations administered by U.S. Customs and Border Protection; (E)&nbsp;the EU <FONT STYLE="white-space:nowrap">Dual-Use</FONT> Regulation, Council Regulation (EC) No 428/2009 (and associated
amendments); and&nbsp;(F) all other applicable import and export controls in the countries in which the party conducts business, except to the extent inconsistent with U.S. law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as, individually or in the aggregate, has not had and is not reasonably expected to have a Material Adverse Effect on such party:
(i)&nbsp;in the past five (5)&nbsp;years, such party and its subsidiaries (A)&nbsp;are and at all times have been subject to policies and procedures reasonably designed to ensure compliance with applicable Trade Sanctions Laws and Trade Control
Laws, and (B)&nbsp;have obtained, and are in compliance with, all required export and import licenses, license exceptions and other consents, notices, approvals, orders, permits, authorizations, declarations, classifications and filings with any
Governmental Entity required for the import, export and <FONT STYLE="white-space:nowrap">re-export</FONT> of products, software and technology and (ii)&nbsp;there are not currently, and there has not been in the past five (5)&nbsp;years, any actual,
pending, or, to such party&#146;s knowledge, threatened investigation, litigation, or inquiry by any Governmental Entity with respect to compliance with any applicable Trade Sanctions Laws or Trade Control Laws by such party or its Subsidiaries.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.25. </B><U>Healthcare Compliance Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of Laguna and Orca, as applicable, and each of its Subsidiaries, (i)&nbsp;is in compliance and since January&nbsp;1, 2019 has been in
compliance with all Health Care Laws applicable to it or any assets owned or used by it, and (ii)&nbsp;neither Laguna nor Orca, as applicable, nor any of its Subsidiaries has received any written communication since January&nbsp;1, 2019 from a
Governmental Entity that remains uncured or unresolved and that alleges that such party or any of its Subsidiaries is not in compliance with any Health Care Law, except in the case of clauses (i)&nbsp;and (ii) where any <FONT
STYLE="white-space:nowrap">non-compliance,</FONT> individually or in the aggregate, has not had and would not reasonably be expected to have, a Material Adverse Effect. Neither Laguna nor Orca, as applicable, nor, to the knowledge of such party, any
of its Subsidiaries is a party to or has any ongoing reporting obligations pursuant to or under any corporate integrity agreements, deferred or <FONT STYLE="white-space:nowrap">non-prosecution</FONT> agreements, monitoring agreements, consent
decrees, settlement orders, plans of correction or similar agreements with or imposed by any Governmental Entity. Additionally, since January&nbsp;1, 2019, none of Laguna or Orca, as applicable, or any of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its Subsidiaries or any of its respective employees, officers, directors or, to the knowledge of such party, agents (A)&nbsp;has been excluded, suspended or debarred from participation in any
U.S. state or federal health care program, (B)&nbsp;to the knowledge of such party, has been convicted of any crime or is subject to a governmental inquiry, investigation, Proceeding, or other similar action, or (C)&nbsp;to the knowledge of such
party, has engaged in any conduct, that could reasonably be expected to result in debarment, suspension, or exclusion, except for any exclusion, suspension, debarment, conviction or conduct that, individually or in the aggregate has not had and
would not reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of Laguna and Orca, as applicable, and each of its
Subsidiaries has, maintains and is operating in material compliance with, and all of its products are designed, manufactured, imported, exported, processed, developed, labeled, stored, tested and marketed in compliance with, all Permits of the
United States Food and Drug Administration (&#147;FDA&#148;) and comparable Governmental Entities which are required for the conduct of its business as currently conducted (collectively, the &#147;<U>FDA Permits</U>&#148;), and all such FDA Permits
are valid, subsisting, and in full force and effect, except where the failure to have, maintain or operate in material compliance with the FDA Permits has not had, and would not reasonably be expected to have, individually or in the aggregate, a
Material Adverse Effect. Since January&nbsp;1, 2019, each of Laguna and Orca, as applicable, and each of its Subsidiaries have fulfilled and performed all of their material obligations with respect to the FDA Permits, and no event has occurred which
allows, or with notice or lapse of time or both, would allow revocation or termination thereof or results in any other material impairment of the rights of the holder of any FDA Permit, except where the failure to so fulfill or perform, or the
occurrence of such event, would not result in a Material Adverse Effect. Each of Laguna and Orca, as applicable, and each of its Subsidiaries have operated and currently are in compliance in all material respects with applicable Laws administered or
enforced by the FDA and comparable Governmental Entities, except where the failure to so comply would not result in a Material Adverse Effect. Each of Laguna and Orca, as applicable, and each of its Subsidiaries has not received, since
January&nbsp;1, 2019, written notice of any pending or threatened Proceeding (other than FDA audits) from the FDA, any Governmental Entity, any <FONT STYLE="white-space:nowrap">qui-tam</FONT> relator or applicable foreign Governmental Entity
alleging that any operation or activity of such party or any of its Subsidiaries is in material violation of any applicable Health Care Law which violation would reasonably be expected to have a material and adverse impact on such party and its
Subsidiaries, taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as has not had and would not reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect, since January&nbsp;1, 2019, all applications, notifications, submissions, information, claims, reports and statistics, and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection
with any and all requests for a FDA Permit from the FDA or other Governmental Entity relating to Laguna or Orca, as applicable, and each of its Subsidiaries, businesses and products, when submitted to the FDA or other Governmental Entity were true,
complete and correct as of the date of submission and any necessary or required updates, changes, corrections or modification to such applications, submissions, information and data have been submitted to the FDA or other Governmental Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, since
January&nbsp;1, 2019, each of Laguna and Orca, as applicable, and each of its Subsidiaries has not had any product or manufacturing site (whether owned by such party or its Subsidiary(s), or a contract manufacturer for its products) subject to a
Governmental Entity (including FDA) shutdown or import or export prohibition, nor received any FDA Form 483 or other Governmental Entity notice of inspectional observations, &#147;warning letters,&#148; &#147;untitled letters&#148; or requests or
requirements to make changes to the products, or similar correspondence or notice from the FDA or other Governmental Entity alleging or asserting noncompliance with any applicable Law, Permit or such requests or requirements of a Governmental
Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Section&nbsp;4.25(e)</U> of the Laguna Disclosure Letter or Orca Disclosure Letter, as applicable, sets forth a list of
(i)&nbsp;all material recalls, removals, field notifications, field corrections, market withdrawals or replacements, corrective actions, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory
compliance (collectively, &#147;<U>Safety Notices</U>&#148;) with respect to the products of Laguna or Orca, as applicable, and its respective Subsidiaries, respectively, since January&nbsp;1, 2019 and (ii)&nbsp;the date on which any such Safety
Notice was resolved or closed (as applicable). To the knowledge of Laguna or Orca, as applicable, (A)&nbsp;since January&nbsp;1, 2019, there have been no material complaints with respect to its products that are currently unresolved, (B)&nbsp;there
are no facts that would be reasonably likely to result in (x)&nbsp;a material Safety Notice with respect to its products or offerings, (y)&nbsp;a material change in marketing classification or labeling of any such products, or (z)&nbsp;a termination
or suspension of marketing or testing of any of its products or offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither Laguna nor Orca, as applicable, nor any of its
Subsidiaries is the subject of any pending or, to the knowledge of Laguna or Orca, as applicable, threatened investigation in respect of such party, its Subsidiaries or its products, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the FDA pursuant to its &#147;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#148; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any
amendments thereto. Since January&nbsp;1, 2019, neither Laguna nor Orca, as applicable, nor, to the knowledge of such party, any of its officers, employees or agents (within the meaning of the applicable Law) has been convicted of any crime or
engaged in any conduct that could result in a material debarment or exclusion under (i) 21 U.S.C. Section&nbsp;335a or (ii)&nbsp;any similar Law. As of the date hereof, no Proceedings that would reasonably be expected to result in such a debarment
or exclusion are pending or, to the knowledge of Laguna or Orca, as applicable, threatened against such party, its Subsidiaries, or any of their respective officers, employees or agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Since January&nbsp;1, 2019, all studies, tests and preclinical and clinical studies being conducted by or on behalf of or sponsored by
Laguna or Orca, as applicable, or its Subsidiaries, or in which Laguna or Orca, as applicable, or its Subsidiaries has participated, were and, if still pending, are being conducted in material compliance with applicable Laws, including, without
limitation, the Health Care Laws including 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812. Laguna and Orca have made all such filings and obtained all such approvals, authorizations or exemptions as may be required by the FDA or any other Healthcare
Regulatory Authority for the conduct of such tests or studies. Since January&nbsp;1, 2019, each of Laguna or Orca, as applicable, and its Subsidiaries, has not received any written notices, correspondence or other communication from any
institutional review board or ethics committee, the FDA or any other Governmental Entity, recommending or requiring the termination, suspension, or material modification of any ongoing studies or tests conducted or proposed to be conduct by, or on
behalf of, or supervised by, such party or its Subsidiaries, or in which the products or investigational products of such party or its Subsidiaries have participated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) As used in this Agreement, &#147;<U>Health Care Laws</U>&#148; means all applicable federal, state, local and foreign healthcare Laws,
including, without limitation, (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 et seq.); (ii) the Controlled Substances Act (21 U.S.C. &#167; 801 et seq.); (iii) the Public Health Service Act (42 U.S.C. &#167; 201 et seq.);
(iv) all applicable federal, state, local and all applicable foreign health care related fraud and abuse, false claims, and anti-kickback laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the U.S. Physician Payment Sunshine Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h)</FONT> and similar gift and disclosure Laws, the U.S. Civil False Claims Act (31 U.S.C. &#167; 3729
et seq.), the criminal False Claims Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. &#167;&#167; 286 and 287, and the
health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;) (42 U.S.C. &#167; 1320d et seq.), the exclusion laws (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7),</FONT> the civil monetary penalties law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42
U.S.C. &#167; 17921 et seq.), Laws pertaining to privacy, data protection and information security, and the regulations promulgated pursuant to such statutes; (v)&nbsp;state Laws relating to the manufacture, sale and distribution of medical
products; (vi)&nbsp;Medicare (Title XVIII of the Social Security Act) and (vii)&nbsp;Medicaid (Title XIX of the Social Security Act); (viii) any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof; and (ix)&nbsp;the
regulations promulgated pursuant to such laws identified in subparts (i)&nbsp;to (viii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.26.
</B><U>Information in Public Filings</U>. The information supplied or to be supplied by Laguna or Orca, as applicable, expressly for inclusion or incorporation by reference in the Registration Statement or the Proxy Statement/Prospectus (and, in
each case, any amendment thereof or supplement thereto) will not, when filed with the applicable Regulatory Authority and when distributed or disseminated to such party&#146;s stockholders, contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading, or not otherwise comply with applicable Law. The
Registration Statement and the Proxy Statement/Prospectus will comply as to form in all material respects with the provisions of any applicable securities Laws and will not, when filed with the applicable Regulatory Authority and when distributed or
disseminated to such party&#146;s stockholders, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the
circumstances under which they were made, not misleading, or not otherwise comply with applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.27. </B><U>Brokers</U>. Except for (x)&nbsp;Laguna&#146;s obligations to Perella Weinberg Partners LP and
Citigroup Global Markets Inc., the fees and expenses of which will be paid by Laguna, and (y)&nbsp;Orca&#146;s obligations to J.P. Morgan Securities LLC, the fees and expenses of which will be paid by Orca, no broker, investment banker, financial
advisor or other Person is entitled to any brokerage, finders&#146;, advisory or similar fee or commission, or the reimbursement of expenses, in connection with the transactions contemplated by this Agreement (including the Combinations), based upon
arrangements made by or on behalf of such party or any of its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE V </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COVENANTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.1. </B><U>Interim Operations</U>. Each of Laguna and Orca covenants and agrees as to itself and its
Subsidiaries that, after the date hereof and until the earlier of the Laguna Effective Time or the termination of this Agreement in accordance with its terms, unless Laguna (in the case of any action or omission proposed with respect to Orca or any
Subsidiary of Orca) or Orca (in the case of any action or omission with respect to Laguna or any Subsidiary of Laguna) shall otherwise approve in writing (which approval shall not be unreasonably withheld, delayed or conditioned by the party from
whom it is requested) and except as required by applicable Law, Self-Regulatory Organization, the Orca Scheme or as expressly contemplated by this Agreement or, in the case of Orca, as otherwise set forth in Section&nbsp;5.1 of the Orca Disclosure
Letter or, in the case of Laguna, as otherwise set forth in Section&nbsp;5.1 of the Laguna Disclosure Letter: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) each of it and its
Subsidiaries shall use its commercially reasonable efforts (i)&nbsp;to conduct its business in the ordinary and usual course consistent with past practice and (ii)&nbsp;to preserve intact its business organization and consistent with prior practice
maintain its existing relations and goodwill with all Governmental Entities (including applicable Regulatory Authorities) and Self-Regulatory Organizations, clients, customers, suppliers, distributors, creditors, lessors, employees, stockholders and
other Persons with which it or Laguna or Orca, as applicable, and its Subsidiaries has material business relations, as applicable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;(i) neither it nor its Subsidiaries shall amend, modify, waive, rescind or otherwise change any provisions of its Organizational
Documents; (ii)&nbsp;neither Laguna nor Orca, as applicable, shall split, combine or reclassify its outstanding shares of capital stock or other equity interests; (iii)&nbsp;neither it nor its Subsidiaries shall declare, set aside or pay any type of
dividend or other distribution, whether payable in cash, stock, property or a combination thereof, in respect of any capital stock or other equity interests, as appropriate, other than dividends payable by direct or indirect wholly owned
Subsidiaries of Laguna or Orca, as applicable, to Laguna or Orca, respectively, or another of its direct or indirect wholly owned Subsidiaries in the ordinary and usual course of business (including in connection with acquisitions entered into after
the date of this Agreement as permitted by Section&nbsp;5.1(h)) or to service existing indebtedness for borrowed money; (iv)&nbsp;neither it nor its Subsidiaries shall adopt a plan of merger, consolidation or complete or partial liquidation or
resolutions providing for a merger, consolidation or complete or partial liquidation, dissolution, restructuring, recapitalization or other reorganization; and (v)&nbsp;except (x) for the acquisition by such party of shares of its capital stock or
other equity interests in connection with the surrender of such shares by holders of Laguna Stock Awards or Orca Stock Awards, as applicable, in order to pay the exercise price of such Stock Awards in accordance with the terms of such Stock Awards
as in effect on the date of this Agreement and Disclosed to the other party, (y)&nbsp;for the withholding or disposition of shares of capital stock or other equity interests to satisfy withholding Tax obligations with respect to Laguna Stock Awards
or Orca Stock Awards, as applicable, granted pursuant to the Laguna Stock Plans and the Orca Stock Plans, as applicable, in accordance with the terms of such Stock Awards as in effect on the date of this Agreement and Disclosed to the other party,
neither it nor its Subsidiaries it shall repurchase, redeem or otherwise acquire any shares of any capital stock or other equity interests of Laguna or Orca or their respective Subsidiaries, as applicable, or any securities convertible into or
exchangeable or exercisable for any such shares of capital stock or other equity interests, as applicable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) neither it nor any of its
Subsidiaries shall (i)&nbsp;issue, sell, pledge, dispose of or encumber any shares of, or securities convertible into or exchangeable or exercisable for, or options, warrants, calls, profits interests, commitments or rights of any kind to acquire,
capital stock or other equity interests, or any bonds, debentures, notes or other obligations the holders of which have the right to vote (or convertible into or exercisable for securities having the right to vote) with its stockholders on any
matter or any other property or assets, except for (x)&nbsp;Laguna Shares or Orca Shares (as applicable) issuable or transferable pursuant to Laguna Stock Awards or Orca Stock Awards outstanding on or awarded prior to the date hereof or made by
Laguna or Orca, as applicable, (y)&nbsp;in amounts not to exceed the maximum amounts set forth respectively, in the case of Orca, on Section&nbsp;5.1 of the Orca Disclosure Letter or, in the case of Laguna, on Section&nbsp;5.1 of the Laguna
Disclosure Letter, or (z)&nbsp;issuances to Subsidiaries of Laguna or Orca, as applicable, in connection with internal reorganizations entered into in the ordinary and usual course of business solely among the Subsidiaries of Laguna or Orca, as
applicable, which will not adversely affect the Intended Tax Treatment; (ii)&nbsp;incur any indebtedness for borrowed money (including any guarantee of indebtedness) or issue any debt securities except for borrowing in amounts not to exceed
$25,000,000 in the aggregate (including pursuant to any drawdowns of credit facilities outstanding as of the date hereof); or (iii)&nbsp;make or authorize or commit to any material capital expenditures, other than in the ordinary and usual course of
business and consistent with past practice; <U>provided</U> that, to the extent permitted by Law, it shall inform the other party of material capital expenditures not contemplated by such party&#146;s capital budget; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) neither it nor any of its Subsidiaries shall (i)&nbsp;terminate, establish, adopt, enter
into, or materially amend any Benefit Plan, as the case may be, or any other arrangement that would be a Laguna Benefit Plan or an Orca Benefit Plan if in effect on the date of this Agreement; (ii)&nbsp;materially increase the salary, wage, bonus,
fringe benefits or other compensation of any director, manager, officer or employee or enter into any contract, agreement, commitment or arrangement to do any of the foregoing; <U>provided</U>, however, that any compensation or benefits that vest,
accelerate or result in any payment or funding in connection with any of the transactions contemplated by this Agreement shall not be considered a breach of the foregoing clauses (i)&nbsp;and (ii); (iii) enter into any contract, agreement,
commitment or arrangement providing for the payment to any director, manager, officer or employee of such party or the funding of compensation or benefits in connection with, contingent upon, or the terms of which are materially altered in
connection with, any of the transactions contemplated by this Agreement either alone or, except as provided below, in conjunction with any other event; or (iv)&nbsp;provide, with respect to any stock option, restricted stock, restricted stock unit
or other equity-related award, that the vesting of any such stock option, restricted stock, restricted stock unit or other equity-related award or any Benefit Plan shall accelerate or otherwise be affected by or result in any payment or funding in
connection with any of the transactions contemplated by this Agreement, except (x)&nbsp;with respect to the foregoing clauses (i)&#151;(iv), as required by applicable Law or the terms of any Benefit Plan existing and in effect on the date of this
Agreement and Disclosed to the other party or (y)&nbsp;with respect to the foregoing clause (ii), in the usual course of business consistent with past practice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) except in the ordinary course of business or as may be required by applicable Law or the terms of any Benefit Plan existing and in effect
on the date of this Agreement and that is set forth, in the case of Orca, in Section&nbsp;5.1 of the Orca Disclosure Letter or, in the case of Laguna, that is set forth in Section&nbsp;5.1 of the Laguna Disclosure Letter, neither it nor any of its
Subsidiaries shall establish, adopt, enter into, materially amend or terminate any collective bargaining or similar agreement with a labor union or similar organization; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) neither it nor any of its Subsidiaries shall lease, license, transfer, exchange or swap, mortgage (including securitizations) pledge,
abandon, allow to lapse, or otherwise dispose of (whether by way of merger, consolidation, sale of stock or assets, or otherwise) any portion of its assets, including the capital stock or other equity interests of its Subsidiaries except for
(i)&nbsp;dispositions of assets that, individually or in the aggregate with all other such dispositions, have fair market value of less than $25,000,000; (ii)&nbsp;transactions between it and any of its direct or indirect Subsidiaries or
transactions between such Subsidiaries; or (iii)&nbsp;activities in the ordinary and usual course of business consistent with past practice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) neither it nor any of its Subsidiaries shall, except in the ordinary and usual course of business and consistent with past practices,
sell, lease, license, transfer, exchange or swap, mortgage (including securitizations) pledge, abandon, allow to lapse or otherwise dispose of any Material Intellectual Property of such party or any of its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) neither it nor any of its Subsidiaries shall acquire or agree to acquire (whether by merger, consolidation, purchase or otherwise) any
Person, division or assets (including real property), except for acquisitions: (i)&nbsp;entered into on an arm&#146;s length basis; (ii)&nbsp;the expected gross expenditures and commitments (including the amount of any indebtedness assumed) of which
do not exceed, in the aggregate, $25,000,000; and (iii)&nbsp;which are not reasonably likely, individually or in the aggregate, to prevent or materially delay the satisfaction of the conditions set forth in Section&nbsp;6.1(e); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) neither it nor any of its Subsidiaries shall settle or compromise (other than any claims or litigation brought by Laguna against Orca or
brought by Orca against Laguna arising out of or relating to this Agreement) any material claims or litigation, if such settlement or compromise would involve, individually or together with all such other settlements or compromises, the payment of
money by such party or its Subsidiaries in excess of $25,000,000 over the available insurance coverage or applicable reserves, if any, at the time of such settlement or would involve any admission of material wrongdoing or any material conduct
requirement or restriction by such party or its affiliates, except, in each case, in the ordinary and usual course of business consistent with past practice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) neither it nor any of its Subsidiaries shall modify, renew, amend or (excluding expirations in accordance with their terms) terminate in
any material respect any of its Material Contracts or waive, release or assign any material rights or claims thereunder in excess of $20,000,000 individually or in the aggregate or enter into or amend any Contract that, if existing on the date
hereof, would be a Material Contract, except, in each case, in the ordinary and usual course of business consistent with past practice or as permitted pursuant Section&nbsp;5.1(c)(ii) or 5.1(c)(iii), or 5.1(d); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) neither it nor any of its Subsidiaries shall make or change any material Tax election, adopt or change any material method of Tax
accounting, file any material amended Tax Return, enter into a closing agreement or advance pricing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement in respect of a material amount of Taxes, settle or compromise any material audit, assessment, notice, Tax claim or proceeding relating to Taxes, surrender any material right to claim a
refund or offset of any Taxes, consent to (or request) any extensions or waiver of the limitation period applicable to any material Tax claim or assessment, or change the classification of Laguna or Orca, as applicable, or any of their Subsidiaries
for U.S. Tax purposes, except, in each case, to the extent otherwise required by Law or in the ordinary course of business consistent with past practice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) neither it nor any of its Subsidiaries shall permit any material change in its financial accounting principles, policies or practices,
except to the extent that any such changes in financial accounting principles, policies or practices shall be required by changes in GAAP or SEC rules and regulations or Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> of the Exchange Act and,
in each case, authoritative interpretations thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) neither it nor any of its Subsidiaries shall enter into any Contract that grants
&#147;most favored nation&#148; status to any counterparty, except in the ordinary and usual course of business consistent with past practice, or any <FONT STYLE="white-space:nowrap">&#147;non-compete&#148;</FONT> or similar Contract that, in any
case, would materially restrict the business of the Topco Group following the Laguna Effective Time with respect to engaging or competing in any line of business or in any geographic area; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) neither it nor any of its Subsidiaries shall make any material loans, advances or capital contributions to, or investments in, any other
Person (other than any wholly owned Subsidiary), other than: (i)&nbsp;any routine travel, relocation (of <FONT STYLE="white-space:nowrap">non-executive</FONT> employees) and business advances in the ordinary course of business to employees of it or
its Subsidiaries and (ii)&nbsp;trade credit to customers, in either case, made in the ordinary course of business consistent with past practice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) neither it nor any of its Subsidiaries shall enter into any material new line of business outside of its existing business segments; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) neither it nor any of its Subsidiaries shall convene any regular or special meeting (or any adjournment or postponement thereof) of the
stockholders of it or its Subsidiaries other than (i)&nbsp;the stockholder meetings to adopt this Agreement and approve the Combinations and (ii)&nbsp;regular annual meetings to address matters arising in the ordinary course consistent with past
practice other than this Agreement and the Combinations; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) neither it nor any of its Subsidiaries shall implement or announce any
material plant closing, material reduction in labor force or other material group layoff of employees or service providers other than routine employee terminations for cause or following performance reviews in the ordinary course of business and
consistent with past practice; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) subject to Section&nbsp;5.2, neither it nor any of its Subsidiaries shall take any action that would
reasonably be expected to prevent or materially impair or delay the consummation of the Combinations or any of the other transactions contemplated by this Agreement (including the satisfaction of the conditions set forth in ARTICLE VI); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) neither it nor any of its Subsidiaries shall authorize or enter into an agreement, arrangement or understanding to do any of the foregoing
set forth in Section&nbsp;5.1(a) through (r)&nbsp;if Laguna or Orca, as applicable, would be prohibited by the terms of Section&nbsp;5.1(a) through (r)&nbsp;from doing the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing contained in this Agreement shall give (x)&nbsp;Laguna, directly or indirectly, the right to control or direct the operations of Orca or Topco, or
(y)&nbsp;Orca or Topco, directly or indirectly, the right to control or direct the operations of Laguna, prior to the filing of the Orca Scheme Order with the Registrar and the consummation of the Laguna Merger, respectively. Prior thereto, each of
Laguna and its Subsidiaries, on the one hand, and Orca and its Subsidiaries (including Topco), on the other hand, shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over their
business operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Agreement, any actions or omissions (a)&nbsp;that are reasonably prudent or
reasonably necessary to mitigate the effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the Effects resulting therefrom, or (b)&nbsp;required or prudent to comply with applicable Law, guidelines or best practices of any
Governmental Entity or Orders in connection with or in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the Effects resulting therefrom shall, in each case, be considered to have been taken in the &#147;ordinary course
of business&#148;, &#147;ordinary course&#148; or &#147;usual course&#148;, and shall otherwise be permitted under this Section&nbsp;5.1 so long as, prior to any such material action or omission by or on behalf of Laguna or Orca, or any of their
respective Subsidiaries, after the date of this Agreement and prior to Closing (other than any commercially reasonable action taken in emergency situations for which Laguna or Orca, as applicable, promptly informs Orca or Laguna, respectively, of
any such actions taken (and in any event no later than one Business Day after such action is taken)), Laguna or Orca, as applicable, has consulted with Orca or Laguna, respectively, and considered in good faith its reasonable suggestions with
respect thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;5.1, &#147;<U>Disclosed</U>&#148; (i) with respect to Laguna shall mean
(x)&nbsp;disclosed in any Laguna Report no later than the Business Day immediately preceding the date hereof, (y)&nbsp;set forth in the Laguna Disclosure Letter or (z)&nbsp;included in the &#147;Coronado&#148; data room hosted by Datasite no later
than 6:00 pm ET on the date hereof, and (ii)&nbsp;with respect to Orca shall mean (i)&nbsp;disclosed in any Orca Report no later than the Business Day immediately preceding the date hereof, (ii)&nbsp;set forth in the Orca Disclosure Letter or
(iii)&nbsp;included in the &#147;Project Coronado&#148; data room hosted by Venue no later than 6:00 pm ET on the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.2. </B><U>Acquisition Proposals</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Without limiting any of such party&#146;s other obligations under this Agreement, each of Laguna and Orca agrees that, subject to
Section&nbsp;5.2(b) from and after the date hereof until the earlier of the Laguna Effective Time and the termination of this Agreement in accordance with its terms, neither it nor any of its Subsidiaries nor any of the officers, directors or
employees of it or its Subsidiaries (including any member of the Laguna Board or the Orca Board, as applicable) shall, and that it shall use its reasonable best efforts to cause its and its Subsidiaries&#146; Representatives not to, directly or
indirectly, (i)&nbsp;initiate, solicit or knowingly facilitate or encourage (including by way of furnishing information) any inquiries, discussions or the making, submission or announcement of any proposal, request or offer that constitutes, or
could reasonably be expected to lead to or result in, an Acquisition Proposal; (ii)&nbsp;have any discussion with any Person relating to an Acquisition Proposal (other than, solely with respect to an Acquisition Proposal that does not result from a
material breach of this Section&nbsp;5.2(a), to clarify the terms of an Acquisition Proposal submitted to such party after the date of this Agreement for the sole purpose of enabling the Laguna Board or Orca Board, as applicable, to evaluate such
Acquisition Proposal for the purposes of Section&nbsp;5.2(b)), engage in, continue or otherwise participate in any negotiations concerning an Acquisition Proposal, or knowingly facilitate any effort or attempt to make or implement an Acquisition
Proposal; (iii)&nbsp;provide any <FONT STYLE="white-space:nowrap">non-public</FONT> or confidential information or data or afford access to its books or records or directors, officers, employees or advisors, to any Person in relation to an
Acquisition Proposal; (iv)&nbsp;terminate, amend, release, modify, or fail to enforce any provision of, or grant any permission, waiver or request under, any standstill, confidentiality or similar agreement entered into by it or any of its
Subsidiaries (other than to the extent the Laguna Board or Orca Board, as applicable, determines in good faith, after consultation with its financial and outside legal advisors, that failure to take any such actions under this Section&nbsp;5.2(a)
would reasonably be expected to be inconsistent with the directors&#146; fiduciary duties under applicable Law); (v) approve or recommend, or propose publicly to approve or recommend, any Acquisition Proposal; (vi)&nbsp;approve or recommend, propose
publicly to approve or recommend, or execute or enter into, any letter of intent, agreement in principle, merger agreement, acquisition agreement, business combination agreement, option agreement or other similar agreement relating to any
Acquisition Proposal (any of the preceding in this (vi), an &#147;<U>Alternative Acquisition Agreement</U>&#148;); (vii) take any action to make the provisions of any Takeover Law inapplicable to any transactions contemplated by any Acquisition
Proposal; or (viii)&nbsp;propose publicly or agree to do any of the foregoing related to any Acquisition Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">An
&#147;<U>Acquisition Proposal</U>&#148; with respect to Laguna or Orca means any offer or proposal for, (i)&nbsp;any direct or indirect acquisition or purchase, in a single transaction or a series of related transactions, of Laguna or Orca, as
applicable, or any of its Subsidiaries that constitutes 15% or more of the consolidated gross revenue or consolidated gross assets of Laguna or Orca, as applicable, and its Subsidiaries, taken as a whole (such Subsidiary, a &#147;<U>Major
Subsidiary</U>&#148;); (ii)&nbsp;any direct or indirect acquisition or purchase of (A)&nbsp;15% or more of any class of equity securities or voting power or 15% or more of the consolidated gross assets of Laguna or Orca, as applicable, or
(B)&nbsp;15% or more of any class of equity securities or voting power of any of its Major Subsidiaries; (iii)&nbsp;any tender offer that, if consummated, would result in any Person beneficially owning 15% or more of any class of equity securities
or voting power of Laguna or Orca, as applicable; or (iv)&nbsp;any merger, reorganization, share exchange, consolidation, business combination, recapitalization, liquidation, dissolution or similar transaction involving Laguna or Orca, as
applicable, or any Major Subsidiary of Laguna or Orca, as applicable, in each case, with a Person other than the other party or any of its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything in this Agreement to the contrary, (I)&nbsp;each of Laguna and Orca and the Laguna Board and Orca Board,
respectively, shall be permitted to comply with Rule <FONT STYLE="white-space:nowrap">14d-9</FONT> and Rule <FONT STYLE="white-space:nowrap">14e-2</FONT> of the Exchange Act, <U>provided</U> that, the foregoing shall in no way eliminate or modify
the effect that any such action would otherwise have under this Agreement, <U>provided</U>, further, that any such disclosure (other than a &#147;stop, look and listen&#148; communication or similar communication of the type contemplated by
Section&nbsp;14d 9(f) under the Exchange Act) shall be deemed to be a Change in Laguna Recommendation or a Change in Orca Recommendation, as applicable (including for purposes of Section&nbsp;7.3 and Section&nbsp;7.4), unless the Laguna Board or the
Orca Board, as applicable, expressly reaffirms its recommendation to its stockholders in favor of the approval of this Agreement and the Combinations in such disclosure, and (II)&nbsp;if at any time </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
following the date hereof and (x)&nbsp;in the case of Laguna, prior to the receipt by Laguna of the Laguna Requisite Vote and (y)&nbsp;in the case of Orca, prior to the receipt by Orca of the
Orca Requisite Vote, (i)&nbsp;Laguna or Orca, respectively, has received an unsolicited bona fide written Acquisition Proposal from a third party that was not received or obtained in (or as a result of any) violation of this Section&nbsp;5.2, which
the Laguna Board or the Orca Board, respectively, determines in good faith (after consultation with its outside legal counsel and financial advisors) constitutes, or would reasonably be expected to lead to, a Superior Proposal and (ii)&nbsp;the
Laguna Board or the Orca Board, respectively, determines in good faith (after consultation with its outside legal counsel) that failure to take such action would reasonably be expected to be inconsistent with the directors&#146; fiduciary duties
under applicable Law, then Laguna or Orca, as applicable, may (A)&nbsp;furnish nonpublic information to such Person that has delivered the bona fide written Acquisition Proposal and (B)&nbsp;engage in discussions or negotiations with such Person
with respect to the Acquisition Proposal; <U>provided</U>, that (1)&nbsp;prior to so furnishing such information or engaging in any such discussion or negotiations, as the case may be, the applicable party receives from such Person an executed
confidentiality agreement with confidentiality terms no less restrictive, in the aggregate, than those contained in the Confidentiality Agreement and (2)&nbsp;any <FONT STYLE="white-space:nowrap">non-public</FONT> information concerning Laguna or
Orca, as applicable, provided or made available to such Person shall, to the extent not previously provided or made available to Orca or Laguna, as applicable, be provided or made available to such party as promptly as reasonably practicable (and in
no event later than twenty-four (24)&nbsp;hours) after it is provided or made available to such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) From and after the date
hereof, Laguna or Orca, as applicable, shall promptly (and in any event within twenty-four&nbsp;(24) hours), notify the other party (orally and in writing) in the event that it, one of its Subsidiaries or any of its Representatives receives
(i)&nbsp;any Acquisition Proposal, (ii)&nbsp;any request for <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to such party or any of its Subsidiaries, other than requests for information that are (x)&nbsp;in the ordinary and
usual course of business and consistent with past practice and (y)&nbsp;unrelated to an Acquisition Proposal, or (iii)&nbsp;any inquiry or request for discussions or negotiations regarding any Acquisition Proposal, or in each case, any revision,
supplement or update thereto. Such notice shall include the identity of the Person making such Acquisition Proposal, request or inquiry, and an unredacted copy of such Acquisition Proposal, inquiry or request (or, where no such copy is available, a
reasonably detailed description of such Acquisition Proposal, inquiry or request) including any debt financing materials related thereto, if any. Subject to applicable Law, Laguna or Orca, as applicable, shall keep the other party reasonably
informed on a current basis of the status of any such Acquisition Proposal, inquiry or request, and any material developments, discussions and negotiations related thereto. Laguna and Orca shall not, and shall cause their respective Subsidiaries and
Representatives not to, enter into any Contract that would prohibit Laguna or Orca, as applicable, from providing the information required by this Section&nbsp;5.2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything in this Agreement to the contrary, at any time prior to the earlier of (i)(x) in the case of Laguna, receipt by
Laguna of the Laguna Requisite Vote and (y)&nbsp;in the case of Orca, receipt by Orca of the Orca Requisite Vote, and (ii)&nbsp;the termination of this Agreement in accordance with its terms, the Laguna Board shall be entitled to effect a Change in
Laguna Recommendation and the Orca Board shall be entitled to effect a Change in Orca Recommendation, in each case, (A)&nbsp;if such party receives an unsolicited bona fide Acquisition Proposal that did not result from a material breach of
Section&nbsp;5.2(a) (and as to which the party recipient of such Acquisition Proposal complied with Section&nbsp;5.2(b) and (c)) which the applicable Board of Directors determines in good faith (after consultation with its outside legal counsel and
financial advisors) constitutes a Superior Proposal (after having complied with, and giving effect to all of the adjustments which may be offered by the other party pursuant to Section&nbsp;5.2(e)) or (B)&nbsp;in response to an Intervening Event
(after having complied with, and giving effect to all of the adjustments which may be offered by the other party pursuant to Section&nbsp;5.2(e)); <U>provided</U>, <U>however</U>, that, in each case referred to in the foregoing clauses (A)&nbsp;and
(B), the Laguna Board shall be entitled to effect a Change in Laguna Recommendation or the Orca Board shall be entitled to effect a Change in Orca Recommendation, in each case, only to the extent such Board determines in good faith (after
consultation with its outside legal counsel) that the failure to make such a Change in Laguna Recommendation or Change in Orca Recommendation, as applicable, would be inconsistent with its fiduciary duties under applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intervening Event</U>&#148; means any material event or development or material change in circumstances first
occurring after the date of this Agreement and prior to, in the case of Laguna, receipt by Laguna of the Laguna Requisite Vote and, in the case of Orca, receipt by Orca of the Orca Requisite Vote, to the extent that such event, development or change
in circumstances was not reasonably foreseeable as of or prior to the date of this Agreement; <U>provided</U>, <U>however</U>, that in no event shall the following events, developments or changes in circumstances constitute an Intervening Event:
(A)&nbsp;the receipt, existence or terms of an Acquisition Proposal or any matter relating thereto or consequence thereof, or (B)&nbsp;changes in the market price or trading volume of Orca Shares or Laguna Shares or the fact that a party meets or
exceeds internal or published projections, forecasts or revenue or earnings predictions for any period; <U>provided</U>, <U>however</U>, that the underlying causes of such change or fact shall not be excluded by this clause (B). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Superior Proposal</U>&#148; means, with respect to Laguna or Orca,
a bona fide written Acquisition Proposal that did not result from a material breach of Section&nbsp;5.2(a) and as to which the party recipient of the Acquisition Proposal complied with Section&nbsp;5.2(b) and (c)&nbsp;for or in respect of 80% or
more of the outstanding Laguna Shares or Orca Shares (as applicable) or 80% or more of the assets of Laguna and its Subsidiaries, on a consolidated basis, or Orca and its Subsidiaries, on a consolidated basis, as applicable, in each case on terms
that the Laguna Board or the Orca Board, as applicable, determines in good faith (following receipt of the advice of its financial advisors and outside legal counsel) is reasonably likely to be consummated in accordance with its terms and, taking
into account, among other things, (i)&nbsp;all legal, financial, antitrust or other regulatory, timing and other aspects of the Acquisition Proposal and this Agreement deemed relevant by such Board (including conditions to, expected timing and risks
of consummation of, and the ability of the party making such proposal to obtain financing for such Acquisition Proposal), (ii) any improved terms that Orca (in the case of an Acquisition Proposal for Laguna) or Laguna (in the case of an Acquisition
Proposal for Orca) may have offered pursuant to this Section&nbsp;5.2, is more favorable from a financial point of view to Laguna and its stockholders or Orca and its shareholders, as the case may be, than the transactions contemplated by this
Agreement (after taking into account any such improved terms) and (iii)&nbsp;the value of the synergies expected to be recognized as a result of the Combinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Laguna Board shall not be entitled to effect a Change in Laguna Recommendation unless it is expressly permitted to do so under
Section&nbsp;5.2(d) and (i)&nbsp;Laguna has not breached this Section&nbsp;5.2(e) in any material respect, (ii)&nbsp;Laguna has provided Orca with a written notice (the &#147;<U>Laguna Change in Recommendation Notice</U>&#148;) that Laguna intends
to take such action, which notice includes, as applicable, (x)&nbsp;an unredacted copy of the Superior Proposal that is the basis of such action (including the identity of the third party making the Superior Proposal and any debt financing materials
related thereto, if any) and written notice of the material terms of the Superior Proposal, or (y)&nbsp;a reasonably detailed summary of the Intervening Event that is the basis of such action, (iii)&nbsp;during the five (5)&nbsp;Business Day period
following Orca&#146;s receipt of the Laguna Change in Recommendation Notice, Laguna shall, and shall cause its Representatives to, negotiate with Orca in good faith (to the extent Orca desires to negotiate) to make such adjustments in the terms and
conditions of this Agreement so that such Superior Proposal ceases to constitute a Superior Proposal or, with respect to an Intervening Event, as would permit the Laguna Board (consistent with its fiduciary duties under applicable Law) to not make a
Change in Laguna Recommendation; and (iv)&nbsp;following the end of the five (5)&nbsp;Business Day period, the Laguna Board shall have determined in good faith, after consultation with its financial and outside legal advisors, taking into account
any changes to this Agreement proposed in writing by Orca in response to the Laguna Change in Recommendation Notice or otherwise, that the Superior Proposal giving rise to the Laguna Change in Recommendation Notice continues to constitute a Superior
Proposal or, as applicable, with respect to the Intervening Event, that its fiduciary duties under applicable Law continue to require it to make such an Change in Laguna Recommendation. Any amendment to the financial terms or any other material
amendment of such Superior Proposal or any material change to the facts and circumstances relating to an Intervening Event, as applicable, shall require a new Laguna Change in Recommendation Notice and Laguna shall be required to comply again with
the requirements of this Section&nbsp;5.2(e); <U>provided</U>, <U>however</U>, that for purposes of this sentence, references to the five (5)&nbsp;Business Day period above shall be deemed to be references to a three (3)&nbsp;Business Day period.
The Orca Board shall not be entitled to effect a Change in Orca Recommendation unless it is expressly permitted to do so under Section&nbsp;5.2(d) and (i)&nbsp;Orca has not breached this Section&nbsp;5.2 in any material respect, (ii)&nbsp;Orca has
provided Laguna with a written notice (the &#147;<U>Orca Change in Recommendation Notice</U>&#148;) that Orca intends to take such action, which notice includes, as applicable, (x)&nbsp;an unredacted copy of the Superior Proposal that is the basis
of such action (including the identity of the third party making the Superior Proposal and any debt financing materials related thereto, if any) and written notice of the material terms of the Superior Proposal which enabled the Orca Board to make
the determination that the Acquisition Proposal is a Superior Proposal, or (y)&nbsp;a reasonably detailed summary of the Intervening Event that is the basis of such action, (iii)&nbsp;during the five (5)&nbsp;Business Day period following
Laguna&#146;s receipt of the Orca Change in Recommendation Notice, Orca shall, and shall cause its Representatives to, negotiate with Laguna in good faith (to the extent Laguna desires to negotiate) to make such adjustments in the terms and
conditions of this Agreement so that such Superior Proposal ceases to constitute a Superior Proposal or, with respect to an Intervening Event, as would permit the Orca Board (consistent with its fiduciary duties under applicable Law) to not make a
Change in Orca Recommendation; and (iv)&nbsp;following the end of the five (5)&nbsp;Business Day period, the Orca Board shall have determined in good faith, after consultation with its financial and outside legal advisors, taking into account any
changes to this Agreement proposed in writing by Laguna in response to the Orca Change in Recommendation Notice or otherwise, that the Superior Proposal giving rise to the Orca Change in Recommendation Notice continues to constitute a Superior
Proposal or, as applicable, with respect to the Intervening Event, that its fiduciary duties under applicable Law continue to require it to make such a Change in Orca Recommendation. Any amendment to the financial terms or any other material
amendment of such Superior Proposal or any material change to the facts and circumstances relating to an Intervening Event, as applicable, shall require a new Orca Change in Recommendation Notice and Orca shall be required to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comply again with the requirements of this Section&nbsp;5.2(e); <U>provided</U>, <U>however</U>, that for purposes of this sentence, references to the five (5)&nbsp;Business Day period above
shall be deemed to be references to a three (3)&nbsp;Business Day period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Each of Laguna and Orca agree that they (i)&nbsp;shall not
authorize or approve and (ii)&nbsp;shall use their reasonable best efforts to prevent, any violation of the foregoing restrictions by any Subsidiaries of Laguna or Orca, affiliates of Laguna or Orca, or either party&#146;s respective Representatives
or its Subsidiaries&#146; Representatives. Any violation of the restrictions provided in this Section&nbsp;5.2 by any of either party&#146;s respective affiliates shall be deemed to be a breach of this Section&nbsp;5.2 by Laguna or Orca, as
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Each of Laguna and Orca agrees that it will, and will use reasonable best efforts to cause its Representatives and its
Subsidiaries and such Subsidiaries&#146; Representatives to, immediately cease and cause to be terminated any activities, discussions or negotiations existing as of the date of this Agreement with any Persons conducted heretofore with respect to any
Acquisition Proposal (or that could reasonably be expected to lead to an Acquisition Proposal), and request that any such Person promptly return and destroy (and confirm destruction of) all non-public information. Each of Laguna and Orca agrees that
it will use reasonable best efforts to promptly inform its Representatives of the obligations undertaken in this Section&nbsp;5.2. Nothing in this Section&nbsp;5.2 shall (x)&nbsp;permit Laguna or Orca to terminate this Agreement (except as
specifically provided in Article VII hereof), or (y)&nbsp;affect any other obligation of Laguna or Orca under this Agreement, except as otherwise expressly set forth in this Agreement. Unless this Agreement shall have been earlier terminated,
neither Laguna nor Orca shall submit to the vote of its stockholders any Acquisition Proposal (other than the Combinations). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.3. </B><U>Preparation of Orca Scheme Terms, Registration Statement, Nasdaq Listing Application; Publications;
Stockholders</U><U>&#146;</U><U> Meetings; Recommendation</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Preparation of Orca Scheme Terms</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) As promptly as practicable after the date of this Agreement (having regard to the timing requirements of the Registration Statement), the
parties shall (A)&nbsp;as further detailed and subject to the specific obligations of the respective parties set out in this Section&nbsp;5.3, prepare or cause to be prepared a scheme circular (the &#147;<U>Orca Scheme Document</U>&#148;)
containing, among other things, a letter from the Orca chairman, (subject to (e)) the Orca Recommendation, full terms and conditions of the Orca Scheme and other relevant terms and conditions of the Proposals, a timetable of events relating to the
Orca Scheme (the &#147;Timetable&#148;), a summary of key implications of the Orca Scheme, a scheme of arrangement, an explanatory statement and notices to convene the Orca Shareholder Meetings (together with any revisions, amendments or supplements
to such document, the &#147;<U>Orca Scheme Terms</U>&#148;) in accordance with English Law and the DGCL, as applicable, together with preparation of forms of proxy for each of the Orca Shareholder Meetings, and where the context requires,
preparation of documents to be put on display, court document(s), meeting advertisements or other documents reasonably required in connection with the Orca Scheme; and (B)&nbsp;apply for such written confirmation from Her Majesty&#146;s Revenue and
Customs (&#147;<U>HMRC</U>&#148;) that neither the Orca Scheme Order nor any instrument of transfer transferring the Orca Shares held within The Depository Trust Company (&#147;<U>DTC</U>&#148;) or the Orca Depositary to a DR Nominee is subject to
United Kingdom stamp duty or Stamp Duty Reserve Tax (&#147;<U>SDRT</U>&#148;) and that the only instrument or agreement subject to UK stamp duty or SDRT will be the stock transfer form(s), if any, which transfer Orca Shares not held within DTC or
the Orca Depositary to Topco (or its nominee). For the avoidance of doubt, the failure to obtain any confirmations to be applied for pursuant this Section&nbsp;5.3 shall not by itself constitute any breach of obligations of any party under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Orca shall be responsible for preparation of the Orca Scheme Terms, in each case, to the standard that is required
pursuant to the UK Scheme Regulations to the extent customary or legally required for transactions of the type of the Orca Scheme, and to satisfy any other requirements that may reasonably be expected by, or as directed by, the English Court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Orca shall ensure that the Orca Scheme Document includes customary terms relating to the transfer of shares subject to the Orca Scheme
free from all encumbrances and relating to the form of transfer including without limitation the following terms: (A)&nbsp;on and with effect from the Scheme Effective Date, the DR Nominee on behalf of Topco shall acquire all of the Orca Scheme
Shares, fully paid up with full title guarantee free from all encumbrances and with all rights attaching to them at the Orca Effective Time, including the right to receive all dividends and other distributions declared, made or paid after the Orca
Effective Time; and (B)&nbsp;for the purposes of the Acquisition Proposal, the Orca Scheme Shares shall be transferred to the DR Nominee on behalf of Topco and such transfer shall be effected by means of a form of transfer or other instrument of
transfer and to give effect to such transfers any director of the Orca may be appointed by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
virtue of the Orca Scheme as attorney and/or agent and/or otherwise and shall be authorized pursuant to the Orca Scheme as such attorney and/or agent and/or otherwise on behalf of the relevant
holder of Orca Scheme Shares to execute and deliver as transferor a form of transfer or other instrument or instruction of transfer in a form. In this Clause 5.3(a)(iii), references to Orca Scheme Shares being transferred to or acquired by the DR
Nominee on behalf of Topco shall, to the extent that such Orca Scheme Shares are already held by the DR Nominee at the Orca Effective Time, be construed as references to the DR Nominee ceasing to hold such Orca Scheme Shares on behalf of any other
person and commencing holding such Orca Scheme Shares on behalf of Topco. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Orca shall procure that the Directors of Orca accept
responsibility for all the information in the Orca Scheme Document (and any other document required by applicable Law to be published in connection with the Orca Scheme) relating to themselves (and members of their immediate families, related trusts
and persons connected with them), Topco, the Orca Group, any statements of opinion, belief or expectation of the directors of Orca in relation to the Acquisition Proposal or the Orca Group and any other information in the Orca Scheme Document for
which they are required by applicable Law to accept responsibility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Laguna shall procure that the Directors of Laguna accept
responsibility for all the information in the Orca Scheme Document (and any other document required by applicable Law to be published in connection with the Orca Scheme) relating to themselves (and members of their immediate families, related trusts
and persons connected with them), the Laguna Group, any statements of opinion, belief or expectation of the directors of Laguna in relation to the Acquisition Proposal or the Laguna Group and any other information in the Orca Scheme Document for
which they are required by applicable Law to accept responsibility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) Laguna and Topco shall afford all such cooperation and
assistance as may reasonably be requested of it by Orca in respect of the preparation and verification of any document required for the implementation of the Orca Scheme, including the provision to Orca of such information and confirmations relating
to it, its Subsidiaries and any of its or their respective directors or employees as Orca may reasonably request (including for the purposes of preparing the Orca Scheme Terms and all material ancillary documents in connection thereto) and to do so
in a timely manner. Orca agrees that it shall take reasonable steps to consult with Laguna and its professional advisers as to the form and content of the Orca Scheme Terms and provide Laguna with drafts of the Orca Scheme Terms. Orca shall afford
Laguna and its professional advisers reasonable opportunity to consider, review and provide comments on drafts of the Orca Scheme Terms. Laguna shall review and provide comments (if any) in a reasonably timely manner on all such documentation
submitted to it and Orca shall consider all comments proposed by Laguna and its professional advisers in good faith. To the extent of any inconsistency between this Agreement and the Orca Scheme Terms, the Orca Scheme Terms shall be amended or
modified so as to conform to this Agreement, subject to mandatory provisions of English Law and DGCL, as applicable. The parties will, as promptly as reasonably practicable, notify each other if they become aware of any matter which would reasonably
be expected to materially delay or prevent fulfilment of any of the steps in the Timetable including, filing and/or circulation of the Orca Scheme Document or the Orca Scheme Order. As promptly as practicable following the finalization of the Orca
Scheme Terms, and in accordance with all applicable Law, the Orca Board and the Topco Board, as well as Orca in its capacity as the sole stockholder of Topco, shall approve the Orca Scheme Terms and the transactions contemplated thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) As promptly thereafter as is practicable and in accordance with the Timetable, Orca shall apply to the Court to schedule a hearing of
the English Court (the &#147;<U>Scheme Convening Hearing</U>&#148; (including, where the context requires, any adjournment thereof)) at which the English Court will be invited to: (A)&nbsp;provide directions in connection with the Orca Scheme
(including any issue which may arise in connection with the constitution of meetings of members, creditors or other interested persons) and Orca Scheme Document; and (B)&nbsp;grant an order (the &#147;<U>Scheme Directions Order</U>&#148;) for the
convening of the meeting of the Orca Shareholders in accordance with the UK Scheme Regulations (to approve the Orca Scheme Terms (the &#147;<U>Orca Scheme Meeting</U>&#148;)), and shall make all necessary applications, prepare and file such
documents (including advertising or otherwise providing due notice of the Scheme Convening Hearing to any person affected by the Orca Scheme in accordance with Court&#146;s Practice Statement (Companies: Schemes of Arrangement under Part 26 and Part
26A of the Companies Act 2006) dated 26&nbsp;June 2020). Orca shall apply at the Scheme Convening Hearing for permission to convene the Orca Court Meeting and shall make all necessary applications, prepare and file such documents and take such steps
as may be necessary to facilitate and convene the Orca Court Meeting and the Orca General Meeting including without limitation, filing a notice of the Orca Scheme Meeting to be published in the London Gazette (the &#147;<U>Orca Scheme Meeting
Publication</U>&#148;). Orca shall circulate to the holders of Orca Scheme Shares, relevant Orca Stock Option and Orca Equity Rights Holders the Orca Scheme Document, together with relevant forms of proxy and such other information, documents,
circulars, forms and notices (as the case may be) as are or may be required under the UK Scheme Regulations, as the Court may approve and/or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
direct from time to time in connection with the due implementation of the Orca Scheme and such other information, circulars, forms or notices (as the case may be) as the parties agree in writing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) Following the Orca Scheme Meeting Publication, Orca shall promptly notify Laguna upon receipt of notice of any pending or
threatened opposition rights proceeding initiated by any creditors, holders of bonds (<I>obligations</I>), whether or not redeemable or convertible, or warrants (collectively, &#147;<U>Creditors</U>&#148;) of Orca pursuant to English Law. Such
notice shall describe in reasonable detail the nature of such opposition rights proceeding. With respect to any such opposition rights proceeding, Section&nbsp;5.6 shall apply <I>mutatis mutandis. </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) Orca shall, convene, hold and transact the relevant business at each of the Orca Shareholder Meetings at the time and date specified in
the Scheme Document (or as soon as practicable thereafter) and propose the resolutions set out in the notices of those meetings (as appropriate) without amendments. Orca shall (and shall procure that any relevant member of the Orca Group shall) once
approved by Laguna (pursuant to the terms set out in this Section&nbsp;5.3(a)) and the English Court, not seek (by application to the English Court or otherwise) to: (A)&nbsp;revise the Scheme Document; (B)&nbsp;amend the terms of the Acquisition
Proposal; or (C) (unless required by the Court or subject to Section&nbsp;5.3(f)) adjourn the Orca Shareholder Meetings, in each case, without the prior written consent of Laguna (such consent not to be unreasonably withheld, delayed or
conditioned). Further, Orca shall not (unless required by the English Court) agree to, or apply to the English Court for, an extension of time in connection with, or to any variation, amendment, withdrawal or
<FONT STYLE="white-space:nowrap">non-enforcement</FONT> (in whole or in part) of, the Orca Scheme without the prior written consent of Laguna (such consent not to be unreasonably withheld, delayed or conditioned). Following each of the Orca
Shareholder Meetings and assuming the necessary resolutions are passed by the requisite majorities, subject to and as soon as reasonably practicable (in accordance with the Timetable), make all necessary applications, prepare and file such documents
and take all necessary steps to seek the sanction of the English Court to the Orca Scheme at the Scheme Sanction Hearing. Orca shall attend each of the Orca Scheme Meeting and the Orca General Meeting and, by representation of the Scheme Counsel,
shall attend the Scheme Convening Hearing and the Orca Sanction Hearing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) Promptly following sanction of the Orca Scheme and receipt
of the Orca Scheme Order and in any event no later than one Business Day after the Orca Scheme Order issued by the English Court being available for collection and/or registration, Orca shall deliver to the Registrar for filing by him or her and/or
registration as the case may be originals and office copies of the Orca Scheme Order and any other necessary documents to be filed with the Registrar for the purpose of causing the Orca Scheme to become effective in compliance with the UK Scheme
Regulations and to give effect to the provisions of the Orca Scheme. Orca shall (and shall procure that relevant members of the Orca Group shall) comply with the Scheme Directions Order and the Orca Scheme Order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) For the purposes of this Agreement, &#147;<U>Orca Scheme Shares</U>&#148; shall mean shares of Orca: (A)&nbsp;in issue at the date of
the Orca Scheme Document; (B)&nbsp;issued after the date of the Orca Scheme Document and before the date specified in the Orca Scheme Document by reference to which entitlement to vote at the Orca Scheme Meeting will be determined in accordance with
the UK Scheme Regulations (the &#147;<U>Voting Record Time</U>&#148;); and (C)&nbsp;issued at or after the Voting Record Time and before the Scheme Record Time, either on terms that the original or any subsequent holders of such shares are to be
bound the by Orca Scheme or in respect of which their holders are, or shall have agreed in writing to be, bound by the Orca Scheme. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
As promptly as practicable after the date of this Agreement, the parties shall prepare and Topco shall file with the SEC, a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (together with any supplements or amendments
thereto, the &#147;<U>Registration Statement</U>&#148;) to register the offer and exchange of Topco Shares, as applicable, pursuant to the Combinations. The Registration Statement will include the scheme circular with respect to the Orca Scheme
Terms and a joint proxy statement/prospectus (the &#147;<U>Proxy Statement/Prospectus</U>&#148;) to be used for (i)&nbsp;the Laguna Stockholders&#146; Meeting to approve and adopt this Agreement and the Laguna Merger, (ii)&nbsp;the Orca Shareholder
Meetings to approve and adopt this Agreement and the Orca Scheme and (iii)&nbsp;the issuance of Topco Shares in the Combinations. Topco, Orca and Laguna each shall use reasonable best efforts to cause the Registration Statement to become effective
as promptly as practicable following such filing (including by responding to comments of the SEC), and shall also use its reasonable best efforts to satisfy prior to the effective date of the Registration Statement any applicable United States,
English, foreign or state securities Laws in connection with the issuance of Topco Shares pursuant to the Combinations. After the execution of this Agreement and as promptly as reasonably practicable in accordance with applicable Law: the parties
shall prepare and Topco shall file with Nasdaq a listing application (the &#147;<U>Nasdaq Listing Application</U>&#148;) for the listing of Topco Shares on Nasdaq. Each party and its Subsidiaries shall prepare and furnish all information (including
any required financial statements) concerning itself as may reasonably be requested in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with such actions and the preparation of the Registration Statement and the Nasdaq Listing Application, <U>provided</U> that no party shall use any such information for any other
purpose without the prior written consent of the providing party (which consent shall not be unreasonably withheld, conditioned or delayed) or if doing so would violate or cause a violation of United States, English or other applicable securities
Laws. Each of Laguna and Orca authorizes Topco to utilize in the Registration Statement and in all such filed materials the information concerning Laguna and its Subsidiaries and Orca and its Subsidiaries furnished by each of Laguna and Orca,
respectively. Each party shall provide the other parties with a reasonable opportunity to review the Registration Statement, the Proxy Statement/Prospectus and Nasdaq Listing Application, and any amendment or supplement thereto (which comments shall
be reasonably considered by the party making such filing) prior to their filing. No filing of, or amendment or supplement to, such document shall be made by Topco, Orca or Laguna, without the prior consent of Orca and Laguna, as applicable (which
consent shall not be unreasonably withheld, delayed or conditioned). Subject to applicable Law, the parties agree that the information relating to the parties and their respective businesses included in the Registration Statement and the Nasdaq
Listing Application shall be identical in terms of content to the greatest extent practicable and necessary. The parties agree to correct promptly any information provided by it for use in the Registration Statement and the Nasdaq Listing
Application if and to the extent that such information shall have become false or misleading in any material respect or as otherwise required by applicable Law. Topco shall promptly advise Orca and Laguna of the time of effectiveness of the
Registration Statement, the issuance of any stop order relating thereto or the suspension of the qualification of Topco Shares for offering or sale in any jurisdiction, and each of the parties shall use its reasonable best efforts to have any such
stop order or suspension lifted, reversed or otherwise terminated. The parties shall notify each other promptly of the receipt of any comments from the SEC or its staff or any comments from any other Governmental Entity and of any request by the SEC
or its staff or any request by any other Governmental Entity for amendments or supplements to the Registration Statement, the Proxy Statement/Prospectus or Nasdaq Listing Application, or for additional information relating thereto, and will supply
each other with copies of all correspondence between Laguna, Orca or Topco, as applicable, or any of their respective Representatives, and the SEC or its staff or any other Governmental Entity with respect to the foregoing documents and
applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each of the parties shall also take any other action (other than qualifying to do business in any jurisdiction in which
it is not now so qualified) required to be taken under the Securities Act of 1933, as amended, and the rules and regulations of the SEC promulgated thereunder (the &#147;<U>Securities Act</U>&#148;), the Exchange Act, any applicable English or other
<FONT STYLE="white-space:nowrap">non-United</FONT> States securities Laws or any applicable state securities or &#147;blue sky&#148; laws and the rules and regulations thereunder, in connection with the transactions contemplated by this Agreement
and the issuance and Nasdaq listing of Topco Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Laguna will take, in accordance with applicable Law, the applicable rules and
regulations of the SEC and Nasdaq and the Laguna Organizational Documents, all action necessary to convene a meeting of its stockholders to adopt and approve this Agreement, the Laguna Merger and the ancillary matters contemplated by this Agreement
(the &#147;<U>Laguna Stockholders</U><U>&#146;</U><U> Meeting</U>&#148;) as promptly as practicable after the later of (x)&nbsp;the expiration of any Creditor rights opposition period following the Orca Scheme Terms Publication under English Law and
(y)&nbsp;the date the Registration Statement is declared effective. The Laguna Board shall make the Laguna Recommendation and include the Laguna Recommendation in the Proxy Statement/Prospectus. Laguna shall, unless there has been a Change in Laguna
Recommendation as permitted by this Agreement, use all lawful efforts to solicit from its stockholders proxies in favor of the adoption of this Agreement and the transactions contemplated hereby and to take all other action reasonably necessary or
advisable to secure Laguna&#146;s stockholders&#146; approval thereof. In the event that on or subsequent to the date hereof and prior to the Laguna Stockholders&#146; Meeting (including any adjournment thereof), the Laguna Board determines either
to make no recommendation for the Laguna Merger, or to withdraw, modify or qualify its recommendation for the Laguna Merger in a manner that is adverse to Orca (including by failing to recommend against any Acquisition Proposal structured as a
tender or exchange offer (or any material modification thereto) within ten (10)&nbsp;Business Days after commencement of such offer (or such material modification)) (such determination not to make a recommendation or any such withdrawal,
modification or qualification, a &#147;<U>Change in Laguna Recommendation</U>&#148;), which Change in Laguna Recommendation shall be made only in accordance with Section&nbsp;5.2(d), then Orca shall have a right to terminate this Agreement in
accordance with Section&nbsp;7.4(a). Any Change in Laguna Recommendation shall not limit or modify the obligation of Laguna to present this Agreement for adoption at the Laguna Stockholders&#146; Meeting pursuant to this Section&nbsp;5.3(d), and, if
this Agreement is not otherwise terminated by either Laguna or Orca in accordance with the terms hereof, this Agreement and the transactions contemplated hereby shall be submitted to the stockholders of Laguna at the Laguna Stockholders&#146;
Meeting for the purpose of obtaining the Laguna Requisite Vote; <U>provided</U>, that, the foregoing obligation shall not apply in the event of a Change in Laguna Recommendation made in accordance with Section&nbsp;5.2(d) in response to a Superior
Proposal that (i)&nbsp;includes only cash consideration and (ii)&nbsp;is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fully financed and does not include any financing condition (including any financing contingency to the right of Laguna to seek specific performance) (a &#147;<U>Laguna All Cash Superior
Proposal</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Orca will take, in accordance with applicable Law, the applicable rules and regulations of the SEC and Nasdaq
and the Orca Organizational Documents, all action necessary to convene the Orca Scheme Meeting and an Orca-convened general meeting of Orca Shareholders to resolve and approve the Orca Board implementing the Orca Scheme and adopt the Orca Articles
of Association in the form set out in <U>Exhibit A</U> and the ancillary matters contemplated by this Agreement (the &#147;<U>Orca General Meeting</U>&#148; and, together with the Orca Scheme Meeting, the &#147;<U>Orca Shareholder
Meetings</U>&#148;) as promptly as practicable after the later of (x)&nbsp;the expiration of any Creditor rights opposition period following the Orca Scheme Terms Publication under English Law and (y)&nbsp;the date the Registration Statement is
declared effective. The Orca Board shall make the Orca Recommendation and include the Orca Recommendation in the Proxy Statement/Prospectus. Orca shall, unless there has been a Change in Orca Recommendation as permitted by this Agreement, use all
lawful efforts to solicit from the Orca Shareholders proxies in favor of the approval of the Orca Scheme Terms and the transactions contemplated hereby and to take all other action reasonably necessary or advisable to secure Orca&#146;s
stockholders&#146; approval thereof. Without limitation to the foregoing, Orca shall undertake all reasonable steps to support and facilitate the execution and implementation of irrevocable undertakings and/or support agreements by Carlyle in
relation to the Orca Scheme and securing the Orca Requisite Vote including supporting or facilitating any steps taken by Carlyle (whether under its respective agreements or otherwise) to procure the transfer of legal title in any of its beneficial
interests in Orca Scheme Shares in order to be able to vote directly in its own name in favor of the Orca Requisite Vote. In the event that on or subsequent to the date hereof and prior to the Orca Shareholder Meetings (including any adjournment
thereof), the Orca Board determines either to make no recommendation for the Orca Scheme, or to withdraw, modify or qualify its recommendation for the Orca Scheme in a manner that is adverse to Laguna (including by failing to recommend against any
Acquisition Proposal structured as a tender or exchange offer (or any material modification thereto) within ten (10)&nbsp;Business Days after commencement of such offer (or such material modification)) (such determination not to make a
recommendation or any such withdrawal, modification or qualification, a &#147;<U>Change in Orca Recommendation</U>&#148;), which Change in Orca Recommendation shall be made only in accordance with Section&nbsp;5.2(d), then Laguna shall have a right
to terminate this Agreement in accordance with Section&nbsp;7.3(a). Any Change in Orca Recommendation shall not limit or modify the obligation of Orca to present the Orca Scheme for approval at the Orca Scheme Meeting or the Orca General Meeting
pursuant to this Section&nbsp;5.3(e), and, if this Agreement is not otherwise terminated by either Laguna or Orca in accordance with the terms hereof, this Agreement, the Orca Scheme Terms and the transactions contemplated hereby shall be submitted
to the stockholders. Any Change in Orca Recommendation shall not limit or modify the obligation of Orca to present the Orca Scheme for approval at the Orca Scheme Meeting or the Orca General Meeting pursuant to this Section&nbsp;5.3(e), and, if this
Agreement is not otherwise terminated by either Laguna or Orca in accordance with the terms hereof, this Agreement, the Orca Scheme Terms and the transactions contemplated hereby shall be submitted to the stockholders of Orca at the Orca Shareholder
Meetings for the purpose of obtaining the Orca Requisite Vote; <U>provided</U>, that, the foregoing obligation shall not apply in the event of a Change in Orca Recommendation made in accordance with Section&nbsp;5.2(d) in response to a Superior
Proposal that (i)&nbsp;includes only cash consideration and (ii)&nbsp;is fully financed and does not include any financing condition (including any financing contingency to the right of Orca to seek specific performance) (an &#147;<U>Orca All Cash
Superior Proposal</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) In accordance with the Timetable and subject to any directions or requirements of the English Court,
Laguna and Orca shall each use their reasonable best efforts to cause the Laguna Stockholders&#146; Meeting and the Orca Shareholder Meetings to be held on the same date. Notwithstanding the foregoing, (i)&nbsp;after the Laguna Stockholders&#146;
Meeting has been convened, Laguna shall, upon the request of Orca (and Laguna may, if Orca does not make such request) adjourn the Laguna Stockholders&#146; Meeting on one or more occasions (A)&nbsp;if required by Law or (B)&nbsp;to the extent
necessary to solicit additional proxies in order to obtain the Laguna Requisite Vote, for such time period as determined by Orca (or, if Orca does not make such request, as determined by Laguna) and (ii)&nbsp;after the Orca Shareholder Meetings have
been convened, Orca shall, upon the request of Laguna (and Orca may, if Laguna does not make such request) adjourn the Orca Shareholder Meetings on one or more occasions (A)&nbsp;if required by Law or (B)&nbsp;to the extent necessary to solicit
additional proxies in order to obtain the Orca Requisite Vote, for such time period as determined by Laguna (or, if Laguna does not make such request, as determined by Orca); <U>provided</U>, <U>however</U> that, in each case, (x)&nbsp;such
adjournment shall not exceed fifteen (15)&nbsp;days for each such adjournment, (y)&nbsp;the applicable stockholders&#146; meeting shall not be adjourned without the written approval of both Laguna and Orca by more than thirty (30)&nbsp;days in the
aggregate from the date on which the Laguna Stockholders&#146; Meeting or Orca Shareholder Meetings, as applicable, was originally convened, and (z)&nbsp;no such adjournment shall be permitted if Laguna or Orca, as applicable, shall have received at
the applicable Stockholders&#146; Meeting an aggregate number of proxies necessary to obtain the Laguna Requisite Vote or the Orca Requisite Vote, as applicable, which have not been withdrawn, such that the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
condition in Section&nbsp;6.1(a) would be satisfied (with respect to Laguna or Orca, as applicable) if a vote were taken at the applicable Stockholders&#146; Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.4. </B><U>Reasonable Best Efforts</U><U>; Regulatory Filings and Other Actions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Reasonable Best Efforts; Regulatory Filings</I>. The parties shall cooperate with each other and use (and shall cause their respective
Subsidiaries to use) their respective reasonable best efforts to take or cause to be taken all actions, and do or cause to be done all things, necessary, proper or advisable under this Agreement and applicable Laws to consummate and make effective
the Combinations and the other transactions contemplated by this Agreement as promptly as practicable, including (i)&nbsp;preparing and filing all documentation to effect all necessary Filings as promptly as practicable (and with respect to Filings
pursuant to the HSR Act, no later than 10 Business Days after the date of this Agreement) and obtaining as promptly as practicable all Approvals (including all Antitrust Approvals) necessary or advisable to be obtained from any Person and/or any
Governmental Entity or any Self-Regulatory Organization in order to consummate the transactions contemplated by this Agreement, (ii)&nbsp;using their reasonable best efforts to resolve any objections as may be asserted with respect to the
transactions contemplated by this Agreement under any Laws, including defending and contesting (through litigation on the merits and any appeals) any Proceedings, whether judicial or administrative or otherwise, challenging this Agreement or the
consummation of the transactions contemplated by this Agreement, including seeking to have any Order entered by any court or other Governmental Entity vacated or reversed, and (iii)&nbsp;executing and delivering any additional instruments necessary
to consummate the transactions contemplated by, and to fully carry out the purposes of, this Agreement pursuant to its terms and conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Obligations Relating to Filings</I>. Without limiting the foregoing, the parties shall exercise their respective best efforts to
(i)&nbsp;obtain termination or expiration of the waiting period (and any extension of such period) under the HSR Act and all other Antitrust Approvals, in each case, as soon as practicable (but in any event prior to the Termination Date) and
(ii)&nbsp;otherwise cooperate in connection with any filing and in connection with resolving any investigation or other inquiry of any Governmental Entity relating to the HSR Act and all other Antitrust Approvals, except that nothing in this
Section&nbsp;5.4 shall require, or be construed to require, the parties to proffer or negotiate to, or agree or consent to, sell, license, dispose of or hold separate or agree to sell, license, dispose of or hold separate, or take any other action
(including any contractual, behavioral or conduct restriction, agreement, commitment or remedy) with respect to, before or after the Orca Effective Time, any assets or businesses, or interests in any assets or businesses, of Topco, Laguna, Orca or
any of their respective Subsidiaries, if such action would, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect on the Topco Group. Laguna and Orca (A)&nbsp;shall not (and shall cause their respective
Subsidiaries and affiliates not to), without each of the other parties&#146; prior written consent, offer, negotiate, agree to, commit to, consent to, or effect any action described in the immediately preceding sentence and (B)&nbsp;shall not be
required to take any action described in the immediately preceding sentence unless such action is conditioned on the consummation of the transactions contemplated by this Agreement. Laguna and Orca shall not (and shall cause their respective
Subsidiaries and affiliates not to), without each of the other parties&#146; prior written consent (not to be unreasonably withheld, delayed or conditioned), (x)
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;pull-and-refile&#148;</FONT></FONT> more than one time pursuant to 16 C.F.R. &#167; 803.12, any Filing made under the HSR Act or (y)&nbsp;offer, negotiate or enter into any
commitment or agreement, including any timing agreement, with any Governmental Entity to delay the consummation of, or not to close before a certain date, the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Prior Review of Certain Information</I>. Laguna and Orca shall provide the other party and/or its counsel with a reasonable advance
opportunity to review and comment upon, and consider in good faith the views of the other party in connection with, all submissions, Filings and communications (and the documents submitted therewith) intended to be submitted to any Governmental
Entity or any Self-Regulatory Organization in connection with the Combinations and the other transactions contemplated by this Agreement. Each of the parties agrees not to participate independently in any meeting, teleconference or other discussion
with any Governmental Entity or any Self-Regulatory Organization in connection with the Combinations and the other transactions contemplated by this Agreement and shall provide the other party with reasonable advance notice of the meeting,
teleconference or other discussion and the opportunity to participate therein unless prohibited by the Governmental Entity or Self-Regulatory Organization, as applicable. Laguna and Orca shall keep each other apprised of all discussions with any
Governmental Entity or Self-Regulatory Organization in respect of any Filings, investigation or other inquiry in connection with the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I>Furnishing of Information</I>. Laguna and Orca each shall promptly furnish the other with a copy of all substantive notices or other
communications received or provided by Laguna or Orca, as the case may be, from or to any Governmental Entity or Self-Regulatory Organization in connection with the Combinations and the other transactions contemplated by this
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, and will furnish the other with information concerning itself, its Subsidiaries, directors, officers and stockholders and such other matters as is reasonably necessary or advisable in
connection with any Filing made by or on behalf of the parties or any of their respective Subsidiaries to any Person, Governmental Entity or Self-Regulatory Organization, in connection with the Combinations and the other transactions contemplated by
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <I>Status Updates and Notice</I>. Laguna and Orca each shall keep the other promptly apprised of the status of
matters relating to completion of the transactions contemplated hereby, including promptly furnishing the other with (i)&nbsp;written notice of the occurrence, or <FONT STYLE="white-space:nowrap">non-occurrence,</FONT> of any event as to which they
have knowledge that would reasonably be expected to cause any condition to the obligations of any party to effect the transactions contemplated hereby not to be satisfied; (ii)&nbsp;written notice of the failure of a party to satisfy, or the
material breach by a party of, any covenant, condition or agreement to be complied with or satisfied by it pursuant to this Agreement which would reasonably be expected to result in any condition to the obligations of any party to effect the
transactions contemplated hereby not to be satisfied (provided, however, that the delivery of any notice pursuant to this Section&nbsp;5.4(e) shall not cure any breach of any representation, warranty, covenant or agreement contained in this
Agreement or otherwise limit or affect the remedies available hereunder to the party receiving such notice); and (iii)&nbsp;copies of all substantive notices or other communications received by Laguna or Orca, as the case may be, or any of their
respective Subsidiaries, from any Person, Governmental Entity or Self-Regulatory Organization, with respect to such transactions. Laguna and Orca shall regularly review with each other the progress of any Filings, investigation or other inquiry by
any Governmental Entities or Self-Regulatory Organizations, and discuss with each other the scope, timing and tactics of any actions in relation thereto with a view to obtaining Approvals from the applicable Governmental Entities or Self-Regulatory
Organizations as promptly as practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <I>Treatment of Sensitive/Privileged Information.</I> Notwithstanding anything to the
contrary contained herein, for any information exchanged under this Section&nbsp;5.4, it is understood that Laguna and Orca may, as each deems necessary, reasonably designate any competitively sensitive material provided to the other party under
this Section&nbsp;5.4 or any subsection thereof as &#147;outside counsel only.&#148; Such materials and the information contained therein shall be given only to the outside legal counsel of the recipient and will not be disclosed by such outside
counsel to employees, officers, or directors of the recipient unless express permission is obtained in advance from the source of the materials (Laguna or Orca, as the case may be) or its legal counsel; <U>provided</U>, <U>further</U>, that
materials provided to the other party pursuant to this Section&nbsp;5.4 or any subsection thereof may be redacted to remove references concerning the valuation of the transactions contemplated hereby. Furthermore, it is understood that Laguna and
Orca may each withhold material where the sharing thereof would be reasonably likely to&nbsp;result in the loss of attorney-client privilege; <U>provided</U>, further, that Laguna or Orca, as applicable, shall provide or cause to be provided to the
other party a reasonably detailed description of the materials not provided and shall cooperate in good faith to design and implement alternative disclosure arrangements to enable the other party to evaluate such information without the loss of
attorney-client privilege. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.5. </B><U>Access</U>. From the date of this Agreement to the earlier of
consummation of the Laguna Merger and the termination of this Agreement, the parties shall, and shall cause each of their respective Subsidiaries, and shall direct and use reasonable best efforts to cause their respective directors, officers,
employees, counsel, accountants, consultants (including any investment banker or financial advisor and, in the case of Orca, Carlyle Investment Management L.L.C.) and, to the extent practical, other authorized agents, intermediaries, or third party
representatives that act or perform services for or on behalf of such party (&#147;<U>Representatives</U>&#148;) to: (a)&nbsp;provide to each other and their respective Representatives, upon prior written notice, reasonable access, during normal
business hours in such a manner as not to unreasonably interfere with the operation of any business conducted by Laguna or Orca, as applicable, to its officers, employees, properties, offices, other facilities and books and records; and
(b)&nbsp;furnish promptly such information concerning its business, properties, contracts, assets and liabilities as the parties or their respective Representatives may reasonably request; <U>provided</U>, <U>however</U>, that each party shall not
be required to (or to cause any of their respective Subsidiaries or Representatives to) afford such access or furnish such information (i)&nbsp;to the extent that it reasonably believes in good faith that doing so would: (A)&nbsp;result in the loss
of attorney-client privilege; (B)&nbsp;violate any of its obligations with respect to confidentiality to any third party or otherwise breach, contravene or violate any then effective Contract to which it is party; or (C)&nbsp;breach, contravene,
violate or result in liability under any applicable Law (it being agreed that the parties shall use their respective reasonable best efforts to reduce the scope of or eliminate the applicable restriction); or (ii)&nbsp;if Orca or Topco or any of
their affiliates, on the one hand, and Laguna or any of its affiliates, on the other hand, are adverse parties in any legal proceeding or action, to the extent that is reasonably pertinent to such proceeding or action. The parties shall, and shall
cause each of their respective Subsidiaries and shall direct and use reasonable best efforts to cause their respective Representatives to, hold all information provided or furnished pursuant to this Section&nbsp;5.5 confidential in accordance with
the terms of the Confidentiality Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.6. </B><U>Transaction Litigation</U>. Each of Laguna and
Orca shall give the other party the opportunity to participate in (but not control) the defense or settlement of any stockholder litigation against such party or its officers or directors relating to the Combinations and the other transactions
contemplated by this Agreement in accordance with the terms of a mutually agreed upon joint defense agreement. Prior to the Laguna Effective Time, no such settlement shall be agreed to without the prior written consent of the other party, which
consent shall not be unreasonably withheld, delayed or conditioned. Each of Laguna and Orca shall cooperate, shall cause their respective Subsidiaries to cooperate, and shall use its reasonable best efforts to cause its Representatives to cooperate,
in the defense against such litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.7. </B><U>Publicity</U>. The initial press release regarding this
Agreement and the Combinations shall be a joint press release mutually agreed by Laguna and Orca.<U> </U>Thereafter through the consummation of the Laguna Merger, and so long as this Agreement is in effect, none of the parties hereto shall issue or
cause the publication of any press release or other public announcement concerning this Agreement, the Combinations or the other transactions contemplated hereby without the prior consultation and consent of the other parties hereto (which consent
shall not be unreasonably withheld, delayed or conditioned), except as may be required by applicable Law or by obligations pursuant to any listing agreement with Nasdaq or by any Governmental Entity with jurisdiction over such party. Notwithstanding
the forgoing, this Section&nbsp;5.7 shall not apply to any press release or similar public statement made by Laguna or Orca (a)&nbsp;which is consistent with any press release or similar public statement mutually agreed by Laguna and Orca, and the
terms of this Agreement and does not contain any information relating to Laguna (in the case of Orca), Orca (in the case of Laguna) or the Combinations that has not been previously announced or made public in accordance with the terms of this
Section&nbsp;5.7 or (b)&nbsp;which is made in the ordinary course of business and does not relate to this Agreement or the Combinations. For the avoidance of doubt, the provisions of this Section&nbsp;5.7 do not apply to any announcement, document
or publication in connection with or in response to an Acquisition Proposal, Superior Proposal, Intervening Event or Change in Laguna Recommendation or Change in Orca Recommendation, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.8. </B><U>Certain Tax Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of Laguna and Orca shall, and shall cause their affiliates (to the extent within their control), to (i)&nbsp;cooperate in order to
facilitate the issuance of any opinions relating to Tax matters that the SEC requires to be filed in connection with the Registration Statement, and (ii)&nbsp;deliver to Latham&nbsp;&amp; Watkins LLP or such other counsel mutually agreeable to the
parties (in the case of Tax matters relating to Orca or its stockholders) and Gibson Dunn and Crutcher LLP or such other counsel mutually agreeable to the parties (in the case of Tax matters relating to Laguna or its stockholders), in each case, to
the extent requested by such counsel, a duly executed certificate dated as of the date requested by such counsel, containing such representations, warranties and covenants as shall be reasonably necessary or appropriate to enable such counsel to
render any such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of Laguna, U.S. Merger Sub, U.S. Holdco Sub, U.S. Holdco Sub 2, Orca, and Topco, and their respective
Subsidiaries shall use reasonable best efforts to cause the Combinations to qualify for the Intended Tax Treatment. None of Laguna, U.S. Merger Sub, U.S. Holdco Sub, U.S. Holdco Sub 2, Orca, or Topco or any of their respective Subsidiaries shall
take any action (or, to the extent within their control, permit any affiliate to take any action) that could reasonably be expected to preclude the Combinations from qualifying for the Intended Tax Treatment. Each of Laguna, U.S. Merger Sub, U.S.
Holdco Sub, U.S. Holdco Sub 2, Orca and Topco shall file all income Tax returns consistent with the foregoing except as otherwise required by (i)&nbsp;a change in Law after the date of this Agreement or (ii)&nbsp;a final &#147;determination&#148;
(within the meaning of Section&nbsp;1313(a)(1) of the Code or any comparable provision of state or local Law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All transfer,
documentary, sales, use, value added, excise, stock transfer, stamp duty, recording, registration and any similar Taxes and fees, including any penalties and interest thereon, that are required to be paid under Tax Laws in connection with the
transactions contemplated by this Agreement (&#147;<U>Transfer Taxes</U>&#148;) shall be borne and paid by Topco. For the avoidance of doubt, Transfer Taxes shall not include any federal, state, local or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Taxes measured by or based upon income or gains. The applicable parties shall cooperate in good faith in filing such forms and documents as may be necessary and to obtain any exemption or refund of
any such Transfer Tax and to minimize the amount of any Transfer Taxes payable in connection with the Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Prior to (but not
more than thirty (30)&nbsp;days prior to) the Closing Date of the Combinations, Laguna shall provide to Topco a certificate duly executed, prepared in a manner consistent and in accordance with the requirements of Treasury Regulation Sections <FONT
STYLE="white-space:nowrap">1.897-2(g)</FONT> and <FONT STYLE="white-space:nowrap">1.1445-2(c)(3),</FONT> certifying that no interest in Laguna is, or has been during the relevant period specified in Section&nbsp;897(c)(1)(A)(ii) of the Code, a
&#147;U.S. real property interest&#148; within the meaning of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;897(c) of the Code, and a form of notice to the Internal Revenue Service (which shall be mailed by Topco to the IRS following the Closing) prepared in accordance with the provisions
of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.897-2(h)(2).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No earlier than two days following the
Second Contribution, Orca will convert from a UK public limited company to a UK private limited company pursuant to applicable UK law (the &#147;Orca Conversion&#148;) and U.S. Holdco Sub 2 shall make a valid and timely election pursuant to Treasury
Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;301.7701-3</FONT> to treat Orca as a disregarded entity for U.S. federal income tax purposes which election shall be effective as of the date of the Orca Conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) If Ortho-Clinical Diagnostics S.A. was not converted to a Luxembourg S.&agrave; r.l. prior to the Closing Date, then no earlier than one
day following the Orca Conversion, Orca shall cause (x)&nbsp;an election to be made pursuant to U.S. Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;301.7701-3</FONT> to treat Ortho-Clinical Diagnostics Holdings Luxembourg
S.&agrave; r.l. as a disregarded entity for U.S. federal income tax purposes, effective as of that day, (y)&nbsp;Ortho-Clinical Diagnostics S.A. to convert to a Luxembourg S.&agrave; r.l. and (z)&nbsp;an election to be made pursuant to U.S. Treasury
Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;301.7701-3</FONT> to treat Ortho-Clinical Diagnostics S.A. (after conversion to a Luxembourg S.&agrave; r.l.) as a disregarded entity for U.S. federal income tax purposes, effective as of the
date of the conversion pursuant to clause (y)&nbsp;herein. The parties intend that the Second Contribution, taken together with the Orca Conversion and the election to treat Orca as a disregarded entity, shall be treated as a reorganization within
the meaning of Section&nbsp;368(a)(1)(F) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.9. </B><U>Expenses</U>. Subject to
Section&nbsp;7.5, whether or not the Combinations are consummated, all Expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such Expenses; <U>provided</U>, that
(a)&nbsp;the registration and filing fees and the printing and mailing costs of the Registration Statement (including the scheme circular with respect to the Orca Scheme Terms and the Proxy Statement/Prospectus) and the Nasdaq Listing Application,
and (b)&nbsp;any required filing fees with any Governmental Entity or Self-Regulatory Organization in connection with the transactions contemplated by this Agreement, in each of cases (a)&nbsp;and (b), shall be shared equally by Laguna and Orca
unless prohibited by applicable Law. As used in this Agreement, &#147;Expenses&#148; includes all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including all fees and expenses of counsel,
accountants, investment bankers, experts and consultants to a party and its affiliates) incurred by a party or on its behalf in connection with or related to the authorization, preparation, negotiation, execution and performance of this Agreement
and the transactions contemplated hereby, including the preparation, printing, filing and mailing of the Registration Statement, Proxy Statement/Prospectus and Nasdaq Listing Application, and the solicitation of stockholder approvals and all other
matters related to the transactions contemplated hereby, including in the case of Topco, U.S. Merger Sub, U.S. Holdco Sub, and U.S. Holdco Sub 2 any Expenses incurred by it in connection with the incorporation and financing of Topco, U.S. Merger
Sub, U.S. Holdco Sub, or U.S. Holdco Sub 2 prior to the signing hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.10. </B><U>Indemnification;
Directors</U><U>&#146;</U><U> and Officers</U><U>&#146;</U><U> Insurance</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For a period of six (6)&nbsp;years from and after the
Laguna Effective Time, Topco shall (i)&nbsp;indemnify and hold harmless, and provide advancement of expenses to, all past and present (as of the Laguna Effective Time) directors, officers and employees of Laguna and its Subsidiaries (in all of their
capacities) (A)&nbsp;to the same extent such persons are indemnified or have the right to advancement of expenses as of the date of this Agreement by Laguna pursuant to the Organizational Documents of Laguna or its Subsidiaries and indemnification
agreements, if any, in existence on the date of this Agreement with any directors, officers and employees of Laguna and its Subsidiaries against all costs or expenses (including reasonable attorney&#146;s fees and disbursements), judgments,
inquiries, fines, losses, claims, damages or liabilities incurred by such individual in connection with any civil, criminal, administrative or investigative proceeding arising out of or pertaining to any act or omission of the director, officer or
employee of Laguna or its Subsidiaries and (B)&nbsp;without limitation to clause (A), to the fullest extent permitted by Law, in each case for acts or omissions occurring at or prior to the Laguna Effective Time (including for acts or omissions
occurring in connection with the approval of this Agreement and the consummation of the transactions contemplated hereby), (ii)&nbsp;include and cause to be maintained in effect in Topco&#146;s (or any successor&#146;s) Organizational Documents for
a period of at least six (6)&nbsp;years after the Laguna Effective Time, provisions providing for the elimination of liability of directors, indemnification of officers, directors and employees and advancement of expenses to the fullest extent
permitted by Law and (iii)&nbsp;purchase a <FONT STYLE="white-space:nowrap">six-year</FONT> &#147;tail&#148; prepaid policy on terms and conditions no less advantageous to the insured than the current directors&#146; and officers&#146; liability
insurance and fiduciary liability insurance maintained by Laguna; <U>provided</U>, that Laguna shall have the option to purchase the &#147;tail&#148; prepaid policy in lieu of Topco; <U>provided</U>, further, the amount paid by Topco or Laguna, as
applicable, shall not exceed 300% of the annual premiums (such 300% amount, the &#147;<U>Maximum </U><U>Laguna</U><U> Insurance Amount</U>&#148;) currently paid by Laguna for such insurance. The obligations of Topco, or Laguna, as applicable, under
this Section&nbsp;5.10(a) shall not be terminated or modified in such a manner as to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adversely affect any indemnitee to whom this Section&nbsp;5.10(a) applies without the consent of such affected indemnitee (it being expressly agreed that the indemnitees to whom this
Section&nbsp;5.10(a) applies shall be third-party beneficiaries of this Section&nbsp;5.10(a)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For a period of six (6)&nbsp;years
from and after the Laguna Effective Time, Topco shall (i)&nbsp;indemnify and hold harmless, and provide advancement of expenses to, all past and present (as of the Laguna Effective Time) directors, officers and employees of Orca and its Subsidiaries
(in all of their capacities) (A)&nbsp;to the same extent such persons are indemnified or have the right to advancement of expenses as of the date of this Agreement by Orca pursuant to the Organizational Documents of Orca or its Subsidiaries and
indemnification agreements, if any, in existence on the date of this Agreement with any directors, officers and employees of Orca and its Subsidiaries against all costs or expenses (including reasonable attorney&#146;s fees and disbursements),
judgments, inquiries, fines, losses, claims, damages or liabilities incurred by such individual in connection with any civil, criminal, administrative or investigative proceeding arising out of or pertaining to any act or omission of the director,
officer or employee of Laguna or its Subsidiaries and (B)&nbsp;without limitation to clause (A), to the fullest extent permitted by Law, in each case for acts or omissions occurring at or prior to the Laguna Effective Time (including for acts or
omissions occurring in connection with the approval of this Agreement and the consummation of the transactions contemplated hereby), (ii)&nbsp;include and cause to be maintained in effect in Topco&#146;s (or any successor&#146;s) Organizational
Documents for a period of at least six (6)&nbsp;years after the Laguna Effective Time, provisions providing for the elimination of liability of directors, indemnification of officers, directors and employees and advancement of expenses to the
fullest extent permitted by Law and (iii)&nbsp;purchase a <FONT STYLE="white-space:nowrap">six-year</FONT> &#147;tail&#148; prepaid policy on terms and conditions no less advantageous to the insured than the current directors&#146; and
officers&#146; liability insurance and fiduciary liability insurance maintained by Orca; <U>provided</U>, that the amount paid by Topco shall not exceed 300% of the annual premiums (such 300% amount, the &#147;<U>Maximum Orca Insurance
Amount</U>&#148;) currently paid by Orca for such insurance. The obligations of Topco under this Section&nbsp;5.10(b) shall not be terminated or modified in such a manner as to adversely affect any indemnitee to whom this Section&nbsp;5.10(b)
applies without the consent of such affected indemnitee (it being expressly agreed that the indemnitees to whom this Section&nbsp;5.10(b) applies shall be third-party beneficiaries of this Section&nbsp;5.10(b)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.11. </B><U>Section</U><U></U><U>&nbsp;16 Matters</U>. Prior to the Orca Effective Time, the parties shall take
all such steps as may be required to cause any dispositions of Orca Shares (including derivative securities with respect to Orca Shares) or acquisitions of Topco Shares (including derivative securities with respect to Topco Shares) resulting from
the transactions contemplated by this Agreement by each individual who is subject to the reporting requirements of Section&nbsp;16(a) of the United States Securities Exchange Act of 1934, as amended (including the rules and regulations promulgated
thereunder, the &#147;<U>Exchange Act</U>&#148;) with respect to Orca to be exempt under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. Prior to the Laguna Effective Time, the parties shall take all such steps
as may be required to cause any dispositions of Laguna Shares (including derivative securities with respect to Laguna Shares) or acquisitions of Topco Shares (including derivative securities with respect to Topco Shares) resulting from the
transactions contemplated by this Agreement by each individual who is subject to the reporting requirements of Section&nbsp;16(a) of the Exchange Act with respect to Laguna to be exempt under Rule 16b-3 promulgated under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.12. </B><U>Financing Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Between the date hereof and the Scheme Effective Date, each of Laguna and Orca shall, and shall cause its Subsidiaries to, use reasonable
best efforts (a)&nbsp;to obtain all necessary waivers or consents for the purpose of waiving any terms or provisions of any Contract or series of related Contracts relating to indebtedness that becomes or may become due and payable as a result of
the transactions contemplated hereby, to the extent that the consummation of the transactions contemplated by this Agreement would result in a breach of or default (with or without notice or lapse of time, or both) under, or give rise to any consent
requirement or any right of termination, cancellation or acceleration of any obligation, or to loss of a material benefit under, such terms or provisions, (b)&nbsp;to refinance, renew or replace the indebtedness under such agreements on terms
mutually agreeable to Orca and Laguna; <U>provided</U>, that the transactions contemplated by this Agreement would not result in a breach of or default (with or without notice or lapse of time, or both) under, or give rise to any consent requirement
or any right of termination, cancellation or acceleration of any obligation, or to loss of a material benefit under, any agreement under which such indebtedness is refinanced, renewed or replaced or (c)&nbsp;to ensure that sufficient cash is
available for the prompt payment of any indebtedness under any such agreement. In addition, between the date hereof and the Scheme Effective Date, each of Laguna and Orca shall, and shall cause its Subsidiaries to, use reasonable best efforts to
cooperate to develop an optimal global financing structure for Topco and its Subsidiaries from and after the Scheme Effective Date, and to reasonably cooperate in connection with the arrangement of such financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Prior to the earlier of the Closing or termination of this Agreement in accordance with
Article VII, Orca shall use commercially reasonable efforts to cooperate, and to cause its Subsidiaries and its and their respective Representatives to use commercially reasonable efforts to cooperate, at Laguna&#146;s sole expense, with any debt
financing undertaken by Laguna in order to consummate the Combinations (any such financing, a &#147;<U>Debt Financing&#148;</U>) as may be customary and reasonably requested by Laguna, including by using commercially reasonable efforts (i)&nbsp;to
cause the management of Orca and its Subsidiaries with appropriate seniority and expertise to participate in a reasonable and limited number of conference calls (including lender and ratings agency conference calls) and telephonic or webcast video
presentations, as well as a reasonable and limited number of telephonic or <FONT STYLE="white-space:nowrap">web-based</FONT> video due diligence and drafting sessions; (ii)&nbsp;to assist with the preparation of materials for bank information
memoranda (including a &#147;private supplement&#148; thereto), rating agency presentations and similar documents required in connection with the Debt Financing and delivering customary authorization letters with respect to the same (the
&#147;<U>Authorization Letters</U>&#148;); <U>provided</U> that Laguna shall provide any such documents or other materials that include any material information regarding Orca to Orca for review and comment no fewer than two (2)&nbsp;Business Days
prior to use in connection with the Debt Financing; (iii)&nbsp;to timely furnish Laguna and the Debt Financing Sources with the existing historical financial statements of Orca and its Subsidiaries to the extent reasonably necessary to satisfy any
condition precedent required in connection with the Debt Financing; (iv)&nbsp;to provide Laguna all existing documentation and other information with respect to Orca and its Subsidiaries as shall have been reasonably requested in writing by Laguna
at least six (6)&nbsp;Business Days prior to the Closing Date that is required in connection with the Debt Financing under applicable &#147;know-your-customer&#148; and anti-money laundering rules and regulations; (v)&nbsp;if applicable, to provide
drafts of any customary payoff letters with respect to any Indebtedness of Orca and its Subsidiaries that is being repaid in connection with the Closing and otherwise taking such actions as are reasonably requested by the Laguna and the Debt
Financing Sources in connection with the repayment of existing Indebtedness of Orca and its Subsidiaries and the release of related Liens; (vi)&nbsp;if applicable, to execute and deliver definitive documentation for the Debt Financing (including
credit agreements, guarantee agreements, and pledge and security documents) no earlier than the Closing Date and otherwise reasonably facilitate the granting of a security interest (and perfection thereof) and assist in the negotiation of any such
agreements and other documents, including providing Laguna with any information reasonably necessary to complete customary schedules and closing and perfection certificates as may be required under the Debt Financing (provided that (A)&nbsp;upon the
reasonable request of Laguna, any executed signature pages to such agreements and documents shall be delivered in escrow by Orca and its Subsidiaries a reasonable period of time prior to the Closing Date (but shall not be released from escrow except
on the Closing Date) and (B)&nbsp;any obligations applicable to Orca and its Subsidiaries contained in all such agreements and documents shall be subject to the occurrence of the Closing and shall be effective no earlier than the Closing (other than
with respect to the Authorization Letters)); and (vii)&nbsp;to otherwise reasonably cooperate in Laguna&#146;s efforts to obtain the Debt Financing (including, if applicable, requesting of the appropriate Persons, and using its good faith efforts to
obtain, customary officers certificates, solvency certificates and other similar documents as may reasonably be requested by Laguna and facilitating the pledge of, and granting of security interests in, the stock and assets of Orca and its
Subsidiaries); provided that Orca shall not be required to provide, or cause any of its Subsidiaries to provide, cooperation under this Section&nbsp;5.12(b) that: (A)&nbsp;in the good faith determination of Orca, would unreasonably interfere with
the conduct of ongoing business of Orca and its Subsidiaries, taken as a whole; (B)&nbsp;causes any representation, warranty covenant or agreement in this Agreement to be breached; (C)&nbsp;causes any closing condition set forth in Article VI to
fail to be satisfied; (D)&nbsp;subject to the proviso in clause (vi)&nbsp;above, requires entry into any definitive agreement in respect of the Debt Financing that would be binding on Orca or any of its Subsidiaries prior to the Closing (and the
authorization of the execution, delivery and performance of such agreements shall be at the direction of Laguna and/or the board of directors (or similar body) of Orca or such Subsidiary as constituted by Laguna at Closing); (E) causes Orca or any
of its Subsidiaries or their respective Representatives (1)&nbsp;to take any action that would reasonably be expected to conflict with or violate its organizational documents or applicable law or (2)&nbsp;to incur any liability (excluding, in the
case of Orca and its Subsidiaries, (x)&nbsp;customary expenses to be reimbursed by Laguna and (y)&nbsp;contractual commitments that are not effective prior to the Closing); or (F)&nbsp;could reasonably be expected to adversely affect the Intended
Tax Treatment. The <FONT STYLE="white-space:nowrap">pre-Closing</FONT> board of directors of Orca and the <FONT STYLE="white-space:nowrap">pre-Closing</FONT> directors, managers and general partners of its Subsidiaries, to the extent such Persons
shall not remain in such capacity as of Closing, shall not be required to adopt resolutions approving the agreements, documents and instruments pursuant to which the Debt Financing is obtained. To the extent reasonably desirable or necessary in
connection with the Debt Financing, Orca hereby consents to the use of the logos of Orca and each of its Subsidiaries in connection with the Debt Financing so long as such logos (i)&nbsp;are used solely in a manner that is not intended to, or
reasonably likely to, harm or disparage Orca or any of its Subsidiaries or the reputation or goodwill of Orca or any of its Subsidiaries and (ii)&nbsp;are used solely in connection with a description of Orca or any of its Subsidiaries, its or their
respective businesses and products, or the transactions contemplated hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Laguna shall (i)&nbsp;promptly upon request by Orca following the earlier of the Closing
or the termination of this Agreement in accordance with Article VII, reimburse Orca for all reasonable, documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred in good faith by Orca and
its Subsidiaries and their affiliates and Representatives in connection with the cooperation contemplated by Section&nbsp;5.12(b) and (ii)&nbsp;indemnify and hold harmless Orca and its Subsidiaries and their Affiliates and Representatives from and
against any and all liabilities, losses, damages, claims, reasonable, documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including reasonable, documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> attorney&#146;s fees and expenses), interest, awards, judgments and penalties suffered or incurred by them in connection with the arrangement of the Debt
Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Laguna expressly acknowledges and agrees that its obligations hereunder are not conditioned in any manner upon Laguna
obtaining any financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Debt Financing Sources</U>&#148; means, collectively, (i)&nbsp;Persons (including any agents,
arrangers, commitment parties, lenders and other entities) that have committed to provide or arrange or otherwise entered into agreements in connection with all or any part of the Debt Financing or any other financing in connection with the
transactions contemplated by this Agreement, including the parties to any joinder agreements or credit agreements entered into in connection therewith, (ii)&nbsp;the respective Representatives of each of the Persons specified in clause
(i)&nbsp;above, and (iii)&nbsp;the respective successors and assigns of each of the Persons specified in clauses (i)&nbsp;and (ii) above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.13. </B><U>Employment Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The parties agree that (i)&nbsp;employees of Laguna and its Subsidiaries at the Laguna Effective Time who continue to remain employed with
Laguna or its Subsidiaries (the &#147;<U>Laguna Continuing Employees</U>&#148;) and (ii)&nbsp;the employees of Orca and its Subsidiaries at the Orca Effective Time who continue to remain employed with Orca or its Subsidiaries (the &#147;<U>Orca
Continuing Employees</U>&#148;) shall, during the period commencing at the Laguna Effective Time or Orca Effective Time, respectively, and ending on the one year anniversary of the Laguna Effective Time or Orca Effective Time, respectively, be
provided with base salary or base wage, severance benefit protections, and pension and welfare benefits that are no less favorable, in the aggregate, than those provided to such Laguna Continuing Employees and Orca Continuing Employees, as
applicable, immediately prior to the Effective Time or Orca Effective Time, respectively; provided, however, that the requirements of this sentence shall not apply to Laguna Continuing Employees or Orca Continuing Employees who are covered by a
collective bargaining agreement, union, labor or similar Contract or who cease to be employed for any reason by Laguna and its Subsidiaries or Orca or its Subsidiaries (as the case may be). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) With respect to any Benefit Plan in which any Laguna Continuing Employee or Orca Continuing Employee (collectively, the &#147;<U>Relevant
Continuing Employees</U>&#148;) first becomes eligible to participate on or after the Effective Time or Orca Effective Time, respectively (a &#147;<U>Relevant Benefit Plan&#148;</U>), each party shall use reasonable best efforts to (i)&nbsp;cause
any <FONT STYLE="white-space:nowrap">pre-existing</FONT> conditions or limitations and eligibility waiting periods under any of its group health plans which is a Relevant Benefit Plan to be waived with respect to the other party&#146;s Relevant
Continuing Employees and their eligible dependents, (ii)&nbsp;give the other party&#146;s Relevant Continuing Employees credit for the plan year in which the Laguna Effective Time or Orca Effective Time, respectively, occurs (or the plan year in
which the Relevant Continuing Employee first becomes eligible to participate in the applicable Relevant Benefit Plan, if later) towards applicable deductibles and annual
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> limits for medical expenses incurred during the plan year but prior to the Laguna Effective Time or Orca Effective Time, respectively (or eligibility date,
as applicable), for which payment has been made and (iii)&nbsp;give the other party&#146;s Relevant Continuing Employees service credit for such Relevant Continuing Employee&#146;s employment with the other party for purposes of vesting, benefit
accrual and eligibility to participate under each applicable Relevant Benefit Plan, as if such service had been performed with such party, except for benefit accrual under defined benefit pension plans, for purposes of qualifying for subsidized
early retirement benefits (unless otherwise required under applicable Law) or to the extent it would result in a duplication of benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Nothing contained in this Agreement is intended to (i)&nbsp;be treated as an amendment of any particular Laguna Benefit Plan or Orca
Benefit Plan, (ii)&nbsp;prevent Laguna, Orca, the Laguna Merger Surviving Corporation or any of their affiliates from amending or terminating any of their respective Benefit Plans in accordance with their terms, (iii)&nbsp;prevent Laguna, Orca, the
Laguna Merger Surviving Corporation or any of their affiliates, after the Orca Effective Time, from terminating the employment of any Relevant Continuing Employees or (iv)&nbsp;create any third-party beneficiary rights in any employee of Laguna,
Orca or any of their Subsidiaries or affiliates, any beneficiary or dependent thereof, or any collective bargaining representative thereof, with respect to the compensation, terms and conditions of employment and/or benefits that may be provided to
any Relevant Continuing Employee by Laguna, Orca, the Laguna Merger Surviving Corporation or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of their affiliates or under any Benefit Plan which Laguna, Orca, the Laguna Merger Surviving Corporation or any of their affiliates may maintain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.14. </B><U>Obligations of </U><U>Topco, U.S. Merger Sub, U.S. Holdco Sub and U.S. Holdco Sub 2</U>. Orca shall
take all actions necessary to cause each of Topco, U.S. Merger Sub, U.S. Holdco Sub, and U.S. Holdco Sub 2 to perform its obligations pursuant to this Agreement and to consummate the transactions contemplated by this Agreement upon the terms and
subject to the conditions set forth in this Agreement. Upon the terms and subject to the conditions set forth in this Agreement, Orca, Topco, U.S. Merger Sub, U.S. Holdco Sub, and U.S. Holdco Sub 2 shall be jointly and severally liable for the
failure by any of them to perform and discharge any of their respective covenants, agreements and obligations pursuant to this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VI </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONDITIONS TO THE
COMBINATIONS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.1. </B><U>Condition to Each Party</U><U>&#146;</U><U>s Obligation to Effect the
</U><U>Combinations</U>. The obligations of the parties to consummate the transactions contemplated by this Agreement are subject to the satisfaction or (to the extent permitted by Law) waiver by such parties as of the Closing of each of the
following conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Stockholder Approvals</U>. The Laguna Requisite Vote shall be been obtained at the Laguna Stockholders&#146;
Meeting and the Orca Requisite Vote shall have been obtained at the Orca Shareholder Meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Exchange Listing</U>. The Topco
Shares issuable in the Combinations shall have been authorized for listing on Nasdaq, subject to official notice of issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No
Orders or Laws</U>. No Governmental Entity of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any Order or Law which is in effect and prohibits, restrains, prevents or makes illegal the consummation of the
transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Registration Statement</U>. The Registration Statement shall have been declared
effective by the SEC under the Securities Act, and shall not be the subject of any stop order which is in effect suspending the effectiveness of the Registration Statement or any proceedings for that purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Competition and Other Approvals</U>. Any waiting period (and any extension thereof) required under the Approvals set forth in
Section&nbsp;6.1(e) of the Laguna Disclosure Letter and Section&nbsp;6.1(e) of the Orca Disclosure Letter and such other Approvals as are mutually agreed upon by the parties to be required, and any agreement (including any timing agreement) with any
Governmental Entity not to consummate the transactions contemplated by this Agreement, shall in each case have expired or been terminated and (to the extent applicable) any such Approval shall have been obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Filing with the Registrar</U>. The Orca Scheme Order shall have been sanctioned by the English Court with or without modification (but
subject to any such modification being acceptable to each of Orca, Topco and Laguna) and the Orca Scheme Order shall have been delivered to the Registrar with due confirmatory receipt of the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.2. </B><U>Additional Conditions to Orca</U><U>&#146;</U><U>s and Topco</U><U>&#146;</U><U>s Obligations to
Effect the </U><U>Combinations</U>. The obligations of Orca and Topco to<I> </I>consummate the transactions contemplated by this Agreement are subject to the satisfaction or waiver by Orca<I> </I>as of the Closing of each of the following additional
conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties of Laguna</U>. (i)&nbsp;The representations and warranties of Laguna set forth in
Section&nbsp;4.2(a) shall be true and correct (except for de minimis inaccuracies) as of the Closing Date as though made on and as of such date (except to the extent that any such representation and warranty expressly speaks as of an earlier date,
in which case such representation and warranty shall be so true and correct as of such earlier date), (ii) each of the representations and warranties of Laguna set forth in and Section&nbsp;4.3 shall be true and correct in all material respects as
of the Closing Date as though made on and as of such date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be so true and correct as of such
earlier date), and (iii)&nbsp;each of the other representations and warranties of Laguna set forth in ARTICLE IV shall be true and correct (disregarding all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
qualifications or limitations as to &#147;material&#148;, &#147;Material Adverse Effect&#148; and words of similar import set forth therein) as of the date of this Agreement and as of the Closing
Date as though made on and as of such date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct as of such earlier date),
except in the case of clause (iii)&nbsp;where the failure of such representations and warranties to be so true and correct has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on
Laguna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance of Obligations of Laguna</U>. Laguna shall, in all material respects, have performed and complied with all
obligations required to be performed or complied with by Laguna under this Agreement at or prior to the Laguna Effective Time.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No Material Adverse Effect</U>. At any time after the date of this Agreement there shall not have occurred and be continuing any Effect
that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect on Laguna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
<U>Certificate of Satisfaction of Closing Conditions</U>. Orca shall have received a certificate dated as of the Closing Date executed by a duly authorized officer of Laguna as to the satisfaction of the conditions set forth in Section&nbsp;6.2(a),
(b) and (c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.3. </B><U>Additional Conditions to Laguna</U><U>&#146;</U><U>s Obligations to Effect the
</U><U>Combinations</U>. The obligations of Laguna to consummate the transactions contemplated by this Agreement are subject to the satisfaction or waiver as of the Closing of each of the following additional conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties of Orca</U>. (i)&nbsp;The representations and warranties of Orca set forth in Section&nbsp;4.2(d) and
Section&nbsp;4.2(g) shall be true and correct (except for de minimis inaccuracies) as of the Closing Date as though made on and as of such date (except to the extent that any such representation and warranty expressly speaks as of an earlier date,
in which case such representation and warranty shall be so true and correct as of such earlier date), (ii) each of the representations and warranties of Orca set forth in Section&nbsp;4.2(e), and Section&nbsp;4.3 shall be true and correct in all
material respects as of the Closing Date as though made on and as of such date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be so true
and correct as of such earlier date), and (iii)&nbsp;each of the other representations and warranties of Orca set forth in ARTICLE IV hereof shall be true and correct (disregarding all qualifications or limitations as to &#147;material&#148;,
&#147;Material Adverse Effect&#148; and words of similar import set forth therein) as of the date of this Agreement and as of the Closing Date as though made on and as of such date (except to the extent that any such representation and warranty
expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct as of such earlier date), except in the case of clause (iii)&nbsp;where the failure of such representations and warranties to be so true
and correct has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on Orca. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance of Obligations of Orca</U>. Orca shall, in all material respects, have performed and complied with all obligations required
to be performed or complied with by Orca under this Agreement at or prior to the Orca Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No Material Adverse
Effect</U>. At any time after the date of this Agreement there shall not have occurred and be continuing any Effect that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect on Orca. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Certificate of Satisfaction of Closing Conditions</U>. Laguna shall have received a certificate dated as of the Closing Date executed
by a duly authorized officer of Orca as to the satisfaction of the conditions set forth in Section&nbsp;6.3(a), (b) and (c). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VII
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TERMINATION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.1. </B><U>Termination by Mutual Consent</U>. This Agreement may be terminated by mutual written consent of
Laguna and Orca, by action authorized by their respective boards of directors, at any time prior to the Orca Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.2. </B><U>Termination by Either Laguna or </U><U>Orca</U>.
This Agreement may be terminated by either Laguna or Orca, by action authorized by such Person&#146;s board of directors, at any time prior to the Orca Effective Time: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) if the Orca Effective Time shall not have occurred by September&nbsp;22, 2022 (such date as it may be extended under the proviso below,
the &#147;<U>Termination Date</U>&#148;), whether such date is before or after the date of the receipt of the Laguna Requisite Vote or the Orca Requisite Vote; <U>provided</U>, <U>however</U>, that such date shall automatically be extended to
January&nbsp;22, 2023, if the only conditions that have not been satisfied (other than those conditions that Laguna and Orca have mutually agreed to waive, if and to the extent that such waiver is permitted by applicable Law, and other than those
conditions that by their nature can only be satisfied at or immediately prior to the Scheme Effective Date) are one or more of the conditions set forth in (i)&nbsp;Section&nbsp;6.1(c) to the extent relating to an Approval required by
Section&nbsp;6.1(e) or (ii)&nbsp;Section&nbsp;6.1(e); <U>provided</U>, <U>further</U>, that the right to terminate this Agreement pursuant to this Section&nbsp;7.2(a) may not be exercised by any party whose failure to perform any material covenant
or obligation under this Agreement has been the primary cause of, or primarily resulted in, the failure of any such closing condition to be satisfied on or before the Termination Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if (i)&nbsp;the Laguna Requisite Vote shall not have been obtained after a vote of the Laguna stockholders has been taken and completed at
the Laguna Stockholders&#146; Meeting or at any adjournment or postponement thereof or (ii)&nbsp;the Orca Requisite Vote shall not have been obtained at the Orca Shareholder Meetings (or at any adjournment or postponement thereof) or the Orca Scheme
is not sanctioned and the Orca Scheme Order is not issued by the English Court; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) if any Governmental Entity that must grant a
regulatory approval required under Section&nbsp;6.1(e) has denied such grant in writing and such denial has become final, binding and <FONT STYLE="white-space:nowrap">non-appealable,</FONT> or any Order permanently restraining, enjoining or
otherwise prohibiting consummation of the Combinations shall become final and <FONT STYLE="white-space:nowrap">non-appealable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.3. </B><U>Termination by </U><U>Laguna</U>. This Agreement may be terminated by Laguna by action authorized by
the Laguna Board: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) at any time prior to the receipt of the Orca Requisite Vote, if the Orca Board shall have effected a Change in Orca
Recommendation (whether or not in compliance with Section&nbsp;5.2); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) at any time prior to the Orca Effective Time, if Orca breaches
or fails to perform any of its covenants or agreements contained in this Agreement, or if any of the representations or warranties of Orca contained herein fails to be true and correct, which breach or failure (i)&nbsp;would give rise to the failure
of a condition set forth in Section&nbsp;6.3(a) through (c)&nbsp;and (ii) is not reasonably capable of being cured by Orca by the Termination Date or is not cured by Orca within 45 days after receiving written notice from Laguna; <U>provided</U>,
that the right to terminate this Agreement pursuant to this Section&nbsp;7.3(b) may not be exercised by Laguna if Laguna&#146;s failure to perform any material covenant or obligation under this Agreement has been the primary cause of, or primarily
resulted in, the failure of any such closing condition to be satisfied on or before the Termination Date; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) at any time prior to the
receipt of the Laguna Requisite Vote, if the Laguna Board shall have effected a Change in Laguna Recommendation in compliance with Section&nbsp;5.2 in response to a Laguna All Cash Superior Proposal and in order for Laguna to enter into a merger
agreement, acquisition agreement, purchase agreement or other similar agreement that the Laguna Board has authorized and directed Laguna to execute with respect to such Laguna All Cash Superior Proposal; <U>provided</U>, however, that this Agreement
may not be so terminated unless (i)&nbsp;prior to or simultaneously with such termination the payment required by Section&nbsp;7.5(b) has been made in full to Orca in accordance with Section&nbsp;7.5(b), and (ii)&nbsp;simultaneously or promptly
following such termination Laguna enters into such agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.4. </B><U>Termination by </U><U>Orca</U>.
This Agreement may be terminated by Orca by action authorized by the Orca Board: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) at any time prior to the receipt of the Laguna
Requisite Vote, if the Laguna Board shall have effected a Change in Laguna Recommendation (whether or not in compliance with Section&nbsp;5.2); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) at any time prior to the Orca Effective Time, if Laguna breaches or fails to perform any of its covenants or agreements contained in this
Agreement, or if any of the representations or warranties of Laguna contained herein fails to be true and correct, which breach or failure (i)&nbsp;would give rise to the failure of a condition set forth in Section&nbsp;6.2(a) through (c)&nbsp;and
(ii) is not reasonably capable of being cured by Laguna by the Termination Date or is not cured by Laguna within 45 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
days after receiving written notice from Orca; <U>provided</U>, that the right to terminate this Agreement pursuant to this Section&nbsp;7.4(b) may not be exercised by Orca if Laguna&#146;s
failure to perform any material covenant or obligation under this Agreement has been the primary cause of, or primarily resulted in, the failure of any such closing condition to be satisfied on or before the Termination Date; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) at any time prior to the receipt of the Orca Requisite Vote, if the Orca Board shall have effected a Change in Orca Recommendation in
compliance with Section&nbsp;5.2 in response to an Orca All Cash Superior Proposal and in order for Orca to enter into a merger agreement, acquisition agreement, purchase agreement or other similar agreement that the Orca Board has authorized and
directed Orca to execute with respect to such Orca All Cash Superior Proposal; <U>provided</U>, however, that this Agreement may not be so terminated unless (i)&nbsp;prior to or simultaneously with such termination the payment required by
Section&nbsp;7.5(c) has been made in full to Orca in accordance with Section&nbsp;7.5(c), and (ii)&nbsp;simultaneously or promptly following such termination Laguna enters into such agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.5. </B><U>Effect of Termination and Abandonment</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Effect of Termination and Abandonment</I>. In the event of termination of this Agreement pursuant to this Article&nbsp;VII (other than
Section&nbsp;7.1), written notice thereof shall be given to the other parties to this Agreement specifying the provisions of this ARTICLE VII to which such termination is made and the basis therefore described in reasonable detail, and this
Agreement (other than as set forth in this Section&nbsp;7.5 and 8.1) shall become void and of no effect with no liability on the part of any party (or of any of its directors, officers, employees, agents, legal and financial advisors or other
Representatives); <U>provided</U>, <U>however</U>, that, except as otherwise provided herein, no such termination shall relieve any party of any liability or damages resulting from any fraud or willful and material breach of this Agreement;
<U>provided</U>, <U>further</U>, that the parties shall cooperate with each other in connection with the withdrawal of any applications to or termination of proceedings before any Governmental Entity or any Self-Regulatory Organization in connection
with the transactions contemplated by this Agreement. For purposes of this ARTICLE VII, (i) &#147;fraud&#148; shall mean, with respect to any Person, intentional (and not constructive) misrepresentation of a material fact by such Person with the
actual knowledge (as opposed to imputed or constructive knowledge or knowledge that could have been obtained after inquiry, or recklessness or negligence) of such Person that such representation was false when made and which was made with the
specific intent to induce the Person to whom such representation was made to enter into or consummate the transactions contemplated by this Agreement and (ii) &#147;<U>willful and material breach</U>&#148; shall mean a material breach that is a
consequence of an act undertaken by the breaching party or failure to act by the breaching party with the knowledge that the taking of such act or such failure to act would, or would reasonably be expected to, cause a material breach of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Termination Fee Payable by </I><I>Laguna</I><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) In the event that (A)&nbsp;this Agreement is terminated by Orca pursuant to Section&nbsp;7.4(a) or is terminated by either Laguna or Orca
pursuant to Section&nbsp;7.2(a) or 7.2(b)(i) (and, at the time of such termination pursuant to Section&nbsp;7.2(a) or 7.2(b)(i), Orca had a right to terminate this Agreement pursuant to Section&nbsp;7.4(a)), (B)(x) an Acquisition Proposal for Laguna
shall have been publicly announced or made publicly known or otherwise communicated or made known to Laguna management or the Laguna Board (or any third party shall have publicly announced, communicated or made known a bona fide intention, whether
or not conditional, to make a proposal with respect to an Acquisition Proposal) and not withdrawn prior to termination or such vote to adopt this Agreement, as applicable, at any time after the date of this Agreement and (y)&nbsp;this Agreement is
subsequently terminated by Orca pursuant to Section&nbsp;7.4(b) or is terminated by either Laguna or Orca pursuant to Section&nbsp;7.2(a) or 7.2(b)(i) (and, at the time of such termination pursuant to Section&nbsp;7.2(a) or 7.2(b)(i), Orca had a
right to terminate this Agreement pursuant to Section&nbsp;7.4(b) as a result of a failure by Laguna to perform any of its covenants or agreements contained in this Agreement), or (C)&nbsp;this Agreement is terminated by Laguna pursuant to
Section&nbsp;7.3(c), then, in any such case, Laguna shall, prior to or contemporaneously with such termination, pay or cause to be paid to Orca an amount equal to $207,839,918.46 (the &#147;<U>Laguna Termination </U><U>Payment</U>&#148;) by wire
transfer of same day funds, as reduced by the amount of any applicable Expense Reimbursement for Orca, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) In the event that
(A)&nbsp;an Acquisition Proposal for Laguna shall have been publicly announced or made publicly known or otherwise communicated or made known to management or the Laguna Board (or any third party shall have publicly announced, communicated or made
known a bona fide intention, whether or not conditional, to make a proposal with respect to an Acquisition Proposal) and not withdrawn prior to termination or such vote to adopt this Agreement, as applicable, at any time after the date of this
Agreement, (B)&nbsp;this Agreement is subsequently terminated by Laguna or Orca pursuant to Section&nbsp;7.2(a) or 7.2(b)(i), and (C)&nbsp;within nine (9)&nbsp;months of such termination pursuant to </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;7.2(a) or 7.2(b)(i), Laguna or any of its Subsidiaries executes an Alternative Acquisition Agreement with respect to, or consummates, or approves or recommends to the Laguna
stockholders to accept, any Acquisition Proposal (it being understood that, for purposes of this clause (C), the term &#147;Acquisition Proposal&#148; shall have the meaning assigned to such term in Section&nbsp;5.2(a) except that each reference to
&#147;15% or more&#148; in the definition of &#147;Acquisition Proposal&#148; and &#147;Major Subsidiary&#148; shall be deemed to be a reference to &#147;50% or more&#148;), then Laguna shall, prior to or contemporaneously with the completion of
such acquisition or transaction, pay or cause to be paid to Orca, by wire transfer of same day funds, the Laguna Termination Payment, as reduced by the amount of any Expense Reimbursement for Orca previously paid, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) In the event that this Agreement is terminated by Orca pursuant to Section&nbsp;7.2(b)(i) under circumstances in which the Laguna
Termination Payment is not otherwise payable, then Laguna shall pay to Orca its reasonable documented out of pocket costs, fees, and expenses incurred in connection with its investigation, consideration, documentation, diligence and negotiations of
this Agreement and the transactions contemplated hereby, including all fees and expenses of Orca&#146;s and its Subsidiaries&#146; respective Representatives and financing sources (the &#147;<U>Expense Reimbursement for Orca</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Termination Fee Payable by </I><I>Orca.</I><I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) In the event that (A)&nbsp;this Agreement is terminated by Laguna pursuant to Section&nbsp;7.3(a) or is terminated by either Laguna or
Orca pursuant to Section&nbsp;7.2(a) or 7.2(b)(ii) (and, at the time of such termination pursuant to Section&nbsp;7.2(a) or 7.2(b)(ii), Laguna had a right to terminate this Agreement pursuant to Section&nbsp;7.3(a)), (B)(x) an Acquisition Proposal
for Orca shall have been publicly announced or made publicly known or otherwise communicated or made known to Orca management or the Orca Board (or any third party shall have publicly announced, communicated or made known a bona fide intention,
whether or not conditional, to make a proposal with respect to an Acquisition Proposal) and not withdrawn prior to termination or such vote to adopt this Agreement, as applicable, at any time after the date of this Agreement and (y)&nbsp;this
Agreement is subsequently terminated by Laguna pursuant to Section&nbsp;7.3(b) or is terminated by either Laguna or Orca pursuant to Section&nbsp;7.2(a) or 7.2(b)(ii) (and, at the time of such termination pursuant to Section&nbsp;7.2(a) or
7.2(b)(ii), Laguna had a right to terminate this Agreement pursuant to Section&nbsp;7.3(b) as a result of a failure by Orca to perform any of its covenants or agreements contained in this Agreement), or (C)&nbsp;this Agreement is terminated by Orca
pursuant to Section&nbsp;7.4(c), then, in any such case, Orca shall, prior to or contemporaneously with such termination, pay or cause to be paid to Laguna an amount equal to $46,880,426.11 (the &#147;<U>Orca Termination Payment</U>&#148;) by wire
transfer of same day funds, as reduced by the amount of any applicable Expense Reimbursement for Laguna, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) In the event that
(A)&nbsp;an Acquisition Proposal for Orca shall have been publicly announced or made publicly known or otherwise communicated or made known to management or the Orca Board (or any third party shall have publicly announced, communicated or made known
a bona fide intention, whether or not conditional, to make a proposal with respect to an Acquisition Proposal) and not withdrawn prior to termination or such vote to adopt this Agreement, as applicable, at any time after the date of this Agreement,
(B)&nbsp;this Agreement is subsequently terminated by Laguna or Orca pursuant to Section&nbsp;7.2(a) or 7.2(b)(ii), and (C)&nbsp;within nine (9)&nbsp;months of such termination pursuant to Section&nbsp;7.2(a) or 7.2(b)(ii), Orca or any of its
Subsidiaries executes an Alternative Acquisition Agreement with respect to, or consummates, or approves or recommends to Orca Shareholders to accept, any Acquisition Proposal (it being understood that, for purposes of this clause (C), the term
&#147;Acquisition Proposal&#148; shall have the meaning assigned to such term in Section&nbsp;5.2(a) except that each reference to &#147;15% or more&#148; in the definition of &#147;Acquisition Proposal&#148; and &#147;Major Subsidiary&#148; shall
be deemed to be a reference to &#147;50% or more&#148;), then Orca shall, prior to or contemporaneously with the completion of such acquisition or transaction, pay or cause to be paid to Laguna, by wire transfer of same day funds, the Orca
Termination Payment, as reduced by the amount of any Expense Reimbursement for Laguna previously paid, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) In the event that
this Agreement is terminated by Laguna pursuant to Section&nbsp;7.2(b)(ii) under circumstances in which the Orca Termination Payment is not otherwise payable, then Orca shall pay to Laguna its reasonable documented out of pocket costs, fees, and
expenses incurred in connection with its investigation, consideration, documentation, diligence and negotiations of this Agreement and the transactions contemplated hereby, including all fees and expenses of Laguna and its Subsidiaries&#146;
respective Representatives and financing sources (the &#147;<U>Expense Reimbursement for Laguna</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <I>Nature of Termination
Payment</I>. The parties acknowledge and agree that neither the Laguna Termination Payment nor the Orca Termination Payment is a penalty but rather is a reasonable estimate of damages necessary to compensate Orca or Laguna, as the case may be, in
the circumstances in which the Laguna Termination Payment or the Orca </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Termination Payment, as applicable, is payable. The parties hereby acknowledge and agree that the amount of the Laguna Termination Payment or the Orca Termination Payment, if and as applicable,
is fair, after taking into account the value of the Orca Scheme and Laguna Merger, the other transactions contemplated hereby and all the costs and expenses already incurred by the parties before entering into this Agreement. In no event shall
Laguna, on the one hand, or Orca, on the other hand, be required to pay to the other party more than one Laguna Termination Payment or the Orca Termination Payment, if and as applicable, pursuant to this Section&nbsp;7.5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <I>Exclusive Remedy</I>. Subject to Section&nbsp;7.5(a) (including with respect to willful and material breach or fraud) and
Section&nbsp;7.5(f), in the event that the Laguna Termination Payment or the Orca Termination Payment, as applicable, is paid in accordance with this Section&nbsp;7.5, Orca and Topco, or Laguna, as applicable shall have no further recourse against
Laguna, on the one hand, or Orca and Topco, on the other, in each case, for any and all losses, claims, damages, liabilities, costs, fees, expenses (including reasonable attorney&#146;s fees and disbursements), judgments, inquiries and fines
suffered as a result of any breach of any representation, warranty, covenant or obligation in this Agreement, and neither Laguna and its affiliates nor Orca and its affiliates, as applicable, or any of their respective former, current or future
Representatives, agents, partners, managers, members, stockholders, assignees or affiliates shall have any further liability or obligations relating to or arising out of this Agreement; <U>provided</U>, <U>however</U>, that the foregoing shall not
impair the rights of the parties, if any, to obtain injunctive relief pursuant to Section&nbsp;8.14. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) <I>Interest and Collection
Expenses</I>. Each of Laguna and Orca acknowledges that the agreements contained in this Section&nbsp;7.5 are an integral part of the transactions contemplated by this Agreement, and that, without these agreements, the other party would not enter
into this Agreement; accordingly, if either party fails to promptly pay or cause to be paid the amount due pursuant to this Section&nbsp;7.5, and, in order to obtain such payment, the other party commences a suit that results in a judgment against
such party for the payment set forth in this Section&nbsp;7.5 or any portion of such payment, such party shall pay the other party its costs and expenses (including attorneys&#146; fees) in connection with such suit, together with interest on the
amount of the payment at the prime rate of Citibank, N.A., in effect on the date such payment was required to be paid, from the date on which such payment was required through the date of actual payment. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VIII </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MISCELLANEOUS AND
GENERAL </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.1. </B><U>Survival</U>. This ARTICLE VIII and the agreements of Laguna and Orca contained in
Section&nbsp;5.10 (Indemnification; Directors&#146; and Officers&#146; Insurance) shall survive the consummation of the Combinations. This ARTICLE VIII, the agreements of Laguna and Orca contained in Section&nbsp;5.9 (Expenses), Section&nbsp;7.5
(Effect of Termination and Abandonment) and the Confidentiality Agreement shall survive the termination of this Agreement for the maximum period permitted by Law. No other representations, warranties, covenants and agreements in this Agreement shall
survive the consummation of the Combinations or the termination of this Agreement; <U>provided</U>, that this Section&nbsp;8.1 shall not limit any covenant or agreement of the parties which by its terms contemplates performance after the Laguna
Effective Time, which shall survive to the extent expressly provided for herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.2. </B><U>Modification
or Amendment</U>. Subject to the provisions of applicable Law, and except as otherwise provided in this Agreement, this Agreement may be amended, modified or supplemented only by action taken by or on behalf of their respective boards of directors
and pursuant to a written instrument executed and delivered by all of the parties, whether&nbsp;before or after approval of the matters presented in connection with the Laguna Merger by the Laguna stockholders or the Orca Scheme by the Orca
Shareholders; <U>provided</U> that, after any such approval, no amendment shall be made for which applicable Law or the rules of any relevant stock exchange requires further approval by such stockholders without such further approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.3. </B><U>Extension; Waiver</U>. At any time prior to the Orca Effective Time, the parties may (a)&nbsp;extend
the time for the performance of any of the obligations or other acts of the other parties, (b)&nbsp;waive any inaccuracies in the representations and warranties contained in this Agreement or in any document delivered pursuant to this Agreement,
(c)&nbsp;waive compliance with any covenants and agreements contained in this Agreement or (d)&nbsp;waive the satisfaction of any of the conditions contained in this Agreement. No extension or waiver by Laguna shall require the approval of the
Laguna stockholders unless such approval is required by Law and no extension or waiver by Orca shall require the approval of the Orca Shareholders unless such approval is required by Law. Any agreement on the part of a party to any such extension or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
waiver shall be valid only if set forth in an instrument in writing signed on behalf of such party. The failure of any party to this Agreement to assert any of its rights under this Agreement or
otherwise shall not constitute a waiver of such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.4. </B><U>Counterparts</U>. This Agreement may be
executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. The
exchange of a fully executed Agreement (in counterparts or otherwise) by facsimile or by electronic delivery in .pdf format shall be sufficient to bind the parties to the terms and conditions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.5. </B><U>Governing Law; </U><U>Jurisdiction, Waiver of Trial by Jury</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Governing Law</I>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without
giving effect to conflicts of laws principles that would result in the application of the Law of any other jurisdiction; <U>provided</U>, <U>however</U>, that the Orca Scheme and matters related thereto shall be governed by, and construed in
accordance with, English Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Dispute Resolution</I>. Each party to this Agreement hereby irrevocably and unconditionally submits,
for itself and its property, to the exclusive jurisdiction of the Court of Chancery of the State of Delaware, or, if (and only if) such court finds it lacks subject matter jurisdiction, the Federal court of the United States of America sitting in
Delaware, and appellate courts thereof (the &#147;<U>Chosen Courts</U>&#148;), in any action or proceeding arising out of or relating to this Agreement or the agreements delivered in connection herewith or the transactions contemplated hereby or
thereby or for recognition or enforcement of any judgment relating thereto, and each of the parties to this Agreement hereby irrevocably and unconditionally (i)&nbsp;agrees not to commence any such action or proceeding except in the Court of
Chancery of the State of Delaware, or, if (and only if) such court finds it lacks subject matter jurisdiction, the Federal court of the United States of America sitting in Delaware, and appellate courts thereof, (ii)&nbsp;agrees that any claim in
respect of any such action or proceeding shall be heard and determined in the Court of Chancery of the State of Delaware, or, if (and only if) such court finds it lacks subject matter jurisdiction, the Federal court of the United States of America
sitting in Delaware, and appellate courts thereof, (iii)&nbsp;waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the laying of venue of any such action or proceeding in such courts
and (iv)&nbsp;waives, to the fullest extent permitted by Law, the defense of an inconvenient forum to the maintenance of such action or proceeding in such courts. Each of the parties to this Agreement agrees that a final judgment in any such action
or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law. Notwithstanding the foregoing, the Orca Scheme and matters related to the sanction thereof shall be subject
to the jurisdiction of the English Court and any appellate courts therefrom. Each party irrevocably consents to service of process inside or outside the territorial jurisdiction of the courts referred to in this
<U>Section</U><U></U><U>&nbsp;8.5(b)</U> in the manner provided for notices in <U>Section</U><U></U><U>&nbsp;8.7</U>. Nothing in this Agreement will affect the right of any party to serve process in any other manner permitted by Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER OR RELATE TO THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED
AND DIFFICULT ISSUES, AND THEREFORE SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF
LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B)&nbsp;IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C)&nbsp;IT MAKES THIS WAIVER VOLUNTARILY, AND (D)&nbsp;IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER
THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION</U><U></U><U>&nbsp;8.5</U><I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, this
Section&nbsp;8.5<I> </I>shall survive the consummation of the Combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.6. </B><U>Disclosure
Letters</U>. Any disclosure contained in the Laguna Disclosure Letter or the Orca Disclosure Letter with reference to any section or subsection of this Agreement shall be deemed to apply to any other section or subsection of the Laguna Disclosure
Letter or Orca Disclosure Letter, respectively, where the relevance of such disclosure is reasonably apparent on the face of such disclosure. The mere inclusion of any item in the Laguna Disclosure Letter as an
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exception to a representation or warranty of Laguna in this Agreement or the Orca Disclosure Letter as an exception to a representation or warranty of Orca in this Agreement shall not be deemed
to be an admission that such item is a material exception, fact, event or circumstance, or that such item, individually or in the aggregate, has had or is reasonably expected to have, a Material Adverse Effect on Laguna, Orca or Topco, as
applicable, or trigger any other materiality qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.7. </B><U>Notices</U>. Any notice, request,
instruction or other document to be given hereunder by any party to the others shall be in writing, shall be deemed duly given on the date of delivery, unless such day is not a Business Day in the location of receipt, in which case it shall be
deemed delivered on the next Business Day in the location of receipt, and delivered personally or sent by registered or certified mail, postage prepaid or by prepaid overnight courier (providing written proof of delivery), in each case with a copy
delivered by electronic mail, or by confirmed electronic mail, addressed as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If to Orca, Topco, Merger Sub, U.S. Holdco Sub,
and U.S. Holdco Sub 2, to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Ortho Clinical Diagnostics Holdings plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">1001 US Route 202 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Raritan, NJ
08869 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Christopher Smith </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">&nbsp;Michael Schlesinger </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;[***] </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">&nbsp;[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">with a copy
(which shall not constitute notice) to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">555 Eleventh Street NW, Suite 1000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20004 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">United
States of America </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Attention: David I. Brown </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">&nbsp;Bradley C. Faris </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">&nbsp;Richard Butterwick </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;[***] </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">&nbsp;[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">(b) If to Laguna, to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Quidel
Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">9975 Summers Ridge Rd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Attention:
Robert Bujarski </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">&nbsp;Michelle Hodges </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;[***] </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">&nbsp;[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">with a copy
(which shall not constitute notice) to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Gibson Dunn&nbsp;&amp; Crutcher LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">555 Mission Street, Suite 3000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94105-0921 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">United States of America </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Attention: Ryan A. Murr </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">&nbsp;Stephen I. Glover </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">&nbsp;Branden C. Berns </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;<U>[***] </U> </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">&nbsp;[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">&nbsp;[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other persons or addresses as may be designated in writing by the party to receive such notice as
provided above and notification of the same has been duly given to all other parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.8. </B><U>Entire
Agreement</U>. This Agreement (including any exhibits hereto), the Orca Scheme Terms, the Laguna Disclosure Letter, the Orca Disclosure Letter and the Confidentiality Agreement, dated June&nbsp;1, 2021, between Laguna and Orca (the
&#147;<U>Confidentiality Agreement</U>&#148;) constitute the entire agreement, and supersede all other prior agreements, understandings, representations and warranties both written and oral, among the parties, with respect to the subject matter
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.9. </B><U>No Third-Party Beneficiaries</U>. Except as provided in Section&nbsp;5.10
(Indemnification; Directors&#146; and Officers&#146; Insurance) and Section&nbsp;7.5(e) (Effect of Termination and Abandonment; Exclusive Remedy), each of which shall inure to the benefit of the Persons benefiting therefrom, this Agreement is not
intended to, and does not, confer upon any Person other than the parties any rights or remedies hereunder. The parties agree that the rights of third-party beneficiaries under Section&nbsp;5.10 shall not arise unless and until the Orca Effective
Time occurs. The representations and warranties in this Agreement are the product of negotiations among the parties hereto and are for the sole benefit of the parties hereto. Any inaccuracies in such representations and warranties are subject to
waiver by the parties hereto in accordance with Section&nbsp;8.3 without notice or liability to any other person. In some instances, the representations and warranties in this Agreement may represent an allocation among the parties hereto of risks
associated with particular matters regardless of the knowledge of any of the parties hereto. Consequently, Persons other than the parties hereto may not rely upon the representations and warranties in this Agreement as characterizations of actual
facts or circumstances as of the date of this Agreement or as of any other date. For the avoidance of doubt, this Section&nbsp;8.9<I> </I>shall survive the Scheme Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.10. </B><U>Obligations of </U><U>Laguna</U><U> and </U><U>Orca</U>. Whenever this Agreement requires a
Subsidiary of Topco, Laguna or Orca to take any action, such requirement shall be deemed to include an undertaking on the part of Topco, Laguna or Orca, as appropriate, to cause such Subsidiary to take such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.11. </B><U>Severability</U>. The provisions of this Agreement shall be deemed severable and the invalidity or
unenforceability of any provision shall not affect the validity or enforceability or the other provisions hereof. If any provision of this Agreement, or the application thereof to any Person or any circumstance, is invalid or unenforceable,
(a)&nbsp;a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b)&nbsp;the remainder of this Agreement
and the application of such provision to other Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of such provision, or the
application thereof, in any other jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.12. </B><U>Interpretation; Construction</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The table of contents and headings herein are for convenience of reference only, do not constitute part of this Agreement and shall not
be deemed to limit or otherwise affect any of the provisions hereof. Where a reference in this Agreement is made to a Section, Schedule or Exhibit, such reference shall be to a Section of, Schedule to or Exhibit to this Agreement unless otherwise
indicated. Whenever the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed by the words &#147;without limitation.&#148; The term &#147;knowledge of Laguna &#148;
shall be deemed to mean the actual knowledge of the individuals set forth on <U>Section</U><U></U><U>&nbsp;8.12</U> of the Laguna Disclosure Letter. The term &#147;knowledge of Orca&#148; or &#147;knowledge of Topco&#148; shall be deemed to mean the
actual knowledge of the individuals set forth on <U>Section</U><U></U><U>&nbsp;8.12</U> of the Orca Disclosure Letter. For purposes of this Agreement, whenever the context requires the singular number shall include the plural, and vice versa. All
references in this Agreement to &#147;$&#148; are intended to refer to United States dollars. Any reference to a particular Law means such Law as amended, modified or supplemented (including all rules and regulations promulgated thereunder) and,
unless otherwise provided, as in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The parties have participated jointly in negotiating and drafting this
Agreement. In the event that an ambiguity or a question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party
by virtue of the authorship of any provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.13. </B><U>Assignment</U>. Neither this
Agreement nor any of the rights, interests or obligations under this Agreement shall be assigned, in whole or in part, by any of the parties without the prior written consent of the other parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Any attempted or purported assignment in violation of the preceding sentence shall be null and void and of no effect whatsoever. Subject to the preceding two sentences, this Agreement shall be
binding upon, inure to the benefit of, and be enforceable by, the parties and their respective successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.14. </B><U>Specific Performance</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the
specific terms hereof or were otherwise breached. It is accordingly agreed that prior to the termination of this Agreement in accordance with ARTICLE VII, the parties shall be entitled to an injunction or injunctions to prevent breaches of this
Agreement and to enforce specifically the terms and provisions of this Agreement (without necessity of posting bond or other security (any requirements therefor being expressly waived)) in the Chosen Court, this being in addition to any other remedy
to which they are entitled at Law or in equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of the parties agrees that it will not oppose the granting of an injunction,
specific performance and other equitable relief as provided in this Section&nbsp;8.14 on the basis that (i)&nbsp;the party seeking such relief has an adequate remedy at Law or (ii)&nbsp;an award of specific performance is not an appropriate remedy
for any reason at Law or equity. Any party seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement shall not be required to provide any bond or other security
in connection with any such order or injunction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In no event shall Laguna&#146;s, Topco&#146;s, or Orca&#146;s right to seek specific
performance pursuant to this Section&nbsp;8.14 reduce, restrict or otherwise limit any right of such party to terminate this Agreement and to be paid the Laguna Termination Payment or Orca Termination Payment, as and if applicable; <U>provided</U>,
that in no event shall Laguna, Topco or Orca be entitled to both specific performance pursuant to this Section&nbsp;8.14 and payment of the Laguna Termination Payment or Orca Termination Payment, as applicable, with respect to the same conduct or
action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly
authorized officers of the parties as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">QUIDEL CORPORATION</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Douglas C. Bryant</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt">Name: Douglas C. Bryant</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt">Title:&nbsp;&nbsp;&nbsp;President and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ORTHO&nbsp;CLINICAL&nbsp;DIAGNOSTICS&nbsp;HOLDINGS&nbsp;PLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Christopher Smith</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt">Name: Christopher Smith</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt">Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CORONADO TOPCO, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Joseph Busky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt">Name: Joseph Busky</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt">Title:&nbsp;&nbsp;&nbsp;President</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:440pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Business Combination Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LAGUNA MERGER SUB, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Joseph Busky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt">Name: Joseph Busky</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt">Title:&nbsp;&nbsp;&nbsp;President</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ORCA HOLDCO, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Joseph Busky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Joseph Busky</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:&nbsp;&nbsp;&nbsp;President</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ORCA HOLDCO 2, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Joseph Busky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Joseph Busky</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:&nbsp;&nbsp;&nbsp;President</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:440pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Business Combination Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ANNEX I: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Defined Terms </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Defined Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Section</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Acquisition Proposal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;5.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Alternative Acquisition Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;5.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Anti-Corruption Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.24(a)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Antitrust Approvals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Applicable Data Protection Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.15(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Approvals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Authorization Letters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;5.12(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bankruptcy and Equity Exception</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Benefit Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.10(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bribery Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.24(a)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bryant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;3.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Business Day</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Carlyle</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cash Portion</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.4(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Change in Laguna Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;5.3(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Change in Orca Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;5.3(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chosen Courts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;8.5(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Combination Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.5(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Combinations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Confidentiality Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;8.8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Continuing Employees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;5.13</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Contract</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.4(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Contributions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">COVID-19</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Creditors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;5.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Debt Financing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;5.12(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Debt Financing Sources</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;5.12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Designated Executives</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;3.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DGCL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Disclosed</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;5.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DR Nominee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DTC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;5.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Effect</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">English Court</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">English Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Environmental Claim</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.17</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Environmental Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.17</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Environmental Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.17</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Excess Orca Scheme Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.4(d)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Exchange Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.11</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Exchange Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.7</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Exchange Fund</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.8(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Excluded Laguna Share</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.5(a)(ii)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Excluded Orca Share</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.4(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Expense Reimbursement for Laguna</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5(c)(iii)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Expense Reimbursement for Orca</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5(b)(iii)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">FCPA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.24(a)(ii)</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Defined Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Section</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">FDA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.25(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">FDA Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.25(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Filings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">First Contribution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.9</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Fractional Interests Trust</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.4(d)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">GAAP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Government Official</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.24(a)(ii)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Governmental Entity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">HMRC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">HSR Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.14(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Intended Tax Treatment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2(d)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Intervening Event</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2(d)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">IT Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.14(f)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">knowledge of Laguna</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.12(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">knowledge of Orca</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.12(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Labor Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.12(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preamble</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recitals</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Book-Entry Interests</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.8(b)(i)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.8(b)(i)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Certificate of Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.3(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Change in Recommendation Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2(e)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Continuing Employees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.13</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Disclosure Letter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IV</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.3(c)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Equity Right</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(b)(ii)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna ESPP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(b)(vi)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Exchange Ratio</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recitals</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Group</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recitals</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Merger Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.5(a)(i)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Merger Surviving Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Preferred Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recitals</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Reports</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IV</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Requisite Vote</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recitals</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Stock Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(b)(ii)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Stock Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(b)(i)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Stock Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(b)(i)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Stockholders&#146; Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(d)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laguna Termination Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5(b)(i)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Leased Real Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.19(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Lien</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2(c)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Limited Topco Equity Right</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(a)(ii)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Major Subsidiary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Material Adverse Effect</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Material Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.14(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Maximum Laguna Insurance Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.10(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Maximum Orca Insurance Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.10(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Nasdaq</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.8(b)(i)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Nasdaq Listing Application</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(a)</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Defined Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Section</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Benefit Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10(f)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">OFAC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.24(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preamble</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recitals</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Change in Recommendation Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2(e)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Continuing Employees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.13</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Convening Hearing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Conversion</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.8(e)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Deferred Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Depositary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.4(c)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Disclosure Letter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IV</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.3(c)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Equity Right</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(a)(ii)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Exchange Ratio</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recitals</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6(c)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca General Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(e)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Group</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recitals</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Reports</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IV</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Requisite Vote</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3(c)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Restricted Stock Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(a)(iii)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Sanction Hearing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Scheme</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recitals</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Scheme Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.4(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Scheme Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Scheme Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Scheme Meeting Publication</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Scheme Order</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Scheme Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Scheme Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Shareholder</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.4(e)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Shareholder Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(e)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recitals</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Stock Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(a)(ii)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Stock Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(a)(i)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Stock Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(a)(i)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orca Termination Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5(c)(i)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Orders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.9</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Organizational Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4(ii)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Owned Real Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.19(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Permitted Liens</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Person</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.8(b)(i)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Personal Data</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.15(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Proceedings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.9</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Processing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.15(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Proxy Statement/Prospectus</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Real Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.19(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Registrar</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.3(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Registration Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Regulatory Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Relevant Benefit Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.13</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Representatives</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.5</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Safety Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.25(e)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Scheme Counsel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Defined Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Section</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Scheme Directions Order</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Scheme Effective Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">SDRT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">SEC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IV</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Second Contribution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.9</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Securities Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(c)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Self-Regulatory Organization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.8(b)(i)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Severance Pay</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Share Portion</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.4(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Significant Customer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Significant Supplier</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1(b)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Stock Price Hurdle</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(a)(iv)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Strikes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.12(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Subsidiary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Superior Proposal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2(d)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Tax</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.11(k)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Tax Return</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.11(k)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Taxable</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.11(k)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Taxation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.11(k)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Termination Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Timetable</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Topco</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preamble</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Topco Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(c)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Topco Bylaws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Topco Charter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Topco Group</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Topco Restricted Stock Right</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(a)(iii)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Topco Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recitals</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Topco Stock Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(a)(ii)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Topco Stock Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6(a)(i)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Trade Control Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.24(c)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Trade Sanctions Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.24(c)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Transfer Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.8(c)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">U.S. Holdco Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preamble</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">U.S. Holdco Sub 2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preamble</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">U.S. Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preamble</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">UK Scheme Regulations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recitals</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Voting Record Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3(a)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">willful and material breach</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5(a)</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="exind273090_1"></A>Exhibit D to the BCA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> C<SMALL>ERTIFICATE</SMALL> <SMALL>OF</SMALL> I<SMALL>NCORPORATION</SMALL>
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><SMALL>OF</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ORONADO</SMALL> T<SMALL>OPCO</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Coronado Topco, Inc. (the &#147;<U>Corporation</U>&#148;), a corporation organized and existing under and by virtue of the General Corporation
Law of the State of Delaware, does hereby certify: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FIRST: The name of the Corporation is Coronado Topco, Inc. and the date of filing of
the original Certificate of Incorporation of the Corporation with the Secretary of State of Delaware is December 17, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECOND: The
Certificate of Incorporation of the Corporation is hereby amended and restated as hereinafter set forth, and which is entitled Amended and Restated Certificate of Incorporation of Coronado Topco, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIRD: This amendment and restatement of the Corporation&#146;s Certificate of Incorporation, has been duly adopted in accordance with the
provisions of Sections 242 and 245 of the General Corporation Law of the State of Delaware (&#147;<U>DGCL</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOURTH: The
Certificate of Incorporation of the Corporation, as amended and restated herein, shall, at the effective time of this Amended and Restated Certificate of Incorporation, read as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL>&nbsp;&amp; R<SMALL>ESTATED</SMALL> C<SMALL>ERTIFICATE</SMALL>
<SMALL>OF</SMALL> I<SMALL>NCORPORATION</SMALL> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><SMALL>OF</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ORONADO</SMALL> T<SMALL>OPCO</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The name of the Corporation is Coronado Topco, Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address of the Corporation&#146;s registered office in the State of Delaware is Corporation Trust Center,
1209 Orange Street, Wilmington, New Castle County, Delaware 19801. The name of its registered agent at such address is The Corporation Trust Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The nature of the business or purposes to be conducted or promoted by the Corporation is to engage in any
lawful act or activity for which corporations may be organized under the DGCL. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The total number of shares of all classes of stock which the Corporation has authority to issue is [&#9679;]
shares, consisting of [&#9679;] shares of common stock, $0.001 par value per share (the &#147;<U>Common </U><U>Stock</U>&#148;) and [&#9679;] shares of preferred stock, $0.001 par value per share (the &#147;<U>Preferred </U><U>Stock</U>&#148;).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Common Stock.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Voting </I><I>Rights</I>. Except as set forth herein or as otherwise required by law, each outstanding share
of Common Stock shall be entitled to vote on each matter on which the stockholders of the Corporation shall be entitled to vote, and each holder thereof shall be entitled to one vote for each share of such share of Common Stock held by such holder.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Dividends</I>. The Board of Directors of the Corporation (the &#147;<U>Board of Directors</U>&#148;) may
cause dividends to be paid to holders of shares of Common Stock out of funds legally available for the payment of dividends. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Preferred Stock</I>. The Preferred Stock may be issued from time to time in one or more series. The Board of
Directors is authorized, within the limitations and restrictions stated in this Certificate of Incorporation, to determine or alter the rights, preferences, privileges and restrictions granted to or imposed upon any wholly unissued series of
Preferred Stock, and the number of shares constituting any such series and the designation thereof, or any of them; and to increase or decrease the number of shares constituting any such series and the designation thereof, or any of them; and to
increase or decrease the number of shares of any series subsequent to the issue of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be so decreased, the
shares constituting such decrease shall resume the status which they had prior to the adoption of the resolution originally fixing the number of shares of such series. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Corporation is to have perpetual existence. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly
authorized to make, alter, amend or repeal the Bylaws of the Corporation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of directors which constitute the whole Board of Directors shall be as specified in the Bylaws of
the Corporation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws may provide. The
books of the Corporation may be kept (subject to any provision contained in the statutes) outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the Bylaws of the Corporation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Corporation hereby expressly elects not to be governed by Section&nbsp;203 of the DGCL.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the fullest extent permitted by the DGCL as the same exists or as may hereafter be amended, a director of
the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty owed to the Corporation or its stockholders. Neither any amendment nor repeal of this Article 10, nor the
adoption of any provision of this Certificate of Incorporation inconsistent with this Article 10, nor, to the fullest extent permitted by the DGCL, any modification of law shall eliminate, reduce or otherwise adversely affect any right or protection
of a current or former director of the Corporation existing at the time of such amendment, repeal, adoption or modification. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Advance notice of new business and stockholder nominations for the election of directors shall be given in the
manner and to the extent provided in the Bylaws of the Corporation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Corporation reserves the right to amend, alter, change or repeal any provision contained in this
Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon stockholders herein are granted subject to this reservation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Corporation has caused this Amended and Restated Certificate of Incorporation to be
signed by [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], its [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] as of this &nbsp;&nbsp;&nbsp;&nbsp;
day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:&nbsp;&nbsp;&nbsp;&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
]</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit E to the BCA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL>&nbsp;&amp; R<SMALL>ESTATED</SMALL> B<SMALL>YLAWS</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>F</SMALL> C<SMALL>ORONADO</SMALL> T<SMALL>OPCO</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE OFFICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;1.1 REGISTERED OFFICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the registered office of Coronado Topco, Inc. (the &#147;<B>Corporation</B>&#148;) shall be Corporation Trust Center, 1209
Orange Street, Wilmington, New Castle County, Delaware 19801. The name of the registered agent of the Corporation at such address is The Corporation Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;1.2 OTHER OFFICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may at any time establish other offices at any place or places where the Corporation is qualified to do business. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEETINGS OF
STOCKHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.1 PLACE OF MEETINGS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Meetings of stockholders shall be held at any place, within or outside the State of Delaware, designated by the board of directors of the
Corporation (the &#147;<B>Board of Directors</B>&#148;). In the absence of any such designation, stockholders&#146; meetings shall be held at the principal executive offices of the Corporation. The Board of Directors may determine that a meeting of
stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section&nbsp;211(a)(2) of the Delaware General Corporation Law (the &#147;<B>DGCL</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.2 ANNUAL MEETINGS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The annual meeting of stockholders of the Corporation shall be held each year on a date and at a time designated by the Board of Directors.
The Board of Directors may postpone, reschedule or cancel any annual meeting of stockholders previously scheduled by the Board of Directors. At the meeting, directors shall be elected and any other proper business may be transacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.3 SPECIAL MEETINGS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. A special meeting of the stockholders may be called at any time by (i)&nbsp;the secretary of the Corporation (the
&#147;<B>Secretary</B>&#148;), following the Secretary&#146;s receipt of one or more written demands to call a special meeting of the stockholders in accordance with, and subject to, this Section&nbsp;2.3 from stockholders of record as of the record
date fixed in accordance with Section&nbsp;2.3(e) of these amended and restated bylaws (as amended from time to time in accordance with the provisions hereof, these &#147;<B>Bylaws</B>&#148;) who hold, in the aggregate, not less than fifty percent
(50%) of the voting power of the Corporation&#146;s issued and outstanding capital stock (the &#147;<B>Requisite Percentage</B>&#148;), (ii) the Board of Directors, (iii)&nbsp;the Chairman of the Board (if any) or (iv)&nbsp;the president of the
Corporation (the &#147;<B>President</B>&#148;). Except in accordance with this Section&nbsp;2.3, stockholders shall not be permitted to propose business to be brought before a special meeting of the stockholders. Stockholders who nominate persons
for election to the Board of Directors at a special meeting must also comply with the requirements set forth in Section&nbsp;2.6 of these Bylaws. The Board of Directors may postpone, reschedule or cancel any special meeting of stockholders
previously scheduled by the Board of Directors. The business to be conducted at the special meeting shall be limited to the purpose or purposes stated in the notice of such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Request to Fix Demand Record Date</U>. The Secretary shall not be required to call a special meeting of stockholders pursuant to
Section&nbsp;2.3(a) of these Bylaws unless a stockholder of record shall have first submitted a request in writing that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Board of Directors fix a record date (a &#147;<B>Demand Record Date</B>&#148;) for the purpose of determining the stockholders entitled to demand that the Secretary call such special meeting,
which request shall be in proper written form and delivered personally or sent by registered mail to, and received by, the Secretary at the principal executive offices of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Form of Request</U>. To be in proper written form, a stockholder&#146;s request for the Board of Directors to fix a Demand Record Date
must set forth (i)&nbsp;as to each matter such stockholder or any beneficial owner on whose behalf such business is proposed (each, a &#147;<B>Requesting Party</B>&#148;) proposes to bring before the special meeting, a brief description of the
business desired to be brought before the special meeting and the reasons for conducting such business at the special meeting, (ii)&nbsp;the name and address of each Requesting Party, (iii)(A) the class or series and number of shares of capital
stock of the Corporation that are owned, directly or indirectly, beneficially or of record by each Requesting Party and any Stockholder Associated Person (as defined below) and (B)&nbsp;any derivative positions held or beneficially held by each
Requesting Party and any Stockholder Associated Person and whether and the extent to which any hedging or other transaction or series of transactions has been entered into by or on behalf of, or any other agreement, arrangement or understanding
(including, without limitation, any short position or any borrowing or lending of shares) has been made, the effect or intent of which is to mitigate loss to or manage risk or benefit of share price changes for, or to increase or decrease the voting
power of, any such Requesting Party or any Stockholder Associated Person with respect to shares of the Corporation (which information described in this clause (iii)&nbsp;shall be supplemented by such Requesting Party not later than ten
(10)&nbsp;days after the record date for the meeting to disclose such ownership and other information as of such record date); (iv) a description of all arrangements or understandings between each Requesting Party or any Stockholder Associated
Person and any other person or persons (including their names) in connection with the request for the special meeting or the business proposed to be conducted at the special meeting and any material interest of each Requesting Party and any
Stockholder Associated Person in such business; (v)&nbsp;a representation that such Requesting Party intends to appear in person or by proxy at the special meeting to bring such business before the meeting; (vi)&nbsp;a Business Solicitation
Representation (as defined below) from each Requesting Party; and (vii)&nbsp;any other information relating to each Requesting Party that would be required to be disclosed in a proxy statement or other filings required to be made in connection with
solicitations of proxies for stockholder proposals pursuant to Section&nbsp;14 of the Securities Exchange Act of 1934, as amended (such act, and the rules and regulations promulgated thereunder, the &#147;<B>Exchange Act</B>&#148;) or the rules and
regulations promulgated thereunder (the &#147;<B>Proxy Rules</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Definitions</U>. For purposes of these Bylaws, (i)
&#147;<B>Business Solicitation Representation</B>&#148; shall mean, with respect to any person, a representation as to whether or not such person or any Stockholder Associated Person intends or is part of a group that intends to deliver a proxy
statement and form of proxy to the holders of at least the percentage of the Corporation&#146;s outstanding voting shares required under applicable law to adopt the business proposed by such person or otherwise to solicit proxies from stockholders
in support of such proposed business; and (ii) &#147;<B>Stockholder Associated Person</B>&#148; shall mean, with respect to any person, (A)&nbsp;any person directly or indirectly controlling, controlled by, under common control with or acting in
concert with such person or (B)&nbsp;any member of such person&#146;s immediate family sharing the same household. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Fixing of
Demand Record Date</U>. Within ten (10)&nbsp;days after receipt by the Secretary of a request to fix a Demand Record Date in proper written form and otherwise in compliance with this Section&nbsp;2.3 from any stockholder of record, the Board of
Directors may adopt a resolution fixing a Demand Record Date for the purpose of determining the stockholders entitled to demand that the Secretary call a special meeting, which date shall not precede the date upon which the resolution fixing the
Demand Record Date is adopted by the Board of Directors. If no resolution fixing a Demand Record Date has been adopted by the Board of Directors within the ten <FONT STYLE="white-space:nowrap">(10)-day</FONT> period after the date on which such a
request to fix a Demand Record Date was received by the Secretary, the Demand Record Date in respect thereof shall be deemed to be the twentieth (20th) day after the date on which such a request was received (or, if such twentieth (20th) day is not
a business day, the next business day). Notwithstanding anything in this Section&nbsp;2.3 to the contrary, no Demand Record Date shall be fixed if the Board of Directors determines that the demand or demands that would otherwise be submitted
following such Demand Record Date could not comply with the requirements set forth in clauses (ii), (iv), (v) or (vi)&nbsp;of Section&nbsp;2.3(g) of these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Demand to Call Special Meeting</U>. In no event shall a special meeting of the stockholders be called pursuant to Section&nbsp;2.3(a)
of these Bylaws unless stockholders of record as of the Demand Record Date who hold the Requisite Percentage timely provide one or more demands to call such special meeting in writing and in proper written form to the Secretary at the principal
executive offices of the Corporation. Only stockholders of record on the Demand Record Date shall be entitled to demand that the Secretary call a special meeting of the stockholders pursuant to Section&nbsp;2.3(a) of these Bylaws. To be timely, a
stockholder&#146;s demand to call a special meeting must be delivered personally or sent by registered mail to, and received by, the Secretary at the principal executive offices of the Corporation not later than the thirtieth&nbsp;(30th) day
following the Demand Record Date. To be in proper form for purposes of this Section&nbsp;2.3, a demand to call a special meeting shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in writing and set forth (i)&nbsp;the business proposed to be conducted at the special meeting, (ii)&nbsp;the text of the proposal or business (including the text of any resolutions proposed for
consideration), if applicable, (iii)&nbsp;with respect to any stockholder or stockholders submitting a demand to call a special meeting, the information required to be provided by a Requesting Party pursuant to Section&nbsp;2.3(c) of these Bylaws,
and (iv)&nbsp;any other information required by Sections&nbsp;2.5 or 2.6 below, respectively. A stockholder may revoke a demand to call a special meeting by written revocation delivered to the Secretary at any time prior to the special meeting at
the principal executive offices of the Corporation. If any such revocation(s) are received by the Secretary after the Secretary&#146;s receipt of written demands from the holders of the Requisite Percentage of stockholders, and as a result of such
revocation(s), there no longer are unrevoked demands from the Requisite Percentage of stockholders to call a special meeting, the Board of Directors shall have the discretion to determine whether or not to proceed with the special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Defective Demand</U>. The Secretary shall not accept, and shall consider ineffective, a written demand from a stockholder to call a
special meeting (i)&nbsp;that does not comply with this Section&nbsp;2.3, (ii) that relates to an item of business to be transacted at such meeting that is not a proper subject for stockholder action under applicable law, (iii)&nbsp;that includes an
item of business to be transacted at such meeting that did not appear on the written request that resulted in the determination of the Demand Record Date, (iv)&nbsp;that relates to an item of business (other than the election of directors) that is
identical or substantially similar to an item of business (a &#147;<B>Similar Item</B>&#148;) for which a record date for notice of a stockholder meeting (other than the Demand Record Date) was previously fixed and such demand is delivered between
the time beginning on the sixty-first (61st) day after such previous record date and ending on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of such previous record date, (v)&nbsp;if a Similar Item will be submitted for
stockholder approval at any stockholder meeting to be held on or before the ninetieth (90th) day after the Secretary receives such demand, or (vi)&nbsp;if a Similar Item has been presented at the most recent annual meeting or at any special meeting
held within one year prior to receipt by the Secretary of such demand to call a special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Calling of Special Meeting</U>.
Notwithstanding anything in these Bylaws to the contrary, the Secretary shall not be required to call a special meeting pursuant to this Section&nbsp;2.3 except in accordance with this Section&nbsp;2.3. If the Board of Directors shall determine that
any request to fix a record date for notice and voting for the special meeting or demand to call and hold a special meeting was not properly made in accordance with this Section&nbsp;2.3, or shall determine that the stockholder or stockholders
requesting that the Board of Directors fix such record date or submitting a demand to call the special meeting have not otherwise complied with this Section&nbsp;2.3, then the Board of Directors shall not be required to fix such record date or to
call and hold the special meeting. Subject to Section&nbsp;2.3(f) of these Bylaws, after receipt of demands in proper written form and in accordance with this Section&nbsp;2.3 from a stockholder or stockholders of record holding the Requisite
Percentage, the Board of Directors shall duly call, and determine the date, time and place of, a special meeting of stockholders for the purpose or purposes, and to conduct the business, specified in the demands received by the Corporation.
Notwithstanding anything in these Bylaws to the contrary, the Board of Directors may submit its own proposal or proposals for consideration at such a special meeting. The record date for notice and voting for such a special meeting shall be fixed in
accordance with Section&nbsp;2.14 of these Bylaws. The Board of Directors shall provide written notice of such special meeting to the stockholders in accordance with Section&nbsp;2.4 of these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Exchange Act</U>. Notwithstanding the provisions of this Section&nbsp;2.3, a stockholder shall also comply with all applicable
requirements of the Exchange Act with respect to any request to fix a record date for notice and voting for the special meeting or demand to call a special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.4 NOTICE OF STOCKHOLDERS&#146; MEETINGS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Timing and Content</U>. Whenever stockholders are required or permitted to take any action at a meeting, notice of the meeting shall be
given which shall state the place, if any, date and time of the meeting, the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice
of meeting, the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is
called. Notice of any meeting shall be given not less than ten (10)&nbsp;nor more than sixty (60)&nbsp;days before the date of the meeting, by or at the direction of the Board of Directors, the Chairman of the Board, the President or the Secretary,
to each stockholder entitled to vote at such meeting as of the record date for determining stockholders entitled to notice of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Notice in Writing</U>. Unless otherwise required by law, notice may be given in writing directed to a stockholder&#146;s mailing
address as it appears on the records of the Corporation and shall be given (i)&nbsp;if mailed, when deposited in the United States mail, postage prepaid, and (ii)&nbsp;if delivered by courier service, the earlier of when the notice is received or
left at such stockholder&#146;s address. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Notice by Other Methods</U>. So long as the Corporation is subject to the Proxy
Rules, notice shall be given in the manner required by such rules. To the extent permitted by the Proxy Rules, notice may be given by electronic transmission directed to the stockholder&#146;s electronic mail address and if so given, shall be given
when directed to such stockholder&#146;s electronic mail address unless the stockholder has notified the Corporation in writing or by electronic transmission of an objection to receiving notice by electronic mail or such notice is prohibited by
Section&nbsp;232(e) of the DGCL. If notice is given by electronic mail, such notice shall comply with the applicable provisions of Sections 232(a) and 232(d) of the DGCL. Notice may be given by other means of electronic transmission with the consent
of a stockholder in the manner permitted by Section&nbsp;232(b) of the DGCL, and such notice shall be deemed given as provided therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.5 NATURE OF BUSINESS AT ANNUAL MEETINGS OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. No business may be transacted at an annual meeting of stockholders, other than business that is either (i)&nbsp;specified
in the Corporation&#146;s proxy materials with respect to such meeting given by or at the direction of the Board of Directors (or any duly authorized committee thereof), (ii) otherwise properly brought before the annual meeting by or at the
direction of the Board of Directors (or any duly authorized committee thereof) or (iii)&nbsp;otherwise properly brought before the annual meeting by any stockholder (A)&nbsp;who is a stockholder of record on the date of the giving of the notice
provided for in this Section&nbsp;2.5 and on the record date for the determination of stockholders entitled to notice of and to vote at such annual meeting, (B)&nbsp;who is entitled to vote at such annual meeting and (C)&nbsp;who complies with the
procedures set forth in this Section&nbsp;2.5. In addition to the other requirements set forth in this Section&nbsp;2.5, a stockholder may not transact any business at an annual meeting unless (1)&nbsp;such stockholder and any beneficial owner on
whose behalf such business is proposed (each, a &#147;<B>Proposing Party</B>&#148;) acted in a manner consistent with the representation made in the Business Solicitation Representation delivered as set forth in Section&nbsp;2.5(d) and (2)&nbsp;such
business is a proper matter for stockholder action under the DGCL. For the avoidance of doubt, the foregoing clause (iii)&nbsp;shall be the exclusive means for a stockholder to propose business (other than business included in the Corporation&#146;s
proxy materials pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act) at an annual meeting of stockholders. Stockholders who nominate persons for election to the Board of Directors at an annual meeting must also
comply with the requirements set forth in Section&nbsp;2.6 of these Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Timing of Notice</U>. In addition to any other
applicable requirements, for business to be properly brought before an annual meeting by a stockholder, such stockholder must have given timely notice thereof in proper written form to the Secretary. To be timely, a stockholder&#146;s notice must be
received by the Secretary at the principal executive offices of the Corporation not less than ninety (90)&nbsp;days nor more than one hundred twenty (120)&nbsp;days prior to the first anniversary of the preceding year&#146;s annual meeting of
stockholders; <U>provided</U>, <U>however</U>, that in the event that the annual meeting is convened more than thirty (30)&nbsp;days before or more than sixty (60)&nbsp;days after such anniversary date, or if no annual meeting was held in the
preceding year, notice by the stockholder to be timely must be so received no more than one hundred twenty (120)&nbsp;days prior to such annual meeting nor less than the later of (i)&nbsp;ninety (90) days prior to such annual meeting and
(ii)&nbsp;ten (10) days after the day on which public disclosure of the date of the meeting is first made by the Corporation. For purposes of these Bylaws, &#147;<B>public disclosure</B>&#148; shall mean disclosure in a press release reported by the
Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section&nbsp;13, 14 or 15(d) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>No Effect of Adjournment and Postponement</U>. In no event shall an adjournment of an annual meeting, or a postponement of an annual
meeting for which notice has been given, or the public disclosure thereof, commence a new time period for the giving of a stockholder&#146;s notice as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Form of Notice</U>. To be in proper written form, a stockholder&#146;s notice to the Secretary must set forth (i)&nbsp;as to each
matter each Proposing Party proposes to bring before the annual meeting, a brief description of the business desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting; (ii)&nbsp;the name and
address of each Proposing Party; (iii)(A) the class or series and number of shares of capital stock of the Corporation that are owned, directly or indirectly, beneficially or of record by each Proposing Party and any Stockholder Associated Person
and (B)&nbsp;any derivative positions held or beneficially held by each Proposing Party and any Stockholder Associated Person and whether and the extent to which any hedging or other transaction or series of transactions has been entered into by or
on behalf of, or any other agreement, arrangement or understanding (including, without limitation, any short position or any borrowing or lending of shares) has been made, the effect or intent of which is to mitigate loss to or manage risk or
benefit of share price changes for, or to increase or decrease the voting power of, any such Proposing Party or any Stockholder Associated Person with respect to shares of the Corporation (which information described in this clause (iii)&nbsp;shall
be supplemented by such Proposing Party not later than ten (10)&nbsp;days after the record date for the meeting to disclose such ownership and other information as of such record date); (iv) a description of all arrangements or understandings
between each Proposing Party or any Stockholder Associated Person and any other person or persons (including their names) in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with the proposal of such business by such Proposing Party and any material interest of each Proposing Party or any Stockholder Associated Person in such business; (v)&nbsp;a
representation that such Proposing Party intends to appear in person or by proxy at the annual meeting to bring such business before the meeting; (vi)&nbsp;a Business Solicitation Representation from each Proposing Party; and (vii)&nbsp;any other
information relating to each Proposing Party that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for stockholder proposals pursuant to the Proxy Rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Improper Business</U>. No business shall be conducted at the annual meeting of stockholders of the Corporation except business brought
before the annual meeting in accordance with the procedures set forth in these Bylaws, including this Section&nbsp;2.5. If the Chairman of the Board, the Board of Directors or the chairperson of an annual meeting determines that business was not
properly proposed in accordance with such procedures, such business shall not be transacted. Notwithstanding the foregoing provisions of this Section&nbsp;2.5, unless otherwise required by law, if the stockholder (or a qualified representative of
the stockholder) does not appear at the annual meeting of stockholders of the Corporation to propose business, such proposed business shall not be transacted, notwithstanding that proxies in respect of such business may have been received by the
Corporation. For purposes of this Section&nbsp;2.5, to be considered a qualified representative of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by
such stockholder to act for such stockholder as proxy at the meeting of stockholders, and such person must produce such writing, or a reliable reproduction thereof, at the meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Exchange Act</U>. Notwithstanding the provisions of this Section&nbsp;2.5, a stockholder shall also comply with all applicable
requirements of the Exchange Act with respect to the proposal of business to be transacted at the annual meeting of stockholders. Nothing in this Section&nbsp;2.5 shall be deemed to affect any right of (i)&nbsp;the Corporation to omit a proposal
from the Corporation&#146;s proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act or (ii)&nbsp;stockholders to request inclusion of proposals in the Corporation&#146;s proxy statement pursuant to Rule <FONT
STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.6 NOMINATION OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. Only persons who are nominated in accordance with the procedures set forth in this Section&nbsp;2.6 shall be eligible for
election as directors of the Corporation, except as may be otherwise provided in the certificate of incorporation of the Corporation (as amended and restated from time to time, the &#147;<B>Certificate of Incorporation</B>&#148;), including, without
limitation, the terms of any certificate of designation with respect to any series of preferred stock with respect to the right, if any, of holders of preferred stock of the Corporation to nominate and elect a specified number of directors in
certain circumstances and except as may otherwise be provided in the Proxy Rules; <U>provided</U>, that, the advance notice requirements for nominations for the election of directors in these Bylaws shall not apply to the nominations of directors by
Carlyle Partners VI Cayman Holdings (the &#147;<B>Specified Stockholder</B>&#148;) pursuant to and in accordance with the terms and conditions of the Principal Stockholders Agreement, dated as of December&nbsp;22, 2021, by and among the Corporation,
Quidel Corporation, Ortho Clinical Diagnostics Holdings plc and the Specified Stockholder. Nominations of persons for election to the Board of Directors may be made at any annual meeting of stockholders, or at any special meeting of stockholders
called for the purpose of electing directors, (i)&nbsp;by or at the direction of the Board of Directors (or any duly authorized committee thereof) or (ii)&nbsp;by any stockholder (A)&nbsp;who is a stockholder of record on the date of the giving of
the notice provided for in this Section&nbsp;2.6 and on the record date for the determination of stockholders entitled to notice of and to vote at such meeting, (B)&nbsp;who is entitled to vote at such meeting and (C)&nbsp;who complies with the
procedures set forth in this Section&nbsp;2.6. In addition to the other requirements set forth in this Section&nbsp;2.6, a stockholder may not present a nominee for election at an annual or special meeting unless such stockholder, and any beneficial
owner on whose behalf such nomination is made, acted in a manner consistent with the representation made in the Nominee Solicitation Representation (as defined below) delivered as set forth in Section&nbsp;2.6 (d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Nominee Information</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;To be eligible to be a nominee for election or <FONT STYLE="white-space:nowrap">re-election</FONT> as a director of the Corporation,
a person must deliver to the Secretary at the principal executive offices of the Corporation the following information: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) a written
representation and agreement, which shall be signed by such person and pursuant to which such person shall represent and agree that such person (1)&nbsp;consents to serving as a director if elected and to being named in the Corporation&#146;s proxy
statement and form of proxy as a nominee, and currently intends to serve as a director for the full term for which such person is standing for election; (2)&nbsp;is not and will not become a party to any agreement, arrangement or understanding with,
and has not given any commitment or assurance to, any person as to how the person, if elected as a director, will act or vote on any issue or question that has not been disclosed to the Corporation, or that could limit or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interfere with the person&#146;s ability to comply, if elected as a director, with such person&#146;s fiduciary duties under applicable law; (3)&nbsp;is not and will not become a party to any
agreement, arrangement or understanding with any person other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director or nominee that has not been
disclosed to the Corporation; and (4)&nbsp;if elected as a director, will comply with all of the Corporation&#146;s corporate governance, conflict of interest, confidentiality, and stock ownership and trading policies and guidelines, and any other
Corporation policies and guidelines applicable to directors (which will be promptly provided following a request therefor); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) all
questionnaires prepared by the Corporation, completed and signed (including those questionnaires required of the Corporation&#146;s directors and any other questionnaire the Corporation determines is necessary or advisable to assess whether a
nominee will satisfy any qualifications or requirements imposed by the Certificate of Incorporation or these Bylaws, any law, rule, regulation or listing standard that may be applicable to the Corporation, and the Corporation&#146;s corporate
governance policies and guidelines) (all of the foregoing, &#147;<B>Questionnaires</B>&#148;). The Questionnaires shall be promptly provided following a request therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;such other information as the Corporation may reasonably request. The Corporation may request such additional information as
necessary to permit the Corporation to determine the eligibility of such person to serve as a director of the Corporation, including information relevant to a determination whether such person can be considered an independent director. Such
information shall be considered timely if provided to the Corporation within five&nbsp;(5) business days after a request therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)
In the case of a nominee proposed pursuant to Section&nbsp;2.3 or this Section&nbsp;2.6, the Questionnaires described in Section&nbsp;(b)(i)(B) shall be considered timely if provided to the Corporation by the deadlines specified in these Bylaws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All information provided pursuant to this Section&nbsp;2.6 shall be deemed part of a stockholder&#146;s demand under Section&nbsp;2.3(f) or a
stockholder&#146;s notice submitted pursuant to this Section&nbsp;2.6, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Timing of Notice</U>. In addition to any
other applicable requirements, for a nomination to be made by a stockholder, such stockholder must have given timely notice thereof in proper written form to the Secretary. To be timely, a stockholder&#146;s notice must be received by the Secretary
at the principal executive offices of the Corporation (i)&nbsp;in the case of an annual meeting of stockholders, not less than ninety (90)&nbsp;days nor more than one hundred twenty (120)&nbsp;days prior to the first anniversary of the preceding
year&#146;s annual meeting; <U>provided</U>, <U>however</U>, that in the event that the annual meeting is convened more than thirty (30)&nbsp;days before or more than sixty (60)&nbsp;days after such anniversary date, or if no annual meeting was held
in the preceding year, notice by the stockholder to be timely must be so received no more than one hundred twenty (120)&nbsp;days prior to such annual meeting nor less than the later of (A)&nbsp;ninety (90) days prior to such annual meeting and
(B)&nbsp;ten (10) days after the day on which public disclosure of the date of the meeting is first made by the Corporation; and (ii)&nbsp;in the case of a special meeting of stockholders called for the purpose of electing directors, no more than
one hundred twenty (120)&nbsp;days before such special meeting nor less than the later of (A)&nbsp;ninety (90) days prior to such special meeting and (B)&nbsp;ten (10)&nbsp;days after the day on which public disclosure of the date of the special
meeting is first made by the Corporation. In no event shall an adjournment of an annual or special meeting, or a postponement of such a meeting for which notice has been given, or the public disclosure thereof, commence a new time period for the
giving of a stockholder&#146;s notice as described above. Notwithstanding the foregoing, in the event that the number of directors to be elected to the Board of Directors at the annual meeting is increased effective after the time period for which
nominations would otherwise be due under this Section&nbsp;2.6 and there is no public announcement by the Corporation naming the nominees for the additional directorships at least one hundred (100)&nbsp;days prior to the first anniversary of the
preceding year&#146;s annual meeting, a stockholder&#146;s notice required by this Section&nbsp;2.6 shall also be considered timely, but only with respect to nominees for the additional directorships, if it shall be delivered to the Secretary at the
principal executive offices of the Corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Form of Notice</U>. To be in proper written form, a stockholder&#146;s notice to the Secretary must set forth (i)&nbsp;as to each
person whom the stockholder proposes to nominate for election as a director (A)&nbsp;the name, age, business address and residence address of such person; (B)&nbsp;the principal occupation or employment of such person; (C)&nbsp;the class or series
and number of shares of capital stock (if any) of the Corporation that are owned, directly or indirectly, beneficially or of record by such person; (D)&nbsp;the information required to be submitted by nominees pursuant to Section&nbsp;2.6(b)(i)
above; <U>provided</U>, <U>however</U>, that the Questionnaires described in Section&nbsp;2.6(b)(i)(B) above may be provided within the time period for delivery of a stockholder&#146;s notice under this Section&nbsp;2.6; and (E)&nbsp;any other
information relating to such person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
election of directors in an election contest, or is otherwise required, pursuant to the Proxy Rules; and (ii)&nbsp;as to the stockholder giving the notice and the beneficial owner, if any, on
whose behalf such nomination is made (each, a &#147;<B>Nominating Party</B>&#148;) (A) the name and address of each Nominating Party; (B)(1) the class or series and number of shares of capital stock of the Corporation that are owned, directly or
indirectly, beneficially or of record by each Nominating Party and any Stockholder Associated Person and (2)&nbsp;any derivative positions held or beneficially held by each Nominating Party and any Stockholder Associated Person and whether and the
extent to which any hedging or other transaction or series of transactions has been entered into by or on behalf of, or any other agreement, arrangement or understanding (including, without limitation, any short position or any borrowing or lending
of shares) has been made, the effect or intent of which is to mitigate loss to or manage risk or benefit of share price changes for, or to increase or decrease the voting power of, any such Nominating Party or any Stockholder Associated Person with
respect to shares of the Corporation (which information described in this clause (ii)(B) shall be supplemented by such Nominating Party not later than ten (10)&nbsp;days after the record date for the meeting to disclose such ownership and other
information as of such record date); (C) a description of all arrangements or understandings between each Nominating Party or any Stockholder Associated Person and each proposed nominee or any other person or persons (including their names) pursuant
to which the nomination(s) are to be made; (D)&nbsp;a representation that such Nominating Party intends to appear in person or by proxy at the meeting to nominate the persons named in its notice; (E)&nbsp;a representation (a &#147;<B>Nominee
Solicitation Representation</B>&#148;) as to whether or not such Nominating Party or any Stockholder Associated Person intends or is part of a group that intends to deliver a proxy statement and form of proxy to a number of holders of the
Corporation&#146;s outstanding voting shares reasonably believed by such Nominating Party to be sufficient to elect its nominee or nominees or otherwise to solicit proxies from stockholders in support of such nominee or nominees; and (F)&nbsp;any
other information relating to each Nominating Party that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors pursuant to the Proxy Rules.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Defective Nominations</U>. No person shall be eligible for election as a director of the Corporation unless nominated in
accordance with the procedures set forth in these Bylaws, including this Section&nbsp;2.6. If the Chairman of the Board, the Board of Directors or the chairperson of the meeting determines that a nomination was not made in accordance with such
procedures, such defective nomination shall be disregarded. Notwithstanding the foregoing provisions of this Section&nbsp;2.6, unless otherwise required by law, if the stockholder (or a qualified representative of the stockholder) does not appear at
the annual or special meeting of stockholders of the Corporation to present such stockholder&#146;s nomination, such nomination shall be disregarded, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For
purposes of this Section&nbsp;2.6, to be considered a qualified representative of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder to
act for such stockholder as proxy at the meeting of stockholders, and such person must produce such writing, or a reliable reproduction thereof, at the meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Exchange Act</U>. Notwithstanding the provisions of this Section&nbsp;2.6, a stockholder shall also comply with all applicable
requirements of the Exchange Act with respect to the nomination of directors. Nothing in this Section&nbsp;2.6 shall be deemed to affect any rights of the holders of any series of preferred stock to elect directors as provided in the Certificate of
Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.7 QUORUM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority of the voting power of the Corporation&#146;s capital stock issued and outstanding and entitled to vote thereat,
present in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business except as otherwise provided by law or by the Certificate of Incorporation. Where a separate vote by a class or
series is required, a majority of the voting power of the shares of such class or classes or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to such vote. If a quorum is not present or
represented at any meeting of the stockholders, then either the chairman of the meeting or the stockholders entitled to vote thereat, present in person or represented by proxy, shall have the power to adjourn the meeting from time to time, in the
manner provided in Section&nbsp;2.8 of these Bylaws, until a quorum is present or represented. A quorum, once established, shall not be broken by the withdrawal of enough votes to leave less than a quorum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.8 ADJOURNED MEETING; NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any meeting of stockholders may be adjourned from time to time to reconvene at the same or some other place by holders of a majority of the
voting power of the Corporation&#146;s capital stock issued and outstanding and entitled to vote thereon, present in person or represented by proxy, though less than a quorum, or by any officer entitled to act as chairman or secretary of such
meeting. When a meeting is adjourned to another time or place, if any, unless these Bylaws otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
require, notice need not be given of the adjourned meeting if the time and place, if any, thereof, and the means of remote communications, if any, by which stockholders may be deemed to be
present in person or represented by proxy and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the Corporation may transact any business that might have been transacted at the
original meeting. If the adjournment is for more than thirty (30)&nbsp;days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at such meeting. If, after the adjournment, a new record date for
determination of stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall give notice of the adjourned meeting to each stockholder of record as of the record date so fixed for notice of such adjourned meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.9 CONDUCT OF BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may designate any officer or director of the Corporation to act as chairman of any meeting of stockholders. In the
absence of any such designation, the President shall act as chairman of meetings of stockholders. The Board of Directors may adopt by resolution such rules and regulations for the conduct of any meeting of stockholders as it shall deem appropriate.
Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors, the chairman of any meeting of stockholders shall have the right and authority to convene and (for any or no reason) to recess or adjourn the
meeting, to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairman, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board of
Directors or prescribed by the chairman of the meeting, may include, without limitation, the following: (a)&nbsp;the establishment of an agenda or order of business for the meeting; (b)&nbsp;the determination of when the polls shall open and close
for any given matter to be voted on at the meeting; (c)&nbsp;rules and procedures for maintaining order at the meeting and the safety of those present; (d)&nbsp;limitations on attendance at or participation in the meeting to stockholders of record
of the Corporation, their duly authorized and constituted proxies or such other persons as the chairman of the meeting shall determine; (e)&nbsp;restrictions on entry to the meeting after the time fixed for the commencement thereof; and
(f)&nbsp;limitations on the time allotted to questions or comments by participants. Except to the extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance
with the rules of parliamentary procedure. The Secretary shall act as secretary of the meeting but, in the Secretary&#146;s absence, the chairman of the meeting may appoint any person to act as secretary of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.10 VOTING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Generally</U>. Except as provided in the Certificate of Incorporation, every stockholder having the right to vote shall have one vote
for each share of stock having voting power registered in such stockholder&#146;s name on the books of the Corporation. Such votes may be cast in person or by proxy as provided in Section&nbsp;2.16 of these Bylaws. The Board of Directors, in its
discretion, or the chairman of the meeting, in the chairman&#146;s discretion, may require that any votes cast at such meeting shall be cast by written ballot. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Matters Other Than Election of Directors</U>. Any matter brought before any meeting of stockholders, other than the election of
directors, shall be decided by the affirmative vote of the holders of a majority of the voting power of the Corporation&#146;s capital stock present in person or represented by proxy at the meeting and entitled to vote on such matter, voting as a
single class, unless the matter is one upon which, by express provision of law, the Certificate of Incorporation or these Bylaws, a different vote is required, in which case such express provision shall govern and control the decision of such
matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Election of Directors</U>. Except as otherwise required by law or the Certificate of Incorporation, directors shall be
elected by a plurality of the voting power of the Corporation&#146;s capital stock present in person or represented by proxy at the meeting and entitled to vote on the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.11 VOTING OF STOCK OF CERTAIN HOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of stock of the Corporation standing in the name of another corporation or entity, domestic or foreign, and entitled to vote may be
voted by such officer, agent or proxy as the bylaws or other internal regulations of such corporation or entity may prescribe or, in the absence of such provision, as the board of directors or comparable body of such corporation or entity may
determine. Shares of stock of the Corporation standing in the name of a deceased person, a minor, an incompetent or a debtor in a case under Title 11, United States Code, and entitled to vote may be voted by an administrator, executor, guardian,
conservator, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">debtor-in-possession</FONT></FONT> or trustee, as the case may be, either in person or by proxy, without transfer of such shares into the name of the official or other
person so voting. A stockholder whose shares of stock of the Corporation are pledged shall be entitled to vote such shares, unless on the transfer records of the Corporation such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholder has expressly empowered the pledgee to vote such shares, in which case only the pledgee, or the pledgee&#146;s proxy, may vote such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.12 TREASURY STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of stock of the Corporation belonging to the Corporation, or to another corporation a majority of the shares entitled to vote in the
election of directors of which are held by the Corporation, shall not be voted at any meeting of stockholders of the Corporation and shall not be counted in the total number of outstanding shares for the purpose of determining whether a quorum is
present. Nothing in this Section&nbsp;2.12 shall limit the right of the Corporation to vote shares of stock of the Corporation held by it in a fiduciary capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.13 WAIVER OF NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever notice is required to be given to a stockholder under any provision of the DGCL, the Certificate of Incorporation or these Bylaws, a
written waiver thereof, signed by such stockholder entitled to notice, or a waiver by electronic transmission by such stockholder entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Any
stockholder may waive notice of any meeting before or after the meeting. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the
beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any annual or special meeting of the stockholders need be specified in
any written waiver of notice, or any waiver by electronic transmission, unless so required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.14 RECORD DATE FOR
STOCKHOLDER NOTICE, VOTING AND GIVING CONSENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order that the Corporation may determine the stockholders entitled to notice of any
meeting of stockholders or any adjournment thereof, or entitled to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to
exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date on which the resolution fixing
the record date is adopted and which record date shall not be more than sixty (60)&nbsp;nor less than ten (10)&nbsp;days before the date of such meeting, nor more than sixty (60)&nbsp;days prior to any other action. If the Board of Directors so
fixes a date for any meeting of stockholders or any adjournment thereof, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such
record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board of Directors in accordance with these Bylaws: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of
business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of
Directors adopts the resolution relating thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A determination of stockholders of record entitled to notice of or to vote at a meeting
of stockholders shall apply to any adjournment of the meeting; <U>provided</U>, <U>however</U>, that the Board of Directors may at or after adjournment fix a new record date for the determination of stockholders entitled to vote at the adjourned
meeting, and in such case, shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance with the foregoing
provisions of this Section&nbsp;2.14. Notwithstanding anything to the contrary contained in this Section&nbsp;2.14, the procedures for fixing a Demand Record Date shall be as set forth in Section&nbsp;2.3 of these Bylaws, and the record date for
determining stockholders entitled to express consent to corporate action in writing without a meeting shall be determined in accordance with Section&nbsp;2.15 of these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.15 ACTION BY WRITTEN CONSENT IN LIEU OF A MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. Any action required or permitted to be taken at an annual or special meeting of stockholders may be taken without a
meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, (i)&nbsp;shall be signed by stockholders of record on the record date fixed pursuant to Section&nbsp;2.15(b) below (the
&#147;<B>Written Consent Record Date</B>&#148;) of outstanding shares of the Corporation having not less than the minimum number of votes that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and (ii)&nbsp;shall be delivered personally or sent by
registered mail to, and received by, the Secretary at the principal executive offices of the Corporation. Every written consent shall bear the date of the signature of each stockholder who signs the consent, and no written consent shall be effective
to take corporate action unless, within sixty (60)&nbsp;days of the earliest dated valid consent delivered in the manner described in this Section&nbsp;2.15, written consents signed by a sufficient number of holders to take such action are delivered
to the Corporation in the manner described in this Section&nbsp;2.15. Only stockholders of record on the Written Consent Record Date shall be entitled to consent to corporate action in writing without a meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Request to Fix Written Consent Record Date</U>. Any stockholder of record seeking to have the stockholders of the Corporation authorize
or take any action by written consent shall first request in writing that the Board of Directors fix a record date for the purpose of determining the stockholders entitled to authorize or take such action, which request shall be in proper form and
delivered personally or sent by registered mail, and received by, the Secretary at the principal executive offices of the Corporation. Within ten (10)&nbsp;days after receipt by the Secretary of a request in proper form and otherwise in compliance
with this Section&nbsp;2.15(b) from any such stockholder, the Board of Directors may adopt a resolution fixing a record date for the purpose of determining the stockholders entitled to express consent to corporate action in writing without a
meeting, which date shall not be more than ten (10)&nbsp;days after the date upon which the resolution fixing such record date is adopted by the Board of Directors. If no resolution fixing a record date has been adopted by the Board of Directors
within such ten <FONT STYLE="white-space:nowrap">(10)-day</FONT> period after the date on which such a request is received by the Secretary, the record date for determining stockholders entitled to express consent to such action, (i)&nbsp;when no
prior action of the Board of Directors is required by applicable law, shall be as of the close of business on the first day on which a valid signed written consent setting forth the action taken or proposed to be taken is delivered to the
Corporation in the manner described in this Section&nbsp;2.15 and (ii)&nbsp;when prior action of the Board of Directors is required by applicable law, shall be as of the close of business on the day on which the Board of Directors adopts the
resolution taking such prior action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Form of Request</U>. To be in proper written form, a stockholder&#146;s request for the Board
of Directors to fix a Written Consent Record Date must set forth (i)&nbsp;as to each action such stockholder and any beneficial owner on whose behalf such action is proposed to be taken by written consent (each, a &#147;<B>Soliciting
Party</B>&#148;), a brief description of the action desired to be taken by written consent (including the text of any proposal, the text of any resolutions to be effected by consent and the language of any proposed amendment to these Bylaws) and the
reasons for taking such action; (ii)&nbsp;the name and address of each Soliciting Party; (iii)(A) the class or series and number of shares of capital stock of the Corporation that are owned, directly or indirectly, beneficially or of record by each
Soliciting Party and any Stockholder Associated Person and (B)&nbsp;any derivative positions held or beneficially held by each Soliciting Party and any Stockholder Associated Person and whether and the extent to which any hedging or other
transaction or series of transactions has been entered into by or on behalf of, or any other agreement, arrangement or understanding (including, without limitation, any short position or any borrowing or lending of shares) has been made, the effect
or intent of which is to mitigate loss to or manage risk or benefit of share price changes for, or to increase or decrease the voting power of, any such Soliciting Party or any Stockholder Associated Person with respect to shares of the Corporation
(which information described in this clause (iii)&nbsp;shall be supplemented by such Soliciting Party not later than ten (10)&nbsp;days after the Written Consent Record Date to disclose such ownership and other information as of the Written Consent
Record Date); (iv) a description of all arrangements or understandings between each Soliciting Party or any Stockholder Associated Person and any other person or persons (including their names) in connection with the action proposed to be taken by
written consent and any material interest of each Soliciting Party and any Stockholder Associated Person in such action; (v)&nbsp;any other information that would be required under Section&nbsp;2.5(d) or Section&nbsp;2.6(d) of these Bylaws if such
Soliciting Party had proposed to take action at a stockholder meeting rather than by written consent; (vi)&nbsp;a representation as to whether or not such Soliciting Party or any Stockholder Associated Person intends or is part of a group that
intends to solicit, or participate in the solicitation of, proxies or written consents from the holders of at least the percentage of the Corporation&#146;s outstanding voting shares required under applicable law to take action by written consent or
otherwise to solicit written consents from stockholders in support of such proposal; and (vii)&nbsp;any other information relating to each Soliciting Party that would be required to be disclosed in an information statement or other filings required
to be made in connection with solicitations of consents pursuant to the Proxy Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Deficient Request; Notice to
Stockholders</U>. Notwithstanding anything in these Bylaws to the contrary, no action may be taken by the stockholders by written consent except in accordance with this Section&nbsp;2.15. If the Board of Directors shall determine that any request to
fix a Written Consent Record Date or to take stockholder action by written consent was not properly made in accordance with this Section&nbsp;2.15, or the stockholder or stockholders seeking to take such action do not otherwise comply with this
Section&nbsp;2.15, then the Board of Directors shall not be required to fix a Written Consent Record Date and any such purported action by written consent shall be null and void to the fullest extent permitted by applicable law.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prompt notice of the taking of corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing and who, if the
action had been taken at a meeting, would have been entitled to notice of the meeting if the record date for notice of such meeting had been the date on which written consents signed by a sufficient number of stockholders to take the action were
delivered to the Secretary as provided in this Section&nbsp;2.15. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exchange Act</U>. Notwithstanding the provisions of this
Section&nbsp;2.15, a stockholder shall also comply with all applicable requirements of the Exchange Act with respect to stockholders seeking to take action by written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.16 PROXIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each stockholder entitled to vote at a meeting of stockholders or to express consent to corporate action in writing without a meeting, or such
stockholder&#146;s authorized officer, director, employee or agent, may execute a document authorizing another person or persons to act for such stockholder as proxy, but no such proxy shall be voted or acted upon after three (3)&nbsp;years from its
date, unless the proxy provides for a longer period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.17 LIST OF STOCKHOLDERS ENTITLED TO VOTE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation shall prepare, at least ten (10)&nbsp;days before every meeting of stockholders, a complete list of the stockholders entitled
to vote at such meeting; <U>provided</U>, <U>however</U>, that if the record date for determining the stockholders entitled to vote is less than ten&nbsp;(10) days before the meeting date, the list shall reflect the stockholders entitled to vote as
of the tenth (10th) day before the meeting date, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Nothing in this Section&nbsp;2.17 shall require the
Corporation to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder for any purpose germane to the meeting for a period of at least ten (10)&nbsp;days
prior to the meeting, either (a)&nbsp;during ordinary business hours at the principal executive offices of the Corporation or (b)&nbsp;on a reasonably accessible electronic network, provided that the information required to gain access to such list
is provided with the notice of the meeting. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders
of the Corporation. If the meeting is to be held at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting is to be
held solely by means of remote communication, then the list shall also be open to examination by any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to gain access to such
list shall be provided with the notice of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.18 INSPECTORS OF ELECTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In advance of any meeting of stockholders, the Board of Directors, by resolution, the Chairman of the Board or the President shall appoint one
or more inspectors to act at the meeting and make a written report thereof. One or more other persons may be designated as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of
stockholders, the chairman of the meeting shall appoint one or more inspectors to act at the meeting. Unless otherwise required by applicable law, inspectors may be officers, employees or agents of the Corporation. Each inspector, before entering
upon the discharge of the duties of inspector, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of such inspector&#146;s ability. The inspector shall have the duties
prescribed by law and shall take charge of the polls and, when the vote is completed, shall make a certificate of the result of the vote taken and of such other facts as may be required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.19 DELIVERY TO THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever this Article&nbsp;II requires one or more persons (including a record or beneficial owner of stock) to deliver a document or
information to the Corporation or any officer, employee or agent thereof (including any notice, request, questionnaire, revocation, representation or other document or agreement), the Corporation shall not be required to accept delivery of such
document or information unless the document or information is in writing exclusively (and not in an electronic transmission) and delivered exclusively by hand (including, without limitation, overnight courier service) or by certified or registered
mail, return receipt requested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.1 POWERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors, which may exercise all such
powers of the Corporation and do all such lawful acts and things as are not by law or by the Certificate of Incorporation required to be exercised or done by the stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.2 NUMBER OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of directors that shall constitute the entire Board of Directors shall not be less than five (5)&nbsp;nor more than fourteen (14).
Within such limit, the number of members of the entire Board of Directors shall be fixed, from time to time, exclusively by the Board of Directors, subject to the rights of the holders of preferred stock with respect to the election of directors, if
any. No reduction of the authorized number of directors shall have the effect of removing any director before that director&#146;s term of office expires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.3 QUALIFICATION AND TERM OF OFFICE OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in Section&nbsp;3.4 of these Bylaws, each director, including a director elected to fill a vacancy, shall hold office until
the next annual meeting of stockholders, and until such director&#146;s successor is elected and qualified or until such director&#146;s earlier death, resignation or removal. Directors need not be stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.4 RESIGNATION, REMOVAL AND VACANCIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Resignation</U>. Any director may resign at any time by giving notice in writing or by electronic transmission to the Chairman of the
Board (if any) or the Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the occurrence of some other event, and, unless otherwise specified in such notice, the acceptance of
such resignation shall not be necessary to make it effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Removal</U>. Any director may be removed from office, with or
without cause, by the affirmative vote of the holders of a majority of the voting power of the Corporation&#146;s capital stock entitled to vote on the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Vacancies</U>. If any vacancy occurs in the Board of Directors or if any new directorship is created by any increase in the number of
directors constituting the Board of Directors, a majority of the directors then in office, although less than a quorum, or a sole remaining director may choose a successor to fill the vacancy or to fill the newly created directorship, and a director
so chosen shall hold office until the next annual meeting of stockholders and until such director&#146;s successor is elected and qualified or until such director&#146;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.5 PLACE OF MEETINGS; MEETINGS BY TELEPHONE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may hold meetings, both regular and special, either within or outside the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Members of the Board of Directors may participate in a meeting of the Board of Directors by means of conference telephone or other
communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.6 REGULAR MEETINGS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regular meetings of the Board of Directors may be held without notice at such time, on such date and at such place as shall from time to time
be determined by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.7 SPECIAL MEETINGS; NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special meetings of the Board of Directors for any purpose or purposes may be called at any time by the Chairman of the Board (if any), the
President, the Secretary or the Board of Directors and shall be held at such time, on such date and at such place as may be specified by the person or persons calling the meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of the time, date and place of special meetings shall be: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) delivered personally by hand or by telephone at least twenty-four (24)&nbsp;hours before the time of the meeting; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) sent by United States first-class mail, postage prepaid at least four (4)&nbsp;days before the date of the meeting; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) sent by nationally recognized overnight courier at least two (2)&nbsp;days before the date of the meeting; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) sent by facsimile at least twenty-four (24)&nbsp;hours before the time of the meeting; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) sent by electronic mail at least twenty-four (24)&nbsp;hours before the time of the meeting, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or on such shorter notice as the person or persons calling such meeting may deem necessary or appropriate in the circumstances, directed to each director at
that director&#146;s address, telephone number, facsimile number or electronic mail address, as the case may be, as shown on the records of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the notice is sent by United States mail or sent by overnight courier, such notice shall be deemed to be given at the time when it is
deposited in the United States mail with first-class postage prepaid or deposited with the overnight courier. Notice by facsimile or electronic mail shall be deemed given when the notice is transmitted. The notice need not specify the place of the
meeting (if the meeting is to be held at the principal executive offices of the Corporation) nor the purpose of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.8 QUORUM; ADJOURNED MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At all meetings of the Board of Directors, a majority of the directors constituting the Board of Directors shall constitute a quorum for the
transaction of business and the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of the Board of Directors. A meeting at which a quorum is initially present may continue to transact business
notwithstanding the withdrawal of directors, if any action taken is approved by at least a majority of the required quorum for that meeting. If a quorum is not present at any meeting of the Board of Directors, then the directors present thereat may
adjourn the meeting from time to time, without notice other than announcement at the meeting of the time and place of the adjourned meeting, until a quorum is present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.9 CONDUCT OF BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Meetings of the Board of Directors shall be presided over by the Chairman of the Board (if any) or, in the absence of the Chairman, by the
President or, in the absence of the President, by a chairman chosen by a majority of the directors present. The chairman of any meeting of the Board of Directors shall determine the order of business and the procedures at the meeting. The Secretary
shall act as secretary of the meeting but, in the Secretary&#146;s absence, the chairman of the meeting may appoint any person to act as secretary of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.10 WAIVER OF NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any director may waive notice of any meeting before or after the meeting. Attendance of a director at a meeting shall constitute a waiver of
notice of such meeting, except when the director attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business
to be transacted at, nor the purpose of, any regular or special meeting of the directors need be specified in any notice or any waiver of notice of such meeting, unless required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.11 BOARD ACTION BY WRITTEN CONSENT WITHOUT A MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any action required or permitted to be taken at any meeting of the Board of Directors may be taken without such a meeting if all members of
the Board of Directors consent thereto in writing or by electronic transmission. After an action is taken, the consent or consents relating thereto shall be filed with the minutes or proceedings of the Board of Directors or committee in the same
paper or electronic form as the minutes are maintained. Any person (whether or not then a director) may provide, whether through instruction to an agent or otherwise, that a consent to action shall be effective at a future time (including a time
determined upon the happening of an event), no later than sixty (60)&nbsp;days after such instruction is given or such provision is made and such consent shall be deemed to have been given at such effective time so long as such person is then a
director and did not revoke the consent prior to such time. Any such consent shall be revocable prior to its becoming effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.12 FEES AND COMPENSATION OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors shall have the authority to fix the compensation of directors. The directors shall be paid their reasonable expenses,
if any, of attendance at each meeting of the Board of Directors or any committee thereof and may be paid a fixed sum for attendance at each such meeting or an annual retainer or salary for service as a director or committee member, payable in cash
or securities. No such payment shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.13 CERTAIN TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No contract or transaction between the Corporation and one or more of its directors or officers, or between the Corporation and any other
corporation, partnership, association or other organization in which one or more of the Corporation&#146;s directors or officers are directors or officers or have a financial interest, shall be void or voidable solely for this reason, or solely
because the director or officer is present at or participates in the meeting of the Board of Directors or committee thereof that authorizes the contract or transaction, or solely because any such director&#146;s or officer&#146;s vote is counted for
such purpose if: (a)&nbsp;the material facts as to the director&#146;s or officer&#146;s relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee and the Board of Directors
or committee in good faith authorizes the contract or transaction by the affirmative vote of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; (b)&nbsp;the material facts as to the
director&#146;s or officer&#146;s relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon and the contract or transaction is specifically approved in good faith by vote
of the stockholders; or (c)&nbsp;the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board of Directors, a committee thereof or the stockholders. Common or interested directors may
be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee that authorizes the contract or transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.14 EMERGENCY BYLAWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Section&nbsp;3.14 shall be operative during any emergency condition as contemplated by Section&nbsp;110 of the DGCL (an
&#147;<B>Emergency</B>&#148;), notwithstanding any different or conflicting provisions in these Bylaws, the Certificate of Incorporation or the DGCL. In the event of any Emergency, or other similar emergency condition, as a result of which a quorum
of the Board of Directors or a standing committee of the Board of Directors cannot readily be convened for action, then the director or directors in attendance at the meeting shall constitute a quorum. Such director or directors in attendance may
further take action to appoint one or more of themselves or other directors to membership on any standing or temporary committees of the Board of Directors as they shall deem necessary and appropriate. Except as the Board of Directors may otherwise
determine, during any Emergency, the Corporation and its directors and officers may exercise any authority and take any action or measure contemplated by Section&nbsp;110 of the DGCL. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMITTEES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;4.1 COMMITTEES OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may from time to time designate one or more committees of the Board of Directors, with each committee to consist of one
or more of the directors of the Corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of such committee. In the absence or
disqualification of a member of a committee, and in the absence of a designation by the Board of Directors of an alternate member to replace the absent or disqualified member, the member or members thereof present at any meeting and not disqualified
from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent
permitted by law and provided in the resolutions of the Board of Directors establishing such committee, as such resolutions may be amended from time to time, shall have and may exercise all the powers and authority of the Board of Directors in the
management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority to (a)&nbsp;amend the Certificate of
Incorporation (except that a committee may, to the extent authorized in the resolution or resolutions providing for the issuance of shares of stock adopted by the Board of Directors as provided in Section&nbsp;151(a) of the DGCL, fix the
designations and any of the preferences or rights of such shares relating to dividends, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
redemption, dissolution, any distribution of assets of the Corporation or the conversion into, or the exchange of such shares for, shares of any other class or classes or any other series of the
same or any other class or classes of stock of the Corporation or fix the number of shares of any series of stock or authorize the increase or decrease of the shares of any series), (b) adopt an agreement of merger or consolidation under
Section&nbsp;251 or 252 of the DGCL, (c)&nbsp;recommend to the stockholders the sale, lease or exchange of all or substantially all of the Corporation&#146;s property and assets, (d)&nbsp;recommend to the stockholders a dissolution of the
Corporation or a revocation of a dissolution, or (e)&nbsp;amend the Bylaws of the Corporation; and, unless the resolutions of the Board of Directors establishing the committee, as such resolutions may be amended from time to time, expressly so
provide, no such committee shall have the power or authority to declare a dividend, to authorize the issuance of stock or to adopt a certificate of ownership and merger pursuant to Section&nbsp;253 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;4.2 COMMITTEE MINUTES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each committee shall keep minutes of its meetings and report to the Board of Directors when required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;4.3 MEETINGS AND ACTIONS OF COMMITTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A majority of any committee may determine its action and fix the date, time and place of its meetings, unless the Board of Directors shall
otherwise provide. Unless the resolutions of the Board of Directors establishing the committee, as such resolutions may be amended from time to time, expressly otherwise provide, the Board of Directors shall have power at any time to fill vacancies
in, to change the membership of or to dissolve any such committee. A majority of the directors then serving on a committee shall constitute a quorum for the transaction of business by the committee except as otherwise required by law, the
Certificate of Incorporation or these Bylaws, and except as otherwise provided in a resolution of the Board of Directors; <U>provided</U>, <U>however</U>, that in no case shall a quorum be less than <FONT STYLE="white-space:nowrap">one-third</FONT>
of the directors then serving on the committee. Unless the Certificate of Incorporation, these Bylaws or a resolution of the Board of Directors requires a greater number, the vote of a majority of the members of a committee present at a meeting at
which a quorum is present shall be the act of the committee. Meetings and actions of committees shall be governed by, and held and taken in accordance with the following provisions of Article III of these Bylaws: Section&nbsp;3.5 (Place of Meetings;
Meetings by Telephone), Section&nbsp;3.6 (Regular Meetings), Section&nbsp;3.7 (Special Meetings; Notice), Section&nbsp;3.8 (With Respect to Adjournment), Section&nbsp;3.9 (Conduct of Business), Section&nbsp;3.10 (Waiver of Notice), and
Section&nbsp;3.11 (Board Action by Written Consent Without a Meeting), with such changes in the context of those Bylaws as are necessary to substitute the committee and its members for the Board of Directors and its members; <U>provided</U>,
<U>however</U>, that the time of regular meetings of committees may also be called by resolution of the Board of Directors and that alternative members of a committee shall be entitled to receive notice of special meetings of such committee and
shall have the right to attend all meetings of such committee. The Board of Directors may adopt rules for the government of any committee not inconsistent with the provisions of these Bylaws. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5.1 OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officers of the Corporation shall be a President (who must be a director), a Secretary and a Chief Financial Officer. The Corporation may
also have at the discretion of the Board of Directors, a Chairman of the Board (who must be a director), one or more vice presidents, a treasurer, one or more assistant secretaries, one or more assistant treasurers, and any such other officers as
may be appointed in accordance with the provisions of Section&nbsp;5.11 of these Bylaws. Any number of offices may be held by the same person. The officers of the Corporation need not be stockholders of the Corporation, nor, except in the case of a
Chairman of the Board and the President, need such officers be directors of the Corporation. The officers of the Corporation shall exercise such powers and perform such duties as shall be determined from time to time by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5.2 ELECTION OF OFFICERS; TERM OF OFFICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officers of the Corporation, except such officers as may be appointed in accordance with the provisions of Section&nbsp;5.11 of these
Bylaws, shall be chosen by the Board of Directors. Each officer of the Corporation shall hold office until such officer&#146;s successor is elected and qualified or until such officer&#146;s earlier death, resignation or removal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5.3 REMOVAL AND RESIGNATION OF OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Removal</U>. Any officer may be removed, either with or without cause, at any time by the Board of Directors or, except in the case of
an officer chosen by the Board of Directors, by any officer upon whom such power of removal may be conferred by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Resignation</U>. Any officer may resign at any time by giving notice in writing or by electronic transmission to the Secretary. Any
resignation shall take effect upon receipt unless it is specified to be effective at some other time or upon the occurrence of some other event, and, unless otherwise specified in such notice, the acceptance of such resignation shall not be
necessary to make it effective. Any resignation or acceptance thereof is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5.4 VACANCIES IN OFFICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any vacancy occurring in any office of the Corporation shall be filled in the manner prescribed in this Article V for the regular election to
such office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5.5 CHAIRMAN OF THE BOARD </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Chairman of the Board, if such an officer be elected, shall, if present, preside at meetings of the Board of Directors and exercise and
perform such other powers and duties as may from time to time be assigned by the Board of Directors or as may be prescribed by these Bylaws. Unless otherwise determined by the Board of Directors, if there is no President, then the Chairman of the
Board shall also be the chief executive officer of the Corporation and shall have the powers and duties prescribed in Section&nbsp;5.6 of these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5.6 PRESIDENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to such supervisory powers, if any, as may be given by the Board of Directors to the Chairman of the Board (if any), the President
shall be the chief executive officer of the Corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and the officers of the Corporation. The President shall preside at
all meetings of the stockholders, unless otherwise designated by the Board of Directors, and, in the absence or nonexistence of a Chairman of the Board, the President shall preside at all meetings of the Board of Directors. The President shall have
the general powers and duties of management usually vested in the office of the president of a Corporation and shall have such other powers and duties as from time to time may be prescribed by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5.7 VICE PRESIDENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The vice presidents shall have such powers and duties as from time to time may be prescribed for them respectively by the Board of Directors,
the President, the Chairman of the Board (if any), or their respective superior officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5.8 SECRETARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Secretary shall give the requisite notice of meetings of stockholders and directors and shall record the proceedings of such meetings,
shall have the custody of the seal of the Corporation and shall affix it or cause it to be affixed to such instruments as require the seal and attest it and, besides the Secretary&#146;s powers and duties prescribed by law, shall have such other
powers and duties as from time to time may be prescribed by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5.9 CHIEF FINANCIAL OFFICER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Chief Financial Officer shall keep and maintain, or cause to be kept and maintained, adequate and correct books and records of accounts of
the properties and business transactions of the Corporation, including accounts of its assets, liabilities, receipts, disbursements, gains, losses, capital, retained earnings and shares. The books of account shall at all reasonable times be open to
inspection by any director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Chief Financial Officer shall deposit all money and other valuables in the name and to the credit of the
Corporation with such depositories as may be designated by the Board of Directors. The Chief Financial Officer shall disburse the funds of the Corporation as may be ordered by the Board of Directors, shall render to the President and directors,
whenever they request it, an account of the financial condition of the Corporation, and shall have such other powers and duties as from time to time may be prescribed by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5.10 ASSISTANT SECRETARIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assistant secretary, or, if there is more than one, the assistant secretaries in the order determined by the Board of Directors (or if
there be no such determination, then in the order of their election) shall assist the Secretary in the discharge of the Secretary&#146;s duties, shall have such other powers and duties as may from time to time may be prescribed by the Board of
Directors and, in the absence or disability of the Secretary or the Secretary&#146;s refusal to act, shall perform the duties of the Secretary&#146;s office, subject to the control of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5.11 OTHER OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may appoint, or empower the President to appoint, such other officers as the business of the Corporation may require,
each of whom shall hold office for such period, have such authority and perform such duties as are provided in these Bylaws or as the Board of Directors may from time to time determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5.12 VOTING SECURITIES OWNED BY THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Powers of attorney, proxies, waivers of notice of meeting, consents and other instruments relating to securities owned by the Corporation
(other than as set forth in Section&nbsp;2.12) may be executed in the name of and on behalf of the Corporation by the President or any other officer authorized to do so by the Board of Directors, and any such officer may, in the name of and on
behalf of the Corporation, take all such action as any such officer may deem advisable to vote in person or by proxy at any meeting of security holders of any such entity in which the Corporation may own securities and at any such meeting shall
possess and may exercise any and all rights and power incident to the ownership of such securities and which, as the owner thereof, the Corporation might have exercised and possessed if present. The Board of Directors may, by resolution, from time
to time confer like powers upon any other person or persons. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.1 THIRD-PARTY ACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to Section&nbsp;6.4 of these Bylaws, the Corporation shall, to the fullest extent permitted by the DGCL as the same exists or may
hereafter be amended, indemnify and hold harmless any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative,
whether internal or external, (a &#147;<B>Proceeding</B>&#148;) (other than an action by or in the right of the Corporation) by reason of the fact that such person is or was a director or officer (as defined in Section&nbsp;6.8, below) of the
Corporation, or while a director or officer of the Corporation is or was serving at the request of the Corporation as a director, officer, employee, agent or trustee of another corporation, partnership, joint venture, trust or other enterprise,
including service with respect to an employee benefit plan, whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee, agent or trustee or in any other capacity while serving as a director,
officer, employee, agent or trustee, from and against expenses (including attorneys&#146; fees), judgments, fines, ERISA excise taxes and amounts paid in settlement actually and reasonably incurred by such person in connection with such Proceeding
if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such
person&#146;s conduct was unlawful. The termination of any Proceeding by judgment, order, settlement, conviction or upon a plea of <I>nolo contendere </I>or its equivalent shall not, of itself, create a presumption that the person did not act in
good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that such person&#146;s
conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.2 ACTIONS BY OR IN THE RIGHT OF THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to Section&nbsp;6.4 of these Bylaws, the Corporation shall, to the fullest extent permitted by the DGCL, indemnify any person who was
or is a party or is threatened to be made a party to any threatened, pending or completed Proceeding by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that such person is or was a director or officer of
the Corporation, or while a director or officer of the Corporation is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against
expenses (including attorneys&#146; fees) actually and reasonably incurred by such person in connection with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the defense or settlement of such Proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation
and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Corporation unless and only to the extent that the Delaware Court of Chancery or the court
in which such action or suit was brought shall have determined upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such
expenses which the Court of Chancery or such other court shall deem proper. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.3 SUCCESSFUL DEFENSE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required by Section&nbsp;145(c)(1) of the DGCL, a current or former director or officer (as defined therein) of the Corporation
who has been successful on the merits or otherwise in defense of any Proceeding referred to in Section&nbsp;6.1 or Section&nbsp;6.2 of these Bylaws, or in defense of any claim, issue or matter therein, shall be indemnified under this
Section&nbsp;6.3 against expenses (including attorneys&#146; fees) actually and reasonably incurred by such person in connection therewith. Any other person who is or was an officer of the Corporation, as defined in Section&nbsp;6.8, shall also be
entitled to such indemnification. Indemnification under this Section&nbsp;6.3 shall not be subject to satisfaction of a standard of conduct, and the Corporation may not assert the failure to satisfy a standard of conduct as a basis to deny
indemnification or recover amounts advanced, including in a suit brought pursuant to Section&nbsp;6.11 (notwithstanding anything to the contrary therein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.4 DETERMINATION OF CONDUCT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any indemnification (unless ordered by a court or required by Section&nbsp;6.3) shall be made by the Corporation only as authorized in the
specific case upon a determination that indemnification of the director or officer is proper in the circumstances because such person has met the applicable standard of conduct set forth in Section&nbsp;6.1 or Section&nbsp;6.2 of these Bylaws. Such
determination shall be made (a)&nbsp;by a majority vote of the Disinterested Directors (as defined below), whether or not such majority constitutes a quorum, (b)&nbsp;if there are no Disinterested Directors, or if the Disinterested Directors so
direct, by independent legal counsel in a written opinion or (c)&nbsp;by the stockholders (but only if a majority of the Disinterested Directors, if they constitute a quorum of the Board of Directors, presents the matter to the stockholders for
their determination). Notwithstanding the foregoing, a director or officer of the Corporation shall be able to contest any determination that such person has not met the applicable standard of conduct set forth in Section&nbsp;6.1 or
Section&nbsp;6.2 of these Bylaws by petitioning a court of appropriate jurisdiction. <I></I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.5 PAYMENT OF EXPENSES IN
ADVANCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the fullest extent permitted by the DGCL, expenses incurred in defending or settling a Proceeding by any person who may be
entitled to indemnification pursuant to Section&nbsp;6.1 or Section&nbsp;6.2 of these Bylaws shall be paid by the Corporation in advance of the final disposition of such Proceeding upon receipt of an undertaking by or on behalf of the director or
officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Corporation as authorized in this Article VI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.6 INDEMNITY NOT EXCLUSIVE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indemnification and advancement of expenses provided by, or granted pursuant to, this Article VI shall not be deemed exclusive of, nor
deemed to be a limitation of, any other rights to which those seeking indemnification or advancement of expenses may be entitled under the Certificate of Incorporation or any agreement, vote of stockholders or disinterested directors or otherwise.
The Corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advancement of expenses, to the fullest extent not prohibited by the DGCL or
other applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.7 INSURANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the fullest extent permitted by the DGCL, the Corporation shall have the power to purchase and maintain insurance on behalf of any person
who is or was a director or officer of the Corporation against any liability asserted against such person, whether or not the Corporation would have the power to indemnify such person against such liability under the provisions of this Article VI.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.8 DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Article VI, references to (a) &#147;<B>officer</B>,&#148; when used with respect to the Corporation, means an officer of
the Corporation appointed by the Board of Directors under Article&nbsp;V of these Bylaws; (b) &#147;<B>the Corporation</B>&#148; shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence
had continued, would have had power and authority to indemnify its directors and officers, so that any person who is or was a director or officer of such constituent corporation, or while a director or officer of the constituent corporation, is or
was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Article
VI with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence has continued; (c) &#147;<B>Disinterested Director</B>&#148; shall mean a director of the
Corporation who is not or was not a party to the Proceeding in respect of which indemnification is being sought under Section&nbsp;6.1 or Section&nbsp;6.2 of these Bylaws; (d) &#147;<B>other enterprises</B>&#148; shall include employee benefit
plans; (e) &#147;<B>fines</B>&#148; shall include any excise taxes assessed on a person with respect to an employee benefit plan; (f) &#147;<B>serving at the request of the Corporation</B>&#148; shall include any service as a director, officer,
employee or agent of the Corporation which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and (g)&nbsp;a person who acted in good
faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#147;<B>not opposed to the best interests of the
Corporation</B>&#148; as referred to in this Article VI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.9 INDEMNITY FUND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon resolution passed by the Board of Directors, the Corporation may establish a trust or other designated account, grant a security interest
or use other means (including, without limitation, a letter of credit), to ensure the payment of any or all of its obligations arising under this Article VI or agreements which may be entered into between the Corporation and its officers and
directors from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.10 INDEMNIFICATION OF OTHER PERSONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of this Article VI shall not be deemed to limit the right of the Corporation, to the extent and in the manner permitted by law,
to indemnify and to advance expenses to, or to purchase and maintain insurance on behalf of, persons other than those persons described in the first sentence of Section&nbsp;6.1 of these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.11 DETERMINATION; CLAIM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a claim for indemnification or advancement of expenses under this Article VI is not paid in full within 90 days after receipt by the
Corporation of the written request therefor, the claimant shall be entitled to bring suit against the Corporation seeking an adjudication by a court of competent jurisdiction of such claimant&#146;s entitlement to such indemnification or advancement
of expenses, as applicable. The Corporation shall indemnify such person against any and all expenses that are incurred by such person in connection with any action for indemnification or advancement of expenses from the Corporation under this
Article VI, to the extent such person is successful in such action, and to the extent not prohibited by law. In any such suit, the Corporation shall, to the fullest extent not prohibited by law, have the burden of proving that the claimant is not
entitled to the requested indemnification or advancement of expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.12 EFFECT OF REPEAL OR MODIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of any provision contained in this Article VI shall, unless otherwise required by law, be prospective
only (except to the extent such amendment or change in law permits the Corporation to further limit or eliminate the liability of directors or officers) and shall not adversely affect any right or protection of any current or former director or
officer of the Corporation existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring prior to such amendment, repeal or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.13 SAVINGS CLAUSE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Article VI or any portion thereof shall be invalidated on any ground by any court of competent jurisdiction, then, subject to
Section&nbsp;6.4 of these Bylaws, the Corporation shall nevertheless indemnify each person seeking indemnification hereunder against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement with respect to any
Proceeding, including a grand jury proceeding and an action or suit brought by or in the right of the Corporation, to the full extent permitted by any applicable provision of this Article VI that shall not have been invalidated or by any other
applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.14 CONTINUATION OF INDEMNIFICATION AND ADVANCEMENT OF EXPENSES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indemnification and advancement of expenses provided by, or granted pursuant to, this Article VI shall, unless otherwise provided when
authorized or ratified, continue as to a person who has ceased to be a director or officer and shall inure to the benefit of the heirs, executors and administrators of such person. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORUM FOR
CERTAIN ACTIONS </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Forum</U>. Unless the Corporation, in writing, selects or consents to the selection of an alternative
forum (i)&nbsp;the sole and exclusive forum for any complaint asserting any internal corporate claims (as defined below), to the fullest extent permitted by law, and subject to applicable jurisdictional requirements, shall be the Court of Chancery
of the State of Delaware (or, if the Court of Chancery does not have, or declines to accept, jurisdiction, another state court or a federal court located within the State of Delaware), and (ii)&nbsp;the sole and exclusive forum for any complaint
asserting a cause of action arising under the Securities Act of 1933, to the fullest extent permitted by law, shall be the federal district courts of the United States of America. For the avoidance of doubt, this Article VII shall not apply to suits
brought to enforce a duty or liability created by the Exchange Act. For purposes of this Article VII, &#147;<B>internal corporate claims</B>&#148; means claims, including claims in the right of the Corporation that are based upon a violation of a
duty by a current or former director, officer, employee or stockholder in such capacity, or as to which the DGCL confers jurisdiction upon the Court of Chancery. Any person purchasing or otherwise acquiring or holding any interest in shares of
capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article VII. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Enforceability</U>. If any provision of this Article&nbsp;VII shall be held to be invalid, illegal or unenforceable as applied to any person or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity,
legality and enforceability of such provision in any other circumstance and of the remaining provisions of this Article&nbsp;VII (including, without limitation, each portion of any sentence of this Article&nbsp;VII containing any such provision held
to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or circumstances shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL
MATTERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8.1 CHECKS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the Board of Directors shall determine by resolution which person or persons may sign or endorse all checks, drafts, other
orders for payment of money, notes or other evidences of indebtedness that are issued in the name of or payable to the Corporation, and only the persons so authorized shall sign or endorse those instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8.2 EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may authorize any officer or officers, or any agent or agents, to enter into any contract or execute and deliver any
document or instrument in the name of and on behalf of the Corporation; such authority may be general or confined to specific instances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8.3 STOCK CERTIFICATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of the Corporation shall be represented by certificates, provided that the Board of Directors may provide by resolution or
resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares that may be evidenced by a book-entry system maintained by the registrar of such stock. Any such resolution shall not apply to shares
represented by a certificate until such certificate is surrendered to the Corporation. Notwithstanding the adoption of such a resolution by the Board of Directors, every holder of stock represented by certificates and upon request every holder of
uncertificated shares shall be entitled to have a certificate signed by, or in the name of, the Corporation by any two authorized officers of the Corporation, including the Chairman of the Board, the President, the Chief Financial Officer, the
Secretary or an assistant secretary of the Corporation, representing the number of shares registered in certificate form. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has
signed or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with
the same effect as if such person were such officer, transfer agent or registrar at the date of issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8.4 LOST
CERTIFICATES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in this Section&nbsp;8.4, no new certificates for shares shall be issued to replace a previously
issued certificate unless the latter is surrendered to the Corporation and canceled at the same time. The Corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to
have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or the owner&#146;s legal representative, to give the Corporation a bond that the Corporation determines is sufficient to
indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any certificate or the issuance of such new certificate or uncertificated shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8.5 CONSTRUCTION; DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, the general provisions, rules of construction, and definitions in the DGCL shall govern the
construction of these Bylaws. Without limiting the generality of this provision, (i)&nbsp;the singular number includes the plural and the plural number includes the singular and (ii)&nbsp;the term &#147;<B>person</B>&#148; includes both a
corporation or other type of entity and a natural person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8.6 FISCAL YEAR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fiscal year of the Corporation shall be fixed by resolution of the Board of Directors and may be changed by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8.7 SEAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation may adopt and may subsequently alter the corporate seal, and it may use the same by causing it or a facsimile thereof to be
impressed or affixed or reproduced in any other manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8.8 TRANSFER OF STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon surrender to the Corporation or the transfer agent of the Corporation of a certificate for shares duly endorsed or accompanied by proper
evidence of succession, assignation or authority to transfer, it shall be the duty of the Corporation, as the Corporation may so instruct its transfer agent, if any, to issue a new certificate or uncertificated shares to the person entitled thereto,
cancel the old certificate, and record the transaction in its books. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8.9 REGISTERED STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive
dividends and to vote as such owner, shall be entitled to hold liable for calls and assessments the person registered on its books as the owner of shares, and shall not be bound to recognize any equitable or other claim to or interest in such share
or shares on the part of another person, whether or not it shall have express or other notice thereof, except as otherwise provided by the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8.10 ELECTRONIC SIGNATURES, ETC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by the Certificate of Incorporation or these Bylaws (including, without limitation, as otherwise required by
Section&nbsp;2.19), any document, including, without limitation, any consent, agreement, certificate or instrument, required by the DGCL, the Certificate of Incorporation or these Bylaws to be executed by any officer, director, stockholder, employee
or agent of the Corporation may be executed using a facsimile or other form of electronic signature to the fullest extent permitted by applicable law. All other contracts, agreements, certificates or instruments to be executed on behalf of the
Corporation may be executed using a facsimile or other form of electronic signature to the fullest extent permitted by applicable law. The terms &#147;<B>electronic mail</B>,&#148; &#147;<B>electronic mail address</B>,&#148; &#147;<B>electronic
signature</B>&#148; and &#147;<B>electronic transmission</B>&#148; as used herein shall have the meanings ascribed thereto in the DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These Bylaws
may be adopted, amended, altered or repealed by a majority of the voting power of the Corporation&#146;s capital stock issued and outstanding and entitled to vote thereon, or by the Board of Directors, when such power is conferred upon the Board of
Directors by the Certificate of Incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="exind273090_3"></A><A NAME="rom273090_213"></A>Annex B </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:200pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRINCIPAL STOCKHOLDERS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><SMALL>BY</SMALL> <SMALL>AND</SMALL> <SMALL>AMONG</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ORONADO</SMALL> T<SMALL>OPCO</SMALL>, I<SMALL>NC</SMALL>., </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Q<SMALL>UIDEL</SMALL> C<SMALL>ORPORATION</SMALL>, </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>RTHO</SMALL> C<SMALL>LINICAL</SMALL> D<SMALL>IAGNOSTICS</SMALL> H<SMALL>OLDINGS</SMALL> <SMALL>PLC</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><SMALL>AND</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>HE</SMALL> I<SMALL>NITIAL</SMALL> C<SMALL>ARLYLE</SMALL> S<SMALL>TOCKHOLDER</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER</B><B></B><B>&nbsp;22</B>, <B>2021</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:200pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION I. DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">DraftingConventions; No Construction Against Drafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Defined Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION II. REPRESENTATIONS AND WARRANTIES AND COVENANTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Representations and Warranties of the Initial Carlyle Stockholder</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Representations and Warranties and Covenants of the Company Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION III. REGISTRATION RIGHTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Demand and Piggyback Rights.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices, Cutbacks and Other Matters.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Facilitating Registrations and Offerings.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rule 144</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION IV. BOARD OF DIRECTORS MATTERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION V. CORPORATE OPPORTUNITIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Competition and Corporate Opportunities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Approval of Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION VI. MISCELLANEOUS PROVISIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Information and Access Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Access to Agreement; Amendment and Waiver; Actions of the Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Remedies; Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement; Termination of Prior Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Successors and Assigns; Beneficiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consent to Jurisdiction; Specific Performance; WAIVER OF JURY TRIAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Assurances; Company Logo</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Inconsistent Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">In-Kind</FONT> Distributions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Recapitalization Transactions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>EXHIBIT </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit
A: Form of Joinder Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRINCIPAL STOCKHOLDERS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Principal Stockholders Agreement (this &#147;<U>Agreement</U>&#148;) is made as of December&nbsp;22<B>, </B>2021 by and among Coronado
Topco, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), Carlyle Partners VI Cayman Holdings, L.P., a Cayman Islands exempted limited partnership (the &#147;<U>Initial Carlyle Stockholder</U>&#148;), any Permitted Transferee who from
time to time becomes party to this Agreement by execution of a joinder agreement substantially in the form of Exhibit A (a &#147;<U>Joinder Agreement</U>&#148;) and, solely for purposes of Section&nbsp;2.2, Quidel Corporation, a Delaware corporation
(&#147;<U>Laguna</U>&#148;), and Ortho Clinical Diagnostics Holdings plc, a public limited company incorporated under the laws of England and Wales (&#147;<U>Orca</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Concurrently
with execution of this Agreement, the Company, Laguna and Orca are entering into that certain Business Combination Agreement by and among the Company, Laguna, Orca, Laguna Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the
Company, Orca Holdco, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#147;<U>U.S. Holdco Sub</U>&#148;) and Orca Holdco 2, Inc., a Delaware corporation and a wholly owned subsidiary of U.S. Holdco Sub (the
&#147;<U>BCA</U>&#148;), pursuant to which, among other things, Orca will become a wholly owned subsidiary of the Company pursuant to the Orca Scheme (as defined in the BCA) and the Initial Carlyle Stockholder will receive Topco Shares (as defined
in the BCA). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. As of the date hereof, the Initial Carlyle Stockholder is a shareholder of Orca and is a party to that certain Principal
Shareholders Agreement, dated as of January&nbsp;25, 2021, by and between Orca and the Initial Carlyle Stockholder (the &#147;<U>Existing Principal Shareholders Agreement</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. The Initial Carlyle Stockholder and the Company desire to enter into this Agreement effective (except with respect to Section&nbsp;2.2,
which is effective as of the date hereof) upon the Orca Effective Time (as defined in the BCA) (the &#147;<U>Effective Time</U>&#148;) so that the Initial Carlyle Stockholder will retain the benefit through and until the Effective Time of
(i)&nbsp;the rights set forth in the Existing Principal Shareholders Agreement and (ii)&nbsp;certain rights set forth in the governing documents of Orca, and from and after the Effective Time, the Existing Principal Shareholders Agreement shall
terminate and this Agreement shall be in full force and effect, with such changes hereto, if any, as agreed among the Initial Carlyle Stockholder, the Company, Laguna and Orca. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. The Board of Directors of the Company (the &#147;<U>Board of Directors</U>&#148;) has approved this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E. The parties hereto desire to agree upon the respective rights and obligations after the Effective Time with respect to the securities of
the Company now or hereafter issued and outstanding and held by the parties to this Agreement and certain matters with respect to their investment in the Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Now therefore,
in consideration of the foregoing, and the mutual agreements and covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION I. <U>DEFINITIONS</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Drafting
Conventions; No Construction Against Drafter</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The headings in this Agreement are provided for convenience and do not affect its
meaning. The words &#147;include,&#148; &#147;includes&#148; and &#147;including&#148; are to be read as if they were followed by the phrase &#147;without limitation.&#148; Unless specified otherwise, any reference to an agreement means that
agreement as amended or supplemented, subject to any restrictions on amendment contained in such agreement. Unless specified otherwise, any reference to a statute or regulation means that statute or regulation as amended or supplemented from time to
time and any corresponding provisions of successor statutes or regulations. If any date specified in this Agreement as a date for taking action falls on a day that is not a business day, then that action may be taken on the next business day. Unless
specified otherwise, the words &#147;party&#148; and &#147;parties&#148; refer only to a party named in this Agreement or one who joins this Agreement as a party pursuant to the terms hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The language used in this Agreement shall be deemed to be the language chosen by the
parties to express their mutual intent. If an ambiguity or question of intent or interpretation arises, this Agreement is to be construed as if drafted jointly by the parties and there is to be no presumption or burden of proof or rule of strict
construction favoring or disfavoring any party because of the authorship of any provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Defined Terms</U>.
The following capitalized terms, as used in this Agreement, shall have the meanings set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; shall
mean with respect to any specified Person, any other Person which, directly or indirectly, controls, is controlled by or is under common control with the specified Person, including any partner, officer, director or member of the specified Person
and, if the specified Person is a private equity fund, any investment fund now or hereafter existing that is managed by, or which is controlled by or is under common control with, one or more general partners or managing members of, or shares the
same management company with, the specified Person or any investment fund, managed account vehicle, collective investment scheme or comparable investment vehicle (&#147;<U>Fund</U>&#148;) now or hereafter existing that shares the same management
company or registered investment advisor with such specified Person or any Fund now or hereafter existing that is controlled by, under common control with, managed or advised by the same management company or registered investment advisor that
controls, is under common control with, manages or advises the Fund that controls such specified Person. For the purposes of this definition, &#147;control&#148; (including, with its correlative meanings, the terms &#147;controlled by&#148; and
&#147;under common control with&#148;), as used with respect to any Person, shall mean the possession, directly or indirectly, of the power to direct, or cause the direction of the management and policies of such Person, whether through the
ownership of securities, by contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Beneficial Ownership</U>&#148; by a Person of any securities includes
ownership by any Person who, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares (i)&nbsp;voting power which includes the power to vote, or to direct the voting of, such security; and/or
(ii)&nbsp;investment power which includes the power to dispose, or to direct the disposition, of such security. The terms &#147;<U>Beneficially Own</U>&#148; and &#147;<U>Beneficial Owner</U>&#148; shall have a correlative meaning. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Carlyle Board Representation Number</U>&#148; means the following number as applicable from time to time: (i)&nbsp;two (2), if the
Carlyle Entity-Level Stockholders, collectively, Beneficially Own at least twelve percent (12%) of the outstanding Shares, (ii)&nbsp;one (1), if the Carlyle Entity-Level Stockholders, collectively, Beneficially Own at least five percent (5%) but
less than twelve percent (12%) of the outstanding Shares, or (iii)&nbsp;zero (0), if the Carlyle Entity-Level Stockholders, collectively, Beneficially Own less than five percent (5%) of the outstanding Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Carlyle Entity-Level Stockholders</U>&#148; means the Initial Carlyle Stockholder and any Affiliated entities (i.e., excluding
natural persons) fitting within clause (ii)&nbsp;of the definition of &#147;Carlyle Stockholders.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Carlyle Majority
Interest</U>&#148; shall mean, at any given time, the Carlyle Stockholders holding a majority of the outstanding Shares held at that specified time by all Carlyle Stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Carlyle Stockholders</U>&#148; means (i)&nbsp;the Initial Carlyle Stockholder and (ii)&nbsp;any Permitted Transferee or Affiliate of
the Initial Carlyle Stockholder (x)&nbsp;which is Transferred any shares of Common Stock by any Carlyle Stockholder, and (y)&nbsp;which becomes a party hereto by executing a Joinder Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing</U>&#148; has the meaning ascribed to such term in the BCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Stock</U>&#148; shall mean the common stock, par value $0.001 per share, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company</U>&#148; shall have the meaning set forth in the preamble and shall include any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Competing Director</U>&#148; means any Carlyle Nominee who serves as an officer, director, partner, member, or employee for any
business that competes in any material respect with the Company or its Subsidiaries, if a majority of the independent directors determines in good faith that such Carlyle Nominee&#146;s continued service on the Board would constitute a violation of
the Company&#146;s <I>bona fide</I> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">conflict-of-interest</FONT></FONT> policies, as applied consistently with respect to all actual or potential Directors, provided, however, that
Carlyle Investment Management L.L.C. and its affiliates (excluding any portfolio companies advised by Carlyle Investment Management L.L.C. or its affiliates) will not be considered businesses that compete with the Company or its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>DGCL</U>&#148; shall mean the General Corporation Law of the State of Delaware.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Director</U>&#148; shall mean a member of the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; shall mean the Securities Exchange Act of 1934 and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FINRA</U>&#148; shall mean the Financial Industry Regulatory Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means generally accepted accounting principles, as in effect in the United States of America from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Nasdaq</U>&#148; means the Nasdaq Stock Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Transferee</U>&#148; shall mean, with respect to any Carlyle Stockholder, (i)&nbsp;any Affiliate of such Carlyle
Stockholder, (ii)&nbsp;any director, officer or employee of any Affiliate of such Carlyle Stockholder, and (iii)&nbsp;any direct or indirect member or general or limited partner of such Carlyle Stockholder that is the Transferee of Shares pursuant
to a pro rata distribution of Shares by such Carlyle Stockholder to its partners or members, as applicable (or any subsequent transfer of such Shares by the transferee to another Permitted Transferee), in each instance of clauses (ii)&nbsp;or (iii)
only to the extent that such Transferee (together with its Affiliates) Beneficially Owns at least 1% of the Shares following such Transfer or would not be able to sell under Rule 144 under the Securities Act, without volume or manner of sale
restrictions all Shares Owned by such Transferee and its Affiliates immediately following such distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148;
shall mean an individual, corporation, partnership, limited liability company, joint venture, association, trust, unincorporated organization, government (or agency or political subdivision thereof) or any other entity or group (as defined in
Section&nbsp;13(d) of the Exchange Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC</U>&#148; shall mean the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; shall mean the Securities Act of 1933 and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shares</U>&#148; shall mean, at any time, (i)&nbsp;shares of Common Stock and (ii)&nbsp;any other equity securities now or hereafter
issued by the Company, together with any options, warrants or other rights thereon and any other shares or other equity securities issued or issuable with respect thereto (whether by way of a share dividend, share split or in exchange for or in
replacement or upon conversion of such shares or otherwise in connection with a combination of shares, recapitalization, merger, consolidation or other corporate reorganization). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer</U>&#148; means any direct or indirect transfer, donation, sale, assignment, pledge, hypothecation, grant of a security
interest in or other disposal or attempted disposal of all or any portion of a security, any interest or rights in a security, or any rights under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transferee</U>&#148; means the recipient of a Transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>WKSI</U>&#148; means a well-known seasoned issuer, as defined in the SEC&#146;s Rule 405. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION II. <U>REPRESENTATIONS AND WARRANTIES AND COVENANTS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Representations and Warranties of the Initial Carlyle Stockholder</U>. The Initial Carlyle Stockholder hereby represents, warrants and
covenants to the Company as follows: (a)&nbsp;the Initial Carlyle Stockholder has full limited partnership power and authority to enter into this Agreement and perform its obligations hereunder; (b)&nbsp;this Agreement constitutes the valid and
binding obligation of the Initial Carlyle Stockholder enforceable against it in accordance with its terms; and (c)&nbsp;the execution, delivery and performance by the Initial Carlyle Stockholder of this Agreement: (i)&nbsp;does not and will not
violate any laws, rules or regulations of the United States or any state or other jurisdiction applicable to the Initial Carlyle Stockholder, or require the Initial Carlyle Stockholder to obtain any approval, consent or waiver of, or to make any
filing with, any Person that has not been obtained or made; and (ii)&nbsp;does not constitute a breach of or default under any material agreement to which the Initial Carlyle Stockholder is a party or by which the property of such Initial Carlyle
Stockholder is bound or affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Representations and Warranties and Covenants of the Company Parties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of the Company, Orca and Laguna (each a &#147;<U>Company Party</U>&#148;) hereby represents, warrants and covenants, severally and
not jointly, to the Carlyle Stockholders as follows: (a)&nbsp;such Company Party has full corporate power and authority to enter into this Agreement and perform its obligations hereunder; (b)&nbsp;this Agreement constitutes the valid and binding
obligation of such Company Party enforceable against it in accordance with its terms; and (c)&nbsp;the execution, delivery and performance by such Company Party of this Agreement: (i)&nbsp;does not and will not violate any laws, rules or regulations
of the United States or any state or other jurisdiction applicable to such Company Party, or require such Company Party to obtain any approval, consent or waiver of, or to make any filing with, any Person that has not been obtained or made; and
(ii)&nbsp;does not and will not result in a breach of, constitute a default under, accelerate any obligation under or give rise to a right of termination of any indenture or loan or credit agreement or any other material agreement, contract,
instrument, mortgage, lien, lease, permit, authorization, order, writ, judgment, injunction, decree, determination or arbitration award to which such Company Party is a party or by which the property of such Company Party is bound or affected, or
result in the creation or imposition of any mortgage, pledge, lien, security interest or other charge or encumbrance on any of the assets or properties of such Company Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of the Company Parties acknowledges and agrees with the Carlyle Stockholders that the intent of this Agreement is that the Company
shall acquire Orca and Laguna, and the Company shall issue Common Stock (known as Topco Shares in the BCA), on the terms and subject to the conditions currently contemplated by the BCA, including as to the organizational documents of the Company,
and the Company Parties shall not assign their rights under, or amend, the BCA in any manner such that, if the Closing occurs, (i)&nbsp;the Company would not be the sole issuer of Common Stock in connection with the Combinations as contemplated by
the BCA or (ii)&nbsp;the terms of organizational documents of the Company would be inconsistent (in a manner that is adverse to the Carlyle Stockholders) with such terms contemplated by the BCA to be in effect as of the Orca Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION III. <U>REGISTRATION RIGHTS</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1
<U>Demand and Piggyback Rights.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Right to Demand a <FONT STYLE="white-space:nowrap">Non-Shelf</FONT> Registered Offering</U>.
Upon the demand of any Carlyle Stockholder at any time and from time to time after the Closing, the Company will facilitate in the manner described in this Agreement a <FONT STYLE="white-space:nowrap">non-shelf</FONT> registered offering of the
Shares requested by the demanding Carlyle Stockholders to be included in such offering. A demand by Carlyle Stockholders for a <FONT STYLE="white-space:nowrap">non-shelf</FONT> registered offering that will result in the imposition of a lockup on
the Company and the Carlyle Stockholders may not be made unless: (i)&nbsp;the Shares requested to be sold by the demanding Carlyle Stockholders in such offering have an aggregate market value (based on the most recent closing price of the shares of
Common Stock at the time of the demand) of at least $250&nbsp;million (or such lesser amount if all Shares held by the demanding Carlyle Stockholders are requested to be sold), (ii) the duration of the lockup is no more than 90 days, and
(iii)&nbsp;such lockups occur no more than twice in any <FONT STYLE="white-space:nowrap">12-month</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Right to
Piggyback on a <FONT STYLE="white-space:nowrap">Non-Shelf</FONT> Registered Offering</U>. In connection with any registered offering of shares of Common Stock covered by a <FONT STYLE="white-space:nowrap">non-shelf</FONT> registration statement
(whether pursuant to the exercise of demand rights or at the initiative of the Company), the Carlyle Stockholders may exercise piggyback rights to have included in such offering Shares held by them. The Company will facilitate in the manner
described in this Agreement any such <FONT STYLE="white-space:nowrap">non-shelf</FONT> registered offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Right to Demand and be
Included in a Shelf Registration</U>. Upon the demand of any Carlyle Stockholder, made at any time and from time to time when the Company is eligible to utilize Form <FONT STYLE="white-space:nowrap">S-3</FONT> or a successor form to sell Shares in a
secondary offering on a delayed or continuous basis in accordance with Rule 415 under the Securities Act, the Company will facilitate in the manner described in this Agreement a shelf registration of Shares held by such Carlyle Stockholder. Unless
otherwise requested by any Carlyle Stockholder, any shelf registration filed by the Company covering Shares (whether pursuant to a Carlyle Stockholder demand or at the initiative of the Company) will cover Shares held by each of the Carlyle
Stockholders (regardless of whether they demanded the filing of such shelf or not) up to an equivalent percentage of their original respective holdings as may be agreed upon by the demanding Carlyle Stockholders. If at the time of such request the
Company is a WKSI, such shelf registration would, at the request of such Carlyle Stockholder, cover an unspecified number of Shares to be sold by the Company and the Carlyle Stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Demand and Piggyback Rights for Shelf Takedowns</U>. Upon the demand of one or more Carlyle Stockholders made at any time and from time
to time, the Company will facilitate in the manner described in this Agreement a &#147;takedown&#148; of Shares off of an effective shelf registration statement. In connection with any underwritten shelf takedown (whether
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to the exercise of such demand rights or at the initiative of the Company), the Carlyle Stockholders may exercise piggyback rights to have included in such takedown Shares held by them
that are registered on such shelf. Notwithstanding the foregoing, Carlyle Stockholders may not demand a shelf takedown for an offering that will result in the imposition of a lockup on the Company and the Carlyle Stockholders unless (i)&nbsp;the
Shares requested to be sold by the demanding Carlyle Stockholders in such takedown have an aggregate market value (based on the most recent closing price of the Shares at the time of the demand) of at least $250&nbsp;million (or such lesser amount
if all Shares held by the demanding Carlyle Stockholders are requested to be sold), (ii) the duration of the lockup is no more than 90 days, and (iii)&nbsp;such lockups occur no more than three times in the first 12 months after the Closing
(provided that the aggregate <FONT STYLE="white-space:nowrap">lock-up</FONT> period in such <FONT STYLE="white-space:nowrap">12-month</FONT> period shall not exceed 180 days) and no more than twice in any
<FONT STYLE="white-space:nowrap">12-month</FONT> period after the first anniversary of the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Right to Reload a Shelf</U>.
Upon the written request of a Carlyle Stockholder, the Company will file and seek the effectiveness of a post-effective amendment to an existing resale shelf in order to register up to the number of Shares of the Carlyle Stockholders previously
taken down off of such shelf and not yet &#147;reloaded&#148; onto such shelf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Limitations on Demand and Piggyback Rights</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Any demand for the filing of a registration statement or for a registered offering or takedown will be subject to the
constraints of any applicable lockup arrangements, and such demand must be deferred until such lockup arrangements no longer apply. If a demand has been made for a <FONT STYLE="white-space:nowrap">non-shelf</FONT> registered offering or for an
underwritten takedown, no further demands may be made so long as the related offering is still being pursued. Notwithstanding anything in this Agreement to the contrary, the Carlyle Stockholders will not have piggyback or other registration rights
with respect to registered primary offerings by the Company (i)&nbsp;covered by a Form <FONT STYLE="white-space:nowrap">S-8</FONT> registration statement or a successor form applicable to employee benefit-related offers and sales, (ii)&nbsp;where
the Shares are not being sold for cash or (iii)&nbsp;where the offering is a bona fide offering of securities other than Shares, even if such securities are convertible into or exchangeable or exercisable for Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) The Company may postpone the filing of a demanded registration statement or suspend the effectiveness of any shelf
registration statement or support for a takedown offering for a reasonable &#147;blackout period&#148; not in excess of 90 days if the Board of Directors of the Company determines that such registration or offering could materially interfere with a
bona fide business or financing transaction of the Company or is reasonably likely to require premature disclosure of information, the premature disclosure of which could materially and adversely affect the Company; provided that the Company shall
not postpone the filing of a demanded registration statement or suspend the effectiveness of any shelf registration statement pursuant to this Section&nbsp;3.1(f)(ii) more than once in any 360 day period. The blackout period will end upon the
earlier to occur of (i)&nbsp;a date not later than 90 days from the date such deferral commenced and (ii)&nbsp;the date upon which such information is otherwise disclosed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Expiration of Registration Rights</U>. The rights of the Carlyle Stockholders under <U>Section</U><U></U><U>&nbsp;3.1(a)</U> shall
expire when the Carlyle Stockholders, collectively, Beneficially Own less than five percent (5%) of the outstanding Shares and the other rights of the Carlyle Stockholders under this <U>Section</U><U></U><U>&nbsp;3.1</U> shall expire on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">holder-by-holder</FONT></FONT> basis when a given Carlyle Stockholder Beneficially Owns less than one percent (1%) of the outstanding Shares; <U>provided</U>, in each case, such Carlyle
Stockholder is able to sell the Shares Beneficially Held as of the Effective Date under Rule 144 under the Securities Act, without volume or manner of sale restrictions, at such time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Notices, Cutbacks and Other Matters.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Notifications Regarding Registration Statements</U>. In order for one or more Carlyle Stockholders to exercise their right to demand
that a registration statement be filed, they must so notify the Company in writing indicating the number of Shares sought to be registered and the proposed plan of distribution. The Company will keep the Carlyle Stockholders contemporaneously
apprised of all pertinent aspects of its pursuit of any registration, whether pursuant to a Carlyle Stockholder demand or otherwise, with respect to which a piggyback opportunity is available (and in any event, at least five days before a filing of
a registration statement). Pending any required public disclosure and subject to applicable legal requirements, the parties will maintain the confidentiality of these discussions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Notifications Regarding Registration Piggyback Rights</U>. Any Carlyle Stockholder wishing to exercise its piggyback rights with
respect to a <FONT STYLE="white-space:nowrap">non-shelf</FONT> registration statement must notify the Company and the other Carlyle Stockholders of the number of Shares it seeks to have included in such registration statement. Such notice must be
given as soon as practicable, but in no event later than 5:00 pm, New York City time, on the second trading day prior to (i)&nbsp;if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable, the date on which the preliminary prospectus intended to be used in connection with <FONT STYLE="white-space:nowrap">pre-effective</FONT> marketing efforts for the relevant offering
is expected to be finalized, and (ii)&nbsp;in any case, the date on which the pricing of the relevant offering is expected to occur. No such notice is required in connection with a shelf registration statement, as Shares held by all Carlyle
Stockholders will be included up to the applicable percentage (unless otherwise requested by any Carlyle Stockholder). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Notifications Regarding Demanded Underwritten Takedowns</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Company will keep the Carlyle Stockholders
contemporaneously apprised of all pertinent aspects of any underwritten shelf takedown in order that they may have a reasonable opportunity to exercise their related piggyback rights (and in any event, at least two trading days before the filing of
a prospectus supplement). Without limiting the Company&#146;s obligation as described in the preceding sentence, having a reasonable opportunity requires that the Carlyle Stockholders be notified by the Company of an anticipated underwritten
takedown (whether pursuant to a demand made by other Carlyle Stockholders or made at the Company&#146;s own initiative) no later than 5:00 pm, New York City time, on (i)&nbsp;if applicable, the second trading day prior to the date on which the
preliminary prospectus or prospectus supplement intended to be used in connection with <FONT STYLE="white-space:nowrap">pre-pricing</FONT> marketing efforts for such takedown is finalized, and (ii)&nbsp;in all cases, the second trading day prior to
the date on which the pricing of the relevant takedown occurs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Any Carlyle Stockholder wishing to exercise its
piggyback rights with respect to an underwritten shelf takedown must notify the Company and the other Carlyle Stockholders of the number of Shares it seeks to have included in such takedown. Such notice must be given as soon as practicable, but in
no event later than 5:00 pm, New York City time, on (i)&nbsp;if applicable, the trading day prior to the date on which the preliminary prospectus or prospectus supplement intended to be used in connection with marketing efforts for the relevant
offering is expected to be finalized, and (ii)&nbsp;in all cases, the trading day prior to the date on which the pricing of the relevant takedown occurs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Pending any required public disclosure and subject to applicable legal requirements, the parties will maintain
appropriate confidentiality of their discussions regarding a prospective underwritten takedown. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Plan of Distribution, Underwriters
and Counsel</U>. If (i)&nbsp;a majority of the Shares proposed to be sold in an underwritten offering through a <FONT STYLE="white-space:nowrap">non-shelf</FONT> registration statement or through a shelf takedown are being sold by the Company for
its own account and (ii)&nbsp;such offering was initiated by the Company and not by any Carlyle Stockholder, the Company will be entitled to determine the plan of distribution and select the managing underwriters for such offering. Otherwise, the
Carlyle Stockholders holding a majority of the Shares requested to be included in such offering will be entitled to determine the plan of distribution and select the managing underwriters, and such majority will also be entitled to select counsel
for the selling Carlyle Stockholders (which may be the same as counsel for the Company). In the case of a shelf registration statement, the plan of distribution will provide as much flexibility as is reasonably possible, including with respect to
resales by transferee Carlyle Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Cutbacks</U>. If the managing underwriters advise the Company and the selling Carlyle
Stockholders that, in their opinion, the number of Shares requested to be included in an underwritten offering exceeds the amount that can be sold in such offering without adversely affecting the distribution of the Shares being offered, such
offering will include only the number of Shares that the underwriters advise can be sold in such offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) In the case
of a registered offering upon the demand of one or more Carlyle Stockholders, the selling Carlyle Stockholders (including those Carlyle Stockholders exercising piggyback rights pursuant to Section&nbsp;3.1(b)) collectively will have first priority
and will be subject to cutback pro rata based on the proportion of all outstanding Shares that are held by each such selling Carlyle Stockholder at that time (up to the number of Shares initially requested by them to be included in such offering).
To the extent of any remaining capacity, all other stockholders having similar registration rights will have second priority. Except as contemplated by the immediately preceding two sentences, if the Carlyle Stockholders are subject to a cutback,
other selling stockholders will be included in an underwritten offering only with the consent of Carlyle Stockholders holding a majority of the Shares being sold in such offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) In the case of a registered offering upon the initiative of the Company, the Company will have first priority. To the
extent of any remaining capacity, the selling Carlyle Stockholders as a group, on the one hand, and all other stockholders having similar registration rights as a group, on the other hand, will be subject to cutback pro rata based on the number of
Shares initially requested by such group to be included in such offering. The selling Carlyle Stockholders will be subject to cutback pro rata, based on the proportion of all outstanding Shares (as of the Closing) that were held by the Initial
Carlyle Stockholder at the Closing (up to the number of Shares initially requested by them </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to be included in such offering). Except as contemplated by the immediately preceding sentence, if the Carlyle Stockholders are subject to a cutback, other stockholders will be included in an
underwritten offering only with the consent of a Carlyle Majority Interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Withdrawals</U>. Even if Shares held by a Carlyle
Stockholder have been part of a registered underwritten offering, such Carlyle Stockholder may, no later than the time at which the public offering price and underwriters&#146; discount are determined with the managing underwriter, decline to sell
all or any portion of the Shares being offered for its account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Expenses</U>. All expenses incurred in connection with any
registration statement or registered offering covering Shares held by Carlyle Stockholders, including, without limitation, all registration and filing fees, printing expenses (including printing certificates for the Shares in a form eligible for
deposit with the Depository Trust Company and printing preliminary, supplemental and final prospectuses), word processing, duplicating, telephone and facsimile expenses, messenger and delivery expenses, transfer taxes, expenses incurred in
connection with promotional efforts or &#147;roadshows&#148;, fees and disbursements of counsel (including the fees and disbursements of outside counsel for Carlyle Stockholders (which may be the same as counsel for the Company) and fees and
disbursements of counsel to the underwriters with respect to &#147;blue sky&#148; qualification of such Shares and their determination for eligibility for investment under the laws of the various jurisdictions and in connection with any filing with,
and clearance of any offering by, FINRA (up to the cap on such fees included in any applicable underwriting agreement)) and of the independent certified public accountants of the Company (including with respect to the preparation of customary
financial statements required to be included in any offering document, the provision of any customary comfort letters), and the expense of qualifying such Shares under state blue sky laws (reasonably requested by the Carlyle Stockholders), will be
borne by the Company. However, underwriters&#146;, brokers&#146; and dealers&#146; discounts and commissions applicable to Shares sold for the account of a Carlyle Stockholder will be borne by such Carlyle Stockholder and such underwriter expenses
will be paid by the Carlyle Stockholders. In the event that the Carlyle Stockholders elect to abandon a <FONT STYLE="white-space:nowrap">non-shelf</FONT> registered offering, then such offering-related expenses shall be reimbursed by the Carlyle
Stockholders unless such abandonment is based upon adverse Company-specific information or the imposition of a &#147;blackout&#148; period under Section&nbsp;3.1(c)(ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Facilitating Registrations and Offerings.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. If the Company becomes obligated under this Agreement to facilitate a registration and offering of Shares on behalf of
Carlyle Stockholders, the Company will do so with the same degree of care and dispatch as would reasonably be expected in the case of a registration and offering by the Company of Shares for its own account. Without limiting this general obligation,
the Company will fulfill its specific obligations as described in this Section&nbsp;3.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Registration Statements</U>. In
connection with each registration statement that is demanded by Carlyle Stockholders or as to which piggyback rights otherwise apply, for a period of 12 months from the date of the prospectus relating to such registration of the resale of the
Company will: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) prepare and file (or confidentially submit) with the SEC a registration statement covering the
applicable Shares, (ii)&nbsp;prepare and file (or confidentially submit) such amendments or supplements to such registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective
for a period ending when all of the securities covered by such registration statement have been disposed of in accordance with the intended methods of distribution by the sellers thereof set forth in such registration statement (but not in any event
before the expiration of any longer period required under the Securities Act or, if such registration statement relates to an underwritten public offering, such longer period as in the opinion of counsel for the underwriters a prospectus is required
by law to be delivered in connection with the sale of Shares by an underwriter or dealer), (iii) seek the effectiveness thereof, and (iv)&nbsp;file with the SEC prospectuses and prospectus supplements as may be required, all in consultation with the
Carlyle Stockholders and as reasonably necessary in order to permit the offer and sale of the such Shares in accordance with the applicable plan of distribution; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;(1) within a reasonable time prior to the filing of any registration statement, any prospectus, any amendment to a registration
statement, amendment or supplement to a prospectus or any free writing prospectus, provide copies of such documents to the selling Carlyle Stockholders and to the underwriter or underwriters of an underwritten offering, if applicable, and to their
respective counsel; fairly consider such reasonable changes in any such documents prior to or after the filing thereof as the counsel to the Carlyle Stockholders or the underwriter or the underwriters may request; and make such of the
representatives of the Company as shall be reasonably requested by the selling Carlyle Stockholders or any underwriter available for discussion of such documents; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(2) within a reasonable time prior to the filing of any document which is to be
incorporated by reference into a registration statement or a prospectus, provide copies of such document to counsel for the Carlyle Stockholders and underwriters; fairly consider such reasonable changes in such document prior to the filing thereof
as counsel for such Carlyle Stockholders or such underwriter shall request; and make such of the representatives of the Company as shall be reasonably requested by such counsel available for discussion of such document; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) cause each registration statement and the related prospectus and any amendment or supplement thereto, as of the effective
date of such registration statement, amendment or supplement and during the distribution of the registered Shares (x)&nbsp;to comply in all material respects with the requirements of the Securities Act and the rules and regulations of the SEC and
(y)&nbsp;not to contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) notify each Carlyle Stockholder promptly, and, if requested by such Carlyle Stockholder, confirm such advice in writing,
(i)&nbsp;when a registration statement has become effective and when any post-effective amendments and supplements thereto become effective if such registration statement or post-effective amendment is not automatically effective upon filing
pursuant to Rule 462 under the Securities Act, (ii)&nbsp;of the issuance by the SEC or any state of any stop order, injunction or other order or requirement suspending the effectiveness of a registration statement or the initiation of any
proceedings for that purpose, (iii)&nbsp;if, between the effective date of a registration statement and the closing of any sale of securities covered thereby pursuant to any agreement to which the Company is a party, the representations and
warranties of the Company contained in such agreement cease to be true and correct in all material respects or if the Company receives any notification with respect to the suspension of the qualification of the Shares for sale in any jurisdiction or
the initiation or threatening of any proceeding for such purpose, and (iv)&nbsp;of the happening of any event during the period a registration statement is effective as a result of which such registration statement or the related prospectus contains
any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading and, if required by applicable law, prepare and file a supplement or amendment to
such registration statement or prospectus so that, as thereafter delivered to the purchasers of Shares registered thereby, such registration statement or prospectus will not contain an untrue statement of a material fact or omit to state any fact
necessary to make the statements therein not misleading; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) furnish counsel for each underwriter, if any, and for the
Carlyle Stockholders copies of any correspondence with the SEC or any state securities authority relating to the registration statement or prospectus; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) otherwise comply with all applicable rules and regulations of the SEC, including making available to its security holders
an earnings statement covering at least 12 months which shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 thereunder (or any similar provision then in force); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) use all reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of a registration statement
at the earliest possible time; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U><FONT STYLE="white-space:nowrap">Non-Shelf</FONT> Registered Offerings and Shelf Takedowns</U>. In
connection with any <FONT STYLE="white-space:nowrap">non-shelf</FONT> registered offering or shelf takedown that is demanded by Carlyle Stockholders or as to which piggyback rights otherwise apply, the Company will: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) cooperate with the selling Carlyle Stockholders and the sole underwriter or managing underwriter of an underwritten
offering Shares, if any, to facilitate the timely preparation and delivery of certificates representing the Shares to be sold; and enable such Shares to be in such denominations (consistent with the provisions of the governing documents thereof) and
registered in such names as the selling Carlyle Stockholders or the sole underwriter or managing underwriter of an underwritten offering of Shares, if any, may reasonably request; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) furnish to each Carlyle Stockholder and to each underwriter, if any, participating in the relevant offering, without
charge, as many copies of the applicable prospectus, including each preliminary prospectus, and any amendment or supplement thereto and such other documents as such Carlyle Stockholder or underwriter may reasonably request in order to facilitate the
public sale or other disposition of the Shares; the Company hereby consents to the use of the prospectus, including each preliminary prospectus or prospectus supplement, by each such Carlyle Stockholder and underwriter in connection with the
offering and sale of the Shares covered by the prospectus, the preliminary prospectus or prospectus supplement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;(i) use all reasonable efforts to register or qualify the Shares being offered and sold, no later than the time the
applicable registration statement becomes effective, under all applicable state securities or &#147;blue sky&#148; laws of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
jurisdictions as each underwriter, if any, or any Carlyle Stockholder holding Shares covered by a registration statement, shall reasonably request; (ii)&nbsp;use all reasonable efforts to keep
each such registration or qualification effective during the period such registration statement is required to be kept effective; (iii)&nbsp;comply with the provisions of the Securities Act with respect to the disposition of all securities covered
by such registration statement during such period in accordance with the intended methods of disposition by the sellers thereof set forth in the registration statement and (iv)&nbsp;do any and all other acts and things which may be reasonably
necessary or advisable to enable each such underwriter, if any, and Carlyle Stockholder to consummate the disposition in each such jurisdiction of such Shares owned by such Carlyle Stockholder; <I>provided</I>, <I>however</I>, that the Company shall
not be obligated to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to consent to be subject to general service of process (other than service of process in connection with such
registration or qualification or any sale of Shares in connection therewith) in any such jurisdiction where it would not otherwise be required to qualify but for this subparagraph (iv)&nbsp;or subject itself to taxation in any such jurisdiction;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) use commercially reasonable efforts to (i)&nbsp;cause all Shares being sold to be qualified for inclusion in or
listed on Nasdaq or any other U.S. securities exchange on which Shares issued by the Company are then so qualified or listed, (ii)&nbsp;comply (and continue to comply) with the requirements of any self-regulatory organization applicable to the
Company, including without limitation all corporate governance requirements, (iii)&nbsp;use its best efforts to cause Shares covered by such registration statement to be registered with or approved by such other governmental agencies or authorities
as may be necessary to enable the sellers thereof to consummate the disposition of such Shares and (iv)&nbsp;use best efforts to provide a transfer agent and registrar for all Shares to be sold by the Carlyle Stockholders not later than the
effective date of such registration statement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) cooperate and assist in any filings required to be made with FINRA and
in the performance of any due diligence investigation by any underwriter in an underwritten offering; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) use all
reasonable efforts to facilitate the distribution and sale of any Shares to be offered pursuant to this Agreement, including without limitation by making road show presentations, holding meetings with and making calls to potential investors and
taking such other actions as shall be requested by the Carlyle Stockholders or the lead managing underwriter of an underwritten offering; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) enter into customary agreements (including, in the case of an underwritten offering, underwriting agreements in customary
form, and including provisions with respect to indemnification and contribution in customary form and consistent with the provisions relating to indemnification and contribution contained herein) and take all other customary and appropriate actions
in order to expedite or facilitate the disposition of such Shares in connection therewith, including: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(1) make such representations and
warranties to the selling Carlyle Stockholders and the underwriters, if any, in form, substance and scope as are customarily made by issuers to underwriters in similar underwritten offerings; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(2) obtain opinions of counsel to the Company in all relevant jurisdictions and updates thereof (which counsel and opinions (in form, scope
and substance) shall be reasonably satisfactory to the lead managing underwriter, if any) addressed to each selling Carlyle Stockholder and the underwriters, if any, covering the matters and jurisdictions customarily covered in opinions requested in
sales of securities or underwritten offerings and such other matters as may be reasonably requested by such Carlyle Stockholders and underwriters; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(3) obtain &#147;cold comfort&#148; letters and updates thereof from the Company&#146;s independent certified public accountants addressed to
the selling Carlyle Stockholders, if permissible, and the underwriters, if any, which letters shall be customary in form and shall cover matters of the type customarily covered in &#147;cold comfort&#148; letters to underwriters in connection with
primary underwritten offerings; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(4) to the extent requested by the Carlyle Stockholders, cause the Company&#146;s directors and executive
officers to enter into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements in customary form; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(5) to the extent requested and
customary for the relevant transaction, enter into a securities sales agreement with the Carlyle Stockholders providing for, among other things, the appointment of such representative as agent for the selling Carlyle Stockholders for the purpose of
soliciting purchases of Shares, which agreement shall be customary in form, substance and scope and shall contain customary representations, warranties and covenants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The above shall be done at such times as customarily occur in similar registered offerings or shelf takedowns. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) take all actions to ensure that any free writing prospectus utilized
in connection with any registration or offering hereunder complies in all material respects with the Securities Act in relation to the circulation of a prospectus, is filed in accordance with the Securities Act, is retained in accordance with the
Securities Act and, when taken together with the related prospectus, prospectus supplement and related documents, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) permit any Carlyle Stockholder that, in its
sole exclusive judgment, might be deemed to be an underwriter or a controlling person of the Company, to participate in the preparation of such registrations statement and to allow such Carlyle Stockholder to provide language for insertion therein,
in form and substance satisfactory to the Company, which in the reasonable judgment of such Carlyle Stockholder and its counsel should be included; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) use best efforts to (i)&nbsp;make Form <FONT STYLE="white-space:nowrap">S-3</FONT> available for the sale of Shares and
(ii)&nbsp;prevent the issuance of any stop order suspending the effectiveness of a registration statement, or the issuance of any order suspending or preventing the use of any related prospectus or suspending the qualification of any Shares included
in such registration statement for sale in any jurisdiction, and in the event any such order is issued, use best efforts to obtain promptly the withdrawal of such order; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) if requested by any managing underwriter and reasonably available, include in any prospectus or prospectus supplement
updated financial or business information for the Company&#146;s most recent period or current quarterly period (including estimated results or ranges of results) if required for purposes of marketing the offering in the view of the managing
underwriter; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) take no direct or indirect action prohibited by Regulation M under the Exchange Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii) cooperate with each Carlyle Stockholder covered by the registration statement and each underwriter or agent
participating in the disposition of such Shares and their respective counsel in connection with the preparation and filing of applications, notices, registrations and responses to requests for additional information with FINRA, Nasdaq or any other
national securities exchange on which the Shares are or are to be listed, and to the extent required by the rules and regulations of FINRA, retain a Qualified Independent Underwriter acceptable to the managing underwriter; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) if the Company files an automatic shelf registration statement covering any Shares, use its best efforts to remain a WKSI
(and not become an ineligible issuer (as defined in Rule 405 under the Securities Act)) during the period during which such automatic shelf registration statement is required to remain effective; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv) if the Company does not pay the filing fee covering the Shares at the time an automatic shelf registration statement is
filed, pay such fee at such time or times as the Shares are to be sold; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvi) if the automatic shelf registration
statement has been outstanding for at least three years, at the end of the third year, refile a new automatic shelf registration statement covering the Shares, and, if at any time when the Company is required to
<FONT STYLE="white-space:nowrap">re-evaluate</FONT> its WKSI status the Company determines that it is not a WKSI, use its best efforts to refile the shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and, if such form
is not available, Form <FONT STYLE="white-space:nowrap">S-1</FONT> and keep such registration statement effective during the period during which such registration statement is required to be kept effective; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvii) if the Company plans to file any automatic shelf registration statement for the benefit of the holders of any of its
securities other than the Carlyle Stockholders, and the Carlyle Stockholders do not request that their Shares be included in such shelf registration statement, the Company agrees that, at the request of the Carlyle Majority Interest, include in such
automatic shelf registration statement such disclosures as may be required by Rule 430B under the Securities Act in order to ensure that the Carlyle Stockholders may be added to such shelf registration statement at a later time through the filing of
a prospectus supplement rather than a post-effective amendment (and if the Company has filed any automatic shelf registration statement for the benefit of the holders of any of its securities other than the Carlyle Stockholders, the Company shall,
at the request of the Carlyle Majority Interest, file any post-effective amendments necessary to include therein all disclosure and language necessary to ensure that the Carlyle Stockholders may be added to such Shelf Registration Statement); and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xviii) with respect to any shelf takedown that is demanded by Carlyle Stockholders, use commercially reasonable efforts
to take such actions necessary to facilitate such shelf takedown by the Carlyle Stockholders as soon as possible, and in any event within 72 hours of receipt of notice of any such shelf takedown (but in no event less than two business days after the
receipt of such notice) (the &#147;<U>Preparation Period</U>&#148;); provided that the Company agrees that after such Preparation Period, it shall be prepared to cooperate to use commercially reasonable efforts to facilitate such shelf takedown on
any trading day during the following 15 business days without requiring an additional Preparation Period; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
provided, further that the Carlyle Stockholders shall use commercially reasonable efforts to provide the Company with at least five business days&#146; advanced notice of its intention to submit
a notice of request for registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Due Diligence</U>. In connection with each registration and offering of Shares to be sold by
Carlyle Stockholders, the Company will, in accordance with customary practice, make available for inspection by representatives of the Carlyle Stockholders and underwriters and any counsel or accountant retained by such Carlyle Stockholder or
underwriters all relevant financial and other records, pertinent corporate documents and properties of the Company and cause appropriate officers, managers and employees of the Company to supply all information reasonably requested by any such
representative, underwriter, counsel or accountant in connection with their due diligence exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Information from
Stockholders</U>. Each Carlyle Stockholder that holds Shares covered by any registration statement will timely furnish to the Company such information regarding itself as is required to be included in the registration statement, the ownership of
Shares by such Carlyle Stockholder and the proposed distribution by such Carlyle Stockholder of such Shares as the Company may from time to time reasonably request in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 <U>Indemnification.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Indemnification by the Company</U>. In the event of any registration under the Securities Act by any registration statement of Shares
held by Carlyle Stockholders, the Company will hold harmless Carlyle Stockholders, any such Carlyle Stockholder&#146;s officers, directors, employees, agents, fiduciaries, stockholders, managers, partners, members, affiliates, direct and indirect
equityholders, consultants and representatives, and any successors and assigns thereof, and each underwriter of such securities and each other person, if any, who controls any Carlyle Stockholder or such underwriter within the meaning of the
Securities Act (collectively, the &#147;<U>Indemnified Parties</U>&#148;), against any losses, claims, actions, damages, liabilities or expenses (including with respect to actions or proceedings, whether commenced or threatened, and including
reasonable attorney fees and expenses) (collectively, &#147;<U>Losses</U>&#148;), joint or several, to which Carlyle Stockholders or such underwriter or controlling person may become subject under the Securities Act or otherwise, insofar as such
Losses arise out of or are based upon (i)&nbsp;any untrue or alleged untrue statement of material fact contained in (A)&nbsp;any registration statement, prospectus, preliminary prospectus or free writing prospectus, or any amendment thereof or
supplement thereto or (B)&nbsp;any application or other document or communication (in this Section&nbsp;3.4, collectively called an &#147;<U>application</U>&#148;) executed by or on behalf of the Company or based upon written information furnished
by or on behalf of the Company filed in any jurisdiction in order to qualify any securities covered by such registration under the &#147;blue sky&#148; or securities laws thereof, (ii)&nbsp;any omission or alleged omission of a material fact
required to be stated therein or necessary to make the statements therein not misleading or (iii)&nbsp;any violation or alleged violation by the Company of the Securities Act or any other similar federal or state securities laws or any rule or
regulation promulgated thereunder applicable to the Company and relating to action or inaction required of the Company in connection with any such registration, qualification or compliance; and will reimburse any such Indemnified Party for any legal
or any other expenses reasonably incurred by them in connection with investigating or defending any such Losses; provided, however, that the Company shall not be liable to any such Indemnified Party in any such case to the extent that any such
Losses arise out of or are based upon an untrue statement or alleged untrue statement or omission or alleged omission made in such registration statement, prospectus, preliminary prospectus or free writing prospectus or any amendment or supplement
thereto, or in any application, in reliance upon and in conformity with information furnished to the Company through a written instrument duly executed by such Indemnified Party specifically for use in the preparation thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Indemnification by Carlyle Stockholders</U>. Each Carlyle Stockholder will indemnify and hold harmless (in the same manner and to the
same extent as set forth in Section&nbsp;3.4(a)) the Company, its officers, directors, employees, agents and representatives, and each Person who controls the Company (within the meaning of the Securities Act), with respect to Losses (as determined
by a final and unappealable judgment, order or decree of a court of competent jurisdiction) arising from (i)&nbsp;any statement or omission from such registration statement, or any amendment or supplement to it, if such statement or omission was
made in reliance upon and in conformity with information furnished to the Company through a written instrument duly executed by such Carlyle Stockholder specifically regarding such Carlyle Stockholder for use in the preparation of such registration
statement or amendment or supplement, and (ii)&nbsp;compliance by such Carlyle Stockholder with applicable laws in effecting the sale or other disposition of the securities covered by such registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Indemnification Procedures</U>. Promptly after receipt by an indemnified party of notice of the commencement of any action involving a
claim referred to in Section&nbsp;3.4(a) and Section&nbsp;3.4(b), the indemnified party will, if a resulting claim is to be made or may be made against and indemnifying party, give written notice to the indemnifying party of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commencement of the action. The failure of any indemnified party to give notice shall not relieve the indemnifying party of its obligations in this Section&nbsp;3.4, except to the extent that the
indemnifying party is actually prejudiced by the failure to give notice. If any such action is brought against an indemnified party, the indemnifying party will be entitled to participate in and to assume the defense of the action with counsel
reasonably satisfactory to the indemnified party, and after notice from the indemnifying party to such indemnified party of its election to assume defense of the action, the indemnifying party will not be liable to such indemnified party for any
legal or other expenses incurred by the latter in connection with the action&#146;s defense. An indemnified party shall have the right to employ separate counsel in any action or proceeding and participate in the defense thereof, but the fees and
expenses of such counsel shall be at such indemnified party&#146;s expense unless (i)&nbsp;the employment of such counsel has been specifically authorized in writing by the indemnifying party, which authorization shall not be unreasonably withheld,
(ii)&nbsp;the indemnifying party has not assumed the defense and employed counsel reasonably satisfactory to the indemnified party within 30 days after notice of any such action or proceeding, or (iii)&nbsp;the named parties to any such action or
proceeding (including any impleaded parties) include the indemnified party and the indemnifying party and the indemnified party shall have been advised by such counsel that there may be one or more legal defenses available to the indemnified party
that are different from or additional to those available to the indemnifying party (in which case the indemnifying party shall not have the right to assume the defense of such action or proceeding on behalf of the indemnified party), it being
understood, however, that the indemnifying party shall not, in connection with any one such action or separate but substantially similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances, be
liable for the reasonable fees and expenses of more than one separate firm of attorneys (in addition to all local counsel which is necessary, in the good faith opinion of both counsel for the indemnifying party and counsel for the indemnified party
in order to adequately represent the indemnified parties) for the indemnified party and that all such fees and expenses shall be reimbursed as they are incurred upon written request and presentation of invoices. Whether or not a defense is assumed
by the indemnifying party, the indemnifying party will not be subject to any liability for any settlement made without its consent (such consent not to be unreasonably withheld, delayed or conditioned). No indemnifying party will consent to entry of
any judgment or enter into any settlement which (i)&nbsp;does not include as an unconditional term the giving by the claimant or plaintiff, to the indemnified party, of a release from all liability in respect of such claim or litigation or
(ii)&nbsp;involves the imposition of equitable remedies or the imposition of any <FONT STYLE="white-space:nowrap">non-financial</FONT> obligations on the indemnified party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Contribution</U>. If the indemnification required by this Section&nbsp;3.4 from the indemnifying party is unavailable to or
insufficient to hold harmless an indemnified party in respect of any indemnifiable Losses, then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such Losses in such proportion as is
appropriate to reflect (i)&nbsp;the relative benefit of the indemnifying and indemnified parties and (ii)&nbsp;if the allocation in clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect the relative
benefit referred to in clause (i)&nbsp;and also the relative fault of the indemnified and indemnifying parties, in connection with the actions which resulted in such Losses, as well as any other relevant equitable considerations. The relative fault
of the indemnifying party and the indemnified party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact, has been made by, or relates to
information supplied by, such indemnifying party or parties, and the parties&#146; relative intent, knowledge, access to information, and opportunity to correct or prevent such action. The amount paid or payable by a party as a result of the Losses
referred to above shall be deemed to include any legal or other fees or expenses reasonably incurred by such party in connection with any investigation or proceeding. The Company and Carlyle Stockholders agree that it would not be just and equitable
if contribution pursuant to this Section&nbsp;3.4(d) were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the prior provisions of this
Section&nbsp;3.4(d). Notwithstanding the provisions of this Section&nbsp;3.4(d), no Carlyle Stockholder shall be required to contribute any amount in excess of the amount by which the net proceeds from the sale of the securities by such Carlyle
Stockholder exceeds the amount of any damages which the indemnifying party has otherwise been required to pay by reason of an untrue statement or omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of
the Securities Act) shall be entitled to contribution from any person who was not guilty of such a fraudulent misrepresentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U><FONT
STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedy.</U> The indemnification and contribution provided for under this Agreement will be in addition to any other rights to indemnification or contribution that any indemnified party may have
pursuant to law or contract (and the Company and its subsidiaries shall be considered the indemnitors of first resort in all such circumstances to which this <U>Section</U><U></U><U>&nbsp;3</U> applies) and will remain in full force and effect
regardless of any investigation made by or on behalf of the indemnified party or any officer, director or controlling Person of such indemnified party and will survive the transfer of Shares and the termination or expiration of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5 <U>Rule 144</U>. If the Company is subject to the requirements of Section&nbsp;13, 14 or
15(d) of the Exchange Act, the Company covenants that it will file any reports required to be filed by it under the Securities Act and the Exchange Act (or, if the Company is subject to the requirements of Section&nbsp;13, 14 or 15(d) of the
Exchange Act but is not required to file such reports, it will, upon the request of any Carlyle Stockholder, make publicly available such information) and it will take such further action as any Carlyle Stockholder may reasonably request, so as to
enable such Carlyle Stockholder to sell Shares without registration under the Securities Act within the limitation of the exemptions provided by (a)&nbsp;Rule 144 under the Securities Act, as such Rule may be amended from time to time, or
(b)&nbsp;any similar rule or regulation hereafter adopted by the SEC. Upon the request of any Carlyle Stockholder, the Company will deliver to such Carlyle Stockholder a written statement as to whether it has complied with such requirements.
Furthermore, the Company shall use its reasonable best efforts to facilitate any sale by a Carlyle Stockholder under Rule 144 under the Securities Act, including delivery of any legal opinions and instruction letters required by the Company&#146;s
transfer agent and such other documentation as may be reasonably requested by the Carlyle Stockholder or its broker in connection with such sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION IV. <U>BOARD OF DIRECTORS MATTERS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Board of Directors</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Carlyle Stockholders will have the right to nominate a number of individuals for election to the Board of Directors equal to the
Carlyle Board Representation Number (with each of such individuals being nominated by the Initial Carlyle Stockholder and/or such other Carlyle Stockholders as the Initial Carlyle Stockholder shall from time to time designate in writing to the
Company) and who are reasonably acceptable to the Board of Directors (each, a &#147;<U>Carlyle Nominee</U>&#148;), <U>provided</U>, that each of Stephen Wise, Robert Schmidt and Allan Holt shall be deemed to be reasonably acceptable for purposes of
this <U>Section</U><U></U><U>&nbsp;4.1(a)</U>. For the avoidance of doubt, the Board of Directors may determine that a Carlyle Nominee is not reasonably acceptable if such Carlyle Nominee is a Competing Director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For so long as the Carlyle Stockholders have the right to nominate any Carlyle Nominee, in connection with each election of Directors,
(i)&nbsp;the Company shall nominate each such Carlyle Nominee for election as a Director as part of the slate that is included in the proxy statement (or consent solicitation or similar document) of the Company relating to the election of Directors,
and shall provide the highest level of support for the election of each such Carlyle Nominee as it provides to any other individual standing for election as a Director as part of the Company&#146;s slate of Directors, and the Board of Directors
shall recommend that the stockholders of the Company elect to the Board of Directors each such Carlyle Nominee, and (ii)&nbsp;the Company shall include in the slate that is included in the proxy statement (or consent solicitation or similar
document) of the Company relating to the election of Directors only (A)&nbsp;the Carlyle Nominees nominated by the Carlyle Stockholders in accordance with this <U>Section</U><U></U><U>&nbsp;4.1(a)</U> and (B)&nbsp;the other Director nominees (if
any) nominated by the Board of Directors (or a committee thereof). For so long as the Carlyle Stockholders have the right to nominate any Carlyle Nominee, the Board of Directors (and any committee thereof) shall not nominate (and the Company shall
not include in the slate that is included in the proxy statement (or consent solicitation or similar document) of the Company relating to the election of Directors) a number of nominees for any election of Directors that exceeds the total number of
Directors. For the avoidance of doubt, without limiting the rights of the Carlyle Stockholders under this Agreement, nothing herein shall prevent the Company from including director nominees submitted by stockholders for inclusion in the
Company&#146;s proxy statement under proxy access or similar rules under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If, from time to time, the Carlyle Board
Representation Number shall decrease, the Carlyle Stockholders and the Company shall take all necessary action to cause the applicable number of Carlyle Nominees to resign or be removed immediately, unless otherwise requested in writing by the
Company. Subject to the immediately foregoing sentence, in the event that a Carlyle Nominee shall cease to serve as a Director for any reason (including any removal thereof), the Carlyle Stockholders shall have the right to nominate another Carlyle
Nominee to fill any vacancy resulting therefrom. For the avoidance of doubt, it is understood that the failure of the stockholders of the Company to elect any Carlyle Nominee shall not affect the right of the Carlyle Stockholder to designate the
Carlyle Nominees for election pursuant to this <U>Section</U><U></U><U>&nbsp;4.1(c)</U> in connection with any future election of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I>Other Board of Directors Matters</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall reimburse each director nominated by the Carlyle Stockholders for all reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with his or her attendance at meetings of the Board of Directors and any committees thereof, including travel, lodging and meal
expenses, subject to the Company&#146;s travel and reimbursement policies that are no less favorable than the policies that apply to other Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company shall obtain, for each director nominated by the Carlyle
Stockholders, customary director and officer indemnity insurance on commercially reasonable terms as determined by the Board of Directors and on terms no less favorable than the director and officer indemnity insurance obtained for other Directors.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) In addition to any other indemnification rights that the directors have pursuant to the certificate of incorporation
and the bylaws (or equivalent governing documents) of the Company, each person nominated by the Carlyle Stockholders to serve on the Board of Directors in accordance with this <U>Section</U><U></U><U>&nbsp;4.1</U> shall have the right to enter into,
and the Company agrees to enter into, an indemnification agreement in a form consistent with indemnification agreements customarily entered into between companies and their independent board members. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) If at any time a Carlyle Nominee serving on the Board of Directors becomes a Competing Director, such Competing Director
shall promptly tender his or her resignation to the Board of Directors, provided that the Carlyle Stockholders shall have the right to appoint a new Carlyle Nominee to fill the resulting vacancy, including on any applicable Specified Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION V. <U>CORPORATE OPPORTUNITIES</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1
<U>Competition and Corporate Opportunities</U>. With respect to competition and corporate opportunities: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In recognition and
anticipation that (i)&nbsp;certain directors, principals, officers, employees and/or other representatives of the Initial Carlyle Stockholder may serve as directors, officers or agents of the Company, (ii)&nbsp;the Initial Carlyle Stockholder may
now engage and may continue to engage in the same or similar activities or related lines of business as those in which the Company, directly or indirectly, may engage and/or other business activities that overlap with or compete with those in which
the Company, directly or indirectly, may engage, and (iii)&nbsp;Carlyle Nominees who are not employees of the Company (&#147;<U><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</U>&#148;) and their respective Affiliates may now engage
and may continue to engage in the same or similar activities or related lines of business as those in which the Company, directly or indirectly, may (subject to Section&nbsp;4.1(d)(iv)) engage in and/or other business activities that overlap with or
compete with those in which the Company, directly or indirectly, may engage, the provisions of this ARTICLE V are set forth to regulate and define the conduct of certain affairs of the Company with respect to certain classes or categories of
business opportunities as they may involve any of the Initial Carlyle Stockholder, the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors or their respective Affiliates and the powers, rights, duties and liabilities of the Company and
its directors, officers and stockholders in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Neither (i)&nbsp;the Initial Carlyle Stockholder nor (ii)&nbsp;any <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director (the Persons (as defined below) identified in (i)&nbsp;and (ii) above being referred to, collectively, as &#147;<U>Identified Persons</U>&#148; and, individually, as an &#147;<U>Identified
Person</U>&#148;) shall, to the fullest extent permitted by law, have any duty to refrain from directly or indirectly (1)&nbsp;engaging in the same or similar business activities or lines of business in which the Company or any of its Affiliates now
engages or proposes to engage or (2) otherwise competing with the Company or any of its Affiliates, and, to the fullest extent permitted by law no Identified Person shall be liable to the Company or its stockholders or to any Affiliate of the
Company for breach of any fiduciary duty solely by reason of the fact that such Identified Person engages in any such activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To
the fullest extent permitted from time to time by the laws of the State of Delaware, the Company hereby renounces any interest or expectancy in, or right to be offered an opportunity to participate in, any business opportunity that may be a
corporate opportunity for an Identified Persons and the Company or any of its Affiliates, except as provided in Section&nbsp;5.1(d). Subject to Section&nbsp;5.1(d), in the event that any Identified Person acquires knowledge of a potential
transaction or other business opportunity that may be a corporate opportunity for itself, herself or himself, or any of its or his or her Affiliates, and the Company or any of its Affiliates, such Identified Person shall, to the fullest extent
permitted by law, have no duty to communicate or offer such transaction or other business opportunity to the Company or any of its Affiliates and, to the fullest extent permitted by law, shall not be liable to the Company or its stockholders or to
any Affiliate of the Company for breach of any fiduciary duty as a stockholder, director or officer of the Company solely by reason of the fact that such Identified Person pursues or acquires such corporate opportunity for itself, herself or
himself, or offers or directs such corporate opportunity to another Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding the foregoing, the Company does not
renounce its interest in any corporate opportunity offered to any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director (including any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director who serves as an officer of the Company) if
such opportunity is expressly offered to such person in his or her capacity as a director or officer of the Company, and the provisions of Section&nbsp;5.1(d) shall not apply to any such corporate opportunity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) In addition to and notwithstanding the foregoing provisions of this Article V, a corporate opportunity shall not be deemed to be a
potential corporate opportunity for the Company if it is a business opportunity that (i)&nbsp;the Company is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
neither financially or legally able, nor contractually permitted to undertake, (ii)&nbsp;from its nature, is not in the line of the Company&#146;s business or is of no practical advantage to the
Company or (iii)&nbsp;is one in which the Company has no interest or reasonable expectancy, in each case as determined by the Board of Directors (with the Carlyle Nominees abstaining from any such deliberations or votes) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Approval of Waiver</U>. Topco hereby (a)&nbsp;represents and warrants to the Initial Carlyle Stockholder that, in accordance with the
DGCL, the board of directors of Topco has (i)&nbsp;approved the waiver set forth in the foregoing Section&nbsp;5.1 and (ii)&nbsp;renounced any interest or expectancy of Topco in , or in being offered an opportunity to participate in, the business
opportunities described in Section&nbsp;5.1, and (b)&nbsp;covenants and agrees that such waiver and renouncement shall not be rescinded, revoked or modified in any manner adverse to any Identified Persons during the term of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION VI. <U>MISCELLANEOUS PROVISIONS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>Information and Access Rights</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Available Financial Information</U>. Upon written request, the Company will deliver, or will cause to be delivered, to each Carlyle
Stockholder (until such time as the Carlyle Entity-Level Stockholders, collectively, Beneficially Own less than five percent (5%) of the outstanding Shares) as soon as available after the end of each month and in any event within 30 days thereafter,
a consolidated balance sheet of the Company and its subsidiaries as of the end of such month and consolidated statements of operations, income, cash flows, retained earnings and stockholders&#146; equity of the Company and its subsidiaries, for each
month and for the current fiscal year of the Company to date, together with a comparison of such statements to the corresponding periods of the prior fiscal year and to the Company&#146;s business plan then in effect and approved by the Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Access</U>. Until such time as the Carlyle Entity-Level Stockholders, collectively, Beneficially Own less than ten
percent (10%) of the outstanding Shares, the Company shall, and shall cause its subsidiaries, officers, directors, employees, auditors and other agents to (a)&nbsp;afford the Carlyle Entity-Level Stockholders and their officers, employees, auditors
and other agents, during normal business hours and upon reasonable notice, at all reasonable times to the Company&#146;s and its subsidiaries&#146; officers, employees, auditors, legal counsel, properties, offices, plants and other facilities and to
all books and records from time to time as each such Carlyle Entity-Level Stockholder may reasonably request, and (b)&nbsp;afford the Carlyle Entity-Level Stockholders and their officers, employees, auditors and other agents the opportunity to
discuss the affairs, finances and accounts of the Company and its subsidiaries with their respective officers from time to time as each such Carlyle Stockholder may reasonably request, including a monthly call with the Company&#146;s management,
including its Chief Financial Officer, to discuss the financial condition and performance of, and material updates with respect to, the Company and its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Confidentiality</U>. Each Carlyle Stockholder agrees that it will keep confidential and will not disclose, divulge or use for any
purpose, other than to monitor its investment in the Company and its subsidiaries, any confidential information obtained from the Company pursuant to Section&nbsp;6.1, unless such confidential information (a)&nbsp;is known or becomes known to the
public in general (other than as a result of a breach of any confidentiality obligation by such Carlyle Stockholder or its affiliates), (b) is or has been independently developed or conceived by such Carlyle Stockholder without use of the
Company&#146;s confidential information or (c)&nbsp;is or has been made known or disclosed to such Carlyle Stockholder by a third party (other than an Affiliate of any Carlyle Stockholder) without a breach of any confidentiality obligations or
fiduciary duties such third party may have to the Company that is known to such Carlyle Stockholder; <U>provided</U>, <U>that</U>, a Carlyle Stockholder may disclose confidential information (i)&nbsp;to its attorneys, accountants, consultants and
other professional advisors to the extent necessary to obtain their services in connection with monitoring its investment in the Company, (ii)&nbsp;to any prospective purchaser of any Shares from such Carlyle Stockholder as long as such prospective
purchaser agrees to be bound by the provisions of this Section&nbsp;6.2 as if a Carlyle Stockholder, (iii)&nbsp;to any Affiliate, partner, member, limited partners, prospective partners or related investment fund of such Carlyle Stockholder and
their respective directors, employees, consultants and representatives, in each case in the ordinary course of business (provided that the recipients of such confidential information are subject to a customary confidentiality and <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> obligation at least as restrictive as the confidentiality obligations under this Section&nbsp;6.2 as applied to the Carlyle Stockholders), (iv) as may be reasonably determined by such Carlyle
Stockholder to be necessary in connection with such Carlyle Stockholder&#146;s enforcement of its rights in connection with this Agreement, or (v)&nbsp;as may otherwise be required by law or legal, judicial or regulatory process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Reliance</U>. Each covenant and agreement made by a party in this Agreement or in any certificate, instrument or other document
delivered pursuant to this Agreement on or before the Effective Time is material, shall be deemed to have been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relied upon by the other parties and shall remain operative and in full force and effect after the Effective Time regardless of any investigation. This Agreement shall not be construed so as to
confer any right or benefit upon any Person other than the parties hereto and their respective successors and permitted assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4
<U>Access to Agreement; Amendment and Waiver; Actions of the Board</U>. For so long as this Agreement shall be in effect, this Agreement shall be made available for inspection by any Carlyle Stockholder at the principal executive offices of the
Company. Any party may waive in writing any provision hereof intended for its benefit, provided, that, in the case of any waiver by the Carlyle Stockholders, such waiver is consented to in writing by the Carlyle Majority Interest. No failure or
delay on the part of any party in exercising any right, power or remedy hereunder shall operate as a waiver thereof. The remedies provided for herein are cumulative and are not exclusive of any remedies that may be available to any party at law or
in equity or otherwise. This Agreement may be amended only with the prior written consent of the Carlyle Majority Interest and the Company (and, if such amendment is prior to the Effective Time, with the prior written consent of Laguna and Orca).
Any consent given as provided in the preceding sentence shall be binding on all parties. Further, with the prior written consent of the Carlyle Majority Interest and the Company (and Laguna and Orca, if prior to the Effective Time), at any time
hereafter Permitted Transferees may be made parties hereto, with any such additional parties shall be treated as &#147;Carlyle Stockholders&#148; for all purposes hereunder, by executing a counterpart signature page in the form attached as Exhibit A
hereto, which signature page shall be attached to this Agreement and become a part hereof without any further action of any other party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <U>Notices</U>. Any notice, request, instruction or other document to be given hereunder by any party to the others shall be in writing,
shall be deemed duly given on the date of delivery, unless such day is not a business day in the location of receipt, in which case it shall be deemed delivered on the next business day in the location of receipt, and delivered personally or sent by
registered or certified mail, postage prepaid or by prepaid overnight courier (providing written proof of delivery), or by confirmed electronic mail, addressed as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>If to any Company Party prior to the Closing, in accordance with the BCA. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>If to any Company Party following the Closing, c/o Laguna in accordance with the BCA: </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>If to the Carlyle Stockholders: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c/o The Carlyle Group </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">One Vanderbilt Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Suite 3400 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Stephen H. Wise </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>With a copy (which shall not constitute notice): </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">555 Eleventh Street, N.W., Suite 1000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20004 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: David I. Brown </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or, as to each of the foregoing, at such other address as shall be designated by a party in a written notice to other parties complying as to
delivery with the terms of this Section&nbsp;6.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <U>Counterparts</U>. This Agreement may be executed in two or more counterparts,
and delivered via facsimile, .pdf or other electronic transmission, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7 <U>Remedies; Severability</U>. It is specifically understood and agreed that any breach of the provisions of this Agreement by any party
will result in irreparable injury to the other parties, that the remedy at law alone will be an inadequate remedy for such breach, and that, in addition to any other legal or equitable remedies which they may have, such other parties may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enforce their respective rights by actions for specific performance or injunctive relief (to the extent permitted at law or in equity). If any one or more of the provisions of this Agreement, or
the application thereof in any circumstances, is held invalid, illegal or unenforceable in any respect for any reason, the validity, legality and enforceability of any such provision in every other respect and of the remaining provisions contained
herein are not to be in any way impaired thereby, it being intended that all of the rights and privileges of the parties be enforceable to the fullest extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8 <U>Entire Agreement; Termination of Prior Agreements</U>. This Agreement and the letter agreement entered into as of the date hereof by
and between Orca and the Initial Carlyle Stockholder (regarding appointment rights as of the Orca Effective Time) constitute the entire agreement of the Parties with respect to the subject matter hereof. Effective as of the Closing, the Existing
Principal Shareholders Agreement and that certain Amended and Restated Consulting Services Agreement, dated as of October&nbsp;15, 2020, by and between Ortho-Clinical Diagnostics, Inc., a subsidiary of Orca, and Carlyle Investment Management,
L.L.C., an Affiliate of the Initial Carlyle Stockholder, shall terminate and be of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9 <U>Termination</U>.
This Agreement shall terminate on the earlier of (i)&nbsp;the termination of the BCA prior to the Closing, (ii)&nbsp;the election to terminate by the Carlyle Majority Interest and (iii)&nbsp;such date as the Carlyle Stockholders, in the aggregate,
cease to hold any Shares; provided that notwithstanding any such termination, Section&nbsp;3.4 shall survive any expiration or termination of this Agreement. Termination of this Agreement shall not relieve any party for the breach of any obligations
under this Agreement prior to such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10 <U>Governing Law</U>. This Agreement is to be construed and enforced in accordance
with the laws of the State of Delaware, without giving effect to its principles or rules of conflict of laws to the extent such principles or rules are not mandatorily applicable by statute and would require or permit the application of the laws of
another jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.11 <U>Successors and Assigns; Beneficiaries</U>. This Agreement shall be binding upon and inure to the benefit of
the parties and the respective successors and assigns of the parties as contemplated herein. Any successor to the Company by way of merger or otherwise must specifically agree to be bound by the terms hereof as a condition of such succession. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.12 <U>Consent to Jurisdiction; Specific Performance; WAIVER OF JURY TRIAL</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of the parties hereto irrevocably and unconditionally consents to the sole and exclusive jurisdiction of the state and federal courts
located in Wilmington, Delaware to resolve all disputes, claims or controversies arising out of or relating to this Agreement or any other agreement executed and delivered pursuant to or in connection with this Agreement or the negotiation, breach,
validity, termination or performance hereof and thereof or the transactions contemplated hereby and thereby and agrees that it will not bring any such action in any court other than the federal or state courts located in Wilmington, Delaware. Each
party further irrevocably waives any objection to proceeding in such courts based upon lack of personal jurisdiction or to the laying of venue in such courts and further irrevocably and unconditionally waives and agrees not to make a claim that such
courts are an inconvenient forum. Each of the parties hereto hereby consents to service of process by registered mail at the address to which notices are to be given as provided in Section&nbsp;6.5. Each of the parties hereto agrees that its or his
or her submission to jurisdiction and its or his or her consent to service of process by mail is made for the express benefit of the other parties hereto. The choice of forum set forth in this Section shall not be deemed to preclude the enforcement
of any judgment of a Delaware federal or state court, or the taking of any action under this Agreement to enforce such a judgment, in any other appropriate jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in
accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions
of this Agreement, this being in addition to any other remedy to which such party is entitled at law or in equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) EACH PARTY TO THIS
AGREEMENT WAIVES TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY ANY OF THEM AGAINST THE OTHER ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS AGREEMENT, OR ANY OTHER AGREEMENTS EXECUTED AND DELIVERED PURSUANT TO OR IN CONNECTION
HEREWITH OR THE NEGOTIATION, BREACH, VALIDITY, TERMINATION OR PERFORMANCE HEREOF AND THEREOF OR THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY. FURTHER, (I)&nbsp;NO PARTY TO THIS AGREEMENT SHALL SEEK A JURY TRIAL IN ANY SUCH ACTION AND
(II)&nbsp;NO PARTY WILL SEEK TO CONSOLIDATE ANY SUCH ACTION IN WHICH A JURY TRIAL HAS BEEN WAIVED WITH ANY OTHER ACTION IN WHICH A JURY TRIAL CANNOT BE OR HAS NOT BEEN </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
WAIVED. EACH PARTY TO THIS AGREEMENT CERTIFIES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT OR INSTRUMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS SET FORTH ABOVE IN
THIS SECTION 6.12. NO PARTY HAS IN ANY WAY AGREED WITH OR REPRESENTED TO ANY OTHER PARTY THAT THE PROVISIONS OF THIS SECTION WILL NOT BE FULLY ENFORCED IN ALL INSTANCES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.13 <U>Further Assurances; Company Logo</U>. At any time or from time to time after the Effective Time, the parties hereto agree to cooperate
with each other, and at the request of any other party, to execute and deliver any further instruments or documents and to take all such further action as any other party may reasonably request in order to evidence or effectuate the provisions of
this Agreement and to otherwise carry out the intent of the parties hereunder. The Company hereby grants the Carlyle Stockholders and their respective Affiliates permission to use the Company&#146;s and its subsidiaries&#146; name and logo in
marketing materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.14 <U>Regulatory Matters</U>. The Company shall and shall cause its subsidiaries to keep the Carlyle Stockholders
informed, on a current basis, of any events, discussions, notices or changes with respect to any criminal or regulatory investigation or action involving the Company or any of its subsidiaries, so that the Carlyle Stockholders and their respective
Affiliates will have the opportunity to take appropriate steps to avoid or mitigate any regulatory consequences to them that might arise from such investigation or action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.15 <U>Inconsistent Agreements</U>. Neither the Company nor any Carlyle Stockholder shall enter into any agreement or side letter with, or
grant any proxy to, any Carlyle Stockholder, the Company or any other Person (whether or not such proxy, agreements or side letters are with other Carlyle Stockholders, holders of shares of Common Stock that are not parties to this Agreement or
otherwise) that conflicts with the provisions of this Agreement or which would obligate such Person to breach any provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.16 <U><FONT STYLE="white-space:nowrap">In-Kind</FONT> Distributions</U>. If any of the Carlyle Stockholders (and/or any of their Affiliates)
seeks to effectuate an <FONT STYLE="white-space:nowrap">in-kind</FONT> distribution of all or part of its Shares to its respective direct or indirect equity holders, the Company will, subject to any applicable
<FONT STYLE="white-space:nowrap">lock-ups,</FONT> work with the foregoing Persons to facilitate such <FONT STYLE="white-space:nowrap">in-kind</FONT> distribution in the manner reasonably requested and consistent with the Company&#146;s obligations
under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.17 <U>Recapitalization Transactions</U>. If at any time or from time to time there is any change in the
capital structure of the Company by way of share split, share dividend, combination or reclassification, or through a merger, consolidation, reorganization or recapitalization, or by other means, appropriate adjustments will be made in the provision
hereof so that the rights and privileges granted hereby will continue. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[SIGNATURE PAGE FOLLOWS] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties are signing this Principal Stockholders Agreement as of the
date first set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CORONADO TOPCO, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joseph Busky</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Joseph Busky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:&nbsp;&nbsp;&nbsp;&nbsp;President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">QUIDEL CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Douglas Bryant</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Douglas Bryant</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">Title:&#8201;&#8202;President and Chief Executive Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christopher Smith</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Christopher Smith</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Principal Stockholders Agreement] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B><U>INITIAL CARLYLE STOCKHOLDER:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>C<SMALL>ARLYLE</SMALL> P<SMALL>ARTNERS</SMALL> VI C<SMALL>AYMAN</SMALL>
H<SMALL>OLDINGS</SMALL>, L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>By: TC Group VI Cayman, L.P.</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Its: General Partner</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>By: TC Group VI Cayman, L.L.C.</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Its: General Partner</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert Schmidt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Robert Schmidt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:&nbsp;&nbsp;&nbsp;&nbsp;Authorized Person</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Principal Stockholders Agreement] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Joinder Agreement </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By execution of this
signature page, [&nbsp;&nbsp;&nbsp;&nbsp;] hereby agrees to become a party to, and to be bound by the obligations of, and receive the benefits of, that certain Principal Stockholders Agreement, dated as of December&nbsp;22, 2021, by and among
Coronado Topco, Inc., a Delaware corporation, Quidel Corporation, a Delaware corporation, and Ortho Clinical Diagnostics Holdings plc, a public limited company incorporated under the laws of England and Wales, and Carlyle Partners VI Cayman
Holdings, L.P., a Cayman Islands exempted limited partnership[, and certain other parties named therein,] as amended from time to time thereafter. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[NAME]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice Address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accepted:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#9679;]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="exind273090_4"></A><A NAME="rom273090_214"></A>Annex C </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CARLYLE PARTNERS VI CAYMAN HOLDINGS, L.P. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEED OF IRREVOCABLE UNDERTAKING </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">To:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ortho Clinical Diagnostics Holdings plc</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1001 Route 202</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Raritan, NJ 08869</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Quidel Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9975 Summers Ridge Rd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Diego, CA 92121</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>(&#147;Laguna&#148;)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">22&nbsp;December 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Ladies and Gentlemen, </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deed of irrevocable undertaking
relating to the strategic combination of the businesses of Laguna and Ortho Clinical Diagnostics Holdings plc (&#147;Orca&#148;) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We, being Carlyle Partners VI Cayman Holdings, L.P., a Cayman Islands exempted limited partnership acting by
its general partner TC Group VI Cayman, L.P. (acting by its general partner TC Group VI Cayman, L.L.C.) (hereafter referred to as &#147;<B>we</B>&#148;, &#147;<B>us</B>&#148; and/or &#147;<B>Carlyle</B>&#148;) understand that (1)&nbsp;Orca, (2)
Coronado Topco, Inc., a Delaware corporation and a wholly owned subsidiary of Orca (&#147;<B>Topco</B>&#148;), (3) Laguna Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Topco (&#147;<B>U.S. Merger Sub</B>&#148;), (4) Orca
Holdco, Inc., a Delaware corporation and a wholly owned subsidiary of Topco (&#147;<B>U.S. Holdco Sub</B>&#148;), (5) Orca Holdco 2, Inc., a Delaware corporation and a wholly owned subsidiary of U.S. Holdco Sub (&#147;<B>U.S. Holdco Sub
2</B>&#148;), and (6)&nbsp;Laguna intend to enter into a business combination agreement, a draft of which is attached to this deed at Annex II (the &#147;<B>BCA</B>&#148;), on or around the date of this deed, with such amendments as may be agreed in
writing between the parties thereto, pursuant to which (upon the terms and subject to the conditions set forth therein) Laguna and Orca will effect a strategic combination of their businesses through the Combinations (as defined in the BCA) and
other transactions contemplated thereby (the &#147;<B>Transaction</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Terms not defined in this deed shall bear the same meaning as in the BCA. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We understand that in order to facilitate the Transaction, Orca shall enter into a transfer by way of scheme of
arrangement with Topco pursuant to Part 26 of the UK Companies Act 2006 (the &#147;<B>Companies Act</B>&#148;) such that former Orca shareholders would receive Topco Shares on a 1:0.1055 ratio basis and cash in an amount of $7.14 per Orca ordinary
share (the &#147;<B>Orca </B><B>Scheme</B>&#148;), the terms and conditions of which shall be set out in the Orca Scheme Document to be prepared pursuant to section 5.3(a)(i) of the BCA. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In consideration of Orca and Laguna signing the BCA, Carlyle, by reason of being a shareholder of Orca,
irrevocably and unconditionally warrants, undertakes to and confirms and agrees with you in the following terms: </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interests in Committed Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Carlyle is the beneficial owner of (and, unless specified in Annex I hereto, Carlyle is also the registered
holder and to the extent that Carlyle is not the registered holder Carlyle will procure compliance by such registered holder(s) with the terms of this undertaking) (or where such shares have been transferred to an Affiliate of Carlyle, Carlyle is
otherwise able to control the exercise of all rights attaching to, including voting rights and the ability to procure the transfer of), the number of shares in the capital of Orca (the &#147;<B>Committed Shares</B>&#148;, which expression shall:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">include any other shares or securities in Orca acquired by Carlyle or issued or transferred to Carlyle after
the date hereof and which Carlyle has become the registered holder, beneficial owner or otherwise interested in, in accordance with clause 3.2; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">exclude the 50,001 deferred shares of &pound;1.00 each in the capital of Orca (the &#147;<B>Deferred
Shares</B>&#148;) issued to us on Orca&#146;s incorporation and which we hereby confirm and agree shall be transferred by us to Topco and/or shall be cancelled by Orca, in each case for nil consideration at any time on or after the Orca Scheme
becoming effective in accordance with its terms). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Carlyle has all relevant power and authority and the right (free from any legal or other restrictions) to enter
into this undertaking, to perform the obligations under it in accordance with its terms and Carlyle has full power and authority to (where relevant) exercise any above-mentioned options and vote and transfer the Committed Shares as beneficial owner
with full title guarantee free from all Encumbrances, together with all rights attaching to or enjoyed by them, including but not limited to any voting rights the right to all dividends and other distributions (if any) announced, declared, made or
paid on or after the date of this undertaking. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither Carlyle, nor the registered holder of any Committed Shares (where applicable), will take any action
which would cause them to cease to have all relevant power and authority and right to enter into and perform the obligations in this undertaking in accordance with their terms. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of this deed, the following terms shall have the following meanings: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means with respect to any specified Person, any other Person which, directly or indirectly, controls, is
controlled by or is under common control with the specified Person, including any partner, officer, director or member of the specified Person. For the purposes of this definition, &#147;control&#148; (including, with its correlative meanings, the
terms &#147;controlled by&#148; and &#147;under common control with&#148;), as used with respect to any Person, shall mean the possession, directly or indirectly, of the power to direct, or cause the direction of the management and policies of such
Person, whether through the ownership of securities, by contract or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Connected Persons</B>&#148; means Carlyle&#146;s
subsidiaries, Affiliates and any of their respective directors, employees, agents and professional advisors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Counsel</B>&#148;
means Martin Moore QC of Erskine Chambers, 33 Chancery Lane, London WC2A 1EN, or such other counsel appointed by Orca as is agreed between Orca and Laguna; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Encumbrance</B>&#148; means any charge, option, lien, equity, rights of <FONT STYLE="white-space:nowrap">pre-emption,</FONT>
restriction, encumbrance or third party rights of any kind whatsoever; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Technical Revision</B>&#148; means the occurrence of any
of the following events: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">after the Court Meeting has been held, in circumstances where the Orca Scheme Resolution (as defined below) has
not been lawfully passed due to a technical and/or procedural defect(s) relating to the Orca Scheme being either: (i)&nbsp;on the grounds that the provisions of the Companies Act have not been complied with including, without limitation, the
composition of classes for the purposes of the Court Meeting; or (ii)&nbsp;there is a blot on the scheme (as per the decision of Mr Justice Morgan in Re TDG [2009] 1 BCLC 445 at [29]) (each of (i)&nbsp;and (ii) being a &#147;<B>Scheme Technical
Defect</B>&#148;), which reasonably appears to be capable of remedy and/or rectification without having any adverse commercial or financial impact for Laguna in its judgement (acting reasonably); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">after the General Meeting has been held, in circumstances where the GM Resolutions (or any one of them) have
not been lawfully passed due to a technical and/or procedural defect(s) being either: (i)&nbsp;on the grounds that the relevant provisions of the Companies Act or applicable Laws have not been complied with; or (ii)&nbsp;a failure to comply with the
articles of association or other constitutional documents of Orca, which reasonably appears to be capable of remedy and/or rectification without having any adverse commercial or financial impact for Laguna in its judgement (acting reasonably); or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event that the English Court does not sanction the Orca Scheme at the Orca Sanction Hearing on the
grounds of a technical and/or procedural defect in relation to any aspect of the Orca Scheme or its implementation being a Scheme Technical Defect, or on such other grounds which reasonably appears to be capable of remedy and/or rectification
without having any adverse commercial or financial impact for Laguna in its judgement (acting reasonably), </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">in which
case, subject to the terms of the BCA, Laguna and Orca may implement the Transaction (subject to obtaining the necessary shareholder votes) by way of a new, revised or renewed Orca Scheme or a direct contractual offer (or other similar transaction
structure), subject to such terms and conditions as further particularised in the Orca Scheme Document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dealings in Committed Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless required by the terms of paragraph 4.4 below, Carlyle shall not, and to the extent relevant, shall
procure that the registered holder shall not, until the Termination Date (as defined below): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sell, transfer, charge, pledge, encumber, grant any option or other right over or otherwise deal or dispose of,
or permit the sale, transfer, charging, encumbering, granting of any option or other right over or other disposal of any of Committed Shares or interest in Committed Shares except pursuant to the Transaction, or accept any other offer in respect of
all or any of Committed Shares or any other interest in any of Committed Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">accept or give any undertaking (whether conditional or unconditional) or letter of intent to accept any other
offer made or proposed to be made in respect of the issued and to be issued share capital of Orca by any other Person other than Topco or Laguna (or its Affiliates); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enter into any agreement or arrangement or incur any obligation with any Person (other than in connection with
the Transaction): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to do all or any of the acts referred to in <FONT STYLE="white-space:nowrap">sub-paragraphs</FONT> 3.1.A or
3.1.B above; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which would or might restrict or impede Carlyle (or any Carlyle Affiliate where relevant) from voting in favour
of the Orca Scheme or Carlyle&#146;s ability to comply with this deed, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">and references in this paragraph 3.1.C to any
agreement, arrangement or obligation shall include any such agreement, arrangement or obligation whether or not subject to any conditions or which is to take effect upon or following the Orca Scheme becoming effective or lapsing, or upon or
following this deed ceasing to be binding; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">withdraw the acceptance(s) or proxy appointments referred to in this deed in respect of all or any of the
Committed Shares notwithstanding that Carlyle may have become entitled to effect such withdrawal under other applicable Laws or otherwise and shall procure that any vote in favour of the Orca Scheme and any ancillary matters thereto in respect of
the Committed Shares is not withdrawn; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">E.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">exercise any voting rights attaching to Committed Shares in such manner as to frustrate or otherwise hinder the
Orca Scheme and take any action which might result in any condition of the Orca Scheme not being satisfied. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without limitation to the restrictions in paragraph 3.1, in the event that after the date of this deed, Carlyle
(or any of its Connected Persons) do acquire or purchase any shares, securities or interests in securities of Orca or rights therein (or otherwise become the registered holder or beneficial owner of further shares, securities or interests in
securities of Orca or in respect of which Carlyle becomes entitled to exercise voting rights or interests), such shares, securities, interests or rights shall be deemed to be included in the definition of &#147;Committed Shares&#148; and the
undertakings and agreements as set out in this deed in relation to such Committed Shares shall be performed as soon as reasonably practicable but by no later than one Business Day following the earlier of (i)&nbsp;the date of allotment;
(ii)&nbsp;the registration of the relevant securities in Carlyle&#146;s (or any Affiliate of Carlyle&#146;s) name; or (iii)&nbsp;when Carlyle (or any of its Affiliates) become the beneficial owner or are otherwise entitled to exercise voting rights
in respect of such securities (as applicable). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Carlyle acknowledges that some or all of the information and any terms or other statements made in the course
of, or for the purpose of, negotiations relating to the Transaction (including for the purposes of this irrevocable undertaking) may constitute inside information) and is aware of the prohibitions against insider dealing, encouraging dealing or
disclosing such information contained in applicable legislation and agrees to abide by them. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Scheme </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Carlyle hereby agrees and undertakes to do the following and to procure that its Connected Persons (where
relevant) comply with the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to <FONT STYLE="white-space:nowrap">co-operate</FONT> with you in the production of the Orca Scheme Document,
any associated or supplementary document containing the formal Scheme; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to take no action which may reasonably be viewed as, and which has the intent of being, prejudicial to the
successful outcome of the Orca Scheme. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without limitation and in addition to the general voting undertakings granted in paragraph 5 below, Carlyle
shall exercise (or, where applicable, procure the exercise of) all voting rights (whether on a show of hands or a poll and whether in person or by proxy) attaching to Committed Shares: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at any meeting(s) of Orca Shareholders to be convened by order of the English Court (including any adjournments
or postponements thereof, the &#147;<B>Court Meeting</B>&#148;), in favour of the resolutions at the Court Meeting to vote to approve, implement or effect the Orca Scheme (the &#147;<B>Orca Scheme Resolution</B>&#148;); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at any general meeting (including any adjournments or postponements thereof, the &#147;<B>General
Meeting</B>&#148;) of Orca Shareholders which is convened by Orca in connection with the Orca Scheme, in favour of the resolutions at the General Meeting to approve, implement or effect the Orca Scheme and all related matters (including any proposed
amendment to the articles of association of Orca) (the &#147;<B>GM Resolution</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In particular and without limiting paragraph 4.1 above, as soon as possible and in any event not later than
1:00 p.m. on the date falling five Business Days after the deemed date of receipt of (a)&nbsp;the Orca Scheme Document and (b)&nbsp;the accompanying forms of proxy, Carlyle shall in respect of Committed Shares: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">execute and deliver to Orca (in accordance with the delivery instructions contained therein) (or procure the
execution and delivery to Orca of) such forms of proxy in accordance with the instructions printed on such forms of proxy; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in respect of any Committed Shares in uncertificated form, take (or procure the taking of) any action to make a
valid proxy appointment and give valid proxy instructions, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">to vote in favour of each of the resolutions to be proposed
at the Court Meeting and the General Meeting and, unless instructed to do so by Laguna, shall not thereafter revoke such forms of proxy or proxy appointments and proxy instructions, either in writing or by attendance at any meeting or otherwise.
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In order to secure the lawful passing of the Orca Requisite Vote (or any of the relevant resolutions comprising
the Orca Requisite Vote), if so advised by Counsel and/or confirmed by the English Court at the Orca Scheme Convening Hearing as a lawful means of securing the same, or otherwise reasonably directed by Laguna and Orca, Carlyle hereby undertakes to
direct GTU Ops Inc. and/or Computershare Trust Company N.V. (together &#147;<B>Computershare</B>&#148;) to transfer the legal title in one or more of its Committed Shares, as advised by Counsel, confirmed by the English Court and/or reasonably
directed by Laguna and Orca (as applicable), directly in Carlyle&#146;s name in sufficient time prior to the Voting Record Time (the &#147;<B>Directly Held Shares</B>&#148;) and by no later than five (5)&nbsp;Business Days prior to such date unless
otherwise requested by Laguna and Orca, and to do all such other things to ensure that Carlyle is able to lawfully vote or to procure that the votes on such share(s) and Carlyle hereby further undertakes to exercise all voting rights (whether on a
show of hands or a poll and whether in person or by proxy) in the Directly Held Shares in favour of each of the resolutions relating to the Orca Requisite Vote. For the avoidance of doubt, pursuant to the terms of paragraph 3 above, Carlyle shall
not direct Computershare to transfer the legal title of any of my Committed Shares other than as specifically required by this paragraph 4.4. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Voting &#150; General </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In each case save as specifically set out in paragraph 4: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Carlyle shall exercise (or procure the exercise of) the voting rights attached to Committed Shares on any
resolution which would assist the implementation of the Orca Scheme. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Carlyle shall exercise (or procure the exercise of) the voting rights attached to Committed Shares against any
resolution: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the effect that the text or terms of the resolutions to be proposed at the General Meeting to approve the
Orca Scheme and all related matters be amended, except in the case of amendments in accordance with the BCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to adjourn the General Meeting except in accordance with paragraph 5.3(f) of the BCA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in favour of (i)&nbsp;any Acquisition Proposal of Orca, or (ii)&nbsp;any other action that would reasonably be
expected to impede, interfere with, delay, postpone or adversely affect the Transaction. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Technical Revision </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In this deed, references to the &#147;<B>Orca</B> <B>Scheme</B>&#148; and &#147;<B>Transaction</B>&#148; shall include any revision agreed as
between Orca and Laguna to the Orca Scheme that is a Technical Revision, and, in such circumstances, all of Carlyle&#146;s obligations as set out in this deed shall continue to apply <I>mutatis mutandis</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Warranties and additional undertakings </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Carlyle hereby warrants and undertakes: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the information in relation to the &#147;interests&#148; (as defined in paragraph 1 of Annex 1 hereto) of
Carlyle and its Affiliates in Orca as set out in Annex I hereto (including the information referred to in paragraph 2.1 above) is complete and accurate and, other than as set out in Annex I hereto, Carlyle (and its Affiliates) have no interest in
any Orca Shares or other securities or interests of Orca; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that Carlyle shall transfer (or procure the transfer of) Committed Shares fully paid and free from Encumbrances
and together with all rights attaching or accruing to them at the time of such transfer under the Orca Scheme, including voting rights and the right to receive and retain in full all dividends of any nature and other distributions (if any) declared,
made or paid after the date of such transfer under the Orca Scheme; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any information provided by Carlyle for inclusion in the Orca Scheme Document or the BCA, and any other
announcement or document issued in connection with the Combinations, is and will be true, accurate and not misleading. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Announcements, information and documentation </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Carlyle consents to the inclusion of references to it and its Connected Persons and the provisions of this deed
in the BCA, the Orca Scheme Document and any document in connection with the Combinations that is required by any other legal or regulatory requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Carlyle consents to this deed being published on a website or on or through such other media or platform as may
be necessary in conjunction with the implementation of the Orca Scheme. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All of Carlyle&#146;s obligations, save for the Surviving Covenants (as defined in and in accordance with
paragraph 9.2 below), under this deed shall, without prejudice to any prior breaches, terminate upon the earliest of (a)&nbsp;the Orca Effective Time or (b)&nbsp;the termination of the BCA in accordance with its terms (such earliest date being
referred to herein as the &#147;<B>Termination Date</B>&#148;); provided, that any liability incurred by any party hereto as a result of a breach of a term or condition of this deed prior to such termination shall survive the termination of this
deed. For the avoidance of doubt, except as provided in the immediately preceding sentence, this deed shall not terminate upon a Change in Orca Recommendation (as defined in the BCA) or a Change in Laguna Recommendation (as defined in the BCA).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this deed is terminated in accordance with paragraph 9.1 above, the covenants and undertakings set out in in
paragraphs 1.2, 2.1.B and 10 and 11 (inclusive) of this deed (the &#147;<B>Surviving Covenants</B>&#148;) shall survive termination of this deed. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notices </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any notice, consent or other communication given under this deed shall be in writing and in English and signed
by or on behalf of the party giving it, and shall be delivered by hand or sent by prepaid recorded or special delivery post (or prepaid international recorded airmail if sent internationally) or email in accordance with the details set out:
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>If to Carlyle, to: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">c/o The Carlyle Group</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">One Vanderbilt Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Suite 3400</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">New York, NY 10017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stephen H. Wise</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Zachary Marshall</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>With a copy (which shall not constitute notice): </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Latham&nbsp;&amp; Watkins LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">555 Eleventh Street, N.W., Suite 1000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Washington, D.C. 20004</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention: David I. Brown</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email: [***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>If to Orca, to: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Ortho Clinical Diagnostics Holdings plc</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">1001 US Route 202</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Raritan, NJ 08869</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Christopher Smith</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Michael Schlesinger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>If to Laguna, to: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Quidel Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">9975 Summers Ridge Rd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">San Diego, CA 92121</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Robert Bujarski</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Michelle Hodges</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>with a copy (which shall not constitute notice) to: </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Gibson Dunn&nbsp;&amp; Crutcher LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">555 Mission Street, Suite 3000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">San Francisco, CA 94105-0921</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">United States of America</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ryan A. Murr</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stephen I. Glover</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Branden C. Berns</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties may from time to time notify each other of any other Person or address for the receipt of notices
or copy notices. Any such change shall take effect five Business Days after notice of the change is received or (if later) on the date (if any) specified in the notice as the date on which the change is to take place. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any notice, consent or other communication given in accordance with paragraph 10.1 and received after 5.30 p.m.
on a Business Day, or on any day which is not a Business Day, shall for the purposes of this deed be regarded as received on the next Business Day. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, nothing in this deed shall oblige Orca or Laguna to effect the Combinations.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any date, time or period referred to in this deed shall be of the essence except to the extent to which each of
Orca, Laguna and Carlyle agrees in writing to vary any date, time or period, in which event the varied date, time or period shall be of the essence. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cross-references in this deed to provisions or clauses of the BCA which are incorporated by reference and form
part of this deed shall, for the avoidance of doubt, include all relevant provisions of the BCA which relate to (for purposes of interpretation and/or meaning) or are directly referred to in such cross-referenced provisions or clauses including but
not limited to any relevant definitions, interpretation provisions, recitals or schedules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No party to this deed may assign or otherwise dispose of any rights under this deed, at law or in equity,
including by way of declaration of trust, without the consent of the other parties to this deed. Any purported assignment in breach of this paragraph shall be void and confer no rights on the purported assignee. This deed shall be binding on
Carlyle&#146;s successors and assigns. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except to the extent otherwise specified, Carlyle&#146;s obligations set out in this deed are unconditional and
irrevocable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With regard to any Committed Shares not registered in Carlyle&#146;s name (or the name of any Carlyle
Affiliate), the confirmations, warranties and undertakings contained in this deed are given by Carlyle on behalf of the registered holder(s) and Carlyle undertakes to ensure the compliance by such Person(s) with those confirmations, warranties and
undertakings. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this deed: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all references to time are to London time; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Person will be treated as having an interest in securities if: (i)&nbsp;they own them; (ii)&nbsp;they have
the right (whether conditional or absolute) to exercise or direct the exercise of the voting rights attaching to them or has general control of them; (iii)&nbsp;by virtue of any agreement to purchase, option or derivative they: (a)&nbsp;have the
right or option to call for their delivery, or (b)&nbsp;are under an obligation to take delivery of them, whether the right, option or obligation is conditional or absolute and whether it is in the money or otherwise; or (iv)&nbsp;they are a party
to any derivative whose value is determined by reference to their price and which results, or may result, in them having a long position in them. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Person who is not party to this deed has no right under the Contracts (Rights of Third Parties) Act 1999 to
enforce any term of this deed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The invalidity, illegality or unenforceability of any provision of this deed shall not affect the continuation
in force of the remainder of this deed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This deed, the Orca Scheme Document, the Confidentiality Agreement and the agreements referred to herein and
therein contain the whole agreement between Orca, Laguna and Carlyle relating to the subject matter of this deed at the date hereof to the exclusion of any terms implied by law which may be excluded by contract. Carlyle acknowledges that it has not
been induced to sign this deed by any representation, warranty or undertaking not expressly incorporated into it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Carlyle agrees that damages would not be an adequate remedy for breach by it of any of its obligations under or
pursuant to this deed and accordingly, without prejudice to any other rights or remedies that Orca and Laguna may have, that Orca and/or Laguna shall be entitled to the remedies of specific performance, injunction or other equitable relief for any
threatened or actual breach of any such obligations and no proof of special damages shall be necessary for the enforcement by any party of their rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This deed (and any dispute, controversy, proceedings or claim of any nature arising out of or in connection
with it, including <FONT STYLE="white-space:nowrap">non-contractual</FONT> disputes and claims) shall be governed and construed in accordance with English law. The parties agree to irrevocably submit to the exclusive jurisdiction of the English
courts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of page intentionally left blank; signature page to follow] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS</B> whereof this document has been duly executed and delivered as a deed on the date above
mentioned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Signed</B> as a <B>Deed</B> by </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carlyle
Partners VI Cayman Holdings, L.P.</B>, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in accordance with the laws </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of its country of incorporation </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>By: TC Group VI Cayman, L.P.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Its: General Partner </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>By: TC Group VI Cayman,
L.L.C. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Its: General Partner </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert Schmidt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Robert Schmidt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Person</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERESTS IN ORCA </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interests in Orca </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carlyle&#146;s &#147;interests&#148; (as defined in Part 22 of the Companies Act 2006) including those of its Affiliates in the securities (including
securities convertible thereto, rights to subscribe therefor, options (including traded options) in respect thereof and derivatives referenced thereto) of Orca on the date hereof are as stated below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Registered Holder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number of shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Share class/ class of security</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GTU OPS INC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CARLYLE PARTNERS VI CAYMAN HOLDINGS LP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">118,106,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ordinary Shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CARLYLE PARTNERS VI CAYMAN HOLDINGS LP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CARLYLE PARTNERS VI CAYMAN HOLDINGS LP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">50,001</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Deferred Shares</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="annxd"></A><A NAME="rom273090_215"></A>Annex D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Opinion of Perella Weinberg Partners LP </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g273090g98m94.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">767 Fifth Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">New York, NY 10153</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">T 212.287.3200</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">F 212.287.3201</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="right">pwpartners.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">December 22, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Quidel Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">9975 Summers Ridge Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">San Diego, CA 92121 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Members of the Board: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We understand that Quidel Corporation, a Delaware corporation (the &#147;<U>Company</U>&#148;), Ortho Clinical Diagnostics Holdings plc, a public
limited company incorporated under the laws of England and Wales (&#147;<U>Ortho</U>&#148;), Coronado Topco, Inc., a Delaware corporation and a wholly owned subsidiary of Ortho (&#147;<U>Topco</U>&#148;), Laguna Merger Sub, Inc., a Delaware
corporation and a wholly owned subsidiary of Topco (&#147;<U>U.S. Merger Sub</U>&#148;), Orca Holdco, Inc., a Delaware corporation and wholly owned subsidiary of Topco (&#147;<U>U.S. Holdco Sub</U>&#148;), and Orca Holdco 2, Inc., a Delaware
corporation and wholly owned subsidiary of U.S. Holdco Sub (&#147;<U>U.S. Holdco Sub 2</U>&#148;), propose to enter into a Business Combination Agreement (the &#147;<U>Business Combination Agreement</U>&#148;) pursuant to which, among other things,
(a)&nbsp;Ortho and Topco will undergo a scheme of arrangement (the &#147;Ortho<U> Scheme</U>&#148;) pursuant to which, through a series of transactions, each issued and outstanding ordinary share, par value $0.00001 per share (each, an
&#147;<U>Ortho Ordinary Share</U>&#148;), of Ortho, other than any Ortho Ordinary Shares held by Ortho in treasury, will be exchanged for a combination of (i) 0.1055 shares of common stock, par value $0.001 per share (the &#147;<U>Topco Common
Stock</U>&#148;), of Topco (the &#147;<U>Stock Consideration</U>&#148;) and (ii) $7.14 in cash (the &#147;<U>Cash Consideration</U>&#148; and, together with the Stock Consideration, the &#147;<U>Consideration</U>&#148;), and as a result of which
Ortho will become a wholly owned subsidiary of Topco, and (b)&nbsp;U.S. Merger Sub will merge with and into the Company immediately following consummation of the Ortho Scheme, with the Company surviving the merger as a wholly owned subsidiary of
Topco (the &#147;<U>Company Merger</U>&#148; and, together with the Ortho Scheme, the &#147;<U>Combinations</U>&#148;), pursuant to which each share of common stock, par value $0.001 per share, of the Company (the &#147;<U>Company Common
Stock</U>&#148;), other than Company Common Stock owned by the Company, Ortho or U.S. Merger Sub, shall be converted into the right to receive one share (the &#147;<U>Company Exchange Ratio</U>&#148;) of Topco Common Stock. The terms and conditions
of the Combinations are more fully set forth in the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">You have requested our opinion as to the fairness, from a
financial point of view, to the Company of the Consideration to be paid by the Company pursuant to the Business Combination Agreement taking into account the Company Exchange Ratio. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For purposes of the opinion set forth herein, we have, among other things: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:ARIAL">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reviewed certain publicly available financial statements and other business and financial information with respect
to the Company and Ortho, including equity research analyst reports; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:ARIAL">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reviewed certain internal financial
statements, analyses and forecasts, including sensitivities thereto (the &#147;<U>Company Forecasts</U>&#148;), and other financial and operating data relating to the business of the Company, in each case, prepared by management of the Company; </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">www.pwpartners.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Partners have limited liability status </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">D-1
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:ARIAL">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reviewed certain internal financial statements, analyses and
forecasts (the &#147;<U>Ortho Forecasts</U>&#148;), and other financial and operating data relating to the business of Ortho, in each case, prepared by management of Ortho and approved for our use by management of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:ARIAL">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reviewed certain internal financial statements, analyses and forecasts (the &#147;<U>Company Ortho
Forecasts</U>&#148;) relating to the business of Ortho prepared by management of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:ARIAL">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reviewed
estimates of synergies anticipated by the Company&#146;s and Ortho&#146;s management to result from the Combinations (collectively, the &#147;<U>Anticipated Synergies</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:ARIAL">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; discussed the past and current business, operations, financial condition and prospects of the Company, including
the Anticipated Synergies, with the management and other representatives of the Company, and discussed the past and current business, operations, financial condition and prospects of Ortho with the management and other representatives of the
Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:ARIAL">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reviewed the relative financial contributions of the Company and Ortho to the future financial
performance of Topco on a pro forma basis; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:ARIAL">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; compared the financial performance of the Company and Ortho with
that of certain other publicly traded companies which we believe to be generally relevant; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:ARIAL">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; compared the
financial terms of the proposed Combinations with the publicly available financial terms of certain transactions which we believe to be generally relevant; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:ARIAL">10.&nbsp;&nbsp;&nbsp;&nbsp; reviewed the historical trading prices and trading activity for the Company Common Stock and Ortho Ordinary Shares, and
compared such prices and trading activity of the Company Common Stock and Ortho Ordinary Shares with those of securities of certain other publicly traded companies which we believe to be generally relevant; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:ARIAL">11.&nbsp;&nbsp;&nbsp;&nbsp; participated in discussions among representatives of the Company and Ortho and their respective advisors; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:ARIAL">12.&nbsp;&nbsp;&nbsp;&nbsp; reviewed a draft, dated December 22, 2021, of the Business Combination Agreement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:ARIAL">13.&nbsp;&nbsp;&nbsp;&nbsp; conducted such other financial studies, analyses and investigations, and considered such other factors, as we have deemed
appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In arriving at our opinion, we have assumed and relied upon, without independent verification, the accuracy and completeness of the
financial and other information supplied or otherwise made available to us (including information that is available from generally recognized public sources) for purposes of this opinion and have further relied upon the assurances of the management
of the Company that, to their knowledge, the information furnished, or approved for our use, by them for purposes of our analysis does not contain any material omissions or misstatements of material fact. With respect to the Company Forecasts, we
have been advised by the management of the Company, and have assumed, with your consent, that they have been reasonably prepared on bases reflecting the best currently available estimates and good faith judgments of the management of the Company as
to the future stand-alone financial performance of the Company and the other matters covered thereby and we express no view as to the assumptions on which they are based. With respect to the Ortho Forecasts, we have assumed, with your consent, that
they have been reasonably prepared on bases reflecting the best currently available estimates and good faith judgments of the management of Ortho as to the future stand-alone financial performance of Ortho and the other matters covered thereby and
we express no view as to the assumptions on which they are based. With respect to the Company Ortho Forecasts, we have assumed, with your consent, that they have been reasonably prepared on bases reflecting the best currently available estimates and
good faith judgments of the management of the Company as to the future stand-alone financial performance of Ortho and the other matters covered thereby and we express no view as to the assumptions on which they are based. We have assumed, with your
consent, that the Anticipated Synergies and potential strategic implications and operational benefits (including the amount, timing and achievability thereof) anticipated by management of the Company to result from the Combinations will be realized
in the amounts and at the times projected by management of the Company, and we express no view as to the assumptions on which they are based. We have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">www.pwpartners.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Partners have limited liability status </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">D-2
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
relied without independent verification upon the assessment by the management of the Company of the timing and risks associated with the integration of the Company and Ortho. In arriving at our
opinion, we have not made any independent valuation or appraisal of the assets or liabilities (including any contingent, derivative or off-balance-sheet assets and liabilities) of the Company or Ortho, nor have we been furnished with any such
valuations or appraisals. We have not assumed any obligation to conduct, nor have we conducted, any physical inspection of the properties or facilities of the Company or Ortho. In addition, we have not evaluated the solvency of any party to the
Business Combination Agreement (or the impact of the Combinations thereon), including under any applicable laws relating to bankruptcy, insolvency or similar matters. We have assumed that the final executed Business Combination Agreement will not
differ from the form of the Business Combination Agreement reviewed by us in any respect material to our analysis, and that the Combinations will be consummated in accordance with the terms set forth in the Business Combination Agreement, without
modification, waiver or delay in any respect material to our analysis. We also have assumed that the Company Merger and the Ortho Scheme, taken together as a single integrated transaction, will qualify as an exchange described under Section&nbsp;351
of the U.S. Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;) and that the Company Merger will also qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code. In addition, we have assumed
that in connection with the receipt of all the necessary approvals for the Combinations, no delays, limitations, conditions or restrictions will be imposed that could have an adverse effect on the Company, Ortho or the contemplated benefits expected
to be derived in the proposed Combinations, in each case, in any way meaningful to our analysis. We have relied as to all legal matters relevant to rendering our opinion upon the advice of counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This opinion addresses only the fairness from a financial point of view, as of the date hereof, of the Consideration provided for in the Business
Combination Agreement to the Company taking into account the Company Exchange Ratio. We have not been asked to, nor do we, offer any opinion as to any other term of the Business Combination Agreement or any other document contemplated by or to be
entered into in connection with the Business Combination Agreement or the form or structure of the Combinations or the likely timeframe in which the Combinations will be consummated. In addition, we express no opinion as to the fairness of the
amount or nature of any compensation to be received by any officers, directors or employees of any parties to the Business Combination Agreement, or any class of such persons, whether relative to the Consideration or otherwise. We do not express any
opinion as to any tax or other consequences that may result from the transactions contemplated by the Business Combination Agreement or any related document, nor does our opinion address any legal, tax, regulatory or accounting matters, as to which
we understand the Company has received such advice as it deems necessary from qualified professionals. Our opinion does not address the underlying business decision by the Company to enter into the Business Combination Agreement or the relative
merits of the Combinations as compared with any other strategic alternative which may be available to the Company. We have not been authorized to solicit, and have not solicited, indications of interest in a transaction with the Company from any
party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have acted as financial advisor to the Company in connection with the Combinations and will receive a fee for our services, a portion of
which is payable upon the rendering of this opinion (or would have become payable if we had determined that we were not able to deliver this opinion) and a significant portion of which is contingent upon the consummation of the Combinations. In
addition, the Company has agreed to reimburse us for certain expenses that may arise, and indemnify us for certain liabilities and other items that may arise, out of our engagement. During the two year period prior to the date hereof, no material
relationship existed between Perella Weinberg Partners LP and its corporate advisory affiliates and Ortho pursuant to which compensation was received by Perella Weinberg Partners LP or its corporate advisory affiliates. In the past, Perella Weinberg
Partners LP and its corporate advisory affiliates have provided financial advisory services unrelated to the Combinations to The Carlyle Group, a controlling shareholder of Ortho, or its affiliates pursuant to which compensation was received by
Perella Weinberg Partners LP or its affiliates. In the past, Perella Weinberg Partners LP and its affiliates have provided financial advisory and other financial services to the Company and its affiliates unrelated to the Combinations, for which
they have received compensation. Perella Weinberg Partners LP and its corporate advisory affiliates in the future may provide investment banking and other financial services to the Company, Ortho, The Carlyle Group and their respective affiliates
and in the future may receive compensation for the rendering of such services. In the ordinary course of our business activities, Perella </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">www.pwpartners.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Partners have limited liability status </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">D-3
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Weinberg Partners LP or its affiliates may at any time hold long or short positions, and may trade or otherwise effect transactions, for our own account or the accounts of customers or clients,
in debt or equity or other securities (or related derivative securities) or financial instruments (including bank loans or other obligations) of the Company, Ortho, The Carlyle Group or any of their respective affiliates. The issuance of this
opinion was approved by a fairness opinion committee of Perella Weinberg Partners LP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This opinion is for the information and assistance of the
Board of Directors of the Company in connection with, and for the purposes of its evaluation of, the Combinations. This opinion is not intended to be and does not constitute a recommendation to any holder of Company Common Stock or Ortho Ordinary
Shares, or any other person, as to how such person should vote or otherwise act with respect to the proposed Combinations or any other matter and does not in any manner address the prices at which the Company Common Stock, the Ortho Ordinary Shares
or the Topco Common Stock will trade at any time. In addition, we express no opinion as to the fairness of the Combinations to, or any consideration received in connection with the Combinations by, the holders of any other class of securities,
creditors or other constituencies of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our opinion is necessarily based on financial, economic, market and other conditions as in effect
on, and the information made available to us as of, the date hereof. It should be understood that subsequent developments may affect this opinion and the assumptions used in preparing it, and we do not have any obligation to update, revise, or
reaffirm this opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based upon and subject to the foregoing, including the various assumptions and limitations set forth herein, we are of the
opinion that, taking into account the Company Exchange Ratio, as of the date hereof, the Consideration to be paid by the Company pursuant to the Business Combination Agreement is fair, from a financial point of view, to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">/s/ Perella Weinberg Partners LP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">PERELLA WEINBERG PARTNERS LP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">www.pwpartners.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Partners have limited liability status </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">D-4
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="annxe"></A><A NAME="rom273090_216"></A>Annex E </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g273090g90a70.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;23, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho Clinical Diagnostics Holdings plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1001 Route 202 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Raritan, NJ 08869 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Board of Directors: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You have requested our
opinion as to the fairness, from a financial point of view, to the holders of shares, par value $0.00001&nbsp;per share (the &#147;Company Shares&#148;), of Ortho Clinical Diagnostics Holdings plc (the &#147;Company&#148;), a public limited company
incorporated under the laws of England and Wales, of the consideration to be paid to such holders in the proposed Transaction (as defined below). Pursuant to the Business Combination Agreement, dated as of December&nbsp;22, 2021 (the
&#147;Agreement&#148;), among Quidel Corporation (the &#147;Merger Partner&#148;), a Delaware corporation, Coronado Topco, Inc. (&#147;Topco&#148;), a Delaware corporation and wholly owned subsidiary of the Company, Laguna Merger Sub, Inc.
(&#147;Merger Subsidiary&#148;), a Delaware corporation and wholly owned subsidiary of Topco, Orca Holdco, Inc. (&#147;Holdco Subsidiary&#148;) a Delaware corporation and a wholly owned subsidiary of Topco,<B> </B>Orca Holdco 2, Inc. (&#147;Holdco
Subsidiary 2&#148;), a Delaware corporation and a wholly owned subsidiary of Holdco Subsidiary, and the Company,<B> </B>(i)&nbsp;the Company and Topco will effect a scheme of arrangement, in accordance with the laws of England and Wales (the
&#147;Company Scheme&#148;), upon the consummation of which each Company Share, other than Company Shares held in treasury, will be<B> </B>acquired by (or transferred within) a nominee on behalf of Topco in exchange for the right to receive
consideration per share equal to $7.14 in cash (the &#147;Cash Consideration&#148;)<B> </B>and<B> </B>0.1055 shares (the &#147;Stock Consideration&#148;, and together with the Cash Consideration, the &#147;Consideration&#148;) of common stock, par
value $0.001 per share, of Topco (the &#147;Topco Common Stock&#148;), such that the Company will become a wholly owned subsidiary of Topco and (ii)&nbsp;immediately following the Company Scheme, Merger Subsidiary will merge with and into the Merger
Partner, with the Merger Partner surviving the merger as a wholly owned subsidiary of Topco, and each share of common stock of the Merger Partner, par value $0.001 per share (the &#147;Merger Partner Shares&#148;), other than Merger Partner Shares
owned by the Merger Partner, the Company, Topco, Merger Subsidiary or any of their respective wholly owned subsidiaries, will be converted into the right to receive one share of Topco Common Stock (the transactions described in clauses (i)&nbsp;and
(ii), collectively, the &#147;Transaction&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with preparing our opinion, we have (i)&nbsp;reviewed the Agreement; (ii)&nbsp;reviewed
certain publicly available business and financial information concerning the Company and the Merger Partner and the industries in which they operate; (iii)&nbsp;compared the financial and operating performance of the Company and the Merger Partner
with publicly available information concerning certain other companies we deemed relevant and reviewed the current and historical market prices of the Company Shares and the Merger Partner Shares and certain publicly traded securities of such other
companies; (iv)&nbsp;reviewed certain internal financial analyses and forecasts prepared by the management of the Company relating to its business and the Merger Partner&#146;s business, as well as the estimated amount and timing of the cost savings
and related expenses and synergies expected to result from the Transaction (the &#147;Synergies&#148;); and (v)&nbsp;performed such other financial studies and analyses and considered such other information as we deemed appropriate for the purposes
of this opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we have held discussions with certain members of the management of the Company and the Merger Partner with respect to
certain aspects of the Transaction, and the past and current business operations of the Company and the Merger Partner, the financial condition and future prospects and operations of the Company, the Merger Partner and Topco, the effects of the
Transaction on the financial condition and future prospects of the Company, the Merger Partner and Topco, and certain other matters we believed necessary or appropriate to our inquiry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In giving our opinion, we have relied upon and assumed the accuracy and completeness of all information that was publicly available or was furnished to or
discussed with us by the Company and the Merger Partner or otherwise reviewed by or for us. We have not independently verified any such information or its accuracy or completeness and, pursuant to our engagement letter with the Company, we did not
assume any obligation to undertake any such independent verification. We have not conducted or been provided with any valuation or appraisal of any assets or liabilities, nor have we evaluated the solvency of the Company, the Merger Partner or Topco
under any state or federal laws relating to bankruptcy, insolvency or similar matters. In relying on financial analyses and forecasts provided to us or derived therefrom, including the Synergies, we have assumed that they have been reasonably
prepared based on assumptions reflecting the best currently available </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
estimates and judgments by management as to the expected future results of operations and financial condition of the Company and the Merger Partner to which such analyses or forecasts relate. We
express no view as to such analyses or forecasts (including the Synergies) or the assumptions on which they were based. We have also assumed that the Transaction and the other transactions contemplated by the Agreement will qualify as a <FONT
STYLE="white-space:nowrap">tax-free</FONT> reorganization for United States federal income tax purposes, and will be consummated as described in the Agreement. We have also assumed that the representations and warranties made by the Company and the
Merger Partner in the Agreement and the related agreements are and will be true and correct in all respects material to our analysis. We are not legal, regulatory or tax experts and have relied on the assessments made by advisors to the Company with
respect to such issues. We have further assumed that all governmental, regulatory or other consents and approvals necessary for the consummation of the Transaction will be obtained without any adverse effect on the Company, the Merger Partner or
Topco or on the contemplated benefits of the Transaction, in each case, that would be material to our analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is necessarily based on
economic, market and other conditions as in effect on, and the information made available to us as of, the date hereof. It should be understood that subsequent developments may affect this opinion and that we do not have any obligation to update,
revise, or reaffirm this opinion. Our opinion is limited to the fairness, from a financial point of view, of the Consideration to be paid to the holders of the Company Shares in the proposed Transaction and we express no opinion as to the fairness
of any consideration to be paid in connection with the Transaction to the holders of any other class of securities, creditors or other constituencies of the Company or as to the underlying decision by the Company to engage in the Transaction.
Furthermore, we express no opinion with respect to the amount or nature of any compensation to any officers, directors, or employees of any party to the Transaction, or any class of such persons relative to the Consideration to be paid to the
holders of the Company Shares in the Transaction or with respect to the fairness of any such compensation<B>. </B>We are expressing no opinion herein as to the price at which the Company Shares, the Merger Partner Shares or shares of Topco Common
Stock will trade at any future time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We note that we were not authorized to and did not solicit any expressions of interest from any other parties with
respect to the sale of all or any part of the Company or any other alternative transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as financial advisor to the Company with
respect to the proposed Transaction and will receive a fee from the Company for our services, a substantial portion of which will become payable only if the proposed Transaction is consummated. In addition, the Company has agreed to indemnify us for
certain liabilities arising out of our engagement. During the two years preceding the date of this letter, we and our affiliates have had commercial or investment banking relationships with the Company, for which we and such affiliates have received
customary compensation. Such services during such period have included acting as joint lead bookrunner on offerings of debt securities of Company subsidiaries in May 2020 and January 2020, and joint lead bookrunner on offerings of the Company&#146;s
equity securities in September 2021 and January 2021. During the two years preceding the date of this letter, we and our affiliates have had commercial or investment banking relationships with The Carlyle Group Inc. (&#147;Carlyle&#148;), the
Company&#146;s approximately 50% shareholder, for which we and such affiliates have received customary compensation. Such services during such period have included acting as joint lead bookrunner on an offering of debt securities of a Carlyle
subsidiary in May 2021. In addition, during the two years preceding the date of this letter, we and our affiliates have had commercial or investment banking relationships with Carlyle portfolio companies for which we and such affiliates have
received customary compensation. Such services during such period have included providing debt syndication, equity underwriting, debt underwriting and financial advisory services to Carlyle portfolio companies. Our commercial banking affiliate is an
agent bank and a lender under outstanding credit facilities of Carlyle and Carlyle portfolio companies for which it receives customary compensation or other financial benefits. Please be advised that during the two years preceding the date of this
letter, neither we nor our affiliates have had any material financial advisory or other material commercial or investment banking relationships with the Merger Partner. In addition, we and our affiliates hold, on a proprietary basis, less than 1% of
the outstanding shares of each of the Company, Carlyle and the Merger Partner. In the ordinary course of our businesses, we and our affiliates may actively trade the debt and equity securities or financial instruments (including derivatives, bank
loans or other obligations) of the Company, Carlyle or the Merger Partner for our own account or for the accounts of customers and, accordingly, we may at any time hold long or short positions in such securities or other financial instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of and subject to the foregoing, it is our opinion as of the date hereof that the Consideration to be paid to the holders of the Company Shares
in the proposed Transaction is fair, from a financial point of view, to such holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of this opinion has been approved by a fairness
opinion committee of J.P. Morgan Securities LLC. This letter is provided to the Board of Directors of the Company (in its capacity as such) in connection with and for the purposes of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
evaluation of the Transaction. This opinion does not constitute a recommendation to any shareholder of the Company as to how such shareholder should vote with respect to the Transaction or any
other matter. This opinion may not be disclosed, referred to, or communicated (in whole or in part) to any third party for any purpose whatsoever except with our prior written approval. This opinion may be reproduced in full in any registration,
proxy or information statement mailed to shareholders of the Company but may not otherwise be disclosed publicly in any manner without our prior written approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g273090g90a80.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">F413191 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom273090_217"></A>Annex F </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2021 </B></P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE COMPANIES ACT 2006 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIVATE COMPANY LIMITED BY SHARES </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES OF ASSOCIATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">of </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORTHO CLINICAL DIAGNOSTICS
HOLDINGS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[LIMITED] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Company Number 13084624 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Adopted
by special resolution passed on [&#9679;]<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g273090g11i11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 Bishopsgate </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">London EC2M 3XF </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">United Kingdom
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tel: +44.20.7710.1000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.lw.com </P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Note to draft: Date of special resolution adopting articles to be included. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Article</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DISAPPLICATION OF MODEL ARTICLES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-i</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DEFINITIONS AND INTERPRETATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-i</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITY OF MEMBERS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-iii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DIRECTORS&#146; GENERAL AUTHORITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-iii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>COMPANY NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-iii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>6.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>MEMBERS&#146; RESERVE POWER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-iii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DIRECTORS MAY DELEGATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-iii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>COMMITTEES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-iii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>9.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DIRECTORS TO TAKE DECISIONS COLLECTIVELY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-iii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>UNANIMOUS DECISIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-iv</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CALLING A DIRECTORS&#146; MEETING</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-iv</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>12.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PARTICIPATION IN DIRECTORS&#146; MEETINGS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-iv</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>13.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>QUORUM FOR DIRECTORS&#146; MEETINGS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-iv</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>14.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CHAIRING OF DIRECTORS&#146; MEETINGS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-v</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>15.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASTING VOTE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-v</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>16.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DIRECTORS&#146; INTERESTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-v</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>17.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFLICTS OF INTEREST</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-vi</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>18.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>RECORDS OF DECISIONS TO BE KEPT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-vii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>19.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DIRECTORS&#146; DISCRETION TO MAKE FURTHER RULES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-vii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>20.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NUMBER OF DIRECTORS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-vii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>21.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>METHODS OF APPOINTING DIRECTORS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-vii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>22.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TERMINATION OF DIRECTOR&#146;S APPOINTMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-viii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>23.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>APPOINTMENT AND REMOVAL BY SOLE OR MAJORITY MEMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-viii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>24.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DIRECTORS&#146; REMUNERATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-viii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>25.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DIRECTORS&#146; EXPENSES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-ix</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>26.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>COMPANY SECRETARY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-ix</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>27.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ALL SHARES TO BE FULLY PAID</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-ix</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>28.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>POWER TO ALLOT SHARES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-ix</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>29.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>POWERS TO ISSUE DIFFERENT CLASSES OF SHARE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-ix</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>30.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>COMPANY NOT BOUND BY LESS THAN ABSOLUTE INTERESTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-ix</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>31.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SHARE CERTIFICATES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-x</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>32.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>REPLACEMENT SHARE CERTIFICATES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-x</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>33.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SHARE TRANSFERS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-x</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>34.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TRANSMISSION OF SHARES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-x</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>35.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>EXERCISE OF TRANSMITTEES&#146; RIGHTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xi</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>36.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TRANSMITTEES BOUND BY PRIOR NOTICES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xi</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>37.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROCEDURE FOR DECLARING DIVIDENDS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xi</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>38.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PAYMENT OF DIVIDENDS AND OTHER DISTRIBUTIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xi</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>39.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NO INTEREST ON DISTRIBUTIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>40.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>UNCLAIMED DISTRIBUTIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>41.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">NON-CASH</FONT> DISTRIBUTIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>42.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>WAIVER OF DISTRIBUTIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>43.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AUTHORITY TO CAPITALISE AND APPROPRIATION OF CAPITALISED SUMS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xiii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>44.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ATTENDANCE AND SPEAKING AT GENERAL MEETINGS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xiii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>45.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>QUORUM FOR GENERAL MEETINGS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xiv</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>46.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CHAIRING GENERAL MEETINGS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xiv</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>47.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ATTENDANCE AND SPEAKING BY DIRECTORS AND
<FONT STYLE="white-space:nowrap">NON-MEMBERS</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xiv</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>48.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ADJOURNMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xiv</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>49.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>VOTING: GENERAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xv</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>50.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ERRORS AND DISPUTES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xv</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>51.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>POLL VOTES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xv</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>52.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONTENT OF PROXY NOTICES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xv</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>53.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DELIVERY OF PROXY NOTICES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xvi</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>54.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AMENDMENTS TO RESOLUTIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xvi</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>55.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>MEANS OF COMMUNICATION TO BE USED</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xvi</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>56.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>COMPANY SEALS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xvii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>57.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NO RIGHT TO INSPECT ACCOUNTS AND OTHER RECORDS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xvii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>58.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROVISION FOR EMPLOYEES ON CESSATION OF BUSINESS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xvii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>59.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INDEMNITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xviii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>60.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INSURANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xviii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>61.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SCHEME OF ARRANGEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-xviii</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE COMPANIES ACT 2006 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIVATE COMPANY LIMITED BY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES OF ASSOCIATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORTHO CLINICAL
DIAGNOSTICS HOLDINGS [LIMITED] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Number 13084624 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(the &#147;Company&#148;) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Adopted by special resolution passed on [</B>&#9679;<B></B><B>]<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERPRETATION AND LIMITATION OF LIABILITY </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_1"></A>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DISAPPLICATION OF MODEL ARTICLES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The model articles of association for private companies limited by shares contained in Schedule 1 of The Companies (Model Articles) Regulations
2008 (SI 2009/3229) shall not apply to the Company.<SUP STYLE="font-size:85%; vertical-align:top">3</SUP> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_2"></A>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS AND INTERPRETATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In these Articles, unless the context otherwise requires: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Articles</B>&#148; means the Company&#146;s articles of association for the time being in force; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>bankruptcy</B>&#148; includes individual insolvency proceedings (and, in relation to a corporate person, includes corporate insolvency
proceedings) in a jurisdiction other than England and Wales or Northern Ireland which have an effect similar to that of bankruptcy (or, in relation to corporate persons, insolvency, liquidation or winding up); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>business day</B>&#148; means a day (other than a Saturday or Sunday) on which banks in the City of London are open for ordinary
banking business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>capitalised sum</B>&#148; has the meaning given in Article 43.1(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>chairman</B>&#148; has the meaning given in Article 14; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>chairman of the meeting</B>&#148; has the meaning given in Article 46; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Companies Acts</B>&#148; means the Companies Acts (as defined in section 2 of the Companies Act 2006), in so far as they apply to the
Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>director</B>&#148; means a director for the time being of the Company, and includes any person occupying the position of
director, by whatever name called; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>distribution recipient</B>&#148; has the meaning given in Article 38.2; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>document</B>&#148; includes, unless otherwise specified, any document sent or supplied in electronic form; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>electronic form</B>&#148; has the meaning given in section 1168 of the Companies Act 2006; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>eligible director</B>&#148; has the meaning given in Article 10.3; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>fully paid</B>&#148; in relation to a share, means that the nominal value and any premium to be paid to the Company in respect of that
share have been paid to the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>hard copy form</B>&#148; has the meaning given in section 1168 of the Companies Act 2006;
</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note to draft: </B>Date of special resolution adopting articles to be included. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note to draft: </B>To be amended to the extent that the Company remains a public rather than a limited
company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>holder</B>&#148; in relation to shares means the person whose name is entered in
the register of members as the holder of the shares; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>instrument</B>&#148; means a document in hard copy form; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>member</B>&#148; means a person who is the holder of a share; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>ordinary resolution</B>&#148; has the meaning given in section 282 of the Companies Act 2006; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>paid</B>&#148; means paid or credited as paid; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>participate</B>&#148;, in relation to a directors&#146; meeting, has the meaning given in Article 12.1; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>persons entitled</B>&#148; has the meaning given in Article 43.1(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>proxy notice</B>&#148; has the meaning given in Article 52.1; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>shares</B>&#148; means shares in the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>special resolution</B>&#148; has the meaning given in section 283 of the Companies Act 2006; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>subsidiary</B>&#148; has the meaning given in section 1159 of the Companies Act 2006; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>transmittee</B>&#148; means a person entitled to a share by reason of the death or bankruptcy of a member or otherwise by operation of
law; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>writing</B>&#148; means the representation or reproduction of words, symbols or other information in a visible form by
any method or combination of methods, whether sent or supplied in electronic form or otherwise. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the Articles, unless the context otherwise requires: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">terms used shall, unless otherwise defined herein, bear the meaning ascribed to them in the Companies Act 2006
as in force on the date when the Articles became binding on the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to an Article is a reference to the relevant article of these Articles unless expressly provided
otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to a statute, statutory provision or subordinate legislation is a reference to it as it is in force
from time to time, taking account of: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any subordinate legislation from time to time made under it; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any amendment or <FONT STYLE="white-space:nowrap">re-amendment</FONT> and includes any statute, statutory
provision or subordinate legislation which it amends or <FONT STYLE="white-space:nowrap">re-enacts;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">references to the singular include the plural and vice versa and references that are gender neutral or gender
specific include each gender and no gender; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">references to a &#147;person&#148; includes any individual, partnership, body corporate, corporation sole or
aggregate, state or agency of a state, and any unincorporated association or organisation, in each case whether or not having separate legal personality; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">references to &#147;sterling&#148;, &#147;pounds sterling&#148; or &#147;&pound;&#148; are references to the
lawful currency from time to time of the United Kingdom and any references to &#147;dollars&#148; or &#147;$&#148; are references to the lawful currency from time to time of the United States of America; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">references to times of the day are to London time unless otherwise stated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words introduced by the word &#147;other&#148; shall not be given a restrictive meaning because they are
preceded by words referring to a particular class of acts, matters or things; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">general words shall not be given a restrictive meaning because they are followed by words which are particular
examples of the acts, matters or things covered by the general words and the words &#147;includes&#148; and &#147;including&#148; shall be construed without limitation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The headings and <FONT STYLE="white-space:nowrap">sub-headings</FONT> in the Articles are inserted for
convenience only and shall not affect the construction of the Articles. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_3"></A>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LIABILITY OF MEMBERS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The liability of the members is limited to the amount, if any, unpaid on the shares held by them. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS&#146; POWERS AND RESPONSIBILITIES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_4"></A>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DIRECTORS&#146; GENERAL AUTHORITY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to the Articles, the directors are responsible for the management of the Company&#146;s business, for which purpose they may exercise
all the powers of the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_5"></A>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMPANY NAME </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The directors may resolve in accordance with Article 9 to change the Company&#146;s name. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_6"></A>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MEMBERS&#146; RESERVE POWER </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The members may, by special resolution, direct the directors to take, or refrain from taking, specified action.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No such special resolution invalidates anything which the directors have done before the passing of the
resolution. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_7"></A>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DIRECTORS MAY DELEGATE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Articles, the directors may delegate any of the powers which are conferred on them under the
Articles: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to such person or committee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by such means (including by power of attorney); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to such an extent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in relation to such matters or territories; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on such terms and conditions, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">as they think fit. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the directors so specify, any such delegation may authorise further delegation of the directors&#146; powers
by any person to whom they are delegated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The directors may revoke any delegation in whole or part, or alter its terms and conditions.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_8"></A>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMMITTEES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Committees to which the directors delegate any of their powers must follow procedures which are based as far as
they are applicable on those provisions of the Articles which govern the taking of decisions by directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The directors may make rules of procedure for all or any committees, which prevail over rules derived from the
Articles if they are not consistent with them. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECISION-MAKING BY DIRECTORS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_9"></A>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DIRECTORS TO TAKE DECISIONS COLLECTIVELY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The general rule about decision-making by directors is that any decision of the directors must be either a
majority decision at a meeting or a decision taken in accordance with Article 10. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company only has one director for the time being; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no provision of the Articles requires it to have more than one director, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">the general rule does not apply, and the director may (for so long as he remains the sole
director) take decisions without regard to any of the provisions of the Articles relating to directors&#146; decision-making. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_10"></A>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>UNANIMOUS DECISIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A decision of the directors is taken in accordance with this Article 10 when all eligible directors indicate to
each other by any means that they share a common view on a matter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such a decision may take the form of a resolution in writing, signed by each eligible director (whether or not
each signs the same document) or to which each eligible director has otherwise indicated agreement in writing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">References in these Articles to an &#147;eligible director&#148; means a director who would have been entitled
to vote on the relevant matter had it been proposed as a resolution at a directors&#146; meeting and whose vote would have been counted in respect of such matter. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A decision may not be taken in accordance with this Article 10 if the eligible directors would not have formed
a quorum at such a meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_11"></A>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CALLING A DIRECTORS&#146; MEETING </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any director may call a directors&#146; meeting by giving notice of the meeting to the directors or by
authorising the company secretary (if any) to give such notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of any directors&#146; meeting must indicate: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">its proposed date and time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where it is to take place; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if it is anticipated that directors participating in the meeting will not be in the same place, how it is
proposed that they should communicate with each other during the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Article 11.4, notice of a directors&#146; meeting must be given to each director whether or not he
is absent from the United Kingdom, but need not be in writing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of a directors&#146; meeting need not be given to directors who waive their entitlement to notice of
that meeting, by giving notice to that effect to the Company prior to or not more than seven days after the date on which the meeting is held. Where such notice is given after the meeting has been held, that does not affect the validity of the
meeting, or of any business conducted at it. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_12"></A>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PARTICIPATION IN DIRECTORS&#146; MEETINGS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Articles, directors participate in a directors&#146; meeting, or part of a directors&#146;
meeting, when: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the meeting has been called and takes place in accordance with the Articles; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">they can each communicate to the others any information or opinions they have on any particular item of the
business of the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In determining whether directors are participating in a directors&#146; meeting, it is irrelevant where any
director is or how they communicate with each other. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If all the directors participating in a meeting are not in the same place, they may decide that the meeting is
to be treated as taking place wherever any of them is. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_13"></A>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>QUORUM FOR DIRECTORS&#146; MEETINGS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At a directors&#146; meeting, unless a quorum is participating, no proposal is to be voted on, except a
proposal to call another meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Article 13.3 and save in the case where there is only one director in office, the quorum for the
transaction of business at a meeting of the directors is any two eligible directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of any meeting (or part of a meeting) held pursuant to Article 17 to authorise a
director&#146;s conflict of interest, where there is only one director in office who is not party to the relevant conflict, the quorum for such meeting (or part of a meeting) shall be one eligible director. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the total number of directors for the time being is less than the quorum required, the directors must not
take any decision other than a decision: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to appoint further directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to call a general meeting so as to enable the members to appoint further directors. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_14"></A>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CHAIRING OF DIRECTORS&#146; MEETINGS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The directors may appoint a director to chair their meetings. The person so appointed for the time being is
known as the chairman. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The directors may terminate the chairman&#146;s appointment at any time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the chairman is not participating in a directors&#146; meeting within ten minutes after the time at which it
was to start, or if no director has been appointed chairman, the participating directors must appoint one of themselves to chair it. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_15"></A>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CASTING VOTE </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Article 15.2 if the numbers of votes for and against a proposal at a meeting of directors are equal,
the chairman or other director chairing the meeting has a casting vote. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman or other director chairing a meeting (or part of a meeting) shall not have a casting vote if, in
accordance with the Articles, the chairman, or other director, is not an eligible director for the purposes of that meeting (or part of a meeting). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_16"></A>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DIRECTORS&#146; INTERESTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A director who is in any way, directly or indirectly, interested in a proposed transaction or arrangement with
the Company shall declare the nature and extent of his interest to the other directors before the Company enters into the transaction or arrangement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A director who is in any way, directly or indirectly, interested in a transaction or arrangement that has been
entered into by the Company shall declare the nature and extent of his interest to the other directors as soon as is reasonably practicable, unless the interest has already been declared under Article 16.1. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any declaration required by Article 16.1 may (but need not) be made, and any declaration required by Article
16.2 must be made, either: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at a directors&#146; meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by notice in writing in accordance with section 184 of the Companies Act 2006; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by general notice in accordance with section 185 of the Companies Act 2006. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a declaration made under Article 16.1 or 16.2 proves to be, or becomes, inaccurate or incomplete, a further
declaration must be made under Article 16.1 or 16.2, as appropriate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A director need not declare an interest under Article 16.1 or 16.2: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if it cannot reasonably be regarded as likely to give rise to a conflict of interest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if, or to the extent that, the other directors are already aware of it (and for this purpose the other
directors are treated as aware of anything of which they ought reasonably to be aware); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if, or to the extent that, it concerns terms of his service contract that have been or are to be considered by
a directors&#146; meeting or by a committee of the directors appointed for the purpose under these Articles or any agreement between the members; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the director is not aware of his interest or is not aware of the transaction or arrangement in question (and
for this purpose a director is treated as being aware of matters of which he ought reasonably to be aware). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of the Companies Act 2006 and provided that he has declared the nature and extent of
any direct or indirect interest of his in accordance with Article 16.1 or 16.2, a director notwithstanding his office: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may be a party to, or otherwise be interested in, any transaction or arrangement with the Company or in which
the Company is otherwise (directly or indirectly) interested; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shall be entitled to vote at a meeting of directors (or of a committee of the directors) or participate in any
unanimous decision, in respect of such existing or proposed transaction or arrangement in which he is interested (and shall be an eligible director for these purposes); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may act by himself or through his firm in a professional capacity for the Company (otherwise than as auditor),
and in any such case on such terms as to remuneration and otherwise as the directors may decide; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may be a director or other officer of, or employed or engaged by, or a party to any transaction or arrangement
with, or otherwise be interested in, any body corporate in which the Company is otherwise (directly or indirectly) interested. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_17"></A>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFLICTS OF INTEREST </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A director, notwithstanding his office, may at the time of his appointment or subsequently be a director or
other officer of, employed by, or otherwise interested (including by the holding of shares) in, any subsidiary of the Company, any holding company of the Company, or any subsidiary of a holding company of the Company, from time to time, and no
further authorisation under Article 17.2 or 17.3 shall be necessary in respect of such interest. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The directors may authorise any matter proposed to them which would, if not so authorised, involve a breach of
duty by a director under section 175 of the Companies Act 2006 (and such authorisation may be given on such terms as the directors think fit and may be varied or terminated at any time), provided that any authorisation given under this Article 17.2
shall be effective only if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any requirement as to the quorum at the meeting at which the matter is considered is met without counting the
director in question or any other director interested in the matter under consideration; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the matter was agreed to without such directors voting or would have been agreed to if such directors&#146;
votes had not been counted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Alternatively and without prejudice to the remainder of these Articles or the Companies Act 2006, the Company
may authorise (specifically or generally) any matter proposed to it which would, if not so authorised, involve a breach of duty by a director under section 175 of the Companies Act 2006. Such authorisation shall be effected: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with the consent in writing of the holders of a majority in nominal value of the issued ordinary share capital
for the time being of the Company; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by an ordinary resolution. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A director shall be under no duty to the Company with respect to any information which he obtains or has
obtained otherwise than as a director of the Company and in respect of which he owes a duty of confidentiality to another person. In particular the director shall not be in breach of the general duties he owes to the Company by virtue of sections
171 to 177 of the Companies Act 2006 if he: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fails to disclose any such information to the directors or to any director or other officer or employee of, or
consultant to, the Company; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">does not use or apply any such information in performing his duties as a director of the Company.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">However, to the extent that his relationship with that other person gives rise to a conflict of interest or possible
conflict of interest, this Article 17.4 applies only if the existence of that relationship has been authorised pursuant to Article 17.1, or authorised by the directors pursuant to Article 17.2, or authorised by the members pursuant to Article 17.3
(and, in each case, subject to the terms upon which such authorisation was given). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where the existence of a director&#146;s relationship with another person has been authorised pursuant to
Article 17.1, or authorised by the directors pursuant to Article 17.2, or authorised by the members pursuant to Article 17.3, and his relationship with that person gives rise to a conflict of interest or possible conflict of interest, the director
shall not be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-vi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
in breach of the general duties he owes to the Company by virtue of sections 171 to 177 of the Companies Act 2006 if, at his discretion or at the request or direction of the directors or any
committee of the directors, he: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">absents himself from a directors&#146; meeting (or a committee thereof) at which any matter relating to the
conflict of interest or possible conflict of interest will or may be discussed, or from the discussion of any such matter at a directors&#146; meeting or otherwise; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">makes arrangements not to receive documents and information relating to any matter which gives rise to the
conflict of interest or possible conflict of interest sent or supplied by or on behalf of the Company or for such documents and information to be received and read by a professional adviser on his behalf, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">for so long as he reasonably believes such conflict of interest (or possible conflict of interest) subsists. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of Articles 17.4 and 17.5 are without prejudice to any equitable principle or rule of law which
may excuse the director from: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosing information, in circumstances where disclosure would otherwise be required under these Articles or
any agreement between the members; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">attending meetings or discussions or receiving documents and information as referred to in Article 17.5, in
circumstances where such attendance or receipt would otherwise be required under these Articles or any agreement between the members. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A director shall not, by reason of his office, be accountable to the Company for any remuneration or other
benefit which he derives from any office, employment or engagement or from any transaction or arrangement or from any interest in any body corporate: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the acceptance, entry into or existence of which is authorised pursuant to Article 17.1, or authorised by the
directors pursuant to Article 17.2, or authorised by the members pursuant to Article 17.3 (in each case, subject to the terms upon which such authorisation was given); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which he is permitted to hold or enter into pursuant to Article 16.6 or otherwise pursuant to these Articles or
any agreement between the members, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">and no such transaction, arrangement or interest shall be liable to be avoided on the
ground of any such remuneration or other benefit, nor shall the receipt of any such remuneration or other benefit constitute a breach of his duty under section 176 of the Companies Act 2006. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_18"></A>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RECORDS OF DECISIONS TO BE KEPT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The directors must ensure that the Company keeps a record, in writing, for at least 10 years from the date of the decision recorded, of every
unanimous or majority decision taken by the directors. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_19"></A>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DIRECTORS&#146; DISCRETION TO MAKE FURTHER RULES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to the Articles, the directors may make any rule which they think fit about how they take decisions, and about how such rules are to be
recorded or communicated to directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPOINTMENT OF DIRECTORS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_20"></A>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NUMBER OF DIRECTORS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by ordinary resolution, the number of directors shall not be subject to any maximum, but shall not be less than
one. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_21"></A>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>METHODS OF APPOINTING DIRECTORS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any person who is willing to act as a director, and is permitted by law to do so, may be appointed to be a
director: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by ordinary resolution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by a decision of the directors; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-vii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by a member or members, holding the whole or a majority in nominal value of the issued ordinary share capital
for the time being of the Company, in accordance with Article 23. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In any case where, as a result of death or bankruptcy, the Company has no members and no directors, the
transmittee of the last member to have died or to have a bankruptcy order made against him has the right, by notice in writing, to appoint a person who is willing to act and is permitted to do so, to be a director. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of Article 21.2, where two or more members die in circumstances rendering it uncertain who was
the last to die, a younger member is deemed to have survived an older member. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_22"></A>22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMINATION OF DIRECTOR&#146;S APPOINTMENT </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A person ceases to be a director as soon as: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that person ceases to be a director by virtue of any provision of the Companies Act 2006 or is prohibited from
being a director by law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a bankruptcy order is made against that person; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a composition is made with that person&#146;s creditors generally in satisfaction of that person&#146;s debts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a registered medical practitioner who is treating that person gives a written opinion to the Company stating
that that person has become physically or mentally incapable of acting as a director and may remain so for more than three months; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notification is received by the Company from that person that he is resigning from office, and such resignation
has taken effect in accordance with its terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that person is convicted of a criminal offence (other than a motoring offence not resulting in
disqualification) and the directors resolve that his office be vacated; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">he is removed from office by a member or members, holding the whole or a majority in nominal value of the
issued ordinary share capital for the time being of the Company, in accordance with Article 23. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_23"></A>23.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>APPOINTMENT AND REMOVAL BY SOLE OR MAJORITY MEMBER </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A member or members holding the whole or a majority in nominal value of the issued ordinary share capital for the time being in the Company
shall have power from time to time and at any time to appoint any person as a director or directors either as an additional director or to fill any vacancy and to remove from office any director howsoever appointed. Any such appointment or removal
shall be effected by an instrument in writing signed by the member or members making the same, or in the case of a member being a body corporate signed by one of its directors or other officers on its behalf, and shall take effect upon lodgement at
the registered office of the Company or such later date as may be specified in the instrument. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_24"></A>24.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DIRECTORS&#146; REMUNERATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Directors may undertake any services for the Company that the directors decide. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Directors are entitled to such remuneration as the directors determine: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for their services to the Company as directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for any other service which they undertake for the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Articles, a director&#146;s remuneration may: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take any form; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">include any arrangements in connection with the payment of a pension, allowance or gratuity, or any death,
sickness or disability benefits, to or in respect of that director. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless the directors decide otherwise, directors&#146; remuneration accrues from day to day.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-viii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless the directors decide otherwise, directors are not accountable to the Company for any remuneration which
they receive as directors or other officers or employees of the Company&#146;s subsidiary undertakings or of the Company&#146;s parent undertakings from time to time or of any other body corporate in which the Company or any such parent undertaking
is interested. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_25"></A>25.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DIRECTORS&#146; EXPENSES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may pay any reasonable expenses which the directors and the company secretary (if any) properly
incur in connection with their attendance at: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">meetings of directors or committees of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">general meetings; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">separate meetings of the holders of any class of shares or of debentures of the Company, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">or otherwise in connection with the exercise of their powers and the discharge of their responsibilities in relation to the Company. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_26"></A>26.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMPANY SECRETARY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The directors may appoint any person who is willing to act as the company secretary for such term, at such remuneration, and upon such
conditions as they may think fit and from time to time remove such person and, if the directors so decide, appoint a replacement, in each case by a decision of the directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARES AND DISTRIBUTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_27"></A>27.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ALL SHARES TO BE FULLY PAID </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">27.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No share (other than shares taken on the formation of the company by the subscribers to the company&#146;s
memorandum) may be issued for less than the aggregate of its nominal value and any premium to be paid to the company in consideration for its issue. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_28"></A>28.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>POWER TO ALLOT SHARES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The directors shall not, without the prior written consent of a member or members holding the whole or a
majority in nominal value of the issued ordinary share capital for the time being of the Company, exercise any power of the Company to allot shares or other securities in, or to grant rights to subscribe for, or convert into, shares or other
securities of, the Company to any person other than to a member holding the whole or a majority in nominal value of the issued ordinary share capital for the time being of the Company. The powers of the directors under section 550 of the Companies
Act 2006 are limited accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_29"></A>29.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>POWERS TO ISSUE DIFFERENT CLASSES OF SHARE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Articles, but without prejudice to the rights attached to any existing share, the Company may
issue shares with such rights or restrictions as may be determined by ordinary resolution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may issue shares which are to be redeemed, or are liable to be redeemed at the option of the
Company or the holder, and the directors may determine the terms, conditions and manner of redemption of any such shares. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_30"></A>30.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMPANY NOT BOUND BY LESS THAN ABSOLUTE INTERESTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Except as required by law, no person is to be recognised by the Company as holding any share upon any trust, and except as otherwise required
by law or the Articles, the Company is not in any way to be bound by or recognise any interest in a share other than the holder&#146;s absolute ownership of it and all the rights attaching to it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-ix </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_31"></A>31.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SHARE CERTIFICATES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company must issue each member, free of charge, with one or more certificates in respect of the shares
which that member holds. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Every certificate must specify: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in respect of how many shares, of what class, it is issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the nominal value of those shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the shares are fully paid up; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any distinguishing numbers assigned to them. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No certificate may be issued in respect of shares of more than one class. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If more than one person holds a share, only one certificate may be issued in respect of it.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certificates must: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">have affixed to them the Company&#146;s common seal; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be otherwise executed in accordance with the Companies Acts. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_32"></A>32.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REPLACEMENT SHARE CERTIFICATES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a certificate issued in respect of a member&#146;s shares is: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">damaged or defaced; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">said to be lost, stolen or destroyed, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">that member is entitled to be issued with a replacement certificate in respect of the same shares. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A member exercising the right to be issued with such a replacement certificate: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may at the same time exercise the right to be issued with a single certificate or separate certificates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must return the certificate which is to be replaced to the Company if it is damaged or defaced; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must comply with such conditions as to evidence, indemnity and the payment of a reasonable fee as the directors
decide. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_33"></A>33.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SHARE TRANSFERS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares may be transferred by means of an instrument of transfer in any usual form or any other form approved by
the directors, executed by or on behalf of the transferor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee may be charged for registering any instrument of transfer or other document relating to or affecting the
title to any share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may retain any instrument of transfer which is registered. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The transferor remains the holder of a share until the transferee&#146;s name is entered in the register of
members as holder of it. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_34"></A>34.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSMISSION OF SHARES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">34.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If title to a share passes to a transmittee, the Company may only recognise the transmittee as having any title
to that share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">34.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A transmittee who produces such evidence of entitlement to shares as the directors may properly require:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may, subject to the Articles, choose either to become the holder of those shares or to have them transferred to
another person; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to the Articles, and pending any transfer of the shares to another person, has the same rights as the
holder had. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-x </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">34.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Article 21.2, transmittees do not have the right to attend or vote at a general meeting, or agree to
a proposed written resolution, in respect of shares to which they are entitled, by reason of the holder&#146;s death or bankruptcy or otherwise, unless they become the holders of those shares. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_35"></A>35.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXERCISE OF TRANSMITTEES&#146; RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transmittees who wish to become the holders of shares to which they have become entitled must notify the
Company in writing of that wish. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the transmittee wishes to have a share transferred to another person, the transmittee must execute an
instrument of transfer in respect of it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any transfer made or executed under this Article 35 is to be treated as if it were made or executed by the
person from whom the transmittee has derived rights in respect of the share, and as if the event which gave rise to the transmission had not occurred. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_36"></A>36.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSMITTEES BOUND BY PRIOR NOTICES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If a notice is given to a member in respect of shares and a transmittee is entitled to those shares, the transmittee is bound by the notice if
it was given to the member before the transmittee&#146;s name has been entered in the register of members. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIVIDENDS AND OTHER
DISTRIBUTIONS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_37"></A>37.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PROCEDURE FOR DECLARING DIVIDENDS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">37.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may by ordinary resolution declare dividends, and the directors may decide to pay interim
dividends. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">37.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A dividend must not be declared unless the directors have made a recommendation as to its amount. Such a
dividend must not exceed the amount recommended by the directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">37.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No dividend may be declared or paid unless it is in accordance with members&#146; respective rights.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">37.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless the members&#146; resolution to declare or directors&#146; decision to pay a dividend, or the terms on
which shares are issued, specify otherwise, it must be paid by reference to each member&#146;s holding of shares on the date of the resolution or decision to declare or pay it. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">37.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Company&#146;s share capital is divided into different classes, no interim dividend may be paid on
shares carrying deferred or <FONT STYLE="white-space:nowrap">non-preferred</FONT> rights if, at the time of payment, any preferential dividend is in arrears. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">37.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The directors may pay at intervals any dividend payable at a fixed rate if it appears to them that the profits
available for distribution justify the payment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">37.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the directors act in good faith, they do not incur any liability to the holders of shares conferring
preferred rights for any loss they may suffer by the lawful payment of an interim dividend on shares with deferred or <FONT STYLE="white-space:nowrap">non-preferred</FONT> rights. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_38"></A>38.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PAYMENT OF DIVIDENDS AND OTHER DISTRIBUTIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where a dividend or other sum which is a distribution is payable in respect of a share, it must be paid by one
or more of the following means: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfer to a bank or building society account specified by the distribution recipient either in writing or as
the directors may otherwise decide; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sending a cheque made payable to the distribution recipient by post to the distribution recipient at the
distribution recipient&#146;s registered address (if the distribution recipient is a holder of the share), or (in any other case) to an address specified by the distribution recipient either in writing or as the directors may otherwise decide;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sending a cheque made payable to such person by post to such person at such address as the distribution
recipient has specified either in writing or as the directors may otherwise decide; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-xi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other means of payment as the directors agree with the distribution recipient either in writing or by such
other means as the directors decide. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the Articles, the &#147;<B>distribution recipient</B>&#148; means, in respect of a share in respect of which
a dividend or other sum is payable: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the holder of the share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the share has two or more joint holders, whichever of them is named first in the register of members; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the holder is no longer entitled to the share by reason of death or bankruptcy, or otherwise by operation of
law, the transmittee. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_39"></A>39.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NO INTEREST ON DISTRIBUTIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may not pay interest on any dividend or other sum payable in respect of a share unless otherwise
provided by: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the terms on which the share was issued; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the provisions of another agreement between the holder of that share and the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_40"></A>40.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>UNCLAIMED DISTRIBUTIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">40.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All dividends or other sums which are: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payable in respect of shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">unclaimed after having been declared or become payable, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">may be invested or otherwise made use of by the directors for the benefit of the Company until claimed. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">40.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The payment of any such dividend or other sum into a separate account does not make the Company a trustee in
respect of it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">40.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">twelve years have passed from the date on which a dividend or other sum became due for payment; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the distribution recipient has not claimed it, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">the distribution recipient is no longer entitled to that dividend or other sum and it ceases to remain owing by the Company. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_41"></A>41.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">NON-CASH</FONT> DISTRIBUTIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms of issue of the share in question, the Company may, by ordinary resolution on the
recommendation of the directors, decide to pay all or part of a dividend or other distribution payable in respect of a share by transferring <FONT STYLE="white-space:nowrap">non-cash</FONT> assets of equivalent value (including shares or other
securities in any company). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of paying a <FONT STYLE="white-space:nowrap">non-cash</FONT> distribution, the directors may
make whatever arrangements they think fit, including, where any difficulty arises regarding the distribution: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fixing the value of any assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">paying cash to any distribution recipient on the basis of that value in order to adjust the rights of
recipients; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">vesting any assets in trustees. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_42"></A>42.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WAIVER OF DISTRIBUTIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">42.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Distribution recipients may waive their entitlement to a dividend or other distribution payable in respect of a
share by giving the Company notice in writing to that effect, but if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the share has more than one holder; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-xii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">more than one person is entitled to the share, whether by reason of the death or bankruptcy of one or more
joint holders, or otherwise, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">the notice is not effective unless it is expressed to be given, and signed, by all the
holders or persons otherwise entitled to the share. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAPITALISATION OF PROFITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_43"></A>43.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AUTHORITY TO CAPITALISE AND APPROPRIATION OF CAPITALISED SUMS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">43.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Articles, the directors may, if they are so authorised by an ordinary resolution:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">decide to capitalise any profits of the Company (whether or not they are available for distribution) which are
not required for paying a preferential dividend, or any sum standing to the credit of the Company&#146;s share premium account or capital redemption reserve; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appropriate any sum which they so decide to capitalise (&#147;<B>capitalised sum</B>&#148;) to the persons who
would have been entitled to it if it were distributed by way of dividend (&#147;<B>persons entitled</B>&#148;) and in the same proportions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">43.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Capitalised sums must be applied: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on behalf of the persons entitled; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the same proportions as a dividend would have been distributed to them. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">43.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any capitalised sum may be applied in paying up new shares of a nominal amount equal to the capitalised sum
which are then allotted credited as fully paid to the persons entitled or as they may direct. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">43.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A capitalised sum which was appropriated from profits available for distribution may be applied in paying up
new debentures of the Company which are then allotted credited as fully paid to the persons entitled or as they may direct. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">43.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Articles the directors may: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">apply capitalised sums in accordance with Articles 43.3 and 43.4 partly in one way and partly in another;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make such arrangements as they think fit to deal with shares or debentures becoming distributable in fractions
under this Article 43 (including the issuing of fractional certificates or the making of cash payments); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">authorise any person to enter into an agreement with the Company on behalf of all the persons entitled which is
binding on them in respect of the allotment of shares and debentures to them under this Article 43. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECISION-MAKING
BY MEMBERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORGANISATION OF GENERAL MEETINGS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_44"></A>44.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ATTENDANCE AND SPEAKING AT GENERAL MEETINGS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A person is able to exercise the right to speak at a general meeting when that person is in a position to
communicate to all those attending the meeting, during the meeting, any information or opinions which that person has on the business of the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A person is able to exercise the right to vote at a general meeting when: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that person is able to vote, during the meeting, on resolutions put to the vote at the meeting; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that person&#146;s vote can be taken into account in determining whether or not such resolutions are passed at
the same time as the votes of all the other persons attending the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The directors may make whatever arrangements they consider appropriate to enable those attending a general
meeting to exercise their rights to speak or vote at it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In determining attendance at a general meeting, it is immaterial whether any two or more members attending it
are in the same place as each other. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-xiii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Two or more persons who are not in the same place as each other attend a general meeting if their circumstances
are such that if they have (or were to have) rights to speak and vote at that meeting, they are (or would be) able to exercise them. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_45"></A>45.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>QUORUM FOR GENERAL MEETINGS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">No business other than the appointment of the chairman of the meeting is to be transacted at a general meeting if the persons attending it do
not constitute a quorum. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_46"></A>46.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CHAIRING GENERAL MEETINGS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">46.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the directors have appointed a chairman, the chairman shall chair general meetings if present and willing to
do so. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">46.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the directors have not appointed a chairman, or if the chairman is unwilling to chair the meeting or is not
present within ten minutes of the time at which a meeting was due to start: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the directors present; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(if no directors are present), the meeting, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">must appoint a director or member to chair the meeting, and the appointment of the chairman of the meeting must be the first business of the
meeting. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">46.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The person chairing a meeting in accordance with this Article 46 is referred to as the &#147;<B>chairman of the
meeting</B>&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_47"></A>47.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ATTENDANCE AND SPEAKING BY DIRECTORS AND <FONT STYLE="white-space:nowrap">NON-MEMBERS</FONT>
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Directors may attend and speak at general meetings, whether or not they are members. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman of the meeting may permit other persons who are not: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">members; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">otherwise entitled to exercise the rights of members in relation to general meetings, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">to attend and speak at a general meeting. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_48"></A>48.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ADJOURNMENT </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">48.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the persons attending a general meeting within half an hour of the time at which the meeting was due to
start do not constitute a quorum, or if during a meeting a quorum ceases to be present, the chairman of the meeting must adjourn it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">48.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman of the meeting may adjourn a general meeting at which a quorum is present if:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the meeting consents to an adjournment; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it appears to the chairman of the meeting that an adjournment is necessary to protect the safety of any person
attending the meeting or ensure that the business of the meeting is conducted in an orderly manner. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">48.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman of the meeting must adjourn a general meeting if directed to do so by the meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">48.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When adjourning a general meeting, the chairman of the meeting must: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">either specify the time and place to which it is adjourned or state that it is to continue at a time and place
to be fixed by the directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">have regard to any directions as to the time and place of any adjournment which have been given by the meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">48.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the continuation of an adjourned meeting is to take place more than 14 days after it was adjourned, the
Company must give at least seven clear days&#146; notice of it (that is, excluding the day of the adjourned meeting and the day on which the notice is given): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the same persons to whom notice of the Company&#146;s general meetings is required to be given; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">containing the same information which such notice is required to contain. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-xiv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">48.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No business may be transacted at an adjourned general meeting which could not properly have been transacted at
the meeting if the adjournment had not taken place. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTING AT GENERAL MEETINGS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_49"></A>49.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>VOTING: GENERAL </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A resolution put to the vote of a general meeting must be decided on a show of hands unless a poll is duly demanded in accordance with the
Articles. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_50"></A>50.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ERRORS AND DISPUTES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">50.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No objection may be raised to the qualification of any person voting at a general meeting except at the meeting
or adjourned meeting at which the vote objected to is tendered, and every vote not disallowed at the meeting is valid. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">50.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any such objection must be referred to the chairman of the meeting, whose decision is final.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_51"></A>51.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>POLL VOTES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">51.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A poll on a resolution may be demanded: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in advance of the general meeting where it is to be put to the vote; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at a general meeting, either before a show of hands on that resolution or immediately after the result of a
show of hands on that resolution is declared. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">51.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A poll on a resolution may be demanded by: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the chairman of the meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">two or more persons having the right to vote on the resolution; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a person or persons representing not less than one tenth of the total voting rights of all the members having
the right to vote on the resolution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">51.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A demand for a poll may be withdrawn if: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the poll has not yet been taken; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the chairman of the meeting consents to the withdrawal. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A demand so withdrawn shall not invalidate the result of a show of hands declared before the demand was made. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">51.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Polls must be taken immediately and in such manner as the chairman of the meeting directs.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_52"></A>52.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONTENT OF PROXY NOTICES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">52.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proxies may only validly be appointed by a notice in writing (a &#147;<B>proxy notice</B>&#148;) which:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">states the name and address of the member appointing the proxy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">identifies the person appointed to be that member&#146;s proxy and the general meeting in relation to which
that person is appointed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is signed by or on behalf of the member appointing the proxy, or is authenticated in such manner as the
directors may determine; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is delivered to the Company in accordance with the Articles and any instructions contained in the notice of the
general meeting to which they relate not less than 48 hours before the time appointed for holding the meeting at which the right to vote is to be exercised and in accordance with any instructions contained in the notice of the general meeting to
which they relate, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-xv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">and a proxy notice which is not delivered in such manner shall be invalid unless the
directors in their absolute discretion at any time before the start of the meeting otherwise determine. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">52.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may require proxy notices to be delivered in a particular form, and may specify different forms for
different purposes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">52.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proxy notices may specify how the proxy appointed under them is to vote (or that the proxy is to abstain from
voting) on one or more resolutions and the proxy is obliged to vote or abstain from voting in accordance with the specified instructions. However, the Company is not obliged to check whether a proxy votes or abstains from voting as he has been
instructed and shall incur no liability for failing to do so. Failure by a proxy to vote or abstain from voting as instructed at a meeting shall not invalidate proceedings at that meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">52.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless a proxy notice indicates otherwise, it must be treated as: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">allowing the person appointed under it as a proxy discretion as to how to vote on any ancillary or procedural
resolutions put to the meeting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appointing that person as a proxy in relation to any adjournment of the general meeting to which it relates as
well as the meeting itself. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_53"></A>53.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DELIVERY OF PROXY NOTICES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">53.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A person who is entitled to attend, speak or vote (either on a show of hands or on a poll) at a general meeting
remains so entitled in respect of that meeting or any adjournment of it, even though a valid proxy notice has been delivered to the Company by or on behalf of that person. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">53.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An appointment under a proxy notice may be revoked by delivering to the Company a notice in writing given by or
on behalf of the person by whom or on whose behalf the proxy notice was given. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">53.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A notice revoking a proxy appointment only takes effect if it is delivered before the start of the meeting or
adjourned meeting to which it relates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">53.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a proxy notice is not executed by the person appointing the proxy, it must be accompanied by written
evidence of the authority of the person who executed it to execute it on the appointor&#146;s behalf. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_54"></A>54.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AMENDMENTS TO RESOLUTIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">54.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An ordinary resolution to be proposed at a general meeting may be amended by ordinary resolution if:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notice of the proposed amendment is given to the Company in writing by a person entitled to vote at the general
meeting at which it is to be proposed not less than 48 hours before the meeting is to take place (or such later time as the chairman of the meeting may determine); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the proposed amendment does not, in the reasonable opinion of the chairman of the meeting, materially alter the
scope of the resolution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">54.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A special resolution to be proposed at a general meeting may be amended by ordinary resolution, if:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the chairman of the meeting proposes the amendment at the general meeting at which the resolution is to be
proposed; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the amendment does not go beyond what is necessary to correct a grammatical or other <FONT
STYLE="white-space:nowrap">non-substantive</FONT> error in the resolution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">54.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the chairman of the meeting, acting in good faith, wrongly decides that an amendment to a resolution is out
of order, the chairman&#146;s error does not invalidate the vote on that resolution. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADMINISTRATIVE ARRANGEMENTS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_55"></A>55.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MEANS OF COMMUNICATION TO BE USED </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">55.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Articles, anything sent or supplied by or to the Company under the Articles may be sent or
supplied in any way in which the Companies Act 2006 provides for documents or information which are authorised or required by any provision of the Companies Act 2006 to be sent or supplied by or to the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-xvi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">55.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any notice, document or other information shall be deemed served on or delivered to the intended recipient:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if properly addressed and sent by prepaid United Kingdom first class post to an address in the United Kingdom,
48 hours after it was posted (or five business days after posting either to an address outside the United Kingdom or from outside the United Kingdom to an address within the United Kingdom if (in each case) sent by reputable international overnight
courier addressed to the intended recipient, provided that delivery in at least five business days was guaranteed at the time of sending and the sending party receives a confirmation of delivery from the courier service provider);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if properly addressed and delivered by hand, when it was given or left at the appropriate address;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if properly addressed and sent or supplied by electronic means, one hour after the document or information was
sent or supplied; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if sent or supplied by means of a website, when the material is first made available on the website or (if
later) when the recipient receives (or is deemed to have received) notice of the fact that the material is available on the website. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">For the purposes of this Article 55, no account shall be taken of any part of a day that is not a business day. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">55.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In proving that any notice, document or other information was properly addressed, it shall be sufficient to
show that the notice, document or other information was delivered to an address permitted for the purpose by the Companies Act 2006. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">55.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Articles, any notice or document to be sent or supplied to a director in connection with the
taking of decisions by directors may also be sent or supplied by the means by which that director has asked to be sent or supplied with such notices or documents for the time being. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">55.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A director may agree with the Company that notices or documents sent to that director in a particular way are
to be deemed to have been received within a specified time of their being sent, and for the specified time to be less than 48 hours. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_56"></A>56.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMPANY SEALS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">56.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any common seal may only be used by the authority of the directors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">56.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The directors may decide by what means and in what form any common seal is to be used. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">56.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise decided by the directors, if the Company has a common seal and it is affixed to a document,
the document must also be signed by at least one authorised person in the presence of a witness who attests the signature. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">56.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of this Article 56, an authorised person is: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any director of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the company secretary (if any); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any person authorised by the directors for the purpose of signing documents to which the common seal is
applied. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_57"></A>57.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NO RIGHT TO INSPECT ACCOUNTS AND OTHER RECORDS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Except as provided by law or authorised by the directors or an ordinary resolution of the Company, no person is entitled to inspect any of the
Company&#146;s accounting or other records or documents merely by virtue of being a member. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_58"></A>58.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PROVISION FOR EMPLOYEES ON CESSATION OF BUSINESS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The directors may decide to make provision for the benefit of persons employed or formerly employed by the Company or any of its subsidiaries
(other than a director or former director or shadow director) in connection with the cessation or transfer to any person of the whole or part of the undertaking of the Company or that subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-xvii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS&#146; INDEMNITY AND INSURANCE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_59"></A>59.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEMNITY </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">59.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Article 59.2, but without prejudice to any indemnity to which a relevant officer is otherwise
entitled: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each relevant officer shall be indemnified out of the Company&#146;s assets against all costs, charges, losses,
expenses and liabilities incurred by him as a relevant officer: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the actual or purported execution and/or discharge of his duties, or in relation to them; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in relation to the Company&#146;s (or any associated company&#146;s) activities as trustee of an occupational
pension scheme (as defined in section 235(6) of the Companies Act 2006), </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">including (in each case) any liability
incurred by him in defending any civil or criminal proceedings, or regulatory investigation or action, in which judgment is given in his favour or in which he is acquitted or the proceedings are, or the investigation or action is, otherwise disposed
of without any finding or admission of any material breach of duty on his part or in connection with any application in which the court grants him, in his capacity as a relevant officer, relief from liability for negligence, default, breach of duty
or breach of trust in relation to the Company&#146;s (or any associated company&#146;s) affairs; and </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company may provide any relevant officer with funds to meet expenditure incurred or to be incurred by him
in connection with any proceedings, investigation, action or application referred to in Article 59.1(a) and otherwise may take any action to enable any such relevant officer to avoid incurring such expenditure. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">59.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Article 59 does not authorise any indemnity to the extent it would be prohibited or rendered void by any
provision of the Companies Acts or by any other provision of law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">59.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Article 59: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">companies are associated if one is a subsidiary of the other or both are subsidiaries of the same body
corporate; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a &#147;<B>relevant officer</B>&#148; means any director or other officer or former director or other officer
of the Company or an associated company (including any company which is a trustee of an occupational pension scheme (as defined by section 235(6) of the Companies Act 2006). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_60"></A>60.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INSURANCE </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">60.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The directors may decide to purchase and maintain insurance, at the expense of the Company, for the benefit of
any relevant officer in respect of any relevant loss. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">60.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Article 60: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a &#147;<B>relevant officer</B>&#148; means any director or other officer or former director or other officer
of the Company or an associated company (including any such company which is a trustee of an occupational pension scheme as defined by section 235(6) of the Companies Act 2006); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a &#147;<B>relevant loss</B>&#148; means any loss or liability which has been or may be incurred by a relevant
officer in connection with that relevant officer&#146;s duties or powers in relation to the Company, any associated company or any pension fund or employees&#146; share scheme of the Company or associated company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">companies are associated if one is a subsidiary of the other or both are subsidiaries of the same body
corporate. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><A NAME="annxfrom273090_61"></A>61.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SCHEME OF ARRANGEMENT<SUP STYLE="font-size:85%; vertical-align:top">4</SUP> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Article 61, references to the &#147;<B>Scheme</B>&#148; are to the scheme of arrangement between the
Company and the holders of [Scheme Shares] (as defined in the Scheme) dated [&#149;] 2022 (with or subject to any modification, addition or condition approved or imposed by the High Court of England and Wales and agreed by the Company and [Topco])
under Part 26 of the Companies Act 2006 and terms defined in the Scheme shall have the same meanings in this Article. </P></TD></TR></TABLE>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note to draft: </B>References to Topco entity and other cross-references to terms used in the Scheme to be
confirmed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-xviii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provisions in these Articles or the terms of any resolution, whether ordinary or
special, passed by the Company in general meeting, if the Company issues any shares other than to any member of the [Topco Group] or its nominee(s) on or after the date of the adoption of this Article and prior to the [Scheme Record Time] such
shares shall be issued subject to the terms of the Scheme (and shall be [Scheme Shares] for the purposes thereof) and the original or any subsequent holder or holders of such shares shall be bound by the Scheme accordingly. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provision of these Articles, if any shares are issued to, or transferred or held by,
any person or his nominee other than [Topco] or its nominee(s) (a &#147;<B>New Member</B>&#148;) at or after the [Scheme Record Time], such shares (the &#147;<B>Post-Scheme Shares</B>&#148;) will, provided that the Scheme has become effective, such
shares shall be issued or transferred on terms that they shall, on the Effective Date (as defined in the Scheme) or, if later, on issue or transfer, be immediately transferred to [Topco] or its nominee(s) (which shall be obliged to acquire all of
those Post-Scheme Shares) in consideration for and conditional on, the allotment and issue or transfer to the New Member of such number of Topco] Shares (&#147;<B>Consideration Shares</B>&#148;) and the payment of a cash amount (and the payment in
cash in respect of fractional entitlements, as described in Article [61.5]) (together the &#147;<B>Relevant Consideration</B>&#148;) as that New Member would have been entitled to for those Post-Scheme Shares had they been [Scheme Shares] under the
Scheme, provided that if, in respect of any New Member who is resident, located or has a registered address in a jurisdiction outside the United Kingdom or the United States or whom Topco reasonably believes to be a citizen, resident or national of
a jurisdiction outside the United Kingdom or the United States, Topco is advised that the law of a country outside the United Kingdom and the United States: (i)&nbsp;precludes the allotment, issue and/or delivery to that New Member of Consideration
Shares; or (ii)&nbsp;precludes the matters referred to in (i)&nbsp;except after compliance by the Company or Topco (as the case may be) with any governmental or other consent or any registration, filing or other formality with which the Company
and/or Topco is unable to comply or compliance with which the Company and/or Topco (as the case may be) regards as unduly onerous, then Topco may, in its sole discretion, either: (A)&nbsp;determine that such Consideration Shares shall not be
allotted, issued and delivered to such New Member, but shall instead be allotted, issued and delivered to a person appointed by Topco for such New Member on terms that such person shall, as soon as practicable following the allotment and issue of
such Consideration Shares, sell the Consideration Shares so issued; or (B)&nbsp;determine that such Consideration Shares shall not be allotted, issued and delivered to such New Member, but instead a cash amount equal to the value of the
Consideration Shares shall be paid to the New Member as soon as practicable[, save that any fractional cash entitlements shall be rounded down to the nearest penny]. In the event that the Consideration Shares are to be sold pursuant to (A), the
Company shall appoint a person to act, and who shall be authorised, as attorney or agent for the New Member pursuant to this article and such person shall be authorised on behalf of such New Member to execute and deliver as transferor a form of
transfer or other instrument or instruction of transfer on behalf of the New Member and to give such instructions and to do all other things which he or she may consider necessary or expedient in connection with such sale. The net proceeds of such
sale (after deduction of all expenses and commissions incurred in connection with the sale) shall be paid to the persons entitled thereto in due proportion as soon as practicable following such sale, save that any fractional cash entitlements shall
be rounded down to the nearest penny. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Consideration Shares allotted and issued or transferred to a New Member pursuant to Article 61.3 shall be
credited as fully paid and shall rank <I>pari passu</I> in all respects with the Topco Shares in issue at that time (other than as regards any dividends or other distributions payable by reference to a record date preceding the date of allotment or
transfer). The allotment, issue or transfer of the Consideration Shares shall constitute a complete discharge to [Topco] (or its nominee (as applicable) and Company in respect of their obligations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On any reorganisation of, or material alteration to, the share capital of the Company (including, without
limitation, any subdivision and/or consolidation), the Relevant Consideration shall be adjusted by the directors in such manner as the auditors of the Company or an independent investment bank selected by the Company (whichever in their absolute
discretion the directors may elect) may determine to be fair and reasonable to the New Member reflecting such reorganisation or alteration. References in this Article to Consideration Shares shall, following such adjustment, be construed
accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fraction of a Consideration Share shall be allotted, issued or transferred to any New Member pursuant to
this Article. [Any fraction of a Consideration Share to which a New Member would otherwise have become entitled shall be aggregated with the fractional entitlements of any other New Members whose shares are being transferred under this article on
the same date and the maximum number of Consideration Shares resulting therefrom (rounded [down] to the nearest whole number of Consideration Shares) shall be allotted and issued to a person appointed by Topco to hold such Consideration Shares on
behalf of the relevant holders of Scheme Share. Topco shall procure that such Consideration Shares are sold in the market as soon as practicable after the Combination becomes Effective or, if later,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-xix </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
their allotment and issue, and the net proceeds of sale (after deduction of all expenses and commissions incurred in connection with the sale) shall be distributed in due proportions to the
persons entitled thereto (rounded down to the nearest penny).]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To give effect to any transfer of Post-Scheme Shares required by this Article, the Company may hereby appoint
any person as appointee or agent of the New Member to execute and deliver a form of transfer on behalf of the New Member in favour of [Topco] (or, if applicable, its nominee(s)) and to do all such things and execute and deliver such documents as
may, in the opinion of the appointee or agent, be necessary or desirable to vest such Post-Scheme Shares in [Topco] (or its nominee(s), if applicable) including without limitation giving good receipt for the consideration for the Post-Scheme Shares.
Pending the registration of [Topco] (or its nominee(s), if applicable) as the holder of any Post-Scheme Shares to be transferred pursuant to this Article, each New Member hereby irrevocably appoints [Topco] as its appointee and/or agent and/or
otherwise to exercise on its behalf (in place of and to the exclusion of the relevant New Member) any voting rights attached to the Post-Scheme Shares and any or all rights and privileges attaching to the Post-Scheme Shares, to sign any consent to
short notice of any general or separate class meeting of the Company and on the New Member&#146;s behalf to execute a form of proxy in respect of its Post-Scheme Shares appointing any person nominated by [Topco] (or its nominee(s), if applicable) to
attend general and separate class meetings of the Company and authorises the Company to send to [Topco] and/or its nominee(s) any notice, circular, warrant or other document or communication which may be required to be sent to them as a member of
the Company, such that from the [Effective Date] (as defined in the Scheme), no New Member shall be entitled to exercise any voting rights attached to the Post-Scheme Shares or any other rights or privileges attaching to the Post-Scheme Shares. The
Company shall not be obliged to issue a certificate to the New Member for any Post-Scheme Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provision of these Articles, neither the Company nor the directors shall register the
transfer of any Scheme Shares effected between the [Scheme Record Time] and the date on which the Scheme becomes effective, other than to [Topco] or its nominee(s) pursuant to the Scheme. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Scheme shall not have become effective by the applicable date referred to in (or otherwise set in
accordance with) clause [&#9679;] of the Scheme, this Article 61 shall cease to be of any effect. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-xx </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom273090_217a"></A>Annex G </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUIDEL CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amended and Restated 2018 Equity Incentive Plan </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amended and Restated Effective: [</B>&#9679;<B></B><B>], 2022) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ESTABLISHMENT; PURPOSE OF PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quidel Corporation, a Delaware corporation (the &#147;Company&#148;), hereby establishes the Quidel Corporation 2018 Equity Incentive Plan
(the &#147;Plan&#148;). Upon its original approval by stockholders on May&nbsp;15, 2018, the Plan superseded and replaced the Quidel Corporation 2016 Equity Incentive Plan (the &#147;2016 Plan&#148;) and all Prior Plans. No future awards may be made
pursuant to the 2016 Plan and any other Prior Plan; provided, that, the 2016 Plan and all other Prior Plans shall remain in effect until all awards granted under the 2016 Plan and the Prior Plans have been exercised, forfeited, or cancelled or have
otherwise expired or terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan is intended to promote the interests of the Company and its stockholders by using investment
interests in the Company to attract, retain and motivate its management and other persons, to encourage and reward their contributions to the performance of the Company, and to align their interests with the interests of the Company&#146;s
stockholders. Capitalized terms not otherwise defined herein have the meanings ascribed to them in<I>&nbsp;Article</I><I></I><I>&nbsp;IX</I>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II H </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EFFECTIVE
DATE AND TERM OF PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Term of Plan</B>. This Plan became effective on the Effective Date and will continue in
effect until the earlier of: (a)&nbsp;the Expiration Date; or (b)&nbsp;the date of any Plan termination pursuant to the provisions of<I>&nbsp;Section 4.4</I>&nbsp;or<I>&nbsp;Section</I><I></I><I>&nbsp;8.1</I>. This amendment and restatement of the
Plan will become effective upon approval by the Company&#146;s stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Effect on Awards</B>. Awards may be
granted only during the Plan Term, but each Award properly granted during the Plan Term will remain in effect after the Expiration Date until such Award has been exercised, terminated or expired in accordance with its terms and the terms of this
Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARES SUBJECT TO PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Number of Shares</B>. The maximum number of shares of Common Stock that may be issued pursuant to Awards under this Plan
is 3,150,000, plus (a)&nbsp;any shares of Common Stock that were authorized for issuance under the Prior Plans that, as of the Effective Date, remain available for issuance under the Prior Plans (not including any shares that are subject to, as of
the Effective Date, outstanding awards under the Prior Plans or any shares that prior to the Effective Date were issued pursuant to awards granted under the Prior Plans) and (b)&nbsp;any shares of Common Stock subject to outstanding awards under the
Prior Plans as of the Effective Date (the &#147;Prior Plan Awards&#148;) that on or after such date cease for any reason to be subject to such awards (other than by reason of exercise or settlement of the awards to the extent they are exercised for
or settled in vested and nonforfeitable shares). The aggregate number of shares of Common Stock available for grant under this Plan and the number of shares subject to outstanding Awards shall be subject to adjustment as set forth
in<I>&nbsp;Section</I><I></I><I>&nbsp;3.4</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Source of Shares</B>. The Common Stock to be issued under this Plan
will be made available, at the discretion of the Administrator, either from authorized but unissued shares of Common Stock or from previously issued shares of Common Stock reacquired by the Company, including without limitation shares purchased on
the open market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Share Counting</B>. The following rules shall apply solely for purposes
of determining the number of shares of Common Stock available for grant at any given time: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Fungible
Design</I>. Any shares of Common Stock issued pursuant to Stock Options or SARs under this Plan shall be counted against the limit set forth in<I>&nbsp;Section 3.1</I>&nbsp;on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis and any shares of Common Stock issued pursuant to Awards under this Plan other than Stock Options or SARs shall be counted against the limit set forth
in<I>&nbsp;Section 3.1</I>&nbsp;as 1.5&nbsp;shares for every one share of Common Stock issued pursuant to such Award Any shares of Common Stock that again become available for issuance pursuant to this<I>&nbsp;Section 3.3</I>&nbsp;shall be added
back as one share if such shares were subject to Stock Options or SARs (or subject to stock options or stock appreciation rights granted under the Prior Plans), and as 1.5&nbsp;shares if such shares were subject to Awards other than Stock Options or
SARs (or subject to awards other than stock options or stock appreciation rights granted under the Prior Plans). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Terminated Awards</I>. In the event any Award granted under the Plan (or any Prior Plan Award), is terminated,
expired, forfeited, or cancelled for any reason, the number of shares of Common Stock subject to such Award (or Prior Plan Award) will again be available for grant under the Plan (i.e., any prior charge against the limit set forth in<I>&nbsp;Section
3.1</I>&nbsp;shall be reversed). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Cash Settled Awards</I>. If shares of Common Stock are not delivered in
connection with an Award (or Prior Plan Award) because the Award (or Prior Plan Award) may only be settled in cash rather than in Common Stock, no shares of Common Stock shall be counted against the limit set forth in<I>&nbsp;Section 3.1</I>. If any
Award (or Prior Plan Award) may be settled in cash or Common Stock, the rules set forth in<I>&nbsp;Section 3.3(a)</I>&nbsp;shall apply until the Award (or Prior Plan Award) is settled, at which time the underlying shares of Common Stock will be
added back to the shares available for grant pursuant to<I>&nbsp;Section 3.1</I>&nbsp;but only if the Award (or Prior Plan Award) is settled in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Liberal Share Counting for Options or SARs</I>. The exercise of a Common Stock-settled SAR or broker-assisted
&#147;cashless&#148; exercise of a Stock Option (or a portion thereof) will reduce the number of shares available for grant under<I>&nbsp;Section</I><I></I><I>&nbsp;3.1</I>&nbsp;by the entire number of shares of Common Stock subject to that SAR or
Stock Option (or applicable portion thereof). Shares of Common Stock tendered to pay the exercise price of a Stock Option or SAR or tendered, withheld or otherwise relinquished by a Recipient to satisfy a tax withholding obligation arising in
connection with a Stock Option or SAR Award (or Prior Plan option or stock appreciation rights awards) will not again become Common Stock available for grant under the Plan. Moreover, shares of Common Stock purchased on the open market with cash
proceeds generated by the exercise of a Stock Option will not increase or replenish the number of shares available for grant under<I>&nbsp;Section 3.1</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the provisions of this<I>&nbsp;Section 3.3</I>&nbsp;are inconsistent with the requirements of any regulations issued pursuant to
Section&nbsp;422 of the IRC, the provisions of such regulations shall control over the provisions of this<I>&nbsp;Section 3.3</I>, but only as this<I>&nbsp;Section 3.3</I>&nbsp;relates to Incentive Stock Options. The Administrator may adopt such
other reasonable rules and procedures as it deems to be appropriate for determining the number of shares of Stock that are available for grant under<I>&nbsp;Section 3.1</I>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Adjustment Provisions</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Adjustments</I>. If the Company consummates any Reorganization in which holders of shares of Common Stock are
entitled to receive in respect of such shares any additional shares or new or different shares or securities, cash or other consideration (including, without limitation, a different number of shares of Common Stock), or if the outstanding shares of
Common Stock are increased, decreased, changed or exchanged for a different number or kind of shares or other securities through merger, consolidation, sale or exchange of assets of the Company, reorganization, recapitalization, reclassification,
combination, stock dividend, extraordinary cash dividend, stock split, reverse stock split, <FONT STYLE="white-space:nowrap">spin-off,</FONT> or similar transaction then, subject to<I>&nbsp;Section</I><I></I><I>&nbsp;8.1</I>, an appropriate and
proportionate adjustment shall be made by the Administrator in: (i)&nbsp;the maximum number and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
kind of shares subject to this Plan as provided in<I>&nbsp;Section</I><I></I><I>&nbsp;3.1</I>; (ii)&nbsp;the number and kind of shares or other securities subject to then outstanding Awards;
(iii)&nbsp;the price for each share or other unit of any other securities subject to, or measurement criteria applicable to, then outstanding Awards; and (iv)&nbsp;the number and kind of shares or other securities to be issued as <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Fractional Interests</I>. No fractional
interests will be issued under the Plan resulting from any adjustments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Adjustments Related to Company
Stock</I>. To the extent any adjustments relate to stock or securities of the Company, such adjustments will be made by the Administrator, whose determination in that respect will be final, binding and conclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Right to Make Adjustment</I>. The grant of an Award will not affect in any way the right or power of the Company
to make adjustments, reclassifications, reorganizations or changes of its capital or business structure or to merge or to consolidate or to dissolve, liquidate or sell, or transfer all or any part of its business or assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Limitations</I>. No adjustment to the terms of an Incentive Stock Option may be made unless such adjustment
either: (i)&nbsp;would not cause the Stock Option to lose its status as an Incentive Stock Option; or (ii)&nbsp;is agreed to in writing by the Administrator and the Recipient. Any action taken pursuant to this<I>&nbsp;Section 3.4</I>&nbsp;shall be
taken in a manner consistent with the requirements of Section&nbsp;409A of the IRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Reservation of Shares</B><B>.
</B>The Company will at all times reserve and keep available shares of Common Stock equaling at least the total number of shares of Common Stock issuable pursuant to all outstanding Awards. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADMINISTRATION OF PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1&nbsp;&nbsp;&nbsp;&nbsp;Administrator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Plan Administration</I>. Subject to the provisions of<I>&nbsp;Section</I><I></I><I>&nbsp;4.1(b)</I>, this Plan
will be administered by the Board and may also be administered by a Committee of the Board appointed pursuant to<I>&nbsp;Section</I><I></I><I>&nbsp;4.1(b)</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Administration by Administrator</I>. The Board in its sole discretion may from time to time appoint a Committee
of not less than two (2)&nbsp;Board members with authority to administer this Plan in whole or part and, subject to applicable law, to exercise any or all of the powers, authority and discretion of the Board under this Plan. Unless otherwise
determined by the Board, the Committee shall consist of no less than two (2)&nbsp;directors, each of whom qualify as: (i)&nbsp;a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director; and (ii)&nbsp;an &#147;independent director&#148; for
purposes of the NASDAQ Stock Market Listing Rules (or the rules of any exchange on which the Common Stock is then listed). The Board may from time to time increase or decrease (but not below two (2)) the number of members of the Committee, remove
from membership on the Committee all or any portion of its members, and/or appoint such person or persons as it desires to fill any vacancy existing on the Committee, whether caused by removal, resignation or otherwise. Unless otherwise required by
this<I>&nbsp;Section</I><I></I><I>&nbsp;4.1(b)</I>, the Board may disband the Committee at any time and, in such case, the Board will be responsible for the administration of the Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Authority of Administrator</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Authority to Interpret Plan</I>. Subject to the express provisions of this Plan, the Administrator will have the
power to implement, interpret and construe this Plan and any Awards and Award Documents or other documents defining the rights and obligations of the Company and Recipients hereunder and thereunder, to determine all questions arising hereunder and
thereunder, and to adopt and amend such rules and regulations for the administration hereof and thereof as it may deem desirable. The interpretation and construction by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Administrator of any provisions of this Plan or of any Award or Award Document, and any action taken by, or inaction of, the Administrator relating to this Plan or any Award or Award Document,
will be within the discretion of the Administrator and will be conclusive and binding upon all persons. Subject only to compliance with the express provisions hereof, the Administrator may act in its discretion in matters related to this Plan and
any and all Awards and Award Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Authority to Grant Awards</I>. Subject to the express provisions of
this Plan, the Administrator may from time to time in its discretion select the Eligible Persons to whom, and the time or times at which, Awards will be granted or sold, the nature of each Award, the number of shares of Common Stock or the number of
rights that make up or underlie each Award, the exercise price and period (if applicable) for the exercise of each Award, and such other terms and conditions applicable to each individual Award as the Administrator may determine. Any and all terms
and conditions of Awards may be established by the Administrator without regard to existing Awards or other grants and without incurring any obligation of the Company in respect of subsequent Awards. The Administrator may grant at any time new
Awards to an Eligible Person who has previously received Awards or other grants (including other stock options) regardless of the status of such other Awards or grants. The Administrator may grant Awards singly or in combination or in tandem with
other Awards as it determines in its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Procedures</I>. Subject to the Company&#146;s charters
(including its Compensation Administrator Charter) or bylaws or any Board resolution conferring authority on the Committee, any action of the Administrator with respect to the administration of this Plan must be taken pursuant to a majority vote of
the authorized number of members of the Administrator or by the unanimous written consent of its members; <I>provided, however,</I>&nbsp;that: (i)&nbsp;if the Administrator is the Committee and consists of two (2)&nbsp;members, then actions of the
Administrator must be unanimous; and (ii)&nbsp;actions taken by the Board will be valid if approved in accordance with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Liability</B>. No member of the Board or the Committee or any designee thereof will be liable for any action or
inaction with respect to this Plan or any Award or any transaction arising under this Plan or any Award except in circumstances constituting bad faith of such member. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendments</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Plan Amendments</I>. The Administrator may at any time and from time to time in its discretion, insofar as
permitted by applicable law, rule or regulation and subject to<I>&nbsp;Section</I><I></I><I>&nbsp;4.4(c)</I>, suspend or discontinue this Plan or revise or amend it in any respect whatsoever, and this Plan as so revised or amended will govern all
Awards, including those granted before such revision or amendment. Without limiting the generality of the foregoing, the Administrator is authorized to amend this Plan to comply with or take advantage of amendments to applicable laws, rules or
regulations, including the Securities Act, the Exchange Act, the IRC, or the rules of any exchange or market system upon which the Common Stock is listed or trades, or any rules or regulations promulgated thereunder. No stockholder approval of any
amendment or revision will be required unless such approval is required by applicable law, rule or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Award Amendments; No Repricing</I>. The Administrator may at any time and from time to time in its discretion,
but subject to<I>&nbsp;Section</I><I></I><I>&nbsp;4.4(c)</I><I></I>&nbsp;and compliance with applicable statutory or administrative requirements, accelerate or extend the vesting or exercise period of any Award as a whole or in part, and make such
other modifications in the terms and conditions of an Award as it deems advisable,<I>&nbsp;provided, however,</I>&nbsp;that the Administrator, other than in connection with an adjustment under<I>&nbsp;Section 3.4</I>, may reduce the exercise or base
price of a Stock Option or SAR (either by cancellation of such Stock Option or SAR in exchange for cash, other Awards, or a new Stock Option or SAR at such reduced exercise or base price or by amending the terms of the Stock Option or SAR to reflect
such a reduced exercise or base price) only with stockholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Limitation</I>. Except as otherwise
provided in this Plan or in the applicable Award Document, no amendment, revision, suspension or termination of this Plan or an outstanding Award that would cause an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Incentive Stock Option to cease to qualify as such or that would alter, impair or diminish in any material respect any rights or obligations under any Award theretofore granted under this Plan
may be effected without the written consent of the Recipient to whom such Award was granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Compensation
Plans</B>. The adoption of this Plan will not affect any other stock option, incentive or other compensation plans in effect from time to time for the Company, and this Plan will not preclude the Company from establishing any other forms of
incentive or other compensation for employees, directors, advisors or consultants of the Company, whether or not approved by stockholders. This Plan does not affect in any way any outstanding award grants made under such plans and awards granted
under such plans will continue to be governed by the terms and conditions of such plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Plan Binding on
Successors</B>. This Plan will be binding upon the successors and assigns of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>References to Successor
Statutes, Regulations and Rules</B>. Any reference in this Plan to a particular statute, regulation or rule will also refer to any successor provision of such statute, regulation or rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Invalid Provisions</B>. In the event that any provision of this Plan is found to be invalid or otherwise unenforceable
under any applicable law, such invalidity or unenforceability is not to be construed as rendering any other provisions contained herein invalid or unenforceable, and all such other provisions are to be given full force and effect to the same extent
as though the invalid and unenforceable provision were not contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Governing Law</B>. This Plan will be
governed by and interpreted in accordance with the internal laws of the State of Delaware, without giving effect to the principles of the conflicts of laws thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Interpretation</B>. Headings herein are for convenience of reference only, do not constitute a part of this Plan, and
will not affect the meaning or interpretation of this Plan. References herein to Sections or Articles are references to the referenced Section or Article hereof, unless otherwise specified. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL AWARD
PROVISIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Participation in Plan</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Eligibility to Receive Awards</I>. A person is eligible to receive grants of Awards if, at the time of the grant
of the Award, such person is an Eligible Person or has received an offer of employment from the Company; <I>provided, however,</I>&nbsp;that only <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors are eligible to receive <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Options, and<I>&nbsp;provided further</I>, that Awards granted to a person who has received an offer of employment will terminate and be forfeited without consideration if the employment offer
is not accepted within such time as may be specified by the Company. Status as an Eligible Person will not be construed as a commitment that any Award will be granted under this Plan to an Eligible Person or to Eligible Persons generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Eligibility to Receive Incentive Stock Options</I>. Incentive Stock Options may be granted only to Eligible
Persons meeting the employment requirements of Section&nbsp;422 of the IRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Awards to Foreign
Nationals</I>. Notwithstanding anything to the contrary herein, the Administrator may, in order to fulfill the purposes of this Plan, modify grants of Awards to Recipients who are foreign nationals or employed outside of the United States to
recognize differences in applicable law, tax policy or local custom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Award Documents</B>. Each Award must be
evidenced by an Award Document setting forth such terms and conditions applicable to the Award as the Administrator may in its discretion determine. Awards will not be deemed made or binding upon the Company, and Recipients will have no rights
thereto, until an Award </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Document agreement is entered into between the Company and the Recipient or delivered by the Company to the Recipient, but an Award may have an effective date prior to the date of such an Award
Document, to the extent consistent with applicable law. Award Documents may be (but need not be) identical and must comply with and be subject to the terms and conditions of this Plan, a copy of which will be provided to each Recipient and
incorporated by reference into each Award Document. Any Award Document may contain such other terms, provisions and conditions not inconsistent with this Plan as may be determined by the Administrator. In case of any conflict between this Plan and
any Award Document, this Plan shall control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Payment For Awards</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Payment of Exercise Price</I>. The exercise price or other payment for an Award is payable upon the exercise of a
Stock Option or upon other purchase of shares pursuant to an Award granted hereunder by delivery of cash or certified check or payment of such other consideration as the Administrator may from time to time deem acceptable in any particular instance;
<I>provided, however</I>, that the Administrator may, in the exercise of its discretion, allow exercise of an Award in a broker-assisted or similar transaction in which the exercise price is not received by the Company until promptly after exercise.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Cashless Exercise</I>. If permitted in any case by the Administrator in its discretion, the exercise price
for Awards may be paid by capital stock of the Company delivered in transfer to the Company by or on behalf of the person exercising the Award and duly endorsed in blank or accompanied by stock powers duly endorsed in blank, with signatures
guaranteed in accordance with the Exchange Act if required by the Administrator; or retained by the Company from the stock otherwise issuable upon exercise or surrender of vested and/or exercisable Awards or other equity awards previously granted to
the Recipient and being exercised (if applicable) (in either case valued at Fair Market Value as of the exercise date); or such other consideration as the Administrator may from time to time in the exercise of its discretion deem acceptable in any
particular instance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Precedent</I>. Recipients will have no rights to the exercise techniques described
in<I>&nbsp;Section</I><I></I><I>&nbsp;5.3(b)</I>, and the Company may offer or permit such techniques on an<I>&nbsp;ad hoc</I>&nbsp;basis to any Recipient without incurring any obligation to offer or permit such techniques on other occasions or to
other Recipients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Employment Rights</B>. Nothing contained in this Plan (or in Award Documents or in any other
documents related to this Plan or to Awards) will confer upon any Eligible Person or Recipient any right to continue in the employ of or engagement by the Company or any Affiliated Entity or constitute any contract or agreement of employment or
engagement, or interfere in any way with the right of the Company or any Affiliated Entity to reduce such person&#146;s compensation or other benefits or to terminate the employment or engagement of such Eligible Person or Recipient, with or without
cause. Except as expressly provided in this Plan or in any statement evidencing the grant of an Award, the Company has the right to deal with each Recipient in the same manner as if this Plan and any such statement evidencing the grant of an Award
did not exist, including, without limitation, with respect to all matters related to the hiring, discharge, compensation and conditions of the employment or engagement of the Recipient. Unless otherwise set forth in a written agreement binding upon
the Company or an Affiliated Entity, all employees of the Company or an Affiliated Entity are &#147;at will&#148; employees whose employment may be terminated by the Company or the Affiliated Entity at any time for any reason or no reason, without
payment or penalty of any kind. Any question(s)&nbsp;as to whether and when there has been a termination of a Recipient&#146;s employment or engagement, the reason (if any) for such termination, and/or the consequences thereof under the terms of
this Plan or any statement evidencing the grant of an Award pursuant to this Plan will be determined by the Administrator and the Administrator&#146;s determination thereof will be final and binding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Restrictions Under Applicable Laws and Regulations</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Government Approvals</I>. All Awards will be subject to the requirement that, if at any time the Company
determines, in its discretion, that the listing, registration or qualification of the securities subject to Awards </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
granted under this Plan upon any securities exchange or interdealer quotation system or under any federal, state or foreign law, or the consent or approval of any government or regulatory body,
is necessary or desirable as a condition of, or in connection with, the granting of such an Award or the issuance, if any, or purchase of shares in connection therewith, such Award may not be exercised as a whole or in part unless and until such
listing, registration, qualification, consent or approval has been effected or obtained free of any conditions not acceptable to the Company. During the Plan Term, the Company will use its reasonable efforts to seek to obtain from the appropriate
governmental and regulatory agencies any requisite qualifications, consents, approvals or authorizations in order to issue and sell such number of shares of its Common Stock as is sufficient to satisfy the requirements of this Plan. The inability of
the Company to obtain any such qualifications, consents, approvals or authorizations after such reasonable efforts will relieve the Company of any liability in respect of the nonissuance or sale of such stock as to which such qualifications,
consents, approvals or authorizations pertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Registration Obligation; Recipient Representations</I>.
The Company will be under no obligation to register or qualify the issuance of Awards or underlying securities under the Securities Act or applicable state securities laws. Unless the issuance of Awards and underlying securities have been registered
under the Securities Act and qualified or registered under applicable state securities laws, the Company shall be under no obligation to issue any Awards or underlying securities unless the Awards and underlying securities may be issued pursuant to
applicable exemptions from such registration or qualification requirements. In connection with any such exempt issuance, the Administrator may require the Recipient to provide a written representation and undertaking to the Company, satisfactory in
form and scope to the Company, that such Recipient is acquiring such Awards and underlying securities for such Recipient&#146;s own account as an investment and not with a view to, or for sale in connection with, the distribution of any such
securities, and that such person will make no transfer of the same except in compliance with any rules and regulations in force at the time of such transfer under the Securities Act and other applicable law, and that if securities are issued without
registration, a legend to this effect (together with any other legends deemed appropriate by the Administrator) may be endorsed upon the securities so issued, and to the effect of any additional representations that are appropriate in light of
applicable securities laws and rules. The Company may also order its transfer agent to stop transfers of such shares. The Administrator may also require the Recipient to provide the Company such information and other documents as the Administrator
may request in order to satisfy the Administrator as to the investment sophistication and experience of the Recipient and as to any other conditions for compliance with any such exemptions from registration or qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Additional Conditions</B>. Any Award may be subject to such provisions (whether or not applicable to any other Award or
Recipient) as the Administrator deems appropriate, including without limitation provisions for the forfeiture of or restrictions on resale or other disposition of securities of the Company acquired under this Plan, provisions giving the Company the
right to repurchase securities of the Company acquired under this Plan in the event the Recipient leaves the Company for any reason or elects to effect any disposition thereof, and provisions to comply with federal and state securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Privileges Regarding Stock Ownership or Specific Assets</B>. Except as otherwise set forth herein, a Recipient or a
permitted transferee of an Award will have no rights as a stockholder with respect to any shares issuable or issued in connection with the Award until the Recipient has delivered to the Company all amounts payable and performed all obligations
required to be performed in connection with exercise of the Award and the Company has issued such shares. No person will have any right, title or interest in any fund or in any specific asset (including shares of capital stock) of the Company by
reason of any Award granted hereunder. Neither this Plan (or any documents related hereto) nor any action taken pursuant hereto is to be construed to create a trust of any kind or a fiduciary relationship between the Company and any person. To the
extent that any person acquires a right to receive an Award hereunder, such right shall be no greater than the right of any unsecured general creditor of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Nonassignability</B>. No Award is assignable or transferable except: (a)&nbsp;by will or by the laws of descent and
distribution; or (b)&nbsp;subject to the final sentence of this<I>&nbsp;Section</I><I></I><I>&nbsp;5.8</I>, upon dissolution of marriage pursuant to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
qualified domestic relations order or, in the discretion of the Administrator on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis and under
circumstances that would not adversely affect the interests of the Company, transfers for estate planning purposes or pursuant to a nominal transfer that does not result in a change in beneficial ownership. Subject to the final sentence of
this<I>&nbsp;Section</I><I></I><I>&nbsp;5.8</I>, during the lifetime of a Recipient, an Award granted to such person will be exercisable only by the Recipient (or the Recipient&#146;s permitted transferee) or such person&#146;s guardian or legal
representative. Notwithstanding the foregoing, Stock Options intended to be treated as Incentive Stock Options (or other Awards subject to transfer restrictions under the IRC) (i)&nbsp;may not be assigned or transferred in violation of
Section&nbsp;422(b)(5)&nbsp;of the IRC or the regulations thereunder, and nothing herein is intended to allow such assignment or transfer; and (ii)&nbsp;will be exercisable during a Recipient&#146;s lifetime only by the Recipient. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.9&nbsp;&nbsp;&nbsp;&nbsp;Information To Recipients. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Provision of Information</I>. The Administrator in its sole discretion may determine what, if any, financial and
other information is to be provided to Recipients and when such financial and other information is to be provided after giving consideration to applicable federal and state laws, rules and regulations, including, without limitation, applicable
federal and state securities laws, rules and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Confidentiality</I>. The furnishing of financial
and other information that is confidential to the Company is subject to the Recipient&#146;s agreement to maintain the confidentiality of such financial and other information, and not to use the information for any purpose other than evaluating the
Recipient&#146;s position under this Plan. The Administrator may impose other restrictions on the access to and use of such confidential information and may require a Recipient to acknowledge the Recipient&#146;s obligations under
this<I>&nbsp;Section</I><I></I><I>&nbsp;5.9(b)</I><I></I>&nbsp;(which acknowledgment is not to be a condition to Recipient&#146;s obligations under this<I>&nbsp;Section</I><I></I><I>&nbsp;5.9(b))</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Withholding Taxes</B>. Whenever the granting, vesting or exercise of any Award, or the issuance of any Common Stock or
other securities upon exercise of any Award or transfer thereof, gives rise to tax or tax withholding liabilities or obligations, the Administrator will have the right as a condition thereto to require the Recipient to remit to the Company up to the
maximum statutory amount necessary, in the applicable jurisdiction, to satisfy any federal, state, and local withholding tax requirements on any Award under the Plan. The Administrator may, in the exercise of its discretion, allow satisfaction of
tax withholding requirements by accepting delivery of stock of the Company or by withholding a portion of the stock otherwise issuable in connection with an Award, in each case valued at Fair Market Value as of the date of such delivery or
withholding, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.11</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Legends on Awards and Stock Certificates</B>. Each Award Document and each
certificate representing securities acquired upon grant, vesting or exercise of an Award must be endorsed with all legends, if any, required by applicable federal and state securities and other laws to be placed on the Award Document and/or the
certificate. The determination of which legends, if any, will be placed upon Award Documents or the certificates will be made by the Administrator in its discretion and such decision will be final and binding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.12</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Effect of Termination of Employment on Awards</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination of Vesting</I>. Notwithstanding anything to the contrary herein, but subject
to<I>&nbsp;Section</I><I></I><I>&nbsp;5.12(b)</I><I></I>&nbsp;Awards will be exercisable by a Recipient (or the Recipient&#146;s successor in interest) following such Recipient&#146;s termination of employment or service only to the extent that
installments thereof had become exercisable on<B></B>&nbsp;or prior to the date of such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Alteration of Vesting and Exercise Periods</I>. Notwithstanding anything to the contrary herein, the
Administrator may in its discretion: (i)&nbsp;designate shorter or longer periods following a Recipient&#146;s termination of employment or service during which Awards may vest or be exercised; <I>provided, however,</I>&nbsp;that any shorter periods
determined by the Administrator will be effective only if provided for in this Plan or the instrument that evidences the grant to the Recipient of the affected Award or if such shorter period is agreed to in writing by the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Recipient; and (ii)&nbsp;accelerate the vesting of all or any portion of any Awards by increasing the number of shares purchasable at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Leave of Absence</I>. In the case of any employee on an approved leave of absence, the Administrator may make
such provision respecting continuance of Awards granted to such employee as the Administrator in its discretion deems appropriate, except that in no event will an Award be exercisable after the date such Award would expire in accordance with its
terms had the Recipient remained continuously employed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>General Cessation</I>. Except as otherwise set
forth in this Plan or an Award Document or as determined by the Administrator in its discretion, all Awards granted to a Recipient, and all of such Recipient&#146;s rights thereunder, will terminate upon termination for any reason of such
Recipient&#146;s employment or service with the Company or any Affiliated Entity (or cessation of any other service relationship between the Recipient and the Company or any Affiliated Entity in place as of the date the Award was granted). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.13</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</B>. Each Recipient agrees as a condition to receipt of an
Award that, in connection with any public offering by the Company of its equity securities and upon the request of the Company and the principal underwriter (if any) in such public offering, any shares of Common Stock acquired or that may be
acquired upon exercise or vesting of an Award may not be sold, offered for sale, encumbered, or otherwise disposed of or subjected to any transaction that will involve any sales or other transfer of securities of the Company, or any interest
therein, without the prior written consent of the Company or such underwriter, as the case may be, for a period of not more than 365 days after the commencement date of such public offering. Each Recipient will, if requested by the Company or the
principal underwriter, enter into a separate agreement to the effect of this<I>&nbsp;Section</I><I></I><I>&nbsp;5.13</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.14</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Restrictions on Common Stock and Other Securities</B>. Common Stock or other securities of the Company issued or
issuable in connection with any Award will be subject to all of the restrictions imposed under this Plan upon Common Stock issuable or issued upon exercise of Stock Options, except as otherwise determined by the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.15</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Limits on Awards to Eligible Persons</B>. Notwithstanding any provision in the Plan to the contrary, the aggregate value
of cash compensation and the grant date fair market value of shares of Common Stock subject to Awards (calculated as of the date of grant in accordance with applicable accounting rules) that may be awarded or granted during any single calendar year
to any one Eligible Person who is a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall not exceed $750,000. For the avoidance of doubt, if a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director serves the Company in more
than one capacity during any single calendar year, the total compensation limit described in this<I>&nbsp;Section 5.15</I>&nbsp;shall only apply to the compensation paid for services performed as a
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director. To the extent any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director compensation is deferred, it shall be counted toward this total compensation limit only for the year in
which the compensation was first earned or granted. The limitations set forth in this Section&nbsp;5.15 will be subject to adjustment as provided in<I>&nbsp;Section</I><I></I><I>&nbsp;3.4</I>&nbsp;or
under<I>&nbsp;Article</I><I></I><I>&nbsp;VIII</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.16&nbsp;&nbsp;&nbsp;&nbsp;Section 409A</B>. If any payments under this Plan are subject to the
provisions of Section&nbsp;409A of the IRC, it is intended that the terms of this Plan and the applicable Award Document will comply fully with and meet all of the requirements of Section&nbsp;409A of the IRC. If, at the time of an Eligible
Person&#146;s Separation from Service, the Company has any stock which is publicly traded on an established securities market or otherwise, and if the Eligible Person is considered to be a Specified Employee, to the extent any payment for any Award
is subject to the requirements of Section&nbsp;409A of the IRC and is payable upon the Eligible Person&#146;s Separation from Service, such payment shall not commence prior to the first business day following the date which is six (6)&nbsp;months
after the Eligible Person&#146;s Separation from Service (or if earlier than the end of the six (6)&nbsp;month period, the date of the Eligible Person&#146;s death). Any amounts that would have been distributed during such six (6)&nbsp;month period
will be distributed on the day following the expiration of the six (6)&nbsp;month period. Under no circumstances may the time or schedule of any payment for any Award that is subject to the requirements of Section&nbsp;409A of the IRC be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accelerated or subject to further deferral except as otherwise permitted or required pursuant to regulations and other guidance issued pursuant to Section&nbsp;409A of the IRC. If the Company
fails to make any payment pursuant to the payment provisions applicable to an Award that is subject to Section&nbsp;409A of the IRC, either intentionally or unintentionally, within the time period specified in such provisions, but the payment is
made within the same calendar year, such payment will be treated as made within the specified time period. In addition, in the event of a dispute with respect to any payment, such payment may be delayed in accordance with the regulations and other
guidance issued pursuant to Section&nbsp;409A of the IRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.17&nbsp;&nbsp;&nbsp;&nbsp;Clawback</B>. Every Award issued pursuant to this Plan is
subject to potential forfeiture or recovery to the fullest extent called for by law, any applicable listing standard, or any current or future clawback policy that may be adopted by the Company from time to time, including, without limitation, any
clawback policy adopted to comply with the final rules issued by the Securities and Exchange Commission and the final listing standards to be adopted by the NASDAQ Stock Market (or the rules of any exchange on which the Common Stock is then listed)
pursuant to Section&nbsp;954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. By accepting an Award, each Recipient consents to the potential forfeiture or recovery of his or her Awards pursuant to applicable law, listing standard,
and/or Company clawback policy, and agrees to be bound by and comply with the clawback policy and to return the full amount required by the clawback policy. As a condition to the receipt of any Award, a Recipient may be required to execute any
requested additional documents consenting to and agreeing to abide by the Company clawback policy as it may be amended from time to time. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AWARDS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Stock Options</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Nature of Stock Options</I>. Stock Options may be Incentive Stock Options or Nonqualified Stock Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Option Exercise Price</I>. The exercise price for each Stock Option will be determined by the Administrator as
of the date such Stock Option is granted and shall not be less than the Fair Market Value of the underlying stock on the date of grant; <I>provided, however</I>, that in the case of Stock Options granted to employees upon a merger or acquisition,
and to the extent permitted by Section&nbsp;409A of the IRC, the exercise price may be higher or lower than the Fair Market Value of the underlying stock on the date of grant if such exercise price is required to assume or substitute options held by
employees of the acquired corporation at the time of the acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Option Period and Vesting</I>. Stock
Options granted hereunder will vest and may be exercised as determined by the Administrator, except that the exercise of Stock Options after termination of the Recipient&#146;s employment or service shall be subject
to<I>&nbsp;Section</I><I></I><I>&nbsp;5.12</I>&nbsp;and<I>&nbsp;Section</I><I></I><I>&nbsp;6.1(e)</I>. Each Stock Option granted hereunder and all rights or obligations thereunder shall expire on such date as may be determined by the Administrator,
but not later than ten (10)&nbsp;years after the date the Stock Option is granted and may be subject to earlier termination as provided herein or in the Award Document. Except as otherwise provided herein, a Stock Option will become exercisable, as
a whole or in part, on the date or dates specified by the Administrator and thereafter will remain exercisable until the exercise, expiration or earlier termination of the Stock Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Exercise of Stock Options</I>. The exercise price for Stock Options will be paid as set forth
in<I>&nbsp;Section</I><I></I><I>&nbsp;5.3</I>. No Stock Option will be exercisable except in respect of whole shares, and fractional share interests shall be disregarded. Not fewer than 100 shares of Common Stock (or such other amount as may be set
forth in the applicable Award Document) may be purchased at one time and Stock Options must be exercised in multiples of 100 unless the number purchased is the total number of shares for which the Stock Option is exercisable at the time of exercise.
A Stock Option will be deemed to be exercised when the Secretary or other designated official </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Company receives written notice of such exercise from the Recipient in such form as the Company may specify from time to time, together with payment of the exercise price in accordance
with<I>&nbsp;Section</I><I></I><I>&nbsp;5.3</I>&nbsp;and any amounts required under<I>&nbsp;Section</I><I></I><I>&nbsp;5.10</I>&nbsp;or, with permission of the Administrator, arrangement for such payment. Notwithstanding any other provision of this
Plan, the Administrator may impose, by rule and/or in Award Documents, such conditions upon the exercise of Stock Options (including, without limitation, conditions limiting the time of exercise to specified periods) as may be required to satisfy
applicable regulatory requirements, including, without limitation, <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> and <FONT STYLE="white-space:nowrap">Rule&nbsp;10b-5</FONT> under the Exchange Act, and any amounts required
under<I>&nbsp;Section</I><I></I><I>&nbsp;5.10</I>, or any applicable section of or regulation under the IRC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Termination of Employment. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Termination for Just Cause</I>. Subject to <I>Section</I><I></I><I>&nbsp;5.12</I>&nbsp;and except as
otherwise provided in a written agreement between the Company or an Affiliated Entity and the Recipient, which may be entered into at any time before or after termination of employment or service, in the event of a Just Cause Dismissal of a
Recipient all of the Recipient&#146;s unexercised Stock Options, whether or not vested, will expire and become unexercisable as of the date of such Just Cause Dismissal. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Termination Other Than for Just Cause</I>. Subject to <I>Section</I><I></I><I>&nbsp;5.12</I>&nbsp;and except
as otherwise provided in a written agreement between the Company or an Affiliated Entity and the Recipient, which may be entered into at any time before or after termination of employment or service, if a Recipient&#146;s employment or service with
the Company or any Affiliated Entity terminates for: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any reason other than for Just Cause Dismissal, death, or Permanent Disability, the Recipient&#146;s vested
Stock Options will expire and become unexercisable as of the earlier of: (1)&nbsp;the date such Stock Options would expire in accordance with their terms had the Recipient remained employed; and (2)&nbsp;90 days after the date of termination of
employment or service. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">death or Permanent Disability, the Recipient&#146;s unexercised, vested Stock Options will expire and become
unexercisable as of the earlier of: (1)&nbsp;the date such Stock Options would expire in accordance with their terms had the Recipient remained employed; and (2)&nbsp;one year after the date of termination of employment or service.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Special Provisions Regarding Incentive Stock Options. Notwithstanding anything herein to the
contrary: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The exercise price and vesting period of any Stock Option intended to be treated as an Incentive Stock Option
must comply with the provisions of Section&nbsp;422 of the IRC and the regulations thereunder. As of the Effective Date, such provisions require, among other matters, that: (A)&nbsp;the exercise price must not be less than the Fair Market Value of
the underlying stock as of the date the Incentive Stock Option is granted, and not less than 110% of the Fair Market Value as of such date in the case of a grant to a Significant Stockholder; and (B)&nbsp;that the Incentive Stock Option not be
exercisable after the expiration of ten (10)&nbsp;years from the date of grant or the expiration of five (5)&nbsp;years from the date of grant in the case of an Incentive Stock Option granted to a Significant Stockholder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The aggregate Fair Market Value (determined as of the respective date or dates of grant) of the Common Stock
for which one or more Stock Options granted to any Recipient under this Plan (or any other option plan of the Company or of any Parent Corporation or Subsidiary Corporation) may for the first time become exercisable as Incentive Stock Options under
the federal tax laws during any one calendar year may not exceed $100,000. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Stock Options granted as Incentive Stock Options pursuant to this Plan that for any reason fail or cease to
qualify as such will be treated as Nonqualified Stock Options. If the limit described in <I>Section</I><I></I><I>&nbsp;6.1(f)(ii)</I><I></I>&nbsp;is exceeded, the earliest granted Stock Options will be treated as Incentive Stock Options, up to such
limit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to adjustment as provided in <I>Section</I><I></I><I>&nbsp;3.4</I>, the maximum number of shares of
Common Stock that may be issued as Incentive Stock Options under the Plan shall be the same numeric limit set forth in<I>&nbsp;Section 3.1</I>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Options.
Article</I><I></I><I>&nbsp;VII</I>&nbsp;will govern <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Options to the extent inconsistent with this<I>&nbsp;Section</I><I></I><I>&nbsp;6.1</I>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Performance Awards</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Grant of Performance Award</I>. The Administrator will determine in its discretion the performance goals (which
need not be identical and may be established on an individual or group basis) governing Performance Awards, the terms thereof, and the form and time of payment of Performance Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Payment of Award</I>. Upon satisfaction of the conditions applicable to a Performance Award, payment will be
made to the Recipient in cash, in shares of Common Stock valued at Fair Market Value as of the date payment is due, or in a combination of Common Stock and cash, as the Administrator in its discretion may determine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Restricted Stock</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Award of Restricted Stock</I>. The Administrator will determine the Purchase Price (if any), the terms of payment
of the Purchase Price, the restrictions upon the Restricted Stock, and when such restrictions will lapse. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Requirements of Restricted Stock</I>. All shares of Restricted Stock granted or sold pursuant to this Plan will
be subject to the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>No Transfer</I>. The shares may not be sold, assigned, transferred, pledged, hypothecated or otherwise
disposed of, alienated or encumbered until the restrictions are removed or expire. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Certificates</I>. The Administrator may require that the certificates representing Restricted Stock granted
or sold to a Recipient remain in the physical custody of an escrow holder or the Company until all restrictions are removed or expire. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Restrictive Legends</I>. Each certificate representing Restricted Stock granted or sold to a Recipient
pursuant to this Plan will bear such legend or legends making reference to the restrictions imposed upon such Restricted Stock as the Administrator in its discretion deems necessary or appropriate to enforce such restrictions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Other Restrictions</I>. The Administrator may impose such other conditions on Restricted Stock as the
Administrator may deem advisable, including, without limitation, restrictions under the Securities Act, under the Exchange Act, under the requirements of any stock exchange or interdealer quotation system upon which such Restricted Stock or other
securities of the Company are then listed or traded and under any blue sky or other securities laws applicable to such shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Lapse of Restrictions</I>. The restrictions imposed upon Restricted Stock will lapse in accordance with such
terms or other conditions as are determined by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Rights of Recipient</I>. Subject to the
provisions of<I>&nbsp;Section</I><I></I><I>&nbsp;6.3(b)</I><I></I>&nbsp;and any restrictions imposed upon the Restricted Stock, the Recipient will have all rights of a stockholder with respect to the Restricted Stock granted or sold to such
Recipient under this Plan, including, without limitation, the right to vote the shares and receive all dividends and other distributions paid or made with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination of Employment</I>. Unless the Administrator in its discretion determines otherwise, if a
Recipient&#146;s employment or service with the Company or any Affiliated Entity terminates for any reason, all of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Recipient&#146;s Restricted Stock remaining subject to restrictions on the date of such termination of employment or service will be repurchased by the Company at the Purchase Price (if any)
paid by the Recipient to the Company, without interest or premium, and otherwise returned to the Company without consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Stock Appreciation Rights</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Granting of Stock Appreciation Rights</I>. The Administrator may at any time and from time to time approve the
grant to Eligible Persons of Stock Appreciation Rights, related or unrelated to Stock Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;SARs Related to
Options. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Stock Appreciation Right related to a Stock Option will entitle the holder of the related Stock Option, upon
exercise of the Stock Appreciation Right, to surrender such Stock Option, or any portion thereof to the extent previously vested but unexercised, with respect to the number of shares as to which such Stock Appreciation Right is exercised, and to
receive payment of an amount computed pursuant to <I>Section</I><I></I><I>&nbsp;6.4(b)(iii)</I>. Such Stock Option will, to the extent surrendered, then cease to be exercisable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Stock Appreciation Right related to a Stock Option hereunder will be exercisable at such time or times, and
only to the extent that, the related Stock Option is exercisable, and will not be transferable except to the extent that such related Stock Option may be transferable (and under the same conditions), will expire no later than the expiration of the
related Stock Option, and may be exercised only when the market price of the Common Stock subject to the related Stock Option exceeds the exercise price of the Stock Option. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the exercise of a Stock Appreciation Right related to a Stock Option, the Recipient will be entitled to
receive payment of an amount determined by multiplying: (A)&nbsp;the difference obtained by subtracting the exercise price of a<B></B>&nbsp;share of Common Stock specified in the related Stock Option from the Fair Market Value of a share of Common
Stock on the date of exercise of such Stock Appreciation Right (or as of such other date or as of the occurrence of such event as may have been specified in the instrument evidencing the grant of the Stock Appreciation Right), by (B)&nbsp;the number
of shares as to which such Stock Appreciation Right is exercised. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>SARs Unrelated to
Options</I>. The Administrator may grant Stock Appreciation Rights unrelated to Stock Options. <I>Section</I><I></I><I>&nbsp;6.4(b)(iii)</I><I></I>&nbsp;will govern the amount payable at exercise under such Stock Appreciation Right, except that in
lieu of an option exercise price the initial base amount specified in the Award shall be used. All Stock Appreciation Rights unrelated to Stock Options shall be granted subject to the same terms and conditions applicable to Stock Options as set
forth in<I>&nbsp;Section</I><I></I><I>&nbsp;6.1</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Limits</I>. Notwithstanding the foregoing, the
Administrator, in its discretion, may place a dollar limitation on the maximum amount that will be payable upon the exercise of a Stock Appreciation Right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Payments</I>. Payment of the amount determined under the foregoing provisions may be made solely in whole shares
of Common Stock valued at their Fair Market Value on the date of exercise of the Stock Appreciation Right or, alternatively, at the discretion of the Administrator, in cash or in a combination of cash and shares of Common Stock as the Administrator
deems advisable. The Administrator has full discretion to determine the form in which payment of a Stock Appreciation Right will be made and to consent to or disapprove the election of a Recipient to receive cash in full or partial settlement of a
Stock Appreciation Right. If the Administrator decides to make full payment in shares of Common Stock, and the amount payable results in a fractional share, payment for the fractional share will be made in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Stock Payments</B>. The Administrator may approve Stock Payments to any Eligible Person on such terms and conditions as
the Administrator may determine. Stock Payments will replace cash compensation at the Fair Market Value of the Common Stock on the date payment is due. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Dividend Equivalents and Dividends</B>. The Administrator may grant
dividends and/or Dividend Equivalents to any Recipient who has received an Award denominated in shares of Common Stock other than Stock Options or SARs or, to the extent unearned, Performance Awards. Dividends and Equivalents may be paid in cash,
Common Stock or other Awards, in each case, in accordance with the requirements of Section&nbsp;409A or an exception thereto; the amount of Dividend Equivalents paid other than in cash will be determined by the Administrator by application of such
formula as the Administrator may deem appropriate to translate the cash value of dividends paid to the alternative form of payment of the Dividend Equivalent. Dividends and Dividend Equivalents will be computed as of each dividend record date but in
no event may any dividends or Dividend Equivalents vest or be paid prior to the vesting of the corresponding Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Stock Bonuses</B>. The Administrator may issue Stock Bonuses to Eligible Persons on such terms and conditions as the
Administrator may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Stock Sales</B>. The Administrator may sell to Eligible Persons shares of Common Stock
on such terms and conditions as the Administrator may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Phantom Stock</B>. The Administrator may grant
Awards of Phantom Stock to Eligible Persons. Phantom Stock is a cash payment measured by the Fair Market Value of a specified number of shares of Common Stock on a specified date, or measured by the excess of such Fair Market Value over a specified
minimum, which may but need not include a Dividend Equivalent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Restricted Stock Units</B>. The Administrator is
authorized to make Awards of Restricted Stock Units to Eligible Persons in such amounts and subject to such terms and conditions as determined by the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Voting Rights</I>. During the restricted period, Eligible Persons holding Restricted Stock Units shall have no
voting rights with respect to the Common Stock subject to such Restricted Stock Units. Voting rights will only be available after the issuance of Common Stock pursuant to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Payment for Restricted Stock Units</I>. Payment for any vested Restricted Stock Units will generally be made in
one lump sum payment of shares of Common Stock. As a general rule, with the exception of deferred compensation elections, the shares payable under any Restricted Stock Unit Award will be issued to the Eligible Person within 60 days following the
date on which the Restricted Stock Units vest. Unless the related Award Document is structured to qualify for an exception to the requirements of Section&nbsp;409A of the IRC, such payment is intended to be made at a specified time or pursuant to a
fixed schedule under Treas. Reg. <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(a)(4).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.11</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Other
Stock-Based Benefits</B><B>. </B>The Administrator is authorized to grant Other Stock-Based Benefits. Other Stock-Based Benefits are any arrangements granted under this Plan not otherwise described above that: (a)&nbsp;by their terms might involve
the issuance or sale of Common Stock or other securities of the Company; or (b)&nbsp;involve a benefit that is measured, as a whole or in part, by the value, appreciation, dividend yield or other features attributable to a specified number of shares
of Common Stock or other securities of the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTOR OPTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Vesting</B>. All grants of <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Options shall fully vest and
become exercisable one year following the grant date if the Recipient has remained a director for the entire period from the date of grant to such vesting date. Notwithstanding the foregoing, if the Recipient has remained a director from the period
of the date of grant until the next annual meeting of stockholders following the grant date, but ceases to be a director following the annual meeting of stockholders (either because the director is not
<FONT STYLE="white-space:nowrap">re-elected</FONT> or because the director chooses not to run for another term), the Stock Options that were granted to the director at the annual meeting in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the prior year shall continue to vest following the date that the Recipient ceases to be a director and shall become exercisable one year following the grant date. Except as otherwise provided in
this<I>&nbsp;Section 7.1</I>, all <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Options that have not vested and become exercisable at the time the Recipient ceases to be a director shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Exercise</B>. <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Options will be exercisable, and the exercise
price therefor shall be paid, in the same manner as provided herein for other Stock Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Term of Options and
Effect of Termination</B>. Notwithstanding any other provision of the Plan, no <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Option granted under the Plan shall be exercisable after the expiration of ten years from the effective date
of its grant. In the event that the Recipient of any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Options granted under the Plan shall cease to be a director of the Company, subject
to<I>&nbsp;Section</I><I></I><I>&nbsp;5.12,</I><I></I>&nbsp;all grants of <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Options shall be exercisable, to the extent already exercisable at the date such Recipient ceases to be a
director and regardless of the reason the Recipient ceases to be a director until the expiration of the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Option according to its terms and shall then terminate. In the event of the death
of a Recipient while such Recipient is a director of the Company or within the period after termination of such status during which he or she is permitted to exercise a Stock Option such Stock Option may be exercised by any person or persons
designated by the Recipient on a beneficiary designation form adopted by the Administrator for such purpose or, if there is no effective beneficiary designation form on file with the Company, by the executors or administrators of the
Recipient&#146;s estate or by any person or persons who shall have acquired the Stock Option directly from the Recipient by his or her will or the applicable laws of descent and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendment; Suspension</B>. The Administrator may at any time and from time to time in its discretion: (a)&nbsp;change the
vesting periods associated with the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Options; and (b)&nbsp;suspend and reactivate this<I>&nbsp;Article</I><I></I><I>&nbsp;VII</I>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHANGE IN
CONTROL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Provision for Awards Upon Change in Control</B>. Unless otherwise set forth in an Award Document or in
this<I>&nbsp;Section</I><I></I><I>&nbsp;8.1</I>, as of the effective time and date of any Change in Control, this Plan and any then outstanding Awards (whether or not vested) will automatically terminate unless: (a)&nbsp;provision is made in writing
in connection with such transaction for the continuance of this Plan and for the assumption of such Awards, or for the substitution for such Awards of new awards covering the securities of a successor entity or an affiliate thereof, with appropriate
adjustments as to the number and kind of securities and exercise prices or other measurement criteria, in which event this Plan and such outstanding Awards will continue or be replaced, as the case may be, in the manner and under the terms so
provided; or (b)&nbsp;the Board otherwise provides in writing for such adjustments as it deems appropriate in the terms and conditions of the then-outstanding Awards (whether or not vested), including, without limitation, (i)&nbsp;accelerating the
vesting of outstanding Awards; and/or (ii)&nbsp;providing for the cancellation of Awards and their automatic conversion into the right to receive the securities, cash or other consideration that a holder of the shares underlying such Awards would
have been entitled to receive upon consummation of such Change in Control had such shares been issued and outstanding immediately prior to the effective date and time of the Change in Control (net of the appropriate option exercise prices). If,
pursuant to the foregoing provisions of this<I> Section</I><I></I><I>&nbsp;8.1</I>, this Plan and the Awards terminate by reason of the occurrence of a Change in Control without provision for any of the action(s)&nbsp;described in clause (a)&nbsp;or
(b)&nbsp;hereof, then subject to<I>&nbsp;Section</I><I></I><I>&nbsp;5.12</I>&nbsp;and<I>&nbsp;Section</I><I></I><I>&nbsp;6.1(e)</I>, any Recipient holding outstanding Awards will have the right, at such time prior to the consummation of the Change
in Control as the Board designates, to exercise or receive the full benefit of the Recipient&#146;s Awards to the full extent not theretofore exercised, including any installments which have not yet become vested. Notwithstanding anything to the
contrary in this<I>&nbsp;Section</I><I></I><I>&nbsp;8.1</I>, the vesting provisions of<I>&nbsp;Section</I><I></I><I>&nbsp;7.1</I>&nbsp;or any other provision in the Plan, all <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Options
granted under the Plan shall automatically vest and become exercisable immediately prior to any Change in Control if the optionee is a director of the Company at that time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized terms used in
this Plan and not otherwise defined have the meanings set forth below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Administrator&#148;</I></B>&nbsp;means the Board as
long as no Committee has been appointed and is in effect and also means the Committee to the extent that the Board has delegated authority thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Affiliated</I></B><B><I>&nbsp;Entity&#148;</I></B>&nbsp;means any Parent Corporation of the Company or Subsidiary Corporation of
the Company or any other entity controlling, controlled by, or under common control with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Applicable Dividend
Period&#148;</I></B>&nbsp;means: (a)&nbsp;the period between the date a Dividend Equivalent is granted and the date the related Award terminates or is converted to Common Stock; or (b)&nbsp;such other time as the Administrator may specify in the
written instrument evidencing the grant of the Dividend Equivalent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Award&#148;</I></B>&nbsp;means any Stock Option,
Performance Award, Restricted Stock, Stock Appreciation Right, Stock Payment, Stock Bonus, Stock Sale, Phantom Stock, Dividend Equivalent, Restricted Stock Unit or Other Stock-Based Benefit granted or sold to an Eligible Person under this Plan, or
any similar award granted by the Company prior to the Effective Date and outstanding as of the Effective Date that is governed by this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Award Document&#148;</I></B>&nbsp;means the agreement or confirming memorandum (or other instrument including, without limitation,
electronic instruments) setting forth the terms and conditions of an Award. An Award Document may be in the form of an agreement to be executed by both the Recipient and the Company (or an authorized representative of the Company) or certificates,
notices or similar instruments as approved by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Board&#148;</I></B>&nbsp;means the Board of Directors of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Change in Control&#148;</I></B>&nbsp;means the following and shall be deemed to occur if any of the following events
occurs: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as provided by subparagraph (iii)&nbsp;hereof, the acquisition (other than from the Company) by any
person, entity or &#147;group&#148;, within the meaning of Section&nbsp;13(d)(3)&nbsp;or 14(d)(2)&nbsp;of the Exchange Act (excluding, for this purpose, the Company or its subsidiaries, or any executive benefit plan of the Company or its
subsidiaries which acquires beneficial ownership of voting securities of the Company), of beneficial ownership (within the meaning of <FONT STYLE="white-space:nowrap">Rule&nbsp;13d-3</FONT> promulgated under the Exchange Act) of forty percent (40%)
or more of either the then outstanding shares of Common Stock or the combined voting power of the Company&#146;s then outstanding voting securities entitled to vote generally in the election of directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Individuals who, as of the date hereof, constitute the Board (as of the date hereof, the &#147;Incumbent
Board&#148;) cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to the date hereof whose election, or nomination for election by the Company&#146;s stockholders, is or was
approved by a vote of at least a majority of the directors then comprising the Incumbent Board (other than an election or nomination of an individual whose initial assumption of office is in connection with an actual or threatened election contest
relating to the election of the Directors of the Company, as such terms are used in Rule <FONT STYLE="white-space:nowrap">14a-11</FONT> of Regulation 14A promulgated under the Exchange Act) shall be, for purposes of this Plan, considered as though
such person were a member of the Incumbent Board; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consummation by the Company of a reorganization, merger or consolidation with any other person, entity or
corporation, other than: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a merger or consolidation which would result in the voting securities of the Company outstanding immediately
prior thereto continuing to represent (either by remaining </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
outstanding or by being converted into voting securities of another entity) more than fifty percent (50%) of the combined voting power of the voting securities of the Company or such other entity
outstanding immediately after such merger or consolidation, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in
which no person acquires forty percent (40%) or more of the combined voting power of the Company&#146;s then outstanding voting securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Approval by the stockholders of the Company of a plan of complete liquidation of the Company or an agreement
for the sale or other disposition by the Company of all or substantially all of the Company&#146;s assets. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Committee&#148;</I></B><B><I></I></B>&nbsp;means any committee appointed by the Board to administer this Plan pursuant
to<I>&nbsp;Section</I><I></I><I>&nbsp;4.1</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Common Stock&#148;</I></B><B><I></I></B>&nbsp;means the common stock of the
Company, $0.001 par value per share, as constituted on the Effective Date, and as thereafter adjusted under<I>&nbsp;Section</I><I></I><I>&nbsp;3.4</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Company&#148;</I></B><B><I></I></B>&nbsp;means<B><I></I></B>&nbsp;Quidel Corporation, a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Dividend Equivalent&#148;</I></B>&nbsp;means a right granted by the Company
under<I>&nbsp;Section</I><I></I><I>&nbsp;6.6</I>&nbsp;to a holder of an Award denominated in shares of Common Stock to receive from the Company during the Applicable Dividend Period payments equivalent to the amount of dividends payable to holders
of the number of shares of Common Stock underlying such Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Effective Date&#148;</I></B>&nbsp;means May&nbsp;15, 2018.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Eligible Person&#148;</I></B>&nbsp;includes directors, including <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors, officers, employees, consultants and advisors of the Company or of any Affiliated Entity; <I>provided, however,</I>&nbsp;that in order to be Eligible Persons, consultants and advisors must render<I>&nbsp;bona fide</I>&nbsp;services to the
Company or any Affiliated Entity that are not in connection with capital-raising. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Exchange Act&#148;</I></B>&nbsp;means the
Securities Exchange Act of 1934, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Expiration Date&#148;</I></B>&nbsp;means the tenth (10th) anniversary of the
Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Fair Market Value&#148;</I></B>&nbsp;of a share of the Company&#146;s capital stock as of a particular date
means: (a)&nbsp;if the stock is listed on an established stock exchange or exchanges (including for this purpose, the NASDAQ Stock Market), the closing sale price of the stock for such date on the primary exchange upon which the stock trades, as
measured by volume, as published in<I>&nbsp;The Wall Street Journal</I>, or, if no sale price was quoted for such date, then as of the next preceding date on which such a sale price was quoted; or (b)&nbsp;if the stock is not then listed on an
exchange (including the NASDAQ Stock Market), the average of the closing bid and asked prices per share for the stock in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on such date (in the
case of (a)&nbsp;or (b), subject to adjustment as and if necessary and appropriate to set an exercise price not less than 100% of the fair market value of the stock on the date an Award is granted); or (c)&nbsp;if the stock is not then listed on an
exchange or quoted in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, an amount determined in good faith by the Administrator; <I>provided, however,</I>&nbsp;that (i)&nbsp;when
appropriate, the Administrator in determining Fair Market Value of capital stock of the Company may take into account such other factors as it may deem appropriate under the circumstances, and (ii)&nbsp;if the stock is traded on the NASDAQ SmallCap
Market and both sales prices and bid and asked prices are quoted or available, the Administrator may elect to determine Fair Market Value under either clause (a)&nbsp;or (b)&nbsp;above. Notwithstanding the foregoing, the Fair Market Value of capital
stock for purposes of grants of Stock Options and Stock Appreciation Rights must be determined in a manner consistent with Section&nbsp;409A of the IRC and, to the extent applicable, Section&nbsp;422 of the IRC. The Fair Market Value of rights or
property other than capital stock of the Company means the fair market value thereof as determined by the Administrator on the basis of such factors as it may deem appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Incentive Stock Option&#148;</I></B>&nbsp;means a Stock Option that qualifies as
an incentive stock option under Section&nbsp;422 of the IRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;IRC&#148;</I></B><B><I></I></B>&nbsp;means the Internal Revenue
Code of 1986, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Just Cause Dismissal&#148;</I></B>&nbsp;means a termination of a Recipient&#146;s employment for
any of the following reasons: (a)&nbsp;the Recipient violates any reasonable rule or regulation of the Board, the Company&#146;s President or Chief Executive Officer or the Recipient&#146;s superiors that results in damage to the Company or any
Affiliated Entity or which, after written notice to do so, the Recipient fails to correct within a reasonable time not exceeding 15 days; (b)&nbsp;any willful misconduct or gross negligence by the Recipient in the responsibilities assigned to the
Recipient; (c)&nbsp;any willful failure to perform the Recipient&#146;s job as required to meet the objectives of the Company or any Affiliated Entity; (d)&nbsp;any wrongful conduct of a Recipient which has an adverse impact on the Company
(including, causing reputational harm to the Company) or any Affiliated Entity or which constitutes a misappropriation of assets of the Company or any Affiliated Entity; (e)&nbsp;the Recipient&#146;s performing services for any other person or
entity that competes with the Company while the Recipient is employed by the Company without the written approval of the Chief Executive Officer of the Company; or (f)&nbsp;any other conduct that the Administrator reasonably determines constitutes
Just Cause for Dismissal; <I>provided, however,</I>&nbsp;that if a Recipient is party to an employment agreement with the Company or any Affiliated Entity providing for just cause dismissal (or some comparable concept) of Recipient from
Recipient&#146;s employment with the Company or any Affiliated Entity, &#147;Just Cause Dismissal&#148; for purposes of this Plan will have the same meaning as ascribed thereto or to such comparable concept in such employment agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">&#147;Non-Employee</FONT> Director&#148;</I></B>&nbsp;means a director of the Company who qualifies as
a <FONT STYLE="white-space:nowrap">&#147;Non-Employee</FONT> Director&#148; under <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">&#147;Non-Employee</FONT> Director Option&#148;</I></B>&nbsp;means a right to purchase stock of the
Company granted under<I>&nbsp;Article VII</I>&nbsp;of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Nonqualified Stock Option&#148;</I></B>&nbsp;means a Stock
Option that is not an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Other Stock-Based Benefits&#148;</I></B>&nbsp;means an Award granted
under<I>&nbsp;Section</I><I></I><I>&nbsp;6.10</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Parent Corporation&#148;</I></B>&nbsp;means any Parent Corporation as
defined in Section&nbsp;424(e)&nbsp;of the IRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Performance Award&#148;</I></B><B><I></I></B>&nbsp;means an Award
under<I>&nbsp;Section</I><I></I><I>&nbsp;6.2</I>, payable in cash, Common Stock or a combination thereof, that vests and becomes payable over a period of time upon attainment of performance goals established in connection with the grant of the
Award, which may be based on, among other criteria selected by the Administrator, the Performance Criteria, or other financial performance and/or personal performance evaluations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Performance Criteria&#148;</I></B>&nbsp;means any one or more of the following performance criteria, or derivations of such
performance criteria, either individually, alternatively or in any combination, applied to either the Company as a whole or to a business unit or Affiliated Entity, either individually, alternatively or in any combination, and measured either
annually (or over such shorter period) or cumulatively over a period of years, on an absolute basis or relative to a <FONT STYLE="white-space:nowrap">pre-established</FONT> target, to previous years&#146; results or to a designated comparison group,
in each case as specified by the Administrator: (a)&nbsp;cash flow; (b)&nbsp;earnings and earnings per share (including earnings before interest, taxes, and amortization); (c)&nbsp;return on equity; (d)&nbsp;total Stockholder return; (e)&nbsp;return
on capital; (f)&nbsp;return on assets or net assets; (g)&nbsp;product price or product sales; (h)&nbsp;market share or market penetration with respect to specific designated products and/or geographic areas; (i)&nbsp;revenues, income or net income;
(j)&nbsp;operating income or net operating income; (k)&nbsp;operating margin; (l)&nbsp;return on revenue or operating revenue; and (m)&nbsp;research and development milestones. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Permanent Disability&#148;</I></B>&nbsp;means that the Recipient becomes
physically or mentally incapacitated or disabled so that the Recipient is unable to perform substantially the same services as the Recipient performed prior to incurring such incapacity or disability (the Company, at its option and expense, being
entitled to retain a physician to confirm the existence of such incapacity or disability, and the determination of such physician to be binding upon the Company and the Recipient), and such incapacity or disability continues for a period of three
(3)&nbsp;consecutive months or six (6)&nbsp;months in any <FONT STYLE="white-space:nowrap">12-month</FONT> period or such other period(s)&nbsp;as may be determined by the Administrator with respect to any Award; <I>provided, however,</I>&nbsp;that
for purposes of determining the period during which an Incentive Stock Option may be exercised pursuant to<I>&nbsp;Section</I><I></I><I>&nbsp;6.1(e)</I>, Permanent Disability shall mean &#147;permanent and total disability&#148; as defined in
Section&nbsp;22(e)&nbsp;of the IRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Person&#148;</I></B><I></I><I>&nbsp;means</I><B></B>&nbsp;any person, entity or group,
within the meaning of Section&nbsp;13(d)&nbsp;or 14(d)&nbsp;of the Exchange Act, but excluding: (a)&nbsp;the Company and its subsidiaries; (b)&nbsp;any employee stock ownership or other employee benefit plan maintained by the Company; and
(c)&nbsp;an underwriter or underwriting syndicate that has acquired the Company&#146;s securities solely in connection with a public offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Phantom Stock&#148;</I></B>&nbsp;means an Award granted under<I>&nbsp;Section</I><I></I><I>&nbsp;6.9</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Plan&#148;</I></B><I></I>&nbsp;means this 2018 Equity Incentive Plan of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Plan Term&#148;</I></B>&nbsp;means the period during which this Plan remains in effect (commencing the Effective Date and ending
on the Expiration Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Prior Plans&#148;</I></B><B><I></I></B>&nbsp;mean the 2001 Equity Incentive Plan of the Company, as
amended and the 2010 Equity Incentive Plan of the Company, as amended, and the 2016 Equity Incentive Plan of the Company, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Purchase Price&#148;</I></B>&nbsp;means the purchase price (if any) to be paid by a Recipient for Restricted Stock as determined
by the Administrator (which price shall be at least equal to the minimum price required under applicable laws and regulations for the issuance of Common Stock which is nontransferable and subject to a substantial risk of forfeiture until specific
conditions are met). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Recipient&#148;</I></B>&nbsp;means<B></B>&nbsp;a person who has received an Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Reorganization&#148;</I></B>&nbsp;means any merger, consolidation or other reorganization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Restricted Stock&#148;</I></B><I></I>&nbsp;means Common Stock that is the subject of an Award made
under<I>&nbsp;Section</I><I></I><I>&nbsp;6.3</I>&nbsp;and that is nontransferable and subject to a substantial risk of forfeiture until specific conditions are met, as set forth in this Plan and in any statement evidencing the grant of such Award.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Restricted Stock Unit&#148;</I></B><B><I></I></B>&nbsp;means the right granted to an Eligible Person to receive Common Stock
in the future, at no monetary cost to the Eligible Person, the payment of which is subject to restrictions determined by the Administrator and to risk of forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Securities Act&#148;</I></B>&nbsp;means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Separation from Service&#148;</I></B>&nbsp;is a term that applies only in the context of an Award that the Company concludes is
subject to Section&nbsp;409A of the IRC and shall have the meaning as defined for purposes of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Significant
Stockholder&#148;</I></B>&nbsp;is an individual who, at the time a Stock Option is granted to such individual under this Plan, owns more than 10% of the total combined voting power of all classes of stock of the Company or of any Parent Corporation
or Subsidiary Corporation (after application of the attribution rules set forth in Section&nbsp;424(d)&nbsp;of the IRC). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Specified Employee&#148;</I></B><B><I></I></B>&nbsp;means certain officers and
highly compensated employees of the Company as defined in Treas. Reg. &#167; <FONT STYLE="white-space:nowrap">1.409A-1(i).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Stock Appreciation Right&#148;</I></B>&nbsp;or<B><I>&nbsp;&#147;SAR&#148;</I></B>&nbsp;means a right granted
under<I>&nbsp;Section</I><I></I><I>&nbsp;6.4</I>&nbsp;to receive a payment that is measured with reference to the amount by which the Fair Market Value of a specified number of shares of Common Stock appreciates from a specified date, such as the
date of grant of the SAR, to the date of exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Stock Bonus&#148;</I></B>&nbsp;means an issuance or delivery of
unrestricted or restricted shares of Common Stock under<I>&nbsp;Section</I><I></I><I>&nbsp;6.7</I>&nbsp;as a bonus for services rendered or for any other valid consideration under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Stock Payment&#148;</I></B>&nbsp;means a payment in shares of the Company&#146;s Common Stock
under<I>&nbsp;Section</I><I></I><I>&nbsp;6.5</I>&nbsp;to replace all or any portion of the compensation or other payment (other than base salary) that would otherwise become payable to the Recipient in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Stock Option&#148;</I></B><I></I>&nbsp;means a right to purchase stock of the Company granted
under<I>&nbsp;Section</I><I></I><I>&nbsp;6.1</I>&nbsp;or<I>&nbsp;Article VII</I>&nbsp;of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Stock
Sale&#148;</I></B>&nbsp;means a sale of Common Stock to an Eligible Person under<I>&nbsp;Section</I><I></I><I>&nbsp;6.8</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;</I></B><B><I>Subsidiary Corporation</I></B><B><I>&#148;</I></B>&nbsp;means any Subsidiary Corporation as defined in
Section&nbsp;424(f)&nbsp;of the IRC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom273090_217b"></A>Annex H </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUIDEL CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amended and Restated 1983 EMPLOYEE STOCK PURCHASE PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amended and Restated Effective: [</B>&#9679;<B></B><B>], 2022) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following constitute the provisions of the 1983 Employee Stock Purchase Plan (herein called the &#147;Plan&#148;) of Quidel Corporation, a
Delaware corporation (herein called the &#147;Company&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Purpose</I></B><I>. </I>The purpose of the
Plan is to provide employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock of the Company through accumulated payroll deductions. It is the intention of the Company to have the Plan qualify as an
&#147;Employee Stock Purchase Plan&#148; under Section&nbsp;423 of the Internal Revenue Code of 1986, as amended. The provisions of the Plan shall, accordingly, be construed so as to extend and limit participation in a manner consistent with the
requirements of that section of the Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Definitions</I></B>.<B><I></I></B> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<I>Board</I>&#148; shall mean the Board of Directors of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<I>Code</I>&#148; shall mean the Internal Revenue Code of 1986, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<I>Common Stock</I>&#148; shall mean the Common Stock, no par value, of the Company.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<I>Company</I>&#148; shall mean Quidel Corporation, a Delaware corporation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<I>Compensation</I>&#148; shall mean all regular straight time earnings, payments or overtime, shift
premium, incentive compensation, incentive payments, bonuses and commissions (except to the extent that the exclusion of any such items for all participants is specifically directed by the Board or its committee). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<I>Designated Subsidiaries</I>&#148; shall mean the Subsidiaries which have been designated by the Board
from time to time in its sole discretion as eligible to participate in the Plan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<I>Employee</I>&#148; shall mean any person, including an officer, who is customarily employed for at
least twenty (20)&nbsp;hours per week and more than five (5)&nbsp;months in a calendar year by the Company or one of its Designated Subsidiaries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<I>Exercise Date</I>&#148; shall mean the last day of each offering period of the Plan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<I>Offering Date</I>&#148; shall mean the first day of each offering period of the Plan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<I>Plan</I>&#148; shall mean this Employee Stock Purchase Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<I>Subsidiary</I>&#148; shall mean a corporation, domestic or foreign, of which not less than 50% of the
voting shares are held by the Company or a Subsidiary, whether or not such corporation flow exists or is hereafter organized or acquired by the Company or a Subsidiary. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Eligibility</I></B>.<B><I></I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Any Employee as defined in paragraph&nbsp;2 who shall be employed by the Company on the date his participation in
the Plan is effective shall be eligible to participate in the Plan, subject to limitations imposed by Section&nbsp;423(b) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Any provisions of the Plan to the contrary notwithstanding, no Employee shall be granted an option under the Plan
(i)&nbsp;if, immediately after the grant, such Employee (or any other person whose stock would be attributed to such Employee pursuant to Section&nbsp;425(d) of the Code) would own stock and/or hold outstanding options to purchase stock possessing
five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or of any subsidiary of the Company, or (ii)&nbsp;which permits his rights to purchase stock under all employee stock purchase plans of the
Company and its subsidiaries to accrue at a rate which exceeds Twenty Five Thousand Dollars ($25,000) of fair market value of such stock (determined at the time such option is granted) for each calendar year in which such option is outstanding at
any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Offering Periods</I></B><B><I>. </I></B>The Plan shall be implemented by one offering during
each six month period of the Plan, commencing on or about, and continuing thereafter until terminated in accordance with paragraph&nbsp;19 hereof. The Board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Directors of the Company shall have the power to change the duration of offering periods with respect to future offerings without stockholder approval if such change is announced at least fifteen
(15)&nbsp;days prior to the scheduled beginning at the first offering period to be affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Participation</I></B>.<B><I></I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;An eligible Employee may become a participant in the Plan by completing a subscription agreement authorizing payroll
deduction on the form provided by the Company and filing it with the Company&#146;s payroll office prior to the applicable Offering Date, unless a later time for filing the subscription agreement is set by the Board for all eligible employees with
respect to a given offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Payroll deductions for a participant shall commence on the first payroll
following the Offering Date and shall end on the Exercise Date of the offering to which such authorization is applicable, unless sooner terminated by the participant as provided in paragraph&nbsp;10. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Payroll Deductions</I></B>.<B><I></I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;At the time a participant files his subscription agreement, he shall elect to have payroll deductions made on each
payday during the offering period in an amount not exceeding ten percent (10%) of the Compensation which he received on the payday immediately preceding the Offering Date, and the aggregate of such payroll deductions during the offering period shall
not exceed ten percent (10%) of his aggregate Compensation during said offering period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;All payroll deductions
made by a participant shall be credited to his account under the Plan. A participant may not make any additional payments into such account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;A participant may discontinue his participation in the Plan as provided in paragraph&nbsp;10, or may lower, but not
increase, the rate of his payroll deductions during the offering period by completing or filing with the Company a new authorization for payroll deduction. The change in rate shall be effective fifteen (15)&nbsp;days following the Company&#146;s
receipt of the new authorization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B>7.<B><I>&nbsp;&nbsp;&nbsp;&nbsp;Grant of Option</I></B>.<B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;On the Offering Date of each six month offering period, each eligible Employee participating in the Plan shall be
granted an option to purchase (at the per share option price) up to a number of shares of the Company&#146;s Common Stock determined by dividing such Employee&#146;s payroll deductions to be accumulated during such offering period (not to exceed an
amount equal to ten percent (10%) of his Compensation as of the date of the commencement of the applicable offering period) by eighty-five percent (85%) of the fair market value of a share of the Company&#146;s Common Stock on the Offering Date,
subject to the limitations set forth in Section&nbsp;3(b) and 12 hereof. Fair market value of a share of the Company&#146;s Common Stock shall be determined as provided in Section&nbsp;7(b) herein. Notwithstanding the foregoing, no employee shall be
granted an option to purchase more than 5,000 shares of the Company&#146;s Common Stock during any <FONT STYLE="white-space:nowrap">six-month</FONT> offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The option price per share of the shares offered in a given offering period shall be the lower of: (i)&nbsp;85% of
the fair market value of a share of the Common Stock of the Company on the Offering Date; or (ii)&nbsp;85% of the fair market value of a share of the Common Stock of the Company on the Exercise Date. The fair market value of the Company&#146;s
Common Stock on a given date shall be the mean of the reported bid and asked prices for that date except that the fair market value on the Offering Date of the initial offering period shall be the initial public offering price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Exercise of Option</I></B><B><I>. </I></B>Unless a participant withdraws from the Plan as provided in
paragraph&nbsp;10, his option for the purchase of shares will be exercised automatically on the Exercise Date of the offering period, and the maximum number of full shares subject to option will be purchased for him at the applicable option price
with the accumulated payroll deductions in his account. If the total amount of payroll deductions for a participant during the offering period exceeds the purchase price of such shares as determined in Section&nbsp;7(a), such excess amount will be
refunded to the participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Delivery</I></B><B><I>. </I></B>As promptly as practicable after the
Exercise Date of each offering, the Company shall arrange the delivery to each participant, as appropriate, of a certificate representing the shares purchased upon exercise of his option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Any cash remaining to the credit of a participant&#146;s account under the Plan after a purchase by him of shares at the termination of each offering period, or which is insufficient to purchase
a full share of Common Stock of the Company, shall be returned to said participant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Withdrawal;
Termination of Employment</I></B>.<B><I></I></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;A participant may withdraw all but not less than all the
payroll deductions credited to his account under the Plan up to one week prior to the Exercise Date of the offering period by giving written notice to the Company. All of the participant&#146;s payroll deductions credited to his account will be paid
to him promptly after receipt of his notice of withdrawal and his option for the current period will be automatically terminated, and no further payroll deductions for the purchase of shares will be made during the offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Upon termination of the participant&#146;s employment prior to the Exercise Date of the offering period for any
reason, including retirement or death, the payroll deductions credited to his account will be returned to him or, in the case of his death, to the person or persons entitled thereto under paragraph&nbsp;14, and his option will be automatically
terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;in the event an Employee fails to remain in the continuous employ of the Company for at least
twenty (20)&nbsp;hours per week during the offering period in which the employee is a participant, he will be deemed to have elected to withdraw from the Plan and the payroll deductions credited to his account will be returned to him and his option
terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;A participant&#146;s withdrawal from an offering will not have any effect upon his eligibility to
participate in a succeeding offering or in any similar plan which may hereafter be adopted by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Interest</I></B><I>. </I>No interest shall accrue on the payroll deductions of a participant in the Plan.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Stock</I></B>.<B><I></I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of shares of the Company&#146;s Common Stock that shall be made available for sale under the Plan
shall be 2,250,000 shares, subject to adjustment upon changes in capitalization of the Company as provided in paragraph&nbsp;18. If the total number of shares which would otherwise be subject to options granted pursuant to Section&nbsp;7(a) hereof
on the Offering Date of an offering period exceeds the number of shares then available under the Plan (after deduction of all shares for which options have been exercised or are then outstanding), the Company shall make a pro rata allocation of the
shares remaining available for option grant in as uniform a manner as shall be practicable and as it shall determine to be equitable. In such event, the Company shall give written notice of such reduction of the number of shares subject to the
option to each Employee affected thereby and shall similarly reduce the rate of payroll deductions, if necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The participant will have no interest or voting right in shares covered by his option until such option has been
exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Shares to be delivered to a participant under the Plan will be registered in the name of the
participant or in the name of the participant and his spouse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Administration</I></B><I>. </I>The Plan
shall be administered by the Board of Directors of the Company or a committee appointed by the Board. The administration, interpretation or application of the Plan by the Board or its committee shall be final, conclusive and binding upon all
participants. Members of the Board who are eligible Employees are permitted to participate in the Plan, provided that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Members of the Board who are eligible to participate in the Plan may not vote on any matter affecting the
administration of the Plan or the grant of any option pursuant to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If a committee is established to
administer the Plan, no member of the Board who is eligible to participate in the Plan may be a member of the committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Designation of Beneficiary</I></B>.<B><I></I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;A participant may file&nbsp;a written designation of a beneficiary who is to receive any shares and cash, if any,
from the participant&#146;s account under the Plan in the event of such participant&#146;s death subsequent to the end of the offering period but </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior to delivery to him of such shares and cash. In addition, a participant may file&nbsp;a written designation of a beneficiary who is to receive any cash from the participant&#146;s account
under the Plan in the event of such participant&#146;s death prior to the Exercise Date of the offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Such designation of beneficiary may be changed by the participant at any time by written notice. In the event of
the death of a participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such participant&#146;s death, the Company shall deliver such shares and/or cash to the executor or administrator of the
estate of the participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such shares and/or cash to the spouse or to any one or more dependents or relatives
of the participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Transferability</I></B><I>. </I>Neither payroll deductions credited to a participant&#146;s account nor any
rights with regard to the exercise of an option or to receive shares under the Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in
paragraph&nbsp;14 hereof) by the participant. Any such attempt at assignment, transfer, pledge or other disposition shall be without effect, except that the Company may treat such act as an election to withdraw funds in accordance with
paragraph&nbsp;10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Use of Funds</I></B><I>. </I>All payroll deductions received or held by the Company
under the Plan may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such payroll deductions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Reports</I></B><I>. </I>Individual accounts will be maintained for each participant in the Plan. Statements
of account will be given to participating Employees semi-annually promptly following the Exercise Date, which statements will set forth the amounts of payroll deductions, the per share purchase price, the number of shares purchased and the remaining
cash balance, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Adjustments Upon Changes in Capitalization</I></B><I>. </I>Subject to any required
action by the stockholders of the Company, the number of shares of Common Stock covered by each option under the Plan which has not yet been exercised and the number of shares of Common Stock which have been authorized for issuance under the Plan
but have not yet been placed under option (collectively, the &#147;Reserves&#148;), as well as the price per share of Common Stock covered by each option under the Plan which has not yet been exercised, shall be proportionately adjusted for any
increase or decrease in the number of issued shares of Common Stock resulting from a stock split or the payment of a stock dividend (but only on the Common Stock) or any other increase or decrease in the number of shares of Common Stock effected
without receipt of consideration by the Company; provided, however, that conversion of any convertible securities of the Company shall not be deemed to have been &#147;effected without receipt of consideration&#148;. Such adjustment shall be made by
the Board, whose determination in that respect shall be final, binding and conclusive. Except as expressly provided herein, no issue by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall
affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares of Common Stock subject to an option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may, if it so determines in the exercise of its sole discretion, also make provision for adjusting the Reserves, as well as the
price per share of Common Stock covered by each outstanding option, in the event that the Company effects one or more reorganizations, recapitalizations, rights offerings or other increases or reductions of shares of its outstanding Common Stock,
and in the event of the Company being consolidated with or merged into any other corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Amendment
or Termination</I></B><I>. </I>The Board of Directors of the Company may at any time terminate or amend the Plan. No such termination can affect options previously granted, nor may an amendment make any change in any option theretofore granted which
adversely affects the rights of any participant, nor may an amendment be made without prior approval of the stockholders of the Company if such amendment would: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;increase the number of shares that may be issued under the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Permit payroll deductions at a rate in excess of ten percent (10%) of the participant&#146;s Compensation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Modify the requirements concerning which employees (or class of employees) are eligible for participation in the
Plan; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Materially increase the benefits which may accrue to participants under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Notices</I></B><I>. </I>All notices or other communications
by a participant to the Company under or in connection with the Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Stockholder Approval</I></B><I>. </I>Continuance of the Plan shall be subject to approval by the
stockholders of the Company within twelve months before or after the date the Plan is adopted. If such share- holder approval is obtained at a duly held stockholders&#146; meeting, it may be obtained by the affirmative vote of the holders of a
majority of the outstanding shares of the Company present or represented and entitled to vote thereon, which approval shall be: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;(1) solicited substantially in accordance with Section&nbsp;14(a) of the Securities Act of 1934, as amended (the
&#147;Act&#148;) and the rules and regulations promulgated thereunder, or (2)&nbsp;solicited after the Company has furnished in writing to the holders entitled to vote substantially the same information concerning the Plan as that which would be
required by the rules and regulations in effect under Section&nbsp;14(a) of the Act at the time such information is furnished; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;obtained at or prior to the first annual meeting of stockholders held subsequent to the first registration of
Common Stock under Section&nbsp;12 of the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of approval by written consent, it must be obtained by the unanimous written
consent of all stockholders of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Conditions Upon Issuance of Shares</I></B><I>. </I>Shares
shall not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such shares pursuant thereto shall comply with all applicable provisions of law, domestic or foreign, including, without limitation,
the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, the rules and regulations promulgated thereunder, and the requirements of any stock exchange upon which the shares may then be listed, and shall be further
subject to the approval of counsel for the Company with respect to such compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a condition to the exercise of an option, the
Company may require the person exercising such option to represent and war rant at the time of any such exercise that the shares are being purchased only for investment and without any present intention to sell or distribute such shares if, in the
opinion of counsel for the Company, such a representation is required by any of the aforementioned applicable provisions of law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEMNIFICATION OF DIRECTORS AND OFFICERS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topco is incorporated under the laws of the state of Delaware. Section&nbsp;145(a) of the DGCL authorizes a corporation to indemnify any person who was or is
a party, or is threatened to be made a party, to a threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), by reason of the
fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or
other enterprise, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if the person acted in good faith
and in a manner the person reasonably believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&#146;s conduct was unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(b) of the DGCL provides in relevant part that a corporation may indemnify any person who was or is a party or is threatened to be made a
party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or
was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#146; fees) actually and reasonably incurred
by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no
indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or
suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery
or such other court shall deem proper. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL also provides that indemnification under Sections 145(a) and (b)&nbsp;can only be made upon a
determination that indemnification of the present or former director, officer or employee or agent is proper in the circumstances because such person has met the applicable standard of conduct set forth in Sections 145(a) and (b). Such determination
shall be made, with respect to a person who is a director or officer at the time of such determination, (1)&nbsp;by a majority vote of directors who are not a party to the action at issue (even though less than a quorum), (2) by a majority vote of a
designated committee of these directors (even though less than a quorum), (3) if there are no such directors, or these directors authorize, by the written opinion of independent legal counsel, or (4)&nbsp;by the stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(c) of the DGCL provides that to the extent a present or former director or officer of a corporation has been successful on the merits or
otherwise in defense of any action, suit or proceeding referred to in Sections 145(a) or (b), or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorney&#146;s fees) actually and
reasonably incurred by such person in connection therewith. Section&nbsp;145(e) of the DGCL provides that expenses (including attorneys&#146; fees) incurred by an officer or director of the corporation in defending any civil, criminal,
administrative or investigative action, suit or proceeding may be paid by the corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such
amount if it shall ultimately be determined that such person is not entitled to be indemnified by the corporation as authorized in Section&nbsp;145 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such expenses (including attorneys&#146; fees) incurred by former directors and officers or other employees and agents of the corporation or by persons
serving at the request of the corporation as directors, officers, employees or agents of another corporation, partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as the corporation deems
appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(g) of the DGCL also empowers a corporation to purchase and maintain insurance on behalf of any person who is or was a
director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liability asserted against such person and incurred by such person in any such capacity, or arising out of such person&#146;s status as such, whether or not the corporation would have the power
to indemnify such person against such liability under Section&nbsp;145 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the DGCL permits a corporation to provide
for eliminating or limiting the personal liability of one of its directors for any monetary damages related to a breach of fiduciary duty as a director, as long as the corporation does not eliminate or limit the liability of a director for
(a)&nbsp;a breach of the director&#146;s duty of loyalty to the corporation or its stockholders, (b)&nbsp;acts or omissions not in good faith or involving intentional misconduct or a knowing violation of law, (c)&nbsp;a violation of Section&nbsp;174
of the DGCL (unlawful dividends) or (d)&nbsp;any transaction from which the director derived an improper personal benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 8 of Topco&#146;s
Certificate of Incorporation eliminates the personal liability of Topco&#146;s directors to the fullest extent permitted by the DGCL. Such section eliminates the personal liability of a director to Topco or its stockholders for monetary damages for
breach of fiduciary duty as a director, except for liability (a)&nbsp;for any breach of the director&#146;s duty of loyalty to Topco or its stockholders, (b)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a
knowing violation of law, (c)&nbsp;under Section&nbsp;174 of the DGCL (unlawful dividends) or (d)&nbsp;for any transaction from which the director derived an improper personal benefit. Under the Topco Certificate of Incorporation, Topco agrees that
it is the indemnitor of first resort to provide advancement of expenses or indemnification to directors and officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the BCA filed as Exhibit 2.1
hereto, Topco agrees to (i)&nbsp;indemnify and hold harmless, and provide advancement of expenses to, all past and present (as of the Quidel Effective Time) directors, officers and employees of Quidel and its subsidiaries and Ortho and its
subsidiaries (in all of their capacities)&nbsp;(A) to the same extent such persons are indemnified or have the right to advancement of expenses as of the date of the BCA by Quidel pursuant to the organizational documents of Quidel or its
subsidiaries and indemnification agreements, if any, and by Ortho pursuant to the organizational documents of Ortho or its subsidiaries and indemnification agreements, if any, as applicable, in existence on the date of BCA with any directors,
officers and employees of Quidel and its subsidiaries or Ortho and its subsidiaries, as applicable, against all costs or expenses (including reasonable attorney&#146;s fees and disbursements), judgments, inquiries, fines, losses, claims, damages or
liabilities incurred by such individual in connection with any civil, criminal, administrative or investigative proceeding arising out of or pertaining to any act or omission of the director, officer or employee of Quidel or its subsidiaries or
Ortho and its subsidiaries, as applicable, and (B)&nbsp;without limitation to clause (A), to the fullest extent permitted by law, in each case for acts or omissions occurring at or prior to the Quidel Effective Time (including for acts or omissions
occurring in connection with the approval of the BCA and the consummation of the transactions contemplated thereby)&nbsp;(ii) include and cause to be maintained in effect in Topco&#146;s (or any successor&#146;s) organizational documents for a
period of at least six years after the Quidel Effective Time, provisions providing for the elimination of liability of directors, indemnification of officers, directors and employees and advancement of expenses to the fullest extent permitted by law
and (iii)&nbsp;purchase a <FONT STYLE="white-space:nowrap">six-year</FONT> &#147;tail&#148; prepaid policy on terms and conditions no less advantageous to the insured than the current directors&#146; and officers&#146; liability insurance and
fiduciary liability insurance maintained by Quidel and Ortho, as applicable, or with respect to Quidel, continue coverage for the insured under the current Quidel directors&#146; and officers&#146; liability insurance and fiduciary liability
insurance maintained by Quidel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information on the indemnification and directors&#146; and officers&#146; insurance provisions in the BCA, see
the section entitled &#147;The Business Combination Agreement&#151;Indemnification and Insurance&#148; in the joint proxy statement/prospectus that forms a part of this registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4.</FONT>
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exhibits listed below in the &#147;Exhibit Index&#148; are part of this registration statement and are numbered in accordance with Item 601 of <FONT
STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>UNDERTAKINGS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#149; To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#149; To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would
not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in
volume and price represent no more than 20&nbsp;percent change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective registration statement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#149; To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;That, for the purpose of determining any
liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial <I>bona fide</I> offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;That, for the
purpose of determining any liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule
430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a
purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior
to such date of first use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;That, for the purpose of determining liability of the registrant under the
Securities Act of 1933 to any purchaser in the initial distribution of the securities, in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the
securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such
securities to such purchaser: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#149; Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering
required to be filed pursuant to Rule 424; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#149; Any free writing prospectus relating to the offering prepared by or on behalf of the
undersigned registrant or used or referred to by the undersigned registrant; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#149; The portion of any other free writing prospectus
relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#149; Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;That, for purposes of determining any liability under the Securities Act of 1933, each filing of the
registrant&#146;s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to section 15(d) of the Securities
Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
be the initial bona fide offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;That, prior to any public reoffering of the securities registered
hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c) under the Securities Act of 1933, as amended, the issuer undertakes
that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the
applicable form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;That every prospectus: (i)&nbsp;that is filed pursuant to the immediately preceding paragraph,
or (ii)&nbsp;that purports to meet the requirements of Section&nbsp;10(a)(3) of the Securities Act of 1933, as amended, and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment to the
registration statement and will not be used until </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such amendment is effective, and that, for purposes of determining any liability under the Securities Act of 1933, as amended, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors,
officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or
controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will
be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;To respond to requests for information that is
incorporated by reference into the prospectus pursuant to Items 4, 10(b), 11, or 13 of this Form, within one business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This
includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;To supply by means of a post-effective amendment all information concerning a transaction, and the company being
acquired involved therein, that was not the subject of and included in the registration statement when it became effective. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit <BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.1*+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1906324/000119312522023500/d273090ds4.htm#exind273090_5">Business Combination Agreement, dated as of December&nbsp;
22, 2021, by and among Quidel Corporation, Ortho Clinical Diagnostics Holdings plc, Coronado Topco, Inc., Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc. (included as Annex A to the joint proxy statement/prospectus forming a part of this
 registration statement and incorporated herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.1+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1906324/000119312522023500/d273090ds4.htm#exind273090_1">Form of Certificate of Incorporation of Coronado Topco, Inc. (included as Exhibit D to Annex A to the joint proxy statement/prospectus
 forming a part of this registration statement and incorporated herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.2+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1906324/000119312522023500/d273090ds4.htm#exind273090_2">Form of Bylaws of Coronado Topco, Inc. (included as Exhibit E to Annex A to the joint proxy statement/prospectus forming a part of
this registration statement and incorporated herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/353569/000095012310098084/a57652exv3w1.htm">Restated Certificate of Incorporation of Quidel Corporation (incorporated by reference to Exhibit 3.1 to Quidel Corporation&#146;s Quarterly Report
on Form 10-Q for the quarter ended September 30, 2010) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/353569/000035356915000029/ex31certofamendment.htm">Certificate of Amendment to the Restated Certificate of Incorporation of Quidel Corporation, effective as of May&nbsp;
5, 2015 (incorporated by reference to Exhibit 3.1 to Quidel Corporation&#146;s Form 8-K filed on May 6, 2015) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/353569/000035356920000077/amendedandrestatedbyla.htm">Amended and Restated Bylaws of Quidel Corporation, as of November 9, 2020 (incorporated by reference to Exhibit 3.1 to Quidel Corporation&#146;s
 Form 8-K filed on November 13, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001828443/000119312521029018/d132446dex31.htm">Articles of Association of Ortho Clinical Diagnostics Holdings plc (incorporated by reference to Exhibit 3.1 to Ortho Clinical Diagnostics
 Holdings plc&#146;s Form 8-K filed on February 4, 2021) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1828443/000119312521000950/d95406dex41.htm">Indenture, dated as of January 27, 2020, by and among Ortho-Clinical Diagnostics, Inc., Ortho-Clinical Diagnostics S.A. and Wilmington Trust, National
 Association, as trustee (incorporated by reference to Exhibit&nbsp;4.1 of Ortho Clinical Diagnostic Holdings plc&#146;s Registration Statement on Form S-1 (File No. 333-251875) filed with the SEC on January 4, 2021) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1828443/000119312521000950/d95406dex42.htm">Indenture, dated as of June 11, 2020, by and among Ortho-Clinical Diagnostics, Inc., Ortho-Clinical Diagnostics S.A. and Wilmington Trust, National
 Association, as trustee (incorporated by reference to Exhibit 4.2 of Ortho Clinical Diagnostic Holdings plc&#146;s Registration Statement on Form S-1 (File No. 333-251875) filed with the SEC on January 4, 2021) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.1**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of Latham&nbsp;&amp; Watkins LLP as to the validity of the securities being registered</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>8.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d273090dex81.htm">Opinion of Latham &amp; Watkins LLP regarding certain tax matters </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>8.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d273090dex82.htm">Opinion of Gibson, Dunn &amp; Crutcher LLP regarding certain tax matters </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1906324/000119312522023500/d273090ds4.htm#exind273090_3">Principal Stockholders Agreement, dated as of December&nbsp;
22, 2021, by and among Coronado Topco, Inc., Quidel Corporation, Ortho Clinical Diagnostics Holdings plc and the Initial Carlyle Stockholder (as defined therein) (included as Annex B to the joint proxy statement/prospectus forming a part of this registration
 statement and incorporated herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1906324/000119312522023500/d273090ds4.htm#exind273090_4">Form of Irrevocable Undertaking (included as Annex C to the joint proxy statement/prospectus forming a part of this registration statement
 and incorporated herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000353569/000119312521223723/d182480dex101.htm">Master Agreement, dated as of July 24, 2021, by and among Quidel Corporation, Quidel Cardiovascular, Inc., and Beckman Coulter, Inc. (incorporated
 by reference to Exhibit 10.1 to Quidel Corporation&#146;s Form 8-K filed on July 26, 2021) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1828443/000119312521000950/d95406dex104.htm">Credit Agreement, dated as of June 30, 2014, by and among Ortho-Clinical Diagnostics, Inc., Ortho-Clinical Diagnostics S.A., Ortho-Clinical Diagnostics
Holdings Luxembourg S.&agrave; r.l., the lenders party thereto and Barclays Bank PLC, as administrative agent and collateral agent (incorporated by reference to Exhibit 10.4 of Ortho Clinical Diagnostic Holdings plc&#146;s Registration Statement on
Form S-1 (File No. 333-251875) filed with the SEC on January 4, 2021) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1828443/000119312521000950/d95406dex105.htm">Amendment No. 1 to the Credit Agreement, dated as of June 6, 2017, by and among Ortho-Clinical Diagnostics, Inc., Ortho-Clinical Diagnostics S.A.,
 Ortho-Clinical Diagnostics Holdings Luxembourg S.&agrave; r.l., the lenders party thereto and Barclays Bank PLC, as administrative agent, collateral agent and first amendment incremental term lender (incorporated by reference to Exhibit 10.5 of
Ortho Clinical Diagnostic Holdings plc&#146;s Registration Statement on Form S-1 (File No. 333-251875) filed with the SEC on January 4, 2021) </A></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit <BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1828443/000119312521000950/d95406dex106.htm">Amendment No. 2 to the Credit Agreement, dated as of June 8, 2018, by and among Ortho-Clinical Diagnostics, Inc., Ortho-Clinical Diagnostics S.A.,
 Ortho-Clinical Diagnostics Holdings Luxembourg S.&agrave; r.l., the lenders party thereto and Barclays Bank PLC, as administrative agent and collateral agent (incorporated by reference to Exhibit 10.6 of Ortho Clinical Diagnostic Holdings
plc&#146;s Registration Statement on Form S-1 (File No. 333-251875) filed with the SEC on January 4, 2021) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1828443/000119312521000950/d95406dex107.htm">Amendment No. 3 to the Credit Agreement, dated as of January 7, 2020, by and among Ortho-Clinical Diagnostics, Inc., Ortho-Clinical Diagnostics
 S.A., Ortho-Clinical Diagnostics Holdings Luxembourg S.&agrave; r.l., the lenders party thereto and Barclays Bank PLC, as administrative agent and collateral agent (incorporated by reference to Exhibit 10.7 of Ortho Clinical Diagnostic Holdings
plc&#146;s Registration Statement on Form S-1 (File No. <FONT STYLE="white-space:nowrap">333-251875)</FONT> filed with the SEC on January 4, 2021) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1828443/000119312521000950/d95406dex108.htm">Amendment No. 4 to the Credit Agreement, dated as of January 27, 2020, by and among Ortho-Clinical Diagnostics, Inc., Ortho-Clinical Diagnostics
 S.A., Ortho-Clinical Diagnostics Holdings Luxembourg S.&agrave; r.l., the lenders party thereto and Barclays Bank PLC, as administrative agent and collateral agent (incorporated by reference to Exhibit 10.8 of Ortho Clinical Diagnostic Holdings
plc&#146;s Registration Statement on Form S-1 (File No. <FONT STYLE="white-space:nowrap">333-251875)</FONT> filed with the SEC on January 4, 2021) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1828443/000119312521034394/d116380dex101.htm">Amendment No. 5 to the Credit Agreement, dated as of February 9, 2021, by and among Ortho-Clinical Diagnostics, Inc., Ortho-Clinical Diagnostics
 S.A., Ortho-Clinical Diagnostics Holdings Luxembourg S.&agrave; r.l., the lenders party thereto and Barclays Bank PLC, as administrative agent and collateral agent (incorporated by reference to Exhibit 10.1 of Ortho Clinical Diagnostic Holdings
plc&#146;s Current Report on Form 8-K (File No. 333-39956) filed with the SEC on February 9, 2021) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d273090dex231.htm">Consent of Ernst&nbsp;&amp; Young LLP, Independent Registered Public Accounting Firm </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d273090dex232.htm">Consent of PricewaterhouseCoopers LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Latham&nbsp;&amp; Watkins LLP (included in Exhibits&nbsp;5.1 and <A HREF="d273090dex81.htm">8.1</A>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d273090dex82.htm">Consent of Gibson, Dunn &amp; Crutcher LLP (included in Exhibit&nbsp;8.2)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of proxy card of Quidel Corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of proxy cards of Ortho Clinical Diagnostics Holdings plc</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d273090dex993.htm">Consent of J.P. Morgan Securities LLC </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d273090dex994.htm">Consent of Perella Weinberg Partners LP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#annxd">Opinion of Perella Weinberg Partners LP (included as Annex D to the joint proxy statement/prospectus forming a part of this registration statement and incorporated herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#annxe">Opinion of J.P. Morgan Securities LLC (included as Annex E to the joint proxy statement/prospectus forming a part of this registration statement and incorporated herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1906324/000119312522023500/d273090dexfilingfees.htm">Filing Fee Table </A></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Schedules to the agreement have been omitted pursuant to Item 601(b)(2) of
<FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.&nbsp;The</FONT> registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The schedules and similar attachments to this exhibit have been omitted pursuant to Item 601(a)(5) of
Regulation S-K. Quidel Corporation agrees to furnish copies of any such schedules or similar attachments to the SEC upon request. In addition, certain provisions of this exhibit have been redacted because Quidel Corporation customarily treats the
redacted information as private or confidential and the omitted information is not material. Quidel Corporation agrees to promptly provide to the SEC on a supplemental basis an unredacted copy of the exhibit. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City of Raritan, New Jersey, on March&nbsp;14, 2022. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CORONADO TOPCO, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joseph Busky</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Joseph Busky</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: President, Chief
Executive Officer,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer and Director</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>2
<FILENAME>d273090dex81.htm
<DESCRIPTION>EX-8.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-8.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 8.1 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">


<IMG SRC="g273090g70i38.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">1271 Avenue of the Americas</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">New York,
New York 10020-1401</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Tel: +1.212.906.1200 Fax: +1.212.751.4864</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">www.lw.com</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">FIRM / AFFILIATE OFFICES</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 14, 2022</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ortho Clinical Diagnostics Holdings plc</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1001 Route 202</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Raritan, NJ 08869</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Beijing</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Boston</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Brussels</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Century City</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Chicago</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Dubai</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">D&#252;sseldorf</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Frankfurt</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Hamburg</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Hong Kong</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Houston</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">London</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Los Angeles</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Madrid</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">Milan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Moscow</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Munich</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">New York</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Orange County</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Paris</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Riyadh</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">San Diego</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">San Francisco</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Seoul</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Shanghai</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Silicon Valley</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Singapore</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Tokyo</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">Washington, D.C.</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>U.S. Federal Income Tax Considerations</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the addressees set forth above: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
acted as special United States tax counsel to Ortho Clinical Diagnostics Holdings plc, a public limited company incorporated under the laws of England and Wales (&#147;<B>Ortho</B>&#148;), in connection with the transactions contemplated by the
business combination agreement, dated as of December&nbsp;22, 2021 (as amended or modified from time to time, the &#147;<B>Business Combination Agreement</B>&#148;), by and among Ortho, Quidel Corporation, a Delaware corporation
(&#147;<B>Quidel</B>&#148;), Coronado Topco, Inc., a Delaware Corporation (&#147;<B>Topco</B>&#148;), Orca Holdco, Inc., a Delaware corporation and wholly owned subsidiary of Topco (&#147;<B>U.S. Holdco Sub</B>&#148;), Laguna Merger Sub, Inc., a
Delaware corporation and wholly owned subsidiary of Topco, and Orca Holdco 2, Inc. , a Delaware corporation and wholly owned subsidiary of U.S. Holdco Sub (the &#147;<B>Business Combinations</B>&#148;). Unless otherwise indicated, each capitalized
term used herein has the meaning ascribed to it in the Registration Statement (defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is being delivered in
connection with the Registration Statement (File No.&nbsp;333-262434) of Topco, on Form <FONT STYLE="white-space:nowrap">S-4</FONT> filed on January&nbsp;31, 2022 with the Securities and Exchange Commission and the related proxy
statement/prospectus, each as amended and supplemented through the date hereof (together, the &#147;<B>Registration Statement</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing the opinion set forth below, we have examined and reviewed originals or copies, certified or otherwise identified to our
satisfaction, of: (i)&nbsp;the Registration Statement; (ii)&nbsp;the Business Combination Agreement (including any exhibits and schedules thereto); (iii) the officer&#146;s certificate delivered to us by each of Ortho and Quidel for purposes of this
opinion (collectively, the &#147;<B>Tax Certificates</B>&#148;); and (iv)&nbsp;such other documents and records as we have deemed necessary or appropriate as a basis for our opinion. In such examination, we have assumed the genuineness of all
signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity with originals of all documents submitted to us as copies thereof, and the authenticity of the originals of such
copies. We have not made an independent investigation of the facts set forth in any documents that we have examined. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>March 14, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 2
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g273090g61e00.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering our opinion, we have
assumed that (i)&nbsp;the Business Combinations will be consummated in the manner described in the Registration Statement and the Business Combination Agreement, and will be effective under applicable law, and none of the terms or conditions
contained in either the Registration Statement or the Business Combination Agreement will be waived or modified and (ii)&nbsp;the facts relating to the Business Combinations are accurately and completely reflected in the Registration Statement, the
Business Combination Agreement, the Tax Certificates, and other documents and records referred to above. In addition, our opinion assumes and is expressly conditioned on, among other things, the initial and continuing accuracy of the facts,
information, covenants, representations and warranties set forth in the documents referred to above and all representations made to us in the documents referred to above being true, accurate and complete without regard to any qualifications as to
knowledge or belief. Furthermore, our opinion assumes the accuracy of any advice or opinion rendered by other counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion is
based on the Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;), Treasury regulations promulgated thereunder, judicial decisions, published positions of the Internal Revenue Service (the &#147;<B>Service</B>&#148;), and such
other authorities as we have considered relevant, all as in effect on the date of this opinion and all of which are subject to change or differing interpretations, possibly with retroactive effect. A change in the authorities upon which our opinion
is based could affect the conclusions expressed herein. Moreover, there can be no assurance that positions contrary to our opinion will not be taken by the Service or, if challenged, by a court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the foregoing, and subject to the qualifications, assumptions and limitations set forth herein and in the Registration Statement
under the caption &#147;Material U.S. Federal Income Tax Considerations&#151;Material U.S. Federal Income Tax Considerations to U.S. Holders of Ortho Shares of the Ortho Scheme&#151;Receipt of Topco Shares and Cash in Exchange for Ortho
Shares,&#148; we are of the opinion that under current United States federal income tax law, (1)&nbsp;the Ortho Scheme, taken together with the Quidel Merger, will qualify as a transaction described in Section&nbsp;351 of the Code for United States
federal income tax purposes and (2)&nbsp;as a result, gain (but not loss) will be recognized by a U.S. Holder of Ortho Shares on the exchange of Ortho Shares for a combination of cash and Topco Shares pursuant to the Ortho Scheme in an amount equal
to the lesser of: (a)&nbsp;the excess of (i)&nbsp;the sum of the fair market value of the Topco Shares and the amount of cash received by such U.S. Holder over (ii)&nbsp;such U.S. Holder&#146;s tax basis in its Ortho Shares, and (b)&nbsp;the amount
of cash received by such U.S. Holder pursuant to the Ortho Scheme. We express no opinion on any other potential United States federal income tax consequences of the Ortho Scheme or the Quidel Merger, including the potential United States federal
income tax consequences of the Ortho Scheme pursuant to the passive foreign investment company rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is being delivered
prior to the consummation of the Business Combinations and therefore is prospective and dependent on future events. This opinion is expressed as of the date hereof, and we are under no obligation to supplement or revise our opinion to reflect any
legal developments or any factual matters arising subsequent to the date hereof, or the impact of any information, document, certificate, record, statement, representation, covenant, or assumption relied upon herein that becomes incorrect or untrue.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>March 14, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 3
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g273090g61e00.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly set forth above,
we express no other opinion. This opinion has been prepared solely in connection with the Registration Statement and may not be relied upon for any other purpose without our prior written consent. We hereby consent to the filing of this opinion as
Exhibit 8.1 to the Registration Statement. In giving this consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act of 1933, as amended, or the rules and regulations
of the Securities Exchange Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Latham &amp; Watkins LLP</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.2
<SEQUENCE>3
<FILENAME>d273090dex82.htm
<DESCRIPTION>EX-8.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-8.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 8.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g273090gibson.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;14, 2022 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel
Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9975 Summers Ridge Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA, 92121
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as
United States federal income tax counsel to Quidel Corporation, a Delaware corporation (&#147;<B>Quidel</B>&#148;) in connection with the transactions contemplated by the business combination agreement, dated as of December&nbsp;22, 2021 (as amended
or modified from time to time, the &#147;<B>Business Combination Agreement</B>&#148;), by and among Quidel, Ortho Clinical Diagnostics Holdings plc, a public limited company incorporated under the laws of England and Wales
(&#147;<B>Ortho</B>&#148;), Coronado Topco, Inc., a Delaware Corporation (&#147;<B>Topco</B>&#148;), Orca Holdco, Inc., a Delaware corporation and wholly owned subsidiary of Topco (&#147;<B>U.S. Holdco Sub</B>&#148;), Laguna Merger Sub, Inc., a
Delaware corporation and wholly owned subsidiary of Topco, and Orca Holdco 2, Inc. , a Delaware corporation and wholly owned subsidiary of U.S. Holdco Sub. Unless otherwise indicated, each capitalized term used herein has the meaning ascribed to it
in the Registration Statement (defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is being delivered in connection with the Registration Statement (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-262434)</FONT> of Topco on Form <FONT STYLE="white-space:nowrap">S-4</FONT> filed on January&nbsp;31, 2022, as amended on March&nbsp;14, 2022 with the Securities and Exchange Commission and the related proxy
statement/prospectus, each as amended and supplemented through the date hereof (the &#147;<B>Registration Statement</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
rendering this opinion, we have reviewed (without any independent investigation) the Business Combination Agreement, the Registration Statement and such other documents as we have deemed necessary or appropriate. We have relied upon the truth and
accuracy at all relevant times of the facts, statements, covenants, representations and warranties contained in the Business Combination Agreement and the Registration Statement, and have assumed with your consent that the proposed transaction will
be consummated in accordance with the Business Combination Agreement and without breach or waiver of any material provision thereof and no action will be taken by Ortho, Quidel or any of its subsidiaries after the date hereof that would have the
effect of altering the facts upon which the opinions set forth below are based. In addition, we have relied upon the accuracy and completeness of certain statements, factual representations, covenants and agreements made by each of Quidel and Ortho,
including the accuracy and completeness of all factual representations and covenants set forth in the certificates dated as of the date hereof from an officer of Quidel and an officer of Ortho (the &#147;<B>Officer&#146;s Certificates</B>&#148;)
without regard to any qualification as to knowledge or belief. We have </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g273090gibson.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">also assumed the authenticity of
original documents submitted to us, the conformity to the originals of documents submitted to us as copies, and the due and valid execution and delivery of all such documents where due execution and delivery are a prerequisite to the effectiveness
thereof, as well as the legal capacity of all natural persons, the genuineness of all signatures. We have assumed that such documents, certificates, and records are duly authorized, valid, and enforceable. In making our examination of documents, we
have assumed that the parties thereto had the power, corporate or otherwise, to enter into and perform all obligations thereunder and have also assumed the due authorization by all requisite action, corporate or otherwise, and the execution and
delivery by such parties of such documents and the validity and binding effect thereof on such parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion is based on the
Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;), Treasury regulations promulgated thereunder, judicial decisions, published positions of the Internal Revenue Service (the &#147;<B>Service</B>&#148;), and such other
authorities as we have considered relevant, all as in effect on the date of this opinion and all of which are subject to change or differing interpretations, possibly with retroactive effect. A change in the authorities upon which our opinion is
based could adversely affect the conclusions expressed herein. Moreover, there can be no assurance that the Internal Revenue Service will not successfully assert a contrary position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the foregoing and subject to the assumptions, exceptions, limitations and qualifications set forth herein and in the Registration
Statement under the heading &#147;Material U.S. Federal Income Tax Considerations&#151;Material U.S. Federal Income Tax Considerations to U.S. Holders of Quidel Shares of the Quidel Merger,&#148; we are of the opinion that, for United States federal
income tax purposes, the Quidel Merger, taken together with the Ortho Scheme, will qualify as a transaction described in Section&nbsp;351(a) of the Code and no gain or loss will be recognized on the exchange of Quidel Shares solely for Topco Shares
in the Quidel Merger. We express no opinion on any other potential U.S. federal income tax consequences of the Quidel Merger or the Ortho Scheme. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly set forth above, we express no other opinion. This opinion has been prepared solely in connection with the Registration
Statement and may not be relied upon for any other purpose without our prior written consent. This opinion is being delivered prior to the consummation of the proposed transaction and therefore is prospective and dependent on future events. No
assurance can be given that future legislative, judicial or administrative changes, on either a prospective or retroactive basis, or future factual developments, would not adversely affect the accuracy of the conclusion stated herein. We undertake
no responsibility to advise you of any new developments in the facts or in the application or interpretation of the federal income tax laws. Furthermore, in the event any one of the statements, covenants, representations, warranties or assumptions
upon which we have relied to issue this opinion is incorrect, our opinion might be adversely affected and may not be relied upon. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g273090gibson.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quidel Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to
the use of this opinion as an Exhibit to the Registration Statement and to the use of our name under the caption &#147;Material U.S. Federal Income Tax Considerations&#151;Material U.S. Federal Income Tax Considerations to U.S. Holders of Quidel
Shares of the Quidel Merger&#148;. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act, nor do we thereby admit that we are experts with respect
to any part of such Registration Statement within the meaning of the term &#147;experts&#148; as used in the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ GIBSON, DUNN&nbsp;&amp; CRUTCHER LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d273090dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Ernst&nbsp;&amp; Young LLP, Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our reports dated February&nbsp;17, 2022, with respect to the
consolidated financial statements of Quidel Corporation, and the effectiveness of internal control over financial reporting of Quidel Corporation, included in its Annual Report (Form <FONT STYLE="white-space:nowrap">10-K)</FONT> for the year ended
December&nbsp;31, 2021, filed with the Securities and Exchange Commission and incorporated by reference in Amendment No. 1 to the Registration Statement (Form <FONT STYLE="white-space:nowrap">S-4</FONT> No. 333-262434) and related Prospectus of
Coronado Topco, Inc. for the registration of its common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 11, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>d273090dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in this Registration Statement on Form&nbsp;S-4 of Coronado Topco, Inc. of our report dated March&nbsp;7,
2022 relating to the financial statements, which appears in Ortho Clinical Diagnostics Holdings plc&#146;s Annual Report on Form&nbsp;10-K for the year ended January&nbsp;2, 2022. We also consent to the reference to us under the heading
&#147;Experts&#148; in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Florham Park, New Jersey </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;14, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>6
<FILENAME>d273090dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF J.P. MORGAN SECURITIES LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to (i)&nbsp;the use of our opinion letter dated December&nbsp;23, 2021 to the Board of Directors of Ortho Clinical
Diagnostics Holdings plc (the &#147;Company&#148;) included in Annex E to the Joint Proxy Statement/Prospectus, dated as of the date hereof, relating to the proposed transactions described in the Business Combination Agreement, dated
December&nbsp;22, 2021, by and among Quidel Corporation, a Delaware corporation, Coronado Topco, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#147;Topco&#148;), Laguna Merger Sub, Inc., a Delaware corporation and a
wholly owned subsidiary of Topco, Orca Holdco, Inc., a Delaware corporation and a wholly owned subsidiary of Topco (&#147;U.S. Holdco Sub&#148;), Orca Holdco 2, Inc., a Delaware corporation and a wholly owned subsidiary of U.S. Holdco Sub, and the
Company and (ii)&nbsp;the references to such opinion in such Joint Proxy Statement/Prospectus. In giving such consent, we do not admit that we come within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act
of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder, nor do we hereby admit that we are experts with respect to any part of such Registration Statement within the meaning of the term
&#147;experts&#148; as used in the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ J.P. Morgan Securities LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 14, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>7
<FILENAME>d273090dex994.htm
<DESCRIPTION>EX-99.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF PERELLA WEINBERG PARTNERS LP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
hereby consent to the use in Amendment No. 1 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4/A</FONT> of Coronado Topco, Inc. (the &#147;Amended Registration Statement&#148;) and in the Joint Proxy Statement/Prospectus of
Quidel Corporation and Ortho Clinical Diagnostics Holdings plc, which is part of the Amended Registration Statement, filed on March&nbsp;14, 2022, of our opinion dated December&nbsp;22, 2021 appearing as Annex D to such Joint Proxy
Statement/Prospectus, and to the description of such opinion and to the references to our name contained therein under the heading &#147;<I>Summary&#151;Opinion of Perella Weinberg Partners LP as Financial Advisor to Quidel</I>&#148;, &#147;<I>Risk
Factors&#151;Risks Relating to the Combinations</I>&#148;, &#147;<I>Risk Factors&#151;Risks Relating to Topco Following Completion of the Combinations</I>&#148;, &#147;<I>The Combinations&#151;Background of the Combinations</I>&#148;, &#147;<I>The
Combinations&#151;Quidel Reasons for the Combinations and Recommendation of the Quidel Board of Directors</I>&#148;, &#147;<I>The Combinations&#151;Opinion of Perella Weinberg Partners LP as Financial Advisor to
Quidel&#148;</I>&nbsp;and<I>&nbsp;&#147;The Combinations&#151;Unaudited Forward-Looking Financial Information&#148;</I>.&nbsp;In giving the foregoing consent, we do not admit that we come within the category of persons whose consent is required
under Section&nbsp;7 of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), or the rules and regulations promulgated thereunder, nor do we admit that we are experts with respect to any part of such Registration Statement within
the meaning of the term &#147;experts&#148; as used in the Securities Act or the rules and regulations promulgated thereunder. Additionally, such consent does not cover any future amendments to the Amended Registration Statement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PERELLA WEINBERG PARTNERS LP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Perella Weinberg Partners LP</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March
14, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g273090g04h96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g273090g04h96.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1L\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &R"^:40X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   ( ?P X
M0DE-!"4      !!U^(',E/P+R"#<9+'\9F)8.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             .L   $#          $                          0
M           ! P   .L                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   .L     4F=H=&QO;F<   $#    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #K
M     %)G:'1L;VYG   ! P    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      0G     $   "@    D0   >
M 0_@   0@  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ D0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M//[C_4+MF[_2,7)O
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M! 4&!P@1 !(3"10A%2(7,3)!)$)15QDG-E*6E]76_\0 '0$!  $% 0$!
M          8!! 4'" D" __$ #H1  (! P0 ! ,&! ,)      $" P0%$0 &
M$B$'$R(Q,D%1"!0587&Q(T*1\!:!H20E,U)TE,'"\?_:  P# 0 "$0,1 #\
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M8@XQT2IRA))P#DZY,5TK=YM:0\9JZIV9:27'%KVVC;;%_P"$%-^3(EN$VTS
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MKK!!0M44'WDPI)%.T+&JIWII/,5:E7;C&[%.,B8;!/(#&LK#LBU0T==1+47
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M12AC'&NJF0$V)-GPR8LH;PRX-:ZRQ8S8Q-O$C\2 ](89FR&E-F*Z\RV^;9N
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MN-#3*<AUQ>XI;9.L.*TU%B'?R[$XT9IJ.P3;+0 +35?WU!>&/''3/%3:7(3
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M54&%5U>E&JVLK8D>!75T#8&TX<&!!ALA'B0H42/G#<>+$BL-ML1X[#;;+#(
MTT @(BC33S:?XK<==!S[RXU#I_"L(R')HK<#(\KKZS[S,[^O9<5YBNN<RMG;
M#*;.M8>57X]?-MWH;#RJZTP#BJ7C33+UOTUN$U-7PJFGTC&J:FMBL0:VKJ\\
MVC7UM=!BMBS%A0($/-F8L.'&9 &8\6,TTPPT MM-@ B*--+2DX,\5L?H<^Q>
MNU/$<QW:.&V6O\^I;;*L[R"NR7#K<V3LJ.9%OLHLFV8\LF&D=?A)%F>@JV$D
M0,Q)II,)].CANB=)J%Y$3\(B;(VSTB?Z?]=^--'_  Z.''^T+W_LC;/_ .[\
$::__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g273090g11i11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g273090g11i11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1(24&AO=&]S:&]P(#,N,  X0DE-! 0
M    $?:^19@X0DE-! 0      $,< 5H  QLE1QP"   "/_L< E  "')R,3DU
M-C<V' (% ")-:6-R;W-O9G0@5V]R9" M(#(W,S Y,"!!3DY81BYD;V-X #A"
M24T$)0      $(97K/P+&ZE&3R4N?47C7(XX0DE-!#H      .4    0
M 0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N
M=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M"W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q ;2            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4
M @ " [_^-0 "  (X0DE-!"8       X             /X   #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &               G   "&@         !
M                          $              AH    G
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<    G     %)G:'1L
M;VYG   "&@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG    )P    !29VAT;&]N9P   AH    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     (X0DE-! P
M    !Y0    !    H     P   '@   6@   !W@ &  !_]C_[0 ,061O8F5?
M0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/
M%1@3$Q43$Q@1
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                 /_A/_]H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY4
M8WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B
M('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@
M,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL
M;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT
M87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C(M,#$M,CE4
M,3 Z-#<Z,#0K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP
M.D-R96%T;W)4;V]L/E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR/"]X;7 Z
M0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(R+3 Q
M+3(Y5#$P.C4R.C$S*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @
M/'AM<#I-971A9&%T841A=&4^,C R,BTP,2TR.50Q,#HU,CHQ,RLP-3HS,#PO
M>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @
M(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@,3 N,2XQ
M-B H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N
M=',O,2XQ+R(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D
M9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F
M875L="(^36EC<F]S;V9T(%=O<F0@+2 R-S,P.3 @04Y.6$8N9&]C>#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET
M;&4^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C$Y-38W-CPO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*
M(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z
M<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @
M(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C$U-3,U1#8W0S,X,$5#
M,3%"0T4X03DV,4,W,$(S,3=#/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @
M(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C$S-3,U1#8W0S,X,$5#,3%"
M0T4X03DV,4,W,$(S,3=#/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,3,U,S5$-C=#,S@P
M14,Q,4)#13A!.38Q0S<P0C,Q-T,\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)
M1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C$S-3,U1#8W0S,X,$5#,3%"0T4X03DV,4,W,$(S
M,3=#/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(R+3 Q+3(Y5#$P.C4R.C X*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M,30U,S5$-C=#,S@P14,Q,4)#13A!.38Q0S<P0C,Q-T,\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C(M,#$M
M,CE4,3 Z-3(Z,3,K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@
M9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E
M+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C$U-3,U1#8W0S,X,$5#,3%"0T4X03DV,4,W,$(S
M,3=#/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(R+3 Q+3(Y5#$P.C4R.C$S*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C$T-3,U
M1#8W0S,X,$5#,3%"0T4X03DV,4,W,$(S,3=#/"]S=%)E9CII;G-T86YC94E$
M/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C$S-3,U
M1#8W0S,X,$5#,3%"0T4X03DV,4,W,$(S,3=#/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD
M:60Z,3,U,S5$-C=#,S@P14,Q,4)#13A!.38Q0S<P0C,Q-T,\+W-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O
M;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @
M(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO
M9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO
M>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\
M/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ $ #> P$1  (1 0,1 ?_$ !H
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MK+)[+)*FY^2:KYI.6T82N6:DOBM>7/?YYAJUF[7OVLBK"66J**;!4&*)&'<
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@5JQ9IV8<@]3$M5,4%6Q>B4>Y*TK*Q7;=Q0L68@$__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g273090g15s55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g273090g15s55.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1J>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &H*^9X8X0DE-! 0      !$< @   @  ' (%  50<FEN=  X0DE-!"4
M     !#7"E 5OPPK!?J^/%X(U($!.$))300Z      #W    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    * $$ 9 !O &( 90 @ %  1 !&       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M #^    X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      -!    !@             !
MA0   FH    & &< ,0 U ', -0 U     0                         !
M              )J   !A0                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !A0    !29VAT;&]N9P   FH    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M 84     4F=H=&QO;F<   )J     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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MP  1" !& &\# 2(  A$! Q$!_]T !  '_\0!/P   04! 0$! 0$
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M%AQVN=;>0Z^^USK+;"!M:;;K"Y[MJRJ:W_6'J6<<FVQG3,"TXE6-4]U7J6L
M.1=D/I<RU^Q[FLI9ZGIJ;<7J?2K<VJ@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M",BP<2%X=W)&'3DW\ZH@I+'28QR1T&4:V>-H\IG"R[EJY< @JA"FY,<TM7W
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MQFX_/66JJD@FHLNHFBBD0RBJJIRIIID*'DQU%#B!2$* ")C&$   \B(!U42
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M<BH 08O'OF=ZW<-D([+;JS>7EK-=^HR>4J#(0Q5'J!*IAKSB1.Z)5D.>W9Q
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M[VL'H6VW")S6C6/A"2MQ%MM!U6, ZFCWZ3<E8C)^T=LBH)(AZ03+G33*L5!
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MNE*)Z5FQ4G"LHFJS25Y0K#AE$D3(X5AX8!N"/!Y&M@  4 *4 *4H !2@
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M/CGL5>>/XZS\YN?<NYYHK&Y=PYS<,\"E(9\YEK^6FA0\<I%+?L6'C4\#E48
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M]#G2^,.AD'6;.L8PP[PIQVZ@&*\]P4GP"1P3^>CL7HK(<0]"(NDHB<>4.Q&
MBI#)F$IFU1$I@*< $2F#[*;QX$/V$>FV2#1G(((^L?X_V%;3UR2))U=V^T;H
MZ_T7[,'<C!AR&RH(Y4D<@^"/D'P=<XT!NN&S?\H%,*"P%<9VB"!A3.!5Q#(M
M9*((B)?"@@80*/H]7@P@'[_74<A'O;I\CQ6L<^?CS:^?T^#\Z^C;AEC.RO0
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MO8CXUDV8LD?483F]IHU2203]1Q$QO0F'DPB8?L?/5*1QQJ$C1$0?"JH51_<
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M,7IXJ$CR3,2BUC12CF[<KQ$J+<H ?T:[CLE5BNY6:Q8[4FF3V'<2-W11R6>
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M2UD]D['Z8=(=O[KZJ[W],NZL=MA)[>S=D^[EI<T^02(R;RW11V[4L78KF:>
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M3[F7GM#+R"0-[W&FT/4_L#IM>J]0=F;(ZL]/=KU=D;BPN_\ ,IMVAN7$8O\
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M<W^05]U[5GN8!@& (9\K7>/N3[E7/Q&DW#243K.F^B: E&F/9J=5UE!_%OH
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%HZ::_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g273090g61e00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g273090g61e00.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M#]* "2SMIKF"YEMXGGM]WE2,@+1[AAMIZC(X.* "*SMH+B>XAMXHYIR#+(B
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M6%L+ J5-MY2^7C.<;<8QF@!NFZ1IFCPM#I>G6MC$QRR6T*QJ3ZD*!0!=H *
$"@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g273090g70i38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g273090g70i38.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /7=0\::7IGC&P\+SK,;^^C$D14+L )8<Y;/\!Z T =%0 4
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M<GS;V[/+2R'GJ><#)Q^)ZF@#D?B;_P E7^''_7U)_P"A1T =7\5/^27^(?\
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>@ H * "@ H * "@ H * "@ H * "@ H * "@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g273090g78n03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g273090g78n03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1S$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '*B^<S8X0DE-! 0      $0< 5H  QLE1QP"   " '\< E  "')R,CDS
M-S0Y' (% "--:6-R;W-O9G0@5V]R9" M($-O<F]N861O+2!3+30N9&]C>#A"
M24T$)0      $!S]"]^$2:OHKWJH@N'E"NLX0DE-!#H      .4    0
M 0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N
M=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M"W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q 6             IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4
M @ " [_^-0 "  (X0DE-!"8       X             /X   #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              $H   "50         !
M                          $              E4   $H
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   $H     %)G:'1L
M;VYG   "50    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   !*     !29VAT;&]N9P   E4    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     4X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MAP%['.=M(=,001O<YOI>_P!3:W^1_.HF0ZG(=N?7E-TB&.#1W]WML^EJH 5
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M;_FC_P DA7NSS97]G8&U#?ZPMK+G&6Q3Z+F6-0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@!* )5 P$1  (1 0,1 ?_$ !\   $#!0$! 0
M           &!P@! @,$!0D*"__$ 'H0   & 0(# @8'$ @0"@0)#0$" P0%
M!@<($0 2(1,Q"105(D%1%A=288&1T1@9(S)35UAQDI:AL;+2UM<S.$)VEYBW
MP0HD)28G-#8W8G)T=Z*VU? H5%ES>8*4L[74&D;"X2E#9J6GQ,73\34Y1$5'
M9&>5HZ2TN-C_Q  = 0$  P$! 0$! 0           0(#! 4&!P@)_\0 9A$
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MW) M!LZTRQ7"I) 8N1B!SH13-B'&L<]UF?&K:YEH7MG4\EX<'%)*FN+;7R6
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M^C&'Z80,*A#F+YPCV0G2,)#F2_8S& 1$PE$3;&WVU-?JRZ1N.8CYS""&2HT
M9S4D"M=H/3TD5CIM^8$2<QA,/G;F,(B([F,(;B/7H&P>]MMPBH#!G)SJ=Y?N
MRC-PB8.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(
M.$(.$(.$(.$(.$(.$(.$(.$(.$(YRYA^B!Z!.7K_ -80V^UMT$/5[P<00&4=
M<)^:)=E2VH2<^LCWV]4>3&93-VWA4]-"\[RC%2.G/*,#4DWO*FW]E2D^,A,D
MAU5@%L23>5]L@W>(ARN';%))%3G;E3+QG+4'*'T)SVFH[  VS;1OTBYI<U7!
M/A%/E8E*2+*6&(X2)J,VH*A\5 GSG!$/[X09*.1T5ZE52((BJWQ1;%DNS%$5
M")N6!VZ8G'JL10/%D#G(.Q4U$2%3V(BERQ/8(.UGH-K9M6CN,ZAVH"/'X'SK
M8OA#8BLK!7,FH))4,0"9A(V9.X-#B(+U>*#K<FIKP6**8ASI8/SRF<Q!$><Z
M>+,=$'F,;<3" J'*/,/>=0.XP@;AE*>8AWR.T.Q+US8Y9:'+,?73) \F<*IB
MS5-MLX#U(!M.A<M0,]*#HB/]-Q!C>^X%\*U;K=2*E/V>LY[U?QM>G9^!BI66
M@B1=,86=@$(_?LG#R)!&>DCR2(1ZR )R9E'Y !T853=LR7B<@X2H!AD*, PW
ML'?6M*@<MKO%:)MT666@"4B2RE) '&8U%14JC$IQ%WS9]T.!6I-_*77P*<P\
M46D'<IAS(,H_7<N%EU%W+G3!67RSER=8QU'3A-Z0JPJK"=0%SF4 XJ#S#SS)
M:@$<XO\ =%R-Y<NYH0,Q2FA;JLMCLUINGA=.F!"%6>7=I0 $@I5-M24E0( P
ME2&0X8E 8L P<K1-B/$^<5=5.1\RXXHU^R&XU:9ABI.=R#6H:US,-"4QVPB:
MC"P[ZP,Y%[ QM=B6S \(T:*MF\>9)-=BF@(D'CHER@ ZN<HDDD@T8G,M32M'
M:A:D>;PD5;KFF66R6&U6E%DF2)8E"5.G(3,$P(6H.A8"AB*DL&=R2,B$YJ>3
MQAF"7U41.-])F,,A6C'E8?UG*.9\@!6*R]B9IGC%!U ,**X+2[[<)^3K$&$2
M@T!HE6&#-]$D,18QT$WRO-/"QB 2"VN6:3D0'I0ODPYVL=7!@6VQ3;M%HO&T
MV9%LFS2F7+,TB:E<TJ4%X3@6E:O.QI6 5@!840"B'\FYD\ ^"#DY!=9_(J9L
MP*W?O7RAG+]=TRQE:V:BCQTLW;+N'7:,TS+KKH)K++)@LKS*^>:)95Q$DDEW
MF59G935!'47&V/3M<@2;1PRDI4%!-FDK"@,+XRA1(#!OMA31@QHPI'IWK8*0
M='6ILP@4"(Z>\PK@(  ;"&-;0.Y/<B B'4-A#;<!W#;CM/VHJ+NS T+.[O78
M&SS81^97*M2+[LJ0#A,X!20]09@TH#6AS[H3NB8P!HUTRK%<B($P-BQRB!BG
M7 C@M$A! XHI*$552'M53BB(^>X1!4  Q"&X2E#BT%LPS;:G-JZ/GD!G2.[A
M39C:KYG("!+6)LG[*6"6,J6 Q) YM&T!+%FKXY:L)FBWK3%DC4)@K3)CO'U7
MBLK5ZP0FHOQBKUO*DA:V6=8BJV*SUV'C*7/V)V::E0EJPX=VNQUAV#=R,BS%
MQ%%:.3YS)@3BR!=L3AWIN?4#93,Y']#N6ZT66\;+==IM0M*YMFFJ-G6E4R00
M;&F<A@KFA2:J% :GFA3$3:R%CVC90\)AC>/R368"]0T?H^LT\VBK3&1<]&-)
M=CE>"10D!8R;=TQ<.VQGDDHB":(G26;"J@?G I^.);JGRR><"E5'H @MSF)2
M6;8V0- (\F1:5V'@Q>";$#*G<N0DF6"A0!F<UL+*&-!2EU$*2[FHB%&2B.<7
MTK7GA['CIQ2,+(:H-.<.9>N+*M8BH0N47&-G.0Z_!IQAD&D)#K.'1(-6,8$:
MLHAM87:1D")F5*:B4+&(.IBLI9SM6&!>IT^Y.9<"/N;)=]WVP<&[5;#+\H6B
MQ6J:H+0G&I<HV=",6(.H*E\YE.7-*J$3)RGC2@8'U=:#C89IU5QPK=U\K4JV
MP=$@XJO,K54F.-AE$VT^A -&2$F%0>LF<Q'RL@1?E< *+=0AUA >D C"*BM:
MOH"7RJQJK(Z&/C+GE"WW%PHG3F*KO79C+4M"L04N<?-4MR!, 8RPV%F4V(1D
MT 8?QA:IO4ED^YT6HV"Z4O6]J+:TVVS]?9S=AJS*/FV#QN>L3,JW=.ZN0SB1
M>K@UKJT>DY5<+]L51RJX.>0,A7/?0!BU,]6&E &J_E<);PM(F2+#*EE ,N0#
M@88S,0DAR ZN8SE3@4(:H$.M4D_0+OIPLVH+ NEK'E#J#/,=6FH'/QG-6JF5
M)VR,L\0M/LUI@H2$IL[.K>R&;\K55T[MMAK#D6TF6<;"O'-FKL;\65R@0HG-
M@Y))Q,0[&A;*C%B7:/H>#5E5.MANVW7A:)6*SS5\F"5F4RK*9TL)2X2#FMR]
M062DD$3,R;C;'MK\);AI:T8UHMA&<TW76=F5)JJUR4\KS\)<JC%14G)@[CUD
MWTG7XQ59G%/E^U7BVZZ[9@LD@H8ILY<@B>E1J,*B1H2"W.8-M&ZNZ,;MG3D\
M#>$,N7;;4B5)M,N5*(G34,D3&4E(Q!20HN%"A(42H.HQ@Q3C:BY\U:Z[W.:J
M;4[U(4V9QWCZM0=V@H>T-:=0G6.BRI6%?9RK-UY!86]ZY6L$HLW!-L^?;.'!
M5#HD$MBEU3 =H9ZL"EVJP?>:."&+QPVN>JP7'<7)ESE&T39XF+05 K^R22Q4
M%%ZJ62AW))(9B\*8-4]UTE^#W@;4=2S0'SP2+QBT=2KKRD:=H$;9,JUB.:2!
MQ R$E")U[M*HJV5(HS=0Z:K)8BC994A\,)P!R7"B"0><V(MO+49W-6W1[EZ$
M6&W7SQ:9N)-WV*:GS@E$R9B) RPN E)8N0 "P#1.C6CCNC8A#0Q7<9T2F8_@
MAURXJ>GAJ36H2L0QGZM8N35S)FC8-FP:&?E;H)B=Z9(S@/%TBBI]!)RZH<8$
MXB #4.6SJ>O,ZDO6E?E^#UHY?*O15I4N<4R9?%(G$S"C$J<&3QA.$J).3;W#
MQ&Z(@+_EW45K>3D-,M-SLZ7O3;%Z4E=+Y6*\]IE'9TJ-;0474H^PU&<=Q;2V
MQZQ[ N[BGK=%W-$3>" .DB&2ND@K7B#M3, Y4#-7)]7(+Q]+:$W?=ET<'[9.
MG&1QB+1,4B6DXIH2N7BXQ22@J 6M1*2IB)BF((*H5;_3)J2JM%TE7BYXKQUJ
M7G\&XRLF.+KA"ZVR.%B5=P]A$:]9:I:+-$2-8D[9'U5BG' ]D(./\?(N^3\M
MD!VL*DHE$I2Y]($%RS*(%0&JSN:'.IH.8WU=%YVF^;+=TI5UKGSI:I%JEH$E
MP$(2L%24)*4 I5QA)8.H<PY>E^D3(^.<J8+K-FQACTF):^QD[/6W.,20D#7"
MTFPP=HE6-H8ECJTDC!%%29.]D@=1910D"/2R',8[DYAT*"D#+Z^XN=HZ32/S
MJ^;'/L%XS;+:)@M2\,J9Q@45N%(2H$%1+*2DLIB0^1=P(C:"FX--0'A!8BT$
M34N:6HP)4Z3H532/L&?Q17./C#VQ^U"-9Q!#-HE!J/BK),Z94 2'F >>RJ/*
M;2'-"@L33S$C*HH"7:FCQ]IPK5,^+_!F;)!$A<BV($Q '.5+3*0H%5' FF8P
MJ00HI91)A6:NQ;HZLO!W\O(D0F4<K%7,)DOV1OCIX\8I"9$QB=FY< "A2;B/
M,DF94O;)B(=*E$3I8)/."W#EG9ATTIH-=T>9<%GG6NY>$BU(Q(1*LRA,*:I"
M@O$!BYP<( (>H30,!#'3U"M&9M3GA,,9UF7;0-AOFGW$-6B)=91=-&.D)"I7
M.+9>-)LU$Y<\:L#HB:TO!N&R[,RBR!@4,D<3\JPI5KF *4$\Q@#^ FIV!V.;
M8B^3Q]#/E6*[>"O ^U&=-*YL^U<<@+4$I 7-!( 4P"3]D(U=122HA^KIJ?UV
M@Y(;Z<LQ:0,6XBR99\3V6)@+C4&%'MM8S%C^MJ0+&UPZ[]A',[.V;S@.6[U_
M6;8X=1\@J0'#])T/(8=IR E 89@AP"7#:5Q%PX R?[D"HX+SE3;;+L]XV:WV
MJ=)LZD*69DZ8%V=0F2ONBX2$$I4"PF)2'*RH@*C_ (2B(_&_@K,R97Q;5H2$
MR6FQSI$GM5>BXYC;6\0TR[8()%NXGXI!"5<A UU/QEJB#PZ,.>$:-FH)%C6Y
M4\K)B$IJ@ K8.P#J47H:5+Z=+F/HK^M?*>&ECLLU2K19Q9I:I8G+XQ"EIL4U
M;,MP>+F(0A(9@$A+,D"%QF#%6*,*XJT 9"PI7ZQ7;PXSMIYJQ+75(:+AK+D*
MOWA!Y[+H>QS,0V:R4ZTMZ*[VTRZTHX=HC)HJ2+L%'+A10VOV3"&*B1YM27KJ
M'<AJ[JN12/&LBIMHO2^K-:Y8,J4BT% 6C$!A4 @HQ.B6P(3E4,0R4O&Q XLQ
MSD7)OA/'M]I50N*E<D($]?<6J$BK O%$<X-9"Y6A/*S-X,*=^,>R<. 8"@*J
MC9J=7G.W2,3(RU%<TJ))&1+N!@%2*9%FR%-#2.A=Y3KOD\'\)GH$U<P6F6A1
MXM21.+(6Q920@E)=W.0J\,PKC6CU[1YX.#*4-6:ZVR-/Y]TKMIR\DBV/LXFH
MZ0=.(I^RF[:5N$_*L74<U;L5VS]^X14CV3)DH0S9H@FG>5+.!)=E.0#BK4FF
M1 IIJ&&Z-)%Z\NO^V20)QLG%*2A*BHH"A9U%1"5$IYLP*=@.<'V0YR,?><DZ
MS-:""FG"D:BR0@XUQXT0R%=*I"-Z%09.CEFR1M6B[339\YHN\OWLA*3WDUT1
MM)R_BWCI3K-4P0Y9R29\QSB', &+/F)((!9]AJ:L^8![;R-UV+@KP1F8E2IT
MU5X&TJ3+45SL*TLF<M)25B45\U,Q3)2Y0R4J(TY'#]YK='\%MAS/[2+FK2QR
M]D"JV>'4?IV6*=5\:=DEC!5]^NNS;-)N(2I+F+AGK==B+)R@#ALJDJW.<5>N
M3*)2G%H[Y5J<A45 VUH1%+'/N]<OAE;) 0)-FLEW*LPPIP)F*EE,PH3A2 2M
M)!(2"6PEZ1[@4K'M-QQ36=*Q[3ZO1ZY'INA8UNI0477H!BLY.Y?N56<5#M&4
M>@=T]54?+'1;%,JZ5.N<QU#F./298XL@:FCC+/=I[7/1^,3+4J;;!.F*4H44
M35RD$,- !0!QT4K'C+@-OJA^:7UU#@I_A%K'(9^@D+(7*D/=I5\HN-915*6(
M/5[!'-D""0S542NVXI=H58YRG-S'-QRI1$R:7 =09TU (<#1@X#"E6-7 C]C
MO>T\&[1<G!V7:C>(G(LD\'DW%B3]K +8CB)2&"B&5C*V()!+S9*K266?"(8>
MQ9G.'KM@I%1TK6S)4-!2#(KVE/LKO+]!UN8>-86=-(LW;R$KJIG48=<J[Z.2
M?'5042 A@+926F!)+MX$YN3J"[@Y991\Y=D\W9P?MEKN5,Y*YEH0GC#S;2)>
M+ RU2PDA*B&"7PA*@3Z1@]F&7G,/X]\*5BO%BCBJXLK>1M.AJ\%<45:1U0#,
M<;5 S C *1IT&T2R;=L)EHB-!LA#J3+Q8Z)#+K"?-R%+:E4AG< -NR+C:7KK
M'V]@L\JV6O@M>%JE2S;)]CO%<S&A.):Y&.7*QXAB65H2)@+EL.( .#$P<W8L
MQS@#.NA*;P16*U0;!9\DR^+YYK1XB*@BVK&<W1I>3LJ5C:P39D-A:5:2BXB:
M8O),':49*OSR* I.U3K&DDA0 --KDT(.CL35R2SDM5A'S%DM$^\;)?QMZ.,5
M95RERD3DETJ"Y[8.,<R\82$E.888G!C>T%8JQA$Y5UJS#6AT:-GZ?J.ND'4I
MAE5(%I+5>&5IU?!:'KT@@Q3>0\6H#^0(JPC5FS54'[WG3'QI<#R@'&37,%S7
M1A49.*OU58$UX3WA:+78."H2E7%( 22])C)D$E5 YQ%68/G*:JB3"ZA8AQ0^
M\$18<M256J#/)T%'Y4EH?)B45$-L@0DI4\RV9K4PC+<5L2Q,SLDV+&,C6321
M1[)HH5!J4B2@%XV.(V8U+X2Q+E5%$4.\/N,?3VBW+/P@2;(4S$6'DTA'$("D
MV=37=/*B)2?L0=2$DG 05H ;$!$E(6CP.:O"#XYC,R4NO7)I*>#HK%OG:C;8
M:-FZ^XEG.8XYJMY0@9EL\C'#R(4?R8,1<-3JLBO'1$!3[=7GA*25)<EL*2Q>
MC@."&VD[&USCX^\KU18[MMTNR<;+7RRTI3,EDI(>8LL",):H2:Y.SN\.\WB(
M>M>%3C:O7HYC'U^$\'<A$1<5&-46<8P81V=$VL>V9L6R:39L@R:D2;-T44DT
MD$4RI)%*F4I0HI*N-4RBV 9&@JD%@XV.VARCSY*IDS@^+3-G31,7;4$A4Q94
MV) =R7+CH+*>CN/-%/&%'+X'&;S$%-K 9-C)2>7BLF*0L:%]B743J94AHU..
MMGB@V"/;-HQ,&*)&L@B1)JHJ@0I$SG*:P00@@A1+N!70Z9Z'M.X"/NE3T*X8
M2;O1/6F4N5+29*5$2BCDZR'2&2.<A('-\T -L]!K[B_&]J\)1AP+3CNC6%.?
MTT6VP324W5(&71E)BNVZJ14'*/RR$>X!](0;!1PPAGCL%7,8Q64:,E$&YS)C
M1-F4;2F:H<TH+A@02& -<SGAW4$>2B\PC@=?]W)F**S>&&6HK5C""K$H DN
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M+/61Y*@,XYDV\GQT,:G+V)6""#C&0%9LH8&'B+-%,J#=LFD!2A 3O(2Y9(+
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MS<3\R2*BB8KG,D0#MU(\'PCN211<@4X*;AQ&(/10)(VN35N]G .D  &<, =
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M!;"^]@7ZV/MBP2E'O;@/7?J4@]1$3"/4.\3")M^_<1'OXECN]8>,!,6,DD=
M;_AB_G !$QDBF,8!*(F^F H\VX"(" [#S&$0_P (>G4=XIM3ZR?&(Q+/W!;2
MA9]M V@?HSC54(5178Z9E1-U*3?=, *0 ZAW= (&^^W0/0 !L?++4@ACN->D
M;='&3Q(F$CBRD!QSJ!SF><]2&/50=-A7"*ACB@9(QTEBMECI 5TB14Q"B4RJ
M39;M4E2E,4I1<IE$"[&((IB01FO=KLZ^Z#-0I:N1 SW]FM!'21 0*400+S
MIB<4A X@4YP$-^8P@43&.8I1,.P''H B(<1$QA.)RJ;%0*4"D!,HE "[$V#S
M"E[RD_P0\WWN) 'NH#VQ0E0) %!E0[ME/\HN(5,P%YTA 2@)0Z@(%*8>H% 2
MCT'O$-]A'OX$='0X)[J1*5EV9CK3?L.0C;311Y0$I.@@(=>@[ .VW0=M@VV
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M(:.!1L6<D%\45^,<3"C%".;1Z:B\N@GXPNJN=NID-V[W ?NI)+ER'-6)!)%
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MM.81*GU[78%=^G7M * *;_3[!S;[!PA 5-L4XJ%30*H(  J%*F!Q IEC% 3
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M"#A"/D/\.SS#K,J!!,?D]H:F' @"/*4Y[M?4U#@7?8#*)E*F<VP"<A03$1*
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M_0_2^N'D&[]J>Q/C%GEW4B(F$<U6,1,(&,/L0QGN8P !0,;^QWU$"@!0$=Q
M   Z!P\O6OT/TOKAY!N_:GL3XQ?[(=2@=V;+,'>/]R6-.\1W$?[WGI'J/O\
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M@NA,NVH.CGJ$@ R+%\Z@I\KE*(C[!#$G9)1!_%HMJ"792EQQ;N14).6IW;R
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M^?NZRBK% -19.-D"BFJD?M"B0HD4V 2@!@VV/T  V, AYOF^D \N\+$)8"T
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MS&67YHJ5$);10>E!D"[ N.AB>^S7_)EHF!<M:E)3)3C5SFP*4% J.)B7*'4
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M2H)2Y*G+!^UGHP W 1;A,QLXUYI-=H3GTTSCU*0  2)L !N B.P;;COMO\0
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M)5[%=A^C#XUI^]=W_P!!D^$'SOY?[-;P@G\8DGZ$\.2KV*[#]&'QK3]Z[O\
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M[,E*QFSA(PBA<-H7-28"^#]4*.Y=:6OPH 8AP NH=,! Z?TAP$*9L!B#U*(
M E';80VXL$'0%]I/8SU<:%R1I2-#PIE+3_!]R*S!)LX+@NX<H)/;%Y?!^G*
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MTR<E>F]QA<'A !!,XEPF_3JLK<'C=<BX,!6:@F4;\<')--6>E78$.6#AW<$
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MB&)R7<FI+#1RX ;7)P00Y:/-MEW3;*M<I142C Q43B4Z0LFB2HAC3,G"0<*
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MI:4.LLI\E:N4H91I-3TA"KMY6"83R[=G+MTYQ.!D >J(V%H2D) ) -* TZ@
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M"N6[+&&1;ZI=&D.[N\E(-6:*&-Y;G@K$PJED8HIR9W-=2G6+"&EJBTNU5,7
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MNQ&9)3MH 0 6J*$$U+ N6?C=94A$9,M>/LE41VRFX*SU6LQ#NAB:Y0#VU/\
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M-9(:*ICV#:W9D)U 9(=B#1R *G$[U+#8XM,X-6Z43QAEJ!8I"U#"X("B$JR
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MA:<"PRDI4".)46((((?2/T%-+I")Z>,+D3(4A"XPH0%(0H%*4 J4,  !2@
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MF/C*;QJY5E$H_M6TRS73;.8M<A@D2BW9N7IPDTECA"YAP5R(+L:J8N&IEH]
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MK&0%>N= FJ\>L3%COEU=2]=LD#8E6DUD"[2#%RUF@AUVN"EC&7.NCU.$,7%
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M]@BZ;XMJ$A(M4](#\U*IC!R3I2I)/23%GS,6FL .7V@L,[*&,90 QG3ME#'
M"F,< AMCF,4I0,)MQ$"@ [@ <3R.7\E+_-HBWEFW?RRT>M,]]3VQB^9@TU%
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MW[O]UOQ L4D%Q)E@[0B6#M]';6 OBV@XA:YH4[X@A0+[7Q.\9!TQ:;5 )VF
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M.12M)4H?_;E_5LBPOBUC_P":F@Z\Y9[]8J&F;36!Q4# 6& 4$  3AC.G@<0
MP' !,$)S" '*4X!OT,4#!U !XGD<O/BI;[>+1$^6;7_*YOK+USBGS,NFH.T
M,!88V5(=-4/:SI_T5-0R1U"*?U$\\BAT$#G*;<IC(I&, BF00CDB=)4KU4#Y
MHGRU;/Y9.]9<7#IDTW&,"@X$PT)^8QP..-*<)@.90ZIC@8803<QE5%%#&WW%
M10YQ$3&,(V%E2S<3*/\ -E]6:#[8S-ZVLG%RF:32O&K2:,U'#,WSQ0VF+3:9
M4%S8"PR98#"8%C8SIHJ@83F5$P*#!\X&%0YU!$!W$YC'WYC"(N2H^0E>I+VO
M\GMKTQ4WI:CG:)AZ9RSEEKI%Z>EO38!4^ST_X6*":::*?+C.FEY$D4SH))$
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MHG$;76#OIB._6L5-I8TW' .; .%S !3E #8XI0@!5"'34* #!]"J$44(<
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M^$%OX%G]9#^R*?/7=$?UTWWW@Y,#\'L.';BIX7W6"W&)]8>)A^TEP]%%7/:
M=0$N.VCT@^>OZ(PZ>VJ]#WAQ_DL1^,:>'XN,SPQNP$CC9?62_=%Q\"7#T@-<
MMK(VB4X]A]L8S>%BT1 (A[:[P-O_ .'N31]'^#2C!\1A^#N!\<[JUF)?<H-W
MUBBO@0X?DG_X%:COXK=T" /"QZ(/3E=]O[V/<G?H1Q'QSNOTT^L(C]I#A_\
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M(@5X899RSUBUI^T[0';#$M(>,E$6ZKGL7C:S6YP@L[2:&3?+-T1;BF5! YC
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M7(( 96$:AX\*U? ;P?G6\R$6F?+EKE"PS%R9LID(6E"T2W4><D)PX4K!"76
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MG(%E6K E7YV(=NX21,M*1+BSIN5U5C,WK%(J101,RD7#8P*-ESIFNGA:A0*
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M\'X@XV1YHZ_:8U2E) )2DG:0"<XMXM$X$>BGU1X0<(8$>BGU1X0<(Y9H 6H
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M-\_2\1@4/^]1TY-VL /KZ3C 1[(H )1WYA[@'O,;T!S!TZA\0=VP!U2UVC
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M&5<Y(+A2K):RQ<%Q_P!H6QQ)!<$EP#0BF$_@?-*JHKIK2.3!362.@L0]F9J
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M^P;!Z.*_M?W,:\\@AM#3K!C6S?LHOA)L<OB9)N]* [CDDX9DG),X#7/OBT?
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M6[L(Y@U^Y1M/X$1^Z,X>BG&V'^CS?^"8$]@Z:O!\X$T.&ZC)YL* _N?9I%
M? :I*"&_?U,/4=^G<%OBK=WH#U4?1B#^R,X?G)=C(W6::V3:S.J,!O !:'=Q
M )'-PAZ-KO&@'=UV M4*4/3OL4/3ON.XCFK@M=KG[&3T2W&AH0 /KBP_9%</
M"'4NP/KBL<XGK..M.Z,)OZ'_ -#8B(C(YPW';?:YQY@]'I"K=?YO@X#@Q=H#
M8%#<P3W-3W,3^Z(X<YDV G4BS3TOU<<&V914?Z'ZT.*@7FD<WF O-V?-=(H1
M)SD.DIR@>J")>T3443/U\]-0Y!\PX@,C@S81YDM3"H8)SVY1QSOA^X;35*49
MMD02G" FSJ&%)%0"I94Q+D@EG)T+18;^A]]"_, F>YP$Y$NQ*;V:Q("5$4DT
M>R+M50Y4A0221%,-BBDF0@ARE* 7'!ZQ#.7-?4@9]FYHXE?#?PPF57,LBLAS
MK-.50, .9-"*,&P@,P>KQ:?^A]-#BIN?Q_.!MU17 3W6(,;MA,)C+;FJ!Q[4
M5!,<5.83B81-ON/$_%NQ*#X9@?0X0>L&O;%D_#?PO2 ./LJ6R2+,L = 4LJ'
M6=:4BT_]#WZ$S@<5GN;S'5)V:PC=XC<Z8J"IR'#V*DYB"<>T$HEV$XB<0$PB
M89^*UW&I15B"2)9)W9OW ;7BW[>W#)!I-L:@,\5GFNK\8!>&F0;8-8L-_0^N
MA@IC 24S>4!!,!YL@Q*9A!),B:?,4:MO]#(0A$]]^4A2 78H  2.#%A 8))&
ME4C?DX:N[?%Q\.G"\N<5D3BS";-.8T(TF %P2]-2-3%I?Z'IT*G+S>/YM$#$
M[(>6\Q!RBF4@H@GS!4A Q 3^A\FXE FZ>W*&W$'@U8]@;>2?8XC,_#EPP<M-
ML@!TY,1VXB59DFI.9:D5-_0]&A(RA%%)'.(JIB82'&\P8G3$Y>4PD,I3#J$$
MY/-,('\X.@^;L 9*X.("B)99%&#[JYD:O&*OAJX7+45F98W+5Y+.>@;-$P)R
M&@&^KQ@_]'DT)$'Z')9O(7F3. !?(0@ =(IB)G "4], ,F4QRD,!0$I3& !V
M,.X<'D@5).UBFO40HGMBR?ALX7I8XK,1^(M"2V7-6O$&RJ=I%#&/_P!'FT&@
M8IC2V<2G*<IR[9 A2B10@*%3.0/8EN4Q2K+ 4P;#]&5Y1#M#\P\'DD>+?.!W
M =<%_#EPQYH$VS(&P2@H&IH[DEZYG:,A&'_T=W0:!0$C_-XHE#8I29 B0V*7
MIL0"5/D  Z@  4"@&WP45P9DJS2D@9 A#/D]4N*/J:[HV'PY\,L!2%68 @8B
ME!22#5R$3$@]8J!4QZTZ2],F.M(6$X'!F*C6 ]*KLI892.-9Y)&6F3.+)+N9
MN1%P^08QR:J8/GBX-R@T3%-$")F,H)1.;WKML2;!9S(2P!F+F,& &()% *9)
M#[W,?F?"7A)>/"J\4WG>92JTILTNR@I##BY2YJT:ER\U3FG1$DQ*4>\I1^V
M#^/COCP'(R)'7%.0GN"_<A\G$,-@[!!SM/:8.0GN2_<A\G#"DYI!ZA!R<R3U
MQ04TQ[R$'[92C_-PPI]$=@@Y 8$@',.6[(T%3@550NP !0+L   ?N 'IM\.^
MP>K@PV#L$')H%$;:LQ)_R,:AER@'0JFX[^=YNX]>X3&-S;AMZO1L'3;:O,=B
M$OL(!S'0VO3&@D%0!*MN9+YZFCQG3,F8@#R@;??SCI'.8=A$.IBJ;#MW!MW
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M%VSI[CO]L:S;):Y4E,]<A24*)"2H$.Q+MV'0;"S572+L[E/<@B43% VXG,
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MV=6?>/\ ^N<,>CI]9;BQ0_W2^I1&7O6/*'"FS-2XK U<I4H#,Y##2+RZ-;Z
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M03:/N9-N3?D7*7CH58"H,H$BBDAQF0U"YS)9P:1^C6*\;LD6!<N8N4N>FSR
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MFI90;86R?6@B/1=&V0E0%0VMS5J8QS'$1&:PL/43FW /[!K0 *'<4"MTR%*
M 3G(!3FSXI)JIR=2_P!0CZ5'"6R)2$IN6PK <!2I$M!54N2D4%79J$5&<7AH
MUR& ;!K<U; 'J":PN ?R+<.)1O[8GXRV7[Q7?^:E^$4^8UR']FYJU_\ YUA?
M]2W$\4G:KUC#XRV3[PW?^9E^$7!HUR" ?MV=6@^^,UAG?\&& #\'$<4GTE^M
M]43\9K+]X;N_,2O"&K0K64,&ZL].V/EM0N;LLU'*-8SB^LD-D=Y0Y)BU>4B%
MI3^"\10I^-*X^(=524>;"Z?J;***BERE4Y.,E2U!5%+*7%'-,GRS?)R*:9$C
MN,^QWCP>ONVFZ[%)F6==C$O!9I6)&.9@.%82""0"5@*#I4D$*<"&\;4W-&HS
M6;K)H@:N=1N&*1A-]@.#HM4PV_QS$LD4+QBMC;YIY(*7W#]T([7=2Q9)919"
M6>KD3.5L)VI44F+;,RUXB,:@ PS4#IO-6+Z=)UX)DZQ6*[;LG&PV.9,FRYRE
ME4B47PSY@!8("B "D @%(2FI#!)>M+0=DM1-,X>$3UWF 2%V,6QX$$# !0+S
MB*FG0QA,?;F,(#R"81%, 3$H!LB40D.7.TE5:])[=<XX1?UG%$W78B'+$V>2
MY#D^AELW1D^8,R9_RB>O'[X\ _\ _.?$\3T=JH>7Y'WJL/\ 1Y/T(T5-"N3V
MBX."^$2UUK=@Y9K[.K3IW!$!(<@BR,B33Y$\S9T4H"OX\]6=CVAP:*HH]DFG
MB;(\Q2P6Q-E7( 4H^G>2"*".:?>DB>ZN329+YH1+2E"6 % E+58J)9B27>/0
M:):/F,4SCE9*1D5F;!G&*R3\4S2+Y=N5$AY=]V;9FV[=WR]HZ.V:(-3+JJ&;
M)E1,3;K0D)2$D!P[ER'%2S@..G1]<X\J8J6M>,<T&K,,GPM36CL6H=]/"74U
M1-3U@UGJ:KJMA&Q2L%IZRY@RC464;R:CBX2F%SP\C!:BW%)H#5BHK/Q=S4SW
M(>4)))VFNF]T_-"*E5381P(>;:$6@S5*0"4C"Q!+, EPVO.\ZC9AF$?;W3/N
MM-W2K/.7+QX9V+FA1"U3%*0023A4$,I() -%><.<A@QIJ1MLVAC%]2,V'0KT
MQX4.(N<E8FEUA:?<(W,4W.3VGYO#3\BNUB;1'34*XA%:_'P7C/L"=L25EL5H
M]BS@& EVHAF62Q!\[IU.X.&H^$.['N3;+JE**T<0$' 00E) 3C=1YJ20,))*
MG.14<*026UF\2YO:8$PQ 5G$>H86D;H#9T; M?J$%E2IN\7ZYFTN1@^LUR9.
M)6%>T^-D9%Y5U*M?;4Q+!0<!%V92)L4?'3RC8]%IM8=A,\T, 2P5BK5S0U<
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M=:G!RK],56+";M$9%KO (&VS9!TY37..P!YI2)@8?.\\! PW1)4IFQ=;D]E
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MCON "#"G/"'VL-,NQA#$KTC3*IBA6[<FP$01(!2@0O*D0NQ    @;%#8H
M!0Z  !TZ<3 J4<U$]))]L7"BD(&**28E,/,8HD+L8W?N8-MA'?KN.X\(B $D
MB[\J:9=S'..Q"AN=0PG.8=@^F.<QCG-WF,83"(B(CPA&$Y""*QA*7F^A]>4-
M^H  ]=M^H=/M<(C/$]:_,(T71";*>87^UC&^E#Z;LPZ]W?U'KW]1]?!7FDZ\
MZNM &[-(TDTF4I094S56//CP>G]TWA$ ] >$.R0 >\ 8#TV@ !Z@ .@!W ''
M)9B2JU.2?^TC.O\ \M9X^FX49<'_ /V]9SUF\;S)/6:F/1P3@!P*(=Y=]_M;
M^C[0#\G'7'RT1NU(?1:Y%\N_.G+)F*??;L]TR@._?Z^;;TB(;]-^&S?]?@_1
M&LJ8A&(JS24D;_FH[YCNCP;9:1KXAK"=:BGN5EUZBLT\6;44GE[<_8LVK%:!
M5 @!%>2$'+5;(#KL Y07;*]J';]H/'SEHL<R9;5S$D%*RA@0&HE(V[LJU&K$
M1^N#A_<UGX%R+F5(*[<F:M,Q1U,V=,FH((T$N8@-56C@5CV5TIIB,KD8"G$"
ME:T\0 ^P 8IC6\Q 2Z]&^W]J^D6XI;CU'CW94I<H!)5DG)G\X$UKO Z!39'X
MLW&6J?."0A*IF)*:Y$J<9;7.N><+'53O[%<9[]1]O;#>_I_]>(CT\:G+K3[1
M'U'![]\3?R,SV1)@O]KH_P"2G_(1XF/"F_OD_E9GZQCL%[A_QC_EFX1F,NM7
MM,(B[6!C6(:5E'JY42(LW"Q2)!N]74*W*01:?0'(^-$( =@ ,)'<Q0^A#U(!
MVZLO"NT^]8GN?6HV:C9VY1\,MF\!11,CYEK=<PAD/4;5[7?[#:92R63(GM9Q
ML/ -6LBW?3)(P)B9Q%D:QKL74G#.H\:K1ITC9C+-FIEW0HB[70B<FKOP._A)
M[OEZ7R3I/\(7)8EJ+>C8[K54Q\?)V<,:IQT=4J;6ZF!5'5.2L[)VI*.X%>8<
M)NV9^5:0,FN05BJD 10]&73MR&S8[B(&RFX[]6%6U[#N>9FBO#.O73SA8E U
M99LFLX9?L.3)QZC=$[\ZN%?K]"80S!%I"2DG<*_ R+YG(R*0N3B]JCLZ*RRC
M=-<R22:I^6;.P30'/-8]H!TKXN XI%%(6HD TT%=CUH7J-K,X:D1?U?:0]1>
MI>S,\XS>2F&.:]BJ+D:38*KD1@!&%K;KVRQ3#B9J#VLN+FU5CE63N"B.9A6:
MS8RC"'3;E.FF5RMZ]AM02IADV8H=M?8#UY9^5>-BFK0S!W!#9OT!\P'(<4T<
M$1*'P/&C_4CAFUY R!J,>5Z11L<9738W3JZK]:#3@U"'\J2C0THDA(E5N4J2
MNVM]X\BB\"2AW(.DRK%,7C.U*"YTQ=:X3DV24AW=S6)NV09*$(4#S<1=]JE$
M-M&1))+L0YJ(^A-J'*")>?M!!,H"IW]H()]5-QZ^>/G=>O7J(]_'-'L1NE[A
M_P 8_P"6;A"+N$(.$(.$(^3SPU'A6[YHQUDUK%%2J]3O=??8AKLM.H*1D38I
MVO3:L](/31#EFYG62T:,E N64D@95ND)VSQ%<@*)J$4,_P O?7=MZH?Y[>JO
M^5>F(M:6/"&:U-=\G.$P7@R!:1='(S;/Y&QLVT%%D4GENTBD?'FMJ["2*BP:
M-6QDB%'L!2%H(=HD< @^.T^_0,^V(KT^_1M;,ZU-(G19Y'PMKZ*?M38RTWUU
M=X<':+Q56(AU!%YRNBJ*&<VKMI(Q@4!01/T, @!1[/EX9-T.P'0Q'S#7JB:Y
MYUW5W$DZ$DZ-KOB]:9?PW&-V]JR"O!:?[C#U:M+S#6MUNI5]:T2RS-N 1L?&
M+!:1[5+MTY@ZIP .8W,8._I-,N[WZ8@;G ?=4UZ2]#L--T-YH8UL^$BUAT:]
M7_'^(L!+5RAY"EJ9*L;,,!69)&4BJ_$2ZD>]WM!!158JRRC(!Z *2":G<;<(
MH*;M'R'1EG#-NK4#4 9D;=-G;]&7@_K7J!E&&0(?43CG'.-[$P=0_L?88^NS
M>RM+!&H'D4WLH6,:NWZ#,&CLBS54"NC@==)50Y2',8B<C6NN1Z\J.W7L:D2U
M0,J9N3T/5GW]+FD>EJ)N9(A@.4X" B4Y>XQ-QY!V] \NW,'H-N'HX0C+PA!P
MA!PA!PA$*O"#:B9W23I!SWJ/JU?96BR8LI9YV'@90'WDU\^5>L89)1T,>/C'
M9I^6P P%V$0((=VX@T.E-WS_ #>QX;-0^]M<^EOK<1\FV'_Z)1UW7&PQD]9M
M'T=D/&"<TZB[&]PG!7IU/1GT(2'\2F9QO*03.1:F(=$4TT(XAQ3-VJ@JF.J?
MH1*"D G,O[2#ET=&>V)WMO[V;/Z^P&%9K'\/#0-2NGVZ:?5\-ZB:"YR"]K\;
M)3-IJ51(Q91]6LT);5D5BP3AW.F62"&$CI5585%W)55B$23.1(MC* J!EHY)
MZ1H^0R(#;:A7>U-K#9V^T[(<CP)EZP];M6%$B<7+3,M,Q=0O\K9))W4[9"H)
M5@*H>.=%&8D1\7??U?EJVF;S.1 Y3-@_8B@/.L,HOFPT;, F(9MW>_\ GG\Y
MU^R-L7E03#E*7<!/L78 W.83B/3<-S"83#Z1$1$>O%84TRC/PA!PA'-<_LI_
M\5/\H.)T/2/8J!S3^*K]:(L8F_OJ:J_W\UO^1S'_ !R'[8?Q4_JIC[J\?X)X
M+_E)O]K*A#>#6_:3Z>_WGA_X@_XVE?:T]?ZQCEX=_P 9+3^1LW]WD1.Y']B2
M_P";)^2'&D?'QDX0@X0@X0@X0@X0@X0@X0@X0@X0@X0@X0@X0@X0@X0@X0@X
M0CS_ ,Z?MZ=$W[U=4?\ JOC[CBG?OB7T'_AC[&Z/XLW]^5NW^VGPA]+7[?7P
MF7[XM*7\@S;BTK]]G\1'ZJ8PO?\ @*Y/R=N_O$R/3!K_ &NG_P!?\LW'1+\P
M=*OUC'RZ_/5^,KVF-CB\5@X0@X0@X0@X0@X0@X0@X0@X0@X0@X0@X0@X0C6-
MWN/MI?B+Q)R3T?.8@9JZ?F$:3KZ57_)3?]V7B%>8?YWL$61Y_4/^*//;P>G]
MT_A$?^D/R3_()IMXX['G:?\ S _NUFCZCA1EP?\ _;UG_P#R-YQZ.A].;_%+
M^,_'9'RT-7D_':61XTD0M8)J *BY3<@M$MX)10X%*0!Y33$/))B(>HQ3 !@
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MI_BQ?OY:[_[6="*TM?M]/":_OCTI?R#MN+6;]]3_ /[?ZJ(Y+U_@*X_R5O\
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MS:N0 .F;UI6',Q%ILRB[D%;/=GKR->O5?&73==+L%$S <2D1.D&X%Y4"ID(
M!L8H )C!S /&X2$L0 'SZG IW5SS>!?7IR=P<]<\ZUV$4B?56ICB"*B51T94
MA2 4!4#;?J!QW$1'T[[>L-O7TL3O<D5<=&_=N&P#1F7/2&)S+BKC?OZ=8<X
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M%=H;7=U[MF[:'(K&3\77(_\ 6AD>A6XQP 0+7;C79T1* <O,DM'KNEU=C (
M';G,F.Z0 7L^0MX/L-"U.CV^^4.<AMV1=A,8/.V$X' WTP_5//Y0[BB/02@
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M3AFKEL!W9M'S=3O@-L'3V"F&#G.8<K)0<;EE'+R,T3V&>72R+FGI4ETS;=E
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MQ2D5C]IC).4?2$RHU>J.[B>UB=K<+ R0#^ES5X2 P:IF%+EW[0P"H9[^_OE
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M3U[<^Z*G,U)#]>535O$[=GTQ0CH7L4R=&$PG72%0XF 0'M!.?M.]!L)@ X&
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MD+*-6K5HZ09HW ST.FT.:@48@9:/713QX\R]9!4600DETH)*D@.2G$2*J65
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MC02SA8D#,5SSW$U8UJ*@U.<51PFD2U%0LQ!6!C!\T,"ETL 2^)P]&#'"2F)
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M!C$*/!XB(V7PB/-R[AX1#)9?-+R@($P-IN( [>L0* F']T81-Z>.6R^=:_\
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MC^)2E;G#1*R#.G)1[TK]K3TG*E[@%%CPK"PF2QMRV'8 7TK7;0BM(H),P>:
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M-,QSTGC5'EE'"(#-0J@E6.VV0,<G4!$@  $+N/G ?;IEB64 J9ZN"0^9-:[
MX#%]T8J3SG:O;H!1CO9P3H*@!^H62S&^.8C#37G)XL!CCS.:\C"MS#S"( #J
M9GV8$Y=^0W:-4^4Q1 H'( '/HZ!DI(9J. 2>AP3JU6+U;.(PL* U.M -:5US
MT&>8RY;:,U,(V.;ECZ7<D%:OH:O,4 4G*4HH'D5U9'YN8R=J$HF$[X1Y0W$
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ML7C;X0@X0A@\_0>8;#5&;3",O3X6Z,[+#OBN;NSD'L">-(5;MP<(QH@X%3F
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M?Y0<3H>D>Q4#FG\57ZT18Q-_?4U5_OYK?\CF/^.0_;#^*G]5,?=7C_!/!?\
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M#@ Y=@  #D-T#H'51'U<(1Y79*LZC/(MWC46*SM-"W6('1BAYJ7:RSI8HAN
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M9D]3D VFE)HR$K6WTKDU_$5]P++=SY47I%.K"\N ;"$M-NP*42<HAD]>@.Y
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M&V?VRHF)FRQW.GXER1;L=0"5JOE6I%GL%2K"G_K+.1$6K)Q\"7KT\K.F*$8
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MLU7?-D7*;49 Z!UA(=%FEL0\@8H]/H1BB0.H!L4!WZ"'#W]GB(D)40X!(=J
MYPUF05<3V2.)$9 <U5_#"[:ODDYV08$3\=;MT7+5V@"WG 9!!^D[\X=]Y$HE
MZ<H\1B -3EH7._W ]KQT(NZT3T8TR2I)J%-Z*E)9\BR@7!=J.P(!2L+C/3RD
M(P\93Z"\4@R"88LQ8F6&.(8?&!!5!<!3:$("O.3IU3$IS!N/2,:037KTRWY=
M@;=$^3)X )EK2*4*5NYT( *G)(%6?VJJ/=XDBHP\S%DQ^QAS/2QXRS5&$:QP
M2B1Q; W.\;&!!9=N=+Q7E((=DHD*1P[1,W#%L!W4-12HSTKED#$FPS4'"0Q
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M<VS:NUI-DFA.+!2M30"CT[&+. IP6(,*IF)3-DS%Y-C 8?,*4I0,)S"8!*0
M*!P-N"FP?L@&WZ[\3X#ZNZ,%)*5%)#$&O3J>O.-GA$0<(0<(1S7/[*?_ !4_
MR@XG0](]BH'-/XJOUHBQB;^^IJK_ '\UO^1S'_'(?MA_%3^JF/NKQ_@G@O\
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MGO%\MD+V,*0+J,:.V;B6K-G5DS"":V*;Q'!%Y'9LB@ E"3,BV@Y!(PB'FQQ
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M"5@L*S3-3%8R;2*5<5;+>9;G)J\W,HG$7A[E]W7#IFV\Y\(6J&&5#8 "2%V
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MI"]U03='.C>)QLE"360LH:8;EAR5.D&Y&,W7*MC?(9$UT ,W@DY,KAN'8S!
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M'-5EM:K6)!L>"BYF:"#FW R*CB@(M@G25"YOHR)3;%L\:45)*[R=#@&P=LW
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M4T"@E9QF46YW::)5$2)';))-S()D1(?7WS;+I);1SJ\/\AR]D3EWY=AY>;F
M=MQV^FW';W.P\G+MV?T/EX0C+PA'-<_LI_\ %3_*#B=#TCV*B-1T'VIB*F)?
M[[.JS]_-3_D?HW'(O[<>K]41]U>?\$<%_P >T?VDB$)X-;]I)I^_>2C_ /Y[
M[C63Y@Z/^)<8<._XPVG\G9O[M(B>*:A"II@(["":?H'W #Z XUCXV+^U3]U^
M WR<(0=JG[K\!ODX0@[5/W7X#?)PA!VJ?NOP&^3A"#M4_=?@-\G"$':I^Z_
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M_P (/9![:>H#[%JW_P ).'OTPX8Y_P B/73XQ'D/@?\ Z;2_ZCOC_"0>VGJ
M^Q:M_P#"3A[],.&.?\B/73XP\A\#_P#3:7_4=\?X2*AE74"&W_!:MVW^<K$'
M\UR#\ ?AX8Y_R0'\Y)_XA$^0^!S?QVEO_P"AWS[.1_/%?;5U >C2U;0#U>V-
MATWX37+F'X?M!TXC':/DD^L/I0\B\$!__-4?U+?([N1GVP>VKJ VZ:6K;OZP
MR1A\OQE"Y 7XOM^OB0N?K*'4I/TJ=_5#R)P.)KPVEC_^B7R>_D?S13VU=0(]
M!TM6X0]/]DG$'Z9\,<_Y(>ND_P#$'[HGR'P-_P!-I?3Y$OEO[D\4]M//_P!B
MS;_X2L/#^.XB/#'/^2!_GI'=B/MBOD/@=_IM+_J.^?\ "0>VGJ ^Q:M_\).'
MOTPX8Y_R(]=/C#R'P/\ ]-I?]1WQ_A(/;3U ?8M6_P#A)P]^F'#'/^1'KI\8
M>0^!_P#IM+_J.^/\)![:>H#[%JW_ ,).'OTPX8Y_R(]=/C#R'P/_ --I?]1W
MQ_A(/;3U ?8M6_\ A)P]^F'#'/\ D1ZZ?&'D/@?_ *;2_P"H[X_PD'MIZ@/L
M6K?_  DX>_3#ACG_ "(]=/C#R'P/_P!-I?\ 4=\?X2#VT]0'V+5O_A)P]^F'
M#'/^1'KI\8>0^!_^FTO^H[X_PD'MJ:@ ZAI9M^_K')6(/Q!<@ /@X8Y_R0Z,
M2?;B^:)%Q\#M>&TOH\AWR_\ <R(K[:NH+[%JW?PDX@_3/B0N=K*[%)^E$^0^
M!O\ IM+_ *DOG_!17VU=0&W[5FW;^D?;*Q#O\/\ 7GM^'B,<Y_M0;\9+G]*G
M>^Z(\A\#G_CM+;_T.^?;R/YHI[:NH+[%JW?PDX@_3/ACG_(CUT^,3Y#X&_Z;
M2_ZDOG_!13VU-0 ]^EJW[_YR</?SW$1_#PQS_D1ZZ?&(-Q\#GIPVE_U'?/\
MA![(N]M74  =-+-NW]?ME8@W^':Y 'Q?+PQS_D@/YR3_ ,0;O@+CX':\-I?]
M1WS_ (0^R ,JZ@=^NEJW;?YRL0?IGPQS_D@/YR3_ ,0B3<? W3AM+_J2^?\
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M":OOL <C_P -FF[]:'#C)_R'^\1]*'Q>X ?ZPT?[-7W_ (*#YH35]]@#D?\
MALTW?K0X<9/^0_WB/I0^+W #_6&C_9J^_P#!0?-":OOL <C_ ,-FF[]:'#C)
M_P A_O$?2A\7N '^L-'^S5]_X*#YH35]]@#D?^&S3=^M#AQD_P"0_P!XCZ4/
MB]P _P!8:/\ 9J^_\%!\T)J^^P!R/_#9IN_6APXR?\A_O$?2A\7N '^L-'^S
M5]_X*#YH35]]@#D?^&S3=^M#AQD_Y#_>(^E#XO< /]8:/]FK[_P4'S0FK[[
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2J5.."5/DG&$X#BPA14E3?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g273090g81q04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g273090g81q04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1T.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '/*^=! X0DE-! 0      $0< 5H  QLE1QP"   " '\< E  "')R,CDS
M-S0Y' (% "--:6-R;W-O9G0@5V]R9" M($-O<F]N861O+2!3+30N9&]C>#A"
M24T$)0      $!S]"]^$2:OHKWJH@N'E"NLX0DE-!#H      .4    0
M 0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N
M=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M"W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4
M @ " [_^-0 "  (X0DE-!"8       X             /X   #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              ,B   '5@         !
M                          $             !U8   ,B
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   ,B     %)G:'1L
M;VYG   '5@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   #(@    !29VAT;&]N9P  !U8    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     4X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M2?U<7_N>/^WF_P#DDO5Q?^YX_P"WF_\ DD:'C]J.*7:/^(B&!UO8YKLH'?\
M2.XZ:!GM_1!WT&_X.RK]+^G4+*_K%4X;7^L0'.;!8&[@UVVNS<QKW>M?Z7T?
M3^ST[_TMJL>KB_\ <_\ \&;_ .22]7%_[G_^#-_\DA0[G[4\9ZQ@?\!>W SG
M6^LS).]E=;6:[=SV^JV[U/:^MC;FV_Z)_P"EKJL_P/IH3NG]6>6/=E$O:28#
MR&Z?S3=C:MMG\NQ__&>E_@43U<7_ +GC_MYO_DDO5Q?^YX_[>;_Y)&A_(H$I
M#M_BL68?6FVM?]I:6E[2\$DZ C0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(*J=4D+..E)!J[<E44_-IF21,!S@)2B(@(:I+;JP.L<UB")W^A225$9OL*S
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M8O5IN50!B*J3)FJ986Z0'73UU_>:E.!Y$FKSRI)'$85L1AP78*2R@LV$!+L
MN< ^'B/4/)UY$.,>.-_I[9=V7B/8-KM;7N.ZC>K'#NY/6>"G2L6:Z0/+%7@D
M;<)X4IUG,P5I95Y0[81H6W.](.%5R#AC%&W*^;9IN<R='SD_,7[)^34$<>52
M(C6C%Q"-7KBK/U' 2-P.]Y:\95<B;[J1*S1=<YSHP]QWOI3U:U";;W>P'=I[
M%@"")5"F,$Q$DO.S!8@2O.0>4-@C77^3CR$MN>P\7<3^4'9/*/1I<-STJ579
M.&^&W;?MTM6)IH[LD2;I L?F^U"'-X+&3 7S*\> KYZSN;L6XY"N0N6LK8NH
M]PF(]B88J=ND'7S2$@HDF1T:%9SL@T?N6!WO6D9G,F8YDP(!QZP# &Z>W7@Z
M:V;%>&1P/5>5(^9L#/('8$KGP/M&O$:/!_$G$'G]OA;AGB7>MJJSS@6J6SW;
MX@@5F:(6YJ5>6".<0A6E4, &YB!RXU$.Z#<)8L,R.V9"GLJ_-,<U[A:3B>;=
M27:W!&M:M$;,OEY2#68/&Z)I$HQR M%E^ULQ24.)D#\Q3!%W&])3.WB)4<6[
M\-5RV3B.57)9""/6]48SD8S\&NJ\G' FW\7P>45]UGOTY^#N!-YXGIQ5^G$9
M-QVRQ5A2M=2>&1N@>O()43I2AE&'7&-2!C6^W2Q94SM6+))8N<5>A3E694UK
M3K(:6N\<QE*XG)2A,HPYG"I:[)*OS&6@D"I-P=PXD="4P"!S9H)IGLW(Y#7,
M4+QK#TI.:4*T89O.%)^=MS?0@=BA!]^-!Q!LFT;?PWP5N5"OQ+'N.]T]SGW:
M7=MO%79K$U;<&K5CPW:$:'<*ZPCDNN6D$5L&,,/H1==:SEA>YV5[3*AEK&]I
MMT=UP/ZQ7KM7)F?9BW$2N <Q$?(N'Z/4" @MSH!U0@('Y>&LL=NK+(T45F"2
M5<\T<<T;N,>.55B1CV]NVH&X\&\7;1MT.\;KPOQ#MNU6.3H;E?V;<:E&7J?0
M=.W/7C@;G_W,.>;MC.1J4]2-<UIIIIIIIIIIIIIIIIIIK'7=W_XK&XS_ .Y'
M)_\ _3Y;4+<O^C[W_LEC_P"4^N]\EG_V2^ /_P \>'/_ /;5-6CL'_\ $JVM
M]PA_W#\>^?\ R>9<!_8(=X?"'?K%L_\ T5MW_L=?_P"6NMKY;O\ [+_E)_\
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MM?$,G[G^KQ-N44-:%8]OXLMUMCMWIEJLK1164M].Z59/4M'JL&?UCF7:]K^
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M1:(278I'@Y;N'A%W!52)F,H;JT^7;V:U>GO&RFK#'7,HMPR")%0/$L*LJL%
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M!\1CS/R)\<<7\0>7#<3NW$F]W89MN\H$WFD^Z77I0E-FW.6%8:AF\WBCKO#
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MJY0S+!MY-.[9?:5)E<W#F36<QSA"E1Z\9!!'QQR@E'F3:N%"N3)&'M)Q!0X
M;CQV$5."&U9MH&ZUI84E)8E>6 ,(PJ^"X#'./$G)UYEN?&.];OPSPYPE<DK'
M9^%9-TEVF..M''81]WG2Q=-BPOKV TL:F,/_ +,9 R-0EE'8?@+*EYGLCO$L
MA4:WV]DA'7B4Q3DJWXW+>F;9+LZ!+>RK$DR932Q&W!KVY9N5^=N!43NC$*4
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M4F::WE&[W,=]?9)NIG\FL_37L\BP9QSE:.35* 1S,S9B@!&:0F3(<#G >)N
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M3(QY1ZSDM\.MKN'E,XDW';^,-J:+9J6W<<;GM>[;W3VW:*M"NMO:"QJ>CHH
ML="#F9FE@@41NS,<+DZL7)>P;;WDZ[67(#MOD*E6&\I)(Y!-B[)MRQU&Y!(D
MD#<I[C$UF49,)AR=L'95GIT$GSA#BFNY4 1'6*?9J5B:2<]>%Y0!-YM9FKK,
M "/GJ1,JL<'!; 8CL21VUN^'?+=QUPYLVW;%%)L6\;?LKL^Q#B7AW:-_L[$7
M;G*[3;W&M+8J1"3YXD D:"-P"D:X U?TAM)P8[JV%:3'U,:U4]OUX@\A8R@:
MR^7B6,59*^C(),5WQ2=:K+(*C*/7$@F^555D':QW3M=5<QSFS-ME,QU(1%TX
MJ4Z6*Z1DHJR1A@I./HAZS$AL\S')SK1P>5#C.+<N,-XL;IZ1W3CK9;NP\1W=
MRA2U/:VZ^T#3)"6Y5K,HK0QP&%52")!''&J  5>.VSXA8S^=; YKQYQ3<<>)
M-E>)L+HTQ 3J,-7@J[1HC$.B"V9-#Q =4Y12 066'M F*J!3!>M"JKW',?/Y
M^5\Y20\\;A4Z87D;*A2O8C'?QU%L>4/BJ>CP51COBD/)\MH<+VJ$8J7J3V[Y
MW*65[49$DTHM'F1F^A0<F""W-"=*Z.G;-2++4K$A%W^SM<?2!);'E-ON3[K=
M:!0Y) 1["\K%.L$L\AV:\8 B6*.X1=C&ARF9]4=-,Y(D6QT(9(I L\@@;F@B
MFLSS00M[#'#([(I7Q7L>4X(\!CL=X\OGE$WC;MTH/9V/;9=]KM5W[=MDX<V?
M9]\WJN^.M#N.[4:L5N5+&!YR(WBZ_<2%E)!SIUM]>+Z:::::::::::::::::
M::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
M::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
M::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
M:::::::::::::::::::::::::::::::::::::::::::T"]-QN*SI@9]MZ)AK
M*=OQL6S-LB'GPJT@FR\+#%J5,L?VSK$%P4[(#UUU/  Y>O4^'7&<67;E,T_-
M;,M?G$Q<1,!SX,87FR#X9.,>_7W!^X\X!X*XVAX\;B[AG:N(FVY]A%'TG TW
MFHLC<^OTN61.7J]*+G\<\B^[6AO^D.WR?I2Y>_T\U_[.UQOIK>/JG;^[7\C7
MVO\ O#^1C_JSX4^12_ZC3^D.WR?I2Y>_T\U_[.T]-;Q]4[?W:_D:?O#^1C_J
MSX4^12_ZC4U;?]U72[Y7R1&R&V_/1;Z]H149Z^T?-TY#GIEFJ[M\U:$CE!=0
M3AZBX7<)J(]LAG4;)LDU161=\O,F;9;9NV]O.66Y+.L:AGCG*,K L   0I![
MGN#X?'KY]_=#>2?R3<.\/;)/0X3VOA^6]N-NGYSL\4U>=F6F)D+E9)0PB9,J
MKJR'F)96[JWJ(B-U>75XJ,6F-OD5'2ZL>S4E6#?+C=XW92)VZ9GK1N[)1@*Z
M1;N1522<E H+IE*H!0YN =D-\DP,T6S@9Q83&?;_ +FOAIO)]MX8\O$X*Y/*
M3L\P)7V9 ND X\0#@'(U4/=39,]!$?ZU$OL-JOIQ_I%OE"?D:M_>^H?7,OWH
MF_UFGNILF>@B/]:B7V&T]./](M\H3\C3][ZA]<R_>B;_ %FGNILF>@B/]:B7
MV&T]./\ 2+?*$_(T_>^H?7,OWHF_UFGNILF>@B/]:B7V&T]./](M\H3\C3][
MZA]<R_>B;_6:>ZFR9Z"(_P!:B7V&T]./](M\H3\C3][ZA]<R_>B;_6:>ZFR9
MZ"(_UJ)?8;3TX_TBWRA/R-/WOJ'US+]Z)O\ 6:>ZFR9Z"(_UJ)?8;3TX_P!(
MM\H3\C3][ZA]<R_>B;_6:>ZFR9Z"(_UJ)?8;3TX_TBWRA/R-/WOJ'US+]Z)O
M]9I[J;)GH(C_ %J)?8;3TX_TBWRA/R-/WOJ'US+]Z)O]9I[J;)GH(C_6HE]A
MM/3C_2+?*$_(T_>^H?7,OWHF_P!9I[J;)GH(C_6HE]AM/3C_ $BWRA/R-/WO
MJ'US+]Z)O]9I[J;)GH(C_6HE]AM/3C_2+?*$_(T_>^H?7,OWHF_UFGNILF>@
MB/\ 6HE]AM/3C_2+?*$_(T_>^H?7,OWHF_UFGNILF>@B/]:B7V&T]./](M\H
M3\C3][ZA]<R_>B;_ %FGNILF>@B/]:B7V&T]./\ 2+?*$_(T_>^H?7,OWHF_
MUFGNILF>@B/]:B7V&T]./](M\H3\C3][ZA]<R_>B;_6:>ZFR9Z"(_P!:B7V&
MT]./](M\H3\C3][ZA]<R_>B;_6:>ZFR9Z"(_UJ)?8;3TX_TBWRA/R-/WOJ'U
MS+]Z)O\ 6:>ZFR9Z"(_UJ)?8;3TX_P!(M\H3\C3][ZA]<R_>B;_6:>ZFR9Z"
M(_UJ)?8;3TX_TBWRA/R-/WOJ'US+]Z)O]9I[J;)GH(C_ %J)?8;3TX_TBWRA
M/R-/WOJ'US+]Z)O]9I[J;)GH(C_6HE]AM/3C_2+?*$_(T_>^H?7,OWHF_P!9
MI[J;)GH(C_6HE]AM/3C_ $BWRA/R-/WOJ'US+]Z)O]9I[J;)GH(C_6HE]AM/
M3C_2+?*$_(T_>^H?7,OWHF_UFGNILF>@B/\ 6HE]AM/3C_2+?*$_(T_>^H?7
M,OWHF_UFGNILF>@B/]:B7V&T]./](M\H3\C3][ZA]<R_>B;_ %FGNILF>@B/
M]:B7V&T]./\ 2+?*$_(T_>^H?7,OWHF_UFGNILF>@B/]:B7V&T]./](M\H3\
MC3][ZA]<R_>B;_6:>ZFR9Z"(_P!:B7V&T]./](M\H3\C3][ZA]<R_>B;_6:>
MZFR9Z"(_UJ)?8;3TX_TBWRA/R-/WOJ'US+]Z)O\ 6:>ZFR9Z"(_UJ)?8;3TX
M_P!(M\H3\C3][ZA]<R_>B;_6:>ZFR9Z"(_UJ)?8;3TX_TBWRA/R-/WOJ'US+
M]Z)O]9I[J;)GH(C_ %J)?8;3TX_TBWRA/R-/WOJ'US+]Z)O]9I[J;)GH(C_6
MHE]AM/3C_2+?*$_(T_>^H?7,OWHF_P!9I[J;)GH(C_6HE]AM/3C_ $BWRA/R
M-/WOJ'US+]Z)O]9I[J;)GH(C_6HE]AM/3C_2+?*$_(T_>^H?7,OWHF_UFGNI
MLF>@B/\ 6HE]AM/3C_2+?*$_(T_>^H?7,OWHF_UFGNILF>@B/]:B7V&T]./]
M(M\H3\C3][ZA]<R_>B;_ %FGNILF>@B/]:B7V&T]./\ 2+?*$_(T_>^H?7,O
MWHF_UFGNILF>@B/]:B7V&T]./](M\H3\C3][ZA]<R_>B;_6:>ZFR9Z"(_P!:
MB7V&T]./](M\H3\C3][ZA]<R_>B;_6:>ZFR9Z"(_UJ)?8;3TX_TBWRA/R-/W
MOJ'US+]Z)O\ 6:>ZFR9Z"(_UJ)?8;3TX_P!(M\H3\C3][ZA]<R_>B;_6:>ZF
MR9Z"(_UJ)?8;3TX_TBWRA/R-/WOJ'US+]Z)O]9I[J;)GH(C_ %J)?8;3TX_T
MBWRA/R-/WOJ'US+]Z)O]9I[J;)GH(C_6HE]AM/3C_2+?*$_(T_>^H?7,OWHF
M_P!9I[J;)GH(C_6HE]AM/3C_ $BWRA/R-/WOJ'US+]Z)O]9I[J;)GH(C_6HE
M]AM/3C_2+?*$_(T_>^H?7,OWHF_UFGNILF>@B/\ 6HE]AM/3C_2+?*$_(T_>
M^H?7,OWHF_UFGNILF>@B/]:B7V&T]./](M\H3\C3][ZA]<R_>B;_ %FGNILF
M>@B/]:B7V&T]./\ 2+?*$_(T_>^H?7,OWHF_UFGNILF>@B/]:B7V&T]./](M
M\H3\C3][ZA]<R_>B;_6:>ZFR9Z"(_P!:B7V&T]./](M\H3\C3][ZA]<R_>B;
M_6:>ZFR9Z"(_UJ)?8;3TX_TBWRA/R-/WOJ'US+]Z)O\ 6:>ZFR9Z"(_UJ)?8
M;3TX_P!(M\H3\C3][ZA]<R_>B;_6:>ZFR9Z"(_UJ)?8;3TX_TBWRA/R-/WOJ
M'US+]Z)O]9I[J;)GH(C_ %J)?8;3TX_TBWRA/R-/WOJ'US+]Z)O]9I[J;)GH
M(C_6HE]AM/3C_2+?*$_(T_>^H?7,OWHF_P!9I[J;)GH(C_6HE]AM/3C_ $BW
MRA/R-/WOJ'US+]Z)O]9I[J;)GH(C_6HE]AM/3C_2+?*$_(T_>^H?7,OWHF_U
MFGNILF>@B/\ 6HE]AM/3C_2+?*$_(T_>^H?7,OWHF_UFGNILF>@B/]:B7V&T
M]./](M\H3\C3][ZA]<R_>B;_ %FGNILF>@B/]:B7V&T]./\ 2+?*$_(T_>^H
M?7,OWHF_UFGNILF>@B/]:B7V&T]./](M\H3\C3][ZA]<R_>B;_6:>ZFR9Z"(
M_P!:B7V&T]./](M\H3\C3][ZA]<R_>B;_6:>ZFR9Z"(_UJ)?8;3TX_TBWRA/
MR-/WOJ'US+]Z)O\ 6:>ZFR9Z"(_UJ)?8;3TX_P!(M\H3\C3][ZA]<R_>B;_6
M:X%MUV2$ XGP.RX ''B3*: _ZZ/_ -6GIUAXTF _[]#_ /@=OLG61?)U2;_\
MIXQ]G:91_P#]FKDQYNZ@['98VGWZFR^-)J=>)QU>D'<I'6&I3$HN8Q6T,6P,
M"M%HR8>&*)&+2<B8Q"16,1I'.W;Y1-J.>IO5>S*('1Z\C'"<[(R.?YH=3V8Y
M[*RC/LSC6MWKR>[CME*3<:-ROO%.!.I:\WCE@MUHAXS/6DYA) H[R2033=(>
MM*J*"VLO];G7G^FFFO,]^$)?^$-KW_HF4O\ I:3K@^-/&C_V9_\ XHM?H=^X
M4_V'E(_[SAK_ .'=]>;C7!Z_0+3337H@Z#S#[QW7\X9;?-!)'2LE7L?0:ZI#
M@5TI#IN)^?.@80Y5"(*24,@<Q0'E5!0@CQ*8 [+A>GSQVK# \K%(5[=B5)9_
M?@#*C./$$>\Z^#OW9?%<45W@OA6&0&Q7KW]]NHK>M&MMHZ-$/X\O42O;<#VK
MAL %<;ZO$QO\FG[?JZZOS1/</C_5KXC]*O[S]WIXF-_DT_;]73S1/</C_5IZ
M5?WG[O3Q,;_)I^WZNGFB>X?'^K3TJ_O/W>GB8W^33]OU=/-$]P^/]6GI5_>?
MN]/$QO\ )I^WZNGFB>X?'^K3TJ_O/W>GB8W^33]OU=/-$]P^/]6GI5_>?N]/
M$QO\FG[?JZ>:)[A\?ZM/2K^\_=Z>)C?Y-/V_5T\T3W#X_P!6GI5_>?N]/$QO
M\FG[?JZ>:)[A\?ZM/2K^\_=Z>)C?Y-/V_5T\T3W#X_U:>E7]Y^[T\3&_R:?M
M^KIYHGN'Q_JT]*O[S]WIXF-_DT_;]73S1/</C_5IZ5?WG[O3Q,;_ ":?M^KI
MYHGN'Q_JT]*O[S]WIXF-_DT_;]73S1/</C_5IZ5?WG[O3Q,;_)I^WZNGFB>X
M?'^K3TJ_O/W>GB8W^33]OU=/-$]P^/\ 5IZ5?WG[O3Q,;_)I^WZNGFB>X?'^
MK3TJ_O/W>GB8W^33]OU=/-$]P^/]6GI5_>?N]/$QO\FG[?JZ>:)[A\?ZM/2K
M^\_=Z>)C?Y-/V_5T\T3W#X_U:>E7]Y^[T\3&_P FG[?JZ>:)[A\?ZM/2K^\_
M=Z>)C?Y-/V_5T\T3W#X_U:>E7]Y^[T\3&_R:?M^KIYHGN'Q_JT]*O[S]WIXF
M-_DT_;]73S1/</C_ %:>E7]Y^[T\3&_R:?M^KIYHGN'Q_JT]*O[S]WIXF-_D
MT_;]73S1/</C_5IZ5?WG[O3Q,;_)I^WZNGFB>X?'^K3TJ_O/W>GB8W^33]OU
M=/-$]P^/]6GI5_>?N]?0I;<QBE!)/B80* #Q#B(CP .(E .\?A'3S1/</V^U
MJAW9@"23@#/T6?P#O\0.L $ND3V&KY!+BI+.#,U_/:2TLM<"A9/!P-C--A7"
ML1=&I0,"HC-"#$)$SH(SG_.=LZC\YK5>D-H,O0\Y7K<W)T^G-S<_-R8STN7'
M-ZO-G&<9('<=^W G'J[>=U.Q2^CQ6-LV3N.U<H@$'G)?D%\R9Z/K\G)U/]WD
MYL [ 34A,AN4R!2F$PE !*;O,'G .!/RO\W'N[PUM?-%[97&<?MV'L^T/AUY
M\-X)&0^1XGU\X^R!X?;U95[D*#C&,BYB_P!@B*K&S=FKM,AG,JHHEX6M=MDD
MHBMU^.2(D=9W)S$BL1NT;(IF,;@HJ?D1154)CEBKP -*RHK.D:ELCF=SRHH]
M4Y9CVP,^!SX'4ZA/?W22:+;Z\UN2"K8NSK"0W1IU(S+9LRL2 D4,8YG8GV@#
M)8 WF%+0$PE!$@F#CQ  $1#AY^( 4?\ K#]>LGFJ9QR]QD8'CV^U[?9GQU#.
M[L!DM@'VE\#[.3C&?9G&=0YE3)>',*2M @LE6A&OSN4[$>JT"$0A;%/S%EFD
M$DEW:+.,K<1+O4FD>W61<2<J\0;Q<8@H1=^\;I")PCS>:UVB29@CSOTXDY69
MG<>( 16.%'=CX*.Y(UN-JK[QO4.X3[96:Q!M586MPG-FM7@JPL2J-)+9FA0O
M(RLL42%Y9&4JB,>VOUAC).'MPT//6+#=G2N]?K=A>U:2G&4+8H^)4F8]0Z3Q
M*'D)J'C6MA9H+)*H#+0*LE$F<)*H$>F53.0%<5;:N]9NJJ.8RRJX4L,Y"LRJ
M& P067*]L!L]M4WJ#=^'IJ];>:S4+%FNEJ."2S6DE$,@#(94@FE:N[!@>C8$
M4P!!,>"#J3)Z%B*U S5FF"JHPU?BY"9E5VD?(2CA&/BVJSQZHA'1;1Y)/W!&
MZ"ADF+!HY?.E *@U;K+G(F;,U>-$:1E/(BEF(4G 49/J@<Q./  $DX UK:^X
MRVK$-6$AIK$L<$2--'$&DE8)&"\SQQQJS$ R2.D:]RS* 2/Q6XB&MM>@[3!$
M7<0MCB8^<B5W4;)13I6-E&J3QFHZBY5FRE(UP=NLF99C),VCYH<3(.VR*Y#I
ME)6CD571"4=0RGE*GE89&58 @X\00"/ Z6=PFJ69ZD[*D]::2"5!8BD"R1,4
M<+)$[Q2*&4X>)WC8#F1F7!U60I*1@ Q4"B4?,(%.(#^P0)PU=YHO\W/P^S_+
M/M]VL)W<CQ<#[,@_'K\^)K;Y-/V_5T\U3W#\/XM7#=7/M/W>GB8W^33]OU=/
M-$]P^/\ 5IZ5?WG[O3Q,;_)I^WZNGFB>X?'^K3TJ_O/W>GB8W^33]OU=/-$]
MP^/]6GI5_>?N]/$QO\FG[?JZ>:)[A\?ZM/2K^\_=Z>)C?Y-/V_5T\T3W#X_U
M:>E7]Y^[T\3&_P FG[?JZ>:)[A\?ZM/2K^\_=Z>)C?Y-/V_5T\T3W#X_U:>E
M7]Y^[T\3&_R:?M^KIYHGN'Q_JT]*O[S]WIXF-_DT_;]73S1/</C_ %:>E7]Y
M^[T\3&_R:?M^KIYHGN'Q_JT]*O[S]WIXF-_DT_;]73S1/</C_5IZ5?WG[O3Q
M,;_)I^WZNGFB>X?'^K3TJ_O/W>GB8W^33]OU=/-$]P^/]6GI5_>?N]/$QO\
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M/Y:_JO\ Q>F?)E_:#\7#?XM.'27_ !MB?S=P6G\M?U7_ (O3/DR_M!^+AO\
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M>?8IQX<./#<'QX?!Y_-JN-Z_JOW^-O\ ;[7AJG_T8^[R@?<\-?!\'P#XM/\
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M3ATE_P ;8G\W<%I_+7]5_P"+TSY,O[0?BX;_ !:<.DO^-L3^;N"T_EK^J_\
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MN&LF]CG3IK%2;5W%R"K9\V60)2.W!)+8A60%ZQ43 @J$YUYAZS8# #LQ7LK
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MCN+6GG)$5G+=14K5FFO)+]6Q2,OK"]N!'Z?45I"B2!%(8F-W$:N #W4L?$>
M[^&I\.P[O/6:XM*6.JMJS1:>P#!&ERI3:]-6=I O3E6NA*HX!>0K&OKD WZT
MME4?JR2#"TUI^M#-Q=S"3&>B7:D2T#K.+J3(W=J&CVH=2L/:'8(H\$E!Y^!#
M<,PEB/-B1#R@%L.IY01D%L'U00.Q.!K7M4MH(C)4M1B=N2$R5YD$TG;U(BR
M2OZRX1.9O67MZPSVH>=@["U[?7YN'GF/,4G;8248RS/G.DFN0G:8]=PAS'06
M26*7K.8R2J:@ )#E,-RNCC*.KCWJP8?&"1JV:O8K/T[,$]>3!/3L0R0O@$J3
MR2JK8# J3C 8%3W! JNKM8M------------?0,8H\2F$H_" B _O#35" ?$
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M87IU0J=NQ]78>0KDE+RL2[7KDM)UL L#"/>L[9-!-M"2Q>>0LCVVQ$T(*06
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MR1V#9'B#B'NFR[ELWF7I*!8&W"M);K)U$=S#':GJ,954DQ.9J\A5'PS1<DN
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M]G_\W]LGX,5^:C9_K?G^^Z_'_P!&^..W?7Y\BF9?3'3O5/)?>9JGHZ;Z:/\
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MA 0 =4.WS@$BSD@$@&! "?8,B0D9^QJY.)]F+J#L5A 6 +>EP>4$X+8]&]\
MDX]NO$SN5Z0/)F]2X^*V6\6&PW:\"O9RN2-4>N7H29).7>D2DBR3*2;-%V;E
MBM"%;<HICSE4Y@,8G*8WF^[W9+,B)-&T+0&1 KY4EF8<W;PR O<>(';MCO\
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M]Q7,&1^W:DPM[F,7LVE2QC V9O8:U%M'5890[J2>12;<K!Q)RPO'\J ]I=N
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MQ"HJC/<DD #/<G ).H8R5^%=2.',G77%-UV^.Y>?H5C>UF7?5=:%-$.GS$2
MHK'KR-@;N%&QP.4R9UFJ)AX\3$#NXZ61*Z.Z'JY0D=BO?W'NO;[&,CVGVZW\
M;7)$5P8<. P!#9&<^/K>/V,CW:WE=%_TEECZ1&@0.6F]+CZ93+):;I7F4._$
MHV9H%/02:K'=BR7>QJG:91-RHFHBY#@S.D0R152B8UK1)TC*G/@-CUB._<=^
MP!]N/=[-52>43K#)RY(R2H('P8R3[/P^WV:W&H@ @81 !'B <1#CW</-J/J;
MKGY2_%#]P:::QZL;IP3<SC!DF^DDVBV+,FKK1R638.*B7"R,[1"I.7>)%T#6
M"WO&Y55"-+G'.$HZH)KN(Z0246L;,Q8;Y\^@&6 ,$W83HJL0T?C7QSR$>R0'
ME0=B/6UT-9$/#.Z.8XBZ[KM@60[7/-*JF"]S*F[JPKTT;L7IR(9+9"R(0(&S
MD-J9KGM-----------------------------------------------------
M-------------------------------1;G$S4F%\MG?*123$F-;P9XK.R,[#
MPB;4M9DQ<'F):KD4LL9%E2 YG\A7B'FV;4%7$40SY- HX+6/-I\\N.C)GG9U
M3'(?HFC]=5][)EE'=02-;78N<[UM C$QD.YT @KQ5YIRYM1!1##;Q5EE+8Z<
M=DB!WPLQ$98ZJ^+#-CXQQR=F=@HT/0Z@9JI%/962BSMC5^/% \;(SQ23C]@9
M(2F9O9DA95TW%->1*5X=8 N@_P!A#C!'2CP5+%?H%^A+>L1[BWK$=SWSK#NO
M-Z4W+G$@?S^YSB6.&*4-YQ)S"6*N37CD!SSQP$PHV5B/(%U?>LNH&M!&<LL,
MXG='EF)GW9AJDI:48IXX,)SC!OXM@QC6<V@GWFY6BB1T))),/S\<JL)2BJ@W
MX4/[?#\!['374L2D77".%IZ4B89N@',H\E)5BP8F(8 .18CQVX0;JMUDQ*L@
MN104U$#$4*)B"4=5 )[8)/QY^'V_CT_;PS^WV-0"3?SMWP!9V5H2S_0&TS%*
MB1>-A9DUK4?MA/P<QCUC6$I4ZC9RF7E.0XE,F;D43,55,A@SK6L/]##(?A*D
M#XS@?&?^6JA&).%)/B3COC(^QV_R\3KT$;;]QN+=T^**YE[$EECK+6)YN '4
M9+"9>,DT0 C^*DFRI$7;%\S6XD5;/&[=P0.45$B"/*&-XWC8HZE6'L/N]A!\
M"#[""0?9H00<$8(]FIXU9JFFFFFFFFFFFFFFFFFFFFFFFFFFFFNFJ "<X#YA
M*(#^P2<-.X[CQR/\]4/@?L'7\J&\ PGK/N1DD3D6Y;1D)NJH/^*ZBYR49+@4
MWY/_ !:[8Q0.'F$H"!C=QA] I<K4YB2""DF#]C[ S[/LY\.^-<]+SH\*D8PZ
MX Q[?'V]P0?L=_@[:Z+>_A$%\3*1+A)5V6N,4YHJ)N<4G*[HR'5+F)YE@2XB
MJD(@<A1 3%*4P:YZ\T(%#I,I85\2<N3R^MZH8_SNQR.Y /<#6XKB4K;ZH/\
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M,^[ ^WV\=7#1U9/'U[J-I.U5-)5RP1$@Q9+-W#3MRYWR22#4RSDB9FA7"@E
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MH45.!U,A9S5Y!X<3?E2*O-Y^_P#L&[^ CJI8FHY/](WC[,MW_4#J$W_2*_\
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M:::::::::::I4DNLU;O7+=#M3ALV670;<_5]I610,HDWZP2G!/KE"E3ZP2'
MG-S"4W#@+37\AF7R!9+-E+,$R=9_4Z_;,IWZ>G82/4;NGS!S8;/*3+J$.HX2
M1,Y;M5W9F2RJ0MCN$TSF,0 /R%W]+=>DIB=Y4B9V),:JS'(S@AB.Q((\?@/P
MZ^>D9 K (TB!>7G+8!7P(P/'VYP#JWYK'E"FX"PRM;[8G.0,8O+)FD8X$6SA
M)BH+Q^<[DDHJ<JPH X,D46JA><"D*)0Y #)/8VF6-S DYG525YD*KX\QYF$K
M'.,_[ISV]PU@3TA$\8E:/HDX<J_,P]@Y<QJ "2.Q;59AZU@*7!.U9"E<\1UI
M,^3*9#'#"FNH,D4@S1!HY,>7?-9%*5$JZQ5C&$&A3$*5$PB)N&E$O*Y=9'7P
MP%R.X[9/<#L"<>)_YSV$O@J1E2>P<D]O:.P(]Q'V\@XSJ5*[2]H!TAA@L.[9
MNR6%RLJ@M6,2]G646X L<XNG;@#KJ<PB'G'N,)>'?J0+4D<?()0J=\J8ARDL
M>^<NV2<Y[CMCM@]]6=.6:0<D*/*W90LC<QP#C "9QV\/AR=3MCW:/M5N21Y*
MI-=]LZW(Y417=UFC8Q?1Z;LB9%%6IG#5([,BQ2*I'%N90J@%5(;DX& =6H[8
M#)-CN,D* ,^WN#V\,GVX\1[=)?.HVY)((U< '#,_, 3@,05S@GL&/8L0!W8
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MXSKJX]L.*)6OKC?[G)U2;!\X:%C(JL/IEN,<BB@1LZ[60! %ES]=UB(C^0!
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M(9LM@9.O?@AYC?M#_5K<Z\RUSZ::Q\L:#\VY?&+A-G-'C4\79+3<O4*%5Y"
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M*,=%3=XCG\>_0J2;VQ-4G)(F%62<,72D"Z;F9BX044* D,H@50JVMO+*S1R
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MNFFFFFNDM)1S=VV8.'[)!\\ XLV:SI!)VZ!,.*@MFYU"K+@F'><4B& @=YN
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MUK=TXZ\H6\[<=NXAXRXLW?;;7([T]TWK=;5&STG62)VK6;,D$O2E4.IY6"N
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M/? R.YSV[8^Q[,[7<=UEX@W:?='KI3EW.Y-:F596F6%[,K2SELC #2NSHO\
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M:J\XSUJ13SA>5N8B/J(Z^MCE/J\Q!PI!.H\SA+$892_4DCA7"%E5I2%YY&!
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ML*EX7*,7B 95EY.5F([%@"6"<Q ['.%SD^XQKN86,AE=%GP$A3X6E&8I]P'
M',+D!EP ??$ 4 @  CQ$/R1XB A)8 JX]A!QCP!_8'X?8>V=9(N^#D?19^'
M]OB??WSX? =>AS'3T)+']'D2B!@?5"MO ,'>!@<P[-8!#]0\_'4#4W5Y::::
M::C;,J*KG$646Z+=P\67QY<D4FC2IL[ZZ<J*5V1(1NVH\BJC'W)=8Q@31JSY
M9)G/J&+%.5"(NCF#!9!->< $DQ2  1B8GU3V$1[2D^ C/9_H20#K9;,P7=]K
M9F5%7<:3%WMOMZ(!9C)9[\8:2DJCNUM 7K@&502@&L$]Q>*;Y>:KMP>(8JN&
M;,;US'CMA;L/U:VQV!)XEQDZW6DJ;<7L+XR5R&9-ZOV.;CG%02G3%JCN82=1
M;60/$$ NGW"M++'2;S:2W7CA82UHYA3?JE(^C*5ZD2@1XD0QA_G9<%0V,CVS
MR:<3;)LDW&D$G$VU\&\17]THS;7Q3NFR3<7T_1-:W?;>-GCD6AN-E9-RZM*=
M;YIXO14V@GEA%@YQ;:;-=UGE4Q7DZY/Y:P.<>,-KL7:%H:U@I=)H*TB]\?I&
MHVM_:H^.-X >#%,+LTL5:%UD&N&FEHF13E%4$5]?Z*W$V:MB5B_07;TE*S?/
M6,883O#(7"CDY@)U>/Y\@8H>8#/J4OE<\F(X9XGX<VBO5H1;]-Y2[.V+;VOE
MVFGZ1, V.ONFV0;7-84WH?.IMFEH;@L6Q;@*<=FN:JR-'*]NV5WB&N^6;/A6
M#>4BQS6X3!,YCZY.+$]L\=#T)HK5+#DV74J<O=6K5_&-;6TEI"0K[@S![*@5
M5K'$,R61(,B7:I5FLR5$,+M=IM#*9&D5(08WL/TVEP55PSM&>4L/57"X&N9V
MGRP[-:V;A;;.,+D>];=3X"XVI;[M$5"';9[>^2C<Z/#E5=TJ[/))!9DVR6K#
M!>C$\54E9)L2H6,;VC;-N:&&:-\@8]N.?U.W;A4(9"HY9:8@\7,GV[*TK/T3
M-ZT:E=6[9K".JNX:%CF327G)FB(I':M()PH\6*3!+0O],">&2Z<WN7I615$=
MB6R\D%LKU0 AC887F=X,%51O#70;=Y1O)R+DK[%OVU<"KT. GMONG"TO%?I'
MAO:>&*M+>N#5L'9I))+L6Y),;,\M2E4WMW$TMU.DO-E/N+P_ERR8^VY1]EI]
MBW&1%&B3,LVX\IV0T<;2MYMJE-8QD1=BRCV=JS.:80=C0DGBT*^FF0'/+(3:
M3=RYBTFVMC>JV9*]$20ON"PIRVX(IQ TTO355EYFDB5PD@9BC.,YYN4D8UYG
MP!Q9PKM^^^4"QM^[;?P!:WJT)>#M^W;8'XAJ[+M8W>>S:V<UHJ6Y34YKNWO6
MA2[!3EY15>H[QQV&DU 6/]C6?+9E/$=RRM?IJG)XJQKADRD@WF7ERL,M8*S>
M;Y8Y.E,+<%LCSMU8RN.:I4K?9Y:K3A+G'F<&;*E4ZQ<(<.T79+-66Q.T7FT%
M7)#M,[O'+.SPB7J+]#'TXY9&C?JKD^.&UW.^^6?@?;.&>*MIX8V2INK<3\1<
M78KRU8=HV^K1W+9=BV^OO$^TG:K <6=PCW7=-JVZKNE)MHGZ8<%0J&[PV;35
M*RY<;Q0\?S#9F;='BBS0:S>]O7)7>&V-/AY/(22$;,6Q5J1FO??"YE8MVW1?
M.5UA!LB>,%/ER#:VAL2RP1,!Z0KNN)F/\5$*M,.5Y,$&<MD'N2<#*J -4?*U
M3W?A;:=EWO?:LLW[VO%&W7EDV6&,Q<73;O;@V!WL5-J61Y(MD-0)9C=X8HU^
M>.+(8&Y=J.V2X-8W+%2W'XYD58"^KUZQT4DMD$US0H5 ;2$JK7,$*+!*JO&D
MMC=955ZYF(LBT3.I6#J4IEX:,%,N3;-OE"68[T!*2E'@YINJ(8 6*4SZQ8/
MQ+%@.5N<88E-:[RG^4;:9;'"VZ>3[B"O'>V.._MV]M5V%=GDWK?'AJKN'&RH
M:JQ2U.(51(HZMEDM4GH"1JD)L\VON[O9K;+S2\!XHV_M8^$J>/'N39-R%HDI
MJ9K[99]495>N,9XH6V%LDB69M3OLR,JD]EU8)PX+)K1[MNW% [<]JDGBIUZ7
M*D<#6&/49G3+1MR"0=1'8-(2 W,W(?6*L%Y=/)7Y6]KV7>>..*>.I9[NZ;]#
MPY7C.VUZ=2](L.[54W">B3M5W;X&I[7%U7K/#56ZD9@2Q%(X;5B5^J=('5W;
M%E6"W'Q,KFWAC"5>MVRRX^D9=U:X_%9HWP99;4>8>%+DA/*)"2#:SIPDQ77=
M?3116>-F[A=)#%'%O,9 0R=)*(2.*1XF=I?-^4K)-SX6<V0&60(\94 =@=;F
M]NGD*W*&:;<CM/I?<./9[NX[AM6W;]7JQ;9/Q*MD6-NVL58<\/-PTS5Y-L:[
M4OQ7F>1(WDC5I+0LN.>D!MN.:_4;87)LX@62GDBEC;1BN"F%S-LSU2=K+[)R
MY;&\5?0:>+$)5FR:UF>D)="=;JH28KG5:.0Q20[U+ D<GG##F<862O&YQ:B>
M-ISU?]F*RN J.9.;(<MD8V^W\0>0K:N(-PW7:SPY3?S>DQ-C;>*+U2,2\([I
M2W&'AM#0A6&ZW$TE66>7<*$-1J4@>J$19$$IUNE=(!-6F6CKS<K1"524SM &
MDG]7>T5@X88T2DLBJR[RFR1I"6=(5ES7C8\8N(YY!,)Y"4*X<M4%77A-T:3'
M%O+RLLTLB1M;CR8S$I$ DL%C"W,Y$9BZ"E&0.&!(\2=<SN&\>0NGME:?9MIV
MVYNE;@F^*\.XP;W,D_$3UMA6I%N]<UZL,FXQ7_3L\=F"]/1DKF.*61(_-X5V
MNI%*DF1+K!/R%*3F.8#'-R@ <QS?XQA\YC< XB/'AWZZ'V>/A[?L>_\ YZ^9
M6/,S' &23A1@#))P![ / #V 8UR<Q?C!^\-5U36ES='LXSCDK<U:;I6<:4JX
MC=YW"4IC#<O,Y->5VY[2(W'3^+7N<-5*61FL^F4[&>/E9AJ6M2#!M89"SO(J
MX%"+9IJ*<U>VVU/=DE2".3JO5:"ZT[)+MZP,O52.+',PDY6;$9 <R,),KC/M
MG"O&NP[7PO4HVMSN4_,:^_P[KPO#M26J7&$NYQ2K1GMWBZ1U_-A)#"_G*2/!
M'4CEJ9D?"V3MIZ-6Y8\W&7'(^8*I4+MCS-*.Z>,NU7;H4F/""99'R_)V2L,[
MVO'12<UFBLVZC^""L64_*N'>.)Q)PW2:+L7A316.ELTD%QYK,<<L%D7EE0"(
M<BS3L\:S$+S68Y(@H <_.6[=\]IO%'E.I;CPU3VS9;5NAN6RMPI-2M,;SFQ)
MMNS15;3;>LLA@V2U4OF8R/!$D>Y5^1BXD0]6.8OHP<[U;&%*K6'5Z]M_LA-M
MVZVGY1>49KCZ9'(EWR3;ZP>AU"=/9(R1;)QLW3X%HS>W*,*VE*ZWBF;!!Z@!
MQ V%=DM)7BCKF.I)YE?CG,718S33RIT8W+JPY6C0*TB@,F H<9.=I)Y5.'[6
MZW[6\K8X@JGB?A&[M*7FW"OZ.H;72MC<;D'FKQOU8+MAGCI2EHK+RM*R/RC$
M@Q6QW<$USW4)]SBFBK2K?)N"LB,-VA\K/0O>*,:X\I='A;CMZAZ*5FH]E8N:
M<5FSP2*;"31I4M%W5Y.S+<TNW,17*-KMBY'(:\);KU9AN'7)EKPQ11)+42$C
M)1BDB@*1&1*78%AK6R\><.-L%NNFZWEA;:.(-LDX07:$%'=MTW*]?GH\137R
MW2BD@6U5LDR1F]#+0CKP8A;*Y/9OVG94NV\2EW.J^!R;=[RKC:\[A&J\L1M)
M.LA;='=FE\4(LX;N-*-;7)S=53L3DOY#=ECR-2==:1PD34ZS0GDW**6/E\SE
M,$UM2P#-/3ZC0!4]HD+1\Y[]H5R,>'+[%Q?M%#@N]2MB8\2T5W3;^')%B+1)
MMO$JTX=V,D^#TGIQ07&JKE29-Q=DP58C"''^P;<_3\N[-;D7%]0=2.+Z/C.K
MY%O%CR56K#$5F,JTK;'EGCZY71K36^0-G<,; X1C']%O#FFVURZ9C>X R,<L
M5760[5>CL;=+T(ST(H$EE>:.146-W+A(R@E61@Y*-#*8Y"0)5( UW.Y^4+A6
M]M'&U,;I;2+=;VZV]LHU]KM5I[,MR&HE5[%D67V^Q462NIEBOT8KM14D%"P#
M("*-_1X;G4J]C6N/L34&UW0<1X,IE0SK)Y>6B;#LSLV.9AV]N<M2X-FP<+68
M)Y58EB:.ZD_8.9V555@K288-%%35@V>\$A1J\,DGFU:*.TUDJ^VO"S&0QJH8
MN6YN?,94NPY'P@!.<^4?A5K>Y6H]VOU*(WG?[UW8HMF6:OQK5W*&..C#=FD*
MBLU=5-9TN(\<$*B>L#.6!DZN='1N!<[@WTK:I])/ N1LG[Q+[<X@+&RD9NCS
M^4G\M#T2P5-NJ!T%H.[4SQ97LU5.DH6)L,,Z<K"D68> $A-GNFXS2.!4FFW"
M:12X9HWG+)$\:YP$EB*EXQDJZ')PV!K+'E*X=CX<CAI5R>(-MVK@O;Z<_FTL
M4%^':8X)MPKVW'*ZSTKOGGFUL,O6KSHJY:)2)0WF[#;?/[;L2XFP[3SYBD,>
M7J1M L[!=*76HPKU[57M<9/I6I9#JEOIEQA6J*Z:*[-^\B;;'.A&UP]E<V<[
MQT[S[EM4DE*O7K1><F&5GP\L48RR,H9DEC>*4 '&&(D4X=7+Y.M1P7Y0*=?B
M;>-XWJVNS1;C0BJ\U:C<LRE([D=IXX;FW6JEVE.Q4LLD<<M21!YG+6CJK&J6
MQ-[:>DM-D:DM:_F!E XE4B<01EWB*W>99NA"!:*S4:QGQ*D!,.W4ZC'X]5QP
MA-8M[8X5D%7.2K,8'1G*2XFQO2WHSQ!+'+7Q7654E8!>I'&EOI<Q+<L)A#0*
M023,_<G.)4'%'DP&W7GL;,]G>!+O,M">U0B9K#5;=ZWP^U]8(UKF7<1N71W4
MH1$$VVJO*J\NH<L71Q[BK 9I=)F'D7UVK%4HS.':5[,RU767&'WP6W,-LK\*
MO'2$=$PKB8P\K654I(_9&RT^BDDY7"3;*.BQI-FNR%97!,J1Q*JI9Z><;I)8
ME1"" O-6*=S@%@ ?67.M[5\IG#5824898XZ%NW?>9[&RBWRK-P)3V6G9G66*
M6680;VMH-&#(R5F/(C0,%UZ'D!X((@;B0W5)@8IU 4.4P$ !*=3F-UARCQ Q
M^8><P";B/'CKKQ[![<>&<G]?V=?.!\3@@]SW P#W\0.V ?=@8\-<O$/A#]X:
MKJFOG,7XQ>[S]X=WMTTU]YB_&#]X:::<Q?-S!Q'S!Q#OX>?337P1 0'@8/WA
MY_\ X>P=-/M^&M*=CV:9R?;P)/(2&,:2^%_N.@LSQN[Y;*#U#(->PY%P46P?
M[;D,>BR,_/&R1&,A5Q:H29*.M"3:]D>-_&)(4S<R^V6FW)IA#">:XEE;_683
M)65%1J71*DE7"LF,B(J_/]$#KVVKQKL$?!T>W/N=V,1\,V-CEX/&U(^WV=ZF
ML2R1<3-N/.(Q+&9([8=D-])X%K1'S=@5B/:!T65PQ+ 9"J^;J72\AQ&6ML43
M 24:1*C15?@,HQD\M.+U2Z0D%%MCY0DVTV2(G:GF":?/Y6/;-).(?IE573?/
M8^W[%) DR6HXIA8I!#CIA4G5N8QRJB 3$/RO'99F<8=3@X)W7&?E8H[Q9VZS
ML5R[MLFT\536DE_CTMBSM4L"0+:I33R$;7"T!GAM[-#''%([Q3(6"\B4"6Z,
M7</$8]9UC#SR"Q"Q/LTP/CZ_4.J$H+B%R]F>O7N3LV2XVR2\Q'N9" 06,Y+*
M*72N.6#R==N#IF=*=20@4;9+:Q".N4KKZ.JPR0QB$K8LI*9)UD9AS*"/7ZJ,
MK,Q[L3C4F#RJ<-S;D]K>4GW=_FWXAW.A?MB^L^S;':H1U=KDJP0.D=AE(Z7F
M5A9%KH,A 7+&?L7[-LY5K=W"9!DL9TJ&&OYXRUE:V[MV63GTA?\ ,^+;PPMZ
M%3P7+8^[$D^CV%9"Q5B-5:R<DYJ,2TQ]'2-;;A(/ (C)@VVTFX),88E*V[%B
M7<%F)FLUY1((ZKQ?1!5YT&&)B40J4&2<<YNO&NPVN#[&WQ;G=F\YX>V?:*G!
M[[6D>W[+N]"6FUS?H=QYNG(]KS:W,KQ1BW,^Y2Q6CR)S-<F8=E.9+;N(S ]K
MZ<.K@"V5N]YVK;%2PD:/U=V5APA)X"90Z\0<XE;5L89P2^'FU"%;I6I;KA+U
MZ(*CDL[99DN663D-21);2 OAO/WJM4"E3X1\IZO-X!R>PP28^R\<[-3X<V6.
MSUOFBJ6=OX?M2BL7C'!];?H>(6E$JC+V1,K;?T<L[4U"@%3C6-".P;<_'YN5
MM4)C"GMV<QMR4Q[;K[8<E5NPN7$B7:^ABEK7J.BVK4)?J:\-=&<:B]@9.T6S
M$BD<C*6YHS:V223!I"7:KXM<XAC4-3$,DK3QN>8417Y(QR),F)0I*-))7(YI
M!AW'+TS^4'A278Q4GW2X[P\2>D*>WU]KM546 \5MNSS7RUFQM]Q/,9)62Q!6
MJ;LLAAIN7K1'FO"&V*[AV.8:-*OL4T22G6UUVXW:.W8KY6=I7G"]"Q=2L>0M
M\P)!TA)FHZF8NPN:I;8=N$5(MJ;-,,@2$S/MAD68E6R+M5L68F,$+.):4HW
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M&[=/PAQ_LQ]#K$G$EB/I8VS8&Z/HKEZFRTI _HGFZ75#1GJ^>%L[GSY\_P
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M0N,,8\QYY>VLIXHL&8S>B>' 3;>YR#8J(B#O0&WF$1=/E%54'G"5\=-+O\:
M$O?53>[>8)ZXDW)\D9U;FDY')DDHFSR];VJ#13*,6WB9%M'(I/0(Q8U1-N5Y
MCMFB!4:/)J+R$&5!PL<PU:I&>8FQ9',TQP+,F%ZRA6"@'L$^BB _V3GF7!UC
M3B.PJQ(NU[ >E'MD8+;-29G&U3-/&TC,A+R6V/)N+L<WH@(I^9!C7<:;>X1K
M(,9(N1\W+'8S]%L1&KK+-M78KKT.K+51E&/69WHH.H*PMEC2]UAU"BSM=D(E
M.RI%GR15 N%1 58363AHGP9Y"IZ2<@4J3@JX/-(I&'?UF[ZL;B&=XY(SMNQ
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M[,/7B,88*2003X=CGV^TZWG#FYP[/NJ7[$<DL2U;]=TC;E8K;IS53D^W'6)
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MG;5%98 *'Y:B29TRB' QP-W:SI,Y/J1F3M["Q ^(#&,]L]N_AK5<K'#Y\1C
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M3@Z0-G -7()K&,@J!<0W;;6B>87:YB1E1W#C"LP)4'VCF )';!P<:V\GD?\
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M@G5CO=PV#(Z_ABQ_E>BL\AC$GG?%)Q88]*7"*3CU9<[L43K 0H%B$%I843*
MX\%I*2()"S**X8FNTUF\W:S")RO/TC(H?EY2^<9_F OCQ*@MC SK<P\"<96-
MB/$T'#&]R[ +2TO2L>WV&JFR]A*:Q!PG,2;<B5 P4IYTPK\W6]35VER5CX]3
M+>PNE:"F'K7CD6SFF&1(7Q4[)V\;$+\ZQ4"PX,^+@7YC@W!(!,*G<.LHGA,8
MFZL?2*=02<PY.F1D/S9QRD=\^&-:H\/[XNZ'9#M&X^EUW'T0=N%2<W/2G5Z
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M:::::L#*,VWJV-;_ &)=\$6G"TVRR?A 3\H,CM(AVLDY P]P&25*0Y0\PF
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M^VD&D*LO&RKQJ0JAD#KE24:@LHD<R!2CB:.1P$1Q$V" [() O<')&>^<,!V
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M'X2!\'_+\&L@AB)[E>Y/?M[<^.?M'_G[=7B7P@\B46BKL\LNT%,[=:<DY'S
M<3'4[:W6*NJ8O'D$RI@ ! 0,3N$!E!))<L01CWCQ^QW]_P"W;6&2%,9R.V<@
M=ACP\?\ D?;X>_5+G9M&.8&&.BJ=(O YU7C"3L<,U*=WS"0IA7?I*KB H@00
M,N G*3@ <0X:N\W;';O]@>W/CX8^'W_#G4K;98T8#FS@C)/B>P[>X=_;^#40
MM\H1%0EY%UE&[;>ZY7CHG5AFD>\CX^PE<+I)BHVD)%[*=A*5 W6)%<1[41>B
M7G,FD"H%USZ^ENM(J(_3YRJX5OH0?''V,>P=^_89UUFYKPT*R/$\?G+1J9?6
M7/4(&2,X(/?]>,:YSYXP)*"L9"T4^:2 #=F-$-$+&X<&]XK5K#1\@LY7$. I
MI))'.)P#N$ $0WD5>\R?/58*<9R!VQCW'/L.,?:^#CC9>-_G3 PCLPSV S[/
ML^SO[O#&L[>CZ3C[A)7'(D)6Y&NUIH@2NPOA*J3=*6D7ZRQ'<NX0AYR$A'+F
M/;I),V[=X1%1$5P<]6<P'XZV=6%HL$Y]@^,@G/89/OU%MS"3 !& <]LY\, ^
M/;V_MC6T?6QU!TTTTTTTTTTTTTTTTTTTTTTTTU;\[-Q]<AY&;E5RMH^+:KO7
M:QAX FB@ G,/ZQ'AP* ><1X:C@X(/N.=7@$G/8=@._PKC]O^>M F2W;.Z76T
MV^)GK6QB[)-R4Q'MXV7[,R3:O'*BR I-SM%@3ZPA@4.'6& 5#&.' IB@&%FR
M6R!W)\1W'?\ Y=O^>M[$G+##DL?G:G P1GE& >Q]W;QSXGMVUCM<ZM>'BY%:
MKD20C" 42N?&"*86A4XE$PI]G56(R%JF &$3I%!3G,(F$P<!#6,E?]X9Q[L8
M['[??V'[(S@=M5P0Q"G&>W?.? ?8^SC'OP<XU&ZU.S:7B!,O1(#[W-CZ,$./
MO"(A(A^KAW>]JS*9.0Q^WW\?#XNWO^+5^&QXC.,?0^'Q#./'X/<>^J2XI^=@
M'B3,,, ^]QQW&?"'O>$.'#O]\!_7QU0B/QY<^SOCQ'V\^[5.5CD KX]R5)/M
M'CV_\QXZMEU1LY<!_P"Z[7DP$1X"7&$ )BB("'$HG=B(#PX?Z^(:IE/YOM./
M'Q'CWR,=SX]^Y]_B*,/#EP/#*@G\0\?B^+5Y1-5<L61"2%NN#F04X*R"[&5"
M+9KO#E 7*[=BW;&*R045YC)-DU#D1(($*<0 !&T1'V!0,DC.?:1X@>/M]@'M
M]IU<2!V+-GP[>P>SQS[,>TD> U48V.1C9F)DU9RWNTXV4CWRC9Y8WSEFL1F\
M1<'2=-Q!-)PW.5,2K(G$"*$$2&[A[K^4 @$C(]WL[^&<]B/;]C[6K6\#]$>S
M=B< X'NP0<^X?Y:]5E'N,-?:I$6J 7!>+E6:*[<W#E,3B  9,Y?\4Y#!RB'
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MM8ADVLF4IA\LVA6RZ<&NU9PJW  ,J,R+;$CCHIUG?S*>6QS,%!FDF2PLA8
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I---------------------------------------------------?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g273090g90a70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g273090g90a70.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[16*4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M    /X   #A"24T#\@      "@  ________   X0DE-! T       0   !X
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@              :@   >,          0
M               !              'C    :@                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG    :@    !29VAT;&]N9P   >,
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    $.$))300,      L3
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
M# ,!
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@ (@"; P$1  (1 0,1 ?_$ !X   $$ P$! 0
M   &" D* @,'!0$$_\0 -A    <  0,# P," @L      0(#! 4&!P@ "1$2
M$Q44(5$*%C$B81A!&1HC)3-W@:&QM?#_Q  : 0$  @,!
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M>+<L:[&14<R;R[<OO-QD@$ZZB#ITDIZRG3%/1TF6:?'\6:5I'W,M$*%%!3Z
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g273090g90a80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g273090g90a80.jpg
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M(T%A<9?5,C="4X&1U__$ !@! 0$! 0$                # @0!_\0 ,1$
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MX9C)B4(+Q$/.<5+%G/()SU9QDXXP^6:W7'D2G=8OC8^N/JQO77O8*JY;WO\
M<=6V%;<*2GVCL&M.*BIN",F,^NV>155]?T\X]G7FD S93$>V)61,A122%Q/,
M&&/ Q+5E).+JGR6?S\\R?[P3-0?MO7FZKU[-^PVL.K"2ZF;@L?:_LA4M<5_5
MYAJBTRQ%7S8"]HL5'K3%TBY5C4OWB!\3,<&J&J^+;-R1"GP.SX':FE!.6W9B
MW?<N'>6-NC_Q)[_9,E-W[_;D@H"V7*$TG2FD2U]CNTV.7.,F8-JVDS$-J* G
M"3'*(T6I);U"6/+SF%:EY./&6(E+6X07B_9%SWK-U@T7T]T_6]$]==?JM<:T
MJ_ZB8-,NS+,+8M3N<,F=@L3MG.8YL=B:R1QY,'3DXPZ>.$87&6,(,,8<0;;=
MMV^IW[X/"+_W"=Z$W0#HCN3;\3\=1M.RHS]9:$"^_CEDQV[<EAP2!BO'^G/Y
MHJ2'@ROS3F7F(?E=69A.9L2S0H9QJ$7.27GT7'YS-7#U/[;[HZ9]B:3V>TR_
MP%V;2F+4S&5[P6S4V42P+S5=B36P/$P:9TK> L"L3H9RL9?U?,#&&:(\08B)
MW'9**E'LO;ATY5\VP93]=^A';OV6TKO!W%7OXK)SH.KV3<^UK=>"FI5CVM=S
M!G%V>56JY!@E8M+?/75#^P$129#!!9\U]3SP/S8EG,8RY1T^Q&M\=R6+?S.2
MSM\1WNA8K94-]]&+H\*:BZS#"WAI@8XK,F9-47KF*N;0KH.,V?/(B%=;6E.L
M*\(?CF&-O<[,5GQ'F7C^02UXI-27'?O7'Q]NI=!\$!X!^<\\<<<\\\\<<<<<
M\\\\\_3CCCC^?/////\ +CCCC^O/@%;CV2?)+ZA=3:U9Z=U?LU1[3]D4UD"K
MDM84YV?^RFL1\9&9/73K9"M7A6[5PG_11K?V*DV,TN9HR@P)8 Q ,OQ"L=*4
MFK51>;Q?E=Y)!_4G[*:Q[0NJ\&\0JIAKZ_U.UL=<[;H4!\S1:BN*T!:X@/KK
M,F 8L^LV-"Y5MEN94&)*XN5G7R"&$Z61F:,3@X2IYY/F2@^#(\ ^'9+/6J:F
M,L=OL*.JUY=CAFP?61L C3 8228Q1YF-&9 H(N.<N>$6&4\^'&4F>.&//.67
M''('T@#P6@0;-88(Q7,!8#0& !$)81P946,XQ898^<D!(I$.>$T!$,F<4T6>
M,D>>6&7'/('M> / '@#P!X!J[/>QK]SI?W/[HO.^M6O[7JF\;+UEM1>CF:-:
MD!N740]<H\%@K]9O00TY"S$J%2ZH1[M1&4=57 I/. _) 4&,@Z]-WITG3IKN
M>:?N6TO6IH;T =]-6CW;K/U%T"98*Z(#Q?\ 4FT*Q'9=J:X.GQXPCBM*BX.+
M1*W4%3<9QJ[@L,<UMUEA*/$SX:"L5P(A)ZD73E+G:;I]SY=/0L)T/7]$U94$
M6OM94NJ:[H=7#_;ZU2Z/7E-4JE?!YFE(Y#35]$("I6#9$3SD9PAB0QYSS339
MX\RRYYY";;>6[?-G+O '@#P!X \ > <3O-]HVL*HYO>RKI4]>4>NCX%V"Y7F
MQ)ZE5$0DD\0L9+FPOS%ZA8/(3/ /A,:9!'E/-%#CES))ACR!&;[6M$;R[]>O
M>UZ_Z+;LKBFU7TZFVE%:*[?.5U3VM0 #\RW-/ V-4Y6$ RNS09#&CL!9YDSF
M15$A;%#I&[ N ;@U&5R5I</X^*/M>I?KMV$Z4=!]>ZD[D;66W#8M/,MSIFV+
MMQ=B3:^I[1O*<@I&5WL'Z61H%60N<Y)"I.<52B0Z5 F()1)UI<X\FU*3:5)\
M/F,E-KY-D05:]A&G.X&B]\U:]#W.B53*OM=?;"KMM8ZFV?HAU!QB(-A7VC/*
MMB2PL:M;47)>(WZZR3V^8>.7,(K+P7T6G%Q:6]]Z?,M1=+O?SZ^.T7&@]8.M
MX)Z-V3VE0Z)(_HM@K5P054#;KU6%$\ULJO[9)!3"W/\ $<DX-=&Y>X\//U"U
M:OF(?D\J8Q%Z<U;ITF\]W&MZZF)_M_T+[O=E=[.M-M]?FQ;E7>O"9%4AS(ZG
MM910Z/4M@"W!P5<G^]*4?8E!&R:R76Y4><0<R:YKB4P#&NKD,+DV>*P#4'IJ
M,NTONS6&^&$N3OCC?<L9WK;^IM79+\-F;0UWKO-KC-FKPO5VK51R98#<X<$9
MK\; S7\F8P<YX<39#_EXBYSPXDYQYRX^HD>K1]VZ9V::0LUMMS6.PF(8W)A:
M^CWZJVPT43C/"/DH@1"V/G@&XDDCPYGECQB^^3#'[ONSQXY [.\ IP=]?E:_
MV$[NW%H3K/UA3WDO4UUL^NIMM;6O+(*OM[33FQE>L!"W6U73B-"Z[ [7F1*F
M)&Q59K@&.(S-:J_/C%B+QT;2;=6K26</:W[>I-5Z5O87MWV6=/S-_;IU,BU;
M;5.T[5KN*>FBV$&@WY8A4UIK';J:':6;QR*# :^.JC.#-\_%P>UIES VXFR*
M4J1/4BH2I.\7GATZDNO@P/ *>OR^-]<5WKOU>ZXK+-*(PV;M*Q[.L]9"DYQR
M95?6E?Q3*)G?,6?&7"S*RWC E:$3CD,Q:),S8\>2:_AG$+Z"^YODJ7+)([\;
M/K>LT'ZK].V?)42ON/8QU;]Z7*4R.:.8J)RZ(JU!S&QGXXSP5S:TJM1:A8QX
MXCRS-C3X/OQ.YFE&-5W-],+P_MD]O@F:\OUV]G.Q'9+Y*36RK=Q;")IUHWMV
MG'9)I+6X,JV>BJ36=IS4VCDHI3)%$U;6KT527I!.0^80',*QV+Q"T'C,P'3*
M*6BL*Z3ZVW;_ "S8:>#F(>?<][5$GJTZX*;BG0+;MOG;K1O4]'TMU(1'7^6"
M8(0NS7FV\!SBG$U.DP-$WZU6L*%9/'+U FB,5B''O%0WIP[<JV2RW[=[X>+S
M11:U1U(]T/NE,MN^@6&T-L5%B]/#-V)M3:$-"U5^XY$2?K:WKQ$Z;KD\JA-)
M^04E-K>L$5^N9X<+S(UY<D0\PZ'+3T_MJ^B2;Y9?/Q]BZEZ$_6UV4]:_779V
MONR.RJW9FVQ-A 7"M:[I#YU9*AK,(1+^W,Y1VC=8EAYL%O*R@G?B)EV2F")&
MHFC9L"RC.!A#4DINTJQQK/E^V3L^"9\"U\V7BK67FF<*<KAP@<<U/A_R3PBY
MLO[<3^Q<.N0_\WPIY:?I>&/(O^9X#_-^#_:_;X'>:X2C?()]P?1;L+L>C]KI
MH=M-5EJ8!7_2F]J<!52ZTRA+EXGDH#^D+JZ=7 "8^,,D<H^-GHAJG,=DI2F1
M%PL9!U/2A-)QQU6?!YWY\3I'VZ^\8CVN:JU3KAKU<5:2/U5?B[L!:P]MD["(
M8#M*T<A<(/VV?6],X!&/)D4L^"L6!6462>,:0<CF?@D<>PT^PV^U=JJJN*SN
MRU?ZE.Q<_3GXXFM>R[VD/;W'I?7G9&^!TE;)(N86(:#LEMV1./FPE#.Y4I)Y
M3H#6E@X7L8E%;Q,=Q@GQ"XC3",UVM5I<6EXTK]3,'TN^UEO[5],;3OUFTQAI
MZT:FOX--:0IGIMEIUC%>)N'JLQ*T8K%A@S9?!C*)8$LV!O F&:=K$?\ B>8K
MUPS.'8:5W:O:OW^29CP8-8OTGV-7=+_)+"LM\S,5K<_8'V7UQ)]HDLI UDVS
M9=NZCJL)0_'&,D _-ONJ6%C/GQQB"'D27+Q]@^?'@ZI*]'_UB_*F_0V"O;;V
M)=,>BI>OE_:S>M?U*PVD88'2%QR:W61@TP72B0,&I0-+KUC+1UX"<\2 NROX
M5B"":7\6;'B2.7' <RC*5TFZRZ^>FYF*L9KG2U>Y3GAM5#8$1FJ:+B835[)<
M?!&4">"8/G(.6&8-+$0*3!))#/!)A+%GEAGCER/#WO -=]\LK?\ 8]D=[=1]
M:UYA$M4T;IY,UA282Y?CEV3N%L4T='Y18Y8QYR2U!-KT$3F7'*0?*,[F//&,
MV3'D=.@OM;YNO!?[X?ZS\[Q_%DL-[U+U(3=,[OJ6JW_3FH!-8[MPVD18ZZOV
MC8B'[B[-]I#V6JU.XL9WL]KMUG!Y3N57X0Z9!5DREK"/6QEI3\^5OU]S,=:G
M)RMV[73I^/Z6&?5MZ[*OZ[.E%7ZNF'I+Y96Q5DMV[+0$NE'1WF]W:.$-YP,&
M=AB5.@4UL%'2%,C" <IDDKXIYP()9Q(<(E.3E)RVY=$OE]Y1H]9#.?UC?($#
MT98B" *KAOG:'41G.5)G'FVJNQFAM=U&WFEDYXXX";6;C5MHRE)X^G*_/F63
M\4GTEB'1/[]*]W2?BM_<V!'?CLW)TUZ:]BNS@J..R--0:U<6*O(B/R_H6EK)
MS'1U(5KD/E@1&ESLS53R\E'SQ(A48FRP<\2X8>#FBNU)+FTC5G:3]J/>G0G:
M"X]OJ1O6Q&[HV.0XDV.=;\8;56+V$[*X,G2V*I,^,TN29<1@/S6PEHZW^$X@
MPQJQ(H&&CAX'8].#2C2I;/CY]>/,O8=._9CM_P!GOIG[M[9PH2JN=FM;:C['
MZJ-3T"1N$CM%T'T819:?::4(6<T<)B6T=D$$B22N3R(;*H)S%8#@G@XC/GRS
MFE#L32S5II\:O/2RHEZ&O6KH#V<]B-NZH[ V';M<0:[U!'LE*1J9U5T!![&*
MZ5RLD+'S"T4FZP_HYAG_ .H%'7CK3I)!9Y,3.8H9,/!T:DW!)JLMK-^S1>#N
M5,ZS_'X]9>^K_P!<]9/[ CH,L%SF76-Z6]LFQ=K[ =U+6-497BQX0"8!(1&)
M]6%;<)@%0*RMK#,U"WET7GD>.=7JS2;WQW))O'S<J3]&/DZ]N],[ZV->^Y#F
MT=E]0[&7&20ZT014^HY:WM.;U:4L:Z\ER3X8+Z^LK_[VEFJ1!OZ=QG.J.-98
MLPIF1 M+132[.&N+O*SO^S8=:@V?5]W:FU?NBD9'YTO;NNZ3L^H9M!> 6>=7
MOU:66M!DQ"XEGX#/R4MA.2Q>)IN!R.9(>)9.,/OY;G*\-KD:E;V3=Q.V_:CL
MWN'CM!L*],#*=M6]H4^I6[)F#2M3X([&T315:L47*2%.AE3"BX*S&'"_A\XD
M'S.?L63*<DN4=NG&*C%I+*N\7G?/L6*_CW>['JQTZZIWOKUW:W[::AQ7-H&/
M]*"':^V7L-8HHK]&GS;UQ0PH=<MI"H&&W#.7<20X)>(*4Z8&!D$9,9H!1+5T
MY2E<8[K.4L^-$D?M']^+JF=2=3]D_5BVH^[Z$_V[8==;FVS9=?W@D+3K1(E0
MMZQ4++1[*-2GE;9[)_>#I$KZR+\%A:^ML!4?ZH]D(:",0T_N[,[BZQMGN>4_
M"RGD3MWV;>Y#?#'7>>S]F[SNS8;8.TE>JI;_ #UW6-24UY438WL=-IK%V!3*
MV*("$,G2 A#\,6!>:I?S.<>5S/(.BH::NDME?&^'^RP;\4/V![4=;2V=T-VA
M<GUQHY>OV.W-*Y69L:X)I#NJ-4BNXTI"0PG()%KUE3/HK/ EBSP5*&56;F #
MCEV-G(4):T$DI))6Z=;.]GR_>"\_X.<> 8K]ONEO7#O5J1GICLKKE7>ZL5Q.
M2D9\XX@6^BO9(>88;10K3!'RSK#\;C[>.2 Y,@V8V.:IZ"V2DF+21ZI.+M.G
M\YFNZ[W>NSNSZ%NS=6[%=?+Y=3=1CV#"3479"N!8P<"R%Y\S$:IW6E%X(20L
MS1H,P3E3D62E;-31RF+!,9XGE:K@ZHSCJIQDL\O==Q9<2>^IQV-]+G;OM[JA
M&#K3MKUMK-'HM_KG$4+BO5B[[5M5;HE9VM28F?)^)E9/Q=/+%64MFB,G5V&J
MLJXZPL*L"%R_$7IU-1=]EO#Z>56N/](9/CH;5]G_ &?]A06PB^PF_P#8_7ND
M!V1IV@-VCLRZW/7C$2RUBQ!TVN8*+,W8*)+RQMO"YC6(T\(C-(I2N&&$L:(0
MY<P%-50C&E%*7"L/JWSY9YEZ[M/V1UOU"Z];9[)[:.D"H6HZD99V^ WX_P!P
M;E_E@75^L)\)LXX97UML9RFL(89Y81Y7#<*,B:"'*27 <Z3;26[*YWHH]TW<
MKV8=L-_ZZW%K'7P6EZ[KL_8]=>T-"W62:K99W%(DJ=!=V YJ:/:.+0D8O21B
M#A1'A9U29,P8XE,9X2\5U-.,%%INWAI\>JVVV\5XVD[/9J]2JU8;E;G2VMU2
MIHVUFL]B=&0KTZ&O(0"&CITV/)SC'"6JUHI)QQ<^>$(PL$LTN>.&&7/ B1D*
M_=/ZX;=U[[!=D=9]ATNRZ7UJK\K_ &/7T*6QH-A8QSL0T-=@24G8"FG/&@UP
MM#-15JW8XQL*B6]:B!DV 3Z$YP#?TY=I1:IO;EURKVXF%O7;W\U'M]T?[_=E
MM.:'L=,V=TGUF?>9-?7MV-9*U8('==NC*@NYK"@'1D2@\%TA[/<*_$,"<  O
MXC6NB_W",X4>O3<91BVON:5KO2>_*RFM>^UGN/\ >"[CTC"5LOL.A1. ++/J
MS5-%K=*U;3RC9RA$3J^'UU57T(H8LN1@J%]MBS&\!9XE\ ,\)^2<\AT=G3TO
MNVX6\ON7SO+'/8;L'VR^-_ZS>A^B=84>D[EOUVL>SCMP[$V"!;[-JC7%I/9K
M+Z1JZKB5>PU KB9T7<7(5<;'.A(6HM&MM@%0R&.9,$!^7>126K.3;[*K'-UQ
M?#''XSCGM>]?_M-]P0G2+=^I@P*5I_8O6#6+_8/7N][.)HZ/1^X[%PRMEK?6
M6KLX,#++@8N?5]2O;B(6]V7P5[)6SKJCF&/]6$)PAVK5M-U)).UMC..>_$K;
M^S+TT]A_5E5-.VG>>Q],WB/<C>U(U 6J6=W9R)SZB D8,.6<]NH].CS%GB>#
MQARB8RRR20S_ )1X<.,,LV>/Y_B+0U%-M)-5S)B/5A\:I#V?T_U4[M7OMBR3
MTF[RKMD-].UG4G UCY$K-S8!<UL3:!.RI8 ,V6=?XSS?1T.:<.(K*,9?R1'&
M7P,3U6G**BN5M^V/R90];/6'[Q:K[?PMZ;+W#;^-%5SL ??KCN1EO8=O2MK:
M;(LD[$_7R/4XMK/L(?%NJ//-1#JC>E)Z[1)N1YA2QA4B(HH8<M/L4HKM4EM3
M3QFZS^7QWLC(^4[I/?==]C#?=MRKEH+T=L37&LDVH;MR(>93@,:Q5X5EIHL;
M?'&1:I?C7&&R6B>O22CF3!60=W&/+$PSGY%-%KLUQMWUZ^7X*^6AM\;9ZR;<
MH^]=&W-C0-I:Z<8.ZG:%L014@1?$,HI(QBYF,:I<*68)!2UPD< G*7"PLI<R
M#)#(EAS%9)2335IFRS^/3VT[I]QNE%FW#W/986DC^UJQ)-3;--K%=IC2]T52
MJ4XN#"E=54(*\:KKUNR=U]?8PE(F9Q #5:9F22CD*F')J*,95'Q7)\K[O]\J
M8?MDZ@;?]?G?[9/8RJCZRVMIR[;YMFVM87 U7KK=5#',NUB;7#/6NV=>V,:S
MJ!72&9B>EX"N5?C LHZ["P5HC,R*;%.+Z<E*"C;32KBMN3_3\"W-Z0/>CK[V
M%\C]8[_K!!H[L;2*/*[4I*$-^ET_L*JUSD$-L305DF69M):)<3!R"J$:0V@P
M483-4K\Z 5DO3B&IIN&=XMTGQ[G^_P %C[P3'@&LM^1+LW#>7NANFMMBW/BF
M:RU-#H324%J-$9M :+2'-8J]^N]JE3)PV+,[!0^V3;7) RI<P:LA 1AA12Y^
M!1>!U:2K3M9;M^6$O3U+9K3Y!_ILZY:(2+=5[U9[)2ZNJ-5I%$U'J_5^Q8;F
M:BKJX&NHE"?#8M;U]51(%*@*#D@E[9DPT0@F>,4DYD@H1 BM*;>U=6\?/4R9
MO/L50]A?4AV [Y]+\;64<)U^W6^H@5@11+[M2;U2D[Y6PR>H@S'(.32C,@I;
M#)&N9-U+(-? 4">8 9'-F/.RU-1EC*3[F^?<:W/UO]_;7ZY>S<?9^L:[KFV;
M3!2[?4!DUS<-UH,4MQR7XGO<CU?$ITK",40H7''/G[)L6)$DN?.6./&0ZIP[
M:[-TKX+EPZ$LNQ/E1^Q:W;TUYLBFB:VUAJNGS+.+)U_25U98:WLP7 [*=Y':
M[M:53.]@EM@L_P!M )J36NQ(L(1RQPR3OUDYHQ]&*B\YX/:O#;O]*,^_EMI+
MEL77/KG[#@4ZSK=>'5O:H#R5F!-'G1[/L=1J*WUFKVGC''F-6^:+$EBBB'ER
MQYG(JK:+'_$'],AG0=.2XNO2[_)SSUS_ ":NBG6SI[H#KAM+178&G6/2.KJ?
MKPT_6R'7UTJ%M9(%(XCVY03L[Y1W"QA;GF+"T-%9",K$4YL3'BX8Y\<SR#R6
MC)R;333;?*K=T9T?WLOUC?3Z_P %]MOK]?I]/[*]>?7_ )_^<OT^G^[^OU_E
M_3Z?3GP9^C/IYD47<;Y3N[KIV9T\-Z]$^:71*WBL#VZH[EUO6)+IMVXMK"1"
MVKAQ +ZTS5BK\*LDRU$147"BQ9-26QYQQ _*X 0;CHJGV\/A3V5;]>[H7T?!
MSG36V.N?7S?4(@^\]%:<W- !%G"!#M;6-*V'&##)EEGG$%A;DC?@3#+/++/+
M$?B/CG/+G/Z?=S]?![;6S:,;1_5;ZT164#8?H)T_C-%EXG@YXZ\ZLY%PEQY^
M['/]ORK'*_+G#+Z91\9BY<1Y<8Y8<8\X\<\#WMS_ ,I?_3_9FR'5:NNK,%+7
MUM"#3ADW%<&J8:=>-61Z]B'^WXHH$, ^"N)-B!_D>%<8N(/ ?^6X@_#_ (/!
MD^'KO5^M-0UR.G:FUW1=7U&(PMC%5==U)!2JY&P/RQS..C1UI>L68&&YX89E
ME8B\3D98XY39Y\X\<\ <Z\ P<;^M7HD^[-JNY#7K+K@CLFF<#V0+9N S44K.
MU!XX<!6]C6PV@],<7('.* D"WMZX=903AA6 C6$X4<B,:[4J[-NN7J8Y^RST
MT=7?:+9=17'=]CVG2[/J2!@E$;ZP=U];+9::V8#M3JN\@LM:LXN&$!\$Q*EL
MLA". S8LL2.6$4PT88]CJ2A=5GFO4E*IE1K^OZ?5*%4E^*FJTBM(JC65>$LT
M^"VOUI6*F3+\9R9)2)L0UH0P^,L\LLTG$?&<LF>?.67(P<E\ @V[C^AGK%W2
M[R4+N[L&^[(1ND$E FONLTG".>I[+EUE,-S6,2V+ .9O7!S%X"Y%:1UN1'#9
M.%'PKSK[:8IL0-QU)1BXJJ?'BKW^<"<GP8'@$"_:KT$]?>TWL.I7L!;[7OU)
M=*K'K"X[ UE7$Z617L&T:CP2#59B/:9IH6-3B.65BN*K-".L<%LAE\Q"M@B9
M&9'1"BU'&#BDLWG.+)I]L:KH.\=97S3NTJZ';==;,JCNE72MG931CMZ]8 9E
MS$7@@62 P(C\$^4@;$$@9@N,C@/ )&,'@GC&$VG:PT5!]F?#MU8XM9I^HN\%
MXH5,),)E#K=]TBEV<]6"2<R9C"_Q2DV7JX5CR/SS'!^66M"221?67//*7'GB
M466N^,4_&O9\2PSZN_6SK3U?=;IM!T*WNMD-;'<VNP]B;$?JQ41-KMK-8G0X
MYKZX*<UAKB!:BKZD!<EY<.)(Y<#CR&1)3&?+@2G)S=ONQR,I-+]5^M77)A=6
MN@]#:ETVRV,RB;7H[6M"K=.*M)L$A4PN3B9$O"D*'#F..G!!RRX !G/.F$&A
ME-*SE'C;>[;K:W=':-YHM+V=3['K[8U4KUZHMO4EHK54+8H!?URPICH^8BUC
MA.S@)!/#GPY^F<!,$F'UXQSXXXSQQRX'FVQ0H^39ZM>K_3>B];M_]4M/J-.H
MKA?;IK':JFO-;.:C;/V* .V:\,!5/7;9>@E&7UG8,!,".!<*;%F%S*/SF#AE
MR.G1FY.2DV\)J^F_Y1:&]#&Z,MX^IOIS8"<N?W*DZ^-TPQARY^[*#'2UE=:T
M1\<Y<<\\<_J:K6T!^/']<,#,<,N.,L>?!'453DNMXZY]R0;9?5[K9N4>QC[8
MT%IS8W%N E664BY:WJ#]@Y"E&X$YB-:,5$[*3.(?'# 8C@O$@/F.&026&2&+
M/ 9MK9M5MT*\&W_B8^ON^W<^T:XV9V#TG7V<TY$FO:^_JUOK2B23G+*."ML+
MM66UL# CYYXYY'>V&RS\\<?9$7!']N& HM::58?5K/HT2D="O43U:Z"]=MM=
M<*=Q:ML5??19\^X6FVYD;8NY &(9*S#7<E:9*F1 5Y>H(.P$$P (.R+9L"RV
M97.8L88S*<I--UC:O[9%?ZD?C][<];W?"_\ 9"Q[WU_<]0A4Z]T/52&N@6#/
M8-D26]FKE!)V5 V0K*_52TJY5!*1#5'-IQ;-L8\L"UB_&84H:GJ=N*59PV^J
MO;OWX5MG<Z;ZG?&BV_U&]F.M^T.O^SE/QZWZPV(VOR)4*):U>[C$Q<36(?5C
M=8.LEIA:$]:R_A6T6G"WP2.D6;&:.FARGXA"CV6JI0<6LM)7>+Y^Y<!\$3@.
MUA+P?J[9(&L6$"C9)M!N(FO6I48\PRR\$UUC#4V!$)?&0LL 3[->3+&3CD/G
M'%EC-QS'SEQX!K!-*>U3W2])[/L^I0;#WXTL3NQR2WJJ=BZ;9]MG(K6M)+A8
M$+Q=E!-F548%2S2PN8D\X K;B /,V F0 "6 =;AIRIX7<TOG(YQMCV+^]/V5
M4MWUU*4;AV90;Y$.KM&NM0=7U803X:(X8V&-\\K>O); (L&+%'*GR(L@"F#\
M'!)WTPA_+@\0H:4,VK7%R^9)O?7CZ#NTE1]6GL.TQNV5#J_>G=^NZDQH-!-=
M@N<*9EH!^YV'1(=@.:]*U4+"[W;7&2IR*J(>3U:OPCFE?<XF.1!"<]1.<6LJ
M/A=[[H@*U'L_W0^CEI=UR37.V=#4VR/0#;TNO^G%UZTI<FJ'&=>(:#>"T;NK
MRR?IY<A)7&OKLN*/#Y$C(83PP \1"C^GJUG.:S4ESQ_&BYR/5=T^]GT=0*-L
MH4_6[=G81"*Z53Y*;'!1\GVK=NPNJ;:H$;(D^T+Z'LH*FA38_GG>&+%-AS>)
M<[(*,ID9"%K3U+7W)/\ *I^5LI\U_H'\@'H+9KSJ?0VN>W]&7VUJ)D^>]6WM
ME<Z_NV:G$L1+8<;7KDZ0,7C]&;/D'*\S0O@1BN1V@*XF.46$7<M*5-U=<=T7
M'?4-UV[VW'UY;GT)[;"[S;B-PM-@4=,BV9?,+?MV/15\H:ZMO5EKNZQTY<02
MGLS[/+78G+PJW5^*7/\ /("'PE!#$-1Q[2<,56R25KDJ*S';'XJ?>36^SG0W
M4-Y3M]Z6?%2\("[%>$.N-BH$TI4942;8"NP9IJVYD6YQ#8\.JJR+A>2!X-<J
MS7)LXE0XK'6BU]R:?16O#-_-RS!Z;O3]+TEZ);JZ\=H<*C>+IVP.M..\TE3/
M/+KPFO7]*XH"_6L5B_3*3FDP:,RRL&3<" .(1O;& 2<DL=:*Y/$M2?:DFK25
M5X9OS]C+GUR^ICJGZOQ=JX]=<MD.G&X6",BV6?:=F465[$HK&3B2N59-DAK-
M35KT2J9\V(^O*N=RS(*CS<MV.(*W (>2G*=76-J7GYU^B2XL,,^+B X48R#B
M6&;B$N"(B+B8>7"<>;B.;#/#B6":/":&3[?OBEPPDPYQSQXYX&#V? (V_9=Z
MO=!>T75])UON]Y?J>3KBVSV^EW/6[%,%8%9+$#]J?*21[$DL*9@F>!8"Y%0R
M+HS8#EBPH0^".$L4X:A-P=JL[V9:];.OFNNJ>A]6==-3#,QM>:BJ2^H5GAV?
MBS=EBA\R3E-73# <2$MPY8D&-FLPH0(61YI'Z$ $/B 2$>-MMM[L[O\ !X?*
M>(4=G4FH;*F4V%&SAY'8IGBX-LI8#Y<\9<P&KCX2 RX>><>.>8IX9,.>>..>
M<?KQQX!BW/Z_^AQ1DC GI-U&(/ESYDE.GZW:;F,DSRYYYRSD)DIF4V>>7///
M/.66?/////////U\'MOF_-D%/OK]4O>?NZ5UQK72JQU!+U_UY365*LG7[^->
M-3TM&XS:X3JKE!70!(*L]4Q5_$2NQ+>!\V%8A41XH%9 [UGS *:<XQ;<DVW5
M/#:\Z_/(@I ^(][)BPXR2MN=,59$F..62\O9&Y9B8>>>/KSA+*OT :#SGCS_
M "R_"7-']?\ PR9<?S\%?KQX*7I^V6"_2S\?W'UL;*:]DMX;90;6WV54FM*J
MR37Z]J)K?7RNP2!\V%J,YL(RRPV^Q-! \5(IA2"L+TZHMO!RL:EL!SE@EJ:O
M;5)4KO.7_/F2RUX)#P"OS["?CJ=1_8'V$L?9NP;+W'J+9UW7( KS'1"*BQJE
MF.K")?6$[^1+9*X<<N=?P^I5*V.2]U"M/C6"E\K(&<K(]@*1U905*FNM^S1'
MH9\/3KGGES^W]R-UBX_^G@S7]%.RX_YY0&+N.?\ XQQ\&OKRY1]?V63^BG2O
M5_07J[K_ *L:M/>V.J4F-\4?8[=D%.^ME@MCH^P61RVB!&%708%GLI105HHW
M$"]., OSE,E'E-)$Y2<I.3X^A_4SU\=!V!1)Q_2#J"<<9/*2689UJTP2443-
MGS),021-2\YIYY9,LLY99<\I),\N<LLN<N>>?!Y;YOS9[B/H3T7K#A;8:WTN
MZG5Y^F-'9)WB/KII]2X4L1),9A3UK,"G#F@FC2XXRCE"SQ3PR8XYQR8Y<<<\
M!VI<WYL[YV3K/7>XZ38-:[8H]4V1K^UA<KK)3+LB6V6M.@^9,)L(6"=L.4$1
M^&>.(D63.'F40N& L:2(F&*7 >)M93I\T0=[!^,OZD;RW*;K=,W[6V9DN<\Z
M_7VXKV.HQFEYYRDR%76QE;H0(N<N>>< U_Z4$?CZ1C"PPXXQ\"BU9K_N\TOT
M=:2?%8]5N?T^T7L3#]/_ &]P#<_7^O\ 7\U/E_K]>/Z?3^G'T^G\_J/?K3YI
M^"]CO3KK\<_U?=;MHU';]=UE>[]<J$[76>G\[4V*ULZ%+9$Y,1JAWS6EPR!(
MW+5F0Q& PV )LOA,BA+X"Y)''EB&7J3DJ;P^22\,</CLG3\&!X \ > / '@#
MP!X \ > / '@#P!X \ > / '@%:+Y'/M8[$>NW7NA->]8)PJ=LK?YE]9F;<9
MUY)9^:=5];Y5"(Q15TEH7-ZR98[$=<0^"V+E6SA1I@)L1E_+)T T3BNE!3;O
M9<.=WRY?HJS>Q'WDV3V,>N[K_P!7-O4,_/L3KS<2K9FTMQAQUU/2KS%5JMM*
MG(YDU441Q2)W[E5?%1UFQ%&6(H6ZEGDD7C+68B]8+1T^S-R7_&G2S:NOZNZM
MV6^_C+UMO7O49I,ALO.7\6:^[HLBO$X:87DQ03L=VL$8"XS8893 EY*II!2<
M..82,/K)#GG'ECER(:O_ %)>'HE9/WX)CP!X \ > / '@#P!X \ \<\<<\<L
M,\<<\,\><<\,^.,L<L<N.>,L<L>>.>,L<N.>>.>.>.>.>.>>.>/IX!Y?T_IX
M \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '
M@#P!X \ > / '@#P!X \ > / '@#P!X \ > 5G_E45:L-?6ZILS2N(65CJ^Z
MZG#6; >H7F.Z["\4OHW<2)J0/(>HC<1KE^#7!>0/BPP!#Q+XFQ&@XP%-%OZB
MSO=]</<HL>M:GU*]]V>OU4O%7KMRJ[J]U\-Q6[6D66% V$F8CX3"LD[<4Q<>
M/-AEEA+ 4-+%)ASSCGCSQSSQX+ZC:3IM;[/_ ,4;?1*E3UM.KKU=4K$*!&N"
M4)$:4 56G3J5P\8B]6K6 Q0!+UP D,0H00D$(PH\4<$$4<6&./ Y#Z?@#P!X
M \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '
/@#P!X \ > / '@#P#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g273090g98m94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g273090g98m94.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %AB^5E8X0DE-! 0      $ < 5H  QLE1QP"   "   < E  "')R-3 P
M-S,T' (% !]-:6-R;W-O9G0@5V]R9" M(#(W,S Y,"!!3DY85$)$.$))300E
M       00L!\!<6VQ', O$>1M4)?C#A"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#
MO_XU  (  3A"24T$)@      #@             _@   .$))300-       $
M    >#A"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          3A"24T#]       $@ U     0 M    !@
M     3A"24T#]P      '   _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              +@   'X          $
M                 0             !^    +@
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   +@     4F=H=&QO;F<   'X
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   "X     %)G:'1L;VYG   !^     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     CA"24T$#      ,1
M  $   "@    .@   >   &S    ,*  8  '_V/_M  Q!9&]B95]#30 !_^X
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MHOU8S.E>MG]08*;[V-JIQY#G,K!WO-KF;F>I:_9[&/?L])=+U+,&#@W940
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@X_(368K'<9O+0G*B9 B\R5-?2RB9K(7EE%9DENRY-*:^T'JYID6;XPR$\A
MX<5NNE=;Z,?6]SQV&RO,X]<W&=]T/,NM<2LLA55]G=VM#@JZXK\[8"Z60R/8
MJ!!:5E_:26 E+&#<!%_<9EY#GB)$%)A^?V2!H)XON*JR?:EB;)']Q5<Y5?\
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HZ2?9KR&MF$9%*UKD=UO]$_M^R?LG[)_3_#^WK[Z/1Z/1Z/1Z/7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g273090gibson.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g273090gibson.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M^1JZ_,9/#DM[:7+H8T\Q'C.,C_\ 5FL:4.6KR21M5ES4^9&K9PFWMHXS(\A
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=W]NL<H^ZZNI[@@YJ:<G"5T74BI*S+/T-(JY__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
